The	O
transcription	O
factor	O
NRF2	O
is	O
a	O
master	O
regulator	O
of	O
the	O
cellular	O
antioxidant	O
response	O
,	O
and	O
it	O
is	O
often	O
genetically	O
activated	O
in	O
non	B-Phenotype
-	I-Phenotype
small	I-Phenotype
-	I-Phenotype
cell	I-Phenotype
lung	I-Phenotype
cancers	E-Phenotype
(	O
NSCLCs	S-Phenotype
)	O
by	O
,	O
for	O
instance	O
,	O
mutations	O
in	O
the	O
negative	O
regulator	O
KEAP1	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
show	O
that	O
CD133	O
and	O
HOX	O
genes	O
are	O
important	O
prognostic	O
markers	O
in	O
glioma	S-Phenotype
and	O
shed	O
light	O
on	O
possible	O
treatment	O
strategies	O
for	O
glioma	S-Phenotype
expressing	O
a	O
high	O
level	O
of	O
CD133	O

We	O
observed	O
odds	O
ratios	O
(	O
ORs	O
)	O
of	O
1.7	O
-	O
2.3	O
for	O
lung	B-Phenotype
cancer	E-Phenotype
(	O
LC	O
;	O
P=4.0	O
×	O
10	O
(	O
-	O
4	O
)	O
)	O
,	O
chronic	B-Phenotype
obstructive	I-Phenotype
pulmonary	I-Phenotype
disease	E-Phenotype
(	O
COPD	S-Phenotype
;	O
P=9.3	O
×	O
10	O
(	O
-	O
4	O
)	O
)	O
,	O
peripheral	B-Phenotype
artery	I-Phenotype
disease	E-Phenotype
(	O
PAD	S-Phenotype
;	O
P=0.090	O
)	O
and	O
abdominal	B-Phenotype
aortic	I-Phenotype
aneurysms	E-Phenotype
(	O
AAAs	S-Phenotype
;	O
P=0.12	O
)	O
,	O
and	O
the	O
variant	O
associates	O
strongly	O
with	O
the	O
early	O
-	O
onset	O
forms	O
of	O
LC	O
(	O
OR=4.49	O
,	O
P=2.2	O
×	O
10	O
(	O
-	O
4	O
)	O
)	O
,	O
COPD	O
(	O
OR=3.22	O
,	O
P=2.9	O
×	O
10	O
(	O
-	O
4	O
)	O
)	O
,	O
PAD	O
(	O
OR=3.47	O
,	O
P=9.2	O
×	O
10	O
(	O
-	O
3	O
)	O
)	O
and	O
AAA	O
(	O
OR=6.44	O
,	O
P=6.3	O
×	O
10	O
(	O
-	O
3	O
)	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
employed	O
whole	O
-	O
exome	O
sequencing	O
and	O
identified	O
a	O
homozygous	O
missense	O
mutation	O
c.1522C	O
AAAA	O
A	O
(	O
p.Pro508Thr	O
)	O
in	O
the	O
TRIM36	O
gene	O
as	O
the	O
cause	O
of	O
autosomal	B-Phenotype
recessive	E-Phenotype
APH	O
in	O
an	O
Indian	O
family	O
.	O

Our	O
findings	O
establish	O
lesions	O
in	O
NARS2	O
as	O
a	O
new	O
cause	O
for	O
nonsyndromic	B-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
and	O
Leigh	B-Phenotype
syndrome	E-Phenotype
.	O

CADASIL	O
,	O
CARASIL	O
,	O
Trex1	O
-	O
related	O
microangiopathies	O
,	O
CARASAL	O
,	O
familial	O
forms	O
of	O
cerebral	B-Phenotype
amyloid	I-Phenotype
angiopathy	E-Phenotype
(	O
CAA	S-Phenotype
)	O
have	O
provided	O
interesting	O
cellular	O
and	O
molecular	O
clues	O
to	O
the	O
pathogenesis	O
of	O
sporadic	S-Phenotype
microvascular	O
disease	O
such	O
as	O
arteriolosclerosis	S-Phenotype
and	O
AD	O
-	O
related	O
CAA	O

We	O
examined	O
the	O
effects	O
of	O
MEDI3622	O
,	O
a	O
human	O
mAb	O
and	O
potent	O
ADAM17	O
inhibitor	O
,	O
on	O
NK	O
cell	O
activation	O
by	O
antibody	O
-	O
bound	O
tumor	S-Phenotype
cells	O
.	O

A	O
principal	O
feature	O
of	O
AD	O
is	O
the	O
presence	O
of	O
neurofibrillary	B-Phenotype
tangles	E-Phenotype
(	O
NFT	S-Phenotype
)	O
induced	O
by	O
the	O
aberrant	O
phosphorylation	O
of	O
the	O
microtubule	O
-	O
associated	O
protein	O
tau	O
in	O
the	O
brains	O
of	O
affected	O
individuals	O
.	O

Succinate	O
dehydrogenase	O
subunit	O
B	O
and	O
D	O
(	O
SDHB	O
and	O
SDHD	O
)	O
mutations	O
represent	O
the	O
most	O
frequent	O
cause	O
of	O
hereditary	B-Phenotype
pheochromocytoma	I-Phenotype
and	I-Phenotype
paraganglioma	E-Phenotype
(	O
PPGL	S-Phenotype
)	O
.	O

bResult	O
:	O
/	O
b	O
Three	O
mutant	O
genes	O
(	O
PTPN11	O
gene	O
in	O
chromosome	O
12	O
,	O
RIT1	O
gene	O
in	O
chromosome	O
1	O
and	O
RAF1	O
gene	O
in	O
chromosome	O
3	O
)	O
in	O
five	O
cases	O
all	O
had	O
been	O
reported	O
to	O
be	O
related	O
to	O
hypertrophic	B-Phenotype
cardiomyopathy	E-Phenotype
.	O

Interestingly	O
,	O
de	O
novo	O
loss	O
-	O
of	O
-	O
function	O
and	O
missense	O
variants	O
in	O
KDM5B	O
were	O
identified	O
in	O
patients	O
with	O
intellectual	B-Phenotype
disability	E-Phenotype
(	O
ID	S-Phenotype
)	O
and	O
autism	B-Phenotype
spectrum	I-Phenotype
disorder	E-Phenotype
(	O
ASD	S-Phenotype
)	O
but	O
also	O
in	O
unaffected	O
individuals	O
.	O

Epidermal	O
growth	O
factor	O
receptor	O
tyrosine	O
kinase	O
inhibitors	O
(	O
EGFR	O
-	O
TKIs	O
)	O
are	O
approved	O
for	O
second	O
-	O
line	O
treatment	O
of	O
liEGFR	O
/	O
i	O
wild	O
-	O
type	O
(	O
liEGFR	O
/	O
i	O
-	O
wt	O
)	O
nonsmall	B-Phenotype
cell	I-Phenotype
lung	I-Phenotype
cancer	E-Phenotype
(	O
NSCLC	S-Phenotype
)	O
.	O

Although	O
humans	O
with	O
X	B-Phenotype
-	I-Phenotype
linked	I-Phenotype
hypophosphatemia	E-Phenotype
(	O
XLH	S-Phenotype
)	O
and	O
the	O
Hyp	O
mouse	O
,	O
a	O
murine	O
homolog	O
of	O
XLH	O
,	O
are	O
known	O
to	O
develop	O
degenerative	B-Phenotype
joint	I-Phenotype
disease	E-Phenotype
,	O
the	O
exact	O
mechanism	O
that	O
drives	O
the	O
osteoarthritis	S-Phenotype
(	O
OA	S-Phenotype
)	O
phenotype	O
remains	O
unclear	O
.	O

The	O
existence	O
of	O
the	O
latter	O
profile	O
is	O
a	O
matter	O
of	O
controversy	O
since	O
PgR	O
expressions	O
is	O
induced	O
by	O
ER	O
-	O
dependent	O
pathways	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Yeast	O
trm7D	O
mutants	O
grow	O
poorly	O
due	O
to	O
lack	O
of	O
2	O
*	O
-	O
O	O
-	O
methylated	O
C32	O
(	O
Cm32	O
)	O
and	O
Gm34	O
on	O
tRNA	O
(	O
Phe	O
)	O
,	O
catalyzed	O
by	O
Trm7	O
-	O
Trm732	O
and	O
Trm7	O
-	O
Trm734	O
,	O
respectively	O
,	O
which	O
in	O
turn	O
results	O
in	O
loss	O
of	O
wybutosine	O
at	O
G37	O
.	O

A	O
large	O
,	O
complex	O
,	O
and	O
robust	O
gene	O
network	O
containing	O
well	O
-	O
known	O
lung	B-Phenotype
cancer	E-Phenotype
-	O
related	O
genes	O
,	O
including	O
EGFR	O
and	O
TERT	O
,	O
was	O
identified	O
from	O
combined	O
gene	O
lists	O
for	O
lung	B-Phenotype
adenocarcinoma	E-Phenotype
.	O

Our	O
results	O
suggest	O
that	O
DNAJC12	O
mutations	O
(	O
absent	O
in	O
500	O
early	O
-	O
onset	O
patients	O
with	O
Parkinson	O
*	O
s	O
disease	O
)	O
rarely	O
cause	O
dopa	B-Phenotype
-	I-Phenotype
responsive	I-Phenotype
nonprogressive	I-Phenotype
parkinsonism	E-Phenotype
in	O
adulthood	O
,	O
but	O
broaden	O
the	O
clinical	O
spectrum	O
of	O
DNAJC12	O
deficiency	O
.	O

Furthermore	O
,	O
in	O
humans	O
xeroderma	O
pigmentosum	O
complementation	O
group	O
E	O
,	O
a	O
disease	O
characterized	O
by	O
sun	B-Phenotype
sensitivity	E-Phenotype
and	O
increased	B-Phenotype
risk	I-Phenotype
of	I-Phenotype
cutaneous	I-Phenotype
SCC	E-Phenotype
and	O	
melanomas	S-Phenotype
,	O
is	O
explained	O
by	O
mutations	O
in	O
DDB2	O
.	O

FANCM	O
is	O
a	O
DNA	O
-	O
damage	O
response	O
gene	O
whose	O
heterozygous	O
mutations	O
predispose	O
to	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

In	O
this	O
study	O
,	O
we	O
created	O
a	O
mouse	O
model	O
of	O
IFT172	O
-	O
associated	O
retinal	B-Phenotype
degeneration	E-Phenotype
to	O
investigate	O
the	O
ocular	O
disease	O
mechanism	O
.	O

Charcot	O
-	O
Marie	O
-	O
Tooth	O
disease	O
type	O
4B2	O
with	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
glaucoma	E-Phenotype
(	O
CMT4B2	O
,	O
OMIM	O
604563	O
)	O
is	O
a	O
genetically	O
-	O
heterogeneous	S-Phenotype
childhood	O
-	O
onset	O
neuromuscular	O
disorder	O
.	O

Matr3	O
(	O
Gt	O
-	O
ex13	O
)	O
homozygotes	O
are	O
early	O
embryo	O
lethal	O
,	O
but	O
Matr3	O
(	O
Gt	O
-	O
ex13	O
)	O
heterozygotes	O
exhibit	O
incompletely	O
penetrant	O
BAV	O
,	O
CoA	O
and	O
PDA	O
phenotypes	O
similar	O
to	O
those	O
in	O
the	O
human	O
proband	O
,	O
as	O
well	O
as	O
ventricular	B-Phenotype
septal	I-Phenotype
defect	E-Phenotype
(	O
VSD	S-Phenotype
)	O
and	O
double	B-Phenotype
-	I-Phenotype
outlet	I-Phenotype
right	I-Phenotype
ventricle	E-Phenotype
(	O
DORV	S-Phenotype
)	O
.	O

Two	O
pairwise	O
genetic	O
interactions	O
(	O
B	O
cell	O
lymphocyte	O
kinase	O
(	O
BLK	O
)	O
rs13277113	O
,	O
B	O
cell	O
scaffold	O
protein	O
with	O
ankyrin	O
repeats	O
1	O
(	O
BANK1	O
)	O
rs3733197and	O
BLK	O
rs13277113	O
membrane	O
metalloendopeptidase	O
like	O
1	O
(	O
MMEL1	O
)	O
/	O
tumor	S-Phenotype
necrosis	O
factor	O
receptor	O
superfamily	O
member	O
14	O
(	O
TNFRSF14	O
)	O
rs3890745	O
)	O
have	O
been	O
demonstrated	O
in	O
determining	O
susceptibility	O
to	O
rheumatoid	B-Phenotype
arthritis	E-Phenotype
(	O
RA	S-Phenotype
)	O
without	O
replication	O
,	O
thus	O
this	O
study	O
was	O
performed	O
to	O
examine	O
whether	O
abovementioned	O
genetic	O
polymorphisms	O
were	O
associated	O
with	O
RA	O
and	O
further	O
tests	O
were	O
performed	O
to	O
see	O
whether	O
aforementioned	O
genetic	O
interactions	O
existed	O
in	O
RA	O
among	O
Chinese	O
population	O
.	O

The	O
correlations	O
between	O
the	O
expressions	O
of	O
CTHRC1	O
with	O
clinicopathologic	O
features	O
,	O
E	O
-	O
cadherin	O
and	O
Vimentin	O
expression	O
were	O
analyzed	O
.	O

Result	O
:	O
/	O
bCTHRC1	O
protein	O
expression	O
levels	O
in	O
papillary	B-Phenotype
thyroid	I-Phenotype
carcinoma	E-Phenotype
tissue	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
adjacent	O
normal	O
thyroid	O
tissue	O
and	O
benign	O
disease	O
(	O
liP	O
/	O
iAAAA0.01	O
)	O
;	O
CTHRC1	O
expression	O
was	O
significantly	O
correlated	O
with	O
lymph	O
node	O
metastases	O
(	O
liP	O
/	O
iAAAA0.05	O
)	O
.	O

However	O
,	O
sequencing	O
of	O
large	O
human	O
cohorts	O
reveals	O
a	O
cumulative	O
frequency	O
of	O
additional	O
rare	O
CaM	O
mutations	O
that	O
raise	O
the	O
possibility	O
of	O
CaM	O
variants	O
not	O
exclusively	O
causing	O
severe	O
cardiac	B-Phenotype
arrhythmias	E-Phenotype
.	O

Autosomal	O
recessive	O
CMT	O
cases	O
are	O
generally	O
characterized	O
by	O
earlier	O
onset	O
,	O
usually	O
before	O
the	O
age	O
of	O
2	O
or	O
3	O
years	O
,	O
and	O
rapid	O
clinical	O
progression	O
that	O
results	O
in	O
severe	O
polyneuropathy	S-Phenotype
and	O
more	O
marked	O
distal	O
limb	O
deformities	O
such	O
as	O
pes	O
equino	O
-	O
varus	O
,	O
claw	O
-	O
like	O
hands	O
,	O
and	O
often	O
major	O
spinal	B-Phenotype
deformities	E-Phenotype
.	O

The	O
CNVR_3425.1	O
,	O
overlapping	O
the	O
chr16q24.1	O
with	O
genomic	B-Phenotype
imbalance	E-Phenotype
,	O
was	O
significantly	O
associated	O
with	O
increased	O
risks	O
of	O
lung	B-Phenotype
cancer	E-Phenotype
(	O
OR	O
=	O
1.76	O
;	O
95	O
%	O
CI	O
=	O
1.46	O
-	O
2.11	O
)	O
and	O
COPD	O
(	O
OR	O
=	O
1.98	O
;	O
95	O
%	O
CI	O
=	O
1.57	O
-	O
2.51	O
)	O
.	O

Colorectal	B-Phenotype
,	I-Phenotype
lung	I-Phenotype
,	I-Phenotype
endometrial	I-Phenotype
,	I-Phenotype
breast	I-Phenotype
,	I-Phenotype
and	I-Phenotype
hepatocellular	I-Phenotype
carcinoma	E-Phenotype
accounted	O
for	O
58.6	O
%	O
of	O
all	O
cancer	S-Phenotype
types	O
among	O
1st	O
-	O
and	O
2nd	O
-	O
degree	O
relatives	O
.	O

MORC2	O
was	O
upregulated	O
in	O
liver	B-Phenotype
cancer	E-Phenotype
tissues	O
,	O
and	O
the	O
upregulation	O
was	O
associated	O
with	O
certain	O
clinicopathologic	O
features	O
of	O
patients	O
with	O
liver	B-Phenotype
cancer	E-Phenotype
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
the	O
implication	O
of	O
FIBP	O
in	O
a	O
new	O
autosomal	B-Phenotype
recessive	I-Phenotype
MCA	E-Phenotype
.	O

Furthermore	O
,	O
we	O
used	O
FoxO1	O
conditional	O
knockout	O
mice	O
to	O
show	O
that	O
FoxO1	O
deficiency	O
in	O
myeloid	O
cells	O
exacerbates	O
tumor	S-Phenotype
growth	O
.	O

However	O
,	O
the	O
function	O
and	O
mechanism	O
underlying	O
the	O
action	O
of	O
UCA1	O
in	O
papillary	B-Phenotype
thyroid	I-Phenotype
cancer	E-Phenotype
(	O
PTC	S-Phenotype
)	O
remains	O
unclear	O
.	O

She	O
manifested	O
macrocephaly	S-Phenotype
,	O
preaxial	B-Phenotype
polysyndactyly	E-Phenotype
,	O
psychomotor	B-Phenotype
developmental	I-Phenotype
delay	E-Phenotype
,	O
cerebral	B-Phenotype
cavernous	I-Phenotype
malformations	E-Phenotype
,	O
and	O
glucose	B-Phenotype
intolerance	E-Phenotype
due	O
to	O
a	O
6.2	O
-	O
Mb	O
deletion	O
of	O
7p14.1p12.3	O
which	O
included	O
GLI3	O
,	O
GCK	O
,	O
and	O
CCM2	O
.	O

Glutaric	B-Phenotype
acidemia	I-Phenotype
I	E-Phenotype
(	O
GAI	S-Phenotype
)	O
is	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
metabolic	O
disease	O
caused	O
by	O
a	O
deficiency	O
of	O
glutaryl	O
-	O
CoA	O
dehydrogenase	O
enzyme	O
(	O
GCDH	O
)	O
.	O

Biallelic	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
the	O
RNA	O
-	O
binding	O
protein	O
EIF4A3	O
cause	O
Richieri	O
-	O
Costa	O
-	O
Pereira	O
syndrome	O
(	O
RCPS	O
)	O
,	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
condition	O
mainly	O
characterized	O
by	O
craniofacial	O
and	O
limb	O
malformations	O
.	O

Our	O
association	O
analysis	O
revealed	O
a	O
uniform	O
pattern	O
of	O
Warburg	O
effect	O
mutations	O
influencing	O
prognosis	O
across	O
all	O
tumor	S-Phenotype
types	O
,	O
while	O
copy	O
number	O
alterations	O
in	O
the	O
electron	O
transport	O
chain	O
gene	O
SCO2	O
,	O
fatty	O
acid	O
uptake	O
(	O
CAV1	O
,	O
CD36	O
)	O
and	O
lipogenesis	O
(	O
PPARA	O
,	O
PPARD	O
,	O
MLXIPL	O
)	O
genes	O
were	O
enriched	O
in	O
metastatic	B-Phenotype
tumors	E-Phenotype
.	O

In	O
addition	O
,	O
reduced	O
hair	O
follicles	O
(	O
HFs	O
)	O
while	O
the	O
enlarged	O
and	O
increased	O
number	O
of	O
sebaceous	O
glands	O
(	O
SGs	O
)	O
were	O
also	O
found	O
in	O
the	O
Hoxc13sup	O
-	O
/	O
-	O
/	O
sup	O
rabbits	O
,	O
showing	O
that	O
the	O
disrupted	O
balance	O
between	O
HFs	O
and	O
SGs	O
may	O
respond	O
to	O
hypotrichosis	S-Phenotype
of	O
ECTD	O
-	O
9	O
in	O
an	O
animal	O
model	O
and	O
clinically	O
.	O

Mucolipidosis	O
type	O
IV	O
(	O
MLIV	O
)	O
is	O
a	O
lysosomal	O
storage	O
disease	O
exhibiting	O
progressive	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
motor	O
impairment	O
,	O
and	O
premature	O
death	O
.	O

Using	O
this	O
gene	O
panel	O
,	O
we	O
were	O
able	O
to	O
identify	O
disease	O
-	O
causing	O
variants	O
in	O
17	O
out	O
of	O
87	O
(	O
19.5	O
%	O
)	O
analyzed	O
patients	O
,	O
all	O
found	O
in	O
known	O
epilepsy	S-Phenotype
-	O
associated	O
genes	O
(	O
KCNQ2	O
,	O
CDKL5	O
,	O
STXBP1	O
,	O
SCN1A	O
,	O
PCDH19	O
,	O
POLG	O
,	O
SLC2A1	O
,	O
ARX	O
,	O
ALG13	O
,	O
CHD2	O
,	O
SYNGAP1	O
,	O
and	O
GRIN1	O
)	O
.	O

IGF	O
-	O
2	O
and	O
proteins	O
involved	O
in	O
cell	O
proliferation	O
and	O
mitotic	O
spindle	O
regulation	O
(	O
Ki67	O
,	O
p53	O
,	O
BUB1B	O
,	O
HURP	O
,	O
NEK2	O
)	O
,	O
DNA	O
damage	O
proteins	O
(	O
PBK	O
,	O
γ	O
-	O
H2AX	O
)	O
,	O
regulators	O
of	O
telomeres	O
(	O
DAXX	O
,	O
ATRX	O
)	O
,	O
and	O
beta	O
-	O
catenin	O
revealed	O
characteristic	O
expression	O
profiles	O
enabling	O
the	O
distinction	O
of	O
carcinomas	S-Phenotype
from	O
adenomas	O
.	O

Although	O
PHGDH	O
FKO	O
mice	O
had	O
no	O
apparent	O
defects	O
in	O
adipose	O
tissue	O
development	O
,	O
these	O
mice	O
ameliorated	O
glucose	B-Phenotype
intolerance	E-Phenotype
upon	O
diet	O
-	O
induced	O
obesity	S-Phenotype
.	O

/	O
i	O
,	O
prothoracic	O
gland	O
,	O
also	O
partially	O
rescues	O
global	B-Phenotype
developmental	I-Phenotype
delay	E-Phenotype
in	O
mutant	O
homozygotes	O
.	O

Two	O
common	O
liPOLG	O
mutations	O
usually	O
found	O
liin	O
cis	O
/	O
i	O
in	O
patients	O
primarily	O
with	O
progressive	O
external	B-Phenotype
ophthalmoplegia	E-Phenotype
generate	O
T251I	O
and	O
P587L	O
amino	O
acid	O
substitutions	O
.	O

Based	O
on	O
a	O
patient	O
with	O
a	O
full	O
deletion	O
of	O
IGSF1	O
clinically	O
followed	O
from	O
neonate	O
to	O
adulthood	O
,	O
we	O
investigated	O
a	O
common	O
pituitary	O
origin	O
for	O
hypothyroidism	S-Phenotype
and	O
macroorchidism	S-Phenotype
,	O
and	O
the	O
role	O
of	O
IGSF1	O
as	O
regulator	O
of	O
pituitary	O
hormone	O
secretion	O
.	O

In	O
this	O
report	O
,	O
we	O
used	O
a	O
bioinformatics	O
approach	O
to	O
assess	O
the	O
impact	O
of	O
amino	O
acid	O
(	O
AA	O
)	O
substitutions	O
on	O
the	O
sensitivity	O
of	O
CECMPs	O
to	O
the	O
ST14	O
protease	O
(	O
matriptase	O
I	O
)	O
,	O
a	O
transmembrane	O
serine	O
protease	O
previously	O
implicated	O
in	O
cancer	S-Phenotype
development	O
.	O

In	O
doxorubicin	O
-	O
resistant	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
,	O
RNF6	O
was	O
found	O
to	O
be	O
elevated	O
in	O
association	O
with	O
increased	O
ERa	O
and	O
anti	O
-	O
apoptotic	O
Bcl	O
-	O
xL	O
,	O
but	O
not	O
pro	O
-	O
apoptotic	O
Bim	O
-	O
1	O
.	O

DHEA	O
prevents	O
mitochondrial	B-Phenotype
dysfunction	E-Phenotype
by	O
decreasing	O
the	O
activation	O
of	O
DNM1L	O
and	O
MFF	O
,	O
and	O
increasing	O
MFN1	O
expression	O
.	O

FANCM	O
monoallelic	O
mutations	O
have	O
been	O
reported	O
as	O
moderate	O
risk	O
factors	O
for	O
breast	B-Phenotype
cancer	E-Phenotype
,	O
but	O
there	O
are	O
no	O
reports	O
of	O
any	O
clinical	O
phenotype	O
observed	O
in	O
carriers	O
of	O
biallelic	O
mutations	O
.	O

Methods	O
Breast	B-Phenotype
cancer	E-Phenotype
probands	O
were	O
subjected	O
to	O
mutation	O
analysis	O
by	O
sequencing	O
gene	O
panels	O
or	O
testing	O
DNA	O
damage	O
response	O
genes.ResultsFive	O
cases	O
homozygous	O
for	O
FANCM	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
were	O
identified	O
.	O

The	O
ALDOA	O
-	O
HIF	O
-	O
1α	O
axis	O
may	O
provide	O
a	O
new	O
therapeutic	O
target	O
for	O
metastatic	O
lung	B-Phenotype
cancer	E-Phenotype
treatment	O

This	O
report	O
describes	O
the	O
first	O
putative	O
mutations	O
,	O
p.L70P	O
and	O
p.R450C	O
,	O
in	O
the	O
coding	O
region	O
of	O
the	O
UROC1	O
gene	O
in	O
a	O
girl	O
with	O
urocanic	B-Phenotype
aciduria	E-Phenotype
presenting	O
with	O
mental	B-Phenotype
retardation	E-Phenotype
and	O
intermittent	B-Phenotype
ataxia	E-Phenotype
.	O

TBC1D24	O
-	O
related	O
disorders	O
include	O
a	O
wide	O
phenotypic	O
ranging	O
from	O
mild	O
to	O
lethal	O
seizure	S-Phenotype
disorders	O
,	O
non	O
-	O
syndromic	O
deafness	S-Phenotype
,	O
and	O
composite	O
syndromes	O
such	O
as	O
DOORS	O
(	O
deafness	S-Phenotype
,	O
onychodystrophy	S-Phenotype
,	O
osteodystrophy	S-Phenotype
,	O
mental	B-Phenotype
retardation	E-Phenotype
,	O
and	O
seizures	S-Phenotype
)	O
.	O

We	O
have	O
recently	O
demonstrated	O
that	O
DNA	O
damage	O
signaling	O
from	O
DNA	O
double	O
-	O
strand	O
breaks	O
(	O
DSBs	O
)	O
promotes	O
PD	O
-	O
L1	O
upregulation	O
in	O
cancer	S-Phenotype
cells	O
.	O

While	O
polyglutamine	O
ataxias	S-Phenotype
,	O
linked	O
to	O
CAG	O
repeat	O
expansions	O
in	O
genes	O
such	O
as	O
ATXN1	O
,	O
ATXN2	O
,	O
ATXN3	O
,	O
ATXN7	O
,	O
CACNA1A	O
and	O
TBP	O
,	O
have	O
been	O
extensively	O
characterized	O
in	O
large	O
cohorts	O
,	O
there	O
is	O
a	O
need	O
for	O
comprehensive	O
assessment	O
of	O
frequency	O
and	O
phenotype	O
of	O
more	O
*	O
conventional	O
*	O
ataxias	S-Phenotype
.	O

Logistic	O
regression	O
analysis	O
adjusted	O
for	O
age	O
and	O
gender	O
reported	O
a	O
moderate	O
association	O
between	O
rectal	B-Phenotype
cancer	E-Phenotype
risk	O
and	O
two	O
NLRC5	O
SNPs	O
,	O
rs1684575	O
TAAAAG	O
(	O
OR	O
:	O
1.60	O
,	O
95	O
%	O
CI	O
:	O
1.13	O
-	O
2.27	O
,	O
recessive	O
model	O
)	O
and	O
rs3751710	O
(	O
OR	O
:	O
0.70	O
,	O
95	O
%	O
CI	O
:	O
0.51	O
-	O
0.96	O
,	O
dominant	O
model	O
)	O
.	O

This	O
includes	O
the	O
first	O
two	O
genes	O
linked	O
to	O
recessively	O
inherited	O
isolated	O
dystonia	S-Phenotype
,	O
that	O
is	O
,	O
HPCA	O
(	O
hippocalcin	O
)	O
and	O
COL6A3	O
(	O
collagen	O
VI	O
alpha	O
3	O
)	O
.	O

Our	O
data	O
support	O
ARV1	O
deficiency	O
as	O
a	O
cause	O
of	O
autosomal	B-Phenotype
recessive	I-Phenotype
epileptic	I-Phenotype
encephalopathy	E-Phenotype

PRUNE	O
is	O
a	O
member	O
of	O
the	O
DHH	O
(	O
Asp	O
-	O
His	O
-	O
His	O
)	O
phosphoesterase	O
protein	O
superfamily	O
of	O
molecules	O
important	O
for	O
cell	O
motility	O
,	O
and	O
implicated	O
in	O
cancer	S-Phenotype
progression	O
.	O

In	O
this	O
study	O
,	O
recombinant	O
KLK4	O
protein	O
was	O
generated	O
and	O
affinity	O
-	O
purified	O
KLK4	O
-	O
directed	O
polyclonal	O
antibody	O
pAb587	O
established	O
to	O
allow	O
localization	O
of	O
KLK4	O
protein	O
expression	O
in	O
tumor	S-Phenotype
cell	O
lines	O
and	O
archived	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
TNBC	O
tumor	S-Phenotype
tissue	O
specimens	O
.	O

In	O
2005	O
,	O
CLTC	O
clients	O
were	O
significantly	O
more	O
likely	O
to	O
have	O
chronic	O
conditions	O
,	O
including	O
hypertension	S-Phenotype
,	O
chronic	B-Phenotype
obstructive	I-Phenotype
pulmonary	I-Phenotype
disease	E-Phenotype
,	O
Alzheimer	B-Phenotype
's	I-Phenotype
disease	E-Phenotype
,	O
arthritis	S-Phenotype
,	O
diabetes	S-Phenotype
,	O
and	O
renal	B-Phenotype
failure	E-Phenotype
(	O
all	O
p	O
AAAA	O
0.05	O
)	O
.	O

ERCC6	O
rs1917799	O
also	O
showed	O
a	O
significant	O
interaction	O
with	O
ERCC8	O
rs158916	O
to	O
reduce	O
gastric	B-Phenotype
cancer	E-Phenotype
risk	O
.	O

Human	O
-	O
induced	O
neuronal	O
progenitor	O
cells	O
(	O
iNPCs	O
)	O
carrying	O
dominant	O
and	O
recessive	O
GARS	O
mutations	O
showed	O
alterations	O
of	O
mitochondrial	O
proteins	O
,	O
which	O
were	O
more	O
prominent	O
in	O
iNPCs	O
with	O
dominant	O
,	O
neuropathy	S-Phenotype
-	O
causing	O
mutations	O
.	O

Kleefstra	O
syndrome	O
,	O
a	O
disease	O
with	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
autism	B-Phenotype
spectrum	I-Phenotype
disorders	E-Phenotype
and	O
other	O
developmental	O
defects	O
is	O
caused	O
in	O
humans	O
by	O
haploinsufficiency	O
of	O
EHMT1	O
.	O

Among	O
the	O
proteins	O
enriched	O
in	O
LO	O
,	O
cytokeratin	O
18	O
(	O
CK18	O
)	O
was	O
one	O
of	O
the	O
most	O
abundant	O
(	O
within	O
the	O
top	O
5th	O
percentile	O
)	O
and	O
was	O
used	O
to	O
develop	O
an	O
assay	O
to	O
detect	O
LO	O
in	O
the	O
circulation	O
and	O
tissues	O
of	O
mice	O
and	O
patients	O
with	O
prostate	B-Phenotype
cancer	E-Phenotype
.	O

We	O
report	O
an	O
~1.3	O
Mb	O
tandem	O
duplication	O
at	O
Xp11.23p11.3	O
in	O
an	O
11	O
-	O
year	O
-	O
old	O
boy	O
with	O
pleasant	O
personality	O
,	O
hyperactivity	S-Phenotype
,	O
learning	B-Phenotype
and	I-Phenotype
visual	I-Phenotype
-	I-Phenotype
spatial	I-Phenotype
difficulties	E-Phenotype
,	O
relative	O
microcephaly	S-Phenotype
,	O
long	B-Phenotype
face	E-Phenotype
,	O
stellate	B-Phenotype
iris	E-Phenotype
pattern	O
,	O
and	O
periorbital	B-Phenotype
fullness	E-Phenotype
.	O

Occurring	O
in	O
the	O
sinonasal	O
area	O
of	O
middle	O
-	O
aged	O
patients	O
,	O
SNS	O
is	O
a	O
locally	O
aggressive	O
tumor	S-Phenotype
harboring	O
in	O
90	O
%	O
of	O
cases	O
recurrent	O
gene	O
fusions	O
involving	O
the	O
PAX3	O
gene	O
,	O
in	O
which	O
the	O
chimeric	O
transcription	O
factor	O
induces	O
an	O
aberrant	O
dual	O
myogenic	O
and	O
neural	O
phenotype	O
.	O

Mutations	O
in	O
MYH2	O
are	O
associated	O
with	O
skeletal	B-Phenotype
myopathies	E-Phenotype
,	O
characterized	O
by	O
ophthalmoplegia	S-Phenotype
.	O

Our	O
results	O
show	O
that	O
PSMC3IP	O
and	O
EPSTI1	O
are	O
able	O
to	O
modulate	O
the	O
extrinsic	O
apoptotic	O
pathway	O
in	O
estrogen	O
receptor	O
positive	O
and	O
triple	O
negative	O
breast	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
,	O
highlighting	O
them	O
as	O
potential	O
therapeutic	O
targets	O
.	O

Although	O
MC1R	O
carriers	O
were	O
represented	O
proportionally	O
among	O
the	O
four	O
molecular	O
tumor	S-Phenotype
subtypes	O
,	O
these	O
individuals	O
accounted	O
for	O
69	O
%	O
of	O
ultraviolet	O
(	O
UV	O
)	O
radiation	O
mutational	O
signatures	O
among	O
triple	O
-	O
wild	O
type	O
tumors	S-Phenotype
(	O
p	O
=	O
.040	O
)	O
,	O
highlighting	O
the	O
increased	O
sensitivity	O
to	O
UV	O
exposure	O
among	O
individuals	O
with	O
loss	O
-	O
of	O
-	O
function	O
variants	O
in	O
MC1R	O

Thus	O
,	O
upregulation	O
of	O
this	O
miRNA	O
to	O
selectively	O
increase	O
osteoclast	O
-	O
like	O
activity	O
in	O
calcified	O
vessels	O
of	O
CKD	O
-	O
MBD	O
could	O
alleviate	O
vascular	B-Phenotype
calcification	E-Phenotype
without	O
altering	O
bone	O
structure	O

Furthermore	O
,	O
KPNA3	O
knockout	O
in	O
SCA3	O
mice	O
resulted	O
in	O
an	O
amelioration	O
of	O
molecular	B-Phenotype
and	I-Phenotype
behavioral	I-Phenotype
disturbances	E-Phenotype
such	O
as	O
total	O
activity	O
,	O
anxiety	S-Phenotype
,	O
and	O
gait	O
.	O

However	O
,	O
the	O
prevalence	O
and	O
spectrum	O
of	O
NKX2	O
-	O
5	O
mutations	O
associated	O
with	O
sporadic	S-Phenotype
DCM	O
remain	O
to	O
be	O
evaluated	O
.	O

Moreover	O
,	O
we	O
demonstrated	O
that	O
pharmacological	O
inhibition	O
of	O
15	O
-	O
PGDH	O
enhanced	O
CYP26A1	O
expression	O
,	O
leading	O
to	O
depletion	O
of	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
and	O
expansion	O
of	O
the	O
ALDH1	O
-	O
positive	O
subset	O
in	O
both	O
human	O
PDAC	O
cells	O
and	O
tumor	S-Phenotype
cells	O
of	O
KrassupLSL	O
-	O
G12D	O
/	O
+	O
/	O
sup	O
;	O
Ptf1asupCre	O
/	O
+	O
/	O
sup	O
(	O
KC	O
)	O
mice	O
.	O

Using	O
mouse	O
models	O
of	O
spinocerebellar	B-Phenotype
ataxia	I-Phenotype
type	I-Phenotype
1	I-Phenotype
(	I-Phenotype
SCA1	I-Phenotype
)	I-Phenotype
and	I-Phenotype
2	I-Phenotype
(	I-Phenotype
SCA2	I-Phenotype
)	E-Phenotype
we	O
identify	O
an	O
increase	O
in	O
PKC	O
-	O
mediated	O
substrate	O
phosphorylation	O
in	O
two	O
different	O
forms	O
of	O
inherited	B-Phenotype
cerebellar	I-Phenotype
ataxia	E-Phenotype
.	O

These	O
results	O
demonstrated	O
the	O
existence	O
of	O
a	O
p53	O
-	O
independent	O
mechanism	O
that	O
links	O
cell	O
growth	O
to	O
cell	O
proliferation	O
in	O
mammalian	O
cells	O
,	O
and	O
suggested	O
that	O
selective	O
targeting	O
of	O
the	O
RNA	O
polymerase	O
I	O
transcription	O
machinery	O
might	O
be	O
advisable	O
to	O
hinder	O
proliferation	O
of	O
p53	O
-	O
deficient	O
cancer	S-Phenotype
cells	O

Based	O
upon	O
the	O
development	O
-	O
dependent	O
onsets	O
of	O
these	O
psychotomimetic	O
effects	O
,	O
by	O
using	O
a	O
DNA	O
microarray	O
technique	O
,	O
we	O
identified	O
the	O
WD	O
repeat	O
domain	O
3	O
(	O
WDR3	O
)	O
and	O
chitobiosyldiphosphodolichol	O
beta	O
-	O
mannosyltransferase	O
(	O
ALG1	O
)	O
genes	O
as	O
novel	O
candidates	O
for	O
schizophrenia	S-Phenotype
-	O
related	O
molecules	O
,	O
whose	O
mRNAs	O
were	O
up	O
-	O
regulated	O
in	O
the	O
adult	O
(	O
postnatal	O
week	O
seven	O
)	O
,	O
but	O
not	O
in	O
the	O
infant	O
(	O
postnatal	O
week	O
one	O
)	O
rats	O
by	O
an	O
indirect	O
dopamine	O
agonist	O
,	O
and	O
phencyclidine	O
,	O
an	O
antagonist	O
of	O
the	O
NMDA	O
receptor	O
.	O

Conclusions	O
:	O
Two	O
stable	O
multidrug	O
resistant	O
cell	O
lines	O
of	O
pancreatic	B-Phenotype
cancer	E-Phenotype
,	O
JF305	O
/	O
CDDP	O
and	O
PANC	O
-	O
1	O
/	O
GEM	O
,	O
were	O
successfully	O
established	O
.	O

This	O
led	O
to	O
the	O
identification	O
of	O
compound	O
heterozygous	O
mutations	O
in	O
WDR81	O
,	O
a	O
gene	O
previously	O
associated	O
with	O
cerebellar	B-Phenotype
ataxia	E-Phenotype
,	O
intellectual	B-Phenotype
disability	E-Phenotype
and	O
quadrupedal	O
locomotion	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
transgenic	O
targeting	O
of	O
OGG1	O
to	O
mitochondria	O
confers	O
significant	O
protection	O
from	O
diet	B-Phenotype
-	I-Phenotype
induced	I-Phenotype
obesity	E-Phenotype
,	O
insulin	B-Phenotype
resistance	E-Phenotype
,	O
and	O
adipose	B-Phenotype
tissue	I-Phenotype
inflammation	E-Phenotype
.	O

SNP	O
microarray	O
and	O
whole	O
exome	O
sequencing	O
identified	O
a	O
homozygous	O
frameshift	O
mutation	O
(	O
p.L870V	O
)	O
in	O
SCARF2	O
and	O
predicted	O
damaging	O
mutations	O
in	O
several	O
genes	O
,	O
most	O
notably	O
DGCR2	O
(	O
p.P75L	O
)	O
and	O
NCAM2	O
(	O
p.S147G	O
)	O
,	O
both	O
possible	O
candidates	O
for	O
this	O
child	O
*	O
s	O
intellectual	B-Phenotype
disability	E-Phenotype
.	O

The	O
contiguous	O
deletion	O
of	O
NDP	O
and	O
its	O
neighbouring	O
genes	O
,	O
MAOA	O
/	O
B	O
and	O
EFHC2	O
,	O
reportedly	O
leads	O
to	O
syndromic	O
clinical	O
features	O
such	O
as	O
microcephaly	S-Phenotype
,	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
and	O
epilepsy	S-Phenotype
.	O

Loss	O
of	O
FBXL4	O
was	O
also	O
detected	O
in	O
primary	O
tumours	S-Phenotype
and	O
it	O
was	O
highly	O
associated	O
with	O
prognostic	O
factors	O
including	O
high	O
Gleason	O
score	O
,	O
clinical	O
stage	O
,	O
prostate	O
-	O
specific	O
antigen	O
(	O
PSA	O
)	O
and	O
extent	O
of	O
disease	O
,	O
as	O
well	O
as	O
poor	O
patient	O
survival	O
,	O
suggesting	O
that	O
FBXL4	O
loss	O
contributes	O
to	O
prostate	B-Phenotype
cancer	E-Phenotype
progression	O
.	O

But	O
the	O
role	O
of	O
MFAP5	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
remains	O
unclear	O
.	O

Five	O
individuals	O
who	O
carry	O
IRF2BPL	O
nonsense	O
variants	O
resulting	O
in	O
a	O
premature	O
stop	O
codon	O
display	O
severe	O
neurodevelopmental	B-Phenotype
regression	E-Phenotype
,	O
hypotonia	S-Phenotype
,	O
progressive	B-Phenotype
ataxia	E-Phenotype
,	O
seizures	S-Phenotype
,	O
and	O
a	B-Phenotype
lack	I-Phenotype
of	I-Phenotype
coordination	E-Phenotype
.	O

All	O
lines	O
of	O
evidence	O
suggest	O
that	O
WNT7A	O
has	O
important	O
role	O
in	O
tooth	O
development	O
and	O
its	O
mutation	O
may	O
lead	O
to	O
tooth	B-Phenotype
agenesis	E-Phenotype
,	O
microdontia	S-Phenotype
,	O
and	O
taurodontism	S-Phenotype
.	O

Remarkably	O
,	O
our	O
results	O
also	O
show	O
that	O
antioxidants	O
[	O
such	O
as	O
N	O
-	O
acetyl	O
cysteine	O
(	O
NAC	O
)	O
]	O
can	O
effectively	O
reverse	O
or	O
prevent	O
ethanol	B-Phenotype
-	I-Phenotype
induced	I-Phenotype
oxidative	I-Phenotype
stress	E-Phenotype
in	O
cancer	S-Phenotype
-	O
associated	O
fibroblasts	O
,	O
suggesting	O
a	O
novel	O
strategy	O
for	O
cancer	S-Phenotype
prevention	O
.	O

Targeted	O
expression	O
of	O
a	O
human	O
NGLY1	O
transgene	O
to	O
tissues	O
involved	O
in	O
ecdysteroidogenesis	O
,	O
lie.g	O
.	O

Missense	O
mutations	O
that	O
disrupt	O
the	O
RING	O
domain	O
of	O
the	O
tumor	S-Phenotype
suppressor	O
gene	O
BRCA1	O
lead	O
to	O
increased	O
risk	O
of	O
breast	B-Phenotype
and	I-Phenotype
ovarian	I-Phenotype
cancer	E-Phenotype
.	O

We	O
identified	O
mutations	O
of	O
WTX	O
in	O
32	O
%	O
,	O
CTNNB1	O
in	O
15	O
%	O
,	O
WT1	O
in	O
12	O
%	O
and	O
TP53	O
in	O
5	O
%	O
of	O
tumors	S-Phenotype
.	O

Importantly	O
,	O
the	O
role	O
of	O
sexual	O
dimorphism	O
in	O
the	O
genetic	O
regulation	O
of	O
obesity	S-Phenotype
and	O
body	O
fat	O
distribution	O
was	O
also	O
reported	O
in	O
a	O
few	O
studies	O
.	O

Here	O
,	O
we	O
show	O
that	O
human	O
spSCC	O
tumours	S-Phenotype
also	O
feature	O
strong	O
nuclear	O
localisation	O
of	O
YAP	O
and	O
overexpression	O
of	O
activated	O
YAP	O
(	O
NLS	O
-	O
YAP	O
-	O
5SA	O
)	O
with	O
Keratin	O
-	O
5	O
(	O
K5	O
-	O
CreERt	O
)	O
is	O
sufficient	O
to	O
induce	O
rapid	O
formation	O
of	O
both	O
SCC	O
and	O
spSCC	O
in	O
mice	O
.	O

In	O
lung	B-Phenotype
adenocarcinoma	E-Phenotype
(	O
LADC	S-Phenotype
)	O
,	O
specific	O
thyroxin	O
kinase	O
inhibitors	O
against	O
EGFR	O
mutations	O
and	O
ALK	O
fusions	O
are	O
used	O
as	O
a	O
standard	O
treatment	O
regimen	O
and	O
show	O
significant	O
positive	O
efficacy	O
.	O

Gastric	B-Phenotype
tumor	E-Phenotype
tissues	O
and	O
paired	O
adjacent	O
non	O
-	O
tumor	S-Phenotype
tissues	O
were	O
obtained	O
from	O
21	O
gastric	B-Phenotype
cancer	E-Phenotype
patients	O
,	O
and	O
gastric	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
(	O
AGS	O
,	O
MGC	O
-	O
803	O
,	O
KATO	O
-	O
III	O
,	O
MKN	O
-	O
45	O
,	O
SGC	O
-	O
7901	O
,	O
BGC	O
-	O
823	O
and	O
MKN	O
-	O
74	O
)	O
were	O
cultured	O
.	O

The	O
scope	O
of	O
the	O
present	O
review	O
is	O
to	O
recapitulate	O
and	O
review	O
the	O
evidence	O
of	O
SPINT2	O
participation	O
in	O
cancer	S-Phenotype
development	O
and	O
progression	O
,	O
exploring	O
the	O
clinical	O
,	O
biological	O
and	O
functional	O
descriptions	O
of	O
the	O
involvement	O
of	O
this	O
protein	O
in	O
diverse	O
neoplasias	S-Phenotype
.	O

Clinical	O
specimens	O
revealed	O
that	O
AF1q	O
was	O
up	O
-	O
regulated	O
in	O
human	O
CRC	O
tissues	O
,	O
and	O
that	O
this	O
up	O
-	O
regulation	O
was	O
associated	O
with	O
tumor	S-Phenotype
metastasis	O
and	O
late	O
tumor	S-Phenotype
,	O
lymph	O
node	O
,	O
metastasis	O
(	O
TNM	O
)	O
stage	O
.	O

BACKGROUND	O
RET	O
rearrangements	O
have	O
been	O
reported	O
in	O
30	O
%	O
of	O
papillary	B-Phenotype
thyroid	I-Phenotype
carcinomas	E-Phenotype
and	O
1	O
-	O
2	O
%	O
of	O
non	B-Phenotype
-	I-Phenotype
small	I-Phenotype
cell	I-Phenotype
lung	I-Phenotype
cancer	E-Phenotype
(	O
NSCLC	S-Phenotype
)	O
.	O

It	O
usually	O
reflects	O
biallelic	O
inactivation	O
of	O
the	O
liCASR	O
.	O

Aberrant	O
expression	O
of	O
receptor	O
interacting	O
protein	O
kinase	O
4	O
(	O
RIPK4	O
)	O
,	O
a	O
crucial	O
regulatory	O
protein	O
of	O
Wnt	O
/	O
β	O
-	O
catenin	O
signaling	O
,	O
has	O
recently	O
been	O
reported	O
to	O
be	O
involved	O
in	O
several	O
cancers	S-Phenotype
.	O

Friedreich	B-Phenotype
's	I-Phenotype
ataxia	E-Phenotype
(	O
FA	S-Phenotype
)	O
is	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
disease	O
caused	O
by	O
an	O
intronic	O
GAA	O
triplet	O
expansion	O
in	O
the	O
FXN	O
gene	O
,	O
leading	O
to	O
reduced	O
expression	O
of	O
the	O
mitochondrial	O
protein	O
frataxin	O
.	O

In	O
zebrafish	O
,	O
downregulation	O
of	O
slc7a14	O
expression	O
leads	O
to	O
an	O
abnormal	B-Phenotype
eye	E-Phenotype
phenotype	O
and	O
defective	O
light	O
-	O
induced	O
locomotor	O
response	O
.	O

The	O
MATR3	O
gene	O
is	O
mutated	O
in	O
a	O
form	O
of	O
distal	B-Phenotype
myopathy	E-Phenotype
and	O
amyotrophic	B-Phenotype
lateral	I-Phenotype
sclerosis	E-Phenotype
(	O
ALS	S-Phenotype
)	O
.	O

Independent	O
and	O
pooled	O
analyses	O
verified	O
that	O
higher	O
PYCR1	O
mRNA	O
levels	O
were	O
significantly	O
associated	O
with	O
poor	O
survival	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
patients	O
,	O
regardless	O
of	O
estrogen	O
receptor	O
(	O
ER	O
)	O
status	O
.	O

In	O
this	O
study	O
we	O
present	O
the	O
first	O
two	O
cases	O
from	O
India	O
of	O
a	O
rare	O
inborn	O
error	O
of	O
metabolism	O
manifesting	O
as	O
dystonia	S-Phenotype
and	O
3	B-Phenotype
-	I-Phenotype
methylglutaconic	I-Phenotype
aciduria	E-Phenotype
and	O
a	O
Leigh	O
like	O
lesions	O
in	O
the	O
brain	O
MRI	O
associated	O
with	O
SERAC1	O
gene	O
mutation	O
,	O
a	O
phenotype	O
characteristic	O
of	O
MEGDEL	O
syndrome	O
.	O

RHOA	O
,	O
SMAD2	O
,	O
SMAD4	O
,	O
SMAD5	O
,	O
SMAD6	O
,	O
BMPR1A	O
,	O
SMAD7	O
and	O
MYC	O
-	O
,	O
which	O
thereby	O
emerge	O
as	O
candidate	O
genes	O
to	O
play	O
an	O
important	O
role	O
in	O
CRC	O
tumor	S-Phenotype
metastasis	O

Based	O
upon	O
the	O
development	O
-	O
dependent	O
onsets	O
of	O
these	O
psychotomimetic	O
effects	O
,	O
by	O
using	O
a	O
DNA	O
microarray	O
technique	O
,	O
we	O
identified	O
the	O
WD	O
repeat	O
domain	O
3	O
(	O
WDR3	O
)	O
and	O
chitobiosyldiphosphodolichol	O
beta	O
-	O
mannosyltransferase	O
(	O
ALG1	O
)	O
genes	O
as	O
novel	O
candidates	O
for	O
schizophrenia	S-Phenotype
-	O
related	O
molecules	O
,	O
whose	O
mRNAs	O
were	O
up	O
-	O
regulated	O
in	O
the	O
adult	O
(	O
postnatal	O
week	O
seven	O
)	O
,	O
but	O
not	O
in	O
the	O
infant	O
(	O
postnatal	O
week	O
one	O
)	O
rats	O
by	O
an	O
indirect	O
dopamine	O
agonist	O
,	O
and	O
phencyclidine	O
,	O
an	O
antagonist	O
of	O
the	O
NMDA	O
receptor	O
.	O

Germline	O
mutations	O
in	O
KCNJ5	O
and	O
CACNA1H	O
cause	O
FH	O
-	O
III	O
and	O
FH	O
-	O
IV	O
,	O
respectively	O
,	O
while	O
germline	O
mutations	O
in	O
CACNA1D	O
cause	O
the	O
rare	O
PASNA	O
syndrome	O
,	O
featuring	O
primary	B-Phenotype
aldosteronism	I-Phenotype
seizures	E-Phenotype
and	O
neurological	B-Phenotype
abnormalities	E-Phenotype
.	O

Furthermore	O
,	O
we	O
detected	O
association	O
of	O
rs58978565	O
near	O
TNR	O
(	O
P	O
=	O
2.3	O
×	O
10	O
-	O
8	O
)	O
,	O
rs28368872	O
near	O
ATF7IP2	O
(	O
P	O
=	O
2.9	O
×	O
10	O
-	O
8	O
)	O
and	O
rs142450006	O
near	O
MMP9	O
(	O
P	O
=	O
0.0006	O
)	O
with	O
progression	O
to	O
choroidal	B-Phenotype
neovascularization	E-Phenotype
but	O
not	B-Phenotype
geographic	I-Phenotype
atrophy	E-Phenotype
.	O

We	O
therefore	O
screened	O
patients	O
with	O
hereditary	O
PHPV	O
,	O
as	O
well	O
as	O
bilateral	B-Phenotype
optic	I-Phenotype
nerve	I-Phenotype
aplasia	I-Phenotype
(	I-Phenotype
ONA	I-Phenotype
)	I-Phenotype
or	I-Phenotype
hypoplasia	I-Phenotype
(	I-Phenotype
ONH	I-Phenotype
)	E-Phenotype
,	O
for	O
mutations	O
in	O
ATOH7	O
.	O

These	O
disorders	O
include	O
cancer	S-Phenotype
,	O
bipolar	B-Phenotype
disorder	E-Phenotype
,	O
schizophrenia	S-Phenotype
,	O
autism	S-Phenotype
,	O
Cri	B-Phenotype
-	I-Phenotype
du	I-Phenotype
-	I-Phenotype
chat	I-Phenotype
syndrome	E-Phenotype
,	O
myopia	S-Phenotype
,	O
cortical	B-Phenotype
cataract	I-Phenotype
-	I-Phenotype
linked	I-Phenotype
Alzheimer	I-Phenotype
's	I-Phenotype
disease	E-Phenotype
,	O
and	O
infectious	B-Phenotype
diseases	E-Phenotype
.	O

This	O
study	O
identifies	O
a	O
set	O
of	O
candidate	O
genes	O
and	O
their	O
potential	O
regulatory	O
variants	O
,	O
and	O
provides	O
additional	O
evidence	O
showing	O
the	O
role	O
of	O
long	O
-	O
range	O
chromatin	O
interactions	O
in	O
prostate	B-Phenotype
cancer	E-Phenotype
etiology	O

The	O
presented	O
workflow	O
employed	O
three	O
different	O
peptide	O
microarray	O
formats	O
to	O
discover	O
and	O
resolve	O
the	O
epitopes	O
of	O
human	O
autoantibodies	O
and	O
revealed	O
two	O
potentially	O
new	O
autoantigens	O
:	O
MAP3K7	O
in	O
multiple	O
sclerosis	O
and	O
NRXN1	O
in	O
narcolepsy	S-Phenotype
.	O

In	O
our	O
study	O
,	O
the	O
protein	O
expression	O
of	O
NasubV	O
/	O
sub1.3	O
,	O
NasubV	O
/	O
sub1.6	O
and	O
CaM	O
was	O
significantly	O
increased	O
in	O
the	O
tumor	S-Phenotype
compared	O
to	O
control	O
tissue	O
,	O
while	O
the	O
level	O
of	O
p	O
-	O
CaMKII	O
/	O
CaMKII	O
was	O
significantly	O
decreased	O
in	O
the	O
tumor	S-Phenotype
group	O
as	O
determined	O
by	O
Western	O
Blotting	O
and	O
immunohistochemistry	O
.	O

We	O
found	O
that	O
KLK10	O
was	O
significantly	O
overexpressed	O
in	O
tissues	O
of	O
pancreatic	B-Phenotype
intraepithelial	I-Phenotype
neoplasia	E-Phenotype
(	O
PanIN	S-Phenotype
)	O
and	O
PDAC	O
from	O
Pdx1	O
-	O
Cre	O
;	O
LSL	O
-	O
KrassupG12D	O
/	O
+	O
/	O
sup	O
mice	O
(	O
KC	O
)	O
and	O
Pdx1	O
-	O
Cre	O
;	O
LSL	O
-	O
KrassupG12D	O
/	O
+	O
/	O
sup	O
;	O
LSL	O
-	O
Trp53supR172H	O
/	O
+	O
/	O
sup	O
mice	O
(	O
KPC	O
)	O
by	O
immunohistochemical	O
analysis	O
.	O

Trichothiodystrophy	O
(	O
TTD	O
)	O
,	O
also	O
known	O
as	O
sulfur	B-Phenotype
-	I-Phenotype
deficient	I-Phenotype
brittle	I-Phenotype
hair	E-Phenotype
syndrome	O
,	O
is	O
a	O
rare	O
autosomal	B-Phenotype
recessive	E-Phenotype
multisystem	O
disorder	O
,	O
which	O
manifests	O
with	O
brittle	B-Phenotype
hair	E-Phenotype
,	O
mental	B-Phenotype
retardation	E-Phenotype
,	O
ichthyosis	S-Phenotype
and	O
decreased	B-Phenotype
fertility	E-Phenotype
.	O

The	O
expression	O
signature	O
of	O
microRNAs	O
linked	O
with	O
TGF	O
-	O
b1	O
levels	O
correlated	O
with	O
poor	O
survival	O
of	O
renal	B-Phenotype
cancer	E-Phenotype
patients	O
.	O

COQ8A	O
(	O
ADCK3	O
)	O
is	O
a	O
mammalian	O
UbiB	O
protein	O
associated	O
with	O
ubiquinone	O
(	O
CoQ	O
)	O
biosynthesis	O
and	O
an	O
ataxia	S-Phenotype
(	O
ARCA2	O
)	O
through	O
unclear	O
means	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
microRNA	O
(	O
miR	O
)	O
-	O
587	O
confers	O
resistance	O
to	O
5	O
-	O
fluorouracil	O
(	O
5	O
-	O
FU	O
)	O
-	O
induced	O
apoptosis	O
in	O
vitro	O
and	O
reduces	O
the	O
potency	O
of	O
5	O
-	O
FU	O
in	O
the	O
inhibition	O
of	O
tumor	S-Phenotype
growth	O
in	O
a	O
mouse	O
xenograft	O
model	O
in	O
vivo	O
.	O

The	O
tumor	S-Phenotype
necrosis	O
factor	O
(	O
TNF	O
)	O
family	O
ligand	O
ectodysplasin	O
A	O
(	O
EDA	O
)	O
is	O
produced	O
as	O
2	O
full	O
-	O
length	O
splice	O
variants	O
,	O
EDA1	O
and	O
EDA2	O
,	O
that	O
bind	O
to	O
EDA	O
receptor	O
(	O
EDAR	O
)	O
and	O
X	O
-	O
linked	O
EDA	O
receptor	O
(	O
XEDAR	O
/	O
EDA2R	O
)	O
,	O
respectively	O
.	O

Finally	O
,	O
by	O
immunohistochemical	O
staining	O
of	O
primary	O
breast	O
tissue	O
microarrays	O
we	O
find	O
that	O
EMSY	O
/	O
KDM5A	O
/	O
SIN3B	O
complex	O
subunits	O
are	O
frequently	O
overexpressed	O
in	O
primary	O
breast	B-Phenotype
cancer	E-Phenotype
cases	O
in	O
a	O
correlative	O
manner	O
.	O

Deleted	O
in	O
lung	B-Phenotype
and	I-Phenotype
esophageal	I-Phenotype
cancer	E-Phenotype
1	O
(	O
DLEC1	O
)	O
is	O
a	O
tumor	S-Phenotype
suppressor	O
gene	O
with	O
reduced	O
transcriptional	O
activity	O
and	O
promoter	O
hypermethylation	O
in	O
various	O
cancers	S-Phenotype
,	O
including	O
colorectal	O
cancer	S-Phenotype
.	O

Loss	O
of	O
function	O
of	O
FGFRL1	O
significantly	O
influenced	O
cell	O
proliferation	O
,	O
apoptosis	O
,	O
and	O
migration	O
of	O
OC	O
cells	O
in	O
vitro	O
and	O
tumor	S-Phenotype
growth	O
in	O
vivo	O
.	O

Tumor	S-Phenotype
-	O
initiating	O
cells	O
(	O
TIC	S-Phenotype
)	O
represent	O
a	O
subset	O
of	O
tumor	S-Phenotype
cells	O
with	O
increased	O
self	O
-	O
renewal	O
capability	O
.	O

Eight	O
of	O
the	O
genes	O
,	O
APC	O
,	O
TP53	O
,	O
ATM	O
,	O
CSMD3	O
,	O
LRP1B	O
,	O
RYR2	O
,	O
BIRC6	O
,	O
and	O
MUC17	O
,	O
contained	O
mutations	O
in	O
AAAA20	O
%	O
of	O
the	O
carcinomas	S-Phenotype
.	O

We	O
found	O
monoallelic	O
truncating	O
/	O
functionally	O
deleterious	O
mutations	O
in	O
seven	O
genes	O
,	O
including	O
ATM	O
and	O
CHEK2	O
,	O
which	O
have	O
previously	O
been	O
associated	O
with	O
PrCa	O
predisposition	O
,	O
and	O
five	O
new	O
candidate	O
PrCa	O
associated	O
genes	O
involved	O
in	O
cancer	S-Phenotype
predisposing	O
recessive	O
disorders	O
,	O
namely	O
RAD51C	O
,	O
FANCD2	O
,	O
FANCI	O
,	O
CEP57	O
and	O
RECQL4	O
.	O

The	O
abnormal	O
regulation	O
of	O
miR	O
-	O
483	O
may	O
play	O
an	O
important	O
role	O
in	O
tumorigenesis	S-Phenotype
,	O
and	O
Par3	O
is	O
known	O
to	O
regulate	O
cell	O
polarity	O
,	O
cell	O
migration	O
,	O
and	O
cell	O
division	O
.	O

In	O
addition	O
,	O
FREM2	O
gene	O
and	O
protein	O
expression	O
levels	O
are	O
higher	O
in	O
GB	O
stem	O
-	O
like	O
cell	O
lines	O
than	O
in	O
conventional	O
glioblastoma	S-Phenotype
cell	O
lines	O
.	O

To	O
better	O
understand	O
the	O
biological	O
role	O
of	O
this	O
factor	O
,	O
we	O
generated	O
Tmem70	O
-	O
deficient	O
mice	O
and	O
found	O
that	O
the	O
homozygous	O
Tmem70	O
-	O
/	O
-	O
knockouts	O
exhibited	O
profound	B-Phenotype
growth	I-Phenotype
retardation	E-Phenotype
and	O
embryonic	O
lethality	O
at	O
∼9.5	O
days	O
post	O
coitum	O
.	O

The	O
levels	O
of	O
KLF9	O
expression	O
in	O
adjacent	O
tissues	O
and	O
pancreatic	B-Phenotype
cancer	E-Phenotype
tissues	O
were	O
detected	O
using	O
immunohistochemistry	O
.	O

Furthermore	O
,	O
mutations	O
in	O
KCNK3	O
have	O
been	O
identified	O
as	O
a	O
rare	O
cause	O
of	O
both	O
familial	B-Phenotype
and	I-Phenotype
idiopathic	I-Phenotype
pulmonary	I-Phenotype
arterial	I-Phenotype
hypertension	E-Phenotype
.	O

Furthermore	O
,	O
XIAP	O
enhanced	O
cancer	S-Phenotype
cell	O
proliferation	O
,	O
viability	O
,	O
and	O
colony	O
formation	O
in	O
vitro	O
via	O
suppression	O
of	O
p62	O
.	O

These	O
findings	O
uncover	O
a	O
pivotal	O
role	O
for	O
SMYD2	O
in	O
promoting	O
pancreatic	B-Phenotype
cancer	E-Phenotype
.	O

Thus	O
,	O
our	O
data	O
indicate	O
that	O
miR	O
-	O
132	O
induces	O
temozolomide	O
resistance	O
and	O
promotes	O
the	O
formation	O
of	O
cancer	S-Phenotype
stem	O
cell	O
phenotypes	O
by	O
targeting	O
TUSC3	O
in	O
glioblastoma	S-Phenotype

Both	O
the	O
primary	O
tumor	S-Phenotype
and	O
the	O
JU	O
-	O
PI	O
cells	O
showed	O
nuclear	O
expression	O
of	O
the	O
TFE3	O
transcription	O
factor	O
but	O
TFE3	O
-	O
activating	O
chromosomal	O
rearrangements	O
were	O
not	O
found	O
.	O

Up	O
to	O
half	O
of	O
patients	O
with	O
PC	O
/	O
PGL	O
and	O
renal	B-Phenotype
neoplasia	E-Phenotype
had	O
VHL	O
syndrome	O
,	O
SDH	O
deficiency	O
,	O
or	O
alterations	O
in	O
TMEM127	O
.	O

These	O
findings	O
,	O
together	O
with	O
the	O
role	O
of	O
NOX2	O
in	O
maintaining	O
self	O
-	O
tolerance	O
,	O
imply	O
that	O
NOX2	O
is	O
a	O
targetable	O
immune	O
checkpoint	O
in	O
cancer	S-Phenotype
.	O

Tumor	S-Phenotype
growth	O
in	O
xenografts	O
as	O
well	O
as	O
EGFR	O
signaling	O
were	O
assessed	O
in	O
HCT116	O
cells	O
expressing	O
IL17RD	O
with	O
either	O
a	O
mutant	O
3	O
'	O
untranslated	O
region	O
(	O
UTR	O
)	O
or	O
wild	O
-	O
type	O
(	O
WT	O
)	O
3'UTR.Results	O
:	O
miR	O
-	O
31	O
,	O
miR	O
-	O
34a	O
,	O
miR	O
-	O
106b	O
,	O
and	O
miR	O
-	O
193a	O
-	O
3p	O
were	O
significantly	O
dysregulated	O
in	O
ulcerative	B-Phenotype
colitis	I-Phenotype
-	I-Phenotype
neoplasia	E-Phenotype
and	O
adjacent	O
tissue	O
.	O

We	O
summarize	O
the	O
phenotypic	O
extent	O
of	O
GLI2	O
/	O
3	O
syndromes	O
in	O
the	O
literature	O
and	O
determine	O
that	O
these	O
2	O
syndromes	O
manifest	O
opposite	O
features	O
to	O
a	O
certain	O
extent	O
,	O
such	O
as	O
midface	B-Phenotype
hypoplasia	E-Phenotype
or	O
macrocephaly	S-Phenotype
,	O
and	O
anterior	B-Phenotype
or	I-Phenotype
posterior	I-Phenotype
side	I-Phenotype
of	I-Phenotype
polydactyly	E-Phenotype
.	O

This	O
study	O
examined	O
HS	O
content	O
and	O
distribution	O
in	O
glioblastoma	B-Phenotype
multiforme	E-Phenotype
(	O
GBM	S-Phenotype
)	O
tissues	O
in	O
the	O
context	O
of	O
potential	O
molecular	O
mechanisms	O
underlying	O
its	O
deregulation	O
in	O
brain	B-Phenotype
tumours	E-Phenotype
.	O

In	O
this	O
study	O
,	O
we	O
find	O
that	O
distinct	O
expression	O
patterns	O
of	O
those	O
deafness	S-Phenotype
genes	O
in	O
the	O
cochlea	O
of	O
a	O
non	O
-	O
human	O
primate	O
,	O
the	O
common	O
marmoset	O
(	O
Callithrix	O
jacchus	O
)	O
.	O

Functional	O
assays	O
revealed	O
that	O
ectopic	O
expression	O
of	O
miR	O
-	O
144	O
-	O
5p	O
and	O
miR	O
-	O
144	O
-	O
3p	O
significantly	O
blocked	O
the	O
malignant	O
abilities	O
of	O
LUSQ	O
cells	O
,	O
eg	O
,	O
cancer	S-Phenotype
cell	O
proliferation	O
,	O
migration	O
,	O
and	O
invasion	O
.	O

Alterations	O
in	O
mTOR	O
signaling	O
are	O
involved	O
both	O
in	O
cancer	S-Phenotype
progression	O
and	O
in	O
osteoclast	O
differentiation	O
.	O

Our	O
data	O
implicate	O
rare	O
variants	O
in	O
the	O
AGS	O
genes	O
ADAR	O
and	O
RNASEH2B	O
and	O
a	O
type	O
I	O
interferon	O
signature	O
in	O
glioma	S-Phenotype
and	O
prostate	B-Phenotype
carcinoma	E-Phenotype
risk	O
and	O
tumorigenesis	S-Phenotype
,	O
consistent	O
with	O
a	O
genetic	O
basis	O
underlying	O
inflammation	O
-	O
driven	O
malignant	O
transformation	O
in	O
glioma	S-Phenotype
and	O
prostate	B-Phenotype
carcinoma	E-Phenotype
development	O

ALG3	O
expression	O
was	O
significantly	O
increased	O
in	O
cancer	S-Phenotype
samples	O
with	O
advanced	O
stages	O
(	O
stage	O
III	O
/	O
IV	O
)	O
compared	O
with	O
those	O
in	O
the	O
early	O
stages	O
of	O
disease	O
(	O
stage	O
I	O
/	O
II	O
)	O
(	O
pAAAA0.05	O
)	O
.	O

bObjective	O
:	O
/	O
b	O
To	O
investigate	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
Chinese	O
familial	O
hypertrophic	B-Phenotype
cardiomyopathy	E-Phenotype
(	O
HCM	S-Phenotype
)	O
focusing	O
on	O
the	O
cardiac	O
troponin	O
C	O
gene	O
TNNC1	O
c	O
.	O

The	O
most	O
common	O
vestibular	O
disturbances	O
after	O
SRC	O
include	O
benign	B-Phenotype
paroxysmal	I-Phenotype
positional	I-Phenotype
vertigo	E-Phenotype
,	O
vestibulo	B-Phenotype
-	I-Phenotype
ocular	I-Phenotype
reflex	I-Phenotype
impairment	E-Phenotype
,	O
visual	B-Phenotype
motion	I-Phenotype
sensitivity	E-Phenotype
,	O
and	O
balance	B-Phenotype
impairment	E-Phenotype
.	O

In	O
this	O
study	O
,	O
we	O
conducted	O
targeted	O
sequencing	O
in	O
246	O
clinically	O
heterogeneous	S-Phenotype
patients	O
,	O
mainly	O
with	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
and	I-Phenotype
/	I-Phenotype
or	I-Phenotype
familial	I-Phenotype
neurodegenerative	I-Phenotype
dementia	E-Phenotype
,	O
using	O
a	O
custom	O
-	O
designed	O
next	O
-	O
generation	O
sequencing	O
panel	O
covering	O
27	O
genes	O
known	O
to	O
harbor	O
mutations	O
that	O
can	O
cause	O
different	O
types	O
of	O
dementia	S-Phenotype
,	O
in	O
addition	O
to	O
the	O
detection	O
of	O
C9orf72	O
repeat	O
expansions	O
.	O

Phase	O
2	O
occurs	O
postnatally	O
through	O
adult	O
stages	O
with	O
bone	O
marrow	O
production	O
of	O
granulocyte	O
precursors	O
and	O
positive	O
selection	O
of	O
mutants	O
due	O
to	O
chronic	O
G	O
-	O
CSF	O
therapy	O
to	O
reverse	O
the	O
severe	O
neutropenia	S-Phenotype
.	O

CNGB3	O
encoding	O
the	O
beta	O
subunit	O
of	O
the	O
cyclic	O
nucleotide	O
-	O
gated	O
ion	O
channel	O
in	O
cone	O
photoreceptors	O
is	O
the	O
major	O
achromatopsia	S-Phenotype
gene	O
.	O

More	O
deleterious	O
CPB1	O
variants	O
,	O
defined	O
as	O
having	O
impaired	O
protein	O
secretion	O
and	O
induction	O
of	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
in	O
transfected	O
HEK	O
293T	O
cells	O
,	O
were	O
found	O
in	O
the	O
hospital	O
series	O
of	O
pancreatic	B-Phenotype
cancer	E-Phenotype
cases	O
(	O
5	O
/	O
986	O
,	O
0.5	O
%	O
)	O
than	O
in	O
controls	O
(	O
0	O
/	O
1,045	O
,	O
P	O
=	O
0.027	O
)	O
.	O

Recently	O
,	O
mutations	O
of	O
DNAJC12	O
gene	O
were	O
reported	O
to	O
be	O
associated	O
with	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
parkinsonism	E-Phenotype
,	O
progressive	O
neurodevelopmental	B-Phenotype
delay	E-Phenotype
,	O
and	O
dystonia	S-Phenotype
in	O
several	O
unrelated	O
pedigrees	O
.	O

Familial	B-Phenotype
hypercholesterolemia	E-Phenotype
(	O
FH	S-Phenotype
)	O
is	O
mostly	O
caused	O
by	O
low	O
-	O
density	O
lipoprotein	O
receptor	O
(	O
LDLR	O
)	O
mutations	O
and	O
results	O
in	O
an	O
increased	O
risk	O
of	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
cardiovascular	I-Phenotype
disease	E-Phenotype
due	O
to	O
marked	O
elevation	O
of	O
LDL	O
cholesterol	O
(	O
LDL	O
-	O
C	O
)	O
in	O
blood	O
.	O

Ectopic	O
expression	O
of	O
Cx31	O
in	O
mouse	O
skin	O
results	O
in	O
skin	B-Phenotype
abnormalities	E-Phenotype
resembling	O
human	O
EKV	O
.	O

Some	O
RA	O
patients	O
are	O
likely	O
to	O
increase	O
visceral	O
fat	O
without	O
obesity	S-Phenotype
[	O
Body	O
Mass	O
Index	O
(	O
BMI	O
)	O
≥	O
25	O
]	O
.	O

The	O
best	O
candidate	O
causal	O
variants	O
for	O
ER	O
(	O
-	O
)	O
tumors	S-Phenotype
lie	O
in	O
four	O
separate	O
enhancer	O
elements	O
,	O
and	O
their	O
risk	O
alleles	O
reduce	O
expression	O
of	O
ESR1	O
,	O
RMND1	O
and	O
CCDC170	O
,	O
whereas	O
the	O
risk	O
alleles	O
of	O
the	O
strongest	O
candidates	O
for	O
the	O
remaining	O
independent	O
causal	O
variant	O
disrupt	O
a	O
silencer	O
element	O
and	O
putatively	O
increase	O
ESR1	O
and	O
RMND1	O
expression	O
.	O

Here	O
we	O
investigated	O
multiple	O
families	O
from	O
Oman	O
,	O
India	O
,	O
Iran	O
and	O
Italy	O
with	O
individuals	O
affected	O
by	O
a	O
new	O
autosomal	B-Phenotype
recessive	I-Phenotype
neurodevelopmental	I-Phenotype
and	I-Phenotype
degenerative	I-Phenotype
disorder	E-Phenotype
in	O
which	O
the	O
cardinal	O
features	O
include	O
primary	B-Phenotype
microcephaly	E-Phenotype
and	O
profound	B-Phenotype
global	I-Phenotype
developmental	I-Phenotype
delay	E-Phenotype
.	O

DICER1	O
is	O
an	O
RNase	O
III	O
endoribonuclease	O
central	O
to	O
miRNA	O
biogenesis	O
,	O
and	O
germline	O
liDICER1	O
/	O
i	O
mutations	O
result	O
in	O
a	O
cancer	S-Phenotype
predisposition	O
syndrome	O
,	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
many	O
tumor	S-Phenotype
types	O
.	O

Accordingly	O
,	O
women	O
with	O
high	O
expression	O
of	O
cry1	O
in	O
tumor	S-Phenotype
tissue	O
displayed	O
worse	O
survival	O
,	O
which	O
was	O
not	O
observed	O
in	O
men	O
.	O

In	O
our	O
study	O
,	O
we	O
aim	O
to	O
investigate	O
whether	O
variants	O
of	O
KCNA1	O
,	O
KCNA2	O
,	O
and	O
KCNV2	O
genes	O
influence	O
susceptibility	O
to	O
genetic	O
generalized	O
epilepsies	S-Phenotype
(	O
GGEs	O
)	O
and	O
the	O
efficacy	O
of	O
AEDs	O
.	O

The	O
present	O
study	O
suggests	O
that	O
the	O
SNP	O
rs1801160	O
and	O
the	O
AAAAAAIIStAAAAAA	O
haplotype	O
in	O
the	O
DPYD	O
gene	O
may	O
also	O
have	O
a	O
role	O
in	O
colorectal	B-Phenotype
cancer	E-Phenotype
risk	O

The	O
sideroblastic	B-Phenotype
anemias	E-Phenotype
are	O
a	O
heterogeneous	S-Phenotype
group	O
of	O
inherited	O
and	O
acquired	O
disorders	O
characterized	O
by	O
the	O
presence	O
of	O
ring	O
sideroblasts	O
in	O
the	O
bone	O
marrow	O
.	O

Shh	O
signalling	O
from	O
the	O
prechordal	O
plate	O
and	O
ventral	O
midline	O
of	O
the	O
diencephalon	O
is	O
required	O
for	O
appropriate	O
division	O
of	O
the	O
eyefield	O
and	O
forebrain	O
,	O
with	O
mutation	O
in	O
a	O
number	O
of	O
pathway	O
components	O
associated	O
with	O
Holoprosencephaly	S-Phenotype
,	O
a	O
clinically	O
heterogeneous	S-Phenotype
developmental	O
defect	O
characterized	O
by	O
a	O
failure	O
of	O
the	O
early	O
forebrain	O
vesicle	O
to	O
divide	O
into	O
distinct	O
halves	O
.	O

BACKGROUND	O
Previous	O
research	O
found	O
that	O
ALG3	O
is	O
associated	O
with	O
cervical	B-Phenotype
cancer	E-Phenotype
,	O
but	O
the	O
role	O
of	O
ALG3	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
was	O
still	O
unknown	O
.	O

The	O
action	O
of	O
the	O
collagen	O
binding	O
receptor	O
tyrosine	O
kinase	O
(	O
RTK	O
)	O
discoidin	O
domain	O
receptor	O
2	O
(	O
DDR2	O
)	O
in	O
both	O
tumor	S-Phenotype
and	O
tumor	S-Phenotype
stromal	O
cells	O
has	O
been	O
established	O
as	O
critical	O
for	O
breast	B-Phenotype
cancer	E-Phenotype
metastasis	O
.	O

The	O
results	O
indicated	O
two	O
mutated	O
driver	O
pathways	O
are	O
important	O
for	O
the	O
pathogenesis	O
of	O
MDS	O
:	O
pathway	O
in	O
cancer	S-Phenotype
and	O
in	O
regulation	O
of	O
actin	O
cytoskeleton	O
.	O

By	O
leveraging	O
whole	O
-	O
exome	O
sequencing	O
data	O
on	O
a	O
large	O
family	O
-	O
based	O
ASD	O
cohort	O
,	O
the	O
Simons	O
Simplex	O
Collection	O
,	O
we	O
systematically	O
evaluated	O
the	O
potential	O
role	O
of	O
PMMs	O
in	O
autism	S-Phenotype
risk	O
.	O

In	O
the	O
present	O
study	O
,	O
CUL7	O
expression	O
in	O
EC	O
tissue	O
was	O
revealed	O
to	O
be	O
significantly	O
higher	O
compared	O
with	O
nontumoral	O
tissues	S-Phenotype
,	O
as	O
detected	O
by	O
immunohistochemistry	O
(	O
IHC	O
;	O
P=0.000	O
)	O
.	O

These	O
findings	O
indicated	O
that	O
T	O
-	O
IDO1	O
expression	O
in	O
HCC	O
is	O
common	O
and	O
is	O
dominantly	O
driven	O
by	O
the	O
host	O
antitumor	O
immune	S-Phenotype
response	O
,	O
which	O
is	O
a	O
favorable	O
prognostic	O
factor	O
in	O
HCC	O

De	O
novo	O
loss	O
of	O
function	O
(	O
LOF	O
)	O
mutations	O
in	O
the	O
ASXL3	O
gene	O
cause	O
Bainbridge	O
-	O
Ropers	O
syndrome	O
,	O
a	O
severe	O
form	O
of	O
intellectual	B-Phenotype
disability	E-Phenotype
(	O
ID	S-Phenotype
)	O
and	O
developmental	B-Phenotype
delay	E-Phenotype
,	O
but	O
there	O
is	O
evidence	O
that	O
they	O
also	O
occur	O
in	O
healthy	O
individuals	O
.	O

At	O
least	O
36	O
different	O
forms	O
of	O
ADCA	O
are	O
known	O
,	O
20	O
autosomal	O
-	O
recessive	O
,	O
two	O
X	O
-	O
linked	O
,	O
and	O
several	O
forms	O
of	O
ataxia	S-Phenotype
associated	O
with	O
mitochondrial	O
defects	O
are	O
known	O
to	O
date	O
.	O

Taken	O
together	O
,	O
these	O
results	O
indicate	O
that	O
increased	O
a	O
-	O
actinin	O
-	O
1	O
expression	O
destabilizes	O
E	O
-	O
cadherin	O
-	O
based	O
adhesions	O
,	O
which	O
is	O
likely	O
to	O
promote	O
the	O
migratory	O
potential	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Finally	O
,	O
twenty	O
-	O
four	O
important	O
hub	O
genes	O
(	O
RASGRP2	O
,	O
IKZF1	O
,	O
CXCR5	O
,	O
LTB	O
,	O
BLK	O
,	O
LINGO3	O
,	O
CCR6	O
,	O
P2RY10	O
,	O
RHOH	O
,	O
JUP	O
,	O
KRT14	O
,	O
PLA2G3	O
,	O
SPRR1A	O
,	O
KRT78	O
,	O
SFN	O
,	O
CLDN4	O
,	O
IL1RN	O
,	O
PKP3	O
,	O
CBLC	O
,	O
KRT16	O
,	O
TMEM79	O
,	O
KLK8	O
,	O
LYPD3	O
and	O
LYPD5	O
)	O
were	O
treated	O
as	O
valuable	O
factors	O
involved	O
in	O
the	O
immune	O
response	O
and	O
tumor	S-Phenotype
cell	O
development	O
in	O
tumorigenesis	O
.	O

These	O
findings	O
support	O
that	O
UNC119	O
is	O
a	O
regulator	O
of	O
the	O
RASSF6	O
-	O
MDM2	O
-	O
p53	O
axis	O
and	O
functions	O
as	O
a	O
tumor	S-Phenotype
suppressor	O

We	O
suspected	O
PVOD	O
from	O
CT	O
characteristics	O
and	O
pulmonary	B-Phenotype
edema	E-Phenotype
after	O
PAH	O
-	O
targeted	O
vasodilator	O
therapy	O
,	O
and	O
then	O
started	O
oral	O
imatinib	O
treatment	O
.	O

Two	O
of	O
these	O
genes	O
were	O
independently	O
mutated	O
in	O
more	O
than	O
one	O
family	O
with	O
similar	O
phenotypes	O
,	O
which	O
substantiates	O
their	O
link	O
to	O
human	O
disease	O
(	O
AKAP6	O
in	O
intellectual	B-Phenotype
disability	E-Phenotype
and	O
UBR4	O
in	O
early	O
dementia	S-Phenotype
)	O
.	O

In	O
summary	O
,	O
our	O
results	O
reveal	O
that	O
rare	O
loss	O
-	O
of	O
-	O
function	O
variants	O
in	O
GABRA3	O
increase	O
the	O
risk	O
for	O
a	O
varying	O
combination	O
of	O
epilepsy	S-Phenotype
,	O
intellectual	B-Phenotype
disability	E-Phenotype
/	O
developmental	B-Phenotype
delay	E-Phenotype
and	O
dysmorphic	O
features	O
,	O
presenting	O
in	O
some	O
pedigrees	O
with	O
an	O
X	O
-	O
linked	O
inheritance	O
pattern	O

We	O
therefore	O
examined	O
whether	O
maternal	O
or	O
fetal	O
folate	O
status	O
,	O
together	O
with	O
indices	O
of	O
placental	O
folate	O
transport	O
,	O
were	O
modulated	O
by	O
either	O
maternal	O
pre	O
-	O
pregnancy	O
body	O
mass	O
index	O
(	O
BMI	O
i.e.	O
,	O
overweight	S-Phenotype
:	O
25	O
≤	O
BMI	O
AAAA	O
30	O
or	O
obesity	S-Phenotype
:	O
BMI	O
≥	O
30	O
kg	O
/	O
m²	O
)	O
and	O
/	O
or	O
gestational	B-Phenotype
diabetes	E-Phenotype
mellitus	O
(	O
GD	S-Phenotype
)	O
.	O

TRN	O
-	O
restricted	O
deletion	O
of	O
Ptchd1	O
leads	O
to	O
attention	B-Phenotype
deficits	E-Phenotype
and	O
hyperactivity	S-Phenotype
,	O
both	O
of	O
which	O
are	O
rescued	O
by	O
pharmacological	O
augmentation	O
of	O
SK	O
channel	O
activity	O
.	O

-	O
fetoprotein	O
,	O
CD30	O
,	O
hepatocyte	O
paraffin	O
,	O
and	O
aberrant	O
expression	O
of	O
cytokeratin	O
7	O
and	O
pankeratin	O
.	O

Mutations	O
in	O
DLG3	O
are	O
a	O
rare	O
cause	O
of	O
non	B-Phenotype
-	I-Phenotype
syndromic	I-Phenotype
X	I-Phenotype
-	I-Phenotype
linked	I-Phenotype
intellectual	I-Phenotype
disability	E-Phenotype
(	O
XLID	S-Phenotype
)	O
(	O
MRX90	O
,	O
OMIM	O
*	O
300189	O
)	O
.	O

Conclusions	O
:	O
Genetic	O
polymorphisms	O
of	O
MLH3	O
rs175057	O
and	O
MSH2	O
rs13019654	O
loci	O
can	O
predict	O
the	O
nCRT	O
response	O
,	O
while	O
MLH3	O
rs175057	O
as	O
well	O
as	O
MSH2	O
rs3771273	O
,	O
rs10188090	O
and	O
rs10191478	O
may	O
predict	O
prognosis	O
in	O
patients	O
with	O
locally	O
advanced	O
rectal	B-Phenotype
cancer	E-Phenotype
who	O
received	O
preoperative	O
chemoradiotherapy	O
.	O

LIMKs	O
and	O
SSH	O
promote	O
cancer	S-Phenotype
cell	O
invasion	O
and	O
metastasis	O
and	O
represent	O
novel	O
anti	O
-	O
cancer	S-Phenotype
targets	O
.	O

Mutations	O
in	O
genes	O
involved	O
in	O
the	O
biosynthesis	O
of	O
the	O
glycosylphosphatidylinositol	O
(	O
GPI	O
)	O
anchor	O
cause	O
autosomal	O
recessive	O
glycosylation	O
defects	O
,	O
with	O
a	O
wide	O
phenotypic	O
spectrum	O
of	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
seizures	S-Phenotype
,	O
minor	B-Phenotype
facial	I-Phenotype
dysmorphism	E-Phenotype
,	O
hypotonia	S-Phenotype
,	O
and	O
elevated	O
serum	O
alkaline	O
phosphatase	O
.	O

In	O
the	O
present	O
study	O
,	O
western	O
blotting	O
was	O
used	O
to	O
verified	O
the	O
expression	O
of	O
T	O
lymphocyte	O
CaSR	O
and	O
pathway	O
proteins	O
,	O
including	O
phosphorylated	O
extracellular	O
signal‑regulated	O
kinase	O
(	O
P‑ERK	O
)	O
1	O
/	O
2	O
and	O
phosphorylated	O
c‑Jun	O
N‑terminal	O
kinase	O
(	O
P‑JNK	O
)	O
,	O
and	O
used	O
cytometric	O
bead	O
array	O
to	O
detect	O
the	O
secretion	O
of	O
interleukin	O
(	O
IL	O
)	O
‑4	O
,	O
IL‑6	O
,	O
IL‑10	O
and	O
tumor	S-Phenotype
necrosis	O
factor	O
(	O
TNF	O
)	O
‑α	O
in	O
AMI	O
onset	O
,	O
the	O
results	O
demonstrated	O
that	O
they	O
were	O
all	O
increased	O
.	O

We	O
found	O
that	O
multiple	O
oncogenic	O
tyrosine	O
kinases	O
directly	O
phosphorylated	O
PDP1	O
at	O
Tyr	O
-	O
94	O
,	O
and	O
Tyr	O
-	O
94	O
phosphorylation	O
of	O
PDP1	O
was	O
common	O
in	O
diverse	O
human	O
cancer	S-Phenotype
cells	O
and	O
primary	O
leukemia	S-Phenotype
cells	O
from	O
patients	O
.	O

Recently	O
,	O
we	O
developed	O
a	O
double	O
-	O
retargeting	O
strategy	O
whereby	O
gH	O
carries	O
the	O
GCN4	O
peptide	O
for	O
retargeting	O
to	O
the	O
noncancer	O
producer	O
Vero	O
-	O
GCN4R	O
cell	O
line	O
and	O
gD	O
carries	O
the	O
scFv	O
to	O
HER2	O
for	O
cancer	S-Phenotype
retargeting	O
.	O

Mutations	O
in	O
ganglioside	O
-	O
induced	O
differentiation	O
-	O
associated	O
-	O
protein	O
1	O
(	O
GDAP1	O
)	O
have	O
been	O
associated	O
with	O
both	O
subtypes	O
of	O
Charcot	O
-	O
Marie	O
-	O
Tooth	O
(	O
CMT	O
)	O
disease	O
,	O
autosomal	B-Phenotype
recessive	E-Phenotype
(	O
CMT4A	O
and	O
AR	O
-	O
CMT2K	O
)	O
and	O
autosomal	O
dominant	O
(	O
AD	O
-	O
CMT2K	O
)	O
.	O

We	O
describe	O
an	O
infant	O
with	O
the	O
phenotype	O
of	O
a	O
congenital	B-Phenotype
muscular	I-Phenotype
dystrophy	E-Phenotype
,	O
with	O
borderline	B-Phenotype
microcephaly	E-Phenotype
,	O
hypotonia	S-Phenotype
,	O
camptodactyly	S-Phenotype
,	O
severe	O
motor	B-Phenotype
delay	E-Phenotype
,	O
and	O
elevated	B-Phenotype
creatine	I-Phenotype
kinase	E-Phenotype
.	O

In	O
addition	O
,	O
these	O
POU6F2	O
RGCs	O
die	O
early	O
in	O
the	O
DBA	O
/	O
2J	O
model	O
of	O
glaucoma	S-Phenotype
than	O
most	O
RGCs	O
.	O

bMethods	O
/	O
b	O
:	O
Analysis	O
of	O
publicly	O
available	O
microarray	O
data	O
of	O
oral	O
SCC	O
revealed	O
that	O
AMACR	O
was	O
significantly	O
upregulated	O
in	O
tumor	S-Phenotype
tissue	O
compared	O
with	O
normal	O
mucosa	O
.	O

Our	O
findings	O
uncover	O
a	O
novel	O
function	O
of	O
Trak1	O
as	O
a	O
regulator	O
of	O
mitochondrial	O
fusion	O
and	O
provide	O
evidence	O
linking	O
dysregulated	O
mitochondrial	O
dynamics	O
to	O
hypertonia	S-Phenotype
pathogenesis	O

MAT1A	O
reduction	O
is	O
associated	O
with	O
increased	O
oxidative	B-Phenotype
stress	E-Phenotype
,	O
progenitor	O
cell	O
expansion	O
,	O
genomic	O
instability	O
,	O
and	O
other	O
mechanisms	O
implicated	O
in	O
tumorigenesis	S-Phenotype
.	O

All	O
tumors	S-Phenotype
were	O
positive	O
for	O
AE1	O
-	O
AE3	O
,	O
CK18	O
,	O
PAX	O
8	O
,	O
antimitochondrial	O
antigen	O
,	O
and	O
SDHB	O
.	O

However	O
,	O
mutation	O
screening	O
of	O
these	O
genes	O
revealed	O
two	O
mutated	O
alleles	O
in	O
only	O
just	O
over	O
half	O
of	O
our	O
MKS	O
cohort	O
(	O
46	O
families	O
)	O
,	O
suggesting	O
an	O
even	O
greater	O
level	O
of	O
genetic	O
heterogeneity	S-Phenotype
.	O

Mutations	O
in	O
the	O
SH3PXD2B	O
gene	O
coding	O
for	O
the	O
Tks4	O
protein	O
are	O
responsible	O
for	O
the	O
autosomal	B-Phenotype
recessive	E-Phenotype
Frank	O
-	O
ter	O
Haar	O
syndrome	O
.	O

Ellis	O
-	O
van	O
Creveld	O
syndrome	O
is	O
an	O
autosomal	B-Phenotype
recessive	I-Phenotype
skeletal	I-Phenotype
dysplasia	E-Phenotype
primarily	O
characterized	O
by	O
the	O
features	O
such	O
as	O
disproportionate	B-Phenotype
dwarfism	E-Phenotype
,	O
short	B-Phenotype
ribs	E-Phenotype
,	O
short	B-Phenotype
limbs	E-Phenotype
,	O
dysplastic	B-Phenotype
nails	E-Phenotype
,	O
cardiovascular	B-Phenotype
malformations	E-Phenotype
,	O
post	B-Phenotype
-	I-Phenotype
axial	I-Phenotype
polydactyly	I-Phenotype
(	I-Phenotype
PAP	I-Phenotype
)	I-Phenotype
(	I-Phenotype
bilateral	I-Phenotype
)	I-Phenotype
of	I-Phenotype
hands	I-Phenotype
and	I-Phenotype
feet	E-Phenotype
.	O

Our	O
results	O
identify	O
DDB2	O
as	O
both	O
a	O
partner	O
and	O
regulator	O
of	O
Wnt	O
signaling	O
,	O
with	O
an	O
important	O
role	O
in	O
suppressing	O
colon	B-Phenotype
cancer	E-Phenotype
development	O
.	O

In	O
humans	O
,	O
recessive	O
and	O
dominant	O
ALPL	O
mutations	O
cause	O
hypophosphatasia	O
(	O
HPP	O
)	O
,	O
a	O
metabolic	O
bone	O
disease	O
with	O
highly	O
heterogeneous	S-Phenotype
clinical	O
manifestations	O
,	O
ranging	O
from	O
lethal	O
perinatal	O
hypomineralization	O
to	O
a	O
relatively	O
mild	O
dental	O
disease	O
.	O

In	O
this	O
study	O
,	O
differences	O
in	O
prolyl	O
3	O
-	O
hydroxylation	O
were	O
screened	O
in	O
eye	O
tissues	O
from	O
P3h2	O
-	O
null	O
(	O
P3h2	O
(	O
n	O
/	O
n	O
)	O
)	O
and	O
wild	O
-	O
type	O
mice	O
to	O
seek	O
tissue	O
-	O
specific	O
effects	O
due	O
the	O
lack	O
of	O
P3H2	O
activity	O
on	O
post	O
-	O
translational	O
collagen	O
chemistry	O
that	O
could	O
explain	O
myopia	S-Phenotype
.	O

Our	O
findings	O
show	O
that	O
DPM3	O
mutations	O
may	O
lead	O
to	O
an	O
isolated	O
and	O
mild	O
limb	B-Phenotype
girdle	I-Phenotype
muscular	I-Phenotype
dystrophy	E-Phenotype
phenotype	O
without	O
cardiomyopathy	S-Phenotype

Perhaps	O
unusually	O
for	O
autosomal	B-Phenotype
recessive	E-Phenotype
diseases	O
,	O
heterozygotes	O
for	O
mutations	O
in	O
NPC1	O
manifest	O
many	O
biological	O
variations	O
.	O

We	O
also	O
found	O
that	O
Lin28b	O
is	O
able	O
to	O
bind	O
a	O
conserved	O
GGAG	O
motif	O
of	O
pre	O
-	O
miR	O
-	O
125a	O
and	O
to	O
inhibit	O
its	O
maturation	O
in	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
cells	O
.	O

CYP21A2	O
defects	O
result	O
in	O
congenital	B-Phenotype
adrenal	I-Phenotype
hyperplasia	E-Phenotype
(	O
CAH	S-Phenotype
)	O
,	O
an	O
autosomal	O
recessive	O
disorder	O
characterized	O
by	O
impaired	O
adrenal	O
steroidogenesis	O
.	O

Here	O
,	O
we	O
use	O
a	O
combination	O
of	O
genetic	O
mouse	O
models	O
to	O
demonstrate	O
that	O
Prss56	O
mutations	O
leading	O
to	O
reduced	O
ocular	O
size	O
and	O
hyperopia	S-Phenotype
act	O
via	O
a	O
loss	O
of	O
function	O
mechanism	O
.	O

We	O
report	O
on	O
two	O
children	O
,	O
displaying	O
intellectual	B-Phenotype
disability	E-Phenotype
(	O
ID	S-Phenotype
)	O
and	O
peculiar	O
congenital	O
eyes	O
anomalies	O
,	O
both	O
carrying	O
a	O
de	O
novo	O
nonsense	O
mutation	O
in	O
the	O
ADNP	O
gene	O
.	O

Microrchidia	O
2	O
(	O
MORC2	O
)	O
is	O
important	O
in	O
DNA	O
damage	O
repair	O
and	O
lipogenesis	O
,	O
however	O
,	O
the	O
clinical	O
and	O
functional	O
role	O
of	O
MORC2	O
in	O
liver	B-Phenotype
cancer	E-Phenotype
remains	O
to	O
be	O
fully	O
elucidated	O
.	O

Our	O
results	O
expand	O
the	O
mutational	O
and	O
clinical	O
spectrum	O
of	O
this	O
rare	O
disease	O
,	O
confirm	O
that	O
THOC6	O
is	O
an	O
intellectual	B-Phenotype
disability	E-Phenotype
causing	O
gene	O
,	O
while	O
providing	O
insight	O
into	O
the	O
importance	O
of	O
the	O
THO	O
complex	O
in	O
neurodevelopment	O

However	O
,	O
few	O
reports	O
exist	O
on	O
TNC	O
expression	O
in	O
gastrointestinal	B-Phenotype
stromal	I-Phenotype
tumors	E-Phenotype
(	O
GISTs	S-Phenotype
)	O
.	O

Schwartz	O
-	O
Jampel	O
syndrome	O
type	O
1	O
(	O
SJS1	O
)	O
is	O
a	O
rare	O
autosomal	B-Phenotype
recessive	E-Phenotype
disease	O
caused	O
by	O
mutations	O
in	O
the	O
gene	O
heparan	O
sulfate	O
proteoglycan	O
2	O
(	O
HSPG2	O
;	O
also	O
known	O
as	O
basement	O
membrane‑specific	O
heparin	O
sulfate	O
)	O
.	O

Moreover	O
,	O
the	O
novel	O
mutation	O
,	O
p.R414C	O
,	O
adds	O
up	O
to	O
the	O
literature	O
for	O
the	O
infantile	O
-	O
onset	O
form	O
of	O
autosomal	B-Phenotype
recessive	I-Phenotype
ataxia	E-Phenotype
associated	O
with	O
SPTBN2	O
.	O

Mutations	O
in	O
COL4A1	O
have	O
been	O
reported	O
in	O
schizencephaly	S-Phenotype
and	O
porencephaly	O
combined	O
with	O
microbleeds	O
or	O
calcifications	O
,	O
often	O
associated	O
with	O
ocular	B-Phenotype
and	I-Phenotype
renal	I-Phenotype
abnormalities	E-Phenotype
,	O
myopathy	S-Phenotype
,	O
elevated	B-Phenotype
creatine	I-Phenotype
kinase	E-Phenotype
levels	O
and	O
haemolytic	B-Phenotype
anaemia	E-Phenotype
.	O

Malonyl	O
coenzyme	O
A	O
(	O
CoA	O
)	O
decarboxylase	O
(	O
EC	O
4.1.1.9	O
,	O
MCD	O
)	O
deficiency	O
,	O
or	O
malonic	O
aciduria	S-Phenotype
,	O
is	O
a	O
rare	O
inborn	O
error	O
of	O
metabolism	O
characterised	O
by	O
a	O
variable	O
phenotype	O
of	O
developmental	B-Phenotype
delay	E-Phenotype
,	O
seizures	S-Phenotype
,	O
cardiomyopathy	S-Phenotype
and	O
acidosis	S-Phenotype
.	O

Clinical	O
trials	O
have	O
revealed	O
that	O
inhibition	O
of	O
sonic	O
Hedgehog	O
(	O
SHH	O
)	O
signaling	O
or	O
histone	O
deacetylase	O
(	O
HDAC	O
)	O
holds	O
promise	O
as	O
a	O
treatment	O
for	O
liver	B-Phenotype
cancer	E-Phenotype
.	O

We	O
report	O
these	O
cases	O
to	O
demonstrate	O
the	O
exhaustive	O
work	O
-	O
up	O
prior	O
to	O
finding	O
the	O
changes	O
in	O
IQSEC2	O
gene	O
,	O
recommend	O
that	O
this	O
gene	O
be	O
considered	O
earlier	O
in	O
the	O
diagnostic	O
evaluation	O
of	O
individuals	O
with	O
global	B-Phenotype
developmental	I-Phenotype
delay	E-Phenotype
,	O
microcephaly	S-Phenotype
,	O
and	O
severe	O
,	O
intractable	O
epilepsy	S-Phenotype
,	O
and	O
support	O
the	O
use	O
of	O
intellectual	B-Phenotype
disability	E-Phenotype
panels	O
including	O
IQSEC2	O
in	O
the	O
first	O
-	O
line	O
evaluation	O
of	O
these	O
patients	O

Here	O
,	O
we	O
report	O
that	O
GOF	O
p53	O
induces	O
tumorigenicity	S-Phenotype
through	O
simultaneous	O
activation	O
of	O
key	O
oncogenic	O
pathways	O
including	O
those	O
controlling	O
putative	O
tumor	S-Phenotype
-	O
initiating	O
cell	O
functions	O
.	O

Meningiomas	S-Phenotype
may	O
be	O
classified	O
as	O
neurofibromin	O
2	O
(	O
NF2	O
)	O
-	O
associated	O
and	O
non	O
-	O
NF2	O
meningiomas	S-Phenotype
depending	O
on	O
the	O
presence	O
or	O
absence	O
of	O
molecular	O
alterations	O
in	O
the	O
liNF2	O
/	O
i	O
gene	O
.	O

This	O
study	O
supports	O
heterogeneity	S-Phenotype
for	O
CDPX1	O
-	O
like	O
phenotypes	O
and	O
sorting	O
these	O
out	O
will	O
help	O
to	O
define	O
the	O
biological	O
pathway	O
and	O
genetic	O
contributors	O

Recently	O
,	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
BCAP31	O
were	O
reported	O
in	O
association	O
with	O
severe	O
developmental	B-Phenotype
delay	E-Phenotype
,	O
deafness	S-Phenotype
and	O
dystonia	S-Phenotype
.	O

An	B-Phenotype
earlier	I-Phenotype
onset	I-Phenotype
of	I-Phenotype
hearing	I-Phenotype
impairment	E-Phenotype
and	O
vestibular	B-Phenotype
dysfunction	E-Phenotype
compared	O
to	O
the	O
dominant	O
hearing	B-Phenotype
loss	E-Phenotype
causing	O
COCH	O
variants	O
is	O
observed	O

The	O
aims	O
of	O
the	O
present	O
study	O
were	O
to	O
evaluate	O
the	O
relation	O
of	O
dysregulated	O
MACC1	O
,	O
c	O
-	O
MET	O
,	O
and	O
NM23	O
-	O
H1	O
expression	O
with	O
the	O
histopathological	O
features	O
of	O
tumors	S-Phenotype
in	O
recurrence	O
formation	O
in	O
eCC	O
cases	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
patient	O
with	O
liPIGT	O
/	O
i	O
mutations	O
who	O
experienced	O
recurrent	O
aseptic	O
meningitis	S-Phenotype
121	O
times	O
over	O
16	O
years	O
before	O
developing	O
paroxysmal	B-Phenotype
nocturnal	I-Phenotype
haemoglobinuria	E-Phenotype
(	O
PNH	S-Phenotype
)	O
.	O

Single	O
large	O
-	O
scale	O
mitochondrial	O
DNA	O
deletions	O
disorders	O
are	O
classified	O
into	O
three	O
main	O
phenotypes	O
with	O
frequent	O
clinical	O
overlap	O
:	O
Pearson	O
marrow	O
-	O
pancreas	O
syndrome	O
(	O
PMS	O
)	O
,	O
Kearns	O
-	O
Sayre	O
syndrome	O
(	O
KSS	O
)	O
and	O
chronic	B-Phenotype
progressive	I-Phenotype
external	I-Phenotype
ophtalmoplegia	E-Phenotype
(	O
PEO	S-Phenotype
)	O
.	O

For	O
the	O
site	O
-	O
specific	O
delivery	O
of	O
the	O
anticancer	O
drug	O
into	O
TNBC	O
,	O
anti	O
-	O
Trop2	O
antibody	O
-	O
conjugated	O
nanoparticles	O
(	O
ST	O
-	O
NPs	O
)	O
were	O
prepared	O
as	O
the	O
potential	O
nanocarrier	O
,	O
composed	O
of	O
carboxymethyl	O
dextran	O
(	O
CMD	O
)	O
derivatives	O
with	O
bioreducible	O
disulfide	O
bonds	O
.	O

KMT2B	B-Phenotype
-	I-Phenotype
dystonia	E-Phenotype
(	O
DYT28	S-Phenotype
)	O
is	O
emerging	O
as	O
an	O
important	O
and	O
frequent	O
cause	O
of	O
childhood	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
progressive	I-Phenotype
generalised	I-Phenotype
dystonia	E-Phenotype
and	O
is	O
estimated	O
to	O
potentially	O
account	O
for	O
up	O
to	O
10	O
%	O
of	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
generalised	I-Phenotype
dystonia	E-Phenotype
.	O

Together	O
,	O
our	O
findings	O
suggest	O
that	O
in	O
CRC	O
TIAM1	O
suppresses	O
tumor	S-Phenotype
progression	O
by	O
regulating	O
YAP	O
/	O
TAZ	O
activity	O

In	O
order	O
to	O
investigate	O
essential	O
molecular	O
causes	O
for	O
hearing	B-Phenotype
loss	E-Phenotype
and	O
mutation	O
frequency	O
of	O
deafness	S-Phenotype
-	O
related	O
genes	O
,	O
1315	O
newborns	O
who	O
did	O
not	O
pass	O
the	O
Newborn	O
Hearing	O
Screening	O
(	O
NHS	O
)	O
(	O
audio	O
-	O
no	O
-	O
pass	O
)	O
and	O
1000	O
random	O
-	O
selected	O
infants	O
were	O
subjected	O
to	O
detection	O
for	O
101	O
hotspot	O
mutations	O
in	O
18	O
common	O
deafness	S-Phenotype
-	O
related	O
genes	O
.	O

In	O
patients	O
,	O
Plk1	O
overexpression	O
correlates	O
with	O
improved	O
survival	O
in	O
specific	O
breast	B-Phenotype
cancer	E-Phenotype
subtypes	O
.	O

Analysis	O
of	O
the	O
expression	O
of	O
the	O
central	O
clock	O
genes	O
over	O
a	O
24	O
-	O
36	O
hour	O
period	O
in	O
multiple	O
peripheral	O
tissues	O
including	O
fracture	O
callus	O
,	O
proximal	O
tibia	O
growth	O
plate	O
and	O
cardiac	O
tissues	O
after	O
12	O
days	O
on	O
a	O
low	O
phosphate	O
diet	O
showed	O
higher	O
levels	O
of	O
gene	O
expression	O
in	O
the	O
hypophosphatemia	S-Phenotype
groups	O
(	O
p	O
AAAA	O
0.001	O
)	O
and	O
a	O
3	O
to	O
6	O
hour	O
elongation	O
of	O
the	O
circadian	O
cycle	O
.	O

The	O
Spi	O
-	O
B	O
-	O
expressing	O
cancer	S-Phenotype
cells	O
coexpressed	O
vimentin	O
but	O
repressed	O
E	O
-	O
cadherin	O
and	O
exhibited	O
invasive	O
behavior	O
.	O

At	O
the	O
suggestive	O
threshold	O
(	O
P	O
AAAA	O
.001	O
)	O
,	O
6	O
genes	O
were	O
enriched	O
for	O
rare	O
damaging	O
variants	O
(	O
UHMK1	O
,	O
AP1G2	O
,	O
DNTA	O
,	O
CHST6	O
,	O
FGFR3	O
,	O
and	O
EPHA1	O
)	O
and	O
7	O
genes	O
had	O
associations	O
with	O
pancreatic	B-Phenotype
cancer	E-Phenotype
risk	O
,	O
based	O
on	O
the	O
sequence	O
-	O
kernel	O
association	O
test	O
.	O

Overall	O
,	O
GPT2	O
promotes	O
tumorigenesis	O
and	O
stemness	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
by	O
activating	O
the	O
Shh	O
signaling	O
,	O
suggesting	O
that	O
GTP2	O
is	O
a	O
potential	O
target	O
for	O
breast	B-Phenotype
cancer	E-Phenotype
therapy	O

Results	O
:	O
The	O
relative	O
expression	O
levels	O
of	O
HOXA11	O
-	O
AS	O
in	O
tumor	S-Phenotype
tissue	O
and	O
paired	O
adjacent	O
tissue	O
were	O
0.832+0.387	O
and	O
2.486+1.087	O
,	O
respectively	O
,	O
with	O
significant	O
difference	O
(	O
PAAAA0.001	O
)	O
.	O

The	O
659	O
predisposition	O
variants	O
and	O
18	O
additional	O
large	O
deletions	O
in	O
tumor	S-Phenotype
suppressors	O
,	O
including	O
ATM	O
,	O
BRCA1	O
,	O
and	O
NF1	O
,	O
showed	O
low	O
gene	O
expression	O
and	O
frequent	O
(	O
43	O
%	O
)	O
loss	O
of	O
heterozygosity	O
or	O
biallelic	O
two	O
-	O
hit	O
events	O
.	O

Thus	O
we	O
conclude	O
that	O
the	O
hearing	B-Phenotype
loss	E-Phenotype
in	O
the	O
family	O
described	O
in	O
this	O
report	O
is	O
caused	O
by	O
a	O
novel	O
missense	O
mutation	O
in	O
GIPC3	O
.	O

In	O
humans	O
,	O
mutations	O
in	O
VCP	O
lead	O
to	O
severe	O
myo	O
-	O
and	O
neuro	O
-	O
degenerative	O
disorders	O
such	O
as	O
inclusion	O
body	O
myopathy	S-Phenotype
with	O
Paget	O
disease	O
of	O
the	B-Phenotype
bone	I-Phenotype
and	I-Phenotype
frontotemporal	I-Phenotype
dementia	E-Phenotype
(	O
IBMPFD	S-Phenotype
)	O
,	O
amyotrophic	B-Phenotype
lateral	I-Phenotype
sclerosis	E-Phenotype
(	O
ALS	S-Phenotype
)	O
or	O
and	O
hereditary	B-Phenotype
spastic	I-Phenotype
paraplegia	E-Phenotype
(	O
HSP	S-Phenotype
)	O
.	O

Vitamin	O
K	O
-	O
2	O
is	O
involved	O
in	O
mitochondrial	O
electron	O
transport	O
,	O
SXR	O
nuclear	O
hormone	O
receptor	O
signaling	O
and	O
redox	O
cycling	O
:	O
together	O
these	O
functions	O
may	O
form	O
the	O
basis	O
for	O
tumor	S-Phenotype
suppressor	O
function	O
.	O

Expression	O
of	O
cry2	O
and	O
per2	O
was	O
significantly	O
downregulated	O
in	O
tumor	S-Phenotype
tissue	O
compared	O
to	O
adjacent	O
tissues	O
.	O

Multiple	B-Phenotype
endocrine	I-Phenotype
neoplasia	E-Phenotype
(	O
MEN	S-Phenotype
)	O
has	O
not	O
been	O
reported	O
in	O
baboons	O
,	O
but	O
this	O
condition	O
is	O
well	O
described	O
in	O
humans	O
.	O

As	O
one	O
of	O
the	O
first	O
findings	O
being	O
confirmed	O
by	O
genome	O
-	O
wide	O
association	O
studies	O
for	O
the	O
phenotype	O
of	O
panic	O
disorder	O
and	O
agoraphobia	S-Phenotype
,	O
allelic	O
variation	O
in	O
a	O
gene	O
coding	O
for	O
the	O
glycine	O
receptor	O
beta	O
subunit	O
(	O
GLRB	O
)	O
has	O
recently	O
been	O
associated	O
with	O
increased	O
neural	O
fear	O
network	O
activation	O
and	O
enhanced	O
acoustic	O
startle	O
reflexes	O
.	O

As	O
previously	O
observed	O
in	O
the	O
mutant	O
mouse	O
carrying	O
a	O
disrupted	O
KCNC1	O
gene	O
,	O
these	O
findings	O
reveal	O
that	O
individuals	O
with	O
a	O
KCNC1	O
loss	O
-	O
of	O
-	O
function	O
variant	O
can	O
present	O
intellectual	B-Phenotype
disability	E-Phenotype
without	O
seizure	S-Phenotype
and	O
epilepsy	S-Phenotype

The	O
ADAMTS18	O
gene	O
is	O
often	O
down	O
-	O
regulated	O
by	O
hypermethylation	O
in	O
ccRCC	O
-	O
derived	O
cell	O
lines	O
and	O
primary	O
tumors	S-Phenotype
,	O
indicating	O
its	O
critical	O
role	O
as	O
a	O
TSG	O
in	O
ccRCC	O
.	O

These	O
data	O
are	O
consistent	O
with	O
the	O
fact	O
that	O
expression	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
anti	O
-	O
estrogen	O
resistance	O
1	O
(	O
BCAR1	O
)	O
was	O
increased	O
in	O
O2	O
compared	O
to	O
V1	O
cells	O
(	O
p	O
AAAA	O
0.01	O
)	O
.	O

Objective	O
:	O
To	O
investigate	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
Chinese	O
familial	O
hypertrophic	B-Phenotype
cardiomyopathy	E-Phenotype
(	O
HCM	S-Phenotype
)	O
focusing	O
on	O
the	O
cardiac	O
troponin	O
C	O
gene	O
TNNC1	O
c	O
.	O

Mutations	O
in	O
CRLF1	O
have	O
been	O
associated	O
with	O
autosomal	B-Phenotype
recessive	I-Phenotype
Crisponi	E-Phenotype
or	O
cold	B-Phenotype
-	I-Phenotype
induced	I-Phenotype
sweating	I-Phenotype
syndrome	I-Phenotype
type	I-Phenotype
1	E-Phenotype
(	O
CS	B-Phenotype
/	I-Phenotype
CISS1	E-Phenotype
)	O
,	O
which	O
among	O
other	O
symptoms	O
also	O
manifests	O
with	O
early	B-Phenotype
onset	I-Phenotype
feeding	I-Phenotype
difficulties	E-Phenotype
.	O

Since	O
its	O
identification	O
in	O
a	O
large	O
Oregon	O
family	O
with	O
primary	B-Phenotype
open	I-Phenotype
-	I-Phenotype
angle	I-Phenotype
glaucoma	E-Phenotype
(	O
POAG	S-Phenotype
)	O
,	O
ASB10	O
variants	O
have	O
been	O
associated	O
with	O
disease	O
in	O
US	O
,	O
German	O
and	O
Pakistani	O
cohorts	O
.	O

In	O
this	O
study	O
FISH	O
exhibited	O
sensitivity	O
and	O
specificity	O
in	O
diagnosis	O
of	O
acral	B-Phenotype
melanoma	E-Phenotype
which	O
allows	O
its	O
application	O
as	O
an	O
auxiliary	O
diagnostic	O
test	O
in	O
acral	B-Phenotype
melanocytic	I-Phenotype
tumours	E-Phenotype

Previous	O
studies	O
have	O
shown	O
that	O
c	O
-	O
MET	O
is	O
overexpressed	O
in	O
cases	O
of	O
aggressive	O
bladder	B-Phenotype
cancer	E-Phenotype
(	O
BCa	S-Phenotype
)	O
.	O

Further	O
population	O
study	O
also	O
validated	O
that	O
chemotherapy	O
significantly	O
improved	O
survival	O
in	O
early	B-Phenotype
-	I-Phenotype
stage	I-Phenotype
breast	I-Phenotype
cancer	E-Phenotype
patients	O
with	O
low	O
PYCR1	O
expression	O
levels	O
.	O

Taken	O
together	O
,	O
our	O
data	O
indicate	O
that	O
SOX3	O
may	O
serve	O
as	O
an	O
oncogene	O
in	O
osteosarcoma	S-Phenotype
,	O
and	O
SOX3	O
downregulation	O
may	O
prove	O
to	O
be	O
a	O
novel	O
approach	O
for	O
the	O
inhibition	O
of	O
osteosarcoma	S-Phenotype
progression	O

Collagen	O
type	O
4	O
alpha	O
1	O
(	O
COL4A1	O
)	O
and	O
collagen	O
type	O
13	O
alpha	O
1	O
(	O
COL13A1	O
)	O
produced	O
by	O
urothelial	O
cancer	S-Phenotype
cells	O
support	O
the	O
vital	O
oncogenic	O
property	O
of	O
tumor	S-Phenotype
invasion	O
.	O

When	O
compared	O
with	O
adjacent	O
non	O
-	O
tumor	S-Phenotype
tissues	O
,	O
we	O
found	O
that	O
miR	O
-	O
483	O
was	O
upregulated	O
and	O
Pard3	O
was	O
downregulated	O
in	O
80	O
thyroid	B-Phenotype
tumor	E-Phenotype
samples	O
.	O

p53R2	O
overexpression	O
is	O
associated	O
with	O
increased	O
risk	O
of	O
pelvic	O
lymph	O
node	O
metastasis	O
(	O
PLNM	O
,	O
p	O
=	O
0.001	O
)	O
and	O
cancer	S-Phenotype
relapse	O
(	O
p	O
=	O
0.009	O
)	O
.	O

This	O
report	O
describes	O
for	O
the	O
first	O
time	O
a	O
patient	O
with	O
SEPT5	O
deficiency	O
presenting	O
with	O
cortical	B-Phenotype
dysplasia	E-Phenotype
(	O
polymicrogyria	S-Phenotype
)	O
,	O
developmental	B-Phenotype
delay	E-Phenotype
,	O
and	O
platelet	B-Phenotype
secretion	I-Phenotype
defect	E-Phenotype

We	O
also	O
found	O
that	O
Lin28b	O
is	O
able	O
to	O
bind	O
a	O
conserved	O
GGAG	O
motif	O
of	O
pre	O
-	O
miR	O
-	O
125a	O
and	O
to	O
inhibit	O
its	O
maturation	O
in	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
cells	O
.	O

p53R2	O
is	O
an	O
independent	O
factor	O
for	O
predicting	O
OS	O
and	O
DFS	O
of	O
cervical	B-Phenotype
cancer	E-Phenotype
patients	O
.	O

This	O
study	O
establishes	O
PYROXD1	O
variants	O
as	O
a	O
cause	O
of	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
myopathy	E-Phenotype
and	O
uses	O
biospecimens	O
and	O
cell	O
lines	O
,	O
yeast	O
,	O
and	O
zebrafish	O
models	O
to	O
elucidate	O
the	O
fundamental	O
role	O
of	O
PYROXD1	O
in	O
skeletal	O
muscle	O
.	O

Surprisingly	O
,	O
germline	O
variants	O
in	O
SAMD9	O
or	O
SAMD9L	O
were	O
present	O
in	O
17	O
%	O
of	O
primary	O
MDS	O
patients	O
,	O
and	O
these	O
variants	O
were	O
routinely	O
lost	O
in	O
the	O
tumor	S-Phenotype
cells	O
by	O
chromosomal	O
deletions	O
(	O
e.g.	O
,	O
monosomy	O
7	O
)	O
or	O
copy	O
number	O
neutral	O
loss	O
of	O
heterozygosity	O
(	O
CN	O
-	O
LOH	O
)	O
.	O

To	O
better	O
understand	O
the	O
biology	O
of	O
this	O
molecularly	O
distinct	O
tumor	S-Phenotype
subtype	O
,	O
we	O
analyze	O
the	O
microRNA	O
(	O
miRNA	O
)	O
expression	O
profiles	O
of	O
Xp11	O
RCC	O
compared	O
with	O
normal	O
renal	O
parenchyma	O
using	O
microarray	O
and	O
quantitative	O
reverse	O
-	O
transcription	O
polymerase	O
chain	O
reaction	O
.	O

Autosomal	O
dominant	O
inheritance	S-Phenotype
of	O
AIMAH	O
was	O
confirmed	O
by	O
genotypes	O
of	O
one	O
family	O
member	O
.	O

Abnormal	O
prion	O
proteins	O
are	O
responsible	O
for	O
several	O
fatal	O
neurodegenerative	B-Phenotype
diseases	E-Phenotype
in	O
humans	O
and	O
in	O
animals	O
,	O
including	O
Creutzfeldt	O
-	O
Jakob	O
disease	O
(	O
CJD	O
)	O
,	O
Gerstmann	O
-	O
Sträussler	O
-	O
Scheinker	O
disease	O
,	O
and	O
fatal	O
familial	O
insomnia	S-Phenotype
.	O

Moreover	O
,	O
overexpression	O
of	O
mutant	O
but	O
not	O
normal	O
CCDC174	O
in	O
neuroblastoma	S-Phenotype
cells	O
caused	O
rapid	O
apoptosis	O
.	O

Mutations	O
in	O
MGME1	O
-	O
coding	O
gene	O
lead	O
to	O
severe	O
mitochondrial	O
syndromes	O
characterized	O
by	O
external	B-Phenotype
ophthalmoplegia	E-Phenotype
,	O
emaciation	S-Phenotype
,	O
and	O
respiratory	B-Phenotype
failure	E-Phenotype
in	O
humans	O
.	O

Several	O
known	O
breast	B-Phenotype
cancer	E-Phenotype
susceptibility	O
genes	O
encode	O
proteins	O
involved	O
in	O
DNA	O
damage	O
response	O
(	O
DDR	O
)	O
and	O
are	O
characterized	O
by	O
rare	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
.	O

Multiple	O
studies	O
have	O
now	O
demonstrated	O
the	O
ability	O
for	O
superoxide	O
dismutase	O
-	O
1	O
,	O
43	O
-	O
kDa	O
transactive	O
response	O
(	O
TAR	O
)	O
DNA	O
-	O
binding	O
protein	O
,	O
fused	O
-	O
in	O
sarcoma	S-Phenotype
,	O
and	O
most	O
recently	O
,	O
C9orf72	O
-	O
encoded	O
polypeptides	O
to	O
display	O
properties	O
similar	O
to	O
those	O
of	O
prions	O
.	O

This	O
work	O
provides	O
a	O
relevant	O
hydrocephalus	S-Phenotype
mouse	O
model	O
and	O
demonstrates	O
that	O
liMpdz	O
/	O
i	O
is	O
essential	O
to	O
maintain	O
integrity	O
of	O
the	O
ependyma	O

Here	O
,	O
we	O
report	O
that	O
biallelic	O
mutations	O
in	O
NCAPD2	O
,	O
NCAPH	O
,	O
or	O
NCAPD3	O
,	O
encoding	O
subunits	O
of	O
these	O
complexes	O
,	O
cause	O
microcephaly	S-Phenotype
.	O

The	O
literature	O
supports	O
the	O
evidence	O
of	O
natural	O
compounds	O
exhibiting	O
antioxidant	O
,	O
antimitotic	O
,	O
anti	O
-	O
inflammatory	O
,	O
antibiotic	O
as	O
well	O
as	O
anticancer	O
activity	S-Phenotype
.	O

Inactivation	O
of	O
Chrna2	O
in	O
mice	O
compromised	O
the	O
cold	O
-	O
induced	O
thermogenic	O
response	O
selectively	O
in	O
subcutaneous	O
fat	O
and	O
exacerbated	O
high	B-Phenotype
-	I-Phenotype
fat	I-Phenotype
diet	I-Phenotype
-	I-Phenotype
induced	I-Phenotype
obesity	E-Phenotype
and	O
associated	O
metabolic	O
disorders	O
,	O
indicating	O
that	O
even	O
partial	O
loss	O
of	O
beige	O
fat	O
regulation	O
in	O
vivo	O
had	O
detrimental	O
consequences	O
.	O

Oropharyngeal	B-Phenotype
cancer	E-Phenotype
associations	O
were	O
limited	O
to	O
the	O
human	O
leukocyte	O
antigen	O
(	O
HLA	O
)	O
region	O
,	O
and	O
classical	O
HLA	O
allele	O
imputation	O
showed	O
a	O
protective	O
association	O
with	O
the	O
class	O
II	O
haplotype	O
HLA	O
-	O
DRB1	O
*	O
1301	O
-	O
HLA	O
-	O
DQA1	O
*	O
0103	O
-	O
HLA	O
-	O
DQB1	O
*	O
0603	O
(	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
0.59	O
,	O
P	O
=	O
2.7	O
×	O
10sup	O
-	O
9	O
/	O
sup	O
)	O
.	O

Notch2	O
activation	O
in	O
the	O
microenvironment	O
is	O
a	O
pre	O
-	O
requisite	O
for	O
the	O
activation	O
of	O
canonical	O
Wnt	O
signalling	O
in	O
tumour	S-Phenotype
cells	O

Our	O
data	O
support	O
the	O
very	O
recent	O
and	O
independent	O
identification	O
of	O
ALDH1A3	O
as	O
a	O
disease	O
gene	O
in	O
microphthalmia	S-Phenotype
.	O

Dysfunction	O
of	O
the	O
cerebral	O
glucose	O
transporter	O
GLUT1	O
(	O
encoded	O
by	O
SLC2A1	O
)	O
is	O
known	O
to	O
result	O
in	O
epilepsy	S-Phenotype
,	O
intellectual	B-Phenotype
disability	E-Phenotype
(	O
ID	S-Phenotype
)	O
,	O
and	O
movement	B-Phenotype
disorder	E-Phenotype
.	O

Tubulin	O
alpha	O
8	O
(	O
TUBA8	O
)	O
is	O
highly	O
abundant	O
in	O
murine	O
liver	B-Phenotype
tumors	E-Phenotype
suggesting	O
a	O
role	O
in	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
.	O

The	O
adjusted	O
Analysis	O
of	O
Covariance	O
Test	O
(	O
ANCOVA	O
)	O
model	O
revealed	O
cancer	S-Phenotype
patients	O
to	O
have	O
a	O
lower	O
relative	O
percentage	O
of	O
saturated	O
fatty	O
acids	O
(	O
SFA	O
)	O
(	O
C16:0	O
(	O
5.7	O
%	O
)	O
;	O
C18:0	O
(	O
15.9	O
%	O
)	O
)	O
,	O
and	O
higher	O
monounsaturated	O
fatty	O
acids	O
(	O
MUFA	O
)	O
(	O
9c	O
-	O
C18:1	O
(	O
12.9	O
%	O
)	O
and	O
11c	O
-	O
C18:1	O
(	O
54.5	O
%	O
)	O
)	O
,	O
compared	O
to	O
controls	O
.	O

TNFAIP8	O
mRNA	O
is	O
induced	O
by	O
NF	O
-	O
kB	O
,	O
and	O
overexpression	O
of	O
TNFAIP8	O
has	O
been	O
correlated	O
with	O
poor	O
prognosis	O
in	O
many	O
cancers	S-Phenotype
.	O

The	O
linear	O
ubiquitination	O
-	O
specific	O
deubiquitinase	O
ovarian	B-Phenotype
tumor	E-Phenotype
domain	O
deubiquitinase	O
with	O
linear	O
linkage	O
specificity	O
(	O
OTULIN	O
)	O
can	O
control	O
the	O
immune	O
signaling	O
transduction	O
pathway	O
by	O
restricting	O
the	O
Met1	O
-	O
linked	O
ubiquitination	O
process	O
.	O

Phosphatase	O
and	O
tensin	O
homolog	O
(	O
PTEN	O
)	O
is	O
a	O
well‑known	O
tumor	S-Phenotype
suppressor	O
and	O
serves	O
a	O
vital	O
role	O
in	O
cancer	S-Phenotype
progression	O
.	O

Immunoblot	O
analysis	O
revealed	O
that	O
CDK10	O
protein	O
expression	O
was	O
notably	O
decreased	O
in	O
gastric	B-Phenotype
cancer	E-Phenotype
compared	O
with	O
normal	O
tissues	O
.	O

In	O
addition	O
,	O
we	O
show	O
that	O
liVangl2supLp	O
/	O
+	O
/	O
sup	O
/	O
i	O
lungs	O
exhibit	O
many	O
of	O
the	O
hallmarks	O
of	O
tissue	O
damage	O
,	O
including	O
an	O
altered	O
macrophage	O
population	O
,	O
abnormal	O
elastin	O
deposition	O
and	O
elevated	O
levels	O
of	O
the	O
elastin	O
-	O
modifying	O
enzyme	O
,	O
liMmp12	O
/	O
i	O
,	O
all	O
of	O
which	O
are	O
observed	O
in	O
emphysema	S-Phenotype
.	O

Previous	O
reports	O
have	O
identified	O
SLC6A1	O
variants	O
in	O
patients	O
with	O
generalized	O
epilepsies	S-Phenotype
,	O
such	O
as	O
myoclonic	B-Phenotype
-	I-Phenotype
atonic	I-Phenotype
epilepsy	E-Phenotype
and	O
childhood	B-Phenotype
absence	I-Phenotype
epilepsy	E-Phenotype
.	O

The	O
human	O
Shwachman	O
-	O
Diamond	O
syndrome	O
(	O
SDS	O
)	O
is	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
disease	O
caused	O
by	O
mutations	O
in	O
a	O
highly	O
conserved	O
ribosome	O
assembly	O
factor	O
SBDS	O
.	O

The	O
second	O
most	O
frequently	O
mutated	O
gene	O
,	O
histone	O
methyltransferase	O
liSETD2	O
/	O
i	O
,	O
has	O
known	O
roles	O
in	O
multiple	O
cancers	S-Phenotype
,	O
but	O
has	O
not	O
previously	O
been	O
strongly	O
implicated	O
in	O
osteosarcoma	S-Phenotype
.	O

The	O
hypermethylation	O
of	O
HTLF	O
is	O
frequently	O
observed	O
in	O
various	O
types	O
of	O
cancer	S-Phenotype
,	O
including	O
colorectal	B-Phenotype
cancer	E-Phenotype
(	O
CRC	S-Phenotype
)	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
a	O
custom	O
capture	O
panel	O
(	O
MiamiOtoGenes	O
)	O
to	O
target	O
sequence	O
180	O
deafness	S-Phenotype
-	O
associated	O
genes	O
in	O
5	O
GJB2	O
negative	O
deaf	O
probands	O
with	O
autosomal	B-Phenotype
recessive	E-Phenotype
nonsyndromic	O
HL	O
from	O
Iran	O
.	O

Loss	O
-	O
of	O
-	O
function	O
mutations	O
of	O
GNA11	O
,	O
which	O
encodes	O
G	O
-	O
protein	O
subunit	O
α11	O
(	O
Gα11	O
)	O
,	O
a	O
signaling	O
partner	O
for	O
the	O
calcium	O
-	O
sensing	O
receptor	O
(	O
CaSR	O
)	O
,	O
result	O
in	O
familial	B-Phenotype
hypocalciuric	I-Phenotype
hypercalcemia	I-Phenotype
type	I-Phenotype
2	E-Phenotype
(	O
FHH2	S-Phenotype
)	O
.	O

We	O
show	O
that	O
both	O
Rspo2	O
and	O
Rspo3	O
fusion	O
events	O
are	O
sufficient	O
to	O
initiate	O
hyperplasia	O
and	O
tumour	S-Phenotype
development	O
in	O
vivo	O
,	O
without	O
additional	O
cooperating	O
genetic	O
events	O
.	O

Mutations	O
of	O
the	O
five	O
genes	O
(	O
ARHGEF5	O
,	O
ANKRD20A2	O
,	O
ZNF595	O
,	O
ZNF812	O
,	O
MYO18B	O
)	O
may	O
be	O
potential	O
germline	O
mutations	O
of	O
lung	B-Phenotype
cancer	E-Phenotype
.	O

Significant	O
differences	O
in	O
expression	O
of	O
B	O
cell	O
markers	O
in	O
cells	O
from	O
extracted	O
tumors	S-Phenotype
were	O
detected	O
based	O
upon	O
the	O
presence	O
of	O
vIL	O
-	O
6	O
.	O

In	O
addition	O
,	O
liXPC	O
rs2228001	O
and	O
liERCC2	O
rs238406	O
had	O
statistically	O
significant	O
association	O
with	O
the	O
increased	O
risk	O
of	O
ovarian	B-Phenotype
cancer	E-Phenotype
under	O
dominant	O
genetic	O
model	O
(	O
adjusted	O
OR	O
=	O
1.72	O
,	O
95	O
%	O
CI	O
=	O
1.02	O
-	O
2.92	O
,	O
liP=0.043	O
and	O
adjusted	O
OR	O
=	O
2.07	O
,	O
95	O
%	O
CI	O
=	O
1.07	O
-	O
4.01	O
,	O
liP=0.032	O
respectively	O
)	O
.	O

The	O
mTOR	O
pathway	O
was	O
significantly	O
associated	O
with	O
overall	O
and	O
estrogen	O
receptor	O
-	O
negative	O
(	O
ER	O
-	O
)	O
breast	B-Phenotype
cancer	E-Phenotype
risk	O
(	O
P	O
=	O
0.003	O
and	O
0.03	O
,	O
respectively	O
)	O
.	O

Patients	O
with	O
RIN2	O
syndrome	O
present	O
phenotypic	O
overlap	O
with	O
other	O
conditions	O
,	O
including	O
EDS	O
(	O
especially	O
the	O
dermatosparaxis	S-Phenotype
and	O
kyphoscoliosis	B-Phenotype
subtypes	E-Phenotype
)	O
.	O

On	O
the	O
whole	O
,	O
our	O
findings	O
indicated	O
that	O
KLF9	O
exhibited	O
low	O
expression	O
in	O
pancreatic	B-Phenotype
cancer	E-Phenotype
,	O
and	O
upregulation	O
of	O
KLF9	O
may	O
inhibit	O
the	O
progression	O
of	O
pancreatic	B-Phenotype
cancer	E-Phenotype
.	O

The	O
neurophenotype	O
of	O
these	O
GFAP.HMOX1sup8.5	O
-	O
19m	O
/	O
sup	O
mice	O
is	O
highly	O
consistent	O
with	O
parkinsonism	S-Phenotype
and	O
differs	O
dramatically	O
from	O
the	O
schizophrenia	S-Phenotype
-	O
like	O
features	O
previously	O
documented	O
in	O
younger	O
GFAP.HMOX1sup0	O
-	O
12m	O
/	O
sup	O
mice	O
.	O

Our	O
results	O
have	O
shown	O
that	O
deletion	O
of	O
either	O
Pten	O
or	O
Smad4	O
in	O
murine	O
salivary	O
gland	O
resulted	O
in	O
pleomorphic	O
adenomas	O
,	O
the	O
most	O
common	O
tumor	S-Phenotype
in	O
human	O
SGT	O
patients	O
.	O

Alterations	O
of	O
its	O
normal	O
function	O
may	O
contribute	O
to	O
two	O
different	O
phenotypes	O
:	O
juvenile	O
amyotrophic	B-Phenotype
lateral	I-Phenotype
sclerosis	E-Phenotype
(	O
ALS	B-Phenotype
16	E-Phenotype
)	O
and	O
distal	B-Phenotype
hereditary	I-Phenotype
motor	I-Phenotype
neuropathies	E-Phenotype
(	O
dHMN	S-Phenotype
)	O
.	O

Noise	B-Phenotype
-	I-Phenotype
induced	I-Phenotype
hidden	I-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
(	O
NIHHL	S-Phenotype
)	O
has	O
attracted	O
great	O
attention	O
in	O
hearing	O
research	O
and	O
clinical	O
audiology	O
since	O
the	O
discovery	O
of	O
significant	O
noise	O
-	O
induced	O
synaptic	O
damage	O
in	O
the	O
absence	O
of	O
permanent	O
threshold	O
shifts	O
(	O
PTS	O
)	O
in	O
animal	O
models	O
.	O

We	O
identified	O
22	O
genes	O
including	O
APC	O
,	O
KRAS	O
,	O
TP53	O
,	O
GNAS	O
,	O
NRAS	O
,	O
SMAD4	O
,	O
ARID2	O
,	O
and	O
PIK3CA	O
with	O
non	O
-	O
silent	O
mutations	O
in	O
the	O
cancer	S-Phenotype
Census	O
Genes	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
10	O
-	O
year	O
-	O
old	O
Spanish	O
girl	O
with	O
mutations	O
in	O
NADK2	O
Prenatal	O
central	O
nervous	O
system	O
abnormalities	O
showed	O
ventriculomegaly	S-Phenotype
,	O
colpocephaly	S-Phenotype
,	O
and	O
hypoplasia	B-Phenotype
of	I-Phenotype
the	I-Phenotype
corpus	I-Phenotype
callosum	E-Phenotype
.	O

Further	O
,	O
mice	O
heterozygous	O
for	O
either	O
Magoh	O
or	O
Rbm8a	O
exhibit	O
aberrant	O
neurogenesis	O
and	O
microcephaly	S-Phenotype
.	O

Recently	O
mutations	O
in	O
the	O
CASPR	O
/	O
CNTN1	O
complex	O
have	O
been	O
associated	O
with	O
similar	O
severe	O
phenotypes	O
and	O
CNTNAP1	O
gene	O
mutations	O
,	O
causing	O
loss	O
of	O
the	O
CASPR	O
protein	O
,	O
were	O
shown	O
to	O
cause	O
severe	O
,	O
prenatal	B-Phenotype
onset	I-Phenotype
arthrogryposis	I-Phenotype
multiplex	I-Phenotype
congenita	E-Phenotype
in	O
four	O
unrelated	O
families	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
expression	O
of	O
JIP3	O
in	O
temporal	B-Phenotype
lobe	I-Phenotype
epilepsy	E-Phenotype
(	O
TLE	S-Phenotype
)	O
and	O
in	O
a	O
kainic	O
acid	O
(	O
KA	O
)	O
-	O
induced	O
mouse	O
model	O
of	O
epileptic	B-Phenotype
seizures	E-Phenotype
,	O
and	O
determined	O
whether	O
down	O
-	O
regulation	O
of	O
JIP3	O
can	O
decrease	O
susceptibility	O
to	O
seizures	S-Phenotype
and	O
neuron	O
damage	O
induced	O
by	O
KA	O
.	O

The	O
A	O
Desintegrin	O
And	O
Metalloproteinase	O
23	O
(	O
ADAM23	O
)	O
gene	O
is	O
epigenetically	O
silenced	O
in	O
different	O
types	O
of	O
tumors	S-Phenotype
,	O
and	O
silencing	O
is	O
often	O
associated	O
with	O
advanced	O
disease	O
and	O
metastasis	O
.	O

High	O
mobility	O
group	O
A2	O
(	O
HMGA2	O
)	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
development	O
of	O
cancer	S-Phenotype
.	O

Independently	O
,	O
the	O
same	O
approach	O
identified	O
a	O
second	O
homozygous	O
truncating	O
GZF1	O
variant	O
in	O
another	O
multiplex	O
consanguineous	O
family	O
affected	O
by	O
severe	B-Phenotype
myopia	E-Phenotype
,	O
retinal	B-Phenotype
detachment	E-Phenotype
,	O
and	O
milder	O
skeletal	O
involvement	O
.	O

The	O
results	O
provide	O
evidence	O
that	O
lncRNA	O
-	O
numb	O
is	O
a	O
newly	O
proposed	O
tumor	S-Phenotype
suppressor	O
that	O
is	O
involved	O
in	O
HIC1	O
-	O
induced	O
phenotypes	O
.	O

Recent	O
GWAS	O
completed	O
for	O
three	O
types	O
of	O
common	O
adult	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
glaucoma	E-Phenotype
have	O
identified	O
novel	O
loci	O
for	O
POAG	O
(	O
primary	B-Phenotype
-	I-Phenotype
open	I-Phenotype
-	I-Phenotype
angle	I-Phenotype
glaucoma	E-Phenotype
)	O
(	O
ABCA1	O
,	O
AFAP1	O
,	O
GMDS	O
,	O
PMM2	O
,	O
TGFBR3	O
,	O
FNDC3B	O
,	O
ARHGEF12	O
,	O
GAS7	O
,	O
FOXC1	O
,	O
ATXN2	O
,	O
TXNRD2	O
)	O
;	O
PACG	O
(	O
primary	B-Phenotype
angle	I-Phenotype
-	I-Phenotype
closure	I-Phenotype
glaucoma	E-Phenotype
(	O
EPDR1	O
,	O
CHAT	O
,	O
GLIS3	O
,	O
FERMT2	O
,	O
DPM2	O
-	O
FAM102	O
)	O
;	O
and	O
exfoliation	O
syndrome	O
(	O
XFS	O
)	O
glaucoma	S-Phenotype
(	O
CACNA1A	O
)	O
.	O

Furthermore	O
,	O
both	O
the	O
GnRH2	O
and	O
GnRHR2	O
genes	O
are	O
expressed	O
in	O
human	O
reproductive	O
tumors	S-Phenotype
and	O
represent	O
emerging	O
targets	O
for	O
cancer	S-Phenotype
treatment	O
.	O

This	O
finding	O
provides	O
concrete	O
evidence	O
that	O
inhibition	O
of	O
both	O
MDH1	O
and	O
MDH2	O
may	O
provide	O
a	O
valuable	O
platform	O
for	O
developing	O
novel	O
therapeutics	O
that	O
target	O
cancer	S-Phenotype
metabolism	O
and	O
tumor	S-Phenotype
growth	O

Correct	O
classification	O
of	O
HGSC	O
may	O
have	O
potential	O
impacts	O
for	O
cancer	S-Phenotype
prevention	O
and	O
improve	O
our	O
understanding	O
of	O
ovarian	O
serous	O
carcinogenesis	O

The	O
strongly	O
positive	O
rate	O
of	O
LETM1	O
in	O
TNBC	O
was	O
69.2	O
%	O
(	O
74	O
/	O
107	O
)	O
,	O
which	O
was	O
significantly	O
higher	O
than	O
in	O
both	O
DCIS	O
35.7	O
%	O
(	O
15	O
/	O
42	O
)	O
and	O
adjacent	O
non	O
-	O
tumor	S-Phenotype
tissues	O
12.3	O
%	O
(	O
8	O
/	O
65	O
)	O
.	O

Glutaric	B-Phenotype
aciduria	I-Phenotype
type	I-Phenotype
I	E-Phenotype
(	O
GA	B-Phenotype
-	I-Phenotype
I	E-Phenotype
)	O
is	O
a	O
rare	O
organic	B-Phenotype
aciduria	E-Phenotype
caused	O
by	O
the	O
autosomal	B-Phenotype
recessive	E-Phenotype
inherited	O
deficiency	O
of	O
glutaryl	O
-	O
CoA	O
dehydrogenase	O
(	O
GCDH	O
)	O
.	O

With	O
a	O
combination	O
of	O
whole	O
-	O
genome	O
mapping	O
and	O
exome	O
sequencing	O
,	O
we	O
identified	O
three	O
mutations	O
in	O
REEP2	O
in	O
two	O
families	O
with	O
HSP	O
:	O
a	O
missense	O
variant	O
(	O
c.107TAAAAA	O
[	O
p.Val36Glu	O
]	O
)	O
that	O
segregated	O
in	O
the	O
heterozygous	O
state	O
in	O
a	O
family	O
with	O
autosomal	O
-	O
dominant	O
inheritance	S-Phenotype
and	O
a	O
missense	O
change	O
(	O
c.215TAAAAA	O
[	O
p.Phe72Tyr	O
]	O
)	O
that	O
segregated	O
in	O
trans	O
with	O
a	O
splice	O
site	O
mutation	O
(	O
c.105+3GAAAAT	O
)	O
in	O
a	O
family	O
with	O
autosomal	O
-	O
recessive	O
transmission	O
.	O

EPRS	O
and	O
its	O
regulated	O
estrogenic	O
gene	O
network	O
may	O
offer	O
a	O
promising	O
alternative	O
approach	O
to	O
target	O
ER+	O
breast	B-Phenotype
cancers	E-Phenotype
that	O
are	O
refractory	O
to	O
current	O
anti	O
-	O
estrogens	O

Mutations	O
in	O
KIF1C	O
are	O
responsible	O
for	O
autosomal	B-Phenotype
recessive	I-Phenotype
spastic	I-Phenotype
paraplegia	I-Phenotype
type	I-Phenotype
58	E-Phenotype
(	O
SPG58	S-Phenotype
)	O
and	O
spastic	B-Phenotype
ataxia	I-Phenotype
2	E-Phenotype
(	O
SPAX2	S-Phenotype
)	O
.	O

Results	O
indicate	O
the	O
importance	O
of	O
SLIT2	O
-	O
ROBO1	O
-	O
CDC42	O
signalling	O
pathway	O
in	O
predicting	O
tumour	S-Phenotype
progression	O
.	O

First	O
,	O
we	O
showed	O
that	O
TAMs	O
expressed	O
reduced	O
levels	O
of	O
FoxO1	O
,	O
which	O
was	O
associated	O
with	O
their	O
protumoral	O
M2	S-Phenotype
polarization	O
state	O
.	O

In	O
conclusion	O
,	O
p	O
-	O
STAT3	O
may	O
participate	O
in	O
the	O
progression	O
of	O
the	O
early	O
stage	O
of	O
colon	B-Phenotype
cancer	E-Phenotype
through	O
the	O
up	O
-	O
regulation	O
of	O
CD133	O
,	O
which	O
in	O
turn	O
induces	O
survivin	O
expression	O
.	O

Piezo2	O
is	O
needed	O
by	O
brain	O
metastatic	O
cells	O
from	O
breast	B-Phenotype
cancer	E-Phenotype
(	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
BrM2	O
)	O
to	O
probe	O
their	O
physical	O
environment	O
as	O
they	O
anchor	O
and	O
pull	O
on	O
their	O
surroundings	O
or	O
when	O
confronted	O
with	O
confined	O
migration	O
through	O
narrow	O
pores	O
.	O

Down	O
-	O
regulation	O
of	O
PTPN3	O
also	O
inhibited	O
cell	O
cycle	O
progression	O
,	O
migration	O
,	O
stemness	O
in	O
vitro	O
and	O
the	O
tumorigenicity	O
of	O
resistant	O
ovarian	B-Phenotype
cancer	E-Phenotype
cells	O
in	O
vivo	O
.	O

Ano1	O
is	O
a	O
Ca	O
(	O
2+	O
)	O
activated	O
Cl	O
(	O
-	O
)	O
channel	O
that	O
is	O
related	O
to	O
head	B-Phenotype
and	I-Phenotype
neck	I-Phenotype
cancer	E-Phenotype
,	O
often	O
caused	O
by	O
human	O
papilloma	S-Phenotype
virus	O
(	O
HPV	O
)	O
infection	O
.	O

Encapsulation	O
of	O
mirin	O
in	O
nanoparticles	O
allowed	O
its	O
use	O
on	O
MYCN	O
-	O
amplified	O
neuroblastoma	S-Phenotype
xenografts	O
in	O
vivo	O
,	O
which	O
resulted	O
in	O
a	O
sharp	O
impairment	O
of	O
tumor	S-Phenotype
growth	O
,	O
associated	O
with	O
DDR	O
activation	O
,	O
p53	O
accumulation	O
,	O
and	O
cell	O
death	O
.	O

Here	O
we	O
report	O
that	O
STX3	O
acts	O
as	O
an	O
oncogenic	O
protein	O
in	O
human	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

In	O
ALDHsup+	O
/	O
supCD24sup	O
-	O
/	O
supCD44sup+	O
/	O
sup	O
BCSCs	O
,	O
we	O
identified	O
P4HA2	O
,	O
PTGR1	O
and	O
RAB40B	O
as	O
potential	O
prognostic	O
markers	O
,	O
which	O
were	O
virtually	O
related	O
to	O
the	O
status	O
of	O
BCSCs	O
and	O
tumor	S-Phenotype
growth	O
in	O
TNBC	O
cells	O

Mutations	O
in	O
NOTCH3	O
causes	O
cerebral	B-Phenotype
autosomal	I-Phenotype
dominant	I-Phenotype
arteriopathy	I-Phenotype
with	I-Phenotype
subcortical	I-Phenotype
infarcts	I-Phenotype
and	I-Phenotype
leukoencephalopathy	E-Phenotype
(	O
CADASIL	S-Phenotype
)	O
,	O
a	O
hereditary	O
cerebrovascular	O
disease	O
that	O
leads	O
to	O
ischemic	B-Phenotype
strokes	E-Phenotype
and	O
dementia	S-Phenotype
,	O
but	O
in	O
which	O
migraine	S-Phenotype
is	O
often	O
present	O
,	O
sometimes	O
long	O
before	O
the	O
onset	O
of	O
other	O
symptoms	O
.	O

Single	O
nucleotide	O
polymorphisms	O
in	O
GLIS3	O
genes	O
have	O
been	O
associated	O
with	O
increased	O
risk	O
of	O
several	O
diseases	O
,	O
including	O
type	B-Phenotype
1	I-Phenotype
and	I-Phenotype
type	I-Phenotype
2	I-Phenotype
diabetes	E-Phenotype
,	O
glaucoma	S-Phenotype
,	O
and	O
neurological	O
disorders	O
.	O

A	O
similar	O
compensatory	O
approach	O
rescued	O
the	O
dampened	O
intravasation	O
of	O
LTBP3	O
-	O
deficient	O
HEp	O
-	O
3	O
cells	O
,	O
suggesting	O
that	O
LTBP3	O
regulates	O
the	O
induction	O
of	O
the	O
intravasation	O
-	O
supporting	O
angiogenic	O
vasculature	O
within	O
developing	O
primary	O
tumors	S-Phenotype
.	O

Taken	O
together	O
,	O
our	O
results	O
illustrated	O
that	O
LINC00963	O
-	O
miR	O
-	O
608	O
-	O
NACC1	O
pathway	O
might	O
be	O
a	O
potential	O
target	O
for	O
melanoma	S-Phenotype
therapy	O

studies	O
have	O
shown	O
that	O
mutations	O
in	O
the	O
CHEK2	O
gene	O
are	O
involved	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
susceptibility	O
due	O
to	O
its	O
impact	O

Although	O
mutations	O
in	O
ACAN	O
,	O
FGFR3	O
,	O
NPR2	O
,	O
and	O
SHOX	O
typically	O
lead	O
to	O
skeletal	B-Phenotype
dysplasia	E-Phenotype
,	O
and	O
mutations	O
in	O
GHRHR	O
,	O
GH1	O
,	O
GHR	O
,	O
STAT5B	O
,	O
IGF1	O
,	O
IGFALS	O
,	O
and	O
IGF1R	O
usually	O
underlie	O
hormonal	O
defects	O
of	O
the	O
growth	O
hormone	O
(	O
GH	O
)	O
-	O
insulin	O
-	O
like	O
growth	O
factor	O
1	O
(	O
IGF1	O
)	O
axis	O
,	O
such	O
mutations	O
have	O
also	O
been	O
identified	O
in	O
patients	O
with	O
idiopathic	B-Phenotype
short	I-Phenotype
stature	E-Phenotype
(	O
ISS	S-Phenotype
)	O
.	O

The	O
use	O
of	O
IVF	O
in	O
the	O
indication	O
AAAAAAdeep	O
infiltrating	O
endometriosisAAAAAA	S-Phenotype
allows	O
satisfactory	O
pregnancy	O
rates	O
without	O
significant	O
risk	O
,	O
regarding	O
disease	O
progression	O
or	O
oocyte	O
retrieval	O
procedure	O
morbidity	O

Similar	O
changes	O
of	O
GPNMB	O
and	O
G0S2	O
expression	O
were	O
present	O
in	O
a	O
human	O
liposarcoma	S-Phenotype
database	O
.	O

We	O
sequenced	O
GATM	O
,	O
GAMT	O
and	O
SLC6A8	O
genes	O
in	O
166	O
patients	O
with	O
autism	S-Phenotype
(	O
coding	O
sequence	O
,	O
introns	O
and	O
adjacent	O
untranslated	O
regions	O
)	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
DNAJC12	O
coding	O
mutations	O
in	O
sporadic	S-Phenotype
Chinese	O
Han	O
patients	O
with	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
and	O
test	O
whether	O
an	O
age	O
-	O
of	O
-	O
onset	O
effect	O
exists	O
.	O

Up	O
to	O
now	O
ATP2B2	O
has	O
only	O
been	O
reported	O
as	O
a	O
modifier	O
,	O
or	O
in	O
a	O
digenic	O
mechanism	O
with	O
CDH23	O
for	O
hearing	B-Phenotype
impairment	E-Phenotype
in	O
humans	O
.	O

However	O
,	O
there	O
is	O
no	O
study	O
concerning	O
the	O
specific	O
role	O
of	O
Kank1	O
in	O
the	O
development	O
and	O
progression	O
of	O
lung	B-Phenotype
cancer	E-Phenotype
.	O

Generalized	B-Phenotype
arterial	I-Phenotype
calcification	I-Phenotype
of	I-Phenotype
infancy	E-Phenotype
(	O
GACI	S-Phenotype
)	O
,	O
or	O
idiopathic	B-Phenotype
infantile	I-Phenotype
arterial	I-Phenotype
calcification	E-Phenotype
,	O
is	O
a	O
rare	O
autosomal	O
-	O
recessive	O
disease	O
recognized	O
aAs	O
an	O
inherited	O
disorder	O
characterized	O
by	O
severe	O
pathologic	O
calcification	O
of	O
large	O
-	O
and	O
medium	O
-	O
sized	O
arteries	O
accompanied	O
by	O
smooth	O
muscle	O
cell	O
(	O
SMC	O
)	O
hyperplasia	O
leading	O
to	O
vascular	O
obstruction	O
[	O
1	O
]	O
.	O

Our	O
study	O
expands	O
the	O
genetic	O
heterogeneity	S-Phenotype
of	O
RTT	O
and	O
RTT	O
-	O
like	O
phenotypes	O
.	O

a	O
small	O
fraction	O
of	O
the	O
breast	B-Phenotype
cancer	E-Phenotype
burden	O
,	O
mutations	O
in	O
the	O
BRCA1	O
and	O
BRCA2	O
genes	O
are	O
known	O
to	O
confer	O
a	O
high	O

To	O
decipher	O
a	O
mechanism	O
for	O
this	O
,	O
we	O
previously	O
generated	O
a	O
mathematical	O
model	O
of	O
how	O
estrogen	O
-	O
mediated	O
upregulation	O
of	O
the	O
transcription	O
factor	O
,	O
E2F6	O
,	O
upregulates	O
the	O
ovarian	B-Phenotype
cancer	E-Phenotype
stem	O
/	O
initiating	O
cell	O
marker	O
,	O
c	O
-	O
Kit	O
,	O
by	O
epigenetic	O
silencing	O
the	O
tumor	S-Phenotype
suppressor	O
miR	O
-	O
193a	O
,	O
and	O
a	O
competing	O
endogenous	O
(	O
ceRNA	O
)	O
mechanism	O
.	O

Aminoacyl	O
-	O
tRNA	O
synthetase	O
complex	O
(	O
ARS	O
)	O
-	O
interacting	O
multifunctional	O
protein	O
1	O
(	O
AIMP1	O
)	O
is	O
a	O
cytokine	O
that	O
is	O
known	O
to	O
amplify	O
the	O
actions	O
of	O
tumor	S-Phenotype
necrosis	O
factor	O
-	O
α	O
and	O
to	O
be	O
involved	O
in	O
microglial	O
activation	O
and	O
neuronal	O
death	O
.	O

In	O
this	O
study	O
,	O
a	O
TF	O
-	O
cascade	O
-	O
targeted	O
strategy	O
aiming	O
to	O
disrupt	O
tumor	S-Phenotype
blood	O
vessels	O
was	O
developed	O
by	O
combination	O
of	O
TF	O
-	O
targeted	O
HMME	O
-	O
loaded	O
drug	O
delivery	O
system	O
and	O
PDT	O
.	O

The	O
results	O
showed	O
FRMD4A	O
overexpression	O
in	O
tongue	O
squamous	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
,	O
and	O
the	O
positive	O
reaction	O
was	O
predominately	O
located	O
in	O
the	O
cytoplasm	O
.	O

We	O
report	O
a	O
sibling	O
pair	O
with	O
FTHS	O
caused	O
by	O
a	O
homozygous	O
,	O
novel	O
mutation	O
pLys133Glnfs	O
*	O
13	O
in	O
the	O
SH3PXD2B	O
gene	O
:	O
one	O
sibling	O
had	O
bilateral	B-Phenotype
ocular	I-Phenotype
hypertension	E-Phenotype
and	O
unilateral	B-Phenotype
colobomas	I-Phenotype
of	I-Phenotype
iris	I-Phenotype
,	I-Phenotype
choroid	I-Phenotype
and	I-Phenotype
retina	E-Phenotype
;	O
the	O
other	O
,	O
unilateral	O
myelinated	O
nerve	O
fiber	O
layer	O
of	O
the	O
optic	O
disk	O
and	O
papilledema	S-Phenotype
due	O
to	O
idiopathic	B-Phenotype
intracranial	I-Phenotype
hypertension	E-Phenotype
.	O

Three	O
affected	O
individuals	O
from	O
a	O
small	O
Bedouin	O
clan	O
presented	O
with	O
failure	B-Phenotype
to	I-Phenotype
thrive	E-Phenotype
,	O
hyponatremic	B-Phenotype
dehydration	E-Phenotype
and	O
hyperkalemia	S-Phenotype
with	O
isolated	B-Phenotype
sweat	I-Phenotype
salt	I-Phenotype
wasting	E-Phenotype
.	O

Trop2	O
,	O
a	O
transmembrane	O
glycoprotein	O
,	O
has	O
emerged	O
as	O
a	O
biomarker	O
for	O
targeted	O
cancer	S-Phenotype
therapy	O
since	O
it	O
is	O
overexpressed	O
in	O
80	O
%	O
of	O
triple	O
negative	O
breast	B-Phenotype
cancer	E-Phenotype
(	O
TNBC	O
)	O
patients	O
.	O

The	O
quality	O
of	O
care	O
for	O
LTC	O
residents	O
with	O
COPD	O
is	O
heterogeneous	S-Phenotype
in	O
regard	O
to	O
both	O
the	O
facility	O
and	O
the	O
patient	O
.	O

X	O
-	O
ALD	O
is	O
clinically	O
heterogeneous	S-Phenotype
,	O
with	O
the	O
cerebral	O
form	O
being	O
the	O
most	O
severe	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
mutations	O
of	O
the	O
G	O
protein	O
-	O
coupled	O
receptor	O
143	O
(	O
GPR143	O
)	O
gene	O
for	O
ocular	B-Phenotype
albinism	I-Phenotype
type	I-Phenotype
1	E-Phenotype
(	O
OA1	S-Phenotype
)	O
in	O
Chinese	O
patients	O
.	O

MiRNAs	O
are	O
also	O
secreted	O
through	O
the	O
small	O
vesicles	O
called	O
exosomes	O
,	O
which	O
are	O
endosome	O
-	O
derived	O
vesicles	O
from	O
various	O
cell	O
types	O
including	O
immune	O
and	O
tumor	S-Phenotype
cells	O
.	O

Here	O
we	O
report	O
that	O
UBE3A	O
ubiquitylates	O
and	O
triggers	O
degradation	O
of	O
the	O
tumor	S-Phenotype
-	O
suppressive	O
sirtuin	O
SIRT6	O
in	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
.	O

We	O
previously	O
identified	O
a	O
set	O
of	O
the	O
most	O
frequently	O
mutated	O
cytoskeleton	O
-	O
and	O
extracellular	O
matrix	O
-	O
related	O
proteins	O
(	O
CECMPs	O
)	O
in	O
numerous	O
cancer	S-Phenotype
datasets	O
.	O

Patients	O
with	O
physical	O
findings	O
suggestive	O
of	O
Treacher	B-Phenotype
Collins	I-Phenotype
syndrome	E-Phenotype
(	O
TCS	S-Phenotype
)	O
or	O
mandibulofacial	B-Phenotype
dysostosis	E-Phenotype
(	O
MFD	S-Phenotype
)	O
and	O
macrocytic	B-Phenotype
anemia	E-Phenotype
diagnostic	O
of	O
Diamond	B-Phenotype
-	I-Phenotype
Blackfan	I-Phenotype
anemia	E-Phenotype
(	O
DBA	S-Phenotype
)	O
have	O
been	O
reported	O
.	O

Mutations	O
in	O
liMatrin	O
3	O
/	O
i	O
(	O
liMATR3	O
/	O
i	O
)	O
,	O
a	O
poorly	O
understood	O
DNA	O
-	O
and	O
RNA	O
-	O
binding	O
protein	O
,	O
cause	O
familial	O
ALS	O
/	O
FTD	O
,	O
and	O
MATR3	O
pathology	O
is	O
a	O
feature	O
of	O
sporadic	S-Phenotype
disease	O
,	O
suggesting	O
that	O
MATR3	O
dysfunction	O
is	O
integrally	O
linked	O
to	O
ALS	O
pathogenesis	O
.	O

Ccn6supfl	O
/	O
fl	O
/	O
sup	O
;	O
MMTV	O
-	O
Cre	O
mice	O
developed	O
invasive	O
high	O
grade	O
mammary	O
carcinomas	S-Phenotype
with	O
bona	O
fide	O
EMT	O
,	O
histologically	O
similar	O
to	O
human	O
metaplastic	B-Phenotype
breast	I-Phenotype
carcinomas	E-Phenotype
.	O

We	O
show	O
that	O
active	O
cofilin	O
,	O
LIMK1	O
,	O
LIMK2	O
,	O
and	O
SSH1	O
are	O
overexpressed	O
in	O
human	O
CRC	O
and	O
are	O
associated	O
with	O
tumor	S-Phenotype
progression	O
parameters	O
.	O

Importantly	O
,	O
KLF4	O
inhibitor	O
Kenpaullone	O
sensitizes	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
and	O
xenograft	O
tumors	S-Phenotype
to	O
Paclitaxel	O
and	O
improves	O
therapeutic	O
effects	O
.	O

Screening	O
the	O
PANK2	O
gene	O
in	O
the	O
patients	O
as	O
well	O
as	O
their	O
unaffected	O
family	O
members	O
revealed	O
a	O
functional	O
single	O
nucleotide	O
variation	O
,	O
perfectly	O
segregating	O
in	O
the	O
patient	O
's	O
family	O
in	O
an	O
autosomal	B-Phenotype
recessive	I-Phenotype
mode	I-Phenotype
of	I-Phenotype
inheritance	E-Phenotype
.	O

In	O
SDHB	O
-	O
related	O
syndrome	O
,	O
PPGL	O
maintenance	O
seems	O
to	O
be	O
reduced	O
compared	O
to	O
SDHD	O
(	O
p	O
=	O
0.04	O
vs	O
0.95	O
)	O
due	O
to	O
higher	O
probability	O
of	O
tumor	S-Phenotype
cell	O
regression	O
in	O
SDHB	O
vs	O
SDHD	O
(	O
p	O
=	O
0.87	O
vs	O
0.00	O
)	O
.	O

However	O
,	O
the	O
functions	O
of	O
GLIS3	O
in	O
the	O
thyroid	O
gland	O
and	O
the	O
mechanism	O
by	O
which	O
GLIS3	O
dysfunction	O
causes	O
hypothyroidism	S-Phenotype
are	O
unknown	O
.	O

PLAG1	O
overexpression	O
accelerates	O
growth	O
of	O
Wilms	B-Phenotype
tumor	E-Phenotype
cells	O
in	O
vitro	O
and	O
induces	O
neoplastic	O
growth	O
in	O
the	O
developing	O
mouse	O
kidney	O
in	O
vivo	O
.	O

In	O
vitro	O
and	O
in	O
vivo	O
(	O
a	O
subcutaneous	O
BALB	O
/	O
c	O
nude	O
mouse	O
model	O
)	O
studies	O
showed	O
that	O
exosomal	O
ZIP4	O
can	O
significantly	O
promote	O
pancreatic	B-Phenotype
cancer	E-Phenotype
growth	O
.	O

We	O
show	O
that	O
morpholino	O
-	O
mediated	O
inpp5k	O
loss	O
of	O
function	O
in	O
the	O
zebrafish	O
results	O
in	O
shortened	O
body	O
axis	O
,	O
microphthalmia	S-Phenotype
with	O
disorganized	O
lens	O
,	O
microcephaly	S-Phenotype
,	O
reduced	O
touch	O
-	O
evoked	O
motility	O
,	O
and	O
highly	O
disorganized	O
myofibers	O
.	O

p53R2	O
expression	O
is	O
significantly	O
upregulated	O
at	O
both	O
mRNA	O
and	O
protein	O
levels	O
in	O
cervical	B-Phenotype
cancer	E-Phenotype
cells	O
and	O
tissues	O
,	O
compared	O
with	O
that	O
in	O
matched	O
normal	O
cervical	O
cells	O
and	O
tissues	O
,	O
respectively	O
.	O

Imatinib	O
is	O
a	O
tyrosine	O
kinase	O
inhibitor	O
specific	O
for	O
platelet	O
-	O
derived	O
growth	O
factor	O
receptor	O
and	O
is	O
expected	O
as	O
a	O
treatment	O
option	O
for	O
pulmonary	B-Phenotype
arterial	I-Phenotype
hypertension	E-Phenotype
(	O
PAH	S-Phenotype
)	O
.	O

Oral	B-Phenotype
and	I-Phenotype
pharyngeal	I-Phenotype
cancers	E-Phenotype
combined	O
were	O
associated	O
with	O
loci	O
at	O
6p21.32	O
(	O
rs3828805	O
,	O
HLA	O
-	O
DQB1	O
)	O
,	O
10q26.13	O
(	O
rs201982221	O
,	O
LHPP	O
)	O
and	O
11p15.4	O
(	O
rs1453414	O
,	O
OR52N2	O
-	O
TRIM5	O
)	O
.	O

The	O
transcriptional	O
coactivator	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
-	O
gamma	O
coactivator	O
1	O
-	O
alpha	O
(	O
PGC	O
-	O
1α	O
)	O
has	O
been	O
linked	O
to	O
multiple	O
neurological	O
and	O
psychiatric	B-Phenotype
disorders	E-Phenotype
including	O
schizophrenia	S-Phenotype
,	O
but	O
its	O
involvement	O
in	O
the	O
pathophysiology	O
of	O
these	O
disorders	O
is	O
unclear	O
.	O

Mutations	O
in	O
AP5Z1	O
,	O
encoding	O
a	O
subunit	O
of	O
the	O
AP	O
-	O
5	O
complex	O
,	O
have	O
been	O
reported	O
to	O
cause	O
hereditary	B-Phenotype
spastic	I-Phenotype
paraplegia	E-Phenotype
(	O
HSP	S-Phenotype
)	O
,	O
although	O
their	O
impact	O
at	O
the	O
cellular	O
level	O
has	O
not	O
been	O
assessed	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
function	O
of	O
HOXB1	O
and	O
the	O
relationship	O
between	O
HOXB1	O
and	O
miR	O
-	O
3175	O
in	O
glioma	S-Phenotype
.	O

Carriers	O
of	O
CT	O
or	O
TT	O
genotype	O
of	O
CCL2	O
rs13900	O
had	O
increased	O
risk	O
of	O
hearing	B-Phenotype
loss	E-Phenotype
at	O
birth	O
and	O
at	O
6	O
months	O
of	O
age	O
(	O
aOR	O
=	O
3.59	O
;	O
p	O
=	O
0.028	O
and	O
aOR	O
=	O
4.10	O
;	O
p	O
=	O
0.039	O
,	O
respectively	O
)	O
.	O

Genes	O
harboring	O
the	O
most	O
significant	O
mutations	O
include	O
PCDH9	O
,	O
KLHL12	O
,	O
DCAF4L1	O
,	O
and	O
VHL	O
in	O
sporadic	S-Phenotype
HBs	O
,	O
and	O
ZNF814	O
,	O
DLG2	O
,	O
RIMS1	O
,	O
PNN	O
,	O
and	O
MUC7	O
in	O
familial	O
HBs	O
.	O

RhoA	O
activity	O
is	O
significantly	O
increased	O
in	O
cortical	O
cultures	O
derived	O
from	O
LGI1	O
null	O
mice	O
and	O
using	O
a	O
reconstituted	O
system	O
;	O
we	O
show	O
directly	O
that	O
LGI1	O
antagonizes	O
NgR1	O
-	O
tumor	S-Phenotype
necrosis	O
factor	O
receptor	O
orphan	O
Y	O
(	O
TROY	O
)	O
signaling	O
.	O

Reduced	O
HOXB1	O
expression	O
promoted	O
the	O
proliferation	O
and	O
invasion	O
of	O
glioma	S-Phenotype
cells	O
,	O
and	O
inhibited	O
their	O
apoptosis	O
in	O
vitro	O
,	O
and	O
the	O
downregulation	O
of	O
HOXB1	O
was	O
also	O
associated	O
with	O
worse	O
survival	O
in	O
glioma	S-Phenotype
patients	O
.	O

Previously	O
,	O
we	O
reported	O
that	O
human	O
hepatoma	O
cells	O
that	O
harbor	O
OXPHOS	O
defects	O
exhibit	O
high	O
tumor	S-Phenotype
cell	O
invasiveness	O
via	O
elevated	O
claudin	O
-	O
1	O
(	O
CLN1	O
)	O
.	O

PRA	O
is	O
characterized	O
by	O
visual	B-Phenotype
impairment	E-Phenotype
due	O
to	O
degeneration	O
of	O
the	O
photoreceptors	O
in	O
the	O
retina	O
,	O
usually	O
leading	O
to	O
blindness	S-Phenotype
.	O

The	O
RANK	O
-	O
c	O
-	O
mediated	O
inhibition	O
of	O
cancer	S-Phenotype
cell	O
aggressiveness	S-Phenotype
and	O
nuclear	O
factor	O
-	O
κB	O
(	O
NF	O
-	O
κB	O
)	O
activation	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
seems	O
to	O
rely	O
on	O
a	O
RANK	O
-	O
c	O
/	O
TNF	O
receptor	O
-	O
associated	O
factor	O
-	O
2	O
(	O
TRAF2	O
)	O
protein	O
interaction	O
.	O

Finally	O
,	O
it	O
was	O
observed	O
that	O
4	O
hub	O
genes	O
were	O
highly	O
expressed	O
in	O
gastric	B-Phenotype
cancer	E-Phenotype
tissue	O
compared	O
with	O
para‑carcinoma	O
tissue	O
in	O
the	O
12	O
patients	O
;	O
the	O
increased	O
TSPAN4	O
was	O
significant	O
(	O
AAAA5‑fold	O
)	O
.	O

Spastic	B-Phenotype
paraplegia	E-Phenotype
(	O
SPG	S-Phenotype
)	O
type	O
28	O
is	O
an	O
autosomal	B-Phenotype
recessive	I-Phenotype
SPG	E-Phenotype
caused	O
by	O
mutations	O
in	O
the	O
DDHD1	O
gene	O
.	O

Low	O
-	O
density	O
lipoprotein	O
receptor	O
-	O
related	O
protein	O
4	O
(	O
LRP4	O
)	O
is	O
a	O
multi	O
-	O
functional	O
protein	O
implicated	O
in	O
bone	O
,	O
kidney	O
and	O
neurological	O
diseases	O
including	O
Cenani	B-Phenotype
-	I-Phenotype
Lenz	I-Phenotype
syndactyly	E-Phenotype
(	O
CLS	S-Phenotype
)	O
,	O
sclerosteosis	S-Phenotype
,	O
osteoporosis	S-Phenotype
,	O
congenital	B-Phenotype
myasthenic	I-Phenotype
syndrome	E-Phenotype
and	O
myasthenia	B-Phenotype
gravis	E-Phenotype
.	O

Previous	O
work	O
has	O
demonstrated	O
the	O
effectiveness	O
of	O
inhibiting	O
CHK1	O
with	O
small	O
-	O
molecule	O
inhibitors	O
,	O
but	O
the	O
role	O
of	O
CHK1	O
mediated	O
DDR	O
in	O
medulloblastoma	S-Phenotype
is	O
unknown	O
.	O

Functional	O
assays	O
indicate	O
that	O
SPINT2	O
reactivation	O
ameliorates	O
the	O
malignant	O
phenotype	O
,	O
specifically	O
reducing	O
cell	O
viability	O
,	O
migration	O
and	O
invasion	O
in	O
diverse	O
cancer	S-Phenotype
cell	O
lines	O
.	O

In	O
keeping	O
with	O
this	O
key	O
role	O
in	O
cell	O
fate	O
,	O
liGFI1B	O
/	O
i	O
is	O
emerging	O
as	O
a	O
gene	O
involved	O
in	O
cancer	S-Phenotype
,	O
which	O
also	O
includes	O
solid	O
tumors	S-Phenotype
.	O

BRCA1	O
,	O
BRCA2	O
)	O
that	O
are	O
responsible	O
for	O
familial	O
clustering	O
of	O
ovarian	B-Phenotype
cancer	E-Phenotype
cases	O
;	O
more	O
moderate	O
penetrance	O
susceptibility	O
genes	O
(	O
e.g	O
.	O

Although	O
mammalian	O
MEGF10	O
is	O
expressed	O
in	O
the	O
central	O
nervous	O
system	O
as	O
well	O
as	O
in	O
skeletal	O
muscle	O
,	O
patients	O
carrying	O
mutations	O
in	O
MEGF10	O
do	O
not	O
show	O
symptoms	O
of	O
central	O
nervous	O
system	O
dysfunction	O
.	O

Thus	O
,	O
liJPH3	O
/	O
i	O
was	O
identified	O
as	O
a	O
novel	O
TSG	O
methylated	O
in	O
colorectal	B-Phenotype
and	I-Phenotype
gastric	I-Phenotype
tumors	E-Phenotype
which	O
promotes	O
mitochondrial	O
-	O
mediated	O
apoptosis	O
,	O
also	O
as	O
a	O
potential	O
metastasis	O
and	O
survival	O
biomarker	O
for	O
digestive	O
cancers	S-Phenotype

An	O
additional	O
locus	O
for	O
autosomal	B-Phenotype
recessive	E-Phenotype
Charcot	O
-	O
Marie	O
-	O
Tooth	O
disease	O
type	O
2H	O
on	O
chromosome	O
8q13	O
-	O
21.1	O
was	O
excluded	O
by	O
linkage	O
analysis	O
.	O

Whole	O
exome	O
sequencing	O
of	O
the	O
patient	O
and	O
his	O
parents	O
ruled	O
out	O
mutations	O
in	O
11	O
known	O
hypodontia	S-Phenotype
-	O
associated	O
genes	O
including	O
WNT10A	O
,	O
MSX1	O
,	O
EDA	O
,	O
EDAR	O
,	O
EDARADD	O
,	O
PAX9	O
,	O
AXIN2	O
,	O
GREM2	O
,	O
NEMO	O
,	O
KRT17	O
,	O
and	O
TFAP2B	O
.	O

In	O
neonatal	B-Phenotype
seizures	E-Phenotype
,	O
defects	O
in	O
liALDH7A1	O
and	O
PNPO	O
/	O
i	O
explain	O
a	O
major	O
fraction	O
of	O
cases	O
.	O

Furthermore	O
,	O
in	O
clinical	O
specimens	O
,	O
increased	O
UBE3A	O
levels	O
correlated	O
with	O
reduced	O
SIRT6	O
levels	O
and	O
elevated	O
ANXA2	O
levels	O
in	O
increasing	O
tumor	S-Phenotype
grades	O
.	O

The	O
Kinesin	O
family	O
member	O
2a	O
(	O
KIF2A	O
)	O
,	O
that	O
belongs	O
to	O
the	O
Kinesin	O
-	O
13	O
microtubule	O
depolymerases	O
,	O
plays	O
an	O
important	O
role	O
in	O
cancer	S-Phenotype
cell	O
proliferation	O
,	O
migration	O
and	O
apoptosis	O
in	O
various	O
types	O
of	O
cancer	S-Phenotype
such	O
as	O
gastric	B-Phenotype
cancer	E-Phenotype
,	O
breast	B-Phenotype
cancer	E-Phenotype
,	O
and	O
squamous	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
of	O
the	O
oral	O
tongue	O
,	O
but	O
,	O
its	O
role	O
and	O
mechanism	O
in	O
lung	B-Phenotype
adenocarcinoma	E-Phenotype
(	O
LUAD	S-Phenotype
)	O
is	O
largely	O
unknown	O
.	O

Late	O
onset	O
of	O
clinical	O
symptoms	O
in	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
results	O
in	O
late	O
diagnosis	O
and	O
poor	O
disease	O
outcome	O
.	O

Targeted	O
deletion	O
of	O
Wnt1	O
in	O
mesenchymal	O
progenitors	O
led	O
to	O
spontaneous	B-Phenotype
fractures	E-Phenotype
due	O
to	O
impaired	O
osteoblast	O
function	O
and	O
increased	B-Phenotype
bone	I-Phenotype
resorption	E-Phenotype
,	O
mimicking	O
the	O
severe	O
OI	O
phenotype	O
in	O
humans	O
with	O
homozygous	O
WNT1	O
mutations	O
.	O

Homozygous	O
and	O
compound	O
heterozygous	O
mutations	O
in	O
KATNB1	O
have	O
very	O
recently	O
been	O
described	O
as	O
a	O
cause	O
of	O
microcephaly	S-Phenotype
with	O
brain	B-Phenotype
malformations	E-Phenotype
and	O
seizures	S-Phenotype
.	O

Mutations	O
with	O
milder	O
presentation	O
(	O
homozygous	O
p.D132A	O
/	O
EXOSC3	O
or	O
VRK1	O
)	O
may	O
display	O
additionally	O
signs	O
of	O
upper	O
motor	O
neuron	O
impairment	O
,	O
dystonia	S-Phenotype
or	O
ataxia	S-Phenotype
and	O
die	O
at	O
age	O
between	O
5	O
and	O
18	O
years	O
.	O

In	O
addition	O
,	O
differences	O
in	O
pathology	O
of	O
the	O
kidneys	O
from	O
WDR19	O
mutations	O
may	O
result	O
in	O
heterogeneous	S-Phenotype
features	O
in	O
renal	O
ultrasound	O
findings	O
.	O

Taken	O
together	O
,	O
these	O
results	O
reveal	O
that	O
OVAAL	O
contributes	O
to	O
the	O
survival	O
of	O
cancer	S-Phenotype
cells	O
through	O
dual	O
mechanisms	O
controlling	O
RAF	O
/	O
MEK	O
/	O
ERK	O
signaling	O
and	O
p27	O
-	O
mediated	O
cell	O
senescence	O

Polymorphisms	O
in	O
the	O
genes	O
encoding	O
carbamoyl	O
-	O
phosphate	O
synthase	O
1	O
(	O
CPS1	O
)	O
and	O
N	O
-	O
acetylglutamate	O
synthase	O
(	O
NAGS	O
)	O
were	O
recently	O
reported	O
to	O
be	O
risk	O
factors	O
for	O
the	O
development	O
of	O
hyperammonemia	S-Phenotype
during	O
valproic	O
acid	O
-	O
based	O
therapy	O
.	O

Previously	O
we	O
implicated	O
four	O
missense	O
variants	O
in	O
the	O
X	O
-	O
linked	O
THOC2	O
gene	O
in	O
intellectual	B-Phenotype
disability	E-Phenotype
(	O
ID	S-Phenotype
)	O
.	O

Antiepileptic	O
drugs	O
remain	O
the	O
treatment	O
of	O
choice	O
for	O
PKD	O
and	O
episodic	S-Phenotype
ataxia	S-Phenotype
type	O
1	O
,	O
benzodiazepines	O
are	O
often	O
useful	O
for	O
PNKD	O
,	O
and	O
episodic	B-Phenotype
ataxia	E-Phenotype
type	O
2	O
benefits	O
from	O
acetazolamide	O
regardless	O
of	O
the	O
genetic	O
etiology	O

We	O
expand	O
the	O
knowledge	O
about	O
TTC7A	O
deficiency	O
,	O
describing	O
a	O
patient	O
with	O
the	O
mild	O
phenotype	O
of	O
TTC7A	O
deficiency	O
but	O
presenting	O
overlapping	O
features	O
of	O
SD	O
/	O
THE	O
and	O
MIA	O
-	O
CID	O
:	O
intestinal	B-Phenotype
atresia	E-Phenotype
and	O
inflammatory	B-Phenotype
bowel	I-Phenotype
disease	E-Phenotype
evocative	O
of	O
MIA	O
-	O
CID	O
,	O
but	O
also	O
dental	B-Phenotype
abnormalities	E-Phenotype
,	O
huge	B-Phenotype
forehead	E-Phenotype
,	O
liver	B-Phenotype
abnormalities	E-Phenotype
,	O
autoimmune	B-Phenotype
thyroiditis	E-Phenotype
and	O
hypogammaglobulinemia	S-Phenotype
,	O
evocative	O
of	O
SD	O
/	O
THE	O

p75NTR	O
in	O
HNSCC	O
might	O
be	O
related	O
with	O
NGF	O
-	O
independent	O
therapy	O
resistance	O
,	O
while	O
NTRK1	O
might	O
transduce	O
a	O
survival	O
signal	O
of	O
NGF	O
and	O
contribute	O
in	O
this	O
way	O
to	O
improved	O
tumor	S-Phenotype
cell	O
survival	O
after	O
cell	O
cycle	O
arrest	O

Here	O
,	O
we	O
report	O
that	O
PEPCK	O
-	O
M	O
-	O
dependent	O
glycerol	O
phosphate	O
formation	O
from	O
noncarbohydrate	O
precursors	O
(	O
glyceroneogenesis	O
)	O
occurs	O
in	O
starved	O
lung	B-Phenotype
cancer	E-Phenotype
cells	O
and	O
supports	O
de	O
novo	O
glycerophospholipid	O
synthesis	O
.	O

In	O
vivo	O
,	O
Plk1	O
overexpression	O
prevents	O
the	O
development	O
of	O
Kras	B-Phenotype
-	I-Phenotype
induced	I-Phenotype
and	I-Phenotype
Her2	I-Phenotype
-	I-Phenotype
induced	I-Phenotype
mammary	I-Phenotype
gland	I-Phenotype
tumors	E-Phenotype
,	O
in	O
the	O
presence	O
of	O
increased	O
rates	O
of	O
chromosome	O
instability	O
.	O

Furthermore	O
,	O
we	O
used	O
publicly	O
available	O
datasets	O
to	O
validate	O
that	O
the	O
late	B-Phenotype
-	I-Phenotype
stage	I-Phenotype
lung	I-Phenotype
adenocarcinoma	E-Phenotype
patients	O
showed	O
higher	O
expression	O
HK2	O
and	O
GBE1	O
than	O
early	O
-	O
stage	O
ones	O
.	O

miR	O
-	O
142	O
-	O
3p	O
might	O
therefore	O
help	O
to	O
target	O
cancer	S-Phenotype
stem	O
cells	O

We	O
suggest	O
that	O
leukemias	S-Phenotype
and	O
lymphomas	S-Phenotype
with	O
FLT3	O
fusion	O
genes	O
exhibit	O
similar	O
clinicopathologic	O
features	O
to	O
,	O
and	O
should	O
be	O
included	O
in	O
,	O
the	O
WHO	O
category	O
of	O
AAAAAAMyeloid	B-Phenotype
and	I-Phenotype
lymphoid	I-Phenotype
neoplasms	E-Phenotype
with	O
eosinophilia	S-Phenotype
and	O
abnormalities	O
of	O
PDGFRA	O
,	O
PDGFRB	O
,	O
or	O
FGFR1	O
,	O
or	O
with	O
PCM1	O
-	O
JAK2.AAAAA	O

We	O
confirmed	O
variants	O
in	O
BRCA2	O
as	O
the	O
most	O
common	O
high	O
-	O
penetrant	O
genetic	O
factor	O
associated	O
with	O
pancreatic	B-Phenotype
cancer	E-Phenotype
and	O
we	O
also	O
identified	O
candidate	O
pancreatic	B-Phenotype
cancer	E-Phenotype
genes	O
.	O

In	O
this	O
study	O
we	O
show	O
that	O
downregulation	O
of	O
Lin28b	O
by	O
miR	O
-	O
125a	O
partially	O
accounts	O
for	O
its	O
antiproliferative	O
activity	O
toward	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
cells	O
.	O

Our	O
findings	O
demonstrate	O
that	O
variants	O
disrupting	O
EBF3	O
-	O
mediated	O
transcriptional	O
regulation	O
cause	O
intellectual	B-Phenotype
disability	E-Phenotype
and	O
developmental	B-Phenotype
delay	E-Phenotype
and	O
are	O
present	O
in	O
a0.1	O
%	O
of	O
individuals	O
with	O
unexplained	O
neurodevelopmental	O
disorders	O

This	O
comprehensive	O
update	O
of	O
novel	O
and	O
previously	O
reported	O
breast	B-Phenotype
cancer	E-Phenotype
susceptibility	O
loci	O
contributes	O
to	O
the	O
establishment	O
of	O
a	O
panel	O
of	O
SNPs	O
that	O
modify	O
breast	B-Phenotype
cancer	E-Phenotype
risk	O
in	O
BRCA2	O
mutation	O
carriers	O
.	O

These	O
findings	O
suggest	O
that	O
ZEB1	O
is	O
not	O
only	O
driving	O
EMT	O
,	O
but	O
also	O
contributes	O
to	O
the	O
formation	O
of	O
osteolytic	O
bone	O
metastases	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

In	O
parallel	O
,	O
we	O
recently	O
reported	O
that	O
Cc2d1a	O
-	O
deficient	O
mice	O
present	O
with	O
cognitive	O
and	O
social	O
deficits	O
,	O
hyperactivity	S-Phenotype
and	O
anxiety	S-Phenotype
.	O

This	O
chapter	O
focuses	O
on	O
the	O
current	O
data	O
covering	O
the	O
etiology	O
and	O
epidemiology	O
,	O
clinical	O
presentation	O
,	O
and	O
pathogenesis	O
of	O
four	O
monogenic	O
forms	O
of	O
isolated	O
dystonia	S-Phenotype
:	O
DYT	O
-	O
TOR1A	O
,	O
DYT	O
-	O
THAP1	O
,	O
DYT	O
-	O
GCH1	O
,	O
and	O
DYT	O
-	O
GNAL	O

Recently	O
,	O
pan	O
-	O
TRK	O
inhibitors	O
have	O
been	O
evaluated	O
and	O
their	O
dramatic	O
clinical	O
activity	O
is	O
being	O
shown	O
for	O
a	O
variety	O
of	O
cancer	S-Phenotype
types	O
harboring	O
an	O
NTRK	O
rearrangement	O
in	O
phase	O
I	O
trials	O
.	O

MALT1	O
is	O
an	O
intracellular	O
protease	O
that	O
mediates	O
the	O
activation	O
of	O
several	O
innate	O
and	O
adaptive	O
immune	O
cells	O
in	O
response	O
to	O
multiple	O
receptors	O
,	O
and	O
therapeutic	O
MALT1	O
targeting	O
is	O
believed	O
to	O
be	O
a	O
valid	O
approach	O
for	O
autoimmunity	S-Phenotype
and	O
MALT1	O
-	O
addicted	O
cancers	S-Phenotype
.	O

Variants	O
in	O
the	O
unconventional	O
myosin	O
gene	O
,	O
MYO1A	O
,	O
have	O
been	O
reported	O
to	O
cause	O
non	B-Phenotype
-	I-Phenotype
syndromic	I-Phenotype
sensorineural	I-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
with	O
a	O
pattern	O
of	O
autosomal	O
dominant	O
inheritance	O
.	O

Permanent	B-Phenotype
visual	I-Phenotype
impairment	E-Phenotype
(	O
bilateral	O
best	O
-	O
corrected	O
visual	O
acuity	O
AAAA	O
0.3	O
)	O
was	O
found	O
in	O
7	O
patients	O
,	O
including	O
patients	O
with	O
a	O
mutation	O
in	O
RAF1	O
,	O
SHOC2	O
,	O
and	O
KRAS	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
effect	O
of	O
STAT3	O
inactivation	O
on	O
biologic	O
behavior	O
of	O
primary	O
(	O
Caco	O
-	O
2	O
)	O
and	O
metastatic	O
colon	B-Phenotype
cancer	E-Phenotype
cells	O
(	O
LoVo	O
and	O
SNU407	O
)	O
and	O
the	O
relation	O
of	O
p	O
-	O
STAT3	O
expression	O
with	O
the	O
invasion	O
of	O
colon	B-Phenotype
tumor	E-Phenotype
.	O

We	O
show	O
that	O
the	O
MRTF	O
-	O
SRF	O
pathway	O
is	O
activated	O
in	O
cancer	S-Phenotype
-	O
associated	O
fibroblasts	O
(	O
CAFs	O
)	O
.	O

Galloway	O
-	O
Mowat	O
syndrome	O
(	O
GMS	O
)	O
is	O
an	O
inherited	O
disorder	O
characterized	O
by	O
microcephaly	S-Phenotype
and	O
nephrosis	S-Phenotype
resulting	O
from	O
mutations	O
in	O
the	O
WDR73	O
gene	O
.	O

In	O
silico	O
human	O
gene	O
expression	O
analysis	O
confirmed	O
the	O
down	O
regulation	O
of	O
PrKD1	O
in	O
metastatic	O
prostate	B-Phenotype
cancer	E-Phenotype
correlated	O
inversely	O
with	O
the	O
expression	O
of	O
MAX	O
,	O
but	O
not	O
MYC	O
,	O
and	O
positively	O
with	O
MXD1	O
,	O
a	O
competing	O
heterodimer	O
of	O
MAX	O
,	O
suggesting	O
that	O
the	O
dimerization	O
of	O
MAX	O
with	O
either	O
MYC	O
or	O
MXD1	O
regulates	O
liPrKD1	O
gene	O
expression	O
.	O

More	O
ER	O
stress	O
-	O
inducing	O
CPA1	O
variants	O
were	O
also	O
found	O
in	O
the	O
combined	O
set	O
of	O
hospital	O
and	O
familial	O
cases	O
with	O
pancreatic	B-Phenotype
cancer	E-Phenotype
than	O
in	O
controls	O
[	O
7	O
/	O
1,546	O
vs.	O
1	O
/	O
2,012	O
;	O
P	O
=	O
0.025	O
;	O
odds	O
ratio	O
,	O
9.36	O
(	O
95	O
%	O
CI	O
,	O
1.15	O
-	O
76.02	O
)	O
]	O
.	O

Here	O
we	O
report	O
a	O
novel	O
role	O
of	O
miR	O
-	O
155	O
in	O
cancer	S-Phenotype
metabolism	O
through	O
the	O
up	O
-	O
regulation	O
of	O
thiamine	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

In	O
conclusion	O
,	O
two	O
relevant	O
molecular	O
mechanisms	O
linked	O
to	O
central	B-Phenotype
hypothyroidism	E-Phenotype
and	O
macroorchidism	S-Phenotype
in	O
IGSF1	O
deficiency	O
are	O
identified	O
,	O
revealing	O
IGSF1	O
as	O
an	O
important	O
regulator	O
of	O
TGFβ	O
/	O
Activin	O
pathways	O
in	O
the	O
pituitary	O

Further	O
,	O
cleaved	O
CRIPTO	O
was	O
detected	O
in	O
media	O
from	O
seminoma	S-Phenotype
and	O
embryonal	B-Phenotype
carcinoma	E-Phenotype
cell	O
lines	O
,	O
suggesting	O
that	O
cleaved	O
CRIPTO	O
may	O
provide	O
diagnostic	O
indication	O
of	O
germ	O
cell	O
cancer	S-Phenotype
.	O

In	O
this	O
review	O
,	O
we	O
focus	O
on	O
skeletal	O
conditions	O
belonging	O
to	O
the	O
ciliopathy	O
group	O
:	O
the	O
short	B-Phenotype
rib	I-Phenotype
-	I-Phenotype
polydactyly	I-Phenotype
group	E-Phenotype
(	O
SRPs	S-Phenotype
)	O
that	O
includes	O
Verma	O
-	O
Naumoff	O
syndrome	O
(	O
SRP	O
type	O
III	O
)	O
,	O
Majewski	O
syndrome	O
(	O
SRP	O
type	O
II	O
)	O
,	O
Jeune	O
syndrome	O
(	O
ATD	O
)	O
,	O
as	O
well	O
as	O
Ellis	O
-	O
van	O
Creveld	O
syndrome	O
(	O
EVC	O
)	O
,	O
the	O
Sensenbrenner	O
syndrome	O
,	O
and	O
,	O
finally	O
,	O
Weyers	O
acrofacial	O
dysostosis	O
.	O

Within	O
the	O
last	O
decade	O
,	O
the	O
Bromodomain	O
and	O
Extra	O
-	O
Terminal	O
domain	O
family	O
(	O
BET	O
)	O
of	O
proteins	O
have	O
emerged	O
as	O
promising	O
drug	O
targets	O
in	O
diverse	O
clinical	O
indications	O
including	O
oncology	S-Phenotype
,	O
auto	O
-	O
immune	O
disease	O
,	O
heart	B-Phenotype
failure	E-Phenotype
,	O
and	O
male	O
contraception	O
.	O

Moreover	O
,	O
we	O
show	O
that	O
over	O
-	O
expression	O
of	O
PNPLA8	O
dramatically	O
decreases	O
hepatic	B-Phenotype
steatosis	E-Phenotype
through	O
increased	O
autophagy	O
in	O
hepatocytes	O
of	O
HFD	O
-	O
fed	O
mice	O
.	O

Duplication	O
in	O
LMNB1	O
encoding	O
lamin	O
B1	O
causes	O
autosomal	O
dominant	O
leukodystrophy	S-Phenotype
and	O
mutations	O
in	O
LMNB2	O
encoding	O
lamin	O
B2	O
are	O
associated	O
with	O
acquired	O
partial	O
lipodystrophy	S-Phenotype
.	O

Smith	O
-	O
Magenis	O
syndrome	O
(	O
SMS	O
)	O
,	O
a	O
neurodevelopmental	O
disorder	O
characterized	O
by	O
dysmorphic	O
features	O
,	O
intellectual	B-Phenotype
disability	E-Phenotype
(	O
ID	S-Phenotype
)	O
,	O
and	O
sleep	B-Phenotype
disturbances	E-Phenotype
,	O
results	O
from	O
a	O
17p11.2	O
microdeletion	O
or	O
a	O
mutation	O
in	O
the	O
RAI1	O
gene	O
.	O

The	O
canonical	O
Hippo	O
tumor	S-Phenotype
suppressor	O
pathway	O
in	O
mammalian	O
cells	O
is	O
primarily	O
composed	O
of	O
the	O
MST1	O
/	O
2	O
-	O
SAV1	O
-	O
LATS1	O
/	O
2	O
-	O
MOB1	O
-	O
YAP	O
/	O
TAZ	O
cascade	O
.	O

Using	O
s	O
as	O
a	O
reporter	O
of	O
Sox2	O
transcriptional	O
expression	O
,	O
we	O
demonstrated	O
that	O
Sox2	O
-	O
expressing	O
cells	O
mark	O
a	O
subpopulation	O
of	O
tumor	S-Phenotype
cells	O
that	O
fuel	O
the	O
growth	O
of	O
established	O
BCa	O
.	O

The	O
mutant	O
zebrafish	O
developed	O
an	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
cataract	E-Phenotype
with	O
multiple	O
developmental	O
defects	O
in	O
lens	O
.	O

Our	O
study	O
provides	O
further	O
evidence	O
for	O
validating	O
the	O
role	O
of	O
PARS2	O
in	O
the	O
pathology	O
of	O
related	O
infantile	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
encephalopathy	E-Phenotype
,	O
contributing	O
to	O
the	O
phenotypic	O
features	O
of	O
this	O
condition	O
,	O
and	O
providing	O
clinical	O
and	O
molecular	O
insight	O
for	O
the	O
diagnosis	O
of	O
this	O
disease	O
entity	O

From	O
the	O
integrative	O
analysis	O
of	O
the	O
transcriptome	O
and	O
clinicopathologic	O
data	O
of	O
human	O
multi	O
-	O
stage	O
HCC	O
tissues	O
,	O
we	O
were	O
able	O
to	O
identify	O
barrier	O
-	O
to	O
-	O
autointegration	O
factor	O
1	O
(	O
BANF1	O
)	O
,	O
procollagen	O
-	O
lysine	O
,	O
2	O
-	O
oxoglutarate	O
5	O
-	O
dioxygenase	O
3	O
(	O
PLOD3	O
)	O
and	O
splicing	O
factor	O
3b	O
subunit	O
4	O
(	O
SF3B4	O
)	O
as	O
early	O
HCC	O
biomarkers	O
which	O
could	O
be	O
detected	O
in	O
precancerous	B-Phenotype
lesions	E-Phenotype
of	O
HCC	O
,	O
with	O
superior	O
capabilities	O
to	O
diagnose	O
eHCC	O
compared	O
to	O
the	O
currently	O
popular	O
HCC	O
diagnostic	O
biomarkers	O
:	O
GPC3	O
,	O
GS	O
,	O
and	O
HSP70	O
.	O

In	O
the	O
histologic	O
biopsy	O
of	O
this	O
tumor	S-Phenotype
,	O
the	O
same	O
MEN1	O
mutation	O
was	O
detected	O
as	O
previously	O
found	O
in	O
his	O
children	O
.	O

The	O
glutamatergic	O
hypothesis	O
of	O
schizophrenia	S-Phenotype
lead	O
recently	O
to	O
a	O
first	O
successful	O
mGlu2	O
/	O
3	O
receptor	O
agonistic	O
drug	O
and	O
is	O
underpinned	O
by	O
significant	O
findings	O
in	O
genes	O
regulating	O
the	O
glutamatergic	O
system	O
(	O
SLC1A6	O
,	O
SLC1A2	O
GRIN1	O
,	O
GRIN2A	O
,	O
GRIA1	O
,	O
NRG1	O
,	O
ErbB4	O
,	O
DTNBP1	O
,	O
DAAO	O
,	O
G72	O
/	O
30	O
,	O
GRM3	O
)	O
.	O

Nevertheless	O
,	O
little	O
is	O
known	O
about	O
the	O
roles	O
of	O
WDR34	O
in	O
cancer	S-Phenotype
.	O

Further	O
analysis	O
revealed	O
that	O
the	O
function	O
of	O
cell	O
adhesion	O
,	O
biological	O
adhesion	O
,	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
organization	O
,	O
pathways	O
of	O
ECM	O
-	O
receptor	O
interaction	O
and	O
focal	O
adhesion	O
were	O
the	O
significantly	O
changed	O
terms	O
in	O
colon	B-Phenotype
cancer	E-Phenotype
.	O

Three	O
of	O
these	O
loci	O
also	O
demonstrated	O
genome	O
-	O
wide	O
significant	O
association	O
with	O
refractive	B-Phenotype
astigmatism	E-Phenotype
:	O
LINC00340	O
,	O
HERC2	O
/	O
OCA2	O
and	O
NPLOC4	O
/	O
TSPAN10	O
.	O

Mutations	O
in	O
heat	O
shock	S-Phenotype
transcription	O
factor	O
4	O
(	O
HSF4	O
)	O
have	O
been	O
associated	O
with	O
cataract	S-Phenotype
;	O
however	O
,	O
the	O
mechanisms	O
regarding	O
how	O
mutations	O
in	O
HSF4	O
cause	O
cataract	S-Phenotype
are	O
still	O
obscure	O
.	O

In	O
the	O
PPI	O
network	O
,	O
2	O
clusters	O
of	O
VTE	O
genes	O
,	O
including	O
ribosomal	O
protein	O
family	O
genes	O
and	O
NADH	O
family	O
-	O
ubiquinol	O
-	O
cytochrome	O
genes	O
,	O
were	O
identified	O
,	O
such	O
as	O
ribosomal	O
protein	O
L9	O
(	O
RPL9	O
)	O
,	O
RPL5	O
,	O
RPS20	O
,	O
RPL23	O
,	O
and	O
tumor	S-Phenotype
protein	O
p53	O
(	O
TP53	O
)	O
.The	O
nod	O
-	O
like	O
receptor	O
signaling	O
pathway	O
,	O
ribosomal	O
protein	O
family	O
genes	O
,	O
such	O
as	O
RPL9	O
,	O
RPL5	O
,	O
RPS20	O
,	O
and	O
RPL23	O
,	O
and	O
DEG	O
of	O
TP53	O
may	O
have	O
the	O
potential	O
to	O
be	O
used	O
as	O
targets	O
for	O
diagnosis	O
and	O
treatment	O
of	O
VTE	O

The	O
severe	O
generalized	B-Phenotype
lipodystrophy	E-Phenotype
in	O
this	O
patient	O
with	O
progeroid	O
features	O
has	O
not	O
previously	O
been	O
described	O
in	O
other	O
patients	O
with	O
MFS	O
and	O
FBN1	O
mutations	O
.	O

Among	O
these	O
biomarkers	O
,	O
the	O
optimal	O
cut	O
-	O
off	O
value	O
of	O
COL4A1	O
+	O
COL13A1	O
at	O
1.33	O
ng	O
/	O
mL	O
resulted	O
in	O
57.4	O
%	O
,	O
83.7	O
%	O
,	O
56.1	O
%	O
,	O
80.7	O
%	O
,	O
and	O
91.7	O
%	O
sensitivity	O
for	O
low	O
-	O
grade	O
tumors	S-Phenotype
,	O
high	O
-	O
grade	O
tumors	S-Phenotype
,	O
Ta	O
,	O
T1	O
,	O
and	O
muscle	O
invasive	O
disease	O
,	O
respectively	O
.	O

Here	O
,	O
we	O
applied	O
next	O
-	O
generation	O
sequencing	O
in	O
89	O
patients	O
with	O
a	O
clinical	O
diagnosis	O
of	O
distal	B-Phenotype
renal	I-Phenotype
tubular	I-Phenotype
acidosis	E-Phenotype
,	O
analyzing	O
the	O
prevalence	O
of	O
genetic	O
defects	O
in	O
SLC4A1	O
,	O
ATP6V0A4	O
,	O
and	O
ATP6V1B1	O
genes	O
and	O
the	O
clinical	O
phenotype	O
.	O

Thus	O
,	O
the	O
present	O
study	O
aimed	O
to	O
investigate	O
molecular	O
changes	O
in	O
the	O
OTOF	O
gene	O
in	O
patients	O
with	O
auditory	B-Phenotype
neuropathy	E-Phenotype
,	O
and	O
to	O
develop	O
a	O
DNA	O
chip	O
for	O
the	O
molecular	O
diagnosis	O
of	O
auditory	B-Phenotype
neuropathy	E-Phenotype
using	O
mass	O
spectrometry	O
for	O
genotyping	O
.	O

While	O
these	O
expansions	O
occur	O
in	O
coding	O
and	O
noncoding	O
regions	O
,	O
microsatellite	O
sequence	O
and	O
repeat	O
length	O
diversity	O
is	O
more	O
prominent	O
in	O
introns	O
with	O
eight	O
different	O
trinucleotide	O
to	O
hexanucleotide	O
repeats	O
,	O
causing	O
hereditary	O
diseases	O
such	O
as	O
myotonic	B-Phenotype
dystrophy	I-Phenotype
type	I-Phenotype
2	E-Phenotype
(	O
DM2	S-Phenotype
)	O
,	O
Fuchs	B-Phenotype
endothelial	I-Phenotype
corneal	I-Phenotype
dystrophy	E-Phenotype
(	O
FECD	S-Phenotype
)	O
,	O
and	O
C9orf72	B-Phenotype
amyotrophic	I-Phenotype
lateral	I-Phenotype
sclerosis	E-Phenotype
and	O
frontotemporal	B-Phenotype
dementia	E-Phenotype
(	O
C9	O
-	O
ALS	O
/	O
FTD	O
)	O
.	O

Key	O
steps	O
where	O
CCNs	O
may	O
play	O
a	O
pathogenic	O
metabolic	O
role	O
include	O
:	O
(	O
i	O
)	O
obesity	S-Phenotype
and	O
insulin	B-Phenotype
resistance	E-Phenotype
,	O
where	O
CCN2	O
inhibits	O
fat	O
cell	O
differentiation	O
in	O
vitro	O
and	O
CCN3	O
may	O
induce	O
obesity	S-Phenotype
and	O
insulin	B-Phenotype
resistance	E-Phenotype
;	O
(	O
ii	O
)	O
elevated	O
blood	O
glucose	O
levels	O
to	O
diabetes	B-Phenotype
mellitus	E-Phenotype
onset	O
,	O
where	O
CCN2	O
may	O
contribute	O
to	O
pancreatic	O
beta	O
cell	O
and	O
islet	O
function	O
;	O
and	O
(	O
iii	O
)	O
in	O
diabetes	O
complications	O
,	O
such	O
as	O
nephropathy	S-Phenotype
,	O
retinopathy	S-Phenotype
,	O
liver	B-Phenotype
disease	E-Phenotype
(	O
NAFLD	O
/	O
NASH	O
)	O
,	O
CVD	O
and	O
diabetes	S-Phenotype
with	O
heart	B-Phenotype
failure	E-Phenotype
.	O

The	O
heterogeneity	S-Phenotype
test	O
,	O
sensitivity	O
analysis	O
,	O
and	O
publication	O
bias	O
test	O
was	O
performed	O
by	O
Review	O
Manager	O
5.3	O
software.Overall	O
,	O
22	O
case	O
-	O
control	O
studies	O
with	O
5049	O
cases	O
and	O
4157	O
controls	O
were	O
included	O
in	O
this	O
meta	O
-	O
analysis	O
,	O
which	O
contained	O
20	O
studies	O
of	O
MTHFR	O
C677T	O
polymorphism	O
,	O
12	O
studies	O
of	O
MTHFR	O
A1298C	O
polymorphism	O
and	O
4	O
studies	O
of	O
MTRR	O
A66G	O
polymorphism	O
.	O

RT	O
-	O
PCR	O
analysis	O
showed	O
that	O
the	O
overall	O
transcriptional	O
activity	O
of	O
the	O
main	O
HS	O
biosynthesis	O
-	O
involved	O
genes	O
(	O
EXT1	O
,	O
EXT2	O
,	O
NDST1	O
,	O
NDST2	O
,	O
GLCE	O
,	O
HS2ST1	O
,	O
HS3ST1	O
,	O
HS3ST2	O
,	O
HS6ST1	O
,	O
HS6ST2	O
,	O
SULF1	O
,	O
SULF2	O
,	O
HPSE	O
)	O
was	O
decreased	O
by	O
1.5	O
-	O
2	O
-	O
fold	O
in	O
Grade	O
II	O
-	O
III	O
glioma	S-Phenotype
(	O
p	O
AAAA	O
0.01	O
)	O
and	O
by	O
3	O
-	O
fold	O
in	O
Grade	O
IV	O
glioma	S-Phenotype
(	O
glioblastoma	B-Phenotype
multiforme	E-Phenotype
,	O
GBM	O
)	O
(	O
p	O
AAAA	O
0.05	O
)	O
,	O
as	O
compared	O
with	O
the	O
para	O
-	O
tumourous	S-Phenotype
tissue	O
.	O

However	O
,	O
the	O
role	O
of	O
FUZ	O
in	O
tumor	S-Phenotype
biology	O
remains	O
poorly	O
studied	O
.	O

In	O
cancer	S-Phenotype
patients	O
,	O
elevated	O
levels	O
of	O
Twist1	O
are	O
associated	O
with	O
greater	O
degrees	O
of	O
muscle	B-Phenotype
wasting	E-Phenotype
.	O

Thus	O
,	O
mutated	O
YARS2	O
aggravates	O
mitochondrial	B-Phenotype
dysfunctions	E-Phenotype
associated	O
with	O
the	O
m.11778GAAAAA	O
mutation	O
,	O
exceeding	O
the	O
threshold	O
for	O
the	O
expression	O
of	O
blindness	S-Phenotype
phenotype	O
.	O

Mutations	O
in	O
LCA5	O
are	O
a	O
rare	O
cause	O
of	O
childhood	B-Phenotype
retinal	I-Phenotype
dystrophy	E-Phenotype
accounting	O
for	O
∼2	O
%	O
of	O
disease	O
in	O
this	O
cohort	O
,	O
and	O
the	O
majority	O
of	O
LCA5	O
mutations	O
are	O
likely	O
null	O
.	O

This	O
review	O
discusses	O
recurrent	O
aberrations	O
in	O
NKTCL	O
detected	O
by	O
NGS	O
,	O
which	O
can	O
be	O
categorized	O
into	O
three	O
main	O
groups	O
,	O
specifically	O
,	O
tumor	S-Phenotype
suppressors	O
(	O
TP53	O
,	O
DDX3X	O
,	O
and	O
MGA	O
)	O
,	O
the	O
JAK	O
/	O
STAT	O
cascade	O
,	O
and	O
epigenetic	O
modifiers	O
(	O
KMT2D	O
,	O
BCOR	O
,	O
ARID1A	O
,	O
and	O
EP300	O
)	O
.	O

Here	O
we	O
present	O
a	O
case	O
of	O
a	O
3	O
-	O
year	O
-	O
old	O
boy	O
with	O
compound	O
heterozygous	O
missense	O
mutations	O
in	O
the	O
TMEM67	O
gene	O
manifesting	O
features	O
of	O
both	O
JBTS	O
and	O
NPHP	O
syndromes	O
,	O
with	O
neonatal	O
onset	O
of	O
end	B-Phenotype
-	I-Phenotype
stage	I-Phenotype
renal	I-Phenotype
disease	E-Phenotype
(	O
ESRD	S-Phenotype
)	O
and	O
associated	O
microcephaly	S-Phenotype
.	O

The	O
anti	O
-	O
miR	O
-	O
663	O
reduced	O
OXPHOS	O
complex	O
activity	O
and	O
increased	O
in	O
vitro	O
cellular	O
proliferation	O
and	O
promoted	O
tumor	S-Phenotype
development	O
in	O
vivo	O
in	O
mice	O
.	O

Our	O
data	O
suggest	O
that	O
only	O
a	O
small	O
subset	O
of	O
PTEN	O
-	O
wildtype	O
CS	O
/	O
CS	O
-	O
like	O
and	O
BRRS	O
patients	O
could	O
be	O
accounted	O
for	O
by	O
germline	O
variants	O
in	O
some	O
of	O
the	O
known	O
cancer	S-Phenotype
-	O
related	O
genes	O
.	O

A	O
rare	O
syndromic	O
form	O
of	O
intellectual	B-Phenotype
disability	E-Phenotype
with	O
impaired	O
speech	O
was	O
recently	O
found	O
associated	O
with	O
mutations	O
in	O
CHAMP1	O
(	O
chromosome	O
alignment	O
-	O
maintaining	O
phosphoprotein	O
1	O
)	O
,	O
the	O
protein	O
product	O
of	O
which	O
is	O
directly	O
involved	O
in	O
microtubule	O
-	O
kinetochore	O
attachment	O
.	O

Additionally	O
,	O
of	O
the	O
87	O
postoperative	O
tissue	O
specimens	O
,	O
the	O
results	O
showed	O
that	O
the	O
expression	O
of	O
TYMP	O
in	O
cancer	S-Phenotype
tissues	O
of	O
the	O
patients	O
with	O
CT	O
or	O
TT	O
genotypes	O
were	O
significantly	O
higher	O
than	O
those	O
of	O
the	O
wild	O
type	O
CC	O
genotype	O
patients	O
(	O
liP	O
/	O
i=0.019	O
)	O
.	O

With	O
its	O
highly	O
heterogeneous	S-Phenotype
nature	O
,	O
PCa	O
continues	O
to	O
pose	O
a	O
tremendous	O
challenge	O
in	O
terms	O
of	O
diagnosis	O
and	O
prognosis	O
.	O

In	O
our	O
cohort	O
of	O
27	O
subjects	O
with	O
congenital	B-Phenotype
heart	I-Phenotype
defect	E-Phenotype
,	O
both	O
karyotype	O
analysis	O
and	O
Fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
were	O
performed	O
.	O

BACKGROUND	O
The	O
distribution	O
of	O
fat	O
mass	O
and	O
obesity	S-Phenotype
-	O
associated	O
gene	O
(	O
FTO	O
)	O
genes	O
rs9939609	O
and	O
rs1421085	O
in	O
obese	O
and	O
normal	O
ethnic	O
Mongolians	O
was	O
analyzed	O
to	O
investigate	O
the	O
association	O
of	O
FTO	O
gene	O
polymorphisms	O
with	O
obesity	S-Phenotype
and	O
metabolic	O
syndrome	O
in	O
ethnic	O
Mongolians	O
.	O

The	O
findings	O
in	O
this	O
study	O
expand	O
our	O
understanding	O
of	O
SRPS	O
locus	O
heterogeneity	S-Phenotype
and	O
demonstrate	O
the	O
importance	O
of	O
DYNC2LI1	O
in	O
dynein	O
-	O
2	O
complex	O
stability	O
,	O
cilium	O
function	O
,	O
Hedgehog	O
regulation	O
and	O
skeletogenesis	O
.	O

High	O
-	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
particles	O
have	O
experienced	O
a	O
turbulent	O
decade	O
of	O
falling	S-Phenotype
from	O
grace	O
with	O
widespread	O
demotion	O
from	O
the	O
most	O
-	O
sought	O
-	O
after	O
therapeutic	O
target	O
to	O
reverse	O
cardiovascular	B-Phenotype
disease	E-Phenotype
(	O
CVD	S-Phenotype
)	O
,	O
to	O
mere	O
biomarker	O
status	O
.	O

Phaeochromocytoma	S-Phenotype
and	O
paraganglioma	S-Phenotype
(	O
PHEO	S-Phenotype
/	O
PGL	S-Phenotype
)	O
are	O
rare	O
tumours	S-Phenotype
with	O
an	O
estimated	O
annual	O
incidence	O
of	O
3	O
per	O
million	O
.	O

DIS3	O
encodes	O
a	O
catalytic	O
subunit	O
of	O
the	O
nuclear	O
RNA	O
exosome	O
complex	O
that	O
mediates	O
RNA	O
processing	O
and	O
decay	O
,	O
and	O
is	O
mutated	O
in	O
several	O
cancers	S-Phenotype
.	O

Moreover	O
,	O
a	O
series	O
of	O
LDHA	O
gain	O
-	O
of	O
-	O
function	O
and	O
rescore	O
experiments	O
were	O
carried	O
out	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
MCF7	O
cells	O
expressing	O
endogenous	O
wt	O
-	O
p53	O
,	O
showing	O
that	O
ectopic	O
expression	O
of	O
p53	O
decreases	O
aerobic	O
glycolysis	O
,	O
cell	O
proliferation	O
,	O
migration	O
,	O
invasion	O
and	O
tumor	S-Phenotype
formation	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
and	O
that	O
restoration	O
of	O
the	O
expression	O
of	O
LDHA	O
in	O
p53	O
-	O
overexpressing	O
cells	O
could	O
abolish	O
the	O
suppressive	O
effect	O
of	O
p53	O
on	O
aerobic	O
glycolysis	O
and	O
other	O
malignant	O
phenotypes	O
.	O

Mutant	O
mice	O
lacking	O
Lrrc6	O
show	O
typical	O
PCD	O
defects	O
such	O
as	O
hydrocephalus	S-Phenotype
and	O
laterality	O
defects	O
.	O

D	B-Phenotype
-	I-Phenotype
transposition	I-Phenotype
of	I-Phenotype
the	I-Phenotype
great	I-Phenotype
arteries	E-Phenotype
(	O
TGA	S-Phenotype
)	O
is	O
one	O
of	O
the	O
most	O
common	O
conotruncal	B-Phenotype
heart	I-Phenotype
defects	E-Phenotype
at	O
birth	O
and	O
is	O
characterized	O
by	O
a	O
discordant	O
ventriculoarterial	O
connection	O
with	O
a	O
concordant	O
atrioventricular	O
connection	O
.	O

Other	O
genes	O
such	O
as	O
GBA2	O
and	O
KIF1C	O
were	O
almost	O
simultaneously	O
published	O
as	O
both	O
a	O
hereditary	B-Phenotype
spastic	I-Phenotype
paraplegia	E-Phenotype
and	O
an	O
ataxia	S-Phenotype
gene	O
.	O

HFD	O
-	O
fed	O
Nlrp12sup	O
-	O
/	O
-	O
/	O
sup	O
mice	O
display	O
dysbiosis	O
marked	O
by	O
increased	O
obesity	S-Phenotype
-	O
associated	O
Erysipelotrichaceae	O
,	O
but	O
reduced	O
Lachnospiraceae	O
family	O
and	O
the	O
associated	O
enzymes	O
required	O
for	O
short	O
-	O
chain	O
fatty	O
acid	O
(	O
SCFA	O
)	O
synthesis	O
.	O

Our	O
results	O
suggest	O
the	O
cg07814318	O
site	O
could	O
be	O
involved	O
in	O
orexigenic	O
processes	O
,	O
and	O
also	O
implicate	O
KLF13	O
in	O
obesity	S-Phenotype
.	O

Subsequently	O
,	O
the	O
top	O
12	O
highly	O
mutated	O
genes	O
were	O
selected	O
for	O
validation	O
by	O
polymerase	O
chain	O
reaction	O
and	O
DNA	O
sequencing	O
in	O
an	O
expanded	O
sample	O
set	O
including	O
FLC	O
,	O
sporadic	B-Phenotype
lung	I-Phenotype
cancer	E-Phenotype
,	O
and	O
healthy	O
population	O
.	O

We	O
recently	O
identified	O
a	O
42	O
-	O
year	O
-	O
old	O
man	O
with	O
severe	O
kyphoscoliosis	S-Phenotype
,	O
restrictive	B-Phenotype
/	I-Phenotype
obstructive	I-Phenotype
lung	I-Phenotype
disease	E-Phenotype
,	O
short	B-Phenotype
stature	E-Phenotype
,	O
mild	O
hearing	B-Phenotype
loss	E-Phenotype
,	O
decreased	B-Phenotype
muscle	I-Phenotype
mass	E-Phenotype
,	O
and	O
a	O
dissection	O
of	O
the	O
celiac	O
artery	O
at	O
age	O
41	O
.	O

Mutations	O
in	O
PLA2G6	O
(	O
PARK14	O
)	O
cause	O
neurodegenerative	O
disorders	O
in	O
humans	O
,	O
including	O
autosomal	B-Phenotype
recessive	I-Phenotype
neuroaxonal	I-Phenotype
dystrophy	E-Phenotype
and	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
parkinsonism	E-Phenotype
.	O

In	O
fact	O
,	O
cells	O
which	O
simultaneously	O
express	O
both	O
sets	O
of	O
markers	O
have	O
the	O
highest	O
tumor	S-Phenotype
initiating	O
capacity	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
is	O
to	O
evaluate	O
clock	O
(	O
cry1	O
,	O
cry2	O
and	O
per2	O
)	O
and	O
clock	O
-	O
controlled	O
(	O
vascular	O
endothelial	O
growth	O
factor	O
-	O
a	O
,	O
early	O
growth	O
response	O
protein	O
1	O
and	O
estrogen	O
receptor	O
b	O
)	O
gene	O
expression	O
in	O
colorectal	B-Phenotype
cancer	E-Phenotype
and	O
adjacent	O
tissue	O
and	O
identify	O
a	O
possible	O
link	O
between	O
survival	O
of	O
patients	O
and	O
expression	O
of	O
above	O
mentioned	O
genes	O
.	O

Our	O
findings	O
indicate	O
that	O
BM	O
-	O
derived	O
MSCs	O
from	O
patients	O
with	O
newly	O
diagnosed	O
AML	O
display	O
phenotypic	O
and	O
functional	O
alterations	O
such	O
as	O
proliferative	O
deficiency	O
that	O
could	O
be	O
attributed	O
to	O
tumor	S-Phenotype
progression	O
,	O
but	O
does	O
not	O
seem	O
to	O
play	O
a	O
special	O
role	O
in	O
the	O
leukemic	O
process	O

In	O
patients	O
harboring	O
SEPSECS	O
mutations	O
,	O
severe	O
,	O
progressive	O
,	O
cerebello	B-Phenotype
-	I-Phenotype
cerebral	I-Phenotype
atrophy	E-Phenotype
(	O
pontocerebellar	B-Phenotype
hypoplasia	I-Phenotype
type	I-Phenotype
2D	E-Phenotype
)	O
dominates	O
the	O
phenotype	O
and	O
it	O
is	O
not	O
known	O
whether	O
the	O
disorder	O
is	O
associated	O
with	O
thyroid	O
dysfunction	O

We	O
extend	O
the	O
KATNB1	O
associated	O
phenotype	O
by	O
describing	O
a	O
syndrome	O
characterized	O
by	O
primordial	B-Phenotype
dwarfism	E-Phenotype
,	O
lissencephaly	S-Phenotype
,	O
polysyndactyly	S-Phenotype
,	O
and	O
dental	B-Phenotype
anomalies	E-Phenotype
,	O
which	O
is	O
caused	O
by	O
a	O
homozygous	O
truncating	O
KATNB1	O
mutation	O

Regarding	O
DNA	O
methylation	O
,	O
all	O
four	O
SMARCB1	O
/	O
INI1	O
-	O
deficient	O
tumors	S-Phenotype
showed	O
methylation	O
of	O
RASSF1	O
gene	O
by	O
means	O
of	O
MS	O
-	O
MLPA	O
.	O

Co	O
-	O
mutations	O
of	O
ARID1A	O
,	O
GPRC5A	O
and	O
MLL2	O
introduced	O
by	O
CRISPR	O
/	O
Cas9	O
significantly	O
enhance	O
the	O
capabilities	O
of	O
self	O
-	O
renewal	O
and	O
tumor	S-Phenotype
-	O
initiating	O
of	O
BCNSCs	O
.	O

Limb	B-Phenotype
-	I-Phenotype
girdle	I-Phenotype
muscular	I-Phenotype
dystrophy	I-Phenotype
type	I-Phenotype
2D	E-Phenotype
(	O
LGMD2D	S-Phenotype
)	O
is	O
a	O
rare	O
autosomal	O
-	O
recessive	O
disease	O
,	O
affecting	O
striated	O
muscle	O
,	O
due	O
to	O
mutation	O
of	O
SGCA	O
,	O
the	O
gene	O
coding	O
for	O
α	O
-	O
sarcoglycan	O
.	O

iDLEC1	O
/	O
i	O
was	O
frequently	O
downregulated	O
in	O
ESCC	O
,	O
lung	O
and	O
NPC	O
cell	O
lines	O
and	O
primary	O
tumors	S-Phenotype
,	O
but	O
was	O
readily	O
expressed	O
in	O
normal	O
tissues	O
and	O
immortalized	O
normal	O
epithelial	O
cells	O
,	O
with	O
mutations	O
rarely	O
detected	O
.	O

We	O
evaluated	O
the	O
presence	O
of	O
L1CAM	O
in	O
cyst	O
fluid	O
and	O
tissue	O
from	O
glioblastomas	S-Phenotype
or	O
brain	O
metastases.The	O
amount	O
of	O
L1CAM	O
in	O
cyst	O
fluid	O
of	O
9	O
glioblastomas	S-Phenotype
and	O
11	O
brain	O
metastases	O
was	O
assessed	O
using	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
.	O

Hermansky	O
-	O
Pudlak	O
syndrome	O
(	O
HPS	O
)	O
,	O
first	O
described	O
in	O
1959	O
,	O
is	O
a	O
rare	O
form	O
of	O
syndromic	B-Phenotype
oculocutaneous	I-Phenotype
albinism	E-Phenotype
associated	O
with	O
bleeding	B-Phenotype
diathesis	E-Phenotype
and	O
in	O
some	O
cases	O
pulmonary	B-Phenotype
fibrosis	E-Phenotype
and	O
granulomatous	B-Phenotype
colitis	E-Phenotype
.	O

Mutations	O
in	O
the	O
COL4A5	O
gene	O
result	O
in	O
X	O
-	O
linked	O
Alport	O
syndrome	O
,	O
homozygous	O
or	O
compound	O
heterozygous	O
mutations	O
in	O
COL4A3	O
or	O
COL4A4	O
are	O
responsible	O
for	O
autosomal	B-Phenotype
recessive	I-Phenotype
Alport	I-Phenotype
syndrome	E-Phenotype
,	O
and	O
heterozygous	O
mutations	O
in	O
COL4A3	O
or	O
COL4A4	O
cause	O
autosomal	B-Phenotype
dominant	I-Phenotype
Alport	I-Phenotype
syndrome	E-Phenotype
or	O
benign	B-Phenotype
familial	I-Phenotype
hematuria	E-Phenotype
.	O

TICs	S-Phenotype
display	O
resistance	O
to	O
frontline	O
cancer	S-Phenotype
treatment	O
and	O
retain	O
the	O
ability	O
to	O
repopulate	O
a	O
tumor	S-Phenotype
after	O
therapy	O
,	O
leading	O
to	O
cancer	S-Phenotype
relapse	O
.	O

In	O
2009	O
,	O
four	O
families	O
with	O
a	O
distal	O
duplication	O
of	O
Xq28	O
not	O
including	O
MECP2	O
and	O
mediated	O
by	O
low	O
-	O
copy	O
repeats	O
(	O
LCRs	O
)	O
designated	O
AAAAAAKAAAAAA	O
and	O
AAAAAALAAAAAA	O
were	O
reported	O
with	O
intellectual	B-Phenotype
disability	E-Phenotype
and	O
epilepsy	S-Phenotype
.	O

In	O
particular	O
,	O
MYH9	O
mutations	O
result	O
in	O
congenital	B-Phenotype
macrothrombocytopenia	E-Phenotype
and	O
predispose	B-Phenotype
to	I-Phenotype
kidney	I-Phenotype
failure	E-Phenotype
,	O
hearing	B-Phenotype
loss	E-Phenotype
,	O
and	O
cataracts	S-Phenotype
,	O
MPL	O
and	O
MECOM	O
mutations	O
cause	O
congenital	B-Phenotype
thrombocytopenia	E-Phenotype
evolving	O
into	O
bone	B-Phenotype
marrow	I-Phenotype
failure	E-Phenotype
,	O
whereas	O
thrombocytopenias	S-Phenotype
caused	O
by	O
RUNX1	O
,	O
ANKRD26	O
,	O
and	O
ETV6	O
mutations	O
are	O
characterized	O
by	O
predisposition	B-Phenotype
to	I-Phenotype
hematological	I-Phenotype
malignancies	E-Phenotype
.	O

Aim	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
CMG2	O
mRNA	O
and	O
protein	O
expression	O
in	O
soft	B-Phenotype
tissue	I-Phenotype
sarcoma	E-Phenotype
and	O
their	O
association	O
with	O
patient	O
outcome	O
.	O

We	O
previously	O
described	O
a	O
relatively	O
pure	O
hereditary	B-Phenotype
spastic	I-Phenotype
paraplegia	E-Phenotype
(	O
HSP	S-Phenotype
)	O
phenotype	O
associated	O
with	O
mutations	O
in	O
DDHD1	O
.	O

This	O
study	O
systematically	O
reviewed	O
previous	O
literatures	O
and	O
analyzed	O
the	O
genotype	O
-	O
phenotype	O
relationship	O
between	O
the	O
multiple	B-Phenotype
endocrine	I-Phenotype
neoplasia	I-Phenotype
type	I-Phenotype
2A	E-Phenotype
(	O
MEN	B-Phenotype
2A	E-Phenotype
)	O
-	O
cutaneous	B-Phenotype
lichen	I-Phenotype
amyloidosis	E-Phenotype
(	O
CLA	S-Phenotype
)	O
and	O
RET	O
/	O
OSMR	O
/	O
IL31RA	O
mutations	O
.	O

After	O
CCRT	O
,	O
39	O
of	O
60	O
(	O
65	O
%	O
)	O
LARC	O
patients	O
were	O
classified	O
as	O
responders	O
(	O
pathological	O
tumor	S-Phenotype
regression	O
grade	O
2	O
~	O
4	O
)	O
.	O

Here	O
,	O
we	O
searched	O
for	O
mutations	O
in	O
EXPH5	O
in	O
a	O
4	O
-	O
year	O
-	O
old	O
white	O
boy	O
with	O
EBS	O
in	O
whom	O
initial	O
Sanger	O
sequencing	O
of	O
known	O
genes	O
implicated	O
in	O
intraepidermal	B-Phenotype
skin	I-Phenotype
fragility	I-Phenotype
failed	I-Phenotype
to	I-Phenotype
identify	I-Phenotype
pathogenic	I-Phenotype
mutations	E-Phenotype
.	O

Numerous	O
studies	O
have	O
recently	O
demonstrated	O
that	O
HDAC6	O
expression	O
and	O
activity	O
are	O
increased	O
in	O
kidney	B-Phenotype
disease	E-Phenotype
,	O
such	O
as	O
autosomal	B-Phenotype
dominant	I-Phenotype
polycystic	I-Phenotype
kidney	I-Phenotype
disease	E-Phenotype
(	O
ADPKD	S-Phenotype
)	O
,	O
renal	B-Phenotype
fibrosis	E-Phenotype
,	O
and	O
acute	B-Phenotype
kidney	I-Phenotype
injury	E-Phenotype
(	O
AKI	S-Phenotype
)	O
,	O
among	O
others	O
.	O

TAC2	O
showed	O
the	O
highest	O
sputum	O
neutrophilia	S-Phenotype
,	O
serum	O
C	O
-	O
reactive	O
protein	O
levels	O
and	O
prevalence	O
of	O
eczema	S-Phenotype
.	O

Transcriptome	O
analysis	O
of	O
CXCL1	O
-	O
treated	O
SW620	O
cells	O
indicates	O
that	O
CXCL1	O
increases	O
potential	O
oncogene	O
expression	O
in	O
colon	B-Phenotype
cancer	E-Phenotype
,	O
including	O
liPTHLH	O
/	O
i	O
,	O
liTYRP1	O
/	O
i	O
,	O
liFOXO1	O
/	O
i	O
,	O
liTCF4	O
/	O
i	O
and	O
liZNF880	O
/	O
i	O
.	O

Heparanase	O
(	O
HPSE	O
)	O
expression	O
was	O
identified	O
in	O
50	O
%	O
of	O
GBM	O
tumours	S-Phenotype
by	O
immunostaining	O
,	O
and	O
was	O
characterised	O
by	O
a	O
high	O
intratumoural	O
heterogeneity	O
of	O
the	O
presence	O
of	O
the	O
HPSE	O
protein	O
.	O

Our	O
findings	O
widen	O
the	O
phenotype	O
spectrum	O
caused	O
by	O
TGDS	O
mutations	O
and	O
underline	O
the	O
phenotypic	O
overlap	O
with	O
Temtamy	O
preaxial	O
brachydactyly	S-Phenotype
syndrome	O
.	O

There	O
is	O
only	O
partial	O
overlap	O
between	O
the	O
two	O
conditions	O
(	O
there	O
are	O
a	O
few	O
patients	O
with	O
CT	O
that	O
have	O
SDH	O
subunit	O
mutations	O
)	O
but	O
both	O
lead	O
to	O
increased	O
methylation	O
of	O
the	O
entire	O
genome	O
in	O
the	O
tumors	S-Phenotype
associated	O
with	O
them	O
.	O

Bardet	O
-	O
Biedl	O
syndrome	O
(	O
BBS	O
)	O
is	O
a	O
genetically	O
heterogeneous	S-Phenotype
disorder	O
characterized	O
by	O
retinal	B-Phenotype
dystrophy	E-Phenotype
,	O
polydactyly	S-Phenotype
,	O
obesity	S-Phenotype
,	O
developmental	B-Phenotype
delay	E-Phenotype
,	O
and	O
renal	B-Phenotype
defects	E-Phenotype
.	O

Our	O
results	O
identify	O
AICDA	O
as	O
a	O
driver	O
of	O
epigenetic	O
heterogeneity	S-Phenotype
in	O
B	O
-	O
cell	O
lymphomas	O
with	O
potential	O
significance	O
for	O
other	O
tumors	S-Phenotype
with	O
aberrant	O
expression	O
of	O
cytidine	O
deaminases	O

SLC29A3	O
mutations	O
have	O
been	O
reported	O
as	O
the	O
causal	O
gene	O
in	O
two	O
DOS	O
families	O
,	O
however	O
,	O
genetic	O
heterogeneity	S-Phenotype
has	O
been	O
suggested	O
.	O

High	O
TROP2	O
expression	O
plays	O
an	O
important	O
role	O
in	O
promoting	O
tumor	S-Phenotype
development	O
and	O
aggressiveness	S-Phenotype
,	O
which	O
is	O
correlated	O
with	O
reduced	O
patient	O
survival	O
.	O

Loss	O
of	O
E	O
-	O
cadherin	O
,	O
an	O
important	O
cell	O
-	O
cell	O
adhesion	O
protein	O
,	O
contributes	O
to	O
tumor	S-Phenotype
invasion	O
and	O
metastasis	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
screened	O
for	O
CPA6	O
mutations	O
in	O
patients	O
with	O
juvenile	B-Phenotype
myoclonic	I-Phenotype
epilepsy	E-Phenotype
and	O
identified	O
two	O
novel	O
missense	O
mutations	O
:	O
Arg36His	O
and	O
Asn271Ser	O
.	O

The	O
insulin	B-Phenotype
-	I-Phenotype
secreting	I-Phenotype
pancreatic	I-Phenotype
neuroendocrine	I-Phenotype
tumors	E-Phenotype
,	O
insulinomas	S-Phenotype
,	O
characterized	O
by	O
increased	O
pancreatic	O
islet	O
β	O
-	O
cell	O
proliferation	O
,	O
express	O
the	O
phosphorylated	O
isoform	O
of	O
the	O
β	O
-	O
cell	O
differentiation	O
factor	O
HLXB9	O
that	O
interacts	O
with	O
NONO	O
/	O
p54NRB	O
,	O
a	O
survival	O
factor	O
.	O

B	O
cell	O
markers	O
in	O
tumor	S-Phenotype
cells	O
were	O
also	O
compared	O
to	O
the	O
same	O
cell	O
type	O
in	O
culture	O
,	O
prior	O
to	O
xenotransplantation	O
;	O
B	O
cell	O
markers	O
were	O
mostly	O
downregulated	O
during	O
tumor	S-Phenotype
formation	O
and	O
these	O
changes	O
did	O
not	O
differ	O
based	O
upon	O
the	O
presence	O
of	O
vIL	O
-	O
6	O
.	O

Thus	O
,	O
these	O
findings	O
elucidated	O
the	O
central	O
role	O
of	O
Rab3IP	O
in	O
inducing	O
an	O
invasive	O
phenotype	O
in	O
gastric	B-Phenotype
cancer	E-Phenotype
cells	O
,	O
in	O
addition	O
to	O
its	O
involvement	O
in	O
EMT	O
.	O

Although	O
CHP1	O
is	O
ubiquitously	O
present	O
,	O
it	O
is	O
particularly	O
abundant	O
in	O
the	O
central	O
nervous	O
system	O
and	O
at	O
SMA	O
-	O
relevant	O
sites	O
including	O
motor	O
neuron	O
growth	O
cones	O
and	O
neuromuscular	O
junctions	O
.	O

Plk4	O
depletion	O
suppressed	O
cancer	S-Phenotype
invasion	O
and	O
induced	O
an	O
epithelial	O
phenotype	O
in	O
poorly	O
differentiated	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Canine	B-Phenotype
mast	I-Phenotype
cell	I-Phenotype
tumours	E-Phenotype
(	O
CMCT	S-Phenotype
)	O
are	O
one	O
of	O
the	O
most	O
common	O
skin	B-Phenotype
tumours	E-Phenotype
in	O
dogs	O
with	O
a	O
major	O
impact	O
on	O
canine	O
health	O
.	O

Although	O
Sur8	O
has	O
been	O
shown	O
to	O
be	O
a	O
scaffold	O
protein	O
of	O
the	O
Ras	O
-	O
ERK	O
pathway	O
,	O
its	O
interaction	O
with	O
other	O
signaling	O
pathways	O
and	O
its	O
involvement	O
in	O
tumor	S-Phenotype
malignancy	O
has	O
not	O
been	O
reported	O
.	O

Morphologic	O
features	O
of	O
YWHAE	B-Phenotype
-	I-Phenotype
NUTM2	I-Phenotype
high	I-Phenotype
-	I-Phenotype
grade	I-Phenotype
endometrial	I-Phenotype
stromal	I-Phenotype
sarcoma	E-Phenotype
may	O
overlap	O
with	O
other	O
uterine	O
sarcoma	S-Phenotype
types	O
.	O

Immunohistochemical	O
analyses	O
showed	O
that	O
SIRT1	O
expression	O
correlated	O
with	O
poor	O
clinical	O
outcomes	O
in	O
cervical	B-Phenotype
cancer	E-Phenotype
.	O

Here	O
,	O
we	O
applied	O
domain	O
-	O
focused	O
CRISPR	O
screening	O
to	O
human	O
cancer	S-Phenotype
cell	O
lines	O
to	O
identify	O
the	O
transcription	O
factor	O
(	O
TF	O
)	O
POU2F3	O
(	O
POU	O
class	O
2	O
homeobox	O
3	O
;	O
also	O
known	O
as	O
SKN	O
-	O
1a	O
/	O
OCT	O
-	O
11	O
)	O
as	O
a	O
powerful	O
dependency	O
in	O
a	O
subset	O
of	O
SCLC	O
lines	O
.	O

Numerous	O
other	O
linkages	O
have	O
been	O
reported	O
and	O
new	O
sequencing	O
technologies	O
are	O
set	O
to	O
rapidly	O
expand	O
the	O
number	O
of	O
identified	O
keratoconus	S-Phenotype
genes	O
in	O
these	O
regions	O
.	O

The	O
molecular	O
chaperone	O
Hsp90	O
is	O
overexpressed	O
in	O
prostate	B-Phenotype
cancer	E-Phenotype
(	O
PCa	S-Phenotype
)	O
and	O
is	O
responsible	O
for	O
the	O
folding	O
,	O
stabilization	O
and	O
maturation	O
of	O
multiple	O
oncoproteins	O
,	O
which	O
are	O
implicated	O
in	O
PCa	O
progression	O
.	O

Our	O
results	O
reveal	O
that	O
current	O
SZ	O
diagnoses	O
aggregate	O
over	O
at	O
least	O
two	O
disease	O
subtypes	O
:	O
one	O
part	O
resembles	O
high	O
intelligence	O
and	O
bipolar	B-Phenotype
disorder	E-Phenotype
(	O
BIP	S-Phenotype
)	O
,	O
while	O
the	O
other	O
part	O
is	O
a	O
cognitive	O
disorder	O
that	O
is	O
independent	O
of	O
BIP	S-Phenotype

The	O
clinical	O
presentation	O
was	O
severe	O
,	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
,	I-Phenotype
progressive	I-Phenotype
SMA	I-Phenotype
-	I-Phenotype
like	I-Phenotype
motor	I-Phenotype
neuronopathy	E-Phenotype
,	O
cerebellar	B-Phenotype
atrophy	E-Phenotype
,	O
and	O
in	O
one	O
affected	B-Phenotype
individual	I-Phenotype
,	I-Phenotype
congenital	I-Phenotype
fractures	I-Phenotype
of	I-Phenotype
the	I-Phenotype
long	I-Phenotype
bones	E-Phenotype
.	O

Here	O
,	O
we	O
report	O
that	O
TRIP13	O
is	O
highly	O
overexpressed	O
in	O
multiple	O
lung	B-Phenotype
adenocarcinoma	E-Phenotype
cell	O
lines	O
and	O
tumor	S-Phenotype
tissues	O
.	O

Mutations	O
in	O
PLA2G6	O
(	O
PARK14	O
)	O
cause	O
neurodegenerative	O
disorders	O
in	O
humans	O
,	O
including	O
autosomal	B-Phenotype
recessive	I-Phenotype
neuroaxonal	I-Phenotype
dystrophy	E-Phenotype
and	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
parkinsonism	E-Phenotype
.	O

RASSF7	O
is	O
recently	O
reported	O
to	O
be	O
up	O
-	O
regulated	O
in	O
several	O
types	O
of	O
cancer	S-Phenotype
.	O

The	O
data	O
indicate	O
a	O
significant	O
role	O
of	O
HDAC11	O
for	O
mitotic	O
cell	O
cycle	O
progression	O
and	O
survival	O
of	O
MYCN	O
-	O
amplified	O
neuroblastoma	S-Phenotype
cells	O
,	O
and	O
suggests	O
that	O
HDAC11	O
could	O
be	O
a	O
valuable	O
drug	O
target	O

Intriguingly	O
,	O
one	O
of	O
the	O
most	O
frequently	O
altered	O
genes	O
,	O
mutated	O
exclusively	O
by	O
inactivating	O
mutation	O
,	O
was	O
LYST	O
(	O
10	O
%	O
)	O
,	O
which	O
may	O
represent	O
a	O
novel	O
cancer	S-Phenotype
gene	O
in	O
chordoma.Chordoma	S-Phenotype
is	O
a	O
rare	O
often	O
incurable	O
malignant	O
bone	B-Phenotype
tumour	E-Phenotype
.	O

Conclusions	O
:	O
The	O
growth	O
of	O
ovarian	B-Phenotype
cancer	E-Phenotype
cells	O
could	O
be	O
decreased	O
by	O
S1PR2	O
inhibition	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Our	O
study	O
aimed	O
to	O
investigate	O
the	O
relationship	O
between	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
of	O
claudin	O
10	O
(	O
CLDN10	O
)	O
(	O
rs1325774	O
,	O
rs7333503	O
,	O
rs3751334	O
)	O
and	O
breast	B-Phenotype
cancer	E-Phenotype
and	O
the	O
clinical	O
characteristics	O
of	O
patients.A	O
total	O
of	O
104	O
patients	O
with	O
breast	B-Phenotype
cancer	E-Phenotype
and	O
118	O
healthy	O
controls	O
were	O
recruited	O
in	O
our	O
study	O
between	O
2013	O
and	O
2015	O
.	O

We	O
presented	O
the	O
significant	O
clinical	O
heterogeneity	S-Phenotype
among	O
three	O
Chinese	O
late	O
-	O
onset	O
MADD	O
patients	O
with	O
similar	O
ETFDH	O
genotype	O
by	O
collecting	O
clinical	O
information	O
,	O
muscle	O
histology	O
,	O
and	O
genetic	O
analysis	O
.	O

We	O
studied	O
46	O
cases	O
of	O
extramedullary	B-Phenotype
plasmacytoma	E-Phenotype
by	O
immunostaining	O
with	O
anti	O
-	O
ALK	O
antibody	O
and	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
analysis	O
using	O
an	O
ALK	O
break	O
-	O
apart	O
probe	O
and	O
found	O
one	O
case	O
to	O
be	O
ALK	O
protein	O
-	O
positive	O
and	O
demonstrated	O
the	O
disruption	O
of	O
the	O
ALK	O
gene	O
in	O
this	O
case	O
.	O

NSUN2	O
expression	O
was	O
shown	O
to	O
be	O
significantly	O
higher	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
and	O
tissues	O
than	O
in	O
normal	O
breast	O
epithelial	O
cells	O
and	O
tissues	O
,	O
at	O
both	O
mRNA	O
and	O
protein	O
levels	O
.	O

Soluble	O
L1CAM	O
may	O
represent	O
a	O
motility	O
promoting	O
molecule	O
in	O
cancer	S-Phenotype
progression	O
,	O
a	O
co	O
-	O
factor	O
for	O
development	O
of	O
tumor	S-Phenotype
cysts	O
and	O
a	O
target	O
for	O
new	O
treatment	O
strategies	O

In	O
humans	O
,	O
loss	O
of	O
TBC1D20	O
(	O
TBC1	O
domain	O
family	O
,	O
member	O
20	O
)	O
protein	O
function	O
causes	O
Warburg	O
Micro	O
syndrome	O
4	O
(	O
WARBM4	O
)	O
,	O
an	O
autosomal	O
recessive	O
disorder	O
characterized	O
by	O
congenital	B-Phenotype
eye	E-Phenotype
,	O
brain	B-Phenotype
,	I-Phenotype
and	I-Phenotype
genital	I-Phenotype
abnormalities	E-Phenotype
.	O

Human	O
bladder	B-Phenotype
cancer	E-Phenotype
(	O
BCa	S-Phenotype
)	O
is	O
one	O
of	O
the	O
most	O
commonly	O
diagnosed	O
malignancies	O
worldwide	O
.	O

ARID5B	O
also	O
activates	O
the	O
expression	O
of	O
the	O
oncogene	O
MYC	O
Importantly	O
,	O
ARID5B	O
is	O
required	O
for	O
the	O
survival	O
and	O
growth	O
of	O
T	O
-	O
ALL	O
cells	O
,	O
and	O
forced	O
expression	O
of	O
ARID5B	O
in	O
immature	O
thymocytes	O
results	O
in	O
thymus	O
retention	O
,	O
differentiation	O
arrest	O
,	O
radioresistance	O
,	O
and	O
tumor	S-Phenotype
formation	O
in	O
zebrafish	O
.	O

Among	O
these	O
diseases	O
,	O
X	B-Phenotype
-	I-Phenotype
linked	I-Phenotype
hypophosphatemia	E-Phenotype
(	O
XLH	S-Phenotype
)	O
,	O
which	O
is	O
caused	O
by	O
inactivating	O
mutations	O
in	O
the	O
phosphate	O
-	O
regulating	O
endopeptidase	O
homolog	O
,	O
X	O
-	O
linked	O
(	O
PHEX	O
)	O
gene	O
,	O
is	O
the	O
most	O
prevalent	O
form	O
of	O
genetic	B-Phenotype
FGF23	I-Phenotype
-	I-Phenotype
related	I-Phenotype
hypophosphatemic	I-Phenotype
rickets	E-Phenotype
.	O

Mechanistically	O
,	O
different	O
oncogenic	O
gains	O
and	O
dosages	O
evolve	O
along	O
distinct	O
evolutionary	O
routes	O
,	O
licensed	O
by	O
defined	O
allelic	O
states	O
and	O
/	O
or	O
combinations	O
of	O
hallmark	O
tumour	S-Phenotype
suppressor	O
alterations	O
(	O
Cdkn2a	O
,	O
Trp53	O
,	O
Tgfβ	O
-	O
pathway	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
HIC1	O
acted	O
as	O
a	O
tumor	S-Phenotype
suppressor	O
and	O
that	O
its	O
expression	O
was	O
downregulated	O
in	O
UM	O
.	O

Proliferative	B-Phenotype
vasculopathy	I-Phenotype
and	I-Phenotype
hydranencephaly	I-Phenotype
-	I-Phenotype
hydrocephaly	I-Phenotype
syndrome	E-Phenotype
(	O
PVHH	O
,	O
OMIM	O
225790	O
)	O
,	O
also	O
known	O
as	O
Fowler	O
syndrome	O
,	O
is	O
a	O
rare	O
autosomal	O
recessive	O
disorder	O
,	O
caused	O
by	O
mutations	O
in	O
FLVCR2	O
.	O

Impact	O
statement	O
WWOX	O
was	O
originally	O
designated	O
as	O
a	O
tumor	S-Phenotype
suppressor	O
.	O

Our	O
data	O
provide	O
liin	O
vivo	O
/	O
i	O
evidence	O
that	O
liL2hgdh	O
/	O
i	O
mutation	O
leads	O
to	O
L	B-Phenotype
-	I-Phenotype
2	I-Phenotype
-	I-Phenotype
HG	I-Phenotype
accumulation	E-Phenotype
,	O
leukoencephalopathy	S-Phenotype
,	O
and	O
neurodegeneration	S-Phenotype
in	O
mice	O
,	O
thereby	O
offering	O
new	O
insights	O
into	O
the	O
pathophysiology	O
of	O
L	B-Phenotype
-	I-Phenotype
2	I-Phenotype
-	I-Phenotype
HGA	E-Phenotype
in	O
humans	O

Models	O
evaluated	O
include	O
a	O
neuroblastoma	S-Phenotype
cell	O
line	O
(	O
SK	O
-	O
N	O
-	O
AS	O
)	O
and	O
immortalized	O
keratinocytes	O
(	O
HaCaT	O
)	O
as	O
a	O
control	O
of	O
high	O
PTHLH	O
production	O
.	O

Two	O
recent	O
reports	O
describe	O
a	O
new	O
syndrome	O
of	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
short	B-Phenotype
stature	E-Phenotype
,	O
microcephaly	S-Phenotype
,	O
and	O
young	B-Phenotype
onset	I-Phenotype
diabetes	E-Phenotype
or	O
disturbed	B-Phenotype
glucose	I-Phenotype
metabolism	E-Phenotype
in	O
association	O
with	O
inactivating	O
mutations	O
in	O
the	O
TRMT10A	O
gene	O
.	O

We	O
investigate	O
the	O
association	O
of	O
MUC1	O
with	O
castration	B-Phenotype
-	I-Phenotype
resistant	I-Phenotype
prostate	I-Phenotype
cancer	E-Phenotype
(	O
CRPC	S-Phenotype
)	O
,	O
bone	O
metastasis	O
,	O
and	O
PC	O
recurrence	O
.	O

XRCC4	O
is	O
one	O
of	O
the	O
essential	O
proteins	O
of	O
this	O
pathway	O
and	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
of	O
this	O
gene	O
are	O
reported	O
to	O
be	O
associated	O
with	O
cancer	S-Phenotype
risks	O
.	O

A	O
growing	O
body	O
of	O
clinical	O
literature	O
emphasizes	O
the	O
impact	O
of	O
cerebral	B-Phenotype
edema	E-Phenotype
in	O
early	O
brain	O
injury	O
following	O
aneurysmal	B-Phenotype
subarachnoid	I-Phenotype
hemorrhage	E-Phenotype
(	O
aSAH	S-Phenotype
)	O
.	O

Congenital	O
erythropoietic	O
porphyria	O
(	O
CEP	O
)	O
is	O
an	O
inborn	O
error	O
of	O
heme	O
biosynthesis	O
characterized	O
by	O
uroporphyrinogen	O
III	O
synthase	O
(	O
UROS	O
)	O
deficiency	O
resulting	O
in	O
deleterious	O
porphyrin	O
accumulation	O
in	O
blood	O
cells	O
responsible	O
for	O
hemolytic	B-Phenotype
anemia	E-Phenotype
and	O
cutaneous	B-Phenotype
photosensitivity	E-Phenotype
.	O

This	O
study	O
illustrates	O
the	O
value	O
of	O
knockout	O
mice	O
in	O
identifying	O
genetic	O
factors	O
involved	O
in	O
the	O
development	O
of	O
congenital	B-Phenotype
hydrocephalus	E-Phenotype
.	O

Here	O
we	O
used	O
an	O
integrative	O
strategy	O
to	O
examine	O
the	O
hypothesis	O
that	O
genetic	O
variants	O
at	O
FOXA1	O
/	O
2	O
binding	O
elements	O
may	O
be	O
associated	O
with	O
sexual	O
dimorphism	O
of	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
risk	O
.	O

Mounting	O
evidence	O
has	O
shown	O
that	O
miR	O
-	O
23b	O
-	O
3p	O
,	O
which	O
is	O
associated	O
with	O
cell	O
proliferation	O
,	O
invasion	O
,	O
and	O
apoptosis	O
,	O
acts	O
as	O
a	O
biomarker	O
for	O
diagnosis	O
and	O
outcomes	O
in	O
numerous	O
cancers	S-Phenotype
.	O

CRELD1	O
gene	O
is	O
implicated	O
in	O
causation	O
of	O
sporadic	S-Phenotype
AVSD	O
.	O

the	O
quantitative	O
aspects	O
of	O
the	O
Ca2+	O
-	O
feedback	O
to	O
Ret	O
-	O
GCs	O
in	O
regulating	O
the	O
light	O
sensitivity	O
and	O
adaptation	O
in	O
intact	O
rods	O
;	O
2.	O
functional	O
differences	O
between	O
GCAP1	O
and	O
GCAP2	O
in	O
intact	O
rod	O
photoreceptors	O
;	O
and	O
3.	O
whether	O
GCAP	O
mutants	O
with	O
impaired	O
Ca2+	O
binding	O
lead	O
to	O
retinal	B-Phenotype
disease	E-Phenotype
in	O
vivo	O
by	O
constitutive	O
activation	O
of	O
Ret	O
-	O
GCs	O
and	O
elevation	O
of	O
intracellular	O
cGMP	O
,	O
as	O
predicted	O
from	O
in	O
vitro	O
studies	O

RESULTS	O
IHC	O
showed	O
high	O
levels	O
of	O
expression	O
of	O
S100A8	O
protein	O
in	O
endometrial	B-Phenotype
carcinoma	E-Phenotype
tissues	O
,	O
and	O
HEC	O
-	O
1A	O
adenocarcinoma	O
cells	O
(	O
in	O
G1	O
and	O
G2	O
)	O
.	O

It	O
was	O
hypothesized	O
that	O
the	O
whorl	O
formation	O
of	O
meningiomas	S-Phenotype
may	O
occur	O
as	O
a	O
result	O
of	O
a	O
disturbance	O
in	O
the	O
planar	O
cell	O
polarity	O
(	O
PCP	O
)	O
of	O
arachnoid	O
cells	O
,	O
thus	O
,	O
genes	O
understood	O
to	O
govern	O
PCP	O
signaling	O
were	O
analyzed	O
for	O
alterations	O
.	O

We	O
demonstrate	O
the	O
presence	O
of	O
either	O
biallelic	O
loss	O
of	O
Hippo	O
pathway	O
tumor	S-Phenotype
suppressor	O
genes	O
(	O
TSG	O
)	O
and	O
/	O
or	O
evidence	O
of	O
alteration	O
of	O
Hippo	O
pathway	O
genes	O
in	O
85	O
%	O
of	O
samples	O
.	O

A	O
third	O
patient	O
from	O
a	O
consanguineous	O
Sudanese	O
family	O
diagnosed	O
with	O
catecholaminergic	B-Phenotype
polymorphic	I-Phenotype
ventricular	I-Phenotype
tachycardia	E-Phenotype
(	O
CPVT	S-Phenotype
)	O
had	O
a	O
homozygous	O
splice	O
site	O
mutation	O
(	O
c.331+1GAAAAA	O
)	O
in	O
TECRL	O
Analysis	O
of	O
intracellular	O
calcium	O
(	O
[	O
Ca2+	O
]	O
i	O
)	O
dynamics	O
in	O
human	O
induced	O
pluripotent	O
stem	O
cell	O
-	O
derived	O
cardiomyocytes	O
(	O
hiPSC	O
-	O
CMs	O
)	O
generated	O
from	O
this	O
individual	O
(	O
TECRLHom	O
-	O
hiPSCs	O
)	O
,	O
his	O
heterozygous	O
but	O
clinically	O
asymptomatic	O
father	O
(	O
TECRLHet	O
-	O
hiPSCs	O
)	O
,	O
and	O
a	O
healthy	O
individual	O
(	O
CTRL	O
-	O
hiPSCs	O
)	O
from	O
the	O
same	O
Sudanese	O
family	O
,	O
revealed	O
smaller	O
[	O
Ca2+	O
]	O
i	O
transient	O
amplitudes	O
as	O
well	O
as	O
elevated	O
diastolic	O
[	O
Ca2+	O
]	O
i	O
in	O
TECRLHom	O
-	O
hiPSC	O
-	O
CMs	O
compared	O
with	O
CTRL	O
-	O
hiPSC	O
-	O
CMs	O
.	O

Another	O
polymorphism	O
,	O
rs12970291	O
near	O
gene	O
TSHZ1	O
,	O
was	O
associated	O
with	O
both	O
CRC	O
and	O
EC	O
(	O
OR	O
=	O
1.26	O
,	O
P	O
=	O
4.82	O
x	O
10	O
(	O
-	O
8	O
)	O
)	O
,	O
with	O
the	O
alleles	O
showing	O
opposite	O
effects	O
on	O
the	O
risks	O
of	O
the	O
two	O
cancers	S-Phenotype

Beyond	O
secretion	O
,	O
GUCY2C	O
is	O
a	O
tumor	S-Phenotype
suppressor	O
universally	O
silenced	O
by	O
loss	O
of	O
expression	O
of	O
its	O
paracrine	O
hormone	O
during	O
carcinogenesis	O
.	O

Pre	O
-	O
NACT	O
core	O
needle	O
biopsies	O
and	O
postoperative	O
tumor	S-Phenotype
samples	O
were	O
immunohistochemically	O
stained	O
for	O
nuclear	O
factor	O
erythroid	O
2	O
-	O
related	O
factor	O
2	O
(	O
Nrf2	O
)	O
,	O
Kelch	O
-	O
like	O
ECH	O
-	O
associated	O
protein	O
1	O
(	O
Keap1	O
)	O
,	O
thioredoxin	O
(	O
Trx	O
)	O
,	O
and	O
peroxiredoxin	O
I	O
(	O
Prx	O
I	O
)	O
.	O

We	O
show	O
here	O
that	O
another	O
member	O
of	O
the	O
CLCA	O
gene	O
family	O
,	O
CLCA4	O
,	O
is	O
expressed	O
in	O
mammary	O
epithelial	O
cells	O
and	O
is	O
similarly	O
downregulated	O
in	O
breast	B-Phenotype
tumors	E-Phenotype
and	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
.	O

Schnyder	B-Phenotype
corneal	I-Phenotype
dystrophy	E-Phenotype
(	O
SCD	S-Phenotype
)	O
is	O
a	O
rare	O
autosomal	O
dominant	O
disease	O
in	O
humans	O
,	O
characterized	O
by	O
abnormal	B-Phenotype
deposition	I-Phenotype
of	I-Phenotype
cholesterol	I-Phenotype
and	I-Phenotype
phospholipids	I-Phenotype
in	I-Phenotype
cornea	E-Phenotype
caused	O
by	O
mutations	O
in	O
the	O
UbiA	O
prenyltransferase	O
domain	O
containing	O
1	O
(	O
UBIAD1	O
)	O
gene	O
.	O

On	O
the	O
basis	O
of	O
his	O
symptoms	O
,	O
we	O
diagnosed	O
him	O
as	O
spinocerebellar	B-Phenotype
degeneration	E-Phenotype
(	O
SCD	S-Phenotype
)	O
,	O
and	O
prescribed	O
taltirelin	O
hydrate	O
.	O

In	O
summary	O
,	O
our	O
results	O
demonstrate	O
that	O
SAA1	O
in	O
combination	O
with	O
integrin	O
αV	O
and	O
β3	O
can	O
serve	O
as	O
an	O
indicator	O
of	O
high	O
glioblastoma	S-Phenotype
risk	O
.	O

We	O
show	O
that	O
the	O
miR	O
-	O
106b	O
-	O
25	O
cluster	O
upregulates	O
NOTCH1	O
in	O
multiple	O
breast	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
,	O
representing	O
both	O
estrogen	O
receptor	O
(	O
ER+	O
)	O
and	O
triple	O
negative	O
breast	B-Phenotype
cancer	E-Phenotype
(	O
TNBC	O
)	O
through	O
direct	O
repression	O
of	O
the	O
E3	O
ubiquitin	O
ligase	O
,	O
NEDD4L	O
.	O

The	O
present	O
study	O
aimed	O
to	O
investigate	O
the	O
relationship	O
between	O
the	O
expression	O
of	O
collagen	O
and	O
calcium	O
-	O
binding	O
epidermal	O
growth	O
factor	O
domain	O
-	O
containing	O
protein	O
1	O
(	O
CCBE1	O
)	O
and	O
lymphatic	O
vessel	O
endothelial	O
hyaluronan	O
receptor	O
1	O
(	O
LYVE1	O
)	O
in	O
tumor	S-Phenotype
tissue	O
with	O
the	O
clinical	O
prognosis	O
of	O
lung	B-Phenotype
cancer	E-Phenotype
.	O

The	O
importance	O
of	O
PKC	O
enzymes	O
in	O
Purkinje	O
neuron	O
health	O
is	O
apparent	O
as	O
mutations	O
in	O
PRKCG	O
(	O
encoding	O
PKCγ	O
)	O
cause	O
cerebellar	B-Phenotype
ataxia	E-Phenotype
.	O

Kaplan	O
-	O
Meier	O
and	O
log	O
-	O
rank	O
tests	O
revealed	O
that	O
patients	O
with	O
phospho	O
-	O
ELK1	O
(	O
2+	O
)	O
tumor	S-Phenotype
had	O
marginally	O
and	O
significantly	O
higher	O
risks	O
of	O
disease	O
progression	O
(	O
liP	O
/	O
i	O
=	O
0.055	O
)	O
and	O
cancer	S-Phenotype
-	O
specific	O
mortality	O
(	O
liP	O
/	O
i	O
=	O
0.008	O
)	O
,	O
respectively	O
,	O
compared	O
to	O
those	O
with	O
phospho	O
-	O
ELK1	O
(	O
0	O
/	O
1+	O
)	O
tumor	S-Phenotype
.	O

Genetic	O
alterations	O
were	O
investigated	O
in	O
47	O
patients	O
with	O
hearing	B-Phenotype
loss	E-Phenotype
and	O
clinical	O
diagnosis	O
of	O
auditory	B-Phenotype
neuropathy	E-Phenotype
,	O
and	O
the	O
c.35delG	O
mutation	O
in	O
the	O
GJB2	O
gene	O
was	O
identified	O
in	O
three	O
homozygous	O
patients	O
,	O
and	O
the	O
heterozygous	O
parents	O
of	O
one	O
of	O
these	O
cases	O
.	O

In	O
humans	O
,	O
mutations	O
in	O
CISD2	O
result	O
in	O
Wolfram	O
syndrome	O
2	O
,	O
a	O
disease	O
in	O
which	O
the	O
patients	O
display	O
juvenile	B-Phenotype
diabetes	E-Phenotype
,	O
neuropsychiatric	B-Phenotype
disorders	E-Phenotype
and	O
defective	B-Phenotype
platelet	I-Phenotype
aggregation	E-Phenotype
.	O

In	O
addition	O
,	O
the	O
high	O
HtrA2	O
expression	O
was	O
associated	O
with	O
large	O
tumor	S-Phenotype
size	O
and	O
advanced	O
clinical	O
stage	O
.	O

Our	O
report	O
of	O
variant	O
in	O
ARMC9	O
Leading	O
to	O
Joubert	O
syndrome	O
phenotype	O
(	O
JS30	O
)	O
,	O
elucidates	O
the	O
genetic	O
heterogeneity	S-Phenotype
of	O
Joubert	O
syndrome	O
,	O
and	O
expands	O
the	O
gene	O
list	O
for	O
ciliopathies	O

Similar	O
to	O
the	O
human	O
phenotype	O
,	O
liLima1	O
/	O
i	O
-	O
deficient	O
mice	O
displayed	O
reduced	O
cholesterol	O
absorption	O
and	O
were	O
resistant	O
to	O
diet	B-Phenotype
-	I-Phenotype
induced	I-Phenotype
hypercholesterolemia	E-Phenotype
.	O

Collectively	O
,	O
these	O
data	O
suggest	O
that	O
SLC39A4	O
may	O
be	O
a	O
novel	O
therapeutic	O
target	O
and	O
predictive	O
marker	O
of	O
tumour	S-Phenotype
metastasis	O
in	O
non	B-Phenotype
-	I-Phenotype
small	I-Phenotype
cell	I-Phenotype
lung	I-Phenotype
cancer	E-Phenotype

Among	O
the	O
44	O
cases	O
of	O
gastritis	S-Phenotype
/	O
hyperplasia	O
,	O
two	O
cases	O
(	O
4.5	O
%	O
)	O
were	O
diagnosed	O
as	O
HGD	O
and	O
11	O
cases	O
(	O
25.0	O
%	O
)	O
were	O
diagnosed	O
as	O
cancer	S-Phenotype
after	O
resection	O
.	O

PPM1B	O
is	O
a	O
metal	O
-	O
dependent	O
serine	O
/	O
threonine	O
protein	O
phosphatase	O
,	O
with	O
a	O
similar	O
structure	O
and	O
function	O
to	O
the	O
well	O
-	O
known	O
oncogene	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
,	O
PPM1D	O
(	O
WIP1	O
)	O
.	O

While	O
the	O
patient	O
showed	O
features	O
overlapping	O
with	O
the	O
reported	O
phenotype	O
,	O
such	O
as	O
a	O
short	B-Phenotype
stature	E-Phenotype
and	O
small	B-Phenotype
hands	I-Phenotype
and	I-Phenotype
feet	E-Phenotype
,	O
he	O
also	O
presented	O
with	O
additional	O
features	O
like	O
cleft	B-Phenotype
lip	I-Phenotype
and	I-Phenotype
palate	E-Phenotype
and	O
an	O
aberrant	B-Phenotype
right	I-Phenotype
subclavian	I-Phenotype
artery	E-Phenotype
.	O

Based	O
on	O
our	O
findings	O
we	O
conclude	O
that	O
for	O
new	O
patients	O
with	O
Kabuki	O
-	O
like	O
phenotypes	O
it	O
is	O
possible	O
to	O
choose	O
a	O
specific	O
molecular	O
testing	O
approach	O
that	O
has	O
the	O
highest	O
detection	O
rate	O
for	O
a	O
given	O
MLL2	O
-	O
Kabuki	O
score	O
,	O
thus	O
fostering	O
more	O
precise	O
patient	O
diagnosis	O
and	O
improved	O
management	O
in	O
these	O
genetically	O
-	O
and	O
phenotypically	O
heterogeneous	S-Phenotype
clinical	O
entities	O

Taken	O
together	O
,	O
our	O
studies	O
of	O
UM	O
reveal	O
a	O
critical	O
role	O
of	O
HIC1	O
in	O
the	O
regulation	O
of	O
tumorigenesis	S-Phenotype
,	O
at	O
least	O
partly	O
through	O
its	O
downstream	O
target	O
,	O
lncRNA	O
-	O
numb	O
,	O
and	O
provide	O
a	O
potential	O
therapeutic	O
target	O
for	O
UM	O

Methods	O
of	O
diagnosing	O
malignant	O
pheochromocytoma	S-Phenotype
(	O
PCC	S-Phenotype
)	O
or	O
paraganglioma	S-Phenotype
(	O
PGL	S-Phenotype
)	O
are	O
needed	O
.	O

Biallelic	O
mutations	O
in	O
NDUFAF6	O
have	O
been	O
identified	O
as	O
responsible	O
for	O
cases	O
of	O
autosomal	B-Phenotype
recessive	E-Phenotype
Leigh	O
syndrome	O
associated	O
with	O
mitochondrial	O
complex	O
I	O
deficiency	O
.	O

Until	O
recently	O
,	O
four	O
loci	O
(	O
DFN2	O
,	O
DFN3	O
,	O
DFN4	O
,	O
and	O
DFN6	O
)	O
had	O
been	O
implicated	O
in	O
nonsyndromic	O
X	O
-	O
linked	O
hearing	B-Phenotype
loss	E-Phenotype
;	O
however	O
,	O
a	O
new	O
classification	O
(	O
DFNX1	O
-	O
5	O
)	O
has	O
been	O
proposed	O
to	O
reduce	O
confusion	S-Phenotype
in	O
the	O
terminology	O
.	O

In	O
these	O
tumors	S-Phenotype
,	O
RET	O
gene	O
fusion	O
product	O
provides	O
a	O
constitutively	O
active	O
tyrosine	O
kinase	O
(	O
TKR	O
)	O
,	O
leading	O
to	O
uncontrolled	O
cellular	O
proliferation	O
,	O
differentiation	O
,	O
and	O
migration	O
.	O

Through	O
a	O
multi	O
-	O
centric	O
collaboration	O
,	O
we	O
identified	O
three	O
copy	O
-	O
number	O
variant	O
deletions	O
(	O
two	O
de	O
novo	O
and	O
one	O
dominantly	O
inherited	O
in	O
three	O
generations	O
)	O
,	O
one	O
de	O
novo	O
disrupting	O
duplication	O
,	O
and	O
nine	O
de	O
novo	O
point	O
mutations	O
(	O
three	O
truncating	O
,	O
one	O
canonical	O
splice	O
site	O
,	O
and	O
five	O
missense	O
mutations	O
)	O
involving	O
RORA	O
in	O
16	O
individuals	O
from	O
13	O
families	O
with	O
variable	O
neurodevelopmental	B-Phenotype
delay	E-Phenotype
and	O
intellectual	B-Phenotype
disability	E-Phenotype
(	O
ID	S-Phenotype
)	O
-	O
associated	O
autistic	O
features	O
,	O
cerebellar	B-Phenotype
ataxia	E-Phenotype
,	O
and	O
epilepsy	S-Phenotype
.	O

Conditional	O
deletion	O
of	O
Inpp5e	O
in	O
a	O
murine	O
model	O
of	O
constitutively	O
active	O
Smoothened	O
-	O
driven	O
medulloblastoma	S-Phenotype
slowed	O
tumor	S-Phenotype
progression	O
,	O
suppressed	O
cell	O
proliferation	O
,	O
reduced	O
SHH	O
signaling	O
and	O
promoted	O
tumor	S-Phenotype
cell	O
cilia	O
loss	O
.	O

However	O
,	O
the	O
impact	O
of	O
miR	O
-	O
145	O
-	O
3p	O
(	O
the	O
passenger	O
strand	O
)	O
on	O
cancer	S-Phenotype
cells	O
is	O
still	O
ambiguous	O
.	O

Two	O
rare	O
pathogenic	O
variants	O
were	O
identified	O
in	O
the	O
COL15A1	O
gene	O
:	O
one	O
in	O
a	O
sporadic	S-Phenotype
case	O
and	O
another	O
was	O
found	O
to	O
segregate	O
in	O
a	O
family	O
with	O
six	O
affected	O
individuals	O
with	O
CD	O
.	O

These	O
results	O
suggest	O
that	O
MAFB	O
and	O
MAFF	O
play	O
critical	O
roles	O
in	O
the	O
antitumor	O
effects	S-Phenotype
of	O
retinoids	O
by	O
regulating	O
the	O
expression	O
of	O
retinoid	O
target	O
genes	O
such	O
as	O
TFPI2	O
and	O
can	O
be	O
promising	O
for	O
developing	O
therapies	O
to	O
combat	O
HCC	O
invasion	O

RT	O
-	O
PCR	O
analysis	O
showed	O
that	O
the	O
overall	O
transcriptional	O
activity	O
of	O
the	O
main	O
HS	O
biosynthesis	O
-	O
involved	O
genes	O
(	O
EXT1	O
,	O
EXT2	O
,	O
NDST1	O
,	O
NDST2	O
,	O
GLCE	O
,	O
HS2ST1	O
,	O
HS3ST1	O
,	O
HS3ST2	O
,	O
HS6ST1	O
,	O
HS6ST2	O
,	O
SULF1	O
,	O
SULF2	O
,	O
HPSE	O
)	O
was	O
decreased	O
by	O
1.5	O
-	O
2	O
-	O
fold	O
in	O
Grade	O
II	O
-	O
III	O
glioma	S-Phenotype
(	O
p	O
AAAA	O
0.01	O
)	O
and	O
by	O
3	O
-	O
fold	O
in	O
Grade	O
IV	O
glioma	S-Phenotype
(	O
glioblastoma	B-Phenotype
multiforme	E-Phenotype
,	O
GBM	S-Phenotype
)	O
(	O
p	O
AAAA	O
0.05	O
)	O
,	O
as	O
compared	O
with	O
the	O
para	O
-	O
tumourous	S-Phenotype
tissue	O
.	O

PAK3	O
-	O
related	O
intellectual	B-Phenotype
disability	E-Phenotype
is	O
caused	O
by	O
mutations	O
in	O
the	O
gene	O
encoding	O
the	O
p21	O
-	O
activated	O
kinase	O
(	O
PAK	O
)	O
protein	O
.	O

Our	O
findings	O
further	O
elucidate	O
the	O
complex	O
molecular	O
biology	O
of	O
the	O
RANKL	O
/	O
RANK	O
system	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
and	O
provide	O
preliminary	O
data	O
for	O
RANK	O
-	O
c	O
as	O
a	O
possible	O
marker	O
for	O
disease	O
progression	O
and	O
aggressiveness	S-Phenotype

Mutations	O
in	O
the	O
membrane	O
frizzled	O
-	O
related	O
protein	O
(	O
MFRP	O
/	O
Mfrp	O
)	O
gene	O
,	O
specifically	O
expressed	O
in	O
the	O
retinal	O
pigment	O
epithelium	O
(	O
RPE	O
)	O
and	O
ciliary	O
body	O
,	O
cause	O
nanophthalmia	S-Phenotype
or	O
posterior	B-Phenotype
microphthalmia	E-Phenotype
with	O
retinitis	S-Phenotype
pigmentosa	O
in	O
humans	O
,	O
and	O
photoreceptor	O
degeneration	O
in	O
mice	O
.	O

We	O
show	O
that	O
genetic	O
defects	O
in	O
CABP2	O
cause	O
moderate	B-Phenotype
-	I-Phenotype
to	I-Phenotype
-	I-Phenotype
severe	I-Phenotype
sensorineural	I-Phenotype
hearing	I-Phenotype
impairment	E-Phenotype
.	O

Additionally	O
,	O
HOXA11	O
can	O
be	O
a	O
potential	O
tumor	S-Phenotype
suppressor	O

To	O
gain	O
insight	O
into	O
the	O
molecular	O
basis	O
of	O
the	O
heterogeneous	S-Phenotype
phenotype	O
observed	O
in	O
men	O
with	O
the	O
deletion	O
we	O
defined	O
the	O
type	O
of	O
DAZ	O
and	O
CDY1	O
genes	O
deleted	O
.	O

Furthermore	O
,	O
0.3	O
%	O
GTE	O
in	O
drinking	O
water	O
reduced	O
the	O
average	O
number	O
of	O
tumors	S-Phenotype
per	O
mouse	O
from	O
4.1	O
±	O
0.5	O
to	O
2.6	O
±	O
0.4	O
and	O
the	O
percentage	O
of	O
PD	O
-	O
L1	O
positive	O
cells	O
from	O
9.6	O
%	O
to	O
2.9	O
%	O
,	O
a	O
decrease	O
of	O
70	O
%	O
,	O
in	O
lung	B-Phenotype
tumors	E-Phenotype
of	O
A	O
/	O
J	O
mice	O
given	O
a	O
single	O
intraperitoneal	O
injection	O
of	O
4	O
-	O
(	O
methylnitrosamino	O
)	O
-	O
1	O
-	O
(	O
3	O
-	O
pyridyl	O
)	O
-	O
1	O
-	O
butanone	O
(	O
NNK	O
)	O
.	O

Tumor	S-Phenotype
tissue	O
slides	O
further	O
presented	O
that	O
EGFP	O
-	O
EGF1	O
conjugated	O
nanoparticles	O
showed	O
significantly	O
higher	O
accumulation	O
in	O
tumor	S-Phenotype
vasculature	O
than	O
non	O
-	O
conjugated	O
ones	O
.	O

This	O
mini	O
review	O
discusses	O
the	O
roles	O
and	O
underlying	O
molecular	O
mechanisms	O
of	O
FTO	O
in	O
both	O
obesity	S-Phenotype
and	O
cancers	S-Phenotype
,	O
and	O
also	O
summarizes	O
recent	O
advances	O
in	O
the	O
development	O
of	O
FTO	O
inhibitors	O

Our	O
results	O
not	O
only	O
identified	O
the	O
etiology	O
of	O
MICPCH	O
in	O
nearly	O
all	O
the	O
investigated	O
patients	O
but	O
also	O
suggest	O
that	O
MICPCH	O
is	O
a	O
genetically	O
heterogeneous	S-Phenotype
condition	O
,	O
in	O
which	O
CASK	O
inactivating	O
mutations	O
appear	O
to	O
account	O
for	O
the	O
majority	O
of	O
cases	O

In	O
this	O
review	O
,	O
we	O
focus	O
on	O
the	O
association	O
of	O
gene	O
and	O
protein	O
of	O
apoA5	O
with	O
obesity	S-Phenotype
and	O
metabolic	O
syndrome	O
,	O
and	O
provide	O
new	O
insights	O
into	O
the	O
physiological	O
role	O
of	O
apoA5	O
in	O
humans	O
,	O
giving	O
a	O
potential	O
therapeutic	O
target	O
for	O
obesity	S-Phenotype
and	O
associated	O
disorders	O

We	O
report	O
a	O
new	O
(	O
fifth	O
)	O
patient	O
with	O
the	O
cblJ	O
disorder	O
who	O
presented	O
at	O
7	O
days	O
of	O
age	O
with	O
poor	B-Phenotype
feeding	E-Phenotype
,	O
hypotonia	S-Phenotype
,	O
methylmalonic	B-Phenotype
aciduria	E-Phenotype
,	O
and	O
elevated	O
plasma	O
homocysteine	O
and	O
harbored	O
the	O
mutations	O
c.1667_1668delAG	O
[	O
p.Glu556Glyfs	O
*	O
27	O
]	O
and	O
c.1295GAAAAA	O
[	O
p.Arg432Gln	O
]	O
in	O
the	O
ABCD4	O
gene	O
.	O

Oncogenes	O
EGFR	O
and	O
ras	O
are	O
frequently	O
mutated	O
and	O
activated	O
in	O
human	O
lung	B-Phenotype
cancers	E-Phenotype
.	O

Oncogenic	O
PIK3CA	O
mutations	O
are	O
found	O
in	O
a	O
significant	O
fraction	O
of	O
human	O
cancers	S-Phenotype
,	O
but	O
therapeutic	O
inhibition	O
of	O
PI3K	O
has	O
only	O
shown	O
limited	O
success	O
in	O
clinical	O
trials	O
.	O

Examination	O
of	O
tumor	S-Phenotype
-	O
infiltrating	O
immune	O
cells	O
from	O
mice	O
vaccinated	O
with	O
the	O
GM	O
-	O
CSF	O
-	O
expressing	O
exosomes	O
showed	O
robust	O
tumor	S-Phenotype
-	O
reactive	O
CD8sup+	O
/	O
sup	O
T	O
effector	O
responses	O
,	O
Th1	O
cytokine	O
responses	O
,	O
and	O
higher	O
CD8sup+	O
/	O
sup	O
T	O
effector	O
/	O
CD4sup+	O
/	O
supCD25sup+	O
/	O
supFoxp3sup+	O
/	O
sup	O
T	O
regulatory	O
cell	O
ratio	O
in	O
the	O
tumors	S-Phenotype
.	O

BACKGROUND	O
Previous	O
research	O
found	O
that	O
ALG3	O
is	O
associated	O
with	O
cervical	B-Phenotype
cancer	E-Phenotype
,	O
but	O
the	O
role	O
of	O
ALG3	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
was	O
still	O
unknown	O
.	O

The	O
expression	O
profile	O
of	O
ADAMTS1	O
-	O
20	O
in	O
human	O
breast	B-Phenotype
carcinoma	E-Phenotype
was	O
undertaken	O
by	O
real	O
-	O
time	O
PCR	O
using	O
RNA	O
isolated	O
from	O
malignant	O
tumors	S-Phenotype
,	O
nonneoplastic	O
mammary	O
tissue	O
,	O
and	O
breast	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
to	O
identify	O
altered	O
regulation	O
that	O
may	O
have	O
potential	O
pathogenetic	O
and	O
prognostic	O
significance	O
.	O

However	O
,	O
only	O
recently	O
have	O
genetic	O
studies	O
demonstrated	O
sequence	O
variation	O
in	O
HCN1	O
and	O
HCN2	O
genes	O
associated	O
with	O
human	O
epilepsy	S-Phenotype
.	O

The	O
significance	O
of	O
the	O
ubiquitin	O
-	O
proteasome	O
system	O
(	O
UPS	O
)	O
for	O
protein	O
degradation	O
has	O
been	O
highlighted	O
in	O
the	O
context	O
of	O
neurodegenerative	B-Phenotype
diseases	E-Phenotype
,	O
including	O
retinal	B-Phenotype
dystrophies	E-Phenotype
.	O

WTX	O
/	O
AMER1	O
is	O
an	O
important	O
developmental	O
regulator	O
,	O
mutations	O
in	O
which	O
have	O
been	O
identified	O
in	O
a	O
proportion	O
of	O
patients	O
suffering	O
from	O
the	O
renal	B-Phenotype
neoplasm	E-Phenotype
Wilms	O
*	O
tumor	S-Phenotype
and	O
in	O
the	O
bone	O
malformation	O
syndrome	O
Osteopathia	B-Phenotype
Striata	E-Phenotype
with	O
Cranial	B-Phenotype
Sclerosis	E-Phenotype
(	O
OSCS	O
)	O
.	O

Considering	O
the	O
pivotal	O
role	O
of	O
VDR	O
signaling	O
in	O
the	O
colon	O
epithelium	O
both	O
physiologically	O
and	O
pathologically	O
,	O
the	O
correlation	O
between	O
H19	O
and	O
VDR	O
signaling	O
may	O
have	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
colon	B-Phenotype
cancer	E-Phenotype
.	O

Smad3	O
,	O
a	O
major	O
transcription	O
factor	O
in	O
transforming	O
growth	O
factor	O
-	O
β	O
(	O
TGF	O
-	O
β	O
)	O
signaling	O
,	O
plays	O
critical	O
roles	O
in	O
both	O
tumor	S-Phenotype
-	O
suppressive	O
and	O
pro	O
-	O
oncogenic	O
functions	O
.	O

This	O
interval	O
encompasses	O
several	O
genes	O
,	O
especially	O
the	O
short	B-Phenotype
stature	E-Phenotype
homeobox	O
(	O
SHOX	O
)	O
and	O
arylsulfatase	O
(	O
ARSE	O
)	O
genes	O
.	O

We	O
found	O
that	O
miR	O
-	O
UL112	O
-	O
3p	O
expression	O
was	O
significantly	O
elevated	O
in	O
GBM	O
,	O
and	O
its	O
expression	O
levels	O
were	O
highly	O
associated	O
with	O
glioma	S-Phenotype
size	O
,	O
differentiation	O
,	O
WHO	O
stage	O
and	O
the	O
overall	O
and	O
disease	O
-	O
free	O
survival	O
of	O
patients	O
.	O

In	O
those	O
with	O
BRCA1	O
,	O
RAD51C	O
/	O
RAD51D	O
/	O
MMR	O
mutations	O
and	O
the	O
occasional	O
families	O
with	O
a	O
history	O
of	O
ovarian	B-Phenotype
cancer	E-Phenotype
in	O
their	O
40s	O
,	O
surgery	O
needs	O
to	O
be	O
considered	O
at	O
younger	O
than	O
45	O
.	O

Here	O
,	O
we	O
have	O
performed	O
a	O
prospective	O
nationwide	O
genetic	O
association	O
study	O
using	O
the	O
Human	O
Exome	O
BeadChip	O
and	O
identified	O
gene	O
variants	O
in	O
encoding	O
dynactin	O
4	O
(	O
DCTN4	O
)	O
,	O
retinoic	O
acid	O
early	O
transcript	O
1E	O
(	O
RAET1E	O
)	O
,	O
and	O
V	O
-	O
akt	O
murine	O
thymoma	S-Phenotype
viral	O
oncogene	O
homolog	O
3	O
(	O
AKT3	O
)	O
to	O
be	O
associated	O
with	O
unfavourable	O
outcome	O
in	O
patients	O
with	O
pneumococcal	B-Phenotype
meningitis	E-Phenotype
.	O

Through	O
the	O
examination	O
of	O
48	O
candidate	O
genes	O
known	O
to	O
be	O
responsible	O
for	O
autosomal	B-Phenotype
recessive	E-Phenotype
SPG	O
,	O
we	O
identified	O
a	O
novel	O
homozygous	O
4	O
-	O
bp	O
deletion	O
,	O
c.914_917delGTAA	O
,	O
p.Ser305Ilefs	O
*	O
2	O
in	O
exon2	O
of	O
the	O
DDHD1	O
gene	O
encoding	O
phosphatidic	O
acid	O
-	O
preferring	O
phospholipase	O
A1	O
(	O
PA	O
-	O
PLA1	O
)	O
.	O

However	O
,	O
the	O
clinical	O
significance	O
and	O
precise	O
role	O
of	O
ZNF687	O
in	O
cancer	S-Phenotype
progression	O
are	O
largely	O
unknown	O
.	O

These	O
data	O
suggest	O
a	O
previously	O
unrecognized	O
mechanism	O
by	O
which	O
EBNALP	O
coactivates	O
transcription	O
through	O
subverting	O
of	O
EP300	O
and	O
thus	O
affects	O
the	O
expression	O
of	O
LCL	O
genes	O
regulated	O
by	O
a	O
broad	O
range	O
of	O
host	O
TFs.bIMPORTANCE	O
/	O
b	O
Epstein	O
-	O
Barr	O
virus	O
was	O
the	O
first	O
human	O
DNA	O
tumor	S-Phenotype
virus	O
discovered	O
over	O
50	O
years	O
ago	O
.	O

Consistent	O
with	O
a	O
conserved	O
role	O
for	O
this	O
gene	O
in	O
the	O
cochlea	O
,	O
the	O
genetic	O
mapping	O
data	O
presented	O
here	O
support	O
human	O
TMIE	O
as	O
the	O
gene	O
affected	O
at	O
DFNB6	O
,	O
a	O
non	O
-	O
syndromic	O
hearing	B-Phenotype
loss	E-Phenotype
locus	O
.	O

Adult	O
-	O
type	O
granulosa	O
cell	O
tumors	S-Phenotype
of	O
the	O
ovary	O
(	O
aGCTs	O
)	O
are	O
rare	O
gynecologic	O
malignancies	O
that	O
exhibit	O
a	O
high	O
frequency	O
of	O
somatic	O
FOXL2	O
c.C402G	O
(	O
p.Cys134Trp	O
)	O
mutation	O
.	O

This	O
data	O
supports	O
the	O
notion	O
that	O
suppressed	O
DIO1	O
expression	O
and	O
changes	O
in	O
local	O
availability	O
of	O
thyroid	O
hormones	O
might	O
favor	O
a	O
shift	O
from	O
a	O
differentiated	O
to	O
a	O
more	O
proliferation	O
-	O
prone	O
state	O
of	O
cancer	S-Phenotype
tissues	O
and	O
cell	O
lines	O

This	O
study	O
points	O
to	O
the	O
likely	O
importance	O
of	O
histone	O
modifications	O
in	O
osteosarcoma	S-Phenotype
and	O
highlights	O
the	O
strong	O
genetic	O
similarities	O
between	O
human	O
and	O
dog	O
osteosarcoma	S-Phenotype
,	O
suggesting	O
that	O
canine	O
osteosarcoma	S-Phenotype
may	O
serve	O
as	O
an	O
excellent	O
model	O
for	O
developing	O
treatment	O
strategies	O
in	O
both	O
species.Significance	O
:	O
Canine	O
osteosarcoma	S-Phenotype
genomics	O
identify	O
SETD2	O
as	O
a	O
possible	O
oncogenic	O
driver	O
of	O
osteosarcoma	S-Phenotype
,	O
and	O
findings	O
establish	O
the	O
canine	O
model	O
as	O
a	O
useful	O
comparative	O
model	O
for	O
the	O
corresponding	O
human	O
disease	O
.	O

p53R2	O
may	O
be	O
a	O
useful	O
prognostic	O
biomarker	O
and	O
therapeutic	O
target	O
for	O
cervical	O
cancer	O

There	O
are	O
several	O
genetic	O
mutations	O
that	O
lead	O
to	O
ALS	O
development	O
,	O
such	O
as	O
chromosome	O
9	O
hexanucleotide	O
repeat	O
72	O
(	O
C9ORF72	O
)	O
,	O
transactive	O
response	O
DNA	O
-	O
binding	O
protein	O
(	O
TARDBP	O
)	O
,	O
superoxide	O
dismutase	O
1	O
(	O
SOD1	O
)	O
and	O
fused	O
in	O
sarcoma	S-Phenotype
(	O
FUS	O
)	O
.	O

of	O
UNC5C	O
gene	O
(	O
one	O
of	O
the	O
netrin	O
-	O
1	O
receptors	O
)	O
in	O
colorectal	B-Phenotype
cancer	E-Phenotype
patients	O
of	O
Kashmiri	O
population	O
(	O
North	O
India	O
)	O
.	O

Recently	O
,	O
a	O
missense	O
mutation	O
(	O
R7S	O
)	O
in	O
yet	O
another	O
member	O
of	O
this	O
family	O
,	O
HSPB3	O
,	O
was	O
found	O
to	O
cause	O
an	O
axonal	B-Phenotype
motor	I-Phenotype
neuropathy	E-Phenotype
(	O
distal	B-Phenotype
hereditary	I-Phenotype
motor	I-Phenotype
neuropathy	I-Phenotype
type	I-Phenotype
2C	E-Phenotype
,	O
dHMN2C	S-Phenotype
)	O
.	O

Herein	O
we	O
present	O
a	O
case	O
series	O
of	O
six	O
individuals	O
(	O
five	O
males	O
,	O
one	O
female	O
)	O
with	O
intellectual	B-Phenotype
disability	E-Phenotype
and	O
seizures	S-Phenotype
found	O
to	O
have	O
alterations	O
in	O
IQSEC2	O
.	O

iIn	O
vivo	O
/	O
i	O
tumorigenic	O
studies	O
confirmed	O
that	O
miR	O
-	O
612	O
overexpression	O
retarded	O
the	O
growth	O
of	O
A375	O
xenograft	O
tumors	S-Phenotype
,	O
which	O
was	O
coupled	O
with	O
a	O
decline	O
in	O
the	O
percentage	O
of	O
Ki	O
-	O
67	O
-	O
positive	O
proliferating	O
cells	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
sought	O
to	O
identify	O
the	O
factors	O
involved	O
in	O
the	O
RARAAAAAalpha	O
;	O
-	O
mediated	O
transcriptional	O
regulation	O
of	O
the	O
tumor	S-Phenotype
suppressor	O
gene	O
and	O
the	O
tissue	O
factor	O
pathway	O
inhibitor	O
2	O
(	O
TFPI2	O
)	O
in	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
.	O

It	O
is	O
characterized	O
by	O
hyperkeratotic	B-Phenotype
follicular	I-Phenotype
papules	I-Phenotype
coalescing	I-Phenotype
into	I-Phenotype
orange	I-Phenotype
-	I-Phenotype
red	I-Phenotype
scaly	I-Phenotype
plaques	E-Phenotype
,	O
islands	B-Phenotype
of	I-Phenotype
sparing	E-Phenotype
,	O
and	O
palmoplantar	B-Phenotype
keratoderma	E-Phenotype
.	O

Fusion	O
gene	O
detection	O
using	O
a	O
next	O
-	O
generation	O
sequencing	O
-	O
based	O
anchored	O
multiplex	O
PCR	O
technique	O
(	O
Archer	O
FusionPlex	O
Sarcoma	S-Phenotype
Panel	O
)	O
was	O
performed	O
on	O
both	O
the	O
primary	O
renal	B-Phenotype
tumor	E-Phenotype
that	O
showed	O
the	O
morphology	O
of	O
a	O
LGFMS	O
,	O
and	O
a	O
cervical	O
metastasis	O
that	O
showed	O
the	O
morphology	O
of	O
SEF	O
.	O

Gabapentin	O
(	O
GBP	O
;	O
Neurontin	O
)	O
and	O
pregabalin	O
(	O
PGB	O
;	O
Lyrica	O
,	O
S	O
-	O
(	O
+	O
)	O
-	O
3	O
-	O
isobutylgaba	O
)	O
are	O
used	O
clinically	O
to	O
treat	O
several	O
disorders	O
associated	O
with	O
excessive	O
or	O
inappropriate	O
excitability	O
,	O
including	O
epilepsy	S-Phenotype
;	O
pain	B-Phenotype
from	I-Phenotype
diabetic	I-Phenotype
neuropathy	E-Phenotype
,	O
postherpetic	B-Phenotype
neuralgia	E-Phenotype
,	O
and	O
fibromyalgia	S-Phenotype
;	O
and	O
generalized	B-Phenotype
anxiety	I-Phenotype
disorder	E-Phenotype
.	O

The	O
G2019S	O
mutation	O
in	O
Leucine	O
-	O
Rich	O
Repeat	O
Kinase	O
2	O
(	O
LRRK2	O
)	O
is	O
a	O
prevalent	O
cause	O
of	O
late	O
-	O
onset	O
Parkinson	O
*	O
s	O
Disease	O
,	O
producing	O
psychiatric	O
and	O
motor	O
symptoms	O
,	O
including	O
depression	S-Phenotype
,	O
that	O
are	O
indistinguishable	O
from	O
sporadic	S-Phenotype
cases	O
.	O

While	O
control	O
subjects	O
with	O
high	O
PGC	O
-	O
1α	O
expression	O
exhibited	O
high	O
PV	O
and	O
Nefh	O
expression	O
,	O
schizophrenia	S-Phenotype
subjects	O
with	O
high	O
PGC	O
-	O
1α	O
expression	O
did	O
not	O
,	O
suggesting	O
dissociation	O
between	O
PGC	O
-	O
1α	O
expression	O
and	O
these	O
targets	O
in	O
schizophrenia	S-Phenotype
.	O

Overexpression	O
of	O
many	O
factors	O
predicted	O
poor	O
prognosis	O
in	O
breast	O
(	O
EEF1D	O
,	O
EEF1E1	O
,	O
EEF2	O
)	O
and	O
lung	B-Phenotype
cancer	E-Phenotype
(	O
EEF1A2	O
,	O
EEF1B2	O
,	O
EEF1G	O
,	O
EEF1E1	O
)	O
.	O

Triple	B-Phenotype
-	I-Phenotype
negative	I-Phenotype
(	I-Phenotype
TN	I-Phenotype
)	I-Phenotype
breast	I-Phenotype
cancer	E-Phenotype
is	O
an	O
aggressive	O
subtype	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
associated	O
with	O
a	O
unique	O
set	O
of	O
epidemiologic	O
and	O
genetic	O
risk	O
factors	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
the	O
identification	O
of	O
the	O
first	O
insertion	O
mutation	O
,	O
p.W102Vfs	O
*	O
7	O
,	O
in	O
the	O
BSND	O
gene	O
of	O
a	O
newborn	O
girl	O
with	O
acute	O
clinical	O
symptoms	O
including	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
chronic	I-Phenotype
renal	I-Phenotype
failure	E-Phenotype
.	O

Furthermore	O
,	O
parallel	O
immunohistochemical	O
analysis	O
of	O
three	O
PP2A	O
inhibitors	O
demonstrated	O
that	O
two	O
PP2A	O
inhibitors	O
,	O
CIP2A	O
and	O
SET	O
,	O
are	O
highly	O
expressed	O
in	O
both	O
dysplastic	S-Phenotype
and	O
adenocarcinomatous	B-Phenotype
tumors	E-Phenotype
of	O
the	O
Smgb	O
-	O
Tag	O
mice	O
.	O

We	O
conclude	O
that	O
the	O
KCNQ1	O
ion	O
channel	O
is	O
a	O
target	O
gene	O
and	O
regulator	O
of	O
the	O
Wnt	O
/	O
β	O
-	O
catenin	O
pathway	O
,	O
and	O
its	O
repression	O
leads	O
to	O
CRC	O
cell	O
proliferation	O
,	O
EMT	O
,	O
and	O
tumorigenesis	S-Phenotype

In	O
this	O
research	O
,	O
we	O
measured	O
the	O
expression	O
of	O
UQCRC2	O
protein	O
by	O
immunohistochemistry	O
assay	O
in	O
89	O
paired	O
paraffin	O
-	O
embedded	O
tumor	S-Phenotype
tissues	O
and	O
corresponding	O
adjacent	O
normal	O
tissues	O
from	O
patients	O
with	O
colorectal	O
adenocarcinoma	O
and	O
investigated	O
possible	O
correlations	O
of	O
UQCRC2	O
expression	O
with	O
clinicopathological	O
parameters	O
and	O
prognosis	O
.	O

We	O
present	O
a	O
case	O
of	O
a	O
patient	O
with	O
long	B-Phenotype
-	I-Phenotype
standing	I-Phenotype
hyperpigmented	I-Phenotype
macules	E-Phenotype
and	O
erythematous	B-Phenotype
papules	E-Phenotype
over	O
his	O
chest	O
,	O
abdomen	O
,	O
back	O
and	O
arms	O
,	O
suggestive	O
of	O
Dowling	O
-	O
Degos	O
disease	O
(	O
DDD	O
)	O
.	O

Although	O
heterozygous	O
missense	O
mutations	O
in	O
BEST1	O
reveal	O
dominant	O
-	O
negative	O
effects	O
in	O
patients	O
with	O
autosomal	O
dominant	O
Best	O
disease	O
(	O
BD	O
)	O
,	O
heterozygous	O
mutations	O
associated	O
with	O
autosomal	B-Phenotype
recessive	I-Phenotype
bestrophinopathy	E-Phenotype
(	O
ARB	S-Phenotype
)	O
display	O
no	O
disease	O
phenotype	O
.	O

MATERIAL	O
AND	O
METHODS	O
GEPIA	O
and	O
Oncomine	O
cancer	S-Phenotype
databases	O
were	O
mined	O
to	O
predict	O
the	O
CCDC34	O
differential	O
expression	O
level	O
between	O
a	O
CC	O
group	O
and	O
a	O
normal	O
group	O
.	O

Furthermore	O
,	O
the	O
tumorigenesis	S-Phenotype
assay	O
showed	O
that	O
increased	O
expression	O
of	O
hepaCAM	O
suppressed	O
CRC	O
tumor	S-Phenotype
growth	O
and	O
metastasis	O
in	O
vivo	O
.	O

p16	O
is	O
an	O
important	O
tumor	S-Phenotype
suppressor	O
gene	O
encoded	O
by	O
the	O
INK4A	O
/	O
ARF	O
/	O
INK4B	O
gene	O
locus	O
that	O
is	O
conserved	O
in	O
humans	O
,	O
rodents	O
,	O
and	O
canids	O
.	O

In	O
this	O
review	O
,	O
we	O
have	O
selected	O
marine	O
sponges	O
as	O
a	O
prolific	O
source	O
of	O
bioactive	O
compounds	O
which	O
can	O
be	O
explored	O
for	O
their	O
possible	O
use	O
in	O
cancer	S-Phenotype
and	O
have	O
tried	O
to	O
link	O
their	O
role	O
in	O
cancer	S-Phenotype
pathway	O
.	O

Interestingly	O
,	O
REEP1	O
mutations	O
have	O
been	O
linked	O
to	O
neurodegenerative	O
disorders	O
of	O
upper	O
and	O
lower	O
motor	O
neurons	O
,	O
hereditary	B-Phenotype
spastic	I-Phenotype
paraplegia	E-Phenotype
(	O
HSP	S-Phenotype
)	O
and	O
distal	B-Phenotype
hereditary	I-Phenotype
motor	I-Phenotype
neuropathy	I-Phenotype
type	I-Phenotype
V	E-Phenotype
(	O
dHMN	B-Phenotype
-	I-Phenotype
V	E-Phenotype
)	O
.	O

Genotype	O
-	O
phenotype	O
correlation	O
was	O
clarified	O
after	O
combined	O
analysis	O
of	O
the	O
cases	O
and	O
the	O
literature	O
review	O
;	O
anemia	S-Phenotype
was	O
most	O
severe	O
in	O
HS	O
patients	O
with	O
mutations	O
on	O
the	O
ANK1	O
spectrin	O
-	O
binding	O
domain	O
(	O
p	O
AAAA	O
0.05	O
)	O
,	O
and	O
SPTB	O
mutations	O
in	O
HS	O
patients	O
spared	O
the	O
tetramerization	O
domain	O
in	O
which	O
mutations	O
of	O
hereditary	B-Phenotype
elliptocytosis	E-Phenotype
and	O
pyropoikilocytosis	S-Phenotype
are	O
located	O
.	O

QM	O
-	O
MSP	O
can	O
be	O
applied	O
to	O
clinical	O
samples	O
of	O
fresh	O
or	O
fixed	O
ductal	O
cells	O
,	O
ductal	O
fluid	O
,	O
nipple	O
fluid	O
,	O
fine	O
needle	O
aspirates	O
,	O
core	O
biopsies	O
,	O
and	O
tumor	S-Phenotype
tissue	O
sections	O

Integration	O
of	O
the	O
differentially	O
expressed	O
miRNAs	O
with	O
matched	O
mRNA	O
expression	O
profiles	O
identified	O
highly	O
anti	O
-	O
correlated	O
,	O
putative	O
targets	O
,	O
which	O
were	O
significantly	O
enriched	O
in	O
cancer	S-Phenotype
-	O
associated	O
pathways	O
,	O
including	O
phosphatidylinositol	O
(	O
PI	O
)	O
)	O
,	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
,	O
and	O
B	O
-	O
cell	O
receptor	O
(	O
BCR	O
)	O
signaling	O
.	O

While	O
the	O
down	O
regulation	O
of	O
PrKD1	O
by	O
DNA	O
methylation	O
in	O
gastric	B-Phenotype
cancer	E-Phenotype
and	O
by	O
nuclear	O
beta	O
-	O
catenin	O
in	O
colon	B-Phenotype
cancer	E-Phenotype
has	O
been	O
shown	O
,	O
the	O
regulatory	O
mechanisms	O
in	O
other	O
cancers	S-Phenotype
are	O
unknown	O
.	O

Our	O
findings	O
expand	O
the	O
genetic	O
,	O
clinical	O
and	O
neuropathological	O
features	O
of	O
Brown	O
-	O
Vialetto	O
-	O
Van	O
Laere	O
syndrome	O
,	O
implicate	O
mitochondrial	B-Phenotype
dysfunction	E-Phenotype
as	O
a	O
downstream	O
consequence	O
of	O
riboflavin	O
transporter	O
gene	O
defects	O
,	O
and	O
validate	O
riboflavin	O
esters	O
as	O
a	O
potential	O
therapeutic	O
strategy	O

Mutations	O
in	O
Ankyrin	O
repeat	O
and	O
sterile	O
alpha	O
motif	O
domain	O
containing	O
6	O
(	O
ANKS6	O
)	O
play	O
a	O
causative	O
role	O
in	O
renal	B-Phenotype
cyst	E-Phenotype
formation	O
in	O
the	O
PKD	O
/	O
Mhm	O
(	O
cy	O
/	O
+	O
)	O
rat	O
model	O
of	O
polycystic	B-Phenotype
kidney	E-Phenotype
disease	O
and	O
in	O
nephronophthisis	S-Phenotype
in	O
humans	O
.	O

In	O
a	O
consanguineous	O
Saudi	O
family	O
segregating	O
Usher	O
syndrome	O
type	O
1	O
(	O
USH1	O
)	O
,	O
NGS	O
of	O
genes	O
for	O
Usher	O
syndrome	O
,	O
deafness	S-Phenotype
and	O
retinal	B-Phenotype
dystrophy	E-Phenotype
and	O
subsequent	O
whole	O
-	O
exome	O
sequencing	O
each	O
failed	O
to	O
identify	O
a	O
mutation	O
.	O

More	O
recently	O
,	O
evidence	O
has	O
indicated	O
that	O
variations	O
in	O
HFM1	O
gene	O
could	O
be	O
causative	O
for	O
primary	B-Phenotype
ovarian	I-Phenotype
insufficiency	E-Phenotype
(	O
POI	S-Phenotype
)	O
,	O
also	O
known	O
as	O
premature	B-Phenotype
ovarian	I-Phenotype
failure	E-Phenotype
.	O

In	O
humans	O
,	O
nonsynonymous	O
single	O
nucleotide	O
polymorphisms	O
in	O
LTBP4	O
associate	O
with	O
prolonged	O
ambulation	O
in	O
Duchenne	B-Phenotype
muscular	I-Phenotype
dystrophy	E-Phenotype
.	O

Here	O
,	O
we	O
reported	O
a	O
sporadic	S-Phenotype
PVOD	O
patient	O
evidenced	O
by	O
pathology	O
and	O
EIF2AK4	O
biallelic	O
mutation	O
.	O

In	O
cell	O
assays	O
,	O
lucitanib	O
potently	O
inhibited	O
the	O
growth	O
of	O
tumor	S-Phenotype
cell	O
lines	O
with	O
amplified	O
FGFR1	O
or	O
mutated	O
/	O
amplified	O
FGFR2	O
.	O

Therefore	O
,	O
defects	O
in	O
the	O
clock	O
genes	O
not	O
only	O
result	O
in	O
the	O
dysregulation	O
of	O
physiological	O
rhythms	O
but	O
also	O
induce	O
metabolic	O
disorders	O
including	O
diabetes	S-Phenotype
and	O
obesity	S-Phenotype
.	O

In	O
conclusion	O
,	O
polymorphisms	O
of	O
rs2271037	O
and	O
rs3749585	O
in	O
CORIN	O
were	O
significantly	O
associated	O
with	O
hypertension	S-Phenotype
in	O
a	O
Han	O
population	O
of	O
northeastern	O
China	O
.	O

In	O
addition	O
,	O
4	O
/	O
18	O
(	O
18	O
%	O
)	O
of	O
intraductal	B-Phenotype
tubulopapillary	I-Phenotype
neoplasms	E-Phenotype
had	O
FGFR2	O
fusions	O
(	O
FGFR2	O
-	O
CEP55	O
,	O
FGFR2	O
-	O
SASS6	O
,	O
DISP1	O
-	O
FGFR2	O
,	O
FGFR2	O
-	O
TXLNA	O
,	O
and	O
FGFR2	O
-	O
VCL	O
)	O
and	O
1	O
/	O
18	O
(	O
5.5	O
%	O
)	O
had	O
STRN	O
-	O
ALK	O
fusion	O
.	O

Inflammatory	O
chemokine	O
CXCL1	O
,	O
present	O
in	O
large	O
amounts	O
in	O
DCs	O
isolated	O
from	O
colon	B-Phenotype
cancer	E-Phenotype
patients	O
,	O
and	O
SW620	O
-	O
conditioned	O
TADCs	O
,	O
enhance	O
CSC	O
characteristics	O
in	O
cancer	S-Phenotype
,	O
supported	O
by	O
enhanced	O
anchorage	O
-	O
independent	O
growth	O
,	O
CD133	O
expression	O
and	O
aldehyde	O
dehydrogenase	O
activity	O
.	O

We	O
present	O
the	O
case	O
of	O
a	O
severe	O
familial	B-Phenotype
primary	I-Phenotype
hyperparathyroidism	E-Phenotype
related	O
to	O
a	O
germline	O
deletion	O
in	O
the	O
HRPT2	O
(	O
CDC73	O
)	O
gene	O
.	O

Here	O
,	O
we	O
identified	O
a	O
novel	O
de	O
novo	O
frame	O
-	O
shift	O
variant	O
,	O
c.2422_2423delAAinsT	O
which	O
predicts	O
p.	O
(	O
Lys808TyrfsTer40	O
)	O
,	O
in	O
ASH1L	O
in	O
a	O
patient	O
with	O
multiple	O
congenital	O
anomalies	O
(	O
MCA	O
)	O
,	O
fine	B-Phenotype
motor	I-Phenotype
developmental	I-Phenotype
delay	E-Phenotype
,	O
learning	B-Phenotype
difficulties	E-Phenotype
,	O
attention	B-Phenotype
deficit	I-Phenotype
hyperactivity	E-Phenotype
disorder	O
,	O
sleep	B-Phenotype
apnea	E-Phenotype
,	O
and	O
scoliosis	S-Phenotype
.	O

To	O
elucidate	O
the	O
possible	O
functions	O
of	O
EVs	O
in	O
BRAF	O
-	O
mutant	O
melanoma	S-Phenotype
,	O
we	O
determined	O
the	O
RNA	O
content	O
of	O
the	O
EVs	O
,	O
including	O
apoptotic	O
bodies	O
,	O
microvesicles	O
,	O
and	O
exosomes	O
,	O
released	O
from	O
such	O
cancer	S-Phenotype
cells	O
after	O
vemurafenib	O
treatment	O
.	O

Expectedly	O
,	O
the	O
analysis	O
of	O
the	O
DEGs	O
common	O
to	O
all	O
three	O
alterations	O
highlighted	O
a	O
group	O
of	O
BioFunctions	O
that	O
included	O
Cell	O
Proliferation	O
of	O
tumor	S-Phenotype
cell	O
lines	O
(	O
14	O
DEGs	O
)	O
,	O
Invasion	O
of	O
cells	O
(	O
10	O
DEGs	O
)	O
and	O
Migration	O
of	O
tumour	S-Phenotype
cell	O
lines	O
(	O
10	O
DEGs	O
)	O
,	O
with	O
a	O
common	O
core	O
of	O
5	O
genes	O
(	O
ATF3	O
,	O
CDKN1A	O
,	O
GDF15	O
,	O
HBEGF	O
and	O
LCN2	O
)	O
that	O
likely	O
represent	O
downstream	O
effectors	O
of	O
the	O
pro	O
-	O
oncogenic	O
activities	O
of	O
PI3K	O
/	O
AKT	O
signalling	O
.	O

Neurotrophins	O
and	O
their	O
receptors	O
might	O
regulate	O
cell	O
survival	O
in	O
head	B-Phenotype
and	I-Phenotype
neck	I-Phenotype
squamous	I-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
HNSCC	S-Phenotype
)	O
.	O

Prolyl	O
endopeptidase	O
-	O
like	O
(	O
PREPL	O
)	O
deficiency	O
(	O
MIM	O
#	O
616224	O
)	O
is	O
a	O
rare	O
autosomal	B-Phenotype
recessive	E-Phenotype
inherited	O
congenital	O
myasthenic	O
syndrome	O
characterized	O
by	O
neonatal	B-Phenotype
hypotonia	E-Phenotype
,	O
feeding	B-Phenotype
problems	E-Phenotype
,	O
mild	S-Phenotype
dysmorphism	O
,	O
and	O
neuromuscular	O
symptoms	O
,	O
followed	O
by	O
hyperphagia	S-Phenotype
and	O
obesity	S-Phenotype
in	O
later	O
childhood	O
.	O

Our	O
findings	O
will	O
not	O
only	O
augment	O
the	O
mutation	O
spectrum	O
of	O
these	O
three	O
genes	O
,	O
but	O
also	O
provide	O
insights	O
of	O
the	O
contribution	O
of	O
these	O
genes	O
to	O
adult	B-Phenotype
high	I-Phenotype
myopia	E-Phenotype
in	O
Chinese	O
.	O

Moreover	O
,	O
inhibition	O
of	O
MYC	O
target	O
pyrimidine	O
synthesis	O
genes	O
such	O
as	O
CAD	O
,	O
UMPS	O
,	O
and	O
CTPS	O
blocked	O
cell	O
growth	O
,	O
and	O
thus	O
are	O
potential	O
targets	O
for	O
colorectal	B-Phenotype
cancer	E-Phenotype
therapy	O

Our	O
data	O
indicate	O
sex	O
-	O
dependent	O
associations	O
between	O
clock	O
and	O
clock	O
-	O
controlled	O
gene	O
expression	O
in	O
cancer	S-Phenotype
tissue	O
and	O
patient	O
*	O
s	O
survival	O
prognosis	O

Here	O
we	O
developed	O
a	O
novel	O
whole	O
-	O
body	O
insertional	O
mutagenesis	O
screen	O
in	O
mice	O
,	O
which	O
was	O
designed	O
for	O
the	O
discovery	O
of	O
Pten	O
-	O
cooperating	O
tumor	S-Phenotype
suppressors	O
.	O

Mutations	O
in	O
the	O
mitochondrial	O
alanyl	O
-	O
transfer	O
(	O
t	O
)	O
RNA	O
synthetase	O
2	O
(	O
AARS2	O
;	O
OMIM	O
612035	O
)	O
have	O
been	O
linked	O
to	O
leukoencephalopathy	S-Phenotype
recently	O
.	O

uPA	O
may	O
enhance	O
the	O
migratory	O
and	O
invasive	O
capabilities	O
of	O
endometrial	B-Phenotype
tumor	E-Phenotype
cells	O
by	O
the	O
phosphorylation	O
of	O
ERK1	O
/	O
2	O
,	O
Akt	O
and	O
p38	O
molecules	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
TRPS1	O
expression	O
is	O
elevated	O
in	O
luminal	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
and	O
luminal	O
breast	B-Phenotype
cancer	E-Phenotype
tissues	O
as	O
compared	O
with	O
other	O
breast	B-Phenotype
cancer	E-Phenotype
subtypes	O
.	O

A	O
growing	O
number	O
of	O
studies	O
has	O
suggested	O
that	O
long	O
non	O
-	O
coding	O
RNAs	O
(	O
lncRNAs	O
)	O
exert	O
essential	O
roles	O
in	O
the	O
development	O
and	O
progression	O
of	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
.	O

In	O
humans	O
,	O
mutations	O
in	O
CISD2	O
result	O
in	O
Wolfram	O
syndrome	O
2	O
,	O
a	O
disease	O
in	O
which	O
the	O
patients	O
display	O
juvenile	B-Phenotype
diabetes	E-Phenotype
,	O
neuropsychiatric	B-Phenotype
disorders	E-Phenotype
and	O
defective	B-Phenotype
platelet	I-Phenotype
aggregation	E-Phenotype
.	O

Biallelic	O
pathogenic	O
variants	O
in	O
FBXL4	O
are	O
associated	O
with	O
an	O
encephalopathic	O
mtDNA	O
maintenance	O
defect	O
syndrome	O
that	O
is	O
a	O
multisystem	O
disease	O
characterized	O
by	O
lactic	B-Phenotype
acidemia	E-Phenotype
,	O
developmental	B-Phenotype
delay	E-Phenotype
,	O
and	O
hypotonia	S-Phenotype
.	O

We	O
also	O
highlight	O
NCKAP1	O
as	O
another	O
compelling	O
candidate	O
in	O
a	O
large	O
family	O
with	O
autosomal	O
dominant	O
mild	O
intellectual	B-Phenotype
disability	E-Phenotype
that	O
fully	O
segregates	O
with	O
a	O
heterozygous	O
truncating	O
variant	O
.	O

In	O
recent	O
years	O
,	O
genetically	O
determined	O
forms	O
of	O
microangiopathy	O
(	O
e.g	O
.	O

Routine	O
gene	O
testing	O
is	O
not	O
necessary	O
to	O
guide	O
treatment	O
for	O
typical	O
forms	O
of	O
paroxysmal	B-Phenotype
kinesigenic	I-Phenotype
dyskinesia	E-Phenotype
(	O
PKD	S-Phenotype
)	O
,	O
paroxysmal	B-Phenotype
nonkinesigenic	I-Phenotype
dyskinesia	E-Phenotype
(	O
PNKD	S-Phenotype
)	O
,	O
and	O
episodic	B-Phenotype
ataxia	I-Phenotype
type	I-Phenotype
1	I-Phenotype
or	I-Phenotype
2	I-Phenotype
.	E-Phenotype

Moreover	O
,	O
the	O
Kaplan	O
-	O
Meier	O
survival	O
analysis	O
was	O
performed	O
using	O
homologenes	O
(	O
MST1R	O
,	O
PIK3CB	O
and	O
PRKCD	O
)	O
of	O
hub	O
genes	O
in	O
human	O
to	O
evaluate	O
whether	O
exposure	O
to	O
bisphenols	O
may	O
adversely	O
affect	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

We	O
describe	O
an	O
autosomal	O
dominant	O
inherited	O
pedigree	O
with	O
ZASP	O
-	O
MFM	O
that	O
is	O
in	O
line	O
with	O
the	O
typical	O
phenotype	O
of	O
distal	B-Phenotype
myopathy	E-Phenotype
without	O
cardiomyopathy	S-Phenotype
and	O
neuropathy	S-Phenotype
,	O
while	O
mild	O
asymmetrical	B-Phenotype
muscle	I-Phenotype
atrophy	E-Phenotype
can	O
be	O
observed	O
in	O
some	O
affected	O
members	O
.	O

miR‑498	O
overexpression	O
induced	O
cell	O
cycle	O
arrest	O
and	O
apoptosis	O
while	O
it	O
suppressed	O
epithelial‑mesenchymal	O
transition	O
(	O
EMT	O
)	O
in	O
liver	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Here	O
,	O
the	O
homozygous	O
Hoxc13	O
-	O
/	O
-	O
rabbits	O
showed	O
complete	O
loss	O
of	O
hair	O
on	O
the	O
head	O
and	O
dorsum	O
,	O
whereas	O
hypotrichosis	S-Phenotype
in	O
the	O
limbs	O
and	O
tail	O
were	O
determined	O
in	O
the	O
Hoxc13	O
-	O
/	O
-	O
rabbits	O
.	O

CHD4	O
knockdown	O
activates	O
silenced	O
TSGs	O
,	O
revealing	O
their	O
role	O
for	O
blunting	O
colorectal	B-Phenotype
cancer	E-Phenotype
cell	O
proliferation	O
,	O
invasion	O
,	O
and	O
metastases	O
.	O

FLT3	O
fusions	O
are	O
associated	O
with	O
myeloid	B-Phenotype
and	I-Phenotype
lymphoid	I-Phenotype
neoplasms	E-Phenotype
with	O
eosinophilia	S-Phenotype
.	O

Interestingly	O
,	O
PKM2	O
has	O
been	O
recognized	O
as	O
one	O
of	O
the	O
essential	O
genes	O
for	O
the	O
cancer	S-Phenotype
-	O
specific	O
energy	O
metabolism	O
termed	O
the	O
AAAAAldquo	O
;	O
Warburg	O
effectAAAAArdquo	O
;	O
.	O

Expression	O
of	O
miR	O
-	O
17	O
-	O
92a	O
miRNAs	O
improved	O
sensitivity	O
of	O
androgen	O
dependent	O
LNCaP	O
104	O
-	O
S	O
prostate	B-Phenotype
cancer	E-Phenotype
cells	O
to	O
anti	O
-	O
androgen	O
drug	O
Casodex	O
,	O
AKT	O
inhibitor	O
MK	O
-	O
2206	O
2HCl	O
,	O
and	O
docetaxel	O
.	O

Both	O
have	O
PPK	O
and	O
hearing	B-Phenotype
impairment	E-Phenotype
and	O
carried	O
a	O
novel	O
homozygous	O
mutation	O
c.332GAAAAA	O
(	O
p.Cys111Tyr	O
)	O
located	O
in	O
the	O
highly	O
conserved	O
furin	O
-	O
like	O
cysteine	O
-	O
rich	O
domain	O
-	O
2	O
(	O
FU	O
-	O
CRD2	O
)	O
.	O

However	O
,	O
certain	O
chromatin	O
remodeling	O
genes	O
(	O
MLL1	O
,	O
MLL2	O
,	O
MLL3	O
,	O
BAP1	O
,	O
PBRM1	O
,	O
EED	O
,	O
and	O
ATRX	O
)	O
were	O
found	O
to	O
be	O
mutated	O
in	O
7	O
/	O
22	O
(	O
32	O
%	O
)	O
of	O
intraductal	B-Phenotype
tubulopapillary	I-Phenotype
neoplasms	E-Phenotype
and	O
27	O
%	O
harbored	O
phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PI3K	O
)	O
pathway	O
(	O
PIK3CA	O
,	O
PIK3CB	O
,	O
INPP4A	O
,	O
and	O
PTEN	O
)	O
mutations	O
.	O

In	O
wild	O
type	O
(	O
WT	O
)	O
mice	O
,	O
we	O
found	O
that	O
ginsenoside	O
Rg3	O
treatment	O
significantly	O
mitigated	O
pathological	O
damages	O
and	O
reduced	O
myeloperoxidase	O
(	O
MPO	O
)	O
activity	O
as	O
well	O
as	O
the	O
production	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
tumor	S-Phenotype
necrosis	O
factor	O
-	O
a	O
(	O
TNF	O
-	O
a	O
)	O
,	O
interleukin	O
-	O
1b	O
(	O
IL	O
-	O
1b	O
)	O
and	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
)	O
;	O
furthermore	O
,	O
the	O
production	O
of	O
anti	O
-	O
inflammatory	O
mediators	O
interleukin	O
-	O
10	O
(	O
IL	O
-	O
10	O
)	O
and	O
transforming	O
growth	O
factor	O
-	O
b	O
(	O
TGF	O
-	O
b	O
)	O
,	O
polarization	O
of	O
M2	O
macrophages	O
and	O
expression	O
levels	O
of	O
the	O
phosphorylation	O
of	O
phosphatidylinositol	O
3	O
-	O
hydroxy	O
kinase	O
(	O
PI3K	O
)	O
,	O
protein	O
kinase	O
B	O
(	O
PKB	O
,	O
also	O
known	O
as	O
AKT	O
)	O
,	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
and	O
Mer	O
receptor	O
tyrosine	O
kinase	O
(	O
MerTK	O
)	O
were	O
promoted	O
.	O

Mutations	O
of	O
the	O
succinate	O
dehydrogenase	O
(	O
SDH	O
)	O
complex	O
subunits	O
(	O
A	O
,	O
B	O
,	O
C	O
,	O
D	O
,	O
and	O
SDHAF2	O
)	O
have	O
been	O
implicated	O
in	O
predicting	O
metastatic	O
behavior	O
and	O
in	O
identifying	O
possible	O
paraganglioma	S-Phenotype
syndromes	O
.	O

We	O
present	O
her	O
clinical	O
features	O
and	O
particularly	O
highlight	O
her	O
skeletal	O
findings	O
,	O
which	O
confirm	O
the	O
presence	O
of	O
a	O
primary	O
SEMD	O
skeletal	B-Phenotype
dysplasia	E-Phenotype
in	O
a	O
growing	O
list	O
of	O
mitochondrial	O
-	O
related	O
disorders	O
including	O
CAGSSS	O
,	O
CODAS	O
,	O
EVEN	O
-	O
PLUS	O
,	O
and	O
X	O
-	O
linked	O
SEMD	O
-	O
MR	O
syndromes	O

Methylation	O
profiling	O
,	O
metabolite	O
assessment	O
and	O
additional	O
analyses	O
were	O
also	O
performed	O
in	O
selected	O
cases.bResults	O
:	O
/	O
b	O
One	O
of	O
the	O
11	O
tumors	S-Phenotype
was	O
found	O
to	O
carry	O
a	O
known	O
cancer	B-Phenotype
-	I-Phenotype
predisposing	I-Phenotype
somatic	I-Phenotype
mutation	E-Phenotype
in	O
liIDH1	O
/	O
i	O
A	O
variant	O
in	O
liGOT2	O
/	O
i	O
,	O
c.357AAAAAT	O
,	O
found	O
in	O
a	O
patient	O
with	O
multiple	O
tumors	S-Phenotype
,	O
was	O
associated	O
with	O
higher	O
tumor	S-Phenotype
mRNA	O
and	O
protein	O
expression	O
levels	O
,	O
increased	O
GOT2	O
enzymatic	O
activity	O
in	O
lymphoblastic	O
cells	O
,	O
and	O
altered	O
metabolite	O
ratios	O
both	O
in	O
tumors	S-Phenotype
and	O
in	O
GOT2	O
knockdown	O
HeLa	O
cells	O
transfected	O
with	O
the	O
variant	O
.	O

MVD	O
can	O
be	O
improved	O
through	O
weight	B-Phenotype
loss	E-Phenotype
(	O
in	O
obesity	S-Phenotype
)	O
and	O
through	O
exercise	O
.	O

Thus	O
,	O
it	O
is	O
clear	O
that	O
a	O
more	O
complex	O
genetic	O
network	O
of	O
cancer	S-Phenotype
-	O
associated	O
genes	O
than	O
previously	O
hypothesized	O
is	O
involved	O
in	O
BCC	O
carcinogenesis	O
,	O
with	O
a	O
potential	O
impact	O
on	O
the	O
development	O
of	O
new	O
molecular	O
targeted	O
therapies	O
.	O

Addition	O
of	O
exogenous	O
SLURP1	O
(	O
6XHis	O
-	O
tagged	O
,	O
E.	O
coli	O
expressed	O
and	O
partially	O
purified	O
using	O
Ni	O
-	O
ion	O
columns	O
)	O
significantly	O
suppressed	O
the	O
tumor	S-Phenotype
necrosis	O
factor	O
-	O
a	O
(	O
TNF	O
-	O
a	O
)	O
-	O
stimulated	O
human	O
umbilical	O
cord	O
vascular	O
endothelial	O
cell	O
(	O
HUVEC	O
)	O
tube	O
formation	O
.	O

We	O
present	O
a	O
22	O
-	O
year	O
old	O
male	O
with	O
hypotonia	S-Phenotype
,	O
developmental	B-Phenotype
delay	E-Phenotype
,	O
seizure	B-Phenotype
disorder	E-Phenotype
,	O
and	O
dysmorphic	B-Phenotype
facial	I-Phenotype
features	E-Phenotype
who	O
enrolled	O
in	O
our	O
rare	O
disease	O
research	O
center	O
at	O
18	O
years	O
of	O
age	O
,	O
where	O
exome	O
sequencing	O
revealed	O
a	O
novel	O
,	O
likely	O
pathogenic	O
variant	O
in	O
the	O
OPHN1	O
gene	O
.	O

We	O
used	O
exome	O
sequencing	O
to	O
study	O
the	O
molecular	O
basis	O
of	O
disease	O
in	O
an	O
11	O
-	O
year	O
-	O
old	O
female	O
patient	O
who	O
suffered	O
from	O
growth	B-Phenotype
retardation	E-Phenotype
,	O
global	B-Phenotype
developmental	I-Phenotype
delay	E-Phenotype
with	O
absent	B-Phenotype
speech	I-Phenotype
acquisition	E-Phenotype
,	O
agenesis	B-Phenotype
of	I-Phenotype
corpus	I-Phenotype
callosum	E-Phenotype
and	O
paucity	B-Phenotype
of	I-Phenotype
white	I-Phenotype
matter	E-Phenotype
,	O
sensorineural	B-Phenotype
deafness	E-Phenotype
,	O
retinitis	B-Phenotype
pigmentosa	E-Phenotype
,	O
vertebral	B-Phenotype
anomalies	E-Phenotype
,	O
patent	B-Phenotype
ductus	I-Phenotype
arteriosus	E-Phenotype
,	O
and	O
facial	B-Phenotype
dysmorphism	E-Phenotype
reminiscent	O
of	O
STAR	O
syndrome	O
,	O
a	O
suspected	O
ciliopathy	S-Phenotype
.	O

Here	O
,	O
genome	O
-	O
wide	O
quantitative	O
functional	O
profiling	O
,	O
DDR	O
measurements	O
and	O
genetic	O
interaction	O
assays	O
in	O
Schizosaccharomyces	O
pombe	O
reveal	O
a	O
chromate	O
toxicogenomic	O
profile	O
that	O
closely	O
resembles	O
the	O
cancer	S-Phenotype
chemotherapeutic	O
drug	O
camptothecin	O
(	O
CPT	O
)	O
,	O
which	O
traps	O
Topoisomerase	O
1	O
(	O
Top1	O
)	O
-	O
DNA	O
covalent	O
complex	O
(	O
Top1cc	O
)	O
at	O
the	O
3	O
*	O
end	O
of	O
single	O
-	O
stand	O
breaks	O
(	O
SSBs	O
)	O
,	O
resulting	O
in	O
replication	O
fork	O
collapse	O
.	O

Our	O
previous	O
work	O
showed	O
that	O
loss	O
of	O
DIO1	O
enhances	O
proliferation	O
and	O
migration	O
of	O
renal	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Triple	B-Phenotype
-	I-Phenotype
negative	I-Phenotype
breast	I-Phenotype
cancer	E-Phenotype
(	O
TNBC	S-Phenotype
)	O
,	O
lacking	O
the	O
steroid	O
hormone	O
receptors	O
ER	O
and	O
PR	O
and	O
the	O
oncoprotein	O
HER2	O
,	O
is	O
characterized	O
by	O
its	O
aggressive	O
pattern	O
and	O
insensitivity	O
to	O
endocrine	O
and	O
HER2	O
-	O
directed	O
therapy	O
.	O

As	O
a	O
result	O
,	O
two	O
novel	O
heterozygous	O
NKX2	O
-	O
5	O
mutations	O
,	O
p.R139W	O
and	O
p.E167X	O
,	O
were	O
identified	O
in	O
2	O
unrelated	O
patients	O
with	O
sporadic	S-Phenotype
adult	O
-	O
onset	O
DCM	O
,	O
with	O
a	O
mutational	O
prevalence	O
of	O
approximately	O
0.95	O
%	O
.	O

Among	O
them	O
four	O
novel	O
fusion	O
genes	O
SEPT9	O
/	O
CYHR	O
,	O
IGF1R	O
/	O
TTC23	O
,	O
SYT8	O
/	O
TNNI2	O
and	O
CASZ1	O
/	O
DFFA	O
were	O
validated	O
and	O
characterized	O
in	O
48	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
(	O
FFPE	O
)	O
specimens	O
of	O
bladder	B-Phenotype
cancer	E-Phenotype
.	O

In	O
this	O
study	O
,	O
we	O
describe	O
a	O
pathogenic	O
missense	O
mutation	O
in	O
POU4F3	O
in	O
a	O
four	O
-	O
generation	O
Chinese	O
family	O
(	O
6126	O
)	O
with	O
midfrequency	O
,	O
progressive	O
,	O
and	O
postlingual	O
autosomal	B-Phenotype
dominant	I-Phenotype
nonsyndromic	I-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
(	O
ADNSHL	S-Phenotype
)	O
.	O

These	O
findings	O
suggest	O
that	O
CRIPTO	O
expression	O
may	O
be	O
a	O
useful	O
serological	O
marker	O
for	O
diagnostic	O
and	O
/	O
or	O
prognostic	O
purposes	O
during	O
germ	O
cell	O
cancer	S-Phenotype
management	O
.	O

The	O
progressive	O
neurological	B-Phenotype
abnormalities	E-Phenotype
,	O
congenital	B-Phenotype
hypopituitarism	E-Phenotype
and	O
post	B-Phenotype
-	I-Phenotype
retinal	I-Phenotype
visual	I-Phenotype
pathway	I-Phenotype
dysfunction	E-Phenotype
in	O
affected	O
individuals	O
demonstrates	O
for	O
the	O
first	O
time	O
the	O
essential	O
role	O
of	O
ARNT2	O
in	O
the	O
development	O
of	O
the	O
hypothalamo	O
-	O
pituitary	O
axis	O
,	O
post	O
-	O
natal	O
brain	O
growth	O
,	O
and	O
visual	O
and	O
renal	O
function	O
in	O
humans	O
.	O

bMethods	O
:	O
/	O
b	O
A	O
total	O
of	O
3	O
502	O
school	O
-	O
aged	O
children	O
who	O
were	O
included	O
in	O
Beijing	O
Child	O
and	O
Adolescent	O
Metabolic	O
Syndrome	O
(	O
BCAMS	O
)	O
Study	O
were	O
selected	O
,	O
and	O
based	O
on	O
the	O
age	O
and	O
sex	O
specific	O
waist	O
circumference	O
(	O
WC	O
)	O
standards	O
in	O
the	O
BCAMS	O
study	O
,	O
1	O
196	O
central	S-Phenotype
obese	O
cases	O
and	O
2	O
306	O
controls	O
were	O
identified	O
.	O

In	O
addition	O
to	O
describing	O
how	O
to	O
perform	O
the	O
EEG	O
-	O
ECG	O
recordings	O
,	O
we	O
also	O
detail	O
methods	O
to	O
quantify	O
the	O
resulting	O
data	O
for	O
seizures	S-Phenotype
,	O
EEG	O
spectral	O
power	O
,	O
cardiac	O
function	O
,	O
and	O
heart	O
rate	O
variability	O
,	O
which	O
we	O
demonstrate	O
in	O
an	O
example	O
experiment	O
using	O
a	O
mouse	O
with	O
epilepsy	S-Phenotype
due	O
to	O
Kcna1	O
gene	O
deletion	O
.	O

Several	O
therapeutic	O
strategies	O
expressing	O
GM	O
-	O
CSF	O
have	O
been	O
employed	O
in	O
clinical	O
trials	O
for	O
treating	O
metastatic	B-Phenotype
colorectal	I-Phenotype
cancer	E-Phenotype
.	O

All	O
together	O
,	O
our	O
data	O
strongly	O
suggest	O
that	O
recessive	O
mutations	O
in	O
SLC45A1	O
cause	O
ID	O
and	O
epilepsy	S-Phenotype
.	O

Subsequently	O
,	O
a	O
decreased	O
activation	O
of	O
JNK	O
following	O
seizure	S-Phenotype
induction	O
was	O
observed	O
in	O
mice	O
underexpressing	O
JIP3	O
,	O
which	O
also	O
exhibited	O
less	O
neuronal	O
apoptosis	O
in	O
the	O
CA3	O
region	O
of	O
the	O
hippocampus	O
,	O
as	O
assessed	O
three	O
days	O
after	O
KA	O
administration	O
.	O

We	O
demonstrate	O
the	O
effectiveness	O
of	O
morphometric	O
techniques	O
in	O
measuring	O
changes	O
in	O
the	O
relative	O
size	O
of	O
neuroanatomical	O
subdivisions	O
in	O
atoh7	O
morphant	O
larvae	O
and	O
in	O
identifying	O
phenotypes	O
in	O
larvae	O
treated	O
with	O
valproic	O
acid	O
,	O
a	O
chemical	O
demonstrated	O
to	O
increase	O
the	O
risk	O
of	O
autism	S-Phenotype
in	O
humans	O
.	O

By	O
comparing	O
the	O
Src	O
-	O
induced	O
AR	O
-	O
cistrome	O
and	O
/	O
or	O
transcriptome	O
in	O
LNCaP	O
to	O
those	O
in	O
CRPC	O
and	O
LuCaP35.1	O
tumors	S-Phenotype
,	O
we	O
identified	O
an	O
11	O
-	O
gene	O
Src	O
-	O
regulated	O
CRPC	O
signature	O
consisting	O
of	O
AR	O
-	O
dependent	O
,	O
AR	O
binding	O
site	O
(	O
ARBS	O
)	O
-	O
associated	O
genes	O
whose	O
expression	O
is	O
altered	O
by	O
DHT	O
in	O
LNCaP	O
[	O
Src527F	O
]	O
but	O
not	O
in	O
LNCaP	O
cells	O
.	O

The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
investigate	O
whether	O
NTS	O
can	O
modulate	O
the	O
osteoclastogenesis	O
induced	O
by	O
RANKL	O
or	O
cancer	S-Phenotype
cells	O
.	O

Cone	O
-	O
rod	O
degeneration	O
(	O
CRD	O
)	O
belongs	O
to	O
the	O
disease	O
spectrum	O
of	O
retinal	B-Phenotype
degenerations	E-Phenotype
,	O
a	O
group	O
of	O
hereditary	O
disorders	O
characterized	O
by	O
an	O
extreme	O
clinical	O
and	O
genetic	O
heterogeneity	S-Phenotype
.	O

This	O
study	O
expanded	O
the	O
OPA1	O
mutation	O
spectrum	O
,	O
and	O
our	O
results	O
showed	O
that	O
OPA1	O
mutation	O
is	O
another	O
common	O
cause	O
of	O
childhood	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
hereditary	I-Phenotype
optic	I-Phenotype
neuropathy	E-Phenotype
in	O
Chinese	O
pediatric	O
patients	O
,	O
especially	O
those	O
with	O
disease	O
onset	O
during	O
preschool	O
age	O

TRN	O
-	O
restricted	O
deletion	O
of	O
Ptchd1	O
leads	O
to	O
attention	B-Phenotype
deficits	E-Phenotype
and	O
hyperactivity	S-Phenotype
,	O
both	O
of	O
which	O
are	O
rescued	O
by	O
pharmacological	O
augmentation	O
of	O
SK	O
channel	O
activity	O
.	O

The	O
mTOR	O
pathway	O
was	O
significantly	O
associated	O
with	O
overall	O
and	O
estrogen	O
receptor	O
-	O
negative	O
(	O
ER	O
-	O
)	O
breast	B-Phenotype
cancer	E-Phenotype
risk	O
(	O
P	O
=	O
0.003	O
and	O
0.03	O
,	O
respectively	O
)	O
.	O

A	O
retrospective	O
design	O
included	O
the	O
following	O
paraffin	O
-	O
embedded	O
primary	O
NMI	O
tumor	S-Phenotype
types	O
(	O
n	O
=	O
251	O
)	O
:	O
pTa	O
low	O
grade	O
(	O
LG	O
)	O
(	O
n	O
=	O
79	O
)	O
,	O
pT1LG	O
(	O
n	O
=	O
81	O
)	O
,	O
and	O
pT1	O
high	O
grade	O
(	O
HG	O
)	O
(	O
n	O
=	O
91	O
)	O
.	O

Higher	O
pre	O
-	O
NACT	O
nuclear	O
Prx	O
I	O
expression	O
predicted	O
smaller	O
size	O
of	O
a	O
resected	O
tumor	S-Phenotype
(	O
lip	O
/	O
i	O
=	O
0.00052	O
;	O
lir	O
/	O
i	O
=	O
-	O
0.550	O
)	O
,	O
and	O
higher	O
pre	O
-	O
NACT	O
cytoplasmic	O
Prx	O
I	O
expression	O
predicted	O
a	O
lower	O
amount	O
of	O
evacuated	O
nodal	O
metastasis	O
(	O
lip	O
/	O
i	O
=	O
0.0024	O
;	O
lir	O
/	O
i	O
=	O
-	O
0.472	O
)	O
.	O

Our	O
findings	O
support	O
the	O
recently	O
proposed	O
concept	O
of	O
3'UTR	O
-	O
encoded	O
AAAAAAcryptic	O
amyloidogenic	O
elements.AAAAA	O
;	O
Together	O
with	O
a	O
previous	O
report	O
on	O
an	O
aggregation	O
-	O
prone	O
REEP1	O
deletion	O
variant	O
in	O
distal	B-Phenotype
hereditary	I-Phenotype
motor	I-Phenotype
neuropathy	E-Phenotype
,	O
they	O
also	O
suggest	O
that	O
toxic	O
gain	O
of	O
REEP1	O
function	O
,	O
rather	O
than	O
loss	O
-	O
of	O
-	O
function	O
as	O
relevant	O
for	O
HSP	O
,	O
specifically	O
affects	O
lower	O
motor	O
neurons	O
.	O

Review	O
of	O
exome	O
sequencing	O
data	O
of	O
the	O
proband	O
and	O
her	O
unaffected	O
son	O
for	O
40	O
known	O
genes	O
causing	O
congenital	B-Phenotype
nonsyndromic	I-Phenotype
cataracts	E-Phenotype
revealed	O
two	O
variants	O
,	O
namely	O
c.139GAAAAA	O
(	O
p.Asp47Asn	O
;	O
D47N	O
)	O
in	O
the	O
liGJA8	O
/	O
i	O
gene	O
and	O
c.2036CAAAAT	O
in	O
the	O
liFYCO1	O
/	O
i	O
gene	O
to	O
be	O
potentially	O
pathogenic	O
.	O

One	O
of	O
the	O
most	O
extensively	O
propagated	O
hypotheses	O
trying	O
to	O
explain	O
the	O
origin	O
of	O
ER	O
(	O
-	O
)	O
/	O
PgR	O
(	O
+	O
)	O
breast	B-Phenotype
cancers	E-Phenotype
claims	O
that	O
they	O
are	O
technical	O
artifacts	O
dependent	O
on	O
the	O
immunohistochemical	O
procedure	O
.	O

Although	O
open	O
hERG1	O
channels	O
did	O
not	O
interact	O
as	O
strongly	O
with	O
βsub1	O
/	O
sub	O
integrins	O
as	O
did	O
closed	O
channels	O
,	O
current	O
flow	O
through	O
hERG1	O
channels	O
was	O
necessary	O
to	O
activate	O
the	O
integrin	O
-	O
dependent	O
phosphorylation	O
of	O
Tyrsup397	O
/	O
sup	O
in	O
focal	O
adhesion	O
kinase	O
(	O
FAK	O
)	O
in	O
both	O
normal	O
and	O
cancer	S-Phenotype
cells	O
.	O

Patients	O
with	O
adult	O
-	O
onset	O
NCL	O
may	O
present	O
with	O
slowly	O
progressive	B-Phenotype
ataxia	E-Phenotype
,	O
persistent	O
photosensitivity	S-Phenotype
,	O
and	O
seizures	S-Phenotype
without	O
dementia	S-Phenotype
or	O
extrapyramidal	O
findings	O
.	O

These	O
mice	O
displayed	O
hypertension	S-Phenotype
,	O
hyperkalemia	S-Phenotype
,	O
hyperactive	B-Phenotype
NCC	E-Phenotype
,	O
and	O
other	O
features	O
fully	O
recapitulating	O
human	O
and	O
mouse	O
models	O
of	O
PHAII	O
caused	O
by	O
gain	O
-	O
of	O
-	O
function	O
WNK4	O
.	O

We	O
previously	O
mapped	O
a	O
locus	O
(	O
ahl8	O
)	O
contributing	O
to	O
the	O
progressive	B-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
of	O
DBA	O
/	O
2J	O
(	O
D2	O
)	O
mice	O
and	O
later	O
showed	O
that	O
a	O
missense	O
variant	O
of	O
the	O
Fscn2	O
gene	O
,	O
unique	O
to	O
the	O
D2	O
inbred	O
strain	O
,	O
was	O
responsible	O
for	O
the	O
ahl8	O
effect	O
.	O

The	O
rs2042329	O
risk	O
allele	O
was	O
also	O
related	O
to	O
significantly	O
increased	O
expression	O
levels	O
of	O
CWC27	O
mRNA	O
and	O
protein	O
in	O
bladder	B-Phenotype
cancer	E-Phenotype
tissues	O
from	O
Chinese	O
patients	O
.	O

Furthermore	O
,	O
using	O
in	O
silico	O
pathogenicity	O
prediction	O
of	O
missense	O
variants	O
among	O
18	O
genes	O
associated	O
with	O
breast	B-Phenotype
/	I-Phenotype
ovarian	I-Phenotype
cancer	E-Phenotype
and	O
/	O
or	O
Lynch	B-Phenotype
syndrome	E-Phenotype
,	O
followed	O
by	O
KASP	O
genotyping	O
in	O
710	O
healthy	O
controls	O
,	O
we	O
identified	O
AAAAAAlikely	O
pathogenicAAAAAA	O
missense	O
variants	O
in	O
ATM	O
,	O
BRIP1	O
,	O
CHEK2	O
and	O
TP53	O
.	O

The	O
diagnosis	O
of	O
acquired	O
chronic	B-Phenotype
dysimmune	I-Phenotype
neuropathies	E-Phenotype
(	O
CDN	S-Phenotype
)	O
like	O
chronic	B-Phenotype
inflammatory	I-Phenotype
demyelinating	I-Phenotype
polyneuropathy	E-Phenotype
(	O	
CIDP	S-Phenotype
)	O
,	O
Lewis	B-Phenotype
-	I-Phenotype
Sumner	I-Phenotype
Syndrome	E-Phenotype
(	O
LSS	S-Phenotype
)	O
or	O
multifocal	B-Phenotype
motor	I-Phenotype
neuropathy	E-Phenotype
(	O
MMN	S-Phenotype
)	O
can	O
be	O
challenging	O
.	O

In	O
vivo	O
,	O
upregulation	O
of	O
miR	O
-	O
129	O
-	O
5p	O
also	O
inhibited	O
tumor	S-Phenotype
growth	O
.	O

Clinically	O
,	O
low	O
expression	O
of	O
CLCA4	O
signaled	O
lower	O
relapse	O
-	O
free	O
survival	O
in	O
basal	B-Phenotype
and	I-Phenotype
luminal	I-Phenotype
B	I-Phenotype
breast	I-Phenotype
cancers	E-Phenotype
.	O

Here	O
,	O
we	O
hypothesize	O
that	O
PYCR1	O
might	O
be	O
a	O
novel	O
prognostic	O
biomarker	O
and	O
therapeutic	O
target	O
for	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

The	O
corneal	B-Phenotype
abnormalities	E-Phenotype
of	O
Pax6+	O
/	O
-	O
mice	O
provide	O
an	O
excellent	O
model	O
for	O
the	O
corneal	O
changes	O
seen	O
in	O
PAX6+	O
/	O
-	O
humans	O
.	O

Recent	O
studies	O
have	O
linked	O
mutations	O
in	O
the	O
SLC24A4	O
(	O
NCKX4	O
)	O
and	O
SLC24A5	O
(	O
NCKX5	O
)	O
genes	O
to	O
amylogenesis	O
imperfecta	O
(	O
AI	O
)	O
and	O
non	B-Phenotype
-	I-Phenotype
syndromic	I-Phenotype
oculocutaneous	I-Phenotype
albinism	E-Phenotype
(	O
OCA6	S-Phenotype
)	O
,	O
respectively	O
.	O

We	O
expand	O
the	O
knowledge	O
about	O
TTC7A	O
deficiency	O
,	O
describing	O
a	O
patient	O
with	O
the	O
mild	O
phenotype	O
of	O
TTC7A	O
deficiency	O
but	O
presenting	O
overlapping	O
features	O
of	O
SD	O
/	O
THE	O
and	O
MIA	O
-	O
CID	O
:	O
intestinal	B-Phenotype
atresia	E-Phenotype
and	O
inflammatory	B-Phenotype
bowel	I-Phenotype
disease	E-Phenotype
evocative	O
of	O
MIA	O
-	O
CID	O
,	O
but	O
also	O
dental	B-Phenotype
abnormalities	E-Phenotype
,	O
huge	B-Phenotype
forehead	E-Phenotype
,	O
liver	B-Phenotype
abnormalities	E-Phenotype
,	O
autoimmune	O
thyroiditis	S-Phenotype
and	O
hypogammaglobulinemia	S-Phenotype
,	O
evocative	O
of	O
SD	O
/	O
THE	O

Patients	O
with	O
high	O
p53R2	O
expression	O
have	O
a	O
shorter	O
overall	O
survival	O
(	O
OS	O
)	O
and	O
disease	O
-	O
free	O
survival	O
(	O
DFS	O
)	O
.	O

Significant	O
down	O
-	O
regulation	O
of	O
miR	O
-	O
193a	O
-	O
3p	O
was	O
also	O
seen	O
in	O
an	O
independent	O
cohort	O
of	O
ulcerative	B-Phenotype
colitis	I-Phenotype
cancers	E-Phenotype
.	O

The	O
tumor	S-Phenotype
abnormally	O
accumulated	O
FDGin	O
PET	O
-	O
CT	O
examination	O
(	O
SUVmax	O
3.3	O
)	O
.	O

p21	O
-	O
activated	O
kinase	O
4	O
(	O
PAK4	O
)	O
has	O
been	O
shown	O
to	O
regulate	O
many	O
cellular	O
processes	O
in	O
cancer	S-Phenotype
cells	O
,	O
including	O
migration	O
,	O
polarization	O
and	O
proliferation	O
.	O

Transcripts	O
of	O
Prss56	O
,	O
a	O
gene	O
associated	O
with	O
angle	O
-	O
closure	O
glaucoma	S-Phenotype
,	O
posterior	B-Phenotype
microphthalmia	E-Phenotype
and	O
myopia	S-Phenotype
,	O
were	O
increased	O
in	O
Mfrprd6	O
eyes	O
by	O
17	O
-	O
fold	O
.	O

PTEN	O
-	O
wildtype	O
patients	O
(	O
~50	O
%	O
)	O
remain	O
at	O
increased	O
risk	O
of	O
developing	O
certain	O
cancers	S-Phenotype
.	O

B	O
cell	O
-	O
associated	O
protein	O
31	O
(	O
BAP31	O
)	O
was	O
shown	O
to	O
participate	O
in	O
the	O
apoptosis	O
,	O
and	O
to	O
be	O
an	O
immunotherapy	O
target	O
and	O
a	O
,	O
prognostic	O
factor	O
for	O
cancer	S-Phenotype
,	O
but	O
its	O
role	O
in	O
CRC	O
has	O
not	O
been	O
elucidated	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
survey	O
the	O
mutation	O
spectrum	O
of	O
common	O
pathogenic	O
genes	O
(	O
OPA1	O
,	O
OPA3	O
and	O
mtDNA	O
genes	O
)	O
and	O
to	O
analyze	O
the	O
genotype	O
-	O
phenotype	O
characteristics	O
of	O
Chinese	O
patients	O
with	O
suspected	O
childhood	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
hereditary	I-Phenotype
optic	I-Phenotype
neuropathy	E-Phenotype
.	O

We	O
found	O
that	O
NTS	O
inhibits	O
RANKL	O
-	O
or	O
cancer	S-Phenotype
cell	O
-	O
mediated	O
osteoclastogenesis	O
via	O
blockade	O
of	O
TRAF6	O
and	O
NF	O
-	O
κB	O
activation	O
.	O

This	O
multimodality	O
therapy	O
can	O
be	O
one	O
ofthe	O
best	O
strategies	O
for	O
the	O
patients	O
ofesophageal	B-Phenotype
cancer	E-Phenotype
with	O
ERF	O
,	O
even	O
ifthey	O
have	O
poor	O
condition	O

RNA	O
sequencing	O
and	O
quantitative	O
PCR	O
show	O
that	O
cells	O
and	O
EVs	O
from	O
vemurafenib	O
-	O
treated	O
cell	O
cultures	O
and	O
tumor	S-Phenotype
tissues	O
harvested	O
from	O
cell	O
-	O
derived	O
and	O
patient	O
-	O
derived	O
xenografts	O
harbor	O
unique	O
miRNAs	O
,	O
especially	O
increased	O
expression	O
of	O
miR	O
-	O
211	O
-	O
5p	O
.	O

RNA	O
was	O
extracted	O
from	O
the	O
tumor	S-Phenotype
tissue	O
and	O
adjacent	O
parts	O
of	O
the	O
resected	O
colon	O
,	O
and	O
real	O
-	O
time	O
PCR	O
was	O
used	O
for	O
detection	O
of	O
clock	O
gene	O
expression	O
.	O

In	O
ALS	O
,	O
motor	B-Phenotype
neuron	I-Phenotype
degeneration	E-Phenotype
first	O
becomes	O
evident	O
at	O
the	O
motor	O
nerve	O
terminals	O
in	O
neuromuscular	O
junctions	O
(	O
NMJs	O
)	O
,	O
the	O
cholinergic	O
synapse	O
between	O
motor	O
neuron	O
and	O
skeletal	O
muscle	O
;	O
degeneration	O
then	O
progresses	O
proximally	O
,	O
implicating	O
the	O
NMJ	O
as	O
a	O
therapeutic	O
target	O
.	O

The	O
DLEC1	O
,	O
TUSC4	O
and	O
MLH1	O
expression	O
was	O
analysed	O
in	O
lung	B-Phenotype
tumour	E-Phenotype
tissue	O
samples	O
obtained	O
from	O
69	O
patients	O
diagnosed	O
with	O
NSCLC	O
:	O
squamous	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
n	O
=	O
34	O
)	O
,	O
adenocarcinoma	O
(	O
n	O
=	O
24	O
)	O
,	O
large	O
cell	O
carcinoma	S-Phenotype
(	O
n	O
=	O
5	O
)	O
,	O
carcinoma	S-Phenotype
adenosquamosum	O
(	O
n	O
=	O
5	O
)	O
.	O

Among	O
the	O
363	O
outbreaks	O
with	O
a	O
confirmed	O
infectious	O
etiology	O
,	O
212	O
(	O
58	O
%	O
)	O
were	O
caused	O
by	O
Cryptosporidium	O
(	O
which	O
causes	O
predominantly	O
gastrointestinal	O
illness	O
)	O
,	O
57	O
(	O
16	O
%	O
)	O
by	O
Legionella	O
(	O
which	O
causes	O
Legionnaires	O
*	O
disease	O
,	O
a	O
severe	O
pneumonia	S-Phenotype
,	O
and	O
Pontiac	O
fever	S-Phenotype
,	O
a	O
milder	O
illness	O
with	O
flu	O
-	O
like	O
symptoms	O
)	O
,	O
and	O
47	O
(	O
13	O
%	O
)	O
by	O
Pseudomonas	O
(	O
which	O
causes	O
folliculitis	S-Phenotype
[	O
AAAAAAhot	O
tub	O
rashAAAAAA	O
]	O
and	O
otitis	B-Phenotype
externa	E-Phenotype
[	O
AAAAAAswimmers	O
*	O
earAAAAAA	O
]	O
)	O
.	O

We	O
report	O
here	O
two	O
new	O
nonsense	O
mutations	O
(	O
pGln12	O
*	O
and	O
pTyr110	O
*	O
)	O
in	O
CIB2	O
patients	O
displaying	O
nonsyndromic	B-Phenotype
profound	I-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
,	O
with	O
no	B-Phenotype
evidence	I-Phenotype
of	I-Phenotype
vestibular	I-Phenotype
or	I-Phenotype
retinal	I-Phenotype
dysfunction	E-Phenotype
.	O

Herein	O
,	O
we	O
designed	O
a	O
retro	O
-	O
inverso	O
isomer	O
of	O
lLc	O
(	O
LyP	O
-	O
1	O
)	O
,	O
termed	O
lDc	O
(	O
LyP	O
-	O
1	O
)	O
,	O
expecting	O
to	O
inspire	O
brain	O
metastatic	B-Phenotype
tumor	E-Phenotype
targeted	O
drug	O
delivery	O
.	O

Together	O
,	O
these	O
data	O
provide	O
novel	O
insights	O
into	O
a	O
prognostic	O
significance	O
of	O
PLIN1	O
in	O
human	O
breast	B-Phenotype
cancer	E-Phenotype
and	O
reveal	O
a	O
potentially	O
new	O
gene	O
therapy	O
target	O
for	O
breast	B-Phenotype
cancer	E-Phenotype

In	O
summary	O
,	O
a	O
15	O
-	O
lncRNA	O
expression	O
signature	O
(	O
BAIAP2	O
-	O
AS1	O
,	O
RP11	O
-	O
203J24.8	O
,	O
LINC01133	O
,	O
RP1	O
-	O
7G5.6	O
,	O
RP11	O
-	O
147L13.15	O
,	O
SERHL	O
,	O
CTC	O
-	O
537E7.3	O
,	O
RP11	O
-	O
440L14.1	O
,	O
RP11	O
-	O
131N11.4	O
,	O
ILF3	O
-	O
AS1	O
,	O
RP11	O
-	O
80H18.4	O
,	O
RP11	O
-	O
1096G20.5	O
,	O
CTD	O
-	O
2192J16.26	O
,	O
RP11	O
-	O
621L6.3	O
,	O
and	O
RP11	O
-	O
571M6.18	O
)	O
were	O
identified	O
and	O
validated	O
which	O
can	O
predict	O
cervical	B-Phenotype
cancer	E-Phenotype
patient	O
survival	O
.	O

Five	O
of	O
the	O
PHPT	O
syndromes	O
reflect	O
overgrowth	S-Phenotype
of	O
parathyroid	O
tissue	O
;	O
in	O
contrast	O
,	O
familial	B-Phenotype
hypocalciuric	I-Phenotype
hypercalcemia	E-Phenotype
reflects	O
dysregulation	O
of	O
PTH	O
secretion	O
with	O
little	B-Phenotype
or	I-Phenotype
no	I-Phenotype
parathyroid	I-Phenotype
overgrowth	E-Phenotype
.	O

Bardet	O
-	O
Biedl	O
syndrome	O
(	O
BBS	O
)	O
is	O
a	O
defining	O
ciliopathy	O
,	O
notable	O
for	O
extensive	O
allelic	O
and	O
genetic	O
heterogeneity	S-Phenotype
,	O
almost	O
all	O
of	O
which	O
has	O
been	O
identified	O
through	O
sequencing	O
.	O

Moreover	O
,	O
LMP2	O
R	O
/	O
C+C	O
/	O
C	O
genotype	O
was	O
associated	O
with	O
increased	O
tumor	S-Phenotype
invasion	O
depth	O
(	O
p	O
=	O
0.041	O
)	O
.	O

Our	O
study	O
identified	O
a	O
unique	O
gene	O
signature	O
-	O
CCND1	O
,	O
JUN	O
and	O
SPP1	O
-	O
which	O
may	O
be	O
involved	O
in	O
oral	B-Phenotype
cancer	E-Phenotype
lymph	O
node	O
metastasis	O

p53R2	O
expression	O
is	O
significantly	O
upregulated	O
at	O
both	O
mRNA	O
and	O
protein	O
levels	O
in	O
cervical	B-Phenotype
cancer	E-Phenotype
cells	O
and	O
tissues	O
,	O
compared	O
with	O
that	O
in	O
matched	O
normal	O
cervical	O
cells	O
and	O
tissues	O
,	O
respectively	O
.	O

Both	O
in	O
vitro	O
and	O
in	O
vivo	O
antitumor	O
results	S-Phenotype
demonstrated	O
that	O
the	O
sustained	O
-	O
release	O
PTX	O
could	O
induce	O
the	O
microtubules	O
assembly	O
and	O
the	O
over	O
-	O
expression	O
of	O
Bax	O
and	O
Cyclin	O
B1	O
proteins	O
,	O
resulting	O
in	O
the	O
microtubule	O
dynamics	O
disruption	O
,	O
G2	O
/	O
M	O
phase	O
arrest	O
,	O
and	O
cell	O
apoptosis	O
accordingly	O
.	O

The	O
present	O
study	O
also	O
identified	O
in	O
tumor	S-Phenotype
and	O
potentially	O
malignant	O
lesions	O
common	O
alterations	O
of	O
chromosomal	O
regions	O
and	O
genes	O
,	O
including	O
FBXL5	O
,	O
UGT2B15	O
,	O
UGT2B28	O
,	O
KANSL1	O
,	O
GSTT1	O
and	O
DUSP22	O
,	O
being	O
some	O
of	O
these	O
typical	O
aberrations	O
described	O
in	O
oral	B-Phenotype
cancer	E-Phenotype
and	O
others	O
are	O
linked	O
to	O
chemoradioresistance	O
.	O

Gene	O
-	O
based	O
tests	O
highlighted	O
20	O
additional	O
genes	O
of	O
which	O
5	O
had	O
previously	O
been	O
associated	O
to	O
schizophrenia	S-Phenotype
and	O
/	O
or	O
bipolar	B-Phenotype
disorder	E-Phenotype
:	O
CSMD1	O
,	O
CCDC141	O
,	O
SLC1A2	O
,	O
CACNA1C	O
,	O
and	O
SNAP25	O
.	O

In	O
this	O
study	O
,	O
we	O
explored	O
the	O
expression	O
and	O
methylation	O
status	O
of	O
miR	O
-	O
9	O
in	O
HCC	O
samples	O
,	O
as	O
well	O
as	O
the	O
tumor	S-Phenotype
-	O
related	O
functions	O
of	O
miR	O
-	O
9	O
in	O
vitro	O
.	O

This	O
study	O
demonstrates	O
that	O
MYT1L	O
variants	O
are	O
associated	O
with	O
syndromic	O
obesity	S-Phenotype
in	O
humans	O
.	O

Limb	B-Phenotype
girdle	I-Phenotype
muscular	I-Phenotype
dystrophy	I-Phenotype
type	I-Phenotype
2	I-Phenotype
G	E-Phenotype
(	O
LGMD2G	S-Phenotype
)	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
telethonin	O
gene	O
.	O

Increased	O
expression	O
of	O
the	O
Src	O
homology	O
2	O
B	O
adaptor	O
protein	O
1	O
(	O
SH2B1	O
)	O
may	O
stimulate	O
the	O
malignant	O
progression	O
of	O
lung	B-Phenotype
cancer	E-Phenotype
,	O
esophageal	B-Phenotype
cancer	E-Phenotype
and	O
neuroblastoma	S-Phenotype
.	O

FLNB	O
-	O
related	O
disorders	O
are	O
classified	O
as	O
spondylocarpotarsal	B-Phenotype
synostosis	E-Phenotype
(	O
SCT	S-Phenotype
)	O
,	O
Larsen	B-Phenotype
syndrome	E-Phenotype
(	O
LS	S-Phenotype
)	O
,	O
atelosteogenesis	S-Phenotype
(	O
AO	S-Phenotype
)	O
,	O
boomerang	B-Phenotype
dysplasia	E-Phenotype
(	O
BD	S-Phenotype
)	O
,	O
and	O
isolated	B-Phenotype
congenital	I-Phenotype
talipes	I-Phenotype
equinovarus	E-Phenotype
,	O
presenting	O
with	O
scoliosis	S-Phenotype
,	O
short	B-Phenotype
-	I-Phenotype
limbed	I-Phenotype
dwarfism	E-Phenotype
,	O
clubfoot	S-Phenotype
,	O
joint	B-Phenotype
dislocation	E-Phenotype
and	O
other	O
unique	O
skeletal	B-Phenotype
abnormalities	E-Phenotype
.	O

Bartter	O
syndrome	O
type	O
3	O
is	O
a	O
clinically	O
heterogeneous	S-Phenotype
hereditary	O
salt	O
-	O
losing	O
tubulopathy	O
caused	O
by	O
mutations	O
of	O
the	O
chloride	O
voltage	O
-	O
gated	O
channel	O
Kb	O
gene	O
(	O
liCLCNKB	O
/	O
i	O
)	O
,	O
which	O
encodes	O
the	O
ClC	O
-	O
Kb	O
chloride	O
channel	O
involved	O
in	O
NaCl	O
reabsorption	O
in	O
the	O
renal	O
tubule	O
.	O

rs200331695	O
within	O
the	O
EMSY	O
intron	O
is	O
associated	O
with	O
aggressive	O
PrCa	O
and	O
two	O
high	O
linkage	O
disequilibrium	O
(	O
LD	O
)	O
groups	O
of	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
the	O
intergenic	O
region	O
are	O
associated	O
with	O
PrCa	O
death	O
.	O

We	O
present	O
the	O
native	O
3D	O
structures	O
of	O
normal	O
and	O
PCD	O
-	O
causing	O
RSPH1	O
-	O
mutant	O
human	O
respiratory	O
cilia	O
in	O
unprecedented	O
detail	O
;	O
this	O
allows	O
comparisons	O
of	O
cilia	O
structure	O
across	O
evolutionarily	O
distant	O
species	O
and	O
reveals	O
the	O
previously	O
unknown	O
primary	O
defect	O
and	O
the	O
heterogeneous	S-Phenotype
secondary	O
defects	O
in	O
RSPH1	O
-	O
mutant	O
cilia	O
.	O

With	O
particular	O
relevance	O
for	O
muscle	O
physiology	O
,	O
mutations	O
in	O
TRIM32	O
are	O
associated	O
with	O
autosomal	B-Phenotype
recessive	I-Phenotype
Limb	I-Phenotype
-	I-Phenotype
Girdle	I-Phenotype
Muscular	I-Phenotype
Dystrophy	I-Phenotype
2H	E-Phenotype
,	O
a	O
muscle	O
-	O
wasting	O
disease	O
with	O
variable	O
clinical	O
spectrum	O
ranging	O
from	O
almost	O
asymptomatic	O
to	O
wheelchair	O
-	O
bound	O
patients	O
.	O

Among	O
all	O
premature	O
deaths	O
,	O
contributions	O
of	O
cerebrovascular	B-Phenotype
disease	E-Phenotype
(	O
stroke	S-Phenotype
)	O
,	O
ischemic	B-Phenotype
heart	I-Phenotype
disease	E-Phenotype
(	O
IHD	S-Phenotype
)	O
,	O
chronic	B-Phenotype
obstructive	I-Phenotype
pulmonary	I-Phenotype
disease	E-Phenotype
(	O
COPD	S-Phenotype
)	O
,	O
lung	B-Phenotype
cancer	E-Phenotype
(	O
LC	S-Phenotype
)	O
and	O
acute	B-Phenotype
lower	I-Phenotype
respiratory	I-Phenotype
infections	E-Phenotype
(	O
ALRIs	S-Phenotype
)	O
were	O
51.70	O
,	O
26.26	O
,	O
11.77	O
,	O
9.45	O
and	O
0.82	O
%	O
,	O
respectively	O
.	O

The	O
expression	O
of	O
FAM83H	O
is	O
elevated	O
in	O
liver	B-Phenotype
cancer	E-Phenotype
cells	O
,	O
and	O
nuclear	O
expression	O
of	O
FAM83H	O
predicted	O
shorter	O
survival	O
of	O
HCC	O
patients	O
.	O

Mice	O
genetically	O
deficient	O
in	O
DDB2	O
exhibited	O
increased	O
susceptibility	O
to	O
colon	B-Phenotype
tumor	E-Phenotype
development	O
in	O
a	O
manner	O
associated	O
with	O
higher	O
abundance	O
of	O
the	O
Wnt	O
receptor	O
-	O
expressing	O
cells	O
and	O
greater	O
activation	O
of	O
the	O
downstream	O
Wnt	O
pathway	O
.	O

Here	O
we	O
show	O
that	O
the	O
X	B-Phenotype
-	I-Phenotype
linked	I-Phenotype
intellectual	I-Phenotype
disability	E-Phenotype
protein	O
interleukin	O
-	O
1	O
receptor	O
accessory	O
protein	O
like	O
1	O
(	O
IL1RAPL1	O
)	O
regulates	O
dendrite	O
morphology	O
of	O
mice	O
hippocampal	O
neurons	O
and	O
induced	O
pluripotent	O
stem	O
cell	O
-	O
derived	O
neurons	O
from	O
a	O
patient	O
carrying	O
a	O
null	O
mutation	O
of	O
IL1RAPL1	O
gene	O
.	O

To	O
investigate	O
the	O
presence	O
of	O
specific	O
chromosomal	O
and	O
gene	O
alterations	O
,	O
BAP1	O
protein	O
expression	O
,	O
and	O
their	O
relationship	O
with	O
distant	O
progression	O
free	O
survival	O
(	O
DPFS	O
)	O
,	O
we	O
analyzed	O
tumor	S-Phenotype
samples	O
from	O
63	O
UM	O
patients	O
(	O
40	O
men	O
and	O
23	O
women	O
,	O
with	O
a	O
median	O
age	O
of	O
64	O
years	O
)	O
,	O
who	O
underwent	O
eye	O
enucleation	O
by	O
a	O
single	O
cancer	S-Phenotype
ophthalmologist	O
from	O
December	O
2005	O
to	O
June	O
2016	O
.	O

Our	O
data	O
provide	O
in	O
vivo	O
evidence	O
that	O
L2hgdh	O
mutation	O
leads	O
to	O
L	B-Phenotype
-	I-Phenotype
2	I-Phenotype
-	I-Phenotype
HG	I-Phenotype
accumulation	E-Phenotype
,	O
leukoencephalopathy	S-Phenotype
,	O
and	O
neurodegeneration	S-Phenotype
in	O
mice	O
,	O
thereby	O
offering	O
new	O
insights	O
into	O
the	O
pathophysiology	O
of	O
L	B-Phenotype
-	I-Phenotype
2	I-Phenotype
-	I-Phenotype
HGA	E-Phenotype
in	O
humans	O

On	O
the	O
other	O
hand	O
,	O
growing	O
tumors	S-Phenotype
evade	O
immune	O
surveillance	O
by	O
exploiting	O
co	O
-	O
inhibitory	O
signaling	O
through	O
expression	O
of	O
CTLA4	O
,	O
PD1	O
and	O
PDL	O
-	O
1	O
.	O

Finally	O
,	O
XPNPEP3	O
expression	O
correlated	O
with	O
poor	O
survival	O
in	O
many	O
cancers	S-Phenotype
.	O

On	O
these	O
bases	O
,	O
we	O
investigated	O
whether	O
the	O
ligation	O
of	O
ERb	O
by	O
a	O
selective	O
agonist	O
,	O
the	O
2,3	O
-	O
bis	O
(	O
4	O
-	O
hydroxyphenyl	O
)	O
-	O
propionitrile	O
(	O
DPN	O
)	O
,	O
could	O
impact	O
HL	B-Phenotype
tumor	I-Phenotype
growth	E-Phenotype
.	O

Germline	O
CHEK2	O
mutations	O
confer	O
increased	O
cancer	S-Phenotype
risk	O
,	O
for	O
breast	O
and	O
other	O
types	O
,	O
which	O
is	O
variable	O
depending	O
on	O
the	O
specific	O
mutation	O
.	O

GRACILE	O
Syndrome	O
,	O
is	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
disease	O
presenting	O
with	O
growth	B-Phenotype
retardation	E-Phenotype
,	O
severe	B-Phenotype
lactic	I-Phenotype
acidosis	E-Phenotype
,	O
Fanconi	B-Phenotype
type	I-Phenotype
tubulopathy	E-Phenotype
,	O
cholestasis	S-Phenotype
,	O
iron	B-Phenotype
overload	E-Phenotype
and	O
early	B-Phenotype
death	E-Phenotype
without	O
any	O
dysmorphological	O
or	O
neurological	O
features	O
.	O

Cerebral	B-Phenotype
autosomal	I-Phenotype
dominant	I-Phenotype
arteriopathy	I-Phenotype
with	I-Phenotype
subcortical	I-Phenotype
infarcts	I-Phenotype
and	I-Phenotype
leukoencephalopathy	E-Phenotype
(	O
CADASIL	S-Phenotype
)	O
,	O
caused	O
by	O
NOTCH3	O
,	O
primarily	O
affects	O
small	O
cerebral	O
arteries	O
;	O
however	O
,	O
stenosis	O
of	O
major	O
intracranial	O
arteries	O
has	O
occasionally	O
been	O
reported	O
.	O

We	O
summarize	O
the	O
phenotypic	O
extent	O
of	O
GLI2	O
/	O
3	O
syndromes	O
in	O
the	O
literature	O
and	O
determine	O
that	O
these	O
2	O
syndromes	O
manifest	O
opposite	O
features	O
to	O
a	O
certain	O
extent	O
,	O
such	O
as	O
midface	B-Phenotype
hypoplasia	E-Phenotype
or	O
macrocephaly	S-Phenotype
,	O
and	O
anterior	B-Phenotype
or	I-Phenotype
posterior	I-Phenotype
side	I-Phenotype
of	I-Phenotype
polydactyly	E-Phenotype
.	O

The	O
expression	O
of	O
CSTA	O
in	O
tumors	S-Phenotype
was	O
significantly	O
associated	O
with	O
pT	O
classification	O
(	O
deeper	O
tumor	S-Phenotype
invasions	O
)	O
(	O
P	O
=	O
.0118	O
)	O
and	O
advanced	O
TNM	O
stages	O
(	O
P	O
=	O
.0497	O
)	O
.	O

X	B-Phenotype
-	I-Phenotype
linked	I-Phenotype
retinitis	I-Phenotype
pigmentosa	E-Phenotype
(	O
XLRP	S-Phenotype
)	O
caused	O
by	O
mutations	O
in	O
the	O
RPGR	O
gene	O
is	O
an	O
early	O
onset	O
and	O
severe	O
cause	O
of	O
blindness	S-Phenotype
.	O

Although	O
these	O
data	O
further	O
support	O
the	O
pathogenic	O
role	O
of	O
KLHL7	O
mutations	O
in	O
a	O
CS	O
/	O
CISS1	O
-	O
like	O
phenotype	O
,	O
they	O
do	O
not	O
explain	O
all	O
their	O
clinical	O
manifestations	O
and	O
highlight	O
the	O
high	O
phenotypic	O
heterogeneity	S-Phenotype
associated	O
with	O
mutations	O
in	O
KLHL7	O
.	O

Eighteen	O
MCPH	O
loci	O
(	O
MCPH1	O
-	O
MCPH18	O
)	O
have	O
been	O
mapped	O
to	O
date	O
from	O
various	O
populations	O
around	O
the	O
world	O
and	O
contain	O
the	O
following	O
genes	O
:	O
Microcephalin	O
,	O
WDR62	O
,	O
CDK5RAP2	O
,	O
CASC5	O
,	O
ASPM	O
,	O
CENPJ	O
,	O
STIL	O
,	O
CEP135	O
,	O
CEP152	O
,	O
ZNF335	O
,	O
PHC1	O
,	O
CDK6	O
,	O
CENPE	O
,	O
SASS6	O
,	O
MFSD2A	O
,	O
ANKLE2	O
,	O
CIT	O
and	O
WDFY3	O
,	O
clarifying	O
our	O
understanding	O
about	O
the	O
molecular	O
basis	O
of	O
microcephaly	S-Phenotype
genetic	O
disorder	O
.	O

We	O
describe	O
another	O
case	O
of	O
the	O
condition	O
with	O
manifestations	O
of	O
cutaneous	B-Phenotype
mastocytosis	E-Phenotype
associated	O
with	O
a	O
novel	O
do	O
novo	O
mutation	O
GNB1NM_001282539.1	O
:	O
c.230G	O
AAAA	O
T	O
;	O
p.	O
(	O
Gly77Val	O
)	O
.	O

Repression	O
of	O
glioma	S-Phenotype
NOS2	O
expression	O
in	O
vivo	O
led	O
to	O
a	O
reduction	O
in	O
both	O
microglia	O
recruitment	O
and	O
tumor	S-Phenotype
expansion	O
,	O
whereas	O
depletion	O
of	O
microglial	O
caspase	O
-	O
3	O
gene	O
promoted	O
tumor	S-Phenotype
growth	O
.	O

Familial	B-Phenotype
adenomatous	I-Phenotype
polyposis	E-Phenotype
(	O
FAP	S-Phenotype
)	O
is	O
an	O
autosomal	B-Phenotype
dominant‑inherited	I-Phenotype
colorectal	I-Phenotype
cancer	E-Phenotype
.	O

The	O
other	O
tested	O
genes	O
,	O
including	O
the	O
deafness	S-Phenotype
gene	O
COCH	O
,	O
in	O
which	O
mutation	O
recapitulates	O
deafness	S-Phenotype
in	O
mice	O
,	O
were	O
expressed	O
in	O
a	O
similar	O
manner	O
in	O
both	O
species	O
.	O

In	O
pulmonary	B-Phenotype
arterial	I-Phenotype
hypertension	E-Phenotype
(	O
PAH	S-Phenotype
)	O
,	O
lung	O
-	O
angioproliferation	O
leads	O
to	O
increased	B-Phenotype
pulmonary	I-Phenotype
vascular	I-Phenotype
resistance	E-Phenotype
,	O
while	O
simultaneous	O
myocardial	O
microvessel	O
loss	O
contributes	O
to	O
right	O
ventricular	O
(	O
RV	O
)	O
failure	O
.	O

Despite	O
the	O
absence	O
of	O
Ctnnb1	O
mutations	O
,	O
β	O
-	O
catenin	O
was	O
overexpressed	O
in	O
nuclear	O
and	O
plasma	O
membrane	O
fractions	O
from	O
PhIP	O
-	O
induced	O
skin	B-Phenotype
tumors	E-Phenotype
,	O
coinciding	O
with	O
loss	O
of	O
p120	O
-	O
catenin	O
from	O
the	O
plasma	O
membrane	O
,	O
and	O
the	O
appearance	O
of	O
multiple	O
p120	O
-	O
catenin	O
-	O
associated	O
bands	O
in	O
the	O
nuclear	O
extracts	O
.	O

MAT2A	O
/	O
MAT2B	O
induction	O
confers	O
growth	O
and	O
survival	O
advantage	O
to	O
cancerous	S-Phenotype
cells	O
,	O
enhancing	O
tumor	S-Phenotype
migration	O
.	O

Murine	O
double	O
minute	O
2	O
(	O
MDM2	O
)	O
is	O
the	O
E3	O
ubiquitin	O
ligase	O
of	O
the	O
tumor	S-Phenotype
suppressor	O
gene	O
,	O
p53	O
,	O
and	O
inhibition	O
of	O
MDM2	O
can	O
suppress	O
tumor	S-Phenotype
cell	O
growth	O
.	O

In	O
PANC	O
-	O
1	O
and	O
BxPC	O
-	O
3	O
cells	O
,	O
KLF9	O
overexpression	O
decreased	O
the	O
proliferation	O
of	O
pancreatic	B-Phenotype
cancer	E-Phenotype
cells	O
,	O
induced	O
apoptosis	O
,	O
blocked	O
the	O
cell	O
cycle	O
at	O
the	O
S	O
phase	O
,	O
and	O
inhibited	O
the	O
migration	O
and	O
invasion	O
of	O
tumor	S-Phenotype
cells	O
.	O

Moreover	O
,	O
it	O
is	O
known	O
that	O
NARS2	O
mutations	O
cause	O
various	O
clinical	O
phenotypes	O
,	O
including	O
non	B-Phenotype
-	I-Phenotype
syndromic	I-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
,	O
Leigh	B-Phenotype
syndrome	E-Phenotype
,	O
intellectual	B-Phenotype
disability	E-Phenotype
with	O
epilepsy	S-Phenotype
and	O
severe	O
myopathy	S-Phenotype
.	O

Further	O
,	O
two	O
SNPs	O
independent	O
of	O
previously	O
reported	O
signals	O
in	O
ESR1	O
[	O
rs12525163	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
1.15	O
,	O
P	O
=	O
4.9	O
×	O
10	O
(	O
-	O
)	O
(	O
4	O
)	O
]	O
and	O
19p13.1	O
(	O
rs1864112	O
OR	O
=	O
0.84	O
,	O
P	O
=	O
1.8	O
×	O
10	O
(	O
-	O
)	O
(	O
9	O
)	O
)	O
were	O
associated	O
with	O
TN	B-Phenotype
breast	I-Phenotype
cancer	E-Phenotype
.	O

Some	O
genes	O
,	O
such	O
as	O
GSTM1	O
,	O
DNMT3L	O
,	O
and	O
CYP1A1	O
,	O
have	O
been	O
shown	O
to	O
be	O
potentially	O
associated	O
with	O
oligospermia	S-Phenotype
;	O
some	O
,	O
such	O
as	O
CATSPER1	O
,	O
CRISP2	O
,	O
SEPT4	O
,	O
TCTE3	O
,	O
TEKT4	O
,	O
and	O
DNAH1	O
,	O
with	O
asthenospermia	S-Phenotype
;	O
and	O
still	O
others	O
,	O
such	O
as	O
DPY19L2	O
and	O
AURKC	O
,	O
with	O
teratospermia	S-Phenotype
.	O

We	O
demonstrated	O
that	O
SLC6A9	O
-	O
5:2	O
was	O
remarkably	O
downregulated	O
in	O
131I	O
-	O
resistant	O
thyroid	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
and	O
131I	O
-	O
insensitive	O
patients	O
and	O
was	O
positively	O
correlated	O
with	O
Poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
1	O
(	O
PARP	O
-	O
1	O
)	O
expression	O
and	O
its	O
activation	O
.	O

Three	O
patients	O
presented	O
with	O
cognitive	B-Phenotype
impairment	E-Phenotype
,	O
reinforcing	O
the	O
association	O
between	O
the	O
disrupted	O
genes	O
(	O
TSPAN7	O
-	O
MRX58	O
,	O
KIAA2022	O
-	O
MRX98	O
,	O
and	O
IL1RAPL1	O
-	O
MRX21	O
/	O
34	O
)	O
and	O
intellectual	B-Phenotype
disability	E-Phenotype
.	O

We	O
measured	O
the	O
expression	O
of	O
autophagy	O
genes	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
of	O
20	O
patients	O
with	O
Huntington	O
's	O
disease	O
(	O
HD	O
)	O
,	O
20	O
with	O
spinocerebellar	B-Phenotype
ataxia	I-Phenotype
type	I-Phenotype
2	E-Phenotype
(	O
SCA2	S-Phenotype
)	O
,	O
and	O
20	O
healthy	O
individuals	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
a	O
custom	O
-	O
made	O
TES	O
panel	O
to	O
identify	O
the	O
genetic	O
defect	O
of	O
a	O
four	O
-	O
generation	O
Chinese	O
family	O
with	O
bilateral	B-Phenotype
pulverulent	I-Phenotype
nuclear	I-Phenotype
cataracts	E-Phenotype
.	O

The	O
FGF9	O
subfamily	O
,	O
including	O
FGF9	O
,	O
FGF16	O
,	O
and	O
FGF20	O
,	O
in	O
addition	O
to	O
rhFGF16	O
,	O
rhFGF9	O
,	O
and	O
rhFGF20	O
,	O
were	O
shown	O
to	O
stimulate	O
the	O
proliferation	O
and	O
migration	O
of	O
HuH7	O
human	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
cells	O
.	O

Another	O
target	O
of	O
miR	O
-	O
125a	O
is	O
Lin28	O
,	O
a	O
pluripotency	O
factor	O
that	O
is	O
generally	O
undetectable	O
in	O
differentiated	O
cells	O
but	O
is	O
often	O
upregulated	O
/	O
reactivated	O
in	O
tumors	S-Phenotype
where	O
it	O
acts	O
as	O
an	O
oncogenic	O
factor	O
promoting	O
cell	O
proliferation	O
and	O
tumor	S-Phenotype
progression	O
.	O

Factor	O
VII	O
(	O
FVII	O
)	O
activating	O
protease	O
(	O
FSAP	O
)	O
is	O
a	O
circulating	O
serine	O
protease	O
that	O
is	O
likely	O
to	O
be	O
involved	O
in	O
a	O
number	O
of	O
disease	O
conditions	O
such	O
as	O
stroke	S-Phenotype
,	O
atherosclerosis	S-Phenotype
,	O
liver	B-Phenotype
fibrosis	E-Phenotype
,	O
thrombosis	S-Phenotype
and	O
cancer	S-Phenotype
.	O

The	O
results	O
were	O
validated	O
in	O
a	O
second	O
tumor	S-Phenotype
set	O
(	O
n	O
=	O
41	O
)	O
,	O
in	O
lymphoblastoid	O
cell	O
lines	O
(	O
LCLs	O
)	O
(	O
n	O
=	O
38	O
)	O
,	O
and	O
using	O
the	O
GTEx	O
Portal	O
.	O

Disease	O
associated	O
KIF1A	O
mutations	O
have	O
been	O
associated	O
with	O
motor	O
and	O
sensory	O
dysfunctions	O
as	O
well	O
as	O
non	B-Phenotype
-	I-Phenotype
syndromic	I-Phenotype
intellectual	I-Phenotype
disability	E-Phenotype
in	O
humans	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
detect	O
the	O
expression	O
of	O
high	O
-	O
temperature	O
requirement	O
A2	O
(	O
HtrA2	O
)	O
and	O
its	O
diagnostic	O
value	O
in	O
the	O
patients	O
with	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
.The	O
relative	O
serum	O
HtrA2	O
expression	O
at	O
mRNA	O
and	O
protein	O
level	O
was	O
severally	O
detected	O
by	O
quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
and	O
western	O
blot	O
analysis	O
in	O
198	O
HCC	O
patients	O
and	O
48	O
healthy	O
controls	O
.	O

After	O
HDM	O
challenge	O
,	O
these	O
mice	O
also	O
had	O
fewer	O
airway	O
inflammatory	O
cells	O
,	O
reduced	O
interleukin	O
(	O
IL	O
)	O
-	O
5	O
,	O
IL	O
-	O
13	O
,	O
IL	O
-	O
33	O
,	O
tumour	S-Phenotype
necrosis	O
factor	O
(	O
TNF	O
)	O
and	O
CXCL1	O
levels	O
in	O
the	O
lungs	O
,	O
and	O
reduced	O
IL	O
-	O
5	O
,	O
IL	O
-	O
33	O
and	O
TNF	O
levels	O
in	O
lung	O
-	O
draining	O
lymph	O
nodes	O
.	O

The	O
most	O
frequent	O
hearing	B-Phenotype
loss	E-Phenotype
associated	O
allele	O
detected	O
in	O
this	O
population	O
was	O
the	O
235delC	O
variant	O
in	O
GJB2	O
gene	O
.	O

This	O
dual	O
anti	O
-	O
inflammatory	O
and	O
anti	O
-	O
tumourigenic	O
role	O
of	O
the	O
CaSR	O
makes	O
it	O
especially	O
interesting	O
in	O
colitis	B-Phenotype
-	I-Phenotype
associated	I-Phenotype
colorectal	I-Phenotype
cancer	E-Phenotype
.	O

Therefore	O
,	O
our	O
findings	O
demonstrate	O
that	O
Hoxc13sup	O
-	O
/	O
-	O
/	O
sup	O
rabbits	O
can	O
be	O
used	O
as	O
a	O
model	O
for	O
human	O
ECTD	O
-	O
9	O
,	O
especially	O
to	O
understand	O
the	O
pathologic	O
mechanism	O
of	O
hypotrichosis	S-Phenotype
.	O

TREM2	O
protein	O
levels	O
were	O
also	O
negatively	O
correlated	O
with	O
the	O
severity	O
of	O
symptoms	O
in	O
humans	O
affected	O
by	O
autism	S-Phenotype
.	O

These	O
results	O
revealed	O
that	O
mutations	O
in	O
CCDC114	O
are	O
a	O
cause	O
of	O
ciliary	O
dysmotility	O
and	O
PCD	O
and	O
further	O
demonstrate	O
the	O
utility	O
of	O
exome	O
sequencing	O
to	O
identify	O
genetic	O
causes	O
in	O
heterogeneous	S-Phenotype
recessive	O
disorders	O

miR	O
-	O
363	O
-	O
3p	O
and	O
miR	O
-	O
328	O
inhibited	O
proliferation	O
of	O
renal	B-Phenotype
cancer	E-Phenotype
cells	O
,	O
while	O
miR	O
-	O
25	O
-	O
3p	O
inhibited	O
adhesion	O
,	O
promoted	O
proliferation	O
and	O
migration	O
of	O
renal	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

To	O
investigate	O
genetic	O
predispositions	O
for	O
MYCN	O
-	O
amplified	O
neuroblastoma	S-Phenotype
,	O
we	O
performed	O
a	O
meta	O
-	O
analysis	O
of	O
three	O
genome	O
-	O
wide	O
association	O
studies	O
totaling	O
615	O
MYCN	O
-	O
amplified	O
high	O
-	O
risk	O
neuroblastoma	S-Phenotype
cases	O
and	O
1869	O
MYCN	O
-	O
nonamplified	O
non	O
-	O
high	O
-	O
risk	O
neuroblastoma	S-Phenotype
cases	O
as	O
controls	O
using	O
a	O
fixed	O
-	O
effects	O
model	O
with	O
inverse	O
variance	O
weighting	O
.	O

Transcriptomic	O
analysis	O
revealed	O
significant	O
alterations	O
in	O
a	O
number	O
of	O
genes	O
associated	O
with	O
autism	S-Phenotype
,	O
such	O
as	O
adsl	O
,	O
mbd5	O
,	O
shank3	O
,	O
and	O
tsc1b	O
.	O

We	O
also	O
evaluated	O
GZF1	O
expression	O
in	O
various	O
kidney	B-Phenotype
diseases	E-Phenotype
including	O
membranous	B-Phenotype
nephropathy	E-Phenotype
,	O
minimal	O
change	O
nephrotic	B-Phenotype
syndrome	E-Phenotype
with	O
or	O
without	O
acute	B-Phenotype
kidney	I-Phenotype
injury	E-Phenotype
,	O
immunoglobulin	B-Phenotype
A	I-Phenotype
nephropathy	E-Phenotype
,	O
diabetic	B-Phenotype
nephropathy	E-Phenotype
,	O
acute	B-Phenotype
tubular	I-Phenotype
necrosis	E-Phenotype
,	O
and	O
antineutrophil	B-Phenotype
cytoplasmic	I-Phenotype
antibody	I-Phenotype
-	I-Phenotype
related	I-Phenotype
glomerulonephritis	E-Phenotype
.	O

Mutations	O
in	O
one	O
of	O
our	O
candidate	O
genes	O
,	O
Smpx	O
,	O
have	O
been	O
reported	O
as	O
the	O
cause	O
of	O
X	B-Phenotype
-	I-Phenotype
linked	I-Phenotype
deafness	E-Phenotype
in	O
humans	O
.	O

Up	O
-	O
regulation	O
of	O
Smac	O
/	O
DIABLO	O
has	O
been	O
shown	O
to	O
increase	O
tumor	S-Phenotype
cell	O
chemotherapy	O
sensitivity	O
.	O

We	O
identified	O
a	O
highly	O
significant	O
enrichment	O
of	O
de	O
novo	O
variants	O
in	O
YWHAG	O
,	O
establishing	O
their	O
role	O
in	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
epilepsy	E-Phenotype
,	O
and	O
we	O
provide	O
additional	O
support	O
for	O
the	O
prior	O
assignment	O
of	O
SLC1A2	O
.	O

We	O
conclude	O
that	O
POU4F3	O
c.602TAAAAC	O
(	O
p.Leu201Pro	O
)	O
is	O
related	O
to	O
midfrequency	O
hearing	B-Phenotype
loss	E-Phenotype
in	O
this	O
family	O
.	O

Inhibiting	O
naive	O
CD4sup+	O
/	O
sup	O
T	O
cell	O
recruitment	O
into	O
tumors	S-Phenotype
by	O
interfering	O
with	O
PITPNM3	O
recognition	O
of	O
CCL18	O
may	O
be	O
an	O
attractive	O
strategy	O
for	O
anticancer	O
immunotherapy	S-Phenotype

Our	O
data	O
indicate	O
that	O
TNFSF15	O
,	O
a	O
cytokine	O
mainly	O
produced	O
by	O
blood	O
endothelial	O
cells	O
,	O
facilitates	O
tumor	S-Phenotype
lymphangiogenesis	O
by	O
upregulating	O
VEGFC	O
expression	O
in	O
A549	O
cells	O
,	O
contributing	O
to	O
lymphatic	O
metastasis	O
in	O
tumor	S-Phenotype
-	O
bearing	O
mice	O
.	O

Other	O
genes	O
such	O
as	O
GBA2	O
and	O
KIF1C	O
were	O
almost	O
simultaneously	O
published	O
as	O
both	O
a	O
hereditary	B-Phenotype
spastic	I-Phenotype
paraplegia	E-Phenotype
and	O
an	O
ataxia	S-Phenotype
gene	O
.	O

Breakthrough	O
discoveries	O
include	O
the	O
role	O
of	O
somatic	O
variants	O
in	O
the	O
KCNJ5	O
,	O
CACNA1D	O
,	O
ATP1A1	O
,	O
and	O
ATP2B3	O
genes	O
as	O
causes	O
of	O
aldosterone	O
-	O
producing	O
adenomas	O
(	O
APAs	O
)	O
,	O
and	O
the	O
recognition	O
of	O
three	O
novel	O
hyperaldosteronism	S-Phenotype
syndromes	O
with	O
germline	O
variants	O
in	O
the	O
KCNJ5	O
,	O
CACNA1D	O
,	O
and	O
CACNA1H	O
genes	O
.	O

Among	O
those	O
with	O
peripheral	S-Phenotype
tumors	S-Phenotype
,	O
the	O
median	O
tumor	S-Phenotype
number	O
was	O
4	O
in	O
the	O
LZTR1	O
group	O
(	O
median	O
total	O
body	O
tumor	S-Phenotype
volume	O
30	O
cc	O
)	O
and	O
10	O
in	O
the	O
SMARCB1	O
group	O
(	O
median	O
volume	O
85cc	O
)	O
,	O
(	O
P=.2915	O
for	O
tumor	S-Phenotype
number	O
and	O
P	O
=	O
.2289	O
for	O
volume	O
)	O
.	O

Here	O
,	O
we	O
used	O
immunohistochemical	O
staining	O
to	O
measure	O
CCDC8	O
expression	O
in	O
147	O
samples	O
from	O
tumors	S-Phenotype
and	O
30	O
samples	O
from	O
the	O
adjacent	O
normal	O
lung	O
tissues	O
of	O
patients	O
with	O
non	B-Phenotype
-	I-Phenotype
small	I-Phenotype
cell	I-Phenotype
lung	I-Phenotype
cancer	E-Phenotype
.	O

Our	O
results	O
provide	O
evidence	O
that	O
inhibition	O
of	O
the	O
denitrosylation	O
of	O
S	O
-	O
nitrosylated	O
procaspase	O
-	O
3	O
mediated	O
by	O
the	O
redox	O
protein	O
Trx2	O
is	O
a	O
part	O
of	O
the	O
microglial	O
pro	O
-	O
tumoral	O
activation	O
pathway	O
initiated	O
by	O
glioma	B-Phenotype
cancer	E-Phenotype
cells	O

PCa	O
is	O
a	O
heterogeneous	S-Phenotype
disease	O
,	O
most	O
of	O
which	O
are	O
indolent	O
and	O
non	O
-	O
lethal	O
.	O

We	O
report	O
four	O
individuals	O
from	O
three	O
unrelated	O
families	O
who	O
have	O
homozygous	O
missense	O
or	O
compound	O
heterozygous	O
truncating	O
mutations	O
in	O
UNC80	O
and	O
persistent	O
hypotonia	S-Phenotype
,	O
encephalopathy	S-Phenotype
,	O
growth	B-Phenotype
failure	E-Phenotype
,	O
and	O
severe	O
intellectual	B-Phenotype
disability	E-Phenotype
.	O

The	O
canonical	O
Hippo	O
tumor	S-Phenotype
suppressor	O
pathway	O
in	O
mammalian	O
cells	O
is	O
primarily	O
composed	O
of	O
the	O
MST1	O
/	O
2	O
-	O
SAV1	O
-	O
LATS1	O
/	O
2	O
-	O
MOB1	O
-	O
YAP	O
/	O
TAZ	O
cascade	O
.	O

HACE1	O
is	O
a	O
putative	O
Wilms	O
*	O
tumor	S-Phenotype
susceptibility	O
gene	O
.	O

Likewise	O
,	O
HCV	O
replication	O
is	O
severely	O
impaired	O
within	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
tissue	O
in	O
vivo	O
,	O
but	O
the	O
mechanisms	O
responsible	O
for	O
this	O
restriction	O
are	O
presently	O
unknown	O
.	O

Furthermore	O
,	O
SLC6A9	O
-	O
5:2	O
overexpression	O
was	O
positively	O
correlated	O
with	O
PARP	O
-	O
1	O
mRNA	O
and	O
protein	O
levels	O
,	O
which	O
restored	O
the	O
sensitivity	O
of	O
resistant	O
thyroid	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Importantly	O
,	O
AIF	O
deficiency	O
leads	O
to	O
severe	O
mitochondrial	B-Phenotype
dysfunction	E-Phenotype
,	O
causing	O
muscle	B-Phenotype
atrophy	E-Phenotype
and	O
neurodegeneration	S-Phenotype
in	O
model	O
organisms	O
as	O
well	O
as	O
in	O
humans	O
.	O

Our	O
results	O
suggest	O
that	O
HOX	O
genes	O
may	O
play	O
a	O
more	O
important	O
role	O
in	O
progression	O
of	O
glioma	S-Phenotype
when	O
CD133	O
expression	O
is	O
low	O
.	O

We	O
characterize	O
variants	O
in	O
the	O
oxidoreductase	O
PYROXD1	O
as	O
a	O
cause	O
of	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
myopathy	E-Phenotype
with	O
distinctive	O
histopathology	O
and	O
introduce	O
altered	O
redox	O
regulation	O
as	O
a	O
primary	O
cause	O
of	O
congenital	O
muscle	O
disease	O

The	O
gene	O
responsible	O
for	O
an	O
autosomal	B-Phenotype
recessive	I-Phenotype
Pelizaeus	I-Phenotype
-	I-Phenotype
Merzbacher	I-Phenotype
-	I-Phenotype
like	I-Phenotype
disease	E-Phenotype
called	O
HLD5	O
is	O
named	O
fam126a	O
(	O
also	O
known	O
as	O
hyccin	O
or	O
drctnnb1a	O
)	O
.	O

As	O
an	O
important	O
multifunctional	O
protein	O
involved	O
in	O
regulation	O
of	O
mitochondrial	S-Phenotype
metabolism	O
,	O
CHCHD2	O
was	O
identified	O
as	O
a	O
causative	O
gene	O
for	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
,	O
yet	O
the	O
relationship	O
between	O
CHCHD2	O
and	O
neurodegenerative	B-Phenotype
dementia	E-Phenotype
is	O
not	O
well	O
understood	O
.	O

We	O
previously	O
identified	O
tumor	S-Phenotype
necrosis	O
factor	O
superfamily	O
15	O
(	O
TNFSF15	O
)	O
,	O
a	O
blood	O
vascular	O
endothelium	O
-	O
derived	O
cytokine	O
,	O
in	O
lymphatic	O
endothelial	O
cells	O
,	O
as	O
a	O
key	O
molecular	O
modulator	O
during	O
lymphangiogenesis	O
.	O

However	O
,	O
the	O
current	O
knowledge	O
of	O
CDKN1C	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
remains	O
obscure	O
.	O

MATERIAL	O
AND	O
METHODS	O
Human	O
neuroblastoma	S-Phenotype
SH	O
-	O
SY5Y	O
cells	O
were	O
treated	O
for	O
24	O
h	O
with	O
increasing	O
concentrations	O
of	O
aggregated	O
Aβ₂₅₋₃₅	O
(	O
5	O
,	O
15	O
,	O
25	O
,	O
and	O
45	O
μmol	O
)	O
with	O
or	O
without	O
the	O
ACAT1	O
siRNA	O
pretreatment	O
.	O

The	O
MATR3	O
gene	O
is	O
mutated	O
in	O
a	O
form	O
of	O
distal	B-Phenotype
myopathy	E-Phenotype
and	O
amyotrophic	B-Phenotype
lateral	I-Phenotype
sclerosis	E-Phenotype
(	O
ALS	S-Phenotype
)	O
.	O

Our	O
current	O
study	O
found	O
that	O
phosphoserine	O
aminotransferase	O
1	O
(	O
PSAT1	O
)	O
,	O
an	O
enzyme	O
catalyzing	O
serine	O
biosynthesis	O
,	O
was	O
significantly	O
up	O
-	O
regulated	O
in	O
non	B-Phenotype
-	I-Phenotype
small	I-Phenotype
cell	I-Phenotype
lung	I-Phenotype
cancer	E-Phenotype
(	O
NSCLC	S-Phenotype
)	O
and	O
was	O
involved	O
in	O
the	O
regulation	O
of	O
E2F	O
activity	O
.	O

Serine	O
and	O
ribose	O
synthesis	O
have	O
been	O
identified	O
as	O
downstream	O
pathways	O
fed	O
by	O
PEPCK	O
in	O
cancer	S-Phenotype
cells	O
.	O

miR‑132	O
was	O
upregulated	O
in	O
the	O
U87MG	O
-	O
res	O
cells	O
and	O
its	O
overexpression	O
induced	O
temozolomide	O
resistance	O
and	O
the	O
formation	O
of	O
cancer	S-Phenotype
stem	O
cell	O
phenotypes	O
in	O
the	O
U87MG	O
cells	O
.	O

However	O
,	O
inhibition	O
of	O
Chmp1A	O
did	O
not	O
significantly	O
affect	O
tumor	S-Phenotype
cell	O
proliferation	O
in	O
vitro	O
and	O
tumor	S-Phenotype
progression	O
in	O
vivo	O
.	O

Here	O
,	O
the	O
homozygous	O
Hoxc13sup	O
-	O
/	O
-	O
/	O
sup	O
rabbits	O
showed	O
complete	O
loss	O
of	O
hair	O
on	O
the	O
head	O
and	O
dorsum	O
,	O
whereas	O
hypotrichosis	S-Phenotype
in	O
the	O
limbs	O
and	O
tail	O
were	O
determined	O
in	O
the	O
Hoxc13sup	O
-	O
/	O
-	O
/	O
sup	O
rabbits	O
.	O

In	O
addition	O
,	O
GZF1	O
expression	O
was	O
undetectable	O
or	O
very	O
low	O
in	O
most	O
cases	O
of	O
renal	B-Phenotype
cell	I-Phenotype
carcinomas	E-Phenotype
and	O
Wilms	B-Phenotype
tumors	E-Phenotype
.	O

Somatic	O
mutations	O
in	O
four	O
genes	O
(	O
KCNJ5	O
,	O
ATP1A1	O
,	O
ATP2B3	O
and	O
CACNA1D	O
)	O
,	O
differently	O
implicated	O
in	O
intracellular	O
ion	O
homeostasis	O
,	O
have	O
been	O
identified	O
in	O
nearly	O
60	O
%	O
of	O
the	O
sporadic	S-Phenotype
APAs	O
.	O

Mitochondrial	B-Phenotype
dysfunction	E-Phenotype
and	O
epithelial	B-Phenotype
-	I-Phenotype
to	I-Phenotype
-	I-Phenotype
mesenchymal	I-Phenotype
transition	E-Phenotype
(	O
EMT	S-Phenotype
)	O
play	O
important	O
roles	O
in	O
cancer	S-Phenotype
development	O
and	O
metastasis	O
.	O

High	O
UBE2T	O
expression	O
was	O
correlated	O
with	O
higher	O
pathological	O
grade	O
,	O
advanced	O
TNM	O
stage	O
,	O
tumor	S-Phenotype
vascular	O
invasion	O
,	O
and	O
poor	O
overall	O
and	O
disease	O
-	O
free	O
survivals	O
in	O
two	O
independent	O
cohorts	O
containing	O
827	O
patients	O
with	O
HCC	O
.	O

Subsequent	O
mutation	O
analyses	O
identified	O
tumor	S-Phenotype
-	O
associated	O
calcium	O
signal	O
transducer	O
2	O
(	O
TACSTD2	O
;	O
former	O
name	O
,	O
M1S1	O
)	O
as	O
the	O
gene	O
responsible	O
for	O
GDLD	O
.	O

NGLY1	O
patients	O
produce	O
little	O
or	O
no	O
N	O
-	O
glycanase	O
(	O
Ngly1	O
)	O
,	O
and	O
the	O
symptoms	O
include	O
global	B-Phenotype
developmental	I-Phenotype
delay	E-Phenotype
,	O
frequent	O
seizures	S-Phenotype
,	O
complex	O
hyperkinetic	B-Phenotype
movement	E-Phenotype
disorder	O
,	O
difficulty	B-Phenotype
in	I-Phenotype
swallowing	E-Phenotype
/	O
aspiration	S-Phenotype
,	O
liver	B-Phenotype
dysfunction	E-Phenotype
,	O
and	O
a	B-Phenotype
lack	I-Phenotype
of	I-Phenotype
tears	E-Phenotype
.	O

Collectively	O
,	O
this	O
study	O
is	O
the	O
first	O
to	O
report	O
the	O
role	O
of	O
SMPX	O
in	O
Chinese	O
population	O
and	O
identify	O
a	O
novel	O
frameshift	O
mutation	O
in	O
SMPX	O
that	O
causes	O
not	O
only	O
nonsyndromic	O
late	O
-	O
onset	O
progressive	O
HL	O
,	O
but	O
also	O
congenital	B-Phenotype
hearing	I-Phenotype
impairment	E-Phenotype
.	O

In	O
sporadic	B-Phenotype
FGPs	E-Phenotype
,	O
low	B-Phenotype
-	I-Phenotype
grade	I-Phenotype
dysplasia	E-Phenotype
(	O
LGD	S-Phenotype
)	O
is	O
rare	O
,	O
and	O
high	B-Phenotype
-	I-Phenotype
grade	I-Phenotype
dysplasia	E-Phenotype
(	O
HGD	S-Phenotype
)	O
or	O
carcinoma	S-Phenotype
arising	O
from	O
sporadic	B-Phenotype
FGPs	E-Phenotype
is	O
extremely	O
rare	O
.	O

Here	O
,	O
the	O
authors	O
use	O
multi	O
-	O
region	O
sequencing	O
in	O
patient	O
samples	O
to	O
analyse	O
spatial	O
clonal	O
architecture	O
and	O
heterogeneity	S-Phenotype
,	O
providing	O
novel	O
insight	O
into	O
multiple	B-Phenotype
myeloma	E-Phenotype
progression	O
and	O
evolution	O

In	O
total	O
,	O
53	O
women	O
with	O
primarily	O
inoperable	B-Phenotype
or	I-Phenotype
inflammatory	I-Phenotype
breast	I-Phenotype
cancer	E-Phenotype
who	O
were	O
treated	O
with	O
NACT	O
were	O
included	O
in	O
the	O
study	O
.	O

TNFRSF11A	O
mutations	O
have	O
previously	O
been	O
reported	O
in	O
two	O
autosomal	O
dominant	O
diseases	O
(	O
osteolysis	S-Phenotype
,	O
familial	O
expansile	O
and	O
Paget	O
disease	O
of	O
bone	O
2	O
,	O
early	O
-	O
onset	O
)	O
and	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
disease	O
(	O
osteopetrosis	S-Phenotype
,	O
autosomal	O
recessive	O
7	O
)	O
.	O

Epithelial	B-Phenotype
-	I-Phenotype
stromal	I-Phenotype
TGFBI	I-Phenotype
dystrophies	E-Phenotype
,	O
macular	B-Phenotype
corneal	I-Phenotype
dystrophy	E-Phenotype
and	O
Schnyder	B-Phenotype
corneal	I-Phenotype
dystrophy	E-Phenotype
(	O
SCD	S-Phenotype
)	O
showed	O
100	O
%	O
mutation	O
detection	O
rates	O
,	O
while	O
endothelial	B-Phenotype
corneal	I-Phenotype
dystrophies	E-Phenotype
showed	O
lower	O
detection	O
rates	O
of	O
3	O
%	O
.	O

In	O
this	O
study	O
,	O
breast	B-Phenotype
cancer	E-Phenotype
tissue	O
samples	O
were	O
obtained	O
from	O
Zhejiang	O
University	O
(	O
ZJU	O
set	O
)	O
.	O

FBXO32	O
is	O
also	O
amplified	O
in	O
metastatic	O
cancers	S-Phenotype
and	O
its	O
depletion	O
in	O
a	O
NSG	O
mouse	O
xenograft	O
model	O
inhibits	O
tumor	S-Phenotype
growth	O
and	O
metastasis	O
.	O

miR	O
-	O
491	O
-	O
5p	O
is	O
frequently	O
downregulated	O
in	O
GC	O
tissues	O
compared	O
with	O
adjacent	O
non	O
-	O
cancerous	S-Phenotype
tissues	O
.	O

TRIO	O
and	O
RICTOR	O
co	O
-	O
amplification	O
was	O
seen	O
in	O
8	O
(	O
44	O
%	O
)	O
G3	O
and	O
1	O
(	O
10	O
%	O
)	O
G1	O
myxofibrosarcomas	O
and	O
RICTOR	O
amplification	O
alone	O
in	O
4	O
(	O
40	O
%	O
)	O
G1	O
myxofibrosarcomas	O
.	O

Collagen	O
type	O
4	O
alpha	O
1	O
(	O
COL4A1	O
)	O
and	O
collagen	O
type	O
13	O
alpha	O
1	O
(	O
COL13A1	O
)	O
produced	O
by	O
urothelial	O
cancer	S-Phenotype
cells	O
support	O
the	O
vital	O
oncogenic	O
property	O
of	O
tumor	S-Phenotype
invasion	O
.	O

Tissue	O
arrays	O
showed	O
that	O
ZBP	O
-	O
89	O
protein	O
was	O
overexpressed	O
in	O
the	O
early	O
stages	O
of	O
colorectal	B-Phenotype
cancer	E-Phenotype
.	O

Immunostaining	O
showed	O
that	O
the	O
colon	B-Phenotype
cancer	E-Phenotype
was	O
positive	O
for	O
CDX2	O
,	O
SATB2	O
,	O
had	O
a	O
loss	O
of	O
PMS2	O
and	O
intact	O
expression	O
of	O
MLH1	O
,	O
MSH2	O
and	O
MSH6	O
,	O
negative	O
for	O
AMACR	O
,	O
while	O
the	O
prostate	B-Phenotype
cancer	E-Phenotype
was	O
positive	O
for	O
AMACR	O
,	O
had	O
intact	O
expression	O
of	O
PMS2	O
,	O
MLH1	O
,	O
MSH2	O
and	O
MSH6	O
,	O
and	O
negative	O
for	O
CDX2	O
and	O
SATB2	O
.	O

Tbx3	O
,	O
a	O
member	O
of	O
the	O
T	O
-	O
box	O
family	O
of	O
transcription	O
factors	O
,	O
contributes	O
directly	O
to	O
tumor	S-Phenotype
formation	O
,	O
migration	O
,	O
and	O
invasion	O
.	O

As	O
seen	O
in	O
human	O
patients	O
,	O
heterozygous	O
E168d2	O
(	O
AAAAAAE168d2	O
/	O
+AAAAAA	O
)	O
but	O
not	O
R90W	O
(	O
AAAAAAR90W	O
/	O
+AAAAAA	O
)	O
mice	O
show	O
severely	O
impaired	O
retinal	O
function	O
,	O
while	O
mice	O
homozygous	O
for	O
either	O
mutation	O
are	O
blind	O
and	O
undergo	O
rapid	O
photoreceptor	O
degeneration	O
.	O

CGD	O
is	O
a	O
genetically	O
heterogeneous	S-Phenotype
disease	O
with	O
an	O
X	O
-	O
linked	O
recessive	O
(	O
XR	O
-	O
CGD	O
)	O
form	O
caused	O
by	O
mutations	O
in	O
the	O
CYBB	O
gene	O
encoding	O
the	O
gp91	O
(	O
phox	O
)	O
protein	O
,	O
and	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
(	O
AR	O
-	O
CGD	O
)	O
form	O
caused	O
by	O
mutations	O
in	O
the	O
CYBA	O
,	O
NCF1	O
,	O
NCF2	O
,	O
or	O
NCF4	O
genes	O
encoding	O
p22	O
(	O
phox	O
)	O
,	O
p47	O
(	O
phox	O
)	O
,	O
p67	O
(	O
phox	O
)	O
,	O
and	O
p40	O
(	O
phox	O
)	O
,	O
respectively	O
.	O

Altogether	O
,	O
these	O
data	O
point	O
to	O
a	O
pathophysiological	O
mechanism	O
responsible	O
for	O
RGC	O
early	O
degeneration	O
and	O
optic	B-Phenotype
neuropathy	E-Phenotype
and	O
linking	O
RTN4IP1	O
functions	O
to	O
mitochondrial	O
physiology	O
,	O
response	O
to	O
UV	O
light	O
,	O
and	O
dendrite	O
growth	O
during	O
eye	O
maturation	O

In	O
conclusion	O
,	O
we	O
present	O
an	O
oncogenic	O
role	O
of	O
FAM83H	O
in	O
liver	B-Phenotype
cancer	E-Phenotype
,	O
which	O
is	O
closely	O
associated	O
with	O
the	O
oncogene	O
MYC	O
.	O

The	O
expressions	O
of	O
ERCC6	O
,	O
ERCC8	O
and	O
ERCC6	O
-	O
ERCC8	O
combination	O
have	O
similarities	O
that	O
higher	O
positivity	O
was	O
observed	O
in	O
chronic	B-Phenotype
superficial	I-Phenotype
gastritis	E-Phenotype
compared	O
with	O
chronic	B-Phenotype
atrophic	I-Phenotype
gastritis	E-Phenotype
and	O
gastric	B-Phenotype
cancer	E-Phenotype
.	O

In	O
summary	O
,	O
we	O
highlight	O
the	O
broad	O
phenotypic	O
spectrum	O
of	O
WDR81	O
-	O
related	O
brain	O
malformations	O
,	O
which	O
include	O
microcephaly	S-Phenotype
with	O
moderate	O
to	O
extremely	O
reduced	O
gyration	O
and	O
cerebellar	B-Phenotype
anomalies	E-Phenotype
.	O

Microarray	O
analysis	O
between	O
orthotopic	O
tumors	S-Phenotype
with	O
high	O
and	O
low	O
metastatic	O
potentials	O
revealed	O
differential	O
expression	O
of	O
genes	O
related	O
to	O
cell	O
proliferation	O
and	O
migration	O
(	O
TNNT1	O
,	O
COL1A2	O
,	O
and	O
ZIC1	O
)	O
.	O

Functional	O
inhibition	O
of	O
HMGB1	O
and	O
its	O
receptors	O
abrogated	O
HMGB1	O
-	O
induced	O
angiogenic	O
properties	O
of	O
ECs	O
co	O
-	O
cultured	O
with	O
tumour	S-Phenotype
cells	O
.	O

Mildly	O
affected	O
individuals	O
with	O
BRAT1	O
mutations	O
show	O
that	O
BRAT1	O
must	O
be	O
considered	O
as	O
a	O
cause	O
in	O
childhood	B-Phenotype
refractory	I-Phenotype
epilepsy	E-Phenotype
and	O
microcephaly	S-Phenotype
with	O
survival	O
beyond	O
infancy	O
.	O

For	O
the	O
first	O
time	O
,	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
the	O
present	O
study	O
confirmed	O
that	O
MORC2	O
was	O
a	O
novel	O
oncogene	O
in	O
liver	B-Phenotype
cancer	E-Phenotype
.	O

Several	O
tumor	S-Phenotype
suppressor	O
genes	O
and	O
proto	O
-	O
oncogenes	O
have	O
been	O
implicated	O
in	O
BCC	O
pathogenesis	O
,	O
including	O
the	O
key	O
components	O
of	O
the	O
Hedgehog	O
pathway	O
,	O
PTCH1	O
and	O
SMO	O
,	O
the	O
TP53	O
tumor	S-Phenotype
suppressor	O
,	O
and	O
members	O
of	O
the	O
RAS	O
proto	O
-	O
oncogene	O
family	O
.	O

Loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
MTM1	O
cause	O
the	O
severe	O
congenital	B-Phenotype
myopathy	E-Phenotype
called	O
myotubular	B-Phenotype
myopathy	E-Phenotype
(	O
or	O
X	B-Phenotype
-	I-Phenotype
linked	I-Phenotype
centronuclear	I-Phenotype
myopathy	E-Phenotype
)	O
while	O
mutations	O
in	O
the	O
MTM1	O
-	O
related	O
protein	O
MTMR2	O
cause	O
a	O
recessive	B-Phenotype
Charcot	I-Phenotype
-	I-Phenotype
Marie	I-Phenotype
-	I-Phenotype
Tooth	I-Phenotype
peripheral	I-Phenotype
neuropathy	E-Phenotype
.	O

Enamel	O
-	O
renal	O
-	O
gingival	O
syndrome	O
(	O
ERGS	O
;	O
OMIM	O
#	O
204690	O
)	O
,	O
a	O
rare	O
autosomal	O
recessive	O
disorder	O
caused	O
by	O
mutations	O
in	O
FAM20A	O
,	O
is	O
characterized	O
by	O
nephrocalcinosis	S-Phenotype
,	O
nephrolithiasis	S-Phenotype
,	O
amelogenesis	B-Phenotype
imperfecta	E-Phenotype
,	O
hypoplastic	B-Phenotype
type	E-Phenotype
,	O
gingival	B-Phenotype
fibromatosis	E-Phenotype
and	O
other	O
dental	B-Phenotype
abnormalities	E-Phenotype
,	O
including	O
hypodontia	S-Phenotype
and	O
unerupted	B-Phenotype
teeth	I-Phenotype
with	I-Phenotype
large	I-Phenotype
dental	I-Phenotype
follicles	E-Phenotype
.	O

Our	O
results	O
indicate	O
that	O
common	O
genetic	O
variation	O
predisposes	O
to	O
different	O
neuroblastoma	S-Phenotype
genotypes	O
,	O
including	O
the	O
likelihood	O
of	O
somatic	O
MYCN	O
-	O
amplification	O

Primary	O
creatine	O
disorders	O
are	O
inherited	O
as	O
autosomal	B-Phenotype
recessive	E-Phenotype
(	O
mutations	O
affecting	O
GATM	O
[	O
for	O
glycine	O
-	O
amidinotransferase	O
,	O
mitochondrial	O
]	O
)	O
and	O
GAMT	O
genes	O
)	O
or	O
X	O
-	O
linked	O
(	O
SLC6A8	O
gene	O
)	O
traits	O
.	O

IL17RD	O
expression	O
was	O
increased	O
in	O
ulcerative	B-Phenotype
colitis	E-Phenotype
cancers	S-Phenotype
,	O
and	O
miR	O
-	O
193a	O
-	O
3p	O
treatment	O
decreased	O
growth	O
and	O
EGFR	O
signaling	O
of	O
HCT116	O
cells	O
in	O
xenografts	O
expressing	O
both	O
IL17RD	O
with	O
WT	O
3	O
*	O
UTR	O
compared	O
with	O
cells	O
expressing	O
IL17RD	O
with	O
mutant	O
3	O
*	O
UTR.Conclusions	O
:	O
miR	O
-	O
193a	O
-	O
3p	O
is	O
downregulated	O
in	O
ulcerative	B-Phenotype
colitis	E-Phenotype
neoplasia	S-Phenotype
,	O
and	O
its	O
loss	O
promotes	O
carcinogenesis	O
through	O
upregulation	O
of	O
IL17RD	O
.	O

spSCC	O
formation	O
involves	O
epithelial	O
-	O
to	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
,	O
yet	O
the	O
molecular	O
basis	O
of	O
this	O
event	O
remains	O
unknown	O
.	O

The	O
bilateral	B-Phenotype
retinal	I-Phenotype
cherry	I-Phenotype
red	I-Phenotype
spots	E-Phenotype
and	O
failure	B-Phenotype
to	I-Phenotype
thrive	E-Phenotype
observed	O
in	O
our	O
patient	O
are	O
unique	O
features	O
,	O
which	O
have	O
not	O
been	O
described	O
,	O
in	O
previously	O
reported	O
patients	O
with	O
TTC19	O
mutations	O
.	O

We	O
also	O
demonstrated	O
that	O
FBXL4	O
deletion	O
is	O
detectable	O
in	O
circulating	O
tumour	S-Phenotype
cells	O
(	O
CTCs	O
)	O
,	O
making	O
it	O
a	O
potential	O
prognostic	O
biomarker	O
by	O
'liquid	O
biopsy	O
'	O
.	O

Vitamin	O
-	O
Bsub6	O
/	O
sub	O
-	O
dependent	O
epilepsies	S-Phenotype
are	O
a	O
heterogenous	O
group	O
of	O
treatable	O
disorders	O
due	O
to	O
mutations	O
in	O
several	O
genes	O
(	O
liALDH7A1	O
,	O
PNPO	O
,	O
ALPL	O
/	O
i	O
or	O
liALDH4A1	O
/	O
i	O
)	O
.	O

A	O
simultaneous	O
increase	O
in	O
serum	O
thyroid	O
-	O
stimulating	O
hormone	O
(	O
TSH	O
)	O
in	O
response	O
to	O
hypothyroidism	S-Phenotype
(	O
common	O
in	O
autoimmune	B-Phenotype
diseases	E-Phenotype
such	O
as	O
Hashimoto	B-Phenotype
's	I-Phenotype
thyroiditis	E-Phenotype
)	O
would	O
cause	O
senescent	O
tumor	S-Phenotype
cells	O
to	O
overcome	O
OIS	O
and	O
proceed	O
towards	O
malignancy	O
,	O
hence	O
showing	O
the	O
importance	O
of	O
TSH	O
/	O
TSHR	O
signaling	O
in	O
the	O
development	O
of	O
PTCs	O
.	O

In	O
DLBCL	O
patients	O
,	O
overexpression	O
of	O
PCYT1A	O
was	O
in	O
parallel	O
with	O
an	O
increase	O
in	O
tumor	S-Phenotype
MYC	O
,	O
as	O
well	O
as	O
a	O
decrease	O
in	O
serum	O
choline	O
metabolite	O
phosphatidylcholine	O
levels	O
and	O
an	O
International	O
Prognostic	O
Index	O
,	O
indicating	O
intermediate	O
-	O
high	O
or	O
high	O
risk	O
.	O

Single	O
nucleotide	O
polymorphism	O
in	O
infant	O
genes	O
in	O
the	O
folate	O
(	O
MTHFS	O
rs12438477	O
)	O
,	O
homocysteine	O
(	O
TRDMT1	O
rs6602178	O
and	O
GNMT	O
rs11752813	O
)	O
and	O
transsulfuration	O
(	O
GSTP1	O
rs7941395	O
and	O
MGST1	O
rs7294985	O
)	O
pathways	O
were	O
also	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
congenital	B-Phenotype
heart	I-Phenotype
defects	E-Phenotype
.	O

Conclusions O
Common	O
maternal	O
or	O
infant	O
genetic	O
variants	O
in	O
folate	O
,	O
homocysteine	O
,	O
or	O
transsulfuration	O
pathways	O
are	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
certain	O
congenital	B-Phenotype
heart	I-Phenotype
defects	E-Phenotype
among	O
children	O
of	O
women	O
taking	O
SSRIs	O
during	O
cardiogenesis	O

Aberrant	O
expression	O
of	O
the	O
sodium	O
channel	O
gene	O
(	O
SCN5A	O
)	O
has	O
been	O
proposed	O
to	O
disrupt	O
cardiac	O
action	O
potential	O
and	O
cause	O
human	O
cardiac	B-Phenotype
arrhythmias	E-Phenotype
,	O
but	O
the	O
mechanisms	O
of	O
SCN5A	O
gene	O
regulation	O
and	O
dysregulation	O
still	O
remain	O
largely	O
unexplored	O
.	O

HCRP1	O
downregulation	O
was	O
found	O
in	O
57	O
of	O
137	O
human	O
gastric	B-Phenotype
cancer	E-Phenotype
samples	O
and	O
correlated	O
with	O
advanced	O
TNM	O
stage	O
,	O
positive	O
nodal	O
status	O
,	O
and	O
relapse	O
.	O

The	O
importance	O
of	O
mitochondria	O
for	O
white	O
matter	O
is	O
best	O
exemplified	O
in	O
a	O
group	O
of	O
defects	O
of	O
the	O
mitochondria	O
oxidative	O
metabolism	O
called	O
mitochondria	B-Phenotype
leukoencephalopathies	E-Phenotype
or	O
encephalomyopathies	S-Phenotype
.	O

In	O
summary	O
,	O
our	O
data	O
delineates	O
the	O
regulatory	O
mechanisms	O
of	O
GATA3	O
in	O
DNA	O
DSB	O
repair	O
and	O
strongly	O
suggests	O
that	O
it	O
might	O
act	O
as	O
a	O
tumor	S-Phenotype
suppressor	O
by	O
promoting	O
CtIP	O
expression	O
and	O
HR	O
to	O
stabilize	O
genomes	O

These	O
inhibitors	O
,	O
coupled	O
with	O
targeted	O
knockdown	O
of	O
Hhat	O
and	O
Porcn	O
,	O
reveal	O
the	O
essential	O
functions	O
of	O
fatty	O
acylation	O
of	O
secreted	O
morphogens	O
in	O
a	O
wide	O
variety	O
of	O
human	O
tumors	S-Phenotype

Oropharyngeal	B-Phenotype
cancer	E-Phenotype
associations	O
were	O
limited	O
to	O
the	O
human	O
leukocyte	O
antigen	O
(	O
HLA	O
)	O
region	O
,	O
and	O
classical	O
HLA	O
allele	O
imputation	O
showed	O
a	O
protective	O
association	O
with	O
the	O
class	O
II	O
haplotype	O
HLA	O
-	O
DRB1	O
*	O
1301	O
-	O
HLA	O
-	O
DQA1	O
*	O
0103	O
-	O
HLA	O
-	O
DQB1	O
*	O
0603	O
(	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
0.59	O
,	O
P	O
=	O
2.7	O
x	O
10	O
-	O
9	O
)	O
.	O

A	O
third	O
proband	O
was	O
doubly	O
heterozygous	O
for	O
inherited	O
rare	O
variants	O
in	O
additional	O
components	O
of	O
complex	O
I	O
,	O
NDUFAF2	O
and	O
NDUFB9	O
,	O
confirming	O
that	O
Histiocytoid	O
CM	O
is	O
genetically	O
heterogeneous	S-Phenotype
.	O

Posterior	B-Phenotype
microphthalmos	E-Phenotype
(	O
PM	S-Phenotype
)	O
is	O
a	O
relatively	O
infrequent	O
type	O
of	O
microphthalmos	S-Phenotype
where	O
posterior	O
segment	O
is	O
predominantly	O
affected	O
with	O
normal	O
anterior	O
segment	O
measurements	O
.	O

Germline	O
mutations	O
in	O
KCNJ5	O
and	O
CACNA1H	O
cause	O
FH	O
-	O
III	O
and	O
FH	O
-	O
IV	O
,	O
respectively	O
,	O
while	O
germline	O
mutations	O
in	O
CACNA1D	O
cause	O
the	O
rare	O
PASNA	O
syndrome	O
,	O
featuring	O
primary	B-Phenotype
aldosteronism	I-Phenotype
seizures	E-Phenotype
and	O
neurological	B-Phenotype
abnormalities	E-Phenotype
.	O

Here	O
we	O
studied	O
the	O
frequency	O
of	O
a	O
recurrent	O
small	O
22q11.2	O
deletion	O
encompassing	O
PRODH	O
and	O
the	O
neighboring	O
DGCR6	O
gene	O
in	O
three	O
case	O
-	O
control	O
studies	O
,	O
one	O
comprising	O
HPI	O
patients	O
(	O
n	O
=	O
83	O
)	O
,	O
and	O
the	O
other	O
two	O
comprising	O
autism	B-Phenotype
spectrum	I-Phenotype
disorder	E-Phenotype
(	O
ASD	S-Phenotype
)	O
patients	O
(	O
total	O
of	O
n	O
=	O
2800	O
)	O
,	O
analyzed	O
with	O
high	O
-	O
resolution	O
microarrays	O
.	O

Maternal	O
loss	O
-	O
of	O
-	O
methylation	O
at	O
GNAS	O
exon	O
A	O
/	O
B	O
,	O
observed	O
in	O
pseudohypoparathyroidism	B-Phenotype
type	I-Phenotype
1b	E-Phenotype
(	O
PHP1B	S-Phenotype
)	O
,	O
leads	O
to	O
decreased	O
expression	O
of	O
the	O
stimulatory	O
Gsa	O
.	O

Adolescent	B-Phenotype
idiopathic	I-Phenotype
scoliosis	E-Phenotype
(	O
AIS	S-Phenotype
)	O
and	O
pectus	B-Phenotype
excavatum	E-Phenotype
(	O
PE	S-Phenotype
)	O
are	O
common	O
pediatric	B-Phenotype
musculoskeletal	I-Phenotype
disorders	E-Phenotype
.	O

In	O
summary	O
,	O
our	O
genetic	O
findings	O
implicate	O
homozygous	O
SLC6A17	O
mutations	O
in	O
autosomal	B-Phenotype
-	I-Phenotype
recessive	I-Phenotype
intellectual	I-Phenotype
disability	E-Phenotype
,	O
and	O
their	O
pathogenic	O
role	O
is	O
strengthened	O
by	O
genetic	O
evidence	O
and	O
in	O
silico	O
and	O
in	O
vitro	O
functional	O
analyses	O

In	O
our	O
study	O
,	O
RAD50	O
germline	O
mutations	O
were	O
determined	O
using	O
next	O
-	O
generation	O
sequencing	O
in	O
7657	O
consecutive	O
unselected	O
breast	B-Phenotype
cancer	E-Phenotype
patients	O
without	O
BRCA1	O
/	O
2	O
mutations	O
.	O

However	O
,	O
the	O
pathophysiological	O
mechanisms	O
leading	O
to	O
bilateral	B-Phenotype
kidney	I-Phenotype
agenesis	E-Phenotype
(	O
BKA	S-Phenotype
)	O
remain	O
largely	O
elusive	O
.	O

However	O
,	O
the	O
clinical	O
significance	O
and	O
precise	O
role	O
of	O
ZNF687	O
in	O
cancer	S-Phenotype
progression	O
are	O
largely	O
unknown	O
.	O

Changes	O
in	O
methylation	O
of	O
miR	O
-	O
193a	O
or	O
expression	O
of	O
pri	O
-	O
miR	O
-	O
193a	O
were	O
not	O
observed	O
in	O
ulcerative	B-Phenotype
colitis	E-Phenotype
cancer	S-Phenotype
.	O

Planar	O
cell	O
polarity	O
(	O
PCP	O
)	O
signaling	O
has	O
been	O
shown	O
in	O
different	O
studies	O
to	O
either	O
promote	O
or	O
inhibit	O
the	O
malignancy	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

So	O
far	O
,	O
homozygous	O
or	O
compound	O
heterozygous	O
mutations	O
in	O
CWF19L1	O
have	O
been	O
identified	O
in	O
two	O
Turkish	O
siblings	O
and	O
a	O
Dutch	O
girl	O
,	O
respectively	O
,	O
affected	O
by	O
cerebellar	B-Phenotype
ataxia	E-Phenotype
and	O
ID	O
.	O

In	O
addition	O
,	O
conditions	O
such	O
as	O
Gitelman	B-Phenotype
's	I-Phenotype
syndrome	E-Phenotype
,	O
distal	B-Phenotype
renal	I-Phenotype
tubular	I-Phenotype
acidosis	E-Phenotype
and	O
pseudohypoaldosteronism	B-Phenotype
type	I-Phenotype
II	E-Phenotype
,	O
as	O
well	O
as	O
a	O
mitochondrial	B-Phenotype
defect	E-Phenotype
associated	O
with	O
hypomagnesaemia	S-Phenotype
,	O
all	O
change	O
the	O
renal	O
handling	O
of	O
divalent	O
cations	O
.	O

Associated	O
facial	O
dysmorphic	O
features	O
include	O
dolichocephaly	S-Phenotype
with	O
bitemporal	B-Phenotype
narrowing	E-Phenotype
,	O
short	B-Phenotype
philtrum	E-Phenotype
,	O
tented	B-Phenotype
upper	I-Phenotype
lip	E-Phenotype
,	O
palatal	B-Phenotype
abnormalities	E-Phenotype
,	O
and	O
small	B-Phenotype
mandible	E-Phenotype
.	O

This	O
case	O
represents	O
the	O
third	O
pedigree	O
with	O
EXPH5	O
mutations	O
resulting	O
in	O
inherited	O
skin	B-Phenotype
fragility	E-Phenotype
.	O

The	O
effect	O
of	O
garlic	O
extract	O
in	O
cancer	S-Phenotype
prevention	O
was	O
evaluated	O
using	O
the	O
T24	O
BC	O
BALB	O
/	O
C	O
-	O
nude	O
mouse	O
xenograft	O
model	O
.	O

No	O
tumors	S-Phenotype
occurred	O
in	O
single	O
knockout	O
or	O
control	O
mice	O
.	O

Reliable	O
biomarkers	O
for	O
renal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
RCC	S-Phenotype
)	O
have	O
yet	O
to	O
be	O
determined	O
.	O

We	O
therefore	O
suggest	O
that	O
SLC45A2	O
:	O
c.1287delC	O
causes	O
the	O
observed	O
oculocutaneous	B-Phenotype
albinism	E-Phenotype
in	O
the	O
affected	O
Bullmastiff	O

Our	O
results	O
therefore	O
confirm	O
the	O
KCNC3R423H	O
allele	O
as	O
causative	O
for	O
SCA13	O
,	O
through	O
a	O
dominant	O
negative	O
effect	O
on	O
KCNC3WT	O
and	O
links	O
with	O
EGFR	O
that	O
account	O
for	O
dominant	O
inheritance	S-Phenotype
,	O
congenital	O
onset	O
,	O
and	O
disease	O
pathology	O

Nonsynonymous	O
changes	O
or	O
frameshift	O
mutations	O
in	O
PIGL	O
have	O
been	O
identified	O
in	O
patients	O
with	O
CHIME	O
syndrome	O
,	O
a	O
rare	O
autosomal	B-Phenotype
recessive	E-Phenotype
disorder	O
characterized	O
by	O
colobomas	S-Phenotype
,	O
congenital	B-Phenotype
heart	I-Phenotype
defects	E-Phenotype
,	O
early	B-Phenotype
onset	I-Phenotype
migratory	I-Phenotype
ichthyosiform	I-Phenotype
dermatosis	E-Phenotype
,	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
and	O
ear	B-Phenotype
abnormalities	E-Phenotype
.	O

A	O
frequently	O
reported	O
finding	O
is	O
that	O
effects	O
from	O
common	O
genetic	O
variation	O
are	O
associated	O
with	O
a	O
schizophrenia	S-Phenotype
-	O
related	O
structural	O
endophenotype	O
.	O

Recently	O
,	O
mutations	O
in	O
AMMECR1	O
were	O
reported	O
in	O
two	O
maternal	O
half	O
-	O
brothers	O
,	O
presenting	O
with	O
nephrocalcinosis	S-Phenotype
,	O
midface	B-Phenotype
hypoplasia	E-Phenotype
and	O
,	O
in	O
one	O
of	O
the	O
siblings	O
,	O
deafness	S-Phenotype
and	O
elliptocytosis	S-Phenotype
.	O

The	O
cause	O
was	O
identified	O
in	O
only	O
7	O
patients	O
and	O
included	O
methylmalonic	B-Phenotype
aciduria	E-Phenotype
,	O
meningoencephalitis	S-Phenotype
,	O
perinatal	B-Phenotype
hypoxic	I-Phenotype
-	I-Phenotype
ischemic	I-Phenotype
injury	E-Phenotype
,	O
large	O
genomic	O
deletion	O
on	O
chromosome	O
7q21	O
,	O
translocase	O
of	O
inner	O
mitochondrial	O
membrane	O
8	O
homolog	O
A	O
(	O
TIMM8A	O
)	O
mutation	O
(	O
Mohr	O
-	O
Tranebjaerg	O
syndrome	O
)	O
,	O
and	O
chromosome	O
2	O
open	O
reading	O
frame	O
37	O
(	O
C2orf37	O
)	O
mutation	O
(	O
Woodhouse	O
-	O
Sakati	O
syndrome	O
)	O
.	O

Obesity	S-Phenotype
causes	O
several	O
chronic	O
diseases	O
,	O
including	O
cardiovascular	O
and	O
respiratory	O
diseases	O
,	O
osteoarthritis	S-Phenotype
,	O
hypertension	S-Phenotype
,	O
stroke	S-Phenotype
,	O
type	B-Phenotype
II	I-Phenotype
diabetes	E-Phenotype
,	O
obstructive	B-Phenotype
sleep	I-Phenotype
apnea	E-Phenotype
,	O
and	O
several	O
types	O
of	O
cancer	S-Phenotype
.	O

The	O
up	O
-	O
regulation	O
of	O
ALL1	O
-	O
fused	O
gene	O
from	O
chromosome	O
1q	O
(	O
AF1q	O
)	O
is	O
commonly	O
seen	O
in	O
aggressive	O
hematologic	O
malignancies	O
as	O
well	O
as	O
in	O
several	O
solid	O
tumor	S-Phenotype
tissues	O
.	O

The	O
homeodomain	O
transcription	O
factor	O
SIX3	O
was	O
recently	O
reported	O
to	O
be	O
a	O
negative	O
regulator	O
of	O
the	O
Wnt	O
pathway	O
and	O
has	O
an	O
emerging	O
role	O
in	O
cancer	S-Phenotype
.	O

microRNAs	O
have	O
been	O
reported	O
to	O
play	O
vital	O
role	O
in	O
lung	B-Phenotype
cancer	E-Phenotype
proliferation	O
and	O
metastasis	O
;	O
the	O
role	O
of	O
miR	O
-	O
4326	O
in	O
tumor	S-Phenotype
progression	O
has	O
not	O
been	O
studied	O
.	O

The	O
vIL	O
-	O
6	O
gene	O
had	O
no	O
significant	O
impact	O
on	O
tumor	S-Phenotype
mass	O
,	O
but	O
significantly	O
more	O
tumors	S-Phenotype
were	O
detected	O
when	O
vIL	O
-	O
6	O
was	O
present	O
.	O

In	O
conclusion	O
,	O
BLU	O
suppressed	O
tumor	S-Phenotype
formation	O
by	O
strengthening	O
the	O
antitumor	O
immunity	O

Corneal	O
changes	O
in	O
aniridia	B-Phenotype
-	I-Phenotype
related	I-Phenotype
keratopathy	E-Phenotype
(	O
ARK	S-Phenotype
)	O
include	O
peripheral	B-Phenotype
pannus	E-Phenotype
and	O
epithelial	B-Phenotype
abnormalities	E-Phenotype
,	O
which	O
eventually	O
result	O
in	O
corneal	B-Phenotype
opacity	E-Phenotype
and	O
contribute	O
to	O
visual	B-Phenotype
loss	E-Phenotype
.	O

Mutations	O
in	O
the	O
glucosylceramidase	O
beta	O
(	O
GBA	O
)	O
gene	O
are	O
strongly	O
associated	O
with	O
neurodegenerative	B-Phenotype
diseases	E-Phenotype
marked	O
by	O
protein	O
aggregation	O
.	O

To	O
test	O
the	O
hypothesis	O
that	O
GNB3	O
overexpression	O
causes	O
obesity	S-Phenotype
,	O
we	O
created	O
bacterial	O
artificial	O
chromosome	O
(	O
BAC	O
)	O
transgenic	O
mice	O
that	O
carry	O
an	O
extra	O
copy	O
of	O
the	O
human	O
GNB3	O
risk	O
allele	O
.	O

We	O
then	O
validated	O
the	O
anti	O
-	O
SMARCE1	O
antibody	O
specificity	O
by	O
analyzing	O
additional	O
305	O
pediatric	O
and	O
adult	O
meningiomas	S-Phenotype
of	O
various	O
subtypes	O
and	O
15	O
non	B-Phenotype
-	I-Phenotype
meningioma	I-Phenotype
clear	I-Phenotype
cell	I-Phenotype
tumors	E-Phenotype
by	O
SMARCE1	O
immunohistochemistry	O
.	O

For	O
families	O
that	O
PRRT2	O
mutations	O
were	O
not	O
detected	O
by	O
Sanger	O
sequencing	O
,	O
candidate	O
gene	O
mutations	O
were	O
further	O
screened	O
by	O
next	O
-	O
generation	O
sequencing	O
for	O
epilepsy	S-Phenotype
.	O

Polo	O
-	O
like	O
kinase	O
1	O
(	O
Plk1	O
)	O
is	O
overexpressed	O
in	O
a	O
wide	O
spectrum	O
of	O
human	O
tumors	S-Phenotype
,	O
being	O
frequently	O
considered	O
as	O
an	O
oncogene	O
and	O
an	O
attractive	O
cancer	S-Phenotype
target	O
.	O

The	O
staining	O
intensity	O
of	O
ALG3	O
was	O
significantly	O
correlated	O
to	O
the	O
tumor	S-Phenotype
grade	O
(	O
grades	O
2	O
-	O
3	O
versus	O
1	O
,	O
pAAAA0.05	O
)	O
.	O

This	O
is	O
the	O
first	O
study	O
to	O
investigate	O
the	O
effect	O
of	O
vitamin	O
D	O
receptor	O
(	O
VDR	O
)	O
gene	O
single	O
-	O
nucleotide	O
polymorphisms	O
on	O
the	O
clinicopathologic	O
features	O
of	O
papillary	B-Phenotype
thyroid	I-Phenotype
cancer	E-Phenotype
in	O
Turkey	O
.	O

Is	O
BAH	O
due	O
to	O
the	O
bilateral	S-Phenotype
occurrence	O
of	O
APCCs	O
,	O
to	O
germline	O
variants	O
,	O
or	O
perhaps	O
due	O
to	O
unknown	O
serum	O
factors	O
?	O

Auriculocondylar	O
syndrome	O
,	O
mainly	O
characterized	O
by	O
micrognathia	S-Phenotype
,	O
small	B-Phenotype
mandibular	I-Phenotype
condyle	E-Phenotype
,	O
and	O
question	B-Phenotype
mark	I-Phenotype
ears	E-Phenotype
,	O
is	O
a	O
rare	O
disease	O
segregating	O
in	O
an	O
autosomal	O
dominant	O
pattern	O
in	O
the	O
majority	O
of	O
the	O
families	O
reported	O
in	O
the	O
literature	O
.	O

In	O
parallel	O
,	O
we	O
recently	O
reported	O
that	O
liCc2d1a	O
/	O
i	O
-	O
deficient	O
mice	O
present	O
with	O
cognitive	O
and	O
social	O
deficits	O
,	O
hyperactivity	S-Phenotype
and	O
anxiety	S-Phenotype
.	O

After	O
1	O
year	O
,	O
because	O
of	O
worsening	O
in	O
spatial	O
orientation	O
and	O
the	O
onset	O
of	O
dressing	O
apraxia	S-Phenotype
,	O
he	O
was	O
referred	O
to	O
our	O
memory	O
clinic	O
.	O

miR	O
-	O
223	O
is	O
implicated	O
in	O
both	O
vascular	B-Phenotype
calcification	E-Phenotype
and	O
osteoporosis	S-Phenotype
.	O

In	O
the	O
present	O
study	O
,	O
we	O
found	O
that	O
the	O
Kankl	O
gene	O
was	O
significantly	O
downregulated	O
in	O
human	O
lung	B-Phenotype
cancer	E-Phenotype
and	O
lung	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Fragile	O
-	O
X	O
(	O
FraX	O
)	O
individuals	O
also	O
display	O
cellular	O
and	O
morphological	O
traits	O
including	O
branched	B-Phenotype
dendritic	I-Phenotype
spines	E-Phenotype
,	O
large	B-Phenotype
ears	E-Phenotype
,	O
and	O
macroorchidism	S-Phenotype
.	O

Two	O
cases	O
showed	O
acellular	O
collagenous	O
stroma	O
constituted	O
AAAA50	O
%	O
of	O
the	O
tumor	S-Phenotype
confirming	O
to	O
the	O
diagnosis	O
of	O
sclerosing	O
SCT	O
.	O

These	O
findings	O
may	O
provide	O
a	O
better	O
understanding	O
about	O
the	O
mechanism	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
and	O
suggest	O
that	O
MFAP5	O
may	O
be	O
a	O
potential	O
prognostic	O
biomarker	O
and	O
therapeutic	O
target	O
for	O
breast	B-Phenotype
cancer	E-Phenotype
,	O
especially	O
for	O
bone	O
metastasis	O
of	O
breast	B-Phenotype
cancer	E-Phenotype

Here	O
we	O
find	O
that	O
a	O
lymphocyte	O
lineage	O
-	O
restricted	O
transcription	O
factor	O
,	O
Spi	O
-	O
B	O
,	O
is	O
frequently	O
expressed	O
in	O
human	O
lung	B-Phenotype
cancer	E-Phenotype
tissues	O
.	O

We	O
present	O
confirmatory	O
evidence	O
for	O
a	O
role	O
of	O
dystonia	S-Phenotype
genes	O
that	O
had	O
not	O
yet	O
been	O
unequivocally	O
established	O
including	O
PRKRA	O
,	O
TUBB4A	O
,	O
ANO3	O
,	O
and	O
TAF1	O
.	O

The	O
MEG	O
tumors	S-Phenotype
clustered	O
closest	O
to	O
Catalogue	O
of	O
Somatic	O
Mutations	O
in	O
Cancer	S-Phenotype
signatures	O
4	O
and	O
24	O
,	O
which	O
are	O
,	O
respectively	O
,	O
associated	O
with	O
benzo	O
(	O
a	O
)	O
pyrene	O
-	O
and	O
aflatoxin	O
-	O
induced	O
HCCs	O
in	O
humans	O
.	O

Thus	O
,	O
this	O
in	O
vitro	O
study	O
suggests	O
that	O
there	O
are	O
no	O
tumor	S-Phenotype
-	O
promoting	O
effects	O
of	O
Epo	O
in	O
the	O
NSCLC	O
cell	O
lines	O
studied	O
,	O
neither	O
under	O
normoxic	O
nor	O
under	O
hypoxic	O
conditions	O

Therefore	O
,	O
there	O
is	O
a	O
great	O
need	O
for	O
the	O
development	O
of	O
safe	O
and	O
effective	O
nanoparticles	O
for	O
better	O
tumor	S-Phenotype
-	O
specific	O
delivery	O
of	O
anti	O
-	O
cancer	S-Phenotype
therapeutics	O
.	O

Our	O
data	O
suggest	O
that	O
,	O
of	O
the	O
genes	O
within	O
this	O
minimal	O
critical	O
region	O
,	O
C6orf70	O
plays	O
a	O
major	O
role	O
in	O
the	O
control	O
of	O
neuronal	O
migration	O
and	O
its	O
haploinsufficiency	O
or	O
mutation	O
causes	O
periventricular	B-Phenotype
nodular	I-Phenotype
heterotopia	E-Phenotype
.	O

Furthermore	O
,	O
ZEB2	O
knockdown	O
recapitulated	O
the	O
inhibitory	O
effects	O
of	O
miR‑498	O
overexpression	O
in	O
liver	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

3	B-Phenotype
-	I-Phenotype
Methylglutaconic	I-Phenotype
aciduria	E-Phenotype
is	O
associated	O
with	O
variants	O
in	O
genes	O
encoding	O
mitochondrial	S-Phenotype
inner	O
membrane	O
organizing	O
determinants	O
,	O
including	O
TAZ	O
,	O
DNAJC19	O
,	O
SERAC1	O
and	O
QIL1	O
/	O
MIC13	O

Several	O
studies	O
have	O
shown	O
that	O
reproductive	O
factors	O
,	O
such	O
as	O
age	O
at	O
natural	O
menopause	O
,	O
parity	O
and	O
polycystic	O
ovarian	O
syndrome	O
(	O
PCOS	O
)	O
,	O
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
heart	B-Phenotype
failure	E-Phenotype
.	O

However	O
,	O
the	O
expression	O
levels	O
or	O
functions	O
of	O
CCDC8	O
in	O
lung	B-Phenotype
cancer	E-Phenotype
have	O
not	O
been	O
elucidated	O
.	O

Deregulated	O
mitochondrial	O
respiration	O
induced	O
by	O
ClpXP	O
targeting	O
causes	O
oxidative	B-Phenotype
stress	E-Phenotype
,	O
which	O
in	O
turn	O
reduces	O
tumor	S-Phenotype
cell	O
proliferation	O
,	O
suppresses	O
cell	O
motility	O
,	O
and	O
abolishes	O
metastatic	O
dissemination	O
in	O
vivo	O
.	O

During	O
drug	O
discovery	O
efforts	O
targeting	O
inhibition	O
of	O
cytochrome	O
P450	O
11B2	O
(	O
CYP11B2	O
)	O
-	O
mediated	O
production	O
of	O
aldosterone	O
as	O
a	O
therapeutic	O
approach	O
for	O
the	O
treatment	O
of	O
chronic	B-Phenotype
kidney	I-Phenotype
disease	E-Phenotype
and	O
hypertension	S-Phenotype
,	O
(	O
liS	O
/	O
i	O
)	O
-	O
6	O
-	O
(	O
5	O
-	O
fluoro	O
-	O
4	O
-	O
(	O
1	O
-	O
hydroxyethyl	O
)	O
pyridin	O
-	O
3	O
-	O
yl	O
)	O
-	O
3,4	O
-	O
dihydro	O
-	O
1,8	O
-	O
naphthyridine	O
-	O
1	O
(	O
li2H	O
/	O
i	O
)	O
-	O
carboxamide	O
(	O
1	O
)	O
was	O
identified	O
as	O
a	O
potent	O
and	O
selective	O
inhibitor	O
of	O
CYP11B2	O
.	O

We	O
report	O
a	O
new	O
(	O
fifth	O
)	O
patient	O
with	O
the	O
cblJ	O
disorder	O
who	O
presented	O
at	O
7	O
days	O
of	O
age	O
with	O
poor	B-Phenotype
feeding	E-Phenotype
,	O
hypotonia	S-Phenotype
,	O
methylmalonic	B-Phenotype
aciduria	E-Phenotype
,	O
and	O
elevated	O
plasma	O
homocysteine	O
and	O
harbored	O
the	O
mutations	O
c.1667_1668delAG	O
[	O
p.Glu556Glyfs	O
*	O
27	O
]	O
and	O
c.1295GAAAAA	O
[	O
p.Arg432Gln	O
]	O
in	O
the	O
liABCD4	O
/	O
i	O
gene	O
.	O

In	O
humans	O
,	O
narcolepsy	S-Phenotype
is	O
a	O
sleep	O
disorder	O
that	O
is	O
characterized	O
by	O
sleepiness	S-Phenotype
,	O
cataplexy	S-Phenotype
and	O
rapid	B-Phenotype
eye	I-Phenotype
movement	I-Phenotype
(	I-Phenotype
REM	I-Phenotype
)	I-Phenotype
sleep	I-Phenotype
abnormalities	E-Phenotype
.	O

However	O
autosomal	B-Phenotype
recessive	I-Phenotype
inheritance	E-Phenotype
with	O
mutation	O
in	O
the	O
SLC34A2	O
gene	O
is	O
suspected	O

Next	O
,	O
we	O
show	O
that	O
FBXO16	O
functions	O
as	O
a	O
tumor	S-Phenotype
suppressor	O
in	O
GBM	O
.	O

Homozygous	O
recessive	O
mutations	O
in	O
either	O
EFEMP2	O
(	O
encoding	O
fibulin	O
-	O
4	O
)	O
or	O
FBLN5	O
(	O
encoding	O
fibulin	O
-	O
5	O
)	O
,	O
critical	O
genes	O
for	O
elastogenesis	O
,	O
lead	O
to	O
autosomal	B-Phenotype
recessive	I-Phenotype
cutis	I-Phenotype
laxa	I-Phenotype
types	I-Phenotype
1B	I-Phenotype
and	I-Phenotype
1A	E-Phenotype
,	O
respectively	O
.	O

Hsp90ab1	O
is	O
upregulated	O
in	O
numerous	O
solid	O
tumors	S-Phenotype
,	O
which	O
is	O
thought	O
to	O
induce	O
the	O
angiogenesis	O
and	O
promote	O
cancer	S-Phenotype
metastasis	O
.	O

SCA18	O
is	O
a	O
rare	O
autosomal	O
dominant	O
sensory	O
/	O
motor	O
neuropathy	S-Phenotype
with	O
ataxia	S-Phenotype
(	O
OMIM	O
#	O
607458	O
)	O
associated	O
with	O
a	O
single	O
missense	O
variant	O
c.514	O
AAAAAG	O
in	O
the	O
interferon	O
related	O
developmental	O
regulator	O
1	O
(	O
IFRD1	O
)	O
gene	O
previously	O
reported	O
in	O
a	O
five	O
-	O
generation	O
American	O
family	O
of	O
Irish	O
origin	O
.	O

We	O
performed	O
whole	O
-	O
exome	O
sequencing	O
of	O
a	O
patient	O
with	O
severe	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
distinctive	B-Phenotype
facial	I-Phenotype
appearance	E-Phenotype
,	O
fragile	B-Phenotype
nails	E-Phenotype
,	O
and	O
persistent	B-Phenotype
increased	I-Phenotype
serum	I-Phenotype
levels	I-Phenotype
of	I-Phenotype
ALP	E-Phenotype
.	O

We	O
identified	O
a	O
high	O
frequency	O
of	O
mutations	O
in	O
PTEN	O
(	O
50	O
%	O
)	O
and	O
genes	O
involved	O
in	O
the	O
endometrial	O
cancer	S-Phenotype
-	O
related	O
molecular	O
pathway	O
,	O
which	O
involves	O
the	O
IL	O
-	O
7	O
signaling	O
pathway	O
(	O
PIK3R1	O
,	O
n=1	O
;	O
AKT2	O
,	O
n=1	O
;	O
FOXO1	O
,	O
n=1	O
)	O
.	O

We	O
then	O
correlated	O
our	O
findings	O
with	O
clinicopathologic	O
data	O
including	O
tumor	S-Phenotype
-	O
node	O
-	O
metastasis	O
stage	O
,	O
p16	O
status	O
,	O
age	O
,	O
sex	O
,	O
and	O
smoking	O
and	O
alcohol	O
history	O
.	O

This	O
validation	O
revealed	O
that	O
the	O
expression	O
of	O
FREM2AAAAAmdash	O
;	O
but	O
not	O
SPRY1AAAAAmdash	O
;	O
is	O
higher	O
in	O
glioblastoma	S-Phenotype
cell	O
lines	O
when	O
compared	O
to	O
non	O
-	O
malignant	O
astrocytes	O
.	O

PRKAG3	O
(	O
Padj	O
=	O
0.0018	O
)	O
and	O
RPS6KA3	O
(	O
Padj	O
=	O
0.061	O
)	O
were	O
the	O
leading	O
genes	O
for	O
the	O
associations	O
with	O
overall	O
breast	B-Phenotype
cancer	E-Phenotype
risk	O
and	O
ER	O
-	O
breast	B-Phenotype
cancer	E-Phenotype
risk	O
,	O
respectively	O
.	O

Using	O
a	O
transgenic	O
approach	O
,	O
we	O
demonstrate	O
that	O
a	O
594	O
bp	O
sequence	O
encompassing	O
the	O
ECR	O
recapitulates	O
specific	O
aspects	O
of	O
the	O
endogenous	O
Hmx1	O
lateral	S-Phenotype
facial	O
expression	O
pattern	O
.	O

These	O
mice	O
develop	O
prostate	O
tumors	S-Phenotype
similar	O
to	O
a	O
subset	O
of	O
poor	O
outcome	O
,	O
treatment	O
-	O
associated	O
human	O
PC	O
tumors	S-Phenotype
.	O

Translational	O
research	O
suggests	O
that	O
EMP2	O
may	O
be	O
targeted	O
with	O
antibodies	O
to	O
improve	O
tumor	S-Phenotype
control	O
and	O
survival	O
in	O
a	O
variety	O
of	O
murine	O
models	O
and	O
cancer	S-Phenotype
types	O
.	O

These	O
expanded	O
roles	O
underscore	O
the	O
significance	O
of	O
vertebrate	O
PCP	O
proteins	O
as	O
factors	O
contributing	O
to	O
a	O
number	O
of	O
diseases	O
,	O
including	O
neural	B-Phenotype
tube	I-Phenotype
defects	E-Phenotype
,	O
tumor	S-Phenotype
metastases	O
,	O
and	O
various	O
genetic	O
syndromes	O
characterized	O
by	O
abnormal	O
migratory	O
cell	O
behaviors	O

Importantly	O
,	O
cell	O
line	O
and	O
animal	O
experiments	O
both	O
confirmed	O
that	O
E2F6	O
promotes	O
ovarian	B-Phenotype
cancer	E-Phenotype
stemness	O
,	O
whereas	O
E2F6	O
or	O
EZH2	O
depletion	O
derepressed	O
miR	O
-	O
193a	O
,	O
which	O
opposes	O
cancer	S-Phenotype
stemness	O
,	O
by	O
alleviating	O
DNA	O
methylation	O
and	O
repressive	O
chromatin	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
analysed	O
a	O
Chinese	O
family	O
with	O
autosomal	B-Phenotype
recessive	E-Phenotype
RP	O
.	O

To	O
comprehensively	O
identify	O
breast	B-Phenotype
cancer	E-Phenotype
risk	O
modifying	O
loci	O
for	O
BRCA2	O
mutation	O
carriers	O
,	O
we	O
conducted	O
a	O
deep	O
replication	O
of	O
an	O
ongoing	O
GWAS	O
discovery	O
study	O
.	O

XIAP	O
has	O
previously	O
been	O
proposed	O
to	O
promote	O
tumor	S-Phenotype
growth	O
through	O
suppression	O
of	O
autophagy	O
.	O

Here	O
we	O
demonstrate	O
association	O
of	O
variants	O
in	O
the	O
mitochondrial	O
asparaginyl	O
-	O
tRNA	O
synthetase	O
NARS2	O
with	O
human	O
hearing	B-Phenotype
loss	E-Phenotype
and	O
Leigh	O
syndrome	O
.	O

HPS	O
-	O
5	O
therefore	O
appears	O
as	O
a	O
mild	O
form	O
of	O
HPS	O
,	O
which	O
is	O
often	O
clinically	O
undistinguishable	O
from	O
mild	O
oculocutaneous	O
or	O
ocular	O
forms	O
of	O
albinism	S-Phenotype
.	O

In	O
the	O
present	O
study	O
,	O
we	O
revealed	O
that	O
TMEM165	O
is	O
overexpressed	O
in	O
HCC	O
and	O
its	O
depletion	O
weakens	O
the	O
invasive	O
activity	O
of	O
cancer	S-Phenotype
cells	O
through	O
suppression	O
of	O
matrix	O
metalloproteinase‑2	O
(	O
MMP‑2	O
)	O
expression	O
.	O

Dasatinib	O
treatment	O
of	O
the	O
mice	O
with	O
intrasplenic	O
xenografts	O
decreased	O
tumor	S-Phenotype
growth	O
and	O
increased	O
survival	O
times	O
,	O
compared	O
with	O
mice	O
treated	O
with	O
vehicle	O
only	O
.	O

Thus	O
,	O
in	O
addition	O
to	O
the	O
standard	O
therapy	O
with	O
CDCA	O
,	O
the	O
addition	O
of	O
Riluzole	O
may	O
have	O
some	O
therapeutic	O
benefits	O
for	O
ataxia	S-Phenotype
caused	O
by	O
CTX	O
.	O

Here	O
,	O
we	O
have	O
performed	O
a	O
prospective	O
nationwide	O
genetic	O
association	O
study	O
using	O
the	O
Human	O
Exome	O
BeadChip	O
and	O
identified	O
gene	O
variants	O
in	O
encoding	O
dynactin	O
4	O
(	O
DCTN4	O
)	O
,	O
retinoic	O
acid	O
early	O
transcript	O
1E	O
(	O
RAET1E	O
)	O
,	O
and	O
V	O
-	O
akt	O
murine	O
thymoma	S-Phenotype
viral	O
oncogene	O
homolog	O
3	O
(	O
AKT3	O
)	O
to	O
be	O
associated	O
with	O
unfavourable	O
outcome	O
in	O
patients	O
with	O
pneumococcal	B-Phenotype
meningitis	E-Phenotype
.	O

Conclusion	O
rs1049334	O
polymorphismof	O
CAV1	O
upgrade	O
the	O
risk	O
of	O
urinary	B-Phenotype
cancer	E-Phenotype
,	O
while	O
rs1049337	O
and	O
rs7804372	O
polymorphisms	O
may	O
act	O
as	O
a	O
protector	O
of	O
urinary	B-Phenotype
cancer	E-Phenotype
.	O

Furthermore	O
,	O
we	O
demonstrated	O
that	O
silencing	O
CBX3	O
in	O
pancreatic	B-Phenotype
cancer	E-Phenotype
cells	O
inhibited	O
aerobic	O
glycolysis	O
,	O
the	O
basis	O
for	O
providing	O
cancer	S-Phenotype
cells	O
with	O
building	O
blocks	O
for	O
macromolecule	O
synthesis	O
and	O
ATP	O
that	O
required	O
.	O

coli	O
/	O
i	O
exhibited	O
a	O
50	O
%	O
reduction	O
in	O
carcinogen	O
-	O
induced	O
colorectal	B-Phenotype
tumor	E-Phenotype
burden	O
.	O

We	O
have	O
revealed	O
significant	O
association	O
of	O
FGFR2	O
and	O
MAP3K1	O
polymorphisms	O
with	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

Here	O
,	O
we	O
report	O
a	O
reduction	O
of	O
histone	O
deacetylase	O
3	O
(	O
HDAC3	O
)	O
protein	O
amounts	O
in	O
eutopic	O
endometrium	O
of	O
infertile	O
women	O
with	O
endometriosis	S-Phenotype
compared	O
to	O
a	O
control	O
group	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
results	O
obtained	O
from	O
our	O
previously	O
published	O
methylation	O
array	O
were	O
analyzed	O
and	O
10	O
candidate	O
genes	O
involved	O
in	O
DNA	O
repair	O
[	O
protein	O
phosphatase	O
4	O
catalytic	O
subunit	O
(	O
PPP4C	O
)	O
]	O
,	O
apoptosis	O
[	O
runt	O
related	O
transcription	O
factor	O
3	O
(	O
RUNX3	O
)	O
,	O
interferon	O
regulatory	O
factor	O
4	O
(	O
IRF4	O
)	O
,	O
ubiquitin	O
C	O
-	O
terminal	O
hydrolase	O
L1	O
(	O
UCHL1	O
)	O
and	O
tumor	S-Phenotype
protein	O
p53	O
inducible	O
protein	O
3	O
(	O
TP53I3	O
)	O
]	O
,	O
cell	O
proliferation	O
[	O
cyclin	O
D2	O
(	O
CCND2	O
)	O
and	O
Ras	O
association	O
domain	O
family	O
member	O
1	O
(	O
RASSF1	O
)	O
]	O
,	O
drug	O
metabolism	O
[	O
aldehyde	O
dehydrogenase	O
1	O
family	O
member	O
A3	O
(	O
ALDH1A3	O
)	O
and	O
solute	O
carrier	O
family	O
29	O
member	O
1	O
(	O
SLC29A1	O
)	O
]	O
and	O
angiogenesis	O
[	O
human	O
immunodeficiency	S-Phenotype
virus	O
-	O
1	O
tat	O
interactive	O
protein	O
2	O
(	O
HTATIP2	O
)	O
]	O
were	O
selected	O
for	O
quantification	O
of	O
their	O
methylation	O
levels	O
in	O
54	O
CCA	O
and	O
19	O
adjacent	O
normal	O
tissues	O
using	O
methylation	O
-	O
sensitive	O
high	O
-	O
resolution	O
melting	O
.	O

Primary	O
renal	O
PGL	O
and	O
neoplasia	S-Phenotype
was	O
associated	O
with	O
about	O
2	O
%	O
of	O
710	O
cases	O
of	O
PC	O
/	O
PGL	O
.	O

Mutations	O
in	O
components	O
of	O
the	O
major	O
spliceosome	O
have	O
been	O
described	O
in	O
disorders	O
with	O
craniofacial	O
anomalies	O
,	O
e.g.	O
,	O
Nager	O
syndrome	O
and	O
mandibulofacial	B-Phenotype
dysostosis	E-Phenotype
type	O
Guion	O
-	O
Almeida	O
.	O

Hearing	O
impairment	O
(	O
HI	O
)	O
caused	O
by	O
mutations	O
in	O
the	O
connexin	O
-	O
26	O
gene	O
(	O
GJB2	O
)	O
accounts	O
for	O
the	O
majority	O
of	O
cases	O
with	O
inherited	B-Phenotype
,	I-Phenotype
nonsyndromic	I-Phenotype
sensorineural	I-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
.	O

Longer	O
population	O
doubling	O
time	O
in	O
L	O
-	O
MSCs	O
was	O
not	O
related	O
to	O
the	O
AML	O
characteristics	O
at	O
diagnosis	O
(	O
French	O
-	O
American	O
-	O
British	O
type	O
,	O
cytogenetics	O
,	O
or	O
tumor	S-Phenotype
burden	O
)	O
,	O
but	O
was	O
related	O
to	O
patient	O
age	O
and	O
independently	O
associated	O
with	O
poorer	O
patient	O
outcome	O
,	O
as	O
was	O
cytogenetic	O
prognostic	O
feature	O
.	O

Polymorphisms	O
in	O
the	O
MED13L	O
gene	O
have	O
been	O
linked	O
to	O
congenital	B-Phenotype
heart	I-Phenotype
anomalies	E-Phenotype
and	O
intellectual	B-Phenotype
disabilities	E-Phenotype
.	O

Among	O
the	O
available	O
genomic	O
studies	O
,	O
the	O
key	O
findings	O
in	O
Africa	O
were	O
variants	O
in	O
GATA4	O
(	O
P193H	O
)	O
,	O
MTHFR	O
677TT	O
,	O
and	O
MTHFR	O
1298CC	O
that	O
were	O
associated	O
with	O
atrial	B-Phenotype
septal	I-Phenotype
defect	E-Phenotype
,	O
ventricular	B-Phenotype
septal	I-Phenotype
defect	E-Phenotype
(	O
VSD	S-Phenotype
)	O
,	O
Tetralogy	B-Phenotype
of	I-Phenotype
Fallot	E-Phenotype
(	O
TOF	S-Phenotype
)	O
,	O
and	O
patent	B-Phenotype
ductus	I-Phenotype
arteriosus	E-Phenotype
phenotypes	O
and	O
22q.11	O
deletion	O
,	O
which	O
is	O
associated	O
with	O
TOF	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
mice	O
with	O
conditional	O
ablation	O
of	O
the	O
Pjvk	O
gene	O
in	O
all	O
sensory	O
hair	O
cells	O
or	O
only	O
in	O
outer	O
hair	O
cells	O
(	O
OHCs	O
)	O
show	O
similar	O
auditory	O
phenotypes	O
with	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
profound	I-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
.	O

Double	O
-	O
labeling	O
immunohistochemistry	O
for	O
Pit	O
-	O
1	O
/	O
GH	O
,	O
Pit	O
-	O
1	O
/	O
NFP	O
,	O
Pit	O
-	O
1	O
/	O
MAP2	O
,	O
and	O
NeuN	O
/	O
GH	O
was	O
performed	O
in	O
9	O
/	O
10	O
tumors	S-Phenotype
.	O

We	O
report	O
here	O
the	O
in	O
vitro	O
and	O
in	O
vivo	O
antitumor	O
activity	S-Phenotype
of	O
lucitanib	O
in	O
experimental	O
models	O
with	O
or	O
without	O
FGFR1	O
/	O
2	O
amplification	O
or	O
mutations	O
.	O

The	O
overexpression	O
of	O
PARIS	O
selectively	O
leads	O
to	O
the	O
loss	O
of	O
dopaminergic	O
neurons	O
(	O
DN	O
)	O
and	O
mitochondrial	S-Phenotype
abnormalities	O
in	O
the	O
substantia	O
nigra	O
(	O
SN	O
)	O
of	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
models	O
.	O

Taken	O
together	O
,	O
we	O
show	O
that	O
common	O
DNA	O
variants	O
within	O
CPZ	O
at	O
4p16	O
and	O
upstream	O
of	O
MLF1	O
at	O
3q25	O
influence	O
neuroblastoma	S-Phenotype
susceptibility	O
and	O
MLF1	O
likely	O
plays	O
an	O
important	O
role	O
in	O
neuroblastoma	S-Phenotype
tumorigenesis	O

Substitutions	O
of	O
Arg838	O
in	O
the	O
dimerization	O
domain	O
of	O
a	O
human	O
retinal	O
membrane	O
guanylyl	O
cyclase	O
1	O
(	O
RetGC1	O
)	O
linked	O
to	O
autosomal	O
dominant	O
cone	O
-	O
rod	O
degeneration	O
type	O
6	O
(	O
CORD6	O
)	O
change	O
RetGC1	O
regulation	O
in	O
vitro	O
by	O
Ca2+	O
In	O
addition	O
,	O
we	O
find	O
that	O
R838S	O
substitution	O
makes	O
RetGC1	O
less	O
sensitive	O
to	O
inhibition	O
by	O
retinal	B-Phenotype
degeneration	E-Phenotype
-	O
3	O
protein	O
(	O
RD3	O
)	O
.	O

Mechanistic	O
studies	O
showed	O
that	O
Smac	O
can	O
inhibit	O
the	O
expression	O
of	O
Survivin	O
,	O
promote	O
cell	O
apoptosis	O
of	O
drug	B-Phenotype
-	I-Phenotype
resistant	I-Phenotype
ovarian	I-Phenotype
cancer	E-Phenotype
cells	O
and	O
reverse	O
the	O
drug	B-Phenotype
resistance	E-Phenotype

Neonatal	O
-	O
onset	O
multiple	O
acyl	O
-	O
CoA	O
dehydrogenase	O
deficiency	O
(	O
MADD	O
type	O
I	O
)	O
is	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
disorder	O
of	O
the	O
electron	O
transfer	O
flavoprotein	O
function	O
characterized	O
by	O
a	O
severe	O
clinical	O
and	O
biochemical	O
phenotype	O
,	O
including	O
congenital	O
abnormalities	O
with	O
unresponsiveness	O
to	O
riboflavin	O
treatment	O
as	O
distinguishing	O
features	O
.	O

Prominent	O
examples	O
include	O
mutations	O
in	O
the	O
transporters	O
for	O
dopamine	O
(	O
DAT	O
,	O
SLC6A3	O
)	O
,	O
for	O
creatine	O
(	O
CT1	O
,	O
SLC6A8	O
)	O
,	O
and	O
for	O
glycine	O
(	O
GlyT2	O
,	O
SLC6A5	O
)	O
,	O
which	O
result	O
in	O
infantile	B-Phenotype
dystonia	E-Phenotype
,	O
mental	B-Phenotype
retardation	E-Phenotype
,	O
and	O
hyperekplexia	S-Phenotype
,	O
respectively	O
.	O

However	O
,	O
human	O
newborns	O
deficient	O
in	O
WWOX	O
do	O
not	O
spontaneously	O
develop	O
tumors	S-Phenotype
.	O

The	O
two	O
glycoproteins	O
were	O
detected	O
in	O
the	O
cytosol	O
of	O
tumor	S-Phenotype
cells	O
with	O
varying	O
intensity	O
,	O
LAMP	O
-	O
1	O
showing	O
again	O
enhanced	O
expression	O
.	O

With	O
the	O
first	O
filensin	O
(	O
BFSP1	O
)	O
mutation	O
now	O
having	O
been	O
reported	O
to	O
cause	O
a	O
recessive	O
cataract	S-Phenotype
phenotype	O
,	O
there	O
is	O
the	O
suggestion	O
that	O
the	O
mutation	O
could	O
predispose	O
heterozygote	O
carriers	O
to	O
the	O
early	O
onset	O
of	O
age	B-Phenotype
-	I-Phenotype
related	I-Phenotype
nuclear	I-Phenotype
cataract	E-Phenotype
.	O

We	O
found	O
that	O
GATA4	O
expression	O
was	O
high	O
in	O
most	O
hepatoblastomas	S-Phenotype
but	O
weak	O
or	O
negligible	O
in	O
normal	O
hepatocytes	O
.	O

DNA	O
samples	O
from	O
eight	O
families	O
with	O
autosomal	B-Phenotype
recessive	I-Phenotype
retinal	I-Phenotype
dystrophies	E-Phenotype
were	O
subjected	O
to	O
genome	O
wide	O
homozygosity	O
mapping	O
(	O
seven	O
by	O
SNP	O
arrays	O
and	O
one	O
by	O
STR	O
markers	O
)	O
and	O
genes	O
comprised	O
within	O
the	O
detected	O
homozygous	O
regions	O
were	O
analyzed	O
by	O
Sanger	O
sequencing	O
.	O

To	O
test	O
if	O
PPM1B	O
can	O
be	O
a	O
drug	O
target	O
in	O
the	O
cellular	O
proliferation	O
and	O
death	O
pathway	O
,	O
the	O
lentiviral	O
PPM1B	O
shRNA	O
was	O
stably	O
expressed	O
in	O
cancer	S-Phenotype
cell	O
lines	O
and	O
its	O
regulatory	O
function	O
in	O
the	O
RB1	O
-	O
E2F1	O
pathway	O
was	O
examined	O
.	O

We	O
also	O
found	O
that	O
increased	O
miR	O
-	O
663	O
expression	O
in	O
breast	B-Phenotype
tumors	E-Phenotype
consistently	O
correlates	O
with	O
increased	O
patient	O
survival	O
.	O

RNA	O
interference	O
was	O
used	O
to	O
inhibit	O
GATA4	O
in	O
human	O
HUH6	O
hepatoblastoma	S-Phenotype
cells	O
,	O
and	O
changes	O
in	O
cell	O
migration	O
were	O
measured	O
with	O
wound	O
healing	O
and	O
transwell	O
assays	O
.	O

Membrane	O
transporters	O
(	O
such	O
as	O
ABCs	O
,	O
SLCs	O
and	O
ATPases	O
)	O
act	O
in	O
carcinogenesis	O
and	O
chemoresistance	O
development	O
,	O
but	O
their	O
relevance	O
for	O
prognosis	O
of	O
epithelial	B-Phenotype
ovarian	I-Phenotype
cancer	E-Phenotype
(	O
EOC	S-Phenotype
)	O
remains	O
poorly	O
understood	O
.	O

No	O
BCOR	O
staining	O
was	O
seen	O
in	O
the	O
remaining	O
low	B-Phenotype
-	I-Phenotype
grade	I-Phenotype
endometrial	I-Phenotype
stromal	I-Phenotype
sarcomas	E-Phenotype
,	O
endometrial	B-Phenotype
stromal	I-Phenotype
nodules	E-Phenotype
,	O
leiomyosarcomas	S-Phenotype
,	O
or	O
any	O
of	O
the	O
leiomyomas	S-Phenotype
.	O

Recent	O
research	O
published	O
in	O
the	O
Journal	O
of	O
Pathology	O
showed	O
that	O
genetic	O
depletion	O
of	O
any	O
of	O
the	O
NOX2	O
subunits	O
Cyba	O
,	O
Cybb	O
,	O
Ncf1	O
,	O
Ncf2	O
and	O
Ncf4	O
reduced	O
the	O
formation	O
of	O
lung	O
metastases	O
following	O
intravenous	O
injection	O
of	O
murine	O
tumor	S-Phenotype
cells	O
.	O

The	O
present	O
findings	O
did	O
not	O
identify	O
copy	O
number	O
variation	O
and	O
mutations	O
in	O
EDA	O
;	O
therefore	O
,	O
excluding	O
the	O
possibility	O
of	O
EDA‑initiated	B-Phenotype
ectodermal	I-Phenotype
dysplasia	E-Phenotype
syndrome	O
.	O

CNNM2	O
and	O
NT5C2	O
are	O
genes	O
recently	O
identified	O
as	O
susceptibility	O
genes	O
for	O
schizophrenia	S-Phenotype
in	O
Europeans	O
,	O
but	O
the	O
exact	O
mechanism	O
by	O
which	O
these	O
genes	O
confer	O
risk	O
for	O
schizophrenia	S-Phenotype
remains	O
unknown	O
.	O

Zebrafish	O
with	O
ryroxD1	O
knock	O
-	O
down	O
recapitulate	O
features	O
of	O
PYROXD1	O
myopathy	S-Phenotype
with	O
sarcomeric	B-Phenotype
disorganization	E-Phenotype
,	O
myofibrillar	B-Phenotype
aggregates	E-Phenotype
,	O
and	O
marked	B-Phenotype
swimming	I-Phenotype
defect	E-Phenotype
.	O

In	O
89	O
cases	O
where	O
tumour	S-Phenotype
cells	O
were	O
identified	O
by	O
melan	O
-	O
A	O
labelling	O
,	O
100	O
%	O
of	O
tumour	S-Phenotype
cells	O
were	O
positive	O
for	O
nBAP1	O
expression	O
,	O
including	O
eight	O
uveal	O
tract	O
and	O
29	O
oral	B-Phenotype
mucosal	I-Phenotype
melanomas	E-Phenotype
.	O

The	O
presence	O
of	O
minor	O
loss	O
-	O
of	O
-	O
function	O
variants	O
in	O
WFS1	O
predicted	O
isolated	B-Phenotype
diabetes	E-Phenotype
,	O
isolated	B-Phenotype
deafness	E-Phenotype
,	O
or	O
isolated	B-Phenotype
congenital	I-Phenotype
cataracts	E-Phenotype
without	O
development	O
of	O
the	O
full	O
syndrome	O
(	O
sensitivity	O
100	O
%	O
[	O
93	O
%	O
-	O
100	O
%	O
]	O
;	O
specificity	O
78	O
%	O
[	O
73	O
%	O
-	O
82	O
%	O
]	O
)	O
.	O

Small	B-Phenotype
cell	I-Phenotype
lung	I-Phenotype
cancer	E-Phenotype
(	O
SCLC	S-Phenotype
)	O
is	O
the	O
most	O
aggressive	O
type	O
of	O
lung	B-Phenotype
cancer	E-Phenotype
.	O

Missense	O
mutations	O
in	O
the	O
human	O
GPI	O
biosynthesis	O
enzyme	O
pigv	O
are	O
associated	O
with	O
a	O
multiple	O
congenital	O
malformation	O
syndrome	O
with	O
a	O
high	O
frequency	O
of	O
Hirschsprung	B-Phenotype
disease	E-Phenotype
and	O
renal	B-Phenotype
anomalies	E-Phenotype
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
the	O
novel	O
insert	O
mutation	O
in	O
the	O
TM2	O
domain	O
of	O
Cx50	O
protein	O
,	O
which	O
impairs	O
its	O
trafficking	O
to	O
the	O
cell	O
membrane	O
and	O
gap	O
-	O
junction	O
function	O
,	O
is	O
associated	O
with	O
the	O
cataract	S-Phenotype
formation	O
in	O
this	O
Chinese	O
pedigree	O

However	O
,	O
the	O
role	O
of	O
YY1	O
in	O
the	O
promotion	O
or	O
suppression	O
of	O
tumor	S-Phenotype
growth	O
remains	O
controversial	O
and	O
its	O
regulatory	O
effects	O
may	O
be	O
tumor	S-Phenotype
cell	O
type	O
dependent	O
at	O
least	O
in	O
experimental	O
systems	O
.	O

Dysregulated	O
miRNAs	O
are	O
involved	O
in	O
various	O
types	O
of	O
human	O
disease	O
,	O
including	O
cancer	S-Phenotype
.	O

p53R2	O
is	O
an	O
independent	O
factor	O
for	O
predicting	O
OS	O
and	O
DFS	O
of	O
cervical	B-Phenotype
cancer	E-Phenotype
patients	O
.	O

Collectively	O
,	O
these	O
findings	O
demonstrate	O
that	O
mutations	O
in	O
DNAJC21	O
cause	O
a	O
cancer	S-Phenotype
-	O
prone	O
BMF	O
syndrome	O
due	O
to	O
corruption	O
of	O
early	O
nuclear	O
rRNA	O
biogenesis	O
and	O
late	O
cytoplasmic	O
maturation	O
of	O
the	O
60S	O
subunit	O

Additional	O
validation	O
efforts	O
and	O
functional	O
studies	O
are	O
warranted	O
to	O
demonstrate	O
whether	O
PAIP2B	O
is	O
a	O
novel	O
tumor	S-Phenotype
suppressor	O
gene	O
and	O
a	O
potential	O
therapeutic	O
target	O
for	O
pancreatic	B-Phenotype
cancer	E-Phenotype

Genome	O
-	O
wide	O
association	O
studies	O
have	O
identified	O
loci	O
at	O
15q25	O
(	O
IREB2	O
)	O
and	O
4q22	O
(	O
FAM13A	O
)	O
,	O
associated	O
with	O
lung	B-Phenotype
cancer	E-Phenotype
(	O
LC	S-Phenotype
)	O
and	O
chronic	B-Phenotype
obstructive	I-Phenotype
pulmonary	I-Phenotype
disease	E-Phenotype
(	O
COPD	S-Phenotype
)	O
.	O

We	O
chose	O
to	O
study	O
UNCL	O
-	O
Sema3E	O
rather	O
than	O
wild	O
type	O
sema3E	O
because	O
unlike	O
full	O
length	O
sema3E	O
,	O
the	O
major	O
p61	O
-	O
Sema3E	O
peptide	O
that	O
is	O
produced	O
by	O
cleavage	O
of	O
sema3E	O
with	O
furin	O
like	O
pro	O
-	O
protein	O
convertases	O
activates	O
signal	O
transduction	O
mediated	O
by	O
the	O
ErbB2	O
receptor	O
and	O
can	O
promote	O
tumor	S-Phenotype
metastasis	O
in	O
addition	O
to	O
its	O
anti	O
-	O
angiogenic	O
activity	O
.	O

Mutations	O
in	O
peripherin	O
2	O
(	O
PRPH2	O
)	O
,	O
also	O
known	O
as	O
retinal	B-Phenotype
degeneration	I-Phenotype
slow	E-Phenotype
/	O
RDS	S-Phenotype
,	O
lead	O
to	O
various	O
retinal	B-Phenotype
degenerations	E-Phenotype
including	O
retinitis	B-Phenotype
pigmentosa	E-Phenotype
(	O
RP	S-Phenotype
)	O
and	O
macular	B-Phenotype
/	I-Phenotype
pattern	I-Phenotype
dystrophy	E-Phenotype
(	O
MD	S-Phenotype
/	O
PD	S-Phenotype
)	O
.	O

In	O
the	O
past	O
5	O
years	O
,	O
we	O
have	O
found	O
that	O
:	O
1	O
)	O
genetic	O
risk	O
variants	O
play	O
major	O
and	O
similar	O
roles	O
in	O
the	O
development	O
of	O
both	O
familial	B-Phenotype
and	I-Phenotype
sporadic	I-Phenotype
fibrotic	I-Phenotype
idiopathic	I-Phenotype
interstitial	I-Phenotype
pneumonia	E-Phenotype
,	O
accounting	O
for	O
up	O
to	O
35	O
%	O
of	O
the	O
risk	O
of	O
idiopathic	B-Phenotype
interstitial	I-Phenotype
pneumonia	E-Phenotype
(	O
a	O
disease	O
that	O
was	O
previously	O
thought	O
to	O
be	O
idiopathic	O
)	O
;	O
2	O
)	O
a	O
promoter	O
variant	O
in	O
MUC5B	O
rs35705950	O
is	O
the	O
strongest	O
risk	O
factor	O
for	O
the	O
development	O
of	O
IIP	O
and	O
IPF	O
;	O
however	O
,	O
rs35705950	O
has	O
a	O
low	O
penetrance	O
;	O
and	O
3	O
)	O
IPF	O
is	O
a	O
complex	O
genetic	O
disease	O
with	O
11	O
independent	O
loci	O
contributing	O
to	O
the	O
development	O
of	O
this	O
disease	O
,	O
pronounced	O
changes	O
in	O
DNA	O
methylation	O
,	O
and	O
transcriptional	O
subtypes	O
.	O

A	O
case	O
with	O
ARX	O
(	O
C.700GAAAAA	O
)	O
had	O
seizure	S-Phenotype
controlled	O
for	O
6	O
mouths	O
.	O

Here	O
,	O
we	O
investigated	O
TBX19	O
mRNA	O
and	O
protein	O
expressions	O
in	O
colon	B-Phenotype
cancer	E-Phenotype
cells	O
or	O
surgically	O
resected	O
CRC	O
.	O

FRG1	O
regulates	O
various	O
muscle	O
-	O
related	O
functions	O
,	O
but	O
studies	O
have	O
proposed	O
its	O
role	O
in	O
development	O
and	O
angiogenesis	O
also	O
,	O
where	O
it	O
is	O
involved	O
with	O
tumor	S-Phenotype
-	O
associated	O
molecules	O
.	O

In	O
primary	O
forms	O
treatment	O
can	O
stop	O
the	O
progression	O
of	O
both	O
SRNS	O
and	O
encephalopathy	S-Phenotype
,	O
hence	O
the	O
critical	O
importance	O
of	O
a	O
prompt	O
diagnosis	O
.	O

Therefore	O
,	O
despite	O
the	O
therapeutic	O
benefits	O
of	O
inhibiting	O
Plk1	O
due	O
to	O
its	O
essential	O
role	O
in	O
tumor	S-Phenotype
cell	O
cycles	O
,	O
Plk1	O
overexpression	O
has	O
tumor	S-Phenotype
-	O
suppressive	O
properties	O
by	O
perturbing	O
mitotic	O
progression	O
and	O
cytokinesis	O

Human	O
autosomal	B-Phenotype
recessive	I-Phenotype
osteopetrosis	E-Phenotype
(	O
ARO	S-Phenotype
)	O
,	O
also	O
known	O
as	O
infantile	B-Phenotype
malignant	I-Phenotype
osteopetrosis	E-Phenotype
,	O
is	O
a	O
rare	O
genetic	O
bone	O
disorder	O
that	O
often	O
causes	O
death	O
.	O

Concurrently	O
,	O
in	O
vivo	O
nude	O
mice	O
experiments	O
also	O
confirmed	O
that	O
upregulation	O
of	O
Kank1	O
expression	O
led	O
to	O
reduced	O
tumor	S-Phenotype
formation	O
in	O
nude	O
mice	O
and	O
significantly	O
reduced	O
tumor	S-Phenotype
volume	O
.	O

Bhlha9	O
-	O
knockout	O
mice	O
showed	O
syndactyly	S-Phenotype
and	O
poliosis	S-Phenotype
in	O
the	O
limb	O
.	O

This	O
validation	O
revealed	O
that	O
the	O
expression	O
of	O
FREM2AAAAAmdash	O
;	O
but	O
not	O
SPRY1AAAAAmdash	O
;	O
is	O
higher	O
in	O
glioblastoma	S-Phenotype
cell	O
lines	O
when	O
compared	O
to	O
non	O
-	O
malignant	O
astrocytes	O
.	O

The	O
major	O
categories	O
of	O
pancreatic	B-Phenotype
neuroendocrine	I-Phenotype
tumor	E-Phenotype
(	O
PanNET	S-Phenotype
)	O
are	O
well	B-Phenotype
-	I-Phenotype
differentiated	I-Phenotype
NET	E-Phenotype
and	O
poorly	B-Phenotype
differentiated	I-Phenotype
neuroendocrine	I-Phenotype
carcinoma	E-Phenotype
.	O

Moreover	O
,	O
we	O
demonstrate	O
that	O
TD	O
-	O
428	O
,	O
which	O
comprises	O
TD	O
-	O
106	O
linked	O
to	O
a	O
BET	O
inhibitor	O
,	O
JQ1	O
efficiently	O
induce	O
BET	O
protein	O
degradation	O
in	O
the	O
prostate	B-Phenotype
cancer	E-Phenotype
cell	O
line	O
22Rv1	O
.	O

We	O
present	O
two	O
cases	O
of	O
patients	O
with	O
a	O
history	O
of	O
renal	O
lithiasis	O
who	O
were	O
diagnosed	O
with	O
primary	O
hyperoxaluria	S-Phenotype
in	O
the	O
post	O
-	O
transplant	O
period	O
,	O
manifested	O
by	O
early	O
graft	O
failure	O
,	O
with	O
evidence	O
of	O
calcium	O
oxalate	O
crystals	O
in	O
renal	O
biopsy	O
,	O
hyperoxaluria	S-Phenotype
,	O
hyperoxalemia	S-Phenotype
,	O
and	O
genetic	O
test	O
compatible	O
;	O
they	O
were	O
managed	O
with	O
proper	O
diet	O
,	O
abundant	O
oral	O
liquids	O
,	O
pyridoxine	O
,	O
hydrochlorothiazide	O
and	O
potassium	O
citrate	O
;	O
however	O
,	O
they	O
had	O
slow	O
but	O
progressive	O
deterioration	O
of	O
their	O
grafts	O
function	O
until	O
they	O
reached	O
end	B-Phenotype
-	I-Phenotype
stage	I-Phenotype
chronic	I-Phenotype
renal	I-Phenotype
disease	E-Phenotype

ADAT3	B-Phenotype
-	I-Phenotype
related	I-Phenotype
intellectual	I-Phenotype
disability	E-Phenotype
has	O
been	O
recently	O
described	O
in	O
24	O
individuals	O
from	O
eight	O
Saudi	O
families	O
who	O
had	O
cognitive	B-Phenotype
impairment	E-Phenotype
and	O
strabismus	S-Phenotype
.	O

To	O
comprehensively	O
characterize	O
the	O
mutational	O
landscape	O
of	O
this	O
tumor	S-Phenotype
type	O
,	O
and	O
to	O
identify	O
possible	O
targets	O
of	O
treatment	O
,	O
we	O
conducted	O
the	O
first	O
large	O
exome	O
sequencing	O
study	O
on	O
a	O
population	O
-	O
based	O
set	O
of	O
SBA	O
samples	O
from	O
all	O
three	O
small	O
bowel	O
segments	O
.	O

We	O
used	O
a	O
genotypic	O
ascertainment	O
study	O
design	O
to	O
test	O
the	O
association	O
of	O
MYO1A	O
variants	O
with	O
hearing	B-Phenotype
loss	E-Phenotype
.	O

It	O
has	O
been	O
reported	O
that	O
N	O
-	O
myc	O
downstream	O
regulated	O
gene	O
1	O
(	O
NDRG1	O
)	O
is	O
related	O
to	O
the	O
prognosis	O
of	O
non	B-Phenotype
-	I-Phenotype
small	I-Phenotype
cell	I-Phenotype
lung	I-Phenotype
cancer	E-Phenotype
(	O
NSCLC	S-Phenotype
)	O
,	O
and	O
associated	O
with	O
c	O
-	O
Myc	O
degradation	O
in	O
NSCLC	S-Phenotype
cell	O
lines	O
.	O

We	O
show	O
that	O
cfap53	O
is	O
required	O
for	O
cilia	O
rotation	O
specifically	O
in	O
Kupffer	O
*	O
s	O
vesicle	O
,	O
the	O
zebrafish	O
laterality	O
organ	O
,	O
providing	O
a	O
mechanism	O
by	O
which	O
patients	O
with	O
CFAP53	O
mutations	O
develop	O
dextrocardia	S-Phenotype
and	O
heterotaxy	S-Phenotype
,	O
and	O
confirming	O
previous	O
evidence	O
that	O
left	O
-	O
right	O
asymmetry	O
in	O
humans	O
is	O
regulated	O
through	O
cilia	O
-	O
driven	O
fluid	O
flow	O
in	O
a	O
laterality	O
organ	O
.	O

Ectodermal	B-Phenotype
dysplasia	I-Phenotype
-	I-Phenotype
9	E-Phenotype
(	O
ED	B-Phenotype
-	I-Phenotype
9	E-Phenotype
)	O
is	O
a	O
congenital	O
condition	O
characterized	O
by	O
hypotrichosis	S-Phenotype
and	O
nail	B-Phenotype
dystrophy	E-Phenotype
without	O
other	O
disorders	O
,	O
and	O
Hoxc13	O
is	O
a	O
pathogenic	O
gene	O
for	O
ED	B-Phenotype
-	I-Phenotype
9	E-Phenotype
.	O

NEK2	O
overexpression	O
promotes	O
tumorigenesis	S-Phenotype
and	O
is	O
associated	O
with	O
poor	O
prognosis	O
in	O
several	O
cancers	S-Phenotype
.	O

Knockdown	O
of	O
SRP72	O
resulted	O
in	O
significant	O
radiosensitization	O
of	O
HeLa	O
(	O
cervical	O
)	O
,	O
PSN	O
-	O
1	O
(	O
pancreatic	O
)	O
,	O
and	O
T24	O
(	O
bladder	O
)	O
,	O
BT	O
-	O
549	O
(	O
breast	O
)	O
and	O
MCF7	O
(	O
breast	O
)	O
tumor	S-Phenotype
lines	O
as	O
measured	O
by	O
colony	O
formation	O
assays	O
.	O

Risdiplam	O
(	O
RG7916	O
;	O
RO7034067	O
)	O
is	O
an	O
orally	O
administered	O
,	O
small	O
-	O
molecule	O
liSMN2	O
/	O
i	O
pre	O
-	O
mRNA	O
splicing	O
modifier	O
that	O
distributes	O
into	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
and	O
peripheral	O
tissues	O
.	O

We	O
found	O
no	O
correlation	O
between	O
the	O
DLEC1	O
,	O
TUSC4	O
and	O
MLH1	O
gene	O
expression	O
and	O
NSCLC	O
patient	O
characteristics	O
(	O
gender	O
,	O
age	O
and	O
smoking	O
)	O
or	O
cancer	S-Phenotype
histopathology	O
.	O

We	O
hypothesized	O
therefore	O
that	O
some	O
children	O
with	O
hypercalciuria	S-Phenotype
and	O
kidney	B-Phenotype
stones	E-Phenotype
harbor	O
a	O
CLDN14	O
variant	O
that	O
inappropriately	O
increases	O
gene	O
expression	O
.	O

We	O
confirmed	O
previous	O
studies	O
showing	O
that	O
tumor	S-Phenotype
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
α	O
)	O
induced	O
reactivation	O
of	O
infectious	O
virus	O
,	O
and	O
by	O
analyzing	O
expression	O
of	O
the	O
progenitor	O
cell	O
marker	O
CD34	O
as	O
well	O
as	O
myeloid	O
cell	O
differentiation	O
markers	O
in	O
IE+	O
cells	O
after	O
treatment	O
with	O
TNF	O
-	O
α	O
,	O
we	O
showed	O
that	O
TNF	O
-	O
α	O
induced	O
transcriptional	O
reactivation	O
of	O
IE	O
gene	O
expression	O
independently	O
of	O
differentiation	O
.	O

Our	O
data	O
suggested	O
that	O
high	O
expression	O
of	O
PAX2	O
could	O
be	O
associated	O
with	O
better	O
survival	O
in	O
estrogen	O
receptor	O
positive	O
tamoxifen	O
-	O
treated	O
breast	B-Phenotype
carcinoma	E-Phenotype
patients	O

CHIME	O
syndrome	O
is	O
a	O
rare	O
autosomal	B-Phenotype
recessive	I-Phenotype
neuroectodermal	I-Phenotype
disorder	E-Phenotype
associated	O
with	O
biallelic	O
mutations	O
in	O
PIGL	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
rs7521902	O
,	O
rs10859871	O
and	O
rs11031006	O
,	O
mapping	O
to	O
WNT4	O
,	O
VEZT	O
and	O
FSHB	O
genetic	O
loci	O
,	O
respectively	O
,	O
are	O
associated	O
with	O
risk	O
for	O
endometriosis	S-Phenotype
in	O
a	O
Greek	O
population	O
.	O

We	O
documented	O
17	O
malignancies	O
,	O
which	O
amounts	O
to	O
a	O
cancer	S-Phenotype
prevalence	O
of	O
12.9	O
%	O
in	O
affected	O
CTLA4	O
mutation	O
carriers	O
.	O

Biallelic	O
mutations	O
in	O
the	O
SBF1	O
gene	O
have	O
been	O
identified	O
in	O
one	O
family	O
with	O
demyelinating	O
Charcot	O
-	O
Marie	O
-	O
Tooth	O
disease	O
(	O
CMT4B3	O
)	O
and	O
two	O
families	O
with	O
axonal	B-Phenotype
neuropathy	E-Phenotype
and	O
additional	O
neurological	O
and	O
skeletal	O
features	O
.	O

Two	O
additional	O
mutations	O
linked	O
to	O
different	O
forms	O
of	O
retinal	B-Phenotype
dystrophies	E-Phenotype
were	O
identified	O
in	O
two	O
families	O
:	O
a	O
known	O
frameshift	O
deletion	O
in	O
RPGR	O
,	O
a	O
gene	O
responsible	O
for	O
X	O
-	O
linked	O
retinitis	S-Phenotype
pigmentosa	O
and	O
p.Ser163Arg	O
in	O
C1QTNF5	O
associated	O
with	O
Late	B-Phenotype
-	I-Phenotype
Onset	I-Phenotype
Retinal	I-Phenotype
Degeneration	E-Phenotype
.	O

These	O
findings	O
reveal	O
that	O
RTTN	O
contributes	O
to	O
building	O
full	O
-	O
length	O
centrioles	O
and	O
illuminate	O
the	O
molecular	O
mechanism	O
through	O
which	O
the	O
RTTN	O
(	O
A578P	O
)	O
mutation	O
causes	O
primary	O
microcephaly.Mutations	S-Phenotype
in	O
many	O
centriolar	O
protein	O
-	O
encoding	O
genes	O
cause	O
primary	B-Phenotype
microcephaly	E-Phenotype
.	O

The	O
results	O
revealed	O
that	O
the	O
most	O
PR	O
-	O
specific	O
proteins	O
were	O
associated	O
with	O
events	O
involved	O
in	O
tumor	S-Phenotype
development	O
,	O
while	O
chemotherapy	O
in	O
the	O
PS	O
group	O
was	O
associated	O
with	O
side	O
effects	O
of	O
drugs	O
and	O
/	O
or	O
cancer	S-Phenotype
recurrence	O
.	O

In	O
genes	O
that	O
regulate	O
cellular	O
pigmentation	O
pathways	O
,	O
including	O
MC1R	O
,	O
ASIP	O
,	O
IRF4	O
,	O
TYR	O
,	O
TYRP1	O
and	O
OCA	O
,	O
there	O
are	O
different	O
common	O
variants	O
that	O
determine	O
complexion	O
traits	O
,	O
and	O
those	O
variants	O
are	O
also	O
associated	O
with	O
different	O
risks	O
of	O
melanoma	S-Phenotype
.	O

The	O
increase	O
copy	O
of	O
CNVR_3425.1	O
forms	O
a	O
new	O
additional	O
truncated	O
FOXF1	O
adjacent	O
non	O
-	O
coding	O
developmental	O
regulatory	O
RNA	O
(	O
FENDRR	O
)	O
sequences	O
comparing	O
the	O
gene	O
promoter	O
and	O
perturbs	O
the	O
transcriptional	O
factors	O
(	O
TFs	O
)	O
binding	O
to	O
the	O
original	O
FENDRR	O
promoter	O
and	O
further	O
downregulates	O
FENDRR	O
,	O
a	O
long	O
intergenic	O
non	O
-	O
coding	O
RNA	O
(	O
lincRNA	O
)	O
that	O
functions	O
to	O
inhibit	O
lung	B-Phenotype
cancer	E-Phenotype
by	O
affecting	O
expressions	O
of	O
an	O
abundant	O
number	O
of	O
genes	O
,	O
including	O
the	O
tumor	S-Phenotype
suppressor	O
FOXF1	O
.	O

These	O
results	O
suggest	O
that	O
DNA	O
methylation	O
signatures	O
may	O
aid	O
in	O
the	O
diagnosis	O
and	O
risk	O
stratification	O
of	O
pediatric	B-Phenotype
rhabdomyosarcoma	E-Phenotype
and	O
help	O
identify	O
new	O
targets	O
for	O
therapy	O

We	O
generated	O
Cc2d1b	O
knockout	O
(	O
KO	O
)	O
,	O
Cc2d1a	O
/	O
1b	O
double	O
heterozygous	O
and	O
double	O
KO	O
mice	O
,	O
then	O
performed	O
behavioral	O
studies	O
to	O
analyze	O
learning	O
and	O
memory	O
,	O
social	O
interactions	O
,	O
anxiety	S-Phenotype
,	O
and	O
hyperactivity	S-Phenotype
.	O

Atypical	B-Phenotype
teratoid	E-Phenotype
/	O
rhabdoid	B-Phenotype
tumors	E-Phenotype
(	O
AT	S-Phenotype
/	O
RT	S-Phenotype
)	O
and	O
renal	B-Phenotype
/	I-Phenotype
extrarenal	I-Phenotype
malignant	I-Phenotype
rhabdoid	I-Phenotype
tumors	E-Phenotype
of	O
childhood	B-Phenotype
,	I-Phenotype
epithelioid	I-Phenotype
sarcoma	E-Phenotype
and	O
small	B-Phenotype
cell	I-Phenotype
carcinoma	I-Phenotype
of	I-Phenotype
the	I-Phenotype
ovary	I-Phenotype
,	I-Phenotype
hypercalcemic	I-Phenotype
type	E-Phenotype
(	O
SCCOHT	S-Phenotype
)	O
represent	O
the	O
most	O
commonly	O
recognized	O
SWI	O
/	O
SNF	O
-	O
driven	O
neoplasms	S-Phenotype
.	O

This	O
includes	O
unaffected	O
women	O
who	O
have	O
completed	O
their	O
family	O
and	O
have	O
RAD51C	O
,	O
RAD51D	O
,	O
or	O
BRIP1	O
gene	O
mutations	O
;	O
first	O
-	O
degree	O
relatives	O
of	O
women	O
with	O
invasive	B-Phenotype
epithelial	I-Phenotype
ovarian	I-Phenotype
cancer	E-Phenotype
;	O
BRCA	O
mutation	O
-	O
negative	O
women	O
from	O
high	O
-	O
risk	O
breast	B-Phenotype
-	I-Phenotype
and	I-Phenotype
-	I-Phenotype
ovarian	I-Phenotype
cancer	E-Phenotype
or	O
ovarian	O
-	O
cancer	S-Phenotype
-	O
only	O
families	O
.	O

A	O
number	O
of	O
studies	O
report	O
that	O
miRNAs	O
are	O
involved	O
in	O
homeostatic	O
maintenance	O
such	O
as	O
cell	O
cycle	O
regulation	O
,	O
cell	O
division	O
and	O
apoptosis	O
,	O
and	O
that	O
aberrant	O
expression	O
of	O
miRNAs	O
is	O
often	O
detected	O
in	O
various	O
types	O
of	O
diseases	O
,	O
including	O
cancer	S-Phenotype
.	O

A	O
growing	O
body	O
of	O
literature	O
indicates	O
that	O
YY1	O
is	O
overexpressed	O
in	O
multiple	O
cancer	S-Phenotype
types	O
and	O
that	O
increased	O
YY1	O
levels	O
correlate	O
with	O
poor	O
clinical	O
outcomes	O
in	O
many	O
cancers	S-Phenotype
.	O

RESULTS	O
There	O
was	O
an	O
increased	O
expression	O
of	O
ALG3	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
tissues	O
compared	O
to	O
normal	O
breast	O
tissues	O
(	O
pAAAA0.05	O
)	O
.	O

Mutations	O
in	O
the	O
X	O
-	O
linked	O
gene	O
CNKSR2	O
have	O
been	O
described	O
in	O
patients	O
with	O
seizures	S-Phenotype
and	O
neurodevelopmental	O
deficits	O
,	O
especially	O
those	O
affecting	O
language	O
.	O

LTBP4	O
was	O
identified	O
as	O
a	O
genetic	O
modifier	O
of	O
muscular	B-Phenotype
dystrophy	E-Phenotype
in	O
mice	O
and	O
humans	O
.	O

The	O
subcapsular	O
mass	O
-	O
forming	O
tumor	S-Phenotype
was	O
composed	O
of	O
poorly	O
differentiated	O
tumor	S-Phenotype
cells	O
arranged	O
in	O
small	O
vague	O
glandular	O
or	O
slit	O
-	O
lumen	O
nests	O
,	O
and	O
focally	O
fused	O
or	O
anastomosing	O
large	O
trabecular	O
patterns	O
within	O
the	O
prominent	O
fibrotic	O
stroma	O
.	O

Disruption	O
of	O
Sema3C	O
induced	O
apoptosis	O
of	O
GSCs	O
,	O
but	O
not	O
NPCs	O
or	O
NSTCs	O
,	O
and	O
suppressed	O
tumor	S-Phenotype
growth	O
in	O
orthotopic	O
models	O
of	O
glioblastoma	S-Phenotype
.	O

There	O
are	O
two	O
different	O
phenotypes	O
of	O
patients	O
with	O
TTC7A	O
mutations	O
:	O
the	O
severe	O
form	O
,	O
caused	O
by	O
null	O
mutations	O
and	O
leading	O
to	O
the	O
classical	O
MIA	O
-	O
CID	O
;	O
and	O
the	O
mild	O
form	O
,	O
caused	O
by	O
missense	O
mutations	O
and	O
leading	O
to	O
predominant	O
features	O
of	O
VEO	O
-	O
IBD	O
,	O
less	O
severe	O
immunological	O
involvement	O
and	O
hair	B-Phenotype
abnormalities	E-Phenotype
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
genetic	O
inactivation	O
of	O
Prss56	O
rescues	O
axial	O
elongation	O
in	O
a	O
mouse	O
model	O
of	O
myopia	S-Phenotype
caused	O
by	O
a	O
null	O
mutation	O
in	O
Egr1	O
.	O

We	O
report	O
on	O
two	O
children	O
,	O
displaying	O
intellectual	B-Phenotype
disability	E-Phenotype
(	O
ID	S-Phenotype
)	O
and	O
peculiar	O
congenital	O
eyes	O
anomalies	O
,	O
both	O
carrying	O
a	O
de	O
novo	O
nonsense	O
mutation	O
in	O
the	O
ADNP	O
gene	O
.	O

Additionally	O
,	O
multivariate	O
logistic	O
regression	O
analysis	O
identified	O
that	O
the	O
mutant	O
genotype	O
of	O
rs4148323	O
in	O
the	O
UGT1A1	O
gene	O
,	O
ABO	O
incompatibility	O
,	O
G6PD	O
deficiency	O
,	O
and	O
SS	O
genotype	O
at	O
rs1805173	O
locus	O
of	O
the	O
HO	O
-	O
1	O
gene	O
were	O
genetic	O
risk	O
factors	O
of	O
neonatal	B-Phenotype
hyperbilirubinemia	E-Phenotype
.	O

In	O
recent	O
years	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
NgBR	O
plays	O
an	O
important	O
role	O
in	O
human	O
pathophysiological	O
processes	O
,	O
including	O
lipid	O
metabolism	O
,	O
angiogenesis	O
,	O
N	O
-	O
glycosylation	O
,	O
cell	O
apoptosis	O
,	O
chemoresistance	O
in	O
human	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
,	O
and	O
epithelial	O
-	O
mesenchymal	O
transition	O
.	O

Furthermore	O
,	O
we	O
performed	O
in	O
vitro	O
assays	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
,	O
and	O
our	O
results	O
indicated	O
that	O
DCLRE1B	O
,	O
MRPS30	O
,	O
and	O
ATG10	O
played	O
a	O
vital	O
role	O
in	O
breast	B-Phenotype
tumorigenesis	E-Phenotype
via	O
certain	O
disruption	O
of	O
cell	O
behaviors	O
.	O

Cis	O
-	O
eQTL	O
was	O
observed	O
for	O
several	O
SNPs	O
in	O
blood	O
/	O
transformed	O
fibroblasts	O
but	O
not	O
in	O
RCC	O
tumor	S-Phenotype
tissues	O
.	O

High	O
grade	O
transformation	O
cases	O
were	O
analysed	O
,	O
the	O
high	O
grade	O
SCSG	O
components	O
showed	O
a	O
significantly	O
increased	O
Ki	O
-	O
67	O
index	O
and	O
cyclin	O
D1	O
positive	O
tumor	S-Phenotype
cells	O
compared	O
to	O
the	O
conventional	O
SCSG	O
components	O
.	O

The	O
reported	O
hypertrophic	B-Phenotype
cardiomyopathy	E-Phenotype
relevant	O
genes	O
MYPN	O
,	O
MYH6	O
and	O
MYBP3	O
had	O
also	O
been	O
found	O
in	O
case	O
1	O
and	O
2	O
.	O

The	O
WDR4	O
/	O
PML	O
axis	O
induces	O
a	O
set	O
of	O
cell	O
-	O
surface	O
or	O
secreted	O
factors	O
,	O
including	O
CD73	O
,	O
urokinase	O
-	O
type	O
plasminogen	O
activator	O
receptor	O
(	O
uPAR	O
)	O
,	O
and	O
serum	O
amyloid	O
A2	O
(	O
SAA2	O
)	O
,	O
which	O
elicit	O
paracrine	O
effects	O
to	O
stimulate	O
migration	O
,	O
invasion	O
,	O
and	O
metastasis	O
in	O
multiple	O
lung	B-Phenotype
cancer	E-Phenotype
models	O
.	O

Pathway	O
analyses	O
demonstrated	O
that	O
methylation	O
levels	O
associated	O
with	O
age	O
and	O
BMI	O
are	O
overrepresented	O
among	O
genes	O
involved	O
in	O
cancer	S-Phenotype
,	O
type	B-Phenotype
2	I-Phenotype
diabetes	E-Phenotype
and	O
cardiovascular	B-Phenotype
disease	E-Phenotype
.	O

Several	O
recent	O
studies	O
applied	O
targeted	O
genome	O
enrichment	O
(	O
TGE	O
)	O
and	O
massively	O
parallel	O
sequencing	O
(	O
MPS	O
)	O
to	O
simultaneously	O
screen	O
a	O
large	O
set	O
of	O
known	O
hearing	B-Phenotype
loss	E-Phenotype
(	O
HL	S-Phenotype
)	O
genes	O
.	O

Mutations	O
in	O
LINS1	O
were	O
suspected	O
in	O
this	O
non	O
-	O
syndromic	O
ID	O
case	O
with	O
mutism	S-Phenotype
.	O

Idiopathic	B-Phenotype
hypogonadotropic	I-Phenotype
hypogonadism	E-Phenotype
(	O
IHH	S-Phenotype
)	O
is	O
often	O
caused	O
by	O
hyposecretion	O
of	O
gonadotropin	O
and	O
consequently	O
affects	O
male	O
fertility	O
.	O

For	O
this	O
,	O
KLK4	O
protein	O
expression	O
was	O
assessed	O
by	O
immunohistochemistry	O
in	O
primary	O
tumor	S-Phenotype
tissue	O
sections	O
(	O
tissue	O
microarrays	O
)	O
of	O
188	O
TNBC	O
patients	O
,	O
mainly	O
treated	O
with	O
anthracycline	O
-	O
or	O
CMF	O
-	O
based	O
polychemotherapy	O
.	O

The	O
pathological	O
diagnosis	O
of	O
the	O
resected	O
specimen	O
was	O
FGP	O
with	O
HGD	O
mixed	O
in	O
LGD	O
,	O
with	O
no	O
invasive	O
carcinoma	S-Phenotype
.	O

In	O
conclusion	O
,	O
SIRT1	O
enabled	O
HPV	O
-	O
infected	O
cervical	B-Phenotype
cancer	E-Phenotype
cells	O
to	O
continue	O
growing	O
by	O
nullifying	O
AIM2	O
inflammasome	O
-	O
mediated	O
immunity	O
.	O

Co	O
-	O
immunoprecipitation	O
experiments	O
identified	O
associations	O
of	O
β	O
-	O
catenin	O
with	O
p120	O
-	O
catenin	O
isoforms	O
in	O
PhIP	O
-	O
induced	O
skin	B-Phenotype
tumors	E-Phenotype
and	O
human	O
cancer	S-Phenotype
cell	O
lines	O
.	O

His	O
distinctive	O
facial	O
and	O
digital	O
features	O
are	O
further	O
evidence	O
that	O
p.Tyr446Cys	O
results	O
in	O
a	O
clinically	O
recognizable	O
,	O
syndromic	O
form	O
of	O
intellectual	B-Phenotype
disability	E-Phenotype
in	O
contrast	O
to	O
other	O
TBL1XR1	O
mutations	O

Somatic	O
defects	O
at	O
five	O
loci	O
,	O
WT1	O
,	O
CTNNB1	O
,	O
WTX	O
,	O
TP53	O
and	O
the	O
imprinted	O
11p15	O
region	O
,	O
are	O
implicated	O
in	O
Wilms	B-Phenotype
tumor	E-Phenotype
,	O
the	O
commonest	O
childhood	O
kidney	B-Phenotype
cancer	E-Phenotype
.	O

The	O
zinc	O
transporter	O
SLC39A4	O
influences	O
epithelial	O
cell	O
morphology	O
and	O
migration	O
in	O
various	O
cancers	S-Phenotype
;	O
however	O
,	O
its	O
role	O
in	O
regulating	O
cell	O
invasion	O
and	O
chemotherapeutic	O
resistance	O
in	O
human	O
lung	B-Phenotype
cancer	E-Phenotype
is	O
not	O
yet	O
clear	O
.	O

With	O
this	O
data	O
-	O
driven	O
weighting	O
procedure	O
the	O
LRT	O
detected	O
significant	O
signal	O
in	O
genes	O
located	O
in	O
regions	O
already	O
confirmed	O
as	O
associated	O
with	O
schizophrenia	S-Phenotype
-	O
the	O
PRRC2A	O
(	O
p	O
=	O
1.020e	O
-	O
06	O
)	O
and	O
the	O
VARS2	O
(	O
p	O
=	O
2.383e	O
-	O
06	O
)	O
-	O
in	O
the	O
Swedish	O
schizophrenia	S-Phenotype
case	O
-	O
control	O
cohort	O
of	O
11,040	O
individuals	O
with	O
exome	O
-	O
sequencing	O
data	O
.	O

The	O
aims	O
of	O
the	O
present	O
study	O
were	O
to	O
evaluate	O
the	O
relation	O
of	O
dysregulated	O
MACC1	O
,	O
c	O
-	O
MET	O
,	O
and	O
NM23	O
-	O
H1	O
expression	O
with	O
the	O
histopathological	O
features	O
of	O
tumors	S-Phenotype
in	O
recurrence	O
formation	O
in	O
eCC	O
cases	O
.	O

The	O
ability	O
of	O
OX40	O
to	O
promote	O
proliferation	O
and	O
differentiation	O
of	O
activated	O
T	O
cells	O
fueled	O
present	O
attempts	O
to	O
modulate	O
this	O
immune	O
checkpoint	O
to	O
reinforce	O
antitumor	O
immunity	S-Phenotype
.	O

Progressive	B-Phenotype
multifocal	I-Phenotype
leukoencephalopathy	E-Phenotype
(	O
PML	S-Phenotype
)	O
is	O
a	O
lethal	O
brain	O
disease	O
caused	O
by	O
uncontrolled	O
replication	O
of	O
JC	O
polyomavirus	O
(	O
JCV	O
)	O
.	O

We	O
report	O
a	O
case	O
of	O
ALK	B-Phenotype
-	I-Phenotype
positive	I-Phenotype
renal	I-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
coincident	O
with	O
Hodgkin	B-Phenotype
lymphoma	E-Phenotype
.	O

Promoter	O
CpG	O
island	O
hypermethylation	O
is	O
an	O
important	O
mechanism	O
for	O
inactivating	O
key	O
cellular	O
enzymes	O
that	O
mediate	O
epigenetic	O
processes	O
in	O
hepatitis	B-Phenotype
-	I-Phenotype
related	I-Phenotype
hepatocellular	I-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
.	O

Our	O
results	O
indicate	O
that	O
testing	O
for	O
SLX4	O
germline	O
mutations	O
is	O
unlikely	O
to	O
be	O
relevant	O
for	O
the	O
identification	O
of	O
individuals	O
at	O
risk	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
,	O
at	O
least	O
in	O
the	O
Italian	O
population	O

Our	O
findings	O
show	O
that	O
DPM3	O
mutations	O
may	O
lead	O
to	O
an	O
isolated	B-Phenotype
and	I-Phenotype
mild	I-Phenotype
limb	I-Phenotype
girdle	I-Phenotype
muscular	I-Phenotype
dystrophy	E-Phenotype
phenotype	O
without	O
cardiomyopathy	S-Phenotype

In	O
contrast	O
,	O
patients	O
with	O
the	O
non	O
-	O
hereditary	O
Carney	O
triad	O
,	O
including	O
paraganglioma	S-Phenotype
,	O
GIST	O
,	O
and	O
pulmonary	B-Phenotype
chondroma	E-Phenotype
,	O
usually	O
lack	O
germline	O
SDH	O
mutations	O
and	O
instead	O
show	O
epigenetic	O
SDH	O
complex	O
inactivation	O
through	O
SDHC	O
promoter	O
methylation	O
.	O

It	O
was	O
our	O
aim	O
to	O
investigate	O
behavioral	O
and	O
obesity	S-Phenotype
effects	O
evoked	O
by	O
treatment	O
with	O
probiotics	O
via	O
neuroinflammatory	O
factors	O
and	O
namely	O
IL	O
-	O
1b	O
,	O
NLRP3	O
,	O
Caspase	O
-	O
1	O
and	O
NF	O
-	O
kB	O
levels	O
in	O
the	O
Syrian	O
golden	O
hamster	O
.	O

Recent	O
advances	O
in	O
whole	O
exome	O
sequencing	O
technology	O
show	O
promise	O
for	O
further	O
elucidation	O
of	O
disease	O
causing	O
variants	O
as	O
in	O
the	O
recent	O
identification	O
of	O
rare	O
variants	O
within	O
ZNF644	O
segregating	O
with	O
pathological	B-Phenotype
myopia	E-Phenotype
.	O

Mutations	O
in	O
the	O
ALS5	O
/	O
SPG11	O
/	O
KIAA1840	O
gene	O
are	O
a	O
frequent	O
cause	O
of	O
autosomal	B-Phenotype
recessive	I-Phenotype
hereditary	I-Phenotype
spastic	I-Phenotype
paraplegia	E-Phenotype
with	O
thin	B-Phenotype
corpus	I-Phenotype
callosum	E-Phenotype
and	O
peripheral	B-Phenotype
axonal	I-Phenotype
neuropathy	E-Phenotype
,	O
and	O
account	O
for	O
a	O
40	O
%	O
of	O
autosomal	B-Phenotype
recessive	I-Phenotype
juvenile	I-Phenotype
amyotrophic	I-Phenotype
lateral	I-Phenotype
sclerosis	E-Phenotype
.	O

PRA	O
has	O
been	O
reported	O
in	O
dogs	O
from	O
more	O
than	O
100	O
breeds	O
and	O
can	O
be	O
genetically	O
heterogeneous	S-Phenotype
both	O
between	O
and	O
within	O
breeds	O
.	O

Taken	O
together	O
,	O
expression	O
of	O
clock	O
and	O
clock	O
-	O
controlled	O
genes	O
in	O
tumors	S-Phenotype
of	O
males	O
and	O
females	O
clustered	O
according	O
to	O
presence	O
of	O
distant	O
metastases	O
correlated	O
with	O
survival	O
analysis	O
.	O

VLCFA	O
-	O
containing	O
lipids	O
accumulate	O
in	O
X	O
-	O
ALD	O
patients	O
,	O
although	O
the	O
effect	O
of	O
ABCD1	O
-	O
deficiency	O
on	O
each	O
lipid	O
species	O
in	O
the	O
central	O
nervous	O
system	O
has	O
not	O
been	O
fully	O
characterized	O
.	O

These	O
results	O
suggest	O
that	O
MAFB	O
and	O
MAFF	O
play	O
critical	O
roles	O
in	O
the	O
antitumor	O
effects	S-Phenotype
of	O
retinoids	O
by	O
regulating	O
the	O
expression	O
of	O
retinoid	O
target	O
genes	O
such	O
as	O
TFPI2	O
and	O
can	O
be	O
promising	O
for	O
developing	O
therapies	O
to	O
combat	O
HCC	O
invasion	O

Hereby	O
,	O
we	O
describe	O
a	O
18	O
months	O
old	O
girl	O
presenting	O
with	O
trigonocephaly	S-Phenotype
and	O
dysmorphic	B-Phenotype
facial	I-Phenotype
features	E-Phenotype
,	O
including	O
hypotelorism	S-Phenotype
,	O
broad	B-Phenotype
depressed	I-Phenotype
nasal	I-Phenotype
bridge	E-Phenotype
,	O
micrognathia	S-Phenotype
,	O
synophrys	S-Phenotype
,	O
epicanthal	B-Phenotype
folds	E-Phenotype
,	O
and	O
with	O
a	O
stage	O
4	O
neuroblastoma	S-Phenotype
without	O
MYCN	O
amplification	O
,	O
carrying	O
a	O
germline	O
11q	O
deletion	O
(	O
11q14.1	O
-	O
q22.3	O
)	O
,	O
outside	O
from	O
Jacobsen	O
syndrome	O
and	O
from	O
neuroblastoma	S-Phenotype
11q	O
critical	O
regions	O
.	O

Increased	O
expression	O
of	O
MLF1	O
was	O
observed	O
in	O
neuroblastoma	S-Phenotype
cells	O
homozygous	O
for	O
the	O
rs6441201	O
risk	O
allele	O
(	O
P	O
=	O
0.02	O
)	O
,	O
and	O
significant	O
growth	O
inhibition	O
was	O
observed	O
upon	O
depletion	O
of	O
MLF1	O
(	O
P	O
AAAA	O
0.0001	O
)	O
in	O
neuroblastoma	S-Phenotype
cells	O
.	O

Patients	O
with	O
high	O
p53R2	O
expression	O
have	O
a	O
shorter	O
overall	O
survival	O
(	O
OS	O
)	O
and	O
disease	O
-	O
free	O
survival	O
(	O
DFS	O
)	O
.	O

In	O
this	O
review	O
,	O
we	O
describe	O
the	O
clinical	O
and	O
experimental	O
evidence	O
for	O
the	O
role	O
of	O
the	O
CaSR	O
in	O
colonic	B-Phenotype
inflammation	E-Phenotype
and	O
colorectal	B-Phenotype
cancer	E-Phenotype
,	O
the	O
intracellular	O
signalling	O
pathways	O
which	O
are	O
putatively	O
involved	O
in	O
these	O
actions	O
,	O
and	O
the	O
possibilities	O
to	O
exploit	O
these	O
actions	O
of	O
the	O
CaSR	O
for	O
future	O
therapies	O
of	O
colonic	B-Phenotype
inflammation	I-Phenotype
and	I-Phenotype
cancer	E-Phenotype

Here	O
,	O
we	O
show	O
that	O
ablating	O
or	O
silencing	O
the	O
transcription	O
factor	O
Nfix	O
ameliorates	O
pathology	O
in	O
several	O
forms	O
of	O
muscular	B-Phenotype
dystrophy	E-Phenotype
.	O

CDKN1C	O
,	O
also	O
known	O
as	O
p57kip2	O
,	O
is	O
considered	O
to	O
be	O
a	O
potential	O
tumor	S-Phenotype
suppressor	O
implicated	O
in	O
several	O
kinds	O
of	O
human	O
cancers	S-Phenotype
.	O

TRAPPC9	O
gene	O
mutations	O
have	O
been	O
linked	O
recently	O
to	O
autosomal	B-Phenotype
recessive	I-Phenotype
mental	I-Phenotype
retardation	I-Phenotype
13	E-Phenotype
(	O
MRT13	S-Phenotype
;	O
MIM	O
#	O
613192	O
)	O
with	O
only	O
eight	O
families	O
reported	O
world	O
-	O
wide	O
.	O

The	O
trichorhinophalangeal	O
syndrome	O
is	O
a	O
rare	O
genetic	O
syndrome	O
with	O
characteristic	B-Phenotype
craniofacial	E-Phenotype
and	O
skeletal	B-Phenotype
abnormalities	E-Phenotype
including	O
hip	O
pathology	O
in	O
variable	O
manifestation	O
.	O

In	O
subgroup	O
analysis	O
,	O
compared	O
with	O
PD	O
patients	O
with	O
initial	O
symptom	O
of	O
tremor	S-Phenotype
and	O
HCs	O
,	O
the	O
minor	O
allele	O
frequency	O
of	O
NMD3	O
rs34016896	O
in	O
PD	O
patients	O
with	O
initial	O
symptoms	O
of	O
rigidity	S-Phenotype
/	O
bradykinesia	S-Phenotype
was	O
significantly	O
lower	O
.	O

The	O
more	O
common	O
member	O
of	O
this	O
family	B-Phenotype
,	I-Phenotype
intraductal	I-Phenotype
papillary	I-Phenotype
mucinous	I-Phenotype
neoplasm	E-Phenotype
,	O
often	O
carries	O
genetic	O
alterations	O
typical	O
of	O
pancreatic	O
infiltrating	O
ductal	O
adenocarcinoma	O
(	O
KRAS	O
,	O
TP53	O
,	O
and	O
CDKN2A	O
)	O
but	O
additionally	O
has	O
mutations	O
in	O
GNAS	O
and	O
RNF43	O
genes	O
.	O

Intracerebroventricular	O
infusion	O
of	O
Hm1a	O
rescues	O
Dravet	O
syndrome	O
mice	O
from	O
seizures	S-Phenotype
and	O
premature	B-Phenotype
death	E-Phenotype
.	O

Mutations	O
in	O
SLC4A11	O
,	O
a	O
Na+	O
dependent	O
OH	O
-	O
transporter	O
,	O
cause	O
congenital	B-Phenotype
hereditary	I-Phenotype
endothelial	I-Phenotype
dystrophy	E-Phenotype
(	O
CHED	S-Phenotype
)	O
and	O
Fuchs	B-Phenotype
'	I-Phenotype
endothelial	I-Phenotype
corneal	I-Phenotype
dystrophy	E-Phenotype
(	O
FECD	S-Phenotype
)	O
,	O
the	O
two	O
most	O
common	O
forms	O
of	O
endothelial	B-Phenotype
degeneration	E-Phenotype
.	O

We	O
previously	O
found	O
that	O
spinal	O
cord	O
and	O
muscle	O
,	O
organs	O
involved	O
in	O
either	O
ALS	O
or	O
distal	S-Phenotype
myopathy	S-Phenotype
,	O
have	O
relatively	O
lower	O
levels	O
of	O
Matrin	O
3	O
compared	O
to	O
the	O
brain	O
and	O
other	O
peripheral	O
organs	O
in	O
the	O
murine	O
system	O
.	O

By	O
way	O
of	O
whole	O
-	O
exome	O
sequencing	O
,	O
we	O
identified	O
a	O
homozygous	O
missense	O
mutation	O
in	O
VARS2	O
in	O
one	O
subject	O
with	O
microcephaly	S-Phenotype
and	O
epilepsy	S-Phenotype
associated	O
with	O
isolated	O
deficiency	O
of	O
the	O
mitochondrial	S-Phenotype
respiratory	O
chain	O
(	O
MRC	O
)	O
complex	O
I	O
and	O
compound	O
heterozygous	O
mutations	O
in	O
TARS2	O
in	O
two	O
siblings	O
presenting	O
with	O
axial	S-Phenotype
hypotonia	S-Phenotype
and	O
severe	O
psychomotor	B-Phenotype
delay	E-Phenotype
associated	O
with	O
multiple	O
MRC	B-Phenotype
defects	E-Phenotype
.	O

An	O
analysis	O
approach	O
combing	O
supervised	O
significant	O
analysis	O
of	O
microarray	O
(	O
SAM	O
)	O
,	O
prediction	O
analysis	O
of	O
microarray	O
(	O
PAM	O
)	O
,	O
and	O
unsupervised	O
hierarchical	O
cluster	O
methodologies	O
statistically	O
determined	O
211	O
upregulated	O
and	O
78	O
downregulated	O
genes	O
between	O
liver	B-Phenotype
cancer	E-Phenotype
and	O
non	O
-	O
cancer	S-Phenotype
liver	O
tissues	O
,	O
and	O
demonstrated	O
AAAA	O
or	O
=	O
93	O
%	O
accuracy	O
in	O
classifying	O
the	O
tissue	O
samples	O
.	O

Haplotype	O
GAT	O
for	O
GRM6	O
markers	O
rs2067011	O
-	O
rs2645339	O
-	O
rs762724	O
showed	O
significance	O
(	O
P=0.0239	O
)	O
,	O
but	O
such	O
association	O
did	O
not	O
remain	O
significant	O
after	O
multiple	O
testing	O
corrections	O
.	O

Conclusions	O
Our	O
data	O
suggested	O
that	O
genetic	O
variants	O
in	O
GRM6	O
are	O
associated	O
with	O
high	B-Phenotype
myopia	E-Phenotype
.	O

Here	O
,	O
we	O
identify	O
tumor	S-Phenotype
-	O
associated	O
calcium	O
signal	O
transducer	O
2	O
(	O
TACSTD2	O
)	O
,	O
one	O
of	O
the	O
most	O
downregulated	O
genes	O
in	O
primary	O
HCC	O
tissue	O
,	O
as	O
a	O
host	O
factor	O
that	O
interacts	O
with	O
CLDN1	O
and	O
OCLN	O
and	O
regulates	O
their	O
cellular	O
localization	O
.	O

NGLY1	O
patients	O
produce	O
little	O
or	O
no	O
N	O
-	O
glycanase	O
(	O
Ngly1	O
)	O
,	O
and	O
the	O
symptoms	O
include	O
global	B-Phenotype
developmental	I-Phenotype
delay	E-Phenotype
,	O
frequent	O
seizures	S-Phenotype
,	O
complex	O
hyperkinetic	B-Phenotype
movement	E-Phenotype
disorder	O
,	O
difficulty	B-Phenotype
in	I-Phenotype
swallowing	I-Phenotype
/	I-Phenotype
aspiration	E-Phenotype
,	O
liver	B-Phenotype
dysfunction	E-Phenotype
,	O
and	O
a	B-Phenotype
lack	I-Phenotype
of	I-Phenotype
tears	E-Phenotype
.	O

Mutations	O
in	O
the	O
human	O
TRNT1	O
gene	O
encoding	O
tRNA	O
nucleotidyltransferase	O
(	O
tRNA	O
-	O
NT	O
)	O
,	O
an	O
essential	O
enzyme	O
responsible	O
for	O
addition	O
of	O
the	O
CCA	O
(	O
cytidine	O
-	O
cytidine	O
-	O
adenosine	O
)	O
sequence	O
to	O
the	O
3	O
'	O
-	O
termini	O
of	O
tRNAs	O
,	O
have	O
been	O
linked	O
to	O
disease	O
phenotypes	O
including	O
congenital	B-Phenotype
sideroblastic	I-Phenotype
anemia	E-Phenotype
with	O
B	B-Phenotype
-	I-Phenotype
cell	I-Phenotype
immunodeficiency	E-Phenotype
,	O
periodic	B-Phenotype
fevers	E-Phenotype
and	O
developmental	B-Phenotype
delay	E-Phenotype
(	O
SIFD	S-Phenotype
)	O
or	O
retinitis	B-Phenotype
pigmentosa	E-Phenotype
with	O
erythrocyte	B-Phenotype
microcytosis	E-Phenotype
.	O

Additionally	O
,	O
despite	O
GDAP1	O
affecting	O
mitochondrial	O
functionality	O
,	O
and	O
hence	O
being	O
of	O
great	O
importance	O
to	O
cellular	O
function	O
,	O
the	O
GDAP1‑associated	O
Charcot	O
-	O
Marie	O
-	O
Tooth	O
disease	O
is	O
mainly	O
characterized	O
by	O
axonal	B-Phenotype
degeneration	E-Phenotype
.	O

CIB2	O
and	O
GJB2	O
genes	O
variants	O
contribute	O
significantly	O
in	O
familial	O
cases	O
of	O
prelingual	O
recessive	O
hearing	B-Phenotype
loss	E-Phenotype
(	O
HL	S-Phenotype
)	O
.	O

Methods	O
We	O
identified	O
all	O
materials	O
published	O
mentioning	O
both	O
SAg	O
and	O
allergic	B-Phenotype
rhinitis	E-Phenotype
(	O
AR	S-Phenotype
)	O
,	O
chronic	B-Phenotype
sinusitis	E-Phenotype
,	O
asthma	S-Phenotype
,	O
and	O
atopic	B-Phenotype
dermatitis	E-Phenotype
(	O
AD	S-Phenotype
)	O
that	O
are	O
indexed	O
on	O
PubMed	O
,	O
Google	O
,	O
or	O
the	O
ProQuest	O
Central	O
databases	O
.	O

One	O
important	O
line	O
of	O
evidence	O
comes	O
from	O
genetic	O
studies	O
,	O
which	O
have	O
repeatedly	O
detected	O
an	O
association	O
between	O
the	O
neuronal	O
isoform	O
of	O
nitric	O
oxide	O
synthase	O
(	O
nNOS	O
or	O
NOS1	O
)	O
and	O
schizophrenia	S-Phenotype
.	O

Some	O
of	O
the	O
genes	O
causing	O
the	O
Fanconi	B-Phenotype
anemia	E-Phenotype
(	O
FA	S-Phenotype
)	O
syndrome	O
,	O
such	O
as	O
BRCA2	O
,	O
BRIP1	O
,	O
PALB2	O
,	O
and	O
RAD51C	O
,	O
are	O
associated	O
with	O
high	O
or	O
moderate	O
risk	O
of	O
developing	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

Heritability	O
-	O
based	O
analyses	O
are	O
demonstrating	O
strong	O
links	O
between	O
migraine	S-Phenotype
and	O
other	O
neuropsychiatric	O
disorders	O
and	O
brain	O
phenotypes	O
,	O
highlighting	O
genetic	O
links	O
between	O
migraine	S-Phenotype
and	O
major	O
depressive	B-Phenotype
disorder	E-Phenotype
and	O
attention	B-Phenotype
-	I-Phenotype
deficit	I-Phenotype
hyperactivity	E-Phenotype
disorder	O
,	O
among	O
others	O
.	O

We	O
identified	O
CpG	O
loci	O
and	O
regions	O
consistently	O
hyper	O
-	O
methylated	O
throughout	O
the	O
serrated	O
carcinogenesis	O
spectrum	O
,	O
in	O
both	O
our	O
SSA	O
/	O
P	O
specimens	O
and	O
in	O
serrated	B-Phenotype
cancers	E-Phenotype
.	O

These	O
changes	O
were	O
accompanied	O
by	O
cortical	B-Phenotype
atrophy	E-Phenotype
as	O
well	O
as	O
increased	O
expression	O
of	O
angiogenesis	O
-	O
related	O
genes	O
such	O
as	O
Vegfa	O
,	O
Serpine1	O
,	O
and	O
Plau	O
in	O
CD31	O
-	O
positive	O
endothelial	O
cells	O
.	O

bResults	O
:	O
/	O
b	O
Immunohistochemistry	O
results	O
showed	O
that	O
the	O
percentages	O
of	O
Twist2	O
expression	O
in	O
glioma	S-Phenotype
was	O
90	O
%	O
(	O
54	O
/	O
60	O
)	O
compared	O
with	O
30	O
%	O
(	O
6	O
/	O
20	O
)	O
in	O
non	O
-	O
tumor	S-Phenotype
brain	O
tissues	O
(	O
liP	O
/	O
iAAAA0.01	O
)	O
.	O

Therefore	O
,	O
we	O
performed	O
this	O
preliminary	O
clinical	O
study	O
to	O
investigate	O
the	O
possible	O
association	O
between	O
2	O
adipokines	O
,	O
C1q	O
/	O
tumor	S-Phenotype
necrosis	O
factor	O
-	O
related	O
protein	O
-	O
3	O
and	O
-	O
5	O
(	O
CTRP	O
-	O
3	O
and	O
CTRP	O
-	O
5	O
)	O
,	O
with	O
lung	O
function	O
and	O
other	O
markers	O
of	O
inflammation	O
in	O
COPD	O
.	O

However	O
,	O
the	O
exact	O
compounds	O
of	O
areca	O
nut	O
causing	O
oral	B-Phenotype
cancer	E-Phenotype
remain	O
unproven	O
.	O

Zyxin	O
regulates	O
YAP	O
activity	O
through	O
the	O
colon	B-Phenotype
cancer	E-Phenotype
oncogene	O
CDK8	O
.	O

This	O
disorder	O
shows	O
autosomal	B-Phenotype
recessive	I-Phenotype
inheritance	E-Phenotype
and	O
is	O
caused	O
mostly	O
by	O
mutations	O
in	O
the	O
RDH5	O
gene	O
.	O

Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
is	O
a	O
serious	O
neurodegenerative	B-Phenotype
disease	E-Phenotype
,	O
and	O
microRNAs	O
(	O
miRNAs	O
)	O
have	O
been	O
linked	O
to	O
its	O
pathogenesis	O
.	O

Expression	O
of	O
the	O
corresponding	O
wild	O
-	O
type	O
transcripts	O
in	O
immortalized	O
mutant	O
fibroblasts	O
rescued	O
the	O
biochemical	B-Phenotype
impairment	I-Phenotype
of	I-Phenotype
mitochondrial	I-Phenotype
respiration	E-Phenotype
and	O
yeast	B-Phenotype
modeling	I-Phenotype
of	I-Phenotype
the	I-Phenotype
VARS2	I-Phenotype
mutation	E-Phenotype
confirmed	O
its	O
pathogenic	O
role	O
.	O

Given	O
the	O
lack	O
of	O
specific	O
targeted	O
genes	O
and	O
pathways	O
known	O
to	O
be	O
involved	O
in	O
tumour	S-Phenotype
cell	O
dormancy	O
,	O
we	O
proposed	O
enriched	O
candidate	O
genes	O
related	O
to	O
the	O
negative	O
regulation	O
of	O
cell	O
proliferation	O
,	O
signalling	O
pathways	O
regulating	O
pluripotency	O
of	O
stem	O
cells	O
and	O
neuroactive	O
ligand	O
-	O
receptor	O
interaction	O
,	O
and	O
3	O
hub	O
genes	O
(	O
FTH1	O
,	O
GRM1	O
and	O
DDIT3	O
)	O
.	O

Megalencephalic	B-Phenotype
leukoencephalopathy	I-Phenotype
with	I-Phenotype
subcortical	I-Phenotype
cysts	E-Phenotype
(	O
MLC	S-Phenotype
)	O
is	O
a	O
rare	O
type	O
of	O
leukodystrophy	S-Phenotype
characterized	O
by	O
dysfunction	O
of	O
the	O
role	O
of	O
glial	O
cells	O
in	O
controlling	O
brain	O
fluid	O
and	O
ion	O
homeostasis	O
.	O

Kruppel	O
-	O
like	O
factor	O
9	O
(	O
KLF9	O
)	O
,	O
a	O
transcription	O
factor	O
,	O
is	O
critical	O
for	O
the	O
inhibition	O
of	O
growth	O
and	O
development	O
of	O
tumors	S-Phenotype
,	O
whereas	O
its	O
effects	O
in	O
pancreatic	B-Phenotype
cancer	E-Phenotype
remains	O
unclear	O
.	O

Oral	B-Phenotype
cancer	E-Phenotype
was	O
associated	O
with	O
two	O
new	O
regions	O
,	O
2p23.3	O
(	O
rs6547741	O
,	O
GPN1	O
)	O
and	O
9q34.12	O
(	O
rs928674	O
,	O
LAMC3	O
)	O
,	O
and	O
with	O
known	O
cancer	S-Phenotype
-	O
related	O
loci	O
-	O
9p21.3	O
(	O
rs8181047	O
,	O
CDKN2B	O
-	O
AS1	O
)	O
and	O
5p15.33	O
(	O
rs10462706	O
,	O
CLPTM1L	O
)	O
.	O

ADAMTS15	O
has	O
emerged	O
as	O
being	O
an	O
independent	O
predictor	O
of	O
survival	O
,	O
with	O
RNA	O
expression	O
levels	O
significantly	O
lower	O
(	O
P	O
=	O
0.007	O
)	O
in	O
grade	O
3	O
breast	B-Phenotype
carcinoma	E-Phenotype
compared	O
with	O
grade	B-Phenotype
1	I-Phenotype
and	I-Phenotype
2	I-Phenotype
breast	I-Phenotype
carcinoma	E-Phenotype

Our	O
studies	O
show	O
that	O
seven	O
of	O
the	O
ADAMTS	O
genes	O
(	O
ADAMTS1	O
,	O
3	O
,	O
5	O
,	O
8	O
,	O
9	O
,	O
10	O
,	O
and	O
18	O
)	O
are	O
consistently	O
down	O
-	O
regulated	O
in	O
breast	B-Phenotype
carcinomas	E-Phenotype
with	O
respect	O
to	O
nonneoplastic	O
mammary	O
tissue	O
,	O
irrespective	O
of	O
the	O
heterogeneity	S-Phenotype
of	O
the	O
samples	O
and	O
the	O
tumor	S-Phenotype
type	O
or	O
grade	O
(	O
Mann	O
-	O
Whitney	O
U	O
test	O
,	O
P	O
AAAA	O
0.0001	O
for	O
each	O
gene	O
)	O
.	O

We	O
demonstrate	O
spatial	O
genomic	O
heterogeneity	S-Phenotype
in	O
more	O
than	O
75	O
%	O
of	O
patients	O
,	O
including	O
inactivation	O
of	O
CDKN2C	O
and	O
TP53	O
,	O
and	O
mutations	O
affecting	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
genes	O
.	O

In	O
this	O
investigation	O
we	O
assessed	O
the	O
positivity	O
rate	O
of	O
RET	O
gene	O
rearrangement	O
in	O
primary	B-Phenotype
and	I-Phenotype
metastatic	I-Phenotype
non	I-Phenotype
-	I-Phenotype
small	I-Phenotype
cell	I-Phenotype
lung	I-Phenotype
cancer	E-Phenotype
and	O
explored	O
their	O
relationships	O
.	O

However	O
,	O
because	O
dicumarol	O
did	O
not	O
affect	O
well	O
-	O
known	O
apoptosis	O
inducers	O
,	O
such	O
as	O
anti	O
-	O
Fas	O
IgG	O
,	O
tumor	S-Phenotype
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
a	O
,	O
TNF	O
-	O
related	O
apoptosis	O
-	O
inducing	O
ligand	O
,	O
UV	O
-	O
B	O
and	O
H2O2	O
of	O
HeLa	O
cells	O
at	O
all	O
,	O
we	O
concluded	O
that	O
NQO1	O
-	O
related	O
intracellular	O
reduction	O
of	O
CoQ	O
,	O
or	O
its	O
reduced	O
product	O
,	O
ubiquinol	O
,	O
may	O
participate	O
in	O
the	O
apoptosis	O
induction	O
of	O
HeLa	O
cells	O

Our	O
results	O
provide	O
further	O
support	O
that	O
AS3MT	O
,	O
CNNM2	O
and	O
CALHM1	O
are	O
involved	O
with	O
the	O
etiology	O
and	O
pathogenesis	O
of	O
schizophrenia	S-Phenotype
,	O
suggesting	O
these	O
genes	O
are	O
potential	O
targets	O
of	O
interest	O
for	O
the	O
improvement	O
of	O
disease	O
management	O
and	O
the	O
development	O
of	O
novel	O
pharmacological	O
strategies	O

Microtomographic	O
and	O
x	O
-	O
ray	O
studies	O
revealed	O
several	O
hallmarks	O
of	O
AIS	O
,	O
including	O
postnatal	B-Phenotype
onset	I-Phenotype
of	I-Phenotype
scoliosis	E-Phenotype
without	O
malformations	O
of	O
vertebral	O
units	O
.	O

Genomic	B-Phenotype
imbalance	I-Phenotype
of	I-Phenotype
lung	I-Phenotype
cancer	E-Phenotype
was	O
determined	O
by	O
the	O
array	O
comparative	O
genomic	O
hybridization	O
(	O
aCGH	O
)	O
,	O
and	O
common	O
gCNVs	O
at	O
these	O
imbalance	S-Phenotype
regions	O
were	O
genotyped	O
in	O
lung	B-Phenotype
cancer	E-Phenotype
-	O
based	O
and	O
COPD	O
-	O
based	O
retrospective	O
studies	O
.	O

miR	O
-	O
122	O
,	O
the	O
expression	O
of	O
which	O
is	O
regulated	O
by	O
several	O
transcription	O
factors	O
,	O
such	O
as	O
HNF1A	O
,	O
was	O
recently	O
reported	O
to	O
be	O
associated	O
with	O
type	B-Phenotype
2	I-Phenotype
diabetes	E-Phenotype
(	O
T2DM	S-Phenotype
)	O
and	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
.	O

Though	O
KRT5	O
has	O
been	O
identified	O
to	O
be	O
the	O
causal	O
gene	O
of	O
DDD	O
,	O
the	O
heterogeneity	S-Phenotype
of	O
this	O
disease	O
was	O
displayed	O
:	O
for	O
example	O
,	O
POFUT1	O
and	O
POGLUT1	O
were	O
recently	O
identified	O
and	O
confirmed	O
to	O
be	O
additional	O
pathogenic	O
genes	O
of	O
DDD	O
.	O

Although	O
AEBP1	O
immunoreactivity	O
was	O
almost	O
absent	O
in	O
neurons	O
containing	O
neurofibrillary	B-Phenotype
tangles	E-Phenotype
,	O
AEBP1	O
was	O
highly	O
expressed	O
in	O
neurons	O
with	O
pretangles	O
and	O
in	O
the	O
tau	O
-	O
immunopositive	O
,	O
dystrophic	O
neurites	O
of	O
senile	B-Phenotype
plaques	E-Phenotype
.	O

Twenty	O
-	O
one	O
genes	O
showed	O
single	O
or	O
cross	O
-	O
cancer	S-Phenotype
associations	O
,	O
including	O
novel	O
associations	O
of	O
SDHA	O
in	O
melanoma	S-Phenotype
and	O
PALB2	O
in	O
stomach	B-Phenotype
adenocarcinoma	E-Phenotype
.	O

The	O
results	O
also	O
suggest	O
that	O
some	O
schizophrenia	S-Phenotype
-	O
related	O
alleles	O
may	O
be	O
subject	O
to	O
cognitive	O
tradeoffs	O
involving	O
both	O
positive	O
and	O
negative	O
effects	O
on	O
psychological	O
phenotypes	O
,	O
which	O
may	O
help	O
to	O
explain	O
the	O
maintenance	O
of	O
psychiatric	O
-	O
disorder	O
risk	O
alleles	O
in	O
human	O
populations	O

Human	O
genetic	O
and	O
pharmacological	O
animal	O
studies	O
support	O
this	O
hypothesis	O
,	O
but	O
no	O
studies	O
have	O
explored	O
mGluR5	O
dysfunction	O
at	O
the	O
molecular	O
level	O
in	O
the	O
postmortem	O
schizophrenia	S-Phenotype
brain	O
.	O

In	O
the	O
present	O
case	O
,	O
a	O
sporadic	S-Phenotype
FGP	O
with	O
LGD	O
did	O
not	O
develop	O
into	O
invasive	O
carcinoma	S-Phenotype
,	O
but	O
contained	O
foci	O
of	O
HGD	O
14	O
years	O
after	O
diagnosis	O
.	O

Thus	O
,	O
we	O
demonstrated	O
that	O
miR‑498	O
suppresses	O
the	O
growth	O
and	O
metastasis	O
of	O
liver	B-Phenotype
cancer	E-Phenotype
cells	O
,	O
partly	O
at	O
least	O
,	O
by	O
directly	O
targeting	O
ZEB2	O
,	O
suggesting	O
that	O
miR‑498	O
may	O
serve	O
as	O
a	O
potential	O
biomarker	O
for	O
the	O
diagnosis	O
and	O
therapy	O
of	O
liver	B-Phenotype
cancer	E-Phenotype

In	O
this	O
study	O
,	O
we	O
determined	O
that	O
miR	O
-	O
200a	O
was	O
downregulated	O
in	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
tissues	O
and	O
cell	O
lines	O
,	O
consistent	O
with	O
the	O
results	O
of	O
our	O
previous	O
study	O
.	O

PAX6	O
expression	O
and	O
molecular	O
mechanisms	O
by	O
which	O
PAX6	O
modifies	O
the	O
migration	O
capacity	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O

However	O
,	O
to	O
date	O
the	O
genetic	O
cause	O
remains	O
unknown	O
in	O
around	O
40	O
%	O
of	O
SRS	O
cases	O
,	O
suggesting	O
genetic	O
heterogeneity	S-Phenotype
and	O
involvement	O
of	O
other	O
genes	O
.	O

A	O
case	O
with	O
GAMT	O
deficiency	O
(	O
homozygous	O
c.64dupG	O
mutation	O
)	O
presented	O
with	O
neurodevelopmental	B-Phenotype
delay	E-Phenotype
,	O
rare	O
seizures	S-Phenotype
,	O
behavioral	B-Phenotype
disturbances	E-Phenotype
,	O
and	O
mild	S-Phenotype
hypotonia	S-Phenotype
,	O
posing	O
diagnostic	O
challenges	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
,	O
with	O
a	O
break	O
-	O
apart	O
probe	O
strategy	O
,	O
demonstrated	O
FUS	O
rearrangement	O
,	O
consistent	O
in	O
this	O
morphological	O
context	O
with	O
the	O
low	O
-	O
grade	O
fibromyxoid	O
sarcoma	S-Phenotype
-	O
associated	O
FUS	O
-	O
CREB3L2	O
or	O
FUS	O
-	O
CREB3L1	O
fusions	O
.	O

Interestingly	O
,	O
dysregulated	O
expression	O
of	O
KDM4	O
members	O
is	O
involved	O
in	O
the	O
progression	O
of	O
several	O
cancer	S-Phenotype
types	O
and	O
plays	O
a	O
role	O
in	O
the	O
DNA	O
damage	O
response	O
;	O
however	O
,	O
the	O
gene	O
expression	O
profile	O
and	O
the	O
importance	O
of	O
KDM4	O
members	O
in	O
CLL	O
are	O
still	O
unknown	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
an	O
intriguing	O
hypothesis	O
that	O
colorectal	B-Phenotype
cancer	E-Phenotype
arises	O
in	O
a	O
microenvironment	O
of	O
functional	O
GUCY2C	O
inactivation	O
,	O
which	O
can	O
be	O
repaired	O
by	O
oral	O
ligand	O
replacement	O
.	O

Mutations	O
in	O
the	O
POU	O
class	O
4	O
transcription	O
factor	O
3	O
(	O
POU4F3	O
)	O
are	O
known	O
to	O
cause	O
autosomal	B-Phenotype
dominant	I-Phenotype
nonsyndromic	I-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
linked	O
to	O
the	O
loci	O
of	O
DFNA15	O
.	O

In	O
conclusion	O
,	O
we	O
described	O
a	O
novel	O
nonsense	O
MYO6	O
mutation	O
that	O
was	O
responsible	O
for	O
the	O
hearing	B-Phenotype
loss	E-Phenotype
in	O
a	O
Brazilian	O
family	O
.	O

Two	O
pairwise	O
genetic	O
interactions	O
(	O
B	O
cell	O
lymphocyte	O
kinase	O
(	O
BLK	O
)	O
rs13277113	O
,	O
B	O
cell	O
scaffold	O
protein	O
with	O
ankyrin	O
repeats	O
1	O
(	O
BANK1	O
)	O
rs3733197and	O
BLK	O
rs13277113	O
membrane	O
metalloendopeptidase	O
like	O
1	O
(	O
MMEL1	O
)	O
/	O
tumor	S-Phenotype
necrosis	O
factor	O
receptor	O
superfamily	O
member	O
14	O
(	O
TNFRSF14	O
)	O
rs3890745	O
)	O
have	O
been	O
demonstrated	O
in	O
determining	O
susceptibility	O
to	O
rheumatoid	B-Phenotype
arthritis	E-Phenotype
(	O
RA	S-Phenotype
)	O
without	O
replication	O
,	O
thus	O
this	O
study	O
was	O
performed	O
to	O
examine	O
whether	O
abovementioned	O
genetic	O
polymorphisms	O
were	O
associated	O
with	O
RA	O
and	O
further	O
tests	O
were	O
performed	O
to	O
see	O
whether	O
aforementioned	O
genetic	O
interactions	O
existed	O
in	O
RA	O
among	O
Chinese	O
population	O
.	O

Patients	O
with	O
heritable	O
cancer	S-Phenotype
syndromes	O
characterized	O
by	O
germline	O
PTEN	O
mutations	O
(	O
termed	O
PTEN	O
hamartoma	S-Phenotype
tumor	S-Phenotype
syndrome	O
,	O
PHTS	O
)	O
benefit	O
from	O
PTEN	O
-	O
enabled	O
cancer	S-Phenotype
risk	O
assessment	O
and	O
clinical	O
management	O
.	O

Mutations	O
in	O
IDH1	O
and	O
IDH2	O
have	O
recently	O
been	O
observed	O
in	O
multiple	O
tumors	S-Phenotype
,	O
including	O
gliomas	S-Phenotype
,	O
acute	B-Phenotype
myeloid	I-Phenotype
leukemia	E-Phenotype
,	O
myelodysplastic	B-Phenotype
syndromes	E-Phenotype
,	O
and	O
chondrosarcoma	S-Phenotype
.	O

Biallelic	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
TYROBP	O
and	O
TREM2	O
cause	O
a	O
rare	O
disease	O
that	O
resembles	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
frontotemporal	I-Phenotype
dementia	E-Phenotype
with	O
bone	O
lesions	O
called	O
polycystic	B-Phenotype
lipomembranous	I-Phenotype
osteodysplasia	I-Phenotype
with	I-Phenotype
sclerosing	I-Phenotype
leukoencephalopathy	E-Phenotype
(	O
PLOSL	S-Phenotype
)	O
.	O

Coexistence	O
in	O
mice	O
of	O
PlgT	O
/	O
T	O
and	O
Pros1E	O
/	O
E	O
did	O
not	O
affect	O
pulmonary	B-Phenotype
embolism	E-Phenotype
symptoms	O
,	O
compared	O
with	O
those	O
in	O
Pros1E	O
/	O
E	O
mice	O
.	O

Our	O
findings	O
are	O
both	O
important	O
for	O
the	O
differential	O
diagnosis	O
of	O
patients	O
with	O
urea	O
cycle	O
disorders	O
and	O
also	O
broaden	O
the	O
differential	O
diagnosis	O
of	O
hyperammonemia	S-Phenotype
associated	O
with	O
3	B-Phenotype
-	I-Phenotype
methylglutaconic	I-Phenotype
aciduria	E-Phenotype
,	O
which	O
was	O
earlier	O
only	O
reported	O
in	O
TMEM70	O
and	O
SERAC1	O
defect	O

These	O
data	O
expand	O
our	O
knowledge	O
of	O
the	O
mechanisms	O
underlying	O
NOTCH	O
activation	O
and	O
TIC	S-Phenotype
induction	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
,	O
and	O
may	O
provide	O
new	O
avenues	O
for	O
the	O
development	O
of	O
therapies	O
targeting	O
this	O
resistant	O
subset	O
of	O
tumor	S-Phenotype
cells	O

Canonical	O
GLI	O
-	O
dependent	O
Hedgehog	O
signaling	O
is	O
a	O
negative	O
regulator	O
of	O
WNT	O
signaling	O
in	O
normal	O
intestine	O
and	O
intestinal	O
tumors	S-Phenotype
.	O

Here	O
,	O
we	O
identify	O
tumor	S-Phenotype
-	O
associated	O
calcium	O
signal	O
transducer	O
2	O
(	O
TACSTD2	O
)	O
,	O
one	O
of	O
the	O
most	O
downregulated	O
genes	O
in	O
primary	O
HCC	O
tissue	O
,	O
as	O
a	O
host	O
factor	O
that	O
interacts	O
with	O
CLDN1	O
and	O
OCLN	O
and	O
regulates	O
their	O
cellular	O
localization	O
.	O

DACT1	O
is	O
a	O
member	O
of	O
the	O
Wnt	O
-	O
signaling	O
pathway	O
,	O
and	O
mice	O
homozygous	O
for	O
null	O
alleles	O
display	O
multiple	O
congenital	O
anomalies	O
including	O
absent	B-Phenotype
anus	E-Phenotype
with	O
blind	B-Phenotype
-	I-Phenotype
ending	I-Phenotype
colon	E-Phenotype
and	O
genitourinary	B-Phenotype
malformations	E-Phenotype
.	O

Genomics	O
of	O
tumors	S-Phenotype
identified	O
several	O
new	O
genes	O
-	O
including	O
ZNRF3	O
in	O
adrenocortical	B-Phenotype
carcinomas	E-Phenotype
,	O
PRKACA	O
in	O
cortisol	B-Phenotype
-	I-Phenotype
producing	I-Phenotype
adrenal	I-Phenotype
adenomas	E-Phenotype
,	O
ARMC5	O
in	O
primary	B-Phenotype
macronodular	I-Phenotype
adrenal	I-Phenotype
hyperplasia	E-Phenotype
and	O
USP8	O
in	O
pituitary	B-Phenotype
corticotroph	I-Phenotype
adenomas	E-Phenotype
.	O

We	O
suggest	O
that	O
studies	O
of	O
regulatory	O
cancer	S-Phenotype
networks	O
,	O
including	O
the	O
passenger	O
strands	O
of	O
miRNAs	O
,	O
may	O
provide	O
new	O
insights	O
into	O
the	O
pathogenic	O
mechanisms	O
of	O
BC	O

However	O
,	O
because	O
nectin4	O
and	O
CD46	O
have	O
substantially	O
overlapping	O
receptor	O
binding	O
surfaces	O
on	O
H	O
,	O
disruption	O
of	O
nectin4	O
binding	O
compromised	O
CD46	O
binding	O
and	O
greatly	O
diminished	O
the	O
oncolytic	O
potency	O
of	O
these	O
viruses	O
on	O
human	O
cancer	S-Phenotype
cells	O
.	O

BRWD3	O
is	O
therefore	O
a	O
new	O
gene	O
implicated	O
in	O
the	O
etiology	O
of	O
XLMR	O
associated	O
with	O
macrocephaly	S-Phenotype
and	O
may	O
cause	O
disease	O
by	O
altering	O
intracellular	O
signaling	O
pathways	O
affecting	O
cellular	O
proliferation	O

Among	O
these	O
genes	O
,	O
mutations	O
in	O
VCP	O
gene	O
involve	O
in	O
inclusion	O
body	O
myopathy	S-Phenotype
with	O
Paget	O
disease	O
of	O
bone	O
and	O
frontotemporal	B-Phenotype
dementia	E-Phenotype
(	O
IBMPFD	O
)	O
,	O
familial	B-Phenotype
amyotrophic	I-Phenotype
lateral	I-Phenotype
sclerosis	E-Phenotype
(	O
ALS	S-Phenotype
)	O
,	O
autism	B-Phenotype
spectrum	I-Phenotype
disorders	E-Phenotype
(	O
ASD	S-Phenotype
)	O
,	O
and	O
hereditary	B-Phenotype
spastic	I-Phenotype
paraplegia	E-Phenotype
(	O
HSP	S-Phenotype
)	O
.	O

Individuals	O
with	O
PTCHD1	O
deletion	O
show	O
symptoms	O
of	O
ADHD	S-Phenotype
,	O
sleep	B-Phenotype
disruption	E-Phenotype
,	O
hypotonia	S-Phenotype
,	O
aggression	S-Phenotype
,	O
ASD	S-Phenotype
,	O
and	O
ID	S-Phenotype
.	O

We	O
found	O
monoallelic	O
truncating	O
/	O
functionally	O
deleterious	O
mutations	O
in	O
seven	O
genes	O
,	O
including	O
ATM	O
and	O
CHEK2	O
,	O
which	O
have	O
previously	O
been	O
associated	O
with	O
PrCa	O
predisposition	O
,	O
and	O
five	O
new	O
candidate	O
PrCa	O
associated	O
genes	O
involved	O
in	O
cancer	S-Phenotype
predisposing	O
recessive	O
disorders	O
,	O
namely	O
RAD51C	O
,	O
FANCD2	O
,	O
FANCI	O
,	O
CEP57	O
and	O
RECQL4	O
.	O

Survival	O
analysis	O
revealed	O
that	O
the	O
expression	O
of	O
MCM2	O
,	O
MMP2	O
,	O
COL1A1	O
and	O
JUN	O
was	O
associated	O
with	O
the	O
prognosis	O
of	O
the	O
aforementioned	O
gynecological	O
cancer	S-Phenotype
types	O
.	O

The	O
high	O
-	O
risk	O
HPV	O
types	O
(	O
HR	O
HPV	O
)	O
account	O
for	O
approximately	O
5	O
%	O
of	O
the	O
global	O
burden	O
of	O
cancer	S-Phenotype
and	O
thus	O
cause	O
high	O
morbidity	O
and	O
mortality	O
.	O

In	O
vitro	O
,	O
CHRDL1	O
knockdown	O
promoted	O
tumor	S-Phenotype
cell	O
proliferation	O
and	O
migration	O
through	O
BMPR	O
II	O
by	O
activating	O
Akt	O
,	O
Erk	O
and	O
b	O
-	O
catenin	O
.	O

As	O
a	O
brand	O
new	O
tumor	S-Phenotype
-	O
suppressor	O
gene	O
,	O
the	O
expression	O
of	O
Kank1	O
gene	O
has	O
been	O
revealed	O
to	O
be	O
downregulated	O
or	O
absent	O
in	O
many	O
malignant	O
tumors	S-Phenotype
.	O

Noonan	O
syndrome	O
(	O
NS	O
)	O
,	O
the	O
commonest	O
RASopathy	O
,	O
is	O
genetically	O
heterogeneous	S-Phenotype
and	O
caused	O
by	O
functional	O
dysregulation	O
of	O
signal	O
transducers	O
and	O
regulatory	O
proteins	O
with	O
roles	O
in	O
the	O
RAS	O
/	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)	O
signal	O
transduction	O
pathway	O
.	O

MiR	O
-	O
93	O
-	O
5p	O
has	O
been	O
previously	O
found	O
to	O
be	O
associated	O
with	O
gastric	B-Phenotype
cancer	E-Phenotype
(	O
GC	S-Phenotype
)	O
tumorigenesis	S-Phenotype
;	O
however	O
,	O
the	O
current	O
understanding	O
of	O
its	O
function	O
in	O
this	O
context	O
remains	O
largely	O
incomplete	O
.	O

XRCC4	O
is	O
one	O
of	O
the	O
essential	O
proteins	O
of	O
this	O
pathway	O
and	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
of	O
this	O
gene	O
are	O
reported	O
to	O
be	O
associated	O
with	O
cancer	S-Phenotype
risks	O
.	O

Auditory	B-Phenotype
neuropathy	E-Phenotype
is	O
a	O
type	O
of	O
hearing	B-Phenotype
loss	E-Phenotype
that	O
constitutes	O
a	O
change	O
in	O
the	O
conduct	O
of	O
the	O
auditory	O
stimulus	O
by	O
the	O
involvement	O
of	O
inner	O
hair	O
cells	O
or	O
auditory	O
nerve	O
synapses	O
.	O

Analysis	O
of	O
clinical	O
samples	O
of	O
oral	B-Phenotype
cancer	E-Phenotype
found	O
a	O
strong	O
correlation	O
of	O
these	O
genes	O
with	O
short	O
survival	O
,	O
especially	O
JUN	O
expression	O
associated	O
with	O
metastasis	O
.	O

Biotin	B-Phenotype
Thiamine	I-Phenotype
responsive	I-Phenotype
Basal	I-Phenotype
Ganglia	I-Phenotype
Disease	E-Phenotype
(	O
BTBGD	S-Phenotype
)	O
is	O
a	O
rare	O
treatable	O
autosomal	B-Phenotype
recessive	I-Phenotype
metabolic	I-Phenotype
disorder	E-Phenotype
caused	O
by	O
mutations	O
in	O
SLC19A3	O
gene	O
.	O

The	O
results	O
demonstrated	O
that	O
the	O
expression	O
of	O
PHF8	O
was	O
significantly	O
increased	O
in	O
tumor	S-Phenotype
tissues	O
from	O
patients	O
with	O
CRC	O
and	O
was	O
correlated	O
with	O
tumor‑node‑metastasis	O
stage	O
.	O

RESULTS	O
Body	O
mass	O
,	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
,	O
waist	O
circumference	O
(	O
WC	O
)	O
,	O
hip	O
circumference	O
(	O
HC	O
)	O
,	O
waist	O
-	O
hip	O
ratio	O
(	O
WHR	O
)	O
,	O
SBP	O
,	O
DBP	O
,	O
FPG	O
,	O
triglyceride	O
(	O
TG	O
)	O
,	O
total	O
cholesterol	O
(	O
TC	O
)	O
,	O
and	O
low	O
-	O
density	O
lipoprotein	O
cholesterol	O
(	O
LDL	O
-	O
C	O
)	O
were	O
higher	O
,	O
while	O
HDL	O
-	O
C	O
was	O
lower	O
in	O
the	O
obesity	S-Phenotype
group	O
compared	O
with	O
controls	O
.	O

In	O
clinicopathological	O
analysis	O
,	O
we	O
found	O
that	O
increased	O
expression	O
of	O
ANXA11	O
was	O
significantly	O
associated	O
with	O
tumor	S-Phenotype
size	O
,	O
tumor	S-Phenotype
infiltration	O
,	O
local	O
lymph	O
node	O
metastasis	O
,	O
TNM	O
staging	O
,	O
and	O
vascular	O
invasion	O
.	O

80.5	O
%	O
of	O
luminal	O
-	O
type	O
tumours	S-Phenotype
developed	O
bone	O
metastasis	O
as	O
opposed	O
to	O
41.7	O
%	O
of	O
basal	O
and	O
55.6	O
%	O
of	O
HER2	O
-	O
like	O
tumours	S-Phenotype
.	O

In	O
distal	S-Phenotype
renal	O
tubules	O
,	O
FGF23	O
signaling	O
activates	O
with	O
-	O
no	O
-	O
lysine	O
kinase	O
4	O
,	O
leading	O
to	O
increased	O
renal	O
tubular	O
reabsorption	O
of	O
calcium	O
and	O
sodium	O
.	O

In	O
this	O
patient	O
cohort	O
,	O
elevated	O
stroma	O
cell	O
KLK4	O
expression	O
,	O
but	O
not	O
tumor	S-Phenotype
cell	O
KLK4	O
expression	O
,	O
is	O
predictive	O
for	O
poor	O
disease	O
-	O
free	O
survival	O
by	O
univariate	O
analysis	O
(	O
hazard	O
ratio	O
:	O
2.26	O
,	O
p=0.001	O
)	O
and	O
multivariable	O
analysis	O
(	O
hazard	O
ratio	O
:	O
2.12	O
,	O
pAAAA0.01	O
)	O
.	O

Mutations	O
in	O
the	O
LDB3	O
gene	O
have	O
been	O
identified	O
in	O
patients	O
with	O
Z	O
-	O
disc	O
-	O
associated	O
,	O
alternatively	O
spliced	O
,	O
PDZ	O
motif	O
-	O
containing	O
protein	O
(	O
ZASP	O
)	O
-	O
related	O
myofibrillar	B-Phenotype
myopathy	E-Phenotype
(	O
ZASP	O
-	O
MFM	O
)	O
characterized	O
by	O
late	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
distal	I-Phenotype
myopathy	E-Phenotype
with	O
signs	O
of	O
cardiomyopathy	S-Phenotype
and	O
neuropathy	S-Phenotype
.	O

Recently	O
,	O
FLVCR1	O
recessive	O
mutations	O
were	O
also	O
found	O
in	O
two	O
sporadic	S-Phenotype
children	O
with	O
hereditary	B-Phenotype
sensory	I-Phenotype
-	I-Phenotype
autonomic	I-Phenotype
neuropathy	E-Phenotype
(	O
HSAN	S-Phenotype
)	O
.	O

Slurp1	O
expression	O
detected	O
by	O
QPCR	O
,	O
immunoblots	O
and	O
immunofluorescent	O
stain	O
,	O
was	O
significantly	O
decreased	O
in	O
mouse	O
corneas	O
subjected	O
to	O
alkali	O
burn	O
-	O
induced	O
corneal	B-Phenotype
neovascularization	E-Phenotype
(	O
CNV	S-Phenotype
)	O
.	O

Of	O
these	O
five	O
genes	O
,	O
the	O
brain	O
expressed	O
CDK5R1	O
gene	O
constitutes	O
a	O
good	O
candidate	O
for	O
the	O
developmental	B-Phenotype
delay	E-Phenotype
,	O
while	O
the	O
RHOT1	O
gene	O
,	O
involved	O
in	O
mitochondrial	O
trafficking	O
,	O
might	O
underlie	O
the	O
hypotonia	S-Phenotype
and	O
the	O
excessive	O
fatigue	S-Phenotype

These	O
data	O
suggest	O
AMPD2	O
-	O
related	O
PCH	O
as	O
a	O
potentially	O
treatable	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
neurodegenerative	I-Phenotype
disease	E-Phenotype
.	O

A	O
better	O
understanding	O
of	O
the	O
mechanisms	O
coupling	O
thermoregulation	O
to	O
energy	O
homeostasis	O
,	O
including	O
the	O
involvement	O
of	O
thermosensitive	O
TRPs	O
,	O
may	O
uncover	O
additional	O
mechanisms	O
underlying	O
the	O
pathogenesis	O
of	O
obesity	S-Phenotype
and	O
its	O
metabolic	O
consequences	O
in	O
humans	O
,	O
opening	O
new	O
strategies	O
for	O
the	O
diagnosis	O
,	O
treatment	O
,	O
and	O
prevention	O
of	O
this	O
disease	O

Altogether	O
these	O
data	O
demonstrate	O
that	O
mutations	O
in	O
INPP5K	O
cause	O
a	O
congenital	B-Phenotype
muscular	I-Phenotype
dystrophy	E-Phenotype
syndrome	O
with	O
short	B-Phenotype
stature	E-Phenotype
,	O
cataracts	S-Phenotype
,	O
and	O
intellectual	B-Phenotype
disability	E-Phenotype

TAC1	O
had	O
the	O
highest	O
sputum	B-Phenotype
eosinophilia	E-Phenotype
and	O
exhaled	O
nitric	O
oxide	O
fraction	O
,	O
and	O
was	O
restricted	O
to	O
severe	O	
asthma	S-Phenotype
with	O
oral	B-Phenotype
corticosteroid	I-Phenotype
dependency	E-Phenotype
,	O
frequent	B-Phenotype
exacerbations	E-Phenotype
and	O
severe	O
airflow	B-Phenotype
obstruction	E-Phenotype
.	O

IHC	O
detects	O
additional	O
non	O
-	O
KMT2D	O
-	O
mutated	O
aGCTs	O
with	O
loss	O
of	O
nuclear	O
KMT2D	O
expression	O
,	O
suggesting	O
that	O
non	O
-	O
genetic	O
KMT2D	O
inactivation	O
may	O
occur	O
in	O
this	O
tumor	S-Phenotype
type	O
.	O

Silencing	O
of	O
FAK	O
or	O
LAMB3	O
recapitulated	O
the	O
synthetic	O
lethal	O
effects	O
of	O
miR	O
-	O
1298	O
expression	O
in	O
KRAS	O
-	O
driven	O
cancer	S-Phenotype
cells	O
,	O
whereas	O
coexpression	O
of	O
both	O
proteins	O
was	O
critical	O
to	O
rescue	O
miR	O
-	O
1298	O
-	O
induced	O
cell	O
death	O
.	O

In	O
dogs	O
,	O
myotonia	S-Phenotype
is	O
associated	O
with	O
mutations	O
in	O
CLCN1	O
.	O

Pkm2	O
deletion	O
accelerated	O
tumor	S-Phenotype
formation	O
in	O
medulloblastoma	S-Phenotype
-	O
prone	O
ND2	O
:	O
SmoA1	O
mice	O
,	O
indicating	O
the	O
disrupting	O
PKM	O
releases	O
CGNPs	O
from	O
a	O
tumor	S-Phenotype
-	O
suppressive	O
effect	O
.	O

We	O
evaluated	O
the	O
association	O
between	O
dietary	O
and	O
supplemental	O
zinc	O
and	O
prostate	B-Phenotype
cancer	E-Phenotype
within	O
the	O
VITamins	O
And	O
Lifestyle	O
(	O
VITAL	O
)	O
cohort	O
,	O
a	O
study	O
specifically	O
designed	O
to	O
evaluate	O
the	O
impact	O
of	O
dietary	O
supplements	O
and	O
cancer	S-Phenotype
risk	O
.	O

In	O
conclusion	O
,	O
SERP2	O
,	O
EFEMP2	O
,	O
FBN1	O
,	O
SPARC	O
,	O
and	O
LINC0219	O
were	O
revealed	O
to	O
be	O
the	O
recurrence	O
-	O
associated	O
molecular	O
and	O
prognostic	O
indicators	O
in	O
colon	B-Phenotype
cancer	E-Phenotype
by	O
WGCNA	O
co	O
-	O
expression	O
network	O
analysis	O

In	O
a	O
patient	O
with	O
clinical	O
features	O
of	O
BOR	O
syndrome	O
,	O
such	O
as	O
hearing	B-Phenotype
loss	E-Phenotype
,	O
preauricular	B-Phenotype
fistulas	E-Phenotype
and	O
facial	B-Phenotype
dysmorphisms	E-Phenotype
,	O
but	O
no	B-Phenotype
renal	I-Phenotype
anomalies	E-Phenotype
,	O
neither	O
sequencing	O
of	O
the	O
3	O
genes	O
linked	O
to	O
BOR	O
syndrome	O
nor	O
array	O
comparative	O
genomic	O
hybridization	O
and	O
MLPA	O
were	O
able	O
to	O
uncover	O
a	O
causative	O
mutation	O
.	O

This	O
bioinformatics	O
analysis	O
demonstrated	O
that	O
stage	O
-	O
related	O
prognostic	O
DEGs	O
,	O
such	O
as	O
COL3A1	O
,	O
COL1A1	O
,	O
COL1A2	O
,	O
KRAS	O
,	O
and	O
NRAS	O
might	O
play	O
an	O
unfavorable	O
role	O
in	O
the	O
development	O
as	O
well	O
as	O
metastasis	O
of	O
ovarian	B-Phenotype
cancer	E-Phenotype
.	O

bObjective	O
:	O
/	O
b	O
To	O
investigate	O
the	O
significance	O
of	O
Twist2	O
in	O
glioma	S-Phenotype
and	O
whether	O
it	O
is	O
involved	O
in	O
the	O
malignant	O
transformation	O
of	O
glioma	S-Phenotype
by	O
epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
.	O

Friedreich	B-Phenotype
ataxia	E-Phenotype
(	O
FRDA	S-Phenotype
)	O
is	O
the	O
most	O
frequent	O
progressive	O
autosomal	B-Phenotype
recessive	E-Phenotype
disorder	O
associated	O
with	O
unstable	O
expansion	O
of	O
GAA	O
trinucleotide	O
repeats	O
in	O
the	O
first	O
intron	O
of	O
the	O
FXN	O
gene	O
,	O
which	O
encodes	O
for	O
the	O
mitochondrial	O
frataxin	O
protein	O
.	O

Here	O
we	O
report	O
three	O
families	O
with	O
homozygous	O
truncating	O
mutations	O
in	O
TBC1D23	O
who	O
display	O
moderate	O
to	O
severe	O
intellectual	B-Phenotype
disability	E-Phenotype
and	O
microcephaly	S-Phenotype
.	O

Our	O
experimental	O
data	O
are	O
also	O
consistent	O
with	O
the	O
survival	O
prognostic	O
value	O
of	O
LTBP3	O
expression	O
in	O
early	B-Phenotype
-	I-Phenotype
stage	I-Phenotype
head	I-Phenotype
and	I-Phenotype
neck	I-Phenotype
squamous	I-Phenotype
cell	I-Phenotype
carcinomas	E-Phenotype
,	O
further	O
indicating	O
a	O
specific	O
role	O
for	O
LTBP3	O
in	O
cancer	S-Phenotype
progression	O
toward	O
metastatic	O
disease	O

Osteopetrosis	S-Phenotype
(	O
OPT	S-Phenotype
)	O
is	O
a	O
rare	O
skeletal	O
disorder	O
with	O
phenotypic	O
and	O
genotypic	O
heterogeneity	S-Phenotype
:	O
a	O
variety	O
of	O
clinical	O
features	O
besides	O
the	O
bony	O
defect	O
may	O
be	O
present	O
,	O
and	O
at	O
least	O
ten	O
different	O
genes	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
disease	O
pathogenesis	O
.	O

Most	O
of	O
the	O
genes	O
that	O
are	O
commonly	O
associated	O
with	O
colon	B-Phenotype
cancer	E-Phenotype
,	O
including	O
APC	O
,	O
TP53	O
,	O
and	O
KRAS	O
,	O
were	O
all	O
classified	O
as	O
being	O
early	O
driver	O
genes	O
being	O
mutated	O
in	O
both	O
adenomas	S-Phenotype
and	O
carcinomas	S-Phenotype
.	O

Thus	O
,	O
the	O
geographic	O
imbalance	S-Phenotype
in	O
colorectal	B-Phenotype
cancer	E-Phenotype
,	O
in	O
part	O
,	O
may	O
reflect	O
chronic	O
exposure	O
to	O
ST	O
-	O
producing	O
organisms	O
that	O
restore	O
GUCY2C	O
signaling	O
silenced	O
by	O
hormone	O
loss	O
during	O
transformation	O
.	O

Defects	O
in	O
Membrane	O
Frizzled	O
-	O
related	O
Protein	O
(	O
MFRP	O
)	O
cause	O
autosomal	B-Phenotype
recessive	I-Phenotype
retinitis	I-Phenotype
pigmentosa	E-Phenotype
(	O
RP	S-Phenotype
)	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
LASS2	O
protein	O
level	O
was	O
positively	O
related	O
to	O
International	O
Federation	O
of	O
Gynecology	O
and	O
Obstetrics	O
(	O
FIGO	O
)	O
stage	O
and	O
LASS2	O
-	O
negative	O
tumors	S-Phenotype
showed	O
significant	O
association	O
with	O
longer	O
disease	O
-	O
free	O
survival	O
(	O
DFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
in	O
ovarian	B-Phenotype
cancer	E-Phenotype
patients	O
.	O

BACKGROUND	O
This	O
study	O
aimed	O
to	O
investigate	O
the	O
mechanism	O
of	O
CHEK2	O
gene	O
dysfunction	O
in	O
drug	B-Phenotype
resistance	E-Phenotype
of	O
triple	B-Phenotype
negative	I-Phenotype
breast	I-Phenotype
cancer	E-Phenotype
(	O
TNBC	S-Phenotype
)	O
cells	O
.	O

By	O
using	O
exome	O
and	O
capillary	O
sequencing	O
,	O
we	O
here	O
identify	O
biallelic	O
UBE3B	O
mutations	O
in	O
four	O
patients	O
from	O
three	O
unrelated	O
families	O
presenting	O
an	O
autosomal	B-Phenotype
-	I-Phenotype
recessive	I-Phenotype
blepharophimosis	I-Phenotype
-	I-Phenotype
ptosis	I-Phenotype
-	I-Phenotype
intellectual	I-Phenotype
-	I-Phenotype
disability	I-Phenotype
syndrome	E-Phenotype
characterized	O
by	O
developmental	B-Phenotype
delay	E-Phenotype
,	O
growth	B-Phenotype
retardation	E-Phenotype
with	O
a	O
small	B-Phenotype
head	I-Phenotype
circumference	E-Phenotype
,	O
facial	B-Phenotype
dysmorphisms	E-Phenotype
,	O
and	O
low	B-Phenotype
cholesterol	I-Phenotype
levels	E-Phenotype
.	O

Methylation	O
of	O
RARB	O
,	O
CD44	O
,	O
PAX5A	O
,	O
GSTP1	O
,	O
IGSF4	O
(	O
CADM1	O
)	O
,	O
PYCARD	O
,	O
CDH13	O
,	O
TP53	O
,	O
and	O
GATA5	O
classified	O
pTa	O
versus	O
pT1	O
tumors	S-Phenotype
whereas	O
RARB	O
,	O
CD44	O
,	O
GSTP1	O
,	O
IGSF4	O
,	O
CHFR	O
,	O
PYCARD	O
,	O
TP53	O
,	O
STK11	O
,	O
and	O
GATA5	O
distinguished	O
LG	O
versus	O
HG	O
tumors	S-Phenotype
.	O

Loss	O
-	O
of	O
-	O
function	O
mutations	O
of	O
GATAD2B	O
have	O
recently	O
been	O
defined	O
to	O
cause	O
a	O
recognizable	O
syndrome	O
with	O
intellectual	B-Phenotype
disability	E-Phenotype
(	O
ID	S-Phenotype
)	O
.	O

The	O
tumor	S-Phenotype
was	O
diagnosed	O
ACC	O
with	O
immunohistochemistry	O
;	O
positive	O
to	O
ACC	O
phenotype	O
(	O
a1	O
-	O
antitrypsin	O
,	O
a1	O
-	O
antichymotrypsin	O
,	O
BCL10	O
)	O
.	O

We	O
have	O
previously	O
identified	O
a	O
role	O
for	O
the	O
secreted	O
serine	O
protease	O
PRSS56	O
in	O
ocular	O
size	O
determination	O
and	O
PRSS56	O
variants	O
have	O
been	O
implicated	O
in	O
the	O
etiology	O
of	O
both	O
hyperopia	S-Phenotype
and	O
myopia	S-Phenotype
,	O
highlighting	O
its	O
importance	O
in	O
refractive	O
development	O
.	O

After	O
its	O
downregulation	O
in	O
neuroblastoma	S-Phenotype
cells	O
and	O
in	O
brains	O
of	O
Tspan3	O
-	O
deficient	O
mice	O
,	O
ADAM10	O
and	O
APP	O
levels	O
appeared	O
unaltered	O
possibly	O
due	O
to	O
a	O
compensatory	O
increase	O
in	O
the	O
expression	O
of	O
Tspans	O
5	O
and	O
7	O
,	O
respectively	O
.	O

We	O
have	O
previously	O
identified	O
a	O
novel	O
zinc	O
finger	O
protein	O
,	O
glial	O
cell	O
line	O
-	O
derived	O
neurotrophic	O
factor	O
-	O
inducible	O
zinc	O
finger	O
protein	O
1	O
(	O
GZF1	O
)	O
,	O
whose	O
expression	O
was	O
induced	O
in	O
the	O
human	O
neuroblastoma	S-Phenotype
cell	O
line	O
TGW	O
expressing	O
RET	O
by	O
GDNF	O
stimulation	O
and	O
was	O
also	O
detected	O
in	O
mouse	O
metanephric	O
kidney	O
.	O

In	O
this	O
publication	O
,	O
we	O
will	O
review	O
the	O
literature	O
that	O
supports	O
identification	O
of	O
ASB10	O
as	O
a	O
glaucoma	S-Phenotype
-	O
associated	O
gene	O
and	O
the	O
current	O
knowledge	O
of	O
the	O
function	O
of	O
the	O
ASB10	O
protein	O
.	O

A	O
single	O
family	O
with	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
form	O
of	O
OFCS	O
and	O
a	O
homozygous	O
missense	O
mutation	O
in	O
PAX1	O
gene	O
has	O
been	O
described	O
.	O

This	O
case	O
series	O
demonstrates	O
that	O
exercise	B-Phenotype
intolerance	E-Phenotype
,	O
myalgia	S-Phenotype
and	O
rhabdomyolysis	S-Phenotype
may	O
be	O
caused	O
by	O
CAV3	O
mutations	O
and	O
broadens	O
the	O
phenotypic	O
spectrum	O
of	O
caveolinopathies	O
.	O

Next	O
,	O
we	O
took	O
epicardial	O
fat	O
samples	O
from	O
patients	O
with	O
valvular	B-Phenotype
heart	I-Phenotype
disease	E-Phenotype
and	O
non	B-Phenotype
-	I-Phenotype
coronary	I-Phenotype
artery	I-Phenotype
disease	E-Phenotype
.	O

Using	O
whole	O
exome	O
sequencing	O
in	O
14	O
patients	O
with	O
isolated	B-Phenotype
periventricular	I-Phenotype
nodular	I-Phenotype
heterotopia	E-Phenotype
but	O
no	O
copy	O
number	O
variants	O
,	O
we	O
identified	O
one	O
patient	O
with	O
periventricular	B-Phenotype
nodular	I-Phenotype
heterotopia	E-Phenotype
,	O
developmental	B-Phenotype
delay	E-Phenotype
and	O
epilepsy	S-Phenotype
and	O
a	O
de	O
novo	O
missense	O
mutation	O
in	O
the	O
chromosome	O
6	O
open	O
reading	O
frame	O
70	O
(	O
C6orf70	O
)	O
gene	O
,	O
mapping	O
in	O
the	O
minimal	O
critical	O
deleted	O
region	O
.	O

Six	O
genes	O
(	O
ACOX2	O
,	O
MUC1	O
,	O
CRYBB2	O
,	O
PSPH	O
,	O
SQLE	O
,	O
TYMS	O
)	O
were	O
differentially	O
expressed	O
by	O
race	O
among	O
Luminal	O
A	O
breast	B-Phenotype
cancers	E-Phenotype
and	O
were	O
associated	O
with	O
survival	O
(	O
HR	O
AAAA0.8	O
,	O
HR	O
AAAA1.25	O
)	O
.	O

Overall	O
,	O
GPT2	O
promotes	O
tumorigenesis	O
and	O
stemness	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
by	O
activating	O
the	O
Shh	O
signaling	O
,	O
suggesting	O
that	O
GTP2	O
is	O
a	O
potential	O
target	O
for	O
breast	B-Phenotype
cancer	E-Phenotype
therapy	O

In	O
a	O
unique	O
case	O
from	O
a	O
consanguineous	O
union	O
presenting	O
with	O
overgrowth	S-Phenotype
,	O
macrocephaly	S-Phenotype
,	O
retinal	B-Phenotype
coloboma	E-Phenotype
,	O
large	B-Phenotype
thumbs	E-Phenotype
,	O
severe	O
varicose	B-Phenotype
veins	E-Phenotype
and	O
learning	B-Phenotype
disabilities	E-Phenotype
,	O
exome	O
sequencing	O
identified	O
a	O
homozygous	O
nonsense	O
FIBP	O
variant	O
.	O

He	O
has	O
similar	O
clinical	O
findings	O
,	O
including	O
mild	B-Phenotype
facial	I-Phenotype
dysmorphisms	E-Phenotype
and	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
as	O
other	O
individuals	O
with	O
much	O
larger	O
deletions	O
of	O
the	O
terminus	O
of	O
the	O
long	O
arm	O
of	O
chromosome	O
14	O
.	O

We	O
report	O
here	O
that	O
TNFSF15	O
,	O
which	O
is	O
known	O
to	O
inhibit	O
primary	O
tumor	S-Phenotype
growth	O
by	O
suppressing	O
angiogenesis	O
,	O
can	O
promote	O
lymphatic	O
metastasis	O
through	O
facilitating	O
lymphangiogenesis	O
in	O
tumors	S-Phenotype
.	O

Hence	O
,	O
this	O
previously	O
unknown	O
FBW7	O
/	O
Brg1	O
signaling	O
axis	O
provides	O
the	O
molecular	O
basis	O
and	O
the	O
rationale	O
to	O
target	O
Brg1	O
in	O
FBW7	O
-	O
compromised	O
human	O
gastric	B-Phenotype
cancers	E-Phenotype

Heterozygous	O
mutations	O
of	O
the	O
Forkhead	O
-	O
box	O
protein	O
2	O
(	O
FOXP2	O
)	O
gene	O
in	O
humans	O
cause	O
childhood	B-Phenotype
apraxia	I-Phenotype
of	I-Phenotype
speech	E-Phenotype
.	O

We	O
report	O
a	O
case	O
of	O
2	O
-	O
year	O
old	O
child	O
who	O
presented	O
with	O
small	O
bone	O
osteomyelitis	S-Phenotype
involving	O
bilateral	O
feet	O
and	O
was	O
later	O
diagnosed	O
to	O
have	O
autosomal	B-Phenotype
recessive	I-Phenotype
CGD	E-Phenotype
due	O
to	O
mutation	O
in	O
NCF1	O
gene	O

Mutations	O
in	O
bestrophin	O
-	O
1	O
(	O
BEST1	O
)	O
are	O
associated	O
with	O
distinct	O
retinopathies	S-Phenotype
,	O
notably	O
three	O
forms	O
with	O
autosomal	O
dominant	O
inheritance	O
and	O
one	O
condition	O
with	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
mode	O
of	O
transmission	O
.	O

Our	O
results	O
showed	O
that	O
treatment	O
with	O
MEHP	O
enriched	O
the	O
population	O
of	O
cancer	S-Phenotype
-	O
stem	O
-	O
cell	O
(	O
CSC	O
)	O
-	O
like	O
cells	O
and	O
upregulated	O
IL	O
-	O
8	O
expression	O
by	O
inducing	O
the	O
AKT	O
-	O
b	O
-	O
catenin	O
-	O
TCF4	O
signaling	O
pathway	O
.	O

By	O
GEPIA	O
database	O
analysis	O
,	O
we	O
also	O
found	O
that	O
the	O
expression	O
of	O
lncRNA	O
FEZF	O
-	O
AS1	O
and	O
FEZF1	O
were	O
significantly	O
higher	O
in	O
tumour	S-Phenotype
tissues	O
than	O
those	O
of	O
the	O
adjacent	O
non	O
-	O
cancerous	S-Phenotype
tissues	O
in	O
969	O
NSCLC	O
patients	O
(	O
P	O
AAAA	O
0.05	O
)	O
,	O
and	O
lncRNA	O
FEZF	O
-	O
AS1	O
was	O
positively	O
correlated	O
with	O
FEZF1	O
(	O
r	O
=	O
0.90	O
,	O
P	O
AAAA	O
0.001	O
)	O
.	O

Oculopharyngeal	B-Phenotype
muscular	I-Phenotype
dystrophy	E-Phenotype
(	O
OPMD	S-Phenotype
)	O
is	O
an	O
autosomal	O
dominant	O
,	O
late	O
-	O
onset	O
muscle	O
disorder	O
characterized	O
by	O
ptosis	S-Phenotype
,	O
swallowing	B-Phenotype
difficulties	E-Phenotype
,	O
proximal	B-Phenotype
limb	I-Phenotype
weakness	E-Phenotype
and	O
nuclear	B-Phenotype
aggregates	I-Phenotype
in	I-Phenotype
skeletal	I-Phenotype
muscles	E-Phenotype
.	O

Importantly	O
,	O
we	O
found	O
that	O
the	O
antitumor	O
effects	S-Phenotype
of	O
HepaCAM	O
on	O
the	O
resistant	O
cells	O
were	O
associated	O
with	O
the	O
downregulation	O
of	O
Notch	O
signaling	O
.	O

Via	O
its	O
bipartite	O
zona	O
pellucida	O
module	O
(	O
ZP	O
-	O
N	O
/	O
ZP	O
-	O
C	O
)	O
,	O
UMOD	O
forms	O
extracellular	O
filaments	O
that	O
regulate	O
kidney	O
electrolyte	O
balance	O
and	O
innate	O
immunity	O
,	O
as	O
well	O
as	O
protect	O
against	O
renal	B-Phenotype
stones	E-Phenotype
.	O

Furthermore	O
,	O
CDCA7	O
increased	O
the	O
expression	O
of	O
EZH2	O
,	O
a	O
marker	O
of	O
aggressive	O
breast	B-Phenotype
cancer	E-Phenotype
that	O
is	O
involved	O
in	O
tumor	S-Phenotype
progression	O
,	O
by	O
enhancing	O
the	O
transcriptional	O
activity	O
of	O
its	O
promoter	O
.	O

We	O
queried	O
the	O
loci	B-Phenotype
hyper	I-Phenotype
-	I-Phenotype
methylated	I-Phenotype
in	I-Phenotype
serrated	I-Phenotype
cancers	E-Phenotype
within	O
our	O
rightsided	O
SSA	O
/	O
Ps	O
from	O
the	O
New	O
Hampshire	O
Colonoscopy	O
Registry	O
,	O
using	O
the	O
Illumina	O
Infinium	O
Human	O
Methylation	O
450	O
k	O
panel	O
to	O
comprehensively	O
assess	O
the	O
DNA	O
methylation	O
status	O
.	O

Common	B-Phenotype
facial	I-Phenotype
dysmorphisms	E-Phenotype
include	O
a	O
thin	B-Phenotype
upper	I-Phenotype
lip	E-Phenotype
,	O
a	O
tented	B-Phenotype
upper	I-Phenotype
lip	E-Phenotype
,	O
a	O
triangular	B-Phenotype
face	E-Phenotype
,	O
strabismus	S-Phenotype
and	O
microcephaly	S-Phenotype
.	O

Knockout	O
of	O
genes	O
encoding	O
metabotropic	O
glutamate	O
receptor	O
5	O
(	O
mGluR5	O
)	O
or	O
its	O
endogenous	O
regulators	O
,	O
such	O
as	O
Norbin	O
,	O
induce	O
a	O
schizophrenia	S-Phenotype
-	O
like	O
phenotype	O
in	O
rodents	O
,	O
suggesting	O
dysregulation	O
of	O
mGluR5	O
in	O
schizophrenia	S-Phenotype
.	O

We	O
found	O
a	O
genetic	O
association	O
between	O
rs11031006	O
(	O
FSHB	O
)	O
SNP	O
and	O
endometriosis	S-Phenotype
.	O

This	O
disease	O
is	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
disorder	O
,	O
and	O
the	O
gene	O
CSTB	O
,	O
which	O
encodes	O
cystatin	O
B	O
,	O
a	O
cysteine	O
protease	O
inhibitor	O
,	O
is	O
the	O
only	O
gene	O
known	O
to	O
be	O
associated	O
with	O
ULD	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
tumor	S-Phenotype
suppressor	O
candidate	O
3	O
(	O
TUSC3	O
)	O
was	O
downregulated	O
in	O
temozolomide	O
-	O
resistant	O
U87MG	O
cells	O
(	O
U87MG	O
-	O
res	O
cells	O
)	O
and	O
its	O
restoration	O
sensitized	O
U87MG	O
-	O
res	O
cells	O
to	O
temozolomide	O
.	O

In	O
contrast	O
,	O
strong	O
PKP2	O
immunoreactivity	O
was	O
observed	O
in	O
85.7	O
%	O
of	O
metastatic	B-Phenotype
tumors	E-Phenotype
.	O

Insertion	O
of	O
a	O
single	O
-	O
chain	O
variable	O
-	O
fragment	O
antibody	O
(	O
scFv	O
)	O
to	O
HER2	O
(	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2	O
)	O
in	O
gD	O
,	O
gH	O
,	O
or	O
gB	O
gives	O
rise	O
to	O
herpes	O
simplex	O
viruses	O
(	O
HSVs	O
)	O
specifically	O
retargeted	O
to	O
HER2	O
-	O
positive	O
cancer	S-Phenotype
cells	O
,	O
hence	O
to	O
highly	O
specific	O
nonattenuated	O
oncolytic	O
agents	O
.	O

Variants	O
of	O
WNK1	O
(	O
lysine	O
deficient	O
protein	O
kinase	O
1	O
)	O
,	O
ADRB2	O
(	O
b2	O
adrenergic	O
receptor	O
)	O
,	O
NEDD4L	O
(	O
ubiquitin	O
-	O
protein	O
ligase	O
NEDD4	O
-	O
like	O
)	O
,	O
KLK1	O
(	O
kallikrein	O
1	O
)	O
contribute	O
to	O
hypertension	S-Phenotype
,	O
and	O
AKR1C3	O
(	O
aldo	O
-	O
keto	O
reductase	O
family1	O
member	O
C3	O
)	O
,	O
is	O
associated	O
with	O
preeclampsia	S-Phenotype
.	O

Genetic	O
reduction	O
of	O
Adcy1	O
also	O
ameliorates	O
autism	S-Phenotype
-	O
related	O
symptoms	O
including	O
repetitive	B-Phenotype
behaviour	E-Phenotype
,	O
defective	B-Phenotype
social	I-Phenotype
interaction	E-Phenotype
and	O
audiogenic	B-Phenotype
seizures	E-Phenotype
.	O

Mutations	O
in	O
18	O
genes	O
that	O
encode	O
components	O
of	O
GPI	O
-	O
anchor	O
biogenesis	O
result	O
in	O
a	O
phenotypic	O
spectrum	O
that	O
includes	O
learning	B-Phenotype
disability	E-Phenotype
,	O
epilepsy	S-Phenotype
,	O
microcephaly	S-Phenotype
,	O
congenital	B-Phenotype
malformations	E-Phenotype
and	O
mild	O
dysmorphic	O
features	O
.	O

Hermansky	O
-	O
Pudlak	O
syndrome	O
(	O
HPS	O
)	O
,	O
first	O
described	O
in	O
1959	O
,	O
is	O
a	O
rare	O
form	O
of	O
syndromic	B-Phenotype
oculocutaneous	I-Phenotype
albinism	E-Phenotype
associated	O
with	O
bleeding	B-Phenotype
diathesis	E-Phenotype
and	O
in	O
some	O
cases	O
pulmonary	B-Phenotype
fibrosis	E-Phenotype
and	O
granulomatous	B-Phenotype
colitis	E-Phenotype
.	O

The	O
disease	O
family	O
of	O
muscular	B-Phenotype
dystrophy	I-Phenotype
-	I-Phenotype
dystroglycanopathy	E-Phenotype
(	O
MDDG	S-Phenotype
)	O
contains	O
a	O
spectrum	O
of	O
severe	O
to	O
mild	O
disorders	O
,	O
designated	O
as	O
MDDG	O
type	O
A	O
to	O
C	O
.	O

We	O
believe	O
that	O
this	O
strategy	O
combined	O
with	O
multi	O
-	O
dimensional	O
analysis	O
of	O
sialic	O
acid	O
metabolism	O
will	O
ultimately	O
provide	O
novel	O
insights	O
into	O
breast	B-Phenotype
cancer	E-Phenotype
subtypes	O
and	O
provide	O
a	O
foundation	O
for	O
new	O
methods	O
of	O
diagnosis	O

Type	O
II	O
(	O
middle	O
type	O
)	O
patients	O
show	O
development	O
delay	O
and	O
the	O
distinctive	O
facial	O
phenotype	O
(	O
midface	B-Phenotype
retraction	E-Phenotype
,	O
short	B-Phenotype
and	I-Phenotype
upturned	I-Phenotype
nose	E-Phenotype
)	O
,	O
lacking	B-Phenotype
both	I-Phenotype
hydronephrosis	I-Phenotype
and	I-Phenotype
typical	I-Phenotype
skeletal	I-Phenotype
abnormalities	E-Phenotype
,	O
with	O
existence	O
of	O
SETBP1mutation	O
.	O

Low	O
expression	O
of	O
vegf	O
-	O
a	O
in	O
tumor	S-Phenotype
correlated	O
with	O
better	O
survival	O
in	O
men	O
but	O
not	O
in	O
women	O
.	O

Some	O
genes	O
,	O
such	O
as	O
GSTM1	O
,	O
DNMT3L	O
,	O
and	O
CYP1A1	O
,	O
have	O
been	O
shown	O
to	O
be	O
potentially	O
associated	O
with	O
oligospermia	S-Phenotype
;	O
some	O
,	O
such	O
as	O
CATSPER1	O
,	O
CRISP2	O
,	O
SEPT4	O
,	O
TCTE3	O
,	O
TEKT4	O
,	O
and	O
DNAH1	O
,	O
with	O
asthenospermia	S-Phenotype
;	O
and	O
still	O
others	O
,	O
such	O
as	O
DPY19L2	O
and	O
AURKC	O
,	O
with	O
teratospermia	S-Phenotype
.	O

We	O
phenotyped	O
a	O
large	O
population	O
of	O
typical	O
individuals	O
for	O
schizophrenia	S-Phenotype
-	O
spectrum	O
and	O
autism	S-Phenotype
-	O
spectrum	O
traits	O
,	O
and	O
genotyped	O
them	O
for	O
the	O
single	O
-	O
nucleotide	O
polymorphism	O
rs850807	O
,	O
which	O
is	O
putatively	O
functional	O
and	O
linked	O
with	O
MAGEL2	O
and	O
NDN	O
Genetic	O
variation	O
in	O
rs850807	O
was	O
strongly	O
and	O
exclusively	O
associated	O
with	O
the	O
ideas	O
of	O
reference	O
subscale	O
of	O
the	O
schizophrenia	S-Phenotype
spectrum	O
,	O
which	O
is	O
best	O
typified	O
as	O
paranoia	S-Phenotype
.	O

The	O
scope	O
of	O
the	O
present	O
review	O
is	O
to	O
recapitulate	O
and	O
review	O
the	O
evidence	O
of	O
SPINT2	O
participation	O
in	O
cancer	S-Phenotype
development	O
and	O
progression	O
,	O
exploring	O
the	O
clinical	O
,	O
biological	O
and	O
functional	O
descriptions	O
of	O
the	O
involvement	O
of	O
this	O
protein	O
in	O
diverse	O
neoplasias	S-Phenotype
.	O

Moreover	O
,	O
expression	O
of	O
a	O
phosphorylation	O
-	O
deficient	O
PDP1	O
Y94F	O
mutant	O
in	O
cancer	S-Phenotype
cells	O
resulted	O
in	O
increased	O
oxidative	O
phosphorylation	O
,	O
decreased	O
cell	O
proliferation	O
under	O
hypoxia	S-Phenotype
,	O
and	O
reduced	O
tumor	S-Phenotype
growth	O
in	O
mice	O
.	O

We	O
conducted	O
a	O
case	O
-	O
control	O
study	O
within	O
the	O
Hispanic	O
Community	O
Health	O
Study	O
/	O
Study	O
of	O
Latinos	O
to	O
investigate	O
whether	O
sleep	O
disordered	O
breathing	O
,	O
as	O
a	O
model	O
of	O
hypoxemia	S-Phenotype
,	O
is	O
independently	O
associated	O
with	O
elevated	O
cFGF23	O
levels	O
in	O
the	O
general	O
population	O
and	O
with	O
elevated	O
cFGF23	O
and	O
iFGF23	O
levels	O
in	O
patients	O
with	O
chronic	B-Phenotype
kidney	I-Phenotype
disease	E-Phenotype
(	O
CKD	S-Phenotype
)	O
,	O
in	O
whom	O
FGF23	O
cleavage	O
may	O
be	O
impaired	O
.	O

Using	O
super	O
-	O
resolution	O
and	O
electron	O
microscopy	O
,	O
we	O
find	O
that	O
the	O
human	O
microcephaly	S-Phenotype
protein	O
,	O
RTTN	O
,	O
is	O
recruited	O
to	O
the	O
proximal	O
end	O
of	O
the	O
procentriole	O
at	O
early	O
S	O
phase	O
,	O
and	O
is	O
located	O
at	O
the	O
inner	O
luminal	O
walls	O
of	O
centrioles	O
.	O

The	O
Rb	O
tumor	S-Phenotype
suppressor	O
gene	O
performs	O
a	O
critical	O
role	O
in	O
controlling	O
cell	O
proliferation	O
and	O
tumorigenesis	O
;	O
it	O
recruits	O
HDAC1	O
protein	O
into	O
the	O
E2F	O
complexes	O
to	O
repress	O
transcription	O
.	O

Heterogeneous	O
HS	O
distribution	O
in	O
the	O
HS	O
-	O
positive	O
tumours	S-Phenotype
was	O
more	O
related	O
to	O
the	O
necrosis	O
or	O
glandular	O
-	O
like	O
brain	O
zones	O
rather	O
than	O
glioma	S-Phenotype
cells	O
with	O
high	O
or	O
low	O
Ki	O
-	O
67	O
index	O
.	O

Elevated	O
cytokines	O
,	O
such	O
as	O
interferon	O
(	O
IFN	O
)	O
-	O
γ	O
,	O
interleukin	O
(	O
IL	O
)	O
-	O
6	O
and	O
tumor	S-Phenotype
necrosis	O
factor	O
α	O
decreased	O
to	O
normal	O
levels	O
after	O
splenectomy	O
whereas	O
IL	O
-	O
10	O
remained	O
high	O
.	O

Although	O
TUFM	O
knockdown	O
also	O
induced	O
EMT	O
of	O
MCF7	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
,	O
the	O
underlying	O
mechanism	O
appeared	O
somewhat	O
different	O
from	O
that	O
in	O
lung	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Silencing	O
of	O
the	O
contiguous	O
Phf10	O
or	O
Dll1	O
genes	O
only	O
produced	O
slightly	O
delayed	O
migration	O
but	O
not	B-Phenotype
periventricular	I-Phenotype
nodular	I-Phenotype
heterotopia	E-Phenotype
.	O

Moreover	O
,	O
overexpression	O
of	O
mutant	O
but	O
not	O
normal	O
CCDC174	O
in	O
neuroblastoma	S-Phenotype
cells	O
caused	O
rapid	O
apoptosis	O
.	O

For	O
all	O
six	O
genes	O
,	O
tumors	S-Phenotype
in	O
AA	O
had	O
higher	O
expression	O
of	O
poor	O
prognosis	O
genes	O
(	O
CRYBB2	O
,	O
PSPH	O
,	O
SQLE	O
,	O
TYMS	O
)	O
and	O
lower	O
expression	O
of	O
good	O
prognosis	O
genes	O
(	O
ACOX2	O
,	O
MUC1	O
)	O
.	O

Mutations	O
with	O
milder	O
presentation	O
(	O
homozygous	O
p.D132A	O
/	O
EXOSC3	O
or	O
VRK1	O
)	O
may	O
display	O
additionally	O
signs	O
of	O
upper	B-Phenotype
motor	I-Phenotype
neuron	I-Phenotype
impairment	E-Phenotype
,	O
dystonia	S-Phenotype
or	O
ataxia	S-Phenotype
and	O
die	O
at	O
age	O
between	O
5	O
and	O
18	O
years	O
.	O

Our	O
purpose	O
of	O
this	O
study	O
is	O
to	O
discover	O
the	O
physiological	O
effects	O
and	O
mechanism	O
of	O
FUZ	O
in	O
non	B-Phenotype
-	I-Phenotype
small	I-Phenotype
-	I-Phenotype
cell	I-Phenotype
lung	I-Phenotype
cancer	E-Phenotype
(	O
NSCLC	S-Phenotype
)	O
in	O
vitro	O
.	O

TMPRSS2	O
-	O
ERG	O
rearrangement	O
and	O
PTEN	O
loss	O
,	O
events	O
sensitizing	O
to	O
PARPi	O
,	O
occurred	O
frequently	O
along	O
with	O
heterogeneous	S-Phenotype
loss	O
of	O
DNA	O
repair	O
factors	O
53BP1	O
,	O
JMJD1C	O
and	O
Rev7	O
(	O
all	O
studied	O
here	O
for	O
the	O
first	O
time	O
in	O
CaP	O
)	O
whose	O
defects	O
may	O
cause	O
resistance	O
to	O
PARPi	O
.	O

Our	O
study	O
indicates	O
the	O
novel	O
WDR73	O
p.W371G	O
missense	O
mutation	O
causes	O
infantile	B-Phenotype
onset	I-Phenotype
intellectual	I-Phenotype
disability	E-Phenotype
and	O
cerebellar	B-Phenotype
hypoplasia	E-Phenotype
in	O
recessive	O
mode	B-Phenotype
of	I-Phenotype
inheritance	E-Phenotype
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
the	O
presentation	O
of	O
a	O
MHC	O
class	O
II	O
-	O
restricted	O
model	O
Ag	O
(	O
male	O
,	O
DBY	O
)	O
released	O
by	O
dying	O
tumor	S-Phenotype
cells	O
may	O
last	O
more	O
than	O
4	O
wk	O
.	O

Several	O
missense	O
mutations	O
in	O
intestinal	O
cell	O
kinase	O
(	O
ICK	O
)	O
gene	O
lead	O
to	O
endocrine	B-Phenotype
-	I-Phenotype
cerebro	I-Phenotype
-	I-Phenotype
osteodysplasia	E-Phenotype
syndrome	O
or	O
short	B-Phenotype
rib	I-Phenotype
-	I-Phenotype
polydactyly	E-Phenotype
syndrome	O
,	O
lethal	B-Phenotype
recessive	I-Phenotype
developmental	I-Phenotype
ciliopathies	E-Phenotype
.	O

In	O
the	O
present	O
study	O
the	O
expression	O
status	O
of	O
CDK10	O
and	O
its	O
prognostic	O
significance	O
in	O
gastric	B-Phenotype
cancer	E-Phenotype
was	O
determined	O
,	O
as	O
well	O
as	O
its	O
role	O
in	O
cell	O
proliferation	O
and	O
invasion	O
.	O

Moreover	O
,	O
we	O
found	O
that	O
mice	O
carrying	O
a	O
spontaneous	O
mutation	O
allelic	O
to	O
the	O
most	O
common	O
mutation	O
found	O
in	O
patients	O
displayed	O
progressive	B-Phenotype
gait	I-Phenotype
abnormalities	E-Phenotype
and	O
vision	B-Phenotype
loss	E-Phenotype
,	O
in	O
addition	O
to	O
biochemical	O
defects	O
consistent	O
with	O
the	O
major	O
clinical	O
features	O
of	O
the	O
disease	O
.	O

Pyridoxine	O
5	O
*	O
-	O
phosphate	O
oxidase	O
(	O
PNPO	O
)	O
is	O
an	O
enzyme	O
that	O
converts	O
pyridoxine	O
5	O
*	O
-	O
phosphate	O
into	O
pyridoxal	O
5	O
*	O
-	O
phosphate	O
(	O
PLP	O
)	O
,	O
an	O
active	O
form	O
of	O
vitamin	O
B6	O
implicated	O
in	O
several	O
types	O
of	O
cancer	S-Phenotype
.	O

Corresponding	O
implicated	O
genes	O
,	O
such	O
as	O
TNNI3K	O
,	O
ErbB3	O
,	O
MKL2	O
,	O
MTNR1B	O
and	O
PRKD1	O
,	O
may	O
explain	O
the	O
associations	O
between	O
reproductive	O
factors	O
and	O
heart	B-Phenotype
failure	E-Phenotype
.	O

Our	O
results	O
suggest	O
that	O
DNAJC12	O
mutations	O
(	O
absent	O
in	O
500	O
early	O
-	O
onset	O
patients	O
with	O
Parkinson	O
's	O
disease	O
)	O
rarely	O
cause	O
dopa	B-Phenotype
-	I-Phenotype
responsive	I-Phenotype
nonprogressive	I-Phenotype
parkinsonism	E-Phenotype
in	O
adulthood	O
,	O
but	O
broaden	O
the	O
clinical	B-Phenotype
spectrum	I-Phenotype
of	I-Phenotype
DNAJC12	I-Phenotype
deficiency	E-Phenotype
.	O

OBJECTIVES	O
We	O
hypothesised	O
that	O
p16	O
ink4a	O
methylation	O
might	O
have	O
a	O
role	O
in	O
cancer	S-Phenotype
development	O
driven	O
by	O
HPV16	O
,	O
mainly	O
in	O
the	O
presence	O
of	O
intact	O
E1	O
/	O
E2	O
genes	O
.	O

Moreover	O
,	O
our	O
observations	O
support	O
previous	O
findings	O
suggesting	O
that	O
FANCM	O
is	O
a	O
breast	B-Phenotype
cancer	E-Phenotype
-	O
predisposing	O
gene	O
.	O

Mutations	O
in	O
CASK	O
cause	O
a	O
wide	O
spectrum	O
of	O
phenotypes	O
in	O
humans	O
ranging	O
from	O
mild	O
X	B-Phenotype
-	I-Phenotype
linked	I-Phenotype
intellectual	I-Phenotype
disability	E-Phenotype
to	O
a	O
severe	O
microcephaly	S-Phenotype
(	O
MC	S-Phenotype
)	O
and	O
pontocerebellar	B-Phenotype
hypoplasia	I-Phenotype
syndrome	E-Phenotype
.	O

Connexin	O
31	O
(	O
Cx31	O
)	O
is	O
considered	O
a	O
suppressor	O
for	O
many	O
tumors	S-Phenotype
.	O

The	O
JU	O
-	O
PI	O
cells	O
have	O
a	O
sub	O
-	O
tetraploid	O
karyotype	O
including	O
the	O
1	O
;	O
10	O
chromosomal	O
translocation	O
and	O
amplification	O
of	O
the	O
proximal	O
end	O
of	O
3p	O
;	O
these	O
features	O
are	O
considered	O
genetic	O
signatures	O
of	O
myxoinflammatory	B-Phenotype
fibroblastic	I-Phenotype
sarcoma	E-Phenotype
.	O

This	O
arrangement	O
is	O
required	O
for	O
filament	O
formation	O
and	O
is	O
directed	O
by	O
an	O
ordered	O
ZP	O
-	O
N	O
/	O
ZP	O
-	O
C	O
linker	O
that	O
is	O
not	O
observed	O
in	O
ZP2	O
but	O
is	O
conserved	O
in	O
the	O
sequence	O
of	O
deafness	S-Phenotype
/	O
Crohn	B-Phenotype
's	I-Phenotype
disease	E-Phenotype
-	O
associated	O
homopolymeric	O
glycoproteins	O
α	O
-	O
tectorin	O
(	O
TECTA	O
)	O
and	O
glycoprotein	O
2	O
(	O
GP2	O
)	O
.	O

From	O
a	O
GeneMatcher	O
-	O
enabled	O
international	O
collaboration	O
,	O
we	O
identified	O
ten	O
individuals	O
affected	O
by	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
speech	B-Phenotype
delay	E-Phenotype
,	O
ataxia	S-Phenotype
,	O
and	O
facial	B-Phenotype
dysmorphism	E-Phenotype
and	O
carrying	O
a	O
deleterious	O
EBF3	O
variant	O
detected	O
by	O
whole	O
-	O
exome	O
sequencing	O
.	O

We	O
suggest	O
that	O
the	O
combination	O
of	O
reduced	O
NM23	O
-	O
H1	O
,	O
induced	O
MACC1	O
,	O
and	O
the	O
presence	O
of	O
tumor	S-Phenotype
budding	O
are	O
promising	O
biomarkers	O
for	O
the	O
prediction	O
of	O
recurrence	O
and	O
may	O
aid	O
the	O
stratification	O
of	O
patients	O
with	O
stage	B-Phenotype
II	I-Phenotype
colon	I-Phenotype
cancer	E-Phenotype
for	O
adjuvant	O
chemotherapy	O

In	O
addition	O
,	O
haploid	O
clone	O
of	O
tumor	S-Phenotype
DNA	O
was	O
confirmed	O
by	O
germline	O
mutation	O
and	O
somaticmutation	O
,	O
which	O
suggested	O
the	O
pathogenic	O
mechanism	O
of	O
AAAAAAtwo	O
-	O
hit	O
-	O
model.AAAAA	O
;	O
ARMC5	O
was	O
the	O
causative	O
gene	O
of	O
AIMAH	O
pedigrees	O
.	O

Thus	O
,	O
therapeutic	O
inhibition	O
of	O
one	O
GOF	O
p53	O
-	O
induced	O
pathway	O
would	O
be	O
insufficient	O
to	O
prevent	O
tumor	S-Phenotype
growth	O
as	O
the	O
oncoprotein	O
activates	O
a	O
multitude	O
of	O
parallel	O
pathways	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
isolate	O
cancer	S-Phenotype
stem	O
-	O
like	O
cells	O
marked	O
by	O
high	O
expression	O
of	O
CD44	O
,	O
a	O
putative	O
cancer	S-Phenotype
stem	O
cell	O
marker	O
,	O
from	O
primary	O
oral	B-Phenotype
squamous	I-Phenotype
cell	I-Phenotype
carcinomas	E-Phenotype
and	O
identify	O
distinctive	O
gene	O
expression	O
patterns	O
in	O
these	O
cells	O
.	O

Furthermore	O
,	O
Ptrh2	O
expression	O
is	O
altered	O
in	O
skeletal	O
muscle	O
of	O
classical	O
congenital	B-Phenotype
muscular	I-Phenotype
dystrophy	E-Phenotype
mouse	O
models	O
.	O

Gain‑of‑function	O
CTTNB1	O
mutations	O
are	O
detected	O
in	O
bladder	B-Phenotype
cancer	E-Phenotype
,	O
colorectal	B-Phenotype
cancer	E-Phenotype
,	O
gastric	B-Phenotype
cancer	E-Phenotype
,	O
liver	B-Phenotype
cancer	E-Phenotype
,	O
lung	B-Phenotype
cancer	E-Phenotype
,	O
pancreatic	B-Phenotype
cancer	E-Phenotype
,	O
prostate	B-Phenotype
cancer	E-Phenotype
and	O
uterine	B-Phenotype
cancer	E-Phenotype
,	O
whereas	O
loss‑of‑function	O
CTNNB1	O
mutations	O
are	O
also	O
detected	O
in	O
human	O
cancer	S-Phenotype
.	O

Circulating	O
soluble	O
corin	O
has	O
been	O
found	O
to	O
be	O
associated	O
with	O
various	O
cardiovascular	B-Phenotype
diseases	E-Phenotype
,	O
such	O
as	O
hypertension	S-Phenotype
,	O
heart	B-Phenotype
failure	E-Phenotype
,	O
myocardial	B-Phenotype
infarction	E-Phenotype
,	O
preeclampsia	S-Phenotype
,	O
and	O
stroke	S-Phenotype
.	O

It	O
is	O
caused	O
by	O
recessive	O
mutations	O
in	O
liNBEAL2	O
/	O
i	O
,	O
resulting	O
in	O
macrothrombocytopenia	S-Phenotype
and	O
myelofibrosis	S-Phenotype
.	O

It	O
is	O
a	O
genetic	O
disorder	O
caused	O
by	O
a	O
mutation	O
in	O
the	O
dysferlin	O
gene	O
(	O
DYSF	O
)	O
with	O
an	O
autosomal	B-Phenotype
recessive	I-Phenotype
mode	I-Phenotype
of	I-Phenotype
inheritance	E-Phenotype
.	O

Mutations	O
in	O
the	O
kinesin	O
family	O
member	O
1A	O
(	O
KIF1A	O
)	O
gene	O
have	O
been	O
associated	O
with	O
a	O
wide	O
range	O
of	O
phenotypes	O
including	O
recessive	O
mutations	O
causing	O
hereditary	B-Phenotype
sensory	I-Phenotype
neuropathy	E-Phenotype
and	O
hereditary	B-Phenotype
spastic	I-Phenotype
paraplegia	E-Phenotype
and	O
de	O
novo	O
dominant	O
mutations	O
causing	O
a	O
more	O
complex	O
neurological	O
disorder	O
affecting	O
both	O
the	O
central	O
and	O
peripheral	O
nervous	O
system	O
.	O

While	O
there	O
were	O
no	O
significant	O
correlations	O
with	O
both	O
Se	O
status	O
markers	O
,	O
liSELENOF	O
/	O
i	O
,	O
liSELENOK	O
/	O
i	O
,	O
and	O
liTXNRD1	O
/	O
i	O
tumor	S-Phenotype
tissue	O
expression	O
positively	O
correlated	O
with	O
Se	O
,	O
while	O
liTXNRD2	O
/	O
i	O
and	O
liTXNRD3	O
/	O
i	O
negatively	O
correlated	O
with	O
liSELENOP	O
/	O
i	O
.	O

Besides	O
,	O
previous	O
evidence	O
suggested	O
that	O
AHI1	O
expression	O
was	O
changed	O
in	O
schizophrenia	S-Phenotype
patients	O
.	O

The	O
high	O
expression	O
of	O
TAZ	O
/	O
YAP	O
promotes	O
the	O
progression	O
of	O
malignant	B-Phenotype
melanoma	E-Phenotype
and	O
affects	O
the	O
postoperative	O
survival	O
of	O
patients	O

Among	O
patients	O
,	O
29.5	O
%	O
had	O
a	O
phenotype	O
of	O
ante	O
/	O
neonatal	O
Bartter	O
syndrome	O
(	O
polyhydramnios	S-Phenotype
or	O
diagnosis	O
in	O
the	O
first	O
month	O
of	O
life	O
)	O
,	O
44.5	O
%	O
had	O
classic	O
Bartter	O
syndrome	O
(	O
diagnosis	O
during	O
childhood	O
,	O
hypercalciuria	S-Phenotype
,	O
and	O
/	O
or	O
polyuria	S-Phenotype
)	O
,	O
and	O
26.0	O
%	O
had	O
Gitelman	O
-	O
like	O
syndrome	O
(	O
fortuitous	O
discovery	O
of	O
hypokalemia	S-Phenotype
with	O
hypomagnesemia	S-Phenotype
and	O
/	O
or	O
hypocalciuria	S-Phenotype
in	O
childhood	O
or	O
adulthood	O
)	O
.	O

Although	O
the	O
pathophysiological	O
mechanisms	O
that	O
underlie	O
this	O
entity	O
remain	O
unknown	O
,	O
the	O
fact	O
that	O
epilepsy	S-Phenotype
can	O
affect	O
cardiac	O
function	O
is	O
not	O
surprising	O
.	O

Diagnosis	O
of	O
superficial	B-Phenotype
CD34	I-Phenotype
-	I-Phenotype
positive	I-Phenotype
fibroblastic	I-Phenotype
tumor	E-Phenotype
was	O
offered	O
.	O

We	O
report	O
that	O
WTIP	O
is	O
a	O
tumor	S-Phenotype
suppressor	O
in	O
human	O
NSCLC	O
.	O

Here	O
we	O
show	O
that	O
MED1	O
,	O
a	O
Mediator	O
subunit	O
in	O
the	O
Middle	O
module	O
of	O
Mediator	O
complex	O
,	O
is	O
overexpressed	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
and	O
is	O
a	O
negative	O
prognostic	O
factor	O
.	O

BEN	O
is	O
a	O
primary	O
,	O
chronic	B-Phenotype
tubulointerstitial	I-Phenotype
nephritis	E-Phenotype
characterized	O
with	O
chronic	B-Phenotype
anemia	E-Phenotype
,	O
absence	B-Phenotype
of	I-Phenotype
edema	E-Phenotype
,	O
xantoderma	S-Phenotype
,	O
normal	B-Phenotype
blood	I-Phenotype
pressure	E-Phenotype
and	O
normal	B-Phenotype
findings	I-Phenotype
on	I-Phenotype
the	I-Phenotype
fundus	I-Phenotype
oculi	E-Phenotype
.	O

We	O
detected	O
11	O
novel	O
mutations	O
in	O
GJA3	O
,	O
GJA8	O
,	O
CRYAA	O
,	O
CRYBB2	O
,	O
CRYGS	O
,	O
CRYGA	O
,	O
GCNT2	O
,	O
CRYGA	O
,	O
and	O
MIP	O
;	O
and	O
three	O
previously	O
reported	O
cataract	B-Phenotype
-	I-Phenotype
causing	I-Phenotype
mutations	E-Phenotype
in	O
GJA8	O
,	O
CRYAA	O
,	O
and	O
CRYBB2	O
The	O
most	O
commonly	O
mutated	O
genes	O
were	O
those	O
coding	O
for	O
gap	O
junctions	O
and	O
crystallin	O
proteins	O
.	O

However	O
,	O
there	O
is	O
much	O
debate	O
over	O
the	O
roles	O
of	O
the	O
reversionless	O
3	O
-	O
like	O
(	O
REV3L	O
)	O
protein	O
responsible	O
for	O
TLS	O
and	O
p53	O
in	O
regulating	O
cancer	S-Phenotype
cell	O
metabolism	O
.	O

We	O
generated	O
liCc2d1b	O
/	O
i	O
knockout	O
(	O
KO	O
)	O
,	O
liCc2d1a	O
/	O
1b	O
/	O
i	O
double	O
heterozygous	O
and	O
double	O
KO	O
mice	O
,	O
then	O
performed	O
behavioral	O
studies	O
to	O
analyze	O
learning	O
and	O
memory	O
,	O
social	O
interactions	O
,	O
anxiety	S-Phenotype
,	O
and	O
hyperactivity	S-Phenotype
.	O

Thus	O
,	O
our	O
data	O
indicate	O
that	O
in	O
pancreatic	B-Phenotype
cancer	E-Phenotype
cells	O
,	O
the	O
expression	O
of	O
ENG	O
may	O
be	O
controlled	O
by	O
a	O
pathway	O
mediated	O
by	O
SMAD4	O
.	O

Three	O
families	O
(	O
families	O
1	O
,	O
2	O
and	O
3	O
)	O
were	O
found	O
to	O
have	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
(	O
AR	S-Phenotype
)	O
pattern	O
of	O
inheritance	O
while	O
family	O
4	O
displayed	O
an	O
autosomal	B-Phenotype
dominant	I-Phenotype
(	I-Phenotype
AD	I-Phenotype
)	I-Phenotype
mode	I-Phenotype
of	I-Phenotype
inheritance	E-Phenotype
.	O

The	O
knock	O
out	O
animals	O
were	O
protected	O
from	O
HFD	O
induced	O
obesity	S-Phenotype
,	O
fatty	B-Phenotype
liver	E-Phenotype
and	O
insulin	B-Phenotype
resistance	E-Phenotype
.	O

Atypical	O
Rett	O
syndrome	O
is	O
a	O
child	O
neurodevelopmental	O
disorder	O
induced	O
by	O
mutations	O
in	O
CDKL5	O
gene	O
and	O
characterized	O
by	O
a	O
progressive	O
regression	O
in	O
development	O
with	O
loss	B-Phenotype
of	I-Phenotype
purposeful	I-Phenotype
use	I-Phenotype
of	I-Phenotype
the	I-Phenotype
hands	E-Phenotype
,	O
slowed	B-Phenotype
brain	I-Phenotype
and	I-Phenotype
head	I-Phenotype
growth	E-Phenotype
,	O
problems	B-Phenotype
with	I-Phenotype
walking	E-Phenotype
,	O
seizures	S-Phenotype
,	O
and	O
intellectual	B-Phenotype
disability	E-Phenotype
.	O

Erbin	O
(	O
-	O
/	O
-	O
)	O
mice	O
rapidly	O
develop	O
decompensated	O
cardiac	O
hypertrophy	O
,	O
and	O
following	O
severe	O
pressure	O
overload	O
all	O
Erbin	O
(	O
-	O
/	O
-	O
)	O
mice	O
died	O
from	O
heart	B-Phenotype
failure	E-Phenotype
.	O

Bardet	O
Biedl	O
syndrome	O
(	O
BBS	O
)	O
is	O
a	O
multisystem	O
genetically	O
heterogeneous	S-Phenotype
ciliopathy	O
that	O
most	O
commonly	O
leads	O
to	O
obesity	S-Phenotype
,	O
photoreceptor	B-Phenotype
degeneration	E-Phenotype
,	O
digit	B-Phenotype
anomalies	E-Phenotype
,	O
genito	B-Phenotype
-	I-Phenotype
urinary	I-Phenotype
abnormalities	E-Phenotype
,	O
as	O
well	O
as	O
cognitive	B-Phenotype
impairment	E-Phenotype
with	O
autism	S-Phenotype
,	O
among	O
other	O
features	O
.	O

We	O
also	O
demonstrate	O
that	O
ATP	O
-	O
binding	O
cassette	O
subfamily	O
C	O
member	O
2	O
(	O
ABCC2	O
)	O
gene	O
,	O
responsible	O
for	O
hyperbilirubinemia	S-Phenotype
,	O
is	O
linked	O
to	O
ERLIN1	O

Accordingly	O
,	O
the	O
I	O
-	O
branching	O
N	O
-	O
acetylglucosaminyltransferase	O
(	O
GCNT2	O
)	O
converts	O
linear	O
i	O
-	O
antigen	O
to	O
I	O
-	O
branching	O
glycan	O
,	O
and	O
its	O
expression	O
is	O
associated	O
with	O
breast	B-Phenotype
cancer	E-Phenotype
progression	O
.	O

Only	O
a	O
few	O
genes	O
,	O
including	O
SMARCA4	O
,	O
SMO	O
,	O
ZNF44	O
and	O
CHD2	O
,	O
were	O
recurrently	O
and	O
specifically	O
mutated	O
in	O
the	O
SS	O
group	O
,	O
confirming	O
the	O
low	O
recurrence	O
of	O
common	O
mutations	O
in	O
this	O
tumor	S-Phenotype
.	O

Medulloblastoma	S-Phenotype
(	O
MB	S-Phenotype
)	O
is	O
the	O
most	O
common	O
malignant	B-Phenotype
pediatric	I-Phenotype
brain	I-Phenotype
tumor	E-Phenotype
,	O
and	O
overactivation	O
of	O
the	O
Sonic	O
Hedgehog	O
(	O
Shh	O
)	O
signaling	O
pathway	O
,	O
which	O
requires	O
the	O
primary	O
cilium	O
,	O
causes	O
30	O
%	O
of	O
MBs	O
.	O

Recent	O
studies	O
have	O
examined	O
the	O
intrinsic	O
antitumor	O
activity	O
of	O
melatonin	O
in	O
various	O
cancers	S-Phenotype
,	O
including	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
,	O
the	O
primary	O
life	O
-	O
threatening	O
malignancy	O
in	O
both	O
sexes	O
in	O
Taiwan	O
.	O

Whole	O
-	O
exome	O
or	O
targeted	O
exome	O
sequencing	O
of	O
183	O
unrelated	O
familial	O
and	O
/	O
or	O
severe	O
CAKUT	O
-	O
affected	O
case	O
subjects	O
,	O
including	O
54	O
fetuses	O
with	O
BKA	O
,	O
led	O
to	O
the	O
identification	O
of	O
16	O
heterozygous	O
variants	O
in	O
GREB1L	O
(	O
growth	O
regulation	O
by	O
estrogen	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
1	O
-	O
like	O
)	O
,	O
a	O
gene	O
reported	O
as	O
a	O
target	O
of	O
retinoic	O
acid	O
signaling	O
.	O

Structural	O
rearrangements	O
of	O
chromosome	O
10	O
are	O
frequently	O
observed	O
in	O
glioblastoma	S-Phenotype
multiforme	O
and	O
over	O
80	O
%	O
of	O
tumour	S-Phenotype
samples	O
archived	O
in	O
the	O
catalogue	O
of	O
somatic	O
mutations	O
in	O
cancer	S-Phenotype
database	O
had	O
gene	O
copy	O
number	O
loss	O
for	O
PI4K2A	O
which	O
encodes	O
phosphatidylinositol	O
4	O
-	O
kinase	O
type	O
IIalpha	O
.	O

These	O
experiments	O
identify	O
a	O
role	O
for	O
mitofusins	O
in	O
directly	O
regulating	O
mitochondrial	O
transport	O
and	O
offer	O
important	O
insight	O
into	O
the	O
cell	O
type	O
specificity	O
and	O
molecular	O
mechanisms	O
of	O
axonal	B-Phenotype
degeneration	E-Phenotype
in	O
CMT2A	O
and	O
dominant	O
optic	B-Phenotype
atrophy	E-Phenotype

Intraepithelial	B-Phenotype
neoplasia	E-Phenotype
in	O
FGPs	O
,	O
referred	O
to	O
as	O
FGP	O
with	O
dysplasia	O
,	O
is	O
often	O
seen	O
in	O
patients	O
with	O
familial	O
adenomatous	O
polyposis	O
(	O
FAP	O
)	O
.	O

Prostate	B-Phenotype
cancer	E-Phenotype
is	O
the	O
most	O
common	O
non	B-Phenotype
-	I-Phenotype
skin	I-Phenotype
cancer	E-Phenotype
in	O
males	O
,	O
with	O
a	O
∼1.5	O
-	O
2	O
-	O
fold	O
higher	O
incidence	O
in	O
African	O
American	O
men	O
when	O
compared	O
with	O
whites	O
.	O

In	O
addition	O
,	O
ENG	O
was	O
found	O
to	O
be	O
related	O
to	O
the	O
spheroid	O
-	O
forming	O
ability	O
of	O
cells	O
and	O
to	O
be	O
involved	O
in	O
the	O
invasive	O
capacity	O
of	O
pancreatic	B-Phenotype
cancer	E-Phenotype
cells	O

Our	O
findings	O
suggest	O
that	O
the	O
WDR3	O
gene	O
may	O
likely	O
be	O
a	O
sensitive	O
factor	O
in	O
female	O
patients	O
with	O
schizophrenia	S-Phenotype
,	O
and	O
that	O
modification	O
of	O
the	O
WDR3	O
signaling	O
pathway	O
warrants	O
further	O
investigation	O
as	O
to	O
the	O
pathophysiology	O
of	O
schizophrenia	S-Phenotype

Our	O
findings	O
imply	O
that	O
microcephaly	S-Phenotype
is	O
a	O
variable	O
phenotype	O
in	O
WDR73	O
-	O
related	O
disease	O
,	O
suggest	O
WDR73	O
to	O
be	O
a	O
candidate	O
gene	O
of	O
severe	O
intellectual	B-Phenotype
disability	E-Phenotype
and	O
cerebellar	B-Phenotype
hypoplasia	E-Phenotype
,	O
and	O
expand	O
the	O
molecular	O
spectrum	O
of	O
WDR73	O
-	O
related	O
disease	O

We	O
surveyed	O
GATA4	O
expression	O
in	O
24	O
hepatoblastomas	S-Phenotype
using	O
RNA	O
in	O
situ	O
hybridization	O
and	O
immunohistochemistry	O
.	O

Herein	O
,	O
we	O
performed	O
comparative	O
quantitative	O
proteomics	O
on	O
whole	O
plasma	O
sampled	O
from	O
patients	O
with	O
stable	O
angina	S-Phenotype
(	O
NMI	O
)	O
,	O
acute	O
myocardial	B-Phenotype
infarction	E-Phenotype
(	O
MI	S-Phenotype
)	O
,	O
and	O
healthy	O
control	O
subjects	O
(	O
Ctrl	O
)	O
.	O

Germline	O
SMARCE1	O
mutations	O
have	O
been	O
described	O
in	O
hereditary	O
forms	O
of	O
this	O
disease	O
and	O
more	O
recently	O
in	O
small	O
syndromic	O
and	O
sporadic	S-Phenotype
CCM	O
series	O
.	O

Then	O
,	O
the	O
role	O
of	O
PSMB8	O
in	O
migration	O
and	O
proliferation	O
of	O
glioma	S-Phenotype
cells	O
was	O
investigated	O
by	O
conducting	O
wound	O
-	O
healing	O
,	O
trans	O
-	O
well	O
assay	O
,	O
cell	O
counting	O
kit	O
(	O
CCK	O
)	O
-	O
8	O
,	O
flow	O
cytometry	O
assay	O
and	O
colony	O
formation	O
analysis	O
.	O

A	O
recurrent	O
de	O
novo	O
missense	O
variant	O
within	O
the	O
C	O
-	O
terminal	O
Sin3	O
-	O
like	O
domain	O
of	O
ZSWIM6	O
was	O
previously	O
reported	O
to	O
cause	O
acromelic	O
frontonasal	O
dysostosis	O
(	O
AFND	O
)	O
,	O
an	O
autosomal	O
-	O
dominant	O
severe	O
frontonasal	O
and	O
limb	O
malformation	O
syndrome	O
,	O
associated	O
with	O
neurocognitive	O
and	O
motor	B-Phenotype
delay	E-Phenotype
,	O
via	O
a	O
proposed	O
gain	O
-	O
of	O
-	O
function	O
effect	O
.	O

These	O
results	O
suggested	O
that	O
AHI1	O
is	O
likely	O
a	O
risk	O
gene	O
for	O
schizophrenia	S-Phenotype
,	O
at	O
least	O
in	O
European	O
populations	O
.	O

CXCL7	O
-	O
null	O
mice	O
presented	O
with	O
a	O
phenotype	O
of	O
OPLL	O
,	O
showing	O
motor	B-Phenotype
impairment	E-Phenotype
,	O
heterotopic	B-Phenotype
ossification	E-Phenotype
in	O
the	O
posterior	O
ligament	O
tissue	O
,	O
and	O
osteoporosis	S-Phenotype
in	O
vertebrate	O
tissue	O
.	O

Here	O
,	O
we	O
describe	O
the	O
first	O
autosomal	B-Phenotype
recessive	E-Phenotype
Stickler	O
family	O
due	O
to	O
loss	O
of	O
function	O
mutations	O
(	O
c.1176_1198del	O
,	O
p.Gln393Cysfs	O
*	O
25	O
)	O
of	O
COL9A3	O
gene	O
.	O

Mutations	O
in	O
SLC25A22	O
are	O
known	O
to	O
cause	O
neonatal	B-Phenotype
epileptic	I-Phenotype
encephalopathy	E-Phenotype
and	O
migrating	B-Phenotype
partial	I-Phenotype
seizures	I-Phenotype
in	I-Phenotype
infancy	E-Phenotype
.	O

PAK3	B-Phenotype
-	I-Phenotype
related	I-Phenotype
intellectual	I-Phenotype
disability	E-Phenotype
is	O
caused	O
by	O
mutations	O
in	O
the	O
gene	O
encoding	O
the	O
p21	O
-	O
activated	O
kinase	O
(	O
PAK	O
)	O
protein	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
suggest	O
that	O
HCRP1	O
downregulation	O
might	O
serve	O
as	O
an	O
indicator	O
for	O
poor	O
prognosis	O
in	O
gastric	B-Phenotype
cancer	E-Phenotype
patients	O
.	O

Here	O
,	O
we	O
present	O
a	O
comprehensive	O
spectrum	O
of	O
CNGB3	O
mutations	O
and	O
their	O
prevalence	O
in	O
a	O
cohort	O
of	O
1074	O
independent	O
families	O
clinically	O
diagnosed	O
with	O
achromatopsia	S-Phenotype
.	O

MORC2	O
knockdown	O
caused	O
marked	O
inhibition	O
of	O
liver	B-Phenotype
cancer	E-Phenotype
cell	O
proliferation	O
and	O
clonogenicity	O
,	O
whereas	O
the	O
overexpression	O
of	O
MORC2	O
substantially	O
promoted	O
liver	B-Phenotype
cancer	E-Phenotype
cell	O
proliferation	O
.	O

Based	O
on	O
our	O
and	O
published	O
data	O
we	O
propose	O
that	O
the	O
GPKOW	O
gene	O
is	O
essential	O
for	O
fetal	O
development	O
and	O
when	O
disrupted	O
,	O
leads	O
to	O
a	O
severe	O
,	O
male	O
-	O
lethal	O
phenotype	O
characterised	O
by	O
microcephaly	S-Phenotype
and	O
IUGR	S-Phenotype

Dysfunction	O
of	O
the	O
cerebral	O
glucose	O
transporter	O
GLUT1	O
(	O
encoded	O
by	O
SLC2A1	O
)	O
is	O
known	O
to	O
result	O
in	O
epilepsy	S-Phenotype
,	O
intellectual	B-Phenotype
disability	E-Phenotype
(	O
ID	S-Phenotype
)	O
,	O
and	O
movement	B-Phenotype
disorder	E-Phenotype
.	O

In	O
a	O
recent	O
study	O
combining	O
autozygome	O
and	O
exome	O
analysis	O
,	O
a	O
homozygous	O
loss	O
of	O
function	O
mutation	O
in	O
TENM3	O
(	O
previously	O
named	O
ODZ3	O
)	O
was	O
reported	O
in	O
two	O
siblings	O
with	O
isolated	B-Phenotype
bilateral	I-Phenotype
colobomatous	I-Phenotype
microphthalmia	E-Phenotype
from	O
a	O
consanguineous	O
Saudi	O
family	O
.	O

EPAC	O
is	O
also	O
known	O
for	O
its	O
dual	O
role	O
in	O
cancer	S-Phenotype
as	O
pro	O
-	O
and	O
anti	O
-	O
proliferative	O
in	O
addition	O
to	O
metastasis	O
.	O

OX40	O
and	O
its	O
ligand	O
are	O
members	O
of	O
the	O
TNF	O
/	O
TNF	O
receptor	O
superfamily	O
,	O
which	O
includes	O
various	O
molecules	O
influencing	O
cellular	O
signaling	O
and	O
function	O
of	O
both	O
tumor	S-Phenotype
and	O
immune	O
cells	O
.	O

The	O
mechanistic	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
is	O
an	O
established	O
therapeutic	O
target	O
in	O
renal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
RCC	S-Phenotype
)	O
.	O

We	O
validated	O
ZBTB20	O
,	O
CELF2	O
,	O
PARD3	O
,	O
AKAP13	O
and	O
WAC	O
,	O
which	O
were	O
identified	O
by	O
our	O
screens	O
in	O
multiple	O
cancer	S-Phenotype
types	O
,	O
as	O
new	O
tumor	S-Phenotype
suppressor	O
genes	O
in	O
prostate	B-Phenotype
cancer	E-Phenotype
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
one	O
of	O
the	O
first	O
reports	O
on	O
isolated	B-Phenotype
mild	I-Phenotype
ventricular	I-Phenotype
hypertrophy	E-Phenotype
due	O
to	O
ACAD9	O
mutation	O
in	O
a	O
family	O
with	O
moderate	O
symptoms	O
during	O
adolescence	O
.	O

Somewhat	O
arbitrarily	O
,	O
three	O
disorders	O
were	O
successively	O
put	O
forward	O
as	O
the	O
underlying	O
cause	O
of	O
HIES	O
:	O
autosomal	O
dominant	O
(	O
AD	O
)	O
STAT3	O
deficiency	O
,	O
the	O
only	O
disorder	O
corresponding	O
to	O
the	O
original	O
definition	O
of	O
HIES	O
,	O
and	O
autosomal	B-Phenotype
recessive	I-Phenotype
(	I-Phenotype
AR	I-Phenotype
)	I-Phenotype
DOCK8	I-Phenotype
and	I-Phenotype
PGM3	I-Phenotype
deficiencies	E-Phenotype
,	O
in	O
which	O
atopy	O
and	O
high	O
serum	O
IgE	O
levels	O
occur	O
in	O
a	O
context	O
of	O
manifestations	O
not	O
seen	O
in	O
patients	O
with	O
typical	O
HIES	O
.	O

Complex	O
recessive	O
spastic	B-Phenotype
paraplegias	E-Phenotype
have	O
in	O
the	O
past	O
been	O
frequently	O
associated	O
with	O
mutations	O
in	O
SPG11	O
(	O
spatacsin	O
)	O
,	O
ZFYVE26	O
/	O
SPG15	O
,	O
SPG7	O
(	O
paraplegin	O
)	O
and	O
a	O
handful	O
of	O
other	O
rare	O
genes	O
,	O
but	O
many	O
cases	O
remain	O
genetically	O
undefined	O
.	O

Birt	O
-	O
Hogg	O
-	O
Dubé	O
(	O
BHD	O
)	O
syndrome	O
is	O
a	O
rare	O
genetic	O
disorder	O
characterized	O
by	O
cutaneous	B-Phenotype
fibrofolliculomas	E-Phenotype
,	O
pulmonary	B-Phenotype
cysts	E-Phenotype
and	O
renal	B-Phenotype
cell	I-Phenotype
carcinomas	E-Phenotype
.	O

Sushi	O
repeat	O
-	O
containing	O
protein	O
X	O
-	O
linked	O
2	O
(	O
SRPX2	O
)	O
,	O
a	O
novel	O
chondroitin	O
sulfate	O
proteoglycan	O
,	O
is	O
overexpressed	O
in	O
human	O
cancer	S-Phenotype
.	O

In	O
short	O
,	O
the	O
current	O
study	O
suggests	O
XIST	O
plays	O
as	O
an	O
important	O
role	O
in	O
colon	B-Phenotype
cancer	E-Phenotype
progression	O
targeted	O
by	O
miR	O
-	O
34a	O
via	O
Wnt	O
/	O
b	O
-	O
catenin	O
signaling	O
pathway	O
,	O
providing	O
a	O
novel	O
insight	O
for	O
the	O
pathogenesis	O
and	O
underlying	O
therapeutic	O
target	O
for	O
colon	B-Phenotype
cancer	E-Phenotype

These	O
findings	O
suggest	O
that	O
the	O
Warburg	O
pathway	O
enzyme	O
PFKFB4	O
acts	O
as	O
a	O
molecular	O
fulcrum	O
that	O
couples	O
sugar	O
metabolism	O
to	O
transcriptional	O
activation	O
by	O
stimulating	O
SRC	O
-	O
3	O
to	O
promote	O
aggressive	O
metastatic	O
tumours	S-Phenotype

Zinc	O
finger	O
MYND	O
-	O
type	O
-	O
containing	O
10	O
(	O
ZMYND10	O
)	O
,	O
a	O
cytoplasmic	O
protein	O
expressed	O
in	O
ciliated	O
cells	O
,	O
causes	O
primary	B-Phenotype
ciliary	I-Phenotype
dyskinesia	E-Phenotype
(	O
PCD	S-Phenotype
)	O
when	O
mutated	O
;	O
however	O
,	O
its	O
function	O
is	O
poorly	O
understood	O
.	O

The	O
revision	O
was	O
based	O
on	O
data	O
accumulated	O
since	O
the	O
2008	O
WHO	O
classification	O
of	O
MDS	O
,	O
much	O
of	O
which	O
relates	O
to	O
new	O
molecular	O
genetic	O
information	O
about	O
these	O
neoplasms	S-Phenotype
.	O

Even	O
though	O
the	O
role	O
of	O
single	O
nucleotide	O
polymorphisms	O
of	O
ATIC	O
in	O
chemotherapy	O
-	O
induced	O
tumor	S-Phenotype
necrosis	O
has	O
not	O
been	O
investigated	O
yet	O
,	O
the	O
ATIC	O
347CAAAAG	O
polymorphism	O
may	O
influence	O
the	O
levels	O
of	O
adenosine	O
after	O
MTX	O
treatment	O
,	O
which	O
may	O
affect	O
the	O
histologic	O
response	O
of	O
osteosarcoma	S-Phenotype
.	O

Oral	O
-	O
facial	O
-	O
digital	O
syndromes	O
(	O
OFDS	O
)	O
gather	O
rare	O
genetic	O
disorders	O
characterised	O
by	O
facial	B-Phenotype
,	I-Phenotype
oral	I-Phenotype
and	I-Phenotype
digital	I-Phenotype
abnormalities	E-Phenotype
associated	O
with	O
a	O
wide	O
range	O
of	O
additional	O
features	O
(	O
polycystic	B-Phenotype
kidney	E-Phenotype
disease	O
,	O
cerebral	B-Phenotype
malformations	E-Phenotype
and	O
several	O
others	O
)	O
to	O
delineate	O
a	O
growing	O
list	O
of	O
OFDS	O
subtypes	O
.	O

MYCN	O
activation	O
,	O
often	O
due	O
to	O
genetic	O
amplification	O
,	O
represents	O
the	O
driving	O
oncogenic	O
event	O
for	O
a	O
number	O
of	O
human	O
tumors	S-Phenotype
,	O
conferring	O
bad	O
prognosis	O
and	O
predicting	O
very	O
poor	O
responses	O
even	O
to	O
the	O
most	O
aggressive	O
therapeutic	O
protocols	O
.	O

It	O
is	O
highly	O
heterogeneous	S-Phenotype
,	O
with	O
more	O
than	O
80	O
disease	O
-	O
causing	O
genes	O
27	O
of	O
which	O
are	O
known	O
to	O
cause	O
autosomal	O
dominant	O
RP	O
(	O
adRP	O
)	O
,	O
having	O
been	O
identified	O
.	O

In	O
conclusion	O
,	O
our	O
findings	O
showed	O
that	O
repression	O
of	O
LDHA	O
induced	O
by	O
wt	O
-	O
p53	O
blocks	O
tumor	S-Phenotype
growth	O
and	O
invasion	O
through	O
downregulation	O
of	O
aerobic	O
glycolysis	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
,	O
providing	O
new	O
insights	O
into	O
the	O
mechanism	O
by	O
which	O
p53	O
contributes	O
to	O
the	O
development	O
and	O
progression	O
of	O
breast	B-Phenotype
cancer	E-Phenotype

The	O
histological	O
and	O
behavioral	B-Phenotype
abnormalities	E-Phenotype
seen	O
in	O
the	O
affected	O
flies	O
set	O
the	O
stage	O
for	O
further	O
studies	O
examining	O
the	O
signaling	O
pathway	O
modulated	O
by	O
MEGF10	O
/	O
Drpr	O
in	O
muscle	O
,	O
as	O
well	O
as	O
assessing	O
the	O
effects	O
of	O
genetic	O
and	O
/	O
or	O
pharmacological	O
manipulations	O
on	O
the	O
observed	O
muscle	O
defects	O
.	O

Moreover	O
,	O
we	O
observed	O
that	O
well	O
-	O
differentiated	O
RT	O
-	O
112	O
and	O
de	O
-	O
differentiated	O
Cal	O
-	O
29	O
bladder	B-Phenotype
cancer	E-Phenotype
cells	O
show	O
an	O
inverse	O
expression	O
of	O
tricellulin	O
and	O
Itch	S-Phenotype
.	O

Besides	O
,	O
we	O
screened	O
for	O
all	O
the	O
known	O
genes	O
related	O
to	O
axonal	O
autosomal	B-Phenotype
recessive	I-Phenotype
Charcot	I-Phenotype
-	I-Phenotype
Marie	I-Phenotype
-	I-Phenotype
Tooth	I-Phenotype
disease	E-Phenotype
(	O
CMT2A2	O
/	O
HMSN2A2	O
/	O
MFN2	O
,	O
CMT2B1	O
/	O
LMNA	O
,	O
CMT2B2	O
/	O
MED25	O
,	O
CMT2B5	O
/	O
NEFL	O
,	O
ARCMT2F	O
/	O
dHMN2B	O
/	O
HSPB1	O
,	O
CMT2K	O
/	O
GDAP1	O
,	O
CMT2P	O
/	O
LRSAM1	O
,	O
CMT2R	O
/	O
TRIM2	O
,	O
CMT2S	O
/	O
IGHMBP2	O
,	O
CMT2T	O
/	O
HSJ1	O
,	O
CMTRID	O
/	O
COX6A1	O
,	O
ARAN	O
-	O
NM	O
/	O
HINT	O
and	O
GAN	O
/	O
GAN	O
)	O
,	O
for	O
the	O
genes	O
related	O
to	O
autosomal	B-Phenotype
recessive	I-Phenotype
hereditary	I-Phenotype
spastic	I-Phenotype
paraplegia	E-Phenotype
with	O
thin	B-Phenotype
corpus	I-Phenotype
callosum	E-Phenotype
and	O
axonal	B-Phenotype
peripheral	I-Phenotype
neuropathy	E-Phenotype
(	O
SPG7	O
/	O
PGN	O
,	O
SPG15	O
/	O
ZFYVE26	O
,	O
SPG21	O
/	O
ACP33	O
,	O
SPG35	O
/	O
FA2H	O
,	O
SPG46	O
/	O
GBA2	O
,	O
SPG55	O
/	O
C12orf65	O
and	O
SPG56	O
/	O
CYP2U1	O
)	O
,	O
as	O
well	O
as	O
for	O
the	O
causative	O
gene	O
of	O
peripheral	B-Phenotype
neuropathy	E-Phenotype
with	O
or	O
without	B-Phenotype
agenesis	I-Phenotype
of	I-Phenotype
the	I-Phenotype
corpus	I-Phenotype
callosum	E-Phenotype
(	O
SLC12A6	O
)	O
.	O

Both	O
NASH	O
and	O
ASH	O
patients	O
can	O
develop	O
cirrhosis	S-Phenotype
and	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
if	O
left	O
untreated	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
XIST	O
expression	O
level	O
was	O
upregulated	O
in	O
colon	B-Phenotype
cancer	E-Phenotype
tissues	O
and	O
cell	O
lines	O
.	O

An	O
early	O
intervention	O
using	O
biomarkers	O
to	O
predict	O
acute	B-Phenotype
myocardial	I-Phenotype
infarction	E-Phenotype
(	O
AMI	S-Phenotype
)	O
will	O
effectively	O
reduce	O
global	O
heart	B-Phenotype
attack	E-Phenotype
incidence	O
,	O
particularly	O
among	O
high	O
-	O
risk	O
patients	O
with	O
type	B-Phenotype
2	I-Phenotype
diabetes	I-Phenotype
mellitus	E-Phenotype
(	O
T2DM	S-Phenotype
)	O
.	O

SCD	O
patients	O
have	O
some	O
degree	O
of	O
(	O
kypho	O
)	O
scoliosis	S-Phenotype
,	O
short	B-Phenotype
stature	E-Phenotype
and	O
suffer	O
from	O
respiratory	B-Phenotype
impairment	E-Phenotype
due	O
to	O
the	O
reduced	O
size	O
of	O
their	O
thoracic	O
cage	O
.	O

We	O
demonstrated	O
the	O
necessity	O
of	O
EPRS	O
for	O
proliferation	O
of	O
tamoxifen	O
-	O
resistant	O
ER+	O
breast	B-Phenotype
cancer	E-Phenotype
,	O
but	O
not	O
ER	O
-	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Biallelic	O
,	O
partial	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
GNRHR	O
cause	O
a	O
wide	O
spectrum	O
of	O
reproductive	O
phenotypes	O
from	O
constitutional	O
delay	O
of	O
growth	O
and	O
puberty	O
to	O
complete	O
congenital	B-Phenotype
hypogonadotropic	I-Phenotype
hypogonadism	E-Phenotype
.	O

Therefore	O
,	O
STX3	O
promotes	O
the	O
growth	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
by	O
regulating	O
the	O
PTEN	O
-	O
PI3K	O
-	O
Akt	O
-	O
mTOR	O
signaling	O

MED1	O
mediates	O
induction	O
of	O
cell	O
proliferation	O
and	O
migration	O
and	O
the	O
genes	O
associated	O
with	O
it	O
(	O
JUN	O
,	O
FOS	O
,	O
EGFR	O
,	O
VEGF	O
,	O
MMP1	O
,	O
and	O
ERBB4	O
)	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
,	O
which	O
is	O
abrogated	O
when	O
used	O
together	O
with	O
miR	O
-	O
191	O
-	O
inhibition	O
.	O

Wide	O
allelic	O
heterogeneity	S-Phenotype
was	O
noted	O
,	O
with	O
large	O
gene	O
alterations	O
(	O
e.g	O
.	O

INPP5E	O
,	O
SNX17	O
,	O
ERAP2	O
,	O
FN3KRP	O
)	O
,	O
and	O
obesity	S-Phenotype
(	O
e.g	O
.	O

Recessive	O
mutations	O
in	O
WD	O
repeat	O
domain	O
62	O
(	O
WDR62	O
)	O
cause	O
microcephaly	S-Phenotype
and	O
a	B-Phenotype
wide	I-Phenotype	
spectrum	I-Phenotype
of	I-Phenotype
severe	I-Phenotype
brain	I-Phenotype
malformations	E-Phenotype
.	O

The	O
accuracy	O
of	O
this	O
mouse	O
model	O
was	O
emphasized	O
by	O
the	O
finding	O
that	O
various	O
central	O
nervous	O
system	O
and	O
noncentral	O
nervous	O
system	O
tissues	O
from	O
PD	O
patients	O
manifested	O
similar	O
GM1	O
deficiency	O
as	O
the	O
B4galnt1sup+	O
/	O
-	O
/	O
sup	O
mouse	O
.	O

The	O
FGF9	O
subfamily	O
,	O
including	O
FGF9	O
,	O
FGF16	O
,	O
and	O
FGF20	O
,	O
in	O
addition	O
to	O
rhFGF16	O
,	O
rhFGF9	O
,	O
and	O
rhFGF20	O
,	O
were	O
shown	O
to	O
stimulate	O
the	O
proliferation	O
and	O
migration	O
of	O
HuH7	O
human	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
cells	O
.	O

Remarkably	O
,	O
a	O
patient	O
with	O
an	O
isolated	O
deletion	O
at	O
the	O
3	O
'	O
-	O
end	O
of	O
SLC6A8	O
had	O
a	O
similar	O
severe	O
phenotype	O
as	O
seen	O
in	O
BCAP31	O
deficiency	O
but	O
without	O
deafness	S-Phenotype
.	O

In	O
the	O
present	O
study	O
,	O
the	O
results	O
of	O
immumohistochemisty	O
revealed	O
that	O
the	O
positive	O
staining	O
rates	O
of	O
NIBP	O
,	O
NF	O
-	O
kB	O
p65	O
and	O
NF	O
-	O
kB	O
p	O
-	O
p65	O
in	O
gastric	B-Phenotype
cancer	E-Phenotype
tissues	O
were	O
obviously	O
higher	O
than	O
those	O
in	O
normal	O
tissues	O
.	O

Here	O
,	O
we	O
report	O
that	O
the	O
expression	O
of	O
the	O
INTU	O
gene	O
is	O
aberrantly	O
elevated	O
in	O
human	O
basal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
BCC	S-Phenotype
)	O
,	O
coinciding	O
with	O
increased	O
primary	O
cilia	O
formation	O
and	O
activated	O
hedgehog	O
(	O
Hh	O
)	O
signaling	O
.	O

We	O
present	O
the	O
cloning	O
and	O
characterization	O
of	O
a	O
novel	O
gene	O
,	O
CRG	O
-	O
L2	O
(	O
Cancer	S-Phenotype
related	O
gene	O
-	O
Liver	O
2	O
)	O
,	O
which	O
displays	O
high	O
expression	O
in	O
murine	O
and	O
human	O
hepatocellular	B-Phenotype
carcinomas	E-Phenotype
.	O

This	O
study	O
also	O
identified	O
a	O
de	O
novo	O
c.3015_3027dup	O
frameshift	O
mutation	O
predicting	O
p.Lys1010Glnfs	O
*	O
57	O
in	O
NEFH	O
from	O
a	O
CMT2	O
family	O
with	O
an	O
atypical	O
clinical	O
symptom	O
of	O
prominent	O
proximal	S-Phenotype
weakness	S-Phenotype
.	O

Ten	O
-	O
year	O
average	O
intake	O
of	O
supplemental	O
zinc	O
was	O
not	O
associated	O
with	O
a	O
reduced	O
prostate	B-Phenotype
cancer	E-Phenotype
risk	O
overall	O
(	O
adjusted	O
hazard	O
ratio	O
(	O
HR	O
)	O
=	O
0.82	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
0.58	O
-	O
1.14	O
)	O
for	O
AAAA15	O
mg	O
/	O
day	O
vs.	O
nonuse	O
,	O
P	O
for	O
trend	O
=	O
0.44	O
)	O
;	O
however	O
,	O
risk	O
of	O
advanced	O
prostate	B-Phenotype
cancer	E-Phenotype
(	O
regionally	O
invasive	O
or	O
distant	O
metastatic	O
,	O
n	O
=	O
123	O
)	O
decreased	O
with	O
greater	O
intake	O
of	O
supplemental	O
zinc	O
(	O
adjusted	O
HR	O
=	O
0.34	O
,	O
95	O
%	O
CI	O
=	O
0.13	O
-	O
1.09	O
for	O
10	O
-	O
yr	O
average	O
intake	O
AAAA	O
15	O
mg	O
/	O
day	O
vs.	O
nonuse	O
,	O
P	O
for	O
trend	O
=	O
0.04	O
)	O
.	O

Our	O
data	O
demonstrate	O
that	O
CAB39L	O
is	O
a	O
novel	O
tumor	S-Phenotype
suppressor	O
which	O
suppresses	O
tumorigenesis	O
by	O
promoting	O
LKB1	O
-	O
AMPK	O
-	O
PGC1α	O
axis	O
,	O
thereby	O
preventing	O
a	O
metabolic	O
shift	O
that	O
drives	O
carcinogenesis	O
.	O

We	O
found	O
that	O
the	O
impaired	O
homeostatic	O
synaptic	O
downscaling	O
in	O
Fmr1	O
KO	O
neurons	O
is	O
caused	O
by	O
loss	O
-	O
of	O
-	O
function	O
dephosphorylation	O
of	O
an	O
epilepsy	S-Phenotype
-	O
associated	O
ubiquitin	O
E3	O
ligase	O
,	O
neural	O
precursor	O
cell	O
expressed	O
developmentally	O
down	O
-	O
regulated	O
gene	O
4	O
-	O
2	O
,	O
Nedd4	O
-	O
2	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
functions	O
of	O
miR	O
-	O
96	O
-	O
5p	O
in	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
were	O
investigated	O
.	O

But	O
we	O
failed	O
to	O
find	O
any	O
obvious	O
association	O
of	O
rs743572	O
genotypes	O
with	O
endometriosis	S-Phenotype
stages	O
and	O
characteristics	O
.	O

T	O
allele	O
of	O
rs743572	O
polymorphism	O
might	O
act	O
as	O
a	O
risk	O
factor	O
for	O
endometriosis	S-Phenotype
,	O
although	O
it	O
had	O
no	O
effects	O
on	O
the	O
disease	O
stages	O
and	O
basic	O
features	O

However	O
,	O
clinical	O
and	O
preclinical	O
studies	O
have	O
prompted	O
concerns	O
that	O
Epo	O
and	O
the	O
presence	O
of	O
its	O
receptor	O
,	O
EpoR	O
,	O
in	O
tumor	S-Phenotype
cells	O
may	O
be	O
responsible	O
for	O
adverse	O
effects	O
and	O
,	O
eventually	O
,	O
death	O
.	O

Liver	O
-	O
specific	O
knockout	O
of	O
murine	O
Bruce	O
impaired	O
ATR	O
activation	O
and	O
exacerbated	O
inflammation	S-Phenotype
,	O
fibrosis	S-Phenotype
and	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
,	O
which	O
exhibited	O
a	O
trabecular	O
architecture	O
,	O
closely	O
resembling	O
human	O
HCC	S-Phenotype
.	O

Mutations	O
in	O
SPRTN	O
cause	O
premature	B-Phenotype
ageing	E-Phenotype
and	O
liver	B-Phenotype
cancer	E-Phenotype
in	O
humans	O
and	O
mice	O
;	O
thus	O
,	O
defective	O
DPC	O
repair	O
has	O
great	O
clinical	O
ramifications	O
.	O

PCP	O
signalling	O
disruption	O
caused	O
by	O
Vangl2	O
(	O
Vangl2Lp	O
/	O
+	O
)	O
or	O
Celsr1	O
(	O
Celsr1Crsh	O
/	O
+	O
)	O
mutations	O
significantly	O
reduced	O
trabecular	O
bone	O
mass	O
and	O
distal	O
tibial	O
cortical	O
thickness	O
.	O

Compounds	O
exhibit	O
anti	O
-	O
cancer	S-Phenotype
activity	O
via	O
apoptosis	O
and	O
autophagy	O
through	O
inhibition	O
of	O
PI3K	O
/	O
Akt	O
signaling	O
pathway	O
in	O
HeLa	O
cells	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
spatiotemporal	O
distributions	O
of	O
RanGAP1	O
and	O
4	O
representative	O
nucleoporins	O
(	O
GP210	O
,	O
NUP205	O
,	O
NUP107	O
and	O
NUP50	O
)	O
of	O
NPCs	O
in	O
human	O
Cu	O
/	O
Zn	O
superoxide	O
dismutase	O
-	O
1	O
mutation	O
transgenic	O
(	O
SOD1	O
-	O
Tg	O
)	O
mice	O
and	O
sporadic	S-Phenotype
ALS	O
patients	O
.	O

In	O
patients	O
compared	O
to	O
controls	O
,	O
there	O
was	O
an	O
increase	O
of	O
IgG	O
reactivity	O
against	O
zinc	O
finger	O
protein	O
688	O
(	O
ZNF688	O
)	O
,	O
early	O
B	O
cell	O
factor	O
2	O
(	O
EBF2	O
)	O
,	O
crystallin	O
,	O
alpha	O
B	O
(	O
CRYAB	O
)	O
and	O
tumor	S-Phenotype
necrosis	O
factor	O
receptor	O
superfamily	O
member	O
13C	O
(	O
TNFRSF13C	O
)	O
.	O

Of	O
note	O
,	O
all	O
those	O
genes	O
are	O
causative	O
for	O
progressive	B-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
in	O
humans	O
,	O
but	O
not	O
in	O
mice	O
.	O

Multivariate	O
analysis	O
suggested	O
that	O
CDK10	O
expression	O
may	O
serve	O
as	O
an	O
independent	O
prognostic	O
predictor	O
(	O
P=0.001	O
)	O
for	O
the	O
progression	O
of	O
gastric	B-Phenotype
cancer	E-Phenotype
.	O

The	O
gonadoblastoma	S-Phenotype
gene	O
,	O
testis	O
-	O
specific	O
protein	O
Y	O
-	O
encoded	O
(	O
TSPY	O
)	O
,	O
on	O
the	O
Y	O
chromosome	O
and	O
its	O
X	O
-	O
homologue	O
,	O
TSPX	O
,	O
are	O
cell	O
cycle	O
regulators	O
and	O
function	O
as	O
a	O
proto	O
-	O
oncogene	O
and	O
a	O
tumor	S-Phenotype
suppressor	O
respectively	O
in	O
human	O
oncogenesis	O
.	O

Biallelic	O
pathogenic	O
variant	O
in	O
AHI1	O
gene	O
can	O
cause	O
Joubert	O
syndrome	O
-	O
related	O
disorders	O
with	O
oculomotor	B-Phenotype
apraxia	E-Phenotype
characteristics	O
.	O

Genomic	O
DNA	O
of	O
the	O
siblings	O
affected	O
by	O
FH	O
with	O
biopsy	O
-	O
proven	O
FSGS	O
was	O
analyzed	O
,	O
and	O
their	O
father	O
was	O
screened	O
for	O
18	O
gene	O
mutations	O
associated	O
with	O
FSGS	O
[	O
nephrin	O
,	O
podocin	O
,	O
CD2	O
associated	O
protein	O
,	O
phospholipase	O
C	O
e	O
,	O
actinin	O
a	O
4	O
,	O
transient	O
receptor	O
potential	O
cation	O
channel	O
subfamily	O
C	O
member	O
6	O
,	O
inverted	O
formin	O
,	O
FH2	O
and	O
WH2	O
domain	O
containing	O
,	O
Wilms	B-Phenotype
tumor	E-Phenotype
1	O
,	O
LIM	O
homeobox	O
transcription	O
factor	O
1	O
b	O
,	O
laminin	O
subunit	O
b	O
2	O
,	O
laminin	O
subunit	O
b	O
3	O
,	O
galactosida	O
a	O
,	O
integrin	O
subunit	O
b	O
4	O
,	O
scavenger	O
receptor	O
class	O
B	O
member	O
2	O
,	O
coenzyme	O
Q2	O
,	O
decaprenyl	O
diphosphate	O
synthase	O
subunit	O
2	O
,	O
mitochondrially	O
encoded	O
tRNA	O
leucine	O
1	O
(	O
UUA	O
/	O
G	O
;	O
TRNL1	O
)	O
and	O
SWI	O
/	O
SNF	O
related	O
,	O
matrix	O
associated	O
,	O
actin	O
dependent	O
regulator	O
of	O
chromatin	O
,	O
subfamily	O
a	O
like	O
1	O
]	O
using	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
/	O
ionization	O
time	O
-	O
of	O
-	O
flight	O
mass	O
spectrometry	O
technology	O
.	O

Our	O
findings	O
enlarge	O
the	O
spectrum	O
of	O
tubulinopathies	O
and	O
emphasize	O
that	O
mutations	O
of	O
TUBB6	O
should	O
be	O
considered	O
in	O
patients	O
with	O
congenital	B-Phenotype
non	I-Phenotype
-	I-Phenotype
progressive	I-Phenotype
facial	I-Phenotype
palsy	E-Phenotype
.	O

Reviewing	O
the	O
emerging	O
dataset	O
,	O
we	O
underline	O
this	O
unanticipated	O
phenotypic	O
consequence	O
of	O
pathogenic	O
FLNA	O
mutation	O
-	O
associated	O
pulmonary	O
disease	O
.	O

Conclusion	O
:	O
From	O
the	O
emerging	O
data	O
,	O
we	O
suggest	O
that	O
while	O
reviewing	O
complex	O
cases	O
with	O
a	O
sustained	O
oxygen	O
requirement	O
against	O
a	O
clincial	O
background	O
of	O
cardiac	O
concerns	O
or	O
intestinal	B-Phenotype
obstruction	E-Phenotype
to	O
have	O
a	O
high	O
index	O
of	O
suspicion	O
for	O
FLNA	O
related	O
pathology	O
and	O
to	O
instigate	O
early	O
MRI	O
brain	O
scan	O
and	O
FLNA	O
mutation	O
analysis	O
.	O

A	O
major	O
susceptibility	O
locus	O
,	O
HIVAN1	O
,	O
was	O
previously	O
mapped	O
to	O
chromosome	O
3A1	O
-	O
A3	O
in	O
a	O
cross	O
between	O
TgFVB	O
and	O
CAST	O
/	O
EiJ	O
(	O
CAST	O
)	O
strains	O
,	O
and	O
introgression	O
of	O
a	O
51.9	O
Mb	O
segment	O
encompassing	O
HIVAN1	O
from	O
CAST	O
into	O
TgFVB	O
resulted	O
in	O
accelerated	O
development	O
of	O
nephropathy	S-Phenotype
.	O

Patients	O
with	O
mutations	O
in	O
ZNF711	O
all	O
present	O
with	O
mild	B-Phenotype
to	I-Phenotype
moderate	I-Phenotype
ID	E-Phenotype
and	O
poor	B-Phenotype
speech	E-Phenotype
accompanied	O
by	O
additional	O
features	O
in	O
some	O
patients	O
,	O
including	O
autistic	O
features	O
and	O
mild	O
facial	O
dysmorphisms	O
,	O
suggesting	O
that	O
ZNF711	O
mutations	O
cause	O
non	O
-	O
syndromic	O
ID	O

BACKGROUND	O
Epigenetic	O
modifications	O
in	O
host	O
cells	O
,	O
like	O
p16	O
ink4a	O
methylation	O
,	O
have	O
been	O
considered	O
as	O
putative	O
complementary	O
mechanisms	O
for	O
cancer	S-Phenotype
development	O
.	O

A	O
plethora	S-Phenotype
of	O
human	O
diseases	O
are	O
associated	O
with	O
mutations	O
in	O
the	O
genes	O
encoding	O
human	O
SLC26	O
transporters	O
,	O
including	O
chondrodysplasias	O
with	O
varying	O
severity	O
in	O
SLC26A2	O
(	O
~50	O
mutations	O
,	O
27	O
point	O
mutations	O
)	O
,	O
congenital	O
chloride	O
-	O
losing	O
diarrhea	S-Phenotype
in	O
SLC26A3	O
(	O
~70	O
mutations	O
,	O
31	O
point	O
mutations	O
)	O
and	O
Pendred	O
Syndrome	O
or	O
deafness	S-Phenotype
autosomal	O
recessive	O
type	O
4	O
in	O
SLC26A4	O
(	O
~500	O
mutations	O
,	O
203	O
point	O
mutations	O
)	O
.	O

GO	O
exhibits	O
an	O
autosomal	B-Phenotype
recessive	I-Phenotype
inheritance	E-Phenotype
pattern	O
and	O
is	O
caused	O
by	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
GORAB	O
,	O
which	O
encodes	O
a	O
protein	O
important	O
for	O
Golgi	O
-	O
related	O
transport	O
.	O

This	O
pathway	O
is	O
required	O
to	O
maintain	O
levels	O
of	O
GPL	O
,	O
especially	O
phosphatidylethanolamine	O
(	O
PE	O
)	O
,	O
as	O
shown	O
by	O
stable	O
shRNA	O
-	O
mediated	O
silencing	O
of	O
PEPCK	O
-	O
M	O
in	O
H23	O
lung	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

In	O
conclusion	O
,	O
these	O
results	O
indicated	O
that	O
coronin3	O
is	O
significantly	O
dysregulated	O
in	O
HCC	B-Phenotype
tumor	E-Phenotype
tissues	O
,	O
and	O
may	O
exert	O
its	O
function	O
via	O
regulating	O
G6PC3	O
expression	O
.	O

Constitutive	O
activation	O
of	O
interferon	O
signaling	O
pathways	O
has	O
been	O
reported	O
in	O
colorectal	B-Phenotype
cancer	E-Phenotype
(	O
CRC	S-Phenotype
)	O
,	O
leading	O
to	O
a	O
strong	O
CD8+	O
T	O
cell	O
response	O
through	O
stimulation	O
of	O
NLRC5	O
expression	O
.	O

The	O
nonsyndromic	O
form	O
of	O
CSD	O
can	O
be	O
caused	O
by	O
dominant	O
activating	O
mutations	O
in	O
GUCY2C	O
,	O
encoding	O
intestinal	O
receptor	O
guanylate	O
cyclase	O
C	O
(	O
GC	O
-	O
C	O
)	O
,	O
and	O
by	O
autosomal	B-Phenotype
recessive	E-Phenotype
SLC9A3	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
.	O

To	O
better	O
understand	O
LTBP4	O
and	O
its	O
role	O
in	O
modifying	O
muscular	B-Phenotype
dystrophy	E-Phenotype
,	O
we	O
created	O
transgenic	O
mice	O
overexpressing	O
the	O
protective	O
murine	O
allele	O
of	O
LTBP4	O
specifically	O
in	O
mature	O
myofibers	O
using	O
the	O
human	O
skeletal	O
actin	O
promoter	O
.	O

Increasing	O
evidence	O
shows	O
that	O
patients	O
with	O
PHKG2	O
mutations	O
have	O
a	O
severe	O
hepatic	O
phenotype	O
within	O
the	O
heterogeneous	S-Phenotype
GSD	O
IX	O
disorder	O
.	O

Herein	O
,	O
we	O
review	O
variants	O
in	O
KMT2B	O
associated	O
with	O
dystonia	S-Phenotype
,	O
as	O
well	O
as	O
the	O
clinical	O
phenotype	O
,	O
treatment	O
and	O
underlying	O
disease	O
mechanisms	O
.	O

A	O
network	O
of	O
protein	O
partners	O
of	O
ANKS6	O
is	O
emerging	O
and	O
their	O
functional	O
characterization	O
provides	O
important	O
clues	O
to	O
understand	O
the	O
role	O
of	O
ANKS6	O
in	O
renal	O
biology	O
and	O
in	O
mechanisms	O
involved	O
in	O
the	O
formation	O
of	O
renal	B-Phenotype
cysts	E-Phenotype
.	O

No	O
significant	O
associations	O
were	O
detected	O
between	O
these	O
SNPs	O
and	O
schizophrenia	S-Phenotype
in	O
Han	O
Chinese	O
and	O
the	O
PGC	O
data	O
set	O
.	O

ADAT3	B-Phenotype
-	I-Phenotype
related	I-Phenotype
intellectual	I-Phenotype
disability	E-Phenotype
is	O
an	O
important	O
recognizable	O
cause	O
of	O
intellectual	B-Phenotype
disability	E-Phenotype
in	O
Arabia	O

Here	O
we	O
established	O
a	O
mutation	O
detection	O
system	O
based	O
on	O
multiple	O
fluorescent	O
probe	O
technique	O
,	O
which	O
can	O
detect	O
and	O
genotype	O
nine	O
hotspot	O
mutations	O
of	O
four	O
prominent	O
hearing	B-Phenotype
loss	E-Phenotype
-	O
related	O
genes	O
in	O
two	O
reactions	O
on	O
a	O
four	O
-	O
channel	O
real	O
-	O
time	O
PCR	O
instrument	O
,	O
including	O
GJB2	O
(	O
rs750188782	O
,	O
rs80338943	O
,	O
rs1110333204	O
,	O
and	O
rs80338939	O
)	O
,	O
GJB3	O
(	O
rs74315319	O
)	O
,	O
SLC26A4	O
(	O
rs111033313	O
and	O
rs121908362	O
)	O
,	O
and	O
mtDNA	O
12S	O
rRNA	O
(	O
rs267606617	O
and	O
rs267606619	O
)	O
.	O

To	O
date	O
,	O
the	O
genetic	O
alteration	O
of	O
SASS6	O
has	O
not	O
been	O
reported	O
in	O
human	O
cancers	S-Phenotype
.	O

We	O
have	O
identified	O
TUBGCP4	O
variants	O
in	O
individuals	O
with	O
autosomal	B-Phenotype
-	I-Phenotype
recessive	I-Phenotype
microcephaly	I-Phenotype
and	I-Phenotype
chorioretinopathy	E-Phenotype
.	O

In	O
conclusion	O
,	O
our	O
study	O
identified	O
four	O
circulating	O
miRNAs	O
that	O
were	O
influenced	O
by	O
variation	O
in	O
hyperglycemia	S-Phenotype
.	O

Almost	O
all	O
gonadoblastomas	S-Phenotype
occur	O
in	O
patients	O
who	O
have	O
a	O
Y	O
chromosome	O
or	O
part	O
thereof	O
;	O
testis	O
-	O
specific	O
protein	O
Y	O
-	O
encoded	O
1	O
(	O
TSPY1	O
)	O
is	O
the	O
putative	O
gene	O
.	O

Recently	O
,	O
we	O
identified	O
disease	O
-	O
linked	O
mutations	O
in	O
the	O
liCCNF	O
/	O
i	O
gene	O
,	O
which	O
encodes	O
the	O
cyclin	O
F	O
protein	O
,	O
in	O
cohorts	O
of	O
patients	O
with	O
familial	B-Phenotype
and	I-Phenotype
sporadic	I-Phenotype
ALS	E-Phenotype
and	O
frontotemporal	B-Phenotype
dementia	E-Phenotype
(	O
FTD	S-Phenotype
)	O
(	O
Williams	O
KL	O
liet	O
al	O
/	O
i	O
2016	O
liNat	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
effects	O
of	O
NEK2	O
in	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
metastasis	O
and	O
the	O
underlying	O
mechanism	O
.	O

This	O
study	O
identifies	O
the	O
influence	O
of	O
miR	O
-	O
142	O
-	O
3p	O
on	O
mammary	O
stemness	O
properties	O
and	O
breast	B-Phenotype
cancer	E-Phenotype
radioresistance	O
to	O
establish	O
its	O
role	O
in	O
this	O
setting	O
.	O

Mutations	O
in	O
peripherin	O
2	O
(	O
PRPH2	O
)	O
,	O
also	O
known	O
as	O
retinal	B-Phenotype
degeneration	E-Phenotype
slow	O
/	O
RDS	O
,	O
lead	O
to	O
various	O
retinal	B-Phenotype
degenerations	E-Phenotype
including	O
retinitis	B-Phenotype
pigmentosa	E-Phenotype
(	O
RP	S-Phenotype
)	O
and	O
macular	B-Phenotype
/	I-Phenotype
pattern	I-Phenotype
dystrophy	E-Phenotype
(	O
MD	S-Phenotype
/	O
PD	S-Phenotype
)	O
.	O

Tumor	S-Phenotype
-	O
specific	O
methylation	O
changes	O
at	O
IGF2	O
DMR2	O
were	O
observed	O
in	O
59	O
%	O
of	O
cancer	S-Phenotype
patients	O
,	O
IGF2	O
DMR0	O
in	O
38	O
%	O
,	O
DIRAS3	O
DMR	O
in	O
36	O
%	O
,	O
GRB10	O
ICR	O
in	O
23	O
%	O
,	O
PEG3	O
DMR	O
in	O
21	O
%	O
,	O
MEST	O
ICR	O
in	O
19	O
%	O
,	O
H19	O
ICR	O
in	O
18	O
%	O
,	O
KvDMR	O
in	O
8	O
%	O
and	O
SNRPN	O
/	O
SNURF	O
ICR	O
in	O
4	O
%	O
.	O

SDH	O
deficiency	O
may	O
result	O
from	O
germline	O
SDHA	O
,	O
SDHB	O
,	O
SDHC	O
,	O
or	O
SDHD	O
mutations	O
and	O
is	O
found	O
in	O
autosomal	B-Phenotype
-	I-Phenotype
dominant	I-Phenotype
familial	I-Phenotype
paraganglioma	I-Phenotype
/	I-Phenotype	
pheochromocytoma	E-Phenotype
and	O
Carney	B-Phenotype
-	I-Phenotype
Stratakis	I-Phenotype
syndrome	E-Phenotype
,	O
describing	O
the	O
combination	O
of	O
paraganglioma	S-Phenotype
and	O
gastrointestinal	B-Phenotype
stromal	I-Phenotype
tumor	E-Phenotype
(	O
GIST	S-Phenotype
)	O
.	O

Conversely	O
,	O
YAP	O
inhibition	O
impaired	O
the	O
LIFR	O
-	O
silencing	O
promotion	O
of	O
cell	O
migration	O
,	O
invasion	O
,	O
and	O
cancer	S-Phenotype
stem	O
cell	O
marker	O
expression	O
.	O

In	O
conclusion	O
,	O
our	O
study	O
demonstrates	O
for	O
the	O
first	O
time	O
that	O
p53R2	O
protein	O
is	O
overexpressed	S-Phenotype
in	O
early	B-Phenotype
-	I-Phenotype
stage	I-Phenotype
cervical	I-Phenotype
cancer	E-Phenotype
and	O
unravels	O
some	O
unconventional	O
oncogenic	O
functions	O
of	O
p53R2	O
.	O

Mutations	O
of	O
FIG4	O
result	O
in	O
the	O
inherited	O
disorders	O
Charcot	B-Phenotype
-	I-Phenotype
Marie	I-Phenotype
-	I-Phenotype
Tooth	I-Phenotype
disease	I-Phenotype
type	I-Phenotype
4J	E-Phenotype
,	O
Yunis	B-Phenotype
-	I-Phenotype
Varón	I-Phenotype
syndrome	E-Phenotype
,	O
and	O
polymicrogyria	S-Phenotype
with	O
seizures	S-Phenotype
.	O

The	O
expression	O
pattern	O
of	O
HCRP1	O
in	O
gastric	B-Phenotype
cancer	E-Phenotype
tissue	O
and	O
adjacent	O
non	O
-	O
cancerous	O
tissue	O
was	O
detected	O
by	O
immunohistochemistry	O
.	O

Routine	O
gene	O
testing	O
is	O
not	O
necessary	O
to	O
guide	O
treatment	O
for	O
typical	O
forms	O
of	O
paroxysmal	B-Phenotype
kinesigenic	I-Phenotype
dyskinesia	E-Phenotype
(	O
PKD	O
)	O
,	O
paroxysmal	B-Phenotype
nonkinesigenic	I-Phenotype
dyskinesia	E-Phenotype
(	O
PNKD	S-Phenotype
)	O
,	O
and	O
episodic	B-Phenotype
ataxia	I-Phenotype
type	I-Phenotype
1	I-Phenotype
or	I-Phenotype
2	E-Phenotype
.	O

Taken	O
together	O
,	O
these	O
findings	O
offer	O
additional	O
insight	O
into	O
the	O
early	O
transcriptional	O
changes	O
caused	O
by	O
Cryaa	O
and	O
Cryab	O
mutations	O
associated	O
with	O
autosomal	B-Phenotype
dominant	I-Phenotype
human	I-Phenotype
cataracts	E-Phenotype
,	O
and	O
indicate	O
that	O
the	O
transcript	O
levels	O
of	O
certain	O
genes	O
are	O
affected	O
by	O
the	O
expression	O
of	O
mutant	O
a	O
-	O
crystallin	O
in	O
vivo	O

Infantile	B-Phenotype
cerebellar	I-Phenotype
-	I-Phenotype
retinal	I-Phenotype
degeneration	E-Phenotype
associated	O
with	O
mutations	O
in	O
the	O
mitochondrial	O
aconitase	O
2	O
gene	O
(	O
ACO2	O
)	O
has	O
been	O
recently	O
described	O
as	O
a	O
neurodegenerative	B-Phenotype
disease	E-Phenotype
of	O
autosomal	B-Phenotype
recessive	I-Phenotype
inheritance	E-Phenotype
.	O

Conditional	O
analysis	O
identified	O
five	O
secondary	O
association	O
signals	O
,	O
including	O
two	O
at	O
the	O
ESR1	O
locus	O
,	O
resulting	O
in	O
19	O
independent	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
robustly	O
associated	O
with	O
endometriosis	S-Phenotype
,	O
which	O
together	O
explain	O
up	O
to	O
5.19	O
%	O
of	O
variance	O
in	O
endometriosis	S-Phenotype
.	O

There	O
is	O
a	O
great	O
need	O
to	O
develop	O
novel	O
RCC	O
sampling	O
strategies	O
to	O
overcome	O
tumour	B-Phenotype
heterogeneity	E-Phenotype
prior	O
to	O
define	O
precision	O
oncology	S-Phenotype
strategies	O

Given	O
the	O
importance	O
of	O
edema	S-Phenotype
to	O
the	O
outcome	O
of	O
patients	O
with	O
aSAH	O
and	O
its	O
status	O
as	O
a	O
highly	O
modifiable	O
pathological	O
process	O
,	O
a	O
better	O
understanding	O
of	O
cerebral	B-Phenotype
edema	E-Phenotype
in	O
aSAH	O
promises	O
to	O
hasten	O
the	O
development	O
of	O
medical	O
therapies	O
to	O
improve	O
outcomes	O
in	O
this	O
frequently	O
devastating	O
disease	O

Genetic	O
correlation	O
analysis	O
revealed	O
the	O
relationships	O
between	O
POAG	O
and	O
systemic	O
diseases	O
,	O
including	O
type	B-Phenotype
2	I-Phenotype
diabetes	E-Phenotype
and	O
cardiovascular	B-Phenotype
diseases	E-Phenotype
.	O

The	O
fat	O
mass	O
and	O
obesity	S-Phenotype
-	O
associated	O
(	O
FTO	O
)	O
gene	O
is	O
tightly	O
related	O
to	O
body	O
weight	O
and	O
fat	O
mass	O
,	O
and	O
plays	O
a	O
pivotal	O
role	O
in	O
regulating	O
lipid	B-Phenotype
accumulation	I-Phenotype
in	I-Phenotype
hepatocytes	E-Phenotype
.	O

Ablation	O
of	O
Sox2	O
-	O
expressing	O
cells	O
within	O
primary	O
invasive	O
BCa	O
led	O
to	O
enhanced	O
tumor	S-Phenotype
regression	O
,	O
supporting	O
the	O
essential	O
role	O
of	O
SOX2	O
-	O
positive	O
cells	O
in	O
regulating	O
BCa	O
maintenance	O
and	O
progression	O
.	O

Although	O
the	O
most	O
severe	O
phenotype	O
is	O
observed	O
in	O
the	O
homozygous	O
mice	O
,	O
this	O
model	O
will	O
still	O
provide	O
a	O
test	O
-	O
bed	O
for	O
therapies	O
not	O
only	O
for	O
corneal	B-Phenotype
dystrophies	E-Phenotype
but	O
also	O
for	O
other	O
keratinopathies	O
caused	O
by	O
similar	O
mutations	O
.	O

Hypermethylated	B-Phenotype
in	I-Phenotype
cancer	I-Phenotype
1	E-Phenotype
(	O
HIC1	S-Phenotype
)	O
is	O
frequently	O
deleted	O
or	O
epigenetically	O
silenced	O
in	O
various	O
human	O
cancers	S-Phenotype
.	O

Recently	O
,	O
the	O
second	O
focal	O
(	O
temporal	O
lobe	O
)	O
-	O
onset	O
epilepsy	S-Phenotype
gene	O
,	O
LGI1	O
(	O
unknown	O
function	O
)	O
,	O
was	O
discovered	O
.	O

Here	O
we	O
show	O
that	O
the	O
microphthalmia	S-Phenotype
-	O
associated	O
transcription	O
factor	O
,	O
MITF	O
,	O
which	O
plays	O
a	O
central	O
role	O
in	O
the	O
development	O
and	O
function	O
of	O
RPE	O
cells	O
,	O
regulates	O
the	O
expression	O
of	O
two	O
visual	O
cycle	O
genes	O
,	O
Rlbp1	O
which	O
encodes	O
retinaldehyde	O
binding	O
protein	O
-	O
1	O
(	O
RLBP1	O
)	O
,	O
and	O
Rdh5	O
,	O
which	O
encodes	O
retinol	O
dehydrogenase	O
-	O
5	O
(	O
RDH5	O
)	O
.	O

The	O
remaining	O
cases	O
,	O
clinically	O
similar	O
to	O
XLA	O
,	O
are	O
autosomal	B-Phenotype
recessive	I-Phenotype
agammaglobulinemia	E-Phenotype
(	O
ARA	S-Phenotype
)	O
.	O

A	O
risk	O
score	O
of	O
4	O
,	O
4	O
,	O
6	O
,	O
6	O
,	O
7	O
,	O
or	O
6	O
was	O
assigned	O
to	O
diabetes	O
,	O
baseline	O
estimated	O
GFR	O
AAAA	O
45	O
mL	O
/	O
min	O
/	O
1.73	O
m	O
,	O
hypertension	S-Phenotype
,	O
repeated	B-Phenotype
contrast	I-Phenotype
exposure	E-Phenotype
,	O
congestive	B-Phenotype
heart	I-Phenotype
failure	E-Phenotype
,	O
and	O
persistent	B-Phenotype
renal	I-Phenotype
injury	E-Phenotype
(	O
defined	O
as	O
an	O
elevation	O
of	O
serum	O
creatinine	O
≥25	O
%	O
at	O
3	O
months	O
)	O
,	O
respectively	O
.	O

Using	O
a	O
new	O
conditional	O
allele	O
,	O
we	O
first	O
show	O
that	O
Eif4a3	O
haploinsufficiency	O
phenocopies	O
aberrant	O
neurogenesis	O
and	O
microcephaly	S-Phenotype
of	O
Magoh	O
and	O
Rbm8a	O
mutant	O
mice	O
.	O

Progressive	B-Phenotype
retinal	I-Phenotype
atrophy	E-Phenotype
(	O
PRA	S-Phenotype
)	O
is	O
the	O
collective	O
name	O
of	O
a	O
class	O
of	O
hereditary	B-Phenotype
retinal	I-Phenotype
dystrophies	E-Phenotype
in	O
the	O
dog	O
and	O
is	O
often	O
described	O
as	O
the	O
equivalent	O
of	O
retinitis	S-Phenotype
pigmentosa	O
in	O
humans	O
.	O

We	O
identified	O
30	O
new	O
blood	O
pressure	O
-	O
or	O
hypertension	S-Phenotype
-	O
associated	O
genetic	O
regions	O
in	O
the	O
general	O
population	O
,	O
including	O
3	O
rare	O
missense	O
variants	O
in	O
RBM47	O
,	O
COL21A1	O
and	O
RRAS	O
with	O
larger	O
effects	O
(	O
AAAA1.5	O
mm	O
Hg	O
/	O
allele	O
)	O
than	O
common	O
variants	O
.	O

BCS	O
is	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
generalized	O
connective	O
tissue	O
disorder	O
associated	O
with	O
extreme	B-Phenotype
corneal	I-Phenotype
thinning	E-Phenotype
and	O
a	B-Phenotype
high	I-Phenotype
risk	I-Phenotype
of	I-Phenotype
corneal	I-Phenotype
rupture	E-Phenotype
.	O

In	O
vivo	O
MRI	O
sequences	O
consisted	O
of	O
Tsub2w	O
/	O
sub	O
for	O
tumor	S-Phenotype
localization	O
,	O
Tsub2w	O
/	O
sub	O
*	O
to	O
assess	O
YbHPDO3A	O
biodistribution	O
by	O
exploiting	O
its	O
magnetic	O
susceptibility	O
effect	O
and	O
CEST	O
for	O
glioma	S-Phenotype
pHe	O
mapping	O
.	O

In	O
conclusion	O
,	O
LARP7	O
may	O
act	O
as	O
a	O
tumor	S-Phenotype
suppressor	O
in	O
PTC	O
by	O
inhibiting	O
the	O
SHH	O
signaling	O
pathway	O
and	O
may	O
be	O
a	O
promising	O
therapeutic	O
target	O
in	O
patients	O
with	O
PTC	O

Simultaneous	O
video	O
and	O
EEG	O
recordings	O
revealed	O
that	O
Stxbp1+	O
/	O
-	O
mice	O
with	O
different	O
genomic	O
backgrounds	O
recapitulate	O
the	O
seizure	S-Phenotype
/	O
spasm	S-Phenotype
phenotype	O
observed	O
in	O
humans	O
,	O
characterized	O
by	O
myoclonic	B-Phenotype
jerks	E-Phenotype
and	O
spike	O
-	O
wave	O
discharges	O
that	O
were	O
suppressed	O
by	O
the	O
antiepileptic	O
drug	O
levetiracetam	O
.	O

Furthermore	O
,	O
parallel	O
immunohistochemical	O
analysis	O
of	O
three	O
PP2A	O
inhibitors	O
demonstrated	O
that	O
two	O
PP2A	O
inhibitors	O
,	O
CIP2A	O
and	O
SET	O
,	O
are	O
highly	O
expressed	O
in	O
both	O
dysplastic	S-Phenotype
and	O
adenocarcinomatous	B-Phenotype
tumors	E-Phenotype
of	O
the	O
Smgb	O
-	O
Tag	O
mice	O
.	O

We	O
can	O
now	O
report	O
that	O
progressive	B-Phenotype
ataxia	E-Phenotype
of	O
Charolais	O
cattle	O
results	O
from	O
a	O
homozygous	O
single	O
nucleotide	O
polymorphism	O
in	O
the	O
coding	O
region	O
of	O
the	O
KIF1C	O
gene	O
.	O

The	O
volumes	O
of	O
the	O
tumors	S-Phenotype
were	O
similar	O
between	O
those	O
injected	O
with	O
the	O
empty	O
vector	O
and	O
control	O
,	O
but	O
were	O
significantly	O
smaller	O
in	O
the	O
knockdown	O
models	O
,	O
suggesting	O
that	O
the	O
knockdown	O
of	O
the	O
CHAF1B	O
gene	O
inhibited	O
tumor	S-Phenotype
growth	O
.	O

IGSF1	O
(	O
Immunoglobulin	O
Superfamily	O
1	O
)	O
gene	O
defects	O
cause	O
central	B-Phenotype
hypothyroidism	E-Phenotype
and	O
macroorchidism	S-Phenotype
.	O

Although	O
mutations	O
in	O
the	O
gene	O
encoding	O
tricellulin	O
are	O
known	O
to	O
cause	O
deafness	S-Phenotype
in	O
humans	O
(	O
DFNB49	O
)	O
and	O
mice	O
,	O
the	O
influence	O
of	O
its	O
systemic	O
deletion	O
in	O
vivo	O
remains	O
unknown	O
.	O

Moreover	O
,	O
SLC39A4	O
knockdown	O
enhanced	O
cancer	S-Phenotype
cell	O
sensitivity	O
to	O
cisplatin	O
-	O
induced	O
death	O
by	O
inhibiting	O
stemness	O
in	O
lung	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

NAA10	O
-	O
related	O
syndrome	O
is	O
an	O
X	O
-	O
linked	O
condition	O
with	O
a	O
broad	O
spectrum	O
of	O
findings	O
ranging	O
from	O
a	O
severe	O
phenotype	O
in	O
males	O
with	O
p.Ser37Pro	O
in	O
NAA10	O
,	O
originally	O
described	O
as	O
Ogden	O
syndrome	O
,	O
to	O
the	O
milder	B-Phenotype
NAA10	I-Phenotype
-	I-Phenotype
related	I-Phenotype
intellectual	I-Phenotype
disability	E-Phenotype
found	O
with	O
different	O
variants	O
in	O
both	O
males	O
and	O
females	O
.	O

The	O
association	O
of	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
with	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
or	O
the	O
prevalence	O
of	O
obesity	S-Phenotype
and	O
MetS	O
was	O
examined	O
in	O
a	O
generalized	O
estimating	O
equation	O
model	O
.	O

The	O
sonic	O
Hedgehog	O
/	O
GLI	O
signaling	O
pathway	O
(	O
HH	O
)	O
is	O
critical	O
for	O
maintaining	O
tissue	O
polarity	O
in	O
development	O
and	O
contributes	O
to	O
tumor	S-Phenotype
stemness	O
.	O

Overall	O
,	O
our	O
results	O
highlight	O
the	O
importance	O
of	O
HLXB9	O
in	O
conditions	O
of	O
β	O
-	O
cell	O
excess	O
(	O
insulinomas	S-Phenotype
)	O
and	O
in	O
conditions	O
of	O
β	O
-	O
cell	O
loss	O
or	O
dysfunction	O
(	O
diabetes	S-Phenotype
)	O
.	O

Four	O
of	O
the	O
five	O
genes	O
,	O
including	O
AKAP12	O
,	O
SOPB	O
,	O
TCF7L2	O
,	O
COL12A1	O
and	O
TXNIP	O
were	O
downregulated	O
,	O
and	O
were	O
associated	O
with	O
the	O
OS	O
of	O
patients	O
with	O
breast	B-Phenotype
carcinoma	E-Phenotype
.	O

Similarly	O
,	O
homozygous	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
CYP26B1	O
,	O
one	O
of	O
the	O
major	O
RA	O
-	O
metabolizing	O
enzymes	O
,	O
cause	O
advanced	B-Phenotype
bone	I-Phenotype
age	E-Phenotype
,	O
premature	B-Phenotype
epiphyseal	I-Phenotype
fusion	E-Phenotype
,	O
and	O
craniosynostosis	S-Phenotype
.	O

Additionally	O
,	O
US	O
forced	O
the	O
penetration	O
of	O
ZOL	O
within	O
tumors	S-Phenotype
,	O
as	O
demonstrated	O
by	O
the	O
intratumoral	O
accumulation	O
of	O
unprenylated	O
Rap1A	O
,	O
a	O
surrogate	O
marker	O
of	O
ZOL	O
antitumor	O
activity	O
.	O

Tricho	O
-	O
hepato	O
-	O
enteric	O
syndrome	O
(	O
SD	O
/	O
THE	O
)	O
and	O
Multiple	B-Phenotype
intestinal	I-Phenotype
atresia	I-Phenotype
with	I-Phenotype
combined	I-Phenotype
immune	I-Phenotype
deficiency	E-Phenotype
(	O
MIA	B-Phenotype
-	I-Phenotype
CID	E-Phenotype
)	O
are	O
autosomal	B-Phenotype
recessive	E-Phenotype
disorders	O
that	O
present	O
immunological	O
and	O
gastrointestinal	O
features	O
.	O

Using	O
flow	O
cytometric	O
analysis	O
and	O
CCK	O
-	O
8	O
,	O
we	O
evaluated	O
the	O
effects	O
of	O
KLF9	O
expression	O
on	O
cell	O
apoptosis	O
,	O
the	O
cell	O
cycle	O
and	O
proliferation	O
of	O
pancreatic	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Recurrence	O
and	O
metastasis	O
are	O
major	O
challenges	O
in	O
the	O
management	O
of	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
patients	O
after	O
resection	O
.	O

Due	O
to	O
evolving	O
hypopituitarism	S-Phenotype
,	O
she	O
was	O
replaced	O
with	O
thyroxine	O
(	O
from	O
age	O
5	O
)	O
,	O
hydrocortisone	O
(	O
from	O
age	O
13	O
)	O
,	O
GH	O
(	O
from	O
age	O
13	O
until	O
17	O
)	O
,	O
and	O
sex	O
steroids	O
in	O
adolescence	O
and	O
adulthood	O
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
HCRP1	O
up	O
-	O
regulation	O
decreased	O
the	O
levels	O
of	O
p	O
-	O
ERK	O
and	O
p	O
-	O
AKT	O
in	O
glioma	S-Phenotype
cells	O
.	O

Single	O
nucleotide	O
polymorphism	O
in	O
infant	O
genes	O
in	O
the	O
folate	O
(	O
MTHFS	O
rs12438477	O
)	O
,	O
homocysteine	O
(	O
TRDMT1	O
rs6602178	O
and	O
GNMT	O
rs11752813	O
)	O
and	O
transsulfuration	O
(	O
GSTP1	O
rs7941395	O
and	O
MGST1	O
rs7294985	O
)	O
pathways	O
were	O
also	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
congenital	B-Phenotype
heart	I-Phenotype
defects	E-Phenotype
.	O

Conclusions	O
Common	O
maternal	O
or	O
infant	O
genetic	O
variants	O
in	O
folate	O
,	O
homocysteine	O
,	O
or	O
transsulfuration	O
pathways	O
are	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
certain	O
congenital	B-Phenotype
heart	I-Phenotype
defects	E-Phenotype
among	O
children	O
of	O
women	O
taking	O
SSRIs	O
during	O
cardiogenesis	O

This	O
identified	O
11	O
individuals	O
to	O
have	O
9	O
non	O
-	O
synonymous	O
AP2σ	O
variants	O
(	O
Arg3His	O
,	O
Arg15His	O
(	O
x3	O
)	O
,	O
Ala44Thr	O
,	O
Phe52Tyr	O
,	O
Arg61His	O
,	O
Thr112Met	O
,	O
Met117Ile	O
,	O
Glu122Gly	O
and	O
Glu142Lys	O
)	O
with	O
3	O
of	O
the	O
4	O
individuals	O
who	O
had	O
Arg15His	O
and	O
Met117Ile	O
AP2σ	O
variants	O
having	O
mild	O
hypercalcaemia	S-Phenotype
,	O
thereby	O
indicating	O
a	O
prevalence	O
of	O
FHH3	O
-	O
associated	O
AP2σ	O
mutations	O
of	O
∼7.8	O
per	O
100	O
000	O
individuals	O
.	O

This	O
protein	O
is	O
expressed	O
during	O
development	O
of	O
skeletal	O
muscle	O
,	O
central	O
nervous	O
system	O
and	O
neural	O
crest	O
derivatives	O
,	O
and	O
regulates	O
expression	O
of	O
target	O
genes	O
that	O
impact	O
on	O
proliferation	O
,	O
survival	O
,	O
differentiation	O
and	O
motility	O
in	O
these	O
lineages	O
.	O

A	O
recurrent	O
de	O
novo	O
missense	O
variant	O
within	O
the	O
C	O
-	O
terminal	O
Sin3	O
-	O
like	O
domain	O
of	O
ZSWIM6	O
was	O
previously	O
reported	O
to	O
cause	O
acromelic	B-Phenotype
frontonasal	I-Phenotype
dysostosis	E-Phenotype
(	O
AFND	S-Phenotype
)	O
,	O
an	O
autosomal	B-Phenotype
-	I-Phenotype
dominant	I-Phenotype
severe	I-Phenotype
frontonasal	I-Phenotype
and	I-Phenotype
limb	I-Phenotype
malformation	I-Phenotype
syndrome	E-Phenotype
,	O
associated	O
with	O
neurocognitive	O
and	O
motor	B-Phenotype
delay	E-Phenotype
,	O
via	O
a	O
proposed	O
gain	O
-	O
of	O
-	O
function	O
effect	O
.	O

2016	O
)	O
.	O

Another	O
clinically	O
relevant	O
form	O
of	O
FGF23	B-Phenotype
-	I-Phenotype
related	I-Phenotype
hypophosphatemic	I-Phenotype
disease	E-Phenotype
is	O
tumor	B-Phenotype
-	I-Phenotype
induced	I-Phenotype
osteomalacia	E-Phenotype
(	O
TIO	S-Phenotype
)	O
,	O
a	O
paraneoplastic	B-Phenotype
syndrome	E-Phenotype
associated	O
with	O
FGF23	B-Phenotype
-	I-Phenotype
producing	I-Phenotype
tumors	E-Phenotype
.	O

by	O
reactivating	O
pre	O
-	O
existing	O
anti	O
-	O
tumor	S-Phenotype
immune	O
responses	O
against	O
GSC	O
antigens	O
.	O

Our	O
results	O
demonstrate	O
extensively	O
overlapping	O
functions	O
between	O
the	O
HsCYLD	O
and	O
CeCYLD	O
,	O
which	O
establish	O
the	O
C.	O
elegans	O
protein	O
as	O
a	O
valuable	O
model	O
for	O
the	O
elucidation	O
of	O
the	O
complex	O
activity	O
of	O
the	O
human	O
tumor	S-Phenotype
suppressor	O
protein	O

A	O
total	O
of	O
nine	O
non	O
-	O
coding	O
variants	O
on	O
11q13.5	O
predispose	O
men	O
to	O
prostate	B-Phenotype
cancer	E-Phenotype
(	O
PrCa	S-Phenotype
)	O
.	O

We	O
investigated	O
glioma	S-Phenotype
-	O
associated	O
oncogene	O
protein	O
-	O
1	O
(	O
Gli	O
-	O
1	O
)	O
expression	O
in	O
human	O
esophageal	B-Phenotype
carcinoma	E-Phenotype
tissue	O
and	O
the	O
inhibition	O
of	O
cyclopamine	O
on	O
EC9706	O
esophageal	B-Phenotype
carcinoma	E-Phenotype
cell	O
growth	O
.	O

In	O
addition	O
,	O
resorcinol	O
suppressed	O
the	O
expression	O
of	O
melanogenic	O
gene	O
microphthalmia	S-Phenotype
-	O
associated	O
transcriptional	O
factor	O
(	O
MITF	O
)	O
and	O
its	O
downstream	O
target	O
genes	O
tyrosinase	O
,	O
tyrosinase	O
-	O
related	O
protein	O
(	O
TRP	O
)	O
-	O
1	O
,	O
and	O
TRP	O
-	O
2	O
.	O

These	O
changes	O
were	O
accompanied	O
by	O
cortical	B-Phenotype
atrophy	E-Phenotype
as	O
well	O
as	O
increased	O
expression	O
of	O
angiogenesis	O
-	O
related	O
genes	O
such	O
as	O
liVegfa	O
/	O
i	O
,	O
liSerpine1	O
/	O
i	O
,	O
and	O
liPlau	O
/	O
i	O
in	O
CD31	O
-	O
positive	O
endothelial	O
cells	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
LED	O
light	O
at	O
different	O
wavelengths	O
affects	O
the	O
expression	O
profile	O
of	O
143	O
cancer	S-Phenotype
predisposition	O
genes	O
in	O
both	O
diabetic	O
and	O
normal	O
human	O
fibroblasts	O
.	O

In	O
this	O
study	O
,	O
the	O
coding	O
regions	O
and	O
flanking	O
introns	O
of	O
the	O
NKX2	O
-	O
5	O
gene	O
,	O
which	O
encodes	O
a	O
cardiac	O
transcription	O
factor	O
pivotal	O
for	O
cardiac	O
development	O
and	O
structural	O
remodeling	O
,	O
were	O
sequenced	O
in	O
210	O
unrelated	O
patients	O
with	O
sporadic	B-Phenotype
adult	I-Phenotype
-	I-Phenotype
onset	I-Phenotype
DCM	E-Phenotype
.	O

This	O
study	O
is	O
the	O
first	O
to	O
associate	O
NKX2	O
-	O
5	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
with	O
enhanced	O
susceptibility	O
to	O
sporadic	B-Phenotype
DCM	E-Phenotype
,	O
which	O
provides	O
novel	O
insight	O
into	O
the	O
molecular	O
etiology	O
underpinning	O
DCM	O
,	O
and	O
suggests	O
the	O
potential	O
implications	O
for	O
the	O
genetic	O
counseling	O
and	O
personalized	O
treatment	O
of	O
the	O
DCM	O
patients	O

Here	O
,	O
we	O
describe	O
three	O
individuals	O
who	O
are	O
affected	O
by	O
global	B-Phenotype
developmental	I-Phenotype
delay	E-Phenotype
,	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
and	O
expressive	O
speech	B-Phenotype
disorder	E-Phenotype
and	O
carry	O
de	O
novo	O
variants	O
in	O
EBF3	O
.	O

Meanwhile	O
,	O
NET	O
-	O
VMAT2	O
-	O
coexpressing	O
and	O
NET	O
-	O
expressing	O
tumors	S-Phenotype
displayed	O
0.54	O
%	O
and	O
0.19	O
%	O
,	O
respectively	O
,	O
of	O
the	O
injected	O
dose	O
per	O
gram	O
of	O
tissue	O
24	O
h	O
after	O
lsup131	O
/	O
supI	O
-	O
MIBG	O
administration	O
.	O

The	O
reported	O
enamel	B-Phenotype
abnormality	E-Phenotype
in	O
LAMA3	O
mutation	O
carriers	O
could	O
be	O
attributed	O
to	O
a	O
half	O
dose	O
effect	O
of	O
the	O
laminin	O
α3	O
chain	O
(	O
haploinsufficiency	O
)	O

TDP1	O
plays	O
an	O
essential	O
role	O
in	O
the	O
resistance	O
of	O
cancer	S-Phenotype
cells	O
to	O
currently	O
used	O
antitumour	O
drugs	O
based	O
on	O
Top1	O
inhibitors	O
such	O
as	O
topotecan	O
and	O
irinotecan	O
.	O

Our	O
data	O
support	O
the	O
involvement	O
of	O
liKCNQ5	O
/	O
i	O
gene	O
polymorphisms	O
in	O
the	O
genetic	O
susceptibility	O
to	O
high	B-Phenotype
myopia	E-Phenotype
and	O
further	O
exploration	O
of	O
liKCNQ5	O
/	O
i	O
as	O
a	O
risk	O
factor	O
for	O
high	B-Phenotype
myopia	E-Phenotype

Molecular	O
analyses	O
showed	O
mutations	O
of	O
exon	O
3	O
of	O
CTNNB1	O
in	O
more	O
than	O
half	O
of	O
these	O
tumors	S-Phenotype
,	O
and	O
nuclear	O
accumulation	O
of	O
b	O
-	O
catenin	O
and	O
over	O
expression	O
of	O
cyclin	O
D1	O
can	O
be	O
useful	O
for	O
the	O
differential	O
diagnosis	O
of	O
SCT	O
,	O
NOS	O

No	O
clinical	O
replication	O
cohort	O
is	O
available	O
,	O
so	O
we	O
validated	O
the	O
role	O
of	O
one	O
of	O
these	O
targets	O
,	O
AKT3	O
,	O
in	O
a	O
pneumococcal	O
meningitis	S-Phenotype
mouse	O
model	O
.	O

Taken	O
together	O
,	O
these	O
results	O
indicate	O
that	O
increased	O
α	O
-	O
actinin	O
-	O
1	O
expression	O
destabilizes	O
E	O
-	O
cadherin	O
-	O
based	O
adhesions	O
,	O
which	O
is	O
likely	O
to	O
promote	O
the	O
migratory	O
potential	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Structural	O
analyses	O
guided	O
the	O
discovery	O
of	O
a	O
broad	O
,	O
splicing	O
-	O
modulated	O
interaction	O
network	O
between	O
MDGA	O
and	O
NL	O
family	O
members	O
and	O
helped	O
rationalize	O
the	O
impact	O
of	O
autism	B-Phenotype
-	I-Phenotype
linked	I-Phenotype
mutations	E-Phenotype
.	O

Here	O
,	O
we	O
report	O
bi	O
-	O
allelic	O
pathogenic	O
SPTBN4	O
variants	O
(	O
three	O
homozygous	O
and	O
two	O
compound	O
heterozygous	O
)	O
that	O
cause	O
a	O
severe	O
neurological	O
syndrome	O
that	O
includes	O
congenital	B-Phenotype
hypotonia	E-Phenotype
,	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
and	O
motor	B-Phenotype
axonal	I-Phenotype
and	I-Phenotype
auditory	I-Phenotype
neuropathy	E-Phenotype
.	O

Multivariate	O
analysis	O
suggested	O
that	O
CDK10	O
expression	O
may	O
serve	O
as	O
an	O
independent	O
prognostic	O
predictor	O
(	O
P=0.001	O
)	O
for	O
the	O
progression	O
of	O
gastric	B-Phenotype
cancer	E-Phenotype
.	O

However	O
,	O
what	O
kind	O
of	O
role	O
hepaCAM	O
plays	O
in	O
colorectal	B-Phenotype
cancer	E-Phenotype
(	O
CRC	S-Phenotype
)	O
remains	O
unknown	O
.	O

GNB3	O
duplication	O
is	O
responsible	O
for	O
a	O
syndromic	O
form	O
of	O
childhood	O
obesity	S-Phenotype
,	O
and	O
an	O
activating	O
DNA	O
sequence	O
variant	O
(	O
C825T	O
)	O
in	O
GNB3	O
is	O
also	O
associated	O
with	O
obesity	S-Phenotype
.	O

Thus	O
,	O
our	O
findings	O
demonstrate	O
that	O
chemotherapy	O
induces	O
functional	O
tumor	S-Phenotype
-	O
derived	O
endothelial	O
microvessels	O
by	O
mediating	O
Notch	O
signaling	O
and	O
VEGF	O
signaling	O
,	O
and	O
may	O
provide	O
new	O
targets	O
for	O
anti	O
-	O
angiogenesis	O
therapy	O
in	O
breast	B-Phenotype
cancer	E-Phenotype

The	O
SMR	O
single	O
gene	O
analysis	O
results	O
were	O
further	O
subjected	O
to	O
gene	O
set	O
enrichment	O
analysis	O
(	O
GSEA	O
)	O
for	O
identifying	O
obesity	S-Phenotype
associated	O
gene	O
sets	O
.	O

We	O
find	O
that	O
STX3	O
promotes	O
the	O
proliferation	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
by	O
increasing	O
the	O
activation	O
of	O
the	O
Akt	O
-	O
mTOR	O
signaling	O
,	O
and	O
Akt	O
inhibitor	O
Ipatasertib	O
or	O
MK	O
-	O
2206	O
represses	O
STX3	O
effects	O
on	O
the	O
growth	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Our	O
results	O
confirm	O
two	O
previous	O
reports	O
indicating	O
that	O
loss	O
of	O
function	O
of	O
a	O
single	O
allele	O
of	O
SLC6A1	O
causes	O
epilepsy	S-Phenotype
.	O

This	O
study	O
investigated	O
the	O
role	O
of	O
potassium	O
channel	O
gene	O
li	O
(	O
KCNQ5	O
)	O
/	O
i	O
polymorphisms	O
in	O
high	B-Phenotype
myopia	E-Phenotype
.	O

Alazami	O
syndrome	O
(	O
AS	O
)	O
(	O
MIM	O
#	O
615071	O
)	O
is	O
an	O
autosomal	B-Phenotype
recessive	I-Phenotype
microcephalic	I-Phenotype
primordial	I-Phenotype
dwarfism	E-Phenotype
(	O
PD	S-Phenotype
)	O
with	O
recognizable	O
facial	O
features	O
and	O
severe	O
intellectual	B-Phenotype
disability	E-Phenotype
due	O
to	O
depletion	O
or	O
loss	O
of	O
function	O
variants	O
in	O
LARP7	O
.	O

We	O
have	O
applied	O
whole	O
exome	O
sequencing	O
to	O
a	O
patient	O
with	O
congenital	B-Phenotype
lactic	I-Phenotype
acidosis	E-Phenotype
,	O
muscle	B-Phenotype
weakness	E-Phenotype
,	O
profound	B-Phenotype
deficiencies	I-Phenotype
in	I-Phenotype
mitochondrial	I-Phenotype
oxidative	I-Phenotype
phosphorylation	E-Phenotype
associated	O
with	O
loss	O
of	O
mtDNA	O
copy	O
number	O
and	O
MRI	O
abnormalities	O
consistent	O
with	O
Leigh	O
syndrome	O
,	O
identifying	O
biallelic	O
variants	O
in	O
the	O
LONP1	O
(	O
NM_004793.3	O
)	O
gene	O
;	O
c.1693T	O
AAAA	O
C	O
predicting	O
p.	O
(	O
Tyr565His	O
)	O
and	O
c.2197G	O
AAAA	O
A	O
predicting	O
p.	O
(	O
Glu733Lys	O
)	O
;	O
no	O
evidence	O
of	O
the	O
classical	O
skeletal	O
or	O
dental	O
defects	O
observed	O
in	O
CODAS	O
syndrome	O
patients	O
were	O
noted	O
in	O
our	O
patient	O
.	O

Chronic	B-Phenotype
mucocutaneous	I-Phenotype
candidiasis	E-Phenotype
(	O
CMC	S-Phenotype
)	O
occurs	O
in	O
patients	O
with	O
mutations	O
in	O
genes	O
affecting	O
IL	O
-	O
17	O
-	O
mediated	O
immunity	O
,	O
such	O
as	O
liSTAT3	O
,	O
AIRE	O
,	O
RORC	O
,	O
CARD9	O
,	O
IL12B	O
/	O
i	O
,	O
and	O
liIL12RB1	O
/	O
i	O
,	O
or	O
gain	O
of	O
function	O
(	O
GOF	O
)	O
mutations	O
in	O
liSTAT1	O
/	O
i	O
.	O

In	O
tumors	S-Phenotype
with	O
high	O
PIK3R2	O
expression	O
,	O
and	O
independently	O
of	O
PIK3CA	O
,	O
KRAS	O
,	O
or	O
PTEN	O
mutations	O
,	O
PIK3R2	O
depletion	O
induced	O
lung	O
SQCC	O
xenograft	O
regression	O
without	O
triggering	O
PI3K	O
/	O
AKT	O
pathway	O
rebound	O
.	O

Small	B-Phenotype
-	I-Phenotype
cell	I-Phenotype
gallbladder	I-Phenotype
neuroendocrine	I-Phenotype
carcinoma	E-Phenotype
(	O
GB	B-Phenotype
-	I-Phenotype
SCNEC	E-Phenotype
)	O
is	O
a	O
relatively	O
rare	O
histological	O
type	O
of	O
gallbladder	B-Phenotype
cancer	E-Phenotype
,	O
and	O
the	O
genomic	O
landscape	O
of	O
GB	B-Phenotype
-	I-Phenotype
SCNEC	E-Phenotype
is	O
rarely	O
considered	O
in	O
treatment	O
decisions	O
.	O

Over	O
the	O
last	O
5	O
years	O
,	O
several	O
single	O
gene	O
disorders	O
of	O
the	O
autophagy	O
pathway	O
have	O
emerged	O
:	O
EPG5	O
-	O
associated	O
Vici	O
syndrome	O
,	O
WDR45	O
-	O
associated	O
b	O
-	O
propeller	O
protein	O
-	O
associated	O
neurodegeneration	S-Phenotype
,	O
SNX14	O
-	O
associated	O
autosomal	O
-	O
recessive	O
spinocerebellar	O
ataxia	S-Phenotype
20	O
,	O
ATG5	O
-	O
associated	O
autosomal	O
-	O
recessive	O
ataxia	S-Phenotype
syndrome	O
,	O
SQSTM1	O
/	O
p62	O
-	O
associated	O
childhood	O
-	O
onset	O
neurodegeneration	S-Phenotype
,	O
and	O
several	O
forms	O
of	O
the	O
hereditary	B-Phenotype
spastic	I-Phenotype
paraplegias	E-Phenotype
.	O

Alpha	O
-	O
1	O
-	O
antitrypsin	O
deficiency	O
(	O
AATD	O
)	O
is	O
an	O
inherited	O
disease	O
characterized	O
by	O
emphysema	S-Phenotype
and	O
liver	B-Phenotype
disease	E-Phenotype
.	O

Results	O
from	O
the	O
present	O
study	O
support	O
that	O
the	O
NCC	O
-	O
SS1	O
-	O
C1	O
cell	O
line	O
will	O
be	O
an	O
effective	O
tool	O
for	O
sarcoma	S-Phenotype
research	O

In	O
the	O
stratified	O
analyses	O
by	O
cancer	S-Phenotype
types	O
,	O
the	O
risk	O
of	O
PCa	O
is	O
downgrade	O
by	O
rs7804372	O
in	O
all	O
five	O
genetic	O
models	O
.	O

We	O
suggest	O
that	O
the	O
combination	O
of	O
reduced	O
NM23	O
-	O
H1	O
,	O
induced	O
MACC1	O
,	O
and	O
the	O
presence	O
of	O
tumor	S-Phenotype
budding	O
are	O
promising	O
biomarkers	O
for	O
the	O
prediction	O
of	O
recurrence	O
and	O
may	O
aid	O
the	O
stratification	O
of	O
patients	O
with	O
stage	B-Phenotype
II	I-Phenotype
colon	I-Phenotype
cancer	E-Phenotype
for	O
adjuvant	O
chemotherapy	O

Pseudophakic	O
MMEs	O
were	O
more	O
likely	O
to	O
have	O
a	O
history	O
of	O
diabetic	B-Phenotype
retinopathy	E-Phenotype
,	O
epiretinal	B-Phenotype
membrane	E-Phenotype
,	O
and	O
eyes	O
were	O
not	O
treated	O
with	O
topical	O
NSAID	O
.	O

This	O
study	O
showed	O
a	O
wide	O
clinical	O
spectrum	O
of	O
CMLs	O
.	O

We	O
also	O
analyzed	O
specific	O
mutations	O
within	O
the	O
12	O
genes	O
and	O
found	O
that	O
some	O
specific	O
mutations	O
within	O
the	O
MUC12	O
,	O
FOXD4L3	O
and	O
FOXD4L5	O
genes	O
showed	O
higher	O
frequencies	O
in	O
the	O
samples	O
of	O
FLC	O
and	O
/	O
or	O
lung	B-Phenotype
cancer	E-Phenotype
tissue	O
,	O
compared	O
with	O
the	O
healthy	O
population	O
.	O

Here	O
de	O
novo	O
missense	O
mutations	O
in	O
the	O
RPS23	O
gene	O
,	O
which	O
codes	O
for	O
uS12	O
,	O
are	O
reported	O
in	O
two	O
unrelated	O
individuals	O
with	O
microcephaly	S-Phenotype
,	O
hearing	B-Phenotype
loss	E-Phenotype
,	O
and	O
overlapping	O
dysmorphic	O
features	O
.	O

We	O
identified	O
a	O
homozygous	O
frameshift	O
mutation	O
in	O
CWF19L1	O
(	O
c.467delC	O
;	O
p.	O
(	O
P156Hfs	O
*	O
33	O
)	O
)	O
by	O
a	O
combination	O
of	O
linkage	O
analysis	O
and	O
Whole	O
Exome	O
Sequencing	O
in	O
a	O
consanguineous	O
Turkish	O
family	O
with	O
a	O
9	O
-	O
year	O
-	O
old	O
boy	O
affected	O
by	O
early	B-Phenotype
onset	I-Phenotype
cerebellar	I-Phenotype
ataxia	E-Phenotype
and	O
mild	B-Phenotype
ID	E-Phenotype
.	O

After	O
downregulating	O
SLC6A9	O
or	O
blocking	O
PARP	O
-	O
1	O
artificially	O
,	O
the	O
sensitive	O
thyroid	B-Phenotype
cancer	E-Phenotype
cells	O
mostly	O
displayed	O
a	O
tolerant	O
phenotype	O
under	O
131I	O
exposure	O
.	O

Type	O
III	O
(	O
simple	O
type	O
)	O
patients	O
with	O
SETBP1	O
alteration	O
show	O
their	O
major	O
symptom	O
is	O
development	O
delay	O
,	O
in	O
which	O
expressive	B-Phenotype
language	I-Phenotype
delay	E-Phenotype
is	O
the	O
most	O
striking	O
feature	O
.	O

Conversely	O
,	O
LYVE1	O
expression	O
appeared	O
to	O
be	O
upregulated	O
in	O
lung	B-Phenotype
cancer	E-Phenotype
tissue	O
.	O

Segregation	O
analysis	O
of	O
heterozygous	O
variants	O
,	O
related	O
to	O
hearing	B-Phenotype
loss	E-Phenotype
,	O
identified	O
by	O
whole	O
exome	O
sequencing	O
in	O
the	O
child	O
(	O
ILDR1	O
:	O
c.1159TAAAAC	O
,	O
SYNE4	O
:	O
c.313GAAAAC	O
,	O
and	O
GPR98	O
:	O
c.18746TAAAAG	O
)	O
excluded	O
them	O
from	O
being	O
responsible	O
for	O
the	O
hearing	B-Phenotype
loss	E-Phenotype
in	O
the	O
proposita	O
.	O

Our	O
results	O
demonstrate	O
that	O
human	O
COMT	O
overexpression	O
confers	O
a	O
heightened	O
susceptibility	O
to	O
l	O
-	O
DOPA	O
-	O
induced	O
dyskinesia	S-Phenotype
and	O
alters	O
molecular	O
and	O
neurochemical	O
responses	O
in	O
the	O
lesioned	O
striatum	O
of	O
mice	O

Furthermore	O
,	O
silencing	O
of	O
TRIM44	O
dramatically	O
down	O
-	O
regulated	O
the	O
expression	O
of	O
b	O
-	O
catenin	O
,	O
cyclin	O
-	O
D1	O
and	O
c	O
-	O
Myc	O
in	O
PEC	O
cells	O
,	O
and	O
the	O
activator	O
of	O
the	O
Wnt	O
/	O
b	O
-	O
catenin	O
pathway	O
LiCl	O
rescued	O
the	O
anticancer	O
effect	S-Phenotype
of	O
knockdown	O
TRIM44	O
expression	O
in	O
PTC	O
cells	O
.	O

Here	O
,	O
we	O
report	O
that	O
hypoxia	S-Phenotype
-	O
inducible	O
factor	O
(	O
HIF	O
-	O
1α	O
)	O
and	O
cancer	S-Phenotype
-	O
associated	O
fibroblasts	O
(	O
CAFs	O
)	O
-	O
secreted	O
TGF	O
-	O
β2	O
converge	O
to	O
activate	O
the	O
expression	O
of	O
hedgehog	O
transcription	O
factor	O
GLI2	O
in	O
CSCs	O
,	O
resulting	O
in	O
increased	O
stemness	O
/	O
dedifferentiation	O
and	O
intrinsic	O
resistance	O
to	O
chemotherapy	O
.	O

To	O
dissect	O
the	O
genetic	O
architecture	O
of	O
sporadic	B-Phenotype
ALS	E-Phenotype
,	O
we	O
undertook	O
a	O
large	O
sequencing	O
study	O
in	O
755	O
apparently	O
sporadic	O
ALS	O
cases	O
and	O
959	O
controls	O
,	O
analyzing	O
10	O
ALS	O
genes	O
:	O
SOD1	O
,	O
C9orf72	O
,	O
TARDBP	O
,	O
FUS	O
,	O
ANG	O
,	O
CHMP2B	O
,	O
ATXN2	O
,	O
NIPA1	O
,	O
SMN1	O
,	O
and	O
UNC13A	O
.	O

However	O
,	O
the	O
pathophysiological	O
mechanisms	O
leading	O
to	O
bilateral	B-Phenotype
kidney	I-Phenotype
agenesis	E-Phenotype
(	O
BKA	S-Phenotype
)	O
remain	O
largely	O
elusive	O
.	O

We	O
identified	O
six	O
patients	O
with	O
metastatic	O
RCC	O
who	O
initially	O
responded	O
to	O
mTOR	O
inhibitor	O
therapy	O
and	O
then	O
progressed	O
,	O
and	O
had	O
pre	O
-	O
treatment	O
and	O
post	O
-	O
treatment	O
tumor	S-Phenotype
samples	O
available	O
for	O
analysis	O
.	O

Loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
the	O
human	O
PIEZO1	O
gene	O
cause	O
autosomal	B-Phenotype
recessive	I-Phenotype
congenital	I-Phenotype
lymphatic	I-Phenotype
dysplasia	E-Phenotype
.	O

A	O
heterozygous	O
mutation	O
in	O
the	O
Wolfram	O
syndrome	O
type	O
1	O
gene	O
(	O
WFS1	O
)	O
causes	O
autosomal	B-Phenotype
dominant	I-Phenotype
nonsyndromic	I-Phenotype
hereditary	I-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
,	O
DFNA6	O
/	O
14	O
/	O
38	O
,	O
or	O
Wolfram	O
-	O
like	O
syndrome	O
.	O

Inhibitors	O
of	O
molecules	O
of	O
the	O
transforming	O
growth	O
factor	O
-	O
β	O
superfamily	O
have	O
been	O
shown	O
recently	O
to	O
target	O
ineffective	B-Phenotype
erythropoiesis	E-Phenotype
and	O
ameliorate	O
anemia	S-Phenotype
both	O
in	O
animal	O
models	O
of	O
myelodysplastic	B-Phenotype
syndrome	E-Phenotype
and	O
in	O
RARS	O
patients	O
.	O

Gastric	B-Phenotype
stump	I-Phenotype
cancer	E-Phenotype
(	O
GSC	S-Phenotype
)	O
is	O
a	O
carcinoma	S-Phenotype
arising	O
from	O
the	O
remnant	O
stomach	O
following	O
gastric	O
surgery	O
for	O
benign	O
or	O
malignant	O
disease	O
,	O
and	O
is	O
more	O
common	O
in	O
men	O
.	O

Biallelic	O
mutations	O
in	O
FKBP14	O
cause	O
a	O
recessive	O
form	O
of	O
Ehlers	O
-	O
Danlos	O
syndrome	O
(	O
EDS	O
)	O
characterized	O
by	O
progressive	B-Phenotype
kyphoscoliosis	E-Phenotype
,	O
myopathy	S-Phenotype
,	O
and	O
hearing	B-Phenotype
loss	E-Phenotype
.	O

The	O
vFLIP	O
protein	O
has	O
been	O
shown	O
to	O
activate	O
the	O
NF	O
-	O
kB	O
signaling	O
involved	O
in	O
spindle	O
morphology	O
formation	O
both	O
in	O
HUVECs	O
infected	O
with	O
KSHV	O
and	O
Kaposi	O
*	O
s	O
sarcoma	S-Phenotype
(	O
KS	O
)	O
itself	O
.	O

Then	O
the	O
inflammatory	O
corneal	B-Phenotype
neovascularization	E-Phenotype
(	O
CorNV	S-Phenotype
)	O
model	O
and	O
fungal	O
corneal	O
infections	O
were	O
induced	O
in	O
Balb	O
/	O
c	O
mice	O
,	O
and	O
mRNA	O
levels	O
of	O
Mxra7	O
as	O
well	O
as	O
several	O
matrix	O
-	O
remodeling	O
related	O
genes	O
(	O
Mmp3	O
,	O
Mmp13	O
,	O
Ecm1	O
,	O
Timp1	O
)	O
were	O
monitored	O
with	O
RT	O
-	O
PCR	O
.	O

The	O
SNPs	O
rs2124437	O
(	O
RASGRP3	O
)	O
,	O
rs1335022	O
(	O
GRIK2	O
)	O
,	O
rs4512367	O
(	O
PREX2	O
)	O
,	O
rs4748011	O
(	O
CCDC3	O
)	O
,	O
and	O
rs1435218	O
(	O
LNX1	O
)	O
were	O
analyzed	O
in	O
500	O
histopathologically	O
confirmed	O
oral	B-Phenotype
cancers	E-Phenotype
and	O
500	O
healthy	O
controls	O
with	O
a	O
minimum	O
of	O
10	O
years	O
of	O
tobacco	O
usage	O
.	O

Depletion	O
of	O
ASS1	O
led	O
to	O
inhibition	O
of	O
tumor	S-Phenotype
growth	O
and	O
decreased	O
cell	O
invasion	O
via	O
induction	O
of	O
autophagy	O
-	O
lysosome	O
machinery	O
,	O
resulting	O
in	O
degradation	O
of	O
active	O
β	O
-	O
catenin	O
,	O
Snail	O
,	O
and	O
Twist	O
.	O

In	O
the	O
present	O
study	O
,	O
individual	O
driver	O
genes	O
for	O
each	O
type	O
of	O
cancer	S-Phenotype
were	O
identified	O
using	O
integrated	O
analysis	O
of	O
multiple	O
microarray	O
data	O
.	O

In	O
an	O
effort	O
to	O
identify	O
new	O
mutations	O
responsible	O
for	O
DBA	O
,	O
we	O
performed	O
whole	O
-	O
exome	O
sequencing	O
analysis	O
of	O
48	O
patients	O
with	O
no	O
documented	O
mutations	O
/	O
deletions	O
in	O
our	O
first	O
screening	O
and	O
identified	O
a	O
de	O
novo	O
splicing	O
error	O
mutation	O
in	O
RPL27	O
and	O
a	O
frameshift	O
deletion	O
in	O
RPS27	O
in	O
sporadic	S-Phenotype
patients	O
with	O
DBA	O
.	O

A	O
total	O
of	O
3128	O
people	O
participated	O
and	O
were	O
divided	O
into	O
5	O
groups	O
:	O
healthy	O
controls	O
,	O
natural	O
clearance	O
,	O
chronic	B-Phenotype
hepatitis	I-Phenotype
B	E-Phenotype
(	O
CHB	S-Phenotype
)	O
,	O
liver	B-Phenotype
cirrhosis	E-Phenotype
and	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
.	O

This	O
study	O
is	O
to	O
investigate	O
multiple	O
chemotherapeutic	O
agent	O
-	O
and	O
radiation	O
-	O
related	O
genetic	O
biomarkers	O
in	O
locally	B-Phenotype
advanced	I-Phenotype
rectal	I-Phenotype
cancer	E-Phenotype
(	O
LARC	S-Phenotype
)	O
patients	O
following	O
fluoropyrimidine	O
-	O
based	O
concurrent	O
chemoradiotherapy	O
(	O
CCRT	O
)	O
for	O
response	O
prediction	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
recognize	O
the	O
expanded	O
purine	O
repeats	O
(	O
EPRs	O
)	O
in	O
human	O
genome	O
and	O
find	O
their	O
correlation	O
with	O
cancer	S-Phenotype
pathogenesis	O
.	O

Moreover	O
,	O
zebrafish	O
treated	O
with	O
morpholinos	O
against	O
tubgcp4	O
were	O
found	O
to	O
have	O
reduced	O
head	O
volume	O
and	O
eye	O
developmental	O
anomalies	O
with	O
chorioretinal	B-Phenotype
dysplasia	E-Phenotype
.	O

To	O
reveal	O
novel	O
molecular	O
factors	O
behind	O
the	O
development	O
of	O
salivary	B-Phenotype
gland	I-Phenotype
cancer	E-Phenotype
,	O
we	O
performed	O
gene	O
expression	O
analyses	O
from	O
Smgb	O
-	O
Tag	O
mouse	O
salivary	O
gland	O
samples	O
.	O

Mutations	O
,	O
A147T	O
and	O
A165V	O
,	O
within	O
the	O
ZM	O
of	O
ZASP	O
-	O
LDex10	O
cause	O
myofibrillar	B-Phenotype
myopathy	E-Phenotype
,	O
but	O
the	O
mechanism	O
is	O
unknown	O
.	O

Studying	O
consanguineous	O
families	O
with	O
Ghosal	O
hematodiaphyseal	O
dysplasia	O
syndrome	O
(	O
GHDD	O
)	O
,	O
a	O
disorder	O
of	O
increased	B-Phenotype
bone	I-Phenotype
density	E-Phenotype
,	O
we	O
identified	O
mutations	O
in	O
TBXAS1	O
,	O
which	O
encodes	O
thromboxane	O
synthase	O
(	O
TXAS	O
)	O
.	O

Patients	O
with	O
autosomal	B-Phenotype
dominant	I-Phenotype
vibratory	I-Phenotype
urticaria	E-Phenotype
have	O
localized	O
hives	S-Phenotype
and	O
systemic	O
manifestations	O
in	O
response	O
to	O
dermal	O
vibration	O
,	O
with	O
coincident	O
degranulation	O
of	O
mast	O
cells	O
and	O
increased	O
histamine	O
levels	O
in	O
serum	O
.	O

Mutations	O
in	O
PLA2G6	O
(	O
PARK14	O
)	O
cause	O
neurodegenerative	O
disorders	O
in	O
humans	O
,	O
including	O
autosomal	B-Phenotype
recessive	I-Phenotype
neuroaxonal	I-Phenotype
dystrophy	E-Phenotype
and	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
parkinsonism	E-Phenotype
.	O

Whole	O
-	O
exome	O
sequencing	O
analysis	O
identified	O
a	O
novel	O
homozygous	O
c.100	O
G	O
AAAA	O
A	O
change	O
in	O
IFT43	O
segregating	O
with	O
retinal	B-Phenotype
degeneration	E-Phenotype
and	O
not	O
present	O
in	O
ethnicity	O
-	O
matched	O
controls	O
.	O

A	O
significant	O
association	O
of	O
the	O
SNPs	O
in	O
oral	B-Phenotype
cancer	E-Phenotype
was	O
observed	O
in	O
RASGRP3	O
AA	O
(	O
rs2124437	O
)	O
(	O
p	O
AAAA	O
0.000	O
,	O
OR	O
1.34	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1.01	O
-	O
1.76	O
)	O
,	O
GRIK2	O
TT	O
(	O
rs1335022	O
)	O
(	O
p	O
=	O
0.008	O
,	O
OR	O
1.58	O
,	O
95	O
%	O
CI	O
1.23	O
-	O
2.03	O
)	O
,	O
PREX2	O
CC	O
(	O
p	O
=	O
0.008	O
,	O
OR	O
1.56	O
,	O
95	O
%	O
CI	O
1.15	O
-	O
2.1	O
)	O
,	O
and	O
TT	O
(	O
p	O
AAAA	O
0.000	O
,	O
OR	O
2.77	O
,	O
1.68	O
-	O
4.57	O
)	O
genotypes	O
,	O
whereas	O
the	O
heterozygous	O
genotypes	O
showed	O
higher	O
frequencies	O
in	O
controls	O
,	O
i.e.	O
,	O
GRIK2	O
CT	O
(	O
rs1335022	O
)	O
(	O
p	O
=	O
0.029	O
,	O
OR	O
0.68	O
,	O
95	O
%	O
CI	O
0.53	O
-	O
0.87	O
)	O
and	O
PREX2	O
CT	O
(	O
p	O
=	O
0.004	O
,	O
OR	O
0.49	O
,	O
95	O
%	O
CI	O
0.37	O
-	O
0.64	O
)	O
,	O
indicating	O
protection	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
expression	O
of	O
Lin28A	O
,	O
let	O
-	O
7a	O
,	O
and	O
c	O
-	O
Myc	O
in	O
human	O
papillary	B-Phenotype
thyroid	I-Phenotype
carcinoma	E-Phenotype
(	O
PTC	S-Phenotype
)	O
and	O
to	O
investigate	O
their	O
potential	O
mechanisms	O
in	O
the	O
progression	O
of	O
PTC	S-Phenotype
.	O

Our	O
findings	O
suggest	O
that	O
DEGs	O
encoding	O
subunits	O
of	O
NADH	O
,	O
PRIM1	O
,	O
MCM3	O
,	O
MAPK1	O
,	O
STAT3	O
,	O
RAF1	O
,	O
and	O
JAK1	O
might	O
be	O
associated	O
with	O
the	O
development	O
of	O
lung	B-Phenotype
adenocarcinoma	E-Phenotype
.	O

However	O
,	O
certain	O
chromatin	O
remodeling	O
genes	O
(	O
MLL1	O
,	O
MLL2	O
,	O
MLL3	O
,	O
BAP1	O
,	O
PBRM1	O
,	O
EED	O
,	O
and	O
ATRX	O
)	O
were	O
found	O
to	O
be	O
mutated	O
in	O
7	O
/	O
22	O
(	O
32	O
%	O
)	O
of	O
intraductal	B-Phenotype
tubulopapillary	I-Phenotype
neoplasms	E-Phenotype
and	O
27	O
%	O
harbored	O
phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PI3K	O
)	O
pathway	O
(	O
PIK3CA	O
,	O
PIK3CB	O
,	O
INPP4A	O
,	O
and	O
PTEN	O
)	O
mutations	O
.	O

Sickle	O
cell	O
disease	O
(	O
SCD	O
)	O
is	O
one	O
of	O
the	O
most	O
common	O
autosomal	B-Phenotype
recessive	E-Phenotype
diseases	O
in	O
humans	O
,	O
occurring	O
at	O
a	O
frequency	O
of	O
1	O
in	O
365	O
African	O
-	O
American	O
and	O
1	O
in	O
50	O
sub	O
-	O
Saharan	O
African	O
births	O
.	O

We	O
recently	O
reported	O
that	O
centrosomal	O
protein	O
164	O
(	O
CEP164	O
)	O
regulates	O
both	O
cilia	O
and	O
the	O
DNA	O
damage	O
response	O
in	O
the	O
autosomal	B-Phenotype
recessive	I-Phenotype
polycystic	I-Phenotype
kidney	E-Phenotype
disease	O
nephronophthisis	S-Phenotype
.	O

Glycogen	O
storage	O
disease	O
type	O
Ib	O
(	O
GSD	O
-	O
Ib	O
)	O
is	O
characterized	O
by	O
impaired	B-Phenotype
glucose	I-Phenotype
homeostasis	E-Phenotype
,	O
neutropenia	S-Phenotype
and	O
neutrophil	B-Phenotype
dysfunction	E-Phenotype
.	O

By	O
immunohistochemistry	O
of	O
ovarian	B-Phenotype
tumors	E-Phenotype
with	O
BRCA1	O
(	O
+	O
/	O
+	O
)	O
and	O
BRCA1	O
(	O
null	O
)	O
status	O
,	O
we	O
further	O
verified	O
our	O
proteomic	O
-	O
based	O
finding	O
of	O
elevated	O
PFN1	O
expression	O
associated	O
with	O
BRCA1	O
deficiency	O
.	O

Whether	O
they	O
function	O
as	O
direct	O
precursors	O
to	O
a	O
less	O
common	O
form	O
of	O
squamous	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
will	O
require	O
further	O
study	O
,	O
but	O
carcinomas	O
associated	O
with	O
these	O
lesions	O
might	O
warrant	O
testing	O
for	O
PIK3CA	O
mutations	O
to	O
address	O
this	O
question	O

However	O
,	O
there	O
was	O
no	O
research	O
elucidating	O
the	O
genetic	O
association	O
of	O
entire	O
NER	O
pathway	O
with	O
ovarian	B-Phenotype
cancer	E-Phenotype
susceptibility	O
.	O

Biallelic	O
mutations	O
in	O
these	O
genes	O
cause	O
Fanconi	B-Phenotype
anemia	E-Phenotype
(	O
FA	S-Phenotype
)	O
,	O
characterized	O
by	O
malformations	S-Phenotype
,	O
bone	B-Phenotype
marrow	I-Phenotype
failure	E-Phenotype
,	O
chromosome	B-Phenotype
fragility	E-Phenotype
,	O
and	O
cancer	S-Phenotype
predisposition	O
(	O
BRCA2	O
/	O
FANCD1	O
and	O
PALB2	O
/	O
FANCN	O
)	O
,	O
or	O
an	O
FA	O
-	O
like	O
disease	O
presenting	O
a	O
phenotype	O
similar	O
to	O
FA	O
but	O
without	O
bone	B-Phenotype
marrow	I-Phenotype
failure	E-Phenotype
(	O
BRCA1	O
/	O
FANCS	O
)	O
.	O

Here	O
,	O
we	O
have	O
performed	O
a	O
prospective	O
nationwide	O
genetic	O
association	O
study	O
using	O
the	O
Human	O
Exome	O
BeadChip	O
and	O
identified	O
gene	O
variants	O
in	O
encoding	O
dynactin	O
4	O
(	O
DCTN4	O
)	O
,	O
retinoic	O
acid	O
early	O
transcript	O
1E	O
(	O
RAET1E	O
)	O
,	O
and	O
V	O
-	O
akt	O
murine	O
thymoma	S-Phenotype
viral	O
oncogene	O
homolog	O
3	O
(	O
AKT3	O
)	O
to	O
be	O
associated	O
with	O
unfavourable	O
outcome	O
in	O
patients	O
with	O
pneumococcal	B-Phenotype
meningitis	E-Phenotype
.	O

In	O
immunodeficient	O
mice	O
,	O
proliferation	O
was	O
inhibited	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
expressing	O
forms	O
of	O
hERG1	O
with	O
impaired	O
Ksup+	O
/	O
sup	O
flow	O
,	O
whereas	O
metastasis	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
was	O
reduced	O
when	O
the	O
hERG1	O
/	O
βsub1	O
/	O
sub	O
integrin	O
interaction	O
was	O
disrupted	O
.	O

In	O
addition	O
,	O
the	O
coexistence	O
of	O
high	O
MACC1	O
and	O
low	O
NM23	O
-	O
H1	O
expression	O
and	O
tumor	S-Phenotype
budding	O
was	O
associated	O
with	O
short	O
OS	O
(	O
p	O
AAAA	O
0.001	O
)	O
.	O

Our	O
present	O
study	O
confirmed	O
radiation	O
can	O
promote	O
the	O
in	O
vitro	O
migration	O
and	O
invasion	O
of	O
triple	B-Phenotype
negative	I-Phenotype
breast	I-Phenotype
cancer	E-Phenotype
(	O
TNBC	S-Phenotype
)	O
cells	O
and	O
increase	O
the	O
expression	O
of	O
epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
related	O
transcription	O
factor	O
ZEB1	O
,	O
while	O
had	O
no	O
effect	O
on	O
Snail	O
,	O
Slug	O
or	O
Twist	O
.	O

The	O
results	O
suggest	O
a	O
conditional	O
regulation	O
of	O
KRT16	O
gene	O
by	O
ATF4	O
that	O
may	O
be	O
inhibited	O
in	O
normal	O
cells	O
,	O
but	O
engaged	O
during	O
cancer	S-Phenotype
progression	O
.	O

PRNP	O
and	O
PRND	O
appear	O
involved	O
with	O
some	O
important	O
genes	O
related	O
to	O
tumorigenesis	S-Phenotype
and	O
apoptosis	O
.	O

Identification	O
of	O
this	O
mutation	O
reveals	O
the	O
allelic	O
heterogeneity	S-Phenotype
of	O
RDH5	O
in	O
patients	O
with	O
RP	O
phenotype	O
.	O

Despite	O
promising	O
therapeutic	O
avenues	O
,	O
there	O
is	O
currently	O
no	O
effective	O
treatment	O
for	O
Duchenne	B-Phenotype
muscular	I-Phenotype
dystrophy	E-Phenotype
(	O
DMD	S-Phenotype
)	O
,	O
a	O
lethal	O
monogenic	O
disorder	O
caused	O
by	O
the	O
loss	O
of	O
the	O
large	O
cytoskeletal	O
protein	O
,	O
dystrophin	O
.	O

The	O
present	O
study	O
confirmed	O
associations	O
of	O
KCNB2	O
rs2247572	O
,	O
CSMD1	O
rs2616984	O
,	O
and	O
intergenic	O
rs12807809	O
located	O
in	O
SPA17	O
/	O
NRGN	O
with	O
schizophrenia	S-Phenotype
.	O

De	O
novo	O
monoallelic	O
mutations	O
in	O
the	O
GNB1	O
gene	O
,	O
encoding	O
a	O
β	O
subunit	O
of	O
heterotrimeric	O
G	O
proteins	O
,	O
cause	O
a	O
newly	O
recognized	O
disorder	O
with	O
the	O
typical	O
clinical	O
picture	O
of	O
severe	O
developmental	B-Phenotype
delay	E-Phenotype
/	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
hypotonia	S-Phenotype
and	O
extrapyramidal	B-Phenotype
symptoms	E-Phenotype
.	O

Exome	O
sequencing	O
of	O
superior	O
coloboma	S-Phenotype
patients	O
identified	O
rare	O
variants	O
in	O
a	O
Bone	O
Morphogenetic	O
Protein	O
(	O
Bmp	O
)	O
receptor	O
(	O
BMPR1A	O
)	O
and	O
T	O
-	O
box	O
transcription	O
factor	O
(	O
TBX2	O
)	O
.	O

In	O
order	O
to	O
expand	O
the	O
mutation	O
spectrum	O
of	O
the	O
causative	O
genes	O
in	O
Chinese	O
adult	O
population	O
,	O
we	O
investigated	O
three	O
genes	O
,	O
SLC39A5	O
,	O
LEPREL1	O
and	O
LRPAP1	O
,	O
in	O
a	O
cohort	O
of	O
187	O
independent	O
Chinese	O
patients	O
with	O
high	B-Phenotype
myopia	E-Phenotype
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
genetic	O
inactivation	O
of	O
Prss56	O
rescues	O
axial	O
elongation	O
in	O
a	O
mouse	O
model	O
of	O
myopia	S-Phenotype
caused	O
by	O
a	O
null	O
mutation	O
in	O
Egr1	O
.	O

Furthermore	O
,	O
targeting	O
DNA	O
repair	O
defects	O
by	O
PARP1	O
inhibitors	O
(	O
PARPi	O
)	O
as	O
a	O
cancer	S-Phenotype
treatment	O
strategy	O
is	O
emerging	O
yet	O
requires	O
suitable	O
predictive	O
biomarkers	O
.	O

This	O
study	O
establishes	O
PYROXD1	O
variants	O
as	O
a	O
cause	O
of	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
myopathy	E-Phenotype
and	O
uses	O
biospecimens	O
and	O
cell	O
lines	O
,	O
yeast	O
,	O
and	O
zebrafish	O
models	O
to	O
elucidate	O
the	O
fundamental	O
role	O
of	O
PYROXD1	O
in	O
skeletal	O
muscle	O
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
assess	O
the	O
independent	O
prognostic	O
value	O
of	O
miR	O
-	O
361	O
-	O
3p	O
in	O
terms	O
of	O
overall	O
survival	O
(	O
OS	O
)	O
and	O
recurrence	O
-	O
free	O
survival	O
(	O
RFS	O
)	O
in	O
cervical	B-Phenotype
cancer	E-Phenotype
,	O
as	O
well	O
as	O
its	O
possible	O
regulative	O
network	O
.	O

These	O
findings	O
link	O
Cntn5	O
deficiency	O
to	O
obesity	S-Phenotype
and	O
hypertension	S-Phenotype

ZNF687	O
overexpression	O
greatly	O
enhanced	O
HCC	O
cell	O
capability	O
for	O
tumorsphere	S-Phenotype
formation	O
,	O
invasion	O
and	O
chemoresistance	O
in	O
vitro	O
,	O
whereas	O
inhibiting	O
ZNF687	O
reduced	O
these	O
capabilities	O
and	O
inhibited	O
HCC	S-Phenotype
cell	O
tumorigenic	O
capability	O
in	O
vivo	O
.	O

We	O
recently	O
found	O
that	O
DDHD2	O
is	O
a	O
principal	O
triglyceride	O
hydrolase	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
and	O
that	O
genetic	O
deletion	O
of	O
this	O
enzyme	O
in	O
mice	O
leads	O
to	O
ectopic	O
lipid	O
droplet	O
(	O
LD	O
)	O
accumulation	O
in	O
neurons	O
throughout	O
the	O
brain	O
.	O

However	O
,	O
the	O
significance	O
of	O
Brf1	O
overexpression	O
in	O
human	O
breast	B-Phenotype
cancer	E-Phenotype
(	O
HBC	O
)	O
remains	O
to	O
be	O
investigated	O
.	O

Based	O
on	O
the	O
miRNA	O
signature	O
of	O
bladder	B-Phenotype
cancer	E-Phenotype
(	O
BC	S-Phenotype
)	O
obtained	O
by	O
RNA	O
sequencing	O
,	O
we	O
focused	O
on	O
both	O
strands	O
of	O
the	O
miR	O
-	O
223	O
-	O
duplex	O
(	O
miR	O
-	O
223	O
-	O
5p	O
and	O
miR	O
-	O
223	O
-	O
3p	O
)	O
and	O
investigated	O
their	O
functional	O
significance	O
in	O
BC	S-Phenotype
cells	O
.	O

PKP1	O
and	O
PKP3	O
immunoreactivity	O
was	O
inversely	O
correlated	O
with	O
tumor	S-Phenotype
histological	O
grade	O
and	O
was	O
observed	O
only	O
in	O
tumors	S-Phenotype
that	O
did	O
not	O
metastasize	O
.	O

In	O
conclusion	O
,	O
our	O
study	O
demonstrates	O
for	O
the	O
first	O
time	O
that	O
p53R2	O
protein	O
is	O
overexpressed	S-Phenotype
in	O
early	B-Phenotype
-	I-Phenotype
stage	I-Phenotype
cervical	I-Phenotype
cancer	E-Phenotype
and	O
unravels	O
some	O
unconventional	O
oncogenic	O
functions	O
of	O
p53R2	O
.	O

This	O
is	O
,	O
to	O
our	O
knowledge	O
,	O
a	O
most	O
severe	O
phenotype	O
of	O
EVC	O
syndrome	O
,	O
illustrating	O
that	O
the	O
specific	O
pattern	O
of	O
EVC2	O
compound	O
heterozygous	O
mutations	O
may	O
cause	O
severe	O
developmental	B-Phenotype
delay	E-Phenotype
and	O
intestinal	B-Phenotype
malfunction	E-Phenotype
.	O

There	O
was	O
weaker	O
evidence	O
for	O
iCHAV4	O
,	O
located	O
5	O
'	O
of	O
ADO	O
,	O
associated	O
only	O
with	O
ER	O
-	O
positive	O
breast	B-Phenotype
cancer	E-Phenotype
(	O
OR	O
=	O
0.93	O
[	O
0.90	O
-	O
0.96	O
]	O
)	O
.	O

Structural	O
,	O
biophysical	O
,	O
and	O
mutagenesis	O
analyses	O
revealed	O
that	O
cancer	S-Phenotype
-	O
associated	O
mutations	O
disrupt	O
the	O
SRP68	O
-	O
SRP72	O
interaction	O
and	O
their	O
co	O
-	O
localization	O
with	O
ER	O
in	O
mammalian	O
cells	O
.	O

Mutations	O
of	O
the	O
sigma	O
subunit	O
of	O
the	O
heterotetrameric	O
adaptor	O
-	O
related	O
protein	O
complex	O
2	O
(	O
AP2σ	O
)	O
impair	O
signalling	O
of	O
the	O
calcium	O
-	O
sensing	O
receptor	O
(	O
CaSR	O
)	O
,	O
and	O
cause	O
familial	B-Phenotype
hypocalciuric	I-Phenotype
hypercalcaemia	I-Phenotype
type	I-Phenotype
3	E-Phenotype
(	O
FHH3	S-Phenotype
)	O
.	O

Moreover	O
,	O
the	O
overexpression	O
of	O
NIBP	O
was	O
closely	O
related	O
to	O
tumor	S-Phenotype
differentiation	O
,	O
depth	O
of	O
invasion	O
,	O
clinical	O
stage	O
and	O
lymphatic	O
metastasis	O
in	O
gastric	B-Phenotype
cancer	E-Phenotype
.	O

Additional	O
functional	O
analyses	O
suggested	O
that	O
CWC27	O
played	O
an	O
oncogenic	O
role	O
in	O
bladder	B-Phenotype
cancer	E-Phenotype
by	O
inducing	O
cell	O
proliferation	O
and	O
suppressing	O
apoptosis	O
.	O

As	O
a	O
transcriptional	O
regulator	O
of	O
broad	O
developmental	O
processes	O
capable	O
of	O
promoting	O
malignant	O
growth	O
in	O
adult	O
tissues	O
,	O
therapeutically	O
targeting	O
the	O
CtBP1	O
corepressor	O
has	O
the	O
potential	O
to	O
be	O
an	O
effective	O
method	O
for	O
the	O
treatment	O
of	O
diverse	O
tumor	S-Phenotype
types	O
.	O

Furthermore	O
,	O
PEPCK	O
-	O
M	O
silencing	O
abrogated	O
cancer	S-Phenotype
growth	O
in	O
a	O
lung	B-Phenotype
cancer	E-Phenotype
cell	O
xenograft	O
model	O
.	O

Additional	O
protein	O
interaction	O
characterization	O
revealed	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
as	O
a	O
novel	O
interacting	O
partner	O
for	O
RANK	O
-	O
c	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
with	O
a	O
negative	O
effect	O
on	O
EGFR	O
phosphorylation	O
and	O
EGF	O
-	O
dependent	O
downstream	O
signaling	O
pathway	O
activation	O
.	O

Interestingly	O
,	O
heterogeneous	S-Phenotype
nuclear	O
RNA	O
(	O
hnRNA	O
)	O
for	O
insulin	O
and	O
INS	O
-	O
IGF2	O
,	O
both	O
originating	O
from	O
the	O
INS	O
promoter	O
,	O
were	O
essentially	O
undetectable	O
in	O
T1D	O
pancreata	O
,	O
arguing	O
for	O
a	O
silent	O
INS	O
promoter	O
.	O

We	O
will	O
systematically	O
examine	O
seven	O
genes	O
(	O
CHN1	O
,	O
MDH1	O
,	O
PCP4	O
,	O
RTN1	O
,	O
SLC14A1	O
,	O
SNAP25	O
and	O
VSNL1	O
)	O
that	O
are	O
altered	O
in	O
the	O
three	O
neurodegenerative	B-Phenotype
diseases	E-Phenotype
.	O

However	O
,	O
age	O
at	O
menarche	O
,	O
gestational	B-Phenotype
diabetes	E-Phenotype
and	O
PCOS	O
were	O
found	O
to	O
be	O
genetically	O
linked	O
to	O
risk	O
factors	O
for	O
heart	B-Phenotype
failure	E-Phenotype
,	O
such	O
as	O
atrial	B-Phenotype
fibrillation	E-Phenotype
,	O
diabetes	S-Phenotype
and	O
smoking	S-Phenotype
.	O

In	O
conclusion	O
,	O
miR	O
-	O
135b	O
-	O
5p	O
,	O
maybe	O
a	O
novel	O
therapeutic	O
target	O
for	O
pancreatic	B-Phenotype
cancer	E-Phenotype
,	O
promoted	O
migration	O
,	O
invasion	O
and	O
EMT	O
of	O
pancreatic	B-Phenotype
cancer	E-Phenotype
cells	O
by	O
targeting	O
NR3C2	O

A	O
heterozygous	O
nonsense	O
variant	O
was	O
identified	O
in	O
dapper	O
,	O
antagonist	O
of	O
beta	O
-	O
catenin	O
,	O
1	O
(	O
DACT1	O
)	O
via	O
whole	O
-	O
exome	O
sequencing	O
in	O
family	O
members	O
with	O
imperforate	B-Phenotype
anus	E-Phenotype
,	O
structural	B-Phenotype
renal	I-Phenotype
abnormalities	E-Phenotype
,	O
genitourinary	B-Phenotype
anomalies	E-Phenotype
,	O
and	O
/	O
or	O
ear	B-Phenotype
anomalies	E-Phenotype
.	O

These	O
three	O
CNVs	O
are	O
close	O
to	O
two	O
known	O
PWS	O
genes	O
,	O
NDN	O
(	O
necdin	O
homolog	O
)	O
and	O
C15orf2	O
(	O
chromosome	O
15	O
open	O
reading	O
frame	O
2	O
)	O
,	O
and	O
partially	O
overlap	O
with	O
another	O
obesity	S-Phenotype
gene	O
PWRN1	O
(	O
Prader	O
-	O
Willi	O
region	O
nonprotein	O
-	O
coding	O
RNA	O
1	O
)	O
.	O

These	O
tumors	S-Phenotype
often	O
exhibit	O
a	O
plasmablastic	O
morphology	O
,	O
a	O
finding	O
which	O
prompted	O
our	O
interest	O
in	O
looking	O
for	O
ALK	O
fusions	O
in	O
plasma	O
cell	O
neoplasms	S-Phenotype
.	O

p53R2	O
overexpression	O
is	O
associated	O
with	O
increased	O
risk	O
of	O
pelvic	O
lymph	O
node	O
metastasis	O
(	O
PLNM	O
,	O
p	O
=	O
0.001	O
)	O
and	O
cancer	S-Phenotype
relapse	O
(	O
p	O
=	O
0.009	O
)	O
.	O

Numerous	O
evidence	O
has	O
demonstrated	O
for	O
an	O
association	O
between	O
apoA5	O
and	O
the	O
increased	O
risk	O
of	O
obesity	S-Phenotype
and	O
metabolic	O
syndrome	O
,	O
but	O
the	O
mechanism	O
remains	O
to	O
be	O
fully	O
elucidated	O
.	O

These	O
results	O
suggest	O
that	O
UBE2T	O
plays	O
a	O
critical	O
role	O
in	O
gastric	B-Phenotype
cancer	E-Phenotype
,	O
and	O
that	O
it	O
may	O
serve	O
as	O
a	O
useful	O
prognostic	O
biomarker	O
and	O
therapeutic	O
target	O
in	O
gastric	B-Phenotype
cancer	E-Phenotype
patients	O

Lower	O
serum	O
miR	O
-	O
122	O
is	O
a	O
unique	O
feature	O
of	O
HNF1A	O
-	O
DM	O
patients	O
and	O
might	O
partially	O
explain	O
the	O
increased	O
risk	O
for	O
liver	B-Phenotype
neoplasm	E-Phenotype
and	O
abnormal	B-Phenotype
lipid	I-Phenotype
metabolism	E-Phenotype
in	O
HNF1A	O
-	O
DM	O
patients	O

In	O
vivo	O
multispectral	O
fluorescent	O
imaging	O
,	O
the	O
EGFP	O
-	O
EGF1	O
conjugated	O
nanoparticles	O
showed	O
significantly	O
higher	O
accumulation	O
in	O
tumor	S-Phenotype
tissues	O
than	O
non	O
-	O
conjugated	O
ones	O
.	O

Lymphovascular	O
invasion	O
was	O
significantly	O
(	O
liP	O
/	O
i	O
=	O
0.014	O
)	O
more	O
often	O
seen	O
in	O
phospho	O
-	O
ELK1	O
(	O
2+	O
)	O
tumors	S-Phenotype
(	O
80.0	O
%	O
)	O
than	O
in	O
phospho	O
-	O
ELK1	O
(	O
0	O
/	O
1+	O
)	O
tumors	S-Phenotype
(	O
36.0	O
%	O
)	O
.	O

Here	O
,	O
we	O
show	O
that	O
TILs	O
from	O
mice	O
deleted	O
in	O
protocadherin	O
-	O
18	O
had	O
enhanced	O
antitumor	O
activity	S-Phenotype
and	O
that	O
coblockade	O
of	O
PD	O
-	O
1	O
and	O
protocadherin	O
-	O
18	O
in	O
wild	O
-	O
type	O
mice	O
significantly	O
enhanced	O
TIL	O
effector	O
phase	O
function	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
Vps45	O
-	O
related	O
disease	O
in	O
humans	O
,	O
manifesting	O
by	O
neutropenia	S-Phenotype
,	O
thrombasthenia	S-Phenotype
,	O
myelofibrosis	S-Phenotype
,	O
and	O
progressive	O
bone	B-Phenotype
marrow	I-Phenotype
failure	E-Phenotype

Our	O
data	O
suggest	O
that	O
children	O
with	O
the	O
INSM1	O
binding	O
site	O
within	O
the	O
CLDN14	O
risk	O
haplotype	O
have	O
a	O
higher	O
likelihood	O
of	O
hypercalciuria	S-Phenotype
and	O
kidney	B-Phenotype
stones	E-Phenotype
.	O

Importantly	O
,	O
depletion	O
of	O
CDCA7	O
strongly	O
reduced	O
the	O
tumorigenicity	S-Phenotype
and	O
distant	O
colonization	O
capacities	O
of	O
TNBC	O
cells	O
in	O
vivo	O
.	O

DIO1	O
-	O
induced	O
changes	O
in	O
intracellular	O
concentrations	O
of	O
thyroid	O
hormones	O
were	O
quantified	O
by	O
L	O
-	O
MS	O
/	O
MS	O
and	O
correlations	O
between	O
expression	O
of	O
DIO1	O
and	O
potential	O
target	O
genes	O
were	O
determined	O
in	O
tissue	O
samples	O
from	O
renal	B-Phenotype
cancer	E-Phenotype
patients	O
.	O

De	O
novo	O
FOXP1	O
mutations	O
have	O
been	O
associated	O
with	O
intellectual	B-Phenotype
disability	E-Phenotype
(	O
ID	S-Phenotype
)	O
,	O
motor	B-Phenotype
delay	E-Phenotype
,	O
autistic	O
features	O
and	O
a	B-Phenotype
wide	I-Phenotype
spectrum	I-Phenotype
of	I-Phenotype
speech	I-Phenotype
difficulties	E-Phenotype
.	O

Trop2	O
,	O
a	O
transmembrane	O
glycoprotein	O
,	O
has	O
emerged	O
as	O
a	O
biomarker	O
for	O
targeted	O
cancer	S-Phenotype
therapy	O
since	O
it	O
is	O
overexpressed	O
in	O
80	O
%	O
of	O
triple	B-Phenotype
negative	I-Phenotype
breast	I-Phenotype
cancer	E-Phenotype
(	O
TNBC	S-Phenotype
)	O
patients	O
.	O

Heterozygous	O
Edn1H	O
/	O
+	O
females	O
showed	O
no	O
obvious	O
abnormalities	O
before	O
pregnancy	O
,	O
but	O
when	O
mated	O
with	O
wild	O
-	O
type	O
(	O
WT	O
)	O
males	O
developed	O
a	O
full	O
spectrum	O
of	O
preeclampsia	S-Phenotype
-	O
like	O
phenotypes	O
,	O
including	O
increased	B-Phenotype
systolic	I-Phenotype
blood	I-Phenotype
pressure	E-Phenotype
,	O
proteinuria	S-Phenotype
,	O
glomerular	B-Phenotype
endotheliosis	E-Phenotype
,	O
and	O
intrauterine	B-Phenotype
fetal	I-Phenotype
growth	I-Phenotype
restriction	E-Phenotype
.	O

The	O
correlation	O
of	O
the	O
tumor	S-Phenotype
-	O
suppressive	O
function	O
and	O
conformation	O
(	O
open	O
or	O
closed	O
)	O
of	O
neurofibromin	O
2	O
has	O
been	O
subject	O
to	O
much	O
speculation	O
,	O
often	O
based	O
on	O
extrapolation	O
from	O
other	O
ERM	O
proteins	O
,	O
and	O
controversy	O
.	O

Among	O
the	O
182	O
cases	O
of	O
low	O
-	O
grade	O
dysplasia	O
,	O
33	O
cases	O
(	O
18.1	O
%	O
)	O
were	O
diagnosed	O
as	O
HGD	O
and	O
nine	O
cases	O
(	O
5.0	O
%	O
)	O
were	O
diagnosed	O
as	O
cancer	S-Phenotype
after	O
resection	O
.	O

On	O
these	O
bases	O
,	O
we	O
investigated	O
whether	O
the	O
ligation	O
of	O
ERβ	O
by	O
a	O
selective	O
agonist	O
,	O
the	O
2,3	O
-	O
bis	O
(	O
4	O
-	O
hydroxyphenyl	O
)	O
-	O
propionitrile	O
(	O
DPN	O
)	O
,	O
could	O
impact	O
HL	O
tumor	S-Phenotype
growth	O
.	O

Although	O
some	O
recent	O
studies	O
suggest	O
that	O
the	O
obesity	S-Phenotype
-	O
related	O
SNPs	O
in	O
FTO	O
influence	O
obesity	S-Phenotype
susceptibility	O
likely	O
through	O
altering	O
the	O
expression	O
of	O
the	O
adjacent	O
genes	O
such	O
as	O
IRX3	O
and	O
RPGRIP1L	O
,	O
rather	O
than	O
FTO	O
itself	O
,	O
a	O
solid	O
link	O
between	O
the	O
SNP	O
risk	O
genotype	O
and	O
the	O
increased	O
FTO	O
expression	O
in	O
both	O
human	O
blood	O
cells	O
and	O
fibroblasts	O
has	O
been	O
reported	O
.	O

Collectively	O
,	O
these	O
findings	O
demonstrate	O
that	O
LTBP3	O
represents	O
a	O
novel	O
oncotarget	O
that	O
has	O
distinctive	O
functions	O
in	O
the	O
regulation	O
of	O
angiogenesis	O
-	O
dependent	O
tumor	S-Phenotype
cell	O
intravasation	O
,	O
a	O
critical	O
process	O
during	O
early	O
cancer	S-Phenotype
dissemination	O
.	O

The	O
mechanism	O
by	O
which	O
SAMHD1	O
protects	O
against	O
cancer	S-Phenotype
and	O
chronic	B-Phenotype
inflammation	E-Phenotype
is	O
unknown	O
.	O

Based	O
on	O
the	O
function	O
of	O
TBC1D20	O
as	O
a	O
RABGAP	O
and	O
the	O
bs	O
cataract	S-Phenotype
and	O
testicular	O
phenotypes	O
,	O
we	O
hypothesized	O
that	O
mutations	O
in	O
TBC1D20	O
may	O
contribute	O
to	O
Warburg	O
micro	O
syndrome	O
(	O
WARBM	O
)	O
;	O
WARBM	O
constitutes	O
a	O
spectrum	O
of	O
disorders	O
characterized	O
by	O
eye	O
,	O
brain	O
,	O
and	O
endocrine	O
abnormalities	O
caused	O
by	O
mutations	O
in	O
RAB3GAP1	O
,	O
RAB3GAP2	O
,	O
and	O
RAB18	O
.	O

Nephronophthisis	S-Phenotype
(	O
NPHP	S-Phenotype
)	O
,	O
Joubert	O
(	O
JBTS	O
)	O
,	O
and	O
Meckel	O
-	O
Gruber	O
(	O
MKS	O
)	O
syndromes	O
are	O
autosomal	O
-	O
recessive	O
ciliopathies	O
presenting	O
with	O
cystic	B-Phenotype
kidneys	E-Phenotype
,	O
retinal	B-Phenotype
degeneration	E-Phenotype
,	O
and	O
cerebellar	B-Phenotype
/	I-Phenotype
neural	I-Phenotype
tube	I-Phenotype
malformation	E-Phenotype
.	O

Mutations	O
in	O
CHCHD2	O
and	O
CHCHD10	O
were	O
recently	O
reported	O
in	O
a	O
broad	O
spectrum	O
of	O
neurodegenerative	B-Phenotype
diseases	E-Phenotype
,	O
for	O
example	O
,	O
Parkinson	O
's	O
disease	O
,	O
amyotrophic	B-Phenotype
lateral	I-Phenotype
sclerosis	E-Phenotype
,	O
frontotemporal	B-Phenotype
dementia	E-Phenotype
,	O
or	O
mitochondrial	B-Phenotype
myopathy	E-Phenotype
(	O
MM	S-Phenotype
)	O
.	O

PHF8	O
knockdown	O
inhibits	O
proliferation	O
and	O
promotes	O
the	O
apoptosis	O
of	O
ALL	O
cells	O
in	O
vitro	O
as	O
well	O
as	O
attenuates	O
tumor	S-Phenotype
growth	O
in	O
vivo	O
.	O

We	O
therefore	O
sought	O
to	O
understand	O
whether	O
CAF	O
-	O
derived	O
chemokines	O
impact	O
breast	B-Phenotype
tumor	E-Phenotype
cell	O
motility	O
through	O
modification	O
of	O
the	O
formin	O
-	O
assembled	O
F	O
-	O
actin	O
cytoskeleton	O
.	O

Non	B-Phenotype
-	I-Phenotype
small	I-Phenotype
cell	I-Phenotype
lung	I-Phenotype
cancer	E-Phenotype
(	O
NSCLC	S-Phenotype
)	O
is	O
the	O
most	O
common	O
type	O
of	O
lung	B-Phenotype
cancer	E-Phenotype
.	O

Interestingly	O
,	O
ChIP	O
-	O
PCR	O
and	O
bisulphite	O
pyrosequencing	O
showed	O
that	O
E2F6	O
also	O
epigenetically	O
suppresses	O
miR	O
-	O
193a	O
,	O
through	O
recruitment	O
of	O
EZH2	O
,	O
and	O
by	O
a	O
complex	O
ceRNA	O
mechanism	O
in	O
ovarian	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
.	O

These	O
results	O
suggest	O
(	O
i	O
)	O
apparent	O
allelic	O
heterogeneity	S-Phenotype
in	O
CFB	O
and	O
genetic	O
heterogeneity	O
in	O
SLC44A4	O
across	O
different	O
ethnic	O
groups	O
;	O
(	O
ii	O
)	O
shared	O
ulcerative	B-Phenotype
colitis	E-Phenotype
genetic	O
etiological	O
factors	O
among	O
Asians	O
;	O
and	O
finally	O
(	O
iii	O
)	O
re	O
-	O
exploration	O
of	O
GWAS	O
findings	O
together	O
with	O
high	O
-	O
density	O
genotyping	O
/	O
sequencing	O
and	O
trans	O
-	O
ethnic	O
fine	O
mapping	O
approaches	O
may	O
help	O
identify	O
shared	O
and	O
population	O
-	O
specific	O
risk	O
variants	O
and	O
enable	O
to	O
explain	O
missing	O
disease	O
heritability	O

In	O
addition	O
,	O
we	O
verified	O
the	O
co	O
-	O
expression	O
of	O
and	O
interplay	O
between	O
Rab3IP	O
and	O
SSX2	O
during	O
gastric	B-Phenotype
cancer	E-Phenotype
progression	O
.	O

These	O
data	O
do	O
not	O
support	O
a	O
causal	O
relationship	O
of	O
variants	O
in	O
MYO1A	O
to	O
sensorineural	B-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
.	O

Co	O
-	O
housing	O
with	O
wild	O
-	O
type	O
animals	O
,	O
antibiotic	O
treatment	O
,	O
or	O
germ	O
-	O
free	O
condition	O
was	O
sufficient	O
to	O
restrain	O
inflammation	S-Phenotype
,	O
obesity	S-Phenotype
,	O
and	O
insulin	O
tolerance	O
in	O
Nlrp12sup	O
-	O
/	O
-	O
/	O
sup	O
mice	O
,	O
implicating	O
the	O
microbiota	O
.	O

Suggestive	O
evidence	O
of	O
association	O
was	O
found	O
for	O
the	O
D	O
-	O
serine	O
plasma	O
-	O
CSF	O
ratio	O
at	O
the	O
D	O
-	O
amino	O
-	O
acid	O
oxidase	O
(	O
DAO	O
)	O
gene	O
(	O
b=	O
-	O
0.28	O
;	O
P=9.08	O
x	O
10	O
(	O
-	O
8	O
)	O
)	O
,	O
whereas	O
a	O
variant	O
in	O
SRR	O
(	O
that	O
encodes	O
serine	O
racemase	O
and	O
is	O
associated	O
with	O
schizophrenia	S-Phenotype
)	O
constituted	O
the	O
most	O
strongly	O
associated	O
locus	O
for	O
the	O
L	O
-	O
serine	O
to	O
D	O
-	O
serine	O
ratio	O
in	O
CSF	O
.	O

Although	O
no	O
overt	O
changes	O
in	O
corneal	B-Phenotype
opacity	E-Phenotype
were	O
detected	O
by	O
slit	O
-	O
lamp	O
examination	O
,	O
the	O
corneas	O
of	O
homozygous	O
mutant	O
mice	O
exhibited	O
histological	O
and	O
ultrastructural	O
epithelial	O
cell	O
fragility	O
phenotypes	O
.	O

Lentivirus	O
-	O
mediated	O
knockdown	O
of	O
STX3	O
represses	O
in	O
vitro	O
proliferation	O
and	O
colony	O
formation	O
and	O
in	O
vivo	O
growth	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
,	O
whereas	O
STX3	O
overexpression	O
promotes	O
the	O
growth	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

DTNBP1	O
encodes	O
dysbindin	O
protein	O
,	O
which	O
is	O
localized	O
to	O
synaptic	O
sites	O
and	O
is	O
reduced	O
in	O
the	O
prefrontal	O
cortex	O
and	O
hippocampus	O
of	O
patients	O
with	O
schizophrenia	S-Phenotype
,	O
indicating	O
a	O
potential	O
role	O
in	O
schizophrenia	S-Phenotype
etiology	O
.	O

Three	O
subtypes	O
,	O
liPTPN11	O
-	O
,	O
NRAS	O
-	O
/	O
i	O
,	O
and	O
liKRAS	O
/	O
i	O
-	O
mutated	O
JMML	O
,	O
are	O
characterized	O
by	O
heterozygous	O
somatic	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
in	O
non	O
syndromic	O
children	O
,	O
while	O
two	O
subtypes	O
,	O
JMML	O
in	O
neurofibromatosis	S-Phenotype
type	O
1	O
and	O
in	O
JMML	O
in	O
children	O
with	O
CBL	O
syndrome	O
,	O
are	O
characterized	O
by	O
germ	O
line	O
RAS	O
disease	O
and	O
acquired	O
biallelic	O
inactivation	O
of	O
the	O
respective	O
tumor	S-Phenotype
suppressor	O
genes	O
in	O
hematopoietic	O
cells	O
.	O

This	O
review	O
reflects	O
the	O
existing	O
Eph	O
/	O
ephrin	O
literature	O
while	O
focusing	O
on	O
breast	B-Phenotype
cancer	I-Phenotype
heterogeneity	E-Phenotype
.	O

Growth	B-Phenotype
abnormalities	E-Phenotype
,	O
motor	B-Phenotype
dysfunction	E-Phenotype
,	O
hindlimb	B-Phenotype
paralysis	E-Phenotype
,	O
muscle	B-Phenotype
wasting	E-Phenotype
,	O
neurogenic	B-Phenotype
atrophy	E-Phenotype
,	O
motor	B-Phenotype
neuron	I-Phenotype
degeneration	E-Phenotype
,	O
and	O
loss	O
of	O
large	O
-	O
caliber	O
axons	O
in	O
peripheral	O
nerves	O
occurred	O
at	O
an	O
earlier	O
age	O
in	O
Scyl1	O
/	O
Scyl3	O
double	O
-	O
deficient	O
mice	O
than	O
in	O
Scyl1	O
-	O
deficient	O
mice	O
.	O

The	O
role	O
of	O
c	O
-	O
Myc	O
(	O
a	O
target	O
gene	O
of	O
let	O
-	O
7	O
)	O
and	O
the	O
Lin28	O
-	O
let	O
-	O
7	O
-	O
c	O
-	O
Myc	O
pathway	O
in	O
the	O
growth	O
and	O
malignancy	O
of	O
thyroid	B-Phenotype
cancer	E-Phenotype
is	O
unclear	O
.	O

Our	O
findings	O
indicate	O
that	O
mutations	O
in	O
EBF3	O
cause	O
a	O
genetic	O
neurodevelopmental	O
syndrome	O
and	O
suggest	O
that	O
loss	O
of	O
EBF3	O
function	O
might	O
mediate	O
a	O
subset	O
of	O
neurologic	O
phenotypes	O
shared	O
by	O
ARX	O
-	O
related	O
disorders	O
,	O
including	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
abnormal	B-Phenotype
genitalia	E-Phenotype
,	O
and	O
structural	B-Phenotype
CNS	I-Phenotype
malformations	E-Phenotype

FECH	O
and	O
ABCG2	O
)	O
were	O
found	O
to	O
be	O
downregulated	O
in	O
smokers	O
as	O
well	O
as	O
in	O
cancer	S-Phenotype
groups	O
.	O

Importantly	O
,	O
bone	O
cell	O
activity	O
was	O
inversely	O
correlated	O
to	O
tumor	S-Phenotype
cell	O
AR	O
activity	O
(	O
measured	O
as	O
AR	O
,	O
FOXA1	O
,	O
HOXB13	O
,	O
KLK2	O
,	O
KLK3	O
,	O
NKX3	O
-	O
1	O
,	O
STEAP2	O
,	O
and	O
TMPRSS2	O
expression	O
)	O
and	O
to	O
patient	O
serum	O
prostate	O
-	O
specific	O
antigen	O
(	O
PSA	O
)	O
levels	O
.	O

Using	O
our	O
recently	O
developed	O
microtumor	O
model	O
,	O
we	O
confirmed	O
that	O
LTBP3	O
loss	O
resulted	O
in	O
the	O
development	O
of	O
intratumoral	O
vessels	O
with	O
an	O
abnormal	O
microarchitecture	O
incompatible	O
with	O
efficient	O
intravasation	O
of	O
HEp	O
-	O
3	O
carcinoma	S-Phenotype
cells	O
.	O

Hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
is	O
the	O
third	O
leading	O
cause	O
of	O
cancer	S-Phenotype
-	O
related	O
death	O
worldwide	O
;	O
however	O
,	O
the	O
mutational	O
properties	O
of	O
HCC	S-Phenotype
-	O
associated	O
carcinogens	O
remain	O
largely	O
uncharacterized	O
.	O

Furthermore	O
,	O
despite	O
the	O
otolith	O
*	O
s	O
developmental	B-Phenotype
delay	E-Phenotype
until	O
well	O
after	O
postural	O
behaviors	O
normally	O
appear	O
,	O
downstream	O
circuits	O
can	O
drive	O
righting	O
reflexes	O
within	O
a1	O
-	O
2	O
days	O
of	O
its	O
arrival	O
,	O
indicating	O
that	O
vestibular	O
circuit	O
wiring	O
is	O
not	O
impaired	O
by	O
a	O
delay	O
in	O
patterned	O
activity	O
.	O

The	O
musculo	O
-	O
aponeurotic	O
fibrosarcoma	S-Phenotype
oncogene	O
homolog	O
B	O
(	O
MAFB	O
)	O
significantly	O
enhanced	O
the	O
activation	O
of	O
the	O
TFPI2	O
promoter	O
via	O
RARAAAAAalpha	O
;	O
while	O
MAFF	O
inhibited	O
it	O
.	O

The	O
aims	O
of	O
the	O
present	O
study	O
were	O
to	O
evaluate	O
the	O
relation	O
of	O
dysregulated	O
MACC1	O
,	O
c	O
-	O
MET	O
,	O
and	O
NM23	O
-	O
H1	O
expression	O
with	O
the	O
histopathological	O
features	O
of	O
tumors	S-Phenotype
in	O
recurrence	O
formation	O
in	O
eCC	O
cases	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
expression	O
of	O
the	O
long	O
intergenic	O
non	O
-	O
protein	O
coding	O
RNA	O
665	O
(	O
LINC00665	O
)	O
gene	O
and	O
the	O
cell	O
cycle	O
in	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
using	O
database	O
analysis	O
including	O
The	O
Cancer	S-Phenotype
Genome	O
Atlas	O
(	O
TCGA	O
)	O
,	O
the	O
Gene	O
Expression	O
Omnibus	O
(	O
GEO	O
)	O
,	O
and	O
quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
qPCR	O
)	O
.	O

GRACILE	O
syndrome	O
is	O
a	O
rare	O
autosomal	B-Phenotype
recessive	E-Phenotype
disease	O
characterized	O
by	O
fetal	B-Phenotype
growth	I-Phenotype
retardation	E-Phenotype
,	O
Fanconi	B-Phenotype
type	I-Phenotype
aminoaciduria	E-Phenotype
,	O
cholestasis	S-Phenotype
,	O
iron	B-Phenotype
overload	E-Phenotype
,	O
profound	B-Phenotype
lactic	I-Phenotype
acidosis	E-Phenotype
,	O
and	O
early	B-Phenotype
death	E-Phenotype
.	O

We	O
identified	O
a	O
previously	O
unknown	O
missense	O
substitution	O
in	O
ADGRE2	O
(	O
also	O
known	O
as	O
EMR2	O
)	O
,	O
which	O
was	O
predicted	O
to	O
result	O
in	O
the	O
replacement	O
of	O
cysteine	O
with	O
tyrosine	O
at	O
amino	O
acid	O
position	O
492	O
(	O
p.C492Y	O
)	O
,	O
as	O
the	O
only	O
nonsynonymous	O
variant	O
cosegregating	O
with	O
vibratory	B-Phenotype
urticaria	E-Phenotype
in	O
two	O
large	O
kindreds	O
.	O

Moreover	O
,	O
microRNA	O
-	O
22	O
sensitized	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
to	O
paclitaxel	O
by	O
regulation	O
of	O
NRAS	O
.	O

Among	O
familial	O
pancreatic	B-Phenotype
cancer	E-Phenotype
cases	O
,	O
ER	O
stress	O
-	O
inducing	O
CPB1	O
variants	O
were	O
found	O
in	O
4	O
of	O
593	O
(	O
0.67	O
%	O
)	O
vs	O
.	O

Some	O
individuals	O
with	O
heterozygous	O
PRDM5	O
mutations	O
demonstrate	O
a	O
carrier	O
ocular	O
phenotype	O
,	O
which	O
includes	O
a	O
mildly	B-Phenotype
reduced	I-Phenotype
corneal	I-Phenotype
thickness	E-Phenotype
,	O
keratoconus	S-Phenotype
and	O
blue	B-Phenotype
sclera	E-Phenotype
.	O

Mutations	O
in	O
the	O
MID1	O
gene	O
have	O
been	O
associated	O
with	O
the	O
X	O
-	O
linked	O
form	O
of	O
Opitz	O
Syndrome	O
,	O
a	O
developmental	O
disorder	O
characterized	O
by	O
midline	O
defects	O
and	O
intellectual	B-Phenotype
disability	E-Phenotype
.	O

In	O
this	O
study	O
,	O
we	O
employed	O
a	O
siRNA	O
knockdown	O
approach	O
for	O
heparan	O
sulphate	O
(	O
EXT1	O
)	O
and	O
heparan	O
/	O
chondroitin	O
/	O
dermatan	O
sulphate	O
-	O
biosynthetic	O
enzymes	O
(	O
b4GalT7	O
)	O
in	O
the	O
aggressive	O
human	O
breast	B-Phenotype
cancer	E-Phenotype
cell	O
line	O
MDA	O
-	O
MB	O
-	O
231	O
to	O
study	O
the	O
impact	O
on	O
cell	O
behaviour	O
and	O
hyaluronan	O
biosynthesis	O
.	O

PurposeMonoallelic	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
BRCA1	O
/	O
FANCS	O
,	O
BRCA2	O
/	O
FANCD1	O
and	O
PALB2	O
/	O
FANCN	O
genes	O
confer	O
high	O
risk	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

Mutations	O
in	O
SCN8A	O
gene	O
have	O
been	O
described	O
in	O
relation	O
to	O
infantile	B-Phenotype
onset	I-Phenotype
epilepsy	E-Phenotype
with	O
movement	B-Phenotype
disorders	E-Phenotype
and	O
developmental	B-Phenotype
delay	E-Phenotype
.	O

Functionally	O
,	O
Transwell	O
assays	O
indicated	O
that	O
miR	O
-	O
135b	O
-	O
5p	O
was	O
a	O
promoter	O
for	O
migration	O
and	O
invasion	O
of	O
pancreatic	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Downregulation	O
of	O
a	O
-	O
actinin	O
-	O
1	O
in	O
E	O
-	O
cadherin	O
expressing	O
basal	O
-	O
like	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
demonstrate	O
that	O
a	O
-	O
actinin	O
-	O
1	O
-	O
assembled	O
actin	O
fibers	O
destabilize	O
E	O
-	O
cadherin	O
-	O
based	O
adhesions	O
.	O

Serendipitously	O
,	O
we	O
found	O
that	O
overexpression	O
of	O
Twist1	O
in	O
mouse	O
muscle	O
progenitor	O
cells	O
,	O
either	O
constitutively	O
during	O
development	O
or	O
inducibly	O
in	O
adult	O
animals	O
,	O
caused	O
severe	O
muscle	B-Phenotype
atrophy	E-Phenotype
with	O
features	O
reminiscent	O
of	O
cachexia	S-Phenotype
.	O

By	O
analyzing	O
public	O
data	O
sets	O
of	O
gene	O
expression	O
in	O
human	O
breast	B-Phenotype
cancers	E-Phenotype
we	O
observed	O
that	O
increased	O
levels	O
of	O
transcripts	O
encoding	O
the	O
planar	O
cell	O
polarity	O
(	O
PCP	O
)	O
proteins	O
SCRIB	O
and	O
VANGL1	O
correlate	O
with	O
increased	O
risk	O
of	O
patient	O
relapse	O
.	O

So	O
,	O
in	O
conclusion	O
,	O
melanoma	S-Phenotype
associated	O
POT1	O
germline	O
variants	O
seem	O
to	O
be	O
rare	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
role	O
and	O
mechanism	O
of	O
WTIP	O
in	O
cell	O
proliferation	O
and	O
tumorigenesis	S-Phenotype
of	O
non	B-Phenotype
-	I-Phenotype
small	I-Phenotype
-	I-Phenotype
cell	I-Phenotype
lung	I-Phenotype
cancer	E-Phenotype
(	O
NSCLC	S-Phenotype
)	O
.	O

Disruption	O
of	O
MED13L	O
,	O
encoding	O
a	O
component	O
of	O
the	O
Mediator	O
complex	O
,	O
is	O
increasingly	O
recognized	O
as	O
the	O
cause	O
of	O
an	O
intellectual	B-Phenotype
disability	E-Phenotype
syndrome	O
with	O
associated	O
facial	B-Phenotype
dysmorphism	E-Phenotype
.	O

Purpose	O
To	O
compare	O
digital	O
mammography	O
(	O
DM	O
)	O
plus	O
digital	O
breast	O
tomosynthesis	O
(	O
DBT	O
)	O
versus	O
DM	O
alone	O
for	O
breast	B-Phenotype
cancer	E-Phenotype
screening	O
in	O
the	O
Reggio	O
Emilia	O
Tomosynthesis	O
trial	O
,	O
a	O
two	O
-	O
arm	O
test	O
-	O
and	O
-	O
treat	O
randomized	O
controlled	O
trial	O
.	O

An	O
increasing	O
number	O
of	O
studies	O
suggest	O
that	O
long	O
-	O
noncoding	O
RNAs	O
(	O
lncRNAs	O
)	O
play	O
important	O
roles	O
in	O
various	O
biological	O
processes	O
and	O
disease	O
pathologies	O
,	O
including	O
cancer	S-Phenotype
.	O

We	O
analyzed	O
the	O
expression	O
profiles	O
of	O
lncRNA	O
,	O
miRNA	O
,	O
and	O
mRNA	O
,	O
along	O
with	O
the	O
clinical	O
information	O
of	O
BCa	O
patients	O
collected	O
from	O
the	O
Cancer	S-Phenotype
Genome	O
Atlas	O
database	O
to	O
identify	O
lncRNA	O
biomarkers	O
for	O
prognosis	O
.	O

Testing	O
for	O
high	O
-	O
risk	O
(	O
hr	O
)	O
types	O
of	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
is	O
highly	B-Phenotype
sensitive	E-Phenotype
as	O
a	O
screening	O
test	O
of	O
high	O
-	O
grade	O
cervical	O
intraepithelial	O
neoplastic	O
(	O
CIN2	O
/	O
3	O
)	O
disease	O
,	O
the	O
precursor	O
of	O
cervical	B-Phenotype
cancer	E-Phenotype
.	O

In	O
neuroimaging	O
experiments	O
,	O
our	O
analysis	O
involving	O
23	O
participants	O
showed	O
that	O
methylation	O
levels	O
for	O
the	O
cg07814318	O
site	O
,	O
which	O
lies	O
within	O
the	O
KLF13	O
gene	O
,	O
correlated	O
with	O
brain	O
activity	O
in	O
the	O
claustrum	O
,	O
putamen	O
,	O
cingulate	O
gyrus	O
and	O
frontal	O
gyri	O
,	O
some	O
of	O
which	O
have	O
been	O
previously	O
associated	O
to	O
food	O
signaling	O
,	O
obesity	S-Phenotype
or	O
reward	O
.	O

FHH2	O
is	O
characterized	O
by	O
hypercalcemia	S-Phenotype
,	O
inappropriately	B-Phenotype
normal	I-Phenotype
or	I-Phenotype
raised	I-Phenotype
parathyroid	I-Phenotype
hormone	I-Phenotype
(	I-Phenotype
PTH	I-Phenotype
)	I-Phenotype
concentrations	E-Phenotype
,	O
and	O
normal	B-Phenotype
or	I-Phenotype
low	I-Phenotype
urinary	I-Phenotype
calcium	I-Phenotype
excretion	E-Phenotype
.	O

Inhibition	O
of	O
ERα	O
by	O
its	O
siRNA	O
or	O
tamoxifen	O
reduces	O
cellular	O
levels	O
of	O
Brf1	O
and	O
Pol	O
III	O
gene	O
expression	O
and	O
decreases	O
the	O
rate	O
of	O
colony	O
formation	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Mechanistically	O
,	O
the	O
role	O
of	O
ALDOA	O
in	O
pancreatic	B-Phenotype
cancer	E-Phenotype
might	O
attribute	O
to	O
its	O
regulation	O
of	O
c	O
-	O
Myc	O
,	O
HIF1α	O
and	O
NRF2	O
(	O
Nuclear	O
Factor	O
,	O
Erythroid	O
2	O
-	O
Like	O
2	O
)	O
,	O
which	O
were	O
key	O
regulators	O
of	O
glycolysis	O
and	O
antioxidant	O
response	O
control	O
.	O

We	O
hypothesized	O
that	O
de	O
novo	O
mutations	O
(	O
DNMs	O
)	O
in	O
synaptic	O
genes	O
explain	O
an	O
important	O
fraction	O
of	O
sporadic	S-Phenotype
NSID	O
cases	O
.	O

The	O
positive	O
rate	O
of	O
mSEPT9	O
in	O
CRC	O
was	O
correlated	O
with	O
tumor	S-Phenotype
size	O
,	O
histological	O
grade	O
,	O
and	O
general	O
histological	O
type	O
(	O
P	O
AAAA	O
0.05	O
)	O
.	O

Primary	B-Phenotype
ciliary	I-Phenotype
dyskinesia	E-Phenotype
(	O
PCD	S-Phenotype
)	O
is	O
clinically	O
characterized	O
by	O
neonatal	B-Phenotype
respiratory	I-Phenotype
distress	E-Phenotype
,	O
chronic	B-Phenotype
sinusitis	E-Phenotype
,	O
bronchiectasis	S-Phenotype
and	O
infertility	S-Phenotype
,	O
and	O
situs	B-Phenotype
inversus	E-Phenotype
in	O
50	O
%	O
of	O
the	O
patients	O
.	O

De	O
novo	O
variants	O
of	O
ASH1L	O
,	O
which	O
encodes	O
a	O
histone	O
methyltransferase	O
,	O
have	O
been	O
reported	O
in	O
a	O
few	O
patients	O
with	O
intellectual	B-Phenotype
disability	E-Phenotype
and	O
autistic	O
features	O
.	O

UBE2T	O
was	O
highly	O
expressed	O
in	O
gastric	O
tumors	S-Phenotype
and	O
gastric	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Fragile	O
X	O
syndrome	O
(	O
FXS	O
)	O
,	O
caused	O
by	O
the	O
loss	O
of	O
functional	O
FMRP	O
,	O
is	O
a	O
leading	O
cause	O
of	O
autism	S-Phenotype
.	O

In	O
sum	O
,	O
the	O
SPINT2	O
gene	O
is	O
epigenetically	O
silenced	O
or	O
downregulated	O
in	O
human	O
cancers	S-Phenotype
,	O
altering	O
the	O
balance	O
of	O
HGF	O
activation	O
/	O
inhibition	O
ratio	O
,	O
which	O
contributes	O
to	O
cancer	S-Phenotype
development	O
and	O
progression	O

Here	O
,	O
we	O
showed	O
lower	O
expression	O
of	O
ARHGAP17	O
in	O
cell	O
lines	O
and	O
human	O
cervical	B-Phenotype
cancer	E-Phenotype
samples	O
.	O

Deregulated	O
monoubiquitination	O
of	O
histone	O
H2B	O
(	O
H2Bub1	O
)	O
,	O
mainly	O
catalyzed	O
by	O
E3	O
ubiquitin	O
-	O
protein	O
ligase	O
RNF20	O
/	O
RNF40	O
complex	O
,	O
may	O
play	O
an	O
important	O
role	O
in	O
cancer	S-Phenotype
.	O

mGluR5	O
protein	O
was	O
significantly	O
associated	O
with	O
mGluR5	O
mRNA	O
and	O
mGluR5	O
endogenous	O
regulators	O
in	O
control	O
subjects	O
,	O
but	O
these	O
associations	O
were	O
lost	O
in	O
schizophrenia	S-Phenotype
subjects	O
.	O

A	O
recent	O
genome	O
-	O
wide	O
association	O
study	O
(	O
GWAS	O
)	O
linked	O
hypercalciuria	S-Phenotype
and	O
kidney	B-Phenotype
stones	E-Phenotype
to	O
a	O
claudin	O
-	O
14	O
(	O
CLDN14	O
)	O
risk	O
haplotype	O
.	O

Collectively	O
,	O
our	O
findings	O
indicate	O
that	O
up	O
-	O
regulated	O
mRNA	O
expression	O
of	O
RNF31	O
,	O
RBCK1	O
and	O
SHARPIN	O
could	O
potentially	O
be	O
diagnostic	O
biomarkers	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
and	O
RNF31	O
might	O
be	O
a	O
drug	O
target	O
for	O
ERalpha	B-Phenotype
-	I-Phenotype
negative	I-Phenotype
breast	I-Phenotype
cancers	E-Phenotype

Intravascular	O
lithotripsy	O
(	O
IVL	O
)	O
with	O
the	O
Shockwave™	O
system	O
has	O
recently	O
been	O
evaluated	O
as	O
a	O
familiar	O
angioplasty	O
-	O
balloon	O
-	O
based	O
but	O
effective	O
technique	O
for	O
the	O
management	O
of	O
arterial	B-Phenotype
calcification	E-Phenotype
.	O

A	O
large	O
proportion	O
of	O
cases	O
(	O
approximately	O
44	O
%	O
)	O
remain	O
unexplained	O
,	O
indicating	O
that	O
PRA	O
in	O
this	O
breed	O
is	O
genetically	O
heterogeneous	S-Phenotype
and	O
caused	O
by	O
at	O
least	O
three	O
mutations	O
.	O

Here	O
the	O
authors	O
show	O
that	O
human	O
microcephaly	S-Phenotype
protein	O
RTTN	O
directly	O
interacts	O
with	O
STIL	O
and	O
acts	O
downstream	O
of	O
STIL	O
-	O
mediated	O
centriole	O
assembly	O
,	O
contributing	O
to	O
building	O
full	O
-	O
length	O
centrioles	O

Previous	O
studies	O
have	O
implicated	O
coiled	O
-	O
coil	O
domain	O
-	O
containing	O
protein	O
8	O
(	O
CCDC8	O
)	O
as	O
a	O
tumor	S-Phenotype
suppressor	O
in	O
several	O
types	O
of	O
cancer	S-Phenotype
,	O
such	O
as	O
breast	B-Phenotype
and	I-Phenotype
prostate	I-Phenotype
cancers	E-Phenotype
.	O

miR	O
-	O
25	O
-	O
3p	O
,	O
miR	O
-	O
30a	O
-	O
5p	O
,	O
miR	O
-	O
328	O
and	O
miR	O
-	O
363	O
-	O
3p	O
directly	O
targeted	O
adhesion	O
-	O
related	O
genes	O
,	O
including	O
COL5A1	O
,	O
COL11A1	O
,	O
ITGA5	O
,	O
MMP16	O
and	O
THBS2	O
.	O

This	O
novel	O
model	O
provides	O
valuable	O
insights	O
into	O
PDE	O
pathophysiology	O
;	O
further	O
research	O
may	O
offer	O
new	O
opportunities	O
for	O
drug	O
discovery	O
to	O
control	O
seizure	S-Phenotype
activity	O
and	O
improve	O
neurodevelopmental	O
outcomes	O
for	O
PDE	O

In	O
this	O
first	O
whole	O
-	O
exome	O
sequencing	O
study	O
of	O
prostate	B-Phenotype
cancer	E-Phenotype
,	O
our	O
findings	O
do	O
not	O
provide	O
strong	O
support	O
for	O
the	O
hypothesis	O
that	O
NS	O
coding	O
variants	O
down	O
to	O
0.5	O
-	O
1.0	O
%	O
frequency	O
have	O
large	O
effects	O
on	O
prostate	B-Phenotype
cancer	E-Phenotype
risk	O
in	O
men	O
of	O
African	O
ancestry	O
.	O

Mutations	O
in	O
the	O
KIF5A	O
showed	O
a	O
wide	O
phenotypic	O
spectrum	O
from	O
hereditary	B-Phenotype
spastic	I-Phenotype
paraplegia	E-Phenotype
(	O
HSP	S-Phenotype
)	O
to	O
axonal	B-Phenotype
Charcot	I-Phenotype
-	I-Phenotype
Marie	I-Phenotype
-	I-Phenotype
Tooth	I-Phenotype
peripheral	I-Phenotype
neuropathy	I-Phenotype
type	I-Phenotype
2	E-Phenotype
(	O
CMT2	S-Phenotype
)	O
.	O

Notably	O
,	O
in	O
two	O
lung	B-Phenotype
cancer	E-Phenotype
models	O
with	O
FGFR1	O
amplification	O
,	O
the	O
antitumor	O
efficacy	S-Phenotype
was	O
higher	O
,	O
suggesting	O
that	O
the	O
simultaneous	O
inhibition	O
of	O
VEGF	O
and	O
FGF	O
receptors	O
in	O
FGFR1	O
dependent	O
tumors	S-Phenotype
can	O
be	O
therapeutically	O
advantageous	O
.	O

Inhibition	O
of	O
p53	O
-	O
MDM2	O
complex	O
has	O
been	O
emerging	O
as	O
a	O
strategy	O
for	O
antitumoral	O
drug	O
development	O
considering	O
the	O
pro	O
-	O
apoptotic	O
role	O
of	O
functional	O
p53	O
in	O
tumor	S-Phenotype
cells	O
.	O

Glycine	O
cleavage	O
system	O
(	O
GCS	O
)	O
catalyzes	O
the	O
degradation	O
of	O
glycine	O
and	O
disruption	O
of	O
its	O
components	O
encoded	O
by	O
GLDC	O
,	O
AMT	O
and	O
GCSH	O
are	O
the	O
only	O
known	O
causes	O
of	O
glycine	B-Phenotype
encephalopathy	E-Phenotype
,	O
also	O
known	O
as	O
non	B-Phenotype
-	I-Phenotype
ketotic	I-Phenotype
hyperglycinemia	E-Phenotype
(	O
NKH	S-Phenotype
)	O
.	O

We	O
describe	O
a	O
multigenerational	O
Saudi	O
family	O
with	O
an	O
autosomal	O
dominant	O
form	O
of	O
hypohidrotic	B-Phenotype
ectodermal	I-Phenotype
dysplasia	E-Phenotype
in	O
which	O
positional	O
mapping	O
and	O
exome	O
sequencing	O
identified	O
a	O
novel	O
variant	O
in	O
KDF1	O
that	O
fully	O
segregates	O
with	O
the	O
phenotype	O
.	O

Myo3a	O
is	O
expressed	O
in	O
cochlear	O
hair	O
cells	O
and	O
retinal	O
cells	O
and	O
is	O
responsible	O
for	O
human	O
recessive	O
hereditary	O
nonsyndromic	O
deafness	S-Phenotype
(	O
DFNB30	O
)	O
.	O

The	O
hallmarks	O
of	O
this	O
disease	O
are	O
macular	B-Phenotype
drusen	E-Phenotype
,	O
RPE	O
alterations	O
,	O
and	O
geographic	B-Phenotype
atrophy	E-Phenotype
(	O
GA	S-Phenotype
)	O
.	O

Importantly	O
,	O
IL	O
-	O
1β	O
-	O
mediated	O
NF	O
-	O
κB	O
induction	O
in	O
KRAS	O
-	O
mutant	O
tumor	S-Phenotype
cells	O
,	O
as	O
well	O
as	O
their	O
resulting	O
MPE	O
-	O
competence	O
,	O
can	O
only	O
be	O
blocked	O
by	O
co	O
-	O
inhibition	O
of	O
both	O
KRAS	O
and	O
IKKα	O
,	O
a	O
strategy	O
that	O
overcomes	O
drug	B-Phenotype
resistance	E-Phenotype
to	O
individual	O
treatments	O
.	O

Collectively	O
,	O
our	O
study	O
uncovers	O
a	O
protein	O
complex	O
,	O
which	O
consists	O
of	O
FIGNL1	O
and	O
KIAA0146	O
/	O
SPIDR	O
,	O
in	O
DNA	O
repair	O
and	O
provides	O
potential	O
directions	O
for	O
cancer	S-Phenotype
diagnosis	O
and	O
therapy	O
.	O

The	O
SNP	O
rs11102001	O
,	O
which	O
encodes	O
a	O
nonsynonymous	O
amino	O
acid	O
change	O
P356S	O
in	O
EPS8L3	O
,	O
is	O
a	O
potential	O
candidate	O
modifier	O
of	O
the	O
effect	O
of	O
HCAs	O
on	O
prostate	B-Phenotype
cancer	E-Phenotype
risk	O
.	O

Complex	O
recessive	O
spastic	B-Phenotype
paraplegias	E-Phenotype
have	O
in	O
the	O
past	O
been	O
frequently	O
associated	O
with	O
mutations	O
in	O
SPG11	O
(	O
spatacsin	O
)	O
,	O
ZFYVE26	O
/	O
SPG15	O
,	O
SPG7	O
(	O
paraplegin	O
)	O
and	O
a	O
handful	O
of	O
other	O
rare	O
genes	O
,	O
but	O
many	O
cases	O
remain	O
genetically	O
undefined	O
.	O

Hepatocyte	O
growth	O
factor	O
(	O
HGF	O
)	O
/	O
c	O
-	O
MET	O
signaling	O
plays	O
an	O
important	O
role	O
in	O
cell	O
proliferation	O
,	O
survival	O
,	O
migration	O
and	O
motility	O
of	O
cancer	S-Phenotype
cells	O
.	O

RT	O
-	O
PCR	O
analysis	O
showed	O
that	O
the	O
overall	O
transcriptional	O
activity	O
of	O
the	O
main	O
HS	O
biosynthesis	O
-	O
involved	O
genes	O
(	O
liEXT1	O
/	O
i	O
,	O
liEXT2	O
/	O
i	O
,	O
liNDST1	O
/	O
i	O
,	O
liNDST2	O
/	O
i	O
,	O
liGLCE	O
/	O
i	O
,	O
liHS2ST1	O
/	O
i	O
,	O
liHS3ST1	O
/	O
i	O
,	O
liHS3ST2	O
/	O
i	O
,	O
liHS6ST1	O
/	O
i	O
,	O
liHS6ST2	O
/	O
i	O
,	O
liSULF1	O
/	O
i	O
,	O
liSULF2	O
/	O
i	O
,	O
liHPSE	O
/	O
i	O
)	O
was	O
decreased	O
by	O
1.5	O
-	O
2	O
-	O
fold	O
in	O
Grade	O
II	O
-	O
III	O
glioma	S-Phenotype
(	O
lip	O
/	O
i	O
AAAA	O
0.01	O
)	O
and	O
by	O
3	O
-	O
fold	O
in	O
Grade	O
IV	O
glioma	S-Phenotype
(	O
glioblastoma	S-Phenotype
multiforme	O
,	O
GBM	O
)	O
(	O
lip	O
/	O
i	O
AAAA	O
0.05	O
)	O
,	O
as	O
compared	O
with	O
the	O
para	O
-	O
tumourous	S-Phenotype
tissue	O
.	O

TNF	O
-	O
related	O
apoptosis	O
-	O
inducing	O
ligand	O
(	O
TRAIL	O
)	O
was	O
initially	O
described	O
to	O
induce	O
apoptosis	O
of	O
tumor	S-Phenotype
cells	O
and	O
/	O
or	O
virally	O
infected	O
cells	O
,	O
although	O
sparing	O
normal	O
cells	O
,	O
and	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
HIV	O
disease	O
.	O

Excess	O
accumulation	O
of	O
endogenous	O
all	O
-	O
trans	O
-	O
retinal	O
(	O
atRAL	O
)	O
contributes	O
to	O
degeneration	O
of	O
the	O
retinal	O
pigment	O
epithelium	O
(	O
RPE	O
)	O
and	O
photoreceptor	O
cells	O
,	O
and	O
plays	O
a	O
role	O
in	O
the	O
etiologies	O
of	O
age	B-Phenotype
-	I-Phenotype
related	I-Phenotype
macular	I-Phenotype
degeneration	E-Phenotype
(	O
AMD	S-Phenotype
)	O
and	O
Stargardt	O
's	O
disease	O
.	O

Here	O
we	O
found	O
that	O
perilipin	O
-	O
1	O
(	O
PLIN1	O
)	O
mRNA	O
expression	O
is	O
significantly	O
downregulated	O
in	O
human	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

We	O
found	O
that	O
hypermethylation	O
of	O
TRIM36	O
and	O
reduced	O
gene	O
expression	O
was	O
prevalent	O
in	O
several	O
types	O
of	O
human	O
cancers	S-Phenotype
.	O

Today	O
,	O
more	O
than	O
a	O
dozen	O
human	O
CaM	O
missense	O
mutations	O
have	O
been	O
described	O
,	O
all	O
found	O
in	O
patients	O
with	O
severe	O
cardiac	B-Phenotype
arrhythmias	E-Phenotype
.	O

Metastatic	O
bone	O
disease	O
has	O
a	O
major	O
impact	O
on	O
morbidity	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
(	O
BC	S-Phenotype
)	O
patients	O
.	O

BBN	O
tumors	S-Phenotype
showed	O
overexpression	O
of	O
markers	O
of	O
basal	O
cancer	S-Phenotype
subtype	O
,	O
and	O
had	O
a	O
high	O
mutation	O
burden	O
with	O
frequent	O
Trp53	O
(	O
80	O
%	O
)	O
,	O
Kmt2d	O
(	O
70	O
%	O
)	O
,	O
and	O
Kmt2c	O
(	O
90	O
%	O
)	O
mutations	O
by	O
exome	O
sequencing	O
,	O
similar	O
to	O
human	O
MIBC	O
.	O

Transcriptomics	O
revealed	O
that	O
102	O
genes	O
were	O
upregulated	O
and	O
85	O
genes	O
were	O
downregulated	O
in	O
CD44+Lin	O
-	O
compared	O
to	O
CD44	O
-	O
Lin	O
-	O
cells	O
in	O
at	O
least	O
3	O
of	O
the	O
5	O
tumours	S-Phenotype
sequenced	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
heightened	O
levels	O
of	O
COMT	O
on	O
dopamine	O
-	O
regulated	O
motor	O
behaviors	O
and	O
molecular	O
alterations	O
in	O
a	O
mouse	O
model	O
of	O
dyskinesia	S-Phenotype
.	O

These	O
findings	O
provide	O
evidence	O
that	O
15	O
-	O
PGDH	O
inhibition	O
enhances	O
KRAS	O
-	O
driven	O
tumor	S-Phenotype
progression	O
via	O
ATRA	O
depletion	O
in	O
the	O
pancreas	O
.	O

Thus	O
,	O
our	O
data	O
indicate	O
that	O
in	O
pancreatic	B-Phenotype
cancer	E-Phenotype
cells	O
,	O
the	O
expression	O
of	O
ENG	O
may	O
be	O
controlled	O
by	O
a	O
pathway	O
mediated	O
by	O
SMAD4	O
.	O

This	O
was	O
confirmed	O
by	O
BMP4	O
immunoreactivity	O
in	O
tumor	S-Phenotype
cells	O
of	O
metastases	O
with	O
ongoing	O
bone	O
formation	O
,	O
as	O
determined	O
by	O
histological	O
evaluation	O
of	O
van	O
Gieson	O
-	O
stained	O
sections	O
.	O

Amyotrophic	B-Phenotype
lateral	I-Phenotype
sclerosis	E-Phenotype
(	O
ALS	S-Phenotype
)	O
is	O
a	O
fatal	O
neurodegenerative	B-Phenotype
disease	E-Phenotype
.	O

A	O
combined	O
analysis	O
of	O
all	O
subjects	O
showed	O
that	O
levels	O
of	O
anti	O
-	O
GARP	O
antibodies	O
were	O
significantly	O
higher	O
in	O
patients	O
with	O
breast	B-Phenotype
cancer	E-Phenotype
than	O
in	O
healthy	O
controls	O
(	O
mean	O
+	O
SD	O
:	O
7.4	O
+	O
3.5	O
vs.	O
6.9	O
+	O
3.5	O
absorbance	O
units	O
per	O
mL	O
(	O
AU	O
/	O
uL	O
)	O
,	O
p	O
AAAA	O
0.0001	O
)	O
.	O

Constitutive	O
activation	O
of	O
interferon	O
signaling	O
pathways	O
has	O
been	O
reported	O
in	O
colorectal	B-Phenotype
cancer	E-Phenotype
(	O
CRC	S-Phenotype
)	O
,	O
leading	O
to	O
a	O
strong	O
CD8+	O
T	O
cell	O
response	O
through	O
stimulation	O
of	O
NLRC5	O
expression	O
.	O

This	O
result	O
suggests	O
that	O
COL4A3	O
and	O
COL4A4	O
digenic	O
mutations	O
in	O
cis	O
mimicking	O
an	O
autosomal	O
dominant	O
inheritance	S-Phenotype
should	O
be	O
considered	O
as	O
a	O
novel	O
inheritance	O
pattern	O
of	O
benign	O
familial	O
hematuria	S-Phenotype
,	O
although	O
the	O
disease	O
-	O
causing	O
mechanism	O
remains	O
unknown	O

We	O
conducted	O
the	O
largest	O
association	O
study	O
of	O
mitochondrial	O
DNA	O
variants	O
and	O
schizophrenia	S-Phenotype
but	O
did	O
not	O
find	O
an	O
association	O
that	O
survived	O
multiple	O
testing	O
correction	O
.	O

We	O
used	O
Cytoscape	O
network	O
analysis	O
and	O
Search	O
tool	O
for	O
retrieval	O
of	O
interacting	O
genes	O
/	O
proteins	O
(	O
STRING	O
)	O
to	O
study	O
the	O
possible	O
interactions	O
to	O
show	O
the	O
links	O
between	O
the	O
antioxidants	O
,	O
antibiotics	O
,	O
anti	O
-	O
inflammatory	O
and	O
antimitotic	O
agents	O
and	O
their	O
targets	O
for	O
their	O
possible	O
use	O
in	O
cancer	S-Phenotype
.	O

BRAF	O
mutations	O
occur	O
in	O
about	O
40	O
-	O
45	O
%	O
of	O
all	O
papillary	B-Phenotype
thyroid	I-Phenotype
carcinomas	E-Phenotype
(	O
PTCs	S-Phenotype
)	O
and	O
of	O
which	O
99.7	O
%	O
is	O
the	O
BRAFV600E	O
mutation	O
.	O

The	O
APOL1	O
G1	O
polymorphism	O
,	O
an	O
identified	O
risk	O
factor	O
for	O
non	O
-	O
diabetic	O
renal	O
disease	O
,	O
was	O
associated	O
with	O
albuminuria	S-Phenotype
.	O

MATERIAL	O
AND	O
METHODS	O
We	O
analyzed	O
BC	O
microarray	O
studies	O
GSE37751	O
,	O
GSE7390	O
,	O
and	O
GSE21653	O
to	O
investigate	O
the	O
expression	O
of	O
FGF5	O
gene	O
between	O
BC	O
patients	O
and	O
their	O
normal	O
counterparts	O
and	O
the	O
relationship	O
between	O
FGF5	O
expression	O
and	O
age	O
,	O
tumor	S-Phenotype
size	O
,	O
histopathological	O
grading	O
,	O
estrogen	O
receptors	O
,	O
clinical	O
risk	O
group	O
according	O
to	O
St	O
Gallen	O
criteria	O
,	O
clinical	O
risk	O
group	O
according	O
to	O
NPI	O
criteria	O
,	O
clinical	O
risk	O
group	O
according	O
to	O
Veridex	O
signature	O
,	O
distant	O
metastasis	O
-	O
free	O
survival	O
(	O
DMFS	O
)	O
,	O
time	O
to	O
distant	O
metastasis	O
(	O
TDM	O
)	O
,	O
disease	O
-	O
free	O
survival	O
(	O
DFS	O
)	O
,	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
of	O
BC	O
patients	O
.	O

Zic2	O
overexpression	O
promoted	O
,	O
whereas	O
Zic2	O
knockdown	O
inhibited	O
,	O
cell	O
proliferation	O
and	O
migration	O
in	O
vitro	O
as	O
well	O
as	O
tumor	S-Phenotype
growth	O
and	O
metastasis	O
in	O
vivo	O
.	O

Carney	O
triad	O
(	O
CT	O
)	O
is	O
a	O
very	O
rare	O
disease	O
with	O
synchronous	O
or	O
metachronous	O
occurrence	O
of	O
at	O
least	O
three	O
different	O
tumor	S-Phenotype
entities	O
;	O
gastric	B-Phenotype
gastrointestinal	I-Phenotype
stromal	I-Phenotype
tumor	E-Phenotype
(	O
GIST	S-Phenotype
)	O
,	O
paraganglioma	S-Phenotype
(	O
PGL	S-Phenotype
)	O
,	O
and	O
pulmonary	B-Phenotype
chondroma	E-Phenotype
.	O

Complete	O
identification	O
of	O
genes	O
related	O
to	O
one	O
type	O
of	O
cancer	S-Phenotype
facilitates	O
earlier	O
diagnosis	O
and	O
effective	O
treatments	O
.	O

A	O
high	O
proportion	O
of	O
tumors	S-Phenotype
harbors	O
multiple	O
mutations	O
,	O
especially	O
PIK3CA	O
plus	O
PIK3R1	O
mutations	O
(	O
9.0	O
%	O
)	O
.	O

Almost	O
all	O
are	O
inherited	O
in	O
autosomal	B-Phenotype
recessive	E-Phenotype
patterns	O
with	O
a	O
few	O
exceptions	O
such	O
as	O
the	O
X	O
-	O
linked	O
ALG13	O
.	O

Pyridoxine	B-Phenotype
-	I-Phenotype
dependent	I-Phenotype
epilepsy	E-Phenotype
(	O
PDE	S-Phenotype
)	O
is	O
a	O
rare	O
disease	O
characterized	O
by	O
mutations	O
in	O
the	O
lysine	O
degradation	O
gene	O
liALDH7A1	O
/	O
i	O
leading	O
to	O
recurrent	O
neonatal	B-Phenotype
seizures	E-Phenotype
,	O
which	O
are	O
uniquely	O
alleviated	O
by	O
high	O
doses	O
of	O
pyridoxine	O
or	O
pyridoxal	O
5	O
'	O
-	O
phosphate	O
(	O
vitamin	O
B6	O
vitamers	O
)	O
.	O

2014	O
;	O
Yamamoto	O
et	O
al	O
.	O

Higher	O
pre	O
-	O
NACT	O
nuclear	O
Prx	O
I	O
expression	O
predicted	O
smaller	O
size	O
of	O
a	O
resected	O
tumor	S-Phenotype
(	O
p	O
=	O
0.00052	O
;	O
r	O
=	O
-	O
0.550	O
)	O
,	O
and	O
higher	O
pre	O
-	O
NACT	O
cytoplasmic	O
Prx	O
I	O
expression	O
predicted	O
a	O
lower	O
amount	O
of	O
evacuated	O
nodal	O
metastasis	O
(	O
p	O
=	O
0.0024	O
;	O
r	O
=	O
-	O
0.472	O
)	O
.	O

Mutations	O
in	O
the	O
ATP1A3	O
gene	O
,	O
which	O
encodes	O
the	O
alpha3	O
-	O
subunit	O
of	O
sodium	O
-	O
potassium	O
ATPase	O
,	O
are	O
related	O
to	O
a	O
spectrum	O
of	O
neurological	O
diseases	O
including	O
Rapid	B-Phenotype
onset	I-Phenotype
Dystonia	I-Phenotype
-	I-Phenotype
Parkinsonism	E-Phenotype
(	O
RDP	S-Phenotype
)	O
,	O
Alternating	B-Phenotype
Hemiplegia	I-Phenotype
of	I-Phenotype
Childhood	E-Phenotype
(	O
AHC	S-Phenotype
)	O
and	O
Cerebellar	B-Phenotype
ataxia	E-Phenotype
,	O
Areflexia	S-Phenotype
,	O
Pes	B-Phenotype
cavus	E-Phenotype
,	O
Optic	B-Phenotype
atrophy	E-Phenotype
and	O
Sensorineural	B-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
(	O
CAPOS	S-Phenotype
)	O
syndrome	O
.	O

Our	O
study	O
demonstrated	O
that	O
AURKA	O
rs1047972	O
TT	O
and	O
(	O
CC	O
+	O
CT	O
)	O
genotypes	O
were	O
significantly	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
gastric	B-Phenotype
cancer	E-Phenotype
.	O

This	O
report	O
confirmed	O
that	O
haploinsufficiency	O
of	O
the	O
2	O
long	O
forms	O
of	O
SOX5	O
presents	O
common	O
clinical	O
features	O
,	O
including	O
mild	O
intellectual	B-Phenotype
disability	E-Phenotype
and	O
autistic	O
features	O
,	O
which	O
could	O
be	O
useful	O
for	O
the	O
clinical	O
diagnosis	O
of	O
Lamb	O
-	O
Shaffer	O
syndrome	O

Overexpression	O
of	O
EMX2	O
significantly	O
inhibited	O
the	O
proliferation	O
in	O
vitro	O
and	O
CRC	O
tumor	S-Phenotype
growth	O
in	O
nude	O
mice	O
.	O

Identifying	O
the	O
central	O
and	O
peripheral	S-Phenotype
vestibular	O
mechanisms	O
responsible	O
for	O
pathology	O
can	O
aid	O
in	O
management	O
of	O
SRC	O
.	O

A	O
large	O
tissue	O
microarray	O
of	O
lower	O
grade	O
glioma	S-Phenotype
(	O
WHO	O
grades	O
II	O
-	O
III	O
,	O
n	O
=	O
19	O
patients	O
)	O
and	O
glioblastoma	S-Phenotype
(	O
GBM	S-Phenotype
)	O
(	O
WHO	O
grade	O
IV	O
,	O
n	O
=	O
50	O
patients	O
)	O
was	O
stained	O
for	O
EMP2	O
.	O

Primary	B-Phenotype
ciliary	I-Phenotype
dyskinesia	E-Phenotype
(	O
PCD	S-Phenotype
)	O
is	O
an	O
inherited	O
chronic	O
respiratory	O
obstructive	O
disease	O
with	O
randomized	O
body	O
laterality	O
and	O
infertility	S-Phenotype
,	O
resulting	O
from	O
cilia	O
and	O
sperm	O
dysmotility	O
.	O

Angiosarcomas	S-Phenotype
in	O
liaP2	O
-	O
Cre	O
;	O
Dicer1supFlox	O
/	O
-	O
/	O
sup	O
/	O
i	O
mice	O
histologically	O
and	O
genetically	O
resemble	O
human	O
angiosarcoma	S-Phenotype
.	O

The	O
FoxP2	O
transcription	O
factor	O
and	O
its	O
target	O
genes	O
have	O
been	O
implicated	O
in	O
developmental	O
brain	O
diseases	O
with	O
a	O
prominent	O
language	O
component	O
,	O
such	O
as	O
developmental	O
verbal	B-Phenotype
dyspraxia	E-Phenotype
and	O
specific	O
language	B-Phenotype
impairment	E-Phenotype
.	O

Therefore	O
,	O
our	O
findings	O
firstly	O
suggested	O
that	O
miR	O
-	O
34a	O
could	O
modulate	O
the	O
susceptibility	O
of	O
gastric	B-Phenotype
cancer	E-Phenotype
cell	O
to	O
luteolin	O
via	O
targeting	O
HK1	O
,	O
potentially	O
benefiting	O
GC	O
patients	O
'	O
treatment	O
in	O
the	O
future	O

Previously	O
there	O
have	O
been	O
no	O
reports	O
of	O
SCA31	O
associated	O
with	O
dystonia	S-Phenotype
.	O

BACKGROUND	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
expression	O
and	O
silencing	O
of	O
the	O
S100A8	O
gene	O
,	O
which	O
encodes	O
the	O
S100	O
calcium	O
-	O
binding	O
protein	O
A8	O
(	O
S100A8	O
)	O
,	O
and	O
apoptosis	O
and	O
phosphorylation	O
of	O
protein	O
kinase	O
B	O
(	O
Akt	O
)	O
in	O
tissue	O
samples	O
of	O
endometrial	B-Phenotype
carcinoma	E-Phenotype
and	O
HEC	O
-	O
1A	O
endometrial	O
adenocarcinoma	O
cells	O
in	O
vitro	O
.	O

Further	O
supporting	O
a	O
mechanism	O
of	O
haploinsufficiency	O
,	O
individuals	O
with	O
copy	O
-	O
number	O
variant	O
(	O
CNV	O
)	O
deletions	O
involving	O
NAA15	O
and	O
surrounding	O
genes	O
can	O
present	O
with	O
mild	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
mild	O
dysmorphic	O
features	O
,	O
motor	B-Phenotype
delays	E-Phenotype
,	O
and	O
decreased	B-Phenotype
growth	E-Phenotype
.	O

IDS	O
/	O
IDSP1	O
gene	O
inversions	O
,	O
partial	O
to	O
extensive	O
IDS	O
deletions	O
,	O
and	O
one	O
chimeric	O
IDS	O
-	O
IDSP1	O
allele	O
)	O
that	O
occurred	O
at	O
higher	O
frequencies	O
than	O
previously	O
reported	O
(	O
36	O
%	O
vs	O
18.9	O
-	O
29	O
%	O
)	O
.	O

Indeed	O
,	O
patients	O
with	O
PCBD1	O
mutations	O
were	O
shown	O
to	O
suffer	O
hypomagnesemia	S-Phenotype
and	O
MODY5	O
-	O
like	O
diabetes	O
.	O

This	O
essential	O
role	O
of	O
CIB2	O
in	O
mechanotransduction	O
and	O
cell	O
survival	O
that	O
,	O
we	O
show	O
,	O
is	O
restricted	O
to	O
the	O
cochlea	O
,	O
probably	O
accounts	O
for	O
the	O
presence	O
in	O
CIB2	O
-	O
/	O
-	O
mice	O
and	O
CIB2	O
patients	O
,	O
unlike	O
in	O
Usher	O
syndrome	O
,	O
of	O
isolated	O
hearing	B-Phenotype
loss	E-Phenotype
without	O
balance	O
and	O
vision	O
deficits	O

-	O
Zhang	O
,	O
H.	O
,	O
Yu	O
,	O
F.	O
,	O
Qin	O
,	O
F.	O
,	O
Shao	O
,	O
Y.	O
,	O
Chong	O
,	O
W.	O
,	O
Guo	O
,	O
Z.	O
,	O
Liu	O
,	O
X.	O
,	O
Fu	O
,	O
L.	O
,	O
Gu	O
,	O
F.	O
,	O
Ma	O
,	O
Y	O
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
explore	O
the	O
expression	O
profiles	O
of	O
SCN4B	O
in	O
papillary	B-Phenotype
thyroid	I-Phenotype
cancer	E-Phenotype
(	O
PTC	S-Phenotype
)	O
and	O
its	O
prognostic	O
value	O
in	O
terms	O
of	O
recurrence	O
-	O
free	O
survival	O
(	O
RFS	O
)	O
in	O
classical	O
PTC	S-Phenotype
.	O

DHEA	O
prevents	O
mitochondrial	B-Phenotype
dysfunction	E-Phenotype
by	O
decreasing	O
the	O
activation	O
of	O
DNM1L	O
and	O
MFF	O
,	O
and	O
increasing	O
MFN1	O
expression	O
.	O

To	O
further	O
explore	O
this	O
,	O
we	O
investigated	O
the	O
associations	O
of	O
peripheral	O
GR	O
-	O
1subF	O
/	O
sub	O
methylation	O
(	O
52	O
CpGs	O
)	O
with	O
the	O
cortisol	O
stress	O
response	O
(	O
Trier	O
Social	O
Stress	O
Test	O
)	O
and	O
with	O
childhood	O
trauma	O
in	O
three	O
independent	O
studies	O
(	O
total	O
N	O
=	O
241	O
)	O
including	O
healthy	O
controls	O
,	O
patients	O
with	O
schizophrenia	S-Phenotype
and	O
bipolar	B-Phenotype
disorder	E-Phenotype
and	O
unaffected	O
siblings	O
of	O
patients	O
with	O
one	O
of	O
these	O
disorders	O
.	O

In	O
conclusion	O
,	O
the	O
hypermethylation	O
of	O
HOXA11	O
is	O
an	O
independent	O
prognostic	O
biomarker	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

In	O
a	O
model	O
of	O
nude	O
mice	O
,	O
the	O
overexpression	O
of	O
MORC2	O
promoted	O
tumorigenicity	O
and	O
markedly	O
enhanced	O
pulmonary	O
metastasis	O
of	O
liver	B-Phenotype
cancer	E-Phenotype
.	O

The	O
VDR	O
gene	O
FokI	O
CT	O
/	O
TT	O
genotype	O
was	O
associated	O
with	O
an	O
increased	O
papillary	B-Phenotype
thyroid	I-Phenotype
cancer	E-Phenotype
risk	O
(	O
CT	O
vs	O
CC	O
:	O
odds	O
ratio	O
=	O
1.71	O
,	O
95	O
%	O
confidence	O
interval	O
=	O
1.15	O
-	O
2.76	O
,	O
p	O
=	O
0.028	O
;	O
TT	O
vs	O
CC	O
:	O
odds	O
ratio	O
=	O
2.44	O
,	O
95	O
%	O
confidence	O
interval	O
=	O
1.29	O
-	O
4.62	O
,	O
p	O
=	O
0.005	O
;	O
CT	O
/	O
TT	O
vs	O
CC	O
:	O
odds	O
ratio	O
=	O
1.88	O
,	O
95	O
%	O
confidence	O
interval	O
=	O
1.20	O
-	O
2.96	O
,	O
p	O
=	O
0.006	O
;	O
CT	O
/	O
CC	O
vs	O
TT	O
:	O
odds	O
ratio	O
=	O
1.80	O
,	O
95	O
%	O
confidence	O
interval	O
=	O
1.05	O
-	O
3.20	O
,	O
p	O
=	O
0.041	O
)	O
.	O

Lastly	O
,	O
a	O
syndromic	O
form	O
of	O
PCD	S-Phenotype
with	O
retinal	B-Phenotype
degeneration	E-Phenotype
results	O
in	O
normal	O
ciliary	O
ultrastructure	O
through	O
mutations	O
in	O
the	O
RPGR	O
gene	O
.	O

Mutations	O
in	O
four	O
genes	O
(	O
LDLR	O
,	O
APOB	O
,	O
PCSK9	O
and	O
LDLRAP1	O
)	O
account	O
for	O
the	O
majority	O
of	O
cases	O
with	O
familial	B-Phenotype
hypercholesterolemia	E-Phenotype
.	O

Reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
play	O
a	O
vital	O
role	O
in	O
the	O
pathogenesis	O
of	O
many	O
cardiovascular	B-Phenotype
diseases	E-Phenotype
.	O

Because	O
of	O
the	O
unbalanced	O
sex	O
ratio	O
(	O
1.3	O
-	O
1.4	O
to	O
1	O
)	O
observed	O
in	O
intellectual	B-Phenotype
disability	E-Phenotype
(	O
ID	S-Phenotype
)	O
and	O
the	O
identification	O
of	O
large	O
ID	O
-	O
affected	O
families	O
showing	O
X	O
-	O
linked	O
segregation	O
,	O
much	O
attention	O
has	O
been	O
focused	O
on	O
the	O
genetics	O
of	O
X	O
-	O
linked	O
ID	O
(	O
XLID	O
)	O
.	O

We	O
hypothesized	O
that	O
mechanisms	O
underlying	O
chemical	O
-	O
induced	O
HCC	O
can	O
be	O
characterized	O
by	O
evaluating	O
the	O
mutational	O
spectra	O
of	O
these	O
tumors	S-Phenotype
.	O

Further	O
functional	O
studies	O
show	O
that	O
forced	O
expression	O
of	O
LHX3	O
in	O
lung	B-Phenotype
cancer	E-Phenotype
cells	O
obviously	O
promotes	O
cell	O
proliferation	O
and	O
invasion	O
,	O
whereas	O
inhibits	O
cell	O
apoptosis	O
.	O

To	O
further	O
elucidate	O
the	O
molecular	O
pathophysiology	O
of	O
schizophrenia	S-Phenotype
,	O
we	O
have	O
evaluated	O
the	O
genetic	O
association	O
of	O
WDR3	O
and	O
ALG1	O
in	O
schizophrenia	S-Phenotype
.	O

Disorders	O
of	O
sex	O
development	O
comprise	O
a	O
heterogeneous	S-Phenotype
group	O
of	O
congenital	O
conditions	O
associated	O
with	O
atypical	O
development	O
of	O
internal	O
and	O
external	O
genitalia	O
.	O

Pompe	O
disease	O
,	O
also	O
called	O
type	O
II	O
glycogen	O
storage	O
disease	O
,	O
is	O
a	O
rare	O
autosomal	B-Phenotype
recessive	E-Phenotype
inherited	O
disease	O
caused	O
by	O
the	O
storage	O
of	O
glycogen	O
in	O
lysosome	O
due	O
to	O
acid	O
α	O
-	O
glucosidase	O
(	O
GAA	O
)	O
deficiency	O
,	O
with	O
the	O
most	O
severe	O
conditions	O
in	O
the	O
skeletal	O
muscle	O
,	O
the	O
myocardium	O
,	O
and	O
the	O
smooth	O
muscle	O
.	O

Missense	O
mutations	O
in	O
SCN2A	O
(	O
p.Leu1342Pro	O
)	O
and	O
KCNQ2	O
(	O
p.Ala306Thr	O
)	O
were	O
found	O
in	O
two	O
patients	O
with	O
no	O
history	O
of	O
epilepsy	S-Phenotype
before	O
the	O
onset	O
of	O
ISs	O
.	O

Genetic	O
analysis	O
of	O
a	O
large	O
Indian	O
family	O
with	O
an	O
autosomal	O
dominant	O
cataract	S-Phenotype
phenotype	O
allowed	O
us	O
to	O
identify	O
a	O
novel	O
cataract	S-Phenotype
gene	O
,	O
CRYBA4	O
.	O

Hepatic	O
hnRNPA1	O
overexpression	O
also	O
activated	O
the	O
CaM	O
/	O
Akt	O
pathway	O
and	O
repressed	O
the	O
mTOR	O
/	O
SREBP	O
-	O
1C	O
pathway	O
to	O
ameliorate	O
hyperglycemia	S-Phenotype
and	O
steatosis	S-Phenotype
in	O
obese	O
mice	O
.	O

PEPCK	O
-	O
M	O
(	O
PCK2	O
)	O
,	O
the	O
mitochondrial	O
isoform	O
of	O
phosphoenolpyruvate	O
carboxykinase	O
(	O
PEPCK	O
)	O
,	O
has	O
been	O
shown	O
by	O
us	O
and	O
others	O
to	O
be	O
functionally	O
expressed	O
and	O
to	O
mediate	O
gluconeogenesis	O
,	O
the	O
reverse	O
pathway	O
of	O
glycolysis	O
,	O
in	O
different	O
cancer	S-Phenotype
cells	O
.	O

Here	O
,	O
we	O
report	O
mutations	O
in	O
GNB5	O
that	O
are	O
associated	O
with	O
heart	B-Phenotype
-	I-Phenotype
rate	I-Phenotype
disturbance	E-Phenotype
,	O
eye	B-Phenotype
disease	E-Phenotype
,	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
gastric	O
problems	O
,	O
hypotonia	S-Phenotype
,	O
and	O
seizures	S-Phenotype
in	O
nine	O
individuals	O
from	O
six	O
families	O
.	O

Spinocerebellar	B-Phenotype
ataxia	I-Phenotype
type	I-Phenotype
8	E-Phenotype
(	O
SCA8	S-Phenotype
)	O
is	O
a	O
progressive	O
neurological	O
disorder	O
caused	O
by	O
the	O
expanded	O
repeat	O
CTA	O
/	O
CTG	O
of	O
two	O
overlapping	O
genes	O
,	O
ATXN8OS	O
and	O
ATXN8	O
,	O
expressed	O
bidirectionally	O
.	O

These	O
results	O
increase	O
our	O
knowledge	O
about	O
the	O
RAD51C	O
and	O
RAD51D	O
mutation	O
spectrum	O
and	O
support	O
the	O
notion	O
that	O
these	O
genes	O
should	O
be	O
included	O
in	O
the	O
gene	O
panel	O
testing	O
performed	O
on	O
patients	O
with	O
hereditary	B-Phenotype
breast	I-Phenotype
and	I-Phenotype
ovarian	I-Phenotype
cancer	E-Phenotype
syndrome	O

Furthermore	O
,	O
with	O
an	O
increasing	O
number	O
of	O
pathogenic	O
mutations	O
leading	O
to	O
epilepsy	S-Phenotype
and	O
hearing	B-Phenotype
loss	E-Phenotype
being	O
discovered	O
in	O
the	O
TLDc	O
protein	O
TBC1D24	O
,	O
understanding	O
the	O
function	O
of	O
this	O
family	O
has	O
important	O
implications	O
for	O
a	O
range	O
of	O
inherited	O
neurological	O
diseases	O

Mutations	O
in	O
LGI1	O
in	O
humans	O
causes	O
autosomal	B-Phenotype
dominant	I-Phenotype
lateral	I-Phenotype
temporal	I-Phenotype
lobe	I-Phenotype
epilepsy	E-Phenotype
and	O
homozygous	O
deletion	O
of	O
LGI1	O
in	O
mice	O
results	O
in	O
severe	O
epileptic	B-Phenotype
seizures	E-Phenotype
that	O
cause	O
early	B-Phenotype
postnatal	I-Phenotype
death	E-Phenotype
.	O

After	O
exclusive	O
analysis	O
of	O
10	O
common	O
variations	O
of	O
three	O
hearing	B-Phenotype
loss	E-Phenotype
-	O
related	O
genes	O
,	O
GJB2	O
,	O
mtDNA12srRNA	O
and	O
SLC26A4	O
,	O
a	O
novel	O
truncated	O
variant	O
of	O
SMPX	O
,	O
c.87dupA	O
(	O
p.Gly30Argfs	O
*	O
12	O
)	O
(	O
NCBI	O
ClinVar	O
Submission	O
ID	O
:	O
SUB3136126	O
)	O
,	O
was	O
identified	O
by	O
whole	O
-	O
exome	O
sequencing	O
.	O

mitochondrion	O
organization	O
,	O
P=3.21x10	O
-	O
17	O
;	O
mitochondrial	O
ATP	O
synthesis	O
coupled	O
electron	O
transport	O
,	O
P=1.73x10	O
-	O
19	O
and	O
mitochondrial	O
membrane	O
organization	O
,	O
P=4.04x10	O
-	O
8	O
)	O
.	O

We	O
further	O
expand	O
the	O
existing	O
CNTNAP1	O
-	O
associated	O
phenotype	O
to	O
include	O
profound	B-Phenotype
cerebral	I-Phenotype
and	I-Phenotype
cerebellar	I-Phenotype
atrophy	E-Phenotype

To	O
date	O
,	O
CRYBA4	O
was	O
the	O
only	O
gene	O
in	O
this	O
cluster	O
not	O
associated	O
with	O
either	O
human	O
or	O
murine	O
cataracts	S-Phenotype
.	O

Importantly	O
,	O
in	O
regard	O
to	O
early	O
gastric	B-Phenotype
cancer	E-Phenotype
and	O
submucosal	B-Phenotype
tumors	E-Phenotype
(	O
SMTs	S-Phenotype
)	O
of	O
the	O
stomach	O
,	O
ESD	O
and	O
full	O
thickness	O
resection	O
(	O
FTR	O
)	O
can	O
excise	O
these	O
lesions	O
lien	O
-	O
bloc	O
/	O
i	O
and	O
endoscopic	O
suturing	O
is	O
now	O
used	O
to	O
close	O
large	O
defects	O
and	O
perforations	O
.	O

In	O
this	O
report	O
we	O
describe	O
a	O
female	O
child	O
with	O
global	B-Phenotype
developmental	I-Phenotype
delay	E-Phenotype
,	O
microcephaly	S-Phenotype
and	O
myoclonic	B-Phenotype
seizures	E-Phenotype
harbouring	O
a	O
5	O
Mb	O
deletion	O
in	O
14q12	O
locus	O
resulting	O
in	O
deletion	O
of	O
single	O
copy	O
of	O
brain	O
specific	O
genes	O
FOXG1	O
,	O
PRKD1	O
and	O
NOVA1	O
.	O

A	O
novel	O
15	O
-	O
gene	O
signature	O
identified	O
82.4	O
%	O
of	O
the	O
tumours	S-Phenotype
with	O
bone	O
metastasis	O
,	O
85.2	O
%	O
of	O
the	O
tumours	S-Phenotype
which	O
had	O
bone	O
metastasis	O
as	O
first	O
site	O
of	O
metastasis	O
and	O
100	O
%	O
of	O
the	O
ones	O
with	O
bone	O
metastasis	O
only	O
(	O
p	O
9.99e	O
-	O
09	O
)	O
,	O
in	O
the	O
training	O
set	O
.	O

Collectively	O
,	O
CCDC8	O
may	O
suppress	O
the	O
invasion	O
and	O
metastasis	O
of	O
lung	B-Phenotype
cancer	E-Phenotype
cells	O
,	O
and	O
it	O
may	O
represent	O
a	O
promising	O
therapeutic	O
target	O
for	O
non	B-Phenotype
-	I-Phenotype
small	I-Phenotype
cell	I-Phenotype
lung	I-Phenotype
cancer	E-Phenotype

The	O
final	O
analysis	O
of	O
all	O
this	O
information	O
led	O
us	O
to	O
propose	O
TTBK1	O
as	O
a	O
new	O
target	O
for	O
the	O
treatment	O
of	O
neurodegenerative	B-Phenotype
diseases	E-Phenotype
and	O
its	O
selective	O
inhibitors	O
as	O
potential	O
effective	O
drugs	O
for	O
the	O
treatment	O
of	O
these	O
severe	O
unmet	O
disorders	O

Compared	O
to	O
normal	O
tissues	O
,	O
decorin	O
expression	O
was	O
reduced	O
in	O
CRC	O
patients	O
'	O
tumors	S-Phenotype
,	O
while	O
there	O
were	O
increased	O
Met	O
and	O
VEGFA	O
levels	O
.	O

Punctate	B-Phenotype
palmoplantar	I-Phenotype
keratoderma	I-Phenotype
type	I-Phenotype
1	E-Phenotype
(	O
PPPK1	S-Phenotype
)	O
is	O
a	O
rare	O
autosomal	O
dominant	O
inherited	O
skin	O
disease	O
,	O
characterized	O
by	O
multiple	B-Phenotype
hyperkeratotic	I-Phenotype
lesions	I-Phenotype
on	I-Phenotype
the	I-Phenotype
palms	I-Phenotype
and	I-Phenotype
soles	E-Phenotype
.	O

The	O
DFNB79	O
locus	O
harbors	O
TPRN	O
mutations	O
in	O
which	O
have	O
been	O
reported	O
in	O
a	O
few	O
families	O
with	O
deafness	S-Phenotype
.	O

Dendritic	O
cells	O
(	O
DCs	O
)	O
of	O
colon	B-Phenotype
cancer	E-Phenotype
patients	O
were	O
collected	O
for	O
phenotype	O
and	O
CXCL1	O
expression	O
by	O
flow	O
cytometry	O
and	O
Luminex	O
assays	O
.	O

Despite	O
extensive	O
research	O
on	O
cancer	S-Phenotype
stem	O
cells	O
in	O
colorectal	B-Phenotype
cancer	E-Phenotype
,	O
the	O
impact	O
of	O
stem	O
cell	O
markers	O
on	O
patient	O
survival	O
remains	O
unclear	O
,	O
particularly	O
in	O
those	O
with	O
distant	O
metastasis	O
.	O

Patients	O
with	O
WWS	O
frequently	O
demonstrate	O
a	O
complete	O
lack	B-Phenotype
of	I-Phenotype
psychomotor	I-Phenotype
development	E-Phenotype
,	O
severe	O
eye	B-Phenotype
malformations	E-Phenotype
,	O
cobblestone	B-Phenotype
lissencephaly	E-Phenotype
and	O
a	O
hypoplastic	B-Phenotype
cerebellum	I-Phenotype
and	I-Phenotype
brainstem	E-Phenotype
,	O
seizures	S-Phenotype
,	O
hydrocephalus	S-Phenotype
and	O
poor	B-Phenotype
prognosis	E-Phenotype
.	O

However	O
,	O
unconditioned	O
NRGS	O
mice	O
developed	O
less	O
clinically	O
relevant	O
disease	O
,	O
with	O
CDXs	O
forming	O
solid	O
tumors	S-Phenotype
throughout	O
the	O
body	O
,	O
whereas	O
unconditioned	O
NRG	O
mice	O
were	O
incapable	O
of	O
efficiently	O
supporting	O
PDX	O
or	O
human	O
hematopoietic	O
stem	O
cell	O
engraftment	O
.	O

Homozygous	O
null	O
mutation	O
of	O
tumor	S-Phenotype
suppressor	O
WWOX	O
/	O
Wwox	O
gene	O
leads	O
to	O
severe	O
neural	O
diseases	O
,	O
metabolic	O
disorders	O
and	O
early	O
death	O
in	O
the	O
newborns	O
of	O
humans	O
,	O
mice	O
and	O
rats	O
.	O

Here	O
we	O
report	O
a	O
complex	O
form	O
of	O
HSP	O
associated	O
with	O
retinal	B-Phenotype
dystrophy	E-Phenotype
and	O
a	O
pattern	O
of	O
neurodegeneration	S-Phenotype
with	O
brain	O
iron	O
accumulation	O
(	O
NBIA	O
)	O
on	O
brain	O
MRI	O
,	O
due	O
to	O
a	O
novel	O
homozygous	O
mutation	O
in	O
DDHD1	O
.	O

Before	O
and	O
after	O
eight	O
weeks	O
daily	O
treatment	O
with	O
six	O
capsules	O
of	O
FAAAAAamp	O
;	O
V	O
juice	O
concentrate	O
or	O
placebo	O
,	O
peripheral	O
blood	O
gene	O
expression	O
(	O
microarray	O
,	O
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
qPCR	O
)	O
)	O
,	O
plasma	O
tumour	S-Phenotype
necrosis	O
factor	O
(	O
TNF	O
)	O
a	O
(	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
)	O
,	O
body	O
composition	O
(	O
Dual	O
-	O
energy	O
X	O
-	O
ray	O
absorptiometry	O
(	O
DEXA	O
)	O
)	O
and	O
lipid	O
profiles	O
were	O
assessed	O
.	O

However	O
,	O
little	O
information	O
is	O
currently	O
available	O
on	O
the	O
skeletal	B-Phenotype
abnormalities	E-Phenotype
of	O
PRS	O
and	O
the	O
potential	O
contribution	O
of	O
PAX2	O
mutations	O
.	O

Using	O
homozygosity	O
mapping	O
followed	O
by	O
exome	O
sequencing	O
,	O
we	O
identified	O
a	O
Thr224Asn	O
mutation	O
in	O
the	O
VPS45	O
gene	O
in	O
infants	O
from	O
consanguineous	O
families	O
who	O
suffered	O
from	O
life	O
-	O
threatening	O
neutropenia	S-Phenotype
,	O
which	O
was	O
refractory	O
to	O
granulocyte	O
CSF	O
,	O
from	O
defective	B-Phenotype
platelet	I-Phenotype
aggregation	E-Phenotype
and	O
myelofibrosis	S-Phenotype
.	O

We	O
also	O
emphasized	O
that	O
the	O
ERK	O
and	O
AKT	O
signaling	O
pathways	O
were	O
the	O
mechanisms	O
underlying	O
the	O
inhibitory	O
effect	O
of	O
HCRP1	O
on	O
glioma	S-Phenotype
cells	O
.	O

We	O
conducted	O
a	O
large	O
-	O
scale	O
genome	O
-	O
wide	O
association	O
study	O
of	O
erectile	B-Phenotype
dysfunction	E-Phenotype
in	O
36,649	O
men	O
in	O
the	O
multiethnic	O
Kaiser	O
Permanente	O
Northern	O
California	O
Genetic	O
Epidemiology	O
Research	O
in	O
Adult	O
Health	O
and	O
Aging	O
cohort	O
.	O

Conversely	O
,	O
ADAMTS4	O
,	O
6	O
,	O
14	O
,	O
and	O
20	O
are	O
consistently	O
up	O
-	O
regulated	O
in	O
breast	B-Phenotype
carcinomas	E-Phenotype
(	O
P	O
=	O
0.005	O
,	O
P	O
AAAA	O
0.0001	O
,	O
P	O
=	O
0.003	O
,	O
and	O
P	O
=	O
0.001	O
,	O
respectively	O
)	O
.	O

Methods	O
:	O
Quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
qRT	O
-	O
PCR	O
)	O
was	O
applied	O
to	O
detect	O
the	O
expression	O
level	O
of	O
HOXA11	O
-	O
AS	O
in	O
cell	O
lines	O
HET	O
-	O
1A	O
,	O
EC9706	O
,	O
EC109	O
,	O
and	O
in	O
tumor	S-Phenotype
tissue	O
and	O
paired	O
adjacent	O
tissue	O
samples	O
from	O
73	O
ESCC	O
patients	O
who	O
received	O
surgical	O
resection.The	O
correlations	O
of	O
the	O
expression	O
level	O
of	O
HOXA11	O
-	O
AS	O
with	O
clinicopathological	O
features	O
and	O
prognosis	O
were	O
also	O
analyzed	O
.	O

RNF6	O
increased	O
breast	B-Phenotype
cancer	E-Phenotype
cell	O
proliferation	O
,	O
migration	O
and	O
reduced	O
cell	O
sensitivity	O
to	O
doxorubicin	O
.	O

A	O
variant	O
in	O
BAK1	O
(	O
rs210138	O
)	O
was	O
positively	O
associated	O
with	O
GCT	O
(	O
OR	O
[	O
95	O
%	O
CI	O
]	O
:	O
1.70	O
[	O
1.32	O
,	O
2.18	O
]	O
)	O
,	O
with	O
a	O
strong	O
estimated	O
effect	O
for	O
testis	B-Phenotype
tumors	E-Phenotype
(	O
OR	O
[	O
95	O
%	O
CI	O
]	O
:	O
3.31	O
[	O
1.89	O
,	O
5.79	O
]	O
)	O
.	O

Exome	O
and	O
targeted	O
sequencing	O
has	O
recently	O
identified	O
four	O
new	O
genes	O
causing	O
ataxia	S-Phenotype
:	O
TGM6	O
,	O
ANO10	O
,	O
SYT14	O
,	O
and	O
rundataxin	O
.	O

Subsequently	O
,	O
we	O
tested	O
a	O
cohort	O
of	O
19	O
individuals	O
with	O
(	O
mild	O
)	O
features	O
of	O
BMKS	O
and	O
17	O
individuals	O
with	O
isolated	O
choanal	B-Phenotype
atresia	E-Phenotype
for	O
causative	O
variants	O
in	O
TXNL4A	O
by	O
dideoxy	O
-	O
sequence	O
analysis	O
.	O

In	O
total	O
,	O
53	O
women	O
with	O
primarily	O
inoperable	B-Phenotype
or	I-Phenotype
inflammatory	I-Phenotype
breast	I-Phenotype
cancer	E-Phenotype
who	O
were	O
treated	O
with	O
NACT	O
were	O
included	O
in	O
the	O
study	O
.	O

Therefore	O
,	O
the	O
CRB1	O
gene	O
is	O
a	O
key	O
target	O
in	O
the	O
fight	O
against	O
blindness	S-Phenotype
.	O

In	O
a	O
bone	O
metastasis	O
model	O
,	O
mice	O
treated	O
with	O
ZOL+US	O
had	O
osteolytic	O
lesions	O
that	O
were	O
58	O
%	O
smaller	O
than	O
those	O
of	O
ZOL	O
-	O
treated	O
animals	O
as	O
well	O
as	O
a	O
reduced	O
skeletal	B-Phenotype
tumor	E-Phenotype
burden	O
.	O

KLK4	O
protein	O
is	O
localized	O
in	O
the	O
cytoplasm	O
of	O
tumor	S-Phenotype
and	O
stroma	O
cells	O
.	O

Therefore	O
,	O
secreted	O
miRNAs	O
in	O
body	O
fluids	O
have	O
been	O
investigated	O
as	O
a	O
promising	O
biomarkers	O
and	O
therapeutic	O
targets	O
for	O
the	O
treatment	O
of	O
cancer	S-Phenotype
patients	O
.	O

ATP13A2	O
mutations	O
are	O
rare	O
cause	O
of	O
autosomal	B-Phenotype
recessive	I-Phenotype
juvenile	I-Phenotype
-	I-Phenotype
onset	I-Phenotype
Parkinson	I-Phenotype
disease	E-Phenotype
.	O

Clinically	O
,	O
Lin28A	O
was	O
linked	O
to	O
a	O
higher	O
tumor	S-Phenotype
/	O
node	O
/	O
metastasis	O
stage	O
and	O
the	O
presence	O
of	O
lymph	O
node	O
metastases	O
.	O

The	O
RET	O
rearrangement	O
uniformity	O
in	O
metastatic	O
lymph	O
nodes	O
and	O
tumor	S-Phenotype
specimens	O
were	O
contrasted	O
and	O
the	O
relationships	O
between	O
RET	O
rearrangement	O
and	O
patients	O
'	O
clinical	O
features	O
were	O
investigated	O
.	O

Human	O
SAMD9	O
,	O
a	O
tumor	S-Phenotype
suppressor	O
and	O
a	O
restriction	O
factor	O
for	O
poxviruses	O
in	O
cell	O
lines	O
,	O
is	O
antagonized	O
by	O
two	O
classes	O
of	O
poxvirus	O
proteins	O
,	O
represented	O
by	O
vaccinia	O
virus	O
(	O
VACV	O
)	O
K1	O
and	O
C7	O
.	O

A	O
variable	O
-	O
length	O
poly	O
-	O
T	O
variant	O
in	O
intron	O
6	O
of	O
the	O
TOMM40	O
gene	O
,	O
rs10524523	O
,	O
is	O
associated	O
with	O
risk	O
and	O
age	O
-	O
of	O
-	O
onset	O
of	O
sporadic	S-Phenotype
(	O
late	O
-	O
onset	O
)	O
Alzheimer	O
's	O
disease	O
.	O

We	O
described	O
a	O
BAG3	O
mutation	O
patient	O
with	O
atypical	O
phenotype	O
of	O
CMT	O
and	O
myopathy	S-Phenotype
,	O
and	O
those	O
are	O
expected	O
to	O
broaden	O
the	O
clinical	O
spectrum	O
of	O
the	O
disease	O
and	O
help	O
to	O
diagnose	O
it	O

Biallelic	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
affecting	O
POC1A	O
cause	O
SOFT	O
syndrome	O
,	O
an	O
ultra	O
-	O
rare	O
condition	O
characterized	O
by	O
short	B-Phenotype
stature	E-Phenotype
,	O
onychodysplasia	S-Phenotype
,	O
facial	B-Phenotype
dysmorphism	E-Phenotype
and	O
hypotrichosis	S-Phenotype
.	O

Conclusions	O
:	O
Two	O
stable	O
multidrug	O
resistant	O
cell	O
lines	O
of	O
pancreatic	B-Phenotype
cancer	E-Phenotype
,	O
JF305	O
/	O
CDDP	O
and	O
PANC	O
-	O
1	O
/	O
GEM	O
,	O
were	O
successfully	O
established	O
.	O

Significant	O
downregulation	O
of	O
c	O
-	O
Myc	O
,	O
a	O
well	O
-	O
publicized	O
target	O
of	O
BET	O
inhibitors	O
,	O
was	O
largely	O
restricted	O
to	O
hematologic	O
cancer	S-Phenotype
cell	O
lines	O
.	O

Familial	B-Phenotype
microscopic	I-Phenotype
hematuria	E-Phenotype
(	O
FMH	S-Phenotype
)	O
is	O
associated	O
with	O
a	O
genetically	O
heterogeneous	S-Phenotype
group	O
of	O
conditions	O
including	O
the	O
collagen	O
-	O
IV	O
nephropathies	S-Phenotype
,	O
the	O
heritable	O
C3	O
/	O
CFHR5	O
nephropathy	S-Phenotype
and	O
the	O
glomerulopathy	S-Phenotype
with	O
fibronectin	O
deposits	O
.	O

The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
present	O
a	O
comprehensive	O
picture	O
of	O
the	O
impact	O
of	O
FTO	O
on	O
obesity	S-Phenotype
susceptibility	O
and	O
to	O
illuminate	O
these	O
new	O
studies	O
of	O
FTO	O
function	O
in	O
adipose	O
tissue	O

RAB3A	O
interacting	O
protein	O
(	O
Rab3IP	O
)	O
has	O
been	O
determined	O
to	O
be	O
involved	O
in	O
cancer	S-Phenotype
progression	O
;	O
however	O
,	O
its	O
expression	O
pattern	O
and	O
function	O
in	O
gastric	B-Phenotype
cancer	E-Phenotype
remain	O
unknown	O
.	O

We	O
examined	O
the	O
diagnostic	O
and	O
prognostic	O
value	O
of	O
altered	O
reticulin	O
framework	O
and	O
the	O
immunoprofile	O
of	O
biomarkers	O
including	O
IGF	O
-	O
2	O
,	O
proteins	O
involved	O
in	O
cell	O
proliferation	O
and	O
mitotic	O
spindle	O
regulation	O
(	O
Ki67	O
,	O
p53	O
,	O
BUB1B	O
,	O
HURP	O
,	O
NEK2	O
)	O
,	O
DNA	O
damage	O
repair	O
(	O
PBK	O
,	O
γ	O
-	O
H2AX	O
)	O
,	O
telomere	O
regulation	O
(	O
DAX	O
,	O
ATRX	O
)	O
,	O
wnt	O
-	O
signaling	O
pathway	O
(	O
beta	O
-	O
catenin	O
)	O
and	O
PI3K	O
signaling	O
pathway	O
(	O
PTEN	O
,	O
phospho	O
-	O
mTOR	O
)	O
in	O
a	O
tissue	O
microarray	O
of	O
50	O
adenomas	O
and	O
43	O
carcinomas	S-Phenotype
that	O
were	O
characterized	O
for	O
angioinvasion	O
as	O
defined	O
by	O
strict	O
criteria	O
,	O
Weiss	O
score	O
,	O
and	O
mitotic	O
rate	O
-	O
based	O
tumor	S-Phenotype
grade	O
.	O

Surprisingly	O
,	O
either	O
silencing	O
miR	O
-	O
126	O
-	O
3p	O
by	O
LNA	O
-	O
antimiR	O
or	O
overexpressing	O
miR	O
-	O
126	O
-	O
3p	O
by	O
miRNA	O
mimic	O
repressed	O
laser	O
-	O
induced	O
choroidal	B-Phenotype
neovascularization	E-Phenotype
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
the	O
interactions	O
between	O
single	O
nucleotide	O
polymorphisms	O
of	O
ERCC6	O
(	O
rs1917799	O
)	O
and	O
ERCC8	O
(	O
rs158572	O
and	O
rs158916	O
)	O
in	O
gastric	B-Phenotype
cancer	E-Phenotype
and	O
its	O
precancerous	O
diseases	O
.	O

Homozygous	O
null	O
mutation	O
of	O
tumor	S-Phenotype
suppressor	O
liWWOX	O
/	O
Wwox	O
/	O
i	O
gene	O
leads	O
to	O
severe	O
neural	O
diseases	O
,	O
metabolic	O
disorders	O
and	O
early	O
death	O
in	O
the	O
newborns	O
of	O
humans	O
,	O
mice	O
and	O
rats	O
.	O

Furthermore	O
,	O
neurorehabilitation	O
interventions	O
aimed	O
at	O
improving	O
balance	O
and	O
walking	O
performance	O
,	O
fatigue	O
management	O
,	O
and	O
specific	O
pain	S-Phenotype
relief	O
therapy	O
should	O
be	O
considered	O
to	O
ameliorate	O
participation	O
in	O
social	O
life	O
and	O
HR	O
-	O
QoL	O
in	O
anti	O
-	O
MAG	O
neuropathy	S-Phenotype
patients	O

Comprehensive	O
clinical	O
evaluation	O
(	O
CT	O
and	O
MR	O
-	O
imaging	O
,	O
audiological	O
and	O
stabilometric	O
examinations	O
)	O
of	O
available	O
members	O
of	O
this	O
family	O
revealed	O
both	O
already	O
known	O
(	O
mixed	O
progressive	B-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
)	O
and	O
additional	O
(	O
enlargement	O
of	O
semicircular	O
canals	O
and	O
postural	O
disorders	O
)	O
clinical	O
DFNX2	O
features	O
in	O
affected	O
males	O
with	O
c.975GAAAAA	O
(	O
p.Trp325	O
*	O
)	O
.	O

Recently	O
,	O
defects	O
of	O
ZBTB20	O
,	O
a	O
BTB	O
and	O
zinc	O
finger	O
domain	O
containing	O
transcriptional	O
repressor	O
,	O
have	O
been	O
implicated	O
in	O
a	O
wide	O
range	O
of	O
neurodevelopmental	O
disorders	O
,	O
including	O
intellectual	B-Phenotype
disability	E-Phenotype
and	O
autism	S-Phenotype
.	O

Concerning	O
LEP	O
G2548A	O
polymorphism	O
,	O
our	O
results	O
showed	O
that	O
the	O
OR	O
of	O
obesity	S-Phenotype
associated	O
with	O
2548	O
AA	O
/	O
GG	O
was	O
1.87	O
[	O
1.106	O
-	O
2.78	O
]	O
P	O
=	O
.028	O
vs	O
1.41	O
[	O
1.035	O
-	O
1.85	O
]	O
P	O
=	O
.045	O
for	O
223AA	O
/	O
GG	O
polymorphism	O
.	O

Elucidating	O
the	O
exact	O
relationship	O
between	O
these	O
two	O
enzymes	O
when	O
they	O
methylate	O
two	O
distinct	O
sites	O
of	O
the	O
same	O
substrate	O
may	O
aid	O
in	O
developing	O
therapeutics	O
aimed	O
at	O
reducing	O
PRMT5	O
/	O
7	O
activity	O
in	O
cancer	S-Phenotype
and	O
other	O
diseases	O

We	O
present	O
a	O
case	O
of	O
myoclonus	B-Phenotype
-	I-Phenotype
dystonia	E-Phenotype
syndrome	O
illustrated	O
by	O
three	O
videos	O
in	O
which	O
we	O
found	O
a	O
novel	O
SGCE	O
mutation	O
.	O

We	O
detected	O
11	O
novel	O
mutations	O
in	O
liGJA3	O
/	O
i	O
,	O
liGJA8	O
/	O
i	O
,	O
liCRYAA	O
/	O
i	O
,	O
liCRYBB2	O
/	O
i	O
,	O
liCRYGS	O
/	O
i	O
,	O
liCRYGA	O
/	O
i	O
,	O
liGCNT2	O
/	O
i	O
,	O
liCRYGA	O
/	O
i	O
,	O
and	O
liMIP	O
/	O
i	O
;	O
and	O
three	O
previously	O
reported	O
cataract	S-Phenotype
-	O
causing	O
mutations	O
in	O
liGJA8	O
/	O
i	O
,	O
liCRYAA	O
/	O
i	O
,	O
and	O
liCRYBB2	O
/	O
i	O
The	O
most	O
commonly	O
mutated	O
genes	O
were	O
those	O
coding	O
for	O
gap	O
junctions	O
and	O
crystallin	O
proteins	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
organ	O
-	O
specific	O
distribution	O
of	O
miRNAs	O
is	O
one	O
of	O
the	O
principal	O
means	O
by	O
which	O
miRNA	O
establishes	O
characteristics	O
of	O
a	O
tissue	O
and	O
that	O
dysregulation	O
of	O
these	O
miRNAs	O
results	O
in	O
cancer	S-Phenotype
development	O
through	O
a	O
change	O
in	O
the	O
ratio	O
of	O
PKM	O
isoform	O
expression	O
.	O

Our	O
results	O
show	O
that	O
after	O
the	O
GJB2	O
gene	O
mutation	O
in	O
LRTOMT	O
gene	O
is	O
the	O
second	O
cause	O
of	O
congenital	B-Phenotype
hearing	I-Phenotype
impairment	E-Phenotype
in	O
Moroccan	O
patients	O
.	O

DNA	O
damage	O
causes	O
SPINK1	O
expression	O
by	O
engaging	O
NF	O
-	O
κB	O
and	O
C	O
/	O
EBP	O
,	O
while	O
paracrine	O
SPINK1	O
promotes	O
cancer	S-Phenotype
cell	O
aggressiveness	S-Phenotype
particularly	O
chemoresistance	O
.	O

A	O
single	O
family	O
with	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
form	O
of	O
OFCS	O
and	O
a	O
homozygous	O
missense	O
mutation	O
in	O
PAX1	O
gene	O
has	O
been	O
described	O
.	O

Our	O
results	O
suggest	O
that	O
ADAM2	O
,	O
CALR3	O
and	O
SAGE1	O
cancer	S-Phenotype
/	O
testis	O
antigens	O
are	O
not	O
promising	O
targets	O
for	O
immunotherapy	O
of	O
breast	B-Phenotype
and	I-Phenotype
lung	I-Phenotype
cancer	E-Phenotype
.	O

This	O
is	O
supported	O
by	O
the	O
fact	O
that	O
the	O
myeloid	B-Phenotype
neoplasms	E-Phenotype
with	O
genetic	O
predisposition	O
represent	O
a	O
new	O
category	O
in	O
the	O
revised	O
2016	O
World	O
Health	O
Organization	O
classification	O
.	O

However	O
,	O
the	O
biological	O
function	O
and	O
mechanism	O
of	O
TPI1	O
in	O
cancer	S-Phenotype
remain	O
largely	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
presence	O
and	O
functionality	O
of	O
EpoR	O
,	O
as	O
well	O
as	O
the	O
implications	O
of	O
Epo	O
upon	O
the	O
proliferation	O
and	O
survival	O
of	O
lung	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

CRISPR	O
-	O
Cas9	O
knockout	O
in	O
zebrafish	O
and	O
mice	O
recapitulated	O
the	O
human	O
phenotype	O
of	O
primary	B-Phenotype
microcephaly	E-Phenotype
and	O
resulted	O
in	O
early	O
lethality	O
.	O

bObjective	O
:	O
/	O
b	O
To	O
investigate	O
the	O
expression	O
of	O
granulocyte	O
-	O
colony	O
stimulating	O
factor	O
receptor	O
(	O
G	O
-	O
CSFR	O
)	O
in	O
a	O
mouse	O
model	O
of	O
colitis	S-Phenotype
-	O
associated	O
cancer	S-Phenotype
(	O
CAC	O
)	O
,	O
and	O
the	O
roles	O
of	O
G	O
-	O
CSFR	O
positive	O
immune	O
cells	O
in	O
the	O
development	O
of	O
CAC	O
.	O

Previously	O
,	O
we	O
demonstrated	O
that	O
several	O
common	O
pathological	O
gene	O
regulatory	O
programs	O
such	O
as	O
innate	O
inflammatory	O
and	O
profibrotic	O
transcriptional	O
networks	O
were	O
shared	O
by	O
COPD	O
and	O
heart	B-Phenotype
failure	E-Phenotype
.	O

Silencing	O
of	O
FGF12	O
showed	O
significant	O
inhibition	O
in	O
activity	O
of	O
tumor	S-Phenotype
cell	O
proliferation	O
,	O
colony	O
formation	O
,	O
and	O
cell	O
migration	O
.	O

Never	O
in	O
mitosis	O
gene	O
-	O
A	O
(	O
NIMA	O
)	O
-	O
related	O
expressed	O
kinase	O
2	O
(	O
NEK2	O
)	O
has	O
been	O
recently	O
reported	O
to	O
play	O
a	O
role	O
in	O
tumor	S-Phenotype
progression	O
,	O
drug	B-Phenotype
resistance	E-Phenotype
and	O
tumorigenesis	S-Phenotype
.	O

In	O
the	O
current	O
study	O
,	O
we	O
found	O
that	O
the	O
expression	O
of	O
Cx31	O
in	O
thyroid	B-Phenotype
cancer	E-Phenotype
tissues	O
and	O
thyroid	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
normal	O
thyroid	O
epithelial	O
tissues	O
and	O
cell	O
lines	O
.	O

Our	O
data	O
suggest	O
that	O
altered	O
mitochondria	O
-	O
associated	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
membranes	O
(	O
MAM	O
)	O
may	O
be	O
important	O
disease	O
mechanisms	O
leading	O
to	O
neuropathy	S-Phenotype
in	O
this	O
condition	O

Based	O
on	O
the	O
generated	O
interaction	O
network	O
,	O
we	O
examine	O
several	O
apoptotic	O
markers	O
to	O
determine	O
the	O
effect	O
of	O
PSMC3IP	O
and	O
EPSTI1	O
gene	O
expression	O
modulation	O
in	O
two	O
different	O
human	O
breast	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
to	O
suggest	O
potential	O
molecular	O
mechanisms	O
to	O
unveil	O
their	O
role	O
in	O
the	O
disease	O
.	O

Fluorescence	O
in	O
situ	O
hybridisation	O
(	O
FISH	O
)	O
targeting	O
specific	O
genes	O
has	O
been	O
used	O
as	O
an	O
ancillary	O
method	O
for	O
differential	O
diagnosis	O
of	O
melanocytic	B-Phenotype
tumours	E-Phenotype
,	O
but	O
most	O
previous	O
studies	O
have	O
focused	O
on	O
non	B-Phenotype
-	I-Phenotype
acral	I-Phenotype
lesions	E-Phenotype
which	O
may	O
have	O
genetic	O
alterations	O
different	O
from	O
acral	B-Phenotype
lesions	E-Phenotype
.	O

Progressive	O
rod	O
-	O
cone	O
degeneration	O
(	O
prcd	O
)	O
is	O
a	O
canine	B-Phenotype
retinal	I-Phenotype
disease	E-Phenotype
that	O
maps	O
to	O
the	O
centromeric	O
end	O
of	O
CFA9	O
in	O
a	O
region	O
of	O
synteny	O
with	O
the	O
distal	O
part	O
of	O
HSA17q	O
.	O

The	O
DNA	O
damage	O
checkpoint	O
barrier	O
(	O
γH2AX	O
,	O
pATM	O
,	O
p53	O
)	O
mechanism	O
was	O
activated	O
during	O
CaP	O
tumorigenesis	O
,	O
albeit	O
less	O
and	O
with	O
delayed	O
culmination	O
compared	O
to	O
other	O
cancers	S-Phenotype
,	O
possibly	O
reflecting	O
lower	O
replication	O
stress	O
(	O
slow	O
proliferation	O
despite	O
cases	O
of	O
Rb	O
loss	O
and	O
cyclin	O
D1	O
overexpression	O
)	O
and	O
progressive	O
loss	O
of	O
ATM	O
activator	O
NKX3.1	O
.	O

The	O
correlation	O
between	O
the	O
tumor	S-Phenotype
size	O
and	O
the	O
amount	O
of	O
CHL1	O
secretion	O
could	O
be	O
examined	O
in	O
this	O
study	O
,	O
and	O
showed	O
a	O
significant	O
positive	O
correlation	O
in	O
a	O
tumor	S-Phenotype
size	O
-	O
dependent	O
manner	O
.	O

Biallelic	O
GIPC3	O
mutations	O
have	O
recently	O
been	O
reported	O
to	O
cause	O
autosomal	B-Phenotype
recessive	I-Phenotype
nonsyndromic	I-Phenotype
sensorineural	I-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
.	O

CHIP	O
plays	O
a	O
protective	O
role	O
in	O
mouse	O
models	O
of	O
neurodegenerative	B-Phenotype
disease	E-Phenotype
,	O
and	O
in	O
humans	O
,	O
mutations	O
in	O
CHIP	O
cause	O
spinocerebellar	B-Phenotype
ataxia	I-Phenotype
autosomal	I-Phenotype
recessive	I-Phenotype
type	I-Phenotype
16	E-Phenotype
(	O
SCAR16	S-Phenotype
)	O
,	O
a	O
fatal	O
neurodegenerative	B-Phenotype
disease	E-Phenotype
characterized	O
by	O
truncal	B-Phenotype
and	I-Phenotype
limb	I-Phenotype
ataxia	E-Phenotype
that	O
results	O
in	O
gait	B-Phenotype
instability	E-Phenotype
.	O

Few	O
studies	O
have	O
examined	O
the	O
roles	O
of	O
CRELD1	O
and	O
GATA4	O
in	O
cardiac	B-Phenotype
abnormalities	E-Phenotype
or	O
their	O
association	O
with	O
pulmonary	O
artery	O
histopathology	O
.	O

To	O
our	O
knowledge	O
,	O
no	O
study	O
investigates	O
the	O
association	O
of	O
genetic	O
variant	O
distributions	O
of	O
WW	O
domain	O
-	O
containing	O
oxidoreductase	O
(	O
WWOX	O
)	O
gene	O
with	O
development	O
of	O
invasive	O
cancer	S-Phenotype
,	O
clinicopathologic	O
variables	O
and	O
patient	O
survival	O
in	O
uterine	B-Phenotype
cervical	I-Phenotype
cancer	E-Phenotype
for	O
Taiwanese	O
women	O
.	O

Analyses	O
of	O
our	O
original	O
miRNA	O
expression	O
signatures	O
indicated	O
that	O
both	O
strands	O
of	O
miR	O
-	O
144	O
(	O
miR	O
-	O
144	O
-	O
5p	O
,	O
the	O
passenger	O
strand	O
;	O
miR	O
-	O
144	O
-	O
3p	O
,	O
the	O
guide	O
strand	O
)	O
showed	O
decreased	O
expression	O
in	O
cancer	S-Phenotype
tissues	O
.	O

Popliteal	B-Phenotype
pterygium	E-Phenotype
syndrome	O
shares	O
features	O
with	O
van	O
der	O
Woude	O
syndrome	O
but	O
,	O
in	O
addition	O
,	O
is	O
characterized	O
by	O
genital	B-Phenotype
anomalies	E-Phenotype
,	O
syndactyly	B-Phenotype
of	I-Phenotype
fingers	I-Phenotype
and	I-Phenotype
toes	E-Phenotype
,	O
and	O
toenail	B-Phenotype
dysplasia	E-Phenotype
.	O

We	O
phenotyped	O
a	O
large	O
population	O
of	O
typical	O
individuals	O
for	O
schizophrenia	S-Phenotype
-	O
spectrum	O
and	O
autism	S-Phenotype
-	O
spectrum	O
traits	O
,	O
and	O
genotyped	O
them	O
for	O
the	O
single	O
-	O
nucleotide	O
polymorphism	O
rs850807	O
,	O
which	O
is	O
putatively	O
functional	O
and	O
linked	O
with	O
MAGEL2	O
and	O
NDN	O
Genetic	O
variation	O
in	O
rs850807	O
was	O
strongly	O
and	O
exclusively	O
associated	O
with	O
the	O
ideas	O
of	O
reference	O
subscale	O
of	O
the	O
schizophrenia	S-Phenotype
spectrum	O
,	O
which	O
is	O
best	O
typified	O
as	O
paranoia	S-Phenotype
.	O

In	O
childhood	O
tumors	S-Phenotype
,	O
including	O
retinoblastoma	S-Phenotype
,	O
osteosarcoma	S-Phenotype
,	O
and	O
neuroblastoma	S-Phenotype
,	O
the	O
RB	O
-	O
E2F1	O
pathway	O
is	O
inactivated	O
,	O
as	O
a	O
rule	O
.	O

Finally	O
,	O
we	O
will	O
discuss	O
the	O
impact	O
of	O
faulty	O
DPC	O
repair	O
on	O
disease	O
and	O
cancer	S-Phenotype
therapy	O

A	O
moderate	O
to	O
severe	O
reduction	O
(	O
AAAA50	O
%	O
)	O
in	O
PRODH	O
activity	O
resulting	O
from	O
recessive	O
deletions	O
and	O
/	O
or	O
missense	O
mutations	O
has	O
been	O
shown	O
to	O
cause	O
type	B-Phenotype
1	I-Phenotype
hyperprolinemia	E-Phenotype
(	O
HPI	S-Phenotype
)	O
.	O

We	O
observed	O
overexpression	O
and	O
increased	O
intra	O
-	O
nuclear	O
accumulation	O
of	O
the	O
PRMT5	O
/	O
WDR77	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
relative	O
to	O
immortalized	O
breast	O
epithelial	O
cells	O
.	O

Here	O
,	O
we	O
identified	O
three	O
families	O
with	O
mutations	O
in	O
ADD3	O
,	O
encoding	O
for	O
adducin	O
-	O
γ	O
,	O
with	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
microcephaly	S-Phenotype
,	O
cataracts	S-Phenotype
and	O
skeletal	B-Phenotype
defects	E-Phenotype
.	O

Applied	O
to	O
~10,000	O
tumor	S-Phenotype
exomes	O
the	O
approach	O
identifies	O
known	O
and	O
putative	O
CPGs	O
-	O
including	O
the	O
chromatin	O
modifier	O
NSD1	O
-	O
that	O
contribute	O
to	O
cancer	S-Phenotype
through	O
a	O
combination	O
of	O
rare	O
germline	O
variants	O
and	O
somatic	O
loss	O
-	O
of	O
-	O
heterozygosity	O
(	O
LOH	O
)	O
.	O

Here	O
,	O
we	O
use	O
a	O
combination	O
of	O
genetic	O
mouse	O
models	O
to	O
demonstrate	O
that	O
Prss56	O
mutations	O
leading	O
to	O
reduced	O
ocular	O
size	O
and	O
hyperopia	S-Phenotype
act	O
via	O
a	O
loss	O
of	O
function	O
mechanism	O
.	O

Germline	O
and	O
somatic	O
RIT1	O
mutations	O
have	O
been	O
identified	O
in	O
Noonan	O
syndrome	O
(	O
NS	O
)	O
and	O
cancer	S-Phenotype
,	O
respectively	O
.	O

A	O
combination	O
of	O
both	O
EGFP	O
-	O
EGF1	O
modification	O
and	O
PDT	O
provided	O
a	O
positive	O
feed	O
-	O
back	O
target	O
effect	O
to	O
tumor	S-Phenotype
vessels	O
and	O
might	O
have	O
a	O
great	O
potential	O
for	O
tumor	S-Phenotype
therapy	O

In	O
terms	O
of	O
prognostic	O
features	O
,	O
a	O
survival	O
analysis	O
revealed	O
that	O
the	O
high	O
GBE1	O
and	O
HK2	O
expression	O
group	O
exhibited	O
poorer	O
survival	O
in	O
lung	B-Phenotype
adenocarcinoma	E-Phenotype
patients	O
.	O

Here	O
we	O
report	O
three	O
families	O
with	O
homozygous	O
truncating	O
mutations	O
in	O
TBC1D23	O
who	O
display	O
moderate	O
to	O
severe	O
intellectual	B-Phenotype
disability	E-Phenotype
and	O
microcephaly	S-Phenotype
.	O

This	O
mouse	O
model	O
might	O
mimic	O
and	O
explain	O
the	O
pathogenesis	O
of	O
hepatosteatosis	O
occurring	O
in	O
two	O
typical	O
disorders	O
of	O
adipose	B-Phenotype
tissue	I-Phenotype
dysfunction	E-Phenotype
,	O
obesity	S-Phenotype
and	O
lipodystrophy	S-Phenotype
,	O
particularly	O
in	O
lipodystrophic	O
patients	O
with	O
Plin1	O
mutation	O

In	O
this	O
report	O
we	O
describe	O
a	O
female	O
child	O
with	O
global	B-Phenotype
developmental	I-Phenotype
delay	E-Phenotype
,	O
microcephaly	S-Phenotype
and	O
myoclonic	B-Phenotype
seizures	E-Phenotype
harbouring	O
a	O
5	O
Mb	O
deletion	O
in	O
14q12	O
locus	O
resulting	O
in	O
deletion	O
of	O
single	O
copy	O
of	O
brain	O
specific	O
genes	O
FOXG1	O
,	O
PRKD1	O
and	O
NOVA1	O
.	O

The	O
linear	O
ubiquitination	O
-	O
specific	O
deubiquitinase	O
ovarian	B-Phenotype
tumor	E-Phenotype
domain	O
deubiquitinase	O
with	O
linear	O
linkage	O
specificity	O
(	O
OTULIN	O
)	O
can	O
control	O
the	O
immune	O
signaling	O
transduction	O
pathway	O
by	O
restricting	O
the	O
Met1	O
-	O
linked	O
ubiquitination	O
process	O
.	O

In	O
addition	O
,	O
we	O
demonstrated	O
that	O
XIAP	O
-	O
enhanced	O
tumor	S-Phenotype
growth	O
is	O
dependent	O
on	O
depletion	O
of	O
p62	O
in	O
vivo	O
.	O

Global	O
liMpdz	O
/	O
i	O
gene	O
deletion	O
or	O
conditional	O
inactivation	O
in	O
Nestin	O
-	O
positive	O
cells	O
led	O
to	O
formation	O
of	O
supratentorial	B-Phenotype
hydrocephalus	E-Phenotype
in	O
the	O
early	O
postnatal	O
period	O
.	O

She	O
showed	O
an	O
axonal	B-Phenotype
sensory	I-Phenotype
-	I-Phenotype
motor	I-Phenotype
polyneuropathy	E-Phenotype
like	O
Charcot	B-Phenotype
-	I-Phenotype
Marie	I-Phenotype
-	I-Phenotype
Tooth	I-Phenotype
disease	E-Phenotype
(	O
CMT	S-Phenotype
)	O
,	O
myopathy	S-Phenotype
,	O
rigid	B-Phenotype
spine	E-Phenotype
and	O
respiratory	B-Phenotype
dysfunction	E-Phenotype
;	O
however	O
,	O
she	O
did	O
not	O
show	O
any	O
cardiomyopathy	S-Phenotype
,	O
which	O
is	O
a	O
common	O
symptom	O
in	O
BAG3	O
mutation	O
.	O

Here	O
,	O
we	O
identify	O
new	O
patients	O
with	O
dextrocardia	S-Phenotype
who	O
have	O
mutations	O
in	O
CFAP53	O
,	O
a	O
coiled	O
-	O
coil	O
domain	O
containing	O
protein	O
.	O

OTOF	O
gene	O
mutations	O
exert	O
a	O
significant	O
role	O
in	O
auditory	B-Phenotype
neuropathy	E-Phenotype
.	O

The	O
expression	O
levels	O
of	O
NRAS	O
in	O
human	O
clinical	O
specimens	O
were	O
higher	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
tissues	O
when	O
compared	O
to	O
normal	O
tissues	O
.	O

In	O
the	O
present	O
article	O
,	O
we	O
review	O
current	O
evidence	O
supporting	O
the	O
role	O
of	O
SPL	O
in	O
thymic	B-Phenotype
egress	E-Phenotype
,	O
inflammation	S-Phenotype
,	O
and	O
cancer	S-Phenotype
.	O

Strong	O
diffuse	O
nuclear	O
BCOR	O
staining	O
(	O
defined	O
as	O
AAAA95	O
%	O
of	O
tumor	S-Phenotype
cells	O
)	O
was	O
seen	O
in	O
the	O
round	O
cell	O
component	O
of	O
all	O
20	O
(	O
100	O
%	O
)	O
classic	O
YWHAE	O
-	O
NUTM2	O
high	B-Phenotype
-	I-Phenotype
grade	I-Phenotype
endometrial	I-Phenotype
stromal	I-Phenotype
sarcomas	E-Phenotype
and	O
the	O
3	O
unusual	O
high	B-Phenotype
-	I-Phenotype
grade	I-Phenotype
endometrial	I-Phenotype
stromal	I-Phenotype
sarcomas	E-Phenotype
which	O
prompted	O
FISH	O
studies	O
confirming	O
YWHAE	O
rearrangement	O
in	O
2	O
tumors	S-Phenotype
.	O

We	O
investigated	O
the	O
possible	O
association	O
between	O
chemoresistance	O
and	O
cellular	O
redox	O
state	O
regulation	O
in	O
patients	O
undergoing	O
neoadjuvant	O
chemotherapy	O
(	O
NACT	O
)	O
for	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

Prostate	B-Phenotype
cancer	E-Phenotype
(	O
PCa	S-Phenotype
)	O
is	O
the	O
most	O
common	O
cancer	S-Phenotype
among	O
men	O
.	O

Down	O
-	O
regulation	O
of	O
PLZF	O
has	O
been	O
found	O
in	O
various	O
tumor	S-Phenotype
cell	O
lines	O
.	O

Furthermore	O
,	O
SCAR	S-Phenotype
markers	O
BC10	O
-	O
1	O
and	O
BC13	O
-	O
4	O
might	O
be	O
useful	O
diagnostic	O
markers	O
for	O
breast	B-Phenotype
cancer	E-Phenotype
carcinomas	S-Phenotype

She	O
presented	O
with	O
mild	O
abdominal	B-Phenotype
distension	E-Phenotype
and	O
laboratory	O
findings	O
revealed	O
thrombocytopenia	S-Phenotype
and	O
abnormal	B-Phenotype
coagulation	E-Phenotype
,	O
indicating	O
disseminated	B-Phenotype
intravascular	I-Phenotype
coagulation	E-Phenotype
(	O
DIC	S-Phenotype
)	O
.	O

Taken	O
together	O
,	O
we	O
show	O
here	O
that	O
mutations	O
leading	O
either	O
to	O
BCL11B	O
haploinsufficiency	O
or	O
to	O
a	O
truncated	O
BCL11B	O
protein	O
clinically	O
cause	O
a	O
non	B-Phenotype
-	I-Phenotype
syndromic	I-Phenotype
neurodevelopmental	I-Phenotype
delay	E-Phenotype
.	O

By	O
contrast	O
,	O
the	O
higher	O
number	O
of	O
genetic	O
abnormalities	O
required	O
for	O
tumor	S-Phenotype
initiation	O
and	O
maintenance	O
in	O
SDHB	O
PPGL	O
result	O
in	O
a	O
lower	O
penetrance	O
of	O
PGL	O
,	O
but	O
when	O
cells	O
give	O
rise	O
to	O
metastases	O
they	O
are	O
assumed	O
to	O
be	O
better	O
adapted	O
to	O
sustain	O
survival	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
determine	O
the	O
role	O
of	O
serum	O
CK18	O
,	O
MMP	O
-	O
9	O
,	O
and	O
TIMP1	O
levels	O
in	O
predicting	O
R0	O
resection	O
in	O
patients	O
with	O
gastric	B-Phenotype
cancer	E-Phenotype
.	O

Elucidating	O
the	O
exact	O
relationship	O
between	O
these	O
two	O
enzymes	O
when	O
they	O
methylate	O
two	O
distinct	O
sites	O
of	O
the	O
same	O
substrate	O
may	O
aid	O
in	O
developing	O
therapeutics	O
aimed	O
at	O
reducing	O
PRMT5	O
/	O
7	O
activity	O
in	O
cancer	S-Phenotype
and	O
other	O
diseases	O

Overall	O
,	O
16	O
(	O
1	O
%	O
)	O
of	O
1,579	O
pancreatic	B-Phenotype
cancer	E-Phenotype
cases	O
had	O
an	O
ER	O
stress	O
-	O
inducing	O
CPA1	O
or	O
CPB1	O
variant	O
,	O
compared	O
with	O
1	O
of	O
2,068	O
controls	O
(	O
P	O
AAAA	O
0.00001	O
)	O
.	O

Knock	O
-	O
in	O
of	O
nonphosphorylatable	O
PRPS1	O
/	O
2	O
mutants	O
,	O
which	O
have	O
uninhibited	O
activity	O
,	O
in	O
brain	B-Phenotype
tumor	E-Phenotype
cells	O
under	O
energy	O
stress	O
exhausts	O
cellular	O
ATP	O
and	O
NADPH	O
and	O
increases	O
reactive	O
oxygen	O
species	O
levels	O
,	O
thereby	O
promoting	O
cell	O
apoptosis	O
.	O

Bardet	O
-	O
Biedl	O
syndrome	O
(	O
BBS	O
)	O
is	O
a	O
rare	O
ciliopathy	O
disorder	O
that	O
is	O
clinically	O
and	O
genetically	O
heterogeneous	S-Phenotype
with	O
18	O
known	O
genes	O
.	O

Consequently	O
,	O
DOX	O
-	O
ST	O
-	O
NPs	O
exhibited	O
higher	O
toxicity	O
to	O
Trop2	O
-	O
positive	O
MDA	O
-	O
MB	O
-	O
231	O
cancer	S-Phenotype
cells	O
,	O
compared	O
to	O
DOX	O
-	O
loaded	O
control	O
nanoparticles	O
without	O
the	O
disulfide	O
bond	O
or	O
anti	O
-	O
Trop2	O
antibody	O
.	O

Alterations	O
in	O
FOXC1	O
levels	O
cause	O
ocular	O
malformations	O
and	O
disrupt	O
stress	O
response	O
in	O
ocular	O
tissues	O
,	O
thereby	O
contributing	O
to	O
glaucoma	S-Phenotype
progression	O
.	O

We	O
aimed	O
to	O
test	O
effects	O
of	O
such	O
gCNVs	O
on	O
the	O
risk	O
of	O
lung	B-Phenotype
cancer	E-Phenotype
and	O
chronic	B-Phenotype
obstructive	I-Phenotype
pulmonary	I-Phenotype
disease	E-Phenotype
(	O
COPD	S-Phenotype
)	O
.	O

Although	O
there	O
are	O
nearly	O
100	O
different	O
causative	O
genes	O
identified	O
for	O
nonsyndromic	B-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
(	O
NSHL	S-Phenotype
)	O
,	O
Sanger	O
sequencing	O
-	O
based	O
DNA	O
diagnostics	O
usually	O
only	O
analyses	O
three	O
,	O
namely	O
,	O
GJB2	O
,	O
SLC26A4	O
,	O
and	O
OTOF	O
.	O

Conversely	O
,	O
expression	O
of	O
the	O
putative	O
histidine	O
phosphatase	O
LHPP	O
was	O
downregulated	O
specifically	O
in	O
the	O
tumours	S-Phenotype
.	O

Further	O
inference	O
was	O
found	O
in	O
the	O
tumor	S-Phenotype
suppression	O
gene	O
,	O
p53	O
,	O
with	O
a	O
new	O
hypothesis	O
of	O
including	O
the	O
bovine	O
PKM2	O
pathways	O
for	O
targeting	O
the	O
glycolysis	O
preference	O
in	O
many	O
types	O
of	O
cancerous	O
cells	O
,	O
consistent	O
with	O
quantum	O
metabolism	O
models	O
.	O

Gain	O
-	O
of	O
-	O
function	O
mutations	O
in	O
iRHOM2	O
underlie	O
Tylosis	B-Phenotype
with	I-Phenotype
oesophageal	I-Phenotype
cancer	E-Phenotype
(	O
TOC	S-Phenotype
)	O
,	O
characterized	O
by	O
palmoplantar	B-Phenotype
thickening	E-Phenotype
,	O
upregulate	O
K16	O
with	O
robust	O
downregulation	O
of	O
its	O
type	O
II	O
keratin	O
binding	O
partner	O
,	O
K6	O
.	O

The	O
tumor	S-Phenotype
suppressor	O
characteristics	O
of	O
cyclin	O
-	O
dependent	O
kinase	O
10	O
(	O
CDK10	O
)	O
in	O
nasopharyngeal	B-Phenotype
carcinoma	E-Phenotype
and	O
breast	B-Phenotype
cancer	E-Phenotype
have	O
been	O
previously	O
demonstrated	O
.	O

This	O
study	O
reports	O
first	O
case	O
of	O
variants	O
in	O
the	O
genes	O
causing	O
EvC	O
syndrome	O
and	O
profound	B-Phenotype
deafness	E-Phenotype
in	O
the	O
same	O
family	O

Humanization	O
of	O
SCID	O
pigs	O
would	O
thus	O
provide	O
a	O
valuable	O
model	O
system	O
for	O
researchers	O
to	O
study	O
interactions	O
between	O
human	O
tumor	S-Phenotype
and	O
human	O
immune	O
cells	O
.	O

Based	O
upon	O
the	O
development	O
-	O
dependent	O
onsets	O
of	O
these	O
psychotomimetic	O
effects	O
,	O
by	O
using	O
a	O
DNA	O
microarray	O
technique	O
,	O
we	O
identified	O
the	O
WD	O
repeat	O
domain	O
3	O
(	O
WDR3	O
)	O
and	O
chitobiosyldiphosphodolichol	O
beta	O
-	O
mannosyltransferase	O
(	O
ALG1	O
)	O
genes	O
as	O
novel	O
candidates	O
for	O
schizophrenia	S-Phenotype
-	O
related	O
molecules	O
,	O
whose	O
mRNAs	O
were	O
up	O
-	O
regulated	O
in	O
the	O
adult	O
(	O
postnatal	O
week	O
seven	O
)	O
,	O
but	O
not	O
in	O
the	O
infant	O
(	O
postnatal	O
week	O
one	O
)	O
rats	O
by	O
an	O
indirect	O
dopamine	O
agonist	O
,	O
and	O
phencyclidine	O
,	O
an	O
antagonist	O
of	O
the	O
NMDA	O
receptor	O
.	O

Here	O
,	O
we	O
report	O
two	O
affected	O
siblings	O
with	O
compound	O
heterozygous	O
truncating	O
mutations	O
in	O
BRAT1	O
and	O
intra	O
-	O
familial	O
phenotypic	O
heterogeneity	S-Phenotype
,	O
with	O
a	O
less	O
severe	O
disease	O
course	O
in	O
the	O
female	O
sibling	O
.	O

Our	O
study	O
identifies	O
urine	O
D2HG	O
and	O
tissue	O
D2HGDH	O
expression	O
as	O
biomarkers	O
to	O
identify	O
patients	O
at	O
risk	O
for	O
progressing	O
from	O
colitis	S-Phenotype
to	O
cancer	S-Phenotype
.	O

Taken	O
together	O
,	O
our	O
study	O
provides	O
the	O
first	O
functional	O
link	O
between	O
GNB3	O
and	O
obesity	S-Phenotype
,	O
and	O
presents	O
insight	O
into	O
novel	O
pathways	O
that	O
could	O
be	O
applied	O
to	O
combat	O
obesity	S-Phenotype
and	O
type	B-Phenotype
2	I-Phenotype
diabetes	E-Phenotype

Mutations	O
in	O
UBQLN2	O
have	O
been	O
associated	O
with	O
rare	O
cases	O
of	O
X	O
-	O
linked	O
juvenile	O
and	O
adult	O
forms	O
of	O
amyotrophic	B-Phenotype
lateral	I-Phenotype
sclerosis	E-Phenotype
(	O
ALS	S-Phenotype
)	O
and	O
ALS	S-Phenotype
linked	O
to	O
frontotemporal	B-Phenotype
dementia	E-Phenotype
(	O
FTD	S-Phenotype
)	O
.	O

Using	O
whole	O
-	O
exome	O
sequencing	O
,	O
we	O
identified	O
compound	O
heterozygous	O
RMND1	O
variants	O
in	O
a	O
4	O
-	O
year	O
-	O
old	O
patient	O
with	O
congenital	B-Phenotype
lactic	I-Phenotype
acidosis	E-Phenotype
,	O
severe	O
myopathy	S-Phenotype
,	O
hearing	B-Phenotype
loss	E-Phenotype
,	O
renal	B-Phenotype
failure	E-Phenotype
,	O
and	O
dysautonomia	S-Phenotype
.	O

To	O
this	O
end	O
,	O
we	O
generated	O
a	O
set	O
of	O
melanoma	S-Phenotype
and	O
neuroblastoma	S-Phenotype
cell	O
lines	O
stably	O
overexpressing	O
wild	O
-	O
type	O
(	O
WT	O
)	O
,	O
catalytically	O
inactive	O
(	O
D508N	O
)	O
and	O
N	O
-	O
terminal	O
mutants	O
,	O
or	O
shRNA	O
against	O
ATP13A2	O
.	O

DLEC1	O
was	O
decreased	O
in	O
more	O
aggressive	O
subtypes	O
:	O
large	O
cell	O
carcinoma	S-Phenotype
and	O
adenocarcinoma	B-Phenotype
-	I-Phenotype
squamous	I-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
.	O

To	O
date	O
variants	O
in	O
four	O
genes	O
GLI3	O
,	O
ZNF141	O
,	O
MIPOL1	O
and	O
PITX1	O
have	O
been	O
implicated	O
in	O
developing	O
non	O
-	O
syndromic	O
form	O
of	O
polydactyly	S-Phenotype
.	O

Because	O
of	O
technical	O
limitations	O
,	O
this	O
model	O
of	O
UHRF1	O
-	O
dependent	O
DNA	O
methylation	O
inheritance	O
has	O
been	O
constructed	O
largely	O
based	O
on	O
genetics	O
and	O
biochemical	O
observations	O
querying	O
methylated	O
DNA	O
oligonucleotides	O
,	O
synthetic	O
histone	O
peptides	O
,	O
and	O
heterogeneous	S-Phenotype
chromatin	O
extracted	O
from	O
cells	O
.	O

In	O
Japan	O
,	O
26	O
mutations	O
in	O
the	O
ATP2A2	O
gene	O
in	O
7	O
pedigrees	O
and	O
19	O
sporadic	S-Phenotype
cases	O
with	O
DD	O
have	O
been	O
reported	O
,	O
among	O
which	O
one	O
pedigree	O
and	O
one	O
sporadic	O
case	O
were	O
accompanied	O
by	O
neuropsychiatric	O
symptoms	O
.	O

Targeted	O
resequencing	O
was	O
used	O
to	O
screen	O
460	O
unselected	O
epilepsy	S-Phenotype
patients	O
for	O
variants	O
in	O
SLC6A1	O
.	O

The	O
phenotypic	O
spectrum	O
related	O
to	O
PEX10	O
mutations	O
includes	O
slowly	O
progressive	O
,	O
syndromic	O
recessive	O
ataxia	S-Phenotype
.	O

Amyotrophic	B-Phenotype
lateral	I-Phenotype
sclerosis	E-Phenotype
(	O
ALS	S-Phenotype
)	O
is	O
a	O
neurodegenerative	B-Phenotype
disease	E-Phenotype
with	O
strong	O
genetic	O
components	O
.	O

Importantly	O
,	O
the	O
role	O
of	O
CtBP1	O
overexpression	O
in	O
adult	O
tissues	O
in	O
promoting	O
the	O
progression	O
of	O
multiple	O
cancer	S-Phenotype
types	O
through	O
their	O
ability	O
to	O
modulate	O
the	O
transcription	O
of	O
developmental	O
genes	O
ectopically	O
is	O
explored	O
.	O

Mutant	O
mice	O
for	O
Hoxb1	O
were	O
reported	O
to	O
present	O
with	O
facial	B-Phenotype
weakness	E-Phenotype
,	O
resembling	O
MBS	O
.	O

Preclinical	O
studies	O
have	O
demonstrated	O
that	O
EMP2	O
is	O
associated	O
with	O
disease	O
prognosis	O
in	O
a	O
number	O
of	O
human	O
cancers	S-Phenotype
,	O
including	O
glioblastoma	S-Phenotype
.	O

In	O
our	O
present	O
study	O
,	O
β	O
-	O
elemene	O
prevented	O
gastric	B-Phenotype
cancer	E-Phenotype
cell	O
viability	O
in	O
dose	O
-	O
dependent	O
manner	O
,	O
and	O
when	O
combined	O
with	O
TRAIL	O
,	O
obviously	O
inhibited	O
proliferation	O
and	O
promoted	O
apoptosis	O
in	O
gastric	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

The	O
oncogenic	O
potential	O
of	O
ASS1	O
in	O
terms	O
of	O
prognosis	O
and	O
cancer	S-Phenotype
metastasis	O
in	O
arginine	B-Phenotype
prototrophic	I-Phenotype
gastric	I-Phenotype
cancer	E-Phenotype
(	O
GC	S-Phenotype
)	O
remains	O
unclear	O
at	O
present	O
.	O

ABHD12	O
mutations	O
have	O
been	O
linked	O
to	O
neurodegenerative	O
PHARC	O
(	O
polyneuropathy	S-Phenotype
,	O
hearing	B-Phenotype
loss	E-Phenotype
,	O
ataxia	S-Phenotype
,	O
retinitis	S-Phenotype
pigmentosa	O
,	O
and	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
cataract	E-Phenotype
)	O
,	O
a	O
rare	O
,	O
progressive	O
,	O
autosomal	O
,	O
recessive	O
disease	O
.	O

Among	O
all	O
lung	B-Phenotype
adenocarcinomas	E-Phenotype
,	O
the	O
most	O
prevalent	O
subset	O
develops	O
via	O
tumorigenesis	S-Phenotype
and	O
progression	O
from	O
atypical	B-Phenotype
adenomatous	I-Phenotype
hyperplasia	E-Phenotype
(	O
AAH	S-Phenotype
)	O
to	O
adenocarcinoma	B-Phenotype
in	I-Phenotype
situ	E-Phenotype
(	O
AIS	S-Phenotype
)	O
,	O
to	O
minimally	B-Phenotype
invasive	I-Phenotype
adenocarcinoma	E-Phenotype
(	O
MIA	S-Phenotype
)	O
,	O
to	O
overt	B-Phenotype
invasive	I-Phenotype
adenocarcinoma	I-Phenotype
with	I-Phenotype
a	I-Phenotype
lepidic	I-Phenotype
pattern	E-Phenotype
.	O

Moreover	O
,	O
in	O
patients	O
with	O
low	O
MRPL13	O
expression	O
,	O
two	O
oxidative	O
metabolic	O
indicators	O
,	O
pyruvate	O
dehydrogenase	O
B	O
expression	O
and	O
the	O
ratio	O
of	O
lactate	O
dehydrogenase	O
type	O
B	O
to	O
type	O
A	O
,	O
significantly	O
and	O
negatively	O
correlated	O
with	O
CLN1	O
expression	O
,	O
indicating	O
that	O
the	O
combination	O
of	O
elevated	O
glycolysis	O
and	O
deficient	O
MRPL13	O
activity	O
was	O
closely	O
linked	O
to	O
CLN1	O
-	O
mediated	O
tumor	S-Phenotype
activity	O
in	O
LIHC	O
.	O

Induction	O
of	O
p53	O
by	O
5	O
-	O
Aza	O
-	O
dC	O
was	O
tested	O
in	O
vitro	O
using	O
cancer	S-Phenotype
cells	O
.	O

Here	O
,	O
we	O
sought	O
to	O
find	O
lncRNAs	O
differentially	O
regulated	O
in	O
cancer	S-Phenotype
cells	O
resistant	O
to	O
either	O
TNF	O
-	O
related	O
apoptosis	O
-	O
inducing	O
ligand	O
(	O
TRAIL	O
)	O
or	O
the	O
Mcl	O
-	O
1	O
inhibitor	O
UMI	O
-	O
77	O
,	O
agents	O
that	O
act	O
through	O
the	O
extrinsic	O
and	O
intrinsic	O
apoptotic	O
pathways	O
,	O
respectively	O
.	O

A	O
novel	O
hereditary	O
disorder	O
encompassing	O
high	O
blood	O
Mn	O
levels	O
,	O
dystonia	S-Phenotype
,	O
polycythemia	S-Phenotype
,	O
distinctive	O
T1	O
hyperintense	O
signals	O
in	O
the	O
basal	O
ganglia	O
on	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
brain	B-Phenotype
,	I-Phenotype
and	I-Phenotype
chronic	I-Phenotype
liver	I-Phenotype
disease	E-Phenotype
was	O
recently	O
described	O
.	O

RESULTS	O
A	O
nonsynonymous	O
mutation	O
at	O
ovine	O
Chr3:193,691,195	O
,	O
which	O
generated	O
a	O
glycine	O
-	O
to	O
-	O
arginine	O
amino	O
acid	O
change	O
within	O
the	O
predicted	O
Slco1b3	O
protein	O
,	O
was	O
significantly	O
associated	O
with	O
hyperbilirubinemia	S-Phenotype
and	O
predicted	O
to	O
be	O
deleterious	O
.	O

A	O
decreased	O
CMG2	O
expression	O
is	O
a	O
negative	O
prognostic	O
factor	O
for	O
soft	B-Phenotype
tissue	I-Phenotype
sarcoma	E-Phenotype
patients	O
.	O

Although	O
the	O
role	O
of	O
USP18	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
has	O
been	O
elucidated	O
,	O
the	O
underlying	O
mechanisms	O
and	O
clinical	O
role	O
of	O
USP18	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
are	O
currently	O
not	O
well	O
understood	O
.	O

Mutations	O
in	O
genes	O
involved	O
in	O
the	O
biosynthesis	O
of	O
the	O
glycosylphosphatidylinositol	O
(	O
GPI	O
)	O
anchor	O
cause	O
autosomal	B-Phenotype
recessive	I-Phenotype
glycosylation	I-Phenotype
defects	E-Phenotype
,	O
with	O
a	B-Phenotype
wide	I-Phenotype
phenotypic	I-Phenotype
spectrum	I-Phenotype
of	I-Phenotype
intellectual	I-Phenotype
disability	E-Phenotype
,	O
seizures	S-Phenotype
,	O
minor	O
facial	B-Phenotype
dysmorphism	E-Phenotype
,	O
hypotonia	S-Phenotype
,	O
and	O
elevated	O
serum	O
alkaline	O
phosphatase	O
.	O

In	O
an	O
in	O
vitro	O
experiment	O
,	O
FEZF1	O
can	O
promote	O
the	O
proliferation	O
,	O
migration	O
,	O
and	O
invasion	O
of	O
glioma	S-Phenotype
cells	O
and	O
inhibit	O
cell	O
apoptosis	O
by	O
activating	O
Akt	O
-	O
ERK	O
pathway	O
.	O

In	O
this	O
sense	O
,	O
evidence	O
from	O
both	O
clinical	O
and	O
experimental	O
studies	O
indicates	O
that	O
EPO	O
may	O
reverse	O
diabetic	B-Phenotype
neuropathy	E-Phenotype
through	O
an	O
antioxidant	O
action	O
by	O
decreasing	O
pro	O
-	O
inflammatory	O
cytokines	O
,	O
restoring	O
Na+	O
/	O
K+	O
-	O
ATPase	O
activity	O
,	O
and	O
blocking	O
the	O
generation	O
of	O
pro	O
-	O
apoptotic	O
proteins	O
.	O

CD164	O
was	O
co	O
-	O
expressed	O
with	O
KIR3DL2	O
on	O
circulating	O
CD4sup+	O
/	O
sup	O
T	O
cells	O
from	O
high	O
tumor	S-Phenotype
burden	O
SS	O
patients	O
,	O
further	O
providing	O
strong	O
support	O
for	O
CD164	O
as	O
a	O
disease	O
relevant	O
surface	O
biomarker	O

A	O
patient	O
myoblast	O
line	O
showed	O
a	O
severe	O
reduction	O
in	O
complex	O
I	O
,	O
associated	O
with	O
the	O
accumulation	O
of	O
subassemblies	O
centered	O
around	O
a340	O
kDa	O
,	O
and	O
a	O
milder	O
decrease	O
in	O
complex	O
II	O
,	O
all	O
of	O
which	O
were	O
rescued	O
by	O
retroviral	O
expression	O
of	O
wild	O
-	O
type	O
FOXRED1	O
.	O

Furthermore	O
,	O
the	O
xenograft	O
study	O
confirmed	O
the	O
tumor	S-Phenotype
proliferation	O
-	O
promoting	O
role	O
of	O
SPRY4	O
-	O
IT1	O
in	O
PANC1	O
cells	O
.	O

We	O
summarize	O
genetic	O
,	O
clinical	O
and	O
neuropathological	O
findings	O
related	O
to	O
the	O
27	O
genes	O
reported	O
in	O
the	O
literature	O
since	O
1997	O
,	O
associated	O
either	O
with	O
autosomal	O
dominant	O
(	O
AD	O
)	O
:	O
LRRK2	O
,	O
SNCA	O
,	O
VPS35	O
,	O
GCH1	O
,	O
ATXN2	O
,	O
DNAJC13	O
,	O
TMEM230	O
,	O
GIGYF2	O
,	O
HTRA2	O
,	O
RIC3	O
,	O
EIF4G1	O
,	O
UCHL1	O
,	O
CHCHD2	O
,	O
and	O
GBA	O
;	O
or	O
autosomal	B-Phenotype
recessive	E-Phenotype
(	O
AR	O
)	O
inheritance	O
:	O
PRKN	O
,	O
PINK1	O
,	O
DJ1	O
,	O
ATP13A2	O
,	O
PLA2G6	O
,	O
FBXO7	O
,	O
DNAJC6	O
,	O
SYNJ1	O
,	O
SPG11	O
,	O
VPS13C	O
,	O
PODXL	O
,	O
and	O
PTRHD1	O
;	O
or	O
an	O
X	O
-	O
linked	O
transmission	O
:	O
RAB39B	O
.	O

Further	O
validation	O
in	O
cohorts	O
with	O
severe	O
obesity	S-Phenotype
and	O
engineering	O
the	O
variants	O
in	O
model	O
organisms	O
will	O
be	O
needed	O
to	O
explore	O
whether	O
human	O
variants	O
in	O
ANGPTL6	O
and	O
other	O
genes	O
that	O
lead	O
to	O
obesity	S-Phenotype
when	O
deleted	O
in	O
mice	O
,	O
do	O
contribute	O
to	O
obesity	S-Phenotype
.	O

Fragile	O
X	O
syndrome	O
(	O
FXS	O
)	O
,	O
the	O
leading	O
cause	O
of	O
inherited	O
forms	O
of	O
mental	B-Phenotype
retardation	E-Phenotype
and	O
autism	S-Phenotype
,	O
is	O
caused	O
by	O
the	O
transcriptional	O
silencing	O
of	O
fmr1	O
encoding	O
the	O
fragile	O
X	O
mental	B-Phenotype
retardation	E-Phenotype
protein	O
(	O
FMRP	O
)	O
.	O

All	O
DAKO	O
mice	O
developed	O
liposarcoma	S-Phenotype
between	O
11	O
and	O
14	O
months	O
of	O
age	O
.	O

Furthermore	O
,	O
we	O
investigated	O
whether	O
there	O
is	O
an	O
association	O
between	O
the	O
mRNA	O
and	O
protein	O
expression	O
levels	O
of	O
RBCK1	O
,	O
RNF31	O
and	O
SHARPIN	O
and	O
clinicopathological	O
parameters	O
including	O
estrogen	O
receptor	O
(	O
ER	O
)	O
,	O
progesterone	O
receptor	O
(	O
PR	O
)	O
and	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
HER2	O
)	O
status	O
and	O
found	O
that	O
RNF31	O
protein	O
is	O
significantly	O
higher	O
in	O
ERalpha	O
-	O
negative	O
tumors	S-Phenotype
than	O
ERalpha	O
-	O
positive	O
tumors	S-Phenotype
(	O
p	O
=	O
0.034	O
)	O
.	O

We	O
performed	O
a	O
quantitative	O
proteomics	O
study	O
of	O
EOC	O
patient	O
tumor	S-Phenotype
tissues	O
and	O
identified	O
changes	O
in	O
expression	O
of	O
several	O
key	O
regulators	O
of	O
actin	O
cytoskeleton	O
/	O
cell	O
adhesion	O
and	O
cell	O
migration	O
(	O
CAPN1	O
,	O
14	O
-	O
3	O
-	O
3	O
,	O
CAPG	O
,	O
PFN1	O
,	O
SPTBN1	O
,	O
CFN1	O
)	O
associated	O
with	O
loss	O
of	O
BRCA1	O
function	O
.	O

The	O
tumor	S-Phenotype
-	O
node	O
-	O
metastasis	O
(	O
TNM	O
)	O
classification	O
,	O
the	O
presence	O
of	O
a	O
mucinous	O
component	O
,	O
and	O
signet	O
ring	O
cells	O
are	O
well	O
-	O
known	O
criteria	O
for	O
identifying	O
patients	O
at	O
a	O
high	O
risk	O
for	O
recurrence	O
and	O
determining	O
the	O
therapeutic	O
approach	O
for	O
early	B-Phenotype
-	I-Phenotype
stage	I-Phenotype
colon	I-Phenotype
cancer	E-Phenotype
(	O
eCC	S-Phenotype
)	O
.	O

Idiopathic	B-Phenotype
pulmonary	I-Phenotype
fibrosis	E-Phenotype
(	O
IPF	S-Phenotype
)	O
is	O
a	O
complex	O
,	O
heterogeneous	S-Phenotype
genetic	O
disorder	O
that	O
is	O
associated	O
with	O
rare	O
and	O
common	O
sequence	O
variants	O
in	O
many	O
genes	O
(	O
MUC5B	O
,	O
SFTPC	O
,	O
SFTPA2	O
,	O
RTEL1	O
,	O
TERT	O
,	O
and	O
hTR	O
)	O
,	O
11	O
novel	O
loci	O
,	O
and	O
multiple	O
emerging	O
epigenetic	O
and	O
transcriptional	O
profiles	O
.	O

Dystonia	B-Phenotype
-	I-Phenotype
4	E-Phenotype
(	O
DYT4	S-Phenotype
)	O
is	O
another	O
autosomal	O
dominant	O
dystonia	S-Phenotype
that	O
is	O
characterized	O
by	O
onset	B-Phenotype
in	I-Phenotype
the	I-Phenotype
second	I-Phenotype
to	I-Phenotype
third	I-Phenotype
decade	I-Phenotype
of	I-Phenotype
progressive	I-Phenotype
laryngeal	I-Phenotype
dysphonia	E-Phenotype
.	O

p.Asn381Ser	O
also	O
disrupts	O
dimerization	O
of	O
NARS2	O
,	O
while	O
the	O
hearing	B-Phenotype
loss	E-Phenotype
p.Val213Phe	O
variant	O
has	O
no	O
effect	O
on	O
NARS2	O
oligomerization	O
.	O

Reduced	O
representation	O
bisulfite	O
sequencing	O
(	O
RRBS	O
)	O
and	O
gene	O
expression	O
microarrays	O
were	O
performed	O
in	O
the	O
HCC	B-Phenotype
tumor	E-Phenotype
and	O
non	O
-	O
HCC	S-Phenotype
liver	O
tissues	O
to	O
investigate	O
the	O
molecular	O
mechanisms	O
of	O
COX	O
-	O
2	O
-	O
driven	O
HCC	S-Phenotype
.	O

We	O
observed	O
the	O
presence	O
of	O
the	O
mutation	O
at	O
pH1047R	O
of	O
liPIK3CA	O
/	O
i	O
gene	O
in	O
five	O
samples	O
of	O
the	O
tumour	S-Phenotype
,	O
while	O
the	O
remaining	O
15	O
samples	O
did	O
not	O
show	O
any	O
mutation	O
at	O
liPIK3CA	O
/	O
i	O
or	O
any	O
other	O
investigated	O
gene	O
.	O

Recessive	O
variants	O
located	O
in	O
the	O
ligand	O
-	O
binding	O
domain	O
(	O
LBD	O
)	O
of	O
NR2E3	O
cause	O
enhanced	O
short	O
wavelength	O
sensitive	O
-	O
(	O
S	O
-	O
)	O
cone	O
syndrome	O
(	O
ESCS	O
)	O
,	O
a	O
retinal	B-Phenotype
degeneration	E-Phenotype
characterized	O
by	O
an	O
excess	O
of	O
S	O
-	O
cones	O
and	O
non	O
-	O
functional	O
rods	O
.	O

Interestingly	O
,	O
MYST3	O
depletion	O
drastically	O
inhibited	O
proliferation	O
in	O
MYST3	O
-	O
high	O
,	O
ER+	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
,	O
but	O
not	O
in	O
benign	O
breast	O
epithelial	O
cells	O
or	O
in	O
MYST3	O
-	O
low	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

The	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
is	O
a	O
known	O
factor	O
in	O
tumor	S-Phenotype
invasion	O
,	O
and	O
differences	O
in	O
the	O
ECM	O
of	O
nontumor	O
brain	O
and	O
glioblastoma	S-Phenotype
has	O
been	O
proven	O
.	O

Twenty	O
-	O
two	O
previously	O
identified	O
pancreatic	B-Phenotype
cancer	E-Phenotype
risk	O
genes	O
and	O
337	O
germline	O
variants	O
were	O
identified	O
from	O
97	O
informative	O
studies	O
that	O
met	O
our	O
inclusion	O
criteria	O
.	O

LCA	O
is	O
predominantly	O
inherited	O
as	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
trait	O
and	O
contributes	O
to	O
5	O
%	O
of	O
all	O
retinal	B-Phenotype
dystrophies	E-Phenotype
;	O
whereas	O
RP	O
is	O
inherited	O
by	O
all	O
the	O
Mendelian	O
pattern	O
of	O
inheritance	O
and	O
both	O
are	O
leading	O
causes	O
of	O
visual	B-Phenotype
impairment	E-Phenotype
in	O
children	O
and	O
young	O
adults	O
.	O

In	O
addition	O
,	O
FGF23	O
suppresses	O
proximal	S-Phenotype
tubular	O
expression	O
of	O
1α	O
-	O
hydroxylase	O
,	O
the	O
key	O
enzyme	O
responsible	O
for	O
vitamin	O
D	O
hormone	O
production	O
.	O

Females	O
showed	O
associations	O
between	O
aromatase	O
levels	O
in	O
subcortical	O
regions	O
,	O
such	O
as	O
the	O
amygdala	O
and	O
supraoptic	O
nucleus	O
of	O
the	O
hypothalamus	O
,	O
and	O
personality	O
traits	O
such	O
as	O
aggression	S-Phenotype
,	O
novelty	O
seeking	O
,	O
and	O
self	O
-	O
transcendence	O
.	O

Recently	O
,	O
microdeletions	O
encompassing	O
liMIR137HG	O
/	O
i	O
,	O
the	O
host	O
gene	O
which	O
encodes	O
the	O
miRNA	O
miR	O
-	O
137	O
,	O
have	O
been	O
linked	O
to	O
autism	S-Phenotype
and	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
and	O
genome	O
wide	O
association	O
studies	O
have	O
linked	O
this	O
locus	O
to	O
schizophrenia	S-Phenotype
.	O

However	O
,	O
the	O
physiological	O
characters	O
and	O
potential	O
mechanisms	O
of	O
Fli	O
-	O
1	O
in	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
progression	O
remains	O
unclear	O
.	O

In	O
recent	O
years	O
,	O
high	O
-	O
throughput	O
sequencing	O
has	O
been	O
used	O
to	O
analyze	O
exomes	O
of	O
virtually	O
all	O
human	O
tumors	S-Phenotype
,	O
which	O
allowed	O
to	O
construct	O
phylogenetic	O
trees	O
of	O
clonal	B-Phenotype
cancer	E-Phenotype
evolution	O
with	O
special	O
emphasis	O
on	O
driver	O
mutations	O
in	O
FGFR1	O
-	O
4	O
genes	O
.	O

To	O
date	O
,	O
over	O
150	O
disease	O
-	O
associated	O
variants	O
in	O
CRB1	O
have	O
been	O
described	O
,	O
resulting	O
in	O
a	O
range	O
of	O
retinal	B-Phenotype
disease	E-Phenotype
phenotypes	O
including	O
Leber	O
congenital	B-Phenotype
amaurosis	E-Phenotype
and	O
retinitis	S-Phenotype
pigmentosa	O
.	O

BC	O
patients	O
in	O
the	O
FGF5	O
low	O
-	O
expression	O
group	O
were	O
correlated	O
with	O
better	O
clinical	O
characteristics	O
,	O
including	O
tumor	S-Phenotype
size	O
,	O
histopathological	O
grading	O
,	O
estrogen	O
receptors	O
,	O
clinical	O
risk	O
group	O
according	O
to	O
St	O
Gallen	O
criteria	O
,	O
NPI	O
criteria	O
and	O
Veridex	O
signature	O
,	O
DMFS	O
,	O
TDM	O
,	O
and	O
DFS	O
compared	O
with	O
those	O
in	O
the	O
FGF5	O
high	O
-	O
expression	O
cohort	O
.	O

We	O
show	O
that	O
tumour	S-Phenotype
cells	O
specifically	O
induce	O
Notch2	O
activity	O
in	O
mesenchymal	O
stromal	O
cells	O
(	O
MSCs	O
)	O
required	O
for	O
the	O
transcription	O
of	O
the	O
complement	O
factor	O
C1q	O
.	O

The	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
pathway	O
is	O
overactivated	O
in	O
thyroid	B-Phenotype
cancer	E-Phenotype
(	O
TC	S-Phenotype
)	O
.	O

Estrogens	O
and	O
estrogen	O
receptors	O
(	O
ERs	O
)	O
,	O
such	O
as	O
ERα	O
and	O
ERβ	O
,	O
prolactin	O
(	O
PRL	O
)	O
and	O
prolactin	O
receptor	O
(	O
PRLR	O
)	O
have	O
been	O
reported	O
to	O
be	O
involved	O
in	O
the	O
physiopathology	O
of	O
uterine	B-Phenotype
cervical	I-Phenotype
cancer	E-Phenotype
(	O
UCC	S-Phenotype
)	O
.	O

Five	O
genes	O
,	O
including	O
OTOGL	O
,	O
PLCB4	O
,	O
SCEL	O
,	O
THSD4	O
,	O
and	O
WWOX	O
,	O
have	O
CNVs	O
in	O
the	O
six	O
patients	O
with	O
sporadic	S-Phenotype
HBs	O
,	O
and	O
three	O
genes	O
,	O
including	O
ABCA6	O
,	O
CWC27	O
,	O
and	O
LAMA2	O
,	O
have	O
CNVs	O
in	O
the	O
five	O
patients	O
with	O
familial	O
HBs	O
.	O

Before	O
and	O
after	O
eight	O
weeks	O
daily	O
treatment	O
with	O
six	O
capsules	O
of	O
FAAAAAamp	O
;	O
V	O
juice	O
concentrate	O
or	O
placebo	O
,	O
peripheral	O
blood	O
gene	O
expression	O
(	O
microarray	O
,	O
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
qPCR	O
)	O
)	O
,	O
plasma	O
tumour	S-Phenotype
necrosis	O
factor	O
(	O
TNF	O
)	O
α	O
(	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
)	O
,	O
body	O
composition	O
(	O
Dual	O
-	O
energy	O
X	O
-	O
ray	O
absorptiometry	O
(	O
DEXA	O
)	O
)	O
and	O
lipid	O
profiles	O
were	O
assessed	O
.	O

Novel	O
targets	O
ANTXR1	O
and	O
RSPO2	O
were	O
confirmed	O
to	O
be	O
suppressed	O
by	O
miR	O
-	O
493	O
directly	O
,	O
and	O
overexpression	O
of	O
ANTXR1	O
and	O
RSPO2	O
could	O
restore	O
tumorigenesis	S-Phenotype
in	O
miR	O
-	O
493	O
treated	O
HCC	S-Phenotype
cell	O
.	O

Hyperphosphatasia	B-Phenotype
with	I-Phenotype
mental	I-Phenotype
retardation	I-Phenotype
syndrome	E-Phenotype
(	O
HPMRS	S-Phenotype
)	O
is	O
caused	O
by	O
mutations	O
in	O
PIGV	O
and	O
includes	O
hyperphosphatasia	S-Phenotype
as	O
a	O
diagnostic	O
hallmark	O
.	O

We	O
conclude	O
that	O
loss	O
of	O
oncogenic	O
miR	O
-	O
1274a	O
reduced	O
cancer	S-Phenotype
cell	O
proliferation	O
and	O
induced	O
apoptosis	O
in	O
ccRCC	O
through	O
targeting	O
BMPR1B	O
.	O

In	O
acute	B-Phenotype
leukemias	E-Phenotype
,	O
it	O
is	O
not	O
clear	O
whether	O
MSC	O
alterations	O
contribute	O
to	O
the	O
development	O
of	O
the	O
malignant	O
clone	O
or	O
whether	O
they	O
are	O
simply	O
the	O
effect	O
of	O
tumor	S-Phenotype
expansion	O
on	O
the	O
microenvironment	O
.	O

Finally	O
,	O
in	O
patients	O
with	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
,	O
low	O
expression	O
of	O
LHPP	O
correlated	O
with	O
increased	O
tumour	S-Phenotype
severity	O
and	O
reduced	O
overall	O
survival	O
.	O

Overall	O
,	O
our	O
study	O
confirmed	O
the	O
major	O
role	O
played	O
by	O
WNT10A	O
in	O
tooth	B-Phenotype
agenesis	E-Phenotype
and	O
the	O
genetic	O
heterogeneity	S-Phenotype
of	O
this	O
disease	O
.	O

Conclusions	O
:	O
The	O
current	O
meta	O
-	O
analysis	O
shows	O
the	O
associations	O
between	O
five	O
SNPs	O
of	O
PALB2	O
and	O
breast	B-Phenotype
cancer	E-Phenotype
risk	O

The	O
ataxia	S-Phenotype
telangiectasia	S-Phenotype
-	O
mutated	O
and	O
Rad3	O
-	O
related	O
(	O
ATR	O
)	O
kinase	O
is	O
a	O
master	O
regulator	O
of	O
DNA	O
damage	O
response	O
and	O
replication	O
stress	O
in	O
humans	O
,	O
but	O
the	O
mechanism	O
of	O
its	O
activation	O
remains	O
unclear	O
.	O

Through	O
a	O
whole	O
genome	O
sequencing	O
(	O
WGS	O
)	O
analysis	O
of	O
the	O
nine	O
subjects	O
(	O
four	O
lung	B-Phenotype
cancer	E-Phenotype
patients	O
and	O
five	O
normal	O
family	O
members	O
of	O
FLC	O
)	O
,	O
we	O
obtained	O
a	O
whole	O
genome	O
dataset	O
of	O
DNA	O
alterations	O
in	O
FLC	O
samples	O
.	O

We	O
identified	O
a	O
recurrent	O
de	O
novo	O
ATAD3A	O
c.1582CAAAAT	O
(	O
p.Arg528Trp	O
)	O
variant	O
by	O
whole	O
-	O
exome	O
sequencing	O
(	O
WES	O
)	O
in	O
five	O
unrelated	O
individuals	O
with	O
a	O
core	O
phenotype	O
of	O
global	B-Phenotype
developmental	I-Phenotype
delay	E-Phenotype
,	O
hypotonia	S-Phenotype
,	O
optic	B-Phenotype
atrophy	E-Phenotype
,	O
axonal	B-Phenotype
neuropathy	E-Phenotype
,	O
and	O
hypertrophic	B-Phenotype
cardiomyopathy	E-Phenotype
.	O

Analysis	O
of	O
publicly	O
available	O
data	O
reveals	O
CXCL1	O
-	O
driven	O
oncogenes	O
and	O
miR	O
-	O
105	O
have	O
a	O
negative	O
prognostic	O
impact	O
on	O
the	O
outcome	O
of	O
colon	B-Phenotype
cancer	E-Phenotype
.	O

Homeobox	O
A11	O
(	O
HOXA11	O
)	O
is	O
one	O
of	O
the	O
hypermethylated	O
genes	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
and	O
its	O
function	O
in	O
breast	B-Phenotype
tumorigenesis	E-Phenotype
remains	O
elusive	O
.	O

In	O
MCDS	O
mice	O
expressing	O
the	O
Col10a1.pN617K	O
mutation	O
,	O
CBZ	O
reduced	O
the	O
MCDS	O
-	O
associated	O
expansion	O
of	O
the	O
growth	O
plate	O
hypertrophic	O
zone	O
,	O
attenuated	O
enhanced	O
expression	O
of	O
ER	O
stress	O
markers	O
such	O
as	O
Bip	O
and	O
Atf4	O
,	O
increased	O
bone	B-Phenotype
growth	E-Phenotype
,	O
and	O
reduced	O
skeletal	B-Phenotype
dysplasia	E-Phenotype
.	O

Our	O
report	O
of	O
variant	O
in	O
ARMC9	O
Leading	O
to	O
Joubert	O
syndrome	O
phenotype	O
(	O
JS30	O
)	O
,	O
elucidates	O
the	O
genetic	O
heterogeneity	S-Phenotype
of	O
Joubert	O
syndrome	O
,	O
and	O
expands	O
the	O
gene	O
list	O
for	O
ciliopathies	O

Mutations	O
in	O
the	O
TTR	O
gene	O
cause	O
TTR	O
tetramer	O
protein	O
to	O
dissociate	O
to	O
monomer	O
,	O
which	O
is	O
the	O
rate	O
-	O
limiting	O
step	O
in	O
familial	B-Phenotype
amyloid	I-Phenotype
polyneuropathy	E-Phenotype
.	O

Overall	O
,	O
our	O
findings	O
show	O
how	O
the	O
tumor	S-Phenotype
suppressor	O
SIRT6	O
is	O
regulated	O
in	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
and	O
establish	O
the	O
mechanism	O
underlying	O
UBE3A	O
-	O
mediated	O
tumorigenesis	O
in	O
this	O
disease.bSignificance	O
:	O
/	O
b	O
These	O
findings	O
provide	O
mechanistic	O
insights	O
into	O
regulation	O
of	O
the	O
tumor	S-Phenotype
suppressive	O
sirtuin	O
SIRT6	O
and	O
its	O
implications	O
for	O
the	O
development	O
of	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
.	O

Dec1	O
expression	O
was	O
analyzed	O
by	O
immunohistochemistry	O
in	O
157	O
samples	O
of	O
newly	O
diagnosed	O
glioma	S-Phenotype
and	O
63	O
recurrent	O
glioblastoma	S-Phenotype
cases	O
that	O
relapsed	O
during	O
TMZ	O
chemotherapy	O
.	O

FGF23	O
excess	O
induces	O
hypophosphatemia	S-Phenotype
via	O
impaired	O
phosphate	O
reabsorption	O
in	O
the	O
renal	O
proximal	O
tubules	O
and	O
decreased	O
phosphate	O
absorption	O
in	O
the	O
intestines	O
.	O

TASK	O
-	O
3	O
potassium	O
channels	O
are	O
believed	O
to	O
promote	O
proliferation	O
and	O
survival	O
of	O
cancer	S-Phenotype
cells	O
,	O
in	O
part	O
,	O
by	O
augmenting	O
their	O
resistance	O
to	O
both	O
hypoxia	S-Phenotype
and	O
serum	B-Phenotype
deprivation	E-Phenotype
.	O

Functionally	O
,	O
MFAP5	O
overexpression	O
accelerated	O
breast	B-Phenotype
cancer	E-Phenotype
cell	O
proliferation	O
and	O
migration	O
,	O
while	O
an	O
opposite	O
effect	O
was	O
observed	O
when	O
MFAP5	O
was	O
knocked	O
down	O
.	O

GJB2	O
is	O
the	O
primary	O
causative	O
gene	O
for	O
non	O
-	O
syndromic	O
sensorineural	B-Phenotype
deafness	E-Phenotype
and	O
associated	O
with	O
several	O
syndromic	O
sensorineural	B-Phenotype
deafness	E-Phenotype
.	O

The	O
autosomal	B-Phenotype
recessive	E-Phenotype
forms	O
(	O
LGMD2	O
)	O
are	O
:	O
LGMD2A	O
(	O
calpain	O
3	O
)	O
,	O
LGMD2B	O
(	O
dysferlin	O
)	O
,	O
LGMD2C	O
(	O
γ	O
sarcoglycan	O
)	O
,	O
LGMD2D	O
(	O
α	O
sarcoglycan	O
)	O
,	O
LGMD2E	O
(	O
β	O
sarcoglycan	O
)	O
,	O
LGMD2F	O
(	O
δ	O
sarcoglycan	O
)	O
,	O
LGMD2G	O
(	O
telethonin	O
)	O
,	O
LGMD2H	O
(	O
TRIM32	O
)	O
,	O
LGMD2I	O
(	O
FKRP	O
)	O
,	O
LGMD2J	O
(	O
titin	O
)	O
,	O
LGMD2K	O
(	O
POMT1	O
)	O
,	O
LGMD2L	O
(	O
anoctamin	O
5	O
)	O
,	O
LGMD2M	O
(	O
fukutin	O
)	O
,	O
LGMD2N	O
(	O
POMT2	O
)	O
,	O
LGMD2O	O
(	O
POMTnG1	O
)	O
,	O
LGMD2P	O
(	O
dystroglycan	O
)	O
,	O
LGMD2Q	O
(	O
plectin	O
)	O
,	O
LGMD2R	O
(	O
desmin	O
)	O
,	O
LGMD2S	O
(	O
TRAPPC11	O
)	O
,	O
LGMD2T	O
(	O
GMPPB	O
)	O
,	O
LGMD2U	O
(	O
ISPD	O
)	O
,	O
LGMD2V	O
(	O
Glucosidase	O
,	O
alpha	O
)	O
,	O
LGMD2W	O
(	O
PINCH2	O
)	O

The	O
results	O
revealed	O
that	O
only	O
WWOX	O
SNP	O
rs3764340	O
was	O
associated	O
between	O
patients	O
with	O
cervical	B-Phenotype
invasive	I-Phenotype
cancer	E-Phenotype
and	O
normal	O
controls	O
among	O
5	O
WWOX	O
genetic	O
variants	O
.	O

Mutations	O
in	O
the	O
photoreceptor	O
tetraspanin	O
gene	O
peripherin	O
-	O
2	O
/	O
retinal	B-Phenotype
degeneration	I-Phenotype
slow	E-Phenotype
(	O
PRPH2	O
/	O
RDS	O
)	O
cause	O
both	O
rod	O
-	O
and	O
cone	O
-	O
dominant	O
diseases	O
.	O

The	O
nonsense	O
mutation	O
and	O
loss	O
of	O
protein	O
of	O
Rab23	O
has	O
been	O
associated	O
with	O
neural	B-Phenotype
tube	I-Phenotype
defect	E-Phenotype
in	O
mice	O
and	O
aberrant	O
expression	O
in	O
various	O
diseases	O
in	O
human	O
such	O
as	O
neural	O
system	O
,	O
breast	B-Phenotype
,	I-Phenotype
visceral	I-Phenotype
,	I-Phenotype
and	I-Phenotype
cutaneous	I-Phenotype
tumor	E-Phenotype
.	O

DYT1	O
is	O
the	O
prototypic	B-Phenotype
hereditary	I-Phenotype
dystonia	E-Phenotype
and	O
is	O
caused	O
by	O
the	O
mutation	O
of	O
the	O
tor1a	O
gene	O
.	O

A	O
systematic	O
study	O
of	O
serial	O
samples	O
from	O
30	O
patients	O
show	O
that	O
ASXL1	O
c.1934dupG	O
is	O
a	O
somatic	B-Phenotype
mutation	E-Phenotype
in	O
haematological	B-Phenotype
neoplasms	E-Phenotype
including	O
MDS	O
,	O
AML	O
,	O
MPN	O
and	O
MDS	O
/	O
MPN	O
and	O
often	O
is	O
associated	O
with	O
somatic	O
mutations	O
of	O
TET2	O
,	O
EZH2	O
,	O
IDH2	O
,	O
RUNX1	O
,	O
NRAS	O
and	O
DNMT3A	O
.	O

This	O
study	O
illustrates	O
that	O
germline	O
mosaicism	O
is	O
important	O
to	O
consider	O
in	O
apparently	O
sporadic	B-Phenotype
de	I-Phenotype
novo	I-Phenotype
MEN1	I-Phenotype
mutations	E-Phenotype
,	O
because	O
of	O
its	O
particular	O
importance	O
for	O
genetic	O
counseling	O
,	O
specifically	O
when	O
evaluating	O
the	O
risk	O
for	O
family	O
members	O
and	O
when	O
considering	O
the	O
possibility	O
of	O
somatic	B-Phenotype
mosaicism	E-Phenotype
in	O
the	O
parent	O
with	O
germline	O
mosaicism	O

Numerous	O
genes	O
found	O
in	O
this	O
study	O
were	O
also	O
differentially	O
expressed	O
in	O
human	O
HCC	O
and	O
many	O
other	O
human	O
cancers	S-Phenotype
including	O
breast	B-Phenotype
,	I-Phenotype
prostate	I-Phenotype
and	I-Phenotype
lung	I-Phenotype
cancers	E-Phenotype
,	O
etc.	O
,	O
serving	O
as	O
tumor	S-Phenotype
suppressors	O
,	O
promoters	O
,	O
prognostic	O
markers	O
or	O
chemotherapy	O
targets	O
.	O

To	O
gain	O
insight	O
into	O
the	O
molecular	O
basis	O
of	O
the	O
heterogeneous	S-Phenotype
phenotype	O
observed	O
in	O
men	O
with	O
the	O
deletion	O
we	O
defined	O
the	O
type	O
of	O
DAZ	O
and	O
CDY1	O
genes	O
deleted	O
.	O

Developmental	O
and	O
epileptic	B-Phenotype
encephalopathy	E-Phenotype
with	O
hypsarrhythmia	S-Phenotype
is	O
present	O
in	O
most	O
patients	O
with	O
SLC35A2	O
variants	O
,	O
and	O
is	O
drug	O
-	O
resistant	O
in	O
the	O
majority	O
of	O
cases	O
.	O

GEMIN4	O
was	O
independently	O
mutated	O
in	O
families	O
with	O
a	O
syndrome	O
of	O
cataract	S-Phenotype
,	O
global	B-Phenotype
developmental	I-Phenotype
delay	E-Phenotype
with	O
or	O
without	O
renal	O
involvement	O
.	O

Pathogenic	O
or	O
likely	O
pathogenic	O
cancer	S-Phenotype
susceptibility	O
gene	O
alterations	O
were	O
found	O
in	O
7	O
of	O
the	O
87	O
(	O
8	O
%	O
)	O
CS	O
/	O
CS	O
-	O
like	O
and	O
BRRS	O
patients	O
and	O
included	O
MUTYH	O
,	O
RET	O
,	O
TSC2	O
,	O
BRCA1	O
,	O
BRCA2	O
,	O
ERCC2	O
and	O
HRAS	O
.	O

ALG3	O
expression	O
was	O
significantly	O
increased	O
in	O
cancer	S-Phenotype
samples	O
with	O
advanced	O
stages	O
(	O
stage	O
III	O
/	O
IV	O
)	O
compared	O
with	O
those	O
in	O
the	O
early	O
stages	O
of	O
disease	O
(	O
stage	O
I	O
/	O
II	O
)	O
(	O
pAAAA0.05	O
)	O
.	O

The	O
fatty	O
acid	O
(	O
FA	O
)	O
composition	O
of	O
red	O
blood	O
cell	O
(	O
RBC	O
)	O
membrane	O
phospholipids	O
of	O
cancer	S-Phenotype
patients	O
can	O
reflect	O
tumor	S-Phenotype
status	O
,	O
dietary	O
intakes	O
,	O
and	O
cancer	S-Phenotype
type	O
or	O
therapy	O
.	O

Using	O
clinical	O
blood	O
samples	O
,	O
we	O
compared	O
the	O
diagnostic	O
values	O
of	O
serum	O
exosomal	O
ZIP4	O
levels	O
between	O
malignant	O
pancreatic	B-Phenotype
cancer	E-Phenotype
patients	O
(	O
n	O
=	O
24	O
)	O
and	O
benign	O
pancreatic	B-Phenotype
disease	E-Phenotype
patients	O
(	O
n	O
=	O
32	O
,	O
AUC	O
=	O
.89	O
)	O
,	O
and	O
between	O
biliary	O
disease	O
patients	O
(	O
n	O
=	O
32	O
,	O
AUC	O
=	O
.8112	O
)	O
and	O
healthy	O
controls	O
(	O
n	O
=	O
46	O
,	O
AUC	O
=	O
.8931	O
)	O
.	O

DTNA	O
encoding	O
dystrobrevin	O
-	O
a	O
(	O
a	O
-	O
DB	O
)	O
is	O
a	O
putative	O
causal	O
gene	O
associated	O
with	O
left	B-Phenotype
ventricular	I-Phenotype
noncompaction	I-Phenotype
cardiomyopathy	E-Phenotype
(	O
LVNC	S-Phenotype
)	O
.	O

Overall	O
,	O
our	O
findings	O
establish	O
RASSF4	O
as	O
a	O
tumor	S-Phenotype
-	O
suppressive	O
hub	O
in	O
MM	O
and	O
provide	O
a	O
mechanistic	O
rationale	O
for	O
combining	O
trametinib	O
with	O
HDAC	O
inhibitors	O
or	O
bortezomib	O
to	O
treat	O
patients	O
with	O
tumors	S-Phenotype
exhibiting	O
low	O
RASSF4	O
expression.bSignificance	O
:	O
/	O
b	O
These	O
findings	O
provide	O
a	O
mechanistic	O
rationale	O
for	O
combining	O
trametinib	O
with	O
HDAC	O
inhibitors	O
or	O
bortezomib	O
in	O
patients	O
with	O
multiple	B-Phenotype
myeloma	E-Phenotype
whose	O
tumors	S-Phenotype
exhibit	O
low	O
RASSF4	O
expression	O
.	O

DNA	O
was	O
extracted	O
from	O
paraffin	O
-	O
embedded	O
tumor	S-Phenotype
specimens	O
from	O
the	O
patients	O
and	O
peripheral	O
blood	O
lymphocytes	O
from	O
the	O
controls	O
and	O
used	O
for	O
LMP2	O
/	O
LMP7	O
genotyping	O
.	O

Here	O
we	O
provide	O
structural	O
and	O
biochemical	O
data	O
that	O
Cep104	O
contains	O
a	O
tubulin	O
-	O
binding	O
TOG	O
(	O
tumor	S-Phenotype
overexpressed	O
gene	O
)	O
domain	O
and	O
a	O
novel	O
C2HC	O
zinc	O
finger	O
array	O
.	O

We	O
investigated	O
the	O
diagnostic	O
and	O
prognostic	O
capability	O
of	O
COL4A1	O
and	O
COL13A1	O
in	O
voided	O
urine	O
and	O
compared	O
the	O
observed	O
values	O
with	O
those	O
of	O
fragments	O
of	O
cytokeratin	O
-	O
19	O
(	O
CYFRA21	O
-	O
1	O
)	O
,	O
nuclear	O
matrix	O
protein	O
22	O
(	O
NMP	O
-	O
22	O
)	O
,	O
and	O
voided	O
urine	O
cytology	O
in	O
bladder	B-Phenotype
cancer	E-Phenotype
(	O
BCa	S-Phenotype
)	O
.	O

Leiomyoma	O
of	O
deep	O
soft	O
tissue	O
is	O
a	O
rare	O
type	O
of	O
benign	B-Phenotype
smooth	I-Phenotype
muscle	I-Phenotype
tumor	E-Phenotype
that	O
mostly	O
occurs	O
in	O
the	O
retroperitoneum	O
or	O
abdominal	O
cavity	O
of	O
women	O
,	O
and	O
about	O
which	O
very	O
little	O
genetic	O
information	O
exists	O
.	O

GPC3	O
was	O
positive	O
in	O
yolk	O
sac	O
tumor	S-Phenotype
component	O
.	O

Pathway	O
analysis	O
revealed	O
that	O
these	O
miRNAs	O
are	O
involved	O
in	O
potential	O
glaucoma	S-Phenotype
pathways	O
,	O
including	O
focal	O
adhesion	O
,	O
tight	O
junctions	O
,	O
and	O
TGF	O
-	O
ß	O
signaling	O
.	O

In	O
vitro	O
and	O
in	O
vivo	O
experiments	O
revealed	O
that	O
PHF8	O
accelerated	O
cancer	S-Phenotype
cell	O
growth	O
and	O
migration	O
,	O
confirming	O
the	O
oncogenic	O
role	O
of	O
PHF8	O
in	O
human	O
CRC	O
.	O

Well	O
-	O
established	O
intrinsic	O
mechanisms	O
of	O
cognitive	B-Phenotype
decline	E-Phenotype
include	O
aging	S-Phenotype
,	O
apolipoprotein	B-Phenotype
E	E-Phenotype
(	O
APOE	S-Phenotype
)	O
e4	B-Phenotype
carrier	I-Phenotype
status	E-Phenotype
,	O
SORL1	B-Phenotype
mutations	E-Phenotype
,	O
neuroinflammation	S-Phenotype
,	O
mitochondrial	B-Phenotype
dysfunction	E-Phenotype
,	O
amyloid	B-Phenotype
deposition	E-Phenotype
,	O
and	O
demyelination	S-Phenotype
.	O

A	O
de	O
novo	O
heterozygous	O
p.Pro209Leu	O
(	O
c.626CAAAAT	O
)	O
mutation	O
in	O
BAG3	O
was	O
identified	O
in	O
a	O
female	O
myopathy	S-Phenotype
.	O

As	O
proof	O
of	O
concept	O
,	O
we	O
applied	O
CRAFT	O
to	O
epilepsy	S-Phenotype
and	O
predicted	O
the	O
tyrosine	O
kinase	O
receptor	O
Csf1R	O
as	O
a	O
potential	O
therapeutic	O
target	O
.	O

Here	O
,	O
we	O
show	O
that	O
tamoxifen	O
,	O
a	O
well	O
-	O
known	O
drug	O
used	O
against	O
breast	B-Phenotype
cancer	E-Phenotype
,	O
rescues	O
the	O
phenotype	O
of	O
Mtm1	O
-	O
deficient	O
mice	O
.	O

A	O
case	O
with	O
GABRB3	O
(	O
C.905AAAAAG	O
)	O
had	O
seizure	S-Phenotype
controlled	O
for	O
3	O
mouths	O
.	O

Genetic	O
insights	O
into	O
the	O
pathophysiology	O
of	O
amyotrophic	B-Phenotype
lateral	I-Phenotype
sclerosis	E-Phenotype
(	O
ALS	S-Phenotype
)	O
are	O
untangling	O
the	O
clinical	O
heterogeneity	S-Phenotype
that	O
may	O
contribute	O
to	O
poor	O
clinical	O
trial	O
outcomes	O
and	O
thus	O
to	O
a	O
lack	O
of	O
effective	O
treatments	O
.	O

Here	O
we	O
present	O
a	O
novel	O
Mks1	O
(	O
tm1a	O
(	O
EUCOMM	O
)	O
Wtsi	O
)	O
knockout	O
mouse	O
which	O
accurately	O
recapitulates	O
the	O
human	O
condition	O
,	O
consistently	O
developing	O
pre	B-Phenotype
-	I-Phenotype
axial	I-Phenotype
polydactyly	E-Phenotype
,	O
complex	B-Phenotype
posterior	I-Phenotype
fossa	I-Phenotype
defects	E-Phenotype
(	O
including	O
the	O
Dandy	B-Phenotype
-	I-Phenotype
Walker	I-Phenotype
malformation	E-Phenotype
)	O
,	O
and	O
renal	B-Phenotype
cystic	I-Phenotype
dysplasia	E-Phenotype
.	O

The	O
aims	O
of	O
the	O
present	O
study	O
were	O
to	O
evaluate	O
the	O
relation	O
of	O
dysregulated	O
MACC1	O
,	O
c	O
-	O
MET	O
,	O
and	O
NM23	O
-	O
H1	O
expression	O
with	O
the	O
histopathological	O
features	O
of	O
tumors	S-Phenotype
in	O
recurrence	O
formation	O
in	O
eCC	O
cases	O
.	O

We	O
present	O
detailed	O
clinical	O
assessment	O
and	O
functional	O
studies	O
on	O
a	O
de	O
novo	O
variant	O
in	O
a	O
female	O
with	O
an	O
epileptic	B-Phenotype
encephalopathy	E-Phenotype
and	O
discuss	O
an	O
additional	O
four	O
families	O
with	O
rare	O
variants	O
in	O
THOC2	O
with	O
supportive	O
evidence	O
for	O
pathogenicity	O
.	O

Association	O
between	O
autism	S-Phenotype
and	O
single	O
-	O
nucleotide	O
polymorphisms	O
in	O
SLC25A12	O
has	O
been	O
reported	O
in	O
various	O
studies	O
.	O

The	O
expression	O
of	O
AURKB	O
and	O
GMNN	O
was	O
studied	O
by	O
immunostaining	O
84	O
neuroblastomas	S-Phenotype
.	O

The	O
family	O
members	O
harboring	O
1	O
heterozygous	O
mutation	O
in	O
HSPG2	O
did	O
not	O
exhibit	O
any	O
skeletal	B-Phenotype
abnormalities	E-Phenotype
.	O

Additionally	O
,	O
miR	O
-	O
577	O
may	O
act	O
as	O
a	O
valuable	O
tumor	S-Phenotype
marker	O
to	O
predict	O
the	O
prognosis	O
of	O
HCC	S-Phenotype
patients	O
.	O

Recently	O
,	O
Yes	O
-	O
associate	O
protein	O
(	O
YAP	O
)	O
has	O
been	O
reported	O
to	O
promote	O
multiple	O
cancer	S-Phenotype
cell	O
properties	O
,	O
such	O
as	O
promoting	O
cell	O
proliferation	O
,	O
epithelial	O
-	O
mesenchymal	O
transition	O
and	O
drug	B-Phenotype
resistance	E-Phenotype
.	O

Moreover	O
,	O
inhibition	O
of	O
MYC	O
target	O
pyrimidine	O
synthesis	O
genes	O
such	O
as	O
CAD	O
,	O
UMPS	O
,	O
and	O
CTPS	O
blocked	O
cell	O
growth	O
,	O
and	O
thus	O
are	O
potential	O
targets	O
for	O
colorectal	B-Phenotype
cancer	E-Phenotype
therapy	O

In	O
humans	O
,	O
three	O
unrelated	O
patients	O
have	O
been	O
reported	O
:	O
a	O
patient	O
with	O
a	O
homozygous	O
missense	O
mutation	O
in	O
SLC9A1	O
,	O
c.913GAAAAA	O
(	O
p.Gly305Arg	O
)	O
,	O
which	O
caused	O
Lichtenstein	O
-	O
Knorr	O
syndrome	O
characterized	O
by	O
cerebellar	B-Phenotype
ataxia	E-Phenotype
and	O
sensorineural	B-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
,	O
a	O
patient	O
with	O
compound	O
heterozygous	O
mutations	O
,	O
c.1351AAAAAC	O
(	O
p.Ile451Leu	O
)	O
and	O
c.1585CAAAAT	O
(	O
p.His529Tyr	O
)	O
,	O
which	O
caused	O
a	O
neuroXmuscular	O
disorder	O
,	O
and	O
a	O
patient	O
with	O
de	O
novo	O
mutation	O
,	O
c.796AAAAAC	O
(	O
p.Asn266His	O
)	O
which	O
associated	O
multiple	O
anomalies	O
.	O

In	O
OSCC	O
samples	O
,	O
a	O
high	O
GLI3	O
expression	O
was	O
associated	O
with	O
tumour	S-Phenotype
size	O
but	O
not	O
with	O
prognosis	O
.	O

The	O
chromosome	O
22	O
disorder	O
,	O
due	O
to	O
mutations	O
in	O
the	O
nuclear	O
gene	O
TYMP	O
encoding	O
thymidine	O
phosphorylase	O
(	O
TP	O
)	O
,	O
leads	O
to	O
the	O
accumulation	O
of	O
thymidine	O
and	O
deoxyuridine	O
,	O
with	O
mitochondrial	O
dysfunction	O
.	O

This	O
report	O
describes	O
a	O
patient	O
with	O
an	O
MNGIE	O
-	O
like	O
syndrome	O
with	O
a	O
heterozygous	O
TYMP	O
mutation	O
who	O
showed	O
marked	O
,	O
but	O
transient	O
improvement	O
postallogeneic	O
haematopoietic	O
stem	O
cell	O
transplantation	O
(	O
HSCT	O
)	O
.	O

The	O
patient	O
,	O
showing	O
ptosis	S-Phenotype
and	O
ophthalmoplegia	S-Phenotype
,	O
was	O
initially	O
managed	O
for	O
myasthenia	B-Phenotype
gravis	E-Phenotype
.	O

In	O
contrast	O
Flii+	O
/	O
-	O
mice	O
had	O
significantly	O
smaller	O
tumors	S-Phenotype
that	O
were	O
less	O
invasive	O
.	O

Elevated	B-Phenotype
serum	I-Phenotype
PTH	E-Phenotype
concentrations	O
in	O
primary	B-Phenotype
and	I-Phenotype
secondary	I-Phenotype
hyperparathyroidism	E-Phenotype
have	O
been	O
associated	O
with	O
bone	O
disease	O
,	O
hypertension	S-Phenotype
,	O
and	O
in	O
some	O
studies	O
,	O
cardiovascular	O
mortality	O
.	O

We	O
compare	O
and	O
contrast	O
our	O
findings	O
with	O
previous	O
studies	O
reporting	O
on	O
critical	O
1q43	O
-	O
q44	O
regions	O
and	O
their	O
constituent	O
genes	O
associated	O
with	O
seizures	S-Phenotype
,	O
microcephaly	S-Phenotype
,	O
and	O
corpus	B-Phenotype
callosum	I-Phenotype
abnormalities	E-Phenotype
[	O
Ballif	O
et	O
al.	O
,	O
2012	O
;	O
Hum	O
Genet	O
131:145	O
-	O
156	O
;	O
Nagamani	O
et	O
al.	O
,	O
2012	O
;	O
Eur	O
J	O
Hum	O
Genet	O
20:176	O
-	O
179	O
]	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
tumor	S-Phenotype
necrosis	O
factor	O
(	O
TNF	O
)	O
receptor	O
-	O
associated	O
factor	O
5	O
(	O
TRAF5	O
)	O
and	O
TGF	O
-	O
b	O
activated	O
kinase	O
1	O
(	O
MAP3K7	O
)	O
binding	O
protein	O
1	O
(	O
TAB1	O
)	O
were	O
direct	O
targets	O
of	O
miR	O
-	O
873	O
in	O
CRC	O
cells	O
.	O

Congenital	B-Phenotype
hypogonadotrophic	I-Phenotype
hypogonadism	E-Phenotype
(	O
CHH	S-Phenotype
)	O
is	O
a	O
challenging	O
inherited	O
endocrine	O
disorder	O
characterised	O
by	O
absent	O
or	O
incomplete	O
pubertal	O
development	O
and	O
infertility	S-Phenotype
as	O
a	O
result	O
of	O
the	O
low	O
action	O
/	O
secretion	O
of	O
the	O
hypothalamic	O
gonadotrophin	O
-	O
releasing	O
hormone	O
(	O
GnRH	O
)	O
.	O

Our	O
data	O
suggest	O
that	O
pathogenic	O
mutations	O
in	O
KLLN	O
are	O
rare	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
families	O
and	O
the	O
c.339_340delAG	O
variant	O
does	O
not	O
represent	O
a	O
high	O
-	O
penetrance	O
breast	B-Phenotype
cancer	E-Phenotype
risk	O
allele	O

Furthermore	O
,	O
we	O
establish	O
that	O
different	O
levels	O
of	O
impaired	O
PLK4	O
activity	O
result	O
in	O
growth	O
and	O
cilia	O
phenotypes	O
,	O
providing	O
a	O
mechanism	O
by	O
which	O
microcephaly	S-Phenotype
disorders	O
can	O
occur	O
with	O
or	O
without	O
ciliopathic	O
features	O
.	O

These	O
findings	O
support	O
ADAM17	O
as	O
a	O
dynamic	O
inhibitory	O
checkpoint	O
of	O
the	O
potent	O
activating	O
receptor	O
CD16A	O
,	O
which	O
can	O
be	O
targeted	O
by	O
MEDI3622	O
to	O
potentially	O
increase	O
the	O
efficacy	O
of	O
anti	O
-	O
tumor	S-Phenotype
therapeutic	O
antibodies	O

A	O
previous	O
study	O
showed	O
that	O
treatment	O
with	O
resveratrol	O
inhibits	O
muscular	B-Phenotype
atrophy	E-Phenotype
in	O
mdx	O
mice	O
,	O
a	O
model	O
of	O
DMD	O
.	O

PCD	O
is	O
a	O
result	O
of	O
mutations	O
in	O
genes	O
encoding	O
proteins	O
involved	O
in	O
ciliary	O
function	O
,	O
and	O
is	O
primarily	O
inherited	O
in	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
fashion	O
.	O

The	O
most	O
significantly	O
mutated	O
CMG	O
is	O
DNAAF1	O
with	O
biallelic	O
inactivation	O
and	O
loss	O
of	O
DNAAF1	O
expression	O
shown	O
in	O
tumours	S-Phenotype
from	O
carriers	O
.	O

Mutations	O
in	O
the	O
CPA6	O
gene	O
have	O
been	O
identified	O
in	O
patients	O
with	O
temporal	B-Phenotype
lobe	I-Phenotype
epilepsy	E-Phenotype
and	O
febrile	B-Phenotype
seizures	E-Phenotype
.	O

Immunohistochemistry	O
was	O
used	O
to	O
observe	O
the	O
Kif2a	O
expression	O
and	O
its	O
correlation	O
with	O
clinicopathologic	O
factors	O
in	O
oral	B-Phenotype
tongue	I-Phenotype
cancer	E-Phenotype
.	O

Kleefstra	O
syndrome	O
,	O
caused	O
by	O
haploinsufficiency	O
of	O
euchromatin	O
histone	O
methyltransferase	O
1	O
(	O
EHMT1	O
)	O
,	O
is	O
characterized	O
by	O
intellectual	B-Phenotype
disability	E-Phenotype
(	O
ID	S-Phenotype
)	O
,	O
autism	B-Phenotype
spectrum	I-Phenotype
disorder	E-Phenotype
(	O
ASD	S-Phenotype
)	O
,	O
characteristic	O
facial	O
dysmorphisms	O
,	O
and	O
other	O
variable	O
clinical	O
features	O
.	O

Delayed	B-Phenotype
bone	I-Phenotype
age	E-Phenotype
and	O
seizure	S-Phenotype
disorders	O
were	O
overrepresented	O
in	O
the	O
TTDN1	O
group	O
(	O
P=0.009	O
and	O
P=0.024	O
,	O
respectively	O
)	O
,	O
whereas	O
some	O
characteristic	O
TTD	O
clinical	O
,	O
laboratory	O
,	O
and	O
imaging	O
findings	O
were	O
absent	O
.	O

Mutations	O
in	O
SPRTN	O
cause	O
premature	O
ageing	O
and	O
liver	B-Phenotype
cancer	E-Phenotype
in	O
humans	O
and	O
mice	O
;	O
thus	O
,	O
defective	O
DPC	O
repair	O
has	O
great	O
clinical	O
ramifications	O
.	O

By	O
recruiting	O
the	O
methyltransferase	O
DOT1L	O
,	O
C	O
/	O
EBPβ	O
can	O
maintain	O
an	O
open	O
chromatin	O
state	O
by	O
H3K79	O
methylation	O
of	O
multiple	O
drug	O
-	O
resistance	O
genes	O
,	O
thereby	O
augmenting	O
the	O
chemoresistance	O
of	O
tumor	S-Phenotype
cells	O
.	O

Genetic	O
mutations	O
to	O
a	O
specific	O
subset	O
of	O
mitochondrial	O
Fe	O
/	O
S	O
cluster	O
delivery	O
proteins	O
are	O
broadly	O
categorized	O
as	O
disease	O
-	O
related	O
under	O
multiple	B-Phenotype
mitochondrial	I-Phenotype
dysfunction	I-Phenotype
syndrome	E-Phenotype
(	O
MMDS	S-Phenotype
)	O
,	O
with	O
symptoms	O
indicative	O
of	O
a	O
general	O
failure	O
of	O
the	O
metabolic	O
system	O
.	O

OTUD6B	O
encodes	O
a	O
member	O
of	O
the	O
ovarian	B-Phenotype
tumor	E-Phenotype
domain	O
(	O
OTU	O
)	O
-	O
containing	O
subfamily	O
of	O
deubiquitinating	O
enzymes	O
.	O

Here	O
we	O
report	O
that	O
STX3	O
acts	O
as	O
an	O
oncogenic	O
protein	O
in	O
human	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

MicroRNA	O
-	O
873	O
(	O
miR	O
-	O
873	O
)	O
has	O
been	O
reported	O
to	O
be	O
dysregulated	O
in	O
a	O
variety	O
of	O
malignancies	O
,	O
however	O
,	O
the	O
biological	O
function	O
and	O
underlying	O
molecular	O
mechanism	O
of	O
miR	O
-	O
873	O
in	O
colorectal	B-Phenotype
cancer	E-Phenotype
(	O
CRC	S-Phenotype
)	O
remain	O
unclear	O
.	O

Recently	O
,	O
we	O
reported	O
that	O
a	O
series	O
of	O
non‑Hodgkin	O
's	O
lymphoma	S-Phenotype
occurs	O
in	O
children	O
with	O
WBS	O
and	O
thus	O
hypothesized	O
that	O
a	O
predisposition	O
to	O
cancer	S-Phenotype
may	O
be	O
associated	O
with	O
this	O
genetic	O
disorder	O
.	O

These	O
findings	O
represent	O
an	O
approach	O
to	O
inhibiting	O
tumor	S-Phenotype
-	O
stromal	O
interactions	O
and	O
support	O
the	O
development	O
of	O
allosteric	O
inhibitors	O
of	O
DDR2	O
,	O
such	O
as	O
WRG	O
-	O
28	O
,	O
as	O
a	O
promising	O
approach	O
to	O
antimetastasis	O
treatment	O

In	O
addition	O
,	O
silencing	O
of	O
CtBP2	O
markedly	O
increased	O
the	O
apoptosis	O
of	O
PCa	O
cells	O
in	O
vitro	O
,	O
and	O
decreased	O
the	O
expression	O
of	O
IL	O
-	O
8	O
,	O
AT2R	O
,	O
CCND1	O
and	O
MMP9	O
which	O
are	O
associated	O
with	O
cancer	S-Phenotype
progression	O
.	O

Knockdown	O
of	O
PPP2R1B	O
expression	O
increases	O
AKT	O
phosphorylation	O
,	O
which	O
leads	O
to	O
elevated	O
XIAP	O
expression	O
and	O
enhanced	O
5	O
-	O
FU	O
resistance	O
;	O
whereas	O
rescue	O
of	O
PPP2R1B	O
expression	O
in	O
miR	O
-	O
587	O
-	O
expressing	O
cells	O
decreases	O
AKT	O
phosphorylation	O
/	O
XIAP	O
expression	O
,	O
re	O
-	O
sensitizing	O
colon	B-Phenotype
cancer	E-Phenotype
cells	O
to	O
5	O
-	O
FU	O
-	O
induced	O
apoptosis	O
.	O

To	O
identify	O
common	O
genetic	O
variants	O
associated	O
with	O
sporadic	S-Phenotype
non	O
-	O
syndromic	O
CHM	O
in	O
Han	O
Chinese	O
populations	O
,	O
we	O
performed	O
a	O
multistage	O
genome	O
-	O
wide	O
association	O
study	O
(	O
GWAS	O
)	O
in	O
a	O
total	O
of	O
4,225	O
CHM	O
cases	O
and	O
5,112	O
non	O
-	O
CHM	O
controls	O
.	O

Hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
is	O
an	O
aggressive	O
and	O
deadly	O
cancer	S-Phenotype
.	O

The	O
major	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
explore	O
the	O
effects	O
of	O
cullin	O
4B	O
(	O
CUL4B	O
)	O
on	O
the	O
proliferation	O
and	O
invasion	O
of	O
human	O
gastric	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Cystinuria	S-Phenotype
is	O
a	O
heterogeneous	S-Phenotype
,	O
rare	O
but	O
important	O
cause	O
of	O
inherited	O
kidney	B-Phenotype
stone	E-Phenotype
disease	O
due	O
to	O
mutations	O
in	O
2	O
genes	O
:	O
SLC3A1	O
and	O
SLC7A9	O
.	O

Spinocerebellar	B-Phenotype
ataxia	I-Phenotype
type	I-Phenotype
3	E-Phenotype
(	O
SCA3	S-Phenotype
)	O
is	O
a	O
neurodegenerative	O
disorder	O
caused	O
by	O
a	O
CAG	O
expansion	O
in	O
the	O
ATXN3	O
gene	O
leading	O
to	O
a	O
polyglutamine	O
expansion	O
in	O
the	O
ataxin	O
-	O
3	O
protein	O
.	O

Furthermore	O
,	O
a	O
high	O
level	O
of	O
FEZF1	O
in	O
patients	O
with	O
glioma	S-Phenotype
acted	O
as	O
an	O
independent	O
biomarker	O
to	O
predict	O
reduced	O
survival	O
(	O
P	O
=	O
0.026	O
)	O
.	O

Although	O
ABCD1	O
is	O
responsible	O
for	O
X	O
-	O
linked	O
adrenoleukodystrophy	O
(	O
X	O
-	O
ALD	O
)	O
,	O
its	O
phenotype	O
differs	O
from	O
that	O
of	O
CADDS	O
,	O
which	O
manifests	O
with	O
many	O
features	O
of	O
Zellweger	O
syndrome	O
(	O
ZS	O
)	O
,	O
including	O
severe	B-Phenotype
growth	I-Phenotype
and	I-Phenotype
developmental	I-Phenotype
retardation	E-Phenotype
,	O
liver	B-Phenotype
dysfunction	E-Phenotype
,	O
cholestasis	S-Phenotype
and	O
early	B-Phenotype
infantile	I-Phenotype
death	E-Phenotype
.	O

Data	O
on	O
the	O
relationship	O
between	O
ribosome	O
biogenesis	O
and	O
p53	O
function	O
indicate	O
that	O
the	O
tumour	S-Phenotype
suppressor	O
can	O
be	O
activated	O
by	O
either	O
nucleolar	O
disruption	O
or	O
ribosomal	O
protein	O
defects	O
.	O

Furthermore	O
,	O
in	O
utero	O
CRISPR	O
-	O
Cas9	O
-	O
mediated	O
genome	O
editing	O
of	O
Tsc1	O
or	O
Tsc2	O
induced	O
the	O
development	O
of	O
spontaneous	B-Phenotype
behavioral	I-Phenotype
seizures	E-Phenotype
,	O
as	O
well	O
as	O
cytomegalic	B-Phenotype
neurons	E-Phenotype
and	O
cortical	B-Phenotype
dyslamination	E-Phenotype
.	O

We	O
aimed	O
to	O
investigate	O
the	O
effect	O
of	O
the	O
AS	O
to	O
FEZF1	O
gene	O
on	O
non	B-Phenotype
-	I-Phenotype
small	I-Phenotype
cell	I-Phenotype
lung	I-Phenotype
cancer	E-Phenotype
(	O
NSCLC	S-Phenotype
)	O
development	O
.	O

The	O
p.Arg204Trp	O
mutation	O
was	O
identified	O
from	O
a	O
CMT2	O
patient	O
with	O
additional	O
complex	O
phenotypes	O
of	O
HSP	S-Phenotype
,	O
ataxia	S-Phenotype
,	O
fatigability	S-Phenotype
and	O
pyramidal	B-Phenotype
sign	E-Phenotype
,	O
but	O
the	O
p.Arg280His	O
and	O
p.Leu588Pro	O
mutations	O
were	O
identified	O
in	O
each	O
axonal	O
CMT2	O
patient	O
.	O

A	O
plethora	S-Phenotype
of	O
human	O
diseases	O
are	O
associated	O
with	O
mutations	O
in	O
the	O
genes	O
encoding	O
human	O
SLC26	O
transporters	O
,	O
including	O
chondrodysplasias	O
with	O
varying	O
severity	O
in	O
SLC26A2	O
(	O
~50	O
mutations	O
,	O
27	O
point	O
mutations	O
)	O
,	O
congenital	B-Phenotype
chloride	I-Phenotype
-	I-Phenotype
losing	I-Phenotype
diarrhea	E-Phenotype
in	O
SLC26A3	O
(	O
~70	O
mutations	O
,	O
31	O
point	O
mutations	O
)	O
and	O
Pendred	O
Syndrome	O
or	O
deafness	B-Phenotype
autosomal	I-Phenotype
recessive	I-Phenotype
type	I-Phenotype
4	E-Phenotype
in	O
SLC26A4	O
(	O
~500	O
mutations	O
,	O
203	O
point	O
mutations	O
)	O
.	O

Both	O
patients	O
presented	O
the	O
cardinal	O
features	O
of	O
the	O
disease	O
including	O
microcephaly	S-Phenotype
,	O
congenital	B-Phenotype
cataract	E-Phenotype
and	O
postnatal	B-Phenotype
growth	I-Phenotype
failure	E-Phenotype
.	O

With	O
a	O
feature	O
selection	O
algorithm	O
,	O
we	O
selected	O
a	O
panel	O
of	O
five	O
urinary	O
biomarkers	O
(	O
FTL	O
:	O
Ferritin	O
light	O
chain	O
;	O
MAPK1IP1L	O
:	O
Mitogen	O
-	O
Activated	O
Protein	O
Kinase	O
1	O
Interacting	O
Protein	O
1	O
Like	O
;	O
FGB	O
:	O
Fibrinogen	O
Beta	O
Chain	O
;	O
RAB33B	O
:	O
RAB33B	O
,	O
Member	O
RAS	O
Oncogene	O
Family	O
;	O
RAB15	O
:	O
RAB15	O
,	O
Member	O
RAS	O
Oncogene	O
Family	O
)	O
and	O
established	O
a	O
combinatorial	O
model	O
that	O
can	O
correctly	O
classify	O
the	O
majority	O
of	O
lung	B-Phenotype
cancer	E-Phenotype
cases	O
both	O
in	O
the	O
training	O
set	O
(	O
n=46	O
)	O
and	O
the	O
test	O
sets	O
(	O
n=14	O
-	O
47	O
per	O
set	O
)	O
with	O
an	O
AUC	O
ranging	O
from	O
0.8747	O
to	O
0.9853	O
.	O

Thus	O
,	O
our	O
data	O
indicate	O
that	O
in	O
pancreatic	B-Phenotype
cancer	E-Phenotype
cells	O
,	O
the	O
expression	O
of	O
ENG	O
may	O
be	O
controlled	O
by	O
a	O
pathway	O
mediated	O
by	O
SMAD4	O
.	O

Here	O
we	O
describe	O
three	O
unrelated	O
patients	O
showing	O
clinical	O
features	O
overlapping	O
with	O
TCS	O
,	O
but	O
who	O
in	O
addition	O
have	O
developmental	B-Phenotype
delay	E-Phenotype
,	O
microcephaly	S-Phenotype
and	O
a	O
distinct	O
facial	O
gestalt	O
.	O

Patients	O
with	O
HCP	O
show	O
AAAA50	O
%	O
of	O
normal	O
activity	O
and	O
those	O
with	O
the	O
rare	O
autosomal	B-Phenotype
recessive	I-Phenotype
harderoporphyria	E-Phenotype
accumulate	O
harderoporphyrinogen	O
,	O
an	O
intermediate	O
porphyrin	O
of	O
the	O
CPOX	O
reaction	O
.	O

However	O
,	O
the	O
effect	O
of	O
TNFSF15	O
on	O
tumor	S-Phenotype
lymphatic	O
metastasis	O
and	O
the	O
underlying	O
molecular	O
mechanisms	O
remain	O
unclear	O
.	O

Here	O
we	O
describe	O
two	O
unrelated	O
individuals	O
with	O
infantile	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
epilepsy	E-Phenotype
and	O
abnormalities	B-Phenotype
of	I-Phenotype
brain	I-Phenotype
morphology	E-Phenotype
,	O
harboring	O
de	O
novo	O
variants	O
that	O
affect	O
adjacent	O
amino	O
acids	O
in	O
a	O
beta	O
-	O
tubulin	O
gene	O
TUBB2A	O
.	O

Our	O
data	O
highlight	O
the	O
unexpected	O
X	O
-	O
linked	O
inheritance	O
of	O
retinal	B-Phenotype
degeneration	E-Phenotype
in	O
females	O
caused	O
by	O
variants	O
in	O
PRPS1	O
and	O
suggest	O
that	O
tissue	O
-	O
specific	O
skewed	O
X	O
-	O
inactivation	O
or	O
variable	O
levels	O
of	O
pyrophosphate	O
synthetase	O
-	O
1	O
deficiency	O
are	O
the	O
underlying	O
mechanism	O
(	O
s	O
)	O
.	O

Importantly	O
,	O
loss	O
of	O
Arl13b	O
in	O
a	O
Ptch1	O
-	O
deleted	O
mouse	O
model	O
of	O
MB	O
inhibited	O
tumor	S-Phenotype
formation	O
.	O

The	O
most	O
common	O
genetic	O
cause	O
is	O
L1CAM	O
-	O
related	O
X	B-Phenotype
-	I-Phenotype
linked	I-Phenotype
hydrocephalus	E-Phenotype
and	O
that	O
explains	O
only	O
5	O
%	O
-	O
10	O
%	O
of	O
all	O
male	O
cases	O
.	O

Focal	O
alterations	O
affected	O
CDKN2A	O
,	O
CCND1	O
,	O
CCNE1	O
,	O
EGFR	O
,	O
EPHA3	O
,	O
EPHB1	O
,	O
FGFR1	O
,	O
JUN	O
,	O
NF1	O
,	O
RB1	O
,	O
RET	O
,	O
TP53	O
,	O
and	O
additional	O
novel	O
amplifications	O
in	O
CCNE1	O
,	O
KIT	O
,	O
EGFR	O
,	O
RET	O
,	O
BRAF	O
,	O
NTRK2	O
were	O
seen	O
in	O
G3	O
compared	O
with	O
the	O
G1	O
tumor	S-Phenotype
areas	O
.	O

However	O
,	O
very	O
little	O
is	O
known	O
about	O
the	O
connection	O
between	O
mitochondrial	B-Phenotype
dysfunction	E-Phenotype
and	O
EMT	O
.	O

Progression	O
of	O
prostate	B-Phenotype
cancer	E-Phenotype
(	O
PC	O
)	O
to	O
castration	O
-	O
recurrent	O
growth	O
(	O
CRPC	O
)	O
remains	O
dependent	O
on	O
sustained	O
expression	O
and	O
transcriptional	O
activity	O
of	O
the	O
androgen	O
receptor	O
(	O
AR	O
)	O
.	O

Around	O
50	O
%	O
of	O
patient	O
*	O
s	O
relatives	O
with	O
PMAH	O
and	O
30	O
%	O
of	O
apparently	O
sporadic	B-Phenotype
hypercortisolism	E-Phenotype
carried	O
ARMC5	O
mutations	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
demonstrate	O
that	O
knockdown	O
of	O
MLK7	O
-	O
AS1	O
by	O
siRNA	O
inhibits	O
gastric	B-Phenotype
cancer	E-Phenotype
growth	O
by	O
epigenetically	O
regulating	O
miR	O
-	O
375	O
.	O

To	O
identify	O
novel	O
susceptibility	O
genes	O
and	O
gene	O
sets	O
for	O
obesity	S-Phenotype
,	O
we	O
conducted	O
a	O
genomewide	O
expression	O
association	O
analysis	O
of	O
obesity	S-Phenotype
via	O
integrating	O
genomewide	O
association	O
study	O
(	O
GWAS	O
)	O
and	O
expression	O
quantitative	O
trait	O
loci	O
(	O
eQTLs	O
)	O
data	O
.	O

Angioinvasion	O
defined	O
as	O
tumor	S-Phenotype
cells	O
invading	O
through	O
a	O
vessel	O
wall	O
and	O
intravascular	O
tumor	S-Phenotype
cells	O
admixed	O
with	O
thrombus	O
proved	O
to	O
be	O
the	O
best	O
prognostic	O
parameter	O
,	O
predicting	O
adverse	O
outcome	O
in	O
the	O
entire	O
cohort	O
as	O
well	O
as	O
within	O
low	O
-	O
grade	O
ACCs	O
.	O

In	O
conclusion	O
,	O
we	O
identified	O
relevant	O
genetic	O
variations	O
in	O
up	O
to	O
15	O
%	O
of	O
cases	O
after	O
exclusion	O
of	O
polyglutamine	B-Phenotype
expansion	I-Phenotype
spinocerebellar	I-Phenotype
ataxias	E-Phenotype
,	O
and	O
confirmed	O
CACNA1A	O
and	O
SPG7	O
as	O
major	O
ataxia	S-Phenotype
genes	O
.	O

In	O
proximal	S-Phenotype
renal	O
tubules	O
,	O
FGF23	O
suppresses	O
the	O
membrane	O
expression	O
of	O
the	O
sodium	O
-	O
phosphate	O
cotransporters	O
Npt2a	O
and	O
Npt2c	O
which	O
mediate	O
urinary	O
reabsorption	O
of	O
filtered	O
phosphate	O
.	O

Heterozygous	O
missense	O
mutations	O
in	O
ANK3	O
have	O
been	O
associated	O
with	O
autism	B-Phenotype
spectrum	I-Phenotype
disorder	E-Phenotype
.	O

Adipocyte	O
OGT	O
stimulates	O
hyperphagia	S-Phenotype
by	O
transcriptional	O
activation	O
of	O
de	O
novo	O
lipid	O
desaturation	O
and	O
accumulation	O
of	O
N	O
-	O
arachidonyl	O
ethanolamine	O
(	O
AEA	O
)	O
,	O
an	O
endogenous	O
appetite	O
-	O
inducing	O
cannabinoid	O
(	O
CB	O
)	O
.	O

Friedreich	B-Phenotype
ataxia	E-Phenotype
(	O
FRDA	S-Phenotype
)	O
is	O
the	O
most	O
frequent	O
progressive	O
autosomal	O
recessive	O
disorder	O
associated	O
with	O
unstable	O
expansion	O
of	O
GAA	O
trinucleotide	O
repeats	O
in	O
the	O
first	O
intron	O
of	O
the	O
FXN	O
gene	O
,	O
which	O
encodes	O
for	O
the	O
mitochondrial	O
frataxin	O
protein	O
.	O

Patients	O
with	O
ORC1	O
and	O
ORC4	O
mutations	O
appear	O
to	O
have	O
the	O
most	O
severe	B-Phenotype
short	I-Phenotype
stature	E-Phenotype
and	O
microcephaly	S-Phenotype
.	O

In	O
conclusion	O
,	O
autosomal	O
dominant	O
mutations	O
in	O
SRP54	O
,	O
a	O
key	O
member	O
of	O
the	O
cotranslation	O
protein	O
-	O
targeting	O
pathway	O
,	O
lead	O
to	O
syndromic	O
neutropenia	S-Phenotype
with	O
a	O
Shwachman	O
-	O
Diamond	O
-	O
like	O
phenotype	O

Mutations	O
in	O
POMT1	O
,	O
POMT2	O
,	O
POMGNT1	O
,	O
FKTN	O
,	O
FKRP	O
,	O
LARGE	O
,	O
GMPPB	O
,	O
TMEM5	O
and	O
COL4A1	O
and	O
ISPD	O
lead	O
to	O
a	O
wide	O
spectrum	O
of	O
phenotypes	O
of	O
congenital	B-Phenotype
muscular	I-Phenotype
dystrophies	E-Phenotype
with	O
or	O
without	O
eye	O
and	O
brain	O
abnormalities	O
.	O

Mucopolysaccharidosis	O
(	O
MPS	O
)	O
type	O
I	O
is	O
a	O
rare	O
autosomal	B-Phenotype
recessive	E-Phenotype
disease	O
caused	O
by	O
a	O
deficiency	O
of	O
the	O
lysosomal	O
enzyme	O
α	O
-	O
L	O
-	O
iduronidase	O
.	O

Homozygous	O
recessive	O
mutations	O
in	O
the	O
PRICKLE1	O
gene	O
were	O
first	O
described	O
in	O
three	O
consanguineous	O
families	O
with	O
myoclonic	B-Phenotype
epilepsy	E-Phenotype
.	O

L1	O
cell	O
adhesion	O
molecule	O
(	O
L1CAM	O
)	O
is	O
a	O
member	O
of	O
the	O
immunoglobulin	O
-	O
like	O
cell	O
-	O
adhesion	O
molecule	O
family	O
that	O
was	O
shown	O
to	O
be	O
associated	O
with	O
a	O
worse	O
prognosis	O
in	O
several	O
human	O
cancers	S-Phenotype
.	O

Our	O
findings	O
revealed	O
that	O
both	O
PYCR1	O
mRNA	O
and	O
protein	O
expression	O
were	O
significantly	O
associated	O
with	O
tumor	S-Phenotype
size	O
,	O
grade	O
and	O
invasive	O
molecular	O
subtypes	O
of	O
breast	B-Phenotype
cancers	E-Phenotype
.	O

In	O
fact	O
,	O
WRAP53	O
has	O
been	O
considered	O
as	O
a	O
candidate	O
cancer	S-Phenotype
susceptibility	O
gene	O
.	O

Corneal	B-Phenotype
dystrophies	E-Phenotype
may	O
have	O
a	O
simple	O
autosomal	O
dominant	O
,	O
autosomal	B-Phenotype
recessive	E-Phenotype
or	O
X	O
-	O
linked	O
recessive	O
Mendelian	O
mode	B-Phenotype
of	I-Phenotype
inheritance	E-Phenotype
.	O

Primary	B-Phenotype
hyperoxaluria	I-Phenotype
type	I-Phenotype
1	E-Phenotype
(	O
PH1	S-Phenotype
)	O
,	O
a	O
rare	O
autosomal	O
recessive	O
disorder	O
,	O
is	O
characterized	O
by	O
renal	B-Phenotype
stones	E-Phenotype
,	O
nephrocalcinosis	S-Phenotype
,	O
and	O
chronic	B-Phenotype
kidney	I-Phenotype
disease	E-Phenotype
.	O

Results	O
:	O
UNC5C	O
promoter	O
hypermethylation	O
was	O
significantly	O
found	O
to	O
be	O
associated	O
with	O
colorectal	B-Phenotype
cancer	E-Phenotype
cases	O

We	O
compared	O
the	O
distribution	O
and	O
localization	O
of	O
UC	O
and	O
esterified	O
cholesterol	O
(	O
EC	O
)	O
;	O
the	O
age	B-Phenotype
-	I-Phenotype
related	I-Phenotype
macular	I-Phenotype
degeneration	E-Phenotype
(	O
AMD	S-Phenotype
)	O
associated	O
EFEMP1	O
/	O
Fibulin3	O
(	O
Fib3	O
)	O
;	O
and	O
levels	O
of	O
acyl	O
-	O
coenzyme	O
A	O
(	O
CoA	O
)	O
:	O
cholesterol	O
acyltransferases	O
(	O
ACAT	O
)	O
ACAT1	O
,	O
ACAT2	O
and	O
Apolipoprotein	O
B	O
(	O
ApoB	O
)	O
in	O
ARPE	O
-	O
19	O
cells	O
cultured	O
in	O
serum	O
-	O
supplemented	O
and	O
serum	O
-	O
free	O
media	O
.	O

Dec1	O
expression	O
was	O
also	O
compared	O
with	O
the	O
apoptosis	O
index	O
determined	O
by	O
TdT‑mediated	O
dUTP	O
nick	O
ending‑labeling	O
assay	O
in	O
recurrent	O
glioblastomas	S-Phenotype
.	O

Fourteen	O
different	O
(	O
half	O
of	O
them	O
novel	O
)	O
non	O
-	O
GJB2	O
variants	O
causing	O
HL	O
were	O
found	O
in	O
10	O
genes	O
(	O
CHD7	O
,	O
HDAC8	O
,	O
MITF	O
,	O
NEFL	O
,	O
OTOF	O
,	O
SF3B4	O
,	O
SLC26A4	O
,	O
TECTA	O
,	O
TMPRSS3	O
,	O
USH2A	O
)	O
among	O
13	O
probands	O
,	O
confirming	O
the	O
genetic	O
heterogeneity	S-Phenotype
of	O
hereditary	O
HL	O
.	O

Ancestor	O
tumor	S-Phenotype
clones	O
evolved	O
into	O
three	O
subclonal	O
clades	O
:	O
clade1	O
fostered	O
metastatic	O
subclones	O
that	O
carried	O
metastatic	O
features	O
of	O
liPIK3CA	O
and	O
liARHGAP26	O
point	O
mutations	O
as	O
well	O
as	O
chr13	O
arm	O
-	O
level	O
deletion	O
,	O
clade2	O
owned	O
branch	O
-	O
specific	O
liJAK1	O
mutations	O
and	O
liPTEN	O
deletion	O
,	O
and	O
clade3	O
was	O
found	O
in	O
two	O
vertical	O
distribution	O
samples	O
below	O
the	O
primary	O
tumor	S-Phenotype
area	O
,	O
highlighting	O
the	O
fact	O
that	O
it	O
is	O
possible	O
for	O
PMME	O
to	O
disseminate	O
by	O
the	O
submucosal	O
longitudinal	O
lymphatic	O
route	O
at	O
an	O
early	O
stage	O
of	O
metastasis	O
.	O

Zinc	O
finger	O
protein	O
687	O
(	O
ZNF687	O
)	O
,	O
identified	O
as	O
a	O
C2H2	O
zinc	O
finger	O
protein	O
,	O
has	O
been	O
found	O
to	O
be	O
mutated	O
and	O
upregulated	O
in	O
giant	B-Phenotype
cell	I-Phenotype
tumor	I-Phenotype
of	I-Phenotype
bone	E-Phenotype
and	O
acute	B-Phenotype
myeloid	I-Phenotype
leukemia	E-Phenotype
,	O
suggesting	O
an	O
oncogenic	O
role	O
for	O
ZNF687	O
in	O
cancer	S-Phenotype
.	O

We	O
present	O
two	O
pediatric	O
cases	O
of	O
progressive	O
myoclonic	B-Phenotype
epilepsy	E-Phenotype
with	O
SERPINI1	O
pathogenic	O
variants	O
that	O
lead	O
to	O
a	O
severe	O
presentation	O
;	O
we	O
highlight	O
the	O
importance	O
of	O
including	O
this	O
gene	O
,	O
previously	O
known	O
as	O
causing	O
an	O
adult	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
dementia	I-Phenotype
-	I-Phenotype
epilepsy	E-Phenotype
syndrome	O
,	O
in	O
the	O
genetic	O
work	O
-	O
up	O
of	O
childhood	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
progressive	I-Phenotype
myoclonic	I-Phenotype
epilepsies	E-Phenotype

Mutation	O
in	O
FLNA	O
causes	O
a	O
wide	O
spectrum	O
of	O
disease	O
including	O
skeletal	B-Phenotype
dysplasia	E-Phenotype
,	O
neuronal	B-Phenotype
migration	I-Phenotype
abnormality	E-Phenotype
,	O
cardiovascular	B-Phenotype
malformation	E-Phenotype
,	O
intellectual	B-Phenotype
disability	E-Phenotype
and	O
intestinal	B-Phenotype
obstruction	E-Phenotype
.	O

Hair	B-Phenotype
-	I-Phenotype
nail	I-Phenotype
ectodermal	I-Phenotype
dysplasia	E-Phenotype
(	O
HNED	S-Phenotype
;	O
OMIM	O
602032	O
)	O
constitutes	O
a	O
rare	O
subgroup	O
of	O
ectodermal	B-Phenotype
dysplasias	E-Phenotype
characterised	O
by	O
onychodystrophy	S-Phenotype
,	O
hypotrichosis	S-Phenotype
and	O
brittle	B-Phenotype
hair	E-Phenotype
.	O

The	O
fat	O
mass	O
and	O
obesity	S-Phenotype
-	O
associated	O
(	O
FTO	O
)	O
gene	O
is	O
tightly	O
related	O
to	O
body	O
weight	O
and	O
fat	O
mass	O
,	O
and	O
plays	O
a	O
pivotal	O
role	O
in	O
regulating	O
lipid	B-Phenotype
accumulation	I-Phenotype
in	I-Phenotype
hepatocytes	E-Phenotype
.	O

Over	O
140	O
disease	O
-	O
causing	O
mutations	O
have	O
been	O
described	O
so	O
far	O
in	O
GUCY2D	O
,	O
88	O
%	O
of	O
which	O
cause	O
autosomal	B-Phenotype
recessive	I-Phenotype
Leber	I-Phenotype
congenital	I-Phenotype
amaurosis	E-Phenotype
(	O
LCA	S-Phenotype
)	O
while	O
heterozygous	O
missense	O
mutations	O
cause	O
autosomal	O
dominant	O
cone	O
-	O
rod	O
degeneration	O
(	O
adCRD	O
)	O
.	O

Perturbation	O
of	O
MAM	O
function	O
has	O
previously	O
been	O
suggested	O
in	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
as	O
shown	O
in	O
fibroblasts	O
from	O
AD	O
patients	O
and	O
a	O
neuroblastoma	S-Phenotype
cell	O
line	O
containing	O
familial	O
presenilin	O
-	O
2	O
AD	O
mutation	O
.	O

Uncorrected	O
refractive	O
errors	O
constitute	O
the	O
most	O
common	O
cause	O
of	O
vision	B-Phenotype
loss	E-Phenotype
and	O
second	O
leading	O
cause	O
of	O
blindness	S-Phenotype
worldwide	O
.	O

Gene	O
set	O
enrichment	O
analysis	O
was	O
conducted	O
to	O
study	O
the	O
relevant	O
mechanisms	O
.	O

Bladder	O
cancer	S-Phenotype
patients	O
in	O
COL5A2	O
low	O
expression	O
group	O
were	O
associated	O
with	O
better	O
invasiveness	O
(	O
P	O
AAAA	O
.0001	O
)	O
,	O
tumor	S-Phenotype
grade	O
(	O
P	O
=	O
.001	O
)	O
,	O
T	O
staging	O
(	O
P	O
AAAA	O
.0001	O
)	O
,	O
N	O
staging	O
(	O
P	O
=	O
.002	O
)	O
,	O
cancer	S-Phenotype
specific	O
survival	O
(	O
P	O
AAAA	O
.0001	O
)	O
,	O
overall	O
survival	O
(	O
P	O
AAAA	O
.0001	O
)	O
,	O
and	O
a	O
trend	O
of	O
better	O
M	O
staging	O
(	O
P	O
=	O
.053	O
)	O
than	O
those	O
in	O
COL5A2	O
high	O
expression	O
group.COL5A2	O
might	O
affect	O
the	O
progression	O
of	O
bladder	B-Phenotype
cancer	E-Phenotype
through	O
AAAAAACoagulation	O
,	O
AAAAAA	O
AAAAAAHypoxia	O
,	O
AAAAAA	O
AAAAAAApical	O
junction	O
,	O
AAAAAA	O
AAAAAAUltraviolet	O
response	O
,	O
AAAAAA	O
AAAAAAEpithelial	O
mesenchymal	O
transition	O
,	O
AAAAAA	O
AAAAAAAngiogenesis	O
,	O
AAAAAA	O
AAAAAAKRAS	O
(	O
KRAS	O
proto	O
-	O
oncogene	O
,	O
GTPase	O
)	O
signaling	O
,	O
AAAAAAComplement	O
,	O
AAAAAAIL2	O
-	O
STAT5	O
-	O
signaling	O
,	O
AAAAAA	O
AAAAAAInflammatory	O
response	O
,	O
AAAAAA	O
AAAAAAIL6	O
-	O
JAK	O
-	O
STAT3	O
-	O
signaling	O
,	O
AAAAAA	O
AAAAAAMyogenesis	O
,	O
AAAAAA	O
AAAAAATNF	O
a	O
signaling	O
,	O
AAAAAA	O
AAAAAAApoptosis	O
,	O
AAAAAA	O
and	O
AAAAAAHedgehog	O
-	O
signaling.AAAAA	O
;	O
Our	O
results	O
demonstrated	O
that	O
COL5A2	O
was	O
correlated	O
with	O
poor	O
clinical	O
outcomes	O
and	O
survivals	O
of	O
patients	O
with	O
bladder	B-Phenotype
cancer	E-Phenotype
,	O
suggesting	O
that	O
it	O
could	O
be	O
regarded	O
as	O
a	O
biomarker	O
of	O
bladder	B-Phenotype
cancer	E-Phenotype

A	O
preliminary	O
bioinformatics	O
analysis	O
showed	O
that	O
HOXB1	O
is	O
ectopically	O
expressed	O
in	O
glioma	S-Phenotype
,	O
and	O
that	O
HOXB1	O
is	O
a	O
possible	O
target	O
of	O
miR	O
-	O
3175	O
.	O

The	O
data	O
implying	O
there	O
could	O
be	O
a	O
lower	O
association	O
of	O
some	O
specific	O
GATM	O
gene	O
variants	O
with	O
autism	S-Phenotype
is	O
an	O
observation	O
that	O
would	O
need	O
to	O
be	O
corroborated	O
in	O
a	O
larger	O
group	O
of	O
autism	S-Phenotype
patients	O
,	O
and	O
with	O
sub	O
-	O
populations	O
of	O
Asian	O
ethnicities	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
describing	O
sporadic	S-Phenotype
XLID	O
with	O
de	O
novo	O
ZDHHC9	O
mutation	O
identified	O
by	O
targeted	O
next	O
-	O
generation	O
sequencing	O

In	O
a	O
few	O
(	O
non	O
-	O
Swedish	O
)	O
melanoma	S-Phenotype
families	O
,	O
mutations	O
in	O
other	O
genes	O
have	O
been	O
found	O
,	O
including	O
CDK4	O
,	O
TERT	O
,	O
POT1	O
,	O
ACD	O
and	O
TERF2IP	O
.	O

We	O
found	O
that	O
LGR5	O
expression	O
in	O
the	O
epithelium	O
and	O
stroma	O
was	O
associated	O
with	O
tumor	S-Phenotype
stage	O
,	O
and	O
by	O
integrating	O
functional	O
experiments	O
with	O
LGR5	O
-	O
sorted	O
cell	O
RNA	O
sequencing	O
data	O
from	O
adenoma	O
and	O
normal	O
organoids	O
,	O
we	O
found	O
correlations	O
between	O
LGR5	O
and	O
CRC	O
-	O
specific	O
genes	O
,	O
including	O
dickkopf	O
WNT	O
signaling	O
pathway	O
inhibitor	O
4	O
(	O
DKK4	O
)	O
and	O
SPARC	O
-	O
related	O
modular	O
calcium	O
binding	O
2	O
(	O
SMOC2	O
)	O
.	O

Further	O
studies	O
showed	O
that	O
RNF6	O
was	O
closely	O
associated	O
with	O
increased	O
expression	O
of	O
estrogen	O
receptor	O
,	O
a	O
critical	O
factor	O
in	O
the	O
development	O
of	O
breast	B-Phenotype
cancers	E-Phenotype
.	O

PurposePREPL	O
deficiency	O
causes	O
neonatal	B-Phenotype
hypotonia	E-Phenotype
,	O
ptosis	S-Phenotype
,	O
neonatal	B-Phenotype
feeding	I-Phenotype
difficulties	E-Phenotype
,	O
childhood	B-Phenotype
obesity	E-Phenotype
,	O
xerostomia	S-Phenotype
,	O
and	O
growth	B-Phenotype
hormone	I-Phenotype
deficiency	E-Phenotype
.	O

Large	O
-	O
scale	O
tumor	S-Phenotype
sequencing	O
has	O
revolutionized	O
the	O
identification	O
of	O
somatic	O
driver	O
alterations	O
but	O
has	O
had	O
limited	O
impact	O
on	O
the	O
identification	O
of	O
cancer	S-Phenotype
predisposition	O
genes	O
(	O
CPGs	O
)	O
.	O

The	O
APC	O
1A	O
promoter	O
was	O
hypermethylated	O
in	O
7	O
of	O
36	O
tumours	S-Phenotype
from	O
never	O
-	O
smokers	O
(	O
19	O
%	O
)	O
,	O
12	O
of	O
47	O
tumours	S-Phenotype
from	O
former	O
smokers	O
(	O
26	O
%	O
)	O
,	O
and	O
8	O
of	O
13	O
tumours	S-Phenotype
from	O
active	O
smokers	O
(	O
62	O
%	O
)	O
.	O

Furthermore	O
,	O
we	O
observed	O
the	O
hypermethylation	O
of	O
the	O
CHRDL1	O
promoter	O
in	O
gastric	B-Phenotype
cancer	E-Phenotype
,	O
which	O
induced	O
low	O
expression	O
of	O
CHRDL1	O
and	O
decreased	O
its	O
secretion	O
to	O
the	O
supernatant	O
.	O

Furthermore	O
,	O
we	O
found	O
increased	O
concentration	O
of	O
cytochrome	O
c	O
,	O
Smac	O
/	O
Diablo	O
and	O
increased	O
caspase	O
-	O
3	O
and	O
caspase	O
-	O
9	O
activity	O
,	O
cleavage	O
of	O
PARP	O
as	O
well	O
as	O
activation	O
of	O
DNA	O
repair	O
mechanisms	O
in	O
1C	O
-	O
treated	O
HCT116	O
cancer	S-Phenotype
cells	O
.	O

RFT1	O
-	O
congenital	O
disorder	O
of	O
glycosylation	O
(	O
CDG	O
)	O
syndrome	O
,	O
a	O
recessive	O
N	O
-	O
glycosylation	O
disorder	O
caused	O
by	O
mutation	O
in	O
the	O
RFT1	O
gene	O
,	O
is	O
a	O
very	O
rare	O
subtype	O
of	O
CDG	O
syndrome	O
associated	O
with	O
deafness	S-Phenotype
,	O
developmental	B-Phenotype
delay	E-Phenotype
,	O
and	O
non	B-Phenotype
-	I-Phenotype
specific	I-Phenotype
epilepsy	E-Phenotype
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
association	O
between	O
HFM1	O
gene	O
variants	O
and	O
sporadic	S-Phenotype
POI	O
in	O
Chinese	O
women	O
.	O

Peripheral	B-Phenotype
neuropathy	E-Phenotype
(	O
PNP	S-Phenotype
)	O
remains	O
one	O
of	O
the	O
most	O
frequent	O
side	O
-	O
effects	O
experienced	O
by	O
patients	O
who	O
receive	O
these	O
novel	O
agents	O
.	O

A	O
deletion	O
(	O
c.640_644del5	O
)	O
in	O
RNF168	O
,	O
causative	O
for	O
recessive	O
RIDDLE	O
syndrome	O
,	O
had	O
high	O
prevalence	O
in	O
majority	O
of	O
the	O
analyzed	O
cohorts	O
,	O
but	O
did	O
not	O
associate	O
with	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

Selective	O
Ednra	O
blockade	O
or	O
mitochondrial	O
-	O
targeted	O
reactive	O
oxygen	O
species	O
scavenging	O
prevented	O
mitochondrial	B-Phenotype
oxidative	I-Phenotype
stress	E-Phenotype
of	O
endothelial	O
cells	O
and	O
ameliorated	B-Phenotype
diabetes	I-Phenotype
-	I-Phenotype
induced	I-Phenotype
endothelial	I-Phenotype
injury	E-Phenotype
,	O
podocyte	B-Phenotype
loss	E-Phenotype
,	O
albuminuria	S-Phenotype
,	O
and	O
glomerulosclerosis	S-Phenotype
.	O

In	O
vivo	O
,	O
SPINK1	O
is	O
expressed	O
in	O
the	O
stroma	O
of	O
solid	O
tumours	S-Phenotype
and	O
is	O
routinely	O
detectable	O
in	O
peripheral	O
blood	O
of	O
cancer	S-Phenotype
patients	O
after	O
chemotherapy	O
.	O

Several	O
independent	O
research	O
groups	O
,	O
including	O
our	O
own	O
,	O
recently	O
examined	O
the	O
effects	O
of	O
heterozygous	O
deletion	O
of	O
Arid1b	O
in	O
mice	O
and	O
reported	O
severe	O
behavioral	B-Phenotype
abnormalities	E-Phenotype
reminiscent	O
of	O
autism	B-Phenotype
spectrum	I-Phenotype
disorders	E-Phenotype
and	O
intellectual	B-Phenotype
disability	E-Phenotype
as	O
well	O
as	O
marked	O
changes	O
in	O
gene	O
expression	O
and	O
decreased	O
body	O
size	O
.	O

Preoperative	O
lymph	O
node	O
(	O
LN	O
)	O
status	O
is	O
important	O
for	O
the	O
treatment	O
of	O
bladder	B-Phenotype
cancer	E-Phenotype
(	O
BCa	S-Phenotype
)	O
.	O

Accordingly	O
,	O
overexpression	O
of	O
the	O
Aα	O
mutants	O
in	O
EC	O
cells	O
harboring	O
wild	O
-	O
type	O
PPP2R1A	O
increased	O
anchorage	O
-	O
independent	O
growth	O
and	O
tumor	S-Phenotype
formation	O
,	O
and	O
triggered	O
hyperphosphorylation	O
of	O
oncogenic	O
PP2A	O
-	O
B56	O
/	O
B	O
'	O
substrates	O
in	O
the	O
GSK3β	O
,	O
Akt	O
,	O
and	O
mTOR	O
/	O
p70S6K	O
signaling	O
pathways	O
.	O

Other	O
tumors	S-Phenotype
(	O
outside	O
CT	O
and	O
CSS	O
)	O
that	O
have	O
SDH	O
deficiency	O
are	O
associated	O
with	O
increased	O
methylation	O
of	O
the	O
entire	O
genome	O
,	O
but	O
only	O
in	O
CT	O
there	O
is	O
site	O
-	O
specific	O
methylation	O
of	O
the	O
SDHC	O
gene	O
.	O

While	O
none	O
of	O
these	O
miRNAs	O
have	O
been	O
previously	O
linked	O
to	O
glaucoma	S-Phenotype
,	O
miR	O
-	O
122	O
-	O
5p	O
may	O
target	O
three	O
glaucoma	S-Phenotype
-	O
associated	O
genes	O
:	O
OPTN	O
,	O
TMCO1	O
and	O
TGF	O
-	O
ß1	O
.	O

The	O
aetiology	O
of	O
PAH	O
is	O
heterogeneous	S-Phenotype
,	O
and	O
genetics	O
play	O
an	O
important	O
role	O
in	O
some	O
cases	O
.	O

The	O
most	O
frequent	O
hearing	B-Phenotype
loss	E-Phenotype
associated	O
allele	O
detected	O
in	O
this	O
population	O
was	O
the	O
235delC	O
variant	O
in	O
GJB2	O
gene	O
.	O

Tricho	O
-	O
hepato	O
-	O
enteric	O
syndrome	O
(	O
SD	O
/	O
THE	O
)	O
and	O
Multiple	B-Phenotype
intestinal	I-Phenotype
atresia	I-Phenotype
with	I-Phenotype
combined	I-Phenotype
immune	I-Phenotype
deficiency	E-Phenotype
(	O
MIA	B-Phenotype
-	I-Phenotype
CID	E-Phenotype
)	O
are	O
autosomal	B-Phenotype
recessive	E-Phenotype
disorders	O
that	O
present	O
immunological	O
and	O
gastrointestinal	O
features	O
.	O

Here	O
we	O
show	O
,	O
using	O
whole	O
-	O
exome	O
and	O
cancer	S-Phenotype
gene	O
panel	O
sequencing	O
of	O
79	O
aGCTs	O
from	O
two	O
independent	O
cohorts	O
,	O
that	O
truncating	O
mutation	O
of	O
the	O
histone	O
lysine	O
methyltransferase	O
gene	O
KMT2D	O
(	O
also	O
known	O
as	O
MLL2	O
)	O
is	O
a	O
recurrent	O
somatic	O
event	O
in	O
aGCT	O
.	O

Silver	O
-	O
Russell	O
Syndrome	O
(	O
SRS	O
)	O
is	O
clinically	O
heterogeneous	S-Phenotype
disorder	O
characterized	O
by	O
low	B-Phenotype
birth	I-Phenotype
weight	E-Phenotype
,	O
postnatal	B-Phenotype
growth	I-Phenotype
restriction	E-Phenotype
,	O
and	O
variable	O
dysmorphic	O
features	O
.	O

CCDC8	O
was	O
shown	O
to	O
be	O
located	O
predominantly	O
in	O
the	O
cytoplasm	O
and	O
partially	O
on	O
the	O
cell	O
membrane	O
,	O
and	O
its	O
expression	O
level	O
was	O
significantly	O
lower	O
in	O
lung	B-Phenotype
cancer	E-Phenotype
samples	O
than	O
that	O
in	O
the	O
adjacent	O
normal	O
lung	O
tissues	O
(	O
P=.001	O
)	O
.	O

Hyperpolarization	O
-	O
activated	O
cyclic	O
nucleotide	O
-	O
gated	O
channels	O
(	O
HCN	O
)	O
can	O
act	O
as	O
pacemakers	O
in	O
the	O
brain	O
making	O
them	O
strong	O
candidates	O
for	O
driving	O
aberrant	O
hypersynchronous	O
network	O
activity	O
seen	O
in	O
epilepsy	S-Phenotype
.	O

A	O
novel	O
hereditary	O
disorder	O
encompassing	O
high	O
blood	O
Mn	O
levels	O
,	O
dystonia	S-Phenotype
,	O
polycythemia	S-Phenotype
,	O
distinctive	O
T1	O
hyperintense	O
signals	O
in	O
the	O
basal	O
ganglia	O
on	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
brain	B-Phenotype
,	I-Phenotype
and	I-Phenotype
chronic	I-Phenotype
liver	I-Phenotype
disease	E-Phenotype
was	O
recently	O
described	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
look	O
for	O
genetic	O
causes	O
of	O
Currarino	O
Syndrome	O
in	O
sporadic	S-Phenotype
patients	O
after	O
ruling	O
out	O
other	O
causes	O
,	O
like	O
chromosome	O
aberrations	O
,	O
disease	O
-	O
causing	O
variants	O
in	O
possible	O
MNX1	O
cooperating	O
transcription	O
factors	O
and	O
aberrant	O
methylation	O
in	O
the	O
promoter	O
of	O
the	O
MNX1	O
gene	O
.	O

Here	O
we	O
have	O
studied	O
eleven	O
consanguineous	O
LCA	O
and	O
one	O
autosomal	B-Phenotype
recessive	E-Phenotype
RP	O
(	O
arRP	O
)	O
south	O
Indian	O
families	O
to	O
know	O
the	O
prevalence	O
of	O
mutations	O
in	O
known	O
genes	O
and	O
also	O
to	O
know	O
the	O
involvement	O
of	O
novel	O
loci	O
,	O
if	O
any	O
.	O

Feeding	B-Phenotype
difficulties	E-Phenotype
,	O
periods	O
of	O
fever	S-Phenotype
and	O
vomiting	S-Phenotype
as	O
well	O
as	O
a	O
high	O
pain	S-Phenotype
threshold	O
were	O
described	O
as	O
additional	O
characteristic	O
features	O
and	O
the	O
disorder	O
was	O
subsequently	O
termed	O
AAAAAAintellectual	O
developmental	O
disorder	O
with	O
gastrointestinal	O
difficulties	O
and	O
high	O
pain	S-Phenotype
threshold	O
(	O
IDDGIP	O
)	O
AAAAAA	O
in	O
the	O
OMIM	O
database	O
(	O
MIM	O
#	O
617450	O
)	O
.	O

Meesmann	B-Phenotype
epithelial	I-Phenotype
corneal	I-Phenotype
dystrophy	E-Phenotype
(	O
MECD	S-Phenotype
)	O
is	O
a	O
rare	O
autosomal	O
dominant	O
disorder	O
caused	O
by	O
dominant	O
-	O
negative	O
mutations	O
within	O
the	O
KRT3	O
or	O
KRT12	O
genes	O
,	O
which	O
encode	O
the	O
cytoskeletal	O
protein	O
keratins	O
K3	O
and	O
K12	O
,	O
respectively	O
.	O

Expression	O
of	O
miR	O
-	O
17	O
-	O
92a	O
miRNAs	O
caused	O
decreased	O
cell	O
proliferation	O
,	O
reduced	O
activation	O
of	O
AKT	O
and	O
MAP	O
kinases	O
,	O
delayed	O
tumorigenicity	S-Phenotype
and	O
reduced	O
tumor	S-Phenotype
growth	O
in	O
animals	O
.	O

Oculocutaneous	O
albinism	S-Phenotype
type	O
4	O
(	O
OCA4	O
)	O
in	O
humans	O
and	O
similar	O
phenotypes	O
in	O
many	O
animal	O
species	O
are	O
caused	O
by	O
variants	O
in	O
the	O
SLC45A2	O
gene	O
,	O
encoding	O
a	O
putative	O
sugar	O
transporter	O
.	O

Congenital	B-Phenotype
heart	I-Phenotype
defects	E-Phenotype
represent	O
a	O
characteristic	O
part	O
of	O
several	O
genetic	O
syndromes	O
associated	O
with	O
chromosomal	O
abnormalities	O
such	O
as	O
22q11.2	O
deletion	O
syndrome	O
;	O
many	O
genes	O
located	O
in	O
this	O
locus	O
,	O
mainly	O
TBX1	O
,	O
are	O
candidate	O
genes	O
for	O
congenital	B-Phenotype
heart	I-Phenotype
defects	E-Phenotype
.	O

Cancer	S-Phenotype
was	O
distinguished	O
from	O
ILD	O
with	O
a	O
specificity	O
of	O
88	O
%	O
,	O
(	O
95	O
%	O
CI	O
:	O
0.57	O
-	O
1	O
)	O
,	O
and	O
COPD	O
from	O
cancer	S-Phenotype
with	O
a	O
specificity	O
of	O
88	O
%	O
(	O
95	O
%	O
CI	O
:	O
0.64	O
-	O
0.97	O
)	O
.	O

However	O
,	O
whether	O
and	O
how	O
GATA3	O
participates	O
in	O
the	O
process	O
of	O
DNA	O
repair	O
,	O
which	O
is	O
often	O
associated	O
with	O
tumorigenesis	S-Phenotype
,	O
has	O
not	O
been	O
investigated	O
.	O

Interestingly	O
,	O
patients	O
with	O
tumors	S-Phenotype
in	O
which	O
PKP1	O
and	O
PKP3	O
immunoreactivity	O
was	O
reduced	O
or	O
absent	O
exhibited	O
local	O
recurrences	O
or	O
metastases	O
,	O
or	O
both	O
,	O
as	O
well	O
as	O
poor	O
survival	O
.	O

Correlation	O
analysis	O
using	O
microarray	O
data	O
from	O
(	O
TRAMP	O
×	O
PWK	O
/	O
PhJ	O
)	O
F2	O
prostate	O
tumors	S-Phenotype
identified	O
35	O
metastasis	O
-	O
associated	O
transcripts	O
within	O
the	O
two	O
loci	O
.	O

In	O
this	O
study	O
,	O
IDO1	O
expression	O
in	O
tumor	S-Phenotype
cells	O
(	O
T	O
-	O
IDO1	O
)	O
was	O
frequently	O
detected	O
(	O
109	O
/	O
112	O
)	O
by	O
immunohistochemistry	O
in	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
specimens	O
from	O
HCC	O
patients	O
,	O
and	O
the	O
expression	O
patterns	O
were	O
mostly	O
focal	O
(	O
102	O
/	O
109	O
)	O
.	O

The	O
sisters	O
reported	O
here	O
display	O
the	O
distinguishing	O
clinical	O
features	O
of	O
WABS	O
:	O
pre	B-Phenotype
-	I-Phenotype
and	I-Phenotype
post	I-Phenotype
-	I-Phenotype
natal	I-Phenotype
growth	I-Phenotype
restriction	E-Phenotype
,	O
microcephaly	S-Phenotype
,	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
sensorineural	B-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
with	O
cochlear	B-Phenotype
abnormalities	E-Phenotype
,	O
and	O
facial	O
dysmorphic	O
features	O
.	O

Here	O
we	O
present	O
a	O
case	O
of	O
a	O
proband	O
with	O
a	O
complex	O
episodic	B-Phenotype
ataxias	E-Phenotype
(	O
EA	S-Phenotype
)	O
/	O
seizure	S-Phenotype
phenotype	O
with	O
an	O
EA	O
-	O
affected	O
father	O
;	O
and	O
an	O
unaffected	O
mother	O
,	O
all	O
negative	O
for	O
liCACNA1A	O
/	O
i	O
gene	O
mutations	O
.	O

The	O
APC	O
1A	O
promoter	O
was	O
hypermethylated	O
in	O
7	O
of	O
36	O
tumours	S-Phenotype
from	O
never	O
-	O
smokers	O
(	O
19	O
%	O
)	O
,	O
12	O
of	O
47	O
tumours	S-Phenotype
from	O
former	O
smokers	O
(	O
26	O
%	O
)	O
,	O
and	O
8	O
of	O
13	O
tumours	S-Phenotype
from	O
active	O
smokers	O
(	O
62	O
%	O
)	O
.	O

We	O
report	O
brothers	O
with	O
optic	B-Phenotype
neuropathy	E-Phenotype
who	O
had	O
novel	O
mutations	O
in	O
the	O
RTN4IP1	O
gene	O
.	O

In	O
the	O
present	O
article	O
,	O
we	O
describe	O
an	O
infant	O
who	O
smelt	O
of	O
ketones	O
during	O
examination	O
and	O
who	O
was	O
diagnosed	O
with	O
transient	O
NDM	O
caused	O
by	O
a	O
ZFP57	O
mutation	O
,	O
accompanied	O
by	O
ketoacidosis	S-Phenotype
.	O

As	O
a	O
result	O
,	O
patients	O
with	O
LAD	O
suffer	O
from	O
severe	O
bacterial	O
infections	O
and	O
impaired	O
wound	O
healing	O
,	O
accompanied	O
by	O
neutrophilia	S-Phenotype
.	O

These	O
results	O
provided	O
novel	O
insights	O
into	O
the	O
potential	O
role	O
of	O
UQCRC2	O
in	O
the	O
tumorigenesis	S-Phenotype
and	O
progression	O
of	O
CRC	O
,	O
and	O
revealed	O
that	O
UQCRC2	O
may	O
serve	O
as	O
a	O
new	O
prognostic	O
and	O
therapeutic	O
target	O
in	O
CRC	O

Therefore	O
,	O
we	O
conclude	O
that	O
the	O
novel	O
splice	O
-	O
site	O
variant	O
identified	O
in	O
COL27A1	O
is	O
the	O
most	O
likely	O
cause	O
for	O
Steel	O
syndrome	O
in	O
this	O
family	O
and	O
that	O
the	O
hearing	B-Phenotype
loss	E-Phenotype
is	O
part	O
of	O
this	O
syndrome	O
*	O
s	O
phenotype	O

In	O
multiple	O
types	O
of	O
tumors	S-Phenotype
,	O
fibrotic	O
collagen	O
is	O
regarded	O
as	O
the	O
*	O
highway	O
*	O
for	O
cancer	S-Phenotype
cell	O
migration	O
,	O
which	O
is	O
mainly	O
modified	O
by	O
lysyl	O
hydroxylase	O
2	O
(	O
PLOD2	O
)	O
.	O

Aberrant	O
PXDN	O
expression	O
has	O
been	O
associated	O
with	O
kidney	B-Phenotype
fibrosis	E-Phenotype
,	O
cancer	S-Phenotype
,	O
congenital	B-Phenotype
eye	I-Phenotype
defects	E-Phenotype
and	O
various	O
cardiovascular	O
disorders	O
.	O

Naive	O
CD4+	O
T	O
cells	O
adhere	O
to	O
tumor	S-Phenotype
slices	O
in	O
proportion	O
to	O
the	O
abundance	O
of	O
CCL18	O
-	O
producing	O
macrophages	O
.	O

We	O
conducted	O
further	O
optimization	O
of	O
dual	O
enzymatic	O
inhibitions	O
towards	O
FGFR1	O
and	O
DDR2	O
,	O
two	O
important	O
kinases	O
in	O
lung	B-Phenotype
squamous	I-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
expression	O
and	O
clinical	O
significance	O
of	O
p53R2	O
in	O
early	B-Phenotype
-	I-Phenotype
stage	I-Phenotype
cervical	I-Phenotype
cancer	E-Phenotype
.	O

We	O
also	O
provide	O
an	O
example	O
of	O
using	O
the	O
platform	O
to	O
screen	O
compounds	O
for	O
their	O
ability	O
to	O
lower	O
Apolipoprotein	O
B	O
(	O
APOB	O
)	O
produced	O
from	O
iPSC	O
-	O
derived	O
hepatocytes	O
generated	O
from	O
a	O
familial	O
hypercholesterolemia	S-Phenotype
patient	O
.	O

BACKGROUND	O
Hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
is	O
one	O
of	O
the	O
most	O
common	O
malignancies	O
occurring	O
worldwide	O
and	O
is	O
most	O
frequent	O
type	O
of	O
liver	B-Phenotype
cancer	E-Phenotype
.	O

Moreover	O
,	O
ectopic	O
overexpression	O
of	O
WTIP	O
dramatically	O
inhibits	O
cell	O
proliferation	O
and	O
tumorigenesis	S-Phenotype
in	O
vitro	O
and	O
in	O
vivo	O
;	O
conversely	O
,	O
depletion	O
of	O
WTIP	O
expression	O
shows	O
the	O
opposite	O
effects	O
.	O

The	O
use	O
of	O
low	O
fidelity	O
DNA	O
polymerases	O
in	O
the	O
translesional	O
synthesis	O
(	O
TLS	O
)	O
DNA	O
damage	O
response	O
pathway	O
that	O
repairs	O
lesions	O
caused	O
by	O
cisplatin	O
also	O
presents	O
a	O
mutational	O
carcinogenic	O
burden	O
on	O
cells	O
that	O
needs	O
to	O
be	O
regulated	O
by	O
the	O
tumor	S-Phenotype
suppressor	O
protein	O
p53	O
.	O

The	O
colonic	O
expression	O
of	O
D2HGDH	O
is	O
decreased	O
in	O
ulcerative	B-Phenotype
colitis	E-Phenotype
(	O
UC	S-Phenotype
)	O
patients	O
at	O
baseline	O
who	O
progress	O
to	O
cancer	S-Phenotype
.	O

Previously	O
,	O
the	O
combination	O
of	O
hypoparathyroidism	S-Phenotype
,	O
deafness	S-Phenotype
,	O
and	O
renal	B-Phenotype
dysplasia	E-Phenotype
has	O
been	O
proposed	O
to	O
represent	O
a	O
specific	O
syndrome	O
(	O
MIM	O
146255	O
)	O
under	O
the	O
acronym	O
HDR	O
.	O

Indeed	O
,	O
IKKα	O
is	O
required	O
for	O
the	O
MPE	O
-	O
competence	O
of	O
KRAS	O
-	O
mutant	O
tumor	S-Phenotype
cells	O
by	O
activating	O
non	O
-	O
canonical	O
NF	O
-	O
κB	O
signaling	O
.	O

To	O
elucidate	O
the	O
cellular	O
and	O
molecular	O
function	O
of	O
SOX3	O
,	O
we	O
examined	O
the	O
consequences	O
of	O
SOX3	O
knockdown	O
in	O
osteosarcoma	S-Phenotype
cells	O
.	O

However	O
,	O
the	O
mechanism	O
for	O
CD133	O
-	O
mediated	O
glioma	S-Phenotype
progression	O
has	O
yet	O
to	O
be	O
fully	O
elucidated	O
.	O

Large	B-Phenotype
granular	I-Phenotype
lymphocyte	I-Phenotype
(	I-Phenotype
LGL	I-Phenotype
)	I-Phenotype
leukemia	E-Phenotype
has	O
been	O
recognized	O
in	O
the	O
World	O
Health	O
Organization	O
classifications	O
among	O
mature	O
T	O
cell	O
and	O
natural	O
killer	O
cell	O
neoplasms	S-Phenotype
and	O
is	O
divided	O
into	O
three	O
categories	O
.	O

iVEGFC	O
/	O
i	O
,	O
which	O
is	O
a	O
gene	O
encoding	O
the	O
ligand	O
for	O
the	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
3	O
(	O
VEGFR3	O
/	O
FLT4	O
)	O
and	O
important	O
for	O
lymph	O
vessel	O
development	O
during	O
lymphangiogenesis	O
,	O
has	O
been	O
associated	O
with	O
a	O
specific	O
subtype	O
of	O
primary	O
lymphedema	S-Phenotype
.	O

Of	O
these	O
,	O
Frem1	O
,	O
Foxo1	O
,	O
and	O
Setd7	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
nephropathy	S-Phenotype
.	O

Additionally	O
,	O
the	O
previously	O
reported	O
LMO1	O
neuroblastoma	S-Phenotype
risk	O
locus	O
was	O
statistically	O
significant	O
only	O
in	O
patients	O
with	O
MYCN	O
-	O
nonamplified	O
high	O
-	O
risk	O
tumors	S-Phenotype
(	O
OR	O
=	O
0.63	O
,	O
95	O
%	O
CI	O
=	O
0.53	O
to	O
0.75	O
,	O
Pmeta	O
=	O
1.51	O
x	O
10	O
-	O
8	O
;	O
Pmeta	O
=	O
.95	O
)	O
.	O

Gain	O
-	O
of	O
-	O
function	O
mutations	O
in	O
the	O
human	O
PIEZO1	O
gene	O
cause	O
the	O
autosomal	O
dominant	O
hemolytic	B-Phenotype
anemia	E-Phenotype
,	O
hereditary	B-Phenotype
xerocytosis	E-Phenotype
(	O
also	O
known	O
as	O
dehydrated	B-Phenotype
stomatocytosis	E-Phenotype
)	O
.	O

VDR	O
gene	O
FokI	O
T	O
allele	O
and	O
TT	O
genotype	O
correlated	O
with	O
aggressiveness	S-Phenotype
of	O
papillary	B-Phenotype
thyroid	I-Phenotype
cancer	E-Phenotype
;	O
thus	O
,	O
FokI	O
could	O
be	O
useful	O
as	O
a	O
poor	O
prognostic	O
factor	O
to	O
assess	O
the	O
high	O
risk	O
of	O
papillary	B-Phenotype
thyroid	I-Phenotype
cancer	E-Phenotype

Curcumin	O
decreased	O
the	O
expression	O
of	O
steroidogenic	O
acute	O
regulatory	O
proteins	O
,	O
CYP11A1	O
and	O
HSD3B2	O
in	O
prostate	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
,	O
supporting	O
the	O
decrease	O
of	O
testosterone	O
production	O
.	O

In	O
addition	O
to	O
a	O
FOXG1	O
mutation	O
in	O
a	O
patient	O
with	O
all	O
core	O
features	O
of	O
the	O
congenital	O
variant	O
of	O
RTT	O
,	O
we	O
identified	O
a	O
missense	O
(	O
p.Ser240Thr	O
)	O
in	O
CDKL5	O
in	O
a	O
patient	O
who	O
appeared	O
to	O
be	O
seizure	S-Phenotype
free	O
.	O

The	O
common	O
Ser96Ala	O
human	O
genetic	O
variant	O
of	O
HRC	O
strongly	O
correlates	O
with	O
life	O
-	O
threatening	O
ventricular	B-Phenotype
arrhythmias	E-Phenotype
in	O
patients	O
with	O
idiopathic	B-Phenotype
dilated	I-Phenotype
cardiomyopathy	E-Phenotype
.	O

In	O
situ	O
ERCC6	O
and	O
ERCC8	O
protein	O
expression	O
were	O
detected	O
by	O
immunohistochemistry	O
in	O
109	O
chronic	B-Phenotype
superficial	I-Phenotype
gastritis	E-Phenotype
,	O
109	O
chronic	B-Phenotype
atrophic	I-Phenotype
gastritis	E-Phenotype
and	O
109	O
gastric	B-Phenotype
cancer	E-Phenotype
cases	O
.	O

The	O
analysis	O
of	O
the	O
two	O
exons	O
of	O
SLITRK6	O
gene	O
in	O
a	O
Moroccan	O
family	O
allowed	O
us	O
to	O
identify	O
a	O
novel	O
single	O
deleterious	O
mutation	O
c.696delG	O
,	O
p.Trp232Cysfs	O
*	O
10	O
at	O
homozygous	O
state	O
in	O
the	O
exon	O
2	O
of	O
the	O
SLITRK6	O
,	O
a	O
gene	O
reported	O
to	O
cause	O
deafness	S-Phenotype
and	O
myopia	S-Phenotype
in	O
various	O
populations	O

We	O
initially	O
selected	O
6	O
fluoropyrimidine	O
metabolism	O
-	O
related	O
genes	O
(	O
DPYD	O
,	O
ORPT	O
,	O
TYMS	O
,	O
TYMP	O
,	O
TK1	O
,	O
and	O
TK2	O
)	O
and	O
3	O
radiotherapy	O
response	O
-	O
related	O
genes	O
(	O
GLUT1	O
,	O
HIF	O
-	O
1α	O
,	O
and	O
HIF	O
-	O
2α	O
)	O
as	O
targets	O
for	O
gene	O
expression	O
identification	O
in	O
60	O
LARC	O
cancer	S-Phenotype
specimens	O
.	O

The	O
main	O
objective	O
of	O
this	O
study	O
is	O
to	O
provide	O
a	O
brief	O
version	O
of	O
the	O
Spanish	O
translation	O
of	O
the	O
PIP	O
,	O
across	O
a	O
sample	O
consisting	O
of	O
465	O
main	O
familial	O
caregivers	O
(	O
85.2	O
%	O
female	O
,	O
n	O
=	O
396	O
)	O
between	O
27	O
and	O
67	O
years	O
old	O
(	O
[	O
Formula	O
:	O
see	O
text	O
]	O
=	O
44.13	O
;	O
SD	O
=	O
5.35	O
)	O
of	O
paediatric	O
patients	O
between	O
9	O
and	O
18	O
years	O
old	O
(	O
[	O
Formula	O
:	O
see	O
text	O
]	O
=	O
12.10	O
,	O
SD	O
=	O
2.20	O
;	O
56.8	O
%	O
men	O
,	O
n	O
=	O
264	O
)	O
diagnosed	O
with	O
diabetes	B-Phenotype
mellitus	E-Phenotype
type	O
I	O
(	O
20.9	O
%	O
of	O
the	O
sample	O
;	O
n	O
=	O
97	O
)	O
,	O
short	B-Phenotype
stature	E-Phenotype
(	O
32.5	O
%	O
of	O
the	O
sample	O
;	O
n	O
=	O
151	O
)	O
,	O
or	O
a	O
chronic	O
respiratory	O
disease	O
(	O
asthma	S-Phenotype
,	O
cystic	B-Phenotype
fibrosis	E-Phenotype
,	O
bronchiolitis	B-Phenotype
obliterans	E-Phenotype
and	O
bronchiectasis	S-Phenotype
)	O
(	O
46.6	O
%	O
of	O
the	O
sample	O
;	O
n	O
=	O
217	O
)	O
.	O

To	O
further	O
characterize	O
CD164	O
as	O
a	O
potential	O
biomarker	O
for	O
malignant	O
CD4sup+	O
/	O
sup	O
T	O
cells	O
,	O
CD164sup+	O
/	O
sup	O
and	O
CD164sup	O
-	O
/	O
supCD4sup+	O
/	O
sup	O
T	O
cells	O
isolated	O
from	O
patients	O
with	O
high	O
-	O
circulating	O
tumor	S-Phenotype
burden	O
,	O
B2	O
stage	O
,	O
and	O
medium	O
/	O
low	O
tumor	S-Phenotype
burden	O
,	O
B1	O
-	O
B0	O
stage	O
,	O
were	O
assessed	O
for	O
the	O
expression	O
of	O
genes	O
reported	O
to	O
differentiate	O
SS	O
from	O
normal	O
controls	O
,	O
and	O
associated	O
with	O
malignancy	O
and	O
poor	O
prognosis	O
.	O

The	O
aCGH	O
analysis	O
revealed	O
a	O
pathogenic	O
CNV	O
in	O
the	O
14q11.2	O
region	O
,	O
while	O
targeted	O
exome	O
sequencing	O
revealed	O
pathogenic	O
variants	O
in	O
genes	O
associated	O
with	O
intellectual	B-Phenotype
disability	E-Phenotype
(	O
HUWE1	O
,	O
GRIN1	O
)	O
,	O
including	O
a	O
gene	O
coding	O
for	O
mandibulofacial	B-Phenotype
dysostosis	E-Phenotype
with	O
microcephaly	S-Phenotype
(	O
EFTUD2	O
)	O
.	O

BACKGROUND	O
Lin28	O
is	O
a	O
gene	O
involved	O
in	O
many	O
biological	O
processes	O
,	O
including	O
development	O
,	O
glucose	O
metabolism	O
,	O
and	O
tumorigenesis	S-Phenotype
.	O

We	O
previously	O
reported	O
that	O
brain	O
-	O
derived	O
neurotrophic	O
factor	O
(	O
BDNF	O
)	O
/	O
neurotrophic	O
receptor	O
tyrosine	O
kinase	O
2	O
(	O
NTRK2	O
/	O
TRKB	O
)	O
signaling	O
contributes	O
to	O
induction	O
of	O
malignant	O
phenotype	O
of	O
gallbladder	B-Phenotype
cancer	E-Phenotype
(	O
GBC	S-Phenotype
)	O
.	O

In	O
patients	O
with	O
primary	O
serous	O
ovarian	B-Phenotype
cancer	E-Phenotype
in	O
TCGA	O
-	O
OV	O
,	O
the	O
cases	O
with	O
lymphatic	O
invasion	O
(	O
N	O
=	O
133	O
)	O
had	O
significantly	O
higher	O
SLC4A11	O
expression	O
than	O
those	O
without	O
lymphatic	O
invasion	O
(	O
N	O
=	O
77	O
)	O
(	O
p	O
=	O
0.0069	O
)	O
.	O

Conclusions	O
:	O
The	O
expression	O
of	O
HOXA11	O
-	O
AS	O
is	O
upregulated	O
in	O
esophageal	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
and	O
tissues	O
.	O

Mutations	O
in	O
filamin	O
A	O
(	O
FLNA	O
)	O
or	O
ADP	O
-	O
ribosylation	O
factor	O
guanine	O
nucleotide	O
-	O
exchange	O
factor	O
2	O
(	O
ARFGEF2	O
)	O
cause	O
periventricular	B-Phenotype
nodular	I-Phenotype
heterotopia	E-Phenotype
,	O
but	O
most	O
patients	O
with	O
this	O
malformation	O
do	O
not	O
have	O
a	O
known	O
aetiology	O
.	O

Knockdown	O
of	O
SIRT6	O
decreased	O
the	O
proliferation	O
and	O
invasiveness	O
of	O
cancer	S-Phenotype
cells	O
.	O

In	O
addition	O
,	O
p	O
-	O
BS	O
/	O
GS	O
can	O
occur	O
as	O
a	O
result	O
of	O
other	O
inherited	O
diseases	O
such	O
as	O
cystic	B-Phenotype
fibrosis	E-Phenotype
,	O
autosomal	B-Phenotype
dominant	I-Phenotype
hypocalcemia	E-Phenotype
,	O
Dent	B-Phenotype
disease	E-Phenotype
,	O
or	O
congenital	B-Phenotype
chloride	I-Phenotype
diarrhea	E-Phenotype
(	O
CCD	S-Phenotype
)	O
.	O

Recent	O
analyses	O
of	O
our	O
microRNA	O
(	O
miRNA	O
)	O
expression	O
signatures	O
obtained	O
from	O
several	O
types	O
of	O
cancer	S-Phenotype
have	O
provided	O
novel	O
information	O
on	O
their	O
molecular	O
pathology	O
.	O

PDT	O
is	O
a	O
promising	O
new	O
modality	O
in	O
the	O
treatment	O
of	O
cancers	S-Phenotype
,	O
which	O
employs	O
the	O
interaction	O
between	O
a	O
tumor	S-Phenotype
-	O
localizing	O
photosensitizer	O
and	O
light	O
of	O
an	O
appropriate	O
wavelength	O
to	O
bring	O
about	O
ROS	O
-	O
induced	O
cell	O
death	O
.	O

Here	O
,	O
we	O
show	O
that	O
ablating	O
or	O
silencing	O
the	O
transcription	O
factor	O
Nfix	O
ameliorates	O
pathology	O
in	O
several	O
forms	O
of	O
muscular	B-Phenotype
dystrophy	E-Phenotype
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
frequency	O
of	O
mosaicism	O
detected	O
by	O
next	O
-	O
generation	O
sequencing	O
in	O
genes	O
associated	O
with	O
epilepsy	S-Phenotype
-	O
related	O
neurodevelopmental	O
disorders	O
.	O

Methods	O
We	O
conducted	O
a	O
retrospective	O
analysis	O
of	O
893	O
probands	O
with	O
epilepsy	S-Phenotype
who	O
had	O
a	O
multigene	O
epilepsy	S-Phenotype
panel	O
or	O
whole	O
-	O
exome	O
sequencing	O
performed	O
in	O
a	O
clinical	O
diagnostic	O
laboratory	O
and	O
were	O
positive	O
for	O
a	O
pathogenic	O
or	O
likely	O
pathogenic	O
variant	O
in	O
one	O
of	O
nine	O
genes	O
(	O
CDKL5	O
,	O
GABRA1	O
,	O
GABRG2	O
,	O
GRIN2B	O
,	O
KCNQ2	O
,	O
MECP2	O
,	O
PCDH19	O
,	O
SCN1A	O
,	O
or	O
SCN2A	O
)	O
.	O

Depletion	O
of	O
PRODH	O
and	O
GSALDH	O
in	O
humans	O
leads	O
to	O
hyperprolinemia	S-Phenotype
,	O
which	O
is	O
associated	O
with	O
mental	O
disorders	O
such	O
as	O
schizophrenia	S-Phenotype
.	O

The	O
findings	O
of	O
the	O
present	O
study	O
suggest	O
that	O
FRMD4A	O
expression	O
correlates	O
with	O
the	O
development	O
of	O
tongue	B-Phenotype
squamous	I-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
.	O

Whole	O
genome	O
transcriptome	O
analysis	O
(	O
RNA	O
-	O
Seq	O
)	O
on	O
RNA	O
isolated	O
from	O
wildtype	O
larvae	O
and	O
larvae	O
with	O
eye	O
defects	O
that	O
were	O
putative	O
homozygotes	O
for	O
the	O
foxe3	O
indel	O
variant	O
found	O
significant	O
dysregulation	O
of	O
genes	O
expressed	O
in	O
the	O
lens	O
and	O
eye	O
whose	O
orthologues	O
are	O
associated	O
with	O
cataracts	S-Phenotype
in	O
human	O
patients	O
,	O
including	O
cryba2a	O
,	O
cryba1l1	O
,	O
mipa	O
and	O
hsf4	O
.	O

These	O
compounds	O
showed	O
excellent	O
anti	O
-	O
tumor	S-Phenotype
activity	O
against	O
A549	O
,	O
Eca	O
-	O
109	O
,	O
HeLa	O
,	O
HepG2	O
and	O
SGC	O
-	O
7901	O
cell	O
lines	O
.	O

NQO1	O
genotypes	O
of	O
390	O
men	O
did	O
not	O
indicate	O
predisposition	O
to	O
CaP	O
,	O
yet	O
loss	O
of	O
NQO1	O
in	O
CaP	O
suggested	O
potential	O
progression	O
-	O
opposing	O
tumour	S-Phenotype
suppressor	O
role	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
association	O
of	O
the	O
hepatic	O
lipase	O
(	O
LIPC	O
)	O
rs493258	O
polymorphism	O
and	O
susceptibility	O
to	O
age	B-Phenotype
-	I-Phenotype
related	I-Phenotype
macular	I-Phenotype
degeneration	E-Phenotype
(	O
AMD	S-Phenotype
)	O
.	O

Importantly	O
,	O
studies	O
of	O
colorectal	B-Phenotype
cancer	E-Phenotype
specimens	O
indicate	O
that	O
the	O
expression	O
of	O
miR	O
-	O
587	O
and	O
PPP2R1B	O
positively	O
and	O
inversely	O
correlates	O
with	O
chemoresistance	O
,	O
respectively	O
,	O
in	O
colorectal	B-Phenotype
cancer	E-Phenotype
.	O

The	O
PDGFRa	O
-	O
LAMB1	O
pathway	O
supports	O
tumor	S-Phenotype
progression	O
at	O
the	O
invasive	O
front	O
of	O
human	O
HCC	O
through	O
K19	O
expression	O

This	O
study	O
targeted	O
a	O
novel	O
tumor	S-Phenotype
-	O
associated	O
antigen	O
,	O
ring	O
finger	O
protein	O
43	O
(	O
RNF43	O
)	O
.	O

Here	O
,	O
we	O
applied	O
next	O
-	O
generation	O
sequencing	O
in	O
89	O
patients	O
with	O
a	O
clinical	O
diagnosis	O
of	O
distal	B-Phenotype
renal	I-Phenotype
tubular	I-Phenotype
acidosis	E-Phenotype
,	O
analyzing	O
the	O
prevalence	O
of	O
genetic	O
defects	O
in	O
SLC4A1	O
,	O
ATP6V0A4	O
,	O
and	O
ATP6V1B1	O
genes	O
and	O
the	O
clinical	O
phenotype	O
.	O

In	O
all	O
,	O
13	O
tumours	S-Phenotype
were	O
analysed	O
by	O
immunohistochemistry	O
to	O
visualise	O
CD44	O
-	O
expressing	O
cells	O
.	O

Its	O
dysfunction	O
,	O
caused	O
by	O
mutations	O
in	O
either	O
the	O
enzyme	O
itself	O
or	O
AIPL1	O
(	O
aryl	O
hydrocarbon	O
receptor	O
-	O
interacting	O
protein	O
-	O
like	O
1	O
)	O
,	O
leads	O
to	O
retinal	B-Phenotype
diseases	E-Phenotype
culminating	O
in	O
blindness	S-Phenotype
.	O

The	O
importance	O
of	O
Akt	O
actions	O
in	O
human	O
physiology	O
is	O
strengthened	O
by	O
the	O
rarity	O
of	O
modifying	O
mutations	O
in	O
their	O
genes	O
and	O
by	O
the	O
devastating	O
impact	O
caused	O
by	O
these	O
mutations	O
on	O
growth	O
and	O
development	O
and	O
in	O
disorders	O
such	O
as	O
cancer	S-Phenotype
.	O

Epilepsy	S-Phenotype
with	O
mental	B-Phenotype
retardation	E-Phenotype
limited	O
to	O
females	O
(	O
EFMR	O
)	O
is	O
a	O
syndrome	O
characterized	O
by	O
early	B-Phenotype
onset	I-Phenotype
heat	I-Phenotype
-	I-Phenotype
sensitive	I-Phenotype
epilepsy	I-Phenotype
of	I-Phenotype
infancy	E-Phenotype
or	O
early	O
childhood	O
and	O
generally	O
limited	O
to	O
females	O
,	O
which	O
previously	O
reported	O
that	O
the	O
cadherin	O
gene	O
superfamily	O
subtype	O
protocadherin	O
19	O
(	O
PCDH19	O
)	O
gene	O
is	O
its	O
pathogenic	O
gene	O
.	O

Aberrant	O
expression	O
of	O
different	O
family	O
members	O
of	O
the	O
Eph	O
/	O
ephrin	O
system	O
,	O
which	O
comprises	O
the	O
Eph	O
receptors	O
(	O
Ephs	O
)	O
and	O
their	O
ligands	O
(	O
ephrins	O
)	O
,	O
has	O
been	O
implicated	O
in	O
various	O
malignancies	O
including	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

p.	O
(	O
Arg320His	O
)	O
mutation	O
in	O
the	O
KCNC1	O
gene	O
in	O
human	O
11p15.1	O
has	O
recently	O
been	O
identified	O
in	O
patients	O
with	O
progressive	O
myoclonus	S-Phenotype
epilepsies	S-Phenotype
,	O
a	O
group	O
of	O
rare	O
inherited	O
disorders	O
manifesting	O
with	O
action	O
myoclonus	S-Phenotype
,	O
myoclonic	B-Phenotype
epilepsy	E-Phenotype
,	O
and	O
ataxia	S-Phenotype
.	O

Using	O
whole	O
-	O
exome	O
sequencing	O
in	O
four	O
probands	O
with	O
undiagnosed	O
skin	O
hyperkeratosis	S-Phenotype
/	O
ichthyosis	S-Phenotype
,	O
we	O
identified	O
compound	O
heterozygosity	O
for	O
mutations	O
in	O
KDSR	O
,	O
encoding	O
an	O
enzyme	O
in	O
the	O
de	O
novo	O
synthesis	O
pathway	O
of	O
ceramides	O
.	O

320	O
out	O
of	O
578	O
(	O
55.4	O
%	O
)	O
ovarian	B-Phenotype
cancer	E-Phenotype
cases	O
had	O
SLC4A11	O
amplification	O
.	O

Smac	O
/	O
DIABLO	O
expression	O
is	O
markedly	O
different	O
between	O
drug	O
-	O
resistant	O
and	O
chemo	O
sensitive	O
tumor	S-Phenotype
cells	O
.	O

However	O
,	O
we	O
observed	O
nominal	O
significant	O
associations	O
of	O
2	O
SNPs	O
in	O
the	O
NDUFS1	O
gene	O
and	O
4	O
SNPs	O
in	O
the	O
NDUFS2	O
gene	O
with	O
early	B-Phenotype
onset	I-Phenotype
schizophrenia	E-Phenotype
(	O
EOS	S-Phenotype
)	O
,	O
but	O
none	O
of	O
these	O
associations	O
survived	O
the	O
Bonferroni	O
correction	O
.	O

Therefore	O
,	O
hypertrophic	B-Phenotype
cardiomyopathy	E-Phenotype
and	O
tubulopathy	S-Phenotype
may	O
not	O
be	O
considered	O
as	O
constant	O
features	O
of	O
MRPS22	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
relationship	O
between	O
the	O
DLEC1	O
,	O
TUSC4	O
and	O
MLH1	O
mRNA	O
expression	O
,	O
and	O
clinical	O
features	O
of	O
NSCLC	S-Phenotype
patients	O
,	O
tobacco	B-Phenotype
addiction	E-Phenotype
,	O
and	O
tumour	S-Phenotype
histopathological	O
characteristics	O
.	O

An	O
analysis	O
of	O
human	O
SCLC	O
specimens	O
revealed	O
that	O
POU2F3	O
is	O
expressed	O
exclusively	O
in	O
variant	O
SCLC	O
tumors	S-Phenotype
that	O
lack	O
expression	O
of	O
neuroendocrine	O
markers	O
and	O
instead	O
express	O
markers	O
of	O
a	O
chemosensory	O
lineage	O
known	O
as	O
tuft	O
cells	O
.	O

Both	O
RPE65	O
isomerase	O
of	O
the	O
visual	O
cycle	O
and	O
the	O
rhodopsin	O
visual	O
pigment	O
have	O
recently	O
been	O
identified	O
as	O
critical	O
players	O
in	O
mediating	O
light	O
-	O
induced	O
retinal	B-Phenotype
degeneration	E-Phenotype
.	O

In	O
humans	O
,	O
mutations	O
in	O
CISD2	O
result	O
in	O
Wolfram	O
syndrome	O
2	O
,	O
a	O
disease	O
in	O
which	O
the	O
patients	O
display	O
juvenile	B-Phenotype
diabetes	E-Phenotype
,	O
neuropsychiatric	O
disorders	O
and	O
defective	B-Phenotype
platelet	I-Phenotype
aggregation	E-Phenotype
.	O

Our	O
studies	O
show	O
that	O
DKD	O
susceptibility	O
was	O
linked	O
to	O
mitochondrial	B-Phenotype
dysfunction	E-Phenotype
,	O
mediated	O
largely	O
by	O
Edn1	O
-	O
Ednra	O
in	O
glomerular	O
endothelial	O
cells	O
representing	O
an	O
early	O
event	O
in	O
DKD	O
progression	O
,	O
and	O
suggest	O
that	O
cross	O
talk	O
between	O
glomerular	O
endothelial	O
injury	O
and	O
podocytes	O
leads	O
to	O
defects	S-Phenotype
and	O
depletion	S-Phenotype
,	O
albuminuria	S-Phenotype
,	O
and	O
glomerulosclerosis	S-Phenotype

We	O
show	O
that	O
mice	O
lacking	O
COQ8A	O
develop	O
a	O
slowly	O
progressive	B-Phenotype
cerebellar	I-Phenotype
ataxia	E-Phenotype
linked	O
to	O
Purkinje	O
cell	O
dysfunction	O
and	O
mild	O
exercise	B-Phenotype
intolerance	E-Phenotype
,	O
recapitulating	O
ARCA2	O
.	O

AMPK	O
phosphorylates	O
PRPS1	O
/	O
2	O
,	O
converts	O
PRPS1	O
/	O
2	O
hexamers	O
to	O
monomers	O
,	O
and	O
inhibits	O
PRPS1	O
/	O
2	O
activity	O
and	O
subsequent	O
nucleotide	O
and	O
NAD	O
synthesis	O
to	O
maintain	O
tumor	S-Phenotype
cell	O
growth	O
and	O
survival	O
.	O

MTP	O
deficiency	O
should	O
be	O
considered	O
in	O
patients	O
with	O
the	O
combination	O
of	O
peripheral	S-Phenotype
neuropathy	S-Phenotype
and	O
recurrent	O
rhabdomyolysis	S-Phenotype

There	O
were	O
no	O
statistically	O
significant	O
associations	O
between	O
phospho	O
-	O
ELK1	O
expression	O
and	O
tumor	S-Phenotype
grade	O
,	O
presence	O
of	O
concurrent	O
carcinoma	S-Phenotype
in	O
situ	O
or	O
hydronephrosis	S-Phenotype
,	O
or	O
pN	O
status	O
.	O

To	O
identify	O
tumor	S-Phenotype
suppressor	O
genes	O
(	O
TSGs	O
)	O
silenced	O
by	O
hypermethylation	O
and	O
discover	O
new	O
epigenetic	O
biomarkers	O
for	O
early	O
cancer	S-Phenotype
detection	O
.	O

Meanwhile	O
,	O
MLH3	O
rs175057	O
CAAAAT	O
locus	O
was	O
also	O
associated	O
with	O
longer	O
overall	O
survival	O
time	O
in	O
locally	O
advanced	O
rectal	B-Phenotype
cancer	E-Phenotype
(	O
HR=0.44	O
,	O
95	O
%	O
CI	O
:	O
0.20	O
-	O
0.96	O
,	O
P=0.038	O
)	O
,	O
whereas	O
MSH2	O
rs3771273	O
TAAAAA	O
,	O
rs10188090	O
AAAAAG	O
and	O
rs10191478	O
TAAAAG	O
loci	O
were	O
associated	O
with	O
shorter	O
overall	O
survival	O
time	O
(	O
HR=1.74	O
,	O
95	O
%	O
CI	O
:	O
1.06	O
-	O
2.84	O
,	O
P=0.028	O
;	O
HR=1.64	O
,	O
95	O
%	O
CI	O
:	O
1.01	O
-	O
2.66	O
,	O
P=0.046	O
;	O
HR=1.71	O
,	O
95	O
%	O
CI	O
:	O
1.01	O
-	O
2.91	O
,	O
P=0.047	O
,	O
respectively	O
)	O
.	O

We	O
present	O
a	O
young	O
boy	O
whose	O
mild	O
ataxia	S-Phenotype
and	O
abnormal	B-Phenotype
eye	I-Phenotype
movements	E-Phenotype
repeatedly	O
deteriorated	O
with	O
fever	S-Phenotype
,	O
making	O
him	O
unable	O
to	O
sit	O
or	O
walk	O
during	O
fever	S-Phenotype
episodes	O
.	O

Ex	O
vivo	O
data	O
showed	O
that	O
DHC2	O
expression	O
in	O
GBM	O
tissue	O
samples	O
was	O
associated	O
with	O
tumor	S-Phenotype
recurrence	O
after	O
TMZ	O
chemotherapy	O
.	O

We	O
found	O
BAG3	O
mutation	O
in	O
one	O
patient	O
with	O
neuropathy	S-Phenotype
,	O
myopathy	S-Phenotype
and	O
rigid	B-Phenotype
spine	E-Phenotype
syndrome	O
,	O
and	O
performed	O
electrophysiological	O
study	O
,	O
whole	O
body	O
MRI	O
and	O
muscle	O
biopsy	O
on	O
the	O
patient	O
.	O

Further	O
studies	O
are	O
warranted	O
to	O
dissect	O
these	O
mechanisms	O
and	O
establish	O
5	O
-	O
Aza	O
-	O
dC	O
as	O
an	O
effective	O
multi	O
-	O
module	O
anticancer	O
reagent	S-Phenotype

Chemical	O
inhibition	O
of	O
epigenetic	O
regulatory	O
proteins	O
BrdT	O
and	O
Brd4	O
is	O
emerging	O
as	O
a	O
promising	O
therapeutic	O
strategy	O
in	O
contraception	O
,	O
cancer	S-Phenotype
,	O
and	O
heart	O
disease	O
.	O

In	O
particular	O
,	O
MYH9	O
mutations	O
result	O
in	O
congenital	B-Phenotype
macrothrombocytopenia	E-Phenotype
and	O
predispose	O
to	O
kidney	B-Phenotype
failure	E-Phenotype
,	O
hearing	B-Phenotype
loss	E-Phenotype
,	O
and	O
cataracts	S-Phenotype
,	O
MPL	O
and	O
MECOM	O
mutations	O
cause	O
congenital	B-Phenotype
thrombocytopenia	E-Phenotype
evolving	O
into	O
bone	B-Phenotype
marrow	I-Phenotype
failure	E-Phenotype
,	O
whereas	O
thrombocytopenias	S-Phenotype
caused	O
by	O
RUNX1	O
,	O
ANKRD26	O
,	O
and	O
ETV6	O
mutations	O
are	O
characterized	O
by	O
predisposition	B-Phenotype
to	I-Phenotype
hematological	I-Phenotype
malignancies	E-Phenotype
.	O

The	O
eye	O
features	O
were	O
a	O
notable	O
part	O
of	O
this	O
child	O
's	O
presentation	O
and	O
mutations	O
in	O
the	O
linkeropathy	O
genes	O
(	O
XYLT1	O
,	O
XYLT2	O
,	O
B4GALT7	O
,	O
B3GALT6	O
,	O
and	O
B3GAT3	O
)	O
can	O
be	O
associated	O
with	O
ocular	O
findings	O
,	O
including	O
blue	B-Phenotype
sclerae	E-Phenotype
,	O
refractive	B-Phenotype
errors	E-Phenotype
,	O
corneal	B-Phenotype
clouding	E-Phenotype
,	O
strabismus	S-Phenotype
,	O
nystagmus	S-Phenotype
,	O
cataracts	S-Phenotype
,	O
glaucoma	S-Phenotype
,	O
and	O
retinal	B-Phenotype
abnormalities	E-Phenotype
,	O
including	O
retinal	B-Phenotype
detachment	E-Phenotype
.	O

Using	O
western	O
blot	O
analyses	O
,	O
we	O
assessed	O
KLF9	O
expression	O
in	O
human	O
pancreatic	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
.	O

Our	O
findings	O
provide	O
exploratory	O
evidence	O
for	O
hypermethylation	O
of	O
the	O
key	O
tumour	S-Phenotype
suppressor	O
gene	O
APC	O
being	O
implicated	O
in	O
smoking	O
-	O
associated	O
colorectal	O
carcinogenesis	O
.	O

Four	O
of	O
them	O
had	O
seizures	S-Phenotype
(	O
57.1	O
%	O
)	O
,	O
and	O
focal	B-Phenotype
seizures	E-Phenotype
with	O
motionless	O
staring	O
were	O
the	O
most	O
common	O
seizure	S-Phenotype
phenotype	O
,	O
originating	O
from	O
bilateral	O
mesial	O
temporal	O
areas	O
,	O
but	O
interictal	O
spikes	O
were	O
scant	O
.	O

Together	O
,	O
our	O
findings	O
explain	O
the	O
existence	O
of	O
superior	O
coloboma	S-Phenotype
,	O
a	O
congenital	O
ocular	O
anomaly	O
resulting	O
from	O
aberrant	O
morphogenesis	O
of	O
a	O
developmental	O
structure	O

Seborrhoeic	B-Phenotype
Dermatitis	E-Phenotype
(	O
SD	S-Phenotype
)	O
is	O
a	O
common	O
inflammatory	B-Phenotype
skin	I-Phenotype
disease	E-Phenotype
that	O
presents	O
as	O
itchy	O
,	O
flaking	B-Phenotype
skin	E-Phenotype
in	O
the	O
seborrhoeic	O
areas	O
.	O

Four	O
of	O
the	O
five	O
genes	O
,	O
including	O
AKAP12	O
,	O
SOPB	O
,	O
TCF7L2	O
,	O
COL12A1	O
and	O
TXNIP	O
were	O
downregulated	O
,	O
and	O
were	O
associated	O
with	O
the	O
OS	O
of	O
patients	O
with	O
breast	B-Phenotype
carcinoma	E-Phenotype
.	O

Introduction	O
Despite	O
some	O
new	O
treatment	O
possibilities	O
,	O
the	O
improvement	O
in	O
survival	O
rate	O
for	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
patients	O
is	O
still	O
poor	O
due	O
to	O
late	O
diagnosis	O
.	O

Here	O
we	O
discuss	O
'congenital	O
disorders	O
of	O
autophagy	O
'	O
as	O
an	O
emerging	O
subclass	O
of	O
inborn	O
errors	O
of	O
metabolism	O
by	O
using	O
the	O
examples	O
of	O
six	O
recently	O
identified	O
monogenic	O
diseases	O
:	O
EPG5	O
-	O
related	O
Vici	O
syndrome	O
,	O
beta	O
-	O
propeller	O
protein	O
-	O
associated	O
neurodegeneration	S-Phenotype
due	O
to	O
mutations	O
in	O
WDR45	B-Phenotype
,	I-Phenotype
SNX14	I-Phenotype
-	I-Phenotype
associated	I-Phenotype
autosomal	I-Phenotype
-	I-Phenotype
recessive	I-Phenotype
cerebellar	I-Phenotype
ataxia	E-Phenotype
and	O
intellectual	B-Phenotype
disability	E-Phenotype
syndrome	O
,	O
and	O
three	O
forms	O
of	O
hereditary	B-Phenotype
spastic	I-Phenotype
paraplegia	E-Phenotype
,	O
SPG11	O
,	O
SPG15	O
and	O
SPG49	O
caused	O
by	O
SPG11	O
,	O
ZFYVE26	O
and	O
TECPR2	O
mutations	O
,	O
respectively	O
.	O

In	O
keeping	O
with	O
a	O
tumor	S-Phenotype
suppressive	O
role	O
of	O
FBW7	O
in	O
human	O
gastric	B-Phenotype
cancer	E-Phenotype
,	O
we	O
find	O
an	O
inverse	O
correlation	O
between	O
FBW7	O
and	O
Brg1	O
expression	O
in	O
human	O
gastric	B-Phenotype
cancer	E-Phenotype
clinical	O
samples	O
.	O

This	O
is	O
an	O
original	O
FLNC	O
mutation	O
in	O
a	O
MFM	O
family	O
with	O
an	O
atypical	O
clinical	O
and	O
histopathological	O
presentation	O
,	O
given	O
the	O
presence	O
of	O
significantly	O
focal	O
lesions	O
and	O
prominent	O
sarcoplasmic	O
masses	O
in	O
muscle	O
biopsies	O
and	O
the	O
constant	O
heart	O
involvement	O
preceding	O
significantly	O
the	O
onset	O
of	O
the	O
myopathy	S-Phenotype
.	O

We	O
demonstrate	O
that	O
HSPB1	O
and	O
HSPB8	O
mutations	O
are	O
a	O
major	O
cause	O
of	O
inherited	B-Phenotype
motor	I-Phenotype
axonal	I-Phenotype
neuropathy	E-Phenotype
.	O

BAP1	O
has	O
multiple	O
properties	O
,	O
including	O
tumour	S-Phenotype
suppressor	O
activity	O
.	O

BRCA1	O
is	O
a	O
tumor	S-Phenotype
suppressor	O
that	O
regulates	O
DNA	O
repair	O
by	O
homologous	O
recombination	O
.	O

Further	O
experiments	O
demonstrated	O
that	O
the	O
MYEOV	O
ceRNA	O
sequestered	O
miR	O
-	O
30c	O
-	O
2	O
-	O
3p	O
from	O
binding	O
its	O
targets	O
TGFBR2	O
and	O
USP15	O
mRNAs	O
,	O
which	O
in	O
turn	O
leading	O
to	O
constitutive	O
activation	O
of	O
TGF	O
-	O
β	O
signaling	O
and	O
tumor	S-Phenotype
progression	O
in	O
NSCLC	O
.	O

Additionally	O
,	O
the	O
previously	O
reported	O
LMO1	O
neuroblastoma	S-Phenotype
risk	O
locus	O
was	O
statistically	O
significant	O
only	O
in	O
patients	O
with	O
MYCN	O
-	O
nonamplified	O
high	O
-	O
risk	O
tumors	S-Phenotype
(	O
OR	O
=	O
0.63	O
,	O
95	O
%	O
CI	O
=	O
0.53	O
to	O
0.75	O
,	O
Pmeta	O
=	O
1.51	O
x	O
10	O
-	O
8	O
;	O
Pmeta	O
=	O
.95	O
)	O
.	O

By	O
pathway	O
analysis	O
,	O
key	O
breast	B-Phenotype
cancer	E-Phenotype
hallmark	O
genes	O
of	O
epithelial	O
-	O
mesenchymal	O
transition	O
,	O
stemness	O
,	O
cell	O
apoptosis	O
,	O
cell	O
cycle	O
regulation	O
,	O
chromosomal	O
integrity	O
,	O
and	O
DNA	O
damage	O
/	O
repair	O
were	O
highly	O
enriched	O
with	O
NRF1	O
motifs	O
.	O

Finally	O
,	O
the	O
simultaneous	O
increase	O
of	O
CPT1A	O
,	O
CACT	O
and	O
CrAT	O
is	O
fundamental	O
for	O
PCCs	O
to	O
sustain	O
FA	O
oxidation	O
in	O
the	O
presence	O
of	O
heavy	O
lipid	O
load	O
on	O
prostate	B-Phenotype
cancer	E-Phenotype
mitochondria	O
.	O

Conclusions	O
:	O
The	O
expression	O
of	O
HOXA11	O
-	O
AS	O
is	O
upregulated	O
in	O
esophageal	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
and	O
tissues	O
.	O

Identification	O
of	O
novel	O
genetic	O
and	O
epigenetic	O
alterations	O
is	O
required	O
for	O
optimal	O
stratification	O
of	O
patients	O
with	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
at	O
risk	O
for	O
recurrence	O
and	O
adverse	O
prognosis	O
.	O

Interestingly	O
,	O
the	O
other	O
branch	O
of	O
the	O
original	O
family	O
was	O
found	O
to	O
segregate	O
anophthalmia	S-Phenotype
/	O
syndactyly	S-Phenotype
with	O
a	O
novel	O
homozygous	O
SMOC1	O
variant	O
.	O

Radiographic	O
hepatic	O
capsular	O
invasion	O
and	O
nonsmooth	O
tumor	S-Phenotype
margins	O
identified	O
by	O
preoperative	O
CT	O
images	O
,	O
along	O
with	O
AFP	O
levels	O
greater	O
than	O
232.2	O
ng	O
/	O
mL	O
,	O
are	O
important	O
predictors	O
of	O
MVI	O

With	O
regard	O
to	O
the	O
CPS1	O
4217CAAAAA	O
polymorphism	O
,	O
we	O
did	O
not	O
observe	O
a	O
significant	O
association	O
with	O
the	O
development	O
of	O
hyperammonemia	S-Phenotype
.	O

We	O
studied	O
the	O
effect	O
of	O
specific	O
inhibition	O
of	O
rRNA	O
synthesis	O
on	O
cell	O
cycle	O
progression	O
in	O
human	O
cancer	S-Phenotype
cell	O
lines	O
using	O
the	O
small	O
-	O
interfering	O
RNA	O
procedure	O
to	O
silence	O
the	O
POLR1A	O
gene	O
,	O
which	O
encodes	O
the	O
catalytic	O
subunit	O
of	O
RNA	O
polymerase	O
I	O
.	O

In	O
addition	O
,	O
the	O
knockdown	O
of	O
MORC2	O
inhibited	O
the	O
migratory	O
and	O
invasive	O
ability	O
of	O
liver	B-Phenotype
cancer	E-Phenotype
cells	O
,	O
whereas	O
increased	O
migration	O
and	O
invasion	O
rates	O
were	O
observed	O
in	O
cells	O
with	O
ectopic	O
expression	O
of	O
MORC2	O
.	O

Pathogenic	O
variants	O
in	O
CHD2	O
are	O
associated	O
with	O
developmental	B-Phenotype
epileptic	I-Phenotype
encephalopathy	E-Phenotype
(	O
DEE	S-Phenotype
)	O
in	O
humans	O
,	O
however	O
little	O
is	O
known	O
about	O
how	O
these	O
variants	O
contribute	O
to	O
this	O
disorder	O
.	O

Some	O
genes	O
,	O
such	O
as	O
GSTM1	O
,	O
DNMT3L	O
,	O
and	O
CYP1A1	O
,	O
have	O
been	O
shown	O
to	O
be	O
potentially	O
associated	O
with	O
oligospermia	S-Phenotype
;	O
some	O
,	O
such	O
as	O
CATSPER1	O
,	O
CRISP2	O
,	O
SEPT4	O
,	O
TCTE3	O
,	O
TEKT4	O
,	O
and	O
DNAH1	O
,	O
with	O
asthenospermia	S-Phenotype
;	O
and	O
still	O
others	O
,	O
such	O
as	O
DPY19L2	O
and	O
AURKC	O
,	O
with	O
teratospermia	S-Phenotype
.	O

In	O
conclusion	O
,	O
autosomal	O
dominant	O
mutations	O
in	O
SRP54	O
,	O
a	O
key	O
member	O
of	O
the	O
cotranslation	O
protein	O
-	O
targeting	O
pathway	O
,	O
lead	O
to	O
syndromic	O
neutropenia	S-Phenotype
with	O
a	O
Shwachman	O
-	O
Diamond	O
-	O
like	O
phenotype	O

Testing	O
for	O
RET	O
rearrangement	O
in	O
metastases	O
can	O
be	O
used	O
as	O
an	O
alternative	O
to	O
testing	O
of	O
primary	O
tumor	S-Phenotype
tissue	O
if	O
it	O
is	O
inaccessible	O

Though	O
a	O
rare	O
etiology	O
,	O
FLNC	O
gene	O
should	O
not	O
be	O
excluded	O
in	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
arrhythmia	E-Phenotype
,	O
even	O
in	O
the	O
absence	O
of	O
myopathy	S-Phenotype
,	O
which	O
occurs	O
later	O
in	O
the	O
disease	O
course	O

In	O
addition	O
,	O
the	O
expression	O
of	O
miR	O
-	O
214	O
inhibited	O
proliferation	O
of	O
ESCC	O
cells	O
in	O
vitro	O
and	O
inhibit	O
the	O
growth	O
of	O
xenograft	O
tumor	S-Phenotype
in	O
vivo	O
.	O

Prospective	O
outcome	O
data	O
on	O
risk	O
-	O
reducing	O
salpingectomy	O
and	O
delayed	O
-	O
oophorectomy	O
for	O
preventing	O
ovarian	B-Phenotype
cancer	E-Phenotype
is	O
lacking	O
,	O
and	O
hence	O
,	O
this	O
is	O
best	O
offered	O
for	O
primary	O
prevention	O
within	O
the	O
context	O
and	O
safe	O
environment	O
of	O
a	O
clinical	O
trial	O
.	O

Moreover	O
,	O
oncogenic	O
activation	O
of	O
MYC	O
and	O
/	O
or	O
loss	O
of	O
a	O
MYC	O
antagonist	O
,	O
results	O
in	O
an	O
imbalance	S-Phenotype
in	O
the	O
activity	O
of	O
the	O
network	O
as	O
a	O
whole	O
,	O
leading	O
to	O
tumor	S-Phenotype
initiation	O
,	O
progression	O
and	O
maintenance	O

While	O
many	O
downstream	O
effectors	O
of	O
ATR	O
have	O
been	O
established	O
,	O
the	O
upstream	O
regulators	O
of	O
ATR	O
and	O
the	O
impact	O
of	O
such	O
regulation	O
on	O
liver	B-Phenotype
cancer	E-Phenotype
remain	O
unclear	O
.	O

In	O
summary	O
,	O
a	O
15	O
-	O
lncRNA	O
expression	O
signature	O
(	O
BAIAP2	O
-	O
AS1	O
,	O
RP11	O
-	O
203J24.8	O
,	O
LINC01133	O
,	O
RP1	O
-	O
7G5.6	O
,	O
RP11	O
-	O
147L13.15	O
,	O
SERHL	O
,	O
CTC	O
-	O
537E7.3	O
,	O
RP11	O
-	O
440L14.1	O
,	O
RP11	O
-	O
131N11.4	O
,	O
ILF3	O
-	O
AS1	O
,	O
RP11	O
-	O
80H18.4	O
,	O
RP11	O
-	O
1096G20.5	O
,	O
CTD	O
-	O
2192J16.26	O
,	O
RP11	O
-	O
621L6.3	O
,	O
and	O
RP11	O
-	O
571M6.18	O
)	O
were	O
identified	O
and	O
validated	O
which	O
can	O
predict	O
cervical	B-Phenotype
cancer	E-Phenotype
patient	O
survival	O
.	O

Recent	O
evidence	O
suggests	O
that	O
ARS	O
genes	O
may	O
participate	O
in	O
a	O
wide	O
array	O
of	O
cellular	O
processes	O
,	O
and	O
may	O
contribute	O
to	O
the	O
pathology	O
of	O
autoimmune	B-Phenotype
disease	E-Phenotype
,	O
cancer	S-Phenotype
,	O
and	O
other	O
diseases	O
.	O

Interventions	O
on	O
FLNB	O
-	O
related	O
diseases	O
require	O
prenatal	O
surveillance	O
by	O
sonography	O
,	O
gene	O
testing	O
in	O
high	O
-	O
risk	O
carriers	O
,	O
and	O
proper	O
orthosis	O
or	O
orthopedic	O
surgeries	O
to	O
correct	O
malformations	O
including	O
scoliosis	S-Phenotype
,	O
cervical	B-Phenotype
spine	I-Phenotype
instability	E-Phenotype
,	O
large	B-Phenotype
joint	I-Phenotype
dislocation	E-Phenotype
,	O
and	O
clubfoot	S-Phenotype
.	O

Meanwhile	O
,	O
the	O
expression	O
of	O
PTPN3	O
was	O
found	O
to	O
be	O
regulated	O
by	O
miR	O
-	O
199	O
in	O
resistant	O
ovarian	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Approximately	O
one	O
-	O
third	O
of	O
pediatric	B-Phenotype
malignant	I-Phenotype
rhabdoid	I-Phenotype
tumors	E-Phenotype
are	O
linked	O
to	O
germline	O
SWI	O
/	O
SNF	O
alterations	O
(	O
SMARCB1	O
/	O
INI1	O
,	O
rarely	O
SMARCA4	O
)	O
resulting	O
in	O
occasional	O
familial	O
clustering	O
of	O
these	O
highly	O
aggressive	O
malignancies	O
(	O
so	O
-	O
called	O
rhabdoid	B-Phenotype
tumor	E-Phenotype
predisposition	O
syndrome	O
,	O
RTPS	O
,	O
types	O
1	O
and	O
2	O
,	O
respectively	O
)	O
.	O

Taken	O
together	O
,	O
these	O
data	O
provide	O
the	O
first	O
demonstration	O
that	O
germline	O
,	O
hypomorphic	O
mutations	O
in	O
FDXR	O
cause	O
a	O
novel	O
mitochondriopathy	S-Phenotype
and	O
optic	B-Phenotype
atrophy	E-Phenotype
in	O
humans	O

Herein	O
,	O
we	O
newly	O
identified	O
that	O
truncated	O
form	O
of	O
CHL1	O
is	O
produced	O
and	O
released	O
from	O
lung	B-Phenotype
tumor	E-Phenotype
tissue	O
in	O
a	O
mouse	O
model	O
expressing	O
human	O
EML4	O
-	O
ALK	O
fusion	O
gene	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
silenced	O
CBX3	O
expression	O
in	O
pancreatic	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
and	O
identified	O
the	O
positive	O
roles	O
of	O
CBX3	O
in	O
cancer	S-Phenotype
cell	O
proliferation	O
.	O

The	O
lifestyle	O
gradually	O
transformed	O
from	O
Bedouin	O
life	O
to	O
urban	O
sedentary	O
life	O
,	O
along	O
with	O
a	O
sharp	O
increase	O
in	O
obesity	S-Phenotype
and	O
other	O
comorbidities	O
.	O

The	O
presynaptic	O
cytomatrix	O
protein	O
Piccolo	O
,	O
encoded	O
by	O
PCLO	O
,	O
is	O
frequently	O
mutated	O
and	O
amplified	O
in	O
esophageal	B-Phenotype
squamous	I-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
ESCC	S-Phenotype
)	O
,	O
but	O
its	O
exact	O
roles	O
in	O
ESCC	O
remain	O
unclear	O
.	O

This	O
pathway	O
is	O
required	O
to	O
maintain	O
levels	O
of	O
GPL	O
,	O
especially	O
phosphatidylethanolamine	O
(	O
PE	O
)	O
,	O
as	O
shown	O
by	O
stable	O
shRNA	O
-	O
mediated	O
silencing	O
of	O
PEPCK	O
-	O
M	O
in	O
H23	O
lung	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

We	O
recently	O
found	O
that	O
DDHD2	O
is	O
a	O
principal	O
triglyceride	O
hydrolase	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
and	O
that	O
genetic	O
deletion	O
of	O
this	O
enzyme	O
in	O
mice	O
leads	O
to	O
ectopic	O
lipid	O
droplet	O
(	O
LD	O
)	O
accumulation	O
in	O
neurons	O
throughout	O
the	O
brain	O
.	O

Beyond	O
CRC	O
,	O
gastric	B-Phenotype
cancer	E-Phenotype
patients	O
also	O
presented	O
a	O
high	O
positive	O
rate	O
of	O
plasma	O
mSEPT9	O
(	O
70	O
%	O
)	O
.	O

One	O
hundred	O
and	O
forty	O
-	O
eight	O
CTLA4	O
mutation	O
carriers	O
have	O
been	O
reported	O
;	O
patients	O
showed	O
hypogammaglobulinemia	S-Phenotype
,	O
recurrent	B-Phenotype
infectious	I-Phenotype
diseases	E-Phenotype
,	O
various	O
autoimmune	B-Phenotype
diseases	E-Phenotype
,	O
and	O
lymphocytic	B-Phenotype
infiltration	I-Phenotype
into	I-Phenotype
multiple	I-Phenotype
organs	E-Phenotype
.	O

The	O
activation	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
(	O
STAT3	O
)	O
by	O
elevated	O
interleukin	O
(	O
IL	O
)	O
levels	O
has	O
been	O
reported	O
to	O
regulate	O
tumorigenesis	S-Phenotype
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
study	O
was	O
carried	O
out	O
to	O
explore	O
the	O
risk	O
stratification	O
of	O
the	O
poor	O
prognosis	O
for	O
patients	O
underwent	O
surgical	O
treatment.60	O
patients	O
diagnosed	O
with	O
neuroblastoma	S-Phenotype
were	O
primarily	O
enrolled	O
in	O
the	O
study	O
from	O
April	O
2008	O
to	O
April	O
2016	O
.	O

Here	O
,	O
we	O
conducted	O
whole	O
-	O
exome	O
sequencing	O
of	O
patients	O
with	O
optic	B-Phenotype
atrophy	E-Phenotype
and	O
other	O
neurological	O
signs	O
of	O
mitochondriopathy	O
and	O
identified	O
17	O
individuals	O
from	O
13	O
unrelated	O
families	O
with	O
recessive	O
mutations	O
in	O
FDXR	O
,	O
encoding	O
the	O
mitochondrial	O
membrane	O
-	O
associated	O
flavoprotein	O
ferrodoxin	O
reductase	O
required	O
for	O
electron	O
transport	O
from	O
NADPH	O
to	O
cytochrome	O
P450	O
.	O

MAIN	O
CONCLUSIONS	O
There	O
was	O
an	O
increase	O
in	O
methylation	O
of	O
the	O
p16	O
ink4a	O
promoter	O
from	O
pre	O
-	O
neoplastic	O
lesions	O
to	O
cancer	S-Phenotype
.	O

However	O
,	O
in	O
recent	O
clinical	O
reports	O
,	O
autosomal	B-Phenotype
recessive	E-Phenotype
ODDD	O
cases	O
due	O
to	O
by	O
GJA1	O
mutations	O
were	O
also	O
described	O
.	O

However	O
,	O
recent	O
discoveries	O
of	O
Smad3	O
-	O
interacting	O
molecules	O
that	O
preferentially	O
bind	O
phosphorylated	O
Smad3	O
linker	O
serine	O
/	O
threonine	O
residues	O
have	O
shown	O
a	O
multitude	O
of	O
signal	O
transductions	O
that	O
either	O
enhance	O
or	O
suppress	O
TGF	O
-	O
β	O
responses	O
associated	O
with	O
Smad3	O
turnover	O
or	O
cancer	S-Phenotype
progression	O
.	O

BACKGROUND	O
Ellis	O
-	O
van	O
Creveld	O
syndrome	O
is	O
an	O
autosomal	B-Phenotype
recessive	I-Phenotype
chondro	I-Phenotype
-	I-Phenotype
ectodermal	I-Phenotype
dysplasia	E-Phenotype
characterized	O
by	O
disproportionate	B-Phenotype
short	I-Phenotype
stature	E-Phenotype
,	O
limb	B-Phenotype
shortening	E-Phenotype
,	O
narrow	B-Phenotype
chest	E-Phenotype
,	O
postaxial	B-Phenotype
polydactyly	E-Phenotype
and	O
dysplastic	B-Phenotype
nails	I-Phenotype
and	I-Phenotype
teeth	E-Phenotype
.	O

Shwachman	O
-	O
Diamond	O
syndrome	O
(	O
SDS	O
)	O
(	O
OMIM	O
#	O
260400	O
)	O
is	O
a	O
rare	O
inherited	B-Phenotype
bone	I-Phenotype
marrow	I-Phenotype
failure	E-Phenotype
syndrome	O
(	O
IBMFS	S-Phenotype
)	O
that	O
is	O
primarily	O
characterized	O
by	O
neutropenia	S-Phenotype
and	O
exocrine	B-Phenotype
pancreatic	I-Phenotype
insufficiency	E-Phenotype
.	O

Here	O
,	O
we	O
aimed	O
to	O
figure	O
out	O
the	O
role	O
of	O
PDCD10	O
in	O
resistance	O
to	O
anti	O
-	O
cancer	S-Phenotype
agents	O
in	O
different	O
cell	O
lines	O
.	O

Malfunctioning	O
of	O
nucleoporins	O
is	O
well	O
known	O
in	O
human	O
malignancies	O
,	O
such	O
as	O
gene	O
fusions	O
of	O
NUP214	O
and	O
NUP98	O
in	O
hematological	B-Phenotype
neoplasms	E-Phenotype
and	O
overexpression	O
of	O
NUP88	O
in	O
a	O
variety	O
of	O
human	O
cancers	S-Phenotype
.	O

Nude	O
mouse	O
model	O
further	O
confirmed	O
that	O
ADAMTS18	O
suppressed	O
breast	B-Phenotype
cancer	E-Phenotype
metastasis	O
in	O
vivo	O
.	O

We	O
thus	O
provide	O
evidence	O
that	O
PCP	O
signaling	O
can	O
act	O
in	O
a	O
context	O
dependent	O
manner	O
to	O
promote	O
breast	B-Phenotype
cancer	E-Phenotype
progression	O
.	O

Six	O
syndromes	O
of	O
familial	O
hyperparathyroidism	S-Phenotype
are	O
compared	O
:	O
1	O
)	O
Familial	B-Phenotype
hypocalciuric	I-Phenotype
hypercalcemia	E-Phenotype
(	O
FHH	S-Phenotype
)	O
expresses	O
primary	B-Phenotype
hyperparathyroidism	E-Phenotype
(	O
PHPT	S-Phenotype
)	O
beginning	O
at	O
birth	O
with	O
lifelong	O
hypercalcemia	S-Phenotype
.	O

Among	O
these	O
genes	O
,	O
it	O
is	O
affirmative	O
that	O
TBR1	O
is	O
a	O
causative	O
gene	O
for	O
intellectual	B-Phenotype
disability	E-Phenotype
;	O
however	O
,	O
the	O
pathogenic	O
genes	O
of	O
other	O
phenotypes	O
remain	O
unclear	O
.	O

Collectively	O
,	O
ICOSL	O
supports	O
the	O
induction	O
of	O
durable	O
,	O
antigen	O
-	O
specific	O
Th17	O
/	O
Th1	O
-	O
mediated	O
immunity	O
in	O
vivo	O
,	O
establishing	O
a	O
vaccination	O
platform	O
to	O
enhance	O
CD4sup+	O
/	O
sup	O
T	O
cell	O
-	O
mediated	O
antitumor	O
immunity	S-Phenotype
and	O
providing	O
a	O
crucial	O
component	O
of	O
an	O
effective	O
cancer	S-Phenotype
vaccine	O

The	O
present	O
study	O
intended	O
to	O
identify	O
the	O
association	O
between	O
three	O
severe	O
types	O
of	O
gynecological	O
cancer	S-Phenotype
,	O
specifically	O
ovarian	B-Phenotype
cancer	E-Phenotype
,	O
cervical	B-Phenotype
cancer	E-Phenotype
and	O
endometrial	B-Phenotype
cancer	E-Phenotype
,	O
and	O
to	O
identify	O
the	O
connective	O
driver	O
genes	O
,	O
microRNAs	O
(	O
miRNAs	O
)	O
and	O
biological	O
processes	O
associated	O
with	O
these	O
types	O
of	O
gynecological	O
cancer	S-Phenotype
.	O

6q14	O
deletions	O
have	O
been	O
associated	O
with	O
intellectual	B-Phenotype
disability	E-Phenotype
and	O
a	O
distinct	O
pattern	O
of	O
minor	O
anomalies	O
,	O
including	O
upslanted	B-Phenotype
palpebral	I-Phenotype
fissures	E-Phenotype
with	O
epicanthal	B-Phenotype
folds	E-Phenotype
,	O
a	O
short	B-Phenotype
nose	E-Phenotype
with	O
broad	B-Phenotype
nasal	I-Phenotype
tip	E-Phenotype
,	O
anteverted	B-Phenotype
nares	E-Phenotype
,	O
long	B-Phenotype
philtrum	E-Phenotype
,	O
and	O
thin	B-Phenotype
upper	I-Phenotype
lip	E-Phenotype
.	O

Biallelic	O
pathogenic	O
variant	O
in	O
AHI1	O
gene	O
can	O
cause	O
Joubert	O
syndrome	O
-	O
related	O
disorders	O
with	O
oculomotor	B-Phenotype
apraxia	E-Phenotype
characteristics	O
.	O

This	O
case	O
of	O
adult	O
-	O
diagnosed	O
MTP	O
deficiency	O
was	O
characterized	O
by	O
slowly	O
progressive	B-Phenotype
peripheral	I-Phenotype
neuropathy	E-Phenotype
masquerading	O
CMT	O
in	O
addition	O
to	O
muscular	O
symptoms	O
.	O

While	O
genome	O
-	O
wide	O
association	O
studies	O
(	O
GWAS	O
)	O
have	O
implicated	O
RCCD1	O
and	O
ANKLE1	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
risk	O
,	O
they	O
have	O
not	O
identified	O
the	O
remaining	O
three	O
genes	O
.	O

Germline	O
mutations	O
in	O
BRCA1	O
are	O
associated	O
with	O
increased	O
risk	O
of	O
breast	B-Phenotype
and	I-Phenotype
ovarian	I-Phenotype
cancer	E-Phenotype
and	O
BRCA1	O
deficient	O
tumors	S-Phenotype
are	O
exquisitely	O
sensitive	O
to	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
(	O
PARP	O
)	O
inhibitors	O
.	O

We	O
hope	O
that	O
our	O
study	O
will	O
stimulate	O
further	O
studies	O
and	O
a	O
new	O
targeted	O
therapy	O
and	O
early	O
medical	O
intervention	O
for	O
YAP	O
/	O
TAZ	O
could	O
be	O
a	O
useful	O
option	O
for	O
breast	B-Phenotype
cancer	E-Phenotype
cases	O
complicated	O
with	O
LKB1	O
deficiency	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
safety	O
and	O
the	O
tolerability	O
of	O
combined	O
cellular	O
immunotherapy	O
with	O
low	O
-	O
dose	O
cyclophosphamide	O
(	O
CPA	O
)	O
in	O
patients	O
with	O
advanced	O
solid	O
tumors	S-Phenotype
.	O

Based	O
on	O
the	O
array	O
data	O
,	O
we	O
concluded	O
that	O
the	O
deletion	O
was	O
limited	O
to	O
the	O
MEN1	O
gene	O
and	O
that	O
the	O
father	O
had	O
both	O
germline	O
and	O
somatic	B-Phenotype
mosaicism	E-Phenotype
for	O
MEN1	O
.	O

Defects	O
of	O
CIB2	O
,	O
calcium	O
-	O
and	O
integrin	O
-	O
binding	O
protein	O
2	O
,	O
have	O
been	O
reported	O
to	O
cause	O
isolated	O
deafness	S-Phenotype
,	O
DFNB48	O
and	O
Usher	O
syndrome	O
type	O
-	O
IJ	O
,	O
characterized	O
by	O
congenital	B-Phenotype
profound	I-Phenotype
deafness	E-Phenotype
,	O
balance	B-Phenotype
defects	E-Phenotype
and	O
blindness	S-Phenotype
.	O

We	O
performed	O
a	O
clinical	O
,	O
neurophysiological	O
(	O
in	O
vivo	O
electroencephalography	O
-	O
auditory	O
-	O
evoked	O
related	O
potentials	O
)	O
and	O
genetic	O
(	O
whole	O
-	O
exome	O
sequencing	O
)	O
follow	O
-	O
up	O
analysis	O
of	O
two	O
families	O
with	O
known	O
deleterious	O
NLGN4X	O
gene	O
mutations	O
(	O
either	O
truncating	O
or	O
overexpressing	O
)	O
present	O
in	O
individuals	O
with	O
ASD	O
and	O
/	O
or	O
with	O
intellectual	B-Phenotype
disability	E-Phenotype
(	O
ID	S-Phenotype
)	O
.	O

Higher	O
expression	O
of	O
EEF1A2	O
,	O
EEF1B2	O
,	O
EEF1G	O
,	O
EEF1D	O
,	O
EEF1E1	O
and	O
EEF2	O
was	O
observed	O
in	O
most	O
of	O
the	O
cancer	S-Phenotype
types	O
,	O
whereas	O
reverse	O
trend	O
was	O
observed	O
for	O
EEF1A1	O
.	O

The	O
G	O
-	O
protein	O
beta	O
subunit	O
3	O
(	O
GNB3	O
)	O
gene	O
has	O
been	O
implicated	O
in	O
obesity	S-Phenotype
risk	O
;	O
however	O
,	O
the	O
molecular	O
mechanism	O
of	O
GNB3	O
-	O
related	O
disease	O
is	O
unknown	O
.	O

We	O
found	O
that	O
the	O
downregulation	O
of	O
SOX3	O
inhibited	O
the	O
proliferation	O
,	O
migration	O
and	O
invasion	O
of	O
osteosarcoma	S-Phenotype
cells	O
.	O

This	O
report	O
provides	O
evidence	O
that	O
bi	O
-	O
allelic	O
null	O
PAX1	O
mutations	O
may	O
lead	O
to	O
a	O
multi	O
-	O
system	O
autosomal	B-Phenotype
recessive	E-Phenotype
disorders	O
,	O
where	O
SCID	O
might	O
represent	O
the	O
main	O
feature	O

MATERIAL	O
AND	O
METHODS	O
A	O
total	O
of	O
63	O
paired	O
gastric	B-Phenotype
cancer	E-Phenotype
tissues	O
and	O
matched	O
adjacent	O
mucosa	O
were	O
used	O
to	O
measure	O
the	O
ANXA11	O
levels	O
and	O
its	O
correlation	O
with	O
clinical	O
characteristics	O
.	O

As	O
a	O
result	O
,	O
USP13	O
depletion	O
using	O
CRISPR	O
/	O
Cas9	O
nuclease	O
system	O
inhibits	O
tumor	S-Phenotype
growth	O
in	O
xenografted	O
nude	O
mice	O
.	O

Paroxysmal	B-Phenotype
nocturnal	I-Phenotype
hemoglobinuria	E-Phenotype
(	O
PNH	S-Phenotype
)	O
is	O
a	O
clonal	O
hematopoietic	O
disease	O
caused	O
by	O
expansion	O
of	O
a	O
stem	O
cell	O
that	O
harbors	O
a	O
somatic	B-Phenotype
mutation	E-Phenotype
in	O
liPIGA	O
/	O
i	O
PIGA	O
mutant	O
blood	O
cells	O
are	O
deficient	O
in	O
the	O
complement	O
regulator	O
proteins	O
CD55	O
and	O
CD59	O
,	O
making	O
them	O
susceptible	O
to	O
intravascular	O
hemolysis	O
due	O
to	O
a	O
failure	O
to	O
regulate	O
the	O
APC	O
on	O
erythrocytes	O
.	O

CtBP1	O
overexpression	O
is	O
known	O
to	O
be	O
protumorigenic	O
and	S-Phenotype
affects	O
the	O
regulation	O
of	O
gene	O
networks	O
associated	O
with	O
AAAAAAcancer	O
hallmarksAAAAAA	O
and	O
malignant	O
behavior	O
,	O
including	O
increased	O
cell	O
survival	O
,	O
proliferation	O
,	O
migration	O
,	O
invasion	O
,	O
and	O
the	O
epithelial	O
-	O
mesenchymal	O
transition	O
.	O

CCBE1	O
expression	O
appeared	O
to	O
be	O
decreased	O
in	O
lung	B-Phenotype
tumor	E-Phenotype
tissue	O
and	O
further	O
downregulated	O
in	O
samples	O
from	O
patients	O
with	O
LNM	O
,	O
and	O
was	O
revealed	O
to	O
be	O
correlated	O
with	O
poor	O
clinical	O
outcome	O
.	O

Gap	O
junction	O
beta	O
-	O
1	O
(	O
GJB1	O
)	O
gene	O
mutations	O
affecting	O
the	O
gap	O
junction	O
protein	O
connexin32	O
(	O
Cx32	O
)	O
cause	O
the	O
X	O
-	O
linked	O
Charcot	O
-	O
Marie	O
-	O
Tooth	O
disease	O
(	O
CMT1X	O
)	O
,	O
a	O
common	O
inherited	B-Phenotype
neuropathy	E-Phenotype
.	O

Therefore	O
,	O
tumors	S-Phenotype
exploit	O
ClpXP	O
-	O
directed	O
proteostasis	O
to	O
maintain	O
mitochondrial	O
bioenergetics	O
,	O
buffer	O
oxidative	B-Phenotype
stress	E-Phenotype
,	O
and	O
enable	O
metastatic	O
competence	O
.	O

Overexpression	O
of	O
Phgdh	O
in	O
CK5	O
-	O
positive	O
cell	O
lineages	O
,	O
and	O
differential	O
protein	O
isoform	O
expression	O
,	O
was	O
additionally	O
found	O
in	O
other	O
tissues	O
and	O
cancer	S-Phenotype
types	O
,	O
suggesting	O
that	O
overexpression	O
of	O
Phgdh	O
is	O
generally	O
associated	O
with	O
CK5	O
cells	O
,	O
and	O
that	O
oncogenic	O
function	O
may	O
be	O
determined	O
by	O
isoform	O
expression	O
.	O

In	O
summary	O
,	O
the	O
identification	O
of	O
TUBGCP4	O
mutations	O
in	O
individuals	O
with	O
microcephaly	S-Phenotype
and	O
a	O
spectrum	O
of	O
anomalies	O
in	O
eye	O
development	O
,	O
particularly	O
photoreceptor	O
anomalies	O
,	O
provides	O
evidence	O
of	O
an	O
important	O
role	O
for	O
the	O
y	O
-	O
TuRC	O
in	O
brain	O
and	O
eye	O
development	O

The	O
novel	O
myoclonus	S-Phenotype
-	O
dystonia	S-Phenotype
genes	O
KCTD17	O
and	O
CACNA1B	O
also	O
implicate	O
abnormal	O
calcium	O
signaling	O
in	O
dystonia	S-Phenotype
.	O

Mutations	O
and	O
deletions	O
of	O
the	O
interleukin	O
-	O
1	O
receptor	O
accessory	O
protein	O
like	O
1	O
(	O
IL1RAPL1	O
)	O
gene	O
,	O
located	O
on	O
the	O
X	O
chromosome	O
,	O
are	O
associated	O
with	O
intellectual	B-Phenotype
disability	E-Phenotype
(	O
ID	S-Phenotype
)	O
and	O
autism	B-Phenotype
spectrum	I-Phenotype
disorder	E-Phenotype
(	O
ASD	S-Phenotype
)	O
.	O

Analysis	O
of	O
the	O
adult	O
Hnf4a	O
mutant	O
kidney	O
also	O
showed	O
proximal	B-Phenotype
tubule	I-Phenotype
dysgenesis	E-Phenotype
and	O
nephrocalcinosis	S-Phenotype
.	O

Cyclooxygenase	O
(	O
COX	O
)	O
-	O
2	O
is	O
upregulated	O
in	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
.	O

Tenascin	O
-	O
C	O
(	O
TNC	O
)	O
,	O
an	O
extracellular	O
matrix	O
glycoprotein	O
,	O
has	O
been	O
implicated	O
in	O
progression	O
of	O
various	O
types	O
of	O
cancer	S-Phenotype
.	O

Electro	O
-	O
physiologic	O
studies	O
revealed	O
an	O
axonal	O
type	O
of	O
neuropathy	S-Phenotype
(	O
AR	O
-	O
CMT2K	O
and	O
AD	O
-	O
CMT2K	O
)	O
in	O
all	O
affected	O
individuals	O
.	O

Because	O
TMC8	O
is	O
required	O
to	O
lower	O
cytosolic	O
Zn	O
(	O
2+	O
)	O
concentrations	O
by	O
the	O
Zn	O
(	O
2+	O
)	O
transporter	O
ZnT	O
-	O
1	O
,	O
we	O
hypothesize	O
that	O
HPV	O
infections	O
and	O
cancer	S-Phenotype
caused	O
by	O
mutations	O
in	O
TMC8	O
are	O
related	O
to	O
upregulated	O
Zn	O
(	O
2+	O
)	O
/	O
Ca	O
(	O
2+	O
)	O
signaling	O
and	O
activation	O
of	O
Ano1	O
.	O

Our	O
study	O
showed	O
that	O
targeted	O
NGS	O
is	O
an	O
effective	O
tool	O
for	O
diagnosis	O
of	O
genetic	O
deafness	S-Phenotype
and	O
that	O
p.G141R	O
in	O
liILDR1	O
/	O
i	O
may	O
be	O
a	O
relatively	O
frequent	O
mutation	O
for	O
DFNB42	O
in	O
Chinese	O
Hans	O

Although	O
cerebral	B-Phenotype
edema	E-Phenotype
is	O
not	O
a	O
universal	O
feature	O
of	O
aSAH	O
,	O
it	O
portends	O
a	O
poor	O
clinical	O
course	O
,	O
with	O
quantitative	O
analysis	O
revealing	O
a	O
direct	O
correlation	O
between	O
cerebral	B-Phenotype
edema	E-Phenotype
and	O
poor	O
outcome	O
,	O
including	O
mortality	O
and	O
cognitive	B-Phenotype
deficits	E-Phenotype
.	O

Although	O
MPC	O
is	O
composed	O
of	O
two	O
subunits	O
,	O
it	O
has	O
been	O
reported	O
that	O
the	O
MPC1	O
subunit	O
is	O
specifically	O
associated	O
with	O
poor	O
prognosis	O
in	O
several	O
cancers	S-Phenotype
,	O
including	O
colorectal	B-Phenotype
and	I-Phenotype
prostate	I-Phenotype
cancer	E-Phenotype
.	O

Our	O
recent	O
determination	O
of	O
a	O
microRNA	O
(	O
miRNA	O
)	O
expression	O
signature	O
in	O
prostate	B-Phenotype
cancer	E-Phenotype
(	O
PCa	S-Phenotype
)	O
revealed	O
that	O
miR	O
-	O
205	O
-	O
5p	O
was	O
significantly	O
reduced	O
in	O
PCa	O
tissues	O
and	O
that	O
it	O
acted	O
as	O
an	O
antitumor	O
miRNA	O
.	O

We	O
aimed	O
to	O
find	O
the	O
genetic	O
cause	O
of	O
Korean	O
patients	O
with	O
sensory	O
motor	B-Phenotype
polyneuropathy	E-Phenotype
,	O
myopathy	S-Phenotype
and	O
rigid	B-Phenotype
spine	E-Phenotype
.	O

Differentiated	O
embryo	O
chondrocyte	O
expressed	O
gene	O
1	O
(	O
Dec1	O
)	O
,	O
a	O
crucial	O
cell	O
differentiation	O
mediator	O
and	O
apoptosis	O
inhibitor	O
,	O
is	O
abundantly	O
expressed	O
in	O
various	O
types	O
of	O
human	O
cancer	S-Phenotype
and	O
is	O
associated	O
with	O
malignant	O
tumor	S-Phenotype
progression	O
.	O

develop	O
a	O
novel	O
zebrafish	O
model	O
that	O
elucidates	O
a	O
mechanism	O
by	O
which	O
LMO1	O
and	O
MYCN	O
synergistically	O
initiate	O
neuroblastoma	S-Phenotype
and	O
contribute	O
to	O
metastatic	O
disease	O
progression	O

Suppression	O
of	O
UBE2T	O
also	O
attenuated	O
the	O
invasive	O
and	O
metastatic	O
abilities	O
of	O
gastric	B-Phenotype
cancer	E-Phenotype
cells	O
by	O
altering	O
expression	O
of	O
epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
-	O
related	O
factors	O
.	O

RESULTS	O
Overexpression	O
of	O
LINC00665	O
in	O
patients	O
with	O
HCC	O
was	O
significantly	O
associated	O
with	O
gender	O
,	O
tumor	S-Phenotype
grade	O
,	O
stage	O
,	O
and	O
tumor	S-Phenotype
cell	O
type	O
.	O

Knockdown	O
of	O
SNIP1	O
reduced	O
colony	O
formation	O
ability	O
of	O
lung	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Results	O
after	O
perturbing	O
EPAC	O
activity	O
suggests	O
its	O
involvement	O
in	O
cancer	S-Phenotype
cell	O
migration	O
,	O
proliferation	O
,	O
and	O
cytoskeleton	O
remodeling	O
which	O
makes	O
it	O
a	O
potential	O
therapeutic	O
target	O
for	O
cancer	S-Phenotype
treatments	O

Hence	O
,	O
TSPY	O
and	O
TSPX	O
exert	O
opposing	O
effects	O
on	O
the	O
transactivation	O
functions	O
of	O
AR	O
and	O
AR	O
-	O
Vs	O
important	O
for	O
various	O
physiological	O
and	O
disease	O
processes	O
sensitive	O
to	O
male	O
sex	O
hormone	O
actions	O
,	O
thereby	O
not	O
only	O
affecting	O
the	O
pathogenesis	O
of	O
male	O
-	O
specific	O
prostate	B-Phenotype
cancer	E-Phenotype
but	O
also	O
likely	O
contributing	O
to	O
sex	O
differences	O
in	O
the	O
health	O
and	O
diseases	O
of	O
man	O

Indeed	O
,	O
we	O
have	O
previously	O
reported	O
that	O
a	O
vaccine	O
comprises	O
allogeneic	O
murine	O
embryonic	O
stem	O
cells	O
(	O
ESCs	O
)	O
and	O
murine	O
fibroblasts	O
expressing	O
GM	O
-	O
CSF	O
(	O
to	O
amplify	O
immune	O
responses	O
)	O
successfully	O
blocks	O
the	O
outgrowth	O
of	O
an	O
implantable	O
cancer	S-Phenotype
(	O
Lewis	O
lung	O
carcinoma	S-Phenotype
;	O
LLC	O
)	O
and	O
lung	B-Phenotype
tumors	E-Phenotype
generated	O
in	O
mice	O
using	O
a	O
combination	O
of	O
a	O
mutagen	O
followed	O
by	O
chronic	O
pulmonary	O
inflammation	O
.	O

Patients	O
who	O
carry	O
the	O
collagen	O
type	O
IVA3	O
chain	O
(	O
COL4A3	O
)	O
or	O
COL4A4	O
mutations	O
usually	O
exhibit	O
Alport	O
Syndrome	O
(	O
AS	O
)	O
,	O
thin	O
basement	O
membrane	O
neuropathy	S-Phenotype
or	O
familial	B-Phenotype
hematuria	E-Phenotype
(	O
FH	S-Phenotype
)	O
.	O

Low	O
MPC1	O
expression	O
correlated	O
with	O
poor	O
ICC	O
prognosis	O
and	O
was	O
correlated	O
with	O
tumor	S-Phenotype
invasion	O
and	O
distant	O
metastasis	O
.	O

Cell	O
-	O
based	O
assays	O
,	O
using	O
5	O
-	O
aza	O
-	O
cytidine	O
-	O
treated	O
normal	O
(	O
NbE	O
-	O
1	O
)	O
and	O
cancerous	S-Phenotype
(	O
AIT	O
)	O
rat	O
prostate	O
cells	O
,	O
added	O
evidence	O
of	O
DNA	O
methylation	O
-	O
mediated	O
gene	O
expression	O
of	O
6	O
genes	O
(	O
exception	O
:	O
Paqr4	O
)	O
.	O

Hence	O
we	O
show	O
that	O
mutant	O
KRAS	O
facilitates	O
IKKα	O
-	O
mediated	O
responsiveness	O
of	O
tumor	S-Phenotype
cells	O
to	O
host	O
IL	O
-	O
1β	O
,	O
thereby	O
establishing	O
a	O
host	O
-	O
to	O
-	O
tumor	S-Phenotype
signaling	O
circuit	O
that	O
culminates	O
in	O
inflammatory	O
MPE	O
development	O
and	O
drug	B-Phenotype
resistance	E-Phenotype

Another	O
disease	O
that	O
shares	O
two	O
of	O
the	O
tumor	S-Phenotype
components	O
of	O
CT	O
,	O
namely	O
GIST	O
and	O
PGL	O
is	O
the	O
Carney	O
-	O
Stratakis	O
syndrome	O
(	O
CSS	O
)	O
or	O
dyad	O
.	O

Stimulation	O
of	O
BxPC	O
-	O
3	O
,	O
Panc	O
-	O
1	O
,	O
and	O
MIA	O
PaCA	O
-	O
2	O
pancreatic	B-Phenotype
cancer	E-Phenotype
cells	O
with	O
EGF	O
,	O
HGF	O
,	O
FGF	O
-	O
1	O
,	O
FGF	O
-	O
2	O
,	O
FGF	O
-	O
7	O
,	O
and	O
FGF	O
-	O
10	O
growth	O
factors	O
caused	O
changes	O
in	O
the	O
expression	O
of	O
master	O
genes	O
regulating	O
pancreatic	O
development	O
(	O
SOX9	O
,	O
HNF3b	O
,	O
GATA	O
-	O
4	O
,	O
GATA	O
-	O
6	O
,	O
and	O
HES1	O
)	O
.	O

Our	O
study	O
identified	O
a	O
novel	O
protein	O
downstream	O
of	O
Ras	O
and	O
EGFR	O
,	O
which	O
may	O
serve	O
as	O
a	O
potential	O
therapeutic	O
drug	O
target	O
for	O
lung	B-Phenotype
cancer	E-Phenotype
patients	O

Multisystem	O
proteinopathy	O
(	O
MSP	O
)	O
,	O
a	O
newly	O
proposed	O
syndrome	O
including	O
inclusion	O
body	O
myopathy	S-Phenotype
(	O
IBM	O
)	O
,	O
PDB	O
,	O
frontotemporal	B-Phenotype
dementia	E-Phenotype
(	O
FTD	S-Phenotype
)	O
,	O
and	O
amyotrophic	B-Phenotype
lateral	I-Phenotype
sclerosis	E-Phenotype
(	O
ALS	S-Phenotype
)	O
,	O
is	O
mainly	O
caused	O
by	O
mutation	O
in	O
VCP	O
gene	O
.	O

The	O
Gene	O
Expression	O
Profiling	O
Interactive	O
Analyses	O
application	O
(	O
GEPIA	O
)	O
was	O
used	O
to	O
analysis	O
the	O
expression	O
of	O
CLDN10	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
tissues	O
and	O
normal	O
samples.The	O
polymorphism	O
of	O
rs1325774	O
was	O
significantly	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
(	O
T	O
/	O
G	O
vs	O
T	O
/	O
T	O
:	O
OR	O
=	O
2.073	O
,	O
95	O
%	O
CI	O
=	O
1.095	O
-	O
3.927	O
,	O
P	O
=	O
.025	O
)	O
.	O

As	O
the	O
first	O
identified	O
messenger	O
RNA	O
N6	O
-	O
methyladenosine	O
(	O
m6A	O
)	O
demethylase	O
,	O
FTO	O
has	O
been	O
shown	O
recently	O
to	O
play	O
m6A	O
-	O
dependent	O
roles	O
in	O
adipogenesis	O
and	O
tumorigenesis	O
(	O
especially	O
in	O
the	O
development	O
of	O
leukemia	S-Phenotype
and	O
glioblastoma	S-Phenotype
)	O
.	O

Recent	O
GWAS	O
completed	O
for	O
three	O
types	O
of	O
common	O
adult	O
-	O
onset	O
glaucoma	S-Phenotype
have	O
identified	O
novel	O
loci	O
for	O
POAG	O
(	O
primary	O
-	O
open	O
-	O
angle	O
glaucoma	S-Phenotype
)	O
(	O
ABCA1	O
,	O
AFAP1	O
,	O
GMDS	O
,	O
PMM2	O
,	O
TGFBR3	O
,	O
FNDC3B	O
,	O
ARHGEF12	O
,	O
GAS7	O
,	O
FOXC1	O
,	O
ATXN2	O
,	O
TXNRD2	O
)	O
;	O
PACG	O
(	O
primary	O
angle	O
-	O
closure	O
glaucoma	S-Phenotype
(	O
EPDR1	O
,	O
CHAT	O
,	O
GLIS3	O
,	O
FERMT2	O
,	O
DPM2	O
-	O
FAM102	O
)	O
;	O
and	O
exfoliation	O
syndrome	O
(	O
XFS	O
)	O
glaucoma	S-Phenotype
(	O
CACNA1A	O
)	O
.	O

Particularly	O
,	O
NONO	O
expression	O
was	O
statistically	O
higher	O
in	O
tumors	S-Phenotype
with	O
greater	O
tumor	S-Phenotype
invasion	O
depth	O
.	O

UBE2A	O
deficiency	O
is	O
a	O
syndromic	O
condition	O
of	O
X	B-Phenotype
-	I-Phenotype
linked	I-Phenotype
intellectual	I-Phenotype
disability	E-Phenotype
(	O
ID	S-Phenotype
)	O
characterized	O
by	O
typical	O
dysmorphic	O
features	O
that	O
include	O
synophrys	S-Phenotype
,	O
prominent	B-Phenotype
supraorbital	I-Phenotype
ridges	E-Phenotype
,	O
almond	B-Phenotype
-	I-Phenotype
shaped	I-Phenotype
,	I-Phenotype
and	I-Phenotype
deep	I-Phenotype
-	I-Phenotype
set	I-Phenotype
eyes	E-Phenotype
,	O
large	B-Phenotype
ears	E-Phenotype
,	O
wide	B-Phenotype
mouth	E-Phenotype
,	O
myxedematous	B-Phenotype
appearance	E-Phenotype
,	O
hirsutism	S-Phenotype
,	O
micropenis	S-Phenotype
,	O
and	O
onychodystrophy	S-Phenotype
.	O

However	O
,	O
all	O
experimental	O
models	O
of	O
electrolytic	B-Phenotype
deep	I-Phenotype
vein	I-Phenotype
thrombosis	E-Phenotype
,	O
tissue	B-Phenotype
factor	I-Phenotype
-	I-Phenotype
induced	I-Phenotype
pulmonary	I-Phenotype
embolism	E-Phenotype
,	O
transient	B-Phenotype
focal	I-Phenotype
brain	I-Phenotype
ischaemic	I-Phenotype
stroke	E-Phenotype
,	O
or	O
skin	O
-	O
wound	O
healing	O
showed	O
largely	O
similar	O
phenotypes	O
between	O
PlgT	O
/	O
T	O
mice	O
and	O
wild	O
-	O
type	O
mice	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
screen	O
the	O
visual	O
system	O
homeobox	O
1	O
(	O
VSX1	O
)	O
gene	O
in	O
Turkish	O
patients	O
with	O
keratoconus	S-Phenotype
(	O
KC	S-Phenotype
)	O
.	O

We	O
recommend	O
CCDC88C	O
analysis	O
in	O
cases	O
of	O
severe	O
non	B-Phenotype
-	I-Phenotype
syndromic	I-Phenotype
congenital	I-Phenotype
hydrocephalus	E-Phenotype
,	O
especially	O
when	O
aqueduct	B-Phenotype
stenosis	E-Phenotype
with	O
or	O
without	O
a	O
medial	O
diverticulum	O
is	O
seen	O
,	O
in	O
order	O
to	O
aid	O
prognosis	O
discussion	O

VSX1	O
remains	O
as	O
the	O
best	O
characterised	O
keratoconus	S-Phenotype
gene	O
but	O
only	O
accounts	O
for	O
rare	O
cases	O
.	O

In	O
this	O
review	O
,	O
we	O
introduce	O
the	O
current	O
knowledge	O
of	O
miRNA	O
functions	O
in	O
cancer	S-Phenotype
development	O
and	O
discuss	O
the	O
clinical	O
applications	O
of	O
se	O
-	O
miRNAs	O
,	O
eg	O
,	O
as	O
diagnostic	O
markers	O
and	O
therapeutic	O
targets	O

Further	O
studies	O
are	O
warranted	O
to	O
dissect	O
these	O
mechanisms	O
and	O
establish	O
5	O
-	O
Aza	O
-	O
dC	O
as	O
an	O
effective	O
multi	O
-	O
module	O
anticancer	O
reagent	S-Phenotype

In	O
this	O
study	O
,	O
we	O
reported	O
the	O
identification	O
of	O
Calcium	O
Binding	O
Protein	O
39	O
-	O
Like	O
(	O
CAB39L	O
)	O
as	O
a	O
novel	O
regulator	O
of	O
tumor	S-Phenotype
metabolism	O
in	O
GC	O
.	O

One	O
of	O
these	O
two	O
is	O
a	O
novel	O
AMD	O
GWAS	O
locus	O
,	O
near	O
the	O
retinal	O
clusterin	O
-	O
like	O
protein	O
(	O
CLUL1	O
)	O
gene	O
,	O
and	O
the	O
other	O
,	O
near	O
the	O
retinaldehyde	O
binding	O
protein	O
1	O
(	O
RLBP1	O
)	O
,	O
was	O
recently	O
identified	O
in	O
a	O
joint	O
analysis	O
of	O
nuclear	O
and	O
mitochondrial	S-Phenotype
variants	O
.	O

FRMD4A	O
antibodies	O
were	O
used	O
to	O
probe	O
78	O
paraffin	O
-	O
embedded	O
specimens	O
of	O
tongue	B-Phenotype
squamous	I-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
and	O
15	O
normal	O
tongue	O
tissues	O
,	O
which	O
served	O
as	O
controls	O
.	O

Undifferentiated	O
gonadal	O
tissue	O
is	O
the	O
precursor	O
of	O
classical	O
gonadoblastoma	S-Phenotype
and	O
contains	O
germ	O
cells	O
with	O
delayed	O
maturation	O
that	O
express	O
octamer	O
-	O
binding	O
transcription	O
factor	O
4	O
(	O
OCT4	O
)	O
;	O
however	O
,	O
other	O
germ	O
cells	O
show	O
normal	O
maturation	O
and	O
express	O
TSPY1	O
.	O

Taken	O
together	O
,	O
the	O
results	O
indicate	O
that	O
increase	O
of	O
HS	O
content	O
and	O
up	O
-	O
regulation	O
of	O
perlecan	O
/	O
HSPG2	O
expression	O
in	O
glioblastoma	S-Phenotype
tissues	O
contribute	O
to	O
tumour	S-Phenotype
development	O
through	O
the	O
transformation	O
of	O
brain	O
extracellular	O
matrix	O
into	O
tumour	S-Phenotype
microenvironment	O
,	O
and	O
represent	O
negative	O
prognostic	O
factors	O
for	O
glioblastoma	S-Phenotype
progression	O

Herewith	O
we	O
provide	O
a	O
biological	O
and	O
pathophysiological	O
characterization	O
of	O
the	O
immunological	O
layer	O
of	O
cancerous	S-Phenotype
(	O
PCa	O
)	O
versus	O
benign	O
(	O
BPH	O
)	O
disease	O
,	O
derived	O
from	O
antibody	O
profiling	O
on	O
protein	O
microarrays	O

She	O
manifested	O
macrocephaly	S-Phenotype
,	O
preaxial	B-Phenotype
polysyndactyly	E-Phenotype
,	O
psychomotor	B-Phenotype
developmental	I-Phenotype
delay	E-Phenotype
,	O
cerebral	B-Phenotype
cavernous	I-Phenotype
malformations	E-Phenotype
,	O
and	O
glucose	B-Phenotype
intolerance	E-Phenotype
due	O
to	O
a	O
6.2	O
-	O
Mb	O
deletion	O
of	O
7p14.1p12.3	O
which	O
included	O
GLI3	O
,	O
GCK	O
,	O
and	O
CCM2	O
.	O

The	O
four	O
large	O
extracellular	O
domains	O
of	O
EMP2	O
and	O
its	O
association	O
with	O
the	O
extracellular	O
matrix	O
makes	O
it	O
an	O
attractive	O
target	O
for	O
future	O
cancer	S-Phenotype
therapies	O
.	O

By	O
combining	O
targeted	O
capture	O
of	O
129	O
known	O
deafness	S-Phenotype
genes	O
,	O
next	O
-	O
generation	O
sequencing	O
,	O
and	O
bioinformatic	O
analysis	O
,	O
we	O
identified	O
POU4F3	O
c.602TAAAAC	O
(	O
p.Leu201Pro	O
)	O
as	O
the	O
disease	O
-	O
causing	O
variant	O
.	O

Progressive	B-Phenotype
retinal	I-Phenotype
atrophy	E-Phenotype
(	O
PRA	S-Phenotype
)	O
is	O
the	O
canine	O
equivalent	O
of	O
retinitis	B-Phenotype
pigmentosa	E-Phenotype
(	O
RP	S-Phenotype
)	O
.	O

Hereditary	B-Phenotype
sensory	I-Phenotype
and	I-Phenotype
autonomic	I-Phenotype
neuropathy	I-Phenotype
1	E-Phenotype
(	O
HSAN1	S-Phenotype
)	O
is	O
an	O
autosomal	O
dominant	O
disorder	O
that	O
can	O
be	O
caused	O
by	O
variants	O
in	O
SPTLC1	O
or	O
SPTLC2	O
,	O
encoding	O
subunits	O
of	O
serine	O
palmitoyl	O
-	O
CoA	O
transferase	O
.	O

Rarely	O
,	O
patients	O
with	O
severe	O
,	O
salt	O
-	O
wasting	O
CAH	O
have	O
deletions	O
of	O
CYP21A2	O
that	O
extend	O
into	O
TNXB	O
,	O
resulting	O
in	O
a	O
contiguous	O
gene	O
syndrome	O
consisting	O
of	O
CAH	O
and	O
EDS	O
.	O

Mutations	O
in	O
a	O
proline	O
-	O
rich	O
-	O
repeat	O
region	O
(	O
PRR	O
)	O
of	O
UBQLN2	O
cause	O
amyotrophic	B-Phenotype
lateral	I-Phenotype
sclerosis	E-Phenotype
(	O
ALS	S-Phenotype
)	O
/	O
frontotemporal	B-Phenotype
dementia	E-Phenotype
(	O
FTD	S-Phenotype
)	O
;	O
however	O
,	O
neither	O
the	O
normal	O
functions	O
of	O
the	O
PRR	O
nor	O
impacts	O
of	O
ALS	O
-	O
associated	O
mutations	O
within	O
it	O
are	O
well	O
understood	O
.	O

Mutations	O
in	O
subunits	O
of	O
mitochondrial	O
m	O
-	O
AAA	O
proteases	O
in	O
the	O
inner	O
membrane	O
cause	O
neurodegeneration	S-Phenotype
in	O
spinocerebellar	B-Phenotype
ataxia	E-Phenotype
(	O
SCA28	S-Phenotype
)	O
and	O
hereditary	B-Phenotype
spastic	I-Phenotype
paraplegia	E-Phenotype
(	O
HSP7	S-Phenotype
)	O
.	O

To	O
date	O
,	O
there	O
are	O
no	O
reports	O
of	O
symptomatic	O
improvement	O
in	O
CTX	O
related	O
ataxia	S-Phenotype
following	O
treatment	O
with	O
Riluzole	O
.	O

A	O
common	O
form	O
of	O
hereditary	B-Phenotype
autosomal	I-Phenotype
dominant	I-Phenotype
demyelinating	I-Phenotype
neuropathy	E-Phenotype
known	O
as	O
Charcot	O
-	O
Marie	O
-	O
Tooth	O
disease	O
type	O
1A	O
(	O
CMT1A	O
)	O
is	O
linked	O
with	O
duplication	O
of	O
the	O
peripheral	O
myelin	O
protein	O
22	O
(	O
PMP22	O
)	O
gene	O
.	O

The	O
genetic	O
testing	O
revealed	O
a	O
de	O
novo	O
heterozygous	O
mutation	O
of	O
c.2452G	O
AAAA	O
A	O
(	O
p.Glu818Lys	O
)	O
in	O
the	O
ATP1A3	O
gene	O
,	O
which	O
was	O
compatible	O
with	O
the	O
clinical	O
phenotype	O
of	O
CAPOS	O
(	O
cerebellar	B-Phenotype
ataxia	E-Phenotype
,	O
areflexia	S-Phenotype
,	O
pes	B-Phenotype
cavus	E-Phenotype
,	O
optic	B-Phenotype
atrophy	E-Phenotype
,	O
and	O
sensorineural	B-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
)	O
/	O
CAOS	O
syndrome	O
.	O

Further	O
in	O
silico	O
functional	O
analyses	O
revealed	O
that	O
rs2394882	O
affects	O
POU5F1	O
expression	O
,	O
which	O
in	O
turn	O
is	O
significantly	O
correlated	O
with	O
prostate	B-Phenotype
cancer	E-Phenotype
aggressiveness	S-Phenotype
and	O
patient	O
prognosis	O
.	O

In	O
the	O
leiomyomas	O
with	O
12q	O
rearrangements	O
,	O
both	O
HMGA2	O
and	O
PLAG1	O
were	O
expressed	O
whereas	O
in	O
the	O
tumors	S-Phenotype
with	O
8q	O
aberrations	O
,	O
only	O
PLAG1	O
was	O
expressed	O
.	O

The	O
present	O
study	O
aimed	O
to	O
explore	O
ARHGAP17	O
expression	O
in	O
cervical	B-Phenotype
cancer	E-Phenotype
and	O
the	O
possible	O
function	O
in	O
tumor	S-Phenotype
progression	O
.	O

AMMECR1	O
gene	O
is	O
localized	O
in	O
the	O
critical	O
region	O
of	O
contiguous	O
deletion	O
syndrome	O
on	O
Xq22.3	O
implicated	O
in	O
Alport	O
syndrome	O
,	O
mental	B-Phenotype
retardation	E-Phenotype
,	O
midface	B-Phenotype
hypoplasia	E-Phenotype
,	O
and	O
elliptocytosis	S-Phenotype
(	O
AMME	O
complex	O
)	O
.	O

Walker	O
-	O
Warburg	O
syndrome	O
(	O
WWS	O
)	O
is	O
a	O
severe	O
muscular	B-Phenotype
dystrophy	E-Phenotype
with	O
eye	O
and	O
brain	O
malformations	O
.	O

Ectopic	O
expression	O
of	O
miR	O
-	O
451a	O
significantly	O
inhibited	O
cancer	S-Phenotype
cell	O
migration	O
and	O
invasion	O
by	O
RCC	O
cell	O
lines	O
,	O
suggesting	O
that	O
miR	O
-	O
451a	O
had	O
antitumor	O
roles	O
.	O

These	O
studies	O
suggest	O
that	O
compound	O
4d	O
behaves	O
well	O
in	O
lowering	O
body	O
weight	O
and	O
maintaining	O
energy	O
expenditure	O
without	O
a	O
chance	O
of	O
hyperglycaemia	O
,	O
4d	O
has	O
strong	O
clinical	O
potential	O
as	O
an	O
efficient	O
GLP	O
-	O
1	O
/	O
GCGR	O
agonist	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
obesity	S-Phenotype
and	O
dyslipidemia	S-Phenotype

The	O
mutations	O
in	O
the	O
PRPS1	O
gene	O
leads	O
to	O
X	O
-	O
linked	O
Charcot	O
-	O
Marie	O
-	O
Tooth	O
neuropathy	S-Phenotype
type	O
5	O
(	O
CMTX5	O
)	O
,	O
PRS	O
super	O
activity	O
,	O
Arts	O
syndrome	O
,	O
X	O
-	O
linked	O
deafness	S-Phenotype
-	O
1	O
,	O
breast	B-Phenotype
cancer	E-Phenotype
,	O
and	O
colorectal	B-Phenotype
cancer	E-Phenotype
.	O

We	O
hypothesize	O
that	O
two	O
potential	O
mechanisms	O
,	O
loss	O
of	O
cell	O
fate	O
-	O
determining	O
transcription	O
factors	O
by	O
methylation	O
of	O
their	O
promoters	O
and	O
functional	O
inactivation	O
of	O
their	O
corresponding	O
genomic	O
-	O
binding	O
sites	O
by	O
DNA	O
methylation	O
,	O
can	O
promote	O
a	O
differentiation	O
defect	O
of	O
neuroendocrine	O
cells	O
thus	O
enhancing	O
the	O
ability	O
of	O
tumor	S-Phenotype
progenitor	O
cells	O
to	O
transition	O
toward	O
SCLC	O
.	O

Ectopic	O
expression	O
of	O
these	O
miRNAs	O
showed	O
that	O
both	O
miR	O
-	O
223	O
-	O
3p	O
(	O
the	O
guide	O
strand	O
)	O
and	O
miR	O
-	O
223	O
-	O
5p	O
(	O
the	O
passenger	O
strand	O
)	O
inhibited	O
cancer	S-Phenotype
cell	O
migration	O
and	O
invasion	O
of	O
BC	O
cells	O
.	O

This	O
is	O
the	O
first	O
case	O
of	O
PAK3	O
-	O
related	O
intellectual	B-Phenotype
disability	E-Phenotype
presenting	O
with	O
severe	O
self	O
-	O
injury	O
with	O
improvement	O
following	O
treatment	O
.	O

In	O
this	O
study	O
,	O
EPA	O
inhibited	O
the	O
expression	O
of	O
IDO	O
via	O
downregulation	O
of	O
protein	O
kinase	O
B	O
(	O
Akt	O
)	O
/	O
mammalian	O
targets	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
signaling	O
pathway	O
in	O
tumor	S-Phenotype
cells	O
.	O

In	O
humans	O
and	O
mice	O
ALX4	O
mutations	O
or	O
loss	O
of	O
function	O
result	O
in	O
a	O
number	O
of	O
skeletal	O
and	O
organ	O
malformations	O
,	O
including	O
polydactyly	S-Phenotype
,	O
tibial	B-Phenotype
hemimelia	E-Phenotype
,	O
omphalocele	S-Phenotype
,	O
biparietal	B-Phenotype
foramina	E-Phenotype
,	O
impaired	B-Phenotype
mammary	I-Phenotype
epithelial	I-Phenotype
morphogenesis	E-Phenotype
,	O
alopecia	S-Phenotype
,	O
coronal	B-Phenotype
craniosynostosis	E-Phenotype
,	O
hypertelorism	S-Phenotype
,	O
depressed	B-Phenotype
nasal	I-Phenotype
bridge	I-Phenotype
and	I-Phenotype
ridge	E-Phenotype
,	O
bifid	B-Phenotype
nasal	I-Phenotype
tip	E-Phenotype
,	O
hypogonadism	S-Phenotype
,	O
and	O
body	B-Phenotype
agenesis	E-Phenotype
.	O

Interestingly	O
,	O
the	O
positive	O
correlation	O
between	O
PGC	O
-	O
1α	O
and	O
PV	O
,	O
Syt2	O
,	O
or	O
Cplx1	O
expression	O
was	O
lost	O
in	O
schizophrenia	S-Phenotype
patients	O
with	O
low	O
NRF	O
-	O
1	O
expression	O
,	O
suggesting	O
that	O
NRF	O
-	O
1	O
is	O
a	O
critical	O
predictor	O
of	O
these	O
genes	O
in	O
disease	O
.	O

Microarray	O
database	O
analysis	O
further	O
validated	O
the	O
coefficient	O
of	O
SAA1	O
levels	O
in	O
gliomas	S-Phenotype
.	O

They	O
affect	O
AQP2	O
,	O
AQP5	O
and	O
AQP8	O
,	O
where	O
they	O
are	O
associated	O
with	O
nephrogenic	B-Phenotype
diabetes	I-Phenotype
insipidus	E-Phenotype
,	O
keratoderma	B-Phenotype
and	I-Phenotype
colorectal	I-Phenotype
cancer	E-Phenotype
,	O
respectively	O
.	O

Using	O
human	O
neuroblastoma	S-Phenotype
SH	O
-	O
SY5Y	O
cells	O
,	O
we	O
found	O
that	O
the	O
neuroprotective	O
function	O
of	O
CHRNA7	O
is	O
blocked	O
by	O
CHRNA7	O
knockdown	O
using	O
RNA	O
interference	O
.	O

We	O
used	O
the	O
Illumina	O
HumanMethylation450	O
BeadChip	O
microarray	O
to	O
test	O
whether	O
white	O
blood	O
cell	O
DNA	O
,	O
an	O
easily	O
accessible	O
source	O
of	O
DNA	O
,	O
exhibits	O
site	O
-	O
specific	O
changes	O
in	O
DNA	O
methylation	O
in	O
blood	O
of	O
diagnosed	O
HCC	O
patients	O
(	O
post	O
-	O
diagnostic	O
,	O
24	O
cases	O
,	O
24	O
controls	O
)	O
and	O
in	O
prospectively	O
collected	O
blood	O
specimens	O
of	O
HCC	O
patients	O
who	O
were	O
cancer	S-Phenotype
-	O
free	O
at	O
blood	O
collection	O
(	O
pre	O
-	O
diagnostic	O
,	O
21	O
cases	O
,	O
21	O
controls	O
)	O
.	O

X	B-Phenotype
-	I-Phenotype
linked	I-Phenotype
hearing	I-Phenotype
impairment	E-Phenotype
is	O
the	O
rarest	O
form	O
of	O
genetic	O
hearing	B-Phenotype
loss	E-Phenotype
(	O
HL	S-Phenotype
)	O
and	O
represents	O
only	O
a	O
minor	O
fraction	O
of	O
all	O
cases	O
.	O

Global	B-Phenotype
developmental	I-Phenotype
delay	E-Phenotype
associated	O
with	O
microcephaly	S-Phenotype
,	O
growth	B-Phenotype
retardation	E-Phenotype
,	O
progressive	B-Phenotype
ataxia	E-Phenotype
,	O
distal	B-Phenotype
muscle	I-Phenotype
weakness	E-Phenotype
with	O
ankle	B-Phenotype
contractures	E-Phenotype
,	O
demyelinating	B-Phenotype
sensorimotor	I-Phenotype
neuropathy	E-Phenotype
,	O
and	O
sensorineural	B-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
were	O
present	O
in	O
all	O
patients	O
,	O
while	O
facial	B-Phenotype
dysmorphism	E-Phenotype
with	O
widely	B-Phenotype
spaced	I-Phenotype
eyes	E-Phenotype
,	O
exotropia	S-Phenotype
,	O
thin	B-Phenotype
upper	I-Phenotype
lip	E-Phenotype
,	O
proximally	B-Phenotype
placed	I-Phenotype
thumbs	E-Phenotype
,	O
and	O
deformities	B-Phenotype
of	I-Phenotype
the	I-Phenotype
fingers	I-Phenotype
and	I-Phenotype
toes	E-Phenotype
were	O
present	O
in	O
some	O
individuals	O
.	O

Genes	O
involved	O
in	O
tissue	O
development	O
,	O
differentiation	O
,	O
and	O
oncogenesis	O
such	O
as	O
DNAJA4	O
,	O
HES5	O
,	O
IRX1	O
,	O
BMP8A	O
,	O
GATA4	O
,	O
GATA6	O
,	O
ALX3	O
,	O
and	O
P4HTM	O
were	O
hypermethylated	O
in	O
both	O
RMS	O
cell	O
lines	O
and	O
primary	O
samples	O
,	O
implicating	O
aberrant	O
DNA	O
methylation	O
in	O
the	O
pathogenesis	O
of	O
rhabdomyosarcoma	S-Phenotype
.	O

Recently	O
mutations	O
in	O
the	O
CASPR	O
/	O
CNTN1	O
complex	O
have	O
been	O
associated	O
with	O
similar	O
severe	O
phenotypes	O
and	O
CNTNAP1	O
gene	O
mutations	O
,	O
causing	O
loss	O
of	O
the	O
CASPR	O
protein	O
,	O
were	O
shown	O
to	O
cause	O
severe	O
,	O
prenatal	B-Phenotype
onset	I-Phenotype
arthrogryposis	I-Phenotype
multiplex	I-Phenotype
congenita	E-Phenotype
in	O
four	O
unrelated	O
families	O
.	O

Results	O
showed	O
that	O
SLC4A11	O
was	O
upregulated	O
in	O
ovarian	B-Phenotype
cancer	E-Phenotype
compared	O
with	O
normal	O
ovarian	O
epithelial	O
tissues	O
.	O

We	O
show	O
that	O
hypermethylation	O
of	O
p16	O
/	O
Ink4a	O
and	O
p19	O
/	O
Arf	O
in	O
CNT	O
-	O
and	O
asbestos	O
-	O
induced	O
inflammatory	O
lesions	O
precedes	O
mesothelioma	O
;	O
this	O
results	O
in	O
silencing	O
of	O
Cdkn2a	O
(	O
Ink4a	O
/	O
Arf	O
)	O
and	O
loss	O
of	O
p16	O
and	O
p19	O
protein	O
,	O
consistent	O
with	O
epigenetic	O
alterations	O
playing	O
a	O
gatekeeper	O
role	O
in	O
cancer	S-Phenotype
.	O

Defects	O
in	O
ISC	O
biogenesis	O
lead	O
to	O
multiple	O
mitochondrial	B-Phenotype
dysfunction	E-Phenotype
syndromes	O
including	O
:	O
ISCA2	O
with	O
infantile	B-Phenotype
onset	I-Phenotype
leukodystrophy	E-Phenotype
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
functional	O
significance	O
of	O
the	O
expansion	O
of	O
myeloid	O
-	O
derived	O
suppressor	O
cell	O
(	O
MDSC	O
)	O
-	O
like	O
CD11b+Gr	O
-	O
1+	O
cells	O
in	O
response	O
to	O
the	O
macrolide	O
antibiotic	O
clarithromycin	O
(	O
CAM	O
)	O
in	O
mouse	O
models	O
of	O
shock	B-Phenotype
and	I-Phenotype
post	I-Phenotype
-	I-Phenotype
influenza	I-Phenotype
pneumococcal	I-Phenotype
pneumonia	E-Phenotype
as	O
well	O
as	O
in	O
humans	O
.	O

The	O
mutation	O
c.139GAAAAA	O
in	O
the	O
liGJA8	O
/	O
i	O
gene	O
detected	O
in	O
the	O
present	O
study	O
was	O
also	O
previously	O
reported	O
in	O
Caucasian	O
and	O
Chinese	O
families	O
but	O
with	O
different	O
phenotypes	O
,	O
i.e	O
.	O

These	O
data	O
link	O
microRNA	O
impairment	O
to	O
the	O
PLAG1	O
-	O
IGF2	O
pathway	O
,	O
providing	O
new	O
insight	O
into	O
the	O
manner	O
in	O
which	O
common	O
Wilms	B-Phenotype
tumor	E-Phenotype
mutations	O
drive	O
disease	O
pathogenesis	O

VPS45	O
-	O
associated	O
severe	O
congenital	O
neutropenia	S-Phenotype
(	O
SCN	O
)	O
is	O
a	O
rare	O
disorder	O
characterized	O
by	O
life	B-Phenotype
-	I-Phenotype
threating	I-Phenotype
infections	E-Phenotype
,	O
neutropenia	S-Phenotype
,	O
neutrophil	B-Phenotype
and	I-Phenotype
platelet	I-Phenotype
dysfunction	E-Phenotype
,	O
poor	B-Phenotype
response	I-Phenotype
to	I-Phenotype
filgrastim	E-Phenotype
,	O
and	O
myelofibrosis	S-Phenotype
with	O
extramedullary	B-Phenotype
hematopoiesis	E-Phenotype
.	O

We	O
also	O
observed	O
that	O
GBE1	O
and	O
HK2	O
are	O
downstream	O
of	O
HIF1	O
pathway	O
important	O
in	O
hypoxia	B-Phenotype
-	I-Phenotype
conditioned	I-Phenotype
lung	I-Phenotype
cancer	E-Phenotype
cell	O
.	O

Our	O
study	O
identified	O
a	O
group	O
of	O
cell	O
cycle	O
-	O
promoting	O
genes	O
regulated	O
by	O
HDAC11	O
,	O
being	O
both	O
predictors	O
of	O
unfavorable	O
patient	O
outcome	O
and	O
essential	O
for	O
tumor	S-Phenotype
cell	O
viability	O
.	O

The	O
in	O
vivo	O
impact	O
of	O
BRUCE	O
loss	O
on	O
liver	B-Phenotype
tumorigenesis	E-Phenotype
was	O
determined	O
using	O
the	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
model	O
induced	O
by	O
genotoxin	O
Diethylnitrosamine	O
.	O

ZEB2	O
overexpression	O
rescued	O
the	O
inhibition	O
of	O
liver	B-Phenotype
cancer	E-Phenotype
cell	O
proliferation	O
,	O
migration	O
,	O
and	O
invasion	O
by	O
miR‑498	O
,	O
indicating	O
that	O
ZEB2	O
acts	O
as	O
a	O
downstream	O
effector	O
of	O
miR‑498	O
in	O
liver	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Patients	O
with	O
mutations	O
in	O
ZNF711	O
all	O
present	O
with	O
mild	B-Phenotype
to	I-Phenotype
moderate	I-Phenotype
ID	E-Phenotype
and	O
poor	B-Phenotype
speech	E-Phenotype
accompanied	O
by	O
additional	O
features	O
in	O
some	O
patients	O
,	O
including	O
autistic	O
features	O
and	O
mild	O
facial	B-Phenotype
dysmorphisms	E-Phenotype
,	O
suggesting	O
that	O
ZNF711	O
mutations	O
cause	O
non	B-Phenotype
-	I-Phenotype
syndromic	I-Phenotype
ID	E-Phenotype

In	O
addition	O
,	O
the	O
tested	O
peptides	O
inhibited	O
lung	O
colonization	O
after	O
intranasal	O
inoculation	O
of	O
mice	O
with	O
S.	O
pneumoniae	S-Phenotype
.	O

SSRI	O
use	O
was	O
obtained	O
from	O
telephone	O
interviews	O
with	O
mothers	O
.	O

Results	O
For	O
women	O
who	O
reported	O
taking	O
SSRIs	O
periconceptionally	O
,	O
maternal	O
SHMT1	O
(	O
rs9909104	O
)	O
GG	O
and	O
AGgenotypes	O
were	O
associated	O
with	O
a	O
5.9	O
and	O
2.4	O
increased	O
risk	O
of	O
select	O
congenital	B-Phenotype
heart	I-Phenotype
defects	E-Phenotype
in	O
offspring	O
,	O
respectively	O
,	O
versus	O
the	O
AA	O
genotype	O
(	O
BFDP=0.69	O
)	O
.	O

Kluver	O
-	O
Bucy	O
syndrome	O
(	O
KBS	O
)	O
comprises	O
a	O
set	O
of	O
neurobehavioral	O
symptoms	O
with	O
psychic	B-Phenotype
blindness	E-Phenotype
,	O
hypersexuality	S-Phenotype
,	O
disinhibition	S-Phenotype
,	O
hyperorality	S-Phenotype
,	O
and	O
hypermetamorphosis	O
that	O
were	O
originally	O
observed	O
after	O
bilateral	O
lobectomy	O
in	O
Rhesus	O
monkeys	O
.	O

Collectively	O
,	O
we	O
nominate	O
USP13	O
as	O
a	O
novel	O
deubiquitinase	O
which	O
regulates	O
MCL1	O
turnover	O
in	O
diverse	O
solid	O
tumors	S-Phenotype
and	O
propose	O
that	O
USP13	O
may	O
be	O
a	O
potential	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
various	O
malignancies	O

Here	O
we	O
report	O
a	O
patient	O
with	O
a	O
congenital	O
syndrome	O
consisting	O
of	O
severe	B-Phenotype
global	I-Phenotype
developmental	I-Phenotype
delay	E-Phenotype
,	O
microcephaly	S-Phenotype
,	O
heart	B-Phenotype
defects	E-Phenotype
,	O
failure	B-Phenotype
to	I-Phenotype
thrive	E-Phenotype
and	O
liver	B-Phenotype
disease	E-Phenotype
with	O
a	O
previously	O
unreported	O
homozygous	O
NM_015352.1	O
:	O
c.485CAAAAT	O
variant	O
(	O
p.Ser162Leu	O
)	O
in	O
POFUT1	O
detected	O
by	O
exome	O
sequencing	O
.	O

The	O
human	O
Shwachman	O
-	O
Diamond	O
syndrome	O
(	O
SDS	O
)	O
is	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
disease	O
caused	O
by	O
mutations	O
in	O
a	O
highly	O
conserved	O
ribosome	O
assembly	O
factor	O
SBDS	O
.	O

Primary	B-Phenotype
ciliary	I-Phenotype
dyskinesia	E-Phenotype
(	O
PCD	S-Phenotype
)	O
is	O
a	O
rare	O
,	O
autosomal	B-Phenotype
recessive	E-Phenotype
disease	O
with	O
abnormalities	O
in	O
the	O
structure	O
of	O
cilia	O
,	O
causing	O
impairment	O
of	O
muco	O
-	O
ciliary	O
clearance	O
with	O
respiratory	B-Phenotype
tract	I-Phenotype
infections	E-Phenotype
,	O
heterotaxia	S-Phenotype
and	O
abnormal	B-Phenotype
sperm	I-Phenotype
motility	E-Phenotype
with	O
male	B-Phenotype
infertility	E-Phenotype
.	O

Further	O
,	O
exposure	O
to	O
the	O
Notch	O
signaling	O
inhibitor	O
and	O
gene	O
silencing	O
studies	O
showed	O
that	O
Notch	O
signaling	O
inhibition	O
or	O
silencing	O
Nothc4	O
/	O
Dll3	O
decreased	O
endothelial	O
markers	O
and	O
function	O
of	O
tumor	S-Phenotype
-	O
derived	O
endothelial	O
cells	O
under	O
chemotherapy	O
treatment	O
,	O
which	O
may	O
be	O
through	O
VEGFR3	O
.	O

The	O
impact	O
of	O
NOX2	O
and	O
ROS	O
on	O
cancer	S-Phenotype
development	O
is	O
only	O
partly	O
explored	O
.	O

We	O
screened	O
95	O
sporadic	S-Phenotype
patients	O
diagnosed	O
as	O
MBS	O
or	O
HCFP	O
for	O
mutations	O
in	O
HOXB1	O
.	O

Here	O
,	O
we	O
describe	O
a	O
double	O
-	O
retargeting	O
strategy	O
,	O
based	O
on	O
the	O
simultaneous	O
insertion	O
of	O
two	O
ligands	O
in	O
gD	O
,	O
one	O
for	O
retargeting	O
to	O
a	O
producer	O
,	O
universal	O
Vero	O
cell	O
derivative	O
and	O
one	O
for	O
retargeting	O
to	O
the	O
HER2	O
cancer	S-Phenotype
receptor	O
.	O

Sequencing	O
these	O
four	O
genes	O
in	O
50	O
additional	O
sporadic	S-Phenotype
cases	O
of	O
NSID	O
identified	O
a	O
second	O
DNM	O
in	O
GRIN1	O
(	O
c.1679_1681dup	O
/	O
p.Ser560dup	O
)	O
.	O

These	O
experiments	O
suggest	O
that	O
excessive	O
phosphorylation	O
of	O
eIF2a	O
decreases	O
survival	O
of	O
cancer	S-Phenotype
cells	O
;	O
making	O
eIF2a	O
a	O
worthy	O
target	O
for	O
drug	O
development	O
,	O
with	O
the	O
potential	O
to	O
enhance	O
the	O
cytotoxic	O
effects	O
of	O
established	O
anti	O
-	O
neoplastic	O
therapies	O
and	O
circumvent	O
resistance	O
to	O
rapalogues	O
and	O
possibly	O
to	O
other	O
drugs	O
that	O
inhibit	O
upstream	O
components	O
of	O
the	O
mTOR	O
pathway	O

In	O
this	O
study	O
,	O
we	O
describe	O
the	O
function	O
and	O
regulation	O
network	O
of	O
miR	O
-	O
491	O
-	O
5p	O
in	O
GC	O
.	O

However	O
,	O
the	O
function	O
of	O
RASSF7	O
remain	O
unknown	O
in	O
human	O
cancers	S-Phenotype
.	O

Thus	O
loss	O
of	O
ARPC1B	O
produces	O
a	O
unique	O
set	O
of	O
platelet	B-Phenotype
abnormalities	E-Phenotype
,	O
and	O
is	O
associated	O
with	O
haematopoietic	O
/	O
immune	O
symptoms	O
affecting	O
cell	O
lineages	O
where	O
this	O
isoform	O
predominates	O
.	O

We	O
present	O
two	O
new	O
cases	O
of	O
Warsaw	O
Breakage	O
Syndrome	O
(	O
WABS	O
)	O
,	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
cohesinopathy	O
,	O
in	O
sisters	O
aged	O
13	O
and	O
11	O
years	O
who	O
both	O
had	O
compound	O
heterozygous	O
mutations	O
in	O
DDX11	O
.	O

Our	O
study	O
reports	O
the	O
first	O
mutations	O
in	O
the	O
VARS2	O
and	O
TARS2	O
genes	O
,	O
which	O
encode	O
two	O
mitochondrial	S-Phenotype
aminoacyl	O
-	O
tRNA	O
synthetases	O
,	O
as	O
causes	O
of	O
clinically	B-Phenotype
distinct	I-Phenotype
,	I-Phenotype
early	I-Phenotype
-	I-Phenotype
onset	I-Phenotype
mitochondrial	I-Phenotype
encephalopathies	E-Phenotype
.	O

In	O
addition	O
,	O
the	O
analysis	O
of	O
upstream	O
miRNAs	O
showed	O
that	O
FOXF1	O
adjacent	O
non	O
-	O
coding	O
developmental	O
regulatory	O
RNA	O
(	O
FENDRR	O
)	O
had	O
common	O
upstream	O
miRNAs	O
,	O
including	O
miR	O
-	O
18b	O
-	O
5p	O
,	O
with	O
another	O
119	O
differentially	O
expressed	O
genes	O
,	O
and	O
that	O
FENDRR	O
was	O
co	O
-	O
expressed	O
with	O
adenomatosis	O
polyposis	O
coli	O
downregulated	O
1	O
(	O
APCDD1	O
)	O
and	O
v	O
-	O
kit	O
Hardy	O
-	O
Zuckerman	O
4	O
feline	O
sarcoma	S-Phenotype
viral	O
oncogene	O
homolog	O
(	O
KIT	O
)	O
.	O

We	O
show	O
that	O
the	O
tumor	S-Phenotype
microenvironment	O
modulates	O
MSC	O
gene	O
expression	O
and	O
identify	O
a	O
four	O
-	O
gene	O
MSC	O
signature	O
that	O
is	O
functionally	O
implicated	O
in	O
promoting	O
metastasis	O
.	O

Carnitine	O
-	O
acylcarnitine	O
translocase	O
(	O
CACT	O
)	O
deficiency	O
is	O
a	O
rare	O
autosomal	B-Phenotype
recessive	E-Phenotype
disease	O
of	O
fatty	O
acid	O
oxidation	O
,	O
mainly	O
affecting	O
long	O
chain	O
fatty	O
acid	O
utilization	O
.	O

Some	O
of	O
them	O
were	O
cancer	S-Phenotype
-	O
related	O
according	O
to	O
COSMIC	O
and	O
HGMD	O
databases	O
(	O
no	O
founder	O
mutations	O
in	O
BRCA1	O
and	O
BRCA2	O
have	O
been	O
found	O
)	O
.	O

A	O
homozygous	O
splice	O
acceptor	O
site	O
variant	O
(	O
c.395	O
-	O
1GAAAAA	O
)	O
was	O
identified	O
in	O
the	O
IQCE	O
gene	O
,	O
which	O
completely	O
co	O
-	O
segregated	O
with	O
post	B-Phenotype
-	I-Phenotype
axial	I-Phenotype
polydactyly	E-Phenotype
phenotype	O
within	O
the	O
family	O
.	O

This	O
first	O
study	O
addressing	O
effects	O
of	O
deiodinase	O
re	O
-	O
expression	O
on	O
proteome	O
of	O
cancer	S-Phenotype
cells	O
demonstrates	O
that	O
induced	O
DIO1	O
re	O
-	O
expression	O
in	O
renal	B-Phenotype
cancer	E-Phenotype
robustly	O
downregulates	O
oncoproteins	O
,	O
affects	O
key	O
metabolic	O
pathways	O
,	O
and	O
triggers	O
proteins	O
involved	O
in	O
anti	O
-	O
oxidative	O
protection	O
.	O

Besides	O
,	O
we	O
screened	O
for	O
all	O
the	O
known	O
genes	O
related	O
to	O
axonal	O
autosomal	B-Phenotype
recessive	E-Phenotype
Charcot	O
-	O
Marie	O
-	O
Tooth	O
disease	O
(	O
CMT2A2	O
/	O
HMSN2A2	O
/	O
MFN2	O
,	O
CMT2B1	O
/	O
LMNA	O
,	O
CMT2B2	O
/	O
MED25	O
,	O
CMT2B5	O
/	O
NEFL	O
,	O
ARCMT2F	O
/	O
dHMN2B	O
/	O
HSPB1	O
,	O
CMT2K	O
/	O
GDAP1	O
,	O
CMT2P	O
/	O
LRSAM1	O
,	O
CMT2R	O
/	O
TRIM2	O
,	O
CMT2S	O
/	O
IGHMBP2	O
,	O
CMT2T	O
/	O
HSJ1	O
,	O
CMTRID	O
/	O
COX6A1	O
,	O
ARAN	O
-	O
NM	O
/	O
HINT	O
and	O
GAN	O
/	O
GAN	O
)	O
,	O
for	O
the	O
genes	O
related	O
to	O
autosomal	B-Phenotype
recessive	I-Phenotype
hereditary	I-Phenotype
spastic	I-Phenotype
paraplegia	E-Phenotype
with	O
thin	B-Phenotype
corpus	I-Phenotype
callosum	E-Phenotype
and	O
axonal	B-Phenotype
peripheral	I-Phenotype
neuropathy	E-Phenotype
(	O
SPG7	O
/	O
PGN	O
,	O
SPG15	O
/	O
ZFYVE26	O
,	O
SPG21	O
/	O
ACP33	O
,	O
SPG35	O
/	O
FA2H	O
,	O
SPG46	O
/	O
GBA2	O
,	O
SPG55	O
/	O
C12orf65	O
and	O
SPG56	O
/	O
CYP2U1	O
)	O
,	O
as	O
well	O
as	O
for	O
the	O
causative	O
gene	O
of	O
peripheral	B-Phenotype
neuropathy	E-Phenotype
with	O
or	O
without	O
agenesis	B-Phenotype
of	I-Phenotype
the	I-Phenotype
corpus	I-Phenotype
callosum	E-Phenotype
(	O
SLC12A6	O
)	O
.	O

In	O
recent	O
years	O
,	O
many	O
studies	O
have	O
shown	O
that	O
Smac	O
/	O
DIABLO	O
is	O
closely	O
related	O
to	O
tumor	S-Phenotype
drug	B-Phenotype
resistance	E-Phenotype
.	O

Great	O
progress	O
has	O
been	O
achieved	O
in	O
the	O
study	O
of	O
the	O
role	O
of	O
TGF	O
-	O
β	O
signaling	O
in	O
triggering	O
epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
in	O
a	O
variety	O
of	O
cancers	S-Phenotype
;	O
however	O
,	O
the	O
regulation	O
of	O
TGF	O
-	O
β	O
signaling	O
during	O
EMT	O
in	O
mammary	O
tumor	S-Phenotype
metastasis	O
has	O
not	O
been	O
completely	O
defined	O
.	O

The	O
results	O
imply	O
that	O
variants	O
associated	O
with	O
prostate	B-Phenotype
cancer	E-Phenotype
can	O
be	O
identified	O
through	O
expressional	O
change	O
in	O
the	O
PEX6	O
gene	O
,	O
but	O
not	O
in	O
the	O
overlapped	O
glycine	O
N	O
-	O
methyltransferase	O
gene	O
which	O
had	O
been	O
considered	O
as	O
a	O
candidate	O
gene.Further	O
studies	O
are	O
required	O
to	O
understand	O
their	O
underlying	O
mechanisms	O
for	O
the	O
strong	O
eQTLs	O
for	O
the	O
SNHG5	O
and	O
PEX6	O
genes	O

The	O
data	O
presented	O
thus	O
not	O
only	O
identify	O
the	O
yet	O
unknown	O
involvement	O
of	O
OX40	O
/	O
OX40L	O
in	O
ALL	O
pathophysiology	O
and	O
NK	O
cell	O
immunosurveillance	O
but	O
also	O
point	O
to	O
the	O
necessity	O
to	O
thoroughly	O
consider	O
the	O
consequences	O
of	O
modulating	O
the	O
OX40	O
/	O
OX40L	O
molecule	O
system	O
beyond	O
its	O
effects	O
on	O
T	O
cells	O
when	O
developing	O
OX40	O
-	O
targeting	O
approaches	O
for	O
cancer	S-Phenotype
immunotherapy	O

CD133	O
(	O
p	O
=	O
0.021	O
)	O
and	O
HOXA7	O
(	O
p	O
=	O
0.001	O
)	O
were	O
independent	O
prognostic	O
markers	O
when	O
the	O
three	O
glioma	S-Phenotype
patient	O
cohorts	O
were	O
combined	O
(	O
n	O
=	O
231	O
)	O
.	O

Even	O
though	O
the	O
direct	O
relevance	O
of	O
mouse	O
models	O
to	O
hydrocephalus	S-Phenotype
in	O
humans	O
remains	O
uncertain	O
,	O
the	O
high	O
prevalence	O
of	O
familial	O
patterns	O
of	O
inheritance	O
for	O
congenital	B-Phenotype
hydrocephalus	E-Phenotype
in	O
humans	O
suggests	O
that	O
identification	O
of	O
genes	O
responsible	O
for	O
development	O
of	O
hydrocephalus	S-Phenotype
in	O
mice	O
may	O
lead	O
to	O
the	O
identification	O
of	O
homologous	O
modifier	O
genes	O
and	O
susceptibility	O
alleles	O
in	O
humans	O
.	O

SRP72	O
depletion	O
also	O
resulted	O
in	O
the	O
radiosensitization	O
of	O
normal	O
lung	O
fibroblast	O
cell	O
lines	O
(	O
HFL1	O
and	O
MRC	O
-	O
5	O
)	O
,	O
demonstrating	O
that	O
the	O
effect	O
is	O
not	O
restricted	O
to	O
tumor	S-Phenotype
cells	O
.	O

Oral	B-Phenotype
and	I-Phenotype
pharyngeal	I-Phenotype
cancers	E-Phenotype
combined	O
were	O
associated	O
with	O
loci	O
at	O
6p21.32	O
(	O
rs3828805	O
,	O
HLA	O
-	O
DQB1	O
)	O
,	O
10q26.13	O
(	O
rs201982221	O
,	O
LHPP	O
)	O
and	O
11p15.4	O
(	O
rs1453414	O
,	O
OR52N2	O
-	O
TRIM5	O
)	O
.	O

We	O
concluded	O
that	O
genetic	O
polymorphisms	O
in	O
AICDA	O
and	O
CASP14	O
are	O
associated	O
with	O
risk	O
for	O
brain	B-Phenotype
tumor	E-Phenotype
in	O
Korean	O
children	O
.	O

Our	O
WES	O
data	O
is	O
largely	O
matched	O
with	O
the	O
earlier	O
'adenoma	O
-	O
carcinoma	S-Phenotype
model	O
'	O
(	O
APC	O
,	O
KRAS	O
,	O
NRAS	O
and	O
GNAS	O
mutations	O
)	O
,	O
but	O
there	O
are	O
newly	O
identified	O
SMAD4	O
,	O
MTOR	O
,	O
ACVR1B	O
,	O
GNAQ	O
,	O
ATM	O
,	O
CNOT1	O
,	O
EP300	O
,	O
ARID2	O
,	O
RET	O
and	O
MAP2K4	O
mutations	O
in	O
this	O
study	O
.	O

The	O
review	O
then	O
discusses	O
the	O
diseases	O
associated	O
with	O
ClC‑2	O
,	O
including	O
degeneration	B-Phenotype
of	I-Phenotype
the	I-Phenotype
retina	E-Phenotype
,	O
Sjögren	B-Phenotype
's	I-Phenotype
syndrome	E-Phenotype
,	O
age‑related	B-Phenotype
cataracts	E-Phenotype
,	O
degeneration	B-Phenotype
of	I-Phenotype
the	I-Phenotype
testes	E-Phenotype
,	O
azoospermia	S-Phenotype
,	O
lung	B-Phenotype
cancer	E-Phenotype
,	O
constipation	S-Phenotype
,	O
repair	O
of	O
impaired	O
intestinal	O
mucosa	O
barrier	O
,	O
leukemia	S-Phenotype
,	O
cystic	B-Phenotype
fibrosis	E-Phenotype
,	O
leukoencephalopathy	S-Phenotype
,	O
epilepsy	S-Phenotype
and	O
diabetes	B-Phenotype
mellitus	E-Phenotype
.	O

These	O
data	O
demonstrated	O
that	O
down	O
-	O
regulation	O
of	O
PLZF	O
is	O
an	O
important	O
molecular	O
process	O
for	O
tumor	S-Phenotype
progression	O
and	O
loss	O
of	O
PLZF	O
expression	O
detected	O
by	O
routine	O
immunohistochemistry	O
is	O
a	O
promising	O
and	O
valuable	O
biomarker	O
for	O
PCa	O
aggressiveness	S-Phenotype
and	O
metastasis	O
in	O
the	O
personalized	O
care	O
of	O
PCa	O
.	O

Four	O
frameshift	O
mutations	O
in	O
TPRN	O
have	O
been	O
described	O
to	O
cause	O
severe	O
or	O
severe	O
-	O
to	O
-	O
profound	O
hearing	B-Phenotype
loss	E-Phenotype
in	O
Moroccan	O
and	O
Pakistani	O
families	O
,	O
and	O
a	O
single	O
frameshift	O
mutation	O
was	O
associated	O
with	O
progressive	O
hearing	B-Phenotype
loss	E-Phenotype
in	O
deaf	O
individuals	O
in	O
a	O
Dutch	O
family	O
.	O

We	O
previously	O
reported	O
a	O
potential	O
predictive	O
value	O
of	O
HSD17B4	O
hypermethylation	O
for	O
pathological	O
complete	O
response	O
after	O
preoperative	O
trastuzumab	O
plus	O
chemotherapy	O
in	O
HER2	O
-	O
positive	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

We	O
generated	O
tumor	S-Phenotype
xenografts	O
of	O
SQCC	O
cell	O
lines	O
and	O
examined	O
the	O
consequences	O
of	O
targeting	O
PIK3R2	O
expression	O
.	O

Here	O
,	O
we	O
report	O
1	O
known	O
(	O
c.1489CAAAAT	O
,	O
p.Pro497Ser	O
,	O
P497S	O
)	O
and	O
3	O
novel	O
(	O
c.1481CAAAAT	O
,	O
p.Pro494Leu	O
,	O
P494L	O
;	O
c.1498CAAAAT	O
,	O
p.Pro500Ser	O
,	O
P500S	O
;	O
and	O
c.1516CAAAAG	O
,	O
p.Pro506Ala	O
,	O
P506A	O
)	O
missense	O
mutations	O
in	O
the	O
PXX	O
domain	O
of	O
UBQLN2	O
in	O
familial	O
motor	O
neuron	O
diseases	O
including	O
ALS	O
and	O
spastic	B-Phenotype
paraplegia	E-Phenotype
(	O
SP	S-Phenotype
)	O
.	O

Herein	O
,	O
we	O
report	O
that	O
ZNF687	O
was	O
markedly	O
upregulated	O
in	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
cell	O
lines	O
and	O
HCC	O
tissues	O
,	O
and	O
was	O
significantly	O
correlated	O
with	O
relapse	O
-	O
free	O
survival	O
in	O
HCC	S-Phenotype
.	O

We	O
have	O
deleted	O
two	O
major	O
tumor	S-Phenotype
suppressors	O
,	O
Pten	O
,	O
a	O
negative	O
regulator	O
of	O
the	O
PI3K	O
pathway	O
,	O
and	O
Smad4	O
,	O
the	O
central	O
signaling	O
mediator	O
of	O
TGFβ	O
pathway	O
,	O
in	O
the	O
murine	O
salivary	O
gland	O
.	O

3	O
)	O
Multiple	B-Phenotype
endocrine	I-Phenotype
neoplasia	I-Phenotype
type	I-Phenotype
1	E-Phenotype
(	O
MEN1	S-Phenotype
)	O
is	O
most	O
frequently	O
expressed	O
as	O
PHPT	O
with	O
asymmetric	O
enlargement	O
of	O
3	O
-	O
4	O
parathyroids	O
.	O

Mutations	O
and	O
post	O
-	O
translational	O
modifications	O
of	O
PLN	O
may	O
lead	O
to	O
dilated	B-Phenotype
cardiomyopathy	E-Phenotype
(	O
DCM	S-Phenotype
)	O
and	O
heart	B-Phenotype
failure	E-Phenotype
.	O

Elevated	O
keratin	O
-	O
8	O
(	O
KRT8	O
)	O
protein	O
expression	O
is	O
an	O
established	O
diagnostic	O
cancer	S-Phenotype
biomarker	O
in	O
several	O
epithelial	B-Phenotype
cancers	E-Phenotype
(	O
but	O
not	O
ATC	O
)	O
.	O

Mutations	O
with	O
milder	O
presentation	O
(	O
homozygous	O
p.D132A	O
/	O
EXOSC3	O
or	O
VRK1	O
)	O
may	O
display	O
additionally	O
signs	O
of	O
upper	B-Phenotype
motor	I-Phenotype
neuron	I-Phenotype
impairment	E-Phenotype
,	O
dystonia	S-Phenotype
or	O
ataxia	S-Phenotype
and	O
die	O
at	O
age	O
between	O
5	O
and	O
18	O
years	O
.	O

Increasing	O
evidence	O
has	O
shown	O
that	O
WT1	O
-	O
interacting	O
protein	O
(	O
WTIP	O
)	O
plays	O
important	O
roles	O
both	O
physiologically	O
and	O
pathologically	O
in	O
humans	O
;	O
however	O
,	O
the	O
role	O
of	O
WTIP	O
in	O
cancer	S-Phenotype
is	O
unknown	O
.	O

Our	O
analyses	O
revealed	O
that	O
the	O
primary	O
tumor	S-Phenotype
and	O
NCC	O
-	O
SS1	O
-	O
C1	O
cell	O
line	O
harbored	O
the	O
SS18	O
-	O
SSX1	O
fusion	O
gene	O
typical	O
of	O
synovial	B-Phenotype
sarcoma	E-Phenotype
and	O
similar	O
proteomics	O
profiles	O
.	O

Overexpression	O
of	O
LOXL2	O
and	O
SERPINH1	O
was	O
observed	O
in	O
clinical	O
specimens	O
of	O
lung	B-Phenotype
cancer	E-Phenotype
and	O
fibrotic	O
lesions	O
.	O

Mutations	O
in	O
the	O
gene	O
encoding	O
CCTα	O
(	O
liPCYT1A	O
/	O
i	O
)	O
cause	O
three	O
distinct	O
pathologies	O
in	O
humans	O
:	O
lipodystrophy	S-Phenotype
,	O
spondylometaphyseal	B-Phenotype
dysplasia	E-Phenotype
with	O
cone	O
-	O
rod	O
dystrophy	O
(	O
SMD	O
-	O
CRD	O
)	O
,	O
and	O
isolated	O
retinal	B-Phenotype
dystrophy	E-Phenotype
.	O

The	O
present	O
study	O
screened	O
pathogenic	O
genes	O
,	O
ectodysplasin	O
A	O
(	O
EDA	O
)	O
and	O
lamin	O
A	O
/	O
C	O
(	O
LMNA	O
)	O
,	O
in	O
a	O
patient	O
with	O
suspected	O
syndromic	O
hearing	B-Phenotype
impairment	E-Phenotype
and	O
various	O
other	O
symptoms	O
including	O
tooth	B-Phenotype
and	I-Phenotype
skin	I-Phenotype
abnormalities	E-Phenotype
.	O

In	O
gastrointestinal	O
tumors	S-Phenotype
,	O
FEZF1	O
plays	O
an	O
oncogenic	O
role	O
through	O
DNA	O
demethylation	O
.	O

c.7253dupT	O
in	O
TEX15	O
,	O
encoding	O
a	O
DDR	O
factor	O
important	O
in	O
meiosis	O
,	O
associated	O
with	O
hereditary	B-Phenotype
breast	I-Phenotype
cancer	E-Phenotype
(	O
p	O
=	O
0.018	O
)	O
and	O
likely	O
represents	O
a	O
Northern	O
Finnish	O
founder	O
mutation	O
.	O

Studies	O
in	O
humans	O
with	O
autosomal	B-Phenotype
recessive	I-Phenotype
CARD9	I-Phenotype
deficiency	E-Phenotype
have	O
indicated	O
a	O
highly	O
specific	O
role	O
for	O
this	O
molecule	O
in	O
the	O
activation	O
of	O
antifungal	O
immune	O
responses	O
in	O
the	O
central	O
nervous	O
system	O
,	O
the	O
oral	O
mucosa	O
,	O
and	O
the	O
skin	O
.	O

Mucinous	B-Phenotype
tubular	I-Phenotype
and	I-Phenotype
spindle	I-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
MTSCC	O
)	O
is	O
a	O
relatively	O
rare	O
subtype	O
of	O
renal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
RCC	S-Phenotype
)	O
with	O
distinctive	O
morphologic	O
and	O
cytogenetic	O
features	O
.	O

A	O
combination	O
of	O
familial	O
and	O
population	O
based	O
sequencing	O
studies	O
,	O
and	O
genome	O
wide	O
association	O
studies	O
(	O
GWAS	O
)	O
have	O
identified	O
a	O
range	O
of	O
genetic	O
susceptibility	O
alleles	O
for	O
EOC	O
comprising	O
rare	O
but	O
highly	O
penetrant	O
genes	O
(	O
e.g	O
.	O

Mutations	O
in	O
the	O
PGAP2	O
gene	O
cause	O
hyperphosphatasia	B-Phenotype
mental	I-Phenotype
retardation	E-Phenotype
syndrome	O
-	O
3	O
.	O

Also	O
as	O
pro	O
-	O
angiogenic	O
inducer	O
,	O
the	O
role	O
of	O
HMGB1	O
in	O
different	O
redox	O
states	O
has	O
never	O
been	O
defined	O
in	O
tumour	S-Phenotype
angiogenesis	O
.	O

In	O
this	O
study	O
,	O
we	O
use	O
a	O
comprehensive	O
systems	O
-	O
driven	O
approach	O
to	O
investigate	O
the	O
effect	O
of	O
clock	O
disruption	O
on	O
metabolic	O
pathways	O
and	O
its	O
impact	O
on	O
drug	O
response	O
in	O
a	O
cellular	O
model	O
of	O
colon	B-Phenotype
cancer	E-Phenotype
progression	O
.	O

Shwachman	O
-	O
Diamond	O
syndrome	O
(	O
SDS	O
)	O
(	O
OMIM	O
#	O
260400	O
)	O
is	O
a	O
rare	O
inherited	B-Phenotype
bone	I-Phenotype
marrow	I-Phenotype
failure	E-Phenotype
syndrome	O
(	O
IBMFS	S-Phenotype
)	O
that	O
is	O
primarily	O
characterized	O
by	O
neutropenia	S-Phenotype
and	O
exocrine	B-Phenotype
pancreatic	I-Phenotype
insufficiency	E-Phenotype
.	O

Disabling	O
mutations	O
in	O
the	O
FGD1	O
gene	O
cause	O
faciogenital	O
dysplasia	O
(	O
also	O
known	O
as	O
Aarskog	O
-	O
Scott	O
syndrome	O
)	O
,	O
a	O
human	O
X	O
-	O
linked	O
developmental	O
disorder	O
that	O
results	O
in	O
disproportionately	O
short	B-Phenotype
stature	E-Phenotype
,	O
facial	B-Phenotype
,	I-Phenotype
skeletal	I-Phenotype
and	I-Phenotype
urogenital	I-Phenotype
anomalies	E-Phenotype
,	O
and	O
in	O
a	O
number	O
of	O
cases	O
,	O
mild	B-Phenotype
mental	I-Phenotype
retardation	E-Phenotype
.	O

Whole	O
-	O
exome	O
or	O
targeted	O
exome	O
sequencing	O
of	O
183	O
unrelated	O
familial	O
and	O
/	O
or	O
severe	O
CAKUT	O
-	O
affected	O
case	O
subjects	O
,	O
including	O
54	O
fetuses	O
with	O
BKA	O
,	O
led	O
to	O
the	O
identification	O
of	O
16	O
heterozygous	O
variants	O
in	O
GREB1L	O
(	O
growth	O
regulation	O
by	O
estrogen	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
1	O
-	O
like	O
)	O
,	O
a	O
gene	O
reported	O
as	O
a	O
target	O
of	O
retinoic	O
acid	O
signaling	O
.	O

By	O
pooling	O
genetic	O
findings	O
across	O
multiple	O
studies	O
,	O
we	O
have	O
identified	O
six	O
individuals	O
with	O
severe	O
developmental	B-Phenotype
delay	E-Phenotype
(	O
6	O
/	O
6	O
)	O
,	O
refractory	O
seizures	S-Phenotype
(	O
5	O
/	O
6	O
)	O
,	O
and	O
similar	O
dysmorphic	O
features	O
(	O
3	O
/	O
6	O
)	O
,	O
each	O
harboring	O
a	O
de	O
novo	O
mutation	O
in	O
PPP3CA	O
.	O

We	O
identified	O
a	O
novel	O
locus	O
at	O
3p21.31	O
indexed	O
by	O
the	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
rs80059929	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
=	O
2.95	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
=	O
2.17	O
to	O
4.02	O
,	O
Pmeta	O
=	O
6.47	O
×	O
10	O
-	O
12	O
)	O
associated	O
with	O
MYCN	O
-	O
amplified	O
neuroblastoma	S-Phenotype
,	O
which	O
was	O
replicated	O
in	O
127	O
MYCN	O
-	O
amplified	O
cases	O
and	O
254	O
non	O
-	O
high	O
-	O
risk	O
controls	O
(	O
OR	O
=	O
2.30	O
,	O
95	O
%	O
CI	O
=	O
1.12	O
to	O
4.69	O
,	O
Preplication	O
=	O
.02	O
)	O
.	O

T	O
cell	O
-	O
produced	O
TNF	O
and	O
IL	O
-	O
17A	O
further	O
contribute	O
to	O
bone	O
loss	O
in	O
hyperparathyroidism	S-Phenotype
,	O
while	O
T	O
cell	O
production	O
of	O
the	O
anabolic	O
Wingless	O
integration	O
site	O
(	O
Wnt	O
)	O
ligand	O
,	O
Wnt10b	O
,	O
promotes	O
bone	O
formation	O
in	O
response	O
to	O
anabolic	O
parathyroid	O
hormone	O
and	O
the	O
immunomodulatory	O
costimulation	O
inhibitor	O
cytotoxic	O
T	O
lymphocyte	O
-	O
associated	O
protein	O
-	O
4	O
-	O
IgG	O
(	O
abatacept	O
)	O
.	O

An	O
underdeveloped	O
or	O
impaired	O
immune	O
response	O
in	O
young	O
children	O
is	O
associated	O
with	O
increased	O
susceptibility	O
to	O
Streptococcus	B-Phenotype
pneumonia	I-Phenotype
(	I-Phenotype
Spn	I-Phenotype
)	I-Phenotype
infections	E-Phenotype
.	O

First	O
-	O
line	O
surgery	O
and	O
then	O
in	O
vitro	O
fertilization	O
(	O
IVF	O
)	O
in	O
case	O
of	O
persistent	O
infertility	O
or	O
first	O
-	O
line	O
IVF	O
,	O
without	O
surgery	O
?	O

Context	O
Multiple	B-Phenotype
endocrine	I-Phenotype
neoplasia	I-Phenotype
type	I-Phenotype
1	E-Phenotype
(	O
MEN1	S-Phenotype
)	O
is	O
an	O
autosomal	O
dominant	O
disease	O
caused	O
by	O
mutations	O
in	O
the	O
tumor	S-Phenotype
suppressor	O
gene	O
MEN1	O
and	O
can	O
be	O
diagnosed	O
based	O
on	O
clinical	O
,	O
familial	O
and	O
/	O
or	O
genetic	O
criteria	O
.	O

Here	O
we	O
show	O
that	O
metabolic	O
reprogramming	O
of	O
colorectal	O
cancer	S-Phenotype
is	O
caused	O
chiefly	O
by	O
aberrant	O
MYC	O
expression	O
.	O

Duchenne	B-Phenotype
muscular	I-Phenotype
dystrophy	E-Phenotype
(	O
DMD	S-Phenotype
)	O
is	O
characterized	O
by	O
a	O
severe	O
and	O
progressive	O
destruction	O
of	O
muscle	O
fibers	O
associated	O
with	O
altered	O
Casup2+	O
/	O
sup	O
homeostasis	O
.	O

We	O
genotyped	O
a	O
set	O
of	O
mitochondrial	O
SNPs	O
using	O
Illumina	O
HumanExome	O
arrays	O
and	O
tested	O
for	O
association	O
in	O
the	O
Swedish	O
schizophrenia	S-Phenotype
sample	O
(	O
NAAAA	O
10,000	O
)	O
.	O

The	O
expression	O
levels	O
of	O
the	O
up	O
-	O
regulated	O
genes	O
(	O
NAT1	O
,	O
BBS1	O
and	O
PH	O
-	O
4	O
)	O
were	O
also	O
found	O
to	O
be	O
correlated	O
to	O
epithelial	O
to	O
mesenchymal	O
transition	O
status	O
of	O
the	O
tumour	S-Phenotype
.	O

To	O
our	O
knowledge	O
,	O
JU	O
-	O
PI	O
is	O
the	O
first	O
established	O
myxoinflammatory	B-Phenotype
fibroblastic	I-Phenotype
sarcoma	E-Phenotype
cell	O
line	O
.	O

However	O
,	O
the	O
effects	O
of	O
the	O
microRNA	O
miR	O
-	O
142	O
-	O
3p	O
,	O
a	O
small	O
endogenous	O
regulator	O
of	O
gene	O
expression	O
on	O
breast	B-Phenotype
cancer	E-Phenotype
stem	O
cells	O
,	O
have	O
not	O
been	O
investigated	O
.	O

Our	O
studies	O
implicate	O
therapeutic	O
strategies	O
for	O
either	O
reducing	O
β	O
-	O
cell	O
proliferation	O
in	O
insulinomas	S-Phenotype
or	O
alleviating	O
normal	O
β	O
-	O
cell	O
deficiency	O
in	O
diabetes	O
through	O
the	O
modulation	O
of	O
HLXB9	O
phosphorylation	O

Inhibition	O
of	O
the	O
CEP120	O
ortholog	O
in	O
zebrafish	O
produced	O
pleiotropic	O
phenotypes	O
characteristic	O
of	O
cilia	O
defects	O
including	O
abnormal	B-Phenotype
body	I-Phenotype
curvature	E-Phenotype
,	O
hydrocephalus	S-Phenotype
,	O
otolith	B-Phenotype
defects	E-Phenotype
and	O
abnormal	B-Phenotype
renal	E-Phenotype
,	O
head	O
and	O
craniofacial	O
development	O
.	O

We	O
asked	O
whether	O
ROM1	O
could	O
modify	O
the	O
phenotype	O
of	O
a	O
PRPH2	O
mutation	O
associated	O
with	O
a	O
high	O
degree	O
of	O
intrafamilial	O
phenotypic	O
heterogeneity	S-Phenotype
:	O
Y141C	O
.	O

These	O
information	O
revealed	O
that	O
there	O
might	O
be	O
different	O
molecular	O
mechanisms	O
of	O
the	O
tumorigenesis	S-Phenotype
and	O
development	O
of	O
the	O
HCC	O
with	O
single	O
and	O
multiple	O
lesions	O
.	O

The	O
most	O
frequent	O
hearing	B-Phenotype
loss	E-Phenotype
associated	O
allele	O
detected	O
in	O
this	O
population	O
was	O
the	O
235delC	O
variant	O
in	O
GJB2	O
gene	O
.	O

Moreover	O
,	O
RNF20	O
knockdown	O
dramatically	O
suppresses	O
terminal	O
squamous	O
differentiation	O
of	O
cultured	O
bronchial	O
epithelial	O
cells	O
,	O
and	O
significantly	O
enhances	O
proliferation	O
,	O
migration	O
,	O
invasion	O
,	O
and	O
cisplatin	O
resistance	O
of	O
lung	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

In	O
conclusion	O
,	O
novel	O
data	O
on	O
LAMP	O
-	O
1	O
overexpression	O
in	O
HGG	O
are	O
presented	O
suggesting	O
involvement	O
of	O
this	O
gene	O
and	O
protein	O
in	O
cell	O
adhesion	O
and	O
tumor	S-Phenotype
progression	O
.	O

Knockdown	O
of	O
CUL4B	O
in	O
gastric	B-Phenotype
cancer	E-Phenotype
cells	O
suppressed	O
cell	O
proliferation	O
,	O
caused	O
G1	O
arrest	O
and	O
inhibited	O
cell	O
invasion	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggested	O
that	O
USP18	O
may	O
serve	O
a	O
key	O
role	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
development	O
by	O
upregulating	O
EGFR	O
and	O
subsequently	O
activating	O
the	O
AKT	O
/	O
Skp2	O
feedback	O
loop	O
pathway	O
.	O

Thus	O
,	O
our	O
data	O
indicate	O
that	O
miR	O
-	O
132	O
induces	O
temozolomide	O
resistance	O
and	O
promotes	O
the	O
formation	O
of	O
cancer	S-Phenotype
stem	O
cell	O
phenotypes	O
by	O
targeting	O
TUSC3	O
in	O
glioblastoma	S-Phenotype

In	O
this	O
study	O
,	O
we	O
identified	O
EPRS	O
as	O
upregulated	O
in	O
estrogen	O
receptor	O
positive	O
(	O
ER+	O
)	O
human	O
breast	B-Phenotype
tumors	E-Phenotype
in	O
the	O
TCGA	O
and	O
METABRIC	O
cohorts	O
,	O
with	O
copy	O
number	O
gains	O
in	O
nearly	O
50	O
%	O
of	O
samples	O
in	O
both	O
datasets	O
.	O

Bartter	O
syndrome	O
(	O
BS	O
)	O
is	O
a	O
hereditary	O
condition	O
transmitted	O
as	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
(	O
Bartter	O
type	O
1	O
to	O
4	O
)	O
or	O
dominant	O
trait	O
(	O
Bartter	O
type	O
5	O
)	O
.	O

Mutations	O
in	O
IDH1	O
and	O
IDH2	O
have	O
recently	O
been	O
observed	O
in	O
multiple	O
tumors	S-Phenotype
,	O
including	O
gliomas	S-Phenotype
,	O
acute	B-Phenotype
myeloid	I-Phenotype
leukemia	E-Phenotype
,	O
myelodysplastic	B-Phenotype
syndromes	E-Phenotype
,	O
and	O
chondrosarcoma	S-Phenotype
.	O

Biallelic	O
mutations	O
in	O
the	O
photoreceptor	O
-	O
expressed	O
aryl	O
hydrocarbon	O
receptor	O
interacting	O
protein	O
-	O
like	O
1	O
(	O
AIPL1	O
)	O
are	O
associated	O
with	O
autosomal	B-Phenotype
recessive	I-Phenotype
Leber	I-Phenotype
congenital	I-Phenotype
amaurosis	E-Phenotype
(	O
LCA	S-Phenotype
)	O
,	O
the	O
most	O
severe	O
form	O
of	O
inherited	B-Phenotype
retinopathy	E-Phenotype
in	O
early	O
childhood	O
.	O

Analyses	O
of	O
mRNA	O
profiles	O
in	O
comprehensive	O
datasets	O
revealed	O
that	O
high	O
ITGA7	O
expression	O
negatively	O
correlated	O
with	O
survival	O
of	O
patients	O
with	O
both	O
low	O
-	O
and	O
high	O
-	O
grade	O
glioma	S-Phenotype
.	O

We	O
also	O
found	O
that	O
targeting	O
of	O
ITGA7	O
by	O
RNAi	O
or	O
blocking	O
mAbs	O
impaired	O
laminin	O
-	O
induced	O
signaling	O
,	O
and	O
it	O
led	O
to	O
a	O
significant	O
delay	O
in	O
tumor	S-Phenotype
engraftment	O
plus	O
a	O
strong	O
reduction	O
in	O
tumor	S-Phenotype
size	O
and	O
invasion	O
.	O

Our	O
data	O
suggest	O
that	O
mutations	O
of	O
the	O
SRD5A2	O
gene	O
are	O
the	O
main	O
causes	O
of	O
posterior	B-Phenotype
hypospadias	E-Phenotype
and	O
seem	O
to	O
affect	O
the	O
semen	O
quality	O
of	O
adult	O
patients	O
,	O
whereas	O
mutations	O
in	O
AR	O
and	O
HSD17B3	O
gene	O
were	O
rare	O
in	O
these	O
hypospadias	S-Phenotype
patients	O
.	O

There	O
is	O
emerging	O
evidence	O
that	O
BRCA1	O
gene	O
product	O
(	O
BRCA1	O
)	O
also	O
plays	O
a	O
role	O
in	O
cancer	S-Phenotype
cell	O
migration	O
.	O

In	O
this	O
study	O
,	O
we	O
focused	O
on	O
colon	B-Phenotype
cancer	E-Phenotype
with	O
peritoneal	O
metastasis	O
and	O
investigated	O
the	O
association	O
between	O
the	O
expression	O
of	O
CD133	O
,	O
aldehyde	O
dehydrogenase	O
-	O
1	O
(	O
ALDH1	O
)	O
and	O
leucine	O
-	O
rich	O
repeating	O
G	O
-	O
protein	O
coupled	O
receptor	O
-	O
5	O
(	O
Lgr5	O
)	O
,	O
and	O
disease	O
prognosis	O
.	O

Important	O
factors	O
GLI1	O
and	O
GLI2	O
were	O
always	O
expressed	O
,	O
only	O
exceptionally	O
one	O
of	O
them	O
was	O
lowered	O
,	O
suggesting	O
the	O
functionality	O
of	O
HH	O
in	O
all	O
tumors	S-Phenotype
tested	O
.	O

The	O
lack	O
of	O
good	O
molecular	O
markers	O
for	O
diagnosis	O
as	O
well	O
as	O
treatment	O
assessment	O
has	O
rendered	O
the	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
a	O
major	O
challenge	O
in	O
health	O
care	O
.	O

Patients	O
with	O
adult	O
-	O
onset	O
NCL	O
may	O
present	O
with	O
slowly	O
progressive	B-Phenotype
ataxia	E-Phenotype
,	O
persistent	O
photosensitivity	S-Phenotype
,	O
and	O
seizures	S-Phenotype
without	O
dementia	S-Phenotype
or	O
extrapyramidal	O
findings	O
.	O

Chorea	B-Phenotype
-	I-Phenotype
acanthocytosis	E-Phenotype
(	O
ChAc	S-Phenotype
)	O
,	O
a	O
neurodegenerative	B-Phenotype
disease	E-Phenotype
,	O
results	O
from	O
loss	O
-	O
of	O
-	O
function	O
-	O
mutations	O
of	O
the	O
chorein	O
-	O
encoding	O
gene	O
VPS13A	O
.	O

These	O
3	O
patients	O
shared	O
congenital	B-Phenotype
neutropenia	E-Phenotype
linked	O
with	O
various	O
other	O
SDS	O
phenotypes	O
.	O

Overall	O
,	O
40	O
of	O
the	O
73	O
ICA	O
patients	O
(	O
55	O
%	O
)	O
and	O
23	O
of	O
the	O
56	O
kindreds	O
(	O
41	O
%	O
)	O
carry	O
mutations	O
located	O
in	O
translated	O
or	O
untranslated	O
exons	O
of	O
liRPSA	O
.	O

The	O
Y54X	O
mutation	O
in	O
the	O
CDC73	O
gene	O
was	O
previously	O
identified	O
in	O
parathyroid	B-Phenotype
carcinomas	E-Phenotype
,	O
which	O
proved	O
that	O
parathyroid	B-Phenotype
adenomas	E-Phenotype
and	O
carcinomas	S-Phenotype
might	O
possess	O
similar	O
molecular	O
signatures	O
.	O

Transcriptomic	O
analysis	O
revealed	O
significant	O
alterations	O
in	O
a	O
number	O
of	O
genes	O
associated	O
with	O
autism	S-Phenotype
,	O
such	O
as	O
adsl	O
,	O
mbd5	O
,	O
shank3	O
,	O
and	O
tsc1b	O
.	O

Humans	O
who	O
carry	O
HNF1B	O
mutations	O
develop	O
heterogeneous	B-Phenotype
renal	I-Phenotype
abnormalities	E-Phenotype
,	O
including	O
multicystic	B-Phenotype
dysplastic	I-Phenotype
kidneys	E-Phenotype
,	O
glomerulocystic	B-Phenotype
kidney	I-Phenotype
disease	E-Phenotype
,	O
renal	B-Phenotype
agenesis	E-Phenotype
,	O
renal	B-Phenotype
hypoplasia	E-Phenotype
,	O
and	O
renal	B-Phenotype
interstitial	I-Phenotype
fibrosis	E-Phenotype
.	O

Here	O
the	O
authors	O
show	O
that	O
human	O
microcephaly	S-Phenotype
protein	O
RTTN	O
directly	O
interacts	O
with	O
STIL	O
and	O
acts	O
downstream	O
of	O
STIL	O
-	O
mediated	O
centriole	O
assembly	O
,	O
contributing	O
to	O
building	O
full	O
-	O
length	O
centrioles	O

In	O
conclusion	O
,	O
our	O
data	O
offer	O
in	O
vivo	O
support	O
that	O
,	O
in	O
HNSCCs	O
,	O
Eps8	O
is	O
involved	O
in	O
tumor	S-Phenotype
invasion	O
but	O
not	O
necessarily	O
the	O
development	O
of	O
regional	O
LN	O
metastasis	O
.	O

Independent	O
and	O
pooled	O
analyses	O
verified	O
that	O
higher	O
PYCR1	O
mRNA	O
levels	O
were	O
significantly	O
associated	O
with	O
poor	O
survival	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
patients	O
,	O
regardless	O
of	O
estrogen	O
receptor	O
(	O
ER	O
)	O
status	O
.	O

In	O
the	O
two	O
populations	O
with	O
the	O
largest	O
sample	O
size	O
,	O
the	O
probability	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
generally	O
increases	O
as	O
anti	O
-	O
GARP	O
antibody	O
levels	O
increase	O
.	O

We	O
finally	O
discuss	O
selected	O
novel	O
genes	O
for	O
dystonia	S-Phenotype
such	O
as	O
KMT2B	O
and	O
VAC14	O
along	O
with	O
the	O
challenges	O
for	O
gene	O
identification	O
in	O
the	O
NGS	O
era	O
and	O
the	O
translational	O
importance	O
of	O
dystonia	S-Phenotype
genetics	O
in	O
clinical	O
practice	O

Pre	O
-	O
treatment	O
testing	O
of	O
the	O
localized	O
cutaneous	O
tumor	S-Phenotype
lesion	O
on	O
a	O
lymphoid	O
amplicon	O
panel	O
demonstrated	O
an	O
liMYD88	O
/	O
i	O
p.L265P	O
mutation	O
.	O

Similar	O
differences	O
were	O
found	O
among	O
a	O
single	O
gene	O
group	O
,	O
comparing	O
23	O
patients	O
with	O
CACNA1A	O
expansions	O
(	O
spinocerebellar	B-Phenotype
ataxia	I-Phenotype
6	E-Phenotype
)	O
to	O
22	O
patients	O
with	O
CACNA1A	O
point	O
mutations	O
,	O
which	O
had	O
lower	O
average	O
age	O
at	O
onset	O
(	O
25.2	O
versus	O
47.3	O
years	O
)	O
with	O
longer	O
disease	O
duration	O
(	O
18.7	O
versus	O
10.9	O
)	O
,	O
but	O
lower	O
severity	O
indexes	O
(	O
0.39	O
versus	O
0.44	O
)	O
,	O
indicating	O
slower	O
progression	O
of	O
the	O
disease	O
.	O

Clinical	O
lung	B-Phenotype
cancer	E-Phenotype
tissue	O
and	O
normal	O
tissue	O
were	O
collected	O
,	O
and	O
the	O
mRNA	O
expression	O
of	O
TMEM98	O
in	O
cancer	S-Phenotype
tissue	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
normal	O
tissue	O
.	O

Six	O
novel	O
CRYGC	O
mutations	O
(	O
p.Asp65ThrfsX38	O
,	O
p.Arg142GlyfsX5	O
,	O
p.Arg142AlafsX22	O
,	O
p.Tyr144X	O
,	O
p.Arg169X	O
,	O
and	O
p.Tyr46Asp	O
)	O
were	O
identified	O
in	O
other	O
six	O
families	O
with	O
congenital	B-Phenotype
nuclear	I-Phenotype
cataracts	E-Phenotype
,	O
respectively	O
.	O

In	O
colorectal	B-Phenotype
cancer	E-Phenotype
,	O
APC	O
-	O
mediated	O
induction	O
of	O
unregulated	O
cell	O
growth	O
involves	O
posttranslational	O
mechanisms	O
that	O
prevent	O
proteasomal	O
degradation	O
of	O
proto	O
-	O
oncogene	O
b	O
-	O
catenin	O
(	O
CTNNB1	O
)	O
and	O
its	O
eventual	O
translocation	O
to	O
the	O
nucleus	O
.	O

Five	O
genes	O
,	O
including	O
OTOGL	O
,	O
PLCB4	O
,	O
SCEL	O
,	O
THSD4	O
,	O
and	O
WWOX	O
,	O
have	O
CNVs	O
in	O
the	O
six	O
patients	O
with	O
sporadic	S-Phenotype
HBs	O
,	O
and	O
three	O
genes	O
,	O
including	O
ABCA6	O
,	O
CWC27	O
,	O
and	O
LAMA2	O
,	O
have	O
CNVs	O
in	O
the	O
five	O
patients	O
with	O
familial	O
HBs	O
.	O

The	O
expression	O
of	O
N	O
-	O
cadherin	O
and	O
vimentin	O
was	O
positively	O
associated	O
with	O
Twist2	O
in	O
glioma	S-Phenotype
(	O
lir	O
/	O
i=0.971	O
,	O
liP	O
/	O
iAAAA0.01	O
;	O
lir	O
/	O
i=0.968	O
,	O
liP	O
/	O
iAAAA0.01	O
)	O
.	O

We	O
examined	O
differences	O
in	O
the	O
expression	O
levels	O
of	O
EGFR	O
in	O
GC	O
and	O
adjacent	O
non	O
-	O
cancerous	S-Phenotype
tissues	O
.	O

X	O
-	O
linked	O
Myopathy	S-Phenotype
with	O
Excessive	O
Autophagy	O
(	O
XMEA	O
)	O
affects	O
proximal	O
muscles	O
of	O
the	O
lower	O
extremities	O
and	O
follows	O
a	O
progressive	O
course	O
reminiscent	O
of	O
muscular	B-Phenotype
dystrophy	E-Phenotype
.	O

The	O
short	B-Phenotype
-	I-Phenotype
limbed	I-Phenotype
dwarfism	I-Phenotype
metaphyseal	I-Phenotype
chondrodysplasia	I-Phenotype
type	I-Phenotype
Schmid	E-Phenotype
(	O
MCDS	S-Phenotype
)	O
is	O
linked	O
to	O
mutations	O
in	O
type	O
X	O
collagen	O
,	O
which	O
increase	O
ER	O
stress	O
by	O
inducing	O
misfolding	O
of	O
the	O
mutant	O
protein	O
and	O
subsequently	O
disrupting	O
hypertrophic	O
chondrocyte	O
differentiation	O
.	O

Pulmonary	B-Phenotype
arterial	I-Phenotype
hypertension	E-Phenotype
(	O
PAH	S-Phenotype
)	O
is	O
a	O
progressive	O
disease	O
characterised	O
by	O
increased	B-Phenotype
pulmonary	I-Phenotype
vascular	I-Phenotype
resistance	E-Phenotype
and	O
pulmonary	O
artery	O
remodelling	O
as	O
result	O
of	O
increased	O
vascular	O
tone	O
and	O
vascular	O
cell	O
proliferation	O
,	O
respectively	O
.	O

The	O
short	B-Phenotype
-	I-Phenotype
rib	I-Phenotype
polydactyly	I-Phenotype
syndromes	E-Phenotype
(	O
SRPS	S-Phenotype
)	O
are	O
autosomal	B-Phenotype
recessively	I-Phenotype
inherited	I-Phenotype
,	I-Phenotype
genetically	I-Phenotype
heterogeneous	I-Phenotype
skeletal	I-Phenotype
ciliopathies	E-Phenotype
.	O

Aberrant	O
activation	O
of	O
the	O
Hedgehog	O
pathway	O
represents	O
the	O
molecular	O
driver	O
in	O
basal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
pathogenesis	O
,	O
with	O
the	O
majority	O
of	O
BCCs	O
carrying	O
somatic	O
point	O
mutations	O
,	O
mainly	O
ultraviolet	O
(	O
UV	O
)	O
-	O
induced	O
,	O
and	O
/	O
or	O
copy	O
-	O
loss	O
of	O
heterozygosis	O
in	O
the	O
PTCH1	O
gene	O
.	O

Translating	O
our	O
extensive	O
knowledge	O
in	O
Rac	O
pathway	O
biochemistry	O
into	O
a	O
clinical	O
setting	O
still	O
remains	O
a	O
major	O
challenge	O
;	O
nonetheless	O
,	O
remarkable	O
opportunities	O
for	O
cancer	S-Phenotype
therapeutics	O
arise	O
from	O
promising	O
lead	O
compounds	O
targeting	O
Rac	O
and	O
its	O
effectors	O

Interestingly	O
,	O
overexpression	O
of	O
Chmp1A	O
using	O
a	O
eukaryotic	O
plasmid	O
inhibited	O
the	O
proliferation	O
of	O
renal	B-Phenotype
tumor	E-Phenotype
cells	O
in	O
vitro	O
and	O
the	O
growth	O
of	O
renal	B-Phenotype
tumor	E-Phenotype
in	O
vivo	O
.	O

The	O
KSHV	O
viral	O
homolog	O
of	O
interleukin	O
-	O
6	O
gene	O
(	O
vIL	O
-	O
6	O
)	O
may	O
play	O
a	O
significant	O
role	O
in	O
tumor	S-Phenotype
development	O
and	O
may	O
serve	O
as	O
a	O
new	O
anti	O
-	O
cancer	S-Phenotype
target	O
,	O
but	O
its	O
role	O
in	O
tumor	S-Phenotype
formation	O
is	O
only	O
partially	O
understood	O
.	O

Altered	O
ERCC1	O
expression	O
or	O
function	O
is	O
closely	O
associated	O
with	O
cancer	S-Phenotype
development	O
and	O
progression	O
.	O

She	O
manifested	O
macrocephaly	S-Phenotype
,	O
preaxial	B-Phenotype
polysyndactyly	E-Phenotype
,	O
psychomotor	B-Phenotype
developmental	I-Phenotype
delay	E-Phenotype
,	O
cerebral	B-Phenotype
cavernous	I-Phenotype
malformations	E-Phenotype
,	O
and	O
glucose	B-Phenotype
intolerance	E-Phenotype
due	O
to	O
a	O
6.2	O
-	O
Mb	O
deletion	O
of	O
7p14.1p12.3	O
which	O
included	O
GLI3	O
,	O
GCK	O
,	O
and	O
CCM2	O
.	O

Compared	O
with	O
the	O
AA	O
genotype	O
,	O
BHMT	O
(	O
rs492842	O
and	O
rs542852	O
)	O
GG	O
and	O
AG	O
genotypes	O
were	O
associated	O
with	O
twice	O
the	O
riskof	O
congenital	B-Phenotype
heart	I-Phenotype
defects	E-Phenotype
(	O
BFDP=0.74	O
and	O
0.79	O
,	O
respectively	O
)	O
.	O

Therefore	O
our	O
study	O
identifies	O
a	O
compartmentalized	O
PtdIns	O
(	O
3,4,5	O
)	O
Psub3	O
/	O
sub	O
/	O
AKT	O
/	O
GSK3β	O
signaling	O
axis	O
at	O
cilia	O
in	O
SHH	O
-	O
dependent	O
medulloblastoma	S-Phenotype
that	O
is	O
regulated	O
by	O
INPP5E	O
to	O
maintain	O
tumor	S-Phenotype
cell	O
cilia	O
,	O
promote	O
SHH	O
signaling	O
and	O
thereby	O
medulloblastoma	S-Phenotype
progression	O

These	O
results	O
increase	O
our	O
knowledge	O
about	O
the	O
RAD51C	O
and	O
RAD51D	O
mutation	O
spectrum	O
and	O
support	O
the	O
notion	O
that	O
these	O
genes	O
should	O
be	O
included	O
in	O
the	O
gene	O
panel	O
testing	O
performed	O
on	O
patients	O
with	O
hereditary	B-Phenotype
breast	I-Phenotype
and	I-Phenotype
ovarian	I-Phenotype
cancer	E-Phenotype
syndrome	O

More	O
importantly	O
,	O
we	O
show	O
that	O
genetic	O
inhibition	O
of	O
tp53	O
can	O
suppress	O
neuroepithelial	O
cell	O
death	O
and	O
ameliorate	O
the	O
skeletal	B-Phenotype
anomalies	E-Phenotype
in	O
polr1c	O
and	O
polr1d	O
mutants	O
,	O
providing	O
a	O
potential	O
avenue	O
to	O
prevent	O
the	O
pathogenesis	O
of	O
Treacher	B-Phenotype
Collins	I-Phenotype
syndrome	E-Phenotype
.	O

Here	O
,	O
we	O
tested	O
the	O
DCTN1	O
protein	O
-	O
coding	O
exons	O
in	O
510	O
sporadic	S-Phenotype
ALS	O
patients	O
in	O
whom	O
SOD1	O
,	O
TARDBP	O
,	O
FUS	O
,	O
and	O
C9orf72	O
genes	O
were	O
screened	O
before	O
.	O

Our	O
findings	O
suggest	O
that	O
SLC25A12	O
overexpression	O
may	O
be	O
involved	O
in	O
the	O
pathophysiology	O
of	O
autism	S-Phenotype
,	O
modifying	O
neuronal	O
networks	O
in	O
specific	O
subregions	O
,	O
such	O
as	O
the	O
dorsolateral	O
prefrontal	O
cortex	O
and	O
fusiform	O
gyrus	O
,	O
at	O
both	O
pre	O
-	O
and	O
postnatal	O
stages	O

As	O
a	O
mitotic	O
kinesin	O
,	O
kinesin	O
family	O
member	O
14	O
(	O
KIF14	O
)	O
has	O
been	O
reported	O
to	O
serve	O
oncogenic	O
roles	O
in	O
a	O
variety	O
of	O
malignancies	O
;	O
however	O
,	O
its	O
functional	O
role	O
and	O
regulatory	O
mechanisms	O
in	O
colorectal	B-Phenotype
cancer	E-Phenotype
(	O
CRC	S-Phenotype
)	O
remain	O
unclear	O
.	O

In	O
nonobese	O
diabetic	O
/	O
severe	O
combined	O
immunodeficient	O
(	O
NOD	O
/	O
SCID	O
)	O
mice	O
engrafted	O
with	O
HL	O
cells	O
,	O
ERβ	O
activation	O
by	O
DPN	O
was	O
able	O
to	O
reduce	O
lymphoma	S-Phenotype
growth	O
up	O
to	O
60	O
%	O
and	O
this	O
associated	O
with	O
the	O
induction	O
of	O
tumor	S-Phenotype
cell	O
autophagy	O
.	O

Mutations	O
in	O
SAMHD1	O
are	O
implicated	O
in	O
cancer	S-Phenotype
development	O
and	O
in	O
a	O
severe	O
congenital	O
inflammatory	O
disease	O
known	O
as	O
Aicardi	O
-	O
Goutières	O
syndrome	O
.	O

Here	O
,	O
we	O
found	O
that	O
protein	O
tyrosine	O
phosphatase	O
PTPN3	O
gene	O
expression	O
was	O
substantially	O
increased	O
in	O
both	O
cisplatin	O
and	O
doxorubicin	O
-	O
resistant	O
ovarian	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

While	O
,	O
the	O
clinical	O
significance	O
and	O
biological	O
function	O
of	O
SRPX2	O
remain	O
rarely	O
known	O
in	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
.	O

Advanced	O
FECD	O
involves	O
a	O
thickening	O
of	O
the	O
cornea	O
from	O
stromal	B-Phenotype
edema	E-Phenotype
and	O
changes	O
in	O
Descemet	O
membrane	O
.	O

This	O
phenotypic	O
variability	O
should	O
be	O
taken	O
into	O
account	O
when	O
treating	O
patients	O
with	O
BRAT1	B-Phenotype
-	I-Phenotype
associated	I-Phenotype
neurodegenerative	I-Phenotype
disease	E-Phenotype
.	O

To	O
investigate	O
the	O
mechanism	O
of	O
DFNB30	B-Phenotype
-	I-Phenotype
type	I-Phenotype
deafness	E-Phenotype
,	O
we	O
established	O
a	O
mouse	O
model	O
of	O
Myo3a	O
kinase	O
domain	O
Y137C	O
mutation	O
by	O
using	O
CRISPR	O
/	O
Cas9	O
system	O
.	O

We	O
conducted	O
a	O
cis	O
-	O
expression	O
quantitative	O
trait	O
loci	O
(	O
cis	O
-	O
eQTL	O
)	O
analysis	O
using	O
normal	O
or	O
tumor	S-Phenotype
breast	O
transcriptome	O
data	O
from	O
the	O
Molecular	O
Taxonomy	O
of	O
Breast	B-Phenotype
Cancer	E-Phenotype
International	O
Consortium	O
(	O
METABRIC	O
)	O
,	O
The	O
Cancer	S-Phenotype
Genome	O
Atlas	O
(	O
TCGA	O
)	O
,	O
and	O
the	O
Genotype	O
-	O
Tissue	O
Expression	O
(	O
GTEx	O
)	O
project	O
.	O

Missense	O
variants	O
in	O
PRPS1	O
are	O
usually	O
associated	O
with	O
disease	O
in	O
male	O
patients	O
,	O
including	O
Arts	O
syndrome	O
,	O
Charcot	O
-	O
Marie	O
-	O
Tooth	O
,	O
and	O
nonsyndromic	O
sensorineural	B-Phenotype
deafness	E-Phenotype
.	O

However	O
,	O
the	O
clinical	O
implication	O
of	O
p	O
-	O
STAT3	O
expression	O
in	O
colon	B-Phenotype
cancer	E-Phenotype
is	O
still	O
controversial	O
.	O

In	O
addition	O
,	O
different	O
prion	O
mutations	O
were	O
suggested	O
to	O
play	O
a	O
possible	O
role	O
in	O
additional	O
phenotypes	O
,	O
such	O
as	O
Alzheimer	B-Phenotype
's	I-Phenotype
type	I-Phenotype
pathology	E-Phenotype
,	O
spongiform	B-Phenotype
encephalopathy	E-Phenotype
,	O
or	O
frontotemporal	B-Phenotype
dementia	E-Phenotype
.	O

These	O
promising	O
results	O
indicated	O
that	O
PDT	O
enhanced	O
EGFP	O
-	O
EGF1modified	O
PEG	O
-	O
PLGA	O
nanoparticle	O
accumulation	O
in	O
tumor	S-Phenotype
vaculature	O
.	O

The	O
association	O
replicated	O
in	O
the	O
UK	O
Biobank	O
sample	O
(	O
odds	O
ratio	O
=	O
1.25	O
,	O
liP	O
/	O
i	O
=	O
6.8	O
×	O
10sup	O
-	O
14	O
/	O
sup	O
)	O
,	O
and	O
the	O
effect	O
is	O
independent	O
of	O
known	O
erectile	B-Phenotype
dysfunction	E-Phenotype
risk	O
factors	O
,	O
including	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
.	O

The	O
most	O
significant	O
association	O
with	O
childhood	O
brain	B-Phenotype
tumor	E-Phenotype
risk	O
was	O
for	O
IVS1	O
-	O
401GAAAAC	O
in	O
the	O
AICDA	O
gene	O
[	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
2.8	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
95	O
%	O
CI	O
)	O
=	O
1.25	O
-	O
6.46	O
]	O
;	O
the	O
polymorphism	O
*	O
9276AAAAAC	O
of	O
CASP14	O
was	O
associated	O
with	O
decreased	O
brain	B-Phenotype
tumor	E-Phenotype
risk	O
(	O
OR	O
=	O
0.4	O
;	O
95	O
%	O
CI	O
=	O
0.19	O
-	O
0.95	O
)	O
.	O

Our	O
findings	O
show	O
that	O
a	O
high	O
percentage	O
of	O
known	O
HER2+	O
breast	B-Phenotype
cancer	E-Phenotype
susceptibility	O
genes	O
,	O
including	O
EGFR	O
,	O
IGFR	O
,	O
and	O
E2F1	O
,	O
are	O
under	O
transcriptional	O
control	O
of	O
NRF1	O
.	O

Analyses	O
of	O
microRNA	O
(	O
miRNA	O
)	O
expression	O
signatures	O
obtained	O
by	O
RNA	O
sequencing	O
revealed	O
that	O
some	O
passenger	O
miRNAs	O
(	O
miR	O
-	O
144	O
-	O
5p	O
,	O
miR	O
-	O
145	O
-	O
3p	O
,	O
miR	O
-	O
149	O
-	O
3p	O
,	O
miR	O
-	O
150	O
-	O
3p	O
,	O
and	O
miR	O
-	O
199a	O
-	O
3p	O
)	O
acted	O
as	O
anti	O
-	O
tumor	S-Phenotype
miRNAs	O
in	O
several	O
types	O
of	O
cancer	S-Phenotype
cells	O
.	O

The	O
mRNA	O
and	O
protein	O
levels	O
of	O
STX3	O
are	O
significantly	O
up	O
-	O
regulated	O
in	O
human	O
breast	B-Phenotype
cancer	E-Phenotype
compared	O
with	O
matched	O
adjacent	O
non	O
-	O
cancer	S-Phenotype
tissues	O
.	O

Subpopulation	O
screening	O
of	O
the	O
coding	O
exons	O
and	O
flanking	O
introns	O
of	O
SMPX	O
was	O
further	O
performed	O
for	O
338	O
Chinese	O
patients	O
with	O
nonsydromic	O
HL	O
by	O
Sanger	O
sequencing	O
,	O
and	O
another	O
two	O
potential	O
causative	O
substitutions	O
(	O
c.238CAAAAA	O
and	O
c.55AAAAAG	O
)	O
in	O
SMPX	O
were	O
identified	O
in	O
additional	O
sporadic	S-Phenotype
cases	O
of	O
congenital	B-Phenotype
deafness	E-Phenotype
.	O

Finally	O
,	O
in	O
vivo	O
experiments	O
confirmed	O
that	O
CHRDL1	O
acted	O
as	O
a	O
tumor	S-Phenotype
suppressor	O
gene	O
in	O
suppressing	O
tumor	S-Phenotype
growth	O
and	O
metastasis	O

A	O
17	O
-	O
year	O
-	O
old	O
adolescent	O
boy	O
with	O
a	O
history	O
of	O
hypoproteinemia	S-Phenotype
underwent	O
Ga	O
-	O
NEB	O
PET	O
/	O
MRI	O
to	O
evaluate	O
possible	O
lymphatic	O
disorders	O
suggested	O
by	O
FDG	O
PET	O
/	O
CT	O
imaging	O
.	O

The	O
findings	O
indicate	O
the	O
functionality	O
of	O
the	O
PrCa	O
death	O
-	O
predisposing	O
SNPs	O
rs143975731	O
,	O
rs12277366	O
,	O
rs2155225	O
,	O
and	O
rs2155222	O
as	O
DGAT2	O
regulators	O
in	O
prostate	B-Phenotype
tumors	E-Phenotype
.	O

Therefore	O
,	O
we	O
suggest	O
that	O
the	O
screening	O
test	O
of	O
ADSSL1	O
gene	O
should	O
be	O
considered	O
for	O
the	O
diagnosis	O
of	O
distal	B-Phenotype
myopathy	E-Phenotype

Data	O
from	O
the	O
Oncomine	O
databases	O
indicated	O
a	O
strong	O
negative	O
relationship	O
between	O
OVOL2	O
expression	O
and	O
breast	B-Phenotype
cancer	E-Phenotype
progression	O
.	O

These	O
findings	O
suggest	O
that	O
PTPN3	O
promotes	O
tumorigenicity	O
,	O
stemness	O
and	O
drug	B-Phenotype
resistance	E-Phenotype
in	O
ovarian	B-Phenotype
cancer	E-Phenotype
,	O
and	O
thus	O
is	O
a	O
potential	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
ovarian	B-Phenotype
cancer	E-Phenotype

In	O
functional	O
assays	O
performed	O
with	O
RNA	O
knockdown	O
,	O
loss	O
of	O
STEAP3	O
attenuated	O
aggressive	O
phenotypes	O
in	O
glioma	S-Phenotype
cells	O
,	O
including	O
cell	O
proliferation	O
,	O
invasion	O
,	O
and	O
sphere	O
formation	O
in	O
vitro	O
and	O
tumor	S-Phenotype
growth	O
in	O
vivo	O
.	O

Adipose	O
expression	O
of	O
CTRP5	O
was	O
markedly	O
upregulated	O
in	O
obese	O
and	O
diabetic	O
humans	O
and	O
in	O
genetic	O
and	O
dietary	O
models	O
of	O
obesity	S-Phenotype
in	O
rodents	O
.	O

To	O
provide	O
new	O
ideas	O
based	O
on	O
the	O
use	O
of	O
corin	O
for	O
risk	O
prediction	O
,	O
prognostic	O
assessment	O
,	O
and	O
clinical	O
treatment	O
of	O
cardiovascular	B-Phenotype
diseases	E-Phenotype
and	O
to	O
promote	O
the	O
implementation	O
of	O
corin	O
as	O
a	O
routine	O
laboratory	O
index	O
,	O
we	O
summarize	O
the	O
latest	O
studies	O
of	O
the	O
association	O
between	O
corin	O
and	O
cardiovascular	B-Phenotype
diseases	E-Phenotype
in	O
recent	O
years	O
and	O
offer	O
some	O
prospective	O
proposals	O
for	O
future	O
research	O
on	O
corin	O
in	O
this	O
review	O

FGD	O
is	O
a	O
heterogeneous	S-Phenotype
disorder	O
for	O
which	O
causal	O
mutations	O
have	O
been	O
identified	O
in	O
MC2R	O
,	O
MRAP	O
,	O
MCM4	O
and	O
TXNRD2	O
.	O

Mutations	O
of	O
liMYO7A	O
/	O
i	O
/	O
iMyo7a	O
/	O
i	O
have	O
been	O
implicated	O
in	O
inherited	B-Phenotype
deafness	E-Phenotype
in	O
both	O
humans	O
and	O
mice	O
.	O

Group	B-Phenotype
1	I-Phenotype
pulmonary	I-Phenotype
hypertension	E-Phenotype
or	O
pulmonary	B-Phenotype
arterial	I-Phenotype
hypertension	E-Phenotype
(	O
PAH	S-Phenotype
)	O
is	O
a	O
rare	O
disease	O
characterized	O
by	O
proliferation	B-Phenotype
and	I-Phenotype
occlusion	I-Phenotype
of	I-Phenotype
small	I-Phenotype
pulmonary	I-Phenotype
arterioles	E-Phenotype
,	O
leading	O
to	O
progressive	B-Phenotype
elevation	I-Phenotype
of	I-Phenotype
pulmonary	I-Phenotype
artery	I-Phenotype
pressure	E-Phenotype
and	O
pulmonary	B-Phenotype
vascular	I-Phenotype
resistance	E-Phenotype
,	O
and	O
right	B-Phenotype
ventricular	I-Phenotype
failure	E-Phenotype
.	O

Further	O
population	O
study	O
also	O
validated	O
that	O
chemotherapy	O
significantly	O
improved	O
survival	O
in	O
early	B-Phenotype
-	I-Phenotype
stage	I-Phenotype
breast	I-Phenotype
cancer	E-Phenotype
patients	O
with	O
low	O
PYCR1	O
expression	O
levels	O
.	O

Vascular	O
endothelial	O
cell	O
damage	O
is	O
related	O
to	O
many	O
vascular	O
diseases	O
,	O
including	O
cardiovascular	B-Phenotype
disease	E-Phenotype
(	O
CVD	S-Phenotype
)	O
.	O

Four	O
of	O
six	O
variants	O
identified	O
were	O
previously	O
associated	O
with	O
ALS	O
or	O
the	O
motor	O
and	O
sensory	B-Phenotype
neuropathy	E-Phenotype
Charcot	O
-	O
Marie	O
-	O
Tooth	O
disease	O
type	O
4J	O
(	O
CMT4J	O
)	O
,	O
whereas	O
two	O
variants	O
were	O
novel	O
.	O

Furthermore	O
,	O
association	O
signal	O
between	O
AHI1	O
variants	O
and	O
schizophrenia	S-Phenotype
has	O
been	O
reported	O
in	O
several	O
European	O
samples	O
.	O

At	O
last	O
,	O
we	O
collected	O
112	O
lung	B-Phenotype
cancer	E-Phenotype
patients	O
with	O
MTBP	O
information	O
to	O
verify	O
the	O
results	O
of	O
data	O
analysis	O
(	O
GSE30219	O
)	O
.The	O
overall	O
Kaplan	O
-	O
Meier	O
curve	O
results	O
of	O
6	O
eligible	O
data	O
groups	O
were	O
shown	O
in	O
Fig	O
.	O

The	O
overlap	O
of	O
axonal	O
Charcot	O
-	O
Marie	O
-	O
Tooth	O
disease	O
with	O
both	O
diseases	O
,	O
as	O
well	O
as	O
the	O
common	O
autosomal	B-Phenotype
recessive	E-Phenotype
inheritance	O
pattern	O
of	O
thin	B-Phenotype
corpus	I-Phenotype
callosum	E-Phenotype
and	O
axonal	O
Charcot	O
-	O
Marie	O
-	O
Tooth	O
disease	O
in	O
three	O
related	O
patients	O
,	O
prompted	O
us	O
to	O
analyse	O
the	O
ALS5	O
/	O
SPG11	O
/	O
KIAA1840	O
gene	O
in	O
affected	O
individuals	O
with	O
autosomal	O
recessive	O
axonal	O
Charcot	O
-	O
Marie	O
-	O
Tooth	O
disease	O
.	O

Metaplastic	B-Phenotype
breast	I-Phenotype
carcinoma	E-Phenotype
is	O
an	O
aggressive	O
form	O
of	O
invasive	O
breast	B-Phenotype
cancer	E-Phenotype
with	O
histological	O
evidence	O
of	O
epithelial	O
to	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
.	O

We	O
have	O
performed	O
WES	O
for	O
4102	O
(	O
1847	O
female	O
;	O
2255	O
male	O
)	O
intellectual	B-Phenotype
disability	E-Phenotype
/	O
developmental	B-Phenotype
delay	E-Phenotype
cases	O
and	O
we	O
report	O
five	O
patients	O
with	O
a	O
neurodevelopmental	O
disorder	O
associated	O
with	O
developmental	B-Phenotype
delay	E-Phenotype
,	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
behavioral	B-Phenotype
problems	E-Phenotype
,	O
hypotonia	S-Phenotype
,	O
speech	O
problems	O
,	O
microcephaly	S-Phenotype
,	O
pachygyria	S-Phenotype
and	O
dysmorphic	O
features	O
in	O
whom	O
we	O
have	O
identified	O
de	O
novo	O
missense	O
and	O
canonical	O
splice	O
site	O
mutations	O
in	O
CSNK2A1	O
,	O
the	O
gene	O
encoding	O
CK2α	O
,	O
the	O
catalytic	O
subunit	O
of	O
protein	O
kinase	O
CK2	O
,	O
a	O
ubiquitous	O
serine	O
/	O
threonine	O
kinase	O
composed	O
of	O
two	O
regulatory	O
(	O
β	O
)	O
and	O
two	O
catalytic	O
(	O
α	O
and	O
/	O
or	O
α	O
'	O
)	O
subunits	O
.	O

We	O
provide	O
the	O
first	O
evidence	O
for	O
miRNA	O
controlling	O
retrograde	O
signaling	O
,	O
demonstrating	O
its	O
epigenetic	O
regulation	O
and	O
its	O
role	O
in	O
breast	B-Phenotype
tumorigenesis	E-Phenotype

We	O
investigated	O
the	O
association	O
between	O
five	O
HACE1	O
gene	O
polymorphisms	O
and	O
Wilms	O
*	O
tumor	S-Phenotype
susceptibility	O
in	O
a	O
Chinese	O
population	O
consisting	O
of	O
145	O
patients	O
and	O
531	O
controls	O
.	O

Relevant	O
to	O
cancer	S-Phenotype
,	O
clinical	O
studies	O
indicate	O
that	O
SALL2	O
is	O
deregulated	O
in	O
various	O
cancers	S-Phenotype
and	O
is	O
a	O
specific	O
biomarker	O
for	O
Synovial	B-Phenotype
Sarcoma	E-Phenotype
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
TR2	O
-	O
3	O
exhibited	O
potent	O
antitumor	O
activity	S-Phenotype
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

However	O
,	O
its	O
role	O
in	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
remains	O
unclear	O
.	O

We	O
generated	O
a	O
transgenic	O
rat	O
strain	O
with	O
a	O
missense	O
mutation	O
in	O
V286L	O
(	O
V286L	O
-	O
TG	O
)	O
,	O
in	O
the	O
gene	O
encoding	O
the	O
neuronal	O
nicotinic	O
acetylcholine	O
receptor	O
β2	O
subunit	O
(	O
CHRNB2	O
)	O
found	O
in	O
patients	O
with	O
autosomal	B-Phenotype
dominant	I-Phenotype
nocturnal	I-Phenotype
frontal	I-Phenotype
lobe	I-Phenotype
epilepsy	E-Phenotype
(	O
ADNFLE	S-Phenotype
)	O
.	O

Although	O
anti	O
-	O
myelin	O
-	O
associated	O
glycoprotein	O
(	O
MAG	O
)	O
antibody	O
neuropathy	S-Phenotype
is	O
reported	O
as	O
a	O
slowly	O
progressive	O
disease	O
,	O
it	O
can	O
lead	O
to	O
significant	O
disability	O
and	O
impairment	O
of	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HR	O
-	O
QoL	O
)	O
and	O
social	O
participation	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
SNIP1	O
,	O
RB	O
and	O
HDAC1	O
were	O
significantly	O
expressed	O
in	O
same	O
lung	B-Phenotype
cancer	E-Phenotype
tissues	O
in	O
a	O
tissue	O
microarray	O
(	O
TMA	O
)	O
containing	O
300	O
non	B-Phenotype
-	I-Phenotype
small	I-Phenotype
cell	I-Phenotype
lung	I-Phenotype
cancers	E-Phenotype
(	O
NSCLC	S-Phenotype
)	O
.	O

We	O
show	O
that	O
craniosynostosis	S-Phenotype
,	O
which	O
has	O
not	O
been	O
previously	O
reported	O
in	O
association	O
with	O
KAT6B	O
mutations	O
,	O
may	O
be	O
part	O
of	O
the	O
genitopatellar	O
/	O
Say	O
Barber	O
Biesecker	O
Young	O
Simpson	O
spectrum	O
.	O

In	O
some	O
families	O
with	O
multiple	O
cases	O
of	O
uveal	B-Phenotype
and	I-Phenotype
cutaneous	I-Phenotype
melanoma	E-Phenotype
(	O
including	O
a	O
few	O
Swedish	O
families	O
)	O
,	O
mutations	O
in	O
the	O
BAP1	O
gene	O
have	O
been	O
found	O
.	O

Among	O
the	O
differentially	O
expressed	O
genes	O
were	O
oncogenes	O
,	O
tumor	S-Phenotype
suppressors	O
,	O
transcription	O
factors	O
,	O
VEGF	O
-	O
related	O
genes	O
,	O
and	O
members	O
of	O
the	O
WNT	O
pathway	O
.	O

Here	O
,	O
we	O
report	O
the	O
potential	O
clinical	O
implication	O
and	O
biological	O
functions	O
of	O
RIPK4	O
in	O
cervical	B-Phenotype
squamous	I-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
CSCC	S-Phenotype
)	O
.	O

To	O
reveal	O
novel	O
molecular	O
factors	O
behind	O
the	O
development	O
of	O
salivary	B-Phenotype
gland	I-Phenotype
cancer	E-Phenotype
,	O
we	O
performed	O
gene	O
expression	O
analyses	O
from	O
Smgb	O
-	O
Tag	O
mouse	O
salivary	O
gland	O
samples	O
.	O

HMGB1	O
orchestrates	O
the	O
key	O
events	O
of	O
tumour	S-Phenotype
angiogenesis	O
,	O
migration	O
of	O
ECs	O
and	O
their	O
induction	O
to	O
secrete	O
VEGF	O
-	O
A	O
,	O
by	O
adopting	O
distinct	O
redox	O
states	O
.	O

In	O
conclusion	O
,	O
overexpression	O
of	O
the	O
DTNA	O
-	O
p.N49S	O
mutation	O
in	O
a	O
mouse	O
heart	O
can	O
be	O
responsible	O
for	O
the	O
phenotype	O
of	O
deep	B-Phenotype
trabeculation	E-Phenotype
,	O
dilated	B-Phenotype
cardiomyopathy	E-Phenotype
,	O
and	O
cardiac	B-Phenotype
dysfunction	E-Phenotype
,	O
which	O
resembles	O
the	O
phenotype	O
of	O
LVNC	O

Xenograft	O
pancreatic	B-Phenotype
tumors	E-Phenotype
derived	O
from	O
high	O
B7	O
-	O
H5	O
expression	O
PC	O
cells	O
exhibited	O
attenuated	O
growth	O
compared	O
to	O
tumors	S-Phenotype
from	O
low	O
B7	O
-	O
H5	O
expression	O
cells	O
after	O
transfusion	O
with	O
T	O
lymphocytes	O
in	O
immune	O
-	O
deficient	O
mice	O
.	O

Nuclear	O
respiratory	O
factor	O
1	O
(	O
NRF1	O
)	O
transcription	O
factor	O
has	O
recently	O
been	O
shown	O
to	O
control	O
breast	B-Phenotype
cancer	E-Phenotype
progression	O
.	O

CDCA7	O
,	O
a	O
new	O
member	O
of	O
the	O
cell	O
division	O
cycle	O
associated	O
family	O
of	O
genes	O
,	O
is	O
involved	O
in	O
embryonic	O
development	O
and	O
dysregulated	O
in	O
various	O
types	O
of	O
human	O
cancer	S-Phenotype
.	O

The	O
epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
and	O
mesenchymal	O
-	O
epithelial	O
transition	O
(	O
MET	O
)	O
contribute	O
to	O
cancer	S-Phenotype
metastasis	O
of	O
pancreatic	O
ductal	O
adenocarcinoma	O
(	O
PDAC	O
)	O
.	O

Transcriptomic	O
analysis	O
revealed	O
significant	O
alterations	O
in	O
a	O
number	O
of	O
genes	O
associated	O
with	O
autism	S-Phenotype
,	O
such	O
as	O
adsl	O
,	O
mbd5	O
,	O
shank3	O
,	O
and	O
tsc1b	O
.	O

In	O
case	O
of	O
DLEC1	O
and	O
ITGA9	O
,	O
expression	O
levels	O
were	O
decreased	O
in	O
71	O
-	O
78	O
%	O
of	O
tumor	S-Phenotype
samples	O
and	O
significantly	O
different	O
between	O
tumor	S-Phenotype
and	O
normal	O
tissues	O
(	O
P	O
=	O
0.0001	O
)	O
.	O

Although	O
PABPN1	O
plays	O
a	O
critical	O
role	O
in	O
the	O
regulation	O
of	O
RNA	O
processing	O
,	O
mutation	O
of	O
the	O
gene	O
encoding	O
this	O
ubiquitously	O
expressed	O
RNA	O
binding	O
protein	O
causes	O
a	O
specific	O
form	O
of	O
muscular	B-Phenotype
dystrophy	E-Phenotype
termed	O
oculopharyngeal	B-Phenotype
muscular	I-Phenotype
dystrophy	E-Phenotype
(	O
OPMD	S-Phenotype
)	O
.	O

We	O
analyzed	O
the	O
expression	O
of	O
STX3	O
in	O
148	O
patients	O
with	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

Data	O
on	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
type	O
-	O
specific	O
cervical	B-Phenotype
cancer	E-Phenotype
risk	O
in	O
women	O
living	O
with	O
human	O
immunodeficiency	S-Phenotype
virus	O
(	O
WLHIV	O
)	O
are	O
needed	O
to	O
understand	O
HPV⁻HIV	O
interaction	O
and	O
to	O
inform	O
prevention	O
programs	O
for	O
this	O
population	O
.	O

In	O
summary	O
,	O
our	O
findings	O
underscore	O
the	O
biological	O
significance	O
of	O
MRPL33	O
-	O
L	O
and	O
hnRNPK	O
in	O
the	O
tumor	S-Phenotype
formation	O
and	O
identifies	O
hnRNPK	O
as	O
a	O
critical	O
splicing	O
regulator	O
of	O
MRPL33	O
pre	O
-	O
mRNA	O
in	O
cancer	S-Phenotype
cells	O

Antiepileptic	O
drugs	O
remain	O
the	O
treatment	O
of	O
choice	O
for	O
PKD	O
and	O
episodic	B-Phenotype
ataxia	I-Phenotype
type	I-Phenotype
1	E-Phenotype
,	O
benzodiazepines	O
are	O
often	O
useful	O
for	O
PNKD	O
,	O
and	O
episodic	B-Phenotype
ataxia	I-Phenotype
type	I-Phenotype
2	E-Phenotype
benefits	O
from	O
acetazolamide	O
regardless	O
of	O
the	O
genetic	O
etiology	O

These	O
miRNAs	O
may	O
play	O
a	O
role	O
in	O
pathways	O
previously	O
implicated	O
in	O
glaucoma	S-Phenotype
and	O
act	O
as	O
biomarkers	O
for	O
disease	O
pathogenesis	O

Here	O
we	O
show	O
that	O
the	O
DLX3	O
mutation	O
(	O
c.533	O
AAAAAG	O
;	O
Q178R	O
)	O
attenuates	O
osteogenic	O
potential	O
and	O
senescence	O
of	O
bone	O
mesenchymal	O
stem	O
cells	O
(	O
BMSCs	O
)	O
isolated	O
from	O
a	O
TDO	O
patient	O
,	O
providing	O
a	O
molecular	O
explanation	O
for	O
abnormal	B-Phenotype
increased	I-Phenotype
bone	I-Phenotype
density	E-Phenotype
.	O

Charcot	O
-	O
Marie	O
-	O
Tooth	O
disease	O
type	O
1A	O
(	O
CMT1A	O
)	O
is	O
the	O
most	O
common	O
inherited	B-Phenotype
motor	I-Phenotype
and	I-Phenotype
sensory	I-Phenotype
neuropathy	E-Phenotype
,	O
and	O
is	O
caused	O
by	O
duplication	O
of	O
liPMP22	O
/	O
i	O
,	O
alterations	O
of	O
which	O
are	O
a	O
characteristic	O
feature	O
of	O
demyelination	S-Phenotype
.	O

According	O
to	O
The	O
Cancer	S-Phenotype
Genome	O
Atlas	O
data	O
and	O
our	O
previous	O
RNA	O
-	O
sequencing	O
data	O
,	O
the	O
mRNA	O
expression	O
level	O
of	O
PAIP2B	O
but	O
not	O
NAGK	O
,	O
MCEE	O
or	O
DYSF	O
was	O
significantly	O
lower	O
in	O
pancreatic	B-Phenotype
tumors	E-Phenotype
than	O
in	O
normal	O
adjacent	O
tissues	O
.	O

Similar	O
findings	O
were	O
observed	O
in	O
a	O
patient	O
with	O
chronic	B-Phenotype
hypophosphatemia	E-Phenotype
as	O
a	O
result	O
of	O
a	O
mutation	O
in	O
SLC34A3	O
who	O
had	O
a	O
50	O
%	O
reduction	O
in	O
both	O
serum	O
Pi	O
content	O
and	O
muscle	O
VATP	O
After	O
oral	O
Pi	O
repletion	O
and	O
normalization	O
of	O
serum	O
Pi	O
levels	O
,	O
muscle	O
VATP	O
completely	O
normalized	O
in	O
the	O
patient	O
.	O

16q24	O
deletion	O
involving	O
the	O
ANKRD11	O
gene	O
,	O
ranging	O
from	O
137	O
kb	O
to	O
2	O
Mb	O
,	O
have	O
been	O
associated	O
with	O
a	O
microdeletion	O
syndrome	O
characterized	O
by	O
variable	O
cognitive	B-Phenotype
impairment	E-Phenotype
,	O
autism	B-Phenotype
spectrum	I-Phenotype
disorder	E-Phenotype
,	O
facial	O
dysmorphisms	O
with	O
dental	B-Phenotype
anomalies	E-Phenotype
,	O
brain	O
abnormalities	O
essentially	O
affecting	O
the	O
corpus	B-Phenotype
callosum	E-Phenotype
and	O
short	B-Phenotype
stature	E-Phenotype
.	O

Homozygous	O
Otud6b	O
knockout	O
mice	O
were	O
subviable	O
,	O
smaller	O
in	O
size	O
,	O
and	O
had	O
congenital	B-Phenotype
heart	I-Phenotype
defects	E-Phenotype
,	O
consistent	O
with	O
the	O
severity	O
of	O
loss	O
-	O
of	O
-	O
function	O
variants	O
in	O
humans	O
.	O

Because	O
we	O
had	O
demonstrated	O
that	O
PrKD1	O
is	O
the	O
only	O
known	O
kinase	O
to	O
phosphorylate	O
threonine	O
120	O
(	O
T120	O
)	O
of	O
beta	O
-	O
catenin	O
in	O
prostate	B-Phenotype
cancer	E-Phenotype
resulting	O
in	O
increased	O
nuclear	O
beta	O
-	O
catenin	O
,	O
we	O
explored	O
the	O
role	O
of	O
beta	O
-	O
catenin	O
in	O
gene	O
regulation	O
of	O
liPrKD1	O
.	O

Levels	O
of	O
serum	O
CysC	O
might	O
become	O
elevated	O
regardless	O
of	O
renal	O
function	O
,	O
and	O
CysC	O
-	O
eGFR	O
might	O
become	O
unpredictable	O
during	O
the	O
active	O
phase	O
of	O
tumors	S-Phenotype
.	O

SPG56	O
is	O
a	O
rare	O
autosomal	B-Phenotype
recessive	E-Phenotype
early	O
onset	O
complicated	O
form	O
of	O
HSP	O
caused	O
by	O
mutations	O
in	O
CYP2U1	O
.	O

We	O
find	O
mutually	O
exclusive	O
associations	O
between	O
EECTGs	O
and	O
somatic	O
mutations	O
in	O
mutated	O
genes	O
,	O
such	O
as	O
PIK3CA	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

As	O
a	O
result	O
,	O
we	O
identified	O
one	O
gene	O
set	O
with	O
a	O
joint	O
effect	O
significantly	O
associated	O
with	O
schizophrenia	S-Phenotype
and	O
gene	O
expression	O
profiling	O
analysis	O
suggested	O
that	O
they	O
were	O
mainly	O
neuro	O
-	O
and	O
immune	O
-	O
related	O
genes	O
,	O
such	O
as	O
glutamatergic	O
gene	O
(	O
GRM5	O
)	O
,	O
GABAergic	O
genes	O
(	O
GABRB1	O
,	O
GABARAP	O
)	O
and	O
genes	O
located	O
in	O
the	O
MHC	O
region	O
(	O
HLA	O
-	O
C	O
,	O
TAP2	O
,	O
HIST1H1B	O
)	O
.	O

Machine	O
learning	O
search	O
further	O
revealed	O
that	O
the	O
likelihood	O
of	O
HER2	O
-	O
positive	O
breast	B-Phenotype
cancer	E-Phenotype
is	O
almost	O
100	O
%	O
in	O
a	O
patient	O
with	O
the	O
high	O
NRF1	O
expression	O
combined	O
with	O
expression	O
patterns	O
of	O
high	O
E2F3	O
,	O
GSK3B	O
,	O
and	O
MAPK1	O
,	O
low	O
or	O
no	O
change	O
in	O
E2F1	O
and	O
FGFR1	O
,	O
and	O
high	O
or	O
no	O
change	O
in	O
PIK3R3	O
.	O

Homozygous	O
Otud6b	O
knockout	O
mice	O
were	O
subviable	O
,	O
smaller	O
in	O
size	O
,	O
and	O
had	O
congenital	B-Phenotype
heart	I-Phenotype
defects	E-Phenotype
,	O
consistent	O
with	O
the	O
severity	O
of	O
loss	O
-	O
of	O
-	O
function	O
variants	O
in	O
humans	O
.	O

Haploinsufficiency	O
of	O
the	O
chromatin	O
remodeling	O
factor	O
ARID1B	O
leads	O
to	O
autism	B-Phenotype
spectrum	I-Phenotype
disorder	E-Phenotype
and	O
intellectual	B-Phenotype
disability	E-Phenotype
.	O

Here	O
,	O
we	O
report	O
that	O
the	O
expression	O
of	O
microRNA	O
-	O
493	O
(	O
miR	O
-	O
493	O
)	O
is	O
decreased	O
in	O
HCC	O
cell	O
lines	O
and	O
in	O
tumor	S-Phenotype
tissues	O
.	O

Craniofrontonasal	O
syndrome	O
(	O
CFNS	O
)	O
is	O
a	O
very	O
rare	O
genetic	O
disorder	O
with	O
variable	O
clinical	O
phenotypes	O
,	O
including	O
brachycephaly	S-Phenotype
,	O
hypertelorism	S-Phenotype
,	O
and	O
a	O
bifid	B-Phenotype
nasal	I-Phenotype
tip	E-Phenotype
.	O

This	O
review	O
reflects	O
the	O
existing	O
Eph	O
/	O
ephrin	O
literature	O
while	O
focusing	O
on	O
breast	B-Phenotype
cancer	E-Phenotype
heterogeneity	S-Phenotype
.	O

Our	O
observations	O
implicate	O
TASK	O
-	O
3	O
as	O
a	O
critical	O
factor	O
in	O
cell	O
cycle	O
progression	O
and	O
corroborate	O
its	O
potential	O
as	O
a	O
therapeutic	O
target	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
treatment	O

In	O
addition	O
,	O
we	O
investigated	O
the	O
impact	O
of	O
proofreading	O
capabilities	O
of	O
different	O
DNA	O
polymerases	O
on	O
ASXL1	O
c.1934dupG	O
somatic	B-Phenotype
mutation	E-Phenotype
using	O
conventional	O
Sanger	O
sequencing	O
,	O
another	O
common	O
method	O
for	O
ASXL1	O
genotyping	O
.	O

Furthermore	O
,	O
PEPCK	O
-	O
M	O
silencing	O
abrogated	O
cancer	S-Phenotype
growth	O
in	O
a	O
lung	B-Phenotype
cancer	E-Phenotype
cell	O
xenograft	O
model	O
.	O

The	O
high	O
LD	O
SNPs	O
(	O
rs143975731	O
,	O
rs12277366	O
,	O
rs2155225	O
,	O
and	O
rs2155222	O
)	O
were	O
associated	O
with	O
DGAT2	O
expression	O
in	O
both	O
tumors	S-Phenotype
sets	O
(	O
screening	O
P	O
=	O
0.035	O
-	O
0.043	O
;	O
validation	O
P	O
=	O
0.005	O
-	O
0.018	O
)	O
.	O

Spinocerebellar	B-Phenotype
ataxia	I-Phenotype
type	I-Phenotype
35	E-Phenotype
(	O
SCA35	S-Phenotype
)	O
is	O
a	O
rare	O
autosomal	B-Phenotype
-	I-Phenotype
dominant	I-Phenotype
neurodegenerative	I-Phenotype
disease	E-Phenotype
caused	O
by	O
mutations	O
in	O
the	O
TGM6	O
gene	O
,	O
which	O
codes	O
for	O
transglutaminase	O
6	O
(	O
TG6	O
)	O
.	O

Prostate	B-Phenotype
cancer	E-Phenotype
is	O
the	O
most	O
common	O
cancer	S-Phenotype
among	O
western	O
men	O
,	O
with	O
a	O
significant	O
mortality	O
and	O
morbidity	O
reported	O
for	O
advanced	O
metastatic	O
disease	O
.	O

Blood	O
and	O
tissue	O
samples	O
from	O
48	O
osteosarcoma	S-Phenotype
patients	O
were	O
obtained	O
,	O
and	O
the	O
following	O
polymorphisms	O
were	O
analyzed	O
;	O
SLC19A1	O
80GAAAAA	O
,	O
DHFR	O
829CAAAAT	O
,	O
MTHFR	O
677CAAAAT	O
,	O
MTHFR	O
1298AAAAAC	O
,	O
and	O
ATIC	O
347CAAAAG	O
.	O

iBackground	O
:	O
/	O
i	O
YAP	O
/	O
TAZ	O
have	O
been	O
reported	O
to	O
be	O
highly	O
expressed	O
in	O
malignant	O
tumors	S-Phenotype
.	O

Disrupting	O
the	O
CBX3	O
-	O
FBP1	O
signaling	O
axis	O
would	O
be	O
effective	O
to	O
treat	O
pancreatic	B-Phenotype
cancer	E-Phenotype
and	O
prevent	O
aerobic	O
glycolysis	O

Among	O
these	O
genes	O
,	O
mutations	O
in	O
VCP	O
gene	O
involve	O
in	O
inclusion	O
body	O
myopathy	S-Phenotype
with	O
Paget	O
disease	O
of	O
bone	B-Phenotype
and	I-Phenotype
frontotemporal	I-Phenotype
dementia	E-Phenotype
(	O
IBMPFD	O
)	O
,	O
familial	B-Phenotype
amyotrophic	I-Phenotype
lateral	I-Phenotype
sclerosis	E-Phenotype
(	O
ALS	S-Phenotype
)	O
,	O
autism	B-Phenotype
spectrum	I-Phenotype
disorders	E-Phenotype
(	O
ASD	S-Phenotype
)	O
,	O
and	O
hereditary	B-Phenotype
spastic	I-Phenotype
paraplegia	E-Phenotype
(	O
HSP	S-Phenotype
)	O
.	O

The	O
downregulated	O
expression	O
of	O
miR	O
-	O
3175	O
inhibited	O
cell	O
proliferation	O
and	O
invasion	O
,	O
and	O
promoted	O
apoptosis	O
in	O
glioma	S-Phenotype
.	O

Strikingly	O
,	O
SPINK1	O
reprograms	O
the	O
expression	O
profile	O
of	O
cancer	S-Phenotype
cells	O
,	O
causing	O
prominent	O
epithelial	O
-	O
endothelial	O
transition	O
(	O
EET	O
)	O
,	O
a	O
phenotypic	O
switch	O
mediated	O
by	O
EGFR	O
signaling	O
but	O
hitherto	O
rarely	O
reported	O
for	O
a	O
SASP	O
factor	O
.	O

Importantly	O
,	O
extreme	O
limiting	O
dilution	O
analysis	O
revealed	O
that	O
even	O
1	O
×	O
10sup2	O
/	O
sup	O
ZNF687	O
-	O
transduced	O
cells	O
could	O
form	O
tumors	S-Phenotype
in	O
vivo	O
,	O
indicating	O
that	O
ZNF687	O
contributes	O
to	O
HCC	O
recurrence	O
.	O

This	O
review	O
highlights	O
recent	O
advances	O
in	O
our	O
understanding	O
of	O
regulatory	O
insights	O
involving	O
YY1	O
function	O
in	O
a	O
range	O
of	O
cancer	S-Phenotype
types	O
.	O

Marden	O
-	O
Walker	O
syndrome	O
is	O
challenging	O
to	O
diagnose	O
,	O
as	O
there	O
is	O
significant	O
overlap	O
with	O
other	O
multi	O
-	O
system	O
congenital	B-Phenotype
contracture	E-Phenotype
syndromes	O
including	O
Beals	O
congenital	O
contractural	O
arachnodactyly	S-Phenotype
,	O
D4ST1	O
-	O
Deficient	O
Ehlers	O
-	O
Danlos	O
syndrome	O
(	O
adducted	B-Phenotype
thumb	I-Phenotype
-	I-Phenotype
clubfoot	E-Phenotype
syndrome	O
)	O
,	O
Schwartz	O
-	O
Jampel	O
syndrome	O
,	O
Freeman	O
-	O
Sheldon	O
syndrome	O
,	O
Cerebro	O
-	O
oculo	O
-	O
facio	O
-	O
skeletal	O
syndrome	O
,	O
and	O
Van	O
den	O
Ende	O
-	O
Gupta	O
syndrome	O
.	O

MSX2	O
might	O
be	O
a	O
new	O
drug	B-Phenotype
resistance	E-Phenotype
related	O
gene	O
in	O
pancreatic	B-Phenotype
cancer	E-Phenotype
cells	O
by	O
up	O
-	O
regulation	O
of	O
MRP2	O
expression	O

The	O
immunohistochemical	O
expression	O
of	O
L1CAM	O
in	O
corresponding	O
tissue	O
was	O
significantly	O
higher	O
in	O
metastases	O
than	O
in	O
glioblastomas	S-Phenotype
.	O

The	O
present	O
study	O
demonstrates	O
high	O
levels	O
of	O
L1CAM	O
in	O
cyst	O
fluid	O
of	O
glioblastoma	S-Phenotype
and	O
metastatic	O
brain	B-Phenotype
tumors	E-Phenotype
.	O

ARHGEF9	O
alterations	O
,	O
some	O
inherited	O
from	O
unaffected	O
mothers	O
,	O
have	O
been	O
reported	O
in	O
males	O
with	O
autism	S-Phenotype
,	O
seizures	S-Phenotype
and	O
severe	O
neurodevelopmental	B-Phenotype
abnormalities	E-Phenotype
.	O

The	O
major	O
allele	O
of	O
SNP	O
rs3173615	O
is	O
a	O
risk	O
factor	O
in	O
sporadic	S-Phenotype
FTD	O
,	O
whereas	O
the	O
minor	O
allele	O
seems	O
protective	O
in	O
GRN	O
-	O
and	O
C9orf72	O
-	O
mediated	O
FTD	O
.	O

This	O
case	O
of	O
malonic	B-Phenotype
aciduria	E-Phenotype
with	O
cardiomyopathy	S-Phenotype
demonstrates	O
improvement	O
in	O
cardiac	O
function	O
attributable	O
to	O
LCT	O
-	O
restricted	O
/	O
MCT	O
-	O
supplemented	O
diet	O

In	O
a	O
screen	O
of	O
pancreatic	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
,	O
AsPC	O
-	O
1	O
and	O
BxPC	O
-	O
3	O
cells	O
expressed	O
high	O
levels	O
of	O
Gremlin	O
1	O
,	O
but	O
only	O
AsPC	O
-	O
1	O
cells	O
exhibited	O
a	O
high	O
expression	O
level	O
of	O
SHH	O
.	O

Genes	O
with	O
DMRs	O
were	O
involved	O
in	O
inflammatory	O
response	O
(	O
IRAK4	O
and	O
ESM1	O
)	O
,	O
cancer	S-Phenotype
(	O
BRCA1	O
and	O
LASP1	O
)	O
,	O
endocrine	O
function	O
(	O
CNPY1	O
)	O
,	O
and	O
male	O
fertility	O
(	O
IFT140	O
,	O
TESC	O
,	O
and	O
PRDM8	O
)	O
.	O

Clinical	O
features	O
of	O
affected	O
individuals	O
with	O
LGD	O
variants	O
in	O
NAA15	O
include	O
variable	O
levels	O
of	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
delayed	B-Phenotype
speech	E-Phenotype
and	O
motor	O
milestones	O
,	O
and	O
autism	B-Phenotype
spectrum	I-Phenotype
disorder	E-Phenotype
.	O

Protein	O
kinase	O
A	O
(	O
PKA	O
)	O
signaling	O
pathway	O
including	O
AKAP12	O
,	O
RDX	O
,	O
and	O
RAB13	O
genes	O
were	O
identified	O
as	O
potential	O
mechanisms	O
for	O
the	O
activity	O
of	O
garlic	O
extract	O
in	O
cancer	S-Phenotype
prevention	O
.	O

This	O
review	O
highlights	O
recent	O
advances	O
in	O
understanding	O
how	O
the	O
OVOL1	O
-	O
OVOL2	O
axis	O
modulates	O
cell	O
differentiation	O
and	O
proliferation	O
in	O
human	O
keratinocytes	O
,	O
hair	O
follicles	O
,	O
and	O
benign	O
or	O
malignant	O
skin	B-Phenotype
tumors	E-Phenotype
including	O
squamous	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
and	O
malignant	B-Phenotype
melanoma	E-Phenotype
.	O

Furthermore	O
,	O
the	O
growth	O
of	O
cervical	B-Phenotype
cancer	E-Phenotype
xenografts	O
was	O
significantly	O
inhibited	O
by	O
either	O
SIRT1	O
-	O
targeting	O
siRNAs	O
or	O
SIRT1	O
-	O
knockdown	O
-	O
derived	O
extracellular	O
vesicles	O
.	O

Similar	O
findings	O
were	O
observed	O
in	O
a	O
patient	O
with	O
chronic	B-Phenotype
hypophosphatemia	E-Phenotype
as	O
a	O
result	O
of	O
a	O
mutation	O
in	O
SLC34A3	O
who	O
had	O
a	O
50	O
%	O
reduction	O
in	O
both	O
serum	O
Pi	O
content	O
and	O
muscle	O
VATP	O
After	O
oral	O
Pi	O
repletion	O
and	O
normalization	O
of	O
serum	O
Pi	O
levels	O
,	O
muscle	O
VATP	O
completely	O
normalized	O
in	O
the	O
patient	O
.	O

Fat	O
mass	O
and	O
obesity	S-Phenotype
-	O
associated	O
protein	O
(	O
FTO	O
)	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
have	O
been	O
linked	O
to	O
increased	O
body	O
mass	O
and	O
obesity	S-Phenotype
in	O
humans	O
by	O
genome	O
-	O
wide	O
association	O
studies	O
(	O
GWAS	O
)	O
since	O
2007	O
.	O

Univariate	O
(	O
Pearson	O
Chi	O
-	O
squared	O
test	O
,	O
Fisher	O
exact	O
test	O
,	O
T	O
test	O
,	O
Wilcoxon	O
rank	O
sum	O
test	O
,	O
logistic	O
regression	O
)	O
statistics	O
and	O
stepwise	O
multivariate	O
logistic	O
regression	O
were	O
used	O
to	O
identify	O
factors	O
associated	O
with	O
PFH	O
in	O
the	O
analysis O
.	O

Among	O
young	O
patients	O
with	O
EC	O
,	O
the	O
PFH	O
group	O
had	O
younger	O
age	O
-	O
of	O
-	O
onset	O
age	O
of	O
endometrial	B-Phenotype
cancer	E-Phenotype
(	O
≤40	O
years	O
)	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
=	O
2.21	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
95	O
%	O
CI	O
]	O
:	O
1.01	O
-	O
4.82	O
)	O
than	O
the	O
NFH	O
group	O
.	O

We	O
performed	O
whole	O
-	O
exome	O
sequencing	O
on	O
a	O
12	O
-	O
year	O
-	O
old	O
Japanese	O
male	O
with	O
severe	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
congenital	B-Phenotype
bilateral	I-Phenotype
cataracts	E-Phenotype
,	O
spasticity	S-Phenotype
,	O
hypotonia	S-Phenotype
with	O
motor	B-Phenotype
regression	E-Phenotype
and	O
progressive	O
cerebellar	B-Phenotype
atrophy	E-Phenotype
with	O
hyperintensity	O
of	O
the	O
cerebellar	O
cortex	O
on	O
T2	O
-	O
weighted	O
images	O
.	O

By	O
comparing	O
these	O
two	O
additional	O
cases	O
with	O
those	O
previously	O
reported	O
,	O
we	O
strengthen	O
the	O
key	O
features	O
of	O
AS	O
:	O
severe	O
growth	O
restriction	O
,	O
severe	O
intellectual	B-Phenotype
disability	E-Phenotype
and	O
some	O
distinguishing	O
facial	O
features	O
such	O
as	O
broad	B-Phenotype
nose	E-Phenotype
,	O
malar	B-Phenotype
hypoplasia	E-Phenotype
,	O
wide	B-Phenotype
mouth	E-Phenotype
,	O
full	B-Phenotype
lips	E-Phenotype
and	O
abnormally	B-Phenotype
set	I-Phenotype
teeth	E-Phenotype
.	O

Hyperekplexia	S-Phenotype
or	O
startle	O
disease	O
is	O
characterized	O
by	O
an	O
exaggerated	B-Phenotype
startle	I-Phenotype
response	E-Phenotype
,	O
evoked	O
by	O
tactile	O
or	O
auditory	O
stimuli	O
,	O
producing	O
hypertonia	S-Phenotype
and	O
apnea	B-Phenotype
episodes	E-Phenotype
.	O

Genetic	O
sequencing	O
confirmed	O
a	O
homozygous	O
R565Q	O
missense	O
mutation	O
in	O
the	O
catalytic	O
domain	O
of	O
PDE6C	O
,	O
a	O
cone	O
-	O
specific	O
phototransduction	O
enzyme	O
associated	O
with	O
achromatopsia	S-Phenotype
in	O
humans	O
.	O

Here	O
,	O
we	O
report	O
that	O
PEPCK	O
-	O
M	O
-	O
dependent	O
glycerol	O
phosphate	O
formation	O
from	O
noncarbohydrate	O
precursors	O
(	O
glyceroneogenesis	O
)	O
occurs	O
in	O
starved	O
lung	B-Phenotype
cancer	E-Phenotype
cells	O
and	O
supports	O
de	O
novo	O
glycerophospholipid	O
synthesis	O
.	O

We	O
present	O
two	O
families	O
with	O
CCDC88C	O
-	O
related	O
recessive	O
congenital	O
hydrocephalus	S-Phenotype
with	O
children	O
who	O
had	O
severe	B-Phenotype
hydrocephalus	E-Phenotype
.	O

MicroRNA	O
-	O
9	O
(	O
miR	O
-	O
9	O
)	O
dysregulation	O
is	O
implicated	O
in	O
a	O
variety	O
of	O
human	O
malignancies	O
including	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
,	O
but	O
its	O
role	O
remains	O
contradictory	O
.	O

In	O
humans	O
,	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
of	O
KCNJ10	O
,	O
which	O
encodes	O
the	O
inward	O
-	O
rectifying	O
potassium	O
channel	O
KIR4.1	O
,	O
causes	O
seizures	S-Phenotype
and	O
progressive	O
neurological	O
decline	O
.	O

Nagashima	B-Phenotype
-	I-Phenotype
type	I-Phenotype
palmoplantar	I-Phenotype
keratosis	E-Phenotype
(	O
NPPK	S-Phenotype
)	O
is	O
an	O
autosomal	O
recessive	O
skin	O
disorder	O
with	O
a	O
high	O
,	O
unmet	O
medical	O
need	O
that	O
is	O
caused	O
by	O
mutations	O
in	O
SERPINB7	O
.	O

Objective	O
:	O
To	O
explore	O
the	O
expression	O
of	O
long	O
noncoding	O
RNA	O
(	O
lncRNA	O
)	O
HOXA11	O
-	O
AS	O
in	O
esophageal	B-Phenotype
squamous	I-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
tissues	O
and	O
the	O
relationship	O
of	O
HOXA11	O
-	O
AS	O
level	O
with	O
clinical	O
outcomes	O
.	O

Since	O
excessive	O
ingestion	O
of	O
vitamin	O
A	O
is	O
known	O
to	O
induce	O
spontaneous	B-Phenotype
fractures	E-Phenotype
and	O
as	O
the	O
Vegfa	O
-	O
induced	O
femur	O
angulation	O
in	O
mice	O
appears	O
to	O
be	O
caused	O
by	O
intrauterine	O
fractures	O
,	O
we	O
analyzed	O
bones	O
from	O
a	O
CYP26B1	O
deficient	O
human	O
and	O
rats	O
with	O
hypervitaminosis	O
A	O
to	O
further	O
explore	O
Vegfa	O
as	O
a	O
mechanistic	O
link	O
for	O
the	O
effect	O
of	O
vitamin	O
A	O
on	O
bone	O
.	O

The	O
present	O
study	O
indicated	O
that	O
the	O
mislocalization	O
of	O
these	O
proteins	O
of	O
NPCs	O
may	O
underlie	O
the	O
pathogenesis	O
of	O
ALS	O
both	O
in	O
SOD1	O
-	O
Tg	O
mice	O
and	O
human	O
sporadic	S-Phenotype
ALS	O
patients	O
,	O
and	O
these	O
dysfunctions	O
may	O
be	O
a	O
fundamental	O
pathway	O
for	O
ALS	O
that	O
is	O
not	O
specific	O
only	O
in	O
C9	O
-	O
ALS	O
but	O
also	O
in	O
SOD1	O
-	O
ALS	O
,	O
which	O
may	O
be	O
amenable	O
to	O
pharmacotherapeutic	O
intervention	O

Age	B-Phenotype
-	I-Phenotype
related	I-Phenotype
hearing	I-Phenotype
impairment	E-Phenotype
(	O
ARHI	S-Phenotype
)	O
,	O
one	O
of	O
the	O
most	O
common	O
sensory	O
disorders	O
,	O
can	O
be	O
mitigated	O
,	O
but	O
not	O
cured	O
or	O
eliminated	O
.	O

MAX	O
which	O
was	O
involved	O
in	O
small	B-Phenotype
cell	I-Phenotype
lung	I-Phenotype
cancer	E-Phenotype
pathway	O
was	O
a	O
hub	O
gene	O
unique	O
to	O
T2D	O
(	O
OR=1.2	O
,	O
P=0.006	O
)	O
but	O
not	O
in	O
CAD	O
.	O

In	O
this	O
research	O
,	O
we	O
discovered	O
that	O
FEZF1	O
was	O
significantly	O
increased	O
in	O
glioma	S-Phenotype
tissues	O
in	O
contrast	O
to	O
normal	O
brain	O
tissues	O
(	O
NBTs	O
;	O
P	O
AAAA	O
0.05	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
the	O
expression	O
of	O
GFAT1	O
was	O
increased	O
in	O
pancreatic	B-Phenotype
cancer	E-Phenotype
samples	O
compared	O
to	O
peri	O
-	O
tumor	S-Phenotype
tissues	O
.	O

Moreover	O
,	O
adeno	O
-	O
associated	O
virus	O
-	O
mediated	O
exogenous	O
expression	O
of	O
several	O
MTMR2	O
isoforms	O
ameliorates	O
the	O
myopathic	O
phenotype	O
owing	O
to	O
MTM1	O
loss	O
,	O
with	O
increased	O
muscle	O
force	O
,	O
reduced	O
myofiber	O
atrophy	O
,	O
and	O
reduction	O
of	O
the	O
intracellular	O
disorganization	O
hallmarks	O
associated	O
with	O
myotubular	B-Phenotype
myopathy	E-Phenotype
.	O

One	O
of	O
the	O
mechanisms	O
of	O
the	O
growth	O
inhibitory	O
effect	O
is	O
probably	O
that	O
S1PR2	O
inhibition	O
lower	O
the	O
phosphorylation	O
level	O
of	O
extracellular	O
regulated	O
protein	O
kinase	O
1	O
/	O
2	O
(	O
ERK1	O
/	O
2	O
)	O
pathway	O
,	O
which	O
prevent	O
the	O
transformation	O
of	O
ovarian	B-Phenotype
cancer	E-Phenotype
cells	O
from	O
phase	O
G	O
(	O
1	O
)	O
to	O
S	O

myocilin	O
(	O
MYOC	O
)	O
,	O
optineurin	O
(	O
OPTN	O
)	O
,	O
WDR36	O
and	O
neurotrophin	O
-	O
4	O
(	O
NTF4	O
)	O
in	O
primary	B-Phenotype
open	I-Phenotype
angle	I-Phenotype
glaucoma	E-Phenotype
(	O
POAG	S-Phenotype
)	O
and	O
CYP1B1	O
and	O
LTBP2	O
in	O
congenital	B-Phenotype
and	I-Phenotype
developmental	I-Phenotype
glaucomas	E-Phenotype
.	O

PhIP	B-Phenotype
-	I-Phenotype
induced	I-Phenotype
skin	I-Phenotype
tumors	E-Phenotype
were	O
subjected	O
to	O
mutation	O
screening	O
,	O
which	O
identified	O
genetic	O
changes	O
in	O
Hras	O
(	O
7	O
/	O
40	O
,	O
17.5	O
%	O
)	O
and	O
Tp53	O
(	O
2	O
/	O
40	O
,	O
5	O
%	O
)	O
,	O
but	O
not	O
in	O
Ctnnb1	O
,	O
a	O
commonly	O
mutated	O
gene	O
in	O
PhIP	B-Phenotype
-	I-Phenotype
induced	I-Phenotype
colon	I-Phenotype
tumors	E-Phenotype
.	O

However	O
,	O
the	O
currently	O
limited	O
knowledge	O
on	O
CPLX1	O
suggests	O
that	O
loss	O
of	O
complexin	O
1	O
function	O
may	O
lead	O
to	O
a	O
complex	O
but	O
variable	O
clinical	O
phenotype	O
,	O
and	O
our	O
findings	O
encourage	O
further	O
investigations	O
of	O
CPLX1	O
in	O
patients	O
with	O
ID	S-Phenotype
,	O
developmental	B-Phenotype
delay	E-Phenotype
and	O
myoclonic	B-Phenotype
epilepsy	E-Phenotype
to	O
unravel	O
the	O
phenotypic	O
spectrum	O
of	O
carriers	O
of	O
CPLX1	O
variants	O

Our	O
data	O
support	O
that	O
high	O
-	O
grade	O
progression	O
in	O
PanNETs	O
may	O
be	O
the	O
result	O
of	O
the	O
progressive	O
accumulation	O
of	O
genetic	O
changes	O
(	O
CNVs	O
and	O
point	O
mutational	O
changes	O
)	O
within	O
the	O
body	O
of	O
the	O
tumor	S-Phenotype
.	O

These	O
data	O
may	O
improve	O
our	O
understanding	O
of	O
the	O
role	O
of	O
CUL7	O
in	O
tumors	S-Phenotype
and	O
provide	O
supporting	O
evidence	O
for	O
the	O
development	O
of	O
novel	O
therapeutic	O
targets	O
for	O
EC	O

These	O
results	O
provide	O
new	O
insights	O
on	O
the	O
biological	O
relevance	O
of	O
the	O
mTOR	O
pathway	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
progression	O
and	O
underscore	O
the	O
need	O
for	O
more	O
genetic	O
epidemiology	O
studies	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
in	O
the	O
African	O
Diaspora	O

Leber	B-Phenotype
hereditary	I-Phenotype
optic	I-Phenotype
neuropathy	E-Phenotype
(	O
LHON	S-Phenotype
)	O
and	O
dominant	B-Phenotype
optic	I-Phenotype
atrophy	E-Phenotype
(	O
DOA	S-Phenotype
)	O
,	O
the	O
most	O
common	O
forms	O
of	O
hereditary	B-Phenotype
optic	I-Phenotype
neuropathy	E-Phenotype
,	O
are	O
easily	B-Phenotype
confused	E-Phenotype
,	O
and	O
it	O
is	O
difficult	O
to	O
distinguish	O
one	O
from	O
the	O
other	O
in	O
the	O
clinic	O
,	O
especially	O
in	O
young	O
children	O
.	O

BMPR1B	O
is	O
known	O
to	O
be	O
responsible	O
for	O
autosomal	B-Phenotype
dominant	I-Phenotype
brachydactyly	E-Phenotype
and	O
autosomal	B-Phenotype
recessive	I-Phenotype
acromesomelic	I-Phenotype
chondrodysplasia	E-Phenotype
.	O

Here	O
,	O
we	O
investigated	O
whether	O
synonymous	O
changes	O
could	O
affect	O
expression	O
of	O
the	O
potassium	O
voltage	O
-	O
gated	O
channel	O
subfamily	O
H	O
member	O
2	O
(	O
liKCNH2	O
/	O
i	O
)	O
gene	O
,	O
encoding	O
the	O
human	O
ether	O
-	O
a	O
-	O
go	O
-	O
go	O
-	O
related	O
gene	O
(	O
hERG	O
)	O
ion	O
channel	O
,	O
which	O
is	O
linked	O
to	O
hereditary	B-Phenotype
cardiac	I-Phenotype
arrhythmia	E-Phenotype
.	O

A	O
prognostication	O
scoring	O
system	O
was	O
established	O
based	O
on	O
the	O
expression	O
levels	O
of	O
RNASEH2A	O
-	O
,	O
CDK1	O
-	O
,	O
and	O
CD151	O
-	O
related	O
genes	O
,	O
which	O
could	O
effectively	O
predict	O
the	O
overall	O
survival	O
in	O
a	O
TCGA	O
clear	O
cell	O
RCC	O
cohort	O
(	O
n	O
=	O
533	O
,	O
995.3	O
versus	O
2242.2	O
days	O
,	O
p	O
AAAA	O
0.0001	O
)	O
,	O
in	O
another	O
clear	B-Phenotype
cell	I-Phenotype
renal	I-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
ccRCC	S-Phenotype
)	O
cohort	O
E	O
-	O
GEOD	O
-	O
22541	O
(	O
n	O
=	O
44	O
,	O
390.0	O
versus	O
1889.2	O
days	O
,	O
p	O
=	O
0.0007	O
)	O
,	O
and	O
in	O
a	O
TCGA	O
papillary	O
RCC	O
(	O
pRCC	O
)	O
cohort	O
(	O
n	O
=	O
287	O
,	O
741.6	O
versus	O
1623.7	O
days	O
,	O
p	O
AAAA	O
0.0001	O
)	O
.	O

After	O
a	O
rapid	O
overview	O
of	O
current	O
knowledge	O
regarding	O
somatic	O
genomic	O
alterations	O
,	O
this	O
state	O
-	O
of	O
-	O
art	O
addresses	O
pathways	O
to	O
improve	O
small	B-Phenotype
-	I-Phenotype
cell	I-Phenotype
lung	I-Phenotype
cancer	E-Phenotype
outcome	O
such	O
as	O
the	O
targeting	O
of	O
DNA	O
damage	O
repair	O
mechanisms	O
firstly	O
anti	O
-	O
PARPs	O
,	O
inhibitory	O
molecules	O
of	O
EZH2	O
,	O
derepression	O
of	O
the	O
NOTCH	O
pathway	O
,	O
rovalbituzumab	O
-	O
tesirine	O
,	O
inhibition	O
of	O
serine	O
/	O
threonine	O
Aurora	O
A	O
kinase	O
,	O
temozolomide	O
and	O
its	O
dependence	O
on	O
methylation	O
of	O
the	O
MGMT	O
promoter	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
the	O
activities	O
of	O
Notch	O
signaling	O
were	O
elevated	O
,	O
while	O
HepaCAM	O
expression	O
was	O
decreased	O
in	O
CRPC	O
tissues	O
compared	O
with	O
matched	O
primary	B-Phenotype
prostate	I-Phenotype
cancer	E-Phenotype
(	O
PPC	S-Phenotype
)	O
tissues	O
.	O

Two	O
sisters	O
with	O
c.137TAAAAC	O
(	O
p.Leu46Pro	O
)	O
PIGY	O
variants	O
had	O
multi	O
-	O
system	O
disease	O
including	O
dysmorphism	S-Phenotype
,	O
seizures	S-Phenotype
,	O
severe	O
developmental	B-Phenotype
delay	E-Phenotype
,	O
cataracts	S-Phenotype
and	O
early	B-Phenotype
death	E-Phenotype
.	O

We	O
obtained	O
cryo	O
-	O
electron	O
microscopy	O
structures	O
of	O
an	O
activated	O
filament	O
that	O
is	O
allosterically	O
induced	O
by	O
citrate	O
(	O
ACC	O
-	O
citrate	O
)	O
,	O
and	O
an	O
inactivated	O
filament	O
form	O
that	O
results	O
from	O
binding	O
of	O
the	O
BRCT	O
domains	O
of	O
the	O
breast	B-Phenotype
cancer	E-Phenotype
type	O
1	O
susceptibility	O
protein	O
(	O
BRCA1	O
)	O
.	O

The	O
results	O
indicated	O
that	O
compared	O
with	O
the	O
adjacent	O
non	O
-	O
tumor	S-Phenotype
tissues	O
and	O
a	O
normal	O
gastric	O
epithelial	O
cell	O
line	O
,	O
gastric	B-Phenotype
cancer	E-Phenotype
tissues	O
and	O
cell	O
lines	O
exhibited	O
significantly	O
higher	O
expression	O
of	O
CUL4B	O
.	O

Fuchs	B-Phenotype
endothelial	I-Phenotype
corneal	I-Phenotype
dystrophy	E-Phenotype
(	O
FECD	S-Phenotype
)	O
is	O
the	O
most	O
common	O
late	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
,	I-Phenotype
vision	I-Phenotype
-	I-Phenotype
threatening	I-Phenotype
corneal	I-Phenotype
dystrophy	E-Phenotype
in	O
the	O
United	O
States	O
,	O
affecting	O
about	O
4	O
%	O
of	O
the	O
population	O
.	O

iLCAM1	O
/	O
i	O
and	O
liMPDZ	O
/	O
i	O
(	O
liMUPP1	O
/	O
i	O
)	O
are	O
the	O
only	O
known	O
human	O
gene	O
loci	O
associated	O
with	O
non	O
-	O
syndromic	O
hydrocephalus	S-Phenotype
.	O

Therefore	O
,	O
our	O
findings	O
demonstrate	O
that	O
Hoxc13	O
-	O
/	O
-	O
rabbits	O
can	O
be	O
used	O
as	O
a	O
model	O
for	O
human	O
ECTD	O
-	O
9	O
,	O
especially	O
to	O
understand	O
the	O
pathologic	O
mechanism	O
of	O
hypotrichosis	S-Phenotype
.	O

We	O
further	O
identify	O
small	O
molecules	O
that	O
covalently	O
target	O
a	O
conserved	O
cysteine	O
within	O
the	O
NR0B1	O
protein	O
interaction	O
domain	O
,	O
and	O
we	O
demonstrate	O
that	O
these	O
compounds	O
disrupt	O
NR0B1	O
complexes	O
and	O
impair	O
the	O
anchorage	O
-	O
independent	O
growth	O
of	O
KEAP1	O
-	O
mutant	O
cancer	S-Phenotype
cells	O
.	O

CONCLUSIONS	O
The	O
Lin28A	O
/	O
let	O
-	O
7a	O
/	O
c	O
-	O
Myc	O
pathway	O
is	O
involved	O
in	O
cancer	S-Phenotype
growth	O
and	O
malignant	O
behavior	O
in	O
PTC	O
and	O
is	O
a	O
potential	O
target	O
for	O
therapeutic	O
intervention	O
in	O
this	O
disease	O

Ptrh2	O
levels	O
were	O
up	O
-	O
regulated	O
in	O
dystrophin	O
deficient	O
mdx	O
muscle	O
,	O
which	O
correlates	O
with	O
the	O
elevated	O
levels	O
of	O
the	O
α7β1	O
integrin	O
observed	O
in	O
mdx	O
muscle	O
and	O
Duchenne	O
muscular	B-Phenotype
dystrophy	E-Phenotype
patients	O
.	O

iCHRM3	O
/	O
i	O
is	O
located	O
at	O
1q42	O
-	O
43	O
which	O
was	O
reported	O
to	O
associate	O
with	O
bladder	B-Phenotype
cancer	E-Phenotype
.	O

Adoptive	O
transfer	O
of	O
CAM	O
-	O
treated	O
CD11b+Gr	O
-	O
1+	O
cells	O
protected	O
mice	O
from	O
post	B-Phenotype
-	I-Phenotype
influenza	I-Phenotype
pneumococcal	I-Phenotype
pneumonia	E-Phenotype
.	O

We	O
measured	O
the	O
mRNA	O
expression	O
of	O
PGC	O
-	O
1α	O
and	O
these	O
transcripts	O
in	O
postmortem	O
cortical	O
tissue	O
from	O
control	O
and	O
schizophrenia	S-Phenotype
patients	O
and	O
found	O
a	O
reduction	O
in	O
PGC	O
-	O
1α	O
-	O
dependent	O
transcripts	O
without	O
a	O
change	O
in	O
PGC	O
-	O
1α	O
.	O

Survival	O
analyses	O
showed	O
that	O
high	O
KRT5	O
mRNA	O
in	O
stage	O
III	O
/	O
IV	O
serous	O
ovarian	B-Phenotype
cancers	E-Phenotype
was	O
significantly	O
associated	O
with	O
reduced	O
progression	O
-	O
free	O
(	O
HR	O
1.38	O
,	O
P	O
AAAA	O
0.0001	O
)	O
and	O
overall	O
survival	O
(	O
HR	O
1.28	O
,	O
P	O
=	O
0.013	O
)	O
whilst	O
high	O
KRT6	O
mRNA	O
was	O
only	O
associated	O
with	O
reduced	O
progression	O
-	O
free	O
survival	O
(	O
HR	O
1.2	O
,	O
P	O
=	O
0.031	O
)	O
.	O

Multiple	O
linear	O
regression	O
analysis	O
revealed	O
that	O
plasma	O
selenium	O
was	O
not	O
associated	O
with	O
cognitive	O
performance	O
,	O
inflammatory	O
markers	O
nor	O
neurotrophic	O
factors	O
,	O
independent	O
of	O
age	O
,	O
sex	O
,	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
,	O
habitual	O
physical	O
activity	O
,	O
liAPOE	O
/	O
i	O
status	O
,	O
education	O
,	O
and	O
history	O
of	O
cardiovascular	B-Phenotype
disease	E-Phenotype
.	O

The	O
PHKG2	O
and	O
RNF40	O
genes	O
are	O
either	O
overlapping	O
or	O
close	O
to	O
the	O
sequences	O
of	O
SCAR	S-Phenotype
marker	O
BC13	O
-	O
4	O
,	O
while	O
SCAR	S-Phenotype
marker	O
BC10	O
-	O
1	O
is	O
in	O
the	O
intron	O
and	O
overlap	O
the	O
DPEP1	O
gene	O
,	O
suggesting	O
that	O
alterations	O
in	O
the	O
expression	O
of	O
these	O
genes	O
could	O
contribute	O
to	O
cancer	S-Phenotype
progression	O
.	O

However	O
,	O
the	O
role	O
of	O
PAK4	O
in	O
neuroblastoma	S-Phenotype
remains	O
unclear	O
.	O

Additional	O
plasma	O
and	O
52	O
brain	O
tissues	O
obtained	O
from	O
patients	O
with	O
gliomas	S-Phenotype
were	O
used	O
to	O
validate	O
the	O
association	O
rate	O
of	O
serum	O
amyloid	O
A1	O
(	O
SAA1	O
)	O
in	O
different	O
grades	O
of	O
gliomas	S-Phenotype
and	O
its	O
distribution	O
in	O
tumors	S-Phenotype
.	O

The	O
therapeutic	O
capacity	O
of	O
fenretinide	O
(	O
N	O
-	O
[	O
4	O
-	O
hydroxyphenyl	O
]	O
retinamide	O
;	O
4	O
-	O
HPR	O
)	O
has	O
been	O
demonstrated	O
for	O
several	O
conditions	O
,	O
including	O
cancer	S-Phenotype
,	O
obesity	S-Phenotype
,	O
diabetes	S-Phenotype
,	O
and	O
ocular	O
disease	O
.	O

On	O
the	O
other	O
hand	O
,	O
intraperitoneal	O
administration	O
of	O
PQQ	O
exerted	O
protective	O
effects	O
on	O
rats	O
that	O
had	O
received	O
rotenone	O
injection	O
into	O
the	O
medial	O
forebrain	O
bundle	O
through	O
decreasing	O
the	O
apomorphine	O
-	O
evoked	O
rotation	O
,	O
inhibiting	O
neuronal	B-Phenotype
loss	E-Phenotype
and	O
TH	O
down	O
-	O
regulation	O
in	O
SNc	O
,	O
increasing	O
the	O
antioxidative	O
ability	O
,	O
and	O
regulating	O
intracellular	O
expressions	O
of	O
Ndufs1	O
and	O
Ndufs	O
4	O
.	O

Furthermore	O
,	O
1751	O
normal	O
Chinese	O
individuals	O
served	O
as	O
controls	O
,	O
and	O
122	O
Chinese	O
families	O
segregating	O
with	O
apparent	O
ARNSHL	O
,	O
who	O
had	O
been	O
previously	O
excluded	O
for	O
variants	O
in	O
the	O
common	O
deafness	S-Phenotype
genes	O
GJB2	O
and	O
SLC26A4	O
,	O
were	O
subjected	O
to	O
screening	O
for	O
candidate	O
mutations	O
.	O

In	O
the	O
present	O
study	O
,	O
WFS1	O
variants	O
were	O
screened	O
in	O
a	O
large	O
series	O
of	O
Japanese	O
hearing	B-Phenotype
loss	E-Phenotype
(	O
HL	S-Phenotype
)	O
patients	O
to	O
clarify	O
the	O
prevalence	O
and	O
clinical	O
characteristics	O
of	O
DFNA6	O
/	O
14	O
/	O
38	O
and	O
Wolfram	O
-	O
like	O
syndrome	O
.	O

In	O
addition	O
,	O
ectopic	O
CDK10	O
expression	O
inhibited	O
gastric	B-Phenotype
cancer	E-Phenotype
cell	O
proliferation	O
,	O
migration	O
and	O
invasion	O
,	O
while	O
knockdown	O
of	O
CDK10	O
promoted	O
these	O
phenotypes	O
.	O

Methods	O
We	O
identified	O
all	O
materials	O
published	O
mentioning	O
both	O
SAg	O
and	O
allergic	B-Phenotype
rhinitis	E-Phenotype
(	O
AR	S-Phenotype
)	O
,	O
chronic	B-Phenotype
sinusitis	E-Phenotype
,	O
asthma	S-Phenotype
,	O
and	O
atopic	B-Phenotype
dermatitis	E-Phenotype
(	O
AD	S-Phenotype
)	O
that	O
are	O
indexed	O
on	O
PubMed	O
,	O
Google	O
,	O
or	O
the	O
ProQuest	O
Central	O
databases	O
.	O

There	O
was	O
a	O
significantly	O
higher	O
expression	O
level	O
of	O
FOXP1	O
in	O
the	O
tumour	S-Phenotype
than	O
in	O
the	O
adjacent	O
normal	O
tissue	O
(	O
0.0052	O
±	O
0.0021	O
vs	O
0.0027	O
±	O
0.0018	O
,	O
P	O
AAAA	O
0.001	O
)	O
.	O

The	O
mechanism	O
by	O
which	O
SAMHD1	O
protects	O
against	O
cancer	S-Phenotype
and	O
chronic	O
inflammation	O
is	O
unknown	O
.	O

The	O
expression	O
level	O
of	O
lncRNA	O
FEZF	O
-	O
AS1	O
and	O
FEZF1	O
was	O
determined	O
by	O
the	O
quantitative	O
Real	O
-	O
time	O
PCR	O
in	O
160	O
cases	O
of	O
NSCLC	O
tissues	O
and	O
their	O
adjacent	O
non	O
-	O
tumour	S-Phenotype
tissues	O
.	O

The	O
greater	O
detection	O
rate	O
for	O
DM+DBT	O
was	O
stronger	O
for	O
ductal	B-Phenotype
carcinoma	I-Phenotype
in	I-Phenotype
situ	E-Phenotype
(	O
+180	O
%	O
,	O
95	O
%	O
CI	O
:	O
1	O
,	O
665	O
)	O
;	O
it	O
was	O
notable	O
for	O
small	O
and	O
medium	O
invasive	O
cancers	S-Phenotype
,	O
but	O
not	O
for	O
large	O
ones	O
(	O
+94	O
[	O
95	O
%	O
CI	O
:	O
6	O
,	O
254	O
]	O
;	O
+122	O
[	O
95	O
%	O
CI	O
:	O
18	O
,	O
316	O
]	O
;	O
-	O
12	O
[	O
95	O
%	O
CI	O
:	O
-	O
68	O
,	O
141	O
]	O
;	O
for	O
invasive	O
cancers	S-Phenotype
AAAA	O
10	O
mm	O
,	O
10	O
-	O
19	O
mm	O
,	O
and	O
G	O
20	O
mm	O
,	O
respectively	O
)	O
.	O

We	O
identified	O
a	O
new	O
susceptibility	O
locus	O
for	O
bladder	B-Phenotype
cancer	E-Phenotype
at	O
5q12.3	O
,	O
located	O
in	O
the	O
intron	O
of	O
CWC27	O
(	O
rs2042329	O
)	O
,	O
that	O
was	O
significantly	O
associated	O
with	O
disease	O
risk	O
(	O
OR	O
=	O
1.40	O
;	O
P	O
=	O
4.61	O
×	O
10	O
(	O
-	O
11	O
)	O
)	O
.	O

Before	O
performing	O
PET	O
scans	O
,	O
subjects	O
answered	O
the	O
Buss	O
-	O
Perry	O
Aggression	S-Phenotype
Questionnaire	O
and	O
Temperament	O
and	O
Character	O
Inventory	O
to	O
measure	O
their	O
aggression	S-Phenotype
and	O
personality	O
traits	O
,	O
respectively	O
.	O

We	O
used	O
bivariate	O
and	O
multivariate	O
analyses	O
to	O
examine	O
the	O
variations	O
in	O
the	O
rates	O
of	O
TMA	O
complications	O
according	O
to	O
sex	O
,	O
age	O
,	O
race	O
,	O
and	O
comorbid	O
conditions	O
,	O
including	O
nonpalpable	O
pedal	O
pulses	O
,	O
end	B-Phenotype
-	I-Phenotype
stage	I-Phenotype
renal	I-Phenotype
disease	E-Phenotype
,	O
coronary	B-Phenotype
artery	I-Phenotype
disease	E-Phenotype
,	O
hypertension	S-Phenotype
,	O
smoking	O
status	O
,	O
and	O
preoperative	O
albumin	O
AAAA3.5	O
mg	O
/	O
dL	O
.	O

Mutations	O
in	O
EYS	O
are	O
associated	O
with	O
autosomal	B-Phenotype
recessive	I-Phenotype
retinitis	I-Phenotype
pigmentosa	E-Phenotype
(	O
arRP	S-Phenotype
)	O
and	O
autosomal	B-Phenotype
recessive	I-Phenotype
cone	I-Phenotype
-	I-Phenotype
rod	I-Phenotype
dystrophy	E-Phenotype
(	O
arCRD	S-Phenotype
)	O
however	O
,	O
the	O
function	O
of	O
EYS	O
and	O
the	O
molecular	O
mechanisms	O
of	O
how	O
these	O
mutations	O
cause	O
retinal	B-Phenotype
degeneration	E-Phenotype
are	O
still	O
unclear	O
.	O

Signs	O
and	O
symptoms	O
are	O
blisters	S-Phenotype
,	O
skin	B-Phenotype
fragility	E-Phenotype
,	O
erosions	B-Phenotype
hyperpigmentation	E-Phenotype
,	O
sclerodermoid	B-Phenotype
plaques	E-Phenotype
.	O

MDR	O
rectal	O
colonization	O
occurs	O
in	O
6.5	O
%	O
of	O
haematological	O
inpatients	O
and	O
predicts	O
a	O
16	O
%	O
probability	O
of	O
MDRrel	O
BSI	O
,	O
particularly	O
during	O
neutropenia	S-Phenotype
,	O
as	O
well	O
as	O
a	O
higher	O
probability	O
of	O
unfavourable	O
outcomes	O
in	O
CR	O
-	O
rel	O
BSIs	O
.	O

In	O
addition	O
,	O
FGF23	O
suppresses	O
proximal	B-Phenotype
tubular	E-Phenotype
expression	O
of	O
1a	O
-	O
hydroxylase	O
,	O
the	O
key	O
enzyme	O
responsible	O
for	O
vitamin	O
D	O
hormone	O
production	O
.	O

Among	O
these	O
,	O
heterozygous	O
mutations	O
in	O
NOBOX	O
,	O
a	O
homeobox	O
gene	O
encoding	O
a	O
transcription	O
factor	O
expressed	O
specifically	O
by	O
oocyte	O
and	O
granulosa	O
cells	O
within	O
the	O
ovary	O
,	O
have	O
been	O
reported	O
in	O
∼6	O
%	O
of	O
women	O
with	O
sporadic	S-Phenotype
POI	O
.	O

To	O
investigate	O
the	O
direct	O
effects	O
of	O
this	O
SNP	O
in	O
the	O
heterogeneous	S-Phenotype
cellular	O
context	O
of	O
the	O
brain	O
,	O
we	O
generated	O
humanized	O
transgenic	O
mice	O
using	O
a	O
design	O
that	O
maximized	O
the	O
local	O
transcriptional	O
landscape	O
of	O
the	O
human	O
HTR1A	O
gene	O
while	O
also	O
controlling	O
for	O
effects	O
of	O
genomic	O
insertion	O
location	O
.	O

Finally	O
,	O
twenty	O
-	O
four	O
important	O
hub	O
genes	O
(	O
RASGRP2	O
,	O
IKZF1	O
,	O
CXCR5	O
,	O
LTB	O
,	O
BLK	O
,	O
LINGO3	O
,	O
CCR6	O
,	O
P2RY10	O
,	O
RHOH	O
,	O
JUP	O
,	O
KRT14	O
,	O
PLA2G3	O
,	O
SPRR1A	O
,	O
KRT78	O
,	O
SFN	O
,	O
CLDN4	O
,	O
IL1RN	O
,	O
PKP3	O
,	O
CBLC	O
,	O
KRT16	O
,	O
TMEM79	O
,	O
KLK8	O
,	O
LYPD3	O
and	O
LYPD5	O
)	O
were	O
treated	O
as	O
valuable	O
factors	O
involved	O
in	O
the	O
immune	O
response	O
and	O
tumor	S-Phenotype
cell	O
development	O
in	O
tumorigenesis	O
.	O

Backgorund	O
:	O
Sanjad	O
-	O
Sakati	O
syndrome	O
(	O
SSS	O
)	O
is	O
a	O
rare	O
autosomal	B-Phenotype
recessive	E-Phenotype
disease	O
caused	O
by	O
a	O
deletion	O
mutation	O
(	O
155	O
-	O
166del	O
)	O
in	O
exon	O
3	O
of	O
the	O
TBCE	O
gene	O
on	O
chromosome	O
1q42	O
-	O
43	O
.	O

In	O
two	O
tumors	S-Phenotype
with	O
12q	O
rearrangements	O
,	O
RPSAP52	O
on	O
12q14.3	O
was	O
fused	O
with	O
non	O
-	O
coding	O
RNA	O
(	O
accession	O
number	O
XR_944195	O
)	O
from	O
14q32.2	O
or	O
ZFP36L1	O
from14q24.1	O
.	O

The	O
enhanced	O
CXCL1	O
expression	O
in	O
DCs	O
is	O
also	O
noted	O
in	O
mice	O
transplanted	O
with	O
colon	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

We	O
identified	O
16	O
of	O
53	O
participants	O
(	O
30	O
%	O
)	O
with	O
a	O
pathogenic	O
(	O
P	O
)	O
or	O
likely	O
pathogenic	O
(	O
LP	O
)	O
variant	O
that	O
may	O
be	O
related	O
to	O
their	O
hereditary	B-Phenotype
pancreatic	I-Phenotype
cancer	E-Phenotype
predisposition	O
;	O
seven	O
had	O
mutations	O
in	O
genes	O
associated	O
with	O
well	O
-	O
known	O
cancer	S-Phenotype
syndromes	O
(	O
13	O
%	O
)	O
[	O
ATM	O
(	O
2	O
)	O
,	O
BRCA2	O
(	O
3	O
)	O
,	O
MSH2	O
(	O
1	O
)	O
,	O
MSH6	O
(	O
1	O
)	O
]	O
.	O

The	O
immunohistochemical	O
expression	O
of	O
L1CAM	O
in	O
corresponding	O
tissue	O
was	O
significantly	O
higher	O
in	O
metastases	O
than	O
in	O
glioblastomas	S-Phenotype
.	O

The	O
present	O
study	O
demonstrates	O
high	O
levels	O
of	O
L1CAM	O
in	O
cyst	O
fluid	O
of	O
glioblastoma	S-Phenotype
and	O
metastatic	B-Phenotype
brain	I-Phenotype
tumors	E-Phenotype
.	O

Our	O
previous	O
studies	O
of	O
the	O
microRNA	O
(	O
miRNA	O
)	O
expression	O
signature	O
in	O
clear	B-Phenotype
cell	I-Phenotype
renal	I-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
ccRCC	S-Phenotype
)	O
indicated	O
that	O
miRNA	O
-	O
1274a	O
(	O
miR	O
-	O
1274a	O
)	O
was	O
significantly	O
upregulated	O
in	O
clinical	O
specimens	O
,	O
suggesting	O
that	O
miR	O
-	O
1274a	O
may	O
act	O
as	O
an	O
oncogenic	O
miRNA	O
in	O
ccRCC	O
.	O

In	O
a	O
multiplex	O
consanguineous	O
Saudi	O
family	O
affected	O
by	O
severe	O
and	O
recurrent	O
large	B-Phenotype
joint	I-Phenotype
dislocation	E-Phenotype
and	O
severe	B-Phenotype
myopia	E-Phenotype
,	O
we	O
identified	O
a	O
homozygous	O
truncating	O
variant	O
in	O
GZF1	O
through	O
a	O
combined	O
autozygome	O
and	O
exome	O
approach	O
.	O

The	O
aim	O
the	O
present	O
study	O
was	O
to	O
clarify	O
the	O
role	O
of	O
MORC2	O
in	O
liver	B-Phenotype
cancer	E-Phenotype
.	O

However	O
,	O
only	O
a	O
few	O
studies	O
have	O
assessed	O
the	O
clinical	O
significance	O
of	O
MPC1	O
and	O
the	O
molecular	O
mechanisms	O
underlying	O
its	O
influence	O
on	O
cancer	S-Phenotype
progression	O
are	O
not	O
well	O
understood	O
.	O

Existing	O
research	O
points	O
to	O
the	O
potential	O
use	O
of	O
various	O
Eph	O
/	O
ephrin	O
members	O
as	O
biomarkers	O
for	O
assessing	O
prognosis	O
and	O
selecting	O
the	O
most	O
suitable	O
therapeutic	O
strategies	O
in	O
variable	O
clinical	O
scenarios	O
,	O
also	O
for	O
overcoming	O
drug	B-Phenotype
resistance	E-Phenotype
,	O
in	O
the	O
era	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
heterogeneity	S-Phenotype

Eradicating	O
H.	O
pylori	O
and	O
HCV	O
is	O
the	O
optimal	O
approach	O
for	O
the	O
first‑line	O
prevention	O
of	O
gastric	B-Phenotype
cancer	E-Phenotype
and	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
,	O
respectively	O
.	O

Herein	O
,	O
we	O
describe	O
the	O
clinical	O
and	O
genetic	O
characterization	O
of	O
79	O
patients	O
with	O
inherited	O
thiamine	O
defects	O
causing	O
encephalopathy	S-Phenotype
in	O
childhood	O
,	O
identifying	O
outcome	O
predictors	O
in	O
patients	O
with	O
pathogenic	O
SLC19A3	O
variants	O
,	O
the	O
most	O
common	O
genetic	O
etiology	O
.	O

Biotinidase	O
(	O
BTD	O
)	O
deficiency	O
is	O
a	O
rare	O
autosomal	B-Phenotype
recessive	E-Phenotype
metabolic	O
disease	O
,	O
which	O
develops	O
neurological	O
and	O
cutaneous	O
symptoms	O
because	O
of	O
the	O
impaired	O
biotin	O
recycling	O
.	O

The	O
membrane	O
-	O
type	O
frizzled	O
-	O
related	O
protein	O
(	O
MFRP	O
)	O
is	O
the	O
only	O
gene	O
so	O
far	O
reported	O
implicated	O
in	O
autosomal	B-Phenotype
recessive	E-Phenotype
,	O
non	O
-	O
syndromic	O
and	O
syndromic	O
forms	O
of	O
PM	O
.	O

Disorders	O
in	O
the	O
ISC	O
machinery	O
affect	O
numerous	O
Fe	O
-	O
S	O
proteins	O
and	O
lead	O
to	O
a	O
heterogeneous	S-Phenotype
group	O
of	O
diseases	O
with	O
a	O
wide	O
variety	O
of	O
clinical	O
symptoms	O
and	O
combined	O
enzymatic	O
defects	O
.	O

In	O
a	O
gene	O
expression	O
analysis	O
the	O
risk	O
allele	O
of	O
a	O
coding	O
SNP	O
associated	O
with	O
schizophrenia	S-Phenotype
was	O
found	O
to	O
be	O
associated	O
with	O
a	O
reduced	O
expression	O
of	O
DGCR2	O
.	O

To	O
discover	O
additional	O
risk	O
loci	O
,	O
we	O
performed	O
a	O
GWAS	O
of	O
123	O
sporadic	S-Phenotype
HSCR	O
patients	O
and	O
432	O
unaffected	O
controls	O
using	O
a	O
large	O
-	O
scale	O
platform	O
with	O
coverage	O
of	O
over	O
1	O
million	O
polymorphic	O
markers	O
.	O

Mutations	O
in	O
a	O
number	O
of	O
different	O
genes	O
causative	O
for	O
microcephaly	S-Phenotype
have	O
been	O
identified	O
,	O
e.g.	O
,	O
MCPH1	O
,	O
WDR62	O
,	O
and	O
ASPM	O
.	O

We	O
describe	O
three	O
consanguineous	O
Indian	O
families	O
with	O
a	O
distinct	O
form	O
of	O
spondyloepiphyseal	B-Phenotype
dysplasia	E-Phenotype
(	O
SED	O
Omani	O
type	O
)	O
.	O

Changes	O
in	O
methylation	O
of	O
miR	O
-	O
193a	O
or	O
expression	O
of	O
pri	O
-	O
miR	O
-	O
193a	O
were	O
not	O
observed	O
in	O
ulcerative	B-Phenotype
colitis	I-Phenotype
cancer	E-Phenotype
.	O

Vestibular	O
sensory	O
-	O
evoked	O
potentials	O
demonstrate	O
severe	O
to	O
profound	O
vestibular	O
deficits	O
in	O
Dfnb31	O
(	O
neo	O
/	O
neo	O
)	O
and	O
Dfnb31	O
(	O
wi	O
/	O
wi	O
)	O
mice	O
.	O

Dual	O
-	O
specificity	O
tyrosine	O
phosphorylation	O
-	O
regulated	O
kinase	O
1A	O
(	O
Dyrk1A	O
)	O
is	O
a	O
potential	O
target	O
in	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
because	O
of	O
the	O
established	O
correlation	O
between	O
its	O
over	O
-	O
expression	O
and	O
generation	O
of	O
neurofibrillary	B-Phenotype
tangles	E-Phenotype
(	O
NFT	S-Phenotype
)	O
as	O
well	O
as	O
the	O
accumulation	O
of	O
amyloid	O
plaques	O
.	O

In	O
a	O
recent	O
article	O
published	O
in	O
the	O
journal	O
,	O
Yang	O
and	O
his	O
colleagues	O
found	O
pulmonary	B-Phenotype
edema	E-Phenotype
was	O
not	O
demonstrated	O
in	O
2	O
of	O
the	O
6	O
PVOD	O
patients	O
injected	O
with	O
prostacyclin	O
analogues	O
(	O
a	O
kind	O
of	O
PAH	O
-	O
targeted	O
drug	O
)	O
.	O

Importantly	O
,	O
upregulation	O
of	O
TMEM98	O
mRNA	O
in	O
patients	O
with	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
who	O
received	O
transarterial	O
chemoembolization	O
(	O
TACE	O
)	O
treatment	O
was	O
significantly	O
higher	O
than	O
in	O
patients	O
without	O
TACE	O
treatment	O
(	O
P	O
=	O
0.046	O
)	O
.	O

These	O
results	O
indicated	O
that	O
MPC1	O
could	O
be	O
a	O
novel	O
therapeutic	O
target	O
in	O
some	O
cancers	S-Phenotype

TGFBR3	O
-	O
PLAG1	O
promotes	O
a	O
tumorigenic	S-Phenotype
phenotype	O
in	O
vitro	O
,	O
and	O
is	O
absent	O
in	O
723	O
other	O
salivary	B-Phenotype
gland	I-Phenotype
tumors	E-Phenotype
.	O

Heritable	B-Phenotype
pulmonary	I-Phenotype
arterial	I-Phenotype
hypertension	E-Phenotype
(	O
HPAH	S-Phenotype
)	O
is	O
a	O
rare	O
but	O
severe	O
complication	O
of	O
HHT	O
.	O

Loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
the	O
human	O
PIEZO2	O
gene	O
cause	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
syndrome	O
of	O
muscular	B-Phenotype
atrophy	E-Phenotype
with	O
perinatal	B-Phenotype
respiratory	I-Phenotype
distress	E-Phenotype
,	O
arthrogryposis	S-Phenotype
,	O
and	O
scoliosis	S-Phenotype
.	O

CHD	O
proteins	O
play	O
an	O
important	O
role	O
in	O
neurodevelopment	O
,	O
as	O
pathogenic	O
variants	O
in	O
CHD1	O
,	O
CHD2	O
,	O
CHD4	O
,	O
CHD7	O
and	O
CHD8	O
have	O
been	O
associated	O
with	O
a	O
range	O
of	O
neurological	O
phenotypes	O
,	O
including	O
autism	B-Phenotype
spectrum	I-Phenotype
disorder	E-Phenotype
(	O
ASD	S-Phenotype
)	O
,	O
intellectual	B-Phenotype
disability	E-Phenotype
(	O
ID	S-Phenotype
)	O
and	O
epilepsy	S-Phenotype
.	O

Functionally	O
,	O
MFAP5	O
overexpression	O
accelerated	O
breast	B-Phenotype
cancer	E-Phenotype
cell	O
proliferation	O
and	O
migration	O
,	O
while	O
an	O
opposite	O
effect	O
was	O
observed	O
when	O
MFAP5	O
was	O
knocked	O
down	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
performed	O
three	O
-	O
dimensional	O
fluorescence	O
in	O
situ	O
hybridization	O
experiments	O
in	O
the	O
colorectal	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
DLD	O
-	O
1	O
and	O
LoVo	O
using	O
whole	O
chromosome	O
painting	O
probes	O
for	O
chromosomes	O
8	O
and	O
11	O
and	O
BAC	O
clones	O
targeting	O
four	O
genes	O
with	O
different	O
expression	O
levels	O
assessed	O
by	O
gene	O
expression	O
arrays	O
and	O
RT	O
-	O
PCR	O
.	O

PRNP	O
and	O
PRND	O
are	O
significantly	O
over	O
-	O
expressed	O
in	O
osteosarcoma	S-Phenotype
.	O

To	O
study	O
the	O
effect	O
and	O
related	O
mechanism	O
of	O
IL	O
-	O
21	O
alone	O
and	O
in	O
combination	O
with	O
5	O
-	O
Fluorouracil	O
on	O
the	O
proliferation	O
and	O
growth	O
,	O
transferability	O
,	O
and	O
apoptosis	O
of	O
gastric	B-Phenotype
cancer	E-Phenotype
cells	O
,	O
we	O
cultivated	O
gastric	B-Phenotype
cancer	E-Phenotype
cell	O
SGC	O
-	O
7901	O
and	O
created	O
four	O
experimental	O
groups	O
with	O
varying	O
concentrations	O
of	O
IL	O
-	O
21	O
and	O
5	O
-	O
Fluorouracil	O
:	O
IL	O
-	O
21	O
group	O
(	O
IL	O
-	O
21	O
100ng	O
/	O
ml	O
)	O
,	O
semi	O
-	O
combination	O
group	O
(	O
5	O
-	O
Fluorouracil	O
25ug	O
/	O
ml+IL	O
-	O
21	O
100ng	O
/	O
ml	O
)	O
,	O
5	O
-	O
Fluorouracil	O
group	O
(	O
5	O
-	O
Fluorouracil	O
50ug	O
/	O
ml	O
)	O
,	O
and	O
combination	O
group	O
(	O
5	O
-	O
Fluorouracil	O
50ug	O
/	O
ml+IL	O
-	O
21	O
100ng	O
/	O
ml	O
)	O
.	O

Bardet	O
-	O
Biedl	O
syndrome	O
(	O
BBS	O
)	O
is	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
disorder	O
characterized	O
by	O
central	B-Phenotype
obesity	E-Phenotype
,	O
mental	B-Phenotype
impairment	E-Phenotype
,	O
rod	B-Phenotype
-	I-Phenotype
cone	I-Phenotype
dystrophy	E-Phenotype
,	O
polydactyly	S-Phenotype
,	O
hypogonadism	S-Phenotype
in	O
males	O
,	O
and	O
renal	B-Phenotype
abnormalities	E-Phenotype
.	O

The	O
most	O
likely	O
causal	O
variant	O
identified	O
was	O
a	O
novel	O
missense	O
variant	O
in	O
the	O
X	O
-	O
linked	O
GRIA3	O
gene	O
,	O
which	O
has	O
been	O
implicated	O
in	O
intellectual	B-Phenotype
disability	E-Phenotype
.	O

Here	O
we	O
characterize	O
Plk4	O
-	O
dependent	O
cancer	S-Phenotype
cell	O
migration	O
and	O
invasion	O
as	O
well	O
as	O
local	O
invasion	O
and	O
metastasis	O
of	O
cancer	S-Phenotype
xenografts	O
.	O

These	O
include	O
the	O
perinatal	B-Phenotype
lethal	I-Phenotype
short	I-Phenotype
-	I-Phenotype
rib	I-Phenotype
polydactyly	I-Phenotype
syndromes	E-Phenotype
(	O
SRPS	S-Phenotype
)	O
and	O
the	O
less	O
severe	O
asphyxiating	B-Phenotype
thoracic	I-Phenotype
dystrophy	E-Phenotype
(	O
ATD	S-Phenotype
)	O
,	O
Ellis	O
-	O
van	O
Creveld	O
(	O
EVC	O
)	O
syndrome	O
,	O
and	O
cranioectodermal	B-Phenotype
dysplasia	E-Phenotype
(	O
CED	S-Phenotype
)	O
phenotypes	O
.	O

To	O
identify	O
the	O
genes	O
that	O
are	O
targets	O
of	O
constitutive	O
PI3K	O
/	O
AKT	O
signalling	O
in	O
lung	B-Phenotype
cancer	E-Phenotype
cells	O
,	O
we	O
performed	O
a	O
comparative	O
transcriptomic	O
analysis	O
of	O
human	O
lung	O
epithelial	O
cells	O
(	O
BEAS	O
-	O
2B	O
)	O
expressing	O
active	O
mutant	O
AKT1	O
(	O
AKT1	O
-	O
E17K	O
)	O
,	O
active	O
mutant	O
PIK3CA	O
(	O
PIK3CA	O
-	O
E545K	O
)	O
or	O
that	O
are	O
silenced	O
for	O
PTEN	O
.	O

Mutations	O
in	O
the	O
Pejvakin	O
(	O
Pjvk	O
)	O
gene	O
cause	O
autosomal	B-Phenotype
recessive	I-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
DFNB59	O
with	O
audiological	O
features	O
of	O
auditory	B-Phenotype
neuropathy	I-Phenotype
spectrum	I-Phenotype
disorder	E-Phenotype
(	O
ANSD	S-Phenotype
)	O
or	O
cochlear	B-Phenotype
dysfunction	E-Phenotype
.	O

Using	O
CRC	O
and	O
EC	O
genome	O
-	O
wide	O
association	O
series	O
,	O
totalling	O
13,265	O
cancer	S-Phenotype
cases	O
and	O
40,245	O
controls	O
,	O
we	O
found	O
that	O
the	O
protective	O
allele	O
[	O
G	O
]	O
at	O
one	O
previously	O
-	O
identified	O
CRC	O
polymorphism	O
,	O
rs2736100	O
near	O
TERT	O
,	O
was	O
associated	O
with	O
EC	O
risk	O
(	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
1.08	O
,	O
P	O
=	O
0.000167	O
)	O
;	O
this	O
polymorphism	O
influences	O
the	O
risk	O
of	O
several	O
other	O
cancers	S-Phenotype
.	O

Furthermore	O
,	O
we	O
identified	O
several	O
unreported	O
tissue	O
-	O
specific	O
TFs	O
that	O
may	O
contribute	O
to	O
breast	B-Phenotype
cancer	E-Phenotype
,	O
including	O
ATOH8	O
,	O
DMRT2	O
,	O
TBX15	O
and	O
ZNF367	O
.	O

CaSR	O
expression	O
is	O
lost	O
in	O
colonic	O
malignancies	O
,	O
indicating	O
that	O
the	O
CaSR	O
is	O
a	O
biomarker	O
for	O
colonic	B-Phenotype
cancer	E-Phenotype
progression	O
.	O

Mice	O
lacking	O
Zbtb20	O
in	O
the	O
liver	O
exhibit	O
hypolipidemia	S-Phenotype
and	O
reduced	O
levels	O
of	O
liver	O
triglycerides	O
,	O
along	O
with	O
impaired	O
hepatic	O
lipogenesis	O
.	O

CMG2	O
may	O
be	O
an	O
interesting	O
candidate	O
gene	O
for	O
the	O
further	O
exploration	O
of	O
soft	B-Phenotype
tissue	I-Phenotype
sarcoma	E-Phenotype
genesis	O
and	O
progression	O

Ribosome	O
profiling	O
and	O
RNA	O
sequencing	O
identified	O
IMP1	O
as	O
a	O
principle	O
node	O
for	O
gene	O
expression	O
regulation	O
downstream	O
from	O
LIN28B	O
In	O
vitro	O
and	O
in	O
vivo	O
data	O
demonstrate	O
that	O
epithelial	O
IMP1	O
loss	O
increases	O
expression	O
of	O
WNT	O
target	O
genes	O
and	O
enhances	O
LIN28B	O
-	O
mediated	O
intestinal	O
tumorigenesis	S-Phenotype
,	O
which	O
was	O
reversed	O
when	O
we	O
overexpressed	O
IMP1	O
independently	O
in	O
vivo	O
.	O

Moreover	O
,	O
CpG	O
island	O
methylation	O
status	O
of	O
HACE1	O
,	O
a	O
candidate	O
tumor	S-Phenotype
-	O
suppressor	O
gene	O
,	O
was	O
determined	O
in	O
ANKL	O
samples	O
.	O

Given	O
the	O
lack	O
of	O
specific	O
targeted	O
genes	O
and	O
pathways	O
known	O
to	O
be	O
involved	O
in	O
tumour	S-Phenotype
cell	O
dormancy	O
,	O
we	O
proposed	O
enriched	O
candidate	O
genes	O
related	O
to	O
the	O
negative	O
regulation	O
of	O
cell	O
proliferation	O
,	O
signalling	O
pathways	O
regulating	O
pluripotency	O
of	O
stem	O
cells	O
and	O
neuroactive	O
ligand	O
-	O
receptor	O
interaction	O
,	O
and	O
3	O
hub	O
genes	O
(	O
FTH1	O
,	O
GRM1	O
and	O
DDIT3	O
)	O
.	O

The	O
novel	O
potential	O
autism	S-Phenotype
susceptibility	O
genes	O
PTDSS1	O
and	O
AREG	O
were	O
uncovered	O
and	O
warrant	O
further	O
genetic	O
and	O
functional	O
analyses	O
.	O

SNORD115	O
abnormalities	O
with	O
varying	O
downstream	O
multigene	O
involvement	O
would	O
account	O
for	O
catatonia	O
across	O
the	O
life	O
span	O
within	O
some	O
subtypes	O
of	O
autism	B-Phenotype
spectrum	I-Phenotype
disorders	E-Phenotype
,	O
schizophrenia	S-Phenotype
,	O
bipolar	B-Phenotype
and	I-Phenotype
major	I-Phenotype
depressive	I-Phenotype
disorder	E-Phenotype
,	O
psychosis	S-Phenotype
,	O
genetic	O
disorders	O
,	O
and	O
in	O
immune	O
disorders	O
such	O
as	O
anti	O
-	O
N	O
-	O
methyl	O
-	O
d	O
-	O
aspartate	O
receptor	O
(	O
NMDAR	O
)	O
antibody	O
encephalitis	S-Phenotype
as	O
well	O
as	O
the	O
susceptibility	O
to	O
the	O
neuroleptic	O
malignant	O
syndrome	O
(	O
NMS	O
)	O
if	O
environmentally	O
triggered	O
.	O

The	O
present	O
study	O
demonstrated	O
that	O
coronin	O
3	O
is	O
significantly	O
upregulated	O
in	O
clinical	O
primary	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
samples	O
by	O
reverse	O
transcription‑quantitative	O
polymerase	O
chain	O
reaction	O
(	O
RT‑qPCR	O
)	O
and	O
immunohistochemical	O
staining	O
.	O

As	O
rare	O
polymorphisms	O
have	O
been	O
described	O
in	O
IKBKG	O
and	O
polygenic	B-Phenotype
inheritance	E-Phenotype
remains	O
an	O
option	O
in	O
the	O
presented	O
case	O
,	O
this	O
study	O
emphasizes	O
the	O
need	O
for	O
thorough	O
functional	O
and	O
genetic	O
evaluation	O
when	O
encountering	O
and	O
interpreting	O
suspected	O
disease	O
-	O
causing	O
NEMO	O
-	O
ID	O
variants	O

uPA	O
is	O
a	O
dysregulated	O
gene	O
involved	O
in	O
the	O
tumorigenesis	S-Phenotype
,	O
bio	O
-	O
pathological	O
features	O
and	O
outcomes	O
of	O
EEC	O
.	O

Altogether	O
,	O
our	O
data	O
strongly	O
suggest	O
that	O
mutations	O
in	O
CEP78	O
cause	O
a	O
previously	O
undescribed	O
clinical	O
entity	O
of	O
a	O
ciliary	O
nature	O
characterized	O
by	O
blindness	S-Phenotype
and	O
deafness	S-Phenotype
but	O
clearly	O
distinct	O
from	O
Usher	O
syndrome	O
,	O
a	O
condition	O
for	O
which	O
visual	B-Phenotype
impairment	E-Phenotype
is	O
due	O
to	O
retinitis	B-Phenotype
pigmentosa	E-Phenotype
.	O

Possible	O
candidate	O
genes	O
in	O
6q14	O
for	O
intellectual	B-Phenotype
disability	E-Phenotype
might	O
be	O
FILIP1	O
,	O
MYO6	O
,	O
HTR1B	O
,	O
and	O
SNX14	O

We	O
investigated	O
the	O
impact	O
of	O
these	O
polymorphisms	O
on	O
the	O
clinical	O
outcome	O
of	O
103	O
patients	O
with	O
recurrent	B-Phenotype
or	I-Phenotype
metastatic	I-Phenotype
squamous	I-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
of	O
the	O
head	O
and	O
neck	O
treated	O
with	O
a	O
platinum	O
compound	O
,	O
fluorouracil	O
and	O
cetuximab	O
as	O
palliative	O
first	O
-	O
line	O
therapy	O
.	O

Ginsenoside	O
(	O
Rg1	O
)	O
is	O
a	O
traditional	O
Chinese	O
herb	O
that	O
is	O
widely	O
acknowledged	O
due	O
to	O
its	O
anti	O
-	O
tumor	S-Phenotype
characteristics	O
.	O

The	O
effect	O
of	O
Atg5	O
on	O
exosome	O
production	O
promotes	O
the	O
migration	O
and	O
in	O
vivo	O
metastasis	O
of	O
orthotopic	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Here	O
we	O
identify	O
a	O
set	O
of	O
genes	O
that	O
is	O
highly	O
expressed	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
bone	O
metastasis	O
and	O
activated	O
by	O
ZEB1	O
.	O

Haploinsufficiency	O
of	O
EBF3	O
may	O
affect	O
brain	O
development	O
and	O
function	O
,	O
resulting	O
in	O
developmental	B-Phenotype
delay	E-Phenotype
,	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
and	O
behavioral	O
differences	O
observed	O
in	O
individuals	O
with	O
a	O
deleterious	O
variant	O
in	O
EBF3	O

KLLN	O
is	O
a	O
p53	O
target	O
gene	O
with	O
DNA	O
binding	O
function	O
and	O
represents	O
a	O
highly	O
plausible	O
candidate	O
breast	B-Phenotype
cancer	E-Phenotype
predisposition	O
gene	O
.	O

This	O
case	O
unravels	O
a	O
previously	O
unrecognized	O
phenotype	O
of	O
camptodactyly	S-Phenotype
due	O
to	O
a	O
significant	O
skeletal	O
deformity	O
of	O
PRS	O
with	O
a	O
heterogeneous	S-Phenotype
PAX2	O
mutation	O
of	O
hexanucleotide	O
duplication	O
.	O

Recent	O
studies	O
reported	O
germline	O
variants	O
in	O
POT1	O
in	O
melanoma	S-Phenotype
families	O
.	O

Here	O
,	O
we	O
found	O
that	O
cervical	B-Phenotype
cancer	E-Phenotype
cells	O
undergo	O
massive	O
death	O
by	O
SIRT1	O
knockdown	O
,	O
but	O
this	O
effect	O
is	O
reversed	O
by	O
SIRT1	O
restoration	O
.	O

Blocking	O
the	O
expression	O
of	O
integrin	O
a2b1	O
,	O
which	O
was	O
accomplished	O
by	O
transduction	O
of	O
a2	O
-	O
specific	O
shRNA	O
,	O
resulted	O
in	O
significant	O
inhibition	O
of	O
proliferation	O
and	O
clonal	O
activity	O
in	O
human	O
MCF	O
-	O
7	O
breast	B-Phenotype
carcinoma	E-Phenotype
and	O
SK	O
-	O
Mel	O
-	O
147	O
melanoma	S-Phenotype
cells	O
.	O

One	O
patient	O
had	O
a	O
retroperitoneal	O
composite	O
PGL	O
-	O
ganglioneuroma	S-Phenotype
in	O
the	O
setting	O
of	O
neurofibromatosis	S-Phenotype
type	O
1	O
.	O

Molecular	O
diagnosis	O
is	O
consistent	O
with	O
the	O
genetic	O
heterogeneity	S-Phenotype
of	O
the	O
HPRT1	O
gene	O
responsible	O
for	O
HGprt	O
deficiency	O
.	O

We	O
further	O
report	O
that	O
genetic	O
or	O
pharmacological	O
inhibition	O
of	O
USP13	O
considerably	O
reduces	O
MCL1	O
protein	O
abundance	O
and	O
significantly	O
increases	O
tumor	S-Phenotype
cell	O
sensitivity	O
to	O
BH3	O
mimetic	O
inhibitors	O
targeting	O
BCL	O
-	O
2	O
and	O
BCL	O
-	O
XL	O
.	O

Here	O
,	O
we	O
utilized	O
the	O
CRISPR	O
-	O
Cas9	O
system	O
to	O
generate	O
Kcnj13	O
mutant	O
mice	O
by	O
zygote	O
injection	O
to	O
verify	O
the	O
pathogenic	O
role	O
of	O
human	O
KCNJ13	O
,	O
mutations	O
of	O
which	O
are	O
thought	O
to	O
cause	O
Leber	B-Phenotype
congenital	I-Phenotype
amaurosis	E-Phenotype
(	O
LCA	S-Phenotype
)	O
,	O
an	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
form	I-Phenotype
of	I-Phenotype
blindness	E-Phenotype
.	O

In	O
this	O
review	O
,	O
we	O
describe	O
the	O
significance	O
and	O
paradoxical	O
requirement	O
of	O
RUNX1	O
tumor	S-Phenotype
suppressor	O
in	O
hematological	O
malignancies	O
based	O
on	O
recent	O
findings	O
such	O
as	O
AAAAAAGenetic	O
compensation	O
of	O
RUNX	O
family	O
transcription	O
factors	O
in	O
leukemia	S-Phenotype
,	O
AAAAAA	O
AAAAAARUNX1	O
inhibition	O
-	O
induced	O
inhibitory	O
effects	O
on	O
leukemia	S-Phenotype
cells	O
through	O
p53	O
activationAAAAAA	O
and	O
our	O
novel	O
promising	O
theory	O
AAAAAACluster	O
regulation	O
of	O
RUNX	O
(	O
CROX	O
)	O
AAAAAA	O
through	O
the	O
RUNX	O
gene	O
switch	O
method	O
using	O
pyrrole	O
-	O
imidazole	O
polyamides	O
as	O
a	O
new	O
technique	O
that	O
could	O
contribute	O
to	O
the	O
next	O
generation	O
of	O
leukemia	S-Phenotype
treatment	O
strategies	O

Accordingly	O
,	O
TRIP13	O
-	O
silenced	O
xenograft	O
tumors	S-Phenotype
displayed	O
significant	O
growth	O
inhibition	O
in	O
vivo	O
.	O

Missense	O
mutations	O
in	O
the	O
mitochondrial	O
seryl	O
-	O
tRNA	O
synthetase	O
gene	O
,	O
SARS2	O
,	O
have	O
been	O
identified	O
in	O
HUPRA	O
syndrome	O
(	O
hyperuricemia	S-Phenotype
,	O
pulmonary	B-Phenotype
hypertension	E-Phenotype
,	O
renal	B-Phenotype
failure	I-Phenotype
in	I-Phenotype
infancy	E-Phenotype
,	O
and	O
alkalosis	S-Phenotype
)	O
.	O

By	O
real	O
-	O
time	O
PCR	O
and	O
analysis	O
of	O
GEO	O
database	O
,	O
we	O
determined	O
the	O
up	O
-	O
regulated	O
expression	O
of	O
miR	O
-	O
135b	O
-	O
5p	O
in	O
pancreatic	B-Phenotype
cancer	E-Phenotype
tissues	O
and	O
cell	O
lines	O
.	O

The	O
melanogenic	O
activity	O
of	O
6	O
-	O
benzylaminopurine	O
,	O
the	O
compound	O
identified	O
as	O
the	O
most	O
potent	O
,	O
was	O
further	O
verified	O
by	O
measuring	O
green	O
fluorescent	O
protein	O
concentration	O
in	O
tyrp1	O
a	O
:	O
eGFP	O
(	O
tyrosinase	O
-	O
related	O
protein	O
1	O
)	O
zebrafish	O
and	O
mitfa	O
:	O
eGFP	O
(	O
microphthalmia	S-Phenotype
associated	O
transcription	O
factor	O
)	O
zebrafish	O
and	O
antioxidative	O
activity	O
.	O

The	O
results	O
revealed	O
that	O
ERα	O
,	O
ERβ	O
,	O
PRLR	O
and	O
Ki67	O
expression	O
levels	O
were	O
increased	O
during	O
the	O
progression	O
of	O
cancer	S-Phenotype
.	O

Mutations	O
in	O
MYH3	O
and	O
MYH8	O
are	O
associated	O
with	O
distal	S-Phenotype
arthrogryposis	S-Phenotype
syndromes	O
.	O

4	O
)	O
Multiple	B-Phenotype
endocrine	I-Phenotype
neoplasia	E-Phenotype
type	O
2A	O
from	O
liRET	O
/	O
i	O
activating	O
mutation	O
rarely	O
presents	O
as	O
familial	B-Phenotype
hyperparathyroidism	E-Phenotype
,	O
because	O
medullary	B-Phenotype
thyroid	I-Phenotype
cancer	E-Phenotype
and	O
pheochromocytoma	S-Phenotype
are	O
more	O
prominent	O
.	O

After	O
screening	O
for	O
agonism	O
in	O
a	O
cell	O
-	O
viability	O
assay	O
in	O
vitro	O
,	O
a	O
novel	O
DR5	O
-	O
specific	O
scFv	O
antibody	O
TR2	O
-	O
3	O
was	O
isolated	O
,	O
which	O
inhibited	O
COLO205	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
tumor	S-Phenotype
cell	O
growth	O
without	O
any	O
cross	O
-	O
linking	O
agents	O
.	O

Our	O
results	O
indicated	O
that	O
the	O
homozygous	O
mutation	O
c.22C	O
AAAA	O
T	O
was	O
the	O
key	O
genetic	O
reason	O
for	O
the	O
proband	O
,	O
and	O
a	O
digenic	O
effect	O
of	O
BSND	O
and	O
GJB2	O
might	O
contributed	O
to	O
sensorineural	B-Phenotype
deafness	E-Phenotype
.	O

Mutations	O
in	O
the	O
PCYT1A	O
gene	O
have	O
been	O
recently	O
linked	O
to	O
two	O
different	O
phenotypes	O
:	O
one	O
characterized	O
by	O
spondylometaphyseal	B-Phenotype
dysplasia	E-Phenotype
and	O
cone	B-Phenotype
-	I-Phenotype
rod	I-Phenotype
dystrophy	E-Phenotype
(	O
SMD	O
-	O
CRD	O
)	O
and	O
the	O
other	O
by	O
congenital	B-Phenotype
lipodystrophy	E-Phenotype
,	O
severe	O
fatty	B-Phenotype
liver	E-Phenotype
disease	O
,	O
and	O
reduced	O
HDL	O
cholesterol	O
without	O
any	O
retinal	O
or	O
skeletal	O
involvement	O
.	O

We	O
conclude	O
that	O
miR	O
-	O
142	O
-	O
3p	O
downregulates	O
cancer	S-Phenotype
stem	O
cell	O
characteristics	O
and	O
radioresistance	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
,	O
mediated	O
by	O
a	O
reduced	O
role	O
of	O
b	O
-	O
catenin	O
in	O
miR	O
-	O
142	O
-	O
3p	O
-	O
overexpressing	O
cells	O
.	O

CD44	O
was	O
expressed	O
on	O
the	O
surface	O
of	O
poorly	O
differentiated	O
tumour	S-Phenotype
cells	O
,	O
and	O
within	O
the	O
The	O
Cancer	S-Phenotype
Genome	O
Atlas	O
-	O
Head	O
and	O
Neck	O
Squamous	B-Phenotype
Cell	I-Phenotype
Carcinoma	E-Phenotype
samples	O
,	O
its	O
messenger	O
RNA	O
levels	O
were	O
higher	O
in	O
tumours	S-Phenotype
compared	O
to	O
normal	O
.	O

Chudley	O
-	O
McCullough	O
syndrome	O
(	O
CMS	O
)	O
is	O
a	O
rare	O
autosomal	B-Phenotype
recessive	E-Phenotype
disorder	O
characterized	O
by	O
sensorineural	B-Phenotype
deafness	E-Phenotype
,	O
agenesis	B-Phenotype
of	I-Phenotype
the	I-Phenotype
corpus	I-Phenotype
callosum	E-Phenotype
,	O
frontal	B-Phenotype
polymicrogyria	E-Phenotype
,	O
interhemispheric	B-Phenotype
cyst	E-Phenotype
,	O
and	O
ventricular	B-Phenotype
enlargement	E-Phenotype
.	O

Genetic	O
workup	O
confirmed	O
the	O
clinical	O
diagnosis	O
of	O
camptodactyly	B-Phenotype
-	I-Phenotype
arthropathy	I-Phenotype
-	I-Phenotype
coxa	I-Phenotype
vara	I-Phenotype
-	I-Phenotype
pericarditis	E-Phenotype
(	O
CACP	S-Phenotype
)	O
syndrome	O
CACP	S-Phenotype
syndrome	O
and	O
also	O
revealed	O
a	O
rare	O
mutation	O
in	O
the	O
causative	O
gene	O

Genome	O
-	O
wide	O
studies	O
examining	O
common	O
genetic	O
risk	O
factors	O
identified	O
common	O
variants	O
in	O
SCN1A	O
,	O
indicating	O
a	O
convergence	O
of	O
shared	O
pathophysiological	O
pathways	O
in	O
various	O
types	O
of	O
epilepsies	S-Phenotype
.	O

The	O
SNP	O
rs7744813	O
,	O
previously	O
shown	O
to	O
be	O
associated	O
with	O
refractive	O
error	O
and	O
myopia	S-Phenotype
in	O
two	O
GWAS	O
,	O
showed	O
an	O
odds	O
ratio	O
of	O
0.75	O
(	O
95	O
%	O
CI	O
0.63	O
-	O
0.90	O
;	O
liP	O
/	O
isubemp	O
/	O
sub	O
=	O
0.0058	O
)	O
for	O
the	O
minor	O
allele	O
.	O

This	O
study	O
aimed	O
to	O
investigate	O
the	O
expression	O
of	O
PLZF	O
by	O
immunohistochemistry	O
in	O
different	O
grade	O
as	O
well	O
as	O
metastatic	O
PCa	O
and	O
to	O
correlate	O
the	O
alteration	O
of	O
PLZF	O
expression	O
with	O
PCa	O
aggressiveness	S-Phenotype
.	O

Lastly	O
,	O
a	O
syndromic	O
form	O
of	O
PCD	O
with	O
retinal	B-Phenotype
degeneration	E-Phenotype
results	O
in	O
normal	O
ciliary	O
ultrastructure	O
through	O
mutations	O
in	O
the	O
RPGR	O
gene	O
.	O

Based	O
on	O
our	O
analysis	O
of	O
fold	O
-	O
change	O
in	O
gene	O
expression	O
as	O
a	O
function	O
of	O
disease	O
stage	O
(	O
i.e.	O
,	O
early	O
vs.	O
advanced	O
)	O
,	O
coupled	O
with	O
consideration	O
of	O
the	O
known	O
relevant	O
functions	O
of	O
these	O
genes	O
,	O
we	O
focused	O
on	O
four	O
candidate	O
genes	O
,	O
ACSL4	O
,	O
GNMT	O
,	O
IFI27	O
,	O
and	O
miR122	O
,	O
which	O
are	O
expressed	O
stage	O
-	O
specifically	O
in	O
HCV	O
mono	O
-	O
and	O
HIV	O
-	O
1	O
/	O
HCV	O
co	O
-	O
infective	O
liver	B-Phenotype
disease	E-Phenotype
and	O
are	O
known	O
to	O
play	O
a	O
pivotal	O
role	O
in	O
regulating	O
HCV	O
-	O
mediated	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
.	O

The	O
tumor	S-Phenotype
cells	O
with	O
immunoreactivity	O
to	O
CK7	O
,	O
CK19	O
,	O
Cam5.2	O
,	O
COX2	O
,	O
EMA	O
,	O
BCL	O
-	O
2	O
,	O
MOC	O
-	O
31	O
and	O
AE1	O
/	O
AE3	O
,	O
supported	O
a	O
diagnosis	O
of	O
intrahepatic	B-Phenotype
cholangiocarcinoma	E-Phenotype
.	O

Our	O
observations	O
strengthen	O
the	O
evidence	O
supporting	O
a	O
role	O
for	O
EFHC1	O
in	O
JME	O
in	O
a	O
population	O
ethnically	O
and	O
geographically	O
distinct	O
from	O
the	O
one	O
in	O
which	O
the	O
gene	O
was	O
initially	O
identified	O
,	O
and	O
broaden	O
the	O
extent	O
of	O
allelic	O
heterogeneity	S-Phenotype
in	O
the	O
gene	O

Owing	O
to	O
the	O
lack	O
of	O
universal	O
and	O
specific	O
tumor	S-Phenotype
markers	O
for	O
neuroblastoma	S-Phenotype
(	O
NB	S-Phenotype
)	O
,	O
in	O
this	O
prospective	O
study	O
,	O
we	O
adopted	O
an	O
EpCAM	O
-	O
independent	O
method	O
to	O
detect	O
CTCs	O
in	O
the	O
peripheral	O
blood	O
of	O
NB	O
patients	O
.	O

To	O
explore	O
the	O
relationship	O
between	O
NF2	O
promoter	O
gene	O
mutation	O
and	O
the	O
risk	O
of	O
medulloblastomas	S-Phenotype
(	O
MBs	S-Phenotype
)	O
.	O

Impact	O
statement	O
This	O
review	O
examines	O
the	O
role	O
of	O
methionine	O
adenosyltransferases	O
(	O
MATs	O
)	O
in	O
human	O
cancer	S-Phenotype
development	O
,	O
with	O
a	O
particular	O
focus	O
on	O
liver	B-Phenotype
cancers	E-Phenotype
in	O
which	O
all	O
three	O
MAT	O
genes	O
are	O
implicated	O
in	O
tumorigenesis	S-Phenotype
.	O

In	O
the	O
case	O
-	O
control	O
analysis	O
,	O
the	O
rs9607195	O
AAAAAG	O
on	O
intergenic	O
area	O
250	O
kb	O
away	O
from	O
the	O
ISX	O
gene	O
and	O
the	O
rs12738007	O
AAAAAG	O
on	O
the	O
intron	O
of	O
the	O
MECR	O
gene	O
were	O
the	O
most	O
strongly	O
associated	O
SNPs	O
with	O
the	O
risk	O
of	O
schizophrenia	S-Phenotype
(	O
P	O
=	O
6.2	O
×	O
10	O
(	O
-	O
8	O
)	O
,	O
OR	O
=	O
0.50	O
and	O
P	O
=	O
3.7	O
×	O
10	O
(	O
-	O
7	O
)	O
,	O
OR	O
=	O
2.39	O
,	O
respectively	O
)	O
.	O

The	O
Ksup+	O
/	O
sup	O
channel	O
KCNQ1	O
has	O
been	O
proposed	O
as	O
a	O
tumor	S-Phenotype
suppressor	O
in	O
colorectal	B-Phenotype
cancer	E-Phenotype
(	O
CRC	S-Phenotype
)	O
.	O

These	O
data	O
suggest	O
that	O
schizophrenia	S-Phenotype
involves	O
a	O
disruption	O
in	O
PGC	O
-	O
1α	O
and	O
/	O
or	O
NRF	O
-	O
1	O
-	O
associated	O
transcriptional	O
programs	O
in	O
the	O
cortex	O
and	O
that	O
approaches	O
to	O
enhance	O
the	O
activity	O
of	O
PGC	O
-	O
1α	O
or	O
transcriptional	O
regulators	O
like	O
NRF	O
-	O
1	O
should	O
be	O
considered	O
with	O
the	O
goal	O
of	O
restoring	O
normal	O
gene	O
programs	O
and	O
improving	O
cortical	O
function	O

In	O
conclusion	O
,	O
Taiwanese	O
women	O
with	O
CG	O
/	O
GG	O
in	O
WWOX	O
SNP	O
rs3764340	O
are	O
susceptible	O
to	O
cervical	B-Phenotype
invasive	I-Phenotype
cancer	E-Phenotype
.	O

De	O
novo	O
heterozygous	O
mutations	O
in	O
STXBP1	O
/	O
Munc18	O
-	O
1	O
cause	O
early	B-Phenotype
infantile	I-Phenotype
epileptic	I-Phenotype
encephalopathies	E-Phenotype
(	O
EIEE4	O
,	O
OMIM	O
#	O
612164	O
)	O
characterized	O
by	O
infantile	B-Phenotype
epilepsy	E-Phenotype
,	O
developmental	B-Phenotype
delay	E-Phenotype
,	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
and	O
can	O
include	O
autistic	O
features	O
.	O

bObjective	O
:	O
/	O
b	O
To	O
study	O
the	O
association	O
between	O
Thymidine	O
Phosphorylase	O
(	O
TYMP	O
)	O
genetic	O
variation	O
and	O
clinical	O
outcomes	O
and	O
safety	O
of	O
postoperative	O
colorectal	B-Phenotype
cancer	E-Phenotype
(	O
CRC	S-Phenotype
)	O
patients	O
.	O

To	O
examine	O
if	O
CRC	O
patients	O
have	O
altered	O
decorin	O
levels	O
,	O
expression	O
of	O
decorin	O
and	O
its	O
target	O
genes	O
,	O
Met	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
A	O
(	O
VEGFA	O
)	O
,	O
were	O
analyzed	O
in	O
their	O
tumors	S-Phenotype
.	O

An	O
increasing	O
number	O
of	O
studies	O
suggest	O
that	O
long	O
-	O
noncoding	O
RNAs	O
(	O
lncRNAs	O
)	O
play	O
important	O
roles	O
in	O
various	O
biological	O
processes	O
and	O
disease	O
pathologies	O
,	O
including	O
cancer	S-Phenotype
.	O

We	O
analyzed	O
the	O
expression	O
profiles	O
of	O
lncRNA	O
,	O
miRNA	O
,	O
and	O
mRNA	O
,	O
along	O
with	O
the	O
clinical	O
information	O
of	O
BCa	O
patients	O
collected	O
from	O
the	O
Cancer	S-Phenotype
Genome	O
Atlas	O
database	O
to	O
identify	O
lncRNA	O
biomarkers	O
for	O
prognosis	O
.	O

These	O
analyses	O
revealed	O
significantly	O
higher	O
methylation	O
frequencies	O
in	O
high	O
-	O
grade	O
tumors	S-Phenotype
relative	O
to	O
low	O
-	O
intermediate	O
-	O
grade	O
tumors	S-Phenotype
for	O
the	O
ATP5G2	O
,	O
IRX1	O
and	O
VAX2	O
genes	O
(	O
PAAAA0.05	O
)	O
,	O
and	O
similarly	O
significant	O
increases	O
in	O
mean	O
levels	O
of	O
methylation	O
in	O
high	O
-	O
grade	O
tumors	S-Phenotype
for	O
the	O
ATP5G2	O
,	O
VAX2	O
,	O
INSRR	O
,	O
PRDM14	O
,	O
VSX1	O
,	O
TFAP2b	O
,	O
PRRX1	O
,	O
and	O
HIST1H4F	O
genes	O
(	O
PAAAA0.05	O
)	O
.	O

The	O
molecular	O
features	O
of	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
arising	O
from	O
non	B-Phenotype
-	I-Phenotype
alcoholic	I-Phenotype
fatty	I-Phenotype
liver	E-Phenotype
disease	O
(	O
NAFLD	B-Phenotype
-	I-Phenotype
HCC	E-Phenotype
)	O
are	O
not	O
well	O
known	O
.	O

In	O
dog	O
,	O
two	O
independent	O
SLC45A2	O
variants	O
are	O
known	O
that	O
cause	O
oculocutaneous	B-Phenotype
albinism	E-Phenotype
in	O
Doberman	O
Pinschers	O
and	O
several	O
small	O
dog	O
breeds	O
respectively	O
.	O

EEF1A2	O
gene	O
is	O
highly	O
expressed	O
in	O
the	O
central	O
nervous	O
system	O
and	O
Eef1a2	O
knockout	O
mice	O
show	O
the	O
neuronal	O
degeneration	O
.	O

Oral	B-Phenotype
cancer	E-Phenotype
was	O
associated	O
with	O
two	O
new	O
regions	O
,	O
2p23.3	O
(	O
rs6547741	O
,	O
GPN1	O
)	O
and	O
9q34.12	O
(	O
rs928674	O
,	O
LAMC3	O
)	O
,	O
and	O
with	O
known	O
cancer	S-Phenotype
-	O
related	O
loci	O
-	O
9p21.3	O
(	O
rs8181047	O
,	O
CDKN2B	O
-	O
AS1	O
)	O
and	O
5p15.33	O
(	O
rs10462706	O
,	O
CLPTM1L	O
)	O
.	O

For	O
non	B-Phenotype
-	I-Phenotype
syndromic	I-Phenotype
pediatric	I-Phenotype
cataract	E-Phenotype
,	O
we	O
map	O
a	O
novel	O
locus	O
in	O
a	O
multiplex	O
consanguineous	O
family	O
on	O
4p15.32	O
where	O
exome	O
sequencing	O
revealed	O
a	O
homozygous	O
truncating	O
mutation	O
in	O
TAPT1	O
.	O

The	O
RS	O
-	O
MC	O
was	O
also	O
validated	O
against	O
measurements	O
and	O
simulations	O
in	O
heterogeneous	S-Phenotype
phantoms	O
created	O
by	O
placing	O
lung	O
or	O
bone	O
slabs	O
in	O
a	O
water	O
phantom	O
.	O

Independent	O
and	O
pooled	O
analyses	O
verified	O
that	O
higher	O
PYCR1	O
mRNA	O
levels	O
were	O
significantly	O
associated	O
with	O
poor	O
survival	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
patients	O
,	O
regardless	O
of	O
estrogen	O
receptor	O
(	O
ER	O
)	O
status	O
.	O

Thirty	O
-	O
eight	O
genes	O
were	O
sequenced	O
in	O
a	O
larger	O
independent	O
set	O
of	O
148	O
carcinoma	S-Phenotype
/	O
normal	O
tissue	O
pairs	O
to	O
obtain	O
more	O
precise	O
mutation	O
frequencies	O
.	O

Allelic	O
heterogeneity	S-Phenotype
was	O
observed	O
at	O
LRRK2	O
while	O
European	O
risk	O
SNPs	O
at	O
6	O
other	O
loci	O
including	O
MAPT	O
and	O
GBA	O
-	O
SYT11	O
were	O
non	O
-	O
polymorphic	O
or	O
very	O
rare	O
in	O
our	O
cohort	O
.	O

-	O
Deng	O
,	O
J.	O
,	O
Chen	O
,	O
M.	O
,	O
Liu	O
,	O
Z.	O
,	O
Song	O
,	O
Y.	O
,	O
Sui	O
,	O
T.	O
,	O
Lai	O
,	O
L.	O
,	O
Li	O
,	O
Z	O
.	O

The	O
role	O
of	O
USP18	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
provides	O
a	O
novel	O
insight	O
into	O
the	O
clinical	O
application	O
of	O
the	O
USP18	O
/	O
AKT	O
/	O
Skp2	O
pathway	O

The	O
HOXB1	O
gene	O
plays	O
a	O
critical	O
role	O
as	O
an	O
oncogene	O
in	O
diverse	O
tumors	S-Phenotype
.	O

Moreover	O
,	O
Reg	O
-	O
1α	O
colocalizes	O
with	O
exostosin	O
tumor	S-Phenotype
-	O
like	O
3	O
(	O
EXTL3	O
)	O
,	O
its	O
putative	O
receptor	O
,	O
at	O
the	O
membrane	O
of	O
these	O
cells	O
.	O

Diffuse	O
BCOR	O
staining	O
was	O
strong	O
in	O
three	O
and	O
weak	O
in	O
one	O
BCOR	O
-	O
rearranged	O
high	O
-	O
grade	O
endometrial	O
stromal	O
sarcoma	S-Phenotype
while	O
absent	O
in	O
the	O
remaining	O
four	O
BCOR	O
-	O
rearranged	O
tumors	S-Phenotype
.	O

Ring	O
finger	O
protein	O
6	O
(	O
RNF6	O
)	O
is	O
a	O
key	O
oncogene	O
in	O
both	O
prostate	B-Phenotype
cancer	E-Phenotype
and	O
leukemia	S-Phenotype
,	O
but	O
its	O
role	O
is	O
elusive	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

Furthermore	O
,	O
probably	O
the	O
future	O
is	O
in	O
finding	O
the	O
best	O
optimal	O
combination	O
of	O
tumour	S-Phenotype
markers	O
for	O
diagnosing	O
HCC	O
based	O
on	O
cost	O
-	O
effectiveness	O

Overall	O
,	O
these	O
data	O
support	O
a	O
tumor	S-Phenotype
suppressive	O
role	O
for	O
miR	O
-	O
125a	O
and	O
contribute	O
to	O
the	O
elucidation	O
of	O
its	O
molecular	O
targets	O

Here	O
,	O
we	O
demonstrate	O
that	O
mice	O
with	O
conditional	O
ablation	O
of	O
the	O
Pjvk	O
gene	O
in	O
all	O
sensory	O
hair	O
cells	O
or	O
only	O
in	O
outer	O
hair	O
cells	O
(	O
OHCs	O
)	O
show	O
similar	O
auditory	O
phenotypes	O
with	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
profound	I-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
.	O

In	O
regard	O
to	O
BE	O
,	O
endoscopic	O
submucosal	O
dissection	O
(	O
ESD	O
)	O
which	O
is	O
well	O
established	O
in	O
Asia	O
,	O
is	O
now	O
becoming	O
more	O
mainstream	O
in	O
the	O
West	O
for	O
the	O
treatment	O
of	O
BE	O
with	O
high	O
grade	O
dysplasia	S-Phenotype
,	O
as	O
well	O
as	O
early	B-Phenotype
esophageal	I-Phenotype
cancer	E-Phenotype
.	O

Mutations	O
in	O
the	O
ubiquitously	O
expressed	O
pre	O
-	O
mRNA	O
processing	O
factors	O
3	O
,	O
8	O
,	O
and	O
31	O
(	O
PRPF3	O
,	O
PRPF8	O
,	O
and	O
PRPF31	O
)	O
cause	O
nonsyndromic	B-Phenotype
dominant	I-Phenotype
retinitis	I-Phenotype
pigmentosa	E-Phenotype
in	O
humans	O
,	O
an	O
inherited	B-Phenotype
retinal	I-Phenotype
degeneration	E-Phenotype
.	O

We	O
previously	O
conducted	O
transcriptome	O
analysis	O
of	O
a	O
paired	O
specimen	O
of	O
normal	O
and	O
esophageal	B-Phenotype
squamous	I-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
ESCC	S-Phenotype
)	O
tissues	O
and	O
found	O
that	O
mRNA	O
expression	O
of	O
cystatin	O
A	O
(	O
CSTA	O
)	O
,	O
a	O
member	O
of	O
the	O
cystatin	O
superfamily	O
,	O
was	O
perturbed	O
in	O
tumors	S-Phenotype
compared	O
with	O
that	O
in	O
the	O
background	O
mucosa	O
.	O

Methods	O
:	O
/	O
b	O
Using	O
immunohistochemical	O
method	O
detected	O
the	O
expression	O
level	O
of	O
Twist2	O
in	O
60	O
cases	O
of	O
gliomas	S-Phenotype
(	O
including	O
WHO	O
grades	O
Ⅱ	O
,	O
Ⅲ	O
and	O
Ⅳ	O
,	O
each	O
for	O
20	O
cases	O
)	O
and	O
20	O
cases	O
of	O
non	O
-	O
tumor	S-Phenotype
brain	O
tissues	O
.	O

A	O
48	O
year	O
-	O
old	O
-	O
male	O
presented	O
with	O
a	O
gradually	O
increasing	O
soft	O
-	O
tissue	O
mass	O
in	O
his	O
right	O
forearm	O
of	O
2	O
years	O
'	O
duration	O
,	O
along	O
with	O
multiple	O
subcutaneous	O
soft	O
-	O
tissue	O
nodular	O
lesions	O
,	O
and	O
reminiscent	O
of	O
lipomas	S-Phenotype
over	O
his	O
body	O
.	O

Inhibitory	O
immune	O
receptors	O
,	O
such	O
as	O
NLRP12	O
,	O
dampen	O
inflammation	O
and	O
are	O
important	O
for	O
resolving	O
inflammation	O
,	O
but	O
their	O
role	O
in	O
obesity	S-Phenotype
is	O
unknown	O
.	O

Serine	O
and	O
ribose	O
synthesis	O
have	O
been	O
identified	O
as	O
downstream	O
pathways	O
fed	O
by	O
PEPCK	O
in	O
cancer	S-Phenotype
cells	O
.	O

Swedish	O
CDKN2A	O
mutation	O
carriers	O
have	O
a	O
young	O
median	O
age	O
of	O
onset	O
of	O
melanoma	S-Phenotype
,	O
increased	O
risks	O
of	O
multiple	O
primary	O
melanoma	S-Phenotype
and	O
of	O
tobacco	O
-	O
associated	O
cancers	S-Phenotype
in	O
respiratory	O
and	O
upper	O
digestive	O
tissues	O
,	O
and	O
also	O
worse	O
survival	O
compared	O
to	O
non	O
-	O
carriers	O
.	O

Fatigue	S-Phenotype
,	O
hypotonia	S-Phenotype
,	O
proximal	B-Phenotype
muscular	I-Phenotype
weakness	E-Phenotype
,	O
hearing	B-Phenotype
deficits	E-Phenotype
,	O
rash	S-Phenotype
and	O
respiratory	B-Phenotype
problems	E-Phenotype
are	O
common	O
clinical	O
phenotype	O
of	O
our	O
patients	O
.	O

Humans	O
who	O
carry	O
HNF1B	O
mutations	O
develop	O
heterogeneous	B-Phenotype
renal	I-Phenotype
abnormalities	E-Phenotype
,	O
including	O
multicystic	B-Phenotype
dysplastic	I-Phenotype
kidneys	E-Phenotype
,	O
glomerulocystic	B-Phenotype
kidney	I-Phenotype
disease	E-Phenotype
,	O
renal	B-Phenotype
agenesis	E-Phenotype
,	O
renal	B-Phenotype
hypoplasia	E-Phenotype
,	O
and	O
renal	B-Phenotype
interstitial	I-Phenotype
fibrosis	E-Phenotype
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
clarify	O
the	O
phenotypic	O
spectrum	O
of	O
COL4A1	O
/	O
A2	O
mutations	O
in	O
the	O
context	O
of	O
cortical	B-Phenotype
malformations	E-Phenotype
that	O
include	O
schizencephaly	S-Phenotype
,	O
polymicrogyria	S-Phenotype
and	O
/	O
or	O
heterotopia	S-Phenotype

Patients	O
with	O
ADSSL1	O
mutations	O
demonstrated	O
distal	B-Phenotype
muscle	I-Phenotype
weakness	E-Phenotype
in	O
adolescence	O
,	O
followed	O
by	O
quadriceps	B-Phenotype
muscle	I-Phenotype
weakness	E-Phenotype
in	O
the	O
early	O
30s	O
.	O

Manipulation	O
of	O
ARHGAP17	O
affected	O
cell	O
proliferation	O
in	O
vitro	O
and	O
tumor	S-Phenotype
growth	O
in	O
vivo	O
.	O

Rac1	O
,	O
one	O
of	O
the	O
best	O
characterized	O
Rho	O
GTPases	O
,	O
is	O
an	O
established	O
effector	O
of	O
receptors	O
and	O
an	O
important	O
node	O
in	O
signaling	O
networks	O
crucial	O
for	O
tumorigenesis	S-Phenotype
and	O
metastasis	O
.	O

Primary	B-Phenotype
ciliary	I-Phenotype
dyskinesia	E-Phenotype
(	O
PCD	S-Phenotype
)	O
is	O
a	O
clinical	O
rare	O
peculiar	O
disorder	O
,	O
mainly	O
featured	O
by	O
respiratory	B-Phenotype
infection	E-Phenotype
,	O
tympanitis	S-Phenotype
,	O
nasosinusitis	S-Phenotype
,	O
and	O
male	B-Phenotype
infertility	E-Phenotype
.	O

These	O
results	O
highlight	O
CRAFT	O
as	O
a	O
systems	O
-	O
level	O
framework	O
for	O
target	O
discovery	O
and	O
suggest	O
Csf1R	O
blockade	O
as	O
a	O
novel	O
therapeutic	O
strategy	O
in	O
epilepsy	S-Phenotype
.	O

We	O
describe	O
five	O
affected	O
individuals	O
with	O
similar	O
dysmorphic	B-Phenotype
facies	E-Phenotype
,	O
and	O
three	O
of	O
them	O
had	O
either	O
complete	O
situs	B-Phenotype
inversus	E-Phenotype
,	O
dextrocardia	S-Phenotype
,	O
or	O
transposition	B-Phenotype
of	I-Phenotype
the	I-Phenotype
great	I-Phenotype
arteries	E-Phenotype
;	O
similar	O
cardiac	B-Phenotype
abnormalities	E-Phenotype
were	O
previously	O
identified	O
in	O
a	O
mouse	O
mutant	O
for	O
the	O
orthologous	O
Megf8	O
.	O

Using	O
whole	O
-	O
exome	O
sequencing	O
in	O
four	O
probands	O
with	O
undiagnosed	O
skin	B-Phenotype
hyperkeratosis	E-Phenotype
/	O
ichthyosis	S-Phenotype
,	O
we	O
identified	O
compound	O
heterozygosity	O
for	O
mutations	O
in	O
KDSR	O
,	O
encoding	O
an	O
enzyme	O
in	O
the	O
de	O
novo	O
synthesis	O
pathway	O
of	O
ceramides	O
.	O

However	O
,	O
the	O
underlying	O
mechanism	O
of	O
HtrA3	O
function	O
is	O
unclear	O
in	O
endometrial	B-Phenotype
hyperplasia	E-Phenotype
and	O
cancer	S-Phenotype
.	O

Conversely	O
familial	B-Phenotype
hypobetalipoproteinemia	E-Phenotype
is	O
caused	O
by	O
inactivation	O
of	O
the	O
PCSK9	O
gene	O
which	O
increases	O
the	O
number	O
of	O
LDL	O
receptors	O
and	O
decreases	O
plasma	O
cholesterol	O
.	O

Human	O
bladder	B-Phenotype
cancer	E-Phenotype
(	O
BCa	S-Phenotype
)	O
is	O
one	O
of	O
the	O
most	O
commonly	O
diagnosed	O
malignancies	O
worldwide	O
.	O

TDP1	O
plays	O
an	O
essential	O
role	O
in	O
the	O
resistance	O
of	O
cancer	S-Phenotype
cells	O
to	O
currently	O
used	O
antitumour	O
drugs	O
based	O
on	O
Top1	O
inhibitors	O
such	O
as	O
topotecan	O
and	O
irinotecan	O
.	O

Loss	O
-	O
of	O
-	O
function	O
mutations	O
of	O
CASK	O
are	O
associated	O
with	O
intellectual	B-Phenotype
disability	E-Phenotype
and	O
microcephaly	S-Phenotype
with	O
pontine	B-Phenotype
and	I-Phenotype
cerebellar	I-Phenotype
hypoplasia	E-Phenotype
(	O
MICPCH	O
)	O
,	O
especially	O
in	O
females	O
.	O

Prion	O
proteins	O
(	O
PRNP	O
and	O
PRND	O
)	O
,	O
known	O
mostly	O
for	O
its	O
involvement	O
in	O
neurodegenerative	B-Phenotype
spongiform	I-Phenotype
encephalopathies	E-Phenotype
,	O
have	O
been	O
recently	O
demonstrated	O
to	O
be	O
involved	O
in	O
resistance	O
to	O
apoptosis	O
,	O
tumorigenesis	S-Phenotype
,	O
proliferation	O
,	O
and	O
metastasis	O
.	O

Congenital	B-Phenotype
muscular	I-Phenotype
dystrophy	E-Phenotype
with	O
mitochondrial	O
structural	O
abnormalities	O
(	O
MIM	O
#	O
602541	O
)	O
,	O
or	O
also	O
called	O
megaconial	B-Phenotype
congenital	I-Phenotype
muscular	I-Phenotype
dystrophy	E-Phenotype
,	O
is	O
characterized	O
clinically	O
by	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
muscle	I-Phenotype
wasting	E-Phenotype
and	O
severe	S-Phenotype
mental	B-Phenotype
retardation	E-Phenotype
,	O
and	O
pathologically	O
by	O
peculiar	O
enlarged	O
mitochondria	O
that	O
are	O
prevalent	O
toward	O
the	O
periphery	O
of	O
the	O
fibers	O
but	O
are	O
sparse	O
in	O
the	O
center	O
on	O
muscle	O
biopsy	O
.	O

These	O
findings	O
suggested	O
the	O
CNVR_3425.1	O
to	O
be	O
a	O
possibly	O
predictive	O
biomarker	O
for	O
the	O
risk	O
of	O
lung	B-Phenotype
cancer	E-Phenotype
and	O
COPD	O
,	O
and	O
targeted	O
molecular	O
therapy	O
pertaining	O
to	O
FENDRR	O
upregulation	O
may	O
be	O
a	O
valuable	O
pathway	O
to	O
fight	O
two	O
diseases	O

However	O
,	O
the	O
relationship	O
between	O
miR	O
-	O
34a	O
and	O
luteolin	O
's	O
susceptibility	O
to	O
cancer	S-Phenotype
cells	O
still	O
remains	O
unclear	O
.	O

We	O
have	O
been	O
investigating	O
the	O
pancreas	O
specific	O
transcription	O
factor	O
,	O
1a	O
cre	O
-	O
recombinase	O
;	O
lox	O
-	O
stop	O
-	O
lox	O
-	O
Kristen	O
rat	O
sarcoma	S-Phenotype
,	O
glycine	O
to	O
aspartic	O
acid	O
at	O
the	O
12	O
codon	O
(	O
Ptf1asupcre	O
/	O
+	O
/	O
sup	O
;	O
LSL	O
-	O
KrassupG12D	O
/	O
+	O
/	O
sup	O
)	O
mouse	O
strain	O
as	O
a	O
model	O
of	O
human	O
pancreatic	B-Phenotype
cancer	E-Phenotype
.	O

Here	O
,	O
we	O
applied	O
domain	O
-	O
focused	O
CRISPR	O
screening	O
to	O
human	O
cancer	S-Phenotype
cell	O
lines	O
to	O
identify	O
the	O
transcription	O
factor	O
(	O
TF	O
)	O
POU2F3	O
(	O
POU	O
class	O
2	O
homeobox	O
3	O
;	O
also	O
known	O
as	O
SKN	O
-	O
1a	O
/	O
OCT	O
-	O
11	O
)	O
as	O
a	O
powerful	O
dependency	O
in	O
a	O
subset	O
of	O
SCLC	O
lines	O
.	O

This	O
contributes	O
to	O
the	O
intrinsic	O
aggressiveness	S-Phenotype
of	O
these	O
cells	O
by	O
upregulating	O
Rab27	O
-	O
dependent	O
recycling	O
of	O
the	O
transmembrane	O
matrix	O
metalloprotease	O
,	O
MT1	O
-	O
MMP	O
to	O
promote	O
invasive	O
behaviour	O
leading	O
to	O
basement	O
membrane	O
disruption	O
.	O

iDrosophila	O
/	O
i	O
Fat	O
is	O
involved	O
in	O
PCP	O
,	O
tumor	S-Phenotype
suppression	O
and	O
Hippo	O
(	O
Hpo	O
)	O
signaling	O
,	O
which	O
is	O
associated	O
with	O
Mer	O
.	O

Rare	O
forms	O
of	O
autosomal	O
-	O
dominant	O
Charcot	O
-	O
Marie	O
-	O
Tooth	O
disease	O
(	O
AD	O
-	O
CMT	O
)	O
may	O
be	O
associated	O
with	O
mutations	O
in	O
Fibulin	O
-	O
5	O
(	O
FBLN5	O
)	O
as	O
AD	O
-	O
CMT	O
is	O
genetically	O
heterogeneous	S-Phenotype
.	O

A	O
protective	O
effect	O
was	O
observed	O
for	O
the	O
fetal	O
NOG1	O
SNP	O
on	O
cleft	B-Phenotype
palate	E-Phenotype
only	O
,	O
opposite	O
in	O
direction	O
to	O
the	O
effect	O
on	O
CLO	O
.	O

Autosomal	O
dominant	O
missense	O
mutations	O
in	O
ACTG1	O
are	O
associated	O
with	O
DFNA20	O
/	O
26	O
,	O
a	O
disorder	O
that	O
is	O
typically	O
characterized	O
by	O
post	B-Phenotype
-	I-Phenotype
lingual	I-Phenotype
progressive	I-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
.	O

Corticosteroid	O
-	O
binding	O
globulin	O
(	O
SERPINA6	O
)	O
deficiency	O
is	O
an	O
extremely	O
rare	O
hereditary	O
disorder	O
characterized	O
by	O
reduced	O
corticosteroid	O
-	O
binding	O
capacity	O
with	O
normal	O
or	O
low	O
plasma	O
corticosteroid	O
-	O
binding	O
globulin	O
concentration	O
,	O
and	O
normal	O
or	O
low	O
basal	O
cortisol	O
levels	O
associated	O
with	O
hypo	O
-	O
/	O
hypertension	S-Phenotype
and	O
muscle	B-Phenotype
fatigue	E-Phenotype
.	O

Since	O
the	O
original	O
description	O
of	O
the	O
IARS2	O
-	O
related	O
cataracts	S-Phenotype
,	O
growth	B-Phenotype
hormone	I-Phenotype
deficiency	E-Phenotype
,	O
sensory	B-Phenotype
neuropathy	E-Phenotype
,	O
sensorineural	B-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
,	O
skeletal	B-Phenotype
dysplasia	E-Phenotype
syndrome	O
(	O
CAGSSS	O
;	O
OMIM	O
616007	O
)	O
in	O
an	O
extended	O
consanguineous	O
family	O
of	O
French	O
-	O
Canadian	O
descent	O
,	O
no	O
further	O
patients	O
have	O
been	O
reported	O
.	O

The	O
roles	O
of	O
STX3	O
in	O
human	O
breast	B-Phenotype
cancer	E-Phenotype
remains	O
elusive	O
.	O

We	O
analyzed	O
the	O
nucleotide	O
repeat	O
lengths	O
of	O
6	O
genes	O
(	O
ATXN8	O
,	O
ATXN10	O
,	O
PPP2R2B	O
,	O
NOP56	O
,	O
DMPK	O
,	O
and	O
JPH3	O
)	O
that	O
have	O
previously	O
been	O
associated	O
with	O
neurologic	O
or	O
neuromuscular	O
disorders	O
,	O
in	O
several	O
hundred	O
sporadic	S-Phenotype
patients	O
with	O
ALS	O
and	O
healthy	O
control	O
subjects	O
.	O

Ectopic	O
expression	O
of	O
Kif7	O
in	O
two	O
choriocarcinoma	S-Phenotype
cell	O
lines	O
JAR	O
and	O
JEG	O
-	O
3	O
led	O
to	O
a	O
decrease	O
in	O
cell	O
growth	O
and	O
increase	O
in	O
apoptosis	O
demonstrated	O
by	O
MTT	O
and	O
TUNEL	O
assays	O
,	O
respectively	O
.	O

We	O
found	O
that	O
both	O
mRNA	O
and	O
protein	O
levels	O
of	O
NRF1	O
and	O
its	O
transcriptional	O
activity	O
were	O
significantly	O
higher	O
in	O
ER	O
/	O
PR	O
-	O
ve	O
HER2	O
+ve	O
breast	B-Phenotype
cancer	E-Phenotype
samples	O
compared	O
to	O
normal	O
breast	O
tissues	O
.	O

Thus	O
,	O
increased	O
expression	O
of	O
gene	O
GNRH1	O
in	O
blood	O
cells	O
appears	O
to	O
be	O
associated	O
with	O
the	O
isolated	O
form	O
of	O
hypogonadotropic	B-Phenotype
hypogonadism	E-Phenotype
and	O
,	O
in	O
prospect	O
,	O
may	O
be	O
used	O
as	O
one	O
of	O
the	O
disease	O
markers	O

BCOR	O
staining	O
was	O
weakly	O
positive	O
in	O
AAAA5	O
%	O
of	O
tumor	S-Phenotype
cells	O
in	O
4	O
of	O
66	O
(	O
6	O
%	O
)	O
low	O
-	O
grade	O
endometrial	O
stromal	O
sarcomas	S-Phenotype
and	O
1	O
of	O
18	O
(	O
6	O
%	O
)	O
endometrial	O
stromal	O
nodules	O
and	O
weakly	O
to	O
moderately	O
positive	O
in	O
AAAA5	O
-	O
40	O
%	O
of	O
tumor	S-Phenotype
cells	O
in	O
6	O
of	O
31	O
(	O
19	O
%	O
)	O
leiomyosarcomas	S-Phenotype
.	O

Oral	B-Phenotype
squamous	I-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
studies	O
have	O
correlated	O
Eps8	O
expression	O
with	O
metastatic	O
disease	O
and	O
poor	O
prognosis	O
.	O

cfDNA	O
from	O
400	O
μl	O
serum	O
(	O
n	O
=	O
204	O
)	O
served	O
to	O
test	O
the	O
diagnostic	O
performance	O
of	O
these	O
markers	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
study	O
demonstrated	O
a	O
connection	O
model	O
across	O
three	O
types	O
of	O
gynecological	O
cancer	S-Phenotype
,	O
which	O
was	O
useful	O
in	O
identifying	O
potential	O
diagnostic	O
markers	O
and	O
novel	O
therapeutic	O
targets	O
,	O
in	O
addition	O
to	O
in	O
aiding	O
the	O
prediction	O
of	O
the	O
development	O
of	O
cancer	S-Phenotype
as	O
it	O
progresses	O

Furthermore	O
,	O
the	O
phosphorylation	O
of	O
AKT	O
was	O
enhanced	O
in	O
ARHGAP17	O
silencing	O
cervical	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Idiopathic	B-Phenotype
hypogonadotropic	I-Phenotype
hypogonadism	E-Phenotype
(	O
IHH	S-Phenotype
)	O
is	O
characterized	O
by	O
low	O
levels	O
of	O
gonadotropins	O
and	O
delayed	O
or	O
absent	O
sexual	O
development	O
.	O

Rescue	O
of	O
KLHL9	O
expression	O
induced	O
proteasomal	O
degradation	O
of	O
C	O
/	O
EBP	O
proteins	O
,	O
abrogated	O
the	O
mesenchymal	O
signature	O
,	O
and	O
reduced	O
tumor	S-Phenotype
viability	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

In	O
vitro	O
analysis	O
showed	O
that	O
FBXL4	O
plays	O
a	O
role	O
in	O
regulating	O
the	O
migration	O
and	O
invasion	O
of	O
prostate	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

We	O
identify	O
ZC3H14	O
mRNA	O
transcripts	O
in	O
the	O
human	O
central	O
nervous	O
system	O
,	O
and	O
we	O
find	O
that	O
rodent	O
ZC3H14	O
protein	O
is	O
expressed	O
in	O
hippocampal	O
neurons	O
and	O
colocalizes	O
with	O
poly	O
(	O
A	O
)	O
RNA	O
in	O
neuronal	O
cell	O
bodies	O
.	O

This	O
prevented	O
renal	B-Phenotype
agenesis	E-Phenotype
in	O
Fras1	O
(	O
bl	O
/	O
bl	O
)	O
mice	O
,	O
permitting	O
kidney	O
development	O
and	O
postnatal	O
survival	O
.	O

PM	O
were	O
loaded	O
with	O
a	O
siRNA	O
against	O
AKT2	O
,	O
an	O
important	O
oncogene	O
involved	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
tumorigenesis	S-Phenotype
,	O
with	O
a	O
special	O
role	O
in	O
CSC	O
malignancy	O
.	O

Also	O
,	O
two	O
somatic	O
heterozygous	O
NONO	O
mutations	O
were	O
found	O
in	O
endocrine	O
-	O
related	O
tumors	S-Phenotype
,	O
p.H146R	O
(	O
parathyroid	O
)	O
and	O
p.R293H	O
(	O
small	O
intestine	O
neuroendocrine	O
tumor	S-Phenotype
)	O
.	O

The	O
PR	O
-	O
specific	O
hubs	O
were	O
involved	O
in	O
Wnt	O
SP	O
,	O
signaling	O
by	O
Notch1	O
in	O
cancer	S-Phenotype
,	O
telomere	O
maintenance	O
,	O
and	O
transcriptional	O
misregulation	O
.	O

A	O
heterozygous	O
mutation	O
(	O
c.643CAAAAA	O
;	O
p.Q215X	O
)	O
in	O
the	O
monocarboxylate	O
transporter	O
12	O
-	O
encoding	O
gene	O
MCT12	O
(	O
also	O
known	O
as	O
SLC16A12	O
)	O
that	O
mediates	O
creatine	O
transport	O
was	O
recently	O
identified	O
as	O
the	O
cause	O
of	O
a	O
syndrome	O
with	O
juvenile	B-Phenotype
cataracts	E-Phenotype
,	O
microcornea	S-Phenotype
,	O
and	O
glucosuria	S-Phenotype
in	O
a	O
single	O
family	O
.	O

Mutations	O
in	O
the	O
COL4A5	O
gene	O
result	O
in	O
X	O
-	O
linked	O
Alport	O
syndrome	O
,	O
homozygous	O
or	O
compound	O
heterozygous	O
mutations	O
in	O
COL4A3	O
or	O
COL4A4	O
are	O
responsible	O
for	O
autosomal	B-Phenotype
recessive	E-Phenotype
Alport	O
syndrome	O
,	O
and	O
heterozygous	O
mutations	O
in	O
COL4A3	O
or	O
COL4A4	O
cause	O
autosomal	O
dominant	O
Alport	O
syndrome	O
or	O
benign	O
familial	O
hematuria	S-Phenotype
.	O

Mucopolysaccharidosis	O
Type	O
IIIA	O
(	O
MPSIIIA	O
)	O
,	O
also	O
known	O
as	O
Sanfilippo	O
A	O
syndrome	O
,	O
is	O
an	O
inherited	B-Phenotype
neurodegenerative	I-Phenotype
disease	E-Phenotype
caused	O
by	O
mutations	O
in	O
the	O
lysosomal	O
enzyme	O
,	O
N	O
-	O
sulfoglucosamine	O
sulfohydrolase	O
(	O
SGSH	O
)	O
,	O
also	O
known	O
as	O
sulfamidase	O
.	O

Mutations	O
in	O
human	O
FTSJ1	O
,	O
the	O
likely	O
TRM7	O
homolog	O
,	O
cause	O
nonsyndromic	B-Phenotype
X	I-Phenotype
-	I-Phenotype
linked	I-Phenotype
intellectual	I-Phenotype
disability	E-Phenotype
(	O
NSXLID	S-Phenotype
)	O
,	O
but	O
the	O
role	O
of	O
FTSJ1	O
in	O
tRNA	O
modification	O
is	O
unknown	O
.	O

This	O
study	O
is	O
focused	O
on	O
the	O
application	O
of	O
the	O
YbHPDO3A	O
(	O
ytterbium	O
1,4,7	O
-	O
triscarboxymethyl	O
-	O
1,4,7,10	O
-	O
tetraazacyclododecane	O
)	O
probe	O
for	O
in	O
vivo	O
glioma	S-Phenotype
pHe	O
quantification	O
using	O
chemical	O
exchange	O
saturation	O
transfer	O
(	O
CEST	O
)	O
-	O
MRI	O
and	O
its	O
correlation	O
with	O
tumor	S-Phenotype
metabolism	O
assessed	O
by	O
immunohistochemistry	O
.	O

Pain	S-Phenotype
scores	O
correlated	O
with	O
total	O
body	O
tumor	S-Phenotype
volume	O
(	O
rho	O
=	O
0.32471	O
,	O
P	O
=	O
.0499	O
)	O
,	O
but	O
not	O
with	O
number	O
of	O
tumors	S-Phenotype
(	O
rho	O
=	O
0.23065	O
,	O
P	O
=	O
.1696	O
)	O
.We	O
found	O
no	O
significant	O
difference	O
in	O
quantitative	O
tumor	S-Phenotype
burden	O
between	O
mutational	O
groups	O
,	O
but	O
spinal	B-Phenotype
schwannomas	E-Phenotype
were	O
more	O
common	O
in	O
LZTR1	O
-	O
mutant	O
patients	O
.	O

Crizotinib	O
is	O
a	O
small	O
orally	O
-	O
administered	O
ALK	O
inhibitor	O
for	O
patients	O
with	O
non	B-Phenotype
-	I-Phenotype
small	I-Phenotype
cell	I-Phenotype
lung	I-Phenotype
cancer	E-Phenotype
with	O
EML4	O
-	O
ALK	O
rearrangement	O
(	O
echinoderm	O
microtubule	O
-	O
associated	O
protein	O
-	O
like	O
4	O
and	O
anaplastic	O
lymphoma	S-Phenotype
kinase	O
)	O
.	O

This	O
chapter	O
focuses	O
on	O
the	O
current	O
data	O
covering	O
the	O
etiology	O
and	O
epidemiology	O
,	O
clinical	O
presentation	O
,	O
and	O
pathogenesis	O
of	O
four	O
monogenic	O
forms	O
of	O
isolated	O
dystonia	S-Phenotype
:	O
DYT	O
-	O
TOR1A	O
,	O
DYT	O
-	O
THAP1	O
,	O
DYT	O
-	O
GCH1	O
,	O
and	O
DYT	O
-	O
GNAL	O

However	O
,	O
SPRY2	O
was	O
not	O
dysregulated	O
in	O
normal	O
-	O
hearing	O
humans	O
homozygous	O
for	O
both	O
the	O
GAB1	O
DFNB26	O
deafness	S-Phenotype
variant	O
and	O
the	O
dominant	O
METTL13	O
deafness	S-Phenotype
suppressor	O
,	O
indicating	O
a	O
plausible	O
mechanism	O
of	O
suppression	O
.	O

GJB2	O
donor	O
splicing	O
site	O
IVS1+1GAAAAAgt	O
;	O
A	O
mutation	O
analysis	O
was	O
performed	O
using	O
Sanger	O
sequencing	O
for	O
a	O
total	O
of	O
71	O
Iranian	O
families	O
with	O
at	O
least	O
1	O
deaf	O
child	O
diagnosed	O
with	O
non	O
-	O
syndromic	O
deafness	S-Phenotype
.	O

The	O
subcapsular	O
mass	O
-	O
forming	O
tumor	S-Phenotype
was	O
composed	O
of	O
poorly	O
differentiated	O
tumor	S-Phenotype
cells	O
arranged	O
in	O
small	O
vague	O
glandular	O
or	O
slit	O
-	O
lumen	O
nests	O
,	O
and	O
focally	O
fused	O
or	O
anastomosing	O
large	O
trabecular	O
patterns	O
within	O
the	O
prominent	O
fibrotic	O
stroma	O
.	O

The	O
condition	O
was	O
initially	O
termed	O
MACS	O
syndrome	O
(	O
macrocephaly	S-Phenotype
,	O
alopecia	S-Phenotype
,	O
cutis	B-Phenotype
laxa	E-Phenotype
,	O
and	O
scoliosis	S-Phenotype
)	O
,	O
based	O
on	O
the	O
clinical	O
features	O
of	O
the	O
first	O
identified	O
family	O
;	O
however	O
,	O
with	O
the	O
expansion	O
of	O
the	O
clinical	O
phenotype	O
in	O
additional	O
families	O
,	O
it	O
was	O
subsequently	O
coined	O
RIN2	O
syndrome	O
.	O

Here	O
,	O
we	O
report	O
that	O
the	O
expression	O
of	O
the	O
INTU	O
gene	O
is	O
aberrantly	O
elevated	O
in	O
human	O
basal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
BCC	S-Phenotype
)	O
,	O
coinciding	O
with	O
increased	O
primary	O
cilia	O
formation	O
and	O
activated	O
hedgehog	O
(	O
Hh	O
)	O
signaling	O
.	O

In	O
vitro	O
cell	O
proliferation	O
,	O
apoptosis	O
and	O
migration	O
assays	O
,	O
and	O
in	O
vivo	O
subcutaneous	O
xenograft	O
tumor	S-Phenotype
models	O
were	O
used	O
to	O
determine	O
the	O
role	O
of	O
FGFRL1	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
demonstrated	O
for	O
the	O
first	O
time	O
that	O
enhanced	O
COX	O
-	O
2	O
expression	O
in	O
hepatocytes	O
is	O
sufficient	O
to	O
induce	O
HCC	O
through	O
inducing	O
promoter	O
hypermethylation	O
by	O
reducing	O
TET1	O
,	O
silencing	O
tumor	S-Phenotype
-	O
suppressive	O
genes	O
and	O
activating	O
key	O
oncogenic	O
pathways	O
.	O

Williams	O
-	O
Beuren	O
syndrome	O
(	O
WBS	O
,	O
no	O
.	O

In	O
the	O
pathway	O
analysis	O
,	O
targets	O
of	O
miR	O
-	O
23b	O
-	O
3p	O
were	O
primarily	O
enriched	O
in	O
the	O
signaling	O
pathways	O
of	O
renal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
,	O
hepatitis	B-Phenotype
B	E-Phenotype
and	O
pancreatic	B-Phenotype
cancer	E-Phenotype
(	O
corrected	O
P	O
-	O
value	O
AAAA0.05	O
)	O
.	O

The	O
results	O
revealed	O
that	O
the	O
dual	O
use	O
of	O
the	O
SHH	O
inhibitor	O
and	O
the	O
HDAC	O
inhibitor	O
effectively	O
synergized	O
to	O
inhibit	O
proliferation	O
,	O
and	O
promote	O
apoptosis	O
in	O
liver	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

We	O
have	O
developed	O
a	O
gene	O
-	O
environment	O
interaction	O
model	O
of	O
holoprosencephaly	S-Phenotype
in	O
mice	O
,	O
in	O
which	O
mutation	O
of	O
the	O
Sonic	O
hedgehog	O
coreceptor	O
,	O
Cdon	O
,	O
synergizes	O
with	O
transient	O
in	O
utero	O
exposure	O
to	O
ethanol	O
.	O

RESULTS	O
The	O
expression	O
of	O
ANXA11	O
in	O
cancer	S-Phenotype
tissues	O
was	O
higher	O
than	O
in	O
adjacent	O
mucosa	O
at	O
mRNA	O
and	O
protein	O
levels	O
.	O

We	O
also	O
show	O
expression	O
of	O
ARNT2	O
within	O
the	O
central	O
nervous	O
system	O
,	O
including	O
the	O
hypothalamus	O
,	O
as	O
well	O
as	O
the	O
renal	O
tract	O
during	O
human	O
embryonic	O
development	O
.	O

Several	O
important	O
genetic	O
alterations	O
(	O
i.e.	O
,	O
mutations	O
,	O
deletions	O
)	O
have	O
been	O
identified	O
to	O
be	O
involved	O
in	O
the	O
initiation	O
and	O
progression	O
of	O
pancreatic	B-Phenotype
cancer	E-Phenotype
,	O
including	O
KRAS	O
and	O
inactivation	O
of	O
tumor	S-Phenotype
suppressors	O
,	O
such	O
as	O
TP53	O
,	O
SMAD4	O
and	O
CDKN2A	O
.	O

Interestingly	O
,	O
the	O
naturally	O
occurring	O
microcephaly	S-Phenotype
-	O
associated	O
mutant	O
,	O
RTTN	O
(	O
A578P	O
)	O
,	O
shows	O
a	O
low	O
affinity	O
for	O
STIL	O
binding	O
and	O
blocks	O
centriole	O
assembly	O
.	O

The	O
expression	O
of	O
hepatocyte	O
cell	O
adhesion	O
molecule	O
(	O
HepaCAM	O
)	O
,	O
a	O
novel	O
tumor	S-Phenotype
suppressor	O
,	O
is	O
frequently	O
downregulated	O
or	O
lost	O
in	O
PCa	O
.	O

Real	O
-	O
time	O
fluorescence	O
quantitative	O
PCR	O
and	O
Western	O
blot	O
showed	O
that	O
the	O
expression	O
level	O
of	O
Twist	O
2	O
in	O
gliomas	S-Phenotype
was	O
significantly	O
higher	O
than	O
that	O
in	O
para	O
-	O
cancerous	O
tissues	O
(	O
liP	O
/	O
iAAAA0.01	O
)	O
,	O
and	O
those	O
in	O
WHO	O
grades	O
Ⅳ	O
and	O
Ⅲ	O
gliomas	S-Phenotype
were	O
significantly	O
higher	O
than	O
that	O
in	O
WHO	O
grade	O
Ⅱ	O
glioma	S-Phenotype
(	O
liP	O
/	O
iAAAA0.01	O
)	O
.	O

This	O
is	O
the	O
first	O
case	O
of	O
PAK3	O
-	O
related	O
intellectual	B-Phenotype
disability	E-Phenotype
presenting	O
with	O
severe	O
self	O
-	O
injury	O
with	O
improvement	O
following	O
treatment	O
.	O

Urofacial	O
syndrome	O
(	O
UFS	O
)	O
is	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
disease	O
with	O
severe	O
dysfunctional	O
urination	O
including	O
urinary	B-Phenotype
incontinence	E-Phenotype
(	O
UI	S-Phenotype
)	O
.	O

We	O
report	O
that	O
biallelic	O
mutations	O
in	O
TBCD	O
,	O
encoding	O
one	O
of	O
the	O
five	O
co	O
-	O
chaperones	O
required	O
for	O
assembly	O
and	O
disassembly	O
of	O
the	O
αβ	O
-	O
tubulin	O
heterodimer	O
,	O
the	O
structural	O
unit	O
of	O
microtubules	O
,	O
cause	O
a	O
disease	O
with	O
neurodevelopmental	O
and	O
neurodegenerative	O
features	O
characterized	O
by	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
cortical	I-Phenotype
atrophy	E-Phenotype
,	O
secondary	B-Phenotype
hypomyelination	E-Phenotype
,	O
microcephaly	S-Phenotype
,	O
thin	B-Phenotype
corpus	I-Phenotype
callosum	E-Phenotype
,	O
developmental	B-Phenotype
delay	E-Phenotype
,	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
seizures	S-Phenotype
,	O
optic	B-Phenotype
atrophy	E-Phenotype
,	O
and	O
spastic	B-Phenotype
quadriplegia	E-Phenotype
.	O

Biallelic	O
pathogenic	O
variants	O
in	O
FBXL4	O
are	O
associated	O
with	O
an	O
encephalopathic	O
mtDNA	O
maintenance	O
defect	O
syndrome	O
that	O
is	O
a	O
multisystem	O
disease	O
characterized	O
by	O
lactic	B-Phenotype
acidemia	E-Phenotype
,	O
developmental	B-Phenotype
delay	E-Phenotype
,	O
and	O
hypotonia	S-Phenotype
.	O

We	O
report	O
4	O
cases	O
of	O
acute	O
severe	O
VZV	O
infection	O
affecting	O
the	O
central	O
nervous	O
system	O
or	O
the	O
lungs	O
in	O
unrelated	O
,	O
otherwise	O
healthy	O
children	O
who	O
are	O
heterozygous	O
for	O
rare	O
missense	O
mutations	O
in	O
POLR3A	O
(	O
one	O
patient	O
)	O
,	O
POLR3C	O
(	O
one	O
patient	O
)	O
,	O
or	O
both	O
(	O
two	O
patients	O
)	O
.	O

A	O
7.5	O
year	O
-	O
old	O
boy	O
born	O
to	O
second	O
-	O
degree	O
cousins	O
presented	O
with	O
severe	B-Phenotype
short	I-Phenotype
stature	E-Phenotype
(	O
height	O
SDS	O
-	O
3.7	O
)	O
and	O
bone	O
age	O
of	O
6	O
years	O
.	O

Our	O
study	O
identifies	O
WDR4	O
as	O
an	O
oncoprotein	O
that	O
negatively	O
regulates	O
PML	O
via	O
ubiquitination	O
to	O
promote	O
lung	B-Phenotype
cancer	E-Phenotype
progression	O
by	O
fostering	O
an	O
immunosuppressive	O
and	O
prometastatic	O
tumor	S-Phenotype
microenvironment	O
,	O
suggesting	O
the	O
potential	O
of	O
immune	O
-	O
modulatory	O
approaches	O
for	O
treating	O
lung	B-Phenotype
cancer	E-Phenotype
with	O
aberrant	O
PML	O
degradation	O

We	O
observed	O
a	O
dichotomous	O
pattern	O
of	O
PKM	O
expression	O
,	O
in	O
which	O
postmitotic	O
neurons	O
throughout	O
the	O
brain	O
expressed	O
the	O
constitutively	O
active	O
PKM1	O
isoform	O
,	O
while	O
neural	O
progenitors	O
and	O
medulloblastomas	S-Phenotype
exclusively	O
expressed	O
the	O
less	O
active	O
PKM2	O
.	O

To	O
search	O
for	O
the	O
underlying	O
molecular	O
mechanism	O
,	O
we	O
turned	O
to	O
examine	O
the	O
impact	O
of	O
CBX3	O
on	O
the	O
expression	O
of	O
FBP1	O
,	O
a	O
negative	O
regulator	O
of	O
aerobic	O
glycolysis	O
in	O
pancreatic	B-Phenotype
cancer	E-Phenotype
and	O
indicated	O
that	O
CBX3	O
negatively	O
regulated	O
FBP1	O
expression	O
.	O

Our	O
data	O
suggest	O
a	O
mechanism	O
whereby	O
CAFs	O
promote	O
tumor	S-Phenotype
cell	O
migration	O
and	O
invasion	O
through	O
CXCL12	O
secretion	O
to	O
regulate	O
the	O
mDia2	O
-	O
directed	O
cytoskeleton	O
in	O
breast	B-Phenotype
tumor	E-Phenotype
cells	O

We	O
describe	O
a	O
female	O
proband	O
with	O
primordial	B-Phenotype
dwarfism	E-Phenotype
,	O
skeletal	B-Phenotype
dysplasia	E-Phenotype
,	O
facial	B-Phenotype
dysmorphism	E-Phenotype
,	O
extreme	O
dyslipidaemic	B-Phenotype
insulin	I-Phenotype
resistance	E-Phenotype
and	O
fatty	B-Phenotype
liver	E-Phenotype
associated	O
with	O
a	O
novel	O
homozygous	O
frameshift	O
mutation	O
in	O
POC1A	O
,	O
predicted	O
to	O
affect	O
two	O
of	O
the	O
three	O
protein	O
products	O
of	O
the	O
gene	O
.	O

Eligible	O
patients	O
were	O
resistant	O
to	O
standard	O
therapy	O
,	O
HLA	O
-	O
A	O
*	O
24:02	O
-	O
or	O
A	O
*	O
02:01	O
-	O
positive	O
and	O
exhibiting	O
high	O
RNF43	O
expression	O
in	O
their	O
tumor	S-Phenotype
cells	O
.	O

This	O
report	O
identifies	O
the	O
implication	O
of	O
IFT57	O
in	O
human	O
pathology	O
and	O
highlights	O
the	O
first	O
description	O
of	O
a	O
ciliary	O
transport	O
defect	O
in	O
OFDS	O
,	O
extending	O
the	O
genetic	O
heterogeneity	S-Phenotype
of	O
this	O
subgroup	O
of	O
ciliopathies	O

We	O
found	O
that	O
HOXA11	O
was	O
hypermethylated	O
in	O
cancer	S-Phenotype
tissues	O
(	O
45.08	O
%	O
)	O
,	O
especially	O
in	O
invasive	B-Phenotype
ductal	I-Phenotype
carcinomas	E-Phenotype
(	O
PAAAA0.001	O
)	O
,	O
patients	O
with	O
a	O
family	O
history	O
of	O
cancer	S-Phenotype
(	O
P=0.033	O
)	O
,	O
cases	O
with	O
metastatic	O
lymph	O
nodes	O
(	O
P=0.004	O
)	O
and	O
P53	O
positive	O
group	O
(	O
P=0.017	O
)	O
.	O

The	O
majority	O
of	O
causative	O
genetic	O
variants	O
identified	O
thus	O
far	O
are	O
inherited	O
in	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
manner	O
and	O
impact	O
key	O
cellular	O
pathways	O
such	O
as	O
mitosis	O
,	O
DNA	O
damage	O
response	O
and	O
repair	O
,	O
apoptosis	O
and	O
splicing	O
.	O

In	O
2003	O
,	O
a	O
new	O
syndrome	O
was	O
described	O
in	O
the	O
Sephardi	O
Jewish	O
population	O
,	O
named	O
progressive	B-Phenotype
cerebello	I-Phenotype
-	I-Phenotype
cerebral	I-Phenotype
atrophy	E-Phenotype
(	O
PCCA	S-Phenotype
)	O
based	O
on	O
the	O
typical	O
neuroradiological	O
findings	O
.	O

Affected	O
individuals	O
presented	O
with	O
prenatal	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
spinal	I-Phenotype
muscular	I-Phenotype
atrophy	E-Phenotype
(	O
SMA	S-Phenotype
)	O
,	O
multiple	B-Phenotype
congenital	I-Phenotype
contractures	E-Phenotype
(	O
arthrogryposis	B-Phenotype
multiplex	I-Phenotype
congenita	E-Phenotype
)	O
,	O
respiratory	B-Phenotype
distress	E-Phenotype
,	O
and	O
congenital	B-Phenotype
bone	I-Phenotype
fractures	E-Phenotype
.	O

oeWDR34	O
strongly	O
inhibited	O
IL	O
-	O
6	O
expression	O
,	O
which	O
is	O
closely	O
related	O
to	O
tumoral	S-Phenotype
growth	O
,	O
compared	O
with	O
control	O
cells	O
,	O
suggesting	O
that	O
WDR34	O
would	O
be	O
a	O
critical	O
molecule	O
for	O
control	O
of	O
tumoral	O
progression	O
.	O

These	O
findings	O
may	O
indicate	O
the	O
involvement	O
of	O
SNIP1	O
in	O
progression	O
of	O
lung	B-Phenotype
cancer	E-Phenotype
by	O
regulating	O
the	O
RB	O
/	O
HDAC1	O
interaction	O

Although	O
some	O
potential	O
glioblastoma	S-Phenotype
biomarkers	O
have	O
already	O
been	O
identified	O
,	O
there	O
is	O
a	O
lack	O
of	O
cell	O
membrane	O
-	O
bound	O
biomarkers	O
capable	O
of	O
distinguishing	O
brain	O
tissue	O
from	O
glioblastoma	S-Phenotype
and	O
/	O
or	O
glioblastoma	S-Phenotype
stem	O
cells	O
(	O
GSC	O
)	O
,	O
which	O
are	O
responsible	O
for	O
the	O
rapid	O
post	O
-	O
operative	O
tumor	S-Phenotype
reoccurrence	O
.	O

Treacher	B-Phenotype
Collins	I-Phenotype
syndrome	E-Phenotype
(	O
TCS	S-Phenotype
,	O
OMIM	O
154500	O
)	O
is	O
a	O
well	O
-	O
defined	O
mandibulofacial	B-Phenotype
dysostosis	E-Phenotype
characterized	O
by	O
symmetric	O
facial	B-Phenotype
anomalies	E-Phenotype
consisting	O
of	O
malar	B-Phenotype
hypoplasia	E-Phenotype
,	O
coloboma	B-Phenotype
of	I-Phenotype
the	I-Phenotype
lower	I-Phenotype
eyelid	E-Phenotype
,	O
dysplastic	B-Phenotype
ears	E-Phenotype
,	O
micrognathia	S-Phenotype
,	O
cleft	B-Phenotype
palate	E-Phenotype
and	O
deafness	S-Phenotype
.	O

Taken	O
together	O
,	O
our	O
data	O
provide	O
insight	O
into	O
the	O
molecular	O
pathways	O
of	O
dominantly	O
and	O
recessively	O
acting	O
BEST1	O
missense	O
mutations	O
suggesting	O
that	O
the	O
site	O
of	O
subcellular	O
protein	O
quality	O
control	O
as	O
well	O
as	O
the	O
rate	O
and	O
degree	O
of	O
mutant	O
protein	O
degradation	O
are	O
ultimately	O
responsible	O
for	O
the	O
distinct	O
retinal	B-Phenotype
disease	E-Phenotype
phenotypes	O
in	O
BD	O
and	O
ARB	O

Whereas	O
the	O
majority	O
of	O
mammalian	O
cells	O
carry	O
no	O
more	O
than	O
two	O
centrosomes	O
per	O
cell	O
,	O
exceptions	O
to	O
this	O
rule	O
apply	O
in	O
certain	O
specialized	O
tissues	O
and	O
in	O
select	O
disease	O
states	O
,	O
including	O
cancer	S-Phenotype
.	O

A	O
xenograft	O
model	O
in	O
which	O
nude	O
mice	O
were	O
injected	O
with	O
UBE2T	O
knockdown	O
human	O
gastric	B-Phenotype
cancer	E-Phenotype
cells	O
confirmed	O
that	O
suppression	O
of	O
UBE2T	O
also	O
decreased	O
tumor	S-Phenotype
formation	O
and	O
growth	O
in	O
vivo	O
.	O

However	O
,	O
the	O
role	O
of	O
FEZF1	O
in	O
the	O
prognosis	O
of	O
human	O
glioma	S-Phenotype
prognosis	O
remains	O
unclear	O
.	O

Molecular	O
genetic	O
tests	O
for	O
episodic	B-Phenotype
ataxia	I-Phenotype
type	I-Phenotype
2	E-Phenotype
(	O
EA2	S-Phenotype
)	O
usually	O
target	O
only	O
the	O
specific	O
calcium	O
channel	O
gene	O
(	O
liCACNA1A	O
/	O
i	O
)	O
that	O
is	O
known	O
to	O
cause	O
EA2	S-Phenotype
.	O

Mutations	O
affecting	O
human	O
COG1	O
,	O
COG2	O
and	O
COG4	O
-	O
COG8	O
cause	O
monogenic	O
forms	O
of	O
inherited	O
,	O
autosomal	B-Phenotype
recessive	E-Phenotype
CDGs	O
.	O

The	O
Random	O
Forest	O
algorithm	O
selected	O
FGFR2	O
,	O
MAP3K1	O
and	O
age	O
as	O
important	O
breast	B-Phenotype
cancer	E-Phenotype
predictors	O
.	O

Twenty	O
-	O
eight	O
days	O
after	O
nude	O
mice	O
intraperitoneal	O
injection	O
with	O
JTE	O
-	O
013	O
or	O
PBS	O
,	O
the	O
mice	O
were	O
sacrificed	O
and	O
the	O
number	O
and	O
the	O
weight	O
of	O
visible	O
tumors	S-Phenotype
were	O
calculated	O
.	O

Finally	O
,	O
both	O
genetic	O
and	O
pharmacological	O
inactivation	O
of	O
Twist1	O
in	O
muscle	O
progenitor	O
cells	O
afforded	O
substantial	O
protection	O
against	O
cancer	B-Phenotype
-	I-Phenotype
mediated	I-Phenotype
cachexia	E-Phenotype
,	O
which	O
translated	O
into	O
meaningful	O
survival	O
benefits	O
,	O
implicating	O
Twist1	O
as	O
a	O
possible	O
target	O
for	O
attenuating	O
muscle	O
cachexia	S-Phenotype
in	O
cancer	S-Phenotype
patients	O

Glycoprotein	O
-	O
A	O
repetitions	O
predominant	O
(	O
GARP	O
)	O
is	O
a	O
transmembrane	O
protein	O
that	O
is	O
highly	O
expressed	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

Metabolic	B-Phenotype
cutis	I-Phenotype
laxa	E-Phenotype
results	O
from	O
Menkes	O
syndrome	O
,	O
caused	O
by	O
a	O
defect	O
in	O
the	O
ATPase	O
copper	O
transporting	O
alpha	O
(	O
ATP7A	O
)	O
gene	O
;	O
congenital	O
disorders	O
of	O
glycosylation	O
due	O
to	O
mutations	O
in	O
subunit	O
7	O
of	O
the	O
component	O
of	O
oligomeric	O
Golgi	O
(	O
COG7	O
)	O
-	O
congenital	O
disorders	O
of	O
glycosylation	O
(	O
CDG	O
)	O
complex	O
;	O
combined	O
disorder	O
of	O
N	O
-	O
and	O
O	O
-	O
linked	O
glycosylation	O
,	O
due	O
to	O
mutations	O
in	O
ATPase	O
H+	O
transporting	O
V0	O
subunit	O
a2	O
(	O
ATP6VOA2	O
)	O
gene	O
;	O
pyrroline	O
-	O
5	O
-	O
carboxylate	O
reductase	O
1	O
deficiency	O
;	O
pyrroline	O
-	O
5	O
-	O
carboxylate	O
synthase	O
deficiency	O
;	O
macrocephaly	S-Phenotype
,	O
alopecia	S-Phenotype
,	O
cutis	B-Phenotype
laxa	E-Phenotype
,	O
and	O
scoliosis	S-Phenotype
(	O
MACS	O
)	O
syndrome	O
,	O
due	O
to	O
Ras	O
and	O
Rab	O
interactor	O
2	O
(	O
RIN2	O
)	O
mutations	O
;	O
transaldolase	O
deficiency	O
caused	O
by	O
mutations	O
in	O
the	O
transaldolase	O
1	O
(	O
TALDO1	O
)	O
gene	O
;	O
Gerodermia	O
osteodysplastica	O
due	O
to	O
mutations	O
in	O
the	O
golgin	O
,	O
RAB6	O
-	O
interacting	O
(	O
GORAB	O
or	O
SCYL1BP1	O
)	O
gene	O
;	O
and	O
mitogen	O
-	O
activated	O
pathway	O
(	O
MAP	O
)	O
kinase	O
defects	O
,	O
caused	O
by	O
mutations	O
in	O
several	O
genes	O
[	O
protein	O
tyrosine	O
phosphatase	O
,	O
non	O
-	O
receptor	O
-	O
type	O
11	O
(	O
PTPN11	O
)	O
,	O
RAF	O
,	O
NF	O
,	O
HRas	O
proto	O
-	O
oncogene	O
,	O
GTPase	O
(	O
HRAS	O
)	O
,	O
B	O
-	O
Raf	O
proto	O
-	O
oncogene	O
,	O
serine	O
/	O
threonine	O
kinase	O
(	O
BRAF	O
)	O
,	O
MEK1	O
/	O
2	O
,	O
KRAS	O
proto	O
-	O
oncogene	O
,	O
GTPase	O
(	O
KRAS	O
)	O
,	O
SOS	O
Ras	O
/	O
Rho	O
guanine	O
nucleotide	O
exchange	O
factor	O
2	O
(	O
SOS2	O
)	O
,	O
leucine	O
rich	O
repeat	O
scaffold	O
protein	O
(	O
SHOC2	O
)	O
,	O
NRAS	O
proto	O
-	O
oncogene	O
,	O
GTPase	O
(	O
NRAS	O
)	O
,	O
and	O
Raf	O
-	O
1	O
proto	O
-	O
oncogene	O
,	O
serine	O
/	O
threonine	O
kinase	O
(	O
RAF1	O
)	O
]	O
,	O
which	O
regulate	O
the	O
Ras	O
-	O
MAPK	O
cascade	O
.	O

While	O
these	O
expansions	O
occur	O
in	O
coding	O
and	O
noncoding	O
regions	O
,	O
microsatellite	O
sequence	O
and	O
repeat	O
length	O
diversity	O
is	O
more	O
prominent	O
in	O
introns	O
with	O
eight	O
different	O
trinucleotide	O
to	O
hexanucleotide	O
repeats	O
,	O
causing	O
hereditary	O
diseases	O
such	O
as	O
myotonic	O
dystrophy	O
type	O
2	O
(	O
DM2	O
)	O
,	O
Fuchs	B-Phenotype
endothelial	I-Phenotype
corneal	I-Phenotype
dystrophy	E-Phenotype
(	O
FECD	S-Phenotype
)	O
,	O
and	O
C9orf72	B-Phenotype
amyotrophic	I-Phenotype
lateral	I-Phenotype
sclerosis	E-Phenotype
and	O
frontotemporal	B-Phenotype
dementia	E-Phenotype
(	O
C9	O
-	O
ALS	O
/	O
FTD	O
)	O
.	O

In	O
severe	O
bilateral	O
cases	O
(	O
anophthalmia	S-Phenotype
or	O
severe	O
microphthalmia	S-Phenotype
)	O
the	O
genetic	O
cause	O
is	O
now	O
identifiable	O
in	O
approximately	O
80	O
percent	O
of	O
cases	O
,	O
with	O
de	O
novo	O
heterozygous	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
SOX2	O
or	O
OTX2	O
being	O
the	O
most	O
common	O
.	O

Clinical	O
comparisons	O
showed	O
that	O
ataxias	S-Phenotype
due	O
to	O
channelopathies	O
had	O
a	O
significantly	O
earlier	O
age	O
at	O
onset	O
with	O
an	O
average	O
of	O
24.6	O
years	O
,	O
versus	O
40.9	O
years	O
for	O
polyglutamine	O
expansion	O
spinocerebellar	B-Phenotype
ataxias	E-Phenotype
and	O
37.8	O
years	O
for	O
SPG7	O
-	O
related	O
forms	O
(	O
P	O
=	O
0.001	O
)	O
.	O

Highlights	O
include	O
the	O
discoveries	O
of	O
(	O
i	O
)	O
a	O
new	O
genetic	O
etiology	O
,	O
autosomal	B-Phenotype
recessive	E-Phenotype
SPPL2a	O
deficiency	O
,	O
(	O
ii	O
)	O
TYK2	O
-	O
deficient	O
patients	O
with	O
a	O
clinical	O
phenotype	O
of	O
MSMD	O
,	O
(	O
iii	O
)	O
an	O
allelic	O
form	O
of	O
partial	O
recessive	O
IFN	O
-	O
yR2	O
deficiency	O
,	O
and	O
(	O
iv	O
)	O
two	O
forms	O
of	O
syndromic	O
MSMD	O
:	O
RORy	O
/	O
RORyT	O
and	O
JAK1	O
deficiencies	O
.	O

Similar	O
antitumor	O
activity	O
was	O
observed	O
in	O
FGFR2	O
wild	O
-	O
type	O
and	O
amplified	O
or	O
mutated	O
xenograft	O
models	O
.	O

Overall	O
,	O
this	O
first	O
report	O
of	O
a	O
germline	O
molecular	O
defect	O
in	O
SFTPA1	O
unveils	O
the	O
key	O
role	O
of	O
SP	O
-	O
A1	O
in	O
the	O
occurrence	O
of	O
several	O
chronic	O
respiratory	O
diseases	O
,	O
ranging	O
from	O
severe	O
respiratory	B-Phenotype
insufficiency	E-Phenotype
occurring	O
early	O
in	O
life	O
to	O
the	O
association	O
of	O
lung	B-Phenotype
fibrosis	E-Phenotype
and	O
cancer	S-Phenotype
in	O
adult	O
patients	O
.	O

The	O
immunohistochemical	O
assay	O
using	O
clinical	O
samples	O
of	O
colonic	B-Phenotype
tumors	E-Phenotype
with	O
various	O
invasion	O
depth	O
showed	O
that	O
p	O
-	O
STAT3	O
expression	O
was	O
inversely	O
associated	O
with	O
tumor	S-Phenotype
invasion	O
(	O
p	O
=	O
0.001	O
,	O
hazard	O
ratio	O
(	O
HR	O
)	O
=	O
0.328	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
95	O
%	O
CI	O
)	O
:	O
0.170	O
-	O
0.632	O
)	O
.	O

We	O
report	O
here	O
two	O
new	O
nonsense	O
mutations	O
(	O
pGln12	O
*	O
and	O
pTyr110	O
*	O
)	O
in	O
liCIB2	O
/	O
i	O
patients	O
displaying	O
nonsyndromic	B-Phenotype
profound	I-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
,	O
with	O
no	O
evidence	O
of	O
vestibular	O
or	O
retinal	B-Phenotype
dysfunction	E-Phenotype
.	O

We	O
report	O
a	O
girl	O
with	O
consanguineous	O
parents	O
presenting	O
as	O
collodion	B-Phenotype
baby	E-Phenotype
with	O
contractures	S-Phenotype
of	O
the	O
great	O
joints	O
and	O
palmoplantar	O
hyperlinearity	O
.	O

We	O
found	O
that	O
PRMT1	O
expression	O
in	O
tumor	S-Phenotype
associated	O
macrophages	O
correlated	O
with	O
STAT3	O
activation	O
in	O
human	O
HCC	O
specimens	O
.	O

We	O
describe	O
a	O
previously	O
unreported	O
syndrome	O
characterized	O
by	O
secondary	B-Phenotype
(	I-Phenotype
post	I-Phenotype
-	I-Phenotype
natal	I-Phenotype
)	I-Phenotype
microcephaly	E-Phenotype
with	O
fronto	B-Phenotype
-	I-Phenotype
temporal	I-Phenotype
lobe	I-Phenotype
hypoplasia	E-Phenotype
,	O
multiple	B-Phenotype
pituitary	I-Phenotype
hormone	I-Phenotype
deficiency	E-Phenotype
,	O
seizures	S-Phenotype
,	O
severe	B-Phenotype
visual	I-Phenotype
impairment	E-Phenotype
and	O
abnormalities	B-Phenotype
of	I-Phenotype
the	I-Phenotype
kidneys	I-Phenotype
and	I-Phenotype
urinary	I-Phenotype
tract	E-Phenotype
in	O
a	O
highly	O
consanguineous	O
family	O
with	O
six	O
affected	O
children	O
.	O

Our	O
results	O
therefore	O
confirm	O
the	O
KCNC3R423H	O
allele	O
as	O
causative	O
for	O
SCA13	O
,	O
through	O
a	O
dominant	O
negative	O
effect	O
on	O
KCNC3WT	O
and	O
links	O
with	O
EGFR	O
that	O
account	O
for	O
dominant	O
inheritance	S-Phenotype
,	O
congenital	O
onset	O
,	O
and	O
disease	O
pathology	O

Pathogenic	O
mutations	O
have	O
been	O
identified	O
in	O
the	O
TIMM8A	O
(	O
DDP	O
)	O
and	O
DNAJC19	O
(	O
TIMM14	O
)	O
genes	O
and	O
are	O
linked	O
to	O
Mohr	O
-	O
Tranebjærg	O
syndrome	O
and	O
dilated	B-Phenotype
cardiomyopathy	E-Phenotype
syndrome	O
(	O
with	O
and	O
without	O
ataxia	S-Phenotype
)	O
,	O
respectively	O
.	O

BACKGROUND	O
This	O
case	O
-	O
control	O
study	O
aimed	O
to	O
analyze	O
the	O
association	O
of	O
XRCC2	O
polymorphisms	O
(	O
rs3218408	O
and	O
rs3218384	O
)	O
with	O
colorectal	B-Phenotype
cancer	E-Phenotype
(	O
CRC	S-Phenotype
)	O
risk	O
.	O

Hypomorphic	O
IKBKG	O
mutations	O
in	O
males	O
are	O
typically	O
associated	O
with	O
anhidrotic	B-Phenotype
ectodermal	I-Phenotype
dysplasia	E-Phenotype
with	O
immunodeficiency	S-Phenotype
(	O
EDA	O
-	O
ID	O
)	O
.	O

BACKGROUND	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
prognostic	O
relevance	O
of	O
CEP55	O
in	O
lung	B-Phenotype
cancer	E-Phenotype
(	O
LC	S-Phenotype
)	O
.	O

The	O
deleted	O
in	O
colorectal	B-Phenotype
cancer	E-Phenotype
(	O
DCC	S-Phenotype
)	O
gene	O
encodes	O
the	O
netrin	O
-	O
1	O
(	O
NTN1	O
)	O
receptor	O
DCC	O
,	O
a	O
transmembrane	O
protein	O
required	O
for	O
the	O
guidance	O
of	O
commissural	O
axons	O
.	O

ASS1	O
was	O
highly	O
expressed	O
in	O
GC	O
and	O
positively	O
correlated	O
with	O
GC	O
aggressiveness	S-Phenotype
and	O
poor	O
outcome	O
.	O

Increased	O
NEK2	O
expression	O
during	O
the	O
late	O
pathological	O
stage	O
has	O
been	O
detected	O
in	O
the	O
Oncomine	O
liver	O
dataset	O
and	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
specimens	O
.	O

In	O
human	O
breast	B-Phenotype
cancer	E-Phenotype
xenografts	O
in	O
humanized	O
mice	O
,	O
blocking	O
the	O
recruitment	O
of	O
naive	O
CD4+	O
T	O
cells	O
into	O
tumor	S-Phenotype
by	O
knocking	O
down	O
the	O
expression	O
of	O
PITPNM3	O
,	O
a	O
CCL18	O
receptor	O
,	O
significantly	O
reduces	O
intratumoral	O
Tregs	O
and	O
inhibits	O
tumor	S-Phenotype
progression	O
.	O

bRationale	O
:	O
/	O
b	O
Oncogenic	O
STAT3	O
signaling	O
activation	O
and	O
3p22	O
-	O
21.3	O
locus	O
alteration	O
are	O
common	O
in	O
multiple	O
tumors	S-Phenotype
,	O
especially	O
carcinomas	B-Phenotype
of	I-Phenotype
the	I-Phenotype
nasopharynx	I-Phenotype
,	I-Phenotype
esophagus	I-Phenotype
and	I-Phenotype
lung	E-Phenotype
.	O

We	O
report	O
a	O
boy	O
with	O
intellectual	B-Phenotype
disability	E-Phenotype
carrying	O
two	O
de	O
novo	O
missense	O
mutations	O
in	O
the	O
last	O
exon	O
of	O
ZBTB20	O
(	O
Ser616Phe	O
and	O
Gly741Arg	O
;	O
both	O
previously	O
unreported	O
)	O
.	O

spSCC	O
tumours	S-Phenotype
arise	O
at	O
sites	O
of	O
epithelial	O
scratch	O
wounding	O
,	O
where	O
tumour	S-Phenotype
-	O
initiating	O
epithelial	O
cells	O
undergo	O
EMT	O
to	O
generate	O
spSCC	O
.	O

We	O
characterized	O
the	O
cellular	O
deficits	O
for	O
an	O
allelic	O
series	O
of	O
seven	O
STXBP1	O
mutations	O
and	O
developed	O
four	O
mouse	O
models	O
that	O
recapitulate	O
the	O
abnormal	B-Phenotype
EEG	E-Phenotype
activity	O
and	O
cognitive	O
aspects	O
of	O
human	O
STXBP1	O
-	O
encephalopathy	S-Phenotype
.	O

The	O
characteristic	O
thick	O
and	O
short	B-Phenotype
corpus	I-Phenotype
callosum	E-Phenotype
observed	O
in	O
7	O
/	O
8	O
cases	O
with	O
epilepsy	S-Phenotype
,	O
including	O
the	O
proband	O
,	O
but	O
not	O
in	O
three	O
non	O
-	O
syndromic	O
cases	O
,	O
appears	O
to	O
be	O
specific	O
,	O
and	O
thus	O
useful	O
for	O
indicating	O
the	O
possibility	O
of	O
SZT2	O
mutations	O
.	O

In	O
this	O
review	O
we	O
discuss	O
recent	O
advances	O
in	O
our	O
knowledge	O
of	O
the	O
MPC	O
,	O
and	O
we	O
argue	O
that	O
it	O
may	O
offer	O
a	O
promising	O
target	O
in	O
diseases	O
like	O
cancer	S-Phenotype
and	O
type	B-Phenotype
2	I-Phenotype
diabetes	E-Phenotype
.	O

Our	O
results	O
suggest	O
that	O
β	O
-	O
elemene	O
increases	O
the	O
sensitivity	O
of	O
gastric	B-Phenotype
cancer	E-Phenotype
cells	O
to	O
TRAIL	O
partially	O
by	O
promoting	O
the	O
formation	O
of	O
DISC	O
in	O
lipid	O
rafts	O

(	O
2013	O
)	O
previously	O
reported	O
a	O
homozygous	O
p.Trp284Ser	O
variant	O
in	O
STAC3	O
as	O
the	O
cause	O
of	O
Native	O
American	O
myopathy	S-Phenotype
(	O
NAM	O
)	O
in	O
5	O
Lumbee	O
Native	O
American	O
families	O
with	O
congenital	B-Phenotype
hypotonia	E-Phenotype
and	O
weakness	S-Phenotype
,	O
cleft	B-Phenotype
palate	E-Phenotype
,	O
short	B-Phenotype
stature	E-Phenotype
,	O
ptosis	S-Phenotype
,	O
kyphoscoliosis	S-Phenotype
,	O
talipes	B-Phenotype
deformities	E-Phenotype
,	O
and	O
susceptibility	O
to	O
malignant	B-Phenotype
hyperthermia	E-Phenotype
(	O
MH	S-Phenotype
)	O
.	O

For	O
in	O
vitro	O
studies	O
,	O
inhibition	O
of	O
PYCR1	O
by	O
small	O
-	O
hairpin	O
RNA	O
significantly	O
reduced	O
the	O
growth	O
and	O
invasion	O
capabilities	O
of	O
the	O
cells	O
,	O
while	O
enhancing	O
the	O
cytotoxicity	O
of	O
doxorubicin	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
MCF	O
-	O
7	O
(	O
ER	O
positive	O
)	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
(	O
ER	O
negative	O
)	O
.	O

The	O
novel	O
aspects	O
of	O
this	O
study	O
are	O
the	O
direct	O
identification	O
of	O
serine	O
biosynthesis	O
as	O
a	O
critical	O
mechanism	O
of	O
BRAF	O
V600E	O
inhibitor	O
resistance	O
and	O
the	O
first	O
successful	O
example	O
of	O
using	O
gemcitabine	O
+	O
BRAFis	O
in	O
combination	O
to	O
kill	O
previously	O
drug	O
-	O
resistant	O
cancer	S-Phenotype
cells	O
,	O
creating	O
the	O
translational	O
potential	O
of	O
pretreatment	O
with	O
gemcitabine	O
prior	O
to	O
BRAFi	O
treatment	O
of	O
tumor	S-Phenotype
cells	O
to	O
reverse	O
resistance	O
within	O
the	O
mutational	O
profile	O
and	O
the	O
WT	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
results	O
suggested	O
that	O
CCBE1	O
and	O
LYVE1	O
may	O
have	O
potential	O
as	O
biomarkers	O
for	O
the	O
identification	O
of	O
lung	B-Phenotype
cancer	E-Phenotype
patients	O
at	O
a	O
high	O
risk	O
of	O
LNM	O

The	O
dopamine	O
hypothesis	O
of	O
schizophrenia	S-Phenotype
is	O
based	O
on	O
the	O
fact	O
that	O
all	O
common	O
treatments	O
involve	O
antidopaminergic	O
mechanisms	O
and	O
genes	O
such	O
as	O
DRD2	O
,	O
DRD3	O
,	O
DARPP	O
-	O
32	O
,	O
BDNF	O
or	O
COMT	O
are	O
closely	O
related	O
to	O
dopaminergic	O
system	O
functioning	O
.	O

Two	O
recent	O
studies	O
unveiled	O
new	O
potential	O
functions	O
of	O
FGD1	O
,	O
in	O
particular	O
,	O
its	O
involvement	O
in	O
the	O
regulation	O
of	O
the	O
formation	O
and	O
function	O
of	O
invadopodia	O
and	O
podosomes	O
,	O
which	O
are	O
cellular	O
structures	O
devoted	O
to	O
degradation	O
of	O
the	O
extracellular	O
matrix	O
in	O
tumour	S-Phenotype
and	O
endothelial	O
cells	O
.	O

Fine	O
mapping	O
excluded	O
DFNB53	O
and	O
subsequently	O
homozygous	O
mutations	O
were	O
identified	O
in	O
the	O
lipoma	S-Phenotype
HMGIC	O
fusion	O
partner	O
-	O
like	O
5	O
(	O
LHFPL5	O
)	O
gene	O
,	O
also	O
named	O
tetraspan	O
membrane	O
protein	O
of	O
hair	O
cell	O
stereocilia	O
(	O
TMHS	O
)	O
gene	O
,	O
which	O
was	O
recently	O
shown	O
to	O
be	O
mutated	O
in	O
the	O
AAAAAAhurry	O
scurryAAAAAA	O
mouse	O
and	O
in	O
two	O
DFNB67	O
-	O
linked	O
families	O
from	O
Pakistan	O
.	O

Growth	B-Phenotype
abnormalities	E-Phenotype
,	O
motor	B-Phenotype
dysfunction	E-Phenotype
,	O
hindlimb	B-Phenotype
paralysis	E-Phenotype
,	O
muscle	B-Phenotype
wasting	E-Phenotype
,	O
neurogenic	B-Phenotype
atrophy	E-Phenotype
,	O
motor	B-Phenotype
neuron	I-Phenotype
degeneration	E-Phenotype
,	O
and	O
loss	O
of	O
large	O
-	O
caliber	O
axons	O
in	O
peripheral	O
nerves	O
occurred	O
at	O
an	O
earlier	O
age	O
in	O
liScyl1	O
/	O
i	O
/	O
Sicyl3	O
/	O
i	O
double	O
-	O
deficient	O
mice	O
than	O
in	O
liScyl1	O
/	O
i	O
-	O
deficient	O
mice	O
.	O

Transcripts	O
of	O
Prss56	O
,	O
a	O
gene	O
associated	O
with	O
angle	B-Phenotype
-	I-Phenotype
closure	I-Phenotype
glaucoma	E-Phenotype
,	O
posterior	O
microphthalmia	S-Phenotype
and	O
myopia	S-Phenotype
,	O
were	O
increased	O
in	O
Mfrprd6	O
eyes	O
by	O
17	O
-	O
fold	O
.	O

In	O
humans	O
,	O
mutations	O
in	O
several	O
genes	O
involved	O
in	O
the	O
Notch	O
pathway	O
are	O
associated	O
with	O
SDV	O
,	O
with	O
both	O
autosomal	B-Phenotype
recessive	E-Phenotype
(	O
MESP2	O
,	O
DLL3	O
,	O
LFNG	O
,	O
HES7	O
)	O
and	O
autosomal	O
dominant	O
(	O
TBX6	O
)	O
inheritance	O
.	O

The	O
downstream	O
pathways	O
of	O
Nodal	O
-	O
Foxh1	O
play	O
a	O
critical	O
role	O
not	O
only	O
in	O
L	O
-	O
R	O
determination	O
in	O
the	O
lateral	O
plate	O
mesoderm	O
but	O
also	O
in	O
myocardial	O
specification	O
and	O
differentiation	O
in	O
the	O
AHF	O
,	O
suggesting	O
that	O
TGA	O
is	O
a	O
phenotype	O
in	O
heterotaxia	S-Phenotype
as	O
well	O
as	O
the	O
primary	O
developmental	O
defect	O
of	O
the	O
AHF	O
.	O

The	O
tumor	S-Phenotype
suppressor	O
gene	O
TP53	O
is	O
mutated	O
exclusively	O
with	O
the	O
HYDIN	O
,	O
KRAS	O
,	O
and	O
PTEN	O
genes	O
in	O
large	B-Phenotype
intestine	I-Phenotype
,	I-Phenotype
lung	I-Phenotype
,	I-Phenotype
and	I-Phenotype
endometrial	I-Phenotype
cancers	E-Phenotype
respectively	O
,	O
indicating	O
that	O
TP53	O
takes	O
part	O
in	O
different	O
signaling	O
pathways	O
in	O
different	O
cancers	S-Phenotype
.	O

Here	O
we	O
present	O
a	O
series	O
of	O
eight	O
patients	O
from	O
seven	O
families	O
presenting	O
with	O
exercise	B-Phenotype
intolerance	E-Phenotype
and	O
rhabdomyolysis	S-Phenotype
caused	O
by	O
mutations	O
in	O
CAV3	O
diagnosed	O
by	O
next	O
generation	O
sequencing	O
(	O
NGS	O
)	O
(	O
n	O
=	O
6	O
)	O
.	O

Exome	O
and	O
targeted	O
sequencing	O
has	O
recently	O
identified	O
four	O
new	O
genes	O
causing	O
ataxia	S-Phenotype
:	O
TGM6	O
,	O
ANO10	O
,	O
SYT14	O
,	O
and	O
rundataxin	O
.	O

A	O
replicative	O
analysis	O
of	O
associations	O
of	O
15	O
SNPs	O
located	O
in	O
the	O
regions	O
of	O
11	O
genes	O
(	O
TCF4	O
,	O
VRK2	O
,	O
NOTCH4	O
,	O
ZNF804A	O
,	O
AGBL1	O
,	O
RELN	O
,	O
ZFP64P1	O
,	O
KCNB2	O
,	O
CSMD1	O
,	O
CPVL	O
,	O
NRIP1	O
)	O
and	O
three	O
intergenic	O
regions	O
(	O
SLCO6A1	O
/	O
LINCOO491	O
,	O
LOC105376248	O
/	O
LOC105376249	O
,	O
SPA17	O
/	O
NRGN	O
)	O
with	O
schizophrenia	S-Phenotype
was	O
conducted	O
in	O
the	O
Russian	O
population	O
of	O
the	O
Siberian	O
region	O
.	O

Aberrant	O
expression	O
of	O
different	O
family	O
members	O
of	O
the	O
Eph	O
/	O
ephrin	O
system	O
,	O
which	O
comprises	O
the	O
Eph	O
receptors	O
(	O
Ephs	O
)	O
and	O
their	O
ligands	O
(	O
ephrins	O
)	O
,	O
has	O
been	O
implicated	O
in	O
various	O
malignancies	O
including	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

We	O
investigated	O
the	O
effects	O
of	O
shRNA	O
-	O
mediated	O
knockdown	O
of	O
NOS1AP	O
and	O
SCRIB	O
in	O
vitro	O
,	O
and	O
found	O
that	O
reducing	O
NOS1AP	O
and	O
SCRIB	O
slows	O
breast	B-Phenotype
cancer	E-Phenotype
cell	O
migration	O
and	O
prevents	O
the	O
establishment	O
of	O
leading	O
-	O
trailing	O
polarity	O
.	O

The	O
1p	O
breakpoint	O
disrupts	O
the	O
5	O
'	O
UTR	O
of	O
AHDC1	O
,	O
which	O
encodes	O
AT	O
-	O
hook	O
DNA	O
-	O
binding	O
motif	O
containing	O
-	O
1	O
protein	O
,	O
and	O
AHDC1	O
-	O
truncating	O
mutations	O
have	O
recently	O
been	O
described	O
in	O
a	O
syndrome	O
that	O
includes	O
developmental	B-Phenotype
delay	E-Phenotype
,	O
but	O
not	O
congenital	O
heart	O
disease	O
[	O
Xia	O
,	O
F.	O
,	O
Bainbridge	O
,	O
M.N.	O
,	O
Tan	O
,	O
T.Y.	O
,	O
Wangler	O
,	O
M.F.	O
,	O
Scheuerle	O
,	O
A.E.	O
,	O
Zackai	O
,	O
E.H.	O
,	O
Harr	O
,	O
M.H.	O
,	O
Sutton	O
,	O
V.R.	O
,	O
Nalam	O
,	O
R.L.	O
,	O
Zhu	O
,	O
W.	O
et	O
al	O
.	O

l	O
-	O
DOPA	O
-	O
induced	O
dyskinesia	S-Phenotype
was	O
exacerbated	O
in	O
TG	O
mice	O
without	O
altering	O
l	O
-	O
DOPA	O
motor	O
efficacy	O
as	O
determined	O
by	O
contralateral	O
rotations	O
or	O
motor	O
coordination	O
.	O

Xenografts	O
of	O
PNPO	O
-	O
shRNA	O
-	O
expressing	O
cells	O
into	O
the	O
nude	O
mouse	O
attenuated	O
tumour	S-Phenotype
growth	O
.	O

In	O
human	O
breast	B-Phenotype
cancer	E-Phenotype
xenografts	O
in	O
humanized	O
mice	O
,	O
blocking	O
the	O
recruitment	O
of	O
naive	O
CD4sup+	O
/	O
sup	O
T	O
cells	O
into	O
tumor	S-Phenotype
by	O
knocking	O
down	O
the	O
expression	O
of	O
PITPNM3	O
,	O
a	O
CCL18	O
receptor	O
,	O
significantly	O
reduces	O
intratumoral	O
Tregs	O
and	O
inhibits	O
tumor	S-Phenotype
progression	O
.	O

This	O
seizure	S-Phenotype
type	O
is	O
similar	O
to	O
AAAAAAparoxysmal	O
arousalsAAAAAA	O
that	O
are	O
observed	O
in	O
human	O
ADNFLE	O
.	O

Several	O
tumor	S-Phenotype
suppressor	O
genes	O
and	O
proto	O
-	O
oncogenes	O
have	O
been	O
implicated	O
in	O
BCC	O
pathogenesis	O
,	O
including	O
the	O
key	O
components	O
of	O
the	O
Hedgehog	O
pathway	O
,	O
PTCH1	O
and	O
SMO	O
,	O
the	O
TP53	O
tumor	S-Phenotype
suppressor	O
,	O
and	O
members	O
of	O
the	O
RAS	O
proto	O
-	O
oncogene	O
family	O
.	O

Using	O
exome	O
sequencing	O
,	O
we	O
discovered	O
missense	O
mutations	O
in	O
AFF4	O
,	O
a	O
core	O
component	O
of	O
the	O
SEC	O
,	O
in	O
three	O
unrelated	O
probands	O
with	O
a	O
new	O
syndrome	O
that	O
phenotypically	O
overlaps	O
Cornelia	O
de	O
Lange	O
syndrome	O
(	O
CdLS	O
)	O
that	O
we	O
have	O
named	O
CHOPS	O
syndrome	O
(	O
C	O
for	O
cognitive	B-Phenotype
impairment	E-Phenotype
and	O
coarse	B-Phenotype
facies	E-Phenotype
,	O
H	O
for	O
heart	B-Phenotype
defects	E-Phenotype
,	O
O	O
for	O
obesity	S-Phenotype
,	O
P	O
for	O
pulmonary	O
involvement	O
and	O
S	O
for	O
short	B-Phenotype
stature	E-Phenotype
and	O
skeletal	B-Phenotype
dysplasia	E-Phenotype
)	O
.	O

Our	O
study	O
shows	O
that	O
in	O
neuroblastomas	S-Phenotype
,	O
AURKB	O
-	O
or	O
GMNN	O
-	O
based	O
PI	O
provides	O
valuable	O
prognostic	O
information	O
and	O
high	O
PI	O
indicates	O
aggressive	O
disease	O

We	O
and	O
others	O
have	O
recently	O
demonstrated	O
that	O
c	O
-	O
SRC	O
is	O
a	O
key	O
mediator	O
of	O
growth	O
,	O
invasion	O
,	O
and	O
metastasis	O
,	O
and	O
therefore	O
represents	O
a	O
promising	O
therapeutic	O
target	O
in	O
thyroid	B-Phenotype
cancer	E-Phenotype
.	O

Although	O
p53R2	O
has	O
been	O
linked	O
to	O
human	O
cancer	S-Phenotype
,	O
its	O
role	O
in	O
cervical	B-Phenotype
cancer	E-Phenotype
remains	O
unknown	O
.	O

In	O
the	O
present	O
study	O
,	O
with	O
the	O
aim	O
of	O
reducing	O
the	O
cost	O
of	O
utilizing	O
growth	O
factors	O
in	O
cancer	S-Phenotype
research	O
,	O
a	O
simple	O
and	O
efficient	O
method	O
for	O
the	O
preparation	O
of	O
recombinant	O
human	O
(	O
rh	O
)	O
FGF9	O
in	O
Escherichia	O
coli	O
was	O
established	O
.	O

Primary	B-Phenotype
distal	I-Phenotype
renal	I-Phenotype
tubular	I-Phenotype
acidosis	E-Phenotype
(	O
dRTA	S-Phenotype
)	O
caused	O
by	O
mutations	O
of	O
the	O
SLC4A1	O
gene	O
,	O
which	O
encodes	O
for	O
erythroid	O
and	O
kidney	O
isoforms	O
of	O
anion	O
exchanger	O
,	O
shows	O
marked	O
difference	O
in	O
inheritance	O
patterns	O
and	O
clinical	O
features	O
in	O
different	O
parts	O
of	O
the	O
world	O
.	O

We	O
found	O
that	O
the	O
expression	O
of	O
Sgo1	O
mRNA	O
was	O
relatively	O
low	O
in	O
normal	O
tissues	O
,	O
but	O
was	O
upregulated	O
in	O
82	O
%	O
of	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
,	O
and	O
correlated	O
with	O
elevated	B-Phenotype
alpha	I-Phenotype
-	I-Phenotype
fetoprotein	E-Phenotype
and	O
early	O
disease	O
onset	O
of	O
HCC	S-Phenotype
.	O

Mendelian	O
randomization	O
analyses	O
suggest	O
causal	O
inverse	O
associations	O
,	O
independent	O
of	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
,	O
between	O
puberty	O
timing	O
and	O
risks	O
for	O
breast	B-Phenotype
and	I-Phenotype
endometrial	I-Phenotype
cancers	E-Phenotype
in	O
women	O
and	O
prostate	B-Phenotype
cancer	E-Phenotype
in	O
men	O
.	O

That	O
binding	O
,	O
which	O
interferes	O
with	O
the	O
interaction	O
of	O
RhoA	O
-	O
GTP	O
with	O
the	O
RhoGAP	O
domain	O
,	O
reduces	O
the	O
hydrolysis	O
of	O
RhoA	O
-	O
GTP	O
,	O
the	O
binding	O
of	O
other	O
DLC1	O
ligands	O
,	O
and	O
the	O
colocalization	O
of	O
DLC1	O
with	O
focal	O
adhesions	O
and	O
attenuates	O
tumor	S-Phenotype
suppressor	O
activity	O
.	O

Deregulation	O
of	O
the	O
phosphoinositide	O
3	O
-	O
kinase	O
(	O
PI3K	O
)	O
pathway	O
contributes	O
to	O
the	O
development	O
and	O
progression	O
of	O
tumors	S-Phenotype
.	O

MVA	O
due	O
to	O
biallelic	O
CEP57	O
mutations	O
,	O
or	O
of	O
unknown	O
cause	O
,	O
is	O
not	O
associated	O
with	O
embryonal	B-Phenotype
tumors	E-Phenotype
and	O
cells	O
from	O
these	O
individuals	O
show	O
minimal	O
SAC	O
deficiency	O
.	O

iResults	O
:	O
/	O
i	O
The	O
number	O
of	O
positive	O
cells	O
of	O
TAZ	O
and	O
YAP	O
in	O
malignant	B-Phenotype
melanoma	I-Phenotype
tumor	E-Phenotype
tissues	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
melanocytic	B-Phenotype
nevi	E-Phenotype
tissues	O
,	O
and	O
the	O
expression	O
of	O
both	O
proteins	O
was	O
positively	O
correlated	O
with	O
malignant	B-Phenotype
melanoma	E-Phenotype
(	O
r	O
=	O
0.687	O
,	O
P	O
AAAA0.01	O
)	O
;	O
TAZ	O
and	O
YAP	O
protein	O
expression	O
in	O
malignant	B-Phenotype
melanoma	E-Phenotype
tissue	O
was	O
significantly	O
correlated	O
with	O
tumor	S-Phenotype
thickness	O
,	O
invasive	O
depth	O
grade	O
,	O
lymph	O
node	O
metastasis	O
and	O
TNM	O
stages	O
(	O
P	O
AAAA0.05	O
)	O
,	O
and	O
increased	O
with	O
TNM	O
staging	O
.	O

The	O
patient	O
reported	O
here	O
shares	O
speech	B-Phenotype
difficulties	E-Phenotype
,	O
intellectual	B-Phenotype
disability	E-Phenotype
and	O
autistic	O
features	O
with	O
other	O
FOXP1	O
syndrome	O
patients	O
,	O
and	O
thus	O
the	O
diagnosis	O
for	O
this	O
patient	O
should	O
be	O
changed	O
.	O

The	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
region	O
on	O
chromosome	O
6p21.3	O
is	O
suspected	O
to	O
host	O
susceptibility	O
loci	O
for	O
HIV	O
-	O
related	O
Kaposi	B-Phenotype
's	I-Phenotype
sarcoma	E-Phenotype
(	O
HIV	O
-	O
KS	O
)	O
.	O

In	O
addition	O
,	O
the	O
coexistence	O
of	O
high	O
MACC1	O
and	O
low	O
NM23	O
-	O
H1	O
expression	O
and	O
tumor	S-Phenotype
budding	O
was	O
associated	O
with	O
short	O
OS	O
(	O
p	O
AAAA	O
0.001	O
)	O
.	O

Citrin	O
deficiency	O
is	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
metabolic	O
disorder	O
,	O
which	O
is	O
caused	O
by	O
pathogenic	O
mutations	O
in	O
the	O
SLC25A13	O
gene	O
on	O
chromosome	O
7q21.3	O
,	O
as	O
the	O
causative	O
gene	O
that	O
encodes	O
the	O
liver	O
type	O
aspartate	O
/	O
glutamate	O
carrier	O
isoform	O
2	O
(	O
AGC2	O
)	O
.	O

These	O
results	O
indicate	O
that	O
FGF12	O
has	O
a	O
potential	O
role	O
in	O
ESCC	O
and	O
suggest	O
that	O
cancer	S-Phenotype
genomic	O
datasets	O
with	O
application	O
of	O
in	O
silico	O
approaches	O
are	O
instrumental	O
for	O
biomarker	O
discovery	O
research	O
broadly	O
and	O
specifically	O
,	O
for	O
the	O
identification	O
of	O
FGF12	O
as	O
a	O
putative	O
biomarker	O
in	O
ESCC	O

At	O
least	O
some	O
P5B	O
isoforms	O
are	O
of	O
vital	O
importance	O
for	O
the	O
nervous	O
system	O
,	O
since	O
ATP13A2	O
and	O
ATP13A4	O
are	O
linked	O
to	O
respectively	O
Parkinson	O
disease	O
and	O
autism	B-Phenotype
spectrum	I-Phenotype
disorders	E-Phenotype

We	O
identified	O
novel	O
ALK	O
fusions	O
in	O
a	O
neuroblastoma	S-Phenotype
(	O
BEND5	O
-	O
ALK	O
)	O
and	O
an	O
astrocytoma	S-Phenotype
(	O
PPP1CB	O
-	O
ALK	O
)	O
,	O
novel	O
BRAF	O
fusions	O
in	O
an	O
astrocytoma	S-Phenotype
(	O
BCAS1	O
-	O
BRAF	O
)	O
and	O
a	O
ganglioglioma	S-Phenotype
(	O
TMEM106B	O
-	O
BRAF	O
)	O
,	O
and	O
a	O
novel	O
PAX3	O
-	O
GLI2	O
fusion	O
in	O
a	O
rhabdomyosarcoma	S-Phenotype
.	O

Hormone	O
positive	O
,	O
HER2	O
positive	O
and	O
triple	B-Phenotype
negative	I-Phenotype
breast	I-Phenotype
cancer	E-Phenotype
(	O
TNBC	S-Phenotype
)	O
cell	O
lines	O
,	O
xenografts	O
/	O
mutant	O
animal	O
models	O
and	O
patient	O
samples	O
are	O
examined	O
separately	O
as	O
,	O
in	O
humans	O
,	O
they	O
represent	O
entities	O
with	O
differences	O
in	O
prognosis	O
and	O
treatment	O
.	O

Mutations	O
in	O
MYH7	O
are	O
associated	O
with	O
not	O
only	O
skeletal	O
muscle	O
diseases	O
,	O
such	O
as	O
Laing	B-Phenotype
distal	I-Phenotype
myopathy	E-Phenotype
and	O
myosin	B-Phenotype
storage	I-Phenotype
myopathy	E-Phenotype
,	O
but	O
also	O
hypertrophic	B-Phenotype
cardiomyopathy	E-Phenotype
.	O

Taken	O
together	O
,	O
our	O
study	O
provides	O
the	O
first	O
functional	O
link	O
between	O
GNB3	O
and	O
obesity	S-Phenotype
,	O
and	O
presents	O
insight	O
into	O
novel	O
pathways	O
that	O
could	O
be	O
applied	O
to	O
combat	O
obesity	S-Phenotype
and	O
type	B-Phenotype
2	I-Phenotype
diabetes	E-Phenotype

We	O
have	O
identified	O
nine	O
genes	O
of	O
interest	O
that	O
appear	O
to	O
be	O
involved	O
in	O
cervical	B-Phenotype
cancer	E-Phenotype
development	O
:	O
SPARCL1	O
,	O
SYCP2	O
,	O
KIF4A	O
,	O
PRC1	O
,	O
TOP2A	O
,	O
LAMP3	O
,	O
KIF20A	O
,	O
MCM2	O
,	O
and	O
APOBEC3B	O
.	O

PRKAG3	O
(	O
Padj	O
=	O
0.0018	O
)	O
and	O
RPS6KA3	O
(	O
Padj	O
=	O
0.061	O
)	O
were	O
the	O
leading	O
genes	O
for	O
the	O
associations	O
with	O
overall	O
breast	B-Phenotype
cancer	E-Phenotype
risk	O
and	O
ER	O
-	O
breast	B-Phenotype
cancer	E-Phenotype
risk	O
,	O
respectively	O
.	O

We	O
aimed	O
to	O
investigate	O
the	O
effect	O
of	O
the	O
AS	O
to	O
FEZF1	O
gene	O
on	O
non	B-Phenotype
-	I-Phenotype
small	I-Phenotype
cell	I-Phenotype
lung	I-Phenotype
cancer	E-Phenotype
(	O
NSCLC	S-Phenotype
)	O
development	O
.	O

We	O
show	O
that	O
loss	O
of	O
the	O
Drosophila	O
long	O
-	O
/	O
very	O
-	O
long	O
-	O
chain	O
acyl	O
-	O
CoA	O
synthetase	O
genes	O
bgm	O
and	O
/	O
or	O
dbb	O
is	O
indistinguishable	O
from	O
loss	O
of	O
the	O
Drosophila	O
ABC	O
transporter	O
gene	O
ABCD	O
Shared	O
loss	O
-	O
of	O
-	O
function	O
phenotypes	O
for	O
synthetase	O
and	O
transporter	O
mutants	O
point	O
to	O
a	O
lipid	O
metabolic	O
pathway	O
association	O
with	O
ALD	O
-	O
like	O
neurodegenerative	B-Phenotype
disease	E-Phenotype
in	O
Drosophila	O
;	O
a	O
pathway	O
association	O
that	O
has	O
yet	O
to	O
be	O
established	O
in	O
humans	O
.	O

Our	O
work	O
identifies	O
TUFM	O
as	O
a	O
novel	O
regulator	O
of	O
EMT	O
and	O
suggests	O
a	O
molecular	O
link	O
between	O
mitochondrial	B-Phenotype
dysfunction	E-Phenotype
and	O
EMT	O
induction	O
.	O

The	O
dystrobrevin	O
-	O
binding	O
protein	O
1	O
(	O
DTNBP1	O
)	O
gene	O
is	O
a	O
candidate	O
risk	O
factor	O
for	O
schizophrenia	S-Phenotype
and	O
has	O
been	O
associated	O
with	O
cognitive	O
ability	O
in	O
both	O
patient	O
populations	O
and	O
healthy	O
controls	O
.	O

Mutations	O
in	O
GJA8	O
are	O
associated	O
with	O
hereditary	O
autosomal	O
dominant	O
and	O
recessive	O
cataract	S-Phenotype
formation	O
.	O

Jalili	O
syndrome	O
(	O
JS	O
)	O
is	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
disease	O
characterized	O
by	O
a	O
combination	O
of	O
cone	O
-	O
rode	O
retinal	O
dytrophy	O
(	O
CRD	O
)	O
and	O
amelogenesis	O
imperfect	O
(	O
AI	O
)	O
.	O

Homozygozity	O
mapping	O
and	O
exome	O
sequencing	O
in	O
62	O
isolated	O
individuals	O
with	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
parkinsonism	E-Phenotype
and	O
confirmed	O
consanguinity	O
followed	O
by	O
data	O
mining	O
in	O
the	O
exomes	O
of	O
1,348	O
PD	O
-	O
affected	O
individuals	O
identified	O
,	O
in	O
three	O
isolated	O
subjects	O
,	O
homozygous	O
or	O
compound	O
heterozygous	O
truncating	O
mutations	O
in	O
vacuolar	O
protein	O
sorting	O
13C	O
(	O
VPS13C	O
)	O
.	O

The	O
patient	O
had	O
a	O
history	O
of	O
severe	O
neonatal	B-Phenotype
jaundice	E-Phenotype
,	O
hemolytic	B-Phenotype
crisis	E-Phenotype
with	O
rhabdomyolysis	B-Phenotype
triggered	I-Phenotype
by	I-Phenotype
febrile	I-Phenotype
viral	I-Phenotype
infections	E-Phenotype
,	O
dysarthria	S-Phenotype
,	O
and	O
intellectual	B-Phenotype
disability	E-Phenotype
during	O
early	O
childhood	O
.	O

iDLEC1	O
/	O
i	O
methylation	O
was	O
frequently	O
detected	O
in	O
ESCC	O
tumors	S-Phenotype
and	O
correlated	O
with	O
lymph	O
node	O
metastasis	O
,	O
tumor	S-Phenotype
recurrence	O
and	O
progression	O
,	O
with	O
liDLEC1	O
/	O
i	O
as	O
the	O
most	O
frequently	O
methylated	O
among	O
the	O
established	O
3p22.2	O
tumor	S-Phenotype
suppressors	O
(	O
liRASSF1A	O
,	O
PLCD1	O
/	O
i	O
and	O
liZMYND10	O
/	O
BLU	O
/	O
i	O
)	O
.	O

This	O
work	O
suggests	O
that	O
loss	O
of	O
function	O
of	O
VPS13C	O
is	O
a	O
cause	O
of	O
autosomal	B-Phenotype
-	I-Phenotype
recessive	I-Phenotype
early	I-Phenotype
-	I-Phenotype
onset	I-Phenotype
parkinsonism	E-Phenotype
with	O
a	O
distinctive	O
phenotype	O
of	O
rapid	O
and	O
severe	O
progression	O

The	O
transcriptome	O
of	O
CXCL1	O
-	O
treated	O
cancer	S-Phenotype
cells	O
was	O
established	O
by	O
next	O
generation	O
sequencing	O
.	O

Post	B-Phenotype
-	I-Phenotype
infectious	I-Phenotype
glomerulonephritis	E-Phenotype
(	O
PIGN	S-Phenotype
)	O
is	O
one	O
of	O
the	O
most	O
common	O
causes	O
of	O
acute	O
glomerulonephritis	S-Phenotype
in	O
children	O
.	O

Their	O
expression	O
changes	O
were	O
further	O
validated	O
in	O
U2OS	O
osteosarcoma	S-Phenotype
cell	O
lines	O
and	O
hOB	O
normal	O
cell	O
lines	O
through	O
quantitative	O
PCR	O
(	O
qPCR	O
)	O
and	O
consistent	O
result	O
with	O
microarray	O
analysis	O
was	O
obtained	O
.	O

This	O
report	O
supports	O
the	O
association	O
of	O
TENM3	O
mutations	O
with	O
colobomatous	B-Phenotype
microphthalmia	E-Phenotype
and	O
expands	O
the	O
phenotypic	O
spectrum	O
associated	O
with	O
mutations	O
in	O
this	O
gene	O
.	O

To	O
explore	O
the	O
underlying	O
mechanism	O
of	O
tumor	S-Phenotype
suppression	O
by	O
BLU	O
,	O
its	O
potential	O
to	O
promote	O
apoptosis	O
induced	O
by	O
TRAIL	O
,	O
an	O
effector	O
molecule	O
elaborated	O
by	O
natural	O
killer	O
-	O
T	O
(	O
NKT	O
)	O
cells	O
was	O
investigated	O
.	O

Here	O
,	O
we	O
show	O
that	O
breast	B-Phenotype
-	I-Phenotype
ovarian	I-Phenotype
cancer	I-Phenotype
susceptibility	I-Phenotype
1	E-Phenotype
(	O
BRCA1	S-Phenotype
)	O
interacts	O
directly	O
with	O
ATR	O
-	O
interacting	O
protein	O
(	O
ATRIP	O
)	O
,	O
an	O
obligate	O
partner	O
of	O
ATR	O
.	O

We	O
found	O
that	O
PDCD10	O
expression	O
was	O
cell	O
-	O
and	O
anti	O
-	O
cancer	S-Phenotype
agent	O
-	O
specific	O
;	O
down	O
-	O
regulated	O
in	O
doxorubicin	O
-	O
and	O
docetaxel	O
-	O
resistant	O
MCF7	O
cells	O
while	O
up	O
-	O
regulated	O
in	O
doxorubicin	O
-	O
resistant	O
HeLa	O
cells	O
.	O

The	O
incidence	O
rate	O
of	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
is	O
rising	O
.	O

We	O
have	O
previously	O
identified	O
a	O
role	O
for	O
the	O
secreted	O
serine	O
protease	O
PRSS56	O
in	O
ocular	O
size	O
determination	O
and	O
PRSS56	O
variants	O
have	O
been	O
implicated	O
in	O
the	O
etiology	O
of	O
both	O
hyperopia	S-Phenotype
and	O
myopia	S-Phenotype
,	O
highlighting	O
its	O
importance	O
in	O
refractive	O
development	O
.	O

Mutations	O
in	O
abnormal	O
spindle	O
-	O
like	O
microcephaly	S-Phenotype
-	O
associated	O
(	O
ASPM	O
)	O
,	O
the	O
most	O
common	O
recessive	O
microcephaly	S-Phenotype
gene	O
,	O
reduce	O
cortical	O
volume	O
by	O
at	O
least	O
50	O
%	O
in	O
humanssup2	O
-	O
4	O
/	O
sup	O
,	O
but	O
have	O
little	O
effect	O
on	O
the	O
brains	O
of	O
micesup5	O
-	O
9	O
/	O
sup	O
;	O
this	O
probably	O
reflects	O
evolutionarily	O
divergent	O
functions	O
of	O
ASPMsup10,11	O
/	O
sup	O
.	O

CBG	O
concentration	O
and	O
affinity	O
are	O
affected	O
by	O
a	O
number	O
of	O
common	O
factors	O
including	O
oral	O
contraceptive	O
pills	O
(	O
OCPs	O
)	O
,	O
fever	S-Phenotype
and	O
infection	S-Phenotype
,	O
as	O
well	O
as	O
rare	O
mutations	O
in	O
the	O
serine	O
protease	O
inhibitor	O
A6	O
(	O
SERPINA6	O
)	O
gene	O
,	O
and	O
as	O
such	O
,	O
total	O
cortisol	O
levels	O
might	O
not	O
be	O
the	O
ideal	O
way	O
to	O
assess	O
adrenal	O
function	O
in	O
all	O
clinical	O
circumstances	O
.	O

Here	O
,	O
using	O
a	O
microarray	O
screen	O
,	O
we	O
found	O
that	O
knocking	O
down	O
DJ	O
-	O
1	O
in	O
human	O
neuroblastoma	S-Phenotype
cells	O
results	O
in	O
down	O
-	O
regulation	O
of	O
microRNA	O
-	O
221	O
(	O
miR	O
-	O
221	O
)	O
.	O

The	O
present	O
study	O
aimed	O
to	O
molecularly	O
define	O
and	O
determine	O
the	O
contribution	O
of	O
two	O
rare	O
,	O
apparently	O
novel	O
CHEK2	O
LGRs	O
,	O
among	O
Greek	O
breast	B-Phenotype
cancer	E-Phenotype
patients	O
.	O

Biallelic	O
UNC80	O
mutations	O
cause	O
infantile	B-Phenotype
hypotonia	E-Phenotype
with	O
psychomotor	B-Phenotype
retardation	E-Phenotype
and	O
characteristic	O
facies	O
2	O
(	O
IHPRF2	O
)	O
,	O
which	O
is	O
characterized	O
by	O
hypotonia	S-Phenotype
,	O
developmental	B-Phenotype
delay	E-Phenotype
(	O
DD	S-Phenotype
)	O
/	O
intellectual	B-Phenotype
disability	E-Phenotype
(	O
ID	S-Phenotype
)	O
,	O
intrauterine	B-Phenotype
growth	I-Phenotype
retardation	E-Phenotype
,	O
postnatal	B-Phenotype
growth	I-Phenotype
retardation	E-Phenotype
and	O
characteristic	O
facial	O
features	O
.	O

In	O
particular	O
,	O
we	O
find	O
that	O
PRODH	O
expression	O
and	O
proline	O
catabolism	O
is	O
increased	O
in	O
metastases	O
compared	O
to	O
primary	O
breast	B-Phenotype
cancers	E-Phenotype
of	O
patients	O
and	O
mice	O
.	O

We	O
report	O
the	O
association	O
of	O
many	O
previously	O
unreported	O
variants	O
with	O
retinal	B-Phenotype
disease	E-Phenotype
,	O
as	O
well	O
as	O
new	O
disease	O
phenotypes	O
associated	O
with	O
known	O
genes	O
,	O
including	O
the	O
first	O
association	O
of	O
the	O
SLC24A1	O
gene	O
with	O
retinitis	B-Phenotype
pigmentosa	E-Phenotype
.	O

The	O
alterations	O
of	O
ATM	O
and	O
CADM1	O
are	O
associated	O
with	O
the	O
progression	O
of	O
tumor	S-Phenotype
from	O
CIN	O
to	O
Stage	O
I	O
/	O
II	O
,	O
thus	O
implying	O
their	O
role	O
in	O
early	O
invasiveness	O
.	O

In	O
order	O
to	O
address	O
these	O
questions	O
,	O
we	O
searched	O
for	O
alterations	O
in	O
PLCB4	O
,	O
GNAI3	O
,	O
and	O
EDN1	O
in	O
patients	O
with	O
typical	O
Auriculocondylar	O
syndrome	O
(	O
n	O
=	O
3	O
)	O
,	O
Pierre	B-Phenotype
Robin	I-Phenotype
sequence	E-Phenotype
-	O
plus	O
(	O
n	O
=	O
3	O
)	O
,	O
micrognathia	S-Phenotype
with	O
additional	O
craniofacial	O
malformations	O
(	O
n	O
=	O
4	O
)	O
,	O
or	O
non	O
-	O
specific	O
auricular	O
dysplasia	O
(	O
n	O
=	O
1	O
)	O
,	O
which	O
could	O
represent	O
subtypes	O
of	O
Auriculocondylar	O
syndrome	O
.	O

This	O
study	O
aims	O
to	O
investigate	O
the	O
association	O
of	O
2	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
CORIN	O
(	O
rs2271037	O
and	O
rs3749585	O
)	O
with	O
hypertension	S-Phenotype
,	O
as	O
well	O
as	O
their	O
potential	O
interactions	O
with	O
some	O
risk	O
factors	O
of	O
hypertension	S-Phenotype
in	O
a	O
Han	O
population	O
of	O
northeastern	O
China	O
.	O

The	O
results	O
reported	O
in	O
the	O
present	O
study	O
suggest	O
a	O
sex	O
-	O
specific	O
interaction	O
between	O
miR	O
-	O
146a	O
and	O
RNASEL	O
genes	O
in	O
melanoma	B-Phenotype
skin	I-Phenotype
cancer	E-Phenotype
susceptibility	O
,	O
and	O
could	O
account	O
for	O
possible	O
discordant	O
results	O
in	O
association	O
studies	O
when	O
stratification	O
according	O
to	O
sex	O
is	O
not	O
performed	O

The	O
variants	O
GJB2	O
c.235delC	O
,	O
SLC26A4	O
c.919	O
-	O
2AAAAAG	O
,	O
and	O
mitochondrial	S-Phenotype
variants	O
m.1555AAAAAG	O
and	O
m.1494CAAAAT	O
were	O
assayed	O
using	O
real	O
time	O
PCR	O
.	O

In	O
this	O
investigation	O
,	O
using	O
a	O
large	O
multiethnic	O
cohort	O
(	O
1738	O
subjects	O
)	O
,	O
we	O
aimed	O
to	O
determine	O
whether	O
the	O
magnitude	O
of	O
anti	O
-	O
GARP	O
antibody	O
responsiveness	O
was	O
significantly	O
different	O
in	O
patients	O
with	O
breast	B-Phenotype
cancer	E-Phenotype
from	O
that	O
in	O
matched	O
healthy	O
controls	O
.	O

The	O
dystrobrevin	O
-	O
binding	O
protein	O
1	O
(	O
DTNBP1	O
)	O
gene	O
is	O
a	O
candidate	O
risk	O
factor	O
for	O
schizophrenia	S-Phenotype
and	O
has	O
been	O
associated	O
with	O
cognitive	O
ability	O
in	O
both	O
patient	O
populations	O
and	O
healthy	O
controls	O
.	O

The	O
best	O
candidate	O
causal	O
variants	O
for	O
ER	O
(	O
-	O
)	O
tumors	S-Phenotype
lie	O
in	O
four	O
separate	O
enhancer	O
elements	O
,	O
and	O
their	O
risk	O
alleles	O
reduce	O
expression	O
of	O
ESR1	O
,	O
RMND1	O
and	O
CCDC170	O
,	O
whereas	O
the	O
risk	O
alleles	O
of	O
the	O
strongest	O
candidates	O
for	O
the	O
remaining	O
independent	O
causal	O
variant	O
disrupt	O
a	O
silencer	O
element	O
and	O
putatively	O
increase	O
ESR1	O
and	O
RMND1	O
expression	O
.	O

Interestingly	O
,	O
the	O
naturally	O
occurring	O
microcephaly	S-Phenotype
-	O
associated	O
mutant	O
,	O
RTTN	O
(	O
A578P	O
)	O
,	O
shows	O
a	O
low	O
affinity	O
for	O
STIL	O
binding	O
and	O
blocks	O
centriole	O
assembly	O
.	O

We	O
successfully	O
showed	O
that	O
the	O
combination	O
of	O
immune	O
cell	O
therapy	O
and	O
CPA	O
was	O
safe	O
,	O
might	O
induce	O
tumor	S-Phenotype
-	O
specific	O
immune	O
responses	O
and	O
clinical	O
efficacy	O
,	O
and	O
was	O
accompanied	O
by	O
a	O
decreased	O
ratio	O
of	O
Tregs	O
in	O
patients	O
with	O
RNF43	O
-	O
positive	O
advanced	O
solid	O
tumors	S-Phenotype

Here	O
,	O
we	O
studied	O
the	O
effect	O
of	O
miR	O
-	O
4326	O
on	O
lung	B-Phenotype
cancer	E-Phenotype
cell	O
proliferation	O
;	O
we	O
found	O
that	O
miR	O
-	O
4326	O
was	O
significantly	O
upregulated	O
in	O
lung	B-Phenotype
cancer	E-Phenotype
tissues	O
determined	O
using	O
TCGA	O
dataset	O
and	O
clinical	O
specimens	O
,	O
meanwhile	O
it	O
was	O
also	O
upregulated	O
in	O
lung	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

We	O
report	O
on	O
the	O
case	O
of	O
a	O
77	O
-	O
year	O
-	O
old	O
male	O
with	O
genetically	O
proven	O
spinocerebellar	B-Phenotype
ataxia	I-Phenotype
type	I-Phenotype
31	E-Phenotype
(	O
SCA31	S-Phenotype
)	O
who	O
had	O
dystonia	S-Phenotype
.	O

In	O
fact	O
,	O
the	O
expression	O
levels	O
of	O
ANG	O
were	O
elevated	O
in	O
tumor	S-Phenotype
tissues	O
as	O
compared	O
with	O
normal	O
kidney	O
and	O
the	O
inhibition	O
of	O
ANG	O
activity	O
with	O
a	O
neutralizing	O
antibody	O
significantly	O
suppressed	O
tumor	S-Phenotype
invasion	O
.	O

BRCT	O
-	O
repeat	O
inhibitor	O
of	O
hTERT	O
expression	O
(	O
BRIT1	O
)	O
is	O
involved	O
in	O
the	O
invasion	O
of	O
tumors	S-Phenotype
.	O

Overexpression	O
of	O
Pmp22	O
in	O
rodent	O
models	O
recapitulates	O
several	O
aspects	O
of	O
neuropathy	S-Phenotype
,	O
and	O
reduction	O
of	O
Pmp22	O
in	O
such	O
models	O
results	O
in	O
amelioration	O
of	O
the	O
neuropathy	S-Phenotype
phenotype	O
.	O

The	O
DNA	O
damage	O
checkpoints	O
provide	O
an	O
anti	O
-	O
cancer	S-Phenotype
barrier	O
in	O
diverse	O
tumour	S-Phenotype
types	O
,	O
however	O
this	O
concept	O
has	O
remained	O
unexplored	O
in	O
prostate	B-Phenotype
cancer	E-Phenotype
(	O
CaP	S-Phenotype
)	O
.	O

The	O
esophagorespiratory	B-Phenotype
fistula	E-Phenotype
(	O
ERF	S-Phenotype
)	O
is	O
a	O
fatal	B-Phenotype
complication	I-Phenotype
ofesophageal	I-Phenotype
cancer	E-Phenotype
,	O
because	O
ofadvanced	O
oncological	O
status	O
and	O
poor	O
conditions	O
due	O
to	O
pneumonia	S-Phenotype
and	O
/	O
or	O
malnutrition	O
.	O

We	O
report	O
here	O
a	O
case	O
of	O
patient	O
who	O
was	O
successfully	O
treated	O
for	O
esophageal	B-Phenotype
cancer	E-Phenotype
with	O
ERF	O
with	O
multimodality	O
therapy	O
including	O
three	O
-	O
stage	O
operation	O
.	O

Through	O
genetic	O
mapping	O
of	O
disease	O
loci	O
and	O
whole	O
-	O
exome	O
sequencing	O
in	O
four	O
unrelated	O
multiplex	O
families	O
presenting	O
with	O
severe	O
AMC	O
,	O
we	O
identified	O
biallelic	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
LGI4	O
(	O
leucine	O
-	O
rich	O
glioma	S-Phenotype
-	O
inactivated	O
4	O
)	O
.	O

LKB1	O
-	O
AMPK	O
activation	O
in	O
GC	O
cell	O
lines	O
was	O
tumor	S-Phenotype
suppressive	O
,	O
as	O
metformin	O
(	O
an	O
AMPK	O
activator	O
)	O
inhibited	O
GC	O
cell	O
growth	O
in	O
the	O
CAB39L	O
-	O
silenced	O
cells	O
.	O

Mutations	O
in	O
human	O
crumbs	O
1	O
(	O
liCRB1	O
/	O
i	O
)	O
are	O
a	O
major	O
cause	O
of	O
retinal	B-Phenotype
diseases	E-Phenotype
that	O
lead	O
to	O
blindness	S-Phenotype
.	O

Our	O
report	O
provides	O
further	O
evidence	O
to	O
support	O
loss	O
-	O
of	O
-	O
function	O
alterations	O
of	O
ASH1L	O
as	O
causative	O
for	O
an	O
emergent	O
neurodevelopmental	O
syndrome	O
characterized	O
by	O
MCA	O
,	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
and	O
behavioral	B-Phenotype
problems	E-Phenotype
,	O
and	O
further	O
delineates	O
this	O
genetic	O
disorder	O

A	O
dominant	O
substitution	O
(	O
p.Arg544Gln	O
)	O
of	O
METTL13	O
,	O
encoding	O
a	O
predicted	O
methyltransferase	O
,	O
is	O
the	O
DFNM1	O
suppressor	O
of	O
GAB1	O
-	O
associated	O
deafness	S-Phenotype
.	O

Immunohistochemistry	O
demonstrated	O
that	O
the	O
loss	O
of	O
CDK10	O
expression	O
,	O
which	O
was	O
observed	O
in	O
50.8	O
%	O
of	O
primary	O
gastric	B-Phenotype
cancer	E-Phenotype
tissues	O
(	O
n=128	O
)	O
,	O
significantly	O
correlated	O
with	O
advanced	O
tumor	S-Phenotype
stage	O
(	O
PAAAA0.001	O
)	O
,	O
frequent	O
lymph	O
node	O
metastasis	O
(	O
PAAAA0.001	O
)	O
,	O
distant	O
metastasis	O
(	O
P=0.013	O
)	O
,	O
tumor	S-Phenotype
differentiation	O
(	O
P=0.004	O
)	O
and	O
unfavorable	O
overall	O
survival	O
(	O
PAAAA0.001	O
)	O
.	O

Several	O
candidate	O
genes	O
for	O
obesity	S-Phenotype
and	O
T2D	O
(	O
e.g.	O
,	O
IRS1	O
and	O
VEGFA	O
)	O
were	O
differentially	O
expressed	O
in	O
discordant	O
twins	O
.	O

After	O
ERb	O
activation	O
,	O
both	O
DRAM2	O
and	O
protein	O
1	O
light	O
chain	O
3	O
(	O
LC3	O
)	O
,	O
a	O
key	O
actor	O
in	O
the	O
autophagosome	O
formation	O
,	O
strictly	O
interacted	O
each	O
other	O
and	O
localized	O
at	O
mitochondrial	O
level.Altogether	O
these	O
results	O
suggest	O
that	O
targeting	O
ERb	O
with	O
selective	O
agonists	O
might	O
affect	O
HL	O
cell	O
proliferation	O
and	O
tumor	S-Phenotype
growth	O
via	O
a	O
mechanism	O
that	O
brings	O
into	O
play	O
DRAM2	O
-	O
dependent	O
autophagic	O
cascade	O

The	O
authors	O
report	O
a	O
patient	O
with	O
a	O
novel	O
PAK3	O
mutation	O
,	O
who	O
presented	O
with	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
severe	B-Phenotype
automutilation	E-Phenotype
,	O
and	O
epilepsy	S-Phenotype
.	O

Using	O
whole	O
-	O
exome	O
sequencing	O
,	O
we	O
identified	O
rare	O
homozygous	O
missense	O
variants	O
(	O
c.526CAAAAT	O
[	O
p.Arg176Trp	O
]	O
and	O
c.629CAAAAT	O
[	O
p.Ala210Val	O
]	O
)	O
in	O
SLC45A1	O
,	O
encoding	O
another	O
cerebral	O
glucose	O
transporter	O
,	O
in	O
two	O
consanguineous	O
multiplex	O
families	O
with	O
moderate	O
to	O
severe	O
ID	S-Phenotype
,	O
epilepsy	S-Phenotype
,	O
and	O
variable	O
neuropsychiatric	O
features	O
.	O

Additionally	O
,	O
the	O
SNP	O
of	O
rs57095329	O
showed	O
statistical	O
significances	O
with	O
the	O
appearances	O
of	O
mutism	S-Phenotype
and	O
the	O
positive	O
of	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
protein	O
14	O
-	O
3	O
-	O
3	O
in	O
sCJD	O
patients	O
,	O
while	O
the	O
SNP	O
of	O
ZBTB38	O
-	O
RASA2	O
was	O
significantly	O
related	O
with	O
the	O
appearance	O
of	O
myoclonus	S-Phenotype
in	O
sCJD	O
patients	O
.	O

Here	O
we	O
report	O
a	O
consanguineous	O
Arab	O
family	O
from	O
Qatar	O
with	O
three	O
children	O
having	O
an	O
early	O
lethal	O
form	O
of	O
arthrogryposis	S-Phenotype
multiplex	O
congenita	O
and	O
a	O
novel	O
frameshift	O
mutation	O
in	O
CNTNAP1	O
.	O

However	O
,	O
the	O
variant	O
was	O
also	O
detected	O
in	O
2	O
/	O
182	O
families	O
with	O
known	O
BRCA1	O
or	O
BRCA2	O
mutations	O
and	O
in	O
2	O
/	O
464	O
non	O
-	O
cancer	S-Phenotype
controls	O
.	O

Progressive	O
and	O
systemic	O
loss	O
of	O
motor	O
neurons	O
with	O
gliosis	S-Phenotype
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
is	O
a	O
neuropathological	O
hallmark	O
of	O
ALS	O
.	O

Seipinopathy	O
is	O
an	O
autosomal	O
dominant	O
neurodegenerative	B-Phenotype
disease	E-Phenotype
caused	O
by	O
mutations	O
of	O
the	O
Berardinelli	B-Phenotype
-	I-Phenotype
Seip	I-Phenotype
Congenital	I-Phenotype
Lipodystrophy	I-Phenotype
2	E-Phenotype
(	O
BSCL2	S-Phenotype
)	O
gene	O
.	O

Of	O
the	O
465,447	O
CpG	O
sites	O
analyzed	O
,	O
12	O
showed	O
differential	O
methylation	O
(	O
false	O
discovery	O
rate	O
AAAA0.15	O
)	O
,	O
including	O
markers	O
within	O
genes	O
associated	O
with	O
monogenic	B-Phenotype
diabetes	E-Phenotype
(	O
HNF4A	O
)	O
or	O
obesity	S-Phenotype
(	O
RREB1	O
)	O
.	O

Importantly	O
,	O
we	O
found	O
that	O
CD133	O
expression	O
in	O
glioma	S-Phenotype
was	O
highly	O
correlated	O
with	O
the	O
expression	O
of	O
HOX	O
gene	O
stem	O
cell	O
factors	O
(	O
HOXA5	O
,	O
HOXA7	O
,	O
HOXA10	O
,	O
HOXC4	O
and	O
HOXC6	O
)	O
.	O

Several	O
genetic	O
defects	O
are	O
responsible	O
for	O
impairment	O
of	O
GH	O
and	O
IGF	O
-	O
I	O
actions	O
resulting	O
in	O
short	B-Phenotype
stature	E-Phenotype
that	O
could	O
affect	O
intrauterine	O
growth	O
or	O
be	O
present	O
in	O
the	O
postnatal	O
period	O
.	O

In	O
the	O
Japanese	O
population	O
,	O
most	O
patients	O
with	O
autosomal	B-Phenotype
recessive	I-Phenotype
woolly	I-Phenotype
hair	E-Phenotype
carry	O
one	O
of	O
two	O
founder	O
mutations	O
in	O
the	O
LIPH	O
gene	O
,	O
c.736TAAAAA	O
(	O
p.Cys246Ser	O
)	O
or	O
c.742CAAAAA	O
(	O
p.His248Asn	O
)	O
.	O

The	O
older	O
brother	O
presented	O
with	O
progressive	B-Phenotype
gait	I-Phenotype
difficulties	E-Phenotype
,	O
hypotonia	S-Phenotype
,	O
intermittent	B-Phenotype
dystonia	E-Phenotype
,	O
polycythemia	S-Phenotype
,	O
and	O
characteristic	O
T1	O
-	O
hyperintense	O
lesions	O
on	O
MRI	O
brain	O
.	O

Similarly	O
,	O
SEPT4	O
has	O
lymphoid	O
and	O
non	O
-	O
lymphoid	O
forms	O
;	O
SEPT2	O
has	O
lymphoid	O
and	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
forms	O
;	O
and	O
SEPT6	O
and	O
SEPT9	O
are	O
elevated	O
in	O
lymphoid	O
tissues	O
but	O
both	O
have	O
forms	O
that	O
cluster	O
away	O
from	O
the	O
lymphoid	O
forms	O
.	O

The	O
mRNA	O
and	O
protein	O
levels	O
of	O
STX3	O
are	O
significantly	O
up	O
-	O
regulated	O
in	O
human	O
breast	B-Phenotype
cancer	E-Phenotype
compared	O
with	O
matched	O
adjacent	O
non	O
-	O
cancer	S-Phenotype
tissues	O
.	O

With	O
the	O
notable	O
exception	O
of	O
WNT10A	O
(	O
Tooth	B-Phenotype
agenesis	E-Phenotype
,	O
selective	O
,	O
4	O
,	O
MIM	O
#	O
150400	O
)	O
,	O
the	O
genotype	O
-	O
phenotype	O
relationships	O
described	O
in	O
the	O
present	O
cohort	O
represent	O
an	O
expansion	O
of	O
the	O
clinical	O
spectrum	O
associated	O
with	O
these	O
genes	O
:	O
TSPEAR	O
(	O
Deafness	S-Phenotype
,	O
autosomal	B-Phenotype
recessive	E-Phenotype
98	O
,	O
MIM	O
#	O
614861	O
)	O
,	O
LAMB3	O
(	O
Amelogenesis	B-Phenotype
imperfecta	E-Phenotype
,	O
type	O
IA	O
,	O
MIM	O
#	O
104530	O
;	O
Epidermolysis	O
bullosa	O
,	O
junctional	O
,	O
MIMs	O
#	O
226700	O
and	O
#	O
226650	O
)	O
,	O
and	O
BCOR	O
(	O
Microphthalmia	S-Phenotype
,	O
syndromic	O
2	O
,	O
MIM	O
#	O
300166	O
)	O
.	O

We	O
found	O
that	O
hypertonia	S-Phenotype
-	O
associated	O
mutation	O
impairs	O
Trak1	O
mitochondrial	O
localization	O
and	O
its	O
ability	O
to	O
facilitate	O
mitochondrial	O
tethering	O
and	O
fusion	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggested	O
an	O
essential	O
role	O
of	O
CDKN1C	O
in	O
the	O
tumorgenesis	S-Phenotype
of	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

All	O
intraductal	B-Phenotype
tubulopapillary	I-Phenotype
neoplasms	E-Phenotype
revealed	O
the	O
characteristic	O
histologic	O
(	O
cellular	O
intraductal	O
nodules	O
of	O
back	O
-	O
to	O
-	O
back	O
tubular	O
glands	O
lined	O
by	O
predominantly	O
cuboidal	O
cells	O
with	O
atypical	O
nuclei	O
and	O
no	O
obvious	O
intracellular	O
mucin	O
)	O
and	O
immunohistochemical	O
(	O
immunolabeled	O
with	O
MUC1	O
and	O
MUC6	O
but	O
were	O
negative	O
for	O
MUC2	O
and	O
MUC5AC	O
)	O
features	O
.	O

Further	O
,	O
high	O
IRAK1	O
expression	O
level	O
was	O
correlated	O
with	O
higher	O
tumor	S-Phenotype
stage	O
,	O
lymph	O
node	O
metastasis	O
,	O
myometrial	O
invasion	O
,	O
and	O
lower	O
survival	O
rate	O
.	O

Mutations	O
in	O
ACVRL1	O
,	O
BMPR2	O
,	O
or	O
ENG	O
are	O
associated	O
with	O
hereditary	B-Phenotype
hemorrhagic	I-Phenotype
telangiectasia	E-Phenotype
and	O
pulmonary	B-Phenotype
arterial	I-Phenotype
hypertension	E-Phenotype
in	O
humans	O
[	O
1	O
,	O
2	O
]	O
.	O

Objective	O
:	O
To	O
analyze	O
the	O
clinical	O
and	O
imaging	O
features	O
of	O
hypomyelination	S-Phenotype
with	O
brain	O
stem	O
and	O
spinal	O
cord	O
involvement	O
and	O
leg	B-Phenotype
spasticity	E-Phenotype
(	O
HBSL	O
)	O
due	O
to	O
mutations	O
in	O
DARS	O
,	O
and	O
to	O
identify	O
DARS	O
mutations	O
responsible	O
for	O
HBSL	O
.	O

The	O
tumor	S-Phenotype
suppressor	O
characteristics	O
of	O
cyclin‑dependent	O
kinase	O
10	O
(	O
CDK10	O
)	O
in	O
nasopharyngeal	B-Phenotype
carcinoma	E-Phenotype
and	O
breast	B-Phenotype
cancer	E-Phenotype
have	O
been	O
previously	O
demonstrated	O
.	O

Taken	O
together	O
,	O
FGFRL1	O
is	O
a	O
potential	O
predictor	O
and	O
plays	O
an	O
important	O
role	O
in	O
tumor	S-Phenotype
growth	O
and	O
Hh	O
signaling	O
which	O
could	O
serve	O
as	O
potential	O
therapeutic	O
targets	O
for	O
the	O
treatment	O
of	O
OC	O

RASSF7	O
was	O
significantly	O
up	O
-	O
regulated	O
in	O
HCC	O
tissues	O
and	O
cell	O
lines	O
,	O
and	O
correlated	O
with	O
AFP	O
,	O
poor	O
tumor	S-Phenotype
histology	O
and	O
T	O
stage	O
.	O

Downregulation	O
of	O
TNFAIP8	O
expression	O
has	O
been	O
associated	O
with	O
decreased	O
pulmonary	O
colonization	O
of	O
human	O
tumor	S-Phenotype
cells	O
,	O
and	O
enhanced	O
sensitivities	O
of	O
tumor	S-Phenotype
xenografts	O
to	O
radiation	O
and	O
docetaxel	O
.	O

This	O
was	O
accompanied	O
by	O
neuronal	B-Phenotype
loss	E-Phenotype
and	O
neuro	B-Phenotype
-	I-Phenotype
axonal	I-Phenotype
dysfunction	E-Phenotype
in	O
adult	O
OL	O
-	O
Kcnj10	O
cKO	O
mice	O
as	O
shown	O
by	O
delayed	B-Phenotype
visual	I-Phenotype
evoked	I-Phenotype
potentials	E-Phenotype
,	O
inner	B-Phenotype
retinal	I-Phenotype
thinning	E-Phenotype
and	O
progressive	O
motor	O
deficits	O
.	O

We	O
found	O
no	O
correlation	O
between	O
the	O
DLEC1	O
,	O
TUSC4	O
and	O
MLH1	O
gene	O
expression	O
and	O
NSCLC	O
patient	O
characteristics	O
(	O
gender	O
,	O
age	O
and	O
smoking	O
)	O
or	O
cancer	S-Phenotype
histopathology	O
.	O

Conclusion	O
:	O
These	O
findings	O
establish	O
a	O
new	O
BRUCE	O
-	O
ATR	O
signaling	O
axis	O
in	O
accurate	O
DNA	O
replication	O
and	O
suppression	O
of	O
liver	B-Phenotype
cancer	E-Phenotype
in	O
mice	O
and	O
humans	O
and	O
provides	O
a	O
clinically	O
relevant	O
HCC	O
mouse	O
model	O
.	O

The	O
mutation	O
(	O
p.Trp211Arg	O
)	O
,	O
which	O
segregates	O
with	O
a	O
disease	O
phenotype	O
characterized	O
by	O
either	O
isolated	O
IIP	O
/	O
IPF	O
,	O
or	O
IPF	O
associated	O
with	O
lung	B-Phenotype
adenocarcinoma	E-Phenotype
,	O
is	O
located	O
in	O
the	O
carbohydrate	O
recognition	O
domain	O
(	O
CRD	O
)	O
of	O
SP	O
-	O
A1	O
and	O
involves	O
a	O
residue	O
invariant	O
throughout	O
evolution	O
,	O
not	O
only	O
in	O
SP	O
-	O
A1	O
,	O
but	O
also	O
in	O
its	O
close	O
paralog	O
SP	O
-	O
A2	O
and	O
other	O
CRD	O
-	O
containing	O
proteins	O
.	O

A	O
syndromic	O
form	O
of	O
CSD	O
features	O
choanal	O
and	O
intestinal	B-Phenotype
atresias	E-Phenotype
as	O
well	O
as	O
recurrent	B-Phenotype
corneal	I-Phenotype
erosions	E-Phenotype
.	O

We	O
investigated	O
plasma	O
microRNA	O
(	O
miRNA	O
)	O
profiles	O
associated	O
with	O
variation	O
of	O
hyperglycemia	S-Phenotype
,	O
measured	O
as	O
hemoglobin	O
A1c	O
(	O
HbA1c	O
)	O
,	O
in	O
two	O
panels	O
of	O
patients	O
with	O
type	B-Phenotype
1	I-Phenotype
diabetes	E-Phenotype
(	O
T1D	S-Phenotype
)	O
.	O

(	O
2017	O
)	O
shed	O
light	O
on	O
the	O
mechanism	O
of	O
transport	O
by	O
implicating	O
CEP19	O
,	O
which	O
is	O
associated	O
with	O
an	O
autosomal	O
-	O
recessive	O
obesity	S-Phenotype
syndrome	O
when	O
mutated	O
,	O
in	O
the	O
triggering	O
of	O
intraflagellar	O
transport	O

Recent	O
research	O
published	O
in	O
the	O
Journal	O
of	O
Pathology	O
showed	O
that	O
genetic	O
depletion	O
of	O
any	O
of	O
the	O
NOX2	O
subunits	O
Cyba	O
,	O
Cybb	O
,	O
Ncf1	O
,	O
Ncf2	O
and	O
Ncf4	O
reduced	O
the	O
formation	O
of	O
lung	O
metastases	O
following	O
intravenous	O
injection	O
of	O
murine	O
tumor	S-Phenotype
cells	O
.	O

Patient	O
-	O
derived	O
cells	O
were	O
genetically	O
complemented	O
upon	O
wild	O
-	O
type	O
FANCM	O
complementary	O
DNA	O
expression	O
.	O

Conclusion	O
Loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
FANCM	O
cause	O
a	O
cancer	S-Phenotype
predisposition	O
syndrome	O
clinically	O
distinct	O
from	O
bona	O
fide	O
FA	O
.	O

The	O
CSIRO	O
National	O
NBN	O
Telehealth	O
Trial	O
investigated	O
the	O
effects	O
of	O
introducing	O
at	O
home	O
telemonitoring	O
of	O
vital	O
signs	O
for	O
the	O
management	O
of	O
a	O
heterogeneous	S-Phenotype
group	O
of	O
chronically	O
ill	O
patients	O
.	O

Lactate	O
dehydrogenase	O
-	O
A	O
(	O
LDHA	O
)	O
can	O
promote	O
Warburg	O
effect	O
to	O
produce	O
lactate	O
and	O
Adenosine	O
Triphosphate	O
(	O
ATP	O
)	O
in	O
aerobic	O
condition	O
,	O
which	O
contributes	O
to	O
oncogenesis	O
metastasis	O
and	O
drug	B-Phenotype
resistance	E-Phenotype
in	O
various	O
cancers	S-Phenotype
.	O

High	O
grade	O
transformation	O
cases	O
were	O
analysed	O
,	O
the	O
high	O
grade	O
SCSG	O
components	O
showed	O
a	O
significantly	O
increased	O
Ki	O
-	O
67	O
index	O
and	O
cyclin	O
D1	O
positive	O
tumor	S-Phenotype
cells	O
compared	O
to	O
the	O
conventional	O
SCSG	O
components	O
.	O

Here	O
,	O
we	O
report	O
two	O
novel	O
GUCA1A	O
(	O
the	O
gene	O
for	O
guanylate	O
cyclase	O
activating	O
protein	O
1	O
)	O
mutations	O
identified	O
in	O
unrelated	O
Spanish	O
families	O
affected	O
by	O
autosomal	B-Phenotype
dominant	I-Phenotype
retinal	I-Phenotype
degeneration	E-Phenotype
(	O
adRD	S-Phenotype
)	O
with	O
cone	O
and	O
rod	O
involvement	O
.	O

Genetic	O
screening	O
of	O
patients	O
diagnosed	O
with	O
macular	B-Phenotype
dystrophy	E-Phenotype
disclosed	O
a	O
novel	O
mutation	O
in	O
the	O
GUCA1A	O
gene	O
,	O
namely	O
a	O
c.526C	O
AAAA	O
T	O
substitution	O
leading	O
to	O
the	O
amino	O
acid	O
substitution	O
p.L176F	O
in	O
the	O
guanylate	O
cyclase	O
-	O
activating	O
protein	O
1	O
(	O
GCAP1	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
hypothesized	O
that	O
FERMT3	O
would	O
enhance	O
glioblastoma	S-Phenotype
multiforme	O
(	O
GBM	O
)	O
cell	O
survival	O
.	O

Defects	O
of	O
CIB2	O
,	O
calcium	O
-	O
and	O
integrin	O
-	O
binding	O
protein	O
2	O
,	O
have	O
been	O
reported	O
to	O
cause	O
isolated	O
deafness	S-Phenotype
,	O
DFNB48	O
and	O
Usher	O
syndrome	O
type	O
-	O
IJ	O
,	O
characterized	O
by	O
congenital	B-Phenotype
profound	I-Phenotype
deafness	E-Phenotype
,	O
balance	B-Phenotype
defects	E-Phenotype
and	O
blindness	S-Phenotype
.	O

Familial	B-Phenotype
hypercholesterolemia	E-Phenotype
is	O
usually	O
due	O
to	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
LDLR	O
,	O
the	O
gene	O
coding	O
for	O
low	O
density	O
lipoprotein	O
receptor	O
and	O
genes	O
encoding	O
for	O
proteins	O
that	O
interact	O
with	O
the	O
receptor	O
:	O
APOB	O
,	O
PCSK9	O
and	O
LDLRAP1	O
.	O

We	O
established	O
a	O
genetic	O
diagnosis	O
in	O
six	O
families	O
with	O
autosomal	B-Phenotype
recessive	E-Phenotype
HSP	O
(	O
SPG11	O
in	O
three	O
families	O
and	O
TFG	O
/	O
SPG57	O
,	O
SACS	O
and	O
ALS2	O
in	O
one	O
family	O
each	O
)	O
.	O

Myotonic	O
dystrophy	O
1	O
(	O
DM1	O
)	O
is	O
a	O
multisystem	O
disorder	O
primarily	O
affecting	O
the	O
central	O
nervous	O
system	O
,	O
heart	O
and	O
skeletal	O
muscle	O
.	O

The	O
diagnostic	O
value	O
of	O
SMARCE1	O
in	O
distinguishing	O
between	O
CCM	O
and	O
other	O
meningioma	S-Phenotype
variants	O
has	O
not	O
been	O
yet	O
established	O
.	O

-	O
Deng	O
,	O
J.	O
,	O
Chen	O
,	O
M.	O
,	O
Liu	O
,	O
Z.	O
,	O
Song	O
,	O
Y.	O
,	O
Sui	O
,	O
T.	O
,	O
Lai	O
,	O
L.	O
,	O
Li	O
,	O
Z	O
.	O

Diagnosis	O
of	O
PCD	O
is	O
often	O
a	O
challenging	O
task	O
due	O
to	O
its	O
high	O
clinical	O
and	O
genetic	O
heterogeneities	S-Phenotype
.	O

Collectively	O
,	O
the	O
findings	O
of	O
the	O
present	O
study	O
demonstrated	O
the	O
oncogenic	O
role	O
of	O
KIF14	O
in	O
colorectal	B-Phenotype
tumorigenesis	E-Phenotype
,	O
and	O
also	O
revealed	O
a	O
complexity	O
of	O
regulatory	O
mechanisms	O
mediating	O
KIF14	O
overexpression	O
,	O
which	O
may	O
provide	O
insight	O
for	O
developing	O
novel	O
treatments	O
for	O
patients	O
with	O
CRC	O

Conditional	O
knockout	O
(	O
cKO	O
)	O
of	O
OL	O
-	O
Kcnj10	O
resulted	O
in	O
late	B-Phenotype
onset	I-Phenotype
mitochondrial	I-Phenotype
damage	E-Phenotype
and	O
axonal	B-Phenotype
degeneration	E-Phenotype
.	O

Exome	O
sequencing	O
revealed	O
an	O
insertion	O
mutation	O
in	O
GRXCR2	O
as	O
the	O
cause	O
of	O
moderate	O
-	O
to	O
-	O
severe	O
and	O
likely	O
progressive	B-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
in	O
the	O
affected	O
individuals	O
of	O
the	O
family	O
.	O

Pure	B-Phenotype
hair	I-Phenotype
and	I-Phenotype
nail	I-Phenotype
ectodermal	I-Phenotype
dysplasia	I-Phenotype
9	E-Phenotype
(	O
ECTD	B-Phenotype
-	I-Phenotype
9	E-Phenotype
)	O
is	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
genetic	O
disease	O
caused	O
by	O
mutation	O
of	O
HOXC13	O
and	O
is	O
characterized	O
by	O
hypotrichosis	S-Phenotype
and	O
nail	B-Phenotype
dystrophy	E-Phenotype
in	O
humans	O
.	O

This	O
study	O
investigated	O
the	O
TGFBI	O
gene	O
mutation	O
types	O
in	O
outpatients	O
clinically	O
diagnosed	O
with	O
granular	B-Phenotype
corneal	I-Phenotype
dystrophy	E-Phenotype
(	O
GCD	S-Phenotype
)	O
prior	O
to	O
phototherapeutic	O
keratectomy	O
(	O
PTK	O
)	O
,	O
also	O
calculated	O
the	O
mutation	O
rate	O
of	O
subjects	O
with	O
normal	O
corneas	O
,	O
but	O
positive	O
family	O
history	O
.	O

Mutations	O
in	O
two	O
genes	O
,	O
liPKD1	O
and	O
liPKD2	O
,	O
account	O
for	O
most	O
cases	O
of	O
autosomal	B-Phenotype
dominant	I-Phenotype
polycystic	I-Phenotype
kidney	E-Phenotype
disease	O
,	O
one	O
of	O
the	O
most	O
common	O
monogenetic	O
disorders	O
.	O

Primary	B-Phenotype
ciliary	I-Phenotype
dyskinesia	E-Phenotype
(	O
PCD	S-Phenotype
)	O
is	O
a	O
recessively	O
inherited	O
disease	O
that	O
leads	O
to	O
chronic	O
respiratory	O
disorders	O
owing	O
to	O
impaired	O
mucociliary	O
clearance	O
.	O

A	O
key	O
aspect	O
of	O
several	O
adult	O
lung	B-Phenotype
diseases	E-Phenotype
,	O
such	O
as	O
idiopathic	B-Phenotype
pulmonary	I-Phenotype
fibrosis	E-Phenotype
(	O
IPF	S-Phenotype
)	O
and	O
chronic	B-Phenotype
obstructive	I-Phenotype
pulmonary	I-Phenotype
disease	E-Phenotype
(	O
COPD	S-Phenotype
)	O
,	O
including	O
emphysema	S-Phenotype
,	O
is	O
aberrant	O
tissue	O
repair	O
,	O
which	O
leads	O
to	O
an	O
accumulation	O
of	O
damage	O
and	O
impaired	O
respiratory	O
function	O
.	O

As	O
the	O
striking	O
syndactyly	S-Phenotype
observed	O
in	O
the	O
present	O
case	O
is	O
typical	O
for	O
FLPIS	O
,	O
we	O
suggest	O
CREBBP	O
analysis	O
in	O
saliva	O
samples	O
for	O
FLPIS	O
syndrome	O
cases	O
in	O
which	O
no	O
causal	O
CKAP2L	O
variant	O
is	O
detected	O

This	O
essential	O
role	O
of	O
CIB2	O
in	O
mechanotransduction	O
and	O
cell	O
survival	O
that	O
,	O
we	O
show	O
,	O
is	O
restricted	O
to	O
the	O
cochlea	O
,	O
probably	O
accounts	O
for	O
the	O
presence	O
in	O
liCIB2	O
/	O
isup	O
-	O
/	O
-	O
/	O
sup	O
mice	O
and	O
liCIB2	O
/	O
i	O
patients	O
,	O
unlike	O
in	O
Usher	O
syndrome	O
,	O
of	O
isolated	O
hearing	B-Phenotype
loss	E-Phenotype
without	O
balance	O
and	O
vision	O
deficits	O

Methylation	O
status	O
of	O
the	O
p16	O
ink4a	O
promoter	O
was	O
assessed	O
by	O
methylation	O
-	O
specific	O
PCR	O
in	O
87	O
cervical	O
specimens	O
comprising	O
29	O
low	O
-	O
grade	O
(	O
LSIL	O
)	O
,	O
41	O
high	O
-	O
grade	O
(	O
HSIL	O
)	O
lesions	O
,	O
and	O
17	O
cervical	B-Phenotype
cancers	E-Phenotype
(	O
CC	S-Phenotype
)	O
.	O

Mutations	O
of	O
SLC49A1	O
encoding	O
FLVCR1	O
are	O
noted	O
in	O
patients	O
with	O
a	O
rare	O
neurodegenerative	O
disorder	O
:	O
posterior	B-Phenotype
column	I-Phenotype
ataxia	E-Phenotype
with	O
retinitis	B-Phenotype
pigmentosa	E-Phenotype
.	O

Here	O
,	O
we	O
showed	O
that	O
the	O
homeostatic	O
synaptic	O
downscaling	O
is	O
absent	O
in	O
the	O
hippocampal	O
neurons	O
of	O
Fmr1	O
KO	O
mice	O
,	O
the	O
mouse	O
model	O
of	O
the	O
most	O
common	O
inherited	O
autism	S-Phenotype
,	O
fragile	O
X	O
syndrome	O
(	O
FXS	O
)	O
.	O

It	O
was	O
reduced	O
in	O
all	O
ESCC	O
tissue	O
samples	O
compared	O
with	O
normal	O
tissues	O
;	O
however	O
,	O
CSTA	O
expression	O
levels	O
in	O
tumors	S-Phenotype
showed	O
considerable	O
variation	O
.	O

In	O
a	O
previous	O
report	O
,	O
we	O
described	O
the	O
clinical	O
and	O
radiographical	O
features	O
of	O
three	O
related	O
subjects	O
with	O
the	O
disease	O
and	O
suggest	O
that	O
due	O
to	O
the	O
unusual	O
combination	O
of	O
limb	O
defects	O
and	O
to	O
its	O
phenotypic	O
similarity	O
with	O
the	O
limb	O
malformative	O
pattern	O
induced	O
by	O
disrupting	O
the	O
Hoxd13	O
gene	O
in	O
mouse	O
,	O
the	O
triphalangeal	B-Phenotype
thumb	I-Phenotype
-	I-Phenotype
brachyectrodactyly	I-Phenotype
syndrome	E-Phenotype
might	O
be	O
caused	O
by	O
mutations	O
in	O
a	O
HOX	O
gene	O
.	O

However	O
,	O
EMT	O
also	O
contributes	O
to	O
the	O
initiation	O
and	O
development	O
of	O
primary	O
tumors	S-Phenotype
.	O

Spinal	B-Phenotype
muscular	I-Phenotype
atrophy	E-Phenotype
(	O
SMA	S-Phenotype
)	O
refers	O
to	O
a	O
group	O
of	O
disorders	O
affecting	O
lower	O
motor	O
neurons	O
.	O

By	O
targeting	O
DDR2	O
,	O
WRG	O
-	O
28	O
inhibits	O
tumor	S-Phenotype
invasion	O
and	O
migration	O
,	O
as	O
well	O
as	O
tumor	S-Phenotype
-	O
supporting	O
roles	O
of	O
the	O
stroma	O
,	O
and	O
inhibits	O
metastatic	O
breast	B-Phenotype
tumor	E-Phenotype
cell	O
colonization	O
in	O
the	O
lungs	O
.	O

In	O
human	O
breast	B-Phenotype
cancer	E-Phenotype
xenografts	O
in	O
humanized	O
mice	O
,	O
blocking	O
the	O
recruitment	O
of	O
naive	O
CD4+	O
T	O
cells	O
into	O
tumor	S-Phenotype
by	O
knocking	O
down	O
the	O
expression	O
of	O
PITPNM3	O
,	O
a	O
CCL18	O
receptor	O
,	O
significantly	O
reduces	O
intratumoral	O
Tregs	O
and	O
inhibits	O
tumor	S-Phenotype
progression	O
.	O

Mutations	O
in	O
TRAPPC9	O
should	O
be	O
considered	O
in	O
non	B-Phenotype
-	I-Phenotype
syndromic	I-Phenotype
autosomal	I-Phenotype
recessive	I-Phenotype
intellectual	I-Phenotype
disability	E-Phenotype
with	O
severe	O
speech	B-Phenotype
disorder	E-Phenotype

In	O
the	O
present	O
study	O
,	O
our	O
results	O
indicated	O
that	O
SPOP	O
expression	O
was	O
significantly	O
downregulated	O
in	O
HCC	O
and	O
was	O
associated	O
with	O
tumor	S-Phenotype
size	O
,	O
differentiation	O
and	O
metastasis	O
.	O

Five	O
of	O
the	O
PHPT	O
syndromes	O
reflect	O
overgrowth	S-Phenotype
of	O
parathyroid	O
tissue	O
;	O
in	O
contrast	O
,	O
familial	B-Phenotype
hypocalciuric	I-Phenotype
hypercalcemia	E-Phenotype
reflects	O
dysregulation	O
of	O
PTH	O
secretion	O
with	O
little	B-Phenotype
or	I-Phenotype
no	I-Phenotype
parathyroid	I-Phenotype
overgrowth	E-Phenotype
.	O

High	O
expression	O
of	O
TAZ	O
/	O
YAP	O
significantly	O
reduced	O
the	O
postoperative	O
survival	O
rate	O
in	O
patients	O
with	O
malignant	B-Phenotype
melanoma	E-Phenotype
.	O

Mutations	O
in	O
the	O
KARS	O
gene	O
,	O
which	O
encodes	O
both	O
the	O
cytosolic	O
and	O
mitochondrial	O
isoform	O
of	O
lysyl	O
-	O
tRNA	O
synthetase	O
,	O
cause	O
predominantly	O
neurological	O
diseases	O
that	O
often	O
involve	O
deafness	S-Phenotype
,	O
but	O
have	O
also	O
been	O
linked	O
to	O
cardiomyopathy	S-Phenotype
,	O
developmental	B-Phenotype
delay	E-Phenotype
and	O
lactic	B-Phenotype
acidosis	E-Phenotype
.	O

High	O
expression	O
of	O
Dec1	O
,	O
which	O
was	O
significantly	O
associated	O
with	O
high	O
pathological	O
tumor	S-Phenotype
grade	O
and	O
poor	O
response	O
to	O
TMZ	O
chemotherapy	O
,	O
was	O
demonstrated	O
to	O
be	O
an	O
unfavorable	O
independent	O
prognostic	O
factor	O
and	O
predicted	O
poor	O
survival	O
in	O
patients	O
with	O
newly	O
diagnosed	O
glioma	S-Phenotype
.	O

RESULTS	O
Circ	O
-	O
CFH	O
expression	O
was	O
significantly	O
upregulated	O
in	O
glioma	S-Phenotype
tissue	O
and	O
was	O
correlated	O
with	O
tumor	S-Phenotype
grade	O
.	O

Further	O
,	O
we	O
show	O
for	O
the	O
first	O
time	O
that	O
NEDD4L	O
expression	O
alone	O
is	O
significantly	O
associated	O
with	O
a	O
better	O
relapse	O
-	O
free	O
prognosis	O
for	O
breast	B-Phenotype
cancer	E-Phenotype
patients	O
.	O

Markers	O
such	O
as	O
SERPINI1	O
,	O
ZCCHC24	O
,	O
and	O
ZMYND8	O
were	O
modulated	O
by	O
ABBV	O
-	O
075	O
and	O
other	O
BET	O
inhibitors	O
across	O
cancer	S-Phenotype
cell	O
lines	O
and	O
xenograft	O
tumors	S-Phenotype
but	O
not	O
in	O
blood	O
and	O
skin	O
.	O

Bardet	O
-	O
Biedl	O
syndrome	O
(	O
BBS	O
)	O
is	O
a	O
genetically	O
heterogeneous	S-Phenotype
disorder	O
characterized	O
by	O
retinal	B-Phenotype
dystrophy	E-Phenotype
,	O
polydactyly	S-Phenotype
,	O
obesity	S-Phenotype
,	O
developmental	B-Phenotype
delay	E-Phenotype
,	O
and	O
renal	B-Phenotype
defects	E-Phenotype
.	O

The	O
tumors	S-Phenotype
were	O
characterized	O
by	O
immunohistochemistry	O
for	O
pituitary	O
hormones	O
,	O
cytokeratins	O
,	O
Pit	O
-	O
1	O
,	O
and	O
the	O
neuronal	O
markers	O
NeuN	O
,	O
neurofilaments	O
(	O
NFP	O
)	O
,	O
and	O
MAP2	O
.	O

In	O
conclusion	O
,	O
PSMB8	O
is	O
closely	O
associated	O
with	O
migration	O
,	O
proliferation	O
,	O
and	O
apoptosis	O
of	O
glioma	S-Phenotype
cells	O
,	O
and	O
might	O
be	O
considered	O
as	O
a	O
novel	O
prognostic	O
indicator	O
in	O
patients	O
with	O
gliomas	S-Phenotype

Forty	O
unique	O
IFNGR1	O
mutations	O
have	O
been	O
reported	O
and	O
they	O
exert	O
either	O
an	O
autosomal	O
dominant	O
or	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
effect	O
.	O

The	O
present	O
study	O
demonstrated	O
that	O
MFAP5	O
was	O
up	O
-	O
regulated	O
in	O
breast	B-Phenotype
cancers	E-Phenotype
compared	O
with	O
that	O
in	O
normal	O
breast	O
tissues	O
,	O
and	O
further	O
increased	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
bone	B-Phenotype
metastasis	E-Phenotype
.	O

Liposarcoma	S-Phenotype
is	O
an	O
often	O
fatal	O
cancer	S-Phenotype
of	O
fat	O
cells	O
.	O

Finally	O
,	O
we	O
found	O
that	O
inclusion	O
of	O
MRPL33	O
exon	O
3	O
was	O
promoted	O
in	O
human	O
colorectal	B-Phenotype
cancer	E-Phenotype
tissues	O
and	O
this	O
was	O
correlated	O
with	O
hnRNPK	O
levels	O
.	O

We	O
conclude	O
that	O
a2d	O
-	O
4	O
plays	O
an	O
essential	O
role	O
in	O
maintaining	O
the	O
structural	O
and	O
functional	O
integrity	O
of	O
rod	O
and	O
cone	O
synapses	O
,	O
the	O
disruption	O
of	O
which	O
may	O
contribute	O
to	O
visual	B-Phenotype
impairment	E-Phenotype
in	O
humans	O
with	O
CACNA2D4	O
mutations	O
.	O

SIGNIFICANCE	O
STATEMENT	O
In	O
the	O
retina	O
,	O
visual	O
information	O
is	O
first	O
communicated	O
by	O
the	O
synapse	O
formed	O
between	O
photoreceptors	O
and	O
second	O
-	O
order	O
neurons	O
.	O

Primary	B-Phenotype
ciliary	I-Phenotype
dyskinesia	E-Phenotype
(	O
PCD	S-Phenotype
)	O
is	O
a	O
rare	O
autosomal	O
-	O
recessive	O
condition	O
resulting	O
from	O
structural	O
and	O
/	O
or	O
functional	O
defects	O
of	O
the	O
axoneme	O
in	O
motile	O
cilia	O
and	O
sperm	O
flagella	O
.	O

Of	O
the	O
2	O
204	O
genes	O
that	O
were	O
mutated	O
,	O
APC	O
,	O
TTN	O
,	O
TP53	O
,	O
KRAS	O
,	O
OBSCN	O
,	O
SOX9	O
,	O
PCDH17	O
,	O
SIGLEC10	O
,	O
MYH6	O
,	O
and	O
BRD9	O
were	O
consistent	O
with	O
genes	O
being	O
an	O
early	O
driver	O
of	O
carcinogenesis	O
,	O
in	O
that	O
they	O
were	O
mutated	O
in	O
multiple	O
adenomas	O
and	O
multiple	O
carcinomas	S-Phenotype
.	O

The	O
oncogenic	O
capacity	O
of	O
LASS2	O
in	O
ovarian	B-Phenotype
cancer	E-Phenotype
may	O
be	O
mediated	O
by	O
increased	O
expression	O
of	O
YAP	O
/	O
TAZ	O
.	O

Several	O
mouse	O
models	O
have	O
been	O
described	O
for	O
this	O
gene	O
;	O
mice	O
heterozygous	O
for	O
loss	O
-	O
of	O
-	O
function	O
defects	O
display	O
a	O
rapidly	O
progressive	O
high	B-Phenotype
-	I-Phenotype
frequency	I-Phenotype
hearing	I-Phenotype
impairment	E-Phenotype
.	O

Our	O
results	O
reveal	O
a	O
novel	O
genetic	O
PMF	O
-	O
like	O
mouse	O
model	O
and	O
identify	O
a	O
tumor	S-Phenotype
suppressor	O
role	O
for	O
liNOL3	O
/	O
i	O
in	O
the	O
pathogenesis	O
of	O
myeloid	O
malignancies	O

Moreover	O
,	O
the	O
expression	O
of	O
CDKN1C	O
was	O
correlated	O
with	O
age	O
and	O
tumor	S-Phenotype
size	O
in	O
the	O
TCGA	O
cohort	O
containing	O
708	O
cases	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

As	O
such	O
,	O
the	O
current	O
study	O
investigated	O
the	O
role	O
of	O
ASPH	O
hydroxylase	O
activity	O
in	O
downstream	O
signalling	O
of	O
HCC	B-Phenotype
tumorgenesis	E-Phenotype
and	O
,	O
specifically	O
,	O
metastasis	O
development	O
.	O

In	O
support	O
of	O
this	O
view	O
,	O
hypoxia	S-Phenotype
is	O
shown	O
to	O
negatively	O
regulate	O
MHC	O
expression	O
in	O
a	O
HIF	O
-	O
dependent	O
manner	O
as	O
evidenced	O
by	O
(	O
i	O
)	O
lower	O
MHC	O
expression	O
in	O
the	O
hypoxic	O
TME	O
in	O
vivo	O
and	O
in	O
hypoxic	O
3	O
-	O
dimensional	O
(	O
3D	O
)	O
but	O
not	O
2	O
-	O
dimensional	O
(	O
2D	O
)	O
tumor	S-Phenotype
cell	O
cultures	O
in	O
vitro	O
;	O
(	O
ii	O
)	O
decreased	O
MHC	O
in	O
human	O
renal	B-Phenotype
cell	I-Phenotype
carcinomas	E-Phenotype
with	O
constitutive	O
expression	O
of	O
HIF	O
due	O
to	O
genetic	O
loss	O
of	O
von	O
Hippel	O
-	O
Lindau	O
(	O
VHL	O
)	O
function	O
as	O
compared	O
with	O
isogenically	O
paired	O
cells	O
with	O
restored	O
VHL	O
function	O
,	O
and	O
iii	O
)	O
increased	O
MHC	O
in	O
tumor	S-Phenotype
cells	O
with	O
siRNA	O
-	O
mediated	O
knockdown	O
of	O
HIF	O
.	O

Our	O
study	O
identifies	O
GLIS3	O
as	O
a	O
key	O
regulator	O
of	O
TSH	O
/	O
TSHR	O
-	O
mediated	O
thyroid	O
hormone	O
biosynthesis	O
and	O
proliferation	O
of	O
thyroid	O
follicular	O
cells	O
and	O
uncovers	O
a	O
mechanism	O
by	O
which	O
GLIS3	O
deficiency	O
causes	O
neonatal	B-Phenotype
hypothyroidism	E-Phenotype
and	O
prevents	O
goiter	S-Phenotype
development	O

The	O
RAD51C	O
pathogenic	O
variant	O
c.404G	O
AAAA	O
A	O
was	O
identified	O
in	O
a	O
breast	B-Phenotype
and	I-Phenotype
ovarian	I-Phenotype
cancer	E-Phenotype
family	O
(	O
0.7	O
%	O
)	O
,	O
while	O
the	O
RAD51D	O
pathogenic	O
variant	O
c.694C	O
AAAA	O
T	O
was	O
described	O
in	O
an	O
ovarian	B-Phenotype
cancer	E-Phenotype
family	O
(	O
1.3	O
%	O
)	O
.	O

These	O
comparisons	O
found	O
previously	O
unreported	O
commonalities	O
between	O
the	O
newly	O
identified	O
patients	O
,	O
such	O
as	O
the	O
presence	O
of	O
otitis	B-Phenotype
media	E-Phenotype
and	O
the	O
lack	O
of	O
genitourinary	B-Phenotype
abnormalities	E-Phenotype
(	O
i.e	O
.	O

The	O
prognostic	O
significance	O
and	O
performance	O
of	O
PYCR1	O
mRNA	O
were	O
validated	O
on	O
13	O
worldwide	O
independent	O
microarray	O
data	O
sets	O
,	O
composed	O
of	O
2500	O
assessable	O
breast	B-Phenotype
cancer	E-Phenotype
cases	O
.	O

The	O
protein	O
expression	O
of	O
IRAK1	O
and	O
downstream	O
molecules	O
tumor	S-Phenotype
necrosis	O
factor	O
receptor	O
-	O
associated	O
factor	O
6	O
(	O
TRAF6	O
)	O
,	O
inhibitor	O
of	O
nuclear	O
factor	O
kappa	O
-	O
B	O
kinase	O
(	O
IKK	O
)	O
,	O
NF	O
-	O
kappa	O
-	O
B	O
inhibitor	O
alpha	O
(	O
IKBa	O
)	O
,	O
and	O
NF	O
-	O
kB	O
was	O
detected	O
by	O
Western	O
-	O
blot	O
analysis	O
.	O

Helicase‑like	O
transcription	O
factor	O
(	O
HLTF	O
)	O
has	O
been	O
identified	O
as	O
a	O
tumor	S-Phenotype
suppressor	O
gene	O
.	O

Transcriptomics	O
revealed	O
that	O
102	O
genes	O
were	O
upregulated	O
and	O
85	O
genes	O
were	O
downregulated	O
in	O
CD44+Lin	O
-	O
compared	O
to	O
CD44	O
-	O
Lin	O
-	O
cells	O
in	O
at	O
least	O
3	O
of	O
the	O
5	O
tumours	S-Phenotype
sequenced	O
.	O

In	O
the	O
remaining	O
cases	O
,	O
next	O
generation	O
sequencing	O
was	O
carried	O
out	O
revealing	O
variants	O
in	O
a	O
number	O
of	O
other	O
known	O
complex	O
spastic	B-Phenotype
paraplegia	E-Phenotype
genes	O
,	O
including	O
five	O
in	O
SPG7	O
(	O
5	O
/	O
97	O
)	O
,	O
four	O
in	O
FA2H	O
(	O
also	O
known	O
as	O
SPG35	O
)	O
(	O
4	O
/	O
97	O
)	O
and	O
two	O
in	O
ZFYVE26	O
/	O
SPG15	O
Variants	O
were	O
identified	O
in	O
genes	O
usually	O
associated	O
with	O
pure	B-Phenotype
spastic	I-Phenotype
paraplegia	E-Phenotype
and	O
also	O
in	O
the	O
Parkinson	O
*	O
s	O
disease	O
-	O
associated	O
gene	O
ATP13A2	O
,	O
neuronal	O
ceroid	O
lipofuscinosis	O
gene	O
TPP1	O
and	O
the	O
hereditary	O
motor	O
and	O
sensory	B-Phenotype
neuropathy	E-Phenotype
DNMT1	O
gene	O
,	O
highlighting	O
the	O
genetic	O
heterogeneity	S-Phenotype
of	O
spastic	B-Phenotype
paraplegia	E-Phenotype
.	O

Finally	O
,	O
we	O
show	O
evidence	O
that	O
abnormal	O
protein	O
homeostasis	O
is	O
a	O
prevalent	O
mechanism	O
responsible	O
for	O
UROS	O
deficiency	O
and	O
that	O
modulators	O
of	O
UROS	O
proteolysis	O
such	O
as	O
proteasome	O
inhibitors	O
or	O
chemical	O
chaperones	O
may	O
represent	O
an	O
attractive	O
therapeutic	O
option	O
to	O
reduce	O
porphyrin	O
accumulation	O
and	O
prevent	O
skin	B-Phenotype
photosensitivity	E-Phenotype
in	O
CEP	O
patients	O
when	O
the	O
genotype	O
includes	O
a	O
missense	O
variant	O

We	O
show	O
that	O
hypermethylation	O
of	O
p16	O
/	O
Ink4a	O
and	O
p19	O
/	O
Arf	O
in	O
CNT	O
-	O
and	O
asbestos	O
-	O
induced	O
inflammatory	O
lesions	O
precedes	O
mesothelioma	O
;	O
this	O
results	O
in	O
silencing	O
of	O
Cdkn2a	O
(	O
Ink4a	O
/	O
Arf	O
)	O
and	O
loss	O
of	O
p16	O
and	O
p19	O
protein	O
,	O
consistent	O
with	O
epigenetic	O
alterations	O
playing	O
a	O
gatekeeper	O
role	O
in	O
cancer	S-Phenotype
.	O

We	O
further	O
expand	O
the	O
existing	O
CNTNAP1	O
-	O
associated	O
phenotype	O
to	O
include	O
profound	B-Phenotype
cerebral	I-Phenotype
and	I-Phenotype
cerebellar	I-Phenotype
atrophy	E-Phenotype

SMARCA4	B-Phenotype
-	I-Phenotype
deficient	I-Phenotype
thoracic	I-Phenotype
sarcoma	E-Phenotype
is	O
a	O
recently	O
proposed	O
new	O
entity	O
of	O
soft	B-Phenotype
tissue	I-Phenotype
sarcomas	E-Phenotype
with	O
an	O
undifferentiated	O
round	O
cell	O
morphology	O
that	O
is	O
diagnostically	O
challenging	O
.	O

These	O
findings	O
suggest	O
that	O
reduction	O
in	O
FRG1	O
expression	O
in	O
gastric	B-Phenotype
,	I-Phenotype
colon	I-Phenotype
and	I-Phenotype
oral	I-Phenotype
cavity	I-Phenotype
tumor	E-Phenotype
might	O
have	O
a	O
role	O
in	O
tumor	S-Phenotype
progression	O
,	O
by	O
regulating	O
cell	O
migration	O
and	O
invasiveness	O
.	O

Our	O
present	O
findings	O
revealed	O
that	O
the	O
upregulation	O
of	O
SASS6	O
expression	O
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
CRC	O
and	O
is	O
associated	O
with	O
a	O
poor	O
prognosis	O
among	O
patients	O
with	O
colon	B-Phenotype
cancer	E-Phenotype
.	O

We	O
recently	O
reported	O
a	O
novel	O
human	O
phenotype	O
resulting	O
from	O
a	O
mutation	O
in	O
the	O
critical	O
coding	O
region	O
of	O
the	O
HBS1L	O
gene	O
characterized	O
by	O
facial	B-Phenotype
dysmorphism	E-Phenotype
,	O
severe	B-Phenotype
growth	I-Phenotype
restriction	E-Phenotype
,	O
axial	B-Phenotype
hypotonia	E-Phenotype
,	O
global	B-Phenotype
developmental	I-Phenotype
delay	E-Phenotype
and	O
retinal	B-Phenotype
pigmentary	I-Phenotype
deposits	E-Phenotype
.	O

Here	O
,	O
we	O
report	O
mutations	O
in	O
PYCR2	O
,	O
which	O
encodes	O
an	O
enzyme	O
in	O
the	O
proline	O
biosynthesis	O
pathway	O
,	O
as	O
the	O
cause	O
of	O
a	O
unique	O
syndrome	O
characterized	O
by	O
postnatal	B-Phenotype
microcephaly	E-Phenotype
,	O
hypomyelination	S-Phenotype
,	O
and	O
reduced	B-Phenotype
cerebral	I-Phenotype
white	I-Phenotype
-	I-Phenotype
matter	I-Phenotype
volume	E-Phenotype
.	O

In	O
this	O
study	O
,	O
we	O
report	O
a	O
family	O
with	O
X	O
-	O
linked	O
recessive	O
syndrome	O
caused	O
by	O
mutated	O
AMMECR1	O
and	O
characterized	O
by	O
elliptocytosis	S-Phenotype
with	O
or	O
without	O
anemia	S-Phenotype
,	O
midface	B-Phenotype
hypoplasia	E-Phenotype
,	O
proportionate	B-Phenotype
short	I-Phenotype
stature	E-Phenotype
and	O
hearing	B-Phenotype
loss	E-Phenotype
.	O

The	O
PCH1sub	O
-	O
types	O
with	O
early	O
death	O
(	O
between	O
ages	O
1	O
day	O
and	O
17	O
months	O
)	O
,	O
seen	O
in	O
patients	O
with	O
p.G31A	O
/	O
EXOSC3	O
or	O
SLC25A46	O
mutations	O
have	O
a	O
SMA	O
type	O
1	O
-	O
like	O
clinical	O
presentation	O
but	O
with	O
global	B-Phenotype
developmental	I-Phenotype
delay	E-Phenotype
,	O
visual	B-Phenotype
and	I-Phenotype
hearing	I-Phenotype
impairment	E-Phenotype
,	O
with	O
or	O
without	O
microcephaly	S-Phenotype
,	O
nystagmus	S-Phenotype
and	O
optic	B-Phenotype
atrophy	E-Phenotype
.	O

In	O
conclusion	O
,	O
GATA4	O
is	O
highly	O
expressed	O
in	O
most	O
hepatoblastomas	S-Phenotype
and	O
correlates	O
with	O
a	O
mesenchymal	O
,	O
migratory	O
phenotype	O
of	O
hepatoblastoma	S-Phenotype
cells	O

In	O
summary	O
,	O
high	O
GFAT1	O
expression	O
is	O
identified	O
as	O
an	O
independent	O
predictor	O
of	O
adverse	O
clinical	O
outcome	O
in	O
our	O
small	O
number	O
of	O
pancreatic	B-Phenotype
cancer	E-Phenotype
patients	O
,	O
and	O
the	O
practical	O
prognostic	O
nomogram	O
model	O
may	O
help	O
clinicians	O
in	O
decision	O
making	O
and	O
the	O
design	O
of	O
clinical	O
studies	O

Suppression	O
of	O
pS14	O
-	O
WWOX	O
by	O
Zfra	O
reduces	O
cancer	S-Phenotype
growth	O
and	O
mitigates	O
Alzheimer	O
*	O
s	O
disease	O
progression	O
,	O
suggesting	O
that	O
pS14	O
-	O
WWOX	O
facilitates	O
disease	O
progression	O
.	O

Moreover	O
,	O
comparison	O
of	O
the	O
porcine	O
results	O
to	O
those	O
reported	O
by	O
human	O
melanoma	S-Phenotype
GWAS	O
indicated	O
shared	O
association	O
signals	O
notably	O
at	O
CDKAL1	O
and	O
TERT	O
loci	O
but	O
also	O
nearby	O
CCND1	O
,	O
FTO	O
,	O
PLA2G6	O
and	O
TMEM38B	O
-	O
RAD23B	O
loci	O
.	O

Leptin	O
(	O
LEP	O
)	O
and	O
fat	O
mass	O
and	O
obesity	S-Phenotype
-	O
associated	O
(	O
FTO	O
)	O
alleles	O
are	O
known	O
to	O
influence	O
body	O
fat	O
mass	O
in	O
humans	O
,	O
potentially	O
via	O
effects	O
on	O
appetite	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
genetic	O
association	O
study	O
that	O
reveals	O
the	O
genetic	O
contribution	O
of	O
liCHRM3	O
/	O
i	O
gene	O
in	O
bladder	B-Phenotype
cancer	E-Phenotype
etiology	O

Real	O
-	O
time	O
RT	O
-	O
PCR	O
revealed	O
that	O
p120	O
-	O
catenin	O
isoforms	O
1	O
and	O
4	O
were	O
upregulated	O
in	O
PhIP	O
-	O
induced	O
skin	B-Phenotype
tumors	E-Phenotype
,	O
whereas	O
p120	O
-	O
catenin	O
isoform	O
3	O
was	O
expressed	O
uniformly	O
,	O
compared	O
with	O
adjacent	O
normal	O
-	O
looking	O
tissue	O
.	O

In	O
addition	O
to	O
cellular	O
miRNAs	O
,	O
secreted	O
miRNAs	O
also	O
play	O
important	O
roles	O
in	O
cancer	S-Phenotype
development	O
and	O
metastasis	O
.	O

Somatic	O
missense	O
mutations	O
in	O
the	O
Ser	O
/	O
Thr	O
protein	O
phosphatase	O
2A	O
(	O
PP2A	O
)	O
Aα	O
scaffold	O
subunit	O
gene	O
PPP2R1A	O
are	O
among	O
the	O
few	O
genomic	O
alterations	O
that	O
occur	O
frequently	O
in	O
serous	O
endometrial	B-Phenotype
carcinoma	E-Phenotype
(	O
EC	S-Phenotype
)	O
and	O
carcinosarcoma	S-Phenotype
,	O
two	O
clinically	O
aggressive	O
subtypes	O
of	O
uterine	B-Phenotype
cancer	E-Phenotype
with	O
few	O
therapeutic	O
options	O
.	O

The	O
present	O
study	O
reports	O
a	O
first	O
ILDR1	O
gene	O
mutation	O
in	O
the	O
UAE	O
population	O
and	O
confirms	O
that	O
the	O
whole	O
-	O
exome	O
sequencing	O
approach	O
is	O
a	O
robust	O
tool	O
for	O
the	O
diagnosis	O
of	O
monogenic	O
diseases	O
with	O
high	O
levels	O
of	O
allelic	O
and	O
locus	O
heterogeneity	S-Phenotype
.	O

Moreover	O
,	O
NEK2	O
mediated	O
liver	B-Phenotype
cancer	E-Phenotype
cell	O
migration	O
via	O
pAKT	O
/	O
NF	O
-	O
κB	O
signaling	O
and	O
matrix	O
metalloproteinase	O
(	O
MMP	O
)	O
activation	O
.	O

Our	O
findings	O
enlarge	O
the	O
spectrum	O
of	O
tubulinopathies	O
and	O
emphasize	O
that	O
mutations	O
of	O
TUBB6	O
should	O
be	O
considered	O
in	O
patients	O
with	O
congenital	B-Phenotype
non	I-Phenotype
-	I-Phenotype
progressive	I-Phenotype
facial	I-Phenotype
palsy	E-Phenotype
.	O

Additionally	O
,	O
interfering	O
PSMB8	O
may	O
induce	O
apoptosis	O
of	O
glioma	S-Phenotype
cells	O
by	O
upregulating	O
caspase	O
-	O
3	O
expression	O
.	O

Herein	O
,	O
we	O
report	O
3	O
patients	O
with	O
heterozygous	O
constitutional	O
CDK13	O
mutations	O
,	O
who	O
were	O
ascertained	O
through	O
exome	O
analysis	O
of	O
children	O
with	O
intellectual	B-Phenotype
disability	E-Phenotype
and	O
minor	O
anomalies	O
,	O
who	O
lacked	O
cardiac	B-Phenotype
anomalies	E-Phenotype
.	O

However	O
,	O
the	O
role	O
of	O
circRNAs	O
in	O
age	B-Phenotype
-	I-Phenotype
related	I-Phenotype
cataract	E-Phenotype
(	O
ARC	S-Phenotype
)	O
,	O
the	O
leading	O
cause	O
of	O
visual	B-Phenotype
impairment	E-Phenotype
worldwide	O
,	O
is	O
still	O
unknown	O
.	O

We	O
find	O
that	O
WIP	O
controls	O
tumor	S-Phenotype
growth	O
by	O
boosting	O
signals	O
that	O
stabilize	O
the	O
YAP	O
/	O
TAZ	O
complex	O
via	O
a	O
mechanism	O
mediated	O
by	O
the	O
endocytic	O
/	O
endosomal	O
system	O
.	O

We	O
aimed	O
to	O
define	O
the	O
role	O
of	O
myeloid	O
PRMT1	O
in	O
alcohol	B-Phenotype
-	I-Phenotype
associated	I-Phenotype
liver	I-Phenotype
tumor	E-Phenotype
progressionusing	O
a	O
mouse	O
model	O
of	O
DEN	O
injection	O
followed	O
by	O
Lieber	O
-	O
DeCarli	O
alcohol	O
liquid	O
diet	O
feeding	O
.	O

Our	O
data	O
showed	O
that	O
Zic2	O
expression	O
gradually	O
increased	O
from	O
normal	O
to	O
cancer	S-Phenotype
to	O
metastatic	O
tissues	O
.	O

Tumor	S-Phenotype
growth	O
in	O
xenografts	O
as	O
well	O
as	O
EGFR	O
signaling	O
were	O
assessed	O
in	O
HCT116	O
cells	O
expressing	O
IL17RD	O
with	O
either	O
a	O
mutant	O
3	O
*	O
untranslated	O
region	O
(	O
UTR	O
)	O
or	O
wild	O
-	O
type	O
(	O
WT	O
)	O
3	O
*	O
UTR.Results	O
:	O
miR	O
-	O
31	O
,	O
miR	O
-	O
34a	O
,	O
miR	O
-	O
106b	O
,	O
and	O
miR	O
-	O
193a	O
-	O
3p	O
were	O
significantly	O
dysregulated	O
in	O
ulcerative	B-Phenotype
colitis	I-Phenotype
-	I-Phenotype
neoplasia	E-Phenotype
and	O
adjacent	O
tissue	O
.	O

Most	O
often	O
,	O
hypogonadotropic	B-Phenotype
hypogonadism	E-Phenotype
is	O
caused	O
by	O
disorder	O
in	O
secretion	O
of	O
gonadoliberin	O
,	O
the	O
product	O
of	O
gene	O
GNRH1	O
.	O

Bartter	O
syndrome	O
type	O
3	O
is	O
a	O
clinically	O
heterogeneous	B-Phenotype
hereditary	I-Phenotype
salt	I-Phenotype
-	I-Phenotype
losing	I-Phenotype
tubulopathy	E-Phenotype
caused	O
by	O
mutations	O
of	O
the	O
chloride	O
voltage	O
-	O
gated	O
channel	O
Kb	O
gene	O
(	O
CLCNKB	O
)	O
,	O
which	O
encodes	O
the	O
ClC	O
-	O
Kb	O
chloride	O
channel	O
involved	O
in	O
NaCl	O
reabsorption	O
in	O
the	O
renal	O
tubule	O
.	O

Since	O
platelet	O
-	O
mediated	O
clot	O
formation	O
is	O
a	O
key	O
event	O
in	O
several	O
fatal	O
diseases	O
,	O
such	O
as	O
myocardial	B-Phenotype
infarction	E-Phenotype
,	O
stroke	S-Phenotype
and	O
pulmonary	B-Phenotype
embolism	E-Phenotype
,	O
understanding	O
TYMP	O
in	O
depth	O
may	O
lead	O
to	O
uncovering	O
novel	O
mechanisms	O
in	O
the	O
development	O
of	O
cardiovascular	B-Phenotype
diseases	E-Phenotype
.	O

Furthermore	O
,	O
cardiovascular	O
risk	O
factors	O
such	O
hyperthyroidism	S-Phenotype
,	O
hypertension	S-Phenotype
and	O
redox	O
homeostasis	O
have	O
been	O
identified	O
to	O
modulate	O
PITX2	O
driven	O
gene	O
regulatory	O
networks	O
.	O

ARHGAP17	O
expression	O
in	O
cervical	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
was	O
assessed	O
by	O
RT	O
-	O
PCR	O
and	O
Western	O
blotting	O
.	O

Immunohistochemical	O
analysis	O
was	O
performed	O
to	O
evaluate	O
PAX2	O
protein	O
expression	O
in	O
36	O
TAM	O
-	O
R	O
and	O
36	O
TAM	O
-	O
S	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
(	O
FFPE	O
)	O
breast	B-Phenotype
tumor	E-Phenotype
tissues	O
.	O

We	O
hypothesized	O
that	O
newly	O
identified	O
genetic	O
risk	O
factors	O
for	O
the	O
general	O
African	O
American	O
population	O
could	O
also	O
impact	O
laboratory	O
biomarkers	O
known	O
to	O
contribute	O
to	O
the	O
clinical	O
disease	O
expression	O
of	O
SCA	O
,	O
including	O
variants	O
influencing	O
the	O
white	O
blood	O
cell	O
count	O
and	O
the	O
development	O
of	O
albuminuria	S-Phenotype
and	O
abnormal	B-Phenotype
glomerular	I-Phenotype
filtration	I-Phenotype
rate	E-Phenotype
.	O

Our	O
results	O
suggest	O
that	O
GZF1	O
mutations	O
cause	O
a	O
phenotype	O
of	O
severe	B-Phenotype
myopia	E-Phenotype
and	O
significant	O
articular	O
involvement	O
not	O
previously	O
described	O
in	O
Larsen	O
syndrome	O

This	O
review	O
discusses	O
recurrent	O
aberrations	O
in	O
NKTCL	O
detected	O
by	O
NGS	O
,	O
which	O
can	O
be	O
categorized	O
into	O
three	O
main	O
groups	O
,	O
specifically	O
,	O
tumor	S-Phenotype
suppressors	O
(	O
TP53	O
,	O
DDX3X	O
,	O
and	O
MGA	O
)	O
,	O
the	O
JAK	O
/	O
STAT	O
cascade	O
,	O
and	O
epigenetic	O
modifiers	O
(	O
KMT2D	O
,	O
BCOR	O
,	O
ARID1A	O
,	O
and	O
EP300	O
)	O
.	O

To	O
identify	O
the	O
disease	O
-	O
causing	O
defect	O
in	O
these	O
families	O
,	O
we	O
first	O
analysed	O
MFRP	O
gene	O
,	O
then	O
some	O
candidate	O
genes	O
(	O
CHX10	O
,	O
OPA1	O
,	O
MITF	O
,	O
SOX2	O
,	O
CRYBB1	O
-	O
3	O
and	O
CRYBA4	O
)	O
and	O
loci	O
(	O
MCOP1	O
,	O
NNO1	O
and	O
NNO2	O
)	O
previously	O
implicated	O
in	O
different	O
forms	O
of	O
microphthalmia	S-Phenotype
.	O

The	O
ubiquitin	O
-	O
fold	O
modifier	O
1	O
(	O
UFM1	O
)	O
-	O
system	O
,	O
a	O
ubiquitin	O
-	O
like	O
protein	O
conjugation	O
system	O
,	O
is	O
involved	O
in	O
the	O
development	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
and	O
several	O
hereditary	O
neurological	O
syndromes	O
.	O

Here	O
,	O
we	O
summarize	O
the	O
cellular	O
functions	O
of	O
PGRN	O
,	O
its	O
roles	O
in	O
the	O
nervous	O
system	O
,	O
and	O
its	O
link	O
to	O
multiple	O
neurodegenerative	B-Phenotype
diseases	E-Phenotype
,	O
with	O
a	O
particular	O
focus	O
dedicated	O
to	O
recent	O
lysosome	O
-	O
related	O
mechanistic	O
developments	O

In	O
this	O
study	O
,	O
the	O
fluorescence	O
lifetime	O
of	O
the	O
metabolic	O
coenzyme	O
NADH	O
reveals	O
that	O
the	O
absence	O
of	O
REV3L	O
can	O
promote	O
the	O
p53	O
-	O
mediated	O
upregulation	O
of	O
oxidative	O
phosphorylation	O
in	O
cisplatin	O
-	O
treated	O
H1299	O
lung	B-Phenotype
carcinoma	E-Phenotype
cells	O
and	O
increases	O
cancer	S-Phenotype
cell	O
sensitivity	O
to	O
this	O
platinum	O
-	O
based	O
chemotherapy	O
.	O

The	O
present	O
study	O
demonstrated	O
that	O
MFAP5	O
was	O
up	O
-	O
regulated	O
in	O
breast	B-Phenotype
cancers	E-Phenotype
compared	O
with	O
that	O
in	O
normal	O
breast	O
tissues	O
,	O
and	O
further	O
increased	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
bone	B-Phenotype
metastasis	E-Phenotype
.	O

The	O
CHAF1B	O
gene	O
in	O
human	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
cell	O
line	O
HUH	O
-	O
7	O
was	O
knocked	O
down	O
using	O
a	O
lentivirus	O
and	O
the	O
transfected	O
cells	O
were	O
assayed	O
for	O
migration	O
and	O
invasion	O
abilities	O
and	O
cell	O
cycle	O
arrest	O
using	O
the	O
scratch	O
wound	O
healingand	O
Transwell	O
assays	O
as	O
well	O
as	O
flow	O
cytometry	O
,	O
respectively	O
.	O

In	O
trans	O
-	O
ethnic	O
meta	O
-	O
analyses	O
of	O
U4C	O
and	O
UK	O
Biobank	O
data	O
,	O
we	O
found	O
significant	O
associations	O
between	O
breast	B-Phenotype
cancer	E-Phenotype
risk	O
and	O
the	O
expression	O
of	O
RCCD1	O
(	O
joint	O
p	O
-	O
value	O
:	O
3.6x10	O
-	O
06	O
)	O
and	O
DHODH	O
(	O
p	O
-	O
value	O
:	O
7.1x10	O
-	O
06	O
)	O
in	O
breast	O
tissue	O
,	O
as	O
well	O
as	O
a	O
suggestive	O
association	O
for	O
ANKLE1	O
(	O
p	O
-	O
value	O
:	O
9.3x10	O
-	O
05	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
tumor	S-Phenotype
suppressor	O
candidate	O
3	O
(	O
TUSC3	O
)	O
was	O
downregulated	O
in	O
temozolomide	O
-	O
resistant	O
U87MG	O
cells	O
(	O
U87MG	O
-	O
res	O
cells	O
)	O
and	O
its	O
restoration	O
sensitized	O
U87MG	O
-	O
res	O
cells	O
to	O
temozolomide	O
.	O

DLEC1	O
was	O
decreased	O
in	O
more	O
aggressive	O
subtypes	O
:	O
large	O
cell	O
carcinoma	S-Phenotype
and	O
adenocarcinoma	B-Phenotype
-	I-Phenotype
squamous	I-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
.	O

In	O
these	O
5	O
families	O
,	O
we	O
detected	O
one	O
reported	O
and	O
six	O
novel	O
mutations	O
in	O
5	O
different	O
deafness	S-Phenotype
autosomal	B-Phenotype
recessive	E-Phenotype
(	O
DFNB	O
)	O
genes	O
(	O
TRIOBP	O
,	O
LHFPL5	O
,	O
CDH23	O
,	O
PCDH15	O
,	O
and	O
MYO7A	O
)	O
.	O

In	O
T2D	O
patients	O
,	O
PAX4	O
Arg192His	O
was	O
associated	O
with	O
earlier	O
age	O
at	O
diagnosis	O
,	O
and	O
GLP1R	O
Arg131Gln	O
was	O
associated	O
with	O
decreased	O
risk	O
of	O
cardiovascular	B-Phenotype
disease	E-Phenotype
.	O

Considering	O
the	O
genetic	O
heterogeneity	S-Phenotype
of	O
HCC	S-Phenotype
,	O
four	O
datasets	O
from	O
four	O
studies	O
consisting	O
of	O
15	O
pairs	O
of	O
HCC	S-Phenotype
and	O
adjacent	O
normal	O
samples	O
were	O
analyzed	O
.	O

The	O
underlining	O
mechanisms	O
of	O
dietary	O
cholesterol	O
and	O
nonalcoholic	O
steatohepatitis	O
(	O
NASH	O
)	O
in	O
contributing	O
to	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
remain	O
undefined	O
.	O

In	O
cancer	S-Phenotype
biology	O
,	O
miRNAs	O
play	O
functional	O
roles	O
in	O
tumor	S-Phenotype
seeding	O
,	O
drug	O
sensitivity	O
,	O
and	O
metastasis	O
.	O

The	O
common	O
Ser96Ala	O
human	O
genetic	O
variant	O
of	O
HRC	O
strongly	O
correlates	O
with	O
life	O
-	O
threatening	O
ventricular	B-Phenotype
arrhythmias	E-Phenotype
in	O
patients	O
with	O
idiopathic	B-Phenotype
dilated	I-Phenotype
cardiomyopathy	E-Phenotype
.	O

The	O
SLC25A26	O
gene	O
encodes	O
the	O
mitochondrial	O
carrier	O
that	O
catalyzes	O
the	O
import	O
of	O
S	O
-	O
adenosylmethionine	O
(	O
SAM	O
)	O
into	O
the	O
mitochondrial	O
matrix	O
,	O
required	O
for	O
mitochondrial	O
methylation	O
processes	O
,	O
and	O
is	O
down	O
-	O
regulated	O
in	O
cervical	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

The	O
impact	O
of	O
NOX2	O
and	O
ROS	O
on	O
cancer	S-Phenotype
development	O
is	O
only	O
partly	O
explored	O
.	O

The	O
single	O
patient	O
not	O
deleted	O
for	O
ANKRD11	O
,	O
whose	O
phenotype	O
is	O
characterized	O
by	O
milder	O
psychomotor	B-Phenotype
delay	E-Phenotype
,	O
cardiac	B-Phenotype
congenital	I-Phenotype
malformation	E-Phenotype
,	O
thrombocytopenia	S-Phenotype
and	O
astigmatism	S-Phenotype
,	O
confirms	O
all	O
this	O
data	O

Here	O
we	O
identified	O
six	O
different	O
de	O
novo	O
missense	O
mutations	O
in	O
DHX30	O
in	O
twelve	O
unrelated	O
individuals	O
affected	O
by	O
global	B-Phenotype
developmental	I-Phenotype
delay	E-Phenotype
(	O
GDD	S-Phenotype
)	O
,	O
intellectual	B-Phenotype
disability	E-Phenotype
(	O
ID	S-Phenotype
)	O
,	O
severe	O
speech	B-Phenotype
impairment	E-Phenotype
and	O
gait	B-Phenotype
abnormalities	E-Phenotype
.	O

We	O
show	O
that	O
the	O
meiosis	O
-	O
related	O
EECTG	O
(	O
MEIOB	O
)	O
and	O
its	O
nearby	O
CT	O
-	O
ncRNA	O
have	O
a	O
role	O
in	O
tumorigenesis	O
in	O
lung	B-Phenotype
adenocarcinoma	E-Phenotype
.	O

We	O
use	O
the	O
BMI	O
-	O
and	O
obesity	S-Phenotype
-	O
associated	O
FTO	O
locus	O
as	O
a	O
subject	O
as	O
it	O
poses	O
an	O
illustrative	O
example	O
on	O
the	O
value	O
of	O
these	O
resources	O
.	O

By	O
analysing	O
prostate	B-Phenotype
cancer	E-Phenotype
bone	B-Phenotype
metastases	E-Phenotype
using	O
high	O
density	O
microarrays	O
,	O
we	O
found	O
a	O
common	O
genomic	O
copy	O
number	O
loss	O
at	O
6q16.1	O
-	O
16.2	O
,	O
containing	O
the	O
FBXL4	O
gene	O
,	O
which	O
was	O
confirmed	O
in	O
larger	O
series	O
of	O
bone	O
metastases	O
by	O
fluorescence	O
in	O
situ	O
hybridisation	O
(	O
FISH	O
)	O
.	O

Bardet	O
Biedl	O
syndrome	O
(	O
BBS	O
)	O
is	O
a	O
multisystem	O
genetically	O
heterogeneous	O
ciliopathy	O
that	O
most	O
commonly	O
leads	O
to	O
obesity	S-Phenotype
,	O
photoreceptor	B-Phenotype
degeneration	E-Phenotype
,	O
digit	B-Phenotype
anomalies	E-Phenotype
,	O
genito	B-Phenotype
-	I-Phenotype
urinary	I-Phenotype
abnormalities	E-Phenotype
,	O
as	O
well	O
as	O
cognitive	B-Phenotype
impairment	E-Phenotype
with	O
autism	S-Phenotype
,	O
among	O
other	O
features	O
.	O

Furthermore	O
,	O
we	O
investigated	O
whether	O
there	O
is	O
an	O
association	O
between	O
the	O
mRNA	O
and	O
protein	O
expression	O
levels	O
of	O
RBCK1	O
,	O
RNF31	O
and	O
SHARPIN	O
and	O
clinicopathological	O
parameters	O
including	O
estrogen	O
receptor	O
(	O
ER	O
)	O
,	O
progesterone	O
receptor	O
(	O
PR	O
)	O
and	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
HER2	O
)	O
status	O
and	O
found	O
that	O
RNF31	O
protein	O
is	O
significantly	O
higher	O
in	O
ERalpha	O
-	O
negative	O
tumors	S-Phenotype
than	O
ERalpha	O
-	O
positive	O
tumors	S-Phenotype
(	O
p	O
=	O
0.034	O
)	O
.	O

Autosomal	B-Phenotype
-	I-Phenotype
recessive	I-Phenotype
optic	I-Phenotype
neuropathies	E-Phenotype
are	O
rare	O
blinding	O
conditions	O
related	O
to	O
retinal	O
ganglion	O
cell	O
(	O
RGC	O
)	O
and	O
optic	B-Phenotype
-	I-Phenotype
nerve	I-Phenotype
degeneration	E-Phenotype
,	O
for	O
which	O
only	O
mutations	O
in	O
TMEM126A	O
and	O
ACO2	O
are	O
known	O
.	O

Previous	O
studies	O
have	O
identified	O
a	O
critical	O
role	O
for	O
the	O
tumor	S-Phenotype
suppressors	O
BRCA1	O
and	O
BRCA2	O
in	O
preventing	O
the	O
degradation	O
of	O
nascent	O
DNA	O
by	O
the	O
MRE11	O
nuclease	O
after	O
replication	O
stress	O
.	O

Occult	B-Phenotype
macular	I-Phenotype
dystrophy	E-Phenotype
(	O
OMD	S-Phenotype
)	O
is	O
an	O
inherited	O
macular	O
disease	O
characterized	O
by	O
progressive	O
visual	O
decline	O
with	O
the	O
absence	O
of	O
visible	O
retinal	O
abnormalities	O
.	O

Global	O
-	O
genome	O
nucleotide	O
excision	O
repair	O
(	O
GG	O
-	O
NER	O
)	O
prevents	O
ultraviolet	B-Phenotype
(	I-Phenotype
UV	I-Phenotype
)	I-Phenotype
light	I-Phenotype
-	I-Phenotype
induced	I-Phenotype
skin	I-Phenotype
cancer	E-Phenotype
by	O
removing	O
mutagenic	O
cyclobutane	O
pyrimidine	O
dimers	O
(	O
CPDs	O
)	O
.	O

EphA2	O
,	O
EphB4	O
and	O
EphB6	O
are	O
the	O
members	O
most	O
extensively	O
studied	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

In	O
this	O
study	O
,	O
we	O
performed	O
exome	O
-	O
wide	O
association	O
studies	O
(	O
EWASs	O
)	O
to	O
identify	O
genetic	O
variants	O
that	O
confer	O
susceptibility	O
to	O
ischemic	B-Phenotype
stroke	E-Phenotype
,	O
intracerebral	B-Phenotype
hemorrhage	E-Phenotype
(	O
ICH	S-Phenotype
)	O
,	O
or	O
subarachnoid	B-Phenotype
hemorrhage	E-Phenotype
(	O
SAH	S-Phenotype
)	O
.	O

Smad4	O
has	O
recently	O
been	O
identified	O
as	O
a	O
tumor	S-Phenotype
suppressor	O
gene	O
in	O
a	O
variety	O
of	O
cancers	S-Phenotype
,	O
yet	O
the	O
role	O
of	O
Smad4	O
in	O
renal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
RCC	S-Phenotype
)	O
remained	O
to	O
be	O
elusive	O
.	O

Our	O
study	O
further	O
emphasizes	O
that	O
NDUFS6	O
sequence	O
should	O
be	O
analyzed	O
in	O
patients	O
presenting	O
with	O
lethal	B-Phenotype
neonatal	I-Phenotype
lactic	I-Phenotype
acidemia	E-Phenotype
due	O
to	O
isolated	O
complex	O
I	O
deficiency	O

PKD1	O
and	O
PKD2	O
germline	O
mutations	O
are	O
found	O
in	O
patients	O
with	O
autosomal	B-Phenotype
dominant	I-Phenotype
polycystic	I-Phenotype
kidney	E-Phenotype
disease	O
(	O
ADPKD	S-Phenotype
)	O
.	O

Through	O
immunohistochemistry	O
,	O
we	O
found	O
that	O
DDX59	O
protein	O
expression	O
correlated	O
with	O
Ras	O
and	O
EGFR	O
mutation	O
status	O
in	O
human	O
lung	B-Phenotype
adenocarcinoma	E-Phenotype
.	O

Five	O
variants	O
were	O
previously	O
reported	O
to	O
confer	O
risk	O
of	O
various	O
malignant	O
or	O
benign	O
tumors	S-Phenotype
(	O
rs78378222	O
in	O
TP53	O
,	O
rs10069690	O
in	O
TERT	O
,	O
rs1800057	O
and	O
rs1801516	O
in	O
ATM	O
,	O
and	O
rs7907606	O
at	O
OBFC1	O
)	O
and	O
four	O
signals	O
are	O
located	O
at	O
established	O
risk	O
loci	O
for	O
hormone	O
-	O
related	O
traits	O
(	O
endometriosis	S-Phenotype
and	O
breast	B-Phenotype
cancer	E-Phenotype
)	O
at	O
1q36.12	O
(	O
CDC42	O
/	O
WNT4	O
)	O
,	O
2p25.1	O
(	O
GREB1	O
)	O
,	O
20p12.3	O
(	O
MCM8	O
)	O
,	O
and	O
6q26.2	O
(	O
SYNE1	O
/	O
ESR1	O
)	O
.	O

Furthermore	O
,	O
targeted	O
knockout	O
of	O
Slc7a14	O
in	O
mice	O
results	O
in	O
retinal	B-Phenotype
degeneration	E-Phenotype
with	O
abnormal	B-Phenotype
ERG	E-Phenotype
response	O
.	O

Variants	O
in	O
the	O
ATL1	O
gene	O
have	O
been	O
repeatedly	O
described	O
as	O
the	O
second	O
most	O
frequent	O
cause	O
of	O
hereditary	B-Phenotype
spastic	I-Phenotype
paraplegia	E-Phenotype
(	O
HSP	S-Phenotype
)	O
,	O
a	O
motor	O
neuron	O
disease	O
manifested	O
by	O
progressive	B-Phenotype
lower	I-Phenotype
limb	I-Phenotype
spasticity	E-Phenotype
and	O
weakness	S-Phenotype
.	O

/	O
i	O
3	O
)	O
Multiple	B-Phenotype
endocrine	I-Phenotype
neoplasia	I-Phenotype
type	I-Phenotype
1	E-Phenotype
(	O
MEN1	S-Phenotype
)	O
is	O
most	O
frequently	O
expressed	O
as	O
PHPT	O
with	O
asymmetric	O
enlargement	O
of	O
3	O
-	O
4	O
parathyroids	O
.	O

In	O
addition	O
,	O
the	O
BRPF1	O
gene	O
is	O
mutated	O
in	O
childhood	O
leukemia	S-Phenotype
and	O
adult	O
medulloblastoma	S-Phenotype
.	O

A	O
frame	O
-	O
shift	O
carboxyl	O
-	O
terminal	O
deletion	O
was	O
reported	O
in	O
DISC1	O
in	O
an	O
American	O
family	O
with	O
schizophrenia	S-Phenotype
,	O
but	O
subsequently	O
found	O
in	O
two	O
controls	O
.	O

Here	O
,	O
for	O
the	O
first	O
time	O
,	O
we	O
demonstrated	O
the	O
roles	O
of	O
FGFRL1	O
in	O
ovarian	B-Phenotype
carcinoma	E-Phenotype
(	O
OC	S-Phenotype
)	O
.	O

Collectively	O
,	O
these	O
findings	O
advance	O
our	O
understanding	O
of	O
PI3K	O
impactful	O
mutations	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
and	O
have	O
important	O
implications	O
for	O
PI3K	O
-	O
targeted	O
therapy	O
in	O
precision	O
oncology	S-Phenotype

Oral	B-Phenotype
cancer	E-Phenotype
was	O
associated	O
with	O
two	O
new	O
regions	O
,	O
2p23.3	O
(	O
rs6547741	O
,	O
GPN1	O
)	O
and	O
9q34.12	O
(	O
rs928674	O
,	O
LAMC3	O
)	O
,	O
and	O
with	O
known	O
cancer	S-Phenotype
-	O
related	O
loci	O
-	O
9p21.3	O
(	O
rs8181047	O
,	O
CDKN2B	O
-	O
AS1	O
)	O
and	O
5p15.33	O
(	O
rs10462706	O
,	O
CLPTM1L	O
)	O
.	O

Using	O
exome	O
sequencing	O
,	O
we	O
identified	O
dominant	O
mutations	O
in	O
DNM1L	O
on	O
chromosome	O
12p11.21	O
in	O
three	O
large	O
families	O
with	O
isolated	O
optic	B-Phenotype
atrophy	E-Phenotype
,	O
including	O
the	O
two	O
families	O
that	O
defined	O
the	O
OPA5	O
locus	O
on	O
chromosome	O
19q12.1	O
-	O
13.1	O
,	O
the	O
existence	O
of	O
which	O
is	O
denied	O
by	O
the	O
present	O
study	O
.	O

Significantly	O
,	O
higher	O
alteration	O
of	O
SLIT2	O
locus	O
was	O
observed	O
in	O
triple	B-Phenotype
negative	I-Phenotype
breast	I-Phenotype
cancer	E-Phenotype
(	O
TNBC	S-Phenotype
)	O
over	O
HER2	O
subtype	O
(	O
P	O
=	O
0.0014	O
)	O
.	O

To	O
address	O
this	O
gap	O
,	O
we	O
performed	O
a	O
longitudinal	O
exome	O
-	O
wide	O
association	O
study	O
to	O
identify	O
susceptibility	O
loci	O
for	O
obesity	S-Phenotype
and	O
MetS	O
in	O
a	O
Japanese	O
population	O
.	O

In	O
addition	O
,	O
reduced	O
hair	O
follicles	O
(	O
HFs	O
)	O
while	O
the	O
enlarged	O
and	O
increased	O
number	O
of	O
sebaceous	O
glands	O
(	O
SGs	O
)	O
were	O
also	O
found	O
in	O
the	O
Hoxc13	O
-	O
/	O
-	O
rabbits	O
,	O
showing	O
that	O
the	O
disrupted	O
balance	O
between	O
HFs	O
and	O
SGs	O
may	O
respond	O
to	O
hypotrichosis	S-Phenotype
of	O
ECTD	O
-	O
9	O
in	O
an	O
animal	O
model	O
and	O
clinically	O
.	O

These	O
findings	O
align	O
with	O
data	O
suggesting	O
that	O
SDHD	O
-	O
related	O
PPGL	O
require	O
less	O
genetic	O
events	O
for	O
tumor	S-Phenotype
initiation	O
and	O
maintenance	O
compared	O
to	O
those	O
related	O
to	O
SDHB	O
,	O
but	O
fail	O
to	O
initiate	O
biology	O
that	O
promotes	O
metastatic	O
spread	O
and	O
metastatic	O
cell	O
survival	O
in	O
host	O
tissues	O
.	O

More	O
ER	O
stress	O
-	O
inducing	O
CPA1	O
variants	O
were	O
also	O
found	O
in	O
the	O
combined	O
set	O
of	O
hospital	O
and	O
familial	O
cases	O
with	O
pancreatic	B-Phenotype
cancer	E-Phenotype
than	O
in	O
controls	O
[	O
7	O
/	O
1,546	O
vs.	O
1	O
/	O
2,012	O
;	O
P	O
=	O
0.025	O
;	O
odds	O
ratio	O
,	O
9.36	O
(	O
95	O
%	O
CI	O
,	O
1.15	O
-	O
76.02	O
)	O
]	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
the	O
impact	O
of	O
Hmx1	O
loss	O
is	O
greater	O
than	O
previously	O
appreciated	O
,	O
with	O
a	O
variety	O
of	O
lateral	B-Phenotype
cranioskeletal	I-Phenotype
defects	E-Phenotype
,	O
auriculofacial	B-Phenotype
nerve	I-Phenotype
deficits	E-Phenotype
,	O
and	O
duplication	O
of	O
the	O
caudal	O
region	O
of	O
the	O
external	O
ear	O
.	O

The	O
tumor	S-Phenotype
cells	O
resembled	O
pro	O
-	O
B	O
cells	O
,	O
and	O
were	O
CD19+IgM	O
-	O
IgD	O
-	O
CD93+CD43+CD21	O
-	O
CD23	O
-	O
VpreB+CXCR4+	O
Consistent	O
with	O
the	O
pro	O
-	O
B	O
-	O
cell	O
stage	O
of	O
B	O
-	O
cell	O
development	O
,	O
microarray	O
analysis	O
revealed	O
enrichment	O
of	O
transcripts	O
,	O
including	O
Rag1	O
,	O
Rag2	O
,	O
CD93	O
,	O
Vpreb1	O
,	O
Vpreb3	O
,	O
and	O
Igll1	O
We	O
confirmed	O
RAG1	O
expression	O
in	O
Tg26	O
tumors	S-Phenotype
,	O
and	O
hypothesized	O
that	O
HIV	O
-	O
1	O
matrix	O
protein	O
p17	O
may	O
directly	O
induce	O
RAG1	O
in	O
B	O
cells	O
.	O

Brain	O
malformations	O
described	O
in	O
association	O
with	O
22q11.2	O
deletion	O
syndrome	O
include	O
polymicrogyria	S-Phenotype
,	O
cerebellar	B-Phenotype
hypoplasia	E-Phenotype
,	O
megacisterna	B-Phenotype
magna	E-Phenotype
,	O
and	O
agenesis	B-Phenotype
of	I-Phenotype
the	I-Phenotype
corpus	I-Phenotype
callosum	E-Phenotype
(	O
ACC	S-Phenotype
)	O
,	O
although	O
these	O
are	O
rare	O
.	O

In	O
conclusion	O
,	O
we	O
successfully	O
established	O
a	O
novel	O
Ewing	B-Phenotype
's	I-Phenotype
sarcoma	E-Phenotype
cell	O
line	O
,	O
NCC	O
-	O
ES1	O
-	O
C1	O
,	O
from	O
primary	O
tumor	S-Phenotype
tissue	O
.	O

In	O
addition	O
,	O
several	O
studies	O
have	O
demonstrated	O
that	O
CaSR	O
dysfunction	O
may	O
be	O
associated	O
with	O
some	O
fatal	O
vascular	O
diseases	O
,	O
such	O
as	O
pulmonary	B-Phenotype
arterial	I-Phenotype
hypertension	E-Phenotype
,	O
primary	O
hypertension	S-Phenotype
,	O
diabetes	S-Phenotype
,	O
acute	O
myocardial	B-Phenotype
infarction	E-Phenotype
and	O
vascular	B-Phenotype
calcification	E-Phenotype
.	O

Of	O
those	O
,	O
POLR1C	O
is	O
also	O
implicated	O
in	O
a	O
mandibulofacial	B-Phenotype
dysostosis	E-Phenotype
syndrome	O
without	O
leukodystrophy	S-Phenotype
as	O
POLR1A	O
is	O
.	O

We	O
investigated	O
this	O
issue	O
by	O
analyzing	O
the	O
expression	O
patterns	O
of	O
APP	O
,	O
APP	O
-	O
processing	O
secretases	O
,	O
and	O
APP	O
metabolites	O
in	O
mitochondria	O
separated	O
from	O
human	O
neuroblastoma	S-Phenotype
SH	O
-	O
SY5Y	O
cells	O
and	O
those	O
expressing	O
Swedish	O
mutant	O
APP	O
.	O

Here	O
,	O
we	O
reveal	O
INPP5E	O
promotes	O
SHH	O
signaling	O
in	O
SHH	O
medulloblastoma	S-Phenotype
by	O
negatively	O
regulating	O
a	O
cilia	O
-	O
compartmentalized	O
PI3	O
-	O
kinase	O
signaling	O
axis	O
that	O
maintains	O
primary	O
cilia	O
on	O
tumor	S-Phenotype
cells	O
.	O

The	O
up	O
-	O
regulation	O
of	O
STX3	O
is	O
correlated	O
with	O
high	O
disease	O
stage	O
and	O
predicts	O
overall	O
and	O
disease	O
-	O
free	O
survival	O
in	O
patients	O
with	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

Altogether	O
these	O
data	O
demonstrate	O
that	O
mutations	O
in	O
INPP5K	O
cause	O
a	O
congenital	B-Phenotype
muscular	I-Phenotype
dystrophy	E-Phenotype
syndrome	O
with	O
short	B-Phenotype
stature	E-Phenotype
,	O
cataracts	S-Phenotype
,	O
and	O
intellectual	B-Phenotype
disability	E-Phenotype

The	O
prevalence	O
of	O
WRAP53	O
overexpression	O
was	O
significantly	O
higher	O
in	O
patients	O
with	O
tumor	S-Phenotype
larger	O
than	O
3.0	O
cm	O
than	O
in	O
patients	O
with	O
tumor	S-Phenotype
smaller	O
than	O
3.0	O
cm	O
.	O

Tumors	S-Phenotype
showing	O
this	O
phenotype	O
,	O
but	O
no	O
alterations	O
in	O
the	O
known	O
predisposing	O
genes	O
,	O
could	O
harbor	O
mutations	O
in	O
other	O
Krebs	O
cycle	O
genes	O
.	O

Experimental	O
Design	O
:	O
We	O
used	O
downregulation	O
and	O
methylation	O
of	O
RBP1	O
,	O
as	O
a	O
marker	O
of	O
a	O
hypermethylation	O
phenotype	O
,	O
to	O
select	O
eleven	O
pheochromocytomas	S-Phenotype
and	O
paragangliomas	S-Phenotype
for	O
targeted	O
exome	O
sequencing	O
of	O
a	O
panel	O
of	O
Krebs	O
cycle	O
-	O
related	O
genes	O
.	O

The	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
effect	O
of	O
DHA	O
on	O
the	O
distribution	O
of	O
apelin	O
and	O
apelin	O
receptor	O
(	O
APJ	O
)	O
in	O
the	O
central	O
nervous	O
system	O
in	O
1	O
-	O
methyl	O
-	O
4	O
-	O
phenyl	O
-	O
1	O
,	O
2	O
,	O
3	O
,	O
6	O
tetrahydropyridine	O
(	O
MPTP	O
)	O
-	O
induced	O
PD	O
model	O
.	O

These	O
findings	O
reveal	O
that	O
Nlrp12	O
reduces	O
HFD	O
-	O
induced	O
obesity	S-Phenotype
by	O
maintaining	O
beneficial	O
microbiota	O

Thus	O
,	O
we	O
comprehensively	O
revealed	O
the	O
anti	O
-	O
tumor	S-Phenotype
mechanism	O
of	O
FIP	O
-	O
nha	O
,	O
which	O
inhibits	O
tumor	S-Phenotype
growth	O
by	O
modulating	O
PI3K	O
/	O
Akt	O
-	O
regulated	O
cell	O
cycle	O
arrest	O
,	O
autophagy	O
,	O
and	O
apoptosis	O
,	O
and	O
provided	O
the	O
basis	O
for	O
further	O
application	O
of	O
fungal	O
immunomodulatory	O
proteins	O
,	O
especially	O
FIP	O
-	O
nha	O

We	O
identified	O
integrin	O
a7	O
(	O
ITGA7	O
)	O
as	O
a	O
major	O
laminin	O
receptor	O
in	O
GSCs	O
and	O
in	O
primary	O
high	O
-	O
grade	O
glioma	S-Phenotype
specimens	O
.	O

The	O
combination	O
of	O
low	O
CD151	O
expression	O
and	O
high	O
RNASEH2A	O
expression	O
resulted	O
in	O
impaired	O
proliferation	O
in	O
four	O
kidney	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
,	O
suggesting	O
potential	O
synthetic	O
dosage	O
lethality	O
(	O
SDL	O
)	O
interactions	O
between	O
the	O
two	O
genes	O
.	O

Moreover	O
,	O
we	O
observed	O
an	O
increase	O
in	O
cry1	O
expression	O
in	O
female	O
patients	O
with	O
distant	O
metastases	O
in	O
tumor	S-Phenotype
compared	O
to	O
adjacent	O
tissue	O
.	O

In	O
the	O
gene	O
expression	O
and	O
network	O
-	O
level	O
information	O
,	O
we	O
revealed	O
significant	O
alterations	O
of	O
molecules	O
related	O
to	O
HIF1	O
and	O
metabolic	O
pathways	O
in	O
the	O
hypoxic	O
-	O
conditioned	O
lung	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Our	O
data	O
confirm	O
the	O
genetic	O
heterogeneity	S-Phenotype
of	O
childhood	O
-	O
onset	O
pure	O
HSP	O
,	O
with	O
SPG4	O
/	O
SPAST	O
and	O
SPG3A	O
/	O
ATL1	O
being	O
the	O
most	O
frequent	O
forms	O
.	O

Tricho	O
-	O
hepato	O
-	O
enteric	O
syndrome	O
(	O
SD	O
/	O
THE	O
)	O
and	O
Multiple	B-Phenotype
intestinal	I-Phenotype
atresia	E-Phenotype
with	O
combined	B-Phenotype
immune	I-Phenotype
deficiency	E-Phenotype
(	O
MIA	O
-	O
CID	O
)	O
are	O
autosomal	O
recessive	O
disorders	O
that	O
present	O
immunological	O
and	O
gastrointestinal	O
features	O
.	O

Heterotaxy	S-Phenotype
,	O
a	O
birth	O
defect	O
involving	O
left	O
-	O
right	O
patterning	O
defects	O
,	O
and	O
primary	B-Phenotype
ciliary	I-Phenotype
dyskinesia	E-Phenotype
(	O
PCD	S-Phenotype
)	O
,	O
a	O
sinopulmonary	O
disease	O
with	O
dyskinetic	B-Phenotype
/	I-Phenotype
immotile	I-Phenotype
cilia	E-Phenotype
in	O
the	O
airway	O
are	O
seemingly	O
disparate	O
diseases	O
.	O

Patients	O
with	O
WDR19	O
mutations	O
can	O
show	O
various	O
extrarenal	O
manifestations	O
such	O
as	O
skeletal	B-Phenotype
disorders	E-Phenotype
,	O
Caroli	B-Phenotype
disease	E-Phenotype
,	O
and	O
retinal	B-Phenotype
dystrophy	E-Phenotype
,	O
and	O
typically	O
display	O
nephronophthisis	S-Phenotype
as	O
a	O
renal	O
phenotype	O
.	O

Erythrokeratodermia	O
variabilis	O
et	O
progressiva	O
(	O
EKVP	O
)	O
is	O
a	O
genodermatosis	O
with	O
clinical	O
and	O
genetic	O
heterogeneity	S-Phenotype
,	O
most	O
often	O
transmitted	O
in	O
an	O
autosomal	O
dominant	O
manner	O
,	O
caused	O
by	O
mutations	O
in	O
GJB3	O
and	O
GJB4	O
genes	O
encoding	O
connexins	O
(	O
Cx	O
)	O
31	O
and	O
30.3	O
,	O
respectively	O
.	O

The	O
activity	O
of	O
TR2	O
-	O
3	O
in	O
inducing	O
apoptosis	O
in	O
cancer	S-Phenotype
cells	O
was	O
evaluated	O
by	O
using	O
an	O
Annexin	O
V	O
-	O
PE	O
apoptosis	O
detection	O
kit	O
in	O
combination	O
with	O
flow	O
cytometry	O
and	O
the	O
Hoechst	O
33342	O
and	O
propidium	O
iodide	O
double	O
staining	O
analysis	O
.	O

We	O
found	O
that	O
rs1042752	O
-	O
located	O
in	O
the	O
3	O
'	O
-	O
UTR	O
of	O
POU2AF1	O
,	O
which	O
plays	O
a	O
vital	O
role	O
in	O
lymphomagenesis	S-Phenotype
-	O
was	O
significantly	O
associated	O
with	O
lymphoma	S-Phenotype
risk	O
in	O
a	O
case	O
-	O
control	O
study	O
with	O
793	O
patients	O
and	O
939	O
controls	O
.	O

TBXAS1	O
mutations	O
result	O
in	O
Ghosal	O
hematodiaphyseal	O
dysplasia	O
(	O
OMIM	O
231095	O
)	O
,	O
the	O
autosomal	B-Phenotype
recessive	E-Phenotype
syndrome	O
associated	O
with	O
abnormal	B-Phenotype
bone	I-Phenotype
structure	E-Phenotype
and	O
BMF	O
.	O

Clinical	O
variables	O
,	O
including	O
age	O
,	O
International	O
Neuroblastoma	S-Phenotype
Staging	O
System	O
(	O
INSS	O
)	O
stage	O
,	O
tumor	S-Phenotype
size	O
and	O
site	O
,	O
histology	O
,	O
and	O
MYCN	O
status	O
were	O
retrospectively	O
analyzed	O
,	O
and	O
EFS	O
was	O
chosen	O
as	O
the	O
endpoint	O
.	O

The	O
median	O
age	O
of	O
patients	O
was	O
8.2	O
months	O
and	O
average	O
follow	O
-	O
up	O
period	O
was	O
40.2	O
±	O
8.6	O
months	O
.	O

Genetic	O
studies	O
have	O
identified	O
a	O
homozygous	O
truncation	O
mutation	O
in	O
Trak1	O
that	O
causes	O
hypertonia	S-Phenotype
in	O
mice	O
.	O

Characteristic	O
findings	O
among	O
all	O
forms	O
of	O
SRP	O
include	O
short	B-Phenotype
horizontal	I-Phenotype
ribs	E-Phenotype
,	O
short	B-Phenotype
limbs	E-Phenotype
and	O
polydactyly	S-Phenotype
.	O

Mutations	O
in	O
one	O
of	O
our	O
candidate	O
genes	O
,	O
Smpx	O
,	O
have	O
been	O
reported	O
as	O
the	O
cause	O
of	O
X	B-Phenotype
-	I-Phenotype
linked	I-Phenotype
deafness	E-Phenotype
in	O
humans	O
.	O

Similarly	O
,	O
chronic	O
alcohol	O
feeding	O
of	O
mice	O
led	O
to	O
a	O
significant	O
inhibition	O
in	O
expression	O
of	O
MTPPT	O
protein	O
,	O
mRNA	O
,	O
heterogeneous	S-Phenotype
nuclear	O
RNA	O
,	O
as	O
well	O
as	O
in	O
activity	O
of	O
SLC25A19	O
promoter	O
in	O
PAC	S-Phenotype
.	O

In	O
aggregate	O
,	O
our	O
findings	O
implicate	O
MYLK	O
as	O
a	O
gene	O
involved	O
in	O
the	O
recessive	O
form	O
of	O
MMIHS	O
,	O
confirming	O
that	O
this	O
disease	O
of	O
the	O
visceral	O
organs	O
is	O
heterogeneous	S-Phenotype
with	O
a	O
myopathic	O
origin	O

We	O
also	O
demonstrated	O
that	O
the	O
exogenous	O
expression	O
of	O
PLIN1	O
in	O
human	O
breast	B-Phenotype
cancer	E-Phenotype
MCF	O
-	O
7	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
significantly	O
inhibits	O
cell	O
proliferation	O
,	O
migration	O
,	O
invasion	O
and	O
in	O
vivo	O
tumorigenesis	O
in	O
mice	O
.	O

Usher	O
syndrome	O
(	O
USH	O
)	O
is	O
the	O
most	O
common	O
cause	O
of	O
inherited	B-Phenotype
deaf	I-Phenotype
-	I-Phenotype
blindness	E-Phenotype
,	O
manifested	O
as	O
USH1	O
,	O
USH2	O
and	O
USH3	O
clinical	O
types	O
.	O

Pyridoxine	B-Phenotype
dependent	I-Phenotype
epilepsy	E-Phenotype
(	O
PDE	S-Phenotype
)	O
is	O
a	O
rare	O
autosomal	O
recessive	O
neurometabolic	O
disorder	O
.	O

Mutations	O
in	O
CASK	O
cause	O
a	O
wide	O
spectrum	O
of	O
phenotypes	O
in	O
humans	O
ranging	O
from	O
mild	O
X	B-Phenotype
-	I-Phenotype
linked	I-Phenotype
intellectual	I-Phenotype
disability	E-Phenotype
to	O
a	O
severe	O
microcephaly	S-Phenotype
(	O
MC	S-Phenotype
)	O
and	O
pontocerebellar	B-Phenotype
hypoplasia	E-Phenotype
syndrome	O
.	O

We	O
found	O
that	O
MYST3	O
was	O
amplified	O
in	O
11	O
%	O
and	O
/	O
or	O
overexpressed	O
in	O
15	O
%	O
of	O
breast	B-Phenotype
tumors	E-Phenotype
,	O
and	O
overexpression	O
of	O
MYST3	O
correlated	O
with	O
worse	O
clinical	O
outcome	O
in	O
estrogen	O
receptor+	O
(	O
ER+	O
)	O
breast	B-Phenotype
cancers	E-Phenotype
.	O

Prostate	B-Phenotype
cancer	E-Phenotype
(	O
PCa	S-Phenotype
)	O
is	O
one	O
of	O
the	O
most	O
common	O
types	O
of	O
cancer	S-Phenotype
in	O
the	O
urinary	O
system	O
in	O
men	O
.	O

In	O
all	O
,	O
13	O
tumours	S-Phenotype
were	O
analysed	O
by	O
immunohistochemistry	O
to	O
visualise	O
CD44	O
-	O
expressing	O
cells	O
.	O

Specific	O
inhibition	O
of	O
mitoribosomal	O
translation	O
by	O
doxycycline	O
,	O
chloramphenicol	O
,	O
or	O
siRNA	O
-	O
mediated	O
MRPL13	O
knockdown	O
decreased	O
mitochondrial	O
protein	O
expression	O
,	O
reduced	O
oxygen	O
consumption	O
rate	O
,	O
and	O
increased	O
CLN1	O
-	O
mediated	O
tumor	S-Phenotype
cell	O
invasiveness	O
in	O
SNU387	O
cells	O
,	O
which	O
have	O
active	O
mitochondria	O
.	O

A	O
bioinformatic	O
analysis	O
of	O
the	O
open	O
RNA	O
-	O
Seq	O
database	O
from	O
The	O
Cancer	S-Phenotype
Genome	O
Atlas	O
(	O
TCGA	O
)	O
liver	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
LIHC	O
)	O
cohort	O
revealed	O
a	O
significant	O
negative	O
correlation	O
between	O
MRPL13	O
and	O
CLN1	O
expression	O
.	O

Stxbp1+	O
/	O
-	O
mice	O
showed	O
impaired	O
cognitive	O
performance	O
,	O
hyperactivity	S-Phenotype
and	O
anxiety	S-Phenotype
-	O
like	O
behaviour	O
,	O
without	O
altered	O
social	O
behaviour	O
.	O

ETV1	O
/	O
4	O
/	O
5	O
factors	O
are	O
often	O
overexpressed	O
in	O
prostate	B-Phenotype
cancer	E-Phenotype
and	O
genome	O
-	O
wide	O
studies	O
in	O
a	O
prostate	B-Phenotype
cancer	E-Phenotype
cell	O
line	O
indicate	O
that	O
ETV4	O
and	O
MED25	O
occupy	O
enhancers	O
that	O
are	O
enriched	O
for	O
ETS	O
-	O
binding	O
sequences	O
and	O
are	O
both	O
functionally	O
important	O
for	O
the	O
transcription	O
of	O
genes	O
regulated	O
by	O
these	O
enhancers	O
.	O

Together	O
,	O
our	O
data	O
provide	O
new	O
evidence	O
for	O
the	O
opposing	O
effects	O
of	O
the	O
LIN28B	O
-	O
IMP1	O
axis	O
on	O
post	O
-	O
transcriptional	O
regulation	O
of	O
canonical	O
WNT	O
signaling	O
,	O
with	O
implications	O
in	O
intestinal	O
homeostasis	O
,	O
regeneration	O
and	O
tumorigenesis	S-Phenotype

Mosaicism	O
was	O
identified	O
for	O
autosomal	O
dominant	O
(	O
JAG1	O
,	O
COL3A1	O
)	O
,	O
autosomal	B-Phenotype
recessive	E-Phenotype
(	O
PYGM	O
)	O
,	O
and	O
X	O
-	O
linked	O
(	O
PHKA2	O
,	O
PDHA1	O
,	O
OTC	O
,	O
and	O
SLC6A8	O
)	O
disorders	O
.	O

Mutations	O
in	O
the	O
gene	O
encoding	O
the	O
nuclear	O
matrix	O
protein	O
Matrin	O
3	O
have	O
been	O
found	O
in	O
familial	O
cases	O
of	O
ALS	O
,	O
as	O
well	O
as	O
autosomal	B-Phenotype
dominant	I-Phenotype
distal	I-Phenotype
myopathy	E-Phenotype
with	O
vocal	B-Phenotype
cord	E-Phenotype
and	O
pharyngeal	B-Phenotype
weakness	E-Phenotype
.	O

In	O
four	O
of	O
them	O
otosclerosis	S-Phenotype
was	O
said	O
to	O
be	O
present	O
,	O
one	O
patient	O
had	O
hearing	B-Phenotype
loss	E-Phenotype
due	O
to	O
severe	O
stapes	O
fixation	O
at	O
the	O
age	O
of	O
6	O
years	O
,	O
providing	O
evidence	O
that	O
hearing	O
loss	O
in	O
the	O
GDF6	O
-	O
related	O
multiple	O
synostoses	O
syndrome	O
can	O
be	O
present	O
in	O
childhood	O
.	O

Recently	O
,	O
a	O
homozygous	O
truncating	O
variant	O
in	O
CPLX1	O
was	O
suggested	O
to	O
be	O
causative	O
for	O
migrating	O
epilepsy	S-Phenotype
and	O
structural	O
brain	O
abnormalities	O
.	O

Recurrent	O
copy	O
number	O
variations	O
are	O
important	O
events	O
in	O
SI	O
-	O
NET	O
and	O
SRC	O
may	O
represent	O
a	O
novel	O
prognostic	O
biomarker	O
for	O
this	O
tumor	S-Phenotype
type	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
possible	O
interaction	O
between	O
miR	O
-	O
146a	O
and	O
one	O
of	O
its	O
putative	O
targets	O
ribonuclease	O
L	O
(	O
RNASEL	O
)	O
in	O
the	O
risk	O
of	O
sporadic	B-Phenotype
melanoma	E-Phenotype
.	O

Limb	B-Phenotype
girdle	I-Phenotype
muscular	I-Phenotype
dystrophy	I-Phenotype
type	I-Phenotype
2I	E-Phenotype
(	O
LGMD2I	S-Phenotype
)	O
is	O
a	O
progressive	O
disorder	O
caused	O
by	O
mutations	O
in	O
the	O
FuKutin	O
-	O
Related	O
Protein	O
gene	O
(	O
FKRP	O
)	O
.	O

A	O
panel	O
of	O
hypermethylated	O
genes	O
including	O
APC	O
,	O
CSPG2	O
,	O
EPHA5	O
,	O
EYA4	O
,	O
HOXA9	O
,	O
IPF1	O
,	O
ISL1	O
,	O
JAK3	O
,	O
PITX2	O
,	O
SOX1	O
,	O
and	O
TWIST1	O
predicted	O
cancer	S-Phenotype
-	O
specific	O
survival	O
and	O
SOX1	O
(	O
HR	O
=	O
3.46	O
)	O
,	O
PITX2	O
(	O
HR	O
=	O
4.17	O
)	O
,	O
CSPG2	O
(	O
HR	O
=	O
5.35	O
)	O
,	O
and	O
JAK3	O
hypermethylation	O
(	O
HR	O
=	O
0.19	O
)	O
did	O
so	O
independently	O
.	O

Our	O
recent	O
determination	O
of	O
a	O
microRNA	O
(	O
miRNA	O
)	O
expression	O
signature	O
in	O
prostate	B-Phenotype
cancer	E-Phenotype
(	O
PCa	S-Phenotype
)	O
revealed	O
that	O
miR	O
-	O
205	O
-	O
5p	O
was	O
significantly	O
reduced	O
in	O
PCa	O
tissues	O
and	O
that	O
it	O
acted	O
as	O
an	O
antitumor	O
miRNA	O
.	O

TCIRG1	O
knockdown	O
suppressed	O
tumor	S-Phenotype
cell	O
growth	O
and	O
proliferation	O
in	O
HCC	O
cell	O
lines	O
;	O
caused	O
a	O
significant	O
increase	O
in	O
the	O
proportion	O
of	O
cells	O
in	O
the	O
G1	O
/	O
S	O
phase	O
of	O
cell	O
cycle	O
;	O
induced	O
cell	O
death	O
;	O
suppressed	O
the	O
metastatic	O
potential	O
of	O
HCC	O
cells	O
by	O
selectively	O
regulating	O
the	O
epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
regulatory	O
proteins	O
E	O
-	O
cadherin	O
,	O
N	O
-	O
cadherin	O
,	O
Fibronectin	O
,	O
Snail	O
and	O
Slug	O
;	O
and	O
significantly	O
attenuated	O
the	O
metastatic	O
potential	O
of	O
ras	O
-	O
transformed	O
NIH	O
-	O
3T3	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

High	O
expression	O
of	O
Chemokine	O
receptor	O
4	O
(	O
CXCR4	O
)	O
is	O
important	O
in	O
tumor	S-Phenotype
invasion	O
,	O
metastasis	O
,	O
drug	O
-	O
resistance	O
and	O
maintenance	O
of	O
stemness	O
in	O
non	B-Phenotype
-	I-Phenotype
small	I-Phenotype
cell	I-Phenotype
lung	I-Phenotype
cancer	E-Phenotype
(	O
NSCLC	S-Phenotype
)	O
.	O

Since	O
transcriptional	O
control	O
of	O
NRF1	O
seems	O
to	O
be	O
dependent	O
on	O
epidermal	O
growth	O
factor	O
receptor	O
signaling	O
,	O
herein	O
,	O
we	O
investigated	O
the	O
role	O
of	O
NRF1	O
in	O
estrogen	O
receptor	O
/	O
progesterone	O
receptor	O
negative	O
,	O
but	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2	O
-	O
positive	O
(	O
ER	O
/	O
PR	O
-	O
ve	O
HER2	O
+ve	O
)	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

TAC1	O
showed	O
the	O
highest	O
enrichment	O
of	O
gene	O
signatures	O
for	O
interleukin	O
-	O
13	O
/	O
T	O
-	O
helper	O
cell	O
type	O
2	O
(	O
Th2	O
)	O
and	O
innate	O
lymphoid	O
cell	O
type	O
2	O
.	O

This	O
mouse	O
model	O
exhibits	O
key	O
features	O
of	O
the	O
retinal	O
phenotype	O
observed	O
in	O
patients	O
with	O
IFT172	O
-	O
associated	O
blindness	S-Phenotype
and	O
can	O
be	O
used	O
for	O
in	O
vivo	O
testing	O
of	O
ciliopathy	O
therapies	O

Using	O
whole	O
-	O
exome	O
sequencing	O
(	O
WES	O
)	O
,	O
we	O
identified	O
four	O
de	O
novo	O
variants	O
in	O
PPP2R5D	O
in	O
a	O
total	O
of	O
seven	O
unrelated	O
individuals	O
with	O
intellectual	B-Phenotype
disability	E-Phenotype
(	O
ID	S-Phenotype
)	O
and	O
other	O
shared	O
clinical	O
characteristics	O
,	O
including	O
autism	B-Phenotype
spectrum	I-Phenotype
disorder	E-Phenotype
,	O
macrocephaly	S-Phenotype
,	O
hypotonia	S-Phenotype
,	O
seizures	S-Phenotype
,	O
and	O
dysmorphic	O
features	O
.	O

Through	O
whole	O
-	O
exome	O
sequencing	O
in	O
six	O
unrelated	O
nonconsanguineous	O
families	O
having	O
a	O
sporadic	S-Phenotype
case	O
of	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
we	O
identified	O
six	O
novel	O
de	O
novo	O
truncating	O
mutations	O
in	O
CHAMP1	O
:	O
c.1880CAAAAG	O
p.	O
(	O
Ser627	O
*	O
)	O
,	O
c.1489CAAAAT	O
;	O
p.	O
(	O
Arg497	O
*	O
)	O
,	O
c.1876_1877delAG	O
;	O
p.	O
(	O
Ser626Leufs	O
*	O
4	O
)	O
,	O
c.1043GAAAAA	O
;	O
p.	O
(	O
Trp348	O
*	O
)	O
,	O
c.1002GAAAAA	O
;	O
p.	O
(	O
Trp334	O
*	O
)	O
,	O
and	O
c.958_959delCC	O
;	O
p.	O
(	O
Pro320	O
*	O
)	O
.	O

Further	O
in	O
vitro	O
and	O
in	O
vivo	O
results	O
demonstrated	O
that	O
ALDOA	O
was	O
associated	O
with	O
proliferation	O
and	O
metastasis	O
of	O
pancreatic	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

The	O
molecular	O
basis	O
of	O
this	O
condition	O
started	O
to	O
be	O
defined	O
recently	O
,	O
and	O
the	O
genes	O
related	O
to	O
the	O
syndrome	O
(	O
ACTG2	O
-	O
heterozygous	O
variant	O
in	O
sporadic	S-Phenotype
cases	O
;	O
and	O
MYH11	O
(	O
myosin	O
heavy	O
chain	O
11	O
)	O
,	O
LMOD1	O
(	O
leiomodin	O
1	O
)	O
and	O
MYLK	O
(	O
myosin	O
light	O
chain	O
(	O
MLC	O
)	O
kinase	O
)	O
-	O
autosomal	B-Phenotype
recessive	I-Phenotype
inheritance	E-Phenotype
)	O
,	O
encode	O
proteins	O
involved	O
in	O
the	O
smooth	O
muscle	O
contraction	O
,	O
supporting	O
a	O
myopathic	O
basis	O
for	O
the	O
disease	O
.	O

Third	O
,	O
the	O
retinal	B-Phenotype
degeneration	E-Phenotype
associated	O
with	O
the	O
disruption	O
of	O
the	O
visual	O
cycle	O
in	O
Mitf	O
-	O
deficient	O
mice	O
can	O
be	O
partially	O
corrected	O
both	O
structurally	O
and	O
functionally	O
by	O
an	O
exogenous	O
supply	O
of	O
9	O
-	O
cis	O
-	O
retinal	O
.	O

Glioblastoma	B-Phenotype
multiforme	E-Phenotype
(	O
GBM	S-Phenotype
)	O
is	O
a	O
highly	O
malignant	O
type	O
of	O
brain	B-Phenotype
tumor	E-Phenotype
found	O
in	O
humans	O
.	O

Our	O
study	O
supports	O
the	O
targeting	O
of	O
Sema3C	O
to	O
break	O
this	O
GSC	O
-	O
specific	O
autocrine	O
/	O
paracrine	O
loop	O
in	O
order	O
to	O
improve	O
glioblastoma	S-Phenotype
treatment	O
,	O
potentially	O
with	O
a	O
high	O
therapeutic	O
index	O
.	O

In	O
an	O
additional	O
affected	O
individual	O
with	O
RHD	O
and	O
a	O
congenital	B-Phenotype
heart	I-Phenotype
defect	E-Phenotype
,	O
we	O
found	O
a	O
homozygous	O
loss	O
-	O
of	O
-	O
function	O
(	O
LOF	O
)	O
variant	O
in	O
SLIT3	O
,	O
recapitulating	O
phenotypes	O
reported	O
with	O
Slit3	O
inactivation	O
in	O
the	O
mouse	O
.	O

Reduction	O
of	O
liHDAC3	O
/	O
i	O
abrogated	O
decidualization	O
in	O
a	O
primary	O
culture	O
of	O
human	O
endometrial	O
stromal	O
cells	O
(	O
hESCs	O
)	O
similar	O
to	O
that	O
observed	O
in	O
infertile	O
patients	O
with	O
endometriosis	S-Phenotype
.	O

Four	O
established	O
melanoma	S-Phenotype
susceptibility	O
genes	O
achieved	O
nominal	O
statistical	O
significance	O
,	O
MC1R	O
(	O
p	O
=	O
.0014	O
)	O
,	O
MITF	O
(	O
p	O
=	O
.0165	O
)	O
BRCA2	O
(	O
p	O
=	O
.0206	O
)	O
,	O
and	O
MTAP	O
(	O
p	O
=	O
.0393	O
)	O
.	O

Significant	O
down	O
-	O
regulation	O
of	O
miR	O
-	O
193a	O
-	O
3p	O
was	O
also	O
seen	O
in	O
an	O
independent	O
cohort	O
of	O
ulcerative	B-Phenotype
colitis	I-Phenotype
cancers	E-Phenotype
.	O

Mechanistically	O
,	O
we	O
find	O
that	O
stabilization	O
of	O
Brg1	O
in	O
gastric	B-Phenotype
cancer	E-Phenotype
cells	O
suppresses	O
E	O
-	O
cadherin	O
expression	O
,	O
subsequently	O
promoting	O
gastric	B-Phenotype
cancer	E-Phenotype
metastasis	O
.	O

Furthermore	O
,	O
in	O
cultured	O
human	O
BMSCs	O
,	O
TGF	O
-	O
a	O
stimulated	O
production	O
of	O
procancer	O
cytokines	S-Phenotype
including	O
IL	O
-	O
6	O
,	O
VEGF	O
,	O
FGF10	O
,	O
FGF17	O
,	O
and	O
TGF	O
-	O
b1	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

When	O
stratified	O
by	O
tumor	S-Phenotype
histology	O
,	O
three	O
SNPs	O
(	O
ENO1	O
rs2274971A	O
AAAA	O
G	O
,	O
PFKM	O
rs11168417C	O
AAAA	O
T	O
,	O
and	O
PDK2	O
rs3785921G	O
AAAA	O
A	O
)	O
were	O
significantly	O
associated	O
with	O
OS	O
and	O
/	O
or	O
DFS	O
only	O
in	O
squamous	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
,	O
whereas	O
PFKP	O
rs1132173C	O
AAAA	O
T	O
exhibited	O
a	O
significant	O
association	O
with	O
survival	O
outcomes	O
only	O
in	O
adenocarcinoma	O
.	O

Here	O
,	O
integrative	O
genomic	O
analysis	O
identified	O
MYST3	O
as	O
a	O
potential	O
oncogene	O
target	O
that	O
is	O
frequently	O
amplified	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

Here	O
,	O
we	O
examined	O
the	O
expression	O
level	O
of	O
Chmp1A	O
in	O
human	O
RCC	O
tissues	O
and	O
renal	B-Phenotype
tumor	E-Phenotype
cells	O
by	O
real	O
-	O
time	O
quantitative	O
RT	O
-	O
PCR	O
and	O
western	O
blot	O
.	O

To	O
identify	O
potential	O
biological	O
differences	O
by	O
race	O
among	O
Luminal	O
A	O
breast	B-Phenotype
cancers	E-Phenotype
,	O
gene	O
expression	O
data	O
from	O
108	O
CAU	O
and	O
57	O
AA	O
breast	B-Phenotype
tumors	E-Phenotype
were	O
analyzed	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
determine	O
the	O
impact	O
of	O
genetic	O
polymorphisms	O
in	O
the	O
caspase	O
(	O
CASP	O
)	O
genes	O
on	O
prognosis	O
of	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
.	O

Dendritic	O
cell	O
(	O
DC	O
)	O
-	O
based	O
immunotherapies	O
have	O
been	O
created	O
for	O
a	O
broad	O
expanse	O
of	O
cancers	S-Phenotype
,	O
and	O
DC	O
vaccines	O
prepared	O
with	O
Wilms	O
'	O
tumor	S-Phenotype
protein	O
1	O
(	O
WT1	O
)	O
peptides	O
have	O
shown	O
great	O
therapeutic	O
efficacy	O
in	O
these	O
diseases	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
miR	O
-	O
587	O
/	O
PPP2R1B	O
/	O
pAKT	O
/	O
XIAP	O
signaling	O
axis	O
has	O
an	O
important	O
role	O
in	O
mediating	O
response	O
to	O
chemotherapy	O
in	O
colorectal	B-Phenotype
cancer	E-Phenotype
.	O

Targeted	O
disruption	O
of	O
Grxcr2	O
is	O
concurrently	O
reported	O
to	O
cause	O
hearing	B-Phenotype
loss	E-Phenotype
in	O
mice	O
.	O

We	O
found	O
that	O
the	O
expression	O
level	O
of	O
Chmp1A	O
is	O
significantly	O
lower	O
in	O
RCC	O
tissues	O
and	O
renal	B-Phenotype
tumor	E-Phenotype
cells	O
compared	O
with	O
adjacent	O
non	O
-	O
tumorous	O
tissues	O
and	O
normal	O
renal	O
cells	O
.	O

Bowen	O
-	O
Conradi	O
syndrome	O
(	O
BCS	O
)	O
is	O
an	O
autosomal	O
-	O
recessive	O
disorder	O
characterized	O
by	O
severely	O
impaired	B-Phenotype
prenatal	E-Phenotype
and	O
postnatal	B-Phenotype
growth	E-Phenotype
,	O
profound	B-Phenotype
psychomotor	I-Phenotype
retardation	E-Phenotype
,	O
and	O
death	B-Phenotype
in	I-Phenotype
early	I-Phenotype
childhood	E-Phenotype
.	O

The	O
anti	O
-	O
miR	O
-	O
663	O
reduced	O
OXPHOS	O
complex	O
activity	O
and	O
increased	O
in	O
vitro	O
cellular	O
proliferation	O
and	O
promoted	O
tumor	S-Phenotype
development	O
in	O
vivo	O
in	O
mice	O
.	O

It	O
is	O
reported	O
the	O
expression	O
of	O
HCRP1	O
is	O
inversely	O
related	O
to	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
and	O
lead	O
to	O
resistance	O
to	O
cetuximab	O
in	O
ovarian	B-Phenotype
cancer	E-Phenotype
.	O

Furthermore	O
,	O
we	O
showed	O
that	O
low	O
-	O
level	O
expression	O
of	O
LIM2	O
in	O
CD133	O
-	O
high	O
glioma	S-Phenotype
was	O
associated	O
with	O
poorer	O
survival	O
,	O
suggesting	O
that	O
LIM2	O
could	O
be	O
a	O
therapeutic	O
target	O
for	O
glioma	S-Phenotype
expressing	O
a	O
high	O
level	O
of	O
CD133	O
.	O

Knockdown	O
of	O
MYC	O
in	O
colorectal	B-Phenotype
cancer	E-Phenotype
cells	O
reset	O
the	O
altered	O
metabolism	O
and	O
suppressed	O
cell	O
growth	O
.	O

The	O
FOXO3	O
is	O
a	O
tumor	S-Phenotype
suppressor	O
gene	O
and	O
found	O
to	O
interact	O
with	O
p53	O
,	O
the	O
trigger	O
for	O
apoptosis	O
through	O
BCl2	O
family	O
genes	O
and	O
a	O
regulator	O
of	O
Notch	O
signaling	O
pathway	O
for	O
the	O
self	O
-	O
renewal	O
of	O
stem	O
cells	O
.	O

Pathogenic	O
variant	O
in	O
COCH	O
are	O
a	O
known	O
cause	O
of	O
DFNA9	B-Phenotype
autosomal	I-Phenotype
dominant	I-Phenotype
progressive	I-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
and	O
vestibular	B-Phenotype
dysfunction	E-Phenotype
with	O
adult	O
onset	O
.	O

Considering	O
these	O
results	O
,	O
the	O
measurement	O
of	O
circulating	O
CHL1	O
level	O
may	O
contribute	O
to	O
assess	O
a	O
tumor	S-Phenotype
progression	O
in	O
human	O
lung	B-Phenotype
tumor	E-Phenotype
patients	O

Similar	O
to	O
salubrinal	O
-	O
-	O
the	O
phosphomimetic	O
eIF2a	O
variant	O
-	O
-	O
S51D	O
-	O
-	O
increased	O
sensitivity	O
to	O
radiation	O
,	O
and	O
both	O
abrogated	O
radiation	O
-	O
induced	O
increase	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
type	O
1	O
susceptibility	O
gene	O
,	O
thus	O
implicating	O
enhanced	O
phosphorylation	O
of	O
eIF2a	O
in	O
modulation	O
of	O
DNA	O
repair	O
.	O

To	O
evaluate	O
the	O
effectiveness	O
of	O
TGE	O
and	O
MPS	O
on	O
screening	O
sporadic	S-Phenotype
NSHL	O
patients	O
,	O
we	O
recruited	O
63	O
unrelated	O
sporadic	O
NSHL	O
probands	O
,	O
who	O
had	O
various	O
levels	O
of	O
HL	O
and	O
were	O
excluded	O
for	O
mutations	O
in	O
GJB2	O
,	O
MT	O
-	O
RNR1	O
,	O
and	O
SLC26A4	O
genes	O
.	O

Renal	B-Phenotype
agenesis	E-Phenotype
and	O
hypodysplasia	S-Phenotype
(	O
RHD	O
)	O
are	O
major	O
causes	O
of	O
pediatric	B-Phenotype
chronic	I-Phenotype
kidney	I-Phenotype
disease	E-Phenotype
and	O
are	O
highly	O
genetically	O
heterogeneous	S-Phenotype
.	O

However	O
,	O
after	O
4	O
mo	O
in	O
males	O
and	O
8	O
mo	O
in	O
females	O
,	O
Ndufs6	O
(	O
gt	O
/	O
gt	O
)	O
mice	O
are	O
at	O
increased	O
risk	O
of	O
cardiac	B-Phenotype
failure	E-Phenotype
and	O
death	O
.	O

In	O
contrast	O
,	O
LRIG2	O
appears	O
to	O
function	O
as	O
a	O
tumor	S-Phenotype
promoter	O
,	O
while	O
LRIG3	O
appears	O
to	O
have	O
a	O
function	O
similar	O
to	O
that	O
of	O
LRIG1	O
.	O

The	O
data	O
showed	O
that	O
interfering	O
PSMB8	O
may	O
inhibit	O
the	O
migration	O
and	O
proliferation	O
of	O
glioma	S-Phenotype
cells	O
by	O
reducing	O
expression	O
of	O
cyclin	O
A	O
,	O
cyclin	O
B1	O
,	O
cyclin	O
D1	O
,	O
Vimentin	O
,	O
and	O
N	O
-	O
cadherin	O
,	O
and	O
by	O
increasing	O
expression	O
of	O
E	O
-	O
cadherin	O
.	O

The	O
most	O
common	O
and	O
severe	O
form	O
,	O
primary	O
hyperoxaluria	S-Phenotype
Type	O
I	O
,	O
is	O
due	O
to	O
the	O
deficit	O
of	O
liver	O
peroxisomal	O
alanine	O
/	O
glyoxylate	O
aminotransferase	O
(	O
AGT	O
)	O
.	O

In	O
the	O
present	O
review	O
,	O
22	O
loci	O
of	O
glaucoma	S-Phenotype
are	O
presented	O
,	O
including	O
the	O
relevant	O
genes	O
(	O
myocilin	O
,	O
interleukin	O
20	O
receptor	O
subunit	O
B	O
,	O
optineurin	O
,	O
ankyrin	O
repeat‑	O
and	O
SOCS	O
box‑containing	O
protein	O
10	O
,	O
WD	O
repeat‑containing	O
protein	O
36	O
,	O
EGF‑containing	O
fibulin‑like	O
extracellular	O
matrix	O
protein	O
1	O
,	O
neurotrophin	O
4	O
,	O
TANK‑binding	O
kinase	O
1	O
,	O
cytochrome	O
P450	O
subfamily	O
I	O
polypeptide	O
1	O
,	O
latent	O
transforming	O
growth	O
factor	O
β	O
binding	O
protein	O
2	O
and	O
TEK	O
tyrosine	O
kinase	O
endothelial	O
)	O
and	O
74	O
other	O
genes	O
(	O
including	O
toll‑like	O
receptor	O
4	O
,	O
sine	O
oculis	O
homeobox	O
Drosophila	O
homolog	O
of	O
1	O
,	O
doublecortin‑like	O
kinase	O
1	O
,	O
RE	O
repeats‑encoding	O
gene	O
,	O
retinitis	S-Phenotype
pigmentosa	O
GTPase	O
regulator‑interacting	O
protein	O
,	O
lysyl	O
oxidase‑like	O
protein	O
1	O
,	O
heat‑shock	O
70‑kDa	O
protein	O
1A	O
,	O
baculoviral	O
IAP	O
repeat‑containing	O
protein	O
6	O
,	O
5,10‑methylenetetrahydrofolate	O
reductase	O
and	O
nitric	O
oxide	O
synthase	O
3	O
and	O
nanophthalmos	S-Phenotype
1	O
)	O
that	O
are	O
more	O
closely	O
associated	O
with	O
glaucoma	S-Phenotype
.	O

We	O
asked	O
whether	O
ROM1	O
could	O
modify	O
the	O
phenotype	O
of	O
a	O
PRPH2	O
mutation	O
associated	O
with	O
a	O
high	O
degree	O
of	O
intrafamilial	O
phenotypic	O
heterogeneity	S-Phenotype
:	O
Y141C	O
.	O

The	O
tumor	S-Phenotype
samples	O
were	O
divided	O
into	O
three	O
groups	O
depending	O
on	O
the	O
SOX9	O
expression	O
level	O
.	O

The	O
RAD51C	O
pathogenic	O
variant	O
c.404G	O
AAAA	O
A	O
was	O
identified	O
in	O
a	O
breast	B-Phenotype
and	I-Phenotype
ovarian	I-Phenotype
cancer	E-Phenotype
family	O
(	O
0.7	O
%	O
)	O
,	O
while	O
the	O
RAD51D	O
pathogenic	O
variant	O
c.694C	O
AAAA	O
T	O
was	O
described	O
in	O
an	O
ovarian	B-Phenotype
cancer	E-Phenotype
family	O
(	O
1.3	O
%	O
)	O
.	O

A	O
genetically	O
determined	O
generalized	O
hyperexcitability	O
had	O
been	O
predicted	O
in	O
primarily	B-Phenotype
generalized	I-Phenotype
seizures	E-Phenotype
,	O
but	O
surprisingly	O
the	O
first	O
epilepsy	S-Phenotype
gene	O
discovered	O
,	O
CHRNA4	O
,	O
was	O
in	O
a	O
focal	O
(	O
frontal	O
lobe	O
)	O
-	O
onset	O
syndrome	O
.	O

We	O
now	O
report	O
that	O
zebrafish	O
with	O
genetic	O
lesions	O
in	O
zebrafish	O
zic2	O
orthologs	O
,	O
zic2a	O
and	O
zic2b	O
,	O
develop	O
with	O
retinal	B-Phenotype
coloboma	E-Phenotype
and	O
craniofacial	B-Phenotype
anomalies	E-Phenotype
.	O

In	O
subgroup	O
analysis	O
,	O
compared	O
with	O
PD	O
patients	O
with	O
initial	O
symptom	O
of	O
tremor	S-Phenotype
and	O
HCs	O
,	O
the	O
minor	O
allele	O
frequency	O
of	O
NMD3	O
rs34016896	O
in	O
PD	O
patients	O
with	O
initial	O
symptoms	O
of	O
rigidity	S-Phenotype
/	O
bradykinesia	S-Phenotype
was	O
significantly	O
lower	O
.	O

In	O
survival	O
analyses	O
,	O
we	O
found	O
that	O
ALDH5A1	O
was	O
positively	O
linked	O
to	O
prognosis	O
in	O
patients	O
with	O
OC	O
,	O
particularly	O
in	O
those	O
with	O
serous	B-Phenotype
ovarian	I-Phenotype
cancer	E-Phenotype
(	O
SOC	S-Phenotype
)	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
characterize	O
the	O
PARS2	O
-	O
related	O
phenotype.Three	O
siblings	O
with	O
biallelic	O
PARS2	O
mutations	O
presented	O
from	O
birth	O
with	O
infantile	B-Phenotype
spasms	E-Phenotype
,	O
secondary	B-Phenotype
microcephaly	E-Phenotype
,	O
and	O
similar	B-Phenotype
facial	I-Phenotype
dysmorphy	E-Phenotype
.	O

Hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
is	O
the	O
most	O
common	O
primary	O
malignant	O
liver	B-Phenotype
tumor	E-Phenotype
.	O

To	O
identify	O
additional	O
prostate	B-Phenotype
cancer	E-Phenotype
susceptibility	O
loci	O
,	O
we	O
genotyped	O
nine	O
SNPs	O
that	O
were	O
nominally	O
associated	O
with	O
prostate	B-Phenotype
cancer	E-Phenotype
(	O
P	O
AAAA	O
1	O
×	O
10	O
(	O
-	O
4	O
)	O
)	O
in	O
our	O
previous	O
GWAS	O
in	O
three	O
independent	O
studies	O
of	O
prostate	B-Phenotype
cancer	E-Phenotype
in	O
Japanese	O
men	O
(	O
2,557	O
individuals	O
with	O
prostate	B-Phenotype
cancer	E-Phenotype
(	O
cases	O
)	O
and	O
3,003	O
controls	O
)	O
.	O

Another	O
polymorphism	O
in	O
ZBTB38	O
-	O
RASA2	O
has	O
been	O
observed	O
to	O
be	O
associated	O
with	O
the	O
susceptibility	O
of	O
sporadic	S-Phenotype
Creutzfeldt	O
-	O
Jacob	O
disease	O
(	O
sCJD	O
)	O
in	O
UK	O
.	O

Joubert	O
syndrome	O
exhibits	O
genetic	O
heterogeneity	S-Phenotype
,	O
with	O
mutations	O
identified	O
in	O
more	O
than	O
30	O
genes	O
,	O
including	O
INPP5E	O
,	O
a	O
gene	O
encoding	O
inositol	O
polyphosphate	O
5	O
-	O
phosphatase	O
E	O
,	O
which	O
is	O
important	O
in	O
the	O
development	O
and	O
stability	O
of	O
the	O
primary	O
cilium	O
.	O

This	O
study	O
aimed	O
to	O
investigate	O
PAX2	O
expression	O
in	O
tamoxifen	O
resistant	O
(	O
TAM	O
-	O
R	O
)	O
and	O
tamoxifen	O
sensitive	O
(	O
TAM	O
-	O
S	O
)	O
breast	B-Phenotype
carcinoma	E-Phenotype
patients	O
and	O
analyze	O
its	O
correlation	O
with	O
clinicopathological	O
characteristics	O
and	O
survival	O
.	O

Accumulated	O
evidence	O
has	O
suggested	O
that	O
microRNAs	O
(	O
miRNAs	O
)	O
have	O
an	O
important	O
role	O
in	O
tumor	S-Phenotype
development	O
and	O
progression	O
by	O
regulating	O
diverse	O
signaling	O
pathways	O
.	O

(	O
2013	O
)	O
Nature	O
Genetics	O
,	O
45	O
:	O
1405	O
-	O
1408	O
show	O
the	O
wide	O
range	O
of	O
phenotypic	O
spectrum	O
from	O
lethal	B-Phenotype
arthrogryposis	I-Phenotype
multiplex	I-Phenotype
congenital	E-Phenotype
to	O
autism	B-Phenotype
spectrum	I-Phenotype
disorder	E-Phenotype
(	O
ASD	S-Phenotype
)	O
and	O
mild	O
intellectual	B-Phenotype
disability	E-Phenotype
(	O
ID	S-Phenotype
)	O
.	O

Collectively	O
,	O
our	O
findings	O
identified	O
LSD1	O
as	O
a	O
novel	O
negative	O
regulator	O
of	O
autophagy	O
through	O
the	O
mTOR	O
signaling	O
pathway	O
in	O
ovarian	B-Phenotype
cancer	E-Phenotype
HO8910	O
cells	O
and	O
indicated	O
that	O
LSD1	O
may	O
function	O
as	O
a	O
driving	O
factor	O
of	O
ovarian	B-Phenotype
cancer	E-Phenotype
progression	O
via	O
deregulating	O
autophagy	O

The	O
RANK	O
/	O
RANKL	O
axis	O
emerges	O
as	O
a	O
key	O
regulator	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
initiation	O
,	O
progression	O
,	O
and	O
metastasis	O
.	O

However	O
,	O
the	O
molecular	O
and	O
phenotypic	O
consequences	O
of	O
GATA4	O
expression	O
in	O
hepatoblastoma	S-Phenotype
are	O
not	O
fully	O
understood	O
.	O

Biallelic	O
PARS2	O
or	O
NARS2	O
mutations	O
are	O
reported	O
to	O
cause	O
Alpers	O
*	O
syndrome	O
,	O
which	O
is	O
an	O
autosomal	O
recessive	O
neurodegenerative	O
disorder	O
characterized	O
by	O
psychomotor	B-Phenotype
regression	E-Phenotype
and	O
epilepsy	S-Phenotype
with	O
variable	O
degree	O
of	O
liver	O
involvement	O
.	O

Furthermore	O
,	O
the	O
overexpression	O
of	O
HepaCAM	O
induced	O
by	O
transfection	O
with	O
a	O
HepaCAM	O
overexpression	O
vector	O
(	O
Ad	O
-	O
HepaCAM	O
)	O
exerted	O
antitumor	O
effects	S-Phenotype
by	O
decreasing	O
the	O
proliferation	O
,	O
and	O
suppressing	O
the	O
invasion	O
and	O
migration	O
of	O
bicalutamide	O
-	O
resistant	O
(	O
Bica	O
-	O
R	O
)	O
cells	O
and	O
enzalutamide	O
-	O
resistant	O
(	O
Enza	O
-	O
R	O
)	O
cells	O
.	O

In	O
conclusion	O
,	O
glycerol	O
phosphate	O
formation	O
for	O
de	O
novo	O
GPL	O
synthesis	O
via	O
glyceroneogenesis	O
is	O
a	O
newly	O
characterized	O
anabolic	O
pathway	O
in	O
cancer	S-Phenotype
cells	O
mediated	O
by	O
PEPCK	O
-	O
M	O
under	O
conditions	O
of	O
severe	O
nutrient	O
deprivation	O

ETV1	O
/	O
4	O
/	O
5	O
factors	O
are	O
often	O
overexpressed	O
in	O
prostate	B-Phenotype
cancer	E-Phenotype
and	O
genome	O
-	O
wide	O
studies	O
in	O
a	O
prostate	B-Phenotype
cancer	E-Phenotype
cell	O
line	O
indicate	O
that	O
ETV4	O
and	O
MED25	O
occupy	O
enhancers	O
that	O
are	O
enriched	O
for	O
ETS	O
-	O
binding	O
sequences	O
and	O
are	O
both	O
functionally	O
important	O
for	O
the	O
transcription	O
of	O
genes	O
regulated	O
by	O
these	O
enhancers	O
.	O

Congenital	B-Phenotype
dyserythropoietic	I-Phenotype
anemia	I-Phenotype
type	I-Phenotype
I	E-Phenotype
(	O
CDAI	S-Phenotype
)	O
is	O
a	O
rare	O
autosomal	B-Phenotype
recessive	E-Phenotype
disease	O
characterized	O
by	O
macrocytic	B-Phenotype
anemia	E-Phenotype
,	O
ineffective	B-Phenotype
erythropoiesis	E-Phenotype
,	O
and	O
secondary	B-Phenotype
hemochromatosis	E-Phenotype
.	O

There	O
is	O
increasing	O
evidence	O
of	O
a	O
clinical	O
,	O
neuropathological	O
and	O
genetic	O
overlap	O
between	O
frontotemporal	B-Phenotype
dementia	E-Phenotype
(	O
FTD	S-Phenotype
)	O
and	O
amyotrophic	B-Phenotype
lateral	I-Phenotype
sclerosis	E-Phenotype
(	O
ALS	S-Phenotype
)	O
.	O

Cerebrospinal	O
fluid	O
of	O
20	O
non	O
-	O
tumor	S-Phenotype
patients	O
served	O
as	O
controls.Mean	O
levels	O
of	O
L1CAM	O
in	O
tumor	S-Phenotype
cyst	O
fluid	O
were	O
significantly	O
higher	O
in	O
glioblastoma	S-Phenotype
(	O
6118	O
+	O
4095	O
ng	O
/	O
mL	O
)	O
and	O
metastasis	O
patients	O
(	O
8001	O
+	O
6535	O
ng	O
/	O
mL	O
)	O
than	O
in	O
CSF	O
of	O
control	O
patients	O
(	O
714	O
+	O
22	O
ng	O
/	O
mL	O
)	O
.	O

For	O
example	O
,	O
administration	O
of	O
3	O
-	O
keto	O
-	O
HPR	O
instead	O
of	O
fenretinide	O
may	O
be	O
preferential	O
if	O
inhibition	O
of	O
SCD1	O
or	O
DES1	O
activity	O
is	O
the	O
goal	O
(	O
cancer	S-Phenotype
)	O
,	O
while	O
MPR	O
may	O
be	O
better	O
for	O
BCO1	O
modulation	O
(	O
carotenoid	O
metabolism	O
)	O
.	O

Genetic	O
discoveries	O
have	O
established	O
the	O
importance	O
of	O
SETX	O
for	O
neural	O
function	O
,	O
as	O
recessive	O
mutations	O
in	O
the	O
SETX	O
gene	O
cause	O
Ataxia	S-Phenotype
with	O
Oculomotor	B-Phenotype
Apraxia	I-Phenotype
type	I-Phenotype
2	E-Phenotype
(	O
AOA2	S-Phenotype
)	O
(	O
OMIM	O
:	O
606002	O
)	O
,	O
which	O
is	O
the	O
third	O
most	O
common	O
form	O
of	O
recessive	O
ataxia	S-Phenotype
,	O
after	O
Friedreich	B-Phenotype
's	I-Phenotype
ataxia	E-Phenotype
and	O
Ataxia	B-Phenotype
-	I-Phenotype
Telangiectasia	E-Phenotype
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
a	O
patient	O
with	O
a	O
phenotype	O
compatible	O
with	O
MOTA	O
syndrome	O
(	O
aberrant	B-Phenotype
anterior	I-Phenotype
hair	I-Phenotype
line	E-Phenotype
,	O
hypertelorism	S-Phenotype
,	O
unilateral	S-Phenotype
anophthalmia	S-Phenotype
,	O
and	O
bifid	B-Phenotype
and	I-Phenotype
broad	I-Phenotype
nasal	I-Phenotype
tip	E-Phenotype
)	O
in	O
whom	O
two	O
novel	O
FREM1	O
mutations	O
(	O
c.305	O
A	O
AAAA	O
G	O
,	O
p.Asp102Gly	O
;	O
and	O
c.2626delG	O
,	O
p.Val876Tyrfs	O
*	O
16	O
)	O
were	O
identified	O
in	O
the	O
compound	O
heterozygous	O
state	O
,	O
thus	O
broadening	O
the	O
mutational	O
spectrum	O
of	O
the	O
disease	O
.	O

In	O
this	O
study	O
,	O
we	O
applied	O
this	O
strategy	O
to	O
identify	O
novel	O
gene	O
interactions	O
in	O
KRAS	O
-	O
mutant	O
cancer	S-Phenotype
cells	O
.	O

In	O
zebrafish	O
,	O
downregulation	O
of	O
slc7a14	O
expression	O
leads	O
to	O
an	O
abnormal	B-Phenotype
eye	E-Phenotype
phenotype	O
and	O
defective	O
light	O
-	O
induced	O
locomotor	O
response	O
.	O

Here	O
we	O
presented	O
a	O
case	O
(	O
BS	O
type	O
Ⅱ	O
)	O
of	O
a	O
17	O
years	O
old	O
female	O
presented	O
with	O
polyhydramnios	S-Phenotype
,	O
polyuria	S-Phenotype
,	O
nephrocalcinosis	S-Phenotype
and	O
hypokalemia	S-Phenotype
,	O
which	O
was	O
alleviated	O
after	O
treatment	O
with	O
celecoxib	O
and	O
vitamin	O
D	O
(	O
3	O
)	O
.	O

Further	O
analyses	O
of	O
The	O
Cancer	S-Phenotype
Genome	O
Atlas	O
(	O
TCGA	O
)	O
and	O
Gene	O
Expression	O
Omnibus	O
(	O
GEO	O
)	O
datasets	O
revealed	O
correlations	O
of	O
the	O
expression	O
of	O
DRD2	O
with	O
an	O
invasive	O
tumor	S-Phenotype
,	O
tumor	S-Phenotype
metastasis	O
,	O
and	O
the	O
lower	O
survival	O
rate	O
in	O
patients	O
with	O
UCC	O
.	O

Moreover	O
,	O
the	O
disrupted	O
balance	O
between	O
HFs	O
and	O
SGs	O
,	O
especially	O
in	O
the	O
Hoxc13sup	O
-	O
/	O
-	O
/	O
sup	O
rabbits	O
,	O
can	O
be	O
used	O
as	O
an	O
ideal	O
animal	O
model	O
for	O
dermatology	O
ailments	O
,	O
such	O
as	O
acne	S-Phenotype
and	O
hypotrichosis	S-Phenotype
,	O
in	O
preclinical	O
studies	O
.	O

2015	O
;	O
Morris	O
-	O
Rosendahl	O
and	O
Kaindl	O
2015	O
;	O
Basit	O
et	O
al	O
.	O

In	O
gene	O
-	O
level	O
analyses	O
,	O
CDC25C	O
,	O
SCC1	O
/	O
RAD21	O
,	O
TLK2	O
,	O
and	O
SMC6L1	O
were	O
associated	O
(	O
P	O
AAAA	O
0.05	O
)	O
with	O
overall	O
breast	B-Phenotype
cancer	E-Phenotype
risk	O
,	O
CDC6	O
,	O
CDC27	O
,	O
SUMO3	O
,	O
RASSF1	O
,	O
KIF2	O
,	O
and	O
CDC14A	O
were	O
associated	O
with	O
high	O
grade	O
breast	B-Phenotype
cancer	E-Phenotype
risk	O
,	O
and	O
EIF3S10	O
and	O
CDC25A	O
were	O
associated	O
with	O
both	O
.	O

In	O
this	O
review	O
,	O
we	O
give	O
a	O
brief	O
review	O
on	O
the	O
functions	O
of	O
Rab23	O
,	O
summarize	O
the	O
involvement	O
of	O
Rab23	O
in	O
genetic	O
research	O
,	O
membrane	O
trafficking	O
,	O
and	O
potential	O
autophagy	O
pathway	O
,	O
especially	O
focus	O
on	O
tumor	S-Phenotype
promotion	O
,	O
disease	O
pathogenesis	O
,	O
and	O
discuss	O
the	O
possible	O
underlying	O
mechanisms	O
that	O
are	O
regulated	O
by	O
Rab23	O

For	O
complex	O
disease	O
sites	O
like	O
breast	B-Phenotype
,	I-Phenotype
head	I-Phenotype
and	I-Phenotype
neck	I-Phenotype
,	I-Phenotype
and	I-Phenotype
lung	I-Phenotype
cancer	E-Phenotype
,	O
the	O
RS	O
-	O
MC	O
algorithm	O
will	O
provide	O
significantly	O
more	O
accurate	O
treatment	O
planning	O

After	O
exhaustive	O
literature	O
analysis	O
,	O
we	O
suggest	O
the	O
following	O
recommendations	O
:	O
studies	O
focusing	O
on	O
spontaneous	O
fertility	O
of	O
infertile	O
patients	O
with	O
deeply	O
infiltrating	O
endometriosis	O
found	O
spontaneous	O
pregnancy	O
rates	O
about	O
10	O
%	O
.	O

The	O
roles	O
and	O
model	O
of	O
action	O
of	O
the	O
chromatin	O
assembly	O
complex	O
factor	O
-	O
1B	O
(	O
CHAF1B	O
)	O
gene	O
in	O
liver	B-Phenotype
cancer	E-Phenotype
have	O
not	O
been	O
fully	O
elucidated	O
.	O

A	O
TERE1	O
-	O
TBL2	O
complex	O
likely	O
functions	O
in	O
oxidative	O
/	O
nitrosative	O
stress	O
,	O
lipid	O
metabolism	O
,	O
and	O
SXR	O
signaling	O
pathways	O
in	O
its	O
role	O
as	O
a	O
tumor	S-Phenotype
suppressor	O

As	O
prostate	B-Phenotype
cancer	E-Phenotype
xenografts	O
in	O
mice	O
,	O
these	O
cells	O
had	O
decreased	O
visibility	O
on	O
diffusion	O
weighted	O
MRI	O
and	O
decreased	O
perfusion	O
,	O
which	O
correlated	O
with	O
immunostaining	O
showing	O
decreased	O
cell	O
density	O
and	O
proliferation	O
.	O

Here	O
,	O
we	O
examined	O
the	O
possibility	O
that	O
PIEZO1	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
synovial	B-Phenotype
sarcoma	E-Phenotype
cell	O
-	O
viability	O
.	O

Leptin	O
(	O
LEP	O
)	O
and	O
fat	O
mass	O
and	O
obesity	S-Phenotype
-	O
associated	O
(	O
FTO	O
)	O
alleles	O
are	O
known	O
to	O
influence	O
body	O
fat	O
mass	O
in	O
humans	O
,	O
potentially	O
via	O
effects	O
on	O
appetite	O
.	O

The	O
third	O
subject	O
was	O
an	O
infant	O
with	O
growth	B-Phenotype
deficiency	E-Phenotype
,	O
microcephaly	S-Phenotype
,	O
ichthyotic	B-Phenotype
skin	I-Phenotype
lesions	E-Phenotype
,	O
anemia	S-Phenotype
,	O
hypertonia	S-Phenotype
,	O
distinctive	O
facial	O
features	O
,	O
low	O
serine	O
and	O
glycine	O
in	O
plasma	O
and	O
CSF	O
,	O
and	O
a	O
novel	O
homozygous	O
mutation	O
in	O
PHGDH	O
gene	O
.	O

The	O
reason	O
why	O
CHRNA4	O
causes	O
focal	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
seizures	E-Phenotype
is	O
unknown	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
diagnostic	O
sensitivity	O
and	O
specificity	O
of	O
protein	O
induced	O
by	O
vitamin	O
K	O
absence	O
or	O
antagonist	O
-	O
II	O
(	O
PIVKAII	O
)	O
,	O
Glypican	O
-	O
3	O
(	O
GP3	O
)	O
,	O
Cystatin	O
B	O
(	O
CSTB	O
)	O
,	O
squamous	B-Phenotype
cell	I-Phenotype
carcinoma	I-Phenotype
antigen	I-Phenotype
1	E-Phenotype
(	O
SCCA1	S-Phenotype
)	O
and	O
hepatocyte	O
growth	O
factor	O
(	O
HGF	O
)	O
as	O
potential	O
tumour	S-Phenotype
markers	O
for	O
HCC	O
in	O
patients	O
with	O
alcoholic	B-Phenotype
liver	I-Phenotype
cirrhosis	E-Phenotype
(	O
ALC	S-Phenotype
)	O
using	O
imaging	O
techniques	O
(	O
MSCT	O
and	O
MRI	O
)	O
as	O
reference	O
standards	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
effect	O
of	O
STAT3	O
inactivation	O
on	O
biologic	O
behavior	O
of	O
primary	O
(	O
Caco	O
-	O
2	O
)	O
and	O
metastatic	O
colon	B-Phenotype
cancer	E-Phenotype
cells	O
(	O
LoVo	O
and	O
SNU407	O
)	O
and	O
the	O
relation	O
of	O
p	O
-	O
STAT3	O
expression	O
with	O
the	O
invasion	O
of	O
colon	B-Phenotype
tumor	E-Phenotype
.	O

Mutations	O
affecting	O
both	O
alleles	O
of	O
TNXB	O
cause	O
a	O
severe	O
,	O
autosomal	B-Phenotype
recessive	E-Phenotype
form	O
of	O
Ehlers	O
-	O
Danlos	O
syndrome	O
(	O
EDS	O
)	O
.	O

Five	O
individuals	O
who	O
carry	O
IRF2BPL	O
nonsense	O
variants	O
resulting	O
in	O
a	O
premature	O
stop	O
codon	O
display	O
severe	O
neurodevelopmental	B-Phenotype
regression	E-Phenotype
,	O
hypotonia	S-Phenotype
,	O
progressive	S-Phenotype
ataxia	S-Phenotype
,	O
seizures	S-Phenotype
,	O
and	O
a	B-Phenotype
lack	I-Phenotype
of	I-Phenotype
coordination	E-Phenotype
.	O

In	O
this	O
study	O
,	O
breast	B-Phenotype
cancer	E-Phenotype
tissue	O
samples	O
were	O
obtained	O
from	O
Zhejiang	O
University	O
(	O
ZJU	O
set	O
)	O
.	O

Prostate	B-Phenotype
cancer	E-Phenotype
(	O
PCa	S-Phenotype
)	O
is	O
a	O
leading	O
cause	O
of	O
cancer‑associated	O
mortality	O
in	O
men	O
;	O
however	O
,	O
the	O
factors	O
that	O
contribute	O
to	O
disease	O
development	O
have	O
yet	O
to	O
be	O
fully	O
elucidated	O
.	O

Therefore	O
,	O
it	O
seems	O
plausible	O
that	O
mutations	O
in	O
DMRT2	O
are	O
associated	O
with	O
a	O
different	O
(	O
novel	O
)	O
subtype	O
of	O
SCD	O
mainly	O
characterized	O
by	O
severe	O
rib	B-Phenotype
anomalies	E-Phenotype
but	O
lacking	O
clear	O
segmentation	O
defects	O
of	O
the	O
vertebral	O
bodies	O

The	O
most	O
important	O
finding	O
is	O
the	O
recurrently	O
mutated	O
gene	O
,	O
ASXL3	O
,	O
which	O
has	O
never	O
been	O
reported	O
in	O
parathyroid	B-Phenotype
tumors	E-Phenotype
before	O
.	O

Collectively	O
,	O
our	O
study	O
uncovers	O
a	O
protein	O
complex	O
,	O
which	O
consists	O
of	O
FIGNL1	O
and	O
KIAA0146	O
/	O
SPIDR	O
,	O
in	O
DNA	O
repair	O
and	O
provides	O
potential	O
directions	O
for	O
cancer	S-Phenotype
diagnosis	O
and	O
therapy	O
.	O

Considering	O
that	O
CRYBA4	O
associates	O
with	O
CRYBB2	O
and	O
that	O
the	O
latter	O
protein	O
has	O
been	O
implicated	O
in	O
microphthalmia	S-Phenotype
,	O
mutational	O
analysis	O
of	O
CRYBA4	O
was	O
performed	O
in	O
32	O
patients	O
affected	O
with	O
microphthalmia	S-Phenotype
(	O
small	O
eye	O
)	O
.	O

FANCM	O
is	O
a	O
DNA	O
-	O
damage	O
response	O
gene	O
whose	O
heterozygous	O
mutations	O
predispose	O
to	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

Functional	O
studies	O
suggested	O
that	O
CAB39L	O
functions	O
as	O
a	O
tumor	S-Phenotype
suppressor	O
,	O
as	O
overexpression	O
of	O
CAB39L	O
elicited	O
suppression	O
of	O
multiple	O
cancer	S-Phenotype
phenotypes	O
both	O
in	O
GC	O
cells	O
and	O
an	O
orthotopic	O
mouse	O
model	O
;	O
whilst	O
its	O
knockdown	O
promoted	O
tumorigenesis	O
.	O

Meier	O
-	O
Gorlin	O
syndrome	O
(	O
MGS	O
)	O
is	O
a	O
genetically	O
heterogeneous	B-Phenotype
primordial	I-Phenotype
dwarfism	E-Phenotype
syndrome	O
known	O
to	O
be	O
caused	O
by	O
biallelic	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
one	O
of	O
five	O
genes	O
encoding	O
pre	O
-	O
replication	O
complex	O
proteins	O
:	O
ORC1	O
,	O
ORC4	O
,	O
ORC6	O
,	O
CDT1	O
,	O
and	O
CDC6	O
.	O

RAD51C	O
and	O
RAD51D	O
have	O
been	O
defined	O
as	O
susceptibility	O
genes	O
for	O
hereditary	B-Phenotype
breast	I-Phenotype
and	I-Phenotype
ovarian	I-Phenotype
cancer	E-Phenotype
syndrome	O
in	O
several	O
studies	O
.	O

5	O
-	O
20	O
%	O
of	O
melanoma	S-Phenotype
families	O
have	O
germline	O
mutations	O
in	O
the	O
CDKN2A	O
gene	O
.	O

Results	O
on	O
CcO	O
composition	O
in	O
tissues	O
from	O
adult	O
animals	O
and	O
the	O
review	O
of	O
data	O
from	O
recent	O
literature	O
strongly	O
suggest	O
that	O
NDUFA4	O
is	O
not	O
a	O
14th	O
subunit	O
of	O
CcO	O
but	O
may	O
represent	O
an	O
assembly	O
factor	O
for	O
CcO	O
or	O
supercomplexes	O
(	O
respirasomes	O
)	O
in	O
mitochondria	O
of	O
growing	O
cells	O
and	O
cancer	S-Phenotype
tissues	O

The	O
pH	O
-	O
sensing	O
receptor	O
ovarian	B-Phenotype
cancer	E-Phenotype
G	O
protein	O
-	O
coupled	O
receptor	O
1	O
(	O
OGR1	O
;	O
GPR68	O
)	O
is	O
expressed	O
in	O
the	O
gut	O
.	O

Over	O
-	O
expression	O
of	O
aspartyl	O
(	O
asparagynal	O
)	O
-	O
b	O
-	O
hydroxylase	O
(	O
ASPH	O
)	O
contributes	O
to	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
invasiveness	O
,	O
but	O
the	O
role	O
of	O
ASPH	O
hydroxylase	O
activity	O
in	O
this	O
process	O
remains	O
to	O
be	O
defined	O
.	O

Using	O
a	O
proteomics	O
screen	O
,	O
we	O
now	O
show	O
that	O
the	O
mitochondrial	O
unfoldase	O
-	O
peptidase	O
complex	O
ClpXP	O
associates	O
with	O
the	O
oncoprotein	O
survivin	O
and	O
the	O
respiratory	O
chain	O
Complex	O
II	O
subunit	O
succinate	O
dehydrogenase	O
B	O
(	O
SDHB	O
)	O
in	O
mitochondria	O
of	O
tumor	S-Phenotype
cells	O
.	O

The	O
created	O
databases	O
include	O
ACAD8	O
(	O
isobutyryl	O
-	O
CoA	O
dehydrogenase	O
deficiency	O
(	O
IBD	O
)	O
)	O
,	O
ACADSB	O
(	O
short	O
-	O
chain	O
acyl	O
-	O
CoA	O
dehydrogenase	O
(	O
SCAD	O
)	O
deficiency	O
)	O
,	O
AUH	O
(	O
3	B-Phenotype
-	I-Phenotype
methylglutaconic	I-Phenotype
aciduria	E-Phenotype
(	O
3	O
-	O
MGCA	O
)	O
)	O
,	O
DHCR7	O
(	O
Smith	O
-	O
Lemli	O
-	O
Opitz	O
syndrome	O
)	O
,	O
HMGCS2	O
(	O
3	O
-	O
hydroxy	O
-	O
3	O
-	O
methylglutaryl	O
-	O
CoA	O
synthase	O
2	O
deficiency	O
)	O
,	O
HSD17B10	O
(	O
17	O
-	O
beta	O
-	O
hydroxysteroid	O
dehydrogenase	O
X	O
deficiency	O
)	O
,	O
FKBP14	O
(	O
Ehlers	O
-	O
Danlos	O
syndrome	O
with	O
progressive	O
kyphoscoliosis	S-Phenotype
,	O
myopathy	S-Phenotype
,	O
and	O
hearing	B-Phenotype
loss	E-Phenotype
;	O
EDSKMH	O
)	O
and	O
ROGDI	O
(	O
Kohlschutter	O
-	O
Tonz	O
syndrome	O
)	O
.	O

miRNAs	O
are	O
a	O
kind	O
of	O
endogenous	O
non	O
-	O
coding	O
small	O
RNAs	O
,	O
which	O
involved	O
in	O
occurrence	O
and	O
development	O
of	O
multi	O
cancer	S-Phenotype
,	O
including	O
miR	O
-	O
34a	O
.	O

The	O
increased	O
RhoA	O
-	O
GTP	O
results	O
from	O
AKT	O
phosphorylating	O
three	O
serines	O
(	O
S298	O
,	O
S329	O
,	O
and	O
S567	O
)	O
in	O
the	O
DLC1	O
tumor	S-Phenotype
suppressor	O
,	O
a	O
Rho	O
GTPase	O
-	O
activating	O
protein	O
(	O
RhoGAP	O
)	O
associated	O
with	O
focal	O
adhesions	O
.	O

Here	O
,	O
we	O
examined	O
the	O
effects	O
of	O
UBE2T	O
on	O
the	O
progression	O
of	O
gastric	B-Phenotype
cancer	E-Phenotype
.	O

Analyses	O
of	O
mRNA	O
profiles	O
in	O
comprehensive	O
datasets	O
revealed	O
that	O
high	O
ITGA7	O
expression	O
negatively	O
correlated	O
with	O
survival	O
of	O
patients	O
with	O
both	O
low	O
-	O
and	O
high	O
-	O
grade	O
glioma	S-Phenotype
.	O

In	O
conclusion	O
,	O
our	O
findings	O
firstly	O
revealed	O
that	O
GSDME	O
switches	O
chemotherapy	O
drug	O
-	O
induced	O
caspase	O
-	O
3	O
dependent	O
apoptosis	O
into	O
pyroptosis	O
in	O
gastric	B-Phenotype
cancer	E-Phenotype
cells	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
functional	O
roles	O
of	O
miR	O
-	O
1274a	O
and	O
identify	O
downstream	O
tumor	S-Phenotype
-	O
suppressive	O
targets	O
regulated	O
by	O
miR	O
-	O
1274a	O
in	O
ccRCC	O
cells	O
.	O

Superficial	B-Phenotype
CD34	I-Phenotype
-	I-Phenotype
positive	I-Phenotype
fibroblastic	I-Phenotype
tumor	E-Phenotype
is	O
a	O
recently	O
described	O
soft	O
-	O
tissue	O
tumor	S-Phenotype
entity	O
.	O

Her	O
epilepsy	S-Phenotype
onset	O
was	O
earlier	O
than	O
is	O
typical	O
for	O
RTT	O
patients	O
.	O

To	O
evaluate	O
whether	O
germline	O
variants	O
in	O
genes	O
encoding	O
pancreatic	O
secretory	O
enzymes	O
contribute	O
to	O
pancreatic	B-Phenotype
cancer	E-Phenotype
susceptibility	O
,	O
we	O
sequenced	O
the	O
coding	O
regions	O
of	O
CPB1	O
and	O
other	O
genes	O
encoding	O
pancreatic	O
secretory	O
enzymes	O
and	O
known	O
pancreatitis	S-Phenotype
susceptibility	O
genes	O
(	O
PRSS1	O
,	O
CPA1	O
,	O
CTRC	O
,	O
and	O
SPINK1	O
)	O
in	O
a	O
hospital	O
series	O
of	O
pancreatic	B-Phenotype
cancer	E-Phenotype
cases	O
and	O
controls	O
.	O

Our	O
data	O
,	O
therefore	O
,	O
highlight	O
ITGA7	O
as	O
a	O
glioblastoma	S-Phenotype
biomarker	O
and	O
candidate	O
therapeutic	O
target	O

This	O
paper	O
deals	O
with	O
the	O
molecular	O
investigation	O
of	O
Waardenburg	O
syndrome	O
(	O
WS	O
)	O
in	O
a	O
sample	O
of	O
49	O
clinically	O
diagnosed	O
probands	O
(	O
most	O
from	O
southeastern	O
Brazil	O
)	O
,	O
24	O
of	O
them	O
having	O
the	O
type	O
1	O
(	O
WS1	O
)	O
variant	O
(	O
10	O
familial	O
and	O
14	O
isolated	B-Phenotype
cases	E-Phenotype
)	O
and	O
25	O
being	O
affected	O
by	O
the	O
type	O
2	O
(	O
WS2	O
)	O
variant	O
(	O
five	O
familial	O
and	O
20	O
isolated	O
cases	O
)	O
.	O

More	O
important	O
,	O
Col5a2	O
haploinsufficiency	O
markedly	O
increased	O
the	O
incidence	O
and	O
severity	O
of	O
abdominal	B-Phenotype
aortic	I-Phenotype
aneurysms	E-Phenotype
,	O
and	O
caused	O
aortic	O
arch	O
ruptures	O
and	O
dissections	O
,	O
indicating	O
that	O
α2	O
(	O
V	O
)	O
chain	O
deficits	O
may	O
play	O
roles	O
in	O
these	O
pathologies	O
in	O
humans	O

Altogether	O
,	O
these	O
data	O
suggest	O
that	O
Polyphyllin	O
I	O
can	O
inhibit	O
the	O
proliferation	O
of	O
gastric	B-Phenotype
cancer	E-Phenotype
cells	O
by	O
downregulating	O
the	O
expression	O
of	O
FAP	O
and	O
HGF	O
in	O
CAFs	O
in	O
vivo	O

This	O
research	O
was	O
aimed	O
to	O
study	O
the	O
expression	O
of	O
TAZ	O
/	O
YAP	O
protein	O
in	O
malignant	B-Phenotype
melanoma	E-Phenotype
and	O
to	O
investigate	O
its	O
relationship	O
to	O
the	O
clinicopathology	O
and	O
prognosis	O
of	O
patients	O
with	O
malignant	B-Phenotype
melanoma	E-Phenotype
.	O

Collectively	O
,	O
our	O
data	O
suggest	O
that	O
FYCO1	O
regulates	O
MB	O
degradation	O
,	O
and	O
we	O
present	O
the	O
first	O
evidence	O
that	O
cancer	S-Phenotype
invasiveness	O
is	O
a	O
feature	O
that	O
can	O
be	O
modulated	O
by	O
the	O
accumulation	O
of	O
MBs	O
in	O
cancer	S-Phenotype
stem	O
cells	O
.	O

This	O
article	O
has	O
an	O
associated	O
First	O
Person	O
interview	O
with	O
the	O
first	O
author	O
of	O
the	O
paper	O

Recently	O
,	O
autosomal	B-Phenotype
recessive	E-Phenotype
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
EXPH5	O
(	O
encoding	O
exophilin	O
-	O
5	O
,	O
also	O
known	O
as	O
Slac2	O
-	O
b	O
,	O
a	O
protein	O
involved	O
in	O
intracellular	O
vesicle	O
transport	O
)	O
were	O
identified	O
in	O
a	O
new	O
mechanobullous	O
disease	O
resembling	O
a	O
form	O
of	O
epidermolysis	O
bullosa	O
simplex	O
(	O
EBS	O
)	O
.	O

Monoallelic	O
and	O
biallelic	O
deleterious	O
sequence	O
variants	O
in	O
FOXE3	O
cause	O
aphakia	S-Phenotype
,	O
cataracts	S-Phenotype
,	O
sclerocornea	S-Phenotype
and	O
microphthalmia	S-Phenotype
in	O
humans	O
.	O

Mutations	O
in	O
ANTXR1	O
have	O
been	O
associated	O
with	O
GAPO	O
(	O
growth	B-Phenotype
retardation	E-Phenotype
,	O
alopecia	S-Phenotype
,	O
pseudoanodontia	S-Phenotype
,	O
and	O
optic	B-Phenotype
atrophy	E-Phenotype
)	O
syndrome	O
and	O
infantile	B-Phenotype
hemangioma	E-Phenotype
,	O
however	O
no	O
clinical	O
characteristics	O
associated	O
with	O
these	O
conditions	O
were	O
observed	O
in	O
our	O
study	O
family	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
methylation	O
status	O
of	O
HOXA11	O
in	O
264	O
paired	O
breast	B-Phenotype
cancer	E-Phenotype
and	O
normal	O
tissue	O
as	O
well	O
as	O
in	O
matched	O
serum	O
samples	O
by	O
MethyLight	O
assay	O
.	O

Immunohistochemistry	O
demonstrated	O
that	O
the	O
loss	O
of	O
CDK10	O
expression	O
,	O
which	O
was	O
observed	O
in	O
50.8	O
%	O
of	O
primary	O
gastric	B-Phenotype
cancer	E-Phenotype
tissues	O
(	O
n=128	O
)	O
,	O
significantly	O
correlated	O
with	O
advanced	O
tumor	S-Phenotype
stage	O
(	O
PAAAA0.001	O
)	O
,	O
frequent	O
lymph	O
node	O
metastasis	O
(	O
PAAAA0.001	O
)	O
,	O
distant	O
metastasis	O
(	O
P=0.013	O
)	O
,	O
tumor	S-Phenotype
differentiation	O
(	O
P=0.004	O
)	O
and	O
unfavorable	O
overall	O
survival	O
(	O
PAAAA0.001	O
)	O
.	O

In	O
Ewing	B-Phenotype
sarcoma	E-Phenotype
,	O
the	O
oncogenic	O
fusion	O
protein	O
EWS	O
-	O
FLI1	O
induces	O
chromatin	O
features	O
typical	O
of	O
active	O
enhancers	O
at	O
GGAA	O
microsatellite	O
repeats	O
,	O
but	O
the	O
function	O
of	O
these	O
sites	O
has	O
not	O
been	O
directly	O
demonstrated	O
.	O

The	O
older	O
brother	O
presented	O
with	O
progressive	B-Phenotype
gait	I-Phenotype
difficulties	E-Phenotype
,	O
hypotonia	S-Phenotype
,	O
intermittent	B-Phenotype
dystonia	E-Phenotype
,	O
polycythemia	S-Phenotype
,	O
and	O
characteristic	B-Phenotype
T1	I-Phenotype
-	I-Phenotype
hyperintense	I-Phenotype
lesions	I-Phenotype
on	I-Phenotype
MRI	I-Phenotype
brain	E-Phenotype
.	O

Patients	O
with	O
genotype	O
AA	O
were	O
found	O
to	O
have	O
remarkably	O
higher	O
FOXP1	O
expression	O
in	O
the	O
tumour	S-Phenotype
than	O
those	O
with	O
genotype	O
CC	O
(	O
P	O
=	O
0.01	O
)	O
.	O

Extensive	O
IDS	O
gene	O
deletions	O
were	O
identified	O
in	O
four	O
patients	O
;	O
using	O
DNA	O
microarray	O
analysis	O
two	O
patients	O
showed	O
the	O
loss	O
of	O
the	O
entire	O
AFF2	O
gene	O
,	O
and	O
epilepsy	S-Phenotype
developed	O
in	O
only	O
one	O
of	O
them	O
.	O

The	O
gene	O
expression	O
levels	O
of	O
Ki	O
-	O
67	O
,	O
BCL11A	O
,	O
FOXC1	O
,	O
HOXD13	O
,	O
PCDHGB7	O
and	O
her	O
-	O
2	O
were	O
used	O
as	O
an	O
auxiliary	O
diagnostic	O
index	O
for	O
patients	O
with	O
breast	B-Phenotype
cancer	E-Phenotype
in	O
the	O
early	O
stage	O
.	O

Overexpression	O
of	O
miR	O
-	O
4326	O
promoted	O
lung	B-Phenotype
cancer	E-Phenotype
cell	O
proliferation	O
analyzed	O
by	O
MTT	O
,	O
soft	O
agar	O
growth	O
,	O
and	O
BrdU	O
incorporation	O
assay	O
,	O
while	O
miR	O
-	O
4326	O
knockdown	O
suppressed	O
lung	B-Phenotype
cancer	E-Phenotype
cell	O
proliferation	O
.	O

As	O
∆Esub3	O
/	O
sub	O
is	O
modulated	O
by	O
cellular	O
signalling	O
and	O
linked	O
to	O
various	O
types	O
of	O
cancer	S-Phenotype
,	O
we	O
anticipate	O
that	O
∆Esub3	O
/	O
sub	O
contributes	O
to	O
environmentally	O
tuned	O
REST	O
function	O
and	O
may	O
have	O
a	O
broad	O
range	O
of	O
clinical	O
implications	O

Array	O
methylation	O
-	O
based	O
analysis	O
uncovered	O
a	O
somatic	O
epigenetic	O
mutation	O
in	O
liSDHC	O
/	O
i	O
in	O
a	O
patient	O
with	O
multiple	O
pheochromocytomas	S-Phenotype
and	O
a	O
gastrointestinal	B-Phenotype
stromal	I-Phenotype
tumor	E-Phenotype
.	O

This	O
report	O
describes	O
the	O
first	O
putative	O
mutations	O
,	O
p.L70P	O
and	O
p.R450C	O
,	O
in	O
the	O
coding	O
region	O
of	O
the	O
UROC1	O
gene	O
in	O
a	O
girl	O
with	O
urocanic	B-Phenotype
aciduria	E-Phenotype
presenting	O
with	O
mental	B-Phenotype
retardation	E-Phenotype
and	O
intermittent	B-Phenotype
ataxia	E-Phenotype
.	O

However	O
,	O
in	O
HaCaT	O
and	O
HEK293T	O
cells	O
that	O
display	O
transformed	O
phenotypes	O
,	O
but	O
do	O
not	O
originate	O
from	O
patient	O
-	O
derived	O
tumors	S-Phenotype
,	O
the	O
ER	O
stress	O
-	O
inducing	O
treatments	O
resulted	O
in	O
an	O
upregulation	O
of	O
FAM129A	O
and	O
HKDC1	O
,	O
but	O
not	O
KRT16	O
transcripts	O
,	O
By	O
a	O
luciferase	O
reporter	O
approach	O
we	O
identified	O
a	O
highly	O
active	O
ATF4	O
-	O
responsive	O
element	O
within	O
the	O
upstream	O
region	O
of	O
the	O
KRT16	O
gene	O
.	O

Mutations	O
in	O
MYH3	O
and	O
MYH8	O
are	O
associated	O
with	O
distal	B-Phenotype
arthrogryposis	E-Phenotype
syndromes	O
.	O

Substitution	O
of	O
endogenous	O
PGAM2	O
with	O
an	O
acetylation	O
mimetic	O
mutant	O
K100Q	O
reduces	O
cellular	O
NADPH	O
production	O
and	O
inhibits	O
cell	O
proliferation	O
and	O
tumor	S-Phenotype
growth	O
.	O

The	O
fetus	O
inherited	O
an	O
additional	O
likely	O
pathogenic	O
novel	O
missense	O
change	O
to	O
a	O
second	O
MKS	O
gene	O
,	O
CEP290	O
;	O
p.R2210C	O
,	O
suggesting	O
oligogenic	B-Phenotype
inheritance	E-Phenotype
in	O
this	O
disorder	O

Mice	O
with	O
a	O
homozygous	O
null	O
mutation	O
in	O
Slc9a1	O
(	O
Nhe1	O
)	O
exhibited	O
ataxia	S-Phenotype
,	O
recurrent	O
seizures	S-Phenotype
,	O
and	O
selective	O
neuronal	O
cell	O
death	O
.	O

Steroid	O
21	O
-	O
Hydroxylase	O
deficiency	O
is	O
an	O
inherited	B-Phenotype
autosomal	I-Phenotype
recessive	E-Phenotype
metabolic	O
disorder	O
of	O
the	O
adrenal	O
steroidogenesis	O
caused	O
due	O
to	O
mutations	O
in	O
the	O
CYP21A2	O
gene	O
in	O
95	O
%	O
of	O
CAH	O
cases	O
.	O

By	O
combining	O
meta	O
-	O
analysis	O
results	O
and	O
identification	O
of	O
two	O
unrelated	O
HCM	O
patients	O
with	O
homozygous	O
CSRP3	O
truncating	O
variants	O
,	O
we	O
suggest	O
that	O
the	O
association	O
of	O
CSRP3	O
as	O
a	O
validated	O
HCM	O
-	O
causing	O
gene	O
require	O
additional	O
studies	O
and	O
those	O
CSRP3	O
variants	O
could	O
result	O
in	O
HCM	O
with	O
an	O
autosomal	B-Phenotype
recessive	I-Phenotype
inheritance	E-Phenotype
rather	O
than	O
with	O
an	O
autosomal	O
dominant	O
transmission	O
as	O
usually	O
reported	O
on	O
HCM	O
(	O
OMIM	O
612124	O
)	O

Based	O
on	O
the	O
data	O
from	O
the	O
present	O
study	O
,	O
it	O
was	O
concluded	O
that	O
an	O
abnormal	O
expression	O
level	O
of	O
Gremlin	O
1	O
in	O
pancreatic	B-Phenotype
cancer	E-Phenotype
was	O
induced	O
by	O
SHH	O
signaling	O
,	O
and	O
that	O
the	O
overexpression	O
of	O
Gremlin	O
1	O
enabled	O
pancreatic	B-Phenotype
cancer	E-Phenotype
progression	O

However	O
,	O
there	O
is	O
considerable	O
clinical	O
heterogeneity	S-Phenotype
among	O
patients	O
,	O
and	O
the	O
molecular	O
basis	O
for	O
the	O
evolution	O
of	O
immunodeficiency	S-Phenotype
into	O
MDS	O
/	O
AML	O
remains	O
unknown	O
.	O

CCR7	O
rs3136685	O
AG+GG	O
(	O
p=0.032	O
)	O
was	O
associated	O
with	O
a	O
1.52	O
-	O
1.70	O
fold	O
increase	O
in	O
the	O
risk	O
of	O
high	O
grade	O
cancer	S-Phenotype
(	O
Gleason	O
scoreG7	O
)	O
among	O
obese	O
men	O
.	O

Our	O
study	O
identified	O
complex	O
PTEN	O
-	O
cooperating	O
tumor	S-Phenotype
suppressor	O
networks	O
in	O
different	O
cancer	S-Phenotype
types	O
,	O
with	O
potential	O
clinical	O
implications	O

In	O
humans	O
,	O
mutations	O
in	O
the	O
CACNA2D4	O
gene	O
encoding	O
a2d	O
-	O
4	O
cause	O
heterogeneous	S-Phenotype
forms	O
of	O
vision	O
impairment	O
in	O
humans	O
,	O
the	O
underlying	O
pathogenic	O
mechanisms	O
of	O
which	O
remain	O
unclear	O
.	O

B1	O
induced	O
readthrough	O
at	O
all	O
three	O
nonsense	O
codons	O
in	O
cultured	O
cancer	S-Phenotype
cells	O
with	O
liTP53	O
(	O
tumor	S-Phenotype
protein	O
p53	O
)	O
mutations	O
,	O
in	O
cells	O
from	O
patients	O
with	O
nonsense	O
mutations	O
in	O
the	O
liTPP1	O
(	O
tripeptidyl	O
peptidase	O
1	O
)	O
,	O
liDMD	O
(	O
dystrophin	O
)	O
,	O
liSMARCAL1	O
(	O
SWI	O
/	O
SNF	O
-	O
related	O
,	O
matrix	O
-	O
associated	O
,	O
actin	O
-	O
dependent	O
regulator	O
of	O
chromatin	O
,	O
subfamily	O
a	O
-	O
like	O
1	O
)	O
,	O
and	O
liCOL7A1	O
(	O
collagen	O
type	O
VII	O
alpha	O
1	O
chain	O
)	O
genes	O
,	O
and	O
in	O
an	O
in	O
vivo	O
tumor	S-Phenotype
xenograft	O
model	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
a	O
splice	O
-	O
site	O
mutation	O
(	O
c.637+1GAAAAT	O
)	O
in	O
Ca	O
(	O
2+	O
)	O
-	O
binding	O
protein	O
2	O
(	O
CABP2	O
)	O
in	O
three	O
consanguineous	O
Iranian	O
families	O
affected	O
by	O
moderate	B-Phenotype
-	I-Phenotype
to	I-Phenotype
-	I-Phenotype
severe	I-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
.	O

Loss	O
-	O
and	O
gain	O
-	O
of	O
-	O
function	O
experiments	O
demonstrated	O
that	O
PSAT1	O
promoted	O
cell	O
cycle	O
progression	O
,	O
cell	O
proliferation	O
and	O
tumorigenesis	S-Phenotype
.	O

Finally	O
,	O
through	O
a	O
xenograft	O
nude	O
mice	O
model	O
,	O
we	O
demonstrated	O
that	O
DDX59	O
is	O
pivotal	O
for	O
EGFR	O
mutated	O
lung	B-Phenotype
cancer	E-Phenotype
cell	O
growth	O
in	O
vivo	O
.	O

Human	O
genetic	O
evidence	O
demonstrates	O
that	O
WNT1	O
mutations	O
cause	O
osteogenesis	B-Phenotype
imperfecta	E-Phenotype
(	O
OI	S-Phenotype
)	O
and	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
osteoporosis	E-Phenotype
,	O
implicating	O
WNT1	O
as	O
a	O
major	O
regulator	O
of	O
bone	O
metabolism	O
.	O

De	O
novo	O
in	O
-	O
frame	O
deletions	O
and	O
duplications	O
in	O
the	O
SPTAN1	O
gene	O
,	O
encoding	O
the	O
non	O
-	O
erythrocyte	O
aII	O
spectrin	O
,	O
have	O
been	O
associated	O
with	O
severe	O
West	B-Phenotype
syndrome	E-Phenotype
with	O
hypomyelination	S-Phenotype
and	O
pontocerebellar	B-Phenotype
atrophy	E-Phenotype
.	O

In	O
this	O
case	O
report	O
,	O
a	O
14	O
-	O
month	O
-	O
old	O
boy	O
had	O
the	O
clinical	O
manifestations	O
of	O
delayed	B-Phenotype
development	E-Phenotype
,	O
unusual	B-Phenotype
facies	E-Phenotype
(	O
prominent	B-Phenotype
forehead	E-Phenotype
,	O
midface	B-Phenotype
retraction	E-Phenotype
,	O
hypertelorism	S-Phenotype
,	O
low	B-Phenotype
-	I-Phenotype
set	I-Phenotype
ears	E-Phenotype
,	O
upturned	B-Phenotype
nose	E-Phenotype
,	O
and	O
micrognathia	S-Phenotype
)	O
,	O
and	O
multiple	B-Phenotype
congenital	I-Phenotype
malformations	E-Phenotype
(	O
including	O
cerebral	B-Phenotype
dysplasia	E-Phenotype
,	O
dislocation	B-Phenotype
of	I-Phenotype
the	I-Phenotype
hip	I-Phenotype
joint	E-Phenotype
,	O
and	O
cryptorchidism	S-Phenotype
)	O
.	O

NSUN2	O
is	O
a	O
RNA	O
methyltransferase	O
that	O
has	O
been	O
shown	O
to	O
be	O
implicated	O
in	O
development	O
of	O
human	O
cancer	S-Phenotype
.	O

Overall	O
,	O
our	O
findings	O
identify	O
PRSS56	O
as	O
a	O
potential	O
therapeutic	O
target	O
for	O
modulating	O
ocular	O
growth	O
aimed	O
at	O
preventing	O
or	O
slowing	O
down	O
myopia	S-Phenotype
,	O
which	O
is	O
reaching	O
epidemic	O
proportions	O

We	O
report	O
a	O
novel	O
gene	O
duplication	O
syndrome	O
(	O
10q21.2q21.3	O
microduplication	O
)	O
and	O
present	O
a	O
new	O
evidence	O
for	O
VIPR2	O
duplication	O
,	O
as	O
a	O
candidate	O
gene	O
for	O
autism	S-Phenotype
.	O

In	O
conclusion	O
,	O
our	O
results	O
reveal	O
a	O
role	O
for	O
the	O
KCNQ1	O
potassium	O
channel	O
in	O
the	O
regulation	O
of	O
human	O
growth	O
,	O
and	O
show	O
that	O
growth	B-Phenotype
hormone	I-Phenotype
deficiency	E-Phenotype
associated	O
with	O
maternally	B-Phenotype
inherited	I-Phenotype
gingival	I-Phenotype
fibromatosis	E-Phenotype
is	O
an	O
allelic	O
disorder	O
with	O
cardiac	B-Phenotype
arrhythmia	E-Phenotype
syndromes	O
caused	O
by	O
KCNQ1	O
mutations	O

Here	O
,	O
we	O
applied	O
domain	O
-	O
focused	O
CRISPR	O
screening	O
to	O
human	O
cancer	S-Phenotype
cell	O
lines	O
to	O
identify	O
the	O
transcription	O
factor	O
(	O
TF	O
)	O
POU2F3	O
(	O
POU	O
class	O
2	O
homeobox	O
3	O
;	O
also	O
known	O
as	O
SKN	O
-	O
1a	O
/	O
OCT	O
-	O
11	O
)	O
as	O
a	O
powerful	O
dependency	O
in	O
a	O
subset	O
of	O
SCLC	O
lines	O
.	O

The	O
autism	S-Phenotype
susceptibility	O
locus	O
on	O
human	O
chromosome	O
7q32	O
contains	O
the	O
maternally	O
imprinted	O
MEST	O
and	O
the	O
non	O
-	O
imprinted	O
COPG2	O
and	O
TSGA14	O
genes	O
.	O

Overall	O
,	O
our	O
results	O
demonstrate	O
that	O
small	O
-	O
molecule	O
inhibition	O
of	O
CHK1	O
in	O
combination	O
with	O
,	O
cisplatin	O
,	O
is	O
more	O
advantageous	O
than	O
either	O
treatment	O
alone	O
,	O
especially	O
for	O
Group	O
3	O
medulloblastoma	S-Phenotype
,	O
and	O
therefore	O
this	O
combined	O
therapeutic	O
approach	O
serves	O
as	O
an	O
avenue	O
for	O
further	O
investigation	O

Regarding	O
the	O
important	O
role	O
of	O
arginine	O
(	O
Arg	O
)	O
in	O
the	O
regulation	O
of	O
multiple	O
metabolic	O
and	O
signaling	O
pathways	O
,	O
its	O
deprivation	O
has	O
been	O
proposed	O
as	O
a	O
good	O
strategy	O
for	O
tumor	S-Phenotype
regression	O
in	O
tumors	S-Phenotype
with	O
defected	O
Arg	O
metabolic	O
enzymes	O
like	O
argininosuccinate	O
synthase	O
1	O
(	O
ASS1	O
)	O
.	O

In	O
this	O
family	O
,	O
whole	O
-	O
exome	O
sequencing	O
yielded	O
rare	O
,	O
simultaneously	O
heterozygous	O
variants	O
in	O
the	O
Aicardi	O
-	O
Goutieres	O
syndrome	O
(	O
AGS	O
)	O
genes	O
ADAR	O
and	O
RNASEH2B	O
co	O
-	O
segregating	O
with	O
the	O
tumor	S-Phenotype
phenotype	O
.	O

Knockdown	O
of	O
LTBP3	O
in	O
all	O
tested	O
cell	O
lines	O
led	O
to	O
significant	O
inhibition	O
of	O
tumor	S-Phenotype
cell	O
intravasation	O
,	O
but	O
did	O
not	O
affect	O
primary	O
tumor	S-Phenotype
growth	O
.	O

The	O
Glis3	O
mutant	O
mice	O
have	O
been	O
characterized	O
for	O
their	O
propensity	O
to	O
develop	O
congenital	B-Phenotype
hypothyroidism	E-Phenotype
,	O
polycystic	B-Phenotype
kidney	E-Phenotype
disease	O
,	O
and	O
some	O
types	O
of	O
cancer	S-Phenotype
.	O

This	O
study	O
aimed	O
to	O
assess	O
the	O
effect	O
of	O
long	O
noncoding	O
RNAs	O
(	O
lncRNAs	O
)	O
taurine	O
-	O
upregulated	O
gene	O
1	O
(	O
TUG1	O
)	O
on	O
cells	O
proliferation	O
and	O
apoptosis	O
as	O
well	O
as	O
its	O
targeting	O
genes	O
in	O
epithelial	B-Phenotype
ovarian	I-Phenotype
cancer	E-Phenotype
(	O
EOC	S-Phenotype
)	O
cells	O
.	O

Blank	O
mimic	O
,	O
lncRNA	O
TUG1	O
mimic	O
,	O
blank	O
inhibitor	O
,	O
and	O
lncRNA	O
TUG1	O
inhibitor	O
plasmids	O
were	O
transfected	O
into	O
SK	O
-	O
OV	O
-	O
3	O
(	O
SKOV3	O
)	O
cells	O
.	O

The	O
studied	O
CVD	O
biomarkers	O
include	O
AXL	O
receptor	O
tyrosine	O
kinase	O
,	O
apolipoproteins	O
,	O
cholesterol	O
,	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
,	O
D	O
-	O
dimer	O
,	O
fibrinogen	O
(	O
Fib	O
)	O
,	O
glucose	O
,	O
insulin	O
,	O
interleukins	O
,	O
lipoproteins	O
,	O
myoglobin	O
,	O
N	O
-	O
terminal	O
pro	O
-	O
B	O
-	O
type	O
natriuretic	O
peptide	O
(	O
BNP	O
)	O
,	O
tumor	S-Phenotype
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
α	O
)	O
and	O
troponins	O
(	O
Tns	O
)	O
on	O
electrochemical	O
transduction	O
format	O
.	O

The	O
tumor	S-Phenotype
was	O
afterwards	O
identified	O
as	O
a	O
dMMR	O
melanoma	S-Phenotype
for	O
an	O
exclusive	O
loss	O
of	O
Msh6	O
expression	O
on	O
IHC	O
(	O
Figure	O
1	O
)	O
.	O

Here	O
we	O
report	O
three	O
families	O
with	O
homozygous	O
truncating	O
mutations	O
in	O
TBC1D23	O
who	O
display	O
moderate	O
to	O
severe	O
intellectual	B-Phenotype
disability	E-Phenotype
and	O
microcephaly	S-Phenotype
.	O

Thus	O
,	O
it	O
is	O
clear	O
that	O
a	O
more	O
complex	O
genetic	O
network	O
of	O
cancer	S-Phenotype
-	O
associated	O
genes	O
than	O
previously	O
hypothesized	O
is	O
involved	O
in	O
BCC	O
carcinogenesis	O
,	O
with	O
a	O
potential	O
impact	O
on	O
the	O
development	O
of	O
new	O
molecular	O
targeted	O
therapies	O
.	O

JBTS	O
is	O
genetically	O
heterogeneous	S-Phenotype
,	O
however	O
mutations	O
in	O
CEP290	O
are	O
a	O
common	O
underlying	O
cause	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	O
prevalence	O
of	O
sequence	O
variants	O
in	O
LCA5	O
in	O
patients	O
with	O
Leber	B-Phenotype
congenital	I-Phenotype
amaurosis	E-Phenotype
(	O
LCA	S-Phenotype
)	O
,	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
retinal	I-Phenotype
dystrophy	E-Phenotype
(	O
EORD	S-Phenotype
)	O
,	O
and	O
autosomal	B-Phenotype
recessive	I-Phenotype
retinitis	I-Phenotype
pigmentosa	E-Phenotype
(	O
arRP	S-Phenotype
)	O
;	O
to	O
delineate	O
the	O
ocular	O
phenotypes	O
;	O
and	O
to	O
provide	O
an	O
overview	O
of	O
all	O
published	O
LCA5	O
variants	O
in	O
an	O
online	O
database	O
.	O

Although	O
post	B-Phenotype
-	I-Phenotype
streptococcal	I-Phenotype
glomerulonephritis	E-Phenotype
(	O
PSGN	S-Phenotype
)	O
is	O
still	O
common	O
,	O
there	O
is	O
a	O
wide	O
spectrum	O
of	O
causative	O
agents	O
of	O
PIGN	O
.	O

This	O
discovery	O
suggests	O
enormous	O
selection	O
advantage	O
for	O
cancer	S-Phenotype
cells	O
with	O
GOF	O
p53	O
to	O
induce	O
oncogenic	O
growth	O
,	O
highlighting	O
the	O
problems	O
of	O
cancer	S-Phenotype
therapy	O

Depletion	O
of	O
the	O
exon	O
3	O
-	O
containing	O
long	O
isoform	O
of	O
MRPL33	O
(	O
MRPL33	O
-	O
L	O
)	O
led	O
to	O
impaired	O
proliferation	O
and	O
increased	O
apoptosis	O
in	O
cancer	S-Phenotype
cell	O
lines	O
and	O
in	O
a	O
xenograft	O
model	O
.	O

Only	O
four	O
genetic	O
midfrequency	O
deafness	S-Phenotype
genes	O
,	O
namely	O
,	O
DFNA10	O
(	O
EYA4	O
)	O
,	O
DFNA8	O
/	O
12	O
(	O
TECTA	O
)	O
,	O
DFNA13	O
(	O
COL11A2	O
)	O
,	O
DFNA44	O
(	O
CCDC50	O
)	O
,	O
have	O
been	O
reported	O
to	O
date	O
.	O

Previously	O
,	O
we	O
demonstrated	O
that	O
a	O
unique	O
category	O
of	O
cancer	S-Phenotype
antigens	O
is	O
selectively	O
presented	O
by	O
tumor	S-Phenotype
cells	O
deficient	O
for	O
the	O
peptide	O
transporter	O
TAP	O
,	O
enabling	O
a	O
specific	O
attack	O
of	O
such	O
tumors	S-Phenotype
without	O
causing	O
immunopathology	O
in	O
mouse	O
models	O
.	O

The	O
classical	O
mammalian	O
isoforms	O
of	O
PLD	O
are	O
PLD1	O
and	O
PLD2	O
,	O
and	O
the	O
levels	O
of	O
both	O
mRNA	O
were	O
higher	O
at	O
the	O
primary	O
tumor	S-Phenotype
sites	O
than	O
in	O
normal	O
kidney	O
tissues	O
.	O

These	O
effects	O
are	O
cell	O
-	O
type	O
-	O
selective	O
,	O
cell	O
-	O
autonomous	O
,	O
and	O
involve	O
activation	O
of	O
p53	O
tumour	S-Phenotype
-	O
suppressor	O
protein	O
.	O

In	O
this	O
study	O
,	O
we	O
enrolled	O
16	O
individuals	O
affected	O
by	O
tooth	B-Phenotype
agenesis	E-Phenotype
,	O
prevalently	O
hypodontia	S-Phenotype
,	O
and	O
we	O
carried	O
out	O
direct	O
Sanger	O
sequencing	O
of	O
paired	O
box	O
9	O
(	O
PAX9	O
)	O
and	O
Msh	O
homeobox	O
1	O
(	O
MSX1	O
)	O
genes	O
in	O
9	O
subjects	O
.	O

In	O
colorectal	B-Phenotype
tumors	E-Phenotype
,	O
endogenous	O
GUCY2C	O
ligand	O
expression	O
is	O
lost	O
by	O
a	O
yet	O
undefined	O
mechanism	O
conserved	O
in	O
mice	O
and	O
humans	O
.	O

KRT5	O
and	O
KRT6	O
(	O
KRT6A	O
,	O
KRT6B	O
AAAAA	O
KRT6C	O
)	O
gene	O
expression	O
was	O
assessed	O
in	O
publically	O
available	O
serous	O
ovarian	B-Phenotype
cancer	E-Phenotype
data	O
sets	O
,	O
ovarian	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
and	O
primary	O
serous	O
ovarian	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Using	O
whole	O
-	O
exome	O
sequencing	O
,	O
we	O
identified	O
biallelic	O
mutations	O
in	O
seizure	S-Phenotype
threshold	O
2	O
(	O
SZT2	O
)	O
in	O
both	O
affected	O
children	O
.	O

Through	O
gene	O
set	O
enrichment	O
analysis	O
and	O
bi	O
-	O
clustering	O
,	O
we	O
also	O
found	O
that	O
most	O
of	O
the	O
differential	O
expressed	O
lncRNAs	O
were	O
closely	O
associated	O
with	O
mitochondrial	O
functions	O
(	O
e.g	O
.	O

Primary	B-Phenotype
ciliary	I-Phenotype
dyskinesia	E-Phenotype
(	O
PCD	S-Phenotype
)	O
is	O
a	O
genetic	O
disorder	O
causing	O
chronic	O
oto	O
-	O
sino	O
-	O
pulmonary	O
disease	O
.	O

Ectopic	O
expression	O
of	O
ASS1	O
in	O
GC	O
cells	O
reversed	O
these	O
effects	O
and	O
protected	O
cancer	S-Phenotype
cells	O
from	O
chemotherapy	O
drug	O
-	O
induced	O
apoptosis	O
via	O
activation	O
of	O
the	O
AKT	O
-	O
mammalian	O
target	O
of	O
rapamycin	O
signaling	O
pathway	O
.	O

Patients	O
'	O
baseline	O
characteristics	O
,	O
including	O
gender	O
,	O
age	O
,	O
tumor	S-Phenotype
size	O
,	O
tumor	S-Phenotype
location	O
,	O
tumor	S-Phenotype
grading	O
,	O
clinical	O
TNM	O
staging	O
,	O
tumor	S-Phenotype
infiltrating	O
lymphocytes	O
,	O
CA19	O
-	O
9	O
and	O
chemotherapy	O
treatment	O
,	O
along	O
with	O
the	O
subsequent	O
follow	O
-	O
up	O
data	O
,	O
were	O
documented	O
and	O
analyzed	O
.	O

Addition	O
of	O
exogenous	O
SLURP1	O
(	O
6XHis	O
-	O
tagged	O
,	O
E.	O
coli	O
expressed	O
and	O
partially	O
purified	O
using	O
Ni	O
-	O
ion	O
columns	O
)	O
significantly	O
suppressed	O
the	O
tumor	S-Phenotype
necrosis	O
factor	O
-	O
α	O
(	O
TNF	O
-	O
α	O
)	O
-	O
stimulated	O
human	O
umbilical	O
cord	O
vascular	O
endothelial	O
cell	O
(	O
HUVEC	O
)	O
tube	O
formation	O
.	O

Different	O
corneal	B-Phenotype
dystrophies	E-Phenotype
are	O
caused	O
by	O
mutations	O
in	O
the	O
CHST6	O
,	O
KRT3	O
,	O
KRT12	O
,	O
PIP5K3	O
,	O
SLC4A11	O
,	O
TACSTD2	O
,	O
TGFBI	O
,	O
and	O
UBIAD1	O
genes	O
.	O

In	O
this	O
study	O
,	O
we	O
established	O
PSMB8	O
as	O
a	O
therapeutic	O
target	O
for	O
glioma	S-Phenotype
treatment	O
.	O

Only	O
minor	O
changes	O
in	O
mRNA	O
transcript	O
levels	O
occurred	O
upon	O
exposure	O
to	O
the	O
compounds	O
confirming	O
that	O
metabolic	O
flux	O
alone	O
can	O
be	O
a	O
key	O
determinant	O
of	O
sialoglycoconjugate	O
display	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
;	O
this	O
result	O
complements	O
the	O
well	O
-	O
established	O
role	O
of	O
genetic	O
control	O
(	O
e.g.	O
,	O
the	O
transcription	O
of	O
STs	O
)	O
of	O
sialylation	O
abnormalities	O
ubiquitously	O
associated	O
with	O
cancer	S-Phenotype
.	O

Our	O
results	O
define	O
a	O
novel	O
regulatory	O
pathway	O
in	O
KRAS	O
-	O
driven	O
cancers	S-Phenotype
,	O
which	O
offers	O
a	O
potential	O
therapeutic	O
target	O
for	O
their	O
eradication	O
.	O

Of	O
those	O
,	O
POLR1C	O
is	O
also	O
implicated	O
in	O
a	O
mandibulofacial	B-Phenotype
dysostosis	E-Phenotype
syndrome	O
without	O
leukodystrophy	S-Phenotype
as	O
POLR1A	O
is	O
.	O

We	O
report	O
two	O
further	O
candidates	O
that	O
are	O
biallelically	O
inactivated	O
each	O
in	O
a	O
single	O
cataract	S-Phenotype
family	O
:	O
TAF1A	O
(	O
cataract	S-Phenotype
with	O
global	B-Phenotype
developmental	I-Phenotype
delay	E-Phenotype
)	O
and	O
WDR87	O
(	O
non	O
-	O
syndromic	O
cataract	S-Phenotype
)	O
.	O

Palatable	O
foods	O
(	O
fat	O
and	O
sweet	O
)	O
induce	O
hyperphagia	S-Phenotype
,	O
and	O
facilitate	O
the	O
development	O
of	O
obesity	S-Phenotype
.	O

Concordant	O
modulation	O
of	O
IRGs	O
in	O
both	O
mice	O
and	O
human	O
cells	O
indicates	O
that	O
they	O
might	O
play	O
important	O
roles	O
in	O
regulating	O
CHIKV	O
replication	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O

Humans	O
deficient	O
in	O
IRAK4	O
activity	O
have	O
autosomal	B-Phenotype
recessive	I-Phenotype
primary	I-Phenotype
immune	I-Phenotype
deficiency	E-Phenotype
(	O
PID	S-Phenotype
)	O
.	O

However	O
,	O
the	O
mechanism	O
causing	O
SCD	O
as	O
a	O
result	O
of	O
exercise	O
remains	O
unknown	O
,	O
but	O
exercise	B-Phenotype
-	I-Phenotype
induced	I-Phenotype
ventricular	I-Phenotype
arrhythmias	E-Phenotype
are	O
thought	O
to	O
be	O
responsible	O
for	O
this	O
fatal	O
consequence	O
.	O

Pathogenic	O
sequence	O
variants	O
in	O
the	O
Sorting	O
Nexin	O
10	O
(	O
SNX10	O
)	O
gene	O
have	O
been	O
associated	O
with	O
autosomal	B-Phenotype
recessive	I-Phenotype
osteopetrosis	E-Phenotype
(	O
ARO	S-Phenotype
)	O
in	O
human	O
.	O

Despite	O
the	O
identification	O
of	O
several	O
oncogenic	O
driver	O
mutations	O
leading	O
to	O
constitutive	O
JAK	O
-	O
STAT	O
activation	O
,	O
the	O
cellular	O
and	O
molecular	O
biology	O
of	O
myeloproliferative	B-Phenotype
neoplasms	E-Phenotype
(	O
MPN	S-Phenotype
)	O
remains	O
incompletely	O
understood	O
.	O

The	O
percentage	O
of	O
autosomal	B-Phenotype
recessive	E-Phenotype
forms	O
due	O
to	O
mutations	O
in	O
BMP1	O
,	O
FKBP10	O
,	O
LEPRE1	O
,	O
SERPINF1	O
,	O
and	O
WNT1	O
was	O
unusually	O
high	O
(	O
48	O
%	O
)	O
.	O

However	O
autosomal	B-Phenotype
recessive	I-Phenotype
inheritance	E-Phenotype
with	O
mutation	O
in	O
the	O
SLC34A2	O
gene	O
is	O
suspected	O

Sox2	O
expression	O
is	O
absent	O
in	O
normal	O
urothelial	O
cells	O
,	O
but	O
it	O
begins	O
to	O
be	O
expressed	O
in	O
pre	B-Phenotype
-	I-Phenotype
neoplastic	I-Phenotype
bladder	I-Phenotype
tumors	E-Phenotype
and	O
continues	O
to	O
be	O
expressed	O
in	O
invasive	O
mouse	O
BCa	O
.	O

Hereditary	B-Phenotype
hypotrichosis	I-Phenotype
simplex	E-Phenotype
(	O
HHS	S-Phenotype
)	O
is	O
a	O
form	O
of	O
nonsyndromic	B-Phenotype
inherited	I-Phenotype
hair	I-Phenotype
loss	E-Phenotype
disorders	O
without	O
characteristic	O
hair	O
shaft	O
changes	O
,	O
which	O
has	O
marked	O
genetic	O
and	O
clinical	O
heterogeneity	S-Phenotype
.	O

Moreover	O
,	O
the	O
analysis	O
of	O
human	O
prostate	B-Phenotype
cancer	E-Phenotype
and	O
prostate	O
control	O
specimens	O
confirmed	O
the	O
aberrant	O
expression	O
of	O
miR	O
-	O
124	O
-	O
3p	O
,	O
miR	O
-	O
129	O
-	O
5p	O
and	O
miR	O
-	O
378	O
in	O
primary	O
tumors	S-Phenotype
.	O

A	O
novel	O
15	O
-	O
gene	O
signature	O
identified	O
82.4	O
%	O
of	O
the	O
tumours	S-Phenotype
with	O
bone	O
metastasis	O
,	O
85.2	O
%	O
of	O
the	O
tumours	S-Phenotype
which	O
had	O
bone	O
metastasis	O
as	O
first	O
site	O
of	O
metastasis	O
and	O
100	O
%	O
of	O
the	O
ones	O
with	O
bone	O
metastasis	O
only	O
(	O
p	O
9.99e	O
-	O
09	O
)	O
,	O
in	O
the	O
training	O
set	O
.	O

Hence	O
,	O
we	O
focus	O
on	O
the	O
relationship	O
between	O
YAP	O
/	O
TAZ	O
and	O
serine	O
metabolism	O
to	O
control	O
methylation	O
of	O
DNA	O
or	O
histone	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
with	O
LKB1	O
deficiency	O
.	O

By	O
contrast	O
,	O
loss	O
of	O
Pjvk	O
in	O
adult	O
OHCs	O
causes	O
a	O
slowly	O
progressive	B-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
associated	O
with	O
OHC	O
degeneration	O
and	O
delayed	O
loss	O
of	O
inner	O
hair	O
cells	O
(	O
IHCs	O
)	O
,	O
indicating	O
a	O
primary	O
role	O
for	O
pejvakin	O
in	O
regulating	O
OHC	O
function	O
and	O
survival	O
.	O

Appraisal	O
of	O
the	O
present	O
case	O
against	O
previously	O
reported	O
patients	O
indicate	O
that	O
EXPH5	O
mutations	O
result	O
in	O
a	O
distinctive	O
skin	B-Phenotype
fragility	E-Phenotype
phenotype	O
,	O
with	O
minimal	O
blistering	O
compared	O
with	O
other	O
forms	O
of	O
basal	O
EBS	O

Here	O
we	O
perform	O
an	O
unbiased	O
siRNA	O
screen	O
and	O
identify	O
that	O
the	O
second	O
deubiquitinase	O
,	O
USP13	O
,	O
regulates	O
MCL1	O
stability	O
in	O
lung	B-Phenotype
and	I-Phenotype
ovarian	I-Phenotype
cancer	E-Phenotype
cells	O
.	O

The	O
2016	O
revised	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
classification	O
of	O
lymphoid	B-Phenotype
neoplasms	E-Phenotype
included	O
the	O
category	O
of	O
high	B-Phenotype
-	I-Phenotype
grade	I-Phenotype
B	I-Phenotype
cell	I-Phenotype
lymphomas	E-Phenotype
(	O
HGBLs	S-Phenotype
)	O
with	O
combined	O
MYC	O
and	O
BCL2	O
and	O
/	O
or	O
BCL6	O
rearrangements	O
(	O
double	O
-	O
hit	O
,	O
DH	O
)	O
.	O

Functional	O
studies	O
have	O
elucidated	O
the	O
role	O
of	O
the	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
pathway	O
in	O
breast	O
carcinogenesis	O
,	O
but	O
to	O
date	O
,	O
there	O
is	O
a	O
paucity	O
of	O
data	O
on	O
its	O
contribution	O
to	O
breast	B-Phenotype
cancer	E-Phenotype
risk	O
in	O
women	O
of	O
African	O
ancestry	O
.	O

We	O
evaluated	O
whether	O
methylation	O
of	O
tumor	S-Phenotype
-	O
suppressor	O
genes	O
(	O
TSGs	O
)	O
would	O
classify	O
non	O
-	O
muscle	O
-	O
invasive	O
(	O
NMI	O
)	O
bladder	B-Phenotype
cancer	E-Phenotype
subgroups	O
and	O
predict	O
outcome	O
.	O

We	O
identified	O
a	O
novel	O
locus	O
at	O
3p21.31	O
indexed	O
by	O
the	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
rs80059929	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
=	O
2.95	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
=	O
2.17	O
to	O
4.02	O
,	O
Pmeta	O
=	O
6.47	O
x	O
10	O
-	O
12	O
)	O
associated	O
with	O
MYCN	O
-	O
amplified	O
neuroblastoma	S-Phenotype
,	O
which	O
was	O
replicated	O
in	O
127	O
MYCN	O
-	O
amplified	O
cases	O
and	O
254	O
non	O
-	O
high	O
-	O
risk	O
controls	O
(	O
OR	O
=	O
2.30	O
,	O
95	O
%	O
CI	O
=	O
1.12	O
to	O
4.69	O
,	O
Preplication	O
=	O
.02	O
)	O
.	O

As	O
poor	O
differentiation	O
and	O
low	O
apoptosis	O
are	O
closely	O
associated	O
with	O
poor	O
survival	O
rates	O
and	O
a	O
poor	O
response	O
to	O
radio	O
/	O
chemotherapy	O
in	O
patients	O
with	O
cancer	S-Phenotype
,	O
the	O
prognostic	O
value	O
of	O
Dec1	O
expression	O
was	O
examined	O
in	O
the	O
present	O
study	O
and	O
its	O
correlation	O
with	O
response	O
to	O
temozolomide	O
(	O
TMZ	O
)	O
chemotherapy	O
was	O
analyzed	O
in	O
patients	O
with	O
glioma	S-Phenotype
.	O

Here	O
we	O
show	O
that	O
linc	O
-	O
NeD125	O
,	O
which	O
we	O
previously	O
characterized	O
as	O
a	O
neuronal	O
-	O
induced	O
lncRNA	O
,	O
is	O
significantly	O
overexpressed	O
in	O
Group	B-Phenotype
4	I-Phenotype
medulloblastomas	E-Phenotype
(	O
G4	B-Phenotype
MBs	E-Phenotype
)	O
,	O
the	O
largest	O
and	O
least	O
well	O
characterized	O
molecular	O
MB	O
subgroup	O
.	O

Here	O
we	O
identify	O
mutations	O
in	O
the	O
genes	O
encoding	O
PLK4	O
kinase	O
,	O
a	O
master	O
regulator	O
of	O
centriole	O
duplication	O
,	O
and	O
its	O
substrate	O
TUBGCP6	O
in	O
individuals	O
with	O
microcephalic	B-Phenotype
primordial	I-Phenotype
dwarfism	E-Phenotype
and	O
additional	O
congenital	O
anomalies	O
,	O
including	O
retinopathy	S-Phenotype
,	O
thereby	O
extending	O
the	O
human	O
phenotypic	O
spectrum	O
associated	O
with	O
centriole	O
dysfunction	O
.	O

Sturge	O
-	O
Weber	O
Syndrome	O
(	O
SWS	O
)	O
is	O
a	O
neurocutaneous	O
disease	O
with	O
clinical	O
manifestations	O
including	O
ocular	O
(	O
glaucoma	S-Phenotype
)	O
,	O
cutaneous	O
(	O
port	B-Phenotype
-	I-Phenotype
wine	I-Phenotype
birthmark	E-Phenotype
)	O
,	O
neurologic	O
(	O
seizures	S-Phenotype
)	O
,	O
and	O
vascular	O
problems	O
.	O

Hemangioblastomas	S-Phenotype
(	O
HBs	S-Phenotype
)	O
are	O
uncommon	O
tumors	S-Phenotype
characterized	O
by	O
the	O
presence	O
of	O
inactivating	O
alterations	O
in	O
the	O
von	O
Hippel	O
-	O
Lindau	O
(	O
VHL	O
)	O
gene	O
in	O
inherited	O
cases	O
and	O
by	O
infrequent	O
somatic	B-Phenotype
mutation	E-Phenotype
in	O
sporadic	S-Phenotype
entities	O
.	O

Luciferase	O
assays	O
did	O
not	O
identify	O
SNPs	O
that	O
affect	O
transactivation	O
of	O
ZNF365	O
,	O
but	O
identified	O
a	O
protective	O
haplotype	O
in	O
iCHAV2	O
,	O
associated	O
with	O
silencing	O
of	O
the	O
NRBF2	O
promoter	O
,	O
implicating	O
this	O
gene	O
in	O
the	O
etiology	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

Very	O
recently	O
,	O
PUS7	O
mutations	O
were	O
reported	O
to	O
cause	O
intellectual	B-Phenotype
disability	E-Phenotype
with	O
growth	B-Phenotype
retardation	E-Phenotype
.	O

Associations	O
with	O
TN	O
breast	B-Phenotype
cancer	E-Phenotype
were	O
confirmed	O
for	O
10	O
loci	O
(	O
LGR6	O
,	O
MDM4	O
,	O
CASP8	O
,	O
2q35	O
,	O
2p24.1	O
,	O
TERT	O
-	O
rs10069690	O
,	O
ESR1	O
,	O
TOX3	O
,	O
19p13.1	O
,	O
RALY	O
)	O
,	O
and	O
we	O
identified	O
associations	O
with	O
TN	O
breast	B-Phenotype
cancer	E-Phenotype
for	O
15	O
additional	O
breast	B-Phenotype
cancer	E-Phenotype
loci	O
(	O
P	O
AAAA	O
0.05	O
:	O
PEX14	O
,	O
2q24.1	O
,	O
2q31.1	O
,	O
ADAM29	O
,	O
EBF1	O
,	O
TCF7L2	O
,	O
11q13.1	O
,	O
11q24.3	O
,	O
12p13.1	O
,	O
PTHLH	O
,	O
NTN4	O
,	O
12q24	O
,	O
BRCA2	O
,	O
RAD51L1	O
-	O
rs2588809	O
,	O
MKL1	O
)	O
.	O

Since	O
the	O
distal	O
arthrogryposes	O
(	O
DAs	O
)	O
are	O
genetically	O
heterogeneous	S-Phenotype
,	O
an	O
unbiased	O
approach	O
to	O
mutation	O
identification	O
was	O
undertaken	O
through	O
whole	O
-	O
exome	O
next	O
-	O
generation	O
sequencing	O
of	O
DNA	O
from	O
a	O
single	O
DTD	O
-	O
affected	O
female	O
.	O

Here	O
,	O
we	O
show	O
that	O
deletion	O
of	O
Arl13b	O
reduced	O
Shh	O
signaling	O
levels	O
in	O
the	O
presence	O
of	O
oncogenic	O
SmoA1	O
,	O
suggesting	O
Arl13b	O
acts	O
downstream	O
of	O
known	O
tumor	S-Phenotype
resistance	O
mechanisms	O
.	O

FLVCR1	O
encodes	O
for	O
a	O
ubiquitous	O
heme	O
exporter	O
,	O
whose	O
recessive	O
mutations	O
cause	O
posterior	B-Phenotype
column	I-Phenotype
ataxia	E-Phenotype
with	O
retinitis	B-Phenotype
pigmentosa	E-Phenotype
(	O
PCARP	O
)	O
.	O

FINDINGS	O
We	O
observed	O
a	O
significantly	O
increased	O
trend	O
(	O
nptrend	O
=	O
0.0320	O
)	O
in	O
the	O
proportion	O
of	O
methylated	O
p16	O
ink4a	O
in	O
cervical	O
samples	O
during	O
cancer	S-Phenotype
development	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
anticancer	O
effect	S-Phenotype
of	O
ONO	O
-	O
7579	O
using	O
GBC	O
cells	O
with	O
or	O
without	O
KRAS	O
mutant	O
,	O
NOZ	O
,	O
TYGBK	O
-	O
1	O
.	O

Although	O
PABPN1	O
plays	O
a	O
critical	O
role	O
in	O
the	O
regulation	O
of	O
RNA	O
processing	O
,	O
mutation	O
of	O
the	O
gene	O
encoding	O
this	O
ubiquitously	O
expressed	O
RNA	O
binding	O
protein	O
causes	O
a	O
specific	O
form	O
of	O
muscular	B-Phenotype
dystrophy	E-Phenotype
termed	O
oculopharyngeal	B-Phenotype
muscular	I-Phenotype
dystrophy	E-Phenotype
(	O
OPMD	O
)	O
.	O

Furthermore	O
,	O
in	O
vitro	O
inhibition	O
of	O
cancer	S-Phenotype
-	O
derived	O
BMP4	O
noncanonical	O
signals	O
results	O
in	O
an	O
increase	O
of	O
chemosensitivity	O
in	O
a	O
colorectal	B-Phenotype
cancer	E-Phenotype
cell	O
line	O
.	O

In	O
this	O
report	O
,	O
we	O
found	O
that	O
both	O
EGFR	O
and	O
Ras	O
signaling	O
can	O
upregulate	O
RNA	O
helicase	O
DDX59	O
in	O
lung	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

A	O
previously	O
reported	O
CLCN2	O
gene	O
for	O
epilepsy	S-Phenotype
was	O
excluded	O
as	O
the	O
disease	O
-	O
causing	O
gene	O
in	O
the	O
family	O
by	O
mutational	O
analysis	O
of	O
all	O
exons	O
and	O
exon	O
-	O
intron	O
boundaries	O
of	O
CLCN2	O
and	O
by	O
haplotype	O
analysis	O
.	O

Multivariate	O
analysis	O
data	O
revealed	O
that	O
ERCC1	O
and	O
survivin	O
protein	O
expression	O
were	O
independent	O
predictors	O
of	O
overall	O
survival	O
of	O
ESCC	O
patients	O
after	O
chemotherapy	O
and	O
/	O
or	O
radiotherapy	O
(	O
P	O
AAAA	O
.05	O
)	O
.ERCC1	O
overexpression	O
is	O
an	O
important	O
phenotype	O
that	O
is	O
associated	O
with	O
ESCC	O
lymph	O
node	O
metastasis	O
and	O
advanced	O
tumor	S-Phenotype
clinical	O
stages	O
.	O

However	O
,	O
few	O
studies	O
are	O
available	O
on	O
the	O
expression	O
and	O
clinical	O
significance	O
of	O
Raf1	O
in	O
non‑small	B-Phenotype
cell	I-Phenotype
lung	I-Phenotype
cancer	E-Phenotype
(	O
NSCLC	S-Phenotype
)	O
.	O

EGFR	O
tyrosine	O
kinase	O
inhibitors	O
(	O
TKIs	O
)	O
have	O
been	O
used	O
in	O
patients	O
with	O
EGFR	O
-	O
mutant	O
as	O
an	O
effective	O
targeted	O
therapy	O
in	O
lung	B-Phenotype
adenocarcinoma	E-Phenotype
,	O
but	O
drug	B-Phenotype
resistance	E-Phenotype
and	O
tumor	S-Phenotype
recurrence	O
inevitably	O
occurs	O
.	O

Brown	O
-	O
Vialetto	O
-	O
Van	O
Laere	O
syndrome	O
represents	O
a	O
phenotypic	O
spectrum	O
of	O
motor	B-Phenotype
,	I-Phenotype
sensory	I-Phenotype
,	I-Phenotype
and	I-Phenotype
cranial	I-Phenotype
nerve	I-Phenotype
neuropathy	E-Phenotype
,	O
often	O
with	O
ataxia	S-Phenotype
,	O
optic	B-Phenotype
atrophy	E-Phenotype
and	O
respiratory	B-Phenotype
problems	E-Phenotype
leading	O
to	O
ventilator	O
-	O
dependence	O
.	O

We	O
present	O
the	O
new	O
observations	O
of	O
postoperative	O
microcystic	B-Phenotype
macular	I-Phenotype
edema	E-Phenotype
(	O
MME	S-Phenotype
)	O
as	O
a	O
mild	O
form	O
of	O
cystoid	O
macular	O
lesions	O
(	O
CMLs	O
)	O
after	O
standard	O
phacoemulsification.To	O
report	O
the	O
incidence	O
,	O
risk	O
factors	O
,	O
and	O
pathophysiology	O
of	O
MME	O
compared	O
to	O
conventional	O
concept	O
of	O
pseudophakic	B-Phenotype
cystoid	I-Phenotype
macular	I-Phenotype
edema	E-Phenotype
(	O
CME	S-Phenotype
)	O
,	O
we	O
retrospectively	O
reviewed	O
patients	O
*	O
records	O
.	O

Based	O
on	O
the	O
elastic	O
net	O
,	O
33	O
genes	O
out	O
of	O
1381	O
genes	O
related	O
to	O
bladder	B-Phenotype
cancer	E-Phenotype
were	O
selected	O
.	O

Here	O
,	O
we	O
describe	O
the	O
generation	O
of	O
transgenic	O
,	O
inducible	O
CRISPR	O
-	O
based	O
mouse	O
systems	O
to	O
engineer	O
and	O
study	O
recurrent	O
colon	B-Phenotype
cancer	E-Phenotype
-	O
associated	O
EIF3E	O
-	O
RSPO2	O
and	O
PTPRK	O
-	O
RSPO3	O
chromosome	O
rearrangements	O
in	O
vivo	O
.	O

Here	O
,	O
we	O
report	O
that	O
variants	O
in	O
TRAPPC12	O
result	O
in	O
progressive	B-Phenotype
childhood	I-Phenotype
encephalopathy	E-Phenotype
.	O

We	O
report	O
a	O
pair	O
of	O
siblings	O
carrying	O
a	O
homozygous	O
missense	O
mutation	O
p.P333L	O
in	O
EEF1A2	O
who	O
exhibited	O
global	B-Phenotype
developmental	I-Phenotype
delay	E-Phenotype
,	O
failure	B-Phenotype
to	I-Phenotype
thrive	E-Phenotype
,	O
dilated	B-Phenotype
cardiomyopathy	E-Phenotype
and	O
epilepsy	S-Phenotype
,	O
ultimately	O
leading	O
to	O
death	B-Phenotype
in	I-Phenotype
early	I-Phenotype
childhood	E-Phenotype
.	O

We	O
report	O
associations	O
for	O
6	O
out	O
of	O
23	O
SNPs	O
and	O
for	O
the	O
GRS	O
,	O
which	O
confer	O
obesity	S-Phenotype
risk	O
,	O
a	O
novel	O
finding	O
for	O
Mexican	O
-	O
Mestizo	O
physically	O
active	O
population	O
.	O

OTUD6B	O
encodes	O
a	O
member	O
of	O
the	O
ovarian	B-Phenotype
tumor	E-Phenotype
domain	O
(	O
OTU	O
)	O
-	O
containing	O
subfamily	O
of	O
deubiquitinating	O
enzymes	O
.	O

It	O
has	O
been	O
reported	O
that	O
functionally	O
distinct	O
cancer	S-Phenotype
stem	O
cells	O
(	O
CSCs	O
)	O
exist	O
in	O
human	O
bladder	B-Phenotype
cancer	E-Phenotype
(	O
BCa	S-Phenotype
)	O
.	O

Although	O
a	O
digenic	B-Phenotype
inheritance	E-Phenotype
pattern	O
of	O
hearing	B-Phenotype
impairment	E-Phenotype
has	O
been	O
reported	O
for	O
heterozygous	O
missense	O
variants	O
of	O
ATP2B2	O
and	O
CDH23	O
,	O
our	O
findings	O
indicate	O
a	O
monogenic	O
cause	O
of	O
hearing	O
impairment	O
in	O
cases	O
with	O
loss	O
-	O
of	O
-	O
function	O
variants	O
of	O
ATP2B2	O

While	O
polyglutamine	O
ataxias	S-Phenotype
,	O
linked	O
to	O
CAG	O
repeat	O
expansions	O
in	O
genes	O
such	O
as	O
ATXN1	O
,	O
ATXN2	O
,	O
ATXN3	O
,	O
ATXN7	O
,	O
CACNA1A	O
and	O
TBP	O
,	O
have	O
been	O
extensively	O
characterized	O
in	O
large	O
cohorts	O
,	O
there	O
is	O
a	O
need	O
for	O
comprehensive	O
assessment	O
of	O
frequency	O
and	O
phenotype	O
of	O
more	O
'conventional	O
'	O
ataxias	S-Phenotype
.	O

We	O
constructed	O
an	O
EYS	O
-	O
knockout	O
zebrafish	O
-	O
line	O
by	O
TALEN	O
technology	O
which	O
showed	O
visual	B-Phenotype
impairment	E-Phenotype
at	O
an	O
early	O
age	O
,	O
while	O
the	O
histological	O
and	O
immunofluorescence	O
assays	O
indicated	O
the	O
presence	O
of	O
progressive	B-Phenotype
retinal	I-Phenotype
degeneration	E-Phenotype
with	O
a	O
cone	O
predominately	O
affected	O
pattern	O
.	O

MYH3	O
plays	O
a	O
pivotal	O
role	O
in	O
fetal	O
muscle	O
development	O
and	O
mutations	O
in	O
this	O
gene	O
are	O
associated	O
with	O
Freeman	O
-	O
Sheldon	O
syndrome	O
,	O
distal	B-Phenotype
arthrogryposis	I-Phenotype
8	E-Phenotype
(	O
DA8	S-Phenotype
)	O
,	O
and	O
autosomal	B-Phenotype
dominant	I-Phenotype
spondylocarpotarsal	I-Phenotype
synostosis	E-Phenotype
.	O

The	O
aminoacyl	O
tRNA	O
synthetase	O
complex	O
-	O
interacting	O
multifunctional	O
protein	O
2	O
(	O
AIMP2	O
)	O
splice	O
variant	O
designated	O
DX2	O
is	O
induced	O
by	O
cigarette	O
smoke	O
carcinogens	O
and	O
is	O
often	O
detected	O
in	O
human	O
lung	B-Phenotype
cancer	E-Phenotype
specimens	O
.	O

Taken	O
altogether	O
,	O
our	O
study	O
demonstrates	O
a	O
role	O
of	O
miR	O
-	O
155	O
in	O
thiamine	O
homeostasis	O
and	O
suggests	O
a	O
function	O
of	O
this	O
oncogenic	O
miRNA	O
on	O
breast	B-Phenotype
cancer	E-Phenotype
metabolism	O
.	O

Here	O
,	O
we	O
hypothesize	O
that	O
repression	O
of	O
transcriptional	O
activity	O
of	O
forkhead	O
box	O
O1	O
(	O
FoxO1	O
)	O
via	O
histone	O
deacetylase	O
inhibitors	O
(	O
HDACi	O
)	O
ameliorates	O
hyperglycemia	S-Phenotype
in	O
T2DM	O
rats	O

In	O
the	O
present	O
study	O
,	O
we	O
first	O
analyzed	O
the	O
association	O
and	O
clinical	O
significance	O
of	O
p53	O
and	O
LDHA	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
expressing	O
wild	O
-	O
type	O
p53	O
(	O
wt	O
-	O
p53	O
)	O
and	O
found	O
that	O
LDHA	O
mRNA	O
levels	O
are	O
negatively	O
correlated	O
with	O
wt	O
-	O
p53	O
but	O
not	O
with	O
mutation	O
p53	O
mRNA	O
levels	O
,	O
and	O
low	O
p53	O
and	O
high	O
LDHA	O
expression	O
are	O
significantly	O
associated	O
with	O
poor	O
overall	O
survival	O
rates	O
.	O

We	O
performed	O
exome	O
sequencing	O
in	O
a	O
large	O
family	O
affected	O
by	O
an	O
autosomal	O
-	O
dominant	O
form	O
of	O
mild	O
syndromic	O
ID	S-Phenotype
with	O
ptosis	S-Phenotype
,	O
growth	B-Phenotype
retardation	E-Phenotype
,	O
and	O
hypotonia	S-Phenotype
,	O
and	O
we	O
identified	O
an	O
inherited	O
2	O
bp	O
deletion	O
causing	O
a	O
frameshift	O
in	O
BRPF1	O
(	O
c.1052_1053del	O
)	O
in	O
five	O
affected	O
family	O
members	O
.	O

By	O
contrast	O
,	O
loss	O
of	O
Pjvk	O
in	O
adult	O
OHCs	O
causes	O
a	O
slowly	O
progressive	B-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
associated	O
with	O
OHC	O
degeneration	O
and	O
delayed	O
loss	O
of	O
inner	O
hair	O
cells	O
(	O
IHCs	O
)	O
,	O
indicating	O
a	O
primary	O
role	O
for	O
pejvakin	O
in	O
regulating	O
OHC	O
function	O
and	O
survival	O
.	O

These	O
findings	O
define	O
adipocyte	O
OGT	O
as	O
a	O
fat	O
sensor	O
that	O
regulates	O
peripheral	O
lipid	O
signals	O
,	O
and	O
uncover	O
an	O
unexpected	O
adipose	O
-	O
to	O
-	O
brain	O
axis	O
to	O
induce	O
hyperphagia	S-Phenotype
and	O
obesity	S-Phenotype

Of	O
35,242	O
men	O
who	O
completed	O
the	O
baseline	O
dietary	O
and	O
supplemental	O
questionnaire	O
,	O
832	O
men	O
developed	O
invasive	O
prostate	B-Phenotype
cancers	E-Phenotype
between	O
October	O
2000	O
and	O
December	O
2004	O
.	O

We	O
describe	O
a	O
7	O
-	O
year	O
-	O
old	O
with	O
a	O
novel	O
de	O
novo	O
missense	O
mutation	O
in	O
PRICKLE1	O
associated	O
with	O
epilepsy	S-Phenotype
,	O
autism	B-Phenotype
spectrum	I-Phenotype
disorder	E-Phenotype
and	O
global	B-Phenotype
developmental	I-Phenotype
delay	E-Phenotype

When	O
her	O
brother	O
was	O
found	O
to	O
harbor	O
the	O
same	O
MEN1	O
mutation	O
as	O
our	O
proband	O
and	O
,	O
around	O
the	O
same	O
time	O
,	O
their	O
father	O
was	O
diagnosed	O
with	O
a	O
neuroendocrine	B-Phenotype
carcinoma	E-Phenotype
,	O
this	O
tumor	S-Phenotype
was	O
investigated	O
for	O
the	O
MEN1	O
mutation	O
as	O
well	O
.	O

But	O
the	O
role	O
of	O
MFAP5	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
remains	O
unclear	O
.	O

Loss	O
of	O
ZBTB18	O
contributes	O
to	O
the	O
aggressive	O
phenotype	O
of	O
glioblastoma	S-Phenotype
through	O
regulation	O
of	O
poor	O
prognosis	O
-	O
associated	O
signatures	O
.	O

miR	O
-	O
26a	O
,	O
miR	O
-	O
548l	O
and	O
miR	O
-	O
34a	O
,	O
acting	O
as	O
tumor	S-Phenotype
suppressors	O
,	O
may	O
exert	O
their	O
effects	O
by	O
regulating	O
ST3GAL5	O

In	O
the	O
eyes	O
of	O
Rdh8	O
-	O
/	O
-	O
Abca4	O
-	O
/	O
-	O
mice	O
,	O
a	O
mouse	O
model	O
with	O
defects	O
in	O
retinoid	O
cycle	O
that	O
displays	O
some	O
symbolic	O
characteristics	O
of	O
age	B-Phenotype
-	I-Phenotype
related	I-Phenotype
macular	I-Phenotype
degeneration	E-Phenotype
(	O
AMD	S-Phenotype
)	O
,	O
the	O
level	O
of	O
atRAL	O
-	O
dimer	O
was	O
increased	O
compared	O
to	O
wild	O
-	O
type	O
mice	O
,	O
and	O
was	O
even	O
much	O
greater	O
than	O
that	O
of	O
A2E	O
AAAAA	O
isomers	O
.	O

High	O
expression	O
of	O
GFAT1	O
was	O
positively	O
associated	O
with	O
lymph	O
node	O
metastasis	O
,	O
pTNM	O
stage	O
and	O
shorter	O
overall	O
survival	O
(	O
OS	O
)	O
in	O
pancreatic	B-Phenotype
cancer	E-Phenotype
patients	O
.	O

However	O
,	O
the	O
clinicopathological	O
implication	O
of	O
miR	O
-	O
23b	O
-	O
3p	O
in	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
remains	O
unclear	O
.	O

In	O
addition	O
,	O
we	O
found	O
using	O
Bayesian	O
network	O
-	O
based	O
machine	O
learning	O
that	O
30	O
NRF1	O
motif	O
-	O
enriched	O
genes	O
including	O
growth	O
factor	O
receptors	O
-	O
FGFR1	O
,	O
IGF1R	O
;	O
E2Fs	O
transcription	O
factor	O
family	O
-	O
E2F1	O
,	O
E2F3	O
;	O
MAPK	O
pathway	O
-	O
SHC2	O
,	O
GRB2	O
,	O
MAPK1	O
;	O
PI3K	O
-	O
AKT	O
-	O
mTOR	O
signaling	O
pathway	O
-	O
PIK3CD	O
,	O
PIK3R1	O
,	O
PIK3R3	O
,	O
RPS6KB2	O
;	O
WNT	O
signaling	O
pathway	O
-	O
WNT7B	O
,	O
DLV1	O
,	O
DLV2	O
,	O
GSK3B	O
,	O
NRF1	O
,	O
and	O
DDB2	O
,	O
known	O
for	O
its	O
role	O
in	O
DNA	O
repair	O
and	O
involvement	O
in	O
early	O
events	O
associated	O
with	O
metastatic	O
progression	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
,	O
were	O
associated	O
with	O
HER2	O
-	O
amplified	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

Herein	O
,	O
we	O
report	O
biallelic	O
pathogenic	O
variants	O
in	O
OTUD6B	O
in	O
12	O
individuals	O
from	O
6	O
independent	O
families	O
with	O
an	O
intellectual	B-Phenotype
disability	E-Phenotype
syndrome	O
associated	O
with	O
seizures	S-Phenotype
and	O
dysmorphic	O
features	O
.	O

KCNB1	O
mutations	O
are	O
known	O
to	O
cause	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
infantile	I-Phenotype
epilepsy	E-Phenotype
.	O

We	O
show	O
that	O
morpholino	O
-	O
mediated	O
inpp5k	O
loss	O
of	O
function	O
in	O
the	O
zebrafish	O
results	O
in	O
shortened	B-Phenotype
body	I-Phenotype
axis	E-Phenotype
,	O
microphthalmia	S-Phenotype
with	O
disorganized	B-Phenotype
lens	E-Phenotype
,	O
microcephaly	S-Phenotype
,	O
reduced	B-Phenotype
touch	I-Phenotype
-	I-Phenotype
evoked	I-Phenotype
motility	E-Phenotype
,	O
and	O
highly	B-Phenotype
disorganized	I-Phenotype
myofibers	E-Phenotype
.	O

Knockdown	O
of	O
RIPK4	O
reduced	O
cell	O
migration	O
and	O
invasion	O
via	O
inhibition	O
of	O
Vimentin	O
,	O
MMP2	O
and	O
Fibronectin	O
expression	O
in	O
cervical	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Abnormalities	O
in	O
these	O
pathways	O
cause	O
autosomal	B-Phenotype
dominant	I-Phenotype
polycystic	I-Phenotype
kidney	E-Phenotype
disease	O
(	O
ADPKD	S-Phenotype
)	O
and	O
naevoid	B-Phenotype
basal	I-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
syndrome	O
(	O
NBCCS	S-Phenotype
)	O
respectively	O
.	O

Here	O
,	O
we	O
have	O
described	O
a	O
homozygous	O
missense	O
variant	O
(	O
c.602CAAAAT	O
,	O
p.S201F	O
)	O
in	O
POPDC1	O
,	O
identified	O
by	O
whole	O
-	O
exome	O
sequencing	O
,	O
in	O
a	O
family	O
of	O
4	O
with	O
cardiac	B-Phenotype
arrhythmia	E-Phenotype
and	O
limb	B-Phenotype
-	I-Phenotype
girdle	I-Phenotype
muscular	I-Phenotype
dystrophy	E-Phenotype
(	O
LGMD	S-Phenotype
)	O
.	O

Conclusions	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
reported	O
family	O
with	O
combined	O
germline	O
and	O
somatic	B-Phenotype
mosaicism	E-Phenotype
for	O
MEN1	O
.	O

From	O
a	O
GeneMatcher	O
-	O
enabled	O
international	O
collaboration	O
,	O
we	O
identified	O
ten	O
individuals	O
affected	O
by	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
speech	B-Phenotype
delay	E-Phenotype
,	O
ataxia	S-Phenotype
,	O
and	O
facial	B-Phenotype
dysmorphism	E-Phenotype
and	O
carrying	O
a	O
deleterious	O
EBF3	O
variant	O
detected	O
by	O
whole	O
-	O
exome	O
sequencing	O
.	O

Eight	O
different	O
SRD5A2	O
mutations	O
were	O
detected	O
in	O
15	O
patients	O
with	O
posterior	O
hypospadias	S-Phenotype
(	O
60	O
%	O
,	O
15	O
/	O
25	O
)	O
,	O
including	O
six	O
previously	O
described	O
mutations	O
(	O
p.Q6X	O
,	O
Q71X	O
,	O
p.L20P	O
,	O
p.G203S	O
,	O
p.R227Q	O
,	O
and	O
p.R246Q	O
)	O
and	O
two	O
novel	O
mutations	O
(	O
p.G196R	O
and	O
p.L73Pfs∗17	O
)	O
.	O

Taken	O
together	O
,	O
both	O
strands	O
of	O
miR	O
-	O
145	O
,	O
miR	O
-	O
145	O
-	O
5p	O
and	O
miR	O
-	O
145	O
-	O
3p	O
are	O
functional	O
and	O
play	O
pivotal	O
roles	O
as	O
antitumor	O
miRNAs	S-Phenotype
in	O
lung	O
SCC	O

While	O
overexpression	O
of	O
TASK	O
-	O
3	O
is	O
frequently	O
observed	O
in	O
cancers	S-Phenotype
,	O
the	O
understanding	O
of	O
its	O
role	O
and	O
regulation	O
during	O
tumorigenesis	O
remains	O
incomplete	O
.	O

In	O
addition	O
,	O
we	O
present	O
new	O
data	O
that	O
indicates	O
ASB10	O
expression	O
is	O
up	O
-	O
regulated	O
by	O
the	O
inflammatory	O
cytokines	O
tumor	S-Phenotype
necrosis	O
factor	O
-	O
a	O
and	O
interleukin	O
-	O
1a	O
.	O

High	O
mobility	O
group	O
box	O
3	O
(	O
HMGB3	O
)	O
,	O
a	O
member	O
of	O
the	O
high	O
-	O
mobility	O
group	O
box	O
(	O
HMGB	O
)	O
family	O
,	O
was	O
reported	O
to	O
be	O
over	O
-	O
expressed	O
in	O
gastric	B-Phenotype
carcinoma	E-Phenotype
and	O
bladder	B-Phenotype
cancer	E-Phenotype
.	O

The	O
PCH1sub	O
-	O
types	O
with	O
early	O
death	O
(	O
between	O
ages	O
1	O
day	O
and	O
17	O
months	O
)	O
,	O
seen	O
in	O
patients	O
with	O
p.G31A	O
/	O
EXOSC3	O
or	O
SLC25A46	O
mutations	O
have	O
a	O
SMA	O
type	O
1	O
-	O
like	O
clinical	O
presentation	O
but	O
with	O
global	B-Phenotype
developmental	I-Phenotype
delay	E-Phenotype
,	O
visual	B-Phenotype
and	I-Phenotype
hearing	I-Phenotype
impairment	E-Phenotype
,	O
with	O
or	O
without	O
microcephaly	S-Phenotype
,	O
nystagmus	S-Phenotype
and	O
optic	B-Phenotype
atrophy	E-Phenotype
.	O

Here	O
we	O
have	O
investigated	O
the	O
effects	O
of	O
depletion	O
of	O
TNFAIP8	O
on	O
the	O
mRNA	O
,	O
microRNA	O
and	O
protein	O
expression	O
profiles	O
in	O
prostate	B-Phenotype
and	I-Phenotype
breast	I-Phenotype
cancers	E-Phenotype
and	O
melanoma	S-Phenotype
.	O

PML	O
is	O
frequently	O
downregulated	O
in	O
many	O
cancer	S-Phenotype
types	O
,	O
including	O
lung	B-Phenotype
cancer	E-Phenotype
.	O

Using	O
preclinical	O
models	O
,	O
we	O
have	O
recently	O
found	O
that	O
ELK1	O
,	O
a	O
transcriptional	O
factor	O
that	O
activates	O
downstream	O
targets	O
,	O
including	O
lic	O
-	O
fos	O
/	O
i	O
proto	O
-	O
oncogene	O
,	O
induces	O
bladder	B-Phenotype
cancer	E-Phenotype
outgrowth	O
.	O

In	O
light	O
of	O
more	O
and	O
more	O
evidence	O
point	O
to	O
the	O
importance	O
of	O
Kindlin	O
family	O
members	O
in	O
normal	O
development	O
and	O
human	O
diseases	O
especially	O
in	O
cancers	S-Phenotype
,	O
we	O
aim	O
to	O
portrait	O
the	O
profile	O
of	O
Kindlins	O
in	O
the	O
regulation	O
of	O
embryonic	O
development	O
and	O
cancer	S-Phenotype
progression	O
.	O

4	O
)	O
Multiple	B-Phenotype
endocrine	I-Phenotype
neoplasia	I-Phenotype
type	I-Phenotype
2A	E-Phenotype
from	O
RET	O
activating	O
mutation	O
rarely	O
presents	O
as	O
familial	B-Phenotype
hyperparathyroidism	E-Phenotype
,	O
because	O
medullary	B-Phenotype
thyroid	I-Phenotype
cancer	E-Phenotype
and	O
pheochromocytoma	S-Phenotype
are	O
more	O
prominent	O
.	O

A	O
third	O
proband	O
was	O
doubly	O
heterozygous	O
for	O
inherited	O
rare	O
variants	O
in	O
additional	O
components	O
of	O
complex	O
I	O
,	O
NDUFAF2	O
and	O
NDUFB9	O
,	O
confirming	O
that	O
Histiocytoid	O
CM	O
is	O
genetically	O
heterogeneous	S-Phenotype
.	O

Expression	O
of	O
MET	O
-	O
signaling	O
genes	O
in	O
human	O
lymphoblastoid	O
cells	O
of	O
individuals	O
homozygous	O
for	O
p.Gly116Glu	O
GAB1	O
revealed	O
dysregulation	O
of	O
HGF	O
,	O
MET	O
,	O
SHP2	O
,	O
and	O
SPRY2	O
,	O
all	O
of	O
which	O
have	O
reported	O
variants	O
associated	O
with	O
deafness	S-Phenotype
.	O

Aspm	O
knockout	O
ferrets	O
exhibit	O
severe	O
microcephaly	S-Phenotype
(	O
25	O
-	O
40	O
%	O
decreases	O
in	O
brain	O
weight	O
)	O
,	O
reflecting	O
reduced	O
cortical	O
surface	O
area	O
without	O
significant	O
change	O
in	O
cortical	O
thickness	O
,	O
as	O
has	O
been	O
found	O
in	O
human	O
patientssup3,4	O
/	O
sup	O
,	O
suggesting	O
that	O
loss	O
of	O
'cortical	O
units	O
'	O
has	O
occurred	O
.	O

Loss	O
of	O
function	O
mutations	O
in	O
human	O
Usb1	O
cause	O
the	O
rare	O
disorder	O
poikiloderma	S-Phenotype
with	O
neutropenia	S-Phenotype
(	O
PN	O
)	O
,	O
and	O
result	O
in	O
U6	O
snRNAs	O
with	O
elongated	O
3	O
*	O
ends	O
that	O
are	O
aberrantly	O
adenylated	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
significance	O
of	O
CSTA	O
expression	O
in	O
ESCC.The	O
mRNA	O
expression	O
of	O
CSTA	O
was	O
evaluated	O
by	O
qRT	O
-	O
PCR	O
using	O
28	O
paired	O
frozen	O
samples	O
of	O
tumor	S-Phenotype
and	O
nontumor	O
mucosae	O
.	O

No	O
clinical	O
replication	O
cohort	O
is	O
available	O
,	O
so	O
we	O
validated	O
the	O
role	O
of	O
one	O
of	O
these	O
targets	O
,	O
AKT3	O
,	O
in	O
a	O
pneumococcal	B-Phenotype
meningitis	E-Phenotype
mouse	O
model	O
.	O

Here	O
,	O
we	O
assessed	O
whether	O
disrupting	O
pyruvate	O
kinase	O
-	O
M	O
(	O
Pkm	O
)	O
,	O
an	O
enzyme	O
that	O
acts	O
in	O
the	O
terminal	O
steps	O
of	O
glycolysis	O
,	O
would	O
alter	O
CGNP	O
metabolism	O
,	O
proliferation	O
,	O
and	O
tumorigenesis	S-Phenotype
.	O

Molecular	O
mechanisms	O
of	O
SWS	O
pathogenesis	O
are	O
initiated	O
by	O
the	O
somatic	B-Phenotype
mutation	E-Phenotype
in	O
GNAQ	O
.	O

Analysis	O
of	O
human	O
primary	O
CRC	O
tumor	S-Phenotype
patient	O
databases	O
showed	O
a	O
positive	O
correlation	O
between	O
KCNQ1	O
:	O
KCNE3	O
channel	O
complex	O
expression	O
and	O
disease	O
-	O
free	O
survival	O
.	O

We	O
screened	O
the	O
nucleotide	O
degrading	O
enzyme	O
gene	O
expression	O
in	O
RNAseq	O
data	O
of	O
14	O
cancer	S-Phenotype
types	O
derived	O
from	O
The	O
Cancer	S-Phenotype
Genome	O
Atlas	O
(	O
TCGA	O
)	O
and	O
found	O
that	O
RNASEH2A	O
overexpression	O
was	O
associated	O
with	O
poor	O
patient	O
survival	O
only	O
in	O
renal	B-Phenotype
cell	I-Phenotype
carcinomas	E-Phenotype
(	O
RCCs	S-Phenotype
)	O
.	O

FRG1	O
regulates	O
various	O
muscle	O
-	O
related	O
functions	O
,	O
but	O
studies	O
have	O
proposed	O
its	O
role	O
in	O
development	O
and	O
angiogenesis	O
also	O
,	O
where	O
it	O
is	O
involved	O
with	O
tumor	S-Phenotype
-	O
associated	O
molecules	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
anticancer	O
activity	S-Phenotype
of	O
CP	O
-	O
673451	O
,	O
a	O
potent	O
and	O
selective	O
inhibitor	O
of	O
PDGFRb	O
,	O
on	O
NSCLC	O
cell	O
lines	O
(	O
A549	O
and	O
H358	O
)	O
and	O
the	O
potential	O
mechanism	O
.	O

These	O
collective	O
data	O
indicated	O
that	O
IRAK1	O
overexpression	O
promotes	O
EC	O
tumorigenesis	S-Phenotype
by	O
activating	O
mitotic	O
cell	O
cycle	O
and	O
cell	O
division	O
pathways	O
,	O
and	O
IRAK1	O
may	O
serve	O
as	O
a	O
promising	O
therapeutic	O
strategy	O
for	O
EC	O

To	O
investigate	O
the	O
mechanism	O
by	O
which	O
the	O
α	O
-	O
crystallin	O
mutations	O
Cryaa	O
-	O
R49C	O
and	O
Cryab	O
-	O
R120G	O
lead	O
to	O
cataract	S-Phenotype
formation	O
,	O
we	O
determined	O
whether	O
these	O
mutations	O
cause	O
an	O
altered	O
expression	O
of	O
specific	O
transcripts	O
in	O
the	O
lens	O
at	O
an	O
early	O
postnatal	O
age	O
by	O
RNA	O
-	O
seq	O
analysis	O
.	O

In	O
vitro	O
and	O
in	O
vivo	O
studies	O
showed	O
that	O
suppression	O
of	O
TMEM98	O
in	O
chemoresistant	B-Phenotype
hepatocellular	I-Phenotype
carcinoma	E-Phenotype
cells	O
restored	O
their	O
chemosensitivity	O
,	O
while	O
forced	O
overexpression	O
of	O
TMEM98	O
enhanced	O
their	O
chemoresistance	O
.	O

Historically	O
classified	O
as	O
a	O
subtype	O
of	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
,	O
FLC	O
has	O
a	O
unique	O
clinical	O
,	O
histological	O
,	O
and	O
molecular	O
presentation	O
.	O

This	O
report	O
provides	O
evidence	O
that	O
bi	O
-	O
allelic	O
null	O
PAX1	O
mutations	O
may	O
lead	O
to	O
a	O
multi	O
-	O
system	O
autosomal	B-Phenotype
recessive	E-Phenotype
disorders	O
,	O
where	O
SCID	O
might	O
represent	O
the	O
main	O
feature	O

Sherlock	O
integrative	O
analysis	O
shows	O
that	O
ALMS1	O
,	O
GLT8D1	O
,	O
and	O
CSNK2B	O
are	O
schizophrenia	S-Phenotype
risk	O
genes	O
,	O
which	O
are	O
validated	O
using	O
independent	O
brain	O
expression	O
quantitative	O
trait	O
loci	O
(	O
eQTL	O
)	O
data	O
and	O
integrative	O
analysis	O
method	O
(	O
SMR	O
)	O
.	O

We	O
further	O
identified	O
a	O
reciprocal	O
connection	O
of	O
HKDC1	O
to	O
the	O
clock	O
in	O
the	O
primary	O
tumor	S-Phenotype
,	O
which	O
is	O
lost	O
in	O
the	O
metastatic	O
cells	O
.	O

Breast	O
tissue	O
and	O
blood	O
from	O
patients	O
with	O
invasive	O
breast	B-Phenotype
cancer	E-Phenotype
(	O
n	O
=	O
38	O
)	O
and	O
benign	O
breast	O
disease	O
(	O
n	O
=	O
30	O
)	O
were	O
compared	O
with	O
those	O
from	O
healthy	O
individuals	O
(	O
n	O
=	O
36	O
)	O
,	O
matched	O
with	O
the	O
cancer	S-Phenotype
patients	O
by	O
age	O
at	O
diagnosis	O
,	O
ethnicity	O
,	O
body	O
mass	O
index	O
,	O
menopausal	O
status	O
and	O
familial	O
history	O
of	O
cancer	S-Phenotype
.	O

Developmental	O
exposure	O
to	O
endocrine	O
-	O
disrupting	O
chemicals	O
(	O
EDCs	O
)	O
,	O
17b	O
-	O
estradiol	O
-	O
3	O
-	O
benzoate	O
(	O
EB	O
)	O
and	O
bisphenol	O
A	O
(	O
BPA	O
)	O
,	O
increases	O
susceptibility	O
to	O
prostate	B-Phenotype
cancer	E-Phenotype
(	O
PCa	S-Phenotype
)	O
in	O
rodent	O
models	O
.	O

To	O
investigate	O
the	O
mechanism	O
by	O
which	O
the	O
a	O
-	O
crystallin	O
mutations	O
Cryaa	O
-	O
R49C	O
and	O
Cryab	O
-	O
R120G	O
lead	O
to	O
cataract	S-Phenotype
formation	O
,	O
we	O
determined	O
whether	O
these	O
mutations	O
cause	O
an	O
altered	O
expression	O
of	O
specific	O
transcripts	O
in	O
the	O
lens	O
at	O
an	O
early	O
postnatal	O
age	O
by	O
RNA	O
-	O
seq	O
analysis	O
.	O

Early	O
postnatal	O
overnutrition	O
in	O
humans	O
is	O
associated	O
with	O
long	O
-	O
term	O
negative	O
outcomes	O
including	O
obesity	S-Phenotype
,	O
increased	O
risk	O
of	O
type	B-Phenotype
-	I-Phenotype
II	I-Phenotype
diabetes	E-Phenotype
,	O
and	O
cardiovascular	B-Phenotype
disease	E-Phenotype
.	O

This	O
work	O
provides	O
novel	O
evidence	O
regarding	O
the	O
complex	O
interplay	O
between	O
the	O
circadian	O
clock	O
and	O
metabolic	O
alterations	O
in	O
carcinogenesis	O
and	O
identifies	O
new	O
connections	O
between	O
both	O
systems	O
with	O
pivotal	O
roles	O
in	O
cancer	S-Phenotype
progression	O
and	O
response	O
to	O
therapy	O

Inhibition	O
of	O
CTRP5	O
action	O
may	O
result	O
in	O
the	O
alleviation	O
of	O
insulin	B-Phenotype
resistance	E-Phenotype
associated	O
with	O
obesity	S-Phenotype
and	O
diabetes	O

We	O
show	O
that	O
maternal	O
COL24A1	O
variants	O
have	O
a	O
significant	O
genome	O
-	O
wide	O
interaction	O
with	O
maternal	B-Phenotype
pre	I-Phenotype
-	I-Phenotype
pregnancy	I-Phenotype
overweight	E-Phenotype
/	O
obesity	S-Phenotype
on	O
PTB	O
risk	O
,	O
with	O
rs11161721	O
(	O
PsubG	O
×	O
E	O
/	O
sub=1.8	O
×	O
10sup	O
-	O
8	O
/	O
sup	O
;	O
empirical	O
PsubG	O
×	O
E	O
/	O
sub=1.2	O
×	O
10sup	O
-	O
8	O
/	O
sup	O
)	O
as	O
the	O
top	O
hit	O
.	O

In	O
addition	O
,	O
immunofluorescence	O
analysis	O
showed	O
increased	O
expression	O
of	O
active	O
cofilin	O
,	O
LIMK1	O
,	O
LIMK2	O
,	O
and	O
SSH1	O
in	O
HT29	O
colon	B-Phenotype
cancer	E-Phenotype
cells	O
resistant	O
to	O
5	O
-	O
fluorouracil	O
compared	O
to	O
parental	O
HT29	O
cells	O
.	O

Mutations	O
in	O
CAV3	O
lead	O
to	O
various	O
neuromuscular	O
phenotypes	O
with	O
partial	O
overlap	O
,	O
including	O
limb	B-Phenotype
girdle	I-Phenotype
muscular	I-Phenotype
dystrophy	I-Phenotype
type	I-Phenotype
1C	E-Phenotype
(	O
LGMD1C	S-Phenotype
)	O
,	O
rippling	B-Phenotype
muscle	I-Phenotype
disease	E-Phenotype
,	O
distal	B-Phenotype
myopathy	E-Phenotype
and	O
isolated	B-Phenotype
hyperCKemia	E-Phenotype
.	O

Non	O
-	O
alcoholic	O
steatohepatitis	O
(	O
NASH	O
)	O
is	O
commonly	O
associated	O
with	O
obesity	S-Phenotype
,	O
type	B-Phenotype
2	I-Phenotype
diabetes	E-Phenotype
,	O
and	O
/	O
or	O
hypertriglyceridemia	S-Phenotype
,	O
while	O
alcoholic	B-Phenotype
steatohepatitis	E-Phenotype
(	O
ASH	S-Phenotype
)	O
is	O
associated	O
with	O
alcohol	O
abuse	O
.	O

In	O
this	O
work	O
,	O
we	O
functionally	O
characterize	O
two	O
breast	B-Phenotype
cancer	E-Phenotype
associated	O
genes	O
,	O
the	O
proteasome	O
26S	O
subunit	O
ATPase	O
3	O
interacting	O
protein	O
(	O
PSMC3IP	O
)	O
and	O
the	O
epithelial	O
-	O
stromal	O
interaction	O
1	O
(	O
EPSTI1	O
)	O
,	O
to	O
explore	O
their	O
potential	O
apoptotic	O
role	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

Asthma	S-Phenotype
is	O
characterised	O
by	O
heterogeneous	S-Phenotype
clinical	O
phenotypes	O
.	O

We	O
have	O
previously	O
identified	O
a	O
role	O
for	O
the	O
secreted	O
serine	O
protease	O
PRSS56	O
in	O
ocular	O
size	O
determination	O
and	O
PRSS56	O
variants	O
have	O
been	O
implicated	O
in	O
the	O
etiology	O
of	O
both	O
hyperopia	S-Phenotype
and	O
myopia	S-Phenotype
,	O
highlighting	O
its	O
importance	O
in	O
refractive	O
development	O
.	O

Due	O
to	O
the	O
rarity	O
and	O
the	O
fact	O
that	O
symptoms	O
of	O
HAE	O
imitate	O
other	O
forms	O
of	O
angioedema	S-Phenotype
and	O
other	O
conditions	O
,	O
HAE	O
may	O
be	O
misdiagnosed	O
,	O
especially	O
in	O
emergency	O
settings	O
.	O

In	O
conclusion	O
,	O
heightened	O
TRIP13	O
expression	O
appears	O
to	O
promote	O
lung	B-Phenotype
adenocarcinoma	I-Phenotype
tumor	E-Phenotype
progression	O
and	O
displays	O
potential	O
as	O
a	O
therapeutic	O
target	O
or	O
biomarker	O
for	O
lung	B-Phenotype
adenocarcinoma	E-Phenotype

Therefore	O
,	O
our	O
data	O
suggested	O
that	O
TPI1	O
functioned	O
as	O
a	O
tumor	S-Phenotype
suppressor	O
in	O
HCC	O
and	O
might	O
serve	O
as	O
a	O
potential	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
HCC	S-Phenotype

Surgical	O
tumor	S-Phenotype
specimens	O
were	O
collected	O
for	O
immunohistochemical	O
staining	O
to	O
evaluate	O
B7	O
-	O
H5	O
expression	O
.	O

LncRNA	O
lipancEts	O
-	O
1	O
/	O
i	O
promoted	O
the	O
growth	O
,	O
invasion	O
,	O
and	O
metastasis	O
of	O
neuroblastoma	S-Phenotype
cells	O
liin	O
vitro	O
/	O
i	O
and	O
liin	O
vivo	O
/	O
i	O
Mechanistically	O
,	O
lipancEts	O
-	O
1	O
/	O
i	O
bound	O
to	O
hnRNPK	O
to	O
facilitate	O
its	O
physical	O
interaction	O
with	O
β	O
-	O
catenin	O
,	O
whereas	O
hnRNPK	O
stabilized	O
the	O
β	O
-	O
catenin	O
by	O
inhibiting	O
proteasome	O
-	O
mediated	O
degradation	O
,	O
resulting	O
in	O
transcriptional	O
alteration	O
of	O
target	O
genes	O
associated	O
with	O
neuroblastoma	S-Phenotype
progression	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
protein	O
expression	O
level	O
of	O
dCK	O
in	O
pancreatic	B-Phenotype
cancer	E-Phenotype
tissue	O
is	O
a	O
good	O
predictor	O
of	O
PFS	O
,	O
and	O
thus	O
dCK	O
may	O
be	O
the	O
best	O
biomarker	O
of	O
dFdC	O
sensitivity	O
in	O
pancreatic	B-Phenotype
cancer	E-Phenotype
patients	O
treated	O
with	O
dFdC	O
,	O
although	O
other	O
proteins	O
would	O
also	O
contribute	O
to	O
dFdC	O
-	O
sensitivity	O
at	O
the	O
cellular	O
level	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

SASS6	O
upregulation	O
in	O
colon	B-Phenotype
cancer	E-Phenotype
was	O
also	O
revealed	O
in	O
the	O
Cancer	S-Phenotype
Genome	O
Atlas	O
(	O
TCGA	O
)	O
data	O
and	O
was	O
shown	O
to	O
be	O
an	O
independent	O
predictor	O
of	O
poor	O
survival	O
(	O
multivariate	O
analysis	O
:	O
hazard	O
ratio	O
,	O
2.805	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.244‑7.512	O
;	O
P=0.0112	O
)	O
.	O

MicroRNA	O
-	O
214	O
(	O
miR	O
-	O
214	O
)	O
shows	O
carcinogenesis	O
in	O
various	O
tumor	S-Phenotype
types	O
,	O
but	O
little	O
is	O
known	O
about	O
biological	O
functions	O
of	O
miR	O
-	O
214	O
in	O
esophageal	B-Phenotype
squamous	I-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
ESCC	S-Phenotype
)	O
.	O

In	O
this	O
study	O
we	O
extend	O
these	O
findings	O
by	O
demonstrating	O
that	O
the	O
mRNA	O
levels	O
of	O
RBCK1	O
and	O
SHARPIN	O
are	O
also	O
higher	O
in	O
tumors	S-Phenotype
compared	O
to	O
adjacent	O
non	O
-	O
tumor	S-Phenotype
tissue	O
in	O
the	O
same	O
cross	O
sectional	O
study	O
of	O
samples	O
(	O
p	O
AAAA	O
0.001	O
)	O
.	O

Broad	O
GNAS	O
methylation	O
abnormalities	O
are	O
also	O
observed	O
in	O
most	O
sporadic	S-Phenotype
PHP1B	O
(	O
sporPHP1B	O
)	O
cases	O
.	O

These	O
AF1q	O
-	O
mediated	O
effects	O
were	O
modulated	O
by	O
the	O
protein	O
kinase	O
B	O
(	O
AKT	O
)	O
signaling	O
pathway	O
,	O
and	O
inhibition	O
of	O
AKT	O
signaling	O
attenuated	O
AF1q	O
-	O
induced	O
tumor	S-Phenotype
promotion	O
.	O

In	O
summary	O
,	O
there	O
were	O
no	O
apparent	O
associations	O
of	O
variants	O
in	O
GAMT	O
and	O
SLC6A8	O
genes	O
with	O
autism	S-Phenotype
.	O

Furthermore	O
,	O
LHX3	O
is	O
associated	O
with	O
unfavorable	O
overall	O
survival	O
(	O
n=866	O
,	O
p=0.004	O
)	O
and	O
represents	O
an	O
independent	O
prognostic	O
factor	O
(	O
HR=2.36	O
,	O
p=0.000	O
)	O
in	O
lung	B-Phenotype
adenocarcinoma	E-Phenotype
(	O
ADC	O
)	O
patients	O
,	O
but	O
is	O
not	O
associated	O
with	O
overall	O
survival	O
of	O
squamous	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
SCC	S-Phenotype
)	O
patients	O
(	O
n=524	O
,	O
p=0.27	O
)	O
.	O

reduced	O
xenograft	O
tumor	S-Phenotype
size	O
in	O
nude	O
mice	O
and	O
Moreover	O
,	O
combined	O
EGFR	O
TKI	O
and	O
a	O
YAP	O
inhibitor	O
,	O
statin	O
,	O
prolonged	O
survival	O
among	O
lung	B-Phenotype
cancer	E-Phenotype
patients	O
analyzed	O
by	O
Taiwan	O
National	O
Health	O
Insurance	O
Research	O
database	O
.	O

Growing	O
evidence	O
suggests	O
that	O
mitochondrial	B-Phenotype
dysfunction	E-Phenotype
is	O
an	O
early	O
event	O
in	O
sporadic	S-Phenotype
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
,	O
but	O
the	O
impact	O
of	O
mitochondrial	B-Phenotype
dysfunction	E-Phenotype
on	O
the	O
transition	O
from	O
healthy	O
aging	O
to	O
AD	O
remains	O
elusive	O
.	O

In	O
vitro	O
analysis	O
revealed	O
that	O
knockdown	O
of	O
WWOX	O
protein	O
in	O
neuroblastoma	S-Phenotype
cells	O
results	O
in	O
aggregation	O
of	O
TRAPPC6AD	O
,	O
TIAF1	O
,	O
amyloid	O
b	O
,	O
and	O
Tau	O
in	O
a	O
sequential	O
manner	O
.	O

The	O
results	O
indicated	O
that	O
increased	O
GPD1L	O
in	O
adipose	O
tissue	O
may	O
have	O
a	O
significant	O
therapeutic	O
potential	O
in	O
reducing	O
obesity	S-Phenotype
and	O
insulin	B-Phenotype
resistance	E-Phenotype

MDR	O
rectal	O
colonization	O
occurs	O
in	O
6.5	O
%	O
of	O
haematological	O
inpatients	O
and	O
predicts	O
a	O
16	O
%	O
probability	O
of	O
MDRrel	O
BSI	O
,	O
particularly	O
during	O
neutropenia	S-Phenotype
,	O
as	O
well	O
as	O
a	O
higher	O
probability	O
of	O
unfavourable	O
outcomes	O
in	O
CR	O
-	O
rel	O
BSIs	O
.	O

The	O
aims	O
of	O
the	O
present	O
study	O
were	O
to	O
evaluate	O
the	O
relation	O
of	O
dysregulated	O
MACC1	O
,	O
c	O
-	O
MET	O
,	O
and	O
NM23	O
-	O
H1	O
expression	O
with	O
the	O
histopathological	O
features	O
of	O
tumors	S-Phenotype
in	O
recurrence	O
formation	O
in	O
eCC	O
cases	O
.	O

Furthermore	O
,	O
a	O
series	O
of	O
experiments	O
and	O
rescue	O
experiments	O
revealed	O
that	O
Nuclear	O
Receptor	O
Subfamily	O
3	O
Group	O
C	O
Member	O
2	O
(	O
NR3C2	O
)	O
was	O
the	O
target	O
of	O
miR	O
-	O
135b	O
-	O
5p	O
in	O
pancreatic	B-Phenotype
cancer	E-Phenotype
cells	O
,	O
mediating	O
the	O
promotion	O
effects	O
of	O
miR	O
-	O
135b	O
-	O
5p	O
on	O
the	O
tumor	S-Phenotype
cells	O
migration	O
,	O
invasion	O
and	O
EMT	O
.	O

Growing	O
evidence	O
suggests	O
that	O
SETX	O
may	O
represent	O
an	O
important	O
genetic	O
modifier	O
locus	O
for	O
sporadic	S-Phenotype
ALS	O
.	O

Mutations	O
in	O
the	O
membrane	O
frizzled	O
-	O
related	O
protein	O
(	O
MFRP	O
/	O
Mfrp	O
)	O
gene	O
,	O
specifically	O
expressed	O
in	O
the	O
retinal	O
pigment	O
epithelium	O
(	O
RPE	O
)	O
and	O
ciliary	O
body	O
,	O
cause	O
nanophthalmia	S-Phenotype
or	O
posterior	B-Phenotype
microphthalmia	E-Phenotype
with	O
retinitis	B-Phenotype
pigmentosa	E-Phenotype
in	O
humans	O
,	O
and	O
photoreceptor	O
degeneration	O
in	O
mice	O
.	O

To	O
explore	O
the	O
relationship	O
between	O
mouse	O
double	O
minute	O
2	O
binding	O
protein	O
(	O
MTBP	O
)	O
and	O
the	O
prognosis	O
of	O
cancer	S-Phenotype
patients	O
,	O
a	O
databank	O
-	O
based	O
reanalysis	O
was	O
conducted	O
and	O
a	O
clinical	O
observation	O
about	O
lung	B-Phenotype
adenocarcinoma	E-Phenotype
was	O
taken	O
to	O
verify	O
the	O
result	O
of	O
data	O
analysis.We	O
reanalyzed	O
all	O
the	O
downloaded	O
data	O
in	O
order	O
to	O
make	O
a	O
conclusion	O
about	O
the	O
relationship	O
between	O
MTBP	O
and	O
the	O
prognosis	O
of	O
cancer	S-Phenotype
patients	O
.	O

Chromosomal	O
studies	O
for	O
Individual	O
1	O
identified	O
an	O
X	O
-	O
chromosome	O
deletion	O
due	O
to	O
a	O
de	O
novo	O
pericentric	O
inversion	O
;	O
the	O
inversion	O
breakpoint	O
was	O
associated	O
with	O
deletion	O
of	O
the	O
5'UTR	O
of	O
the	O
USP9X	O
,	O
a	O
gene	O
which	O
has	O
been	O
implicated	O
in	O
a	O
syndromic	O
intellectual	B-Phenotype
disability	E-Phenotype
affecting	O
females	O
.	O

In	O
the	O
remaining	O
cases	O
,	O
next	O
generation	O
sequencing	O
was	O
carried	O
out	O
revealing	O
variants	O
in	O
a	O
number	O
of	O
other	O
known	O
complex	O
spastic	B-Phenotype
paraplegia	E-Phenotype
genes	O
,	O
including	O
five	O
in	O
SPG7	O
(	O
5	O
/	O
97	O
)	O
,	O
four	O
in	O
FA2H	O
(	O
also	O
known	O
as	O
SPG35	O
)	O
(	O
4	O
/	O
97	O
)	O
and	O
two	O
in	O
ZFYVE26	O
/	O
SPG15	O
Variants	O
were	O
identified	O
in	O
genes	O
usually	O
associated	O
with	O
pure	O
spastic	B-Phenotype
paraplegia	E-Phenotype
and	O
also	O
in	O
the	O
Parkinson	O
*	O
s	O
disease	O
-	O
associated	O
gene	O
ATP13A2	O
,	O
neuronal	O
ceroid	O
lipofuscinosis	O
gene	O
TPP1	O
and	O
the	O
hereditary	O
motor	O
and	O
sensory	B-Phenotype
neuropathy	E-Phenotype
DNMT1	O
gene	O
,	O
highlighting	O
the	O
genetic	O
heterogeneity	O
of	O
spastic	B-Phenotype
paraplegia	E-Phenotype
.	O

Our	O
genome	O
-	O
wide	O
study	O
showed	O
that	O
Ppp2r1b	O
,	O
a	O
PP2A	O
subunit	O
encoding	O
tumor	S-Phenotype
suppressor	O
gene	O
,	O
is	O
underexpressed	O
in	O
submandibular	O
gland	O
tumors	S-Phenotype
of	O
Smgb	O
-	O
Tag	O
mice	O
.	O

Neurturin	O
(	O
NRTN	O
)	O
provides	O
trophic	O
support	O
to	O
neurons	O
and	O
is	O
considered	O
a	O
therapeutic	O
agent	O
for	O
neurodegenerative	B-Phenotype
diseases	E-Phenotype
,	O
such	O
as	O
Parkinson	O
's	O
disease	O
.	O

We	O
found	O
that	O
NOTCH1	O
regulates	O
TP53	O
expression	O
from	O
NOTCH1	O
knockdown	O
oral	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Phenotypically	O
,	O
bs	O
mice	O
exhibit	O
nuclear	B-Phenotype
cataracts	E-Phenotype
and	O
male	B-Phenotype
infertility	E-Phenotype
;	O
genetic	O
analyses	O
assigned	O
the	O
bs	O
locus	O
to	O
mouse	O
chromosome	O
2	O
.	O

By	O
exome	O
sequencing	O
,	O
we	O
identified	O
three	O
different	O
bi	O
-	O
allelic	O
truncating	O
mutations	O
in	O
TANGO2	O
in	O
three	O
unrelated	O
individuals	O
with	O
infancy	O
-	O
onset	O
episodic	O
metabolic	O
crises	O
characterized	O
by	O
encephalopathy	S-Phenotype
,	O
hypoglycemia	S-Phenotype
,	O
rhabdomyolysis	S-Phenotype
,	O
arrhythmias	S-Phenotype
,	O
and	O
laboratory	O
findings	O
suggestive	O
of	O
a	O
defect	O
in	O
mitochondrial	O
fatty	O
acid	O
oxidation	O
.	O

We	O
observed	O
significant	O
hearing	B-Phenotype
loss	E-Phenotype
and	O
progressive	O
degeneration	O
of	O
stereocilia	O
in	O
the	O
outer	O
hair	O
cells	O
of	O
Tprn	O
-	O
null	O
mice	O
starting	O
from	O
postnatal	O
day	O
30	O
.	O

The	O
cases	O
with	O
complete	O
clinical	O
data	O
retrieved	O
on	O
literature	O
search	O
at	O
China	O
National	O
Knowledge	O
Infrastructure	O
,	O
Wanfang	O
Data	O
Knowledge	O
Service	O
Platform	O
and	O
PubMed	O
(	O
up	O
to	O
August	O
2016	O
)	O
by	O
using	O
search	O
terms	O
ofAAAAAANDUFV1AAAAAA	O
,	O
AAAAAANDUFS1AAAAAA	O
,	O
orAAAAAAleukoencephalopathyAAAAAA	O
,	O
were	O
summarized	O
.	O

Further	O
,	O
reconstitution	O
of	O
GUCY2C	O
signaling	O
through	O
genetic	O
or	O
oral	O
ligand	O
replacement	O
opposes	O
tumorigenesis	S-Phenotype
in	O
mice	O
.	O

These	O
clinical	O
and	O
imaging	O
findings	O
are	O
unlike	O
that	O
of	O
any	O
recognized	O
severe	O
forms	O
of	O
microcephaly	S-Phenotype
which	O
is	O
believed	O
to	O
be	O
a	O
new	O
microcephalic	B-Phenotype
primordial	I-Phenotype
dwarfism	E-Phenotype
(	O
MPD	S-Phenotype
)	O
with	O
developmental	O
brain	O
malformations	O
with	O
most	O
probably	O
autosomal	B-Phenotype
recessive	I-Phenotype
inheritance	E-Phenotype
based	O
on	O
consanguinity	O
and	O
similarly	O
affected	O
male	O
and	O
female	O
sibs	O

Here	O
,	O
we	O
present	O
cryo	O
-	O
electron	O
microscopy	O
analyses	O
of	O
C1	O
bound	O
to	O
monoclonal	O
antibodies	O
in	O
which	O
we	O
observed	O
heterogeneous	S-Phenotype
structures	O
of	O
single	O
and	O
clustered	O
C1	O
-	O
immunoglobulin	O
G1	O
(	O
IgG1	O
)	O
hexamer	O
complexes	O
.	O

Primary	B-Phenotype
ciliary	I-Phenotype
dyskinesia	E-Phenotype
(	O
PCD	S-Phenotype
)	O
is	O
an	O
autosomal	O
-	O
recessive	O
disease	O
due	O
to	O
functional	O
or	O
ultra	O
-	O
structural	O
defects	O
of	O
motile	O
cilia	O
.	O

Our	O
analyses	O
revealed	O
that	O
the	O
primary	O
tumor	S-Phenotype
and	O
NCC	O
-	O
SS1	O
-	O
C1	O
cell	O
line	O
harbored	O
the	O
SS18	O
-	O
SSX1	O
fusion	O
gene	O
typical	O
of	O
synovial	B-Phenotype
sarcoma	E-Phenotype
and	O
similar	O
proteomics	O
profiles	O
.	O

We	O
describe	O
a	O
multigenerational	O
Saudi	O
family	O
with	O
an	O
autosomal	O
dominant	O
form	O
of	O
hypohidrotic	B-Phenotype
ectodermal	I-Phenotype
dysplasia	E-Phenotype
in	O
which	O
positional	O
mapping	O
and	O
exome	O
sequencing	O
identified	O
a	O
novel	O
variant	O
in	O
KDF1	O
that	O
fully	O
segregates	O
with	O
the	O
phenotype	O
.	O

Neurofibromatosis	B-Phenotype
type	I-Phenotype
2	E-Phenotype
(	O
NF2	S-Phenotype
)	O
is	O
a	O
tumor	S-Phenotype
-	O
forming	O
disease	O
of	O
the	O
nervous	O
system	O
caused	O
by	O
deletion	O
or	O
by	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
NF2	O
,	O
encoding	O
the	O
tumor	S-Phenotype
suppressing	O
protein	O
neurofibromin	O
2	O
(	O
also	O
known	O
as	O
schwannomin	O
or	O
merlin	O
)	O
.	O

This	O
report	O
identifies	O
the	O
first	O
breast	B-Phenotype
cancer	E-Phenotype
risk	O
locus	O
specific	O
to	O
a	O
BRCA2	O
mutation	O
background	O
.	O

In	O
vitro	O
head	B-Phenotype
and	I-Phenotype
neck	I-Phenotype
cancer	E-Phenotype
studies	O
have	O
demonstrated	O
that	O
epidermal	O
growth	O
factor	O
receptor	O
kinase	O
substrate	O
8	O
(	O
Eps8	O
)	O
overexpression	O
contributes	O
to	O
squamous	O
carcinogenesis	O
.	O

Here	O
,	O
we	O
show	O
that	O
ethanol	O
treatment	O
(	O
100	O
mM	O
)	O
promotes	O
ROS	O
production	O
and	O
oxidative	B-Phenotype
stress	E-Phenotype
in	O
cancer	S-Phenotype
-	O
associated	O
fibroblasts	O
,	O
which	O
is	O
sufficient	O
to	O
induce	O
myofibroblastic	O
differentiation	O
.	O

Although	O
there	O
are	O
nearly	O
100	O
different	O
causative	O
genes	O
identified	O
for	O
nonsyndromic	B-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
(	O
NSHL	S-Phenotype
)	O
,	O
Sanger	O
sequencing	O
-	O
based	O
DNA	O
diagnostics	O
usually	O
only	O
analyses	O
three	O
,	O
namely	O
,	O
GJB2	O
,	O
SLC26A4	O
,	O
and	O
OTOF	O
.	O

By	O
demonstrating	O
that	O
MT	O
-	O
bound	O
Tau	O
inhibits	O
the	O
Eg5	O
kinesin	O
and	O
cell	O
mitosis	O
,	O
our	O
work	O
provides	O
a	O
new	O
framework	O
to	O
consider	O
the	O
role	O
of	O
Tau	O
in	O
neurodegenerative	B-Phenotype
diseases	E-Phenotype
.	O

In	O
humans	O
,	O
liGFI1	O
/	O
i	O
mutations	O
are	O
associated	O
with	O
severe	O
congenital	B-Phenotype
neutropenia	E-Phenotype
.	O

We	O
conclude	O
that	O
the	O
phenotype	O
combining	O
features	O
of	O
TCS	O
with	O
DBA	O
is	O
genetically	O
heterogeneous	S-Phenotype
.	O

For	O
example	O
,	O
YY1	O
's	O
roles	O
in	O
tumor	S-Phenotype
growth	O
involve	O
stabilization	O
of	O
hypoxia	S-Phenotype
-	O
inducible	O
factor	O
HIF	O
-	O
1α	O
in	O
a	O
p53	O
independent	O
manner	O
,	O
negative	O
regulation	O
of	O
miR	O
-	O
9	O
transcription	O
,	O
control	O
of	O
MYCT1	O
transcription	O
,	O
a	O
novel	O
miR	O
-	O
193a	O
-	O
5p	O
-	O
YY1	O
-	O
APC	O
axis	O
,	O
intracellular	O
ROS	O
and	O
mitochondrial	O
superoxide	O
generation	O
,	O
p53	O
reduction	O
and	O
EGFR	O
activation	O
,	O
control	O
of	O
genes	O
associated	O
with	O
mitochondrial	O
energy	O
metabolism	O
and	O
miRNA	O
regulatory	O
networks	O
involving	O
miR	O
-	O
7	O
,	O
miR	O
-	O
9	O
,	O
miR	O
-	O
34a	O
,	O
miR	O
-	O
186	O
,	O
miR	O
-	O
381	O
,	O
miR	O
-	O
584	O
-	O
3p	O
and	O
miR	O
-	O
635	O
.	O

ANT1	O
is	O
one	O
of	O
the	O
nuclear	O
genes	O
responsible	O
of	O
autosomal	B-Phenotype
dominant	I-Phenotype
progressive	I-Phenotype
external	I-Phenotype
ophthalmoplegia	E-Phenotype
(	O
adPEO	S-Phenotype
)	O
with	O
mitochondrial	O
DNA	O
multiple	O
deletions	O
.	O

Blocking	O
the	O
expression	O
of	O
integrin	O
a2b1	O
,	O
which	O
was	O
accomplished	O
by	O
transduction	O
of	O
a2	O
-	O
specific	O
shRNA	O
,	O
resulted	O
in	O
significant	O
inhibition	O
of	O
proliferation	O
and	O
clonal	O
activity	O
in	O
human	O
MCF	O
-	O
7	O
breast	B-Phenotype
carcinoma	E-Phenotype
and	O
SK	O
-	O
Mel	O
-	O
147	O
melanoma	S-Phenotype
cells	O
.	O

Spinocerebellar	B-Phenotype
ataxia	I-Phenotype
type	I-Phenotype
17	E-Phenotype
(	O
SCA17	S-Phenotype
)	O
is	O
caused	O
by	O
CAG	O
repeat	O
expansion	O
in	O
the	O
TATA	O
-	O
box	O
binding	O
protein	O
gene	O
.	O

We	O
hypothesized	O
that	O
heterozygous	O
variants	O
in	O
PRDM5	O
and	O
ZNF469	O
predispose	O
to	O
the	O
development	O
of	O
isolated	O
keratoconus	S-Phenotype
.	O

Mucopolysaccharidosis	O
VI	O
(	O
MPS	O
-	O
VI	O
)	O
is	O
an	O
infrequent	O
autosomal	B-Phenotype
recessive	E-Phenotype
disorder	O
caused	O
by	O
mutations	O
in	O
ARSB	O
gene	O
and	O
deficiency	O
in	O
lysosomal	O
enzyyme	O
ARSB	O
activities	O
subsequently	O
.	O

Here	O
,	O
we	O
use	O
a	O
combination	O
of	O
genetic	O
mouse	O
models	O
to	O
demonstrate	O
that	O
Prss56	O
mutations	O
leading	O
to	O
reduced	O
ocular	O
size	O
and	O
hyperopia	S-Phenotype
act	O
via	O
a	O
loss	O
of	O
function	O
mechanism	O
.	O

Solid	O
tumors	S-Phenotype
developed	O
and	O
total	O
tumor	S-Phenotype
mass	O
and	O
the	O
number	O
of	O
tumors	S-Phenotype
were	O
characterized	O
.	O

Partial	O
loss	O
-	O
of	O
-	O
function	O
variants	O
in	O
the	O
TREM2	O
immune	O
receptor	O
are	O
associated	O
with	O
increased	O
risk	O
for	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
and	O
other	O
forms	O
of	O
neurodegenerative	B-Phenotype
disease	E-Phenotype
,	O
but	O
the	O
molecular	O
bases	O
for	O
these	O
connections	O
are	O
unknown	O
.	O

Here	O
we	O
report	O
three	O
individuals	O
with	O
biallelic	O
FANCM	O
truncating	O
mutations	O
who	O
developed	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
cancer	E-Phenotype
and	O
toxicity	O
to	O
chemotherapy	O
but	O
did	O
not	O
present	O
congenital	O
malformations	O
or	O
any	O
hematological	O
phenotype	O
suggestive	O
of	O
FA	O
.	O

Methods	O
Chromosomal	O
breakages	O
,	O
interstrand	O
crosslink	O
sensitivity	O
,	O
and	O
FANCD2	O
monoubiquitination	O
were	O
assessed	O
in	O
primary	O
fibroblasts	O
.	O

In	O
contrast	O
,	O
among	O
the	O
factors	O
supporting	O
the	O
resistance	O
in	O
men	O
can	O
be	O
an	O
elevated	O
concentration	O
of	O
MP	O
-	O
TF	O
which	O
,	O
together	O
with	O
the	O
coexistence	O
of	O
hypertriglyceridemia	S-Phenotype
,	O
may	O
constitute	O
an	O
important	O
mechanism	O
of	O
resistance	O
to	O
clopidogrel	O

Type	O
II	O
(	O
middle	O
type	O
)	O
patients	O
show	O
development	O
delay	O
and	O
the	O
distinctive	O
facial	O
phenotype	O
(	O
midface	B-Phenotype
retraction	E-Phenotype
,	O
short	B-Phenotype
and	I-Phenotype
upturned	I-Phenotype
nose	E-Phenotype
)	O
,	O
lacking	O
both	O
hydronephrosis	S-Phenotype
and	O
typical	O
skeletal	B-Phenotype
abnormalities	E-Phenotype
,	O
with	O
existence	O
of	O
SETBP1mutation	O
.	O

We	O
show	O
that	O
an	O
inhaled	O
PI3Kδ	O
inhibitor	O
improves	O
survival	O
rates	O
following	O
S.	O
pneumoniae	S-Phenotype
infection	O
in	O
wild	O
-	O
type	O
mice	O
and	O
in	O
mice	O
with	O
activated	O
PI3Kδ	O
.	O

CSD	O
refers	O
to	O
an	O
intractable	B-Phenotype
diarrhea	E-Phenotype
of	O
intrauterine	B-Phenotype
onset	E-Phenotype
with	O
high	O
fecal	O
sodium	O
loss	O
.	O

Remarkably	O
,	O
as	O
is	O
the	O
case	O
in	O
human	O
PDE	O
,	O
the	O
seizures	S-Phenotype
show	O
an	O
almost	O
immediate	O
sensitivity	O
to	O
pyridoxine	O
and	O
pyridoxal	O
5	O
'	O
-	O
phosphate	O
,	O
with	O
a	O
resulting	O
extension	O
of	O
the	O
life	O
span	O
.	O

The	O
tumor	S-Phenotype
cells	O
expressed	O
MUC4	O
,	O
GLUT	O
-	O
1	O
,	O
and	O
vimentin	O
and	O
were	O
negative	O
for	O
S	O
-	O
100	O
protein	O
,	O
epithelial	O
membrane	O
antigen	O
,	O
smooth	O
muscle	O
actin	O
,	O
desmin	O
,	O
claudin	O
-	O
1	O
,	O
neurofilament	O
and	O
SOX10	O
.	O

However	O
,	O
in	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
,	O
the	O
characteristics	O
and	O
mechanism	O
of	O
IDO1	O
expression	O
have	O
not	O
been	O
well	O
defined	O
.	O

PHF8	O
knockdown	O
inhibits	O
proliferation	O
and	O
promotes	O
the	O
apoptosis	O
of	O
ALL	O
cells	O
in	O
vitro	O
as	O
well	O
as	O
attenuates	O
tumor	S-Phenotype
growth	O
in	O
vivo	O
.	O

Here	O
,	O
we	O
show	O
that	O
high	O
levels	O
of	O
the	O
actin	O
cytoskeleton	O
-	O
associated	O
protein	O
WIP	O
(	O
WASP	O
-	O
interacting	O
protein	O
)	O
correlates	O
with	O
tumor	S-Phenotype
growth	O
,	O
both	O
of	O
which	O
are	O
linked	O
to	O
the	O
tumor	S-Phenotype
-	O
initiating	O
cell	O
phenotype	O
.	O

Wilms	B-Phenotype
tumors	E-Phenotype
can	O
also	O
overexpress	O
PLAG1	O
through	O
copy	O
number	O
alterations	O
,	O
and	O
PLAG1	O
expression	O
correlates	O
with	O
prognosis	O
in	O
Wilms	B-Phenotype
tumors	E-Phenotype
.	O

Moreover	O
,	O
ZNF131	O
and	O
HAUS5	O
kd	O
phenocopied	O
each	O
other	O
in	O
GSCs	O
,	O
each	O
causing	O
:	O
mitotic	O
arrest	O
,	O
centrosome	O
fragmentation	O
,	O
loss	O
of	O
Augmin	O
/	O
HAUS	O
complex	O
on	O
the	O
mitotic	O
spindle	O
,	O
and	O
loss	O
of	O
GSC	O
self	O
-	O
renewal	O
and	O
tumor	S-Phenotype
formation	O
capacity	O
.	O

Moreover	O
,	O
Wnt	O
/	O
β	O
-	O
catenin	O
signaling	O
pathway	O
,	O
which	O
was	O
reported	O
to	O
be	O
activated	O
by	O
ANTXR1	O
and	O
RSPO2	O
,	O
was	O
also	O
inhibited	O
by	O
miR	O
-	O
493	O
overexpression	O
and	O
might	O
be	O
involved	O
in	O
anti	O
-	O
tumor	S-Phenotype
function	O
of	O
miR	O
-	O
493	O
.	O

Dysregulation	O
of	O
these	O
miRNAs	O
,	O
which	O
are	O
associated	O
with	O
hyperglycemia	S-Phenotype
in	O
patients	O
with	O
T1D	O
,	O
may	O
contribute	O
to	O
the	O
development	O
of	O
diabetes	O
complications	O
.	O

That	O
binding	O
,	O
which	O
interferes	O
with	O
the	O
interaction	O
of	O
RhoA	O
-	O
GTP	O
with	O
the	O
RhoGAP	O
domain	O
,	O
reduces	O
the	O
hydrolysis	O
of	O
RhoA	O
-	O
GTP	O
,	O
the	O
binding	O
of	O
other	O
DLC1	O
ligands	O
,	O
and	O
the	O
colocalization	O
of	O
DLC1	O
with	O
focal	O
adhesions	O
and	O
attenuates	O
tumor	S-Phenotype
suppressor	O
activity	O
.	O

Given	O
the	O
phenotypic	O
similarity	O
,	O
we	O
conclude	O
that	O
missense	O
mutations	O
in	O
TIMM50	O
are	O
likely	O
manifesting	O
by	O
severe	O
intellectual	B-Phenotype
disability	E-Phenotype
and	O
epilepsy	S-Phenotype
accompanied	O
by	O
3	B-Phenotype
-	I-Phenotype
methylglutaconic	I-Phenotype
aciduria	E-Phenotype
and	O
variable	B-Phenotype
mitochondrial	I-Phenotype
complex	I-Phenotype
V	I-Phenotype
deficiency	E-Phenotype
.	O

After	O
ERβ	O
activation	O
,	O
both	O
DRAM2	O
and	O
protein	O
1	O
light	O
chain	O
3	O
(	O
LC3	O
)	O
,	O
a	O
key	O
actor	O
in	O
the	O
autophagosome	O
formation	O
,	O
strictly	O
interacted	O
each	O
other	O
and	O
localized	O
at	O
mitochondrial	O
level.Altogether	O
these	O
results	O
suggest	O
that	O
targeting	O
ERβ	O
with	O
selective	O
agonists	O
might	O
affect	O
HL	O
cell	O
proliferation	O
and	O
tumor	S-Phenotype
growth	O
via	O
a	O
mechanism	O
that	O
brings	O
into	O
play	O
DRAM2	O
-	O
dependent	O
autophagic	O
cascade	O

FBXL4	O
potentially	O
controls	O
cancer	S-Phenotype
metastasis	O
through	O
regulation	O
of	O
ERLEC1	O
levels	O
.	O

These	O
data	O
suggest	O
a	O
pathogenic	O
mechanism	O
of	O
the	O
CHAMP1	O
-	O
associated	O
intellectual	B-Phenotype
disability	E-Phenotype
syndrome	O
mediated	O
by	O
direct	O
interacting	O
partners	O
of	O
CHAMP1	O
,	O
several	O
of	O
which	O
are	O
involved	O
in	O
chromo	O
/	O
kinetochore	O
-	O
related	O
disorders	O
.	O

Metabolic	B-Phenotype
cutis	I-Phenotype
laxa	E-Phenotype
results	O
from	O
Menkes	O
syndrome	O
,	O
caused	O
by	O
a	O
defect	O
in	O
the	O
ATPase	O
copper	O
transporting	O
alpha	O
(	O
ATP7A	O
)	O
gene	O
;	O
congenital	O
disorders	O
of	O
glycosylation	O
due	O
to	O
mutations	O
in	O
subunit	O
7	O
of	O
the	O
component	O
of	O
oligomeric	O
Golgi	O
(	O
COG7	O
)	O
-	O
congenital	O
disorders	O
of	O
glycosylation	O
(	O
CDG	O
)	O
complex	O
;	O
combined	O
disorder	O
of	O
N	O
-	O
and	O
O	O
-	O
linked	O
glycosylation	O
,	O
due	O
to	O
mutations	O
in	O
ATPase	O
H+	O
transporting	O
V0	O
subunit	O
a2	O
(	O
ATP6VOA2	O
)	O
gene	O
;	O
pyrroline	O
-	O
5	O
-	O
carboxylate	O
reductase	O
1	O
deficiency	O
;	O
pyrroline	O
-	O
5	O
-	O
carboxylate	O
synthase	O
deficiency	O
;	O
macrocephaly	S-Phenotype
,	O
alopecia	S-Phenotype
,	O
cutis	B-Phenotype
laxa	E-Phenotype
,	O
and	O
scoliosis	S-Phenotype
(	O
MACS	O
)	O
syndrome	O
,	O
due	O
to	O
Ras	O
and	O
Rab	O
interactor	O
2	O
(	O
RIN2	O
)	O
mutations	O
;	O
transaldolase	O
deficiency	O
caused	O
by	O
mutations	O
in	O
the	O
transaldolase	O
1	O
(	O
TALDO1	O
)	O
gene	O
;	O
Gerodermia	O
osteodysplastica	O
due	O
to	O
mutations	O
in	O
the	O
golgin	O
,	O
RAB6	O
-	O
interacting	O
(	O
GORAB	O
or	O
SCYL1BP1	O
)	O
gene	O
;	O
and	O
mitogen	O
-	O
activated	O
pathway	O
(	O
MAP	O
)	O
kinase	O
defects	O
,	O
caused	O
by	O
mutations	O
in	O
several	O
genes	O
[	O
protein	O
tyrosine	O
phosphatase	O
,	O
non	O
-	O
receptor	O
-	O
type	O
11	O
(	O
PTPN11	O
)	O
,	O
RAF	O
,	O
NF	O
,	O
HRas	O
proto	O
-	O
oncogene	O
,	O
GTPase	O
(	O
HRAS	O
)	O
,	O
B	O
-	O
Raf	O
proto	O
-	O
oncogene	O
,	O
serine	O
/	O
threonine	O
kinase	O
(	O
BRAF	O
)	O
,	O
MEK1	O
/	O
2	O
,	O
KRAS	O
proto	O
-	O
oncogene	O
,	O
GTPase	O
(	O
KRAS	O
)	O
,	O
SOS	O
Ras	O
/	O
Rho	O
guanine	O
nucleotide	O
exchange	O
factor	O
2	O
(	O
SOS2	O
)	O
,	O
leucine	O
rich	O
repeat	O
scaffold	O
protein	O
(	O
SHOC2	O
)	O
,	O
NRAS	O
proto	O
-	O
oncogene	O
,	O
GTPase	O
(	O
NRAS	O
)	O
,	O
and	O
Raf	O
-	O
1	O
proto	O
-	O
oncogene	O
,	O
serine	O
/	O
threonine	O
kinase	O
(	O
RAF1	O
)	O
]	O
,	O
which	O
regulate	O
the	O
Ras	O
-	O
MAPK	O
cascade	O
.	O

Samples	O
analyzed	O
were	O
10	O
pairs	O
of	O
snap	O
-	O
frozen	O
surgical	O
specimens	O
of	O
cancerous	S-Phenotype
and	O
non	O
-	O
cancerous	O
thymic	O
tissue	O
.	O

WNT4	O
and	O
VEZT	O
genes	O
constitute	O
the	O
most	O
consistently	O
associated	O
genes	O
with	O
endometriosis	S-Phenotype
.	O

In	O
the	O
present	O
study	O
,	O
Fli	O
-	O
1	O
was	O
highly	O
expressed	O
in	O
HCC	O
samples	O
and	O
tumor	S-Phenotype
cell	O
lines	O
.	O

Result	O
:	O
Three	O
mutant	O
genes	O
(	O
PTPN11	O
gene	O
in	O
chromosome	O
12	O
,	O
RIT1	O
gene	O
in	O
chromosome	O
1	O
and	O
RAF1	O
gene	O
in	O
chromosome	O
3	O
)	O
in	O
five	O
cases	O
all	O
had	O
been	O
reported	O
to	O
be	O
related	O
to	O
hypertrophic	B-Phenotype
cardiomyopathy	E-Phenotype
.	O

Malfunction	O
of	O
mutant	O
AIPL1	O
proteins	O
triggers	O
a	O
severe	O
form	O
of	O
Leber	B-Phenotype
congenital	I-Phenotype
amaurosis	E-Phenotype
and	O
leads	O
to	O
blindness	S-Phenotype
.	O

Hmx1	O
encodes	O
a	O
homeodomain	O
transcription	O
factor	O
expressed	O
in	O
the	O
developing	O
lateral	O
craniofacial	O
mesenchyme	O
,	O
retina	O
and	O
sensory	O
ganglia	O
.	O

BRIP1	O
,	O
RAD51C	O
/	O
D	O
,	O
MSH6	O
)	O
;	O
and	O
multiple	O
common	O
but	O
low	O
penetrance	O
susceptibility	O
alleles	O
identified	O
by	O
GWAS	O
.	O

We	O
included	O
7	O
consecutive	O
patients	O
with	O
LP	O
with	O
typical	O
intracranial	B-Phenotype
calcifications	E-Phenotype
out	O
of	O
16	O
patients	O
with	O
ECM1	O
mutations	O
and	O
investigated	O
the	O
semiologic	O
features	O
,	O
ictal	O
and	O
interictal	O
EEG	O
findings	O
,	O
and	O
long	O
-	O
term	O
prognosis	O
of	O
epilepsy	S-Phenotype
in	O
this	O
genodermatosis	O
.	O

MESP2	O
,	O
HES7	O
and	O
DUSP6	O
genes	O
may	O
not	O
be	O
involved	O
in	O
the	O
etiopathogenesis	O
of	O
sporadic	S-Phenotype
and	O
non	O
-	O
syndromic	O
CS	O
in	O
Chinese	O
Han	O
population	O

the	O
Partner	O
and	O
localizer	O
of	O
BRCA2	O
(	O
PALB2	O
)	O
gene	O
and	O
risk	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

Mutations	O
in	O
SNAP29	O
gene	O
result	O
in	O
CEDNIK	O
(	O
Cerebral	B-Phenotype
dysgenesis	E-Phenotype
,	O
neuropathy	S-Phenotype
,	O
ichthyosis	S-Phenotype
and	O
palmoplantar	B-Phenotype
keratoderma	E-Phenotype
)	O
syndrome	O
.	O

This	O
study	O
investigates	O
the	O
soluble	O
factors	O
released	O
by	O
tumor	S-Phenotype
-	O
associated	O
dendritic	O
cells	O
(	O
TADCs	O
)	O
responsible	O
for	O
increasing	O
cancer	S-Phenotype
stem	O
cell	O
(	O
CSC	O
)	O
properties	O
,	O
cell	O
mobility	O
,	O
and	O
epithelial	O
-	O
to	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
.	O

Kindler	O
syndrome	O
is	O
a	O
rare	O
,	O
autosomal	B-Phenotype
recessive	E-Phenotype
genodermatosis	O
,	O
caused	O
by	O
mutations	O
in	O
the	O
FERMT1	O
gene	O
.	O

iGPX2	O
/	O
i	O
and	O
liTXNRD3	O
/	O
i	O
showed	O
a	O
higher	O
expression	O
and	O
liGPX3	O
/	O
i	O
,	O
liSELENOP	O
/	O
i	O
,	O
liSELENOS	O
/	O
i	O
,	O
and	O
liSEPHS2	O
/	O
i	O
exhibited	O
a	O
lower	O
expression	O
in	O
the	O
disease	O
tissue	O
from	O
adenomas	O
and	O
both	O
cancer	S-Phenotype
groups	O
(	O
lip	O
/	O
i	O
-	O
values	O
from	O
0.023	O
to	O
AAAA0.001	O
)	O
.	O

Primary	B-Phenotype
ciliary	I-Phenotype
dyskinesia	E-Phenotype
(	O
PCD	S-Phenotype
)	O
is	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
disease	O
characterized	O
by	O
chronic	B-Phenotype
respiratory	I-Phenotype
infections	E-Phenotype
of	O
the	O
upper	O
and	O
lower	O
airways	O
,	O
hypofertility	O
,	O
and	O
,	O
in	O
approximately	O
half	O
of	O
the	O
cases	O
,	O
situs	B-Phenotype
inversus	E-Phenotype
.	O

In	O
order	O
to	O
assess	O
the	O
effects	O
of	O
LTBP4	O
in	O
muscular	B-Phenotype
dystrophy	E-Phenotype
,	O
LTBP4	O
overexpressing	O
mice	O
were	O
bred	O
to	O
mdx	O
mice	O
,	O
a	O
model	O
of	O
Duchenne	O
muscular	B-Phenotype
dystrophy	E-Phenotype
.	O

LINS1	O
alterations	O
affect	O
ELAV1	O
expression	O
and	O
result	O
in	O
reduction	O
in	O
the	O
commissural	O
axonal	O
growth	O
,	O
thus	O
affecting	O
peripheral	O
and	O
central	O
neuronal	O
function	O
.	O

Consistent	O
with	O
our	O
description	O
of	O
this	O
pathway	O
and	O
the	O
phenotype	O
of	O
patients	O
with	O
FGD1	O
mutations	O
,	O
mice	O
with	O
a	O
targeted	O
deletion	O
of	O
Mlk3	O
displayed	O
multiple	O
skeletal	O
defects	O
,	O
including	O
dental	B-Phenotype
abnormalities	E-Phenotype
,	O
deficient	B-Phenotype
calvarial	I-Phenotype
mineralization	E-Phenotype
,	O
and	O
reduced	B-Phenotype
bone	I-Phenotype
mass	E-Phenotype
.	O

Fc	O
-	O
gamma	O
receptor	O
-	O
IIb	O
(	O
FcγRIIb	O
)	O
and	O
its	O
ligand	O
are	O
reported	O
to	O
be	O
associated	O
with	O
obesity	S-Phenotype
and	O
type	B-Phenotype
2	I-Phenotype
diabetes	I-Phenotype
mellitus	E-Phenotype
(	O
T2DM	S-Phenotype
)	O
.	O

Biallelic	O
DNAJC12	O
mutations	O
were	O
described	O
in	O
children	O
with	O
hyperphenylalaninemia	S-Phenotype
,	O
neurodevelopmental	B-Phenotype
delay	E-Phenotype
,	O
and	O
dystonia	S-Phenotype
.	O

Through	O
a	O
whole	O
genome	O
sequencing	O
(	O
WGS	O
)	O
analysis	O
of	O
the	O
nine	O
subjects	O
(	O
four	O
lung	B-Phenotype
cancer	E-Phenotype
patients	O
and	O
five	O
normal	O
family	O
members	O
of	O
FLC	O
)	O
,	O
we	O
obtained	O
a	O
whole	O
genome	O
dataset	O
of	O
DNA	O
alterations	O
in	O
FLC	O
samples	O
.	O

In	O
subsequent	O
fine	O
-	O
mapping	O
analysis	O
,	O
6	O
SNPs	O
of	O
MECR	O
were	O
genotyped	O
with	O
310	O
schizophrenia	S-Phenotype
patients	O
and	O
604	O
control	O
subjects	O
.	O

Interaction	O
studies	O
also	O
showed	O
that	O
CEP78	O
binds	O
to	O
FAM161A	O
,	O
another	O
ciliary	O
protein	O
associated	O
with	O
retinal	B-Phenotype
degeneration	E-Phenotype
.	O

While	O
we	O
do	O
not	O
yet	O
know	O
which	O
SETX	O
activities	O
are	O
most	O
critical	O
to	O
neurodegeneration	S-Phenotype
,	O
our	O
evolving	O
understanding	O
of	O
SETX	O
function	O
will	O
undoubtedly	O
be	O
crucial	O
for	O
not	O
only	O
understanding	O
the	O
role	O
of	O
SETX	O
in	O
ALS	O
and	O
ataxia	S-Phenotype
disease	O
pathogenesis	O
,	O
but	O
also	O
for	O
delineating	O
the	O
mechanistic	O
biology	O
of	O
fundamentally	O
important	O
molecular	O
processes	O
in	O
the	O
cell	O

We	O
validated	O
ZBTB20	O
,	O
CELF2	O
,	O
PARD3	O
,	O
AKAP13	O
and	O
WAC	O
,	O
which	O
were	O
identified	O
by	O
our	O
screens	O
in	O
multiple	O
cancer	S-Phenotype
types	O
,	O
as	O
new	O
tumor	S-Phenotype
suppressor	O
genes	O
in	O
prostate	B-Phenotype
cancer	E-Phenotype
.	O

These	O
results	O
indicate	O
that	O
ZBTB18	O
functions	O
as	O
a	O
tumor	S-Phenotype
suppressor	O
in	O
GBM	O
through	O
the	O
regulation	O
of	O
genes	O
associated	O
with	O
phenotypically	O
aggressive	O
properties	O
. O
b O

Implications	O
:	O
/	O
b	O
This	O
study	O
characterizes	O
the	O
role	O
of	O
the	O
putative	O
tumor	S-Phenotype
suppressor	O
ZBTB18	O
and	O
its	O
regulation	O
by	O
promoter	O
hypermethylation	O
,	O
which	O
appears	O
to	O
be	O
a	O
common	O
mechanism	O
to	O
silence	O
ZBTB18	O
in	O
the	O
mesenchymal	O
subtype	O
of	O
GBM	O
and	O
provides	O
a	O
new	O
mechanistic	O
opportunity	O
to	O
specifically	O
target	O
this	O
tumor	S-Phenotype
subclass	O
.	O

Recently	O
a	O
homozygous	O
mutation	O
,	O
Gly372Ser	O
,	O
in	O
the	O
TIMM50	O
gene	O
,	O
was	O
reported	O
in	O
an	O
abstract	O
form	O
,	O
in	O
three	O
sibs	O
who	O
suffered	O
from	O
intractable	O
epilepsy	S-Phenotype
and	O
developmental	B-Phenotype
delay	E-Phenotype
accompanied	O
by	O
3	B-Phenotype
-	I-Phenotype
methylglutaconic	I-Phenotype
aciduria	E-Phenotype
.	O

It	O
is	O
associated	O
with	O
multiple	O
genetic	O
and	O
environmental	O
risk	O
factors	O
,	O
including	O
mutations	O
in	O
the	O
genes	O
encoding	O
signaling	O
molecules	O
in	O
the	O
sonic	O
hedgehog	O
(	O
Shh	O
)	O
pathway	O
,	O
which	O
are	O
risk	O
factors	O
for	O
cleft	B-Phenotype
palate	E-Phenotype
in	O
both	O
humans	O
and	O
mice	O
.	O

We	O
found	O
that	O
multiple	O
oncogenic	O
tyrosine	O
kinases	O
directly	O
phosphorylated	O
PDP1	O
at	O
Tyr	O
-	O
94	O
,	O
and	O
Tyr	O
-	O
94	O
phosphorylation	O
of	O
PDP1	O
was	O
common	O
in	O
diverse	O
human	O
cancer	S-Phenotype
cells	O
and	O
primary	O
leukemia	S-Phenotype
cells	O
from	O
patients	O
.	O

By	O
using	O
three	O
human	O
tumor	S-Phenotype
cell	O
lines	O
of	O
different	O
tissue	O
origin	O
(	O
epidermoid	O
HEp	O
-	O
3	O
and	O
prostate	O
PC	O
-	O
3	O
carcinomas	S-Phenotype
and	O
HT	O
-	O
1080	O
fibrosarcoma	S-Phenotype
)	O
and	O
several	O
metastasis	O
models	O
conducted	O
in	O
both	O
mammalian	O
and	O
avian	O
settings	O
,	O
we	O
show	O
that	O
LTBP3	O
is	O
involved	O
in	O
the	O
early	O
dissemination	O
of	O
primary	O
cancer	S-Phenotype
cells	O
,	O
namely	O
in	O
the	O
intravasation	O
step	O
of	O
the	O
metastatic	O
cascade	O
.	O

MAGEL2	O
mutations	O
,	O
first	O
reported	O
to	O
be	O
the	O
cause	O
of	O
the	O
Prader	O
-	O
Willi	O
like	O
syndrome	O
with	O
autism	S-Phenotype
by	O
Schaaf	O
et	O
al	O
.	O

BCOR	O
immunohistochemical	O
staining	O
was	O
performed	O
on	O
archival	O
tissue	O
from	O
28	O
high	B-Phenotype
-	I-Phenotype
grade	I-Phenotype
endometrial	I-Phenotype
stromal	I-Phenotype
sarcomas	E-Phenotype
with	O
classic	O
morphology	O
(	O
20	O
YWHAE	O
-	O
NUTM2	O
,	O
5	O
ZC3H7B	O
-	O
BCOR	O
,	O
3	O
BCOR	O
-	O
ZC3H7B	O
)	O
,	O
3	O
high	B-Phenotype
-	I-Phenotype
grade	I-Phenotype
endometrial	I-Phenotype
stromal	I-Phenotype
sarcomas	E-Phenotype
with	O
unusual	O
morphology	O
and	O
unknown	O
gene	O
rearrangement	O
status	O
,	O
66	O
low	B-Phenotype
-	I-Phenotype
grade	I-Phenotype
endometrial	I-Phenotype
stromal	I-Phenotype
sarcomas	E-Phenotype
,	O
21	O
endometrial	B-Phenotype
stromal	I-Phenotype
nodules	E-Phenotype
,	O
38	O
uterine	B-Phenotype
leiomyosarcomas	E-Phenotype
,	O
and	O
19	O
uterine	B-Phenotype
leiomyomas	E-Phenotype
.	O

We	O
examined	O
a	O
Japanese	O
54	O
-	O
years	O
-	O
old	O
male	O
patient	O
with	O
autosomal	B-Phenotype
recessive	E-Phenotype
SPG	O
.	O

RNA	O
sequencing	O
transcriptome	O
analysis	O
revealed	O
that	O
inflammatory	O
mediators	O
such	O
as	O
tumor	S-Phenotype
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
α	O
suppressed	O
expression	O
of	O
R	O
-	O
spondin	O
-	O
1	O
(	O
Rspo1	O
,	O
a	O
critical	O
growth	O
factor	O
for	O
intestinal	O
epithelial	O
cells	O
)	O
in	O
Sirt6	O
-	O
silenced	O
YAMC	O
cells	O
liin	O
vitro	O
/	O
i	O
.	O

In	O
this	O
subset	O
of	O
extra	B-Phenotype
-	I-Phenotype
hepatic	I-Phenotype
cancers	E-Phenotype
,	O
MAT2A	O
and	O
MAT2B	O
are	O
induced	O
via	O
different	O
regulatory	O
mechanisms	O
.	O

Overall	O
,	O
our	O
results	O
suggest	O
that	O
PQQ	O
neuroprotection	O
may	O
be	O
mediated	O
by	O
the	O
inhibition	O
of	O
mitochondrial	B-Phenotype
dysfunction	E-Phenotype
and	O
oxidative	B-Phenotype
stress	E-Phenotype
as	O
well	O
as	O
by	O
the	O
gene	O
modulation	O
of	O
Ndufs1	O
and	O
Ndufs4	O

These	O
findings	O
establish	O
these	O
mutant	O
mice	O
as	O
a	O
suitable	O
model	O
system	O
to	O
elucidate	O
how	O
SERPINB6	O
deficiency	O
causes	O
deafness	S-Phenotype
in	O
humans	O

In	O
20	O
/	O
23	O
cases	O
,	O
MDRrel	O
BSI	O
occurred	O
during	O
neutropenia	S-Phenotype
.	O

Higher	O
melanophilin	O
level	O
in	O
prostate	O
tissue	O
of	O
patients	O
with	O
a	O
favorable	O
PCa	O
risk	O
profile	O
points	O
out	O
a	O
tumor	S-Phenotype
-	O
suppressive	O
effect	O
.	O

Our	O
findings	O
designate	O
NR0B1	O
as	O
a	O
druggable	O
transcriptional	O
regulator	O
that	O
supports	O
NRF2	O
-	O
dependent	O
lung	B-Phenotype
cancers	E-Phenotype

For	O
example	O
,	O
CaSR	O
agonists	O
such	O
as	O
dipeptides	O
have	O
been	O
suggested	O
to	O
reduce	O
colonic	O
inflammation	O
,	O
while	O
dietary	O
calcium	O
was	O
shown	O
to	O
reduce	O
the	O
risk	O
of	O
colorectal	B-Phenotype
cancer	E-Phenotype
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
understand	O
the	O
role	O
of	O
SLIT2	O
-	O
ROBO1	O
/	O
2	O
-	O
CDC42	O
signalling	O
pathways	O
in	O
development	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
(	O
BC	S-Phenotype
)	O
.	O

Connectivity	O
mapping	O
identified	O
vinblastine	O
and	O
vincristine	O
as	O
agents	O
that	O
could	O
reverse	O
the	O
CD133	O
/	O
HOX	O
genes	O
/	O
LIM2	O
-	O
signature	O
,	O
and	O
we	O
confirmed	O
this	O
by	O
in	O
vitro	O
analysis	O
in	O
glioma	S-Phenotype
cell	O
lines	O
,	O
demonstrating	O
that	O
CD133	O
and	O
HOX	O
genes	O
were	O
co	O
-	O
expressed	O
and	O
could	O
be	O
downregulated	O
by	O
vincristine	O
.	O

The	O
TNC	O
mRNA	O
and	O
protein	O
levels	O
were	O
found	O
to	O
significantly	O
downregulated	O
in	O
tumors	S-Phenotype
without	O
progression	O
compared	O
to	O
those	O
tumors	S-Phenotype
which	O
occurred	O
tumor	S-Phenotype
progression	O
during	O
the	O
follow	O
-	O
up	O
period	O
(	O
P	O
AAAA	O
.05	O
)	O
.	O

In	O
44	O
primary	O
acral	S-Phenotype
melanomas	S-Phenotype
,	O
sensitivity	O
was	O
70.5	O
%	O
(	O
31	O
/	O
44	O
)	O
using	O
probe	O
set	O
1	O
alone	O
,	O
and	O
59.1	O
%	O
(	O
26	O
/	O
44	O
)	O
using	O
probe	O
set	O
2	O
alone	O
.	O

Besides	O
dramatic	O
metabolic	O
alterations	O
,	O
cancer	S-Phenotype
cells	O
display	O
severe	O
changes	O
in	O
the	O
clock	O
phenotype	O
with	O
likely	O
consequences	O
in	O
tumor	S-Phenotype
progression	O
and	O
treatment	O
response	O
.	O

These	O
findings	O
support	O
that	O
UNC119	O
is	O
a	O
regulator	O
of	O
the	O
RASSF6	O
-	O
MDM2	O
-	O
p53	O
axis	O
and	O
functions	O
as	O
a	O
tumor	S-Phenotype
suppressor	O

Here	O
,	O
we	O
show	O
that	O
invasive	O
breast	B-Phenotype
tumors	E-Phenotype
exhibit	O
significant	O
ADAM23	O
-	O
ITH	O
and	O
that	O
this	O
heterogeneity	S-Phenotype
is	O
critical	O
for	O
tumor	S-Phenotype
growth	O
and	O
metastasis	O
.	O

Intriguingly	O
,	O
MRE11	O
is	O
highly	O
expressed	O
and	O
predicts	O
bad	O
prognosis	O
in	O
MYCN	O
-	O
amplified	O
neuroblastoma	S-Phenotype
.	O

ClpP	O
is	O
universally	O
overexpressed	O
in	O
primary	O
and	O
metastatic	O
human	O
cancer	S-Phenotype
,	O
correlating	O
with	O
shortened	O
patient	O
survival	O
.	O

To	O
understand	O
the	O
mechanism	O
of	O
TAM	O
-	O
resistance	O
in	O
GPER	O
activated	O
ER+	O
breast	B-Phenotype
cancer	E-Phenotype
,	O
the	O
function	O
of	O
TRIM2	O
and	O
Bim	O
inducing	O
cell	O
apoptosis	O
was	O
studied	O
.	O

In	O
anticipation	O
of	O
the	O
proliferation	O
of	O
time	O
series	O
data	O
sets	O
in	O
the	O
near	O
future	O
,	O
we	O
use	O
the	O
Hopfield	O
model	O
,	O
a	O
recurrent	O
neural	O
network	O
based	O
on	O
spin	O
glasses	O
,	O
to	O
model	O
the	O
dynamics	O
of	O
cell	O
cycle	O
in	O
HeLa	O
(	O
human	O
cervical	B-Phenotype
cancer	E-Phenotype
)	O
and	O
S.	O
cerevisiae	O
cells	O
.	O

Genetic	O
or	O
small	O
-	O
molecule	O
inhibitor	O
-	O
based	O
ablation	O
of	O
HIF	O
-	O
1α	O
/	O
TGF	O
-	O
β2	O
-	O
mediated	O
GLI2	O
signaling	O
effectively	O
reversed	O
the	O
chemoresistance	O
caused	O
by	O
the	O
tumor	S-Phenotype
microenvironment	O
.	O

Recently	O
,	O
we	O
developed	O
a	O
double	O
-	O
retargeting	O
strategy	O
whereby	O
gH	O
carries	O
the	O
GCN4	O
peptide	O
for	O
retargeting	O
to	O
the	O
noncancer	O
producer	O
Vero	O
-	O
GCN4R	O
cell	O
line	O
and	O
gD	O
carries	O
the	O
scFv	O
to	O
HER2	O
for	O
cancer	S-Phenotype
retargeting	O
.	O

Moreover	O
,	O
the	O
novel	O
mutation	O
,	O
p.R414C	O
,	O
adds	O
up	O
to	O
the	O
literature	O
for	O
the	O
infantile	O
-	O
onset	O
form	O
of	O
autosomal	O
recessive	O
ataxia	S-Phenotype
associated	O
with	O
SPTBN2	O
.	O

Usher	O
syndrome	O
type	O
III	O
(	O
USH3A	O
)	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
caused	O
by	O
mutations	O
in	O
clarin	O
-	O
1	O
(	O
CLRN1	O
)	O
gene	O
,	O
leading	O
to	O
progressive	O
retinal	B-Phenotype
degeneration	E-Phenotype
and	O
sensorineural	B-Phenotype
deafness	E-Phenotype
.	O

The	O
staining	O
intensity	O
of	O
ALG3	O
was	O
significantly	O
correlated	O
to	O
the	O
tumor	S-Phenotype
grade	O
(	O
grades	O
2	O
-	O
3	O
versus	O
1	O
,	O
pAAAA0.05	O
)	O
.	O

Moreover	O
,	O
CLCA2	O
depletion	O
in	O
PCa	O
cells	O
injected	O
subcutaneously	O
in	O
MeS	O
mice	O
increased	O
the	O
circulating	O
tumor	S-Phenotype
cells	O
foci	O
compared	O
to	O
control	O
.	O

Evidence	O
for	O
association	O
with	O
endometriosis	S-Phenotype
was	O
also	O
found	O
for	O
the	O
AC	O
genotype	O
of	O
the	O
rs10859871	O
of	O
VEZT	O
.	O

Here	O
,	O
we	O
disrupt	O
the	O
peroxiredoxin	O
1	O
(	O
PRDX1	O
)	O
and	O
7,8	O
-	O
dihydro	O
-	O
8	O
-	O
oxoguanine	O
triphosphatase	O
(	O
MTH1	O
)	O
genes	O
in	O
cancer	S-Phenotype
cells	O
and	O
demonstrate	O
that	O
PRDX1	O
and	O
MTH1	O
cooperate	O
to	O
prevent	O
accumulation	O
of	O
oxidized	O
guanine	O
in	O
the	O
genome	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
found	O
that	O
RNF6	O
was	O
overexpressed	O
in	O
more	O
than	O
70	O
%	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
tissues	O
and	O
it	O
was	O
associated	O
with	O
overall	O
survival	O
.	O

Five	O
haplotypes	O
(	O
GTTAT	O
,	O
ATTGT	O
,	O
GCTAC	O
,	O
ACTAC	O
,	O
and	O
ACCAC	O
)	O
were	O
found	O
significantly	O
associated	O
with	O
low	O
liCHRM3	O
/	O
i	O
mRNA	O
level	O
and	O
contributed	O
to	O
increased	O
susceptibility	O
of	O
bladder	B-Phenotype
cancer	E-Phenotype
in	O
Kaohsiung	O
city	O
after	O
rigid	O
10000	O
consecutive	O
permutation	O
tests	O
.	O

Therefore	O
,	O
FBXL4	O
could	O
be	O
a	O
potential	O
novel	O
prostate	B-Phenotype
cancer	E-Phenotype
suppressor	O
gene	O
,	O
which	O
may	O
prevent	O
cancer	S-Phenotype
progression	O
and	O
metastasis	O
through	O
controlling	O
cell	O
invasion	O

The	O
frequency	O
of	O
CRYGD	O
p.	O
(	O
Tyr56	O
*	O
)	O
in	O
the	O
ExAC	O
dataset	O
was	O
higher	O
than	O
the	O
estimated	O
incidence	O
of	O
congenital	B-Phenotype
cataract	E-Phenotype
in	O
the	O
general	O
population	O
.	O

Downregulation	O
of	O
miR	O
-	O
29a	O
caused	O
overexpression	O
of	O
LOXL2	O
and	O
SERPINH1	O
in	O
lung	B-Phenotype
cancer	E-Phenotype
and	O
IPF	O
,	O
suggesting	O
that	O
these	O
genes	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
these	O
two	O
diseases	O

Here	O
,	O
with	O
a	O
comprehensive	O
literature	O
review	O
,	O
we	O
report	O
a	O
couple	O
with	O
an	O
infertility	S-Phenotype
history	O
of	O
9	O
years	O
and	O
three	O
unsuccessful	O
IVF	O
treatments	O
,	O
where	O
male	O
partner	O
has	O
Kartagener	O
's	O
Syndrome	O
,	O
a	O
subtype	O
of	O
PCD	O
,	O
displaying	O
recurrent	B-Phenotype
respiratory	I-Phenotype
infections	E-Phenotype
,	O
dextrocardia	S-Phenotype
and	O
total	O
asthenozoospermia	O
.	O

We	O
expand	O
the	O
knowledge	O
about	O
TTC7A	O
deficiency	O
,	O
describing	O
a	O
patient	O
with	O
the	O
mild	O
phenotype	O
of	O
TTC7A	O
deficiency	O
but	O
presenting	O
overlapping	O
features	O
of	O
SD	O
/	O
THE	O
and	O
MIA	O
-	O
CID	O
:	O
intestinal	B-Phenotype
atresia	E-Phenotype
and	O
inflammatory	B-Phenotype
bowel	I-Phenotype
disease	E-Phenotype
evocative	O
of	O
MIA	O
-	O
CID	O
,	O
but	O
also	O
dental	B-Phenotype
abnormalities	E-Phenotype
,	O
huge	B-Phenotype
forehead	E-Phenotype
,	O
liver	B-Phenotype
abnormalities	E-Phenotype
,	O
autoimmune	B-Phenotype
thyroiditis	E-Phenotype
and	O
hypogammaglobulinemia	S-Phenotype
,	O
evocative	O
of	O
SD	O
/	O
THE	O

Pulmonary	O
veno	O
-	O
occlusive	O
disease	O
(	O
PVOD	O
)	O
is	O
a	O
rare	O
and	O
fatal	O
cause	O
of	O
pulmonary	B-Phenotype
arterial	I-Phenotype
hypertension	E-Phenotype
(	O
PAH	S-Phenotype
)	O
.	O

Taken	O
together	O
,	O
we	O
show	O
that	O
common	O
DNA	O
variants	O
within	O
CPZ	O
at	O
4p16	O
and	O
upstream	O
of	O
MLF1	O
at	O
3q25	O
influence	O
neuroblastoma	S-Phenotype
susceptibility	O
and	O
MLF1	O
likely	O
plays	O
an	O
important	O
role	O
in	O
neuroblastoma	S-Phenotype
tumorigenesis	O

Utilizing	O
matrix	O
-	O
coated	O
polydimethylsiloxane	O
gels	O
to	O
manipulate	O
substrate	O
compliance	O
,	O
we	O
show	O
that	O
cdGAP	O
,	O
an	O
adhesion	O
-	O
localized	O
Rac1	O
and	O
Cdc42	O
specific	O
GTPase	O
activating	O
protein	O
,	O
is	O
necessary	O
for	O
U2OS	O
osteosarcoma	S-Phenotype
cells	O
to	O
coordinate	O
cell	O
shape	O
changes	O
and	O
migration	O
as	O
a	O
function	O
of	O
extracellular	O
matrix	O
stiffness	O
.	O

Focal	B-Phenotype
cortical	I-Phenotype
dysplasia	E-Phenotype
(	O
FCD	S-Phenotype
)	O
and	O
hemimegalencephaly	S-Phenotype
(	O
HME	S-Phenotype
)	O
are	O
epileptogenic	O
neurodevelopmental	O
malformations	O
caused	O
by	O
mutations	O
in	O
mTOR	O
pathway	O
genes	O
.	O

The	O
possible	O
involvement	O
of	O
FSHR	O
in	O
tumor	S-Phenotype
progression	O
and	O
the	O
use	O
of	O
FSHR	O
examination	O
for	O
diagnostic	O
purposes	O
is	O
also	O
reviewed	O
.	O

In	O
summary	O
,	O
our	O
findings	O
suggest	O
novel	O
roles	O
of	O
NRF1	O
and	O
its	O
regulatory	O
networks	O
in	O
susceptibility	O
to	O
the	O
ER	O
/	O
PR	O
-	O
ve	O
HER2	O
+ve	O
aggressive	O
breast	B-Phenotype
cancer	E-Phenotype
subtype	O
.	O

Thus	O
TNFAIP8	O
seems	O
to	O
regulate	O
the	O
cell	O
survival	O
and	O
cancer	S-Phenotype
progression	O
processes	O
in	O
a	O
multifaceted	O
manner	O
.	O

Patients	O
with	O
SHS	O
present	O
with	O
contractures	S-Phenotype
of	O
the	O
limbs	O
and	O
a	O
distinctive	O
triangular	B-Phenotype
facies	E-Phenotype
with	O
prominent	B-Phenotype
nasolabial	I-Phenotype
folds	E-Phenotype
.	O

Lately	O
,	O
ARMC5	O
was	O
linked	O
to	O
the	O
cyclic	O
AMP	O
signaling	O
pathway	O
,	O
which	O
could	O
be	O
implicated	O
in	O
all	O
of	O
mechanisms	O
of	O
cortisol	O
-	O
secreting	O
by	O
macronodules	B-Phenotype
adrenal	I-Phenotype
hyperplasia	E-Phenotype
and	O
the	O
molecular	O
defects	O
in	O
:	O
G	O
protein	O
aberrant	O
receptors	O
;	O
MC2R	O
;	O
GNAS	O
;	O
PRKAR1A	O
;	O
PDE11A	O
;	O
PDE8B	O
.	O

G	O
-	O
banding	O
showed	O
that	O
three	O
tumors	S-Phenotype
carried	O
rearrangements	O
of	O
the	O
long	O
arm	O
of	O
chromosome	O
12	O
,	O
three	O
others	O
had	O
8q	O
rearrangements	O
,	O
the	O
7th	O
tumor	S-Phenotype
had	O
deletion	O
of	O
the	O
long	O
arm	O
of	O
chromosome	O
7	O
,	O
del	O
(	O
7	O
)	O
(	O
q22	O
)	O
,	O
and	O
the	O
8th	O
had	O
aberrations	O
of	O
chromosome	O
bands	O
3q21~23	O
and	O
11q21~22	O
.	O

These	O
results	O
imply	O
that	O
PPI	O
might	O
be	O
modulated	O
by	O
four	O
genotypes	O
-	O
COMT	O
rs4680	O
(	O
primarily	O
in	O
males	O
)	O
,	O
GRIK3	O
rs1027599	O
,	O
TCF4	O
rs9960767	O
,	O
and	O
PRODH	O
rs385440	O
-	O
indicating	O
a	O
role	O
of	O
these	O
gene	O
variations	O
in	O
the	O
development	O
of	O
early	O
information	O
processing	O
deficits	O
in	O
schizophrenia	S-Phenotype
.	O

Primary	O
human	O
PSCs	O
and	O
pancreatic	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
were	O
exposed	O
to	O
SHH	O
,	O
cyclopamine	O
,	O
GLI	O
family	O
zinc	O
finger	O
-	O
1	O
(	O
Gli	O
-	O
1	O
)	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
,	O
and	O
Gremlin	O
1	O
siRNA	O
to	O
examine	O
their	O
associations	O
and	O
effects	O
using	O
an	O
MTT	O
assay	O
,	O
reverse	O
transcription	O
-	O
quantitative	O
polymerase	O
chain	O
reaction	O
analysis	O
,	O
western	O
blot	O
analysis	O
,	O
and	O
migration	O
or	O
invasion	O
assays	O
.	O

The	O
key	O
clinical	O
features	O
of	O
the	O
patient	O
with	O
SJS1	O
included	O
short	B-Phenotype
stature	E-Phenotype
,	O
joint	B-Phenotype
contractures	E-Phenotype
,	O
pigeon	O
breast	O
,	O
and	O
myotonia	S-Phenotype
that	O
led	O
to	O
progressive	O
stiffness	O
of	O
the	O
face	O
and	O
limbs	O
;	O
barely	O
discernible	O
kyphosis	S-Phenotype
was	O
also	O
noted	O
.	O

While	O
the	O
varied	O
landscapes	O
of	O
mutations	O
driving	O
common	O
cancer	S-Phenotype
types	O
such	O
as	O
lung	B-Phenotype
,	I-Phenotype
breast	I-Phenotype
,	I-Phenotype
and	I-Phenotype
colorectal	I-Phenotype
cancer	E-Phenotype
have	O
been	O
comprehensively	O
charted	O
,	O
the	O
genetic	O
underpinnings	O
of	O
many	O
rare	O
cancers	S-Phenotype
remain	O
poorly	O
defined	O
.	O

We	O
focused	O
on	O
the	O
tumor	S-Phenotype
necrosis	O
factor	O
(	O
TNF	O
)	O
pathway	O
and	O
revealed	O
upregulation	O
of	O
genes	O
related	O
to	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
κB	O
)	O
signaling	O
and	O
senescence	O
-	O
associated	O
secretory	O
phenotype	O
factors	O
.	O

Most	O
studies	O
are	O
in	O
agreement	O
as	O
to	O
the	O
belief	O
that	O
,	O
in	O
a	O
large	O
range	O
of	O
human	O
cancers	S-Phenotype
,	O
the	O
SPINT2	O
gene	O
promoter	O
is	O
frequently	O
methylated	O
,	O
resulting	O
in	O
the	O
epigenetic	O
silence	O
of	O
this	O
gene	O
.	O

Here	O
,	O
we	O
have	O
identified	O
an	O
epileptic	B-Phenotype
encephalopathy	E-Phenotype
additionally	O
featuring	O
cerebral	B-Phenotype
calcifications	E-Phenotype
and	O
coarse	B-Phenotype
facial	I-Phenotype
features	E-Phenotype
caused	O
by	O
recessive	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
DENND5A	O
.	O

In	O
co	O
-	O
culture	O
experiments	O
using	O
F10	O
-	O
OVA	O
melanoma	S-Phenotype
cells	O
and	O
tumor	S-Phenotype
-	O
specific	O
CD3+	O
T	O
cells	O
,	O
EGCG	O
reduced	O
liPD	O
-	O
L1	O
/	O
i	O
mRNA	O
expression	O
about	O
30	O
%	O
in	O
F10	O
-	O
OVA	O
cells	O
and	O
restored	O
liinterleukin	O
-	O
2	O
/	O
i	O
mRNA	O
expression	O
in	O
tumor	S-Phenotype
-	O
specific	O
CD3+	O
T	O
cells	O
.	O

We	O
also	O
describe	O
a	O
mouse	O
model	O
harboring	O
a	O
knockdown	O
mutation	O
in	O
the	O
murine	O
Hbs1l	O
gene	O
that	O
shared	O
several	O
of	O
the	O
phenotypic	O
elements	O
observed	O
in	O
the	O
Hbs1L	O
-	O
deficient	O
human	O
including	O
facial	B-Phenotype
dysmorphism	E-Phenotype
,	O
growth	B-Phenotype
restriction	E-Phenotype
and	O
retinal	B-Phenotype
deposits	E-Phenotype
.	O

Here	O
,	O
we	O
causally	O
link	O
a	O
previously	O
unreported	O
missense	O
mutation	O
in	O
TUBB2A	O
(	O
c.1249GAAAAA	O
,	O
p.D417N	O
)	O
,	O
encoding	O
one	O
of	O
the	O
neuron	O
-	O
specific	O
β	O
-	O
tubulin	O
isotype	O
II	O
,	O
to	O
a	O
disorder	O
characterized	O
by	O
progressive	B-Phenotype
spastic	I-Phenotype
paraplegia	E-Phenotype
,	O
peripheral	B-Phenotype
sensory	I-Phenotype
-	I-Phenotype
motor	I-Phenotype
polyneuropathy	E-Phenotype
and	O
ataxia	S-Phenotype
.	O

Mutations	O
in	O
the	O
proline	O
dehydrogenase	O
gene	O
PRODH	O
are	O
linked	O
to	O
behavioral	O
alterations	O
in	O
schizophrenia	S-Phenotype
and	O
as	O
part	O
of	O
DiGeorge	O
and	O
velo	O
-	O
cardio	O
-	O
facial	O
syndromes	O
,	O
but	O
the	O
role	O
of	O
PRODH	O
in	O
their	O
etiology	O
remains	O
unclear	O
.	O

As	O
the	O
first	O
report	O
in	O
Korea	O
,	O
this	O
study	O
identified	O
three	O
KIF5A	O
mutations	O
as	O
the	O
underlying	O
cause	O
of	O
axonal	B-Phenotype
peripheral	I-Phenotype
neuropathy	E-Phenotype
with	O
or	O
without	O
the	O
HSP	O
phenotype	O
.	O

Moreover	O
,	O
CARD9	O
-	O
dependent	O
functions	O
have	O
recently	O
been	O
indicated	O
to	O
modulate	O
the	O
development	O
of	O
autoimmunity	S-Phenotype
,	O
inflammatory	B-Phenotype
bowel	I-Phenotype
diseases	E-Phenotype
,	O
and	O
cancer	S-Phenotype
.	O

This	O
study	O
involved	O
2	O
primary	O
renal	O
PGL	O
and	O
12	O
cases	O
of	O
PC	O
/	O
PGL	O
with	O
associated	O
renal	B-Phenotype
neoplasia	E-Phenotype
with	O
a	O
mean	O
follow	O
up	O
of	O
74	O
months	O
.	O

In	O
summary	O
,	O
for	O
the	O
first	O
time	O
,	O
we	O
generated	O
a	O
ush2a	O
knockout	O
zebrafish	O
line	O
with	O
auditory	B-Phenotype
disorder	E-Phenotype
and	O
retinal	B-Phenotype
degeneration	E-Phenotype
which	O
mimicked	O
the	O
symptoms	O
of	O
patients	O
,	O
and	O
revealed	O
that	O
disruption	O
of	O
fibronectin	O
assembly	O
may	O
be	O
one	O
of	O
the	O
factors	O
underlying	O
RP	O
.	O

Hepatocyte	O
growth	O
factor	O
(	O
HGF	O
)	O
/	O
c	O
-	O
MET	O
signaling	O
plays	O
an	O
important	O
role	O
in	O
cell	O
proliferation	O
,	O
survival	O
,	O
migration	O
and	O
motility	O
of	O
cancer	S-Phenotype
cells	O
.	O

His	O
facial	O
features	O
included	O
a	O
high	B-Phenotype
anterior	I-Phenotype
hairline	E-Phenotype
,	O
small	B-Phenotype
eyes	I-Phenotype
with	I-Phenotype
narrowed	I-Phenotype
palpebral	I-Phenotype
fissures	E-Phenotype
,	O
a	O
bulbous	B-Phenotype
nasal	I-Phenotype
tip	E-Phenotype
with	O
a	O
short	B-Phenotype
columella	E-Phenotype
,	O
and	O
a	O
large	B-Phenotype
mouth	E-Phenotype
with	O
a	O
thin	B-Phenotype
upper	I-Phenotype
vermilion	E-Phenotype
,	O
and	O
small	B-Phenotype
chin	E-Phenotype
.	O

Although	O
overlapping	O
features	O
with	O
Bohring	O
-	O
Opitz	O
and	O
Bainbridge	O
-	O
Ropers	O
syndromes	O
exist	O
,	O
features	O
that	O
distinguish	O
the	O
ASXL2	O
-	O
associated	O
condition	O
from	O
ASXL1	O
-	O
and	O
ASXL3	O
-	O
related	O
disorders	O
are	O
macrocephaly	S-Phenotype
,	O
absence	B-Phenotype
of	I-Phenotype
growth	I-Phenotype
retardation	E-Phenotype
,	O
and	O
more	O
variability	O
in	O
the	O
degree	O
of	O
intellectual	B-Phenotype
disabilities	E-Phenotype
.	O

HOXA13	O
plays	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
distal	B-Phenotype
limbs	E-Phenotype
and	O
lower	B-Phenotype
genitourinary	I-Phenotype
tract	E-Phenotype
of	O
the	O
fetus	O
.	O

Mutations	O
in	O
the	O
KVS	O
subunit	O
,	O
KV8.2	O
(	O
KCNV2	O
)	O
,	O
lead	O
to	O
severe	B-Phenotype
visual	I-Phenotype
impairment	E-Phenotype
in	O
humans	O
,	O
but	O
the	O
basis	O
of	O
these	O
deficits	O
remains	O
unclear	O
.	O

Nagashima	B-Phenotype
-	I-Phenotype
type	I-Phenotype
palmoplantar	I-Phenotype
keratosis	E-Phenotype
(	O
NPPK	S-Phenotype
)	O
is	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
form	O
of	O
palmoplantar	B-Phenotype
keratoderma	E-Phenotype
(	O
PPK	S-Phenotype
)	O
,	O
which	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
SERPINB7	O
gene	O
.	O

TMEM98	O
mRNA	O
in	O
tumor	S-Phenotype
tissues	O
was	O
significantly	O
higher	O
than	O
nontumor	O
tissues	O
of	O
patients	O
with	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
P	O
AAAA	O
0.0001	O
)	O
.	O

Backgorund	O
:	O
Sanjad	O
-	O
Sakati	O
syndrome	O
(	O
SSS	O
)	O
is	O
a	O
rare	O
autosomal	B-Phenotype
recessive	E-Phenotype
disease	O
caused	O
by	O
a	O
deletion	O
mutation	O
(	O
155	O
-	O
166del	O
)	O
in	O
exon	O
3	O
of	O
the	O
TBCE	O
gene	O
on	O
chromosome	O
1q42	O
-	O
43	O
.	O

Homozygous	O
,	O
loss	O
of	O
function	O
variants	O
in	O
PROKR2	O
was	O
initially	O
implicated	O
in	O
autosomal	B-Phenotype
recessive	E-Phenotype
IGD	O
;	O
however	O
,	O
most	O
IGD	O
-	O
associated	O
PROKR2	O
variants	O
are	O
heterozygous	O
.	O

Hereditary	B-Phenotype
sensory	I-Phenotype
and	I-Phenotype
autonomic	I-Phenotype
neuropathies	E-Phenotype
(	O
HSAN	S-Phenotype
)	O
type	O
II	O
are	O
characterized	O
by	O
autosomal	B-Phenotype
recessive	I-Phenotype
inheritance	E-Phenotype
,	O
onset	O
at	O
birth	O
and	O
self	O
-	O
mutilating	O
behavior	O
.	O

The	O
diagnosis	O
is	O
based	O
on	O
genetic	O
criteria	O
,	O
by	O
the	O
identification	O
of	O
inactivating	O
pathogenic	O
mutation	O
of	O
tumor	S-Phenotype
suppressor	O
genes	O
TSC1	O
and	O
TSC2	O
,	O
and	O
clinical	O
criteria	O
,	O
including	O
cutaneous	O
,	O
renal	O
,	O
pulmonary	O
,	O
cardiac	O
and	O
neurological	O
manifestations	O
.	O

In	O
the	O
previous	O
study	O
,	O
microRNA	O
(	O
miR	O
)	O
‑204	O
inhibited	O
thyroid	B-Phenotype
cancer	E-Phenotype
progression	O
and	O
was	O
regulated	O
by	O
UCA1	O
in	O
other	O
types	O
of	O
cancer	S-Phenotype
.	O

LETM1	O
protein	O
was	O
detected	O
in	O
107	O
TNBC	O
,	O
42	O
ductal	B-Phenotype
carcinoma	I-Phenotype
in	I-Phenotype
situ	E-Phenotype
(	O
DCIS	S-Phenotype
)	O
and	O
65	O
adjacent	O
non	O
-	O
tumor	S-Phenotype
breast	O
tissues	O
using	O
immunohistochemical	O
(	O
IHC	O
)	O
staining	O
.	O

The	O
sterile	O
alpha	O
motif	O
(	O
SAM	O
)	O
domain	O
of	O
the	O
protein	O
ANKS6	O
,	O
a	O
protein	O
-	O
protein	O
interaction	O
domain	O
,	O
is	O
responsible	O
for	O
autosomal	B-Phenotype
dominant	I-Phenotype
polycystic	I-Phenotype
kidney	E-Phenotype
disease	O
.	O

x2	O
analysis	O
confirmed	O
that	O
CUL7	O
expression	O
was	O
positively	O
associated	O
with	O
invasion	O
depth	O
(	O
P=0.000	O
)	O
,	O
lymph	O
node	O
involvement	O
(	O
P=0.033	O
)	O
and	O
advanced	O
clinical	O
stage	O
(	O
P=0.000	O
)	O
.	O

In	O
addition	O
,	O
no	O
somatic	B-Phenotype
mutation	E-Phenotype
was	O
found	O
in	O
SCN4B	O
DNA	O
.	O

As	O
ubiquitination	O
is	O
a	O
versatile	O
post	O
-	O
translational	O
modification	O
that	O
can	O
affect	O
target	O
turnover	O
,	O
sub	O
-	O
cellular	O
localisation	O
or	O
activity	O
,	O
it	O
is	O
likely	O
that	O
diverse	O
substrates	O
may	O
be	O
differentially	O
affected	O
by	O
TRIM32	O
-	O
mediated	O
ubiquitination	O
,	O
reflecting	O
its	O
multi	O
-	O
faceted	O
roles	O
in	O
muscle	O
physiology	O
,	O
cancer	S-Phenotype
and	O
immunity	O
.	O

Finally	O
,	O
we	O
constructed	O
a	O
causal	O
gene	O
network	O
based	O
on	O
over	O
2500	O
ER+	O
breast	B-Phenotype
tumor	E-Phenotype
samples	O
to	O
build	O
up	O
an	O
EPRS	O
-	O
estrogen	O
signaling	O
pathway	O
.	O

We	O
conclude	O
that	O
ADAMTS18	O
gene	O
hypermethylation	O
may	O
be	O
involved	O
in	O
the	O
tumorigenesis	S-Phenotype
of	O
ccRCC	O
and	O
may	O
serve	O
as	O
a	O
novel	O
biomarker	O
for	O
this	O
disease	O
.	O

Western	O
blot	O
was	O
used	O
to	O
analyze	O
the	O
cell	O
cycle	O
-	O
related	O
proteins	O
,	O
serine	O
/	O
threonine	O
kinase	O
ataxia	B-Phenotype
telangiectasia	I-Phenotype
mutant	E-Phenotype
(	O
ATM	O
)	O
,	O
ataxia	S-Phenotype
telangiectasia	S-Phenotype
and	O
Rad3	O
-	O
related	O
protein	O
(	O
ATR	O
)	O
and	O
cyclin	O
B1	O
(	O
CCNB1	O
)	O
.	O

We	O
evaluated	O
the	O
uptake	O
and	O
efflux	O
of	O
lsup131	O
/	O
supI	O
-	O
MIBG	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
in	O
mice	O
bearing	O
transfected	O
tumors	S-Phenotype
.	O

Focal	B-Phenotype
epilepsies	E-Phenotype
,	O
where	O
seizures	S-Phenotype
initiate	O
in	O
spatially	O
limited	O
networks	O
,	O
are	O
the	O
most	O
frequent	O
epilepsy	S-Phenotype
type	O
,	O
accounting	O
for	O
two	O
-	O
thirds	O
of	O
patients	O
.	O

The	O
corneal	B-Phenotype
clouding	E-Phenotype
and	O
cataracts	S-Phenotype
in	O
this	O
patient	O
may	O
thus	O
have	O
been	O
caused	O
by	O
her	O
B4GALT7	O
mutation	O
,	O
but	O
the	O
colobomas	O
are	O
a	O
novel	O
phenotypic	O
finding	O
.	O

This	O
study	O
demonstrates	O
that	O
CSNK2A1	O
and	O
SIRT6	O
are	O
indicators	O
of	O
poor	O
prognosis	O
for	O
breast	B-Phenotype
carcinomas	E-Phenotype
and	O
that	O
CSNK2A1	O
-	O
mediated	O
phosphorylation	O
of	O
SIRT6	O
might	O
be	O
involved	O
in	O
the	O
progression	O
of	O
breast	B-Phenotype
carcinoma	E-Phenotype

We	O
then	O
constructed	O
predictive	O
generalized	O
regression	O
(	O
GR	O
)	O
modeling	O
with	O
a	O
supervised	O
machine	O
learning	O
validation	O
procedure	O
with	O
the	O
target	O
variable	O
(	O
cancer	S-Phenotype
status	O
)	O
being	O
specified	O
to	O
validate	O
the	O
results	O
to	O
allow	O
enhanced	O
prediction	O
and	O
reproducibility	O
.	O

Rather	O
than	O
directly	O
inhibiting	O
PLK1	O
,	O
we	O
found	O
that	O
inhibition	O
of	O
PP2A	O
causes	O
selective	O
lethality	O
to	O
PLK1	O
-	O
overexpressing	O
breast	O
,	O
pancreatic	O
,	O
ovarian	O
,	O
glioblastoma	S-Phenotype
,	O
and	O
prostate	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Hemangioblastomas	O
(	O
HBs	O
)	O
are	O
uncommon	O
tumors	S-Phenotype
characterized	O
by	O
the	O
presence	O
of	O
inactivating	O
alterations	O
in	O
the	O
von	O
Hippel	O
-	O
Lindau	O
(	O
VHL	O
)	O
gene	O
in	O
inherited	O
cases	O
and	O
by	O
infrequent	O
somatic	B-Phenotype
mutation	E-Phenotype
in	O
sporadic	S-Phenotype
entities	O
.	O

The	O
expression	O
of	O
MLPH	O
in	O
primary	O
prostate	O
tumors	S-Phenotype
was	O
significantly	O
lower	O
in	O
those	O
with	O
the	O
G	O
compared	O
with	O
the	O
T	O
allele	O
and	O
correlated	O
significantly	O
with	O
AR	O
protein	O
.	O

Vegetarian	O
and	O
vegan	O
diets	O
have	O
increased	O
worldwide	O
in	O
the	O
last	O
decades	O
,	O
according	O
to	O
the	O
knowledge	O
that	O
they	O
might	O
prevent	O
coronary	B-Phenotype
heart	I-Phenotype
disease	E-Phenotype
,	O
cancer	S-Phenotype
,	O
and	O
cardiac	O
muscle	O
tissue	O
development	O
2	O
diabetes	S-Phenotype
.	O

In	O
conclusion	O
,	O
the	O
present	O
study	O
demonstrated	O
,	O
for	O
the	O
first	O
time	O
,	O
the	O
expression	O
and	O
function	O
of	O
PAK4	O
in	O
neuroblastomas	S-Phenotype
and	O
the	O
inhibitory	O
effect	O
of	O
PF	O
-	O
3758309	O
,	O
which	O
deserves	O
further	O
investigation	O
as	O
an	O
alternative	O
strategy	O
for	O
neuroblastoma	S-Phenotype
treatment	O

At	O
3	O
months	O
,	O
additional	O
dysmorphic	O
features	O
were	O
noted	O
and	O
at	O
18	O
months	O
her	O
radiographic	B-Phenotype
skeletal	I-Phenotype
abnormalities	E-Phenotype
were	O
suggestive	O
of	O
an	O
underlying	O
spondyloepimetaphyseal	B-Phenotype
dysplasia	E-Phenotype
(	O
SEMD	O
)	O
.	O

The	O
human	O
KAT6A	O
and	O
KAT6B	O
genes	O
are	O
recurrently	O
mutated	O
in	O
leukemia	S-Phenotype
,	O
non	O
-	O
hematologic	O
malignancies	O
,	O
and	O
multiple	O
developmental	O
disorders	O
displaying	O
intellectual	B-Phenotype
disability	E-Phenotype
and	O
various	O
other	O
abnormalities	O
.	O

Hence	O
,	O
we	O
focus	O
on	O
the	O
relationship	O
between	O
YAP	O
/	O
TAZ	O
and	O
serine	O
metabolism	O
to	O
control	O
methylation	O
of	O
DNA	O
or	O
histone	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
with	O
LKB1	O
deficiency	O
.	O

Inhibition	O
of	O
CSNK2A1	O
decreased	O
the	O
proliferative	O
and	O
invasive	O
activity	O
of	O
cancer	S-Phenotype
cells	O
.	O

We	O
recently	O
demonstrated	O
that	O
SIRT1	O
is	O
upregulated	O
in	O
melanoma	S-Phenotype
and	O
its	O
inhibition	O
by	O
a	O
small	O
-	O
molecule	O
,	O
tenovin	O
-	O
1	O
,	O
inhibits	O
cell	O
proliferation	O
and	O
clonogenic	O
survival	O
of	O
melanoma	S-Phenotype
cells	O
,	O
possibly	O
via	O
activating	O
p53	O
.	O

By	O
screening	O
a	O
large	O
cohort	O
of	O
132	O
patients	O
with	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
severe	I-Phenotype
sensory	I-Phenotype
,	I-Phenotype
motor	I-Phenotype
and	I-Phenotype
cranial	I-Phenotype
nerve	I-Phenotype
neuropathy	E-Phenotype
we	O
confirmed	O
the	O
strong	O
genetic	O
link	O
between	O
riboflavin	O
transporter	O
mutations	O
and	O
Brown	O
-	O
Vialetto	O
-	O
Van	O
Laere	O
syndrome	O
,	O
identifying	O
22	O
pathogenic	O
mutations	O
in	O
SLC52A2	O
and	O
SLC52A3	O
,	O
14	O
of	O
which	O
were	O
novel	O
.	O

By	O
GEPIA	O
database	O
analysis	O
,	O
we	O
also	O
found	O
that	O
the	O
expression	O
of	O
lncRNA	O
FEZF	O
-	O
AS1	O
and	O
FEZF1	O
were	O
significantly	O
higher	O
in	O
tumour	S-Phenotype
tissues	O
than	O
those	O
of	O
the	O
adjacent	O
non	O
-	O
cancerous	S-Phenotype
tissues	O
in	O
969	O
NSCLC	O
patients	O
(	O
P	O
AAAA	O
0.05	O
)	O
,	O
and	O
lncRNA	O
FEZF	O
-	O
AS1	O
was	O
positively	O
correlated	O
with	O
FEZF1	O
(	O
r	O
=	O
0.90	O
,	O
P	O
AAAA	O
0.001	O
)	O
.	O

Suppression	O
of	O
miR	O
-	O
1274a	O
significantly	O
inhibited	O
cancer	S-Phenotype
cell	O
proliferation	O
and	O
induced	O
apoptosis	O
in	O
the	O
ccRCC	O
cells	O
.	O

The	O
study	O
of	O
the	O
immunome	O
of	O
prostate	B-Phenotype
cancer	E-Phenotype
(	O
PCa	S-Phenotype
)	O
and	O
characterization	O
of	O
autoantibody	O
signature	O
from	O
differentially	O
reactive	O
antigens	O
can	O
uncover	O
disease	O
stage	O
proteins	O
,	O
reveal	O
enriched	O
networks	O
and	O
even	O
expose	O
aberrant	O
cellular	O
mechanisms	O
during	O
the	O
disease	O
process	O
.	O

In	O
humans	O
,	O
the	O
clinical	O
relevance	O
of	O
BRUCE	O
downregulation	O
in	O
liver	B-Phenotype
disease	E-Phenotype
was	O
found	O
in	O
hepatitis	S-Phenotype
,	O
cirrhosis	S-Phenotype
and	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
specimens	O
and	O
deleterious	O
somatic	O
mutations	O
of	O
the	O
Bruce	O
gene	O
was	O
found	O
in	O
human	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
in	O
TCGA	O
database	O
.	O

Our	O
findings	O
indicate	O
that	O
mutations	O
in	O
EBF3	O
cause	O
a	O
genetic	O
neurodevelopmental	O
syndrome	O
and	O
suggest	O
that	O
loss	O
of	O
EBF3	O
function	O
might	O
mediate	O
a	O
subset	O
of	O
neurologic	O
phenotypes	O
shared	O
by	O
ARX	O
-	O
related	O
disorders	O
,	O
including	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
abnormal	B-Phenotype
genitalia	E-Phenotype
,	O
and	O
structural	O
CNS	O
malformations	O

iIn	O
vitro	O
/	O
i	O
analysis	O
revealed	O
that	O
knockdown	O
of	O
WWOX	O
protein	O
in	O
neuroblastoma	S-Phenotype
cells	O
results	O
in	O
aggregation	O
of	O
TRAPPC6AΔ	O
,	O
TIAF1	O
,	O
amyloid	O
β	O
,	O
and	O
Tau	O
in	O
a	O
sequential	O
manner	O
.	O

In	O
this	O
study	O
,	O
we	O
examine	O
the	O
role	O
of	O
proton	O
-	O
sensing	O
ovarian	B-Phenotype
cancer	E-Phenotype
G	O
protein	O
-	O
coupled	O
receptor	O
1	O
(	O
OGR1	O
)	O
in	O
extracellular	O
acidification	O
-	O
induced	O
regulation	O
of	O
cyclooxygenase	O
(	O
COX	O
)	O
-	O
2	O
induction	O
,	O
PGI	O
(	O
2	O
)	O
production	O
,	O
MAPK	O
phosphatase	O
(	O
MKP	O
)	O
-	O
1	O
expression	O
,	O
and	O
plasminogen	O
activator	O
inhibitor	O
(	O
PAI	O
)	O
-	O
1	O
expression	O
and	O
proliferation	O
in	O
human	O
aortic	O
smooth	O
muscle	O
cells	O
(	O
AoSMCs	O
)	O
.	O

To	O
understand	O
the	O
characteristics	O
of	O
ADSSL1	O
myopathy	S-Phenotype
,	O
we	O
investigated	O
the	O
clinical	O
manifestation	O
in	O
Korean	O
patients	O
with	O
ADSSL1	O
mutations	O
.	O

This	O
is	O
prototypically	O
exemplified	O
by	O
neuroblastoma	S-Phenotype
,	O
where	O
MYCN	O
amplification	O
occurs	O
in	O
about	O
25	O
%	O
of	O
the	O
cases	O
.	O

Therefore	O
,	O
this	O
study	O
demonstrated	O
that	O
there	O
exists	O
an	O
RNF6	O
/	O
ERa	O
/	O
Bcl	O
-	O
xL	O
axle	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
which	O
promotes	O
cancer	S-Phenotype
cell	O
proliferation	O
and	O
survival	O
.	O

X	O
-	O
ALD	O
is	O
clinically	O
heterogeneous	S-Phenotype
,	O
with	O
the	O
cerebral	O
form	O
being	O
the	O
most	O
severe	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
boy	O
with	O
a	O
novel	O
pathogenic	O
MYH3	O
mutation	O
,	O
presenting	O
with	O
the	O
classical	O
clinical	O
features	O
of	O
SHS	O
in	O
association	O
with	O
unilateral	B-Phenotype
carpal	I-Phenotype
bone	I-Phenotype
fusion	E-Phenotype
and	O
multiple	O
vertebral	B-Phenotype
fusions	E-Phenotype
.	O

These	O
findings	O
designate	O
CYP3A5	O
as	O
a	O
predictor	O
of	O
therapy	O
response	O
and	O
as	O
a	O
tumor	S-Phenotype
cell	O
-	O
autonomous	O
detoxification	O
mechanism	O
that	O
must	O
be	O
overcome	O
to	O
prevent	O
drug	B-Phenotype
resistance	E-Phenotype

A	O
better	O
understanding	O
of	O
Preb	O
gene	O
expression	O
,	O
during	O
the	O
pathogenesis	O
of	O
hepatic	B-Phenotype
insulin	I-Phenotype
resistance	E-Phenotype
,	O
could	O
ultimately	O
provide	O
new	O
avenues	O
for	O
therapies	O
for	O
metabolic	O
syndrome	O
,	O
obesity	S-Phenotype
,	O
and	O
type	B-Phenotype
-	I-Phenotype
2	I-Phenotype
diabetes	I-Phenotype
mellitus	E-Phenotype
,	O
disorders	O
whose	O
worldwide	O
incidences	O
are	O
increasing	O
drastically	O

Clinicopathologic	O
features	O
such	O
as	O
menarche	O
age	O
,	O
body	O
mass	O
index	O
,	O
personal	O
cancer	S-Phenotype
history	O
,	O
grade	O
,	O
and	O
histologic	O
type	O
were	O
compared	O
between	O
the	O
2	O
groups	O
.	O

PIK3C2A	O
,	O
RBMS1	O
,	O
UFSP1	O
)	O
,	O
gluco	O
-	O
metabolic	O
phenotypes	O
(	O
e.g	O
.	O

Nearly	O
80	O
genes	O
involved	O
in	O
lipid	O
metabolism	O
(	O
encoding	O
structural	O
components	O
of	O
lipoproteins	O
,	O
lipoprotein	O
receptors	O
and	O
related	O
proteins	O
,	O
enzymes	O
,	O
lipid	O
transporters	O
,	O
lipid	O
transfer	O
proteins	O
,	O
and	O
activators	O
or	O
inhibitors	O
of	O
protein	O
function	O
and	O
gene	O
transcription	O
)	O
with	O
single	O
nucleotide	O
variants	O
(	O
SNVs	O
)	O
that	O
are	O
recognized	O
to	O
be	O
associated	O
with	O
hypercholesterolemia	S-Phenotype
and	O
serum	O
lipid	O
traits	O
in	O
genome	O
-	O
wide	O
association	O
studies	O
and	O
candidate	O
gene	O
studies	O
were	O
identified	O
.	O

Drosophila	O
mutants	O
that	O
were	O
null	O
for	O
an	O
orthologue	O
of	O
BRCA2	O
were	O
sterile	O
,	O
and	O
gonadal	B-Phenotype
dysgenesis	E-Phenotype
was	O
present	O
in	O
both	O
sexes	O
.	O

Moreover	O
,	O
drug	O
sensitivity	O
analysis	O
and	O
the	O
Cancer	S-Phenotype
Cell	O
Line	O
Encyclopedia	O
database	O
revealed	O
that	O
LIFR	O
-	O
deficient	O
cells	O
had	O
high	O
sensitivity	O
to	O
a	O
YAP	O
inhibitor	O
and	O
to	O
two	O
other	O
anticancer	O
drugs	S-Phenotype
(	O
PHA	O
-	O
665752	O
,	O
PF2341066	O
)	O
.	O

Moreover	O
,	O
in	O
patients	O
with	O
low	O
MRPL13	O
expression	O
,	O
two	O
oxidative	O
metabolic	O
indicators	O
,	O
pyruvate	O
dehydrogenase	O
B	O
expression	O
and	O
the	O
ratio	O
of	O
lactate	O
dehydrogenase	O
type	O
B	O
to	O
type	O
A	O
,	O
significantly	O
and	O
negatively	O
correlated	O
with	O
CLN1	O
expression	O
,	O
indicating	O
that	O
the	O
combination	O
of	O
elevated	O
glycolysis	O
and	O
deficient	O
MRPL13	O
activity	O
was	O
closely	O
linked	O
to	O
CLN1	O
-	O
mediated	O
tumor	S-Phenotype
activity	O
in	O
LIHC	O
.	O

Stepwise	O
investigations	O
demonstrated	O
that	O
ARHGAP17	O
suppressed	O
malignant	O
phenotype	O
of	O
cervical	B-Phenotype
cancer	E-Phenotype
cells	O
via	O
inhibiting	O
PI3K	O
/	O
AKT	O
signaling	O
pathway	O
.	O

In	O
breast	B-Phenotype
cancer	E-Phenotype
,	O
EMT	O
facilitates	O
invasion	O
of	O
surrounding	O
tissues	O
and	O
correlates	O
closely	O
with	O
cancer	S-Phenotype
metastasis	O
and	O
relapse	O
.	O

Leber	B-Phenotype
*	I-Phenotype
s	I-Phenotype
hereditary	I-Phenotype
optic	I-Phenotype
neuropathy	E-Phenotype
(	O
LHON	S-Phenotype
)	O
is	O
the	O
most	O
common	O
mitochondrial	O
disorder	O
.	O

Promyelocytic	B-Phenotype
leukemia	E-Phenotype
(	O
PML	S-Phenotype
)	O
is	O
a	O
pleiotropic	O
tumor	S-Phenotype
suppressor	O
,	O
but	O
its	O
role	O
in	O
tumor	S-Phenotype
microenvironment	O
regulation	O
is	O
poorly	O
characterized	O
.	O

Among	O
510	O
unrelated	O
patients	O
with	O
distal	B-Phenotype
motor	I-Phenotype
neuropathy	E-Phenotype
,	O
we	O
identified	O
mutations	O
in	O
HSPB1	O
(	O
28	O
index	O
patients	O
/	O
510	O
;	O
5.5	O
%	O
)	O
and	O
HSPB8	O
(	O
four	O
index	O
patients	O
/	O
510	O
;	O
0.8	O
%	O
)	O
genes	O
.	O

To	O
avoid	O
this	O
artifactual	O
early	O
priming	O
of	O
the	O
host	O
precluding	O
the	O
study	O
of	O
the	O
interactions	O
between	O
the	O
immune	O
system	O
and	O
tumors	S-Phenotype
at	O
the	O
steady	O
state	O
,	O
we	O
generated	O
a	O
cell	O
line	O
expressing	O
the	O
DBY	O
Ag	O
in	O
an	O
inducible	O
manner	O
.	O

Its	O
restricted	O
expression	O
in	O
normal	O
tissues	O
and	O
unique	O
early	O
upregulation	O
during	O
tumor	S-Phenotype
development	O
make	O
CRG	O
-	O
L2	O
an	O
excellent	O
candidate	O
as	O
a	O
new	O
clinical	O
marker	O
of	O
HCC	O

Furthermore	O
,	O
we	O
herein	O
summarize	O
the	O
genotypes	O
and	O
phenotypes	O
of	O
patients	O
with	O
UNC80	O
mutations	O
reported	O
in	O
the	O
literature	O
,	O
revealing	O
that	O
IHPRF2	O
is	O
a	O
phenotypically	O
heterogeneous	S-Phenotype
disease	O
.	O

Moreover	O
,	O
we	O
identified	O
two	O
different	O
somatic	B-Phenotype
mutations	E-Phenotype
in	O
the	O
CDC73	O
gene	O
and	O
one	O
somatic	O
mutation	O
in	O
the	O
EZH2	O
gene	O
.	O

Amyotrophic	B-Phenotype
lateral	I-Phenotype
sclerosis	E-Phenotype
(	O
ALS	S-Phenotype
)	O
is	O
a	O
neurodegenerative	B-Phenotype
disease	E-Phenotype
affecting	O
motor	O
neurons	O
that	O
leads	O
to	O
progressive	O
paralysis	S-Phenotype
of	O
skeletal	O
muscle	O
.	O

By	O
combining	O
meta	O
-	O
analysis	O
results	O
and	O
identification	O
of	O
two	O
unrelated	O
HCM	O
patients	O
with	O
homozygous	O
CSRP3	O
truncating	O
variants	O
,	O
we	O
suggest	O
that	O
the	O
association	O
of	O
CSRP3	O
as	O
a	O
validated	O
HCM	O
-	O
causing	O
gene	O
require	O
additional	O
studies	O
and	O
those	O
CSRP3	O
variants	O
could	O
result	O
in	O
HCM	O
with	O
an	O
autosomal	B-Phenotype
recessive	I-Phenotype
inheritance	E-Phenotype
rather	O
than	O
with	O
an	O
autosomal	O
dominant	O
transmission	O
as	O
usually	O
reported	O
on	O
HCM	O
(	O
OMIM	O
612124	O
)	O

X	B-Phenotype
-	I-Phenotype
linked	I-Phenotype
spondylo	I-Phenotype
-	I-Phenotype
epiphyseal	I-Phenotype
dysplasia	I-Phenotype
tarda	E-Phenotype
(	O
SEDT	S-Phenotype
)	O
is	O
an	O
X	O
-	O
linked	O
recessive	O
,	O
late	O
-	O
onset	O
,	O
progressive	O
skeletal	O
disorder	O
characterized	O
by	O
mild	B-Phenotype
-	I-Phenotype
to	I-Phenotype
-	I-Phenotype
moderate	I-Phenotype
short	I-Phenotype
-	I-Phenotype
trunked	I-Phenotype
short	I-Phenotype
stature	E-Phenotype
.	O

Here	O
,	O
we	O
have	O
tested	O
the	O
hypothesis	O
that	O
the	O
common	O
TMC8	O
SNP	O
rs7208422	O
is	O
associated	O
with	O
high	O
-	O
risk	O
HPV	O
infection	O
and	O
risk	O
of	O
head	B-Phenotype
and	I-Phenotype
neck	I-Phenotype
squamous	I-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
HNSCC	S-Phenotype
)	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
expression	O
of	O
ZNF281	O
,	O
a	O
zinc	O
finger	O
factor	O
involved	O
in	O
several	O
cellular	O
processes	O
,	O
decreases	O
during	O
terminal	O
differentiation	O
of	O
murine	O
cortical	O
neurons	O
and	O
in	O
retinoic	O
acid	O
-	O
induced	O
differentiation	O
of	O
neuroblastoma	S-Phenotype
(	O
NB	O
)	O
cells	O
.	O

The	O
diagnostic	O
specificity	O
of	O
serum	O
SPARCL1	O
in	O
cervical	B-Phenotype
cancer	E-Phenotype
occurrence	O
was	O
also	O
compared	O
with	O
other	O
high	O
incidence	O
diseases	O
.	O

Ras	O
-	O
association	O
domain	O
family	O
6	O
(	O
RASSF6	O
)	O
is	O
a	O
tumor	S-Phenotype
suppressor	O
that	O
interacts	O
with	O
MDM2	O
and	O
stabilizes	O
p53	O
.	O

Silencing	O
of	O
C6orf70	O
in	O
the	O
developing	O
rat	O
neocortex	O
produced	O
periventricular	B-Phenotype
nodular	I-Phenotype
heterotopia	E-Phenotype
that	O
was	O
rescued	O
by	O
concomitant	O
expression	O
of	O
wild	O
-	O
type	O
human	O
C6orf70	O
protein	O
.	O

We	O
report	O
here	O
two	O
new	O
nonsense	O
mutations	O
(	O
pGln12	O
*	O
and	O
pTyr110	O
*	O
)	O
in	O
CIB2	O
patients	O
displaying	O
nonsyndromic	B-Phenotype
profound	I-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
,	O
with	O
no	O
evidence	O
of	O
vestibular	O
or	O
retinal	O
dysfunction	O
.	O

Smith	O
-	O
Magenis	O
syndrome	O
(	O
SMS	O
)	O
,	O
a	O
neurodevelopmental	O
disorder	O
characterized	O
by	O
dysmorphic	O
features	O
,	O
intellectual	B-Phenotype
disability	E-Phenotype
(	O
ID	S-Phenotype
)	O
,	O
and	O
sleep	B-Phenotype
disturbances	E-Phenotype
,	O
results	O
from	O
a	O
17p11.2	O
microdeletion	O
or	O
a	O
mutation	O
in	O
the	O
RAI1	O
gene	O
.	O

Loss	O
-	O
of	O
-	O
function	O
experiments	O
revealed	O
that	O
DLX6	O
-	O
AS1	O
knockdown	O
inhibited	O
the	O
proliferation	O
,	O
migration	O
and	O
invasion	O
of	O
HCC	O
cells	O
in	O
vitro	O
,	O
and	O
decreased	O
the	O
tumor	S-Phenotype
growth	O
in	O
vivo	O
.	O

The	O
TBX5	O
variation	O
p.Pro108Thr	O
,	O
located	O
in	O
the	O
T	O
-	O
box	O
domain	O
,	O
was	O
identified	O
in	O
a	O
patient	O
with	O
tricuspid	B-Phenotype
atresia	E-Phenotype
,	O
an	O
exon	O
-	O
intron	O
boundary	O
variation	O
of	O
GATA4	O
(	O
IVS4+5GAAAAA	O
)	O
was	O
detected	O
in	O
a	O
Tetralogy	B-Phenotype
of	I-Phenotype
Fallot	E-Phenotype
patient	O
and	O
an	O
8p23	O
microdeletion	O
was	O
detected	O
in	O
one	O
patient	O
with	O
atrioventricular	B-Phenotype
septal	I-Phenotype
defect	E-Phenotype
and	O
psychomotor	B-Phenotype
delay	E-Phenotype
.	O

Our	O
data	O
,	O
for	O
the	O
first	O
time	O
,	O
functionally	O
link	O
Jalili	O
syndrome	O
gene	O
CNNM4	O
to	O
LCA	O
gene	O
IQCB1	O
,	O
providing	O
important	O
insights	O
into	O
the	O
molecular	O
pathogenic	O
mechanism	O
of	O
retinal	B-Phenotype
dystrophy	E-Phenotype
in	O
Jalili	O
syndrome	O

This	O
SNP	O
was	O
not	O
associated	O
with	O
breast	B-Phenotype
cancer	E-Phenotype
risk	O
either	O
in	O
the	O
general	O
population	O
or	O
in	O
BRCA1	O
mutation	O
carriers	O
.	O

Genes	O
with	O
DMRs	O
were	O
involved	O
in	O
inflammatory	O
response	O
(	O
IRAK4	O
and	O
ESM1	O
)	O
,	O
cancer	S-Phenotype
(	O
BRCA1	O
and	O
LASP1	O
)	O
,	O
endocrine	O
function	O
(	O
CNPY1	O
)	O
,	O
and	O
male	O
fertility	O
(	O
IFT140	O
,	O
TESC	O
,	O
and	O
PRDM8	O
)	O
.	O

Metabolic	B-Phenotype
cutis	I-Phenotype
laxa	E-Phenotype
results	O
from	O
Menkes	O
syndrome	O
,	O
caused	O
by	O
a	O
defect	O
in	O
the	O
ATPase	O
copper	O
transporting	O
alpha	O
(	O
ATP7A	O
)	O
gene	O
;	O
congenital	O
disorders	O
of	O
glycosylation	O
due	O
to	O
mutations	O
in	O
subunit	O
7	O
of	O
the	O
component	O
of	O
oligomeric	O
Golgi	O
(	O
COG7	O
)	O
-	O
congenital	O
disorders	O
of	O
glycosylation	O
(	O
CDG	O
)	O
complex	O
;	O
combined	O
disorder	O
of	O
N	O
-	O
and	O
O	O
-	O
linked	O
glycosylation	O
,	O
due	O
to	O
mutations	O
in	O
ATPase	O
H+	O
transporting	O
V0	O
subunit	O
a2	O
(	O
ATP6VOA2	O
)	O
gene	O
;	O
pyrroline	O
-	O
5	O
-	O
carboxylate	O
reductase	O
1	O
deficiency	O
;	O
pyrroline	O
-	O
5	O
-	O
carboxylate	O
synthase	O
deficiency	O
;	O
macrocephaly	S-Phenotype
,	O
alopecia	S-Phenotype
,	O
cutis	B-Phenotype
laxa	E-Phenotype
,	O
and	O
scoliosis	S-Phenotype
(	O
MACS	O
)	O
syndrome	O
,	O
due	O
to	O
Ras	O
and	O
Rab	O
interactor	O
2	O
(	O
RIN2	O
)	O
mutations	O
;	O
transaldolase	O
deficiency	O
caused	O
by	O
mutations	O
in	O
the	O
transaldolase	O
1	O
(	O
TALDO1	O
)	O
gene	O
;	O
Gerodermia	O
osteodysplastica	O
due	O
to	O
mutations	O
in	O
the	O
golgin	O
,	O
RAB6	O
-	O
interacting	O
(	O
GORAB	O
or	O
SCYL1BP1	O
)	O
gene	O
;	O
and	O
mitogen	O
-	O
activated	O
pathway	O
(	O
MAP	O
)	O
kinase	O
defects	O
,	O
caused	O
by	O
mutations	O
in	O
several	O
genes	O
[	O
protein	O
tyrosine	O
phosphatase	O
,	O
non	O
-	O
receptor	O
-	O
type	O
11	O
(	O
PTPN11	O
)	O
,	O
RAF	O
,	O
NF	O
,	O
HRas	O
proto	O
-	O
oncogene	O
,	O
GTPase	O
(	O
HRAS	O
)	O
,	O
B	O
-	O
Raf	O
proto	O
-	O
oncogene	O
,	O
serine	O
/	O
threonine	O
kinase	O
(	O
BRAF	O
)	O
,	O
MEK1	O
/	O
2	O
,	O
KRAS	O
proto	O
-	O
oncogene	O
,	O
GTPase	O
(	O
KRAS	O
)	O
,	O
SOS	O
Ras	O
/	O
Rho	O
guanine	O
nucleotide	O
exchange	O
factor	O
2	O
(	O
SOS2	O
)	O
,	O
leucine	O
rich	O
repeat	O
scaffold	O
protein	O
(	O
SHOC2	O
)	O
,	O
NRAS	O
proto	O
-	O
oncogene	O
,	O
GTPase	O
(	O
NRAS	O
)	O
,	O
and	O
Raf	O
-	O
1	O
proto	O
-	O
oncogene	O
,	O
serine	O
/	O
threonine	O
kinase	O
(	O
RAF1	O
)	O
]	O
,	O
which	O
regulate	O
the	O
Ras	O
-	O
MAPK	O
cascade	O
.	O

Our	O
results	O
indicate	O
that	O
common	O
genetic	O
variation	O
predisposes	O
to	O
different	O
neuroblastoma	S-Phenotype
genotypes	O
,	O
including	O
the	O
likelihood	O
of	O
somatic	O
MYCN	O
-	O
amplification	O

Knockdown	O
of	O
PMM2	O
in	O
RCC	O
cells	O
inhibited	O
cancer	S-Phenotype
cell	O
migration	O
and	O
invasion	O
,	O
indicating	O
overexpression	O
of	O
PMM2	O
could	O
promote	O
malignancy	O
.	O

Thus	O
,	O
ADAMTS18	O
as	O
an	O
antimetastatic	O
tumor	S-Phenotype
suppressor	O
antagonizes	O
AKT	O
and	O
NF	O
-	O
kB	O
signaling	O
in	O
breast	B-Phenotype
tumorigenesis	E-Phenotype
.	O

We	O
studied	O
the	O
expression	O
of	O
TMEM9	O
and	O
its	O
effect	O
on	O
cytokine	O
secretion	O
in	O
tumor	S-Phenotype
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
a	O
)	O
-	O
induced	O
LX	O
-	O
2	O
cells	O
.	O

In	O
addition	O
,	O
ENG	O
was	O
found	O
to	O
be	O
related	O
to	O
the	O
spheroid	O
-	O
forming	O
ability	O
of	O
cells	O
and	O
to	O
be	O
involved	O
in	O
the	O
invasive	O
capacity	O
of	O
pancreatic	B-Phenotype
cancer	E-Phenotype
cells	O

We	O
conclude	O
that	O
mutations	O
in	O
SZT2	O
cause	O
a	O
severe	O
type	O
of	O
autosomal	B-Phenotype
-	I-Phenotype
recessive	I-Phenotype
infantile	I-Phenotype
encephalopathy	E-Phenotype
with	O
intractable	O
seizures	S-Phenotype
and	O
distinct	O
neuroradiological	O
anomalies	O
.	O

Brain	O
MRI	O
showed	O
diffuse	B-Phenotype
leukoencephalopathy	E-Phenotype
,	O
suggesting	O
CADASIL	O
.	O

Also	O
the	O
well	O
-	O
known	O
gene	O
variants	O
rs7903146	O
in	O
TCF7L2	O
,	O
and	O
rs17817449	O
in	O
FTO	O
,	O
were	O
nominally	O
associated	O
with	O
hyperglycemia	S-Phenotype
(	O
rs7903146	O
)	O
,	O
as	O
well	O
as	O
with	O
higher	O
fasting	O
insulin	O
levels	O
(	O
rs17817449	O
)	O
.	O

The	O
disease	O
phenotype	O
comprises	O
characteristic	O
circumferential	O
skin	O
creases	O
accompanied	O
by	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
a	O
cleft	B-Phenotype
palate	E-Phenotype
,	O
short	B-Phenotype
stature	E-Phenotype
,	O
and	O
dysmorphic	O
features	O
.	O

In	O
a	O
two	O
-	O
stage	O
study	O
,	O
we	O
analyzed	O
the	O
existing	O
genome	O
-	O
wide	O
association	O
study	O
dataset	O
of	O
868	O
pancreatic	B-Phenotype
cancer	E-Phenotype
patients	O
from	O
MD	O
Anderson	O
Cancer	S-Phenotype
Center	O
in	O
relation	O
to	O
overall	O
survival	O
using	O
Cox	O
regression	O
.	O

Using	O
the	O
larval	O
startle	O
response	O
to	O
the	O
buzz	O
of	O
a	O
predator	O
(	O
wasp	O
)	O
,	O
we	O
examined	O
PPI	O
in	O
wild	O
-	O
type	O
flies	O
and	O
two	O
mutants	O
:	O
an	O
fmr1	O
mutant	O
,	O
which	O
is	O
implicated	O
in	O
Fragile	O
X	O
syndrome	O
,	O
and	O
a	O
centaurin	O
gamma	O
1A	O
(	O
CenG1A	O
)	O
mutant	O
,	O
which	O
is	O
associated	O
with	O
GTPase	O
,	O
PH	O
,	O
ArfGAP	O
,	O
and	O
ANK	O
domains	O
and	O
implicated	O
in	O
autism	S-Phenotype
.	O

Defects	O
in	O
motile	O
cilia	O
and	O
sperm	O
flagella	O
cause	O
primary	B-Phenotype
ciliary	I-Phenotype
dyskinesia	E-Phenotype
(	O
PCD	S-Phenotype
)	O
,	O
characterized	O
by	O
chronic	B-Phenotype
airway	I-Phenotype
disease	E-Phenotype
,	O
infertility	S-Phenotype
,	O
and	O
left	B-Phenotype
-	I-Phenotype
right	I-Phenotype
body	I-Phenotype
axis	I-Phenotype
disturbance	E-Phenotype
.	O

In	O
Chinese	O
siblings	O
with	O
late	O
-	O
onset	O
cblC	O
,	O
the	O
main	O
clinic	O
manifestation	O
and	O
abnormal	O
radioimaging	O
were	O
cognitive	B-Phenotype
decline	E-Phenotype
and	O
cerebral	B-Phenotype
atrophy	E-Phenotype
respectively	O
.	O

Overall	O
,	O
the	O
results	O
show	O
that	O
MED1	O
/	O
ER	O
-	O
a	O
/	O
miR	O
-	O
191	O
axis	O
promotes	O
breast	B-Phenotype
cancer	E-Phenotype
cell	O
proliferation	O
and	O
migration	O
and	O
may	O
serve	O
as	O
a	O
novel	O
target	O
for	O
therapy	O

In	O
addition	O
,	O
through	O
data	O
mining	O
analysis	O
,	O
we	O
observed	O
an	O
extremely	O
strong	O
correlation	O
between	O
the	O
expression	O
levels	O
of	O
GATA3	O
and	O
CtIP	O
in	O
paratumors	O
,	O
but	O
the	O
correlation	O
turned	O
insignificant	O
in	O
mammary	O
tumors	S-Phenotype
.	O

A	O
9	O
-	O
month	O
-	O
old	O
intact	O
crossbred	O
female	O
cat	O
was	O
presented	O
with	O
jaundice	S-Phenotype
,	O
intermittent	B-Phenotype
anorexia	E-Phenotype
and	O
lethargy	S-Phenotype
,	O
increased	O
hepatic	O
enzyme	O
activities	O
,	O
and	O
hyperammonemia	S-Phenotype
.	O

Mutations	O
in	O
human	O
ADAMTSL4	O
,	O
encoding	O
an	O
ADAMTS	O
-	O
like	O
protein	O
which	O
has	O
been	O
implicated	O
in	O
fibrillin	O
microfibril	O
biogenesis	O
,	O
cause	O
ectopia	B-Phenotype
lentis	E-Phenotype
(	O
EL	S-Phenotype
)	O
and	O
EL	O
et	O
pupillae	O
.	O

Biallelic	O
mutations	O
of	O
the	O
gene	O
encoding	O
diphthamide	O
biosynthesis	O
1	O
(	O
DPH1	O
,	O
NM_001383.3	O
)	O
cause	O
developmental	B-Phenotype
delay	E-Phenotype
,	O
dysmorphic	O
features	O
,	O
sparse	B-Phenotype
hair	E-Phenotype
,	O
and	O
short	B-Phenotype
stature	E-Phenotype
(	O
MIM	O
*	O
603527	O
)	O
.	O

Altogether	O
these	O
data	O
demonstrate	O
that	O
mutations	O
in	O
INPP5K	O
cause	O
a	O
congenital	B-Phenotype
muscular	I-Phenotype
dystrophy	E-Phenotype
syndrome	O
with	O
short	B-Phenotype
stature	E-Phenotype
,	O
cataracts	S-Phenotype
,	O
and	O
intellectual	B-Phenotype
disability	E-Phenotype

The	O
mechanism	O
of	O
TMEM98	O
in	O
conferring	O
chemoresistance	O
of	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
might	O
be	O
possibly	O
through	O
activation	O
of	O
the	O
AKT	O
pathway	O
and	O
deactivation	O
of	O
p53	O
.	O

These	O
results	O
indicate	O
that	O
TBX19	O
may	O
work	O
as	O
an	O
oncogene	O
in	O
colorectal	B-Phenotype
cancer	E-Phenotype
(	O
CRC	S-Phenotype
)	O
.	O

Idiopathic	B-Phenotype
pulmonary	I-Phenotype
fibrosis	E-Phenotype
(	O
IPF	S-Phenotype
)	O
is	O
a	O
complex	O
,	O
heterogeneous	S-Phenotype
genetic	O
disorder	O
that	O
is	O
associated	O
with	O
rare	O
and	O
common	O
sequence	O
variants	O
in	O
many	O
genes	O
(	O
MUC5B	O
,	O
SFTPC	O
,	O
SFTPA2	O
,	O
RTEL1	O
,	O
TERT	O
,	O
and	O
hTR	O
)	O
,	O
11	O
novel	O
loci	O
,	O
and	O
multiple	O
emerging	O
epigenetic	O
and	O
transcriptional	O
profiles	O
.	O

We	O
expand	O
the	O
knowledge	O
about	O
TTC7A	O
deficiency	O
,	O
describing	O
a	O
patient	O
with	O
the	O
mild	O
phenotype	O
of	O
TTC7A	O
deficiency	O
but	O
presenting	O
overlapping	O
features	O
of	O
SD	O
/	O
THE	O
and	O
MIA	O
-	O
CID	O
:	O
intestinal	B-Phenotype
atresia	E-Phenotype
and	O
inflammatory	B-Phenotype
bowel	I-Phenotype
disease	E-Phenotype
evocative	O
of	O
MIA	O
-	O
CID	O
,	O
but	O
also	O
dental	B-Phenotype
abnormalities	E-Phenotype
,	O
huge	B-Phenotype
forehead	E-Phenotype
,	O
liver	B-Phenotype
abnormalities	E-Phenotype
,	O
autoimmune	B-Phenotype
thyroiditis	E-Phenotype
and	O
hypogammaglobulinemia	S-Phenotype
,	O
evocative	O
of	O
SD	O
/	O
THE	O

Until	O
now	O
,	O
the	O
role	O
of	O
VGSCs	O
and	O
the	O
relationships	O
between	O
calmodulin	O
(	O
CaM	O
)	O
/	O
CaM	O
-	O
dependent	O
protein	O
kinase	O
II	O
(	O
CaMKII	O
)	O
and	O
VGSCs	O
in	O
low	O
-	O
grade	O
astrocytoma	S-Phenotype
have	O
not	O
been	O
demonstrated	O
.	O

KRT5	O
but	O
not	O
KRT6C	O
mRNA	O
expression	O
was	O
increased	O
in	O
chemotherapy	O
resistant	O
primary	O
serous	O
ovarian	B-Phenotype
cancer	E-Phenotype
cells	O
compared	O
to	O
chemotherapy	O
sensitive	O
cells	O
.	O

Mutations	O
in	O
the	O
homeobox	O
gene	O
SHOX	O
cause	O
SHOX	O
deficiency	O
,	O
a	O
condition	O
with	O
clinical	O
manifestations	O
ranging	O
from	O
short	B-Phenotype
stature	E-Phenotype
without	O
dysmorphic	O
signs	O
to	O
severe	O
mesomelic	B-Phenotype
skeletal	I-Phenotype
dysplasia	E-Phenotype
.	O

The	O
percentages	O
of	O
Twist2	O
expression	O
were	O
75	O
%	O
(	O
15	O
/	O
20	O
)	O
,	O
95	O
%	O
(	O
19	O
/	O
20	O
)	O
,	O
and	O
100	O
%	O
(	O
20	O
/	O
20	O
)	O
in	O
the	O
WHO	O
gradesⅡ	O
,	O
Ⅲ	O
and	O
Ⅳ	O
gliomas	S-Phenotype
,	O
respectively	O
.	O

A	O
recent	O
syndromic	O
condition	O
with	O
craniofacial	B-Phenotype
dysmorphisms	E-Phenotype
,	O
comprising	O
congenital	B-Phenotype
ocular	I-Phenotype
defect	E-Phenotype
and	O
neurodevelopmental	B-Phenotype
delay	E-Phenotype
named	O
Helsmoortel	O
-	O
Van	O
der	O
Aa	O
Syndrome	O
(	O
HVDAS	O
)	O
(	O
OMIM	O
#	O
615873	O
)	O
,	O
has	O
been	O
described	O
and	O
molecularly	O
defined	O
,	O
identifying	O
pathogenic	O
mutations	O
in	O
the	O
ADNP	O
gene	O
(	O
OMIM	O
#	O
611386	O
)	O
as	O
biological	O
cause	O
.	O

AXL	O
has	O
been	O
defined	O
as	O
a	O
novel	O
target	O
for	O
cancer	S-Phenotype
therapeutics	O
.	O

miR	O
-	O
142	O
-	O
3p	O
overexpression	O
resulted	O
in	O
a	O
strong	O
decline	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
stem	O
cell	O
characteristics	O
with	O
a	O
decrease	O
in	O
CD44	O
,	O
CD133	O
,	O
ALDH1	O
,	O
Bod1	O
,	O
BRCA2	O
,	O
and	O
mammosphere	O
formation	O
as	O
well	O
as	O
reduced	O
survival	O
after	O
irradiation	O
.	O

L371P	O
mutation	O
in	O
MED17	O
is	O
a	O
founder	O
mutation	O
in	O
the	O
Caucasus	O
Jewish	O
community	O
and	O
that	O
homozygosity	O
for	O
this	O
mutation	O
is	O
associated	O
with	O
infantile	B-Phenotype
cerebral	I-Phenotype
and	I-Phenotype
cerebellar	I-Phenotype
atrophy	E-Phenotype
with	O
poor	B-Phenotype
myelination	E-Phenotype

We	O
found	O
that	O
blocking	O
IL6	O
signaling	O
in	O
alcohol	O
fed	O
mice	O
reducedthe	O
number	O
of	O
tumorsand	S-Phenotype
liver	O
proliferation	O
in	O
wild	O
type	O
mice	O
but	O
not	O
in	O
knockout	O
mice	O
suggesting	O
that	O
reduced	O
IL6	O
in	O
PRMT1	O
knockout	O
mice	O
contributes	O
to	O
the	O
protection	O
from	O
alcohol	O
.	O

Stable	O
re	O
-	O
expression	O
of	O
DIO1	O
,	O
resulted	O
in	O
26	O
downregulated	O
proteins	O
while	O
59	O
proteins	O
were	O
overexpressed	O
in	O
renal	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

We	O
also	O
found	O
that	O
multiple	O
cancers	S-Phenotype
are	O
genetically	O
correlated	O
with	O
non	O
-	O
cancer	S-Phenotype
traits	O
including	O
smoking	O
,	O
psychiatric	O
diseases	O
and	O
metabolic	O
characteristics	O
.	O

Clinically	O
,	O
this	O
PML	O
degradation	O
pathway	O
is	O
hyperactivated	O
in	O
lung	B-Phenotype
cancer	E-Phenotype
and	O
correlates	O
with	O
poor	O
prognosis	O
.	O

Since	O
microtubule	O
severing	O
is	O
an	O
important	O
cellular	O
mechanism	O
of	O
which	O
malfunctions	O
result	O
in	O
serious	O
diseases	O
such	O
as	O
spastic	B-Phenotype
paraplegia	E-Phenotype
,	O
Alzheimer	O
's	O
disease	O
and	O
cell	O
cycle	O
related	O
disorders	O
,	O
identification	O
of	O
KATNB1	O
transcriptional	O
regulation	O
is	O
crucial	O
in	O
understanding	O
the	O
coordination	O
of	O
microtubule	O
severing	O
activity	O
by	O
different	O
proteins	O
in	O
the	O
cells	O
.	O

Furthermore	O
,	O
parallel	O
immunohistochemical	O
analysis	O
of	O
three	O
PP2A	O
inhibitors	O
demonstrated	O
that	O
two	O
PP2A	O
inhibitors	O
,	O
CIP2A	O
and	O
SET	O
,	O
are	O
highly	O
expressed	O
in	O
both	O
dysplastic	B-Phenotype
and	I-Phenotype
adenocarcinomatous	I-Phenotype
tumors	E-Phenotype
of	O
the	O
Smgb	O
-	O
Tag	O
mice	O
.	O

The	O
results	O
from	O
our	O
study	O
provide	O
compelling	O
evidence	O
that	O
mGluR5	O
regulation	O
is	O
altered	O
in	O
schizophrenia	S-Phenotype
,	O
likely	O
contributing	O
to	O
the	O
altered	O
glutamatergic	O
signaling	O
that	O
is	O
associated	O
with	O
the	O
disorder	O

This	O
familial	O
study	O
demonstrates	O
that	O
a	O
deficiency	O
in	O
one	O
of	O
two	O
MAO	O
genes	O
may	O
not	O
lead	O
to	O
psychomotor	B-Phenotype
delay	E-Phenotype
,	O
and	O
deletion	O
of	O
EFHC2	O
may	O
not	O
cause	O
epilepsy	S-Phenotype
.	O

These	O
findings	O
document	O
shared	O
genetic	O
networks	O
between	O
spina	B-Phenotype
bifida	E-Phenotype
risk	O
and	O
bone	O
structure	O
,	O
including	O
PCP	O
components	O
and	O
Zic2	O
.	O

The	O
K109R	O
polymorphism	O
was	O
associated	O
with	O
obesity	S-Phenotype
(	O
P	O
=	O
.025	O
)	O
and	O
seems	O
to	O
significantly	O
decrease	O
the	O
LEP	O
levels	O
(	O
P	O
AAAA	O
.001	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
examine	O
the	O
expression	O
of	O
SLC4A11	O
in	O
ovarian	B-Phenotype
cancer	E-Phenotype
and	O
in	O
normal	O
ovarian	O
tissues	O
,	O
its	O
prognostic	O
value	O
and	O
the	O
possible	O
mechanism	O
of	O
its	O
dysregulation	O
.	O

To	O
gain	O
an	O
insight	O
into	O
the	O
likely	O
molecular	O
basis	O
of	O
their	O
observed	O
cytotoxic	O
effects	O
,	O
Autodock	O
Vina	O
binding	O
free	O
energies	O
of	O
each	O
of	O
the	O
isolated	O
compounds	O
with	O
seven	O
molecular	O
targets	O
implicated	O
in	O
cancer	S-Phenotype
development	O
(	O
MAPK8	O
,	O
MAPK10	O
,	O
MAP3K12	O
,	O
MAPK3	O
,	O
MAPK1	O
,	O
MAPK7	O
and	O
VEGF	O
)	O
,	O
were	O
calculated	O
.	O

Fungal	O
immunomodulatory	O
protein	O
from	O
liNectria	O
haematococca	O
/	O
i	O
(	O
FIP	O
-	O
nha	O
)	O
has	O
potential	O
as	O
a	O
lung	B-Phenotype
cancer	E-Phenotype
therapeutic	O
;	O
as	O
such	O
,	O
illuminating	O
its	O
anti	O
-	O
tumor	S-Phenotype
mechanism	O
is	O
expected	O
to	O
facilitate	O
novel	O
treatment	O
options	O
.	O

uPA	O
may	O
be	O
a	O
potential	O
molecule	O
and	O
target	O
for	O
the	O
detection	O
and	O
treatment	O
of	O
EEC	O
.	O

Crisponi	O
syndrome	O
(	O
CS	O
)	O
/	O
cold	O
-	O
induced	O
sweating	S-Phenotype
syndrome	O
type	O
1	O
(	O
CISS1	O
)	O
is	O
a	O
very	O
rare	O
autosomal	O
-	O
recessive	O
disorder	O
characterized	O
by	O
a	O
complex	O
phenotype	O
with	O
high	O
neonatal	O
lethality	O
,	O
associated	O
with	O
the	O
following	O
main	O
clinical	O
features	O
:	O
hyperthermia	S-Phenotype
and	O
feeding	B-Phenotype
difficulties	E-Phenotype
in	O
the	O
neonatal	O
period	O
,	O
scoliosis	S-Phenotype
,	O
and	O
paradoxical	B-Phenotype
sweating	I-Phenotype
induced	I-Phenotype
by	I-Phenotype
cold	E-Phenotype
since	O
early	O
childhood	O
.	O

The	O
objective	O
of	O
this	O
study	O
is	O
to	O
evaluate	O
the	O
carrier	O
frequency	O
of	O
c.242GAAAAA	O
mutation	O
in	O
LRTOMT	O
gene	O
and	O
define	O
the	O
contribution	O
of	O
this	O
gene	O
in	O
the	O
etiology	O
of	O
deafness	S-Phenotype
in	O
Moroccan	O
population	O
.	O

When	O
co	O
-	O
cultured	O
with	O
T	O
cells	O
,	O
pancreatic	B-Phenotype
cancer	E-Phenotype
PC	O
cells	O
with	O
high	O
B7	O
-	O
H5	O
expression	O
induced	O
a	O
more	O
potent	O
immune	O
reaction	O
,	O
indicated	O
by	O
elevated	O
cytokine	O
release	O
and	O
increased	O
proliferation	O
of	O
T	O
lymphocytes	O
compared	O
with	O
cells	O
exhibiting	O
low	O
B7	O
-	O
H5	O
expression	O
.	O

CNGB1	O
mutations	O
are	O
one	O
cause	O
of	O
autosomal	B-Phenotype
recessive	E-Phenotype
RP	O
making	O
the	O
CNGB1	O
mutant	O
dog	O
a	O
valuable	O
large	O
animal	O
model	O
of	O
the	O
condition	O

Therefore	O
,	O
we	O
evaluated	O
the	O
roles	O
of	O
CSNK2A1	O
,	O
SIRT6	O
,	O
and	O
phosphorylated	O
SIRT6	O
and	O
their	O
relationships	O
in	O
breast	B-Phenotype
carcinoma	E-Phenotype
.	O

Biallelic	O
mutations	O
in	O
the	O
SPATA5	O
gene	O
,	O
encoding	O
ATPase	O
family	O
protein	O
,	O
are	O
an	O
important	O
cause	O
of	O
newly	O
recognized	O
epileptic	B-Phenotype
encephalopathy	E-Phenotype
classified	O
as	O
epilepsy	S-Phenotype
,	O
hearing	B-Phenotype
loss	E-Phenotype
,	O
and	O
mental	B-Phenotype
retardation	E-Phenotype
syndrome	O
(	O
EHLMRS	O
,	O
OMIM	O
:	O
616577	O
)	O
.	O

Molecular	O
genetic	O
studies	O
of	O
PCR	O
and	O
direct	O
sequencing	O
showed	O
CTNNB1	O
mutations	O
in	O
4	O
of	O
7	O
(	O
4	O
/	O
7	O
)	O
cases	O
,	O
4	O
of	O
the	O
four	O
mutation	O
-	O
carrying	O
cases	O
showed	O
diffuse	O
b	O
-	O
catenin	O
nuclear	O
and	O
cytoplasm	O
immunoreactivity	O
and	O
diffuse	O
cyclin	O
D1	O
nuclear	O
immunoreactivity	O
in	O
the	O
tumor	S-Phenotype
cells	O
.	O

Multiple	B-Phenotype
mitochondrial	I-Phenotype
dysfunction	I-Phenotype
syndrome	I-Phenotype
1	E-Phenotype
(	O
MMDS1	S-Phenotype
)	O
arises	O
as	O
a	O
result	O
of	O
the	O
missense	O
mutation	O
in	O
NFU1	O
,	O
an	O
Fe	O
/	O
S	O
cluster	O
scaffold	O
protein	O
,	O
which	O
substitutes	O
a	O
glycine	O
near	O
the	O
Fe	O
/	O
S	O
cluster	O
-	O
binding	O
pocket	O
to	O
a	O
cysteine	O
(	O
p.Gly208Cys	O
)	O
.	O

Interestingly	O
,	O
pyroptotic	O
death	O
signaling	O
in	O
SIRT1	O
-	O
knocked	O
-	O
down	O
cells	O
was	O
transmitted	O
to	O
naïve	B-Phenotype
cervical	I-Phenotype
cancer	E-Phenotype
cells	O
,	O
which	O
was	O
mediated	O
by	O
extracellular	O
vesicles	O
carrying	O
AIM2	O
inflammasome	O
proteins	O
.	O

The	O
present	O
study	O
aimed	O
to	O
identify	O
novel	O
intervertebral	B-Phenotype
disc	I-Phenotype
degeneration	E-Phenotype
(	O
IDD	S-Phenotype
)	O
‑associated	O
long	O
noncoding	O
(	O
lnc	O
)	O
RNAs	O
and	O
genes	O
.	O

LGMD2I	O
displays	O
clinical	O
heterogeneity	S-Phenotype
with	O
onset	O
of	O
severe	O
symptoms	O
in	O
early	O
childhood	O
to	O
mild	O  
calf	O
and	O
thigh	B-Phenotype
hypertrophy	E-Phenotype
in	O
the	O
second	O
or	O
third	O
decade	O
.	O

This	O
review	O
summarizes	O
the	O
current	O
knowledge	O
of	O
tumorigenesis	S-Phenotype
and	O
tumor	S-Phenotype
progression	O
in	O
early	O
lung	B-Phenotype
adenocarcinoma	E-Phenotype
,	O
with	O
special	O
focus	O
on	O
its	O
clinicopathological	O
characteristics	O
and	O
their	O
associations	O
with	O
driver	O
mutations	O
(	O
EGFR	O
,	O
KRAS	O
,	O
and	O
BRAF	O
)	O
as	O
well	O
as	O
on	O
its	O
molecular	O
pathogenesis	O
and	O
progression	O

This	O
study	O
reports	O
first	O
case	O
of	O
variants	O
in	O
the	O
genes	O
causing	O
EvC	O
syndrome	O
and	O
profound	S-Phenotype
deafness	S-Phenotype
in	O
the	O
same	O
family	O

One	O
presently	O
identified	O
eQTL	O
for	O
the	O
PEX6	O
gene	O
was	O
rs10948059	O
,	O
which	O
had	O
been	O
associated	O
with	O
prostate	B-Phenotype
cancer	E-Phenotype
from	O
previous	O
association	O
studies	O
.	O

The	O
Aicardi	O
-	O
Goutières	O
syndrome	O
(	O
AGS	O
)	O
was	O
first	O
described	O
in	O
1984	O
,	O
and	O
over	O
the	O
following	O
years	O
was	O
defined	O
by	O
the	O
clinical	O
and	O
radiological	O
features	O
of	O
an	O
early	O
onset	O
,	O
severe	O
,	O
neurologic	O
disorder	O
with	O
intracranial	B-Phenotype
calcification	E-Phenotype
,	O
leukoencephalopathy	S-Phenotype
,	O
and	O
cerebral	B-Phenotype
atrophy	E-Phenotype
,	O
usually	O
associated	O
with	O
a	O
cerebrospinal	B-Phenotype
fluid	I-Phenotype
(	I-Phenotype
CSF	I-Phenotype
)	I-Phenotype
pleocytosis	E-Phenotype
and	O
elevated	O
CSF	O
interferon	O
α	O
activity	O
.	O

However	O
,	O
there	O
is	O
great	O
variation	O
in	O
the	O
literature	O
due	O
to	O
the	O
heterogeneous	S-Phenotype
nature	O
of	O
the	O
randomised	O
controlled	O
trials	O
conducted	O
.	O

We	O
also	O
found	O
that	O
mice	O
underexpressing	O
JIP3	O
exhibited	O
a	O
delayed	O
pentylenetetrazole	O
(	O
PTZ	O
)	O
-	O
induced	O
kindling	O
seizure	S-Phenotype
process	O

We	O
report	O
the	O
case	O
of	O
an	O
infant	O
with	O
a	O
novel	O
heterozygous	O
TBX1	O
mutation	O
who	O
experienced	O
hypocalcemic	B-Phenotype
seizures	E-Phenotype
.	O

Dear	O
Editor	O
,	O
Immune	O
-	O
checkpoint	O
blockade	O
is	O
a	O
type	O
of	O
passive	O
immunotherapy	O
aimed	O
at	O
enhancing	O
preexisting	O
anti	O
-	O
tumor	S-Phenotype
responses	O
of	O
the	O
organism	O
,	O
blocking	O
self	O
-	O
tolerance	O
molecular	O
interactions	O
between	O
T	O
-	O
lymphocytes	O
and	O
neoplastic	O
cells	O
(	O
1,2	O
)	O
.	O

There	O
is	O
growing	O
evidence	O
shown	O
that	O
microRNAs	O
(	O
miRNAs	O
)	O
are	O
associated	O
with	O
cancer	S-Phenotype
and	O
can	O
play	O
a	O
role	O
in	O
human	O
cancers	S-Phenotype
as	O
oncogenes	O
or	O
tumor	S-Phenotype
suppressor	O
genes	O
.	O

Subsequent	O
quantitative	O
PCR	O
experiments	O
confirmed	O
that	O
PRDX4	O
,	O
CKS2	O
,	O
MAGED2	O
,	O
and	O
an	O
EST	O
(	O
GenBank	O
accession	O
number	O
BF696304	O
)	O
were	O
expressed	O
at	O
significantly	O
higher	O
levels	O
in	O
tumors	S-Phenotype
with	O
metastasis	O
.	O

miR	O
-	O
23b	O
-	O
3p	O
expression	O
was	O
pronouncedly	O
decreased	O
in	O
HCC	O
tissues	O
in	O
contrast	O
with	O
their	O
paired	O
adjacent	O
non	O
-	O
cancerous	S-Phenotype
HCC	O
(	O
PAAAA0.001	O
)	O
with	O
RT	O
-	O
qPCR	O
.	O

Cerebral	O
,	O
ocular	O
,	O
dental	O
,	O
auricular	O
,	O
skeletal	O
(	O
CODAS	O
)	O
syndrome	O
is	O
a	O
rare	O
autosomal	B-Phenotype
recessive	E-Phenotype
multisystem	O
disorder	O
caused	O
by	O
mutations	O
in	O
LONP1	O
.	O

Also	O
,	O
we	O
examined	O
the	O
regulatory	O
mechanisms	O
of	O
PKM	O
isoform	O
expression	O
by	O
testing	O
each	O
of	O
these	O
miRNAs	O
in	O
human	O
cancer	S-Phenotype
cell	O
lines	O
.	O

Renpenning	O
syndrome	O
is	O
a	O
group	O
of	O
X	B-Phenotype
-	I-Phenotype
linked	I-Phenotype
intellectual	I-Phenotype
disability	E-Phenotype
syndromes	O
caused	O
by	O
mutations	O
in	O
human	O
polyglutamine	O
-	O
binding	O
protein	O
1	O
(	O
PQBP1	O
)	O
gene	O
.	O

We	O
found	O
that	O
LGR5	O
expression	O
in	O
the	O
epithelium	O
and	O
stroma	O
was	O
associated	O
with	O
tumor	S-Phenotype
stage	O
,	O
and	O
by	O
integrating	O
functional	O
experiments	O
with	O
LGR5	O
-	O
sorted	O
cell	O
RNA	O
sequencing	O
data	O
from	O
adenoma	O
and	O
normal	O
organoids	O
,	O
we	O
found	O
correlations	O
between	O
LGR5	O
and	O
CRC	O
-	O
specific	O
genes	O
,	O
including	O
dickkopf	O
WNT	O
signaling	O
pathway	O
inhibitor	O
4	O
(	O
DKK4	O
)	O
and	O
SPARC	O
-	O
related	O
modular	O
calcium	O
binding	O
2	O
(	O
SMOC2	O
)	O
.	O

Addition	O
of	O
exogenous	O
SLURP1	O
(	O
6XHis	O
-	O
tagged	O
,	O
E.	O
coli	O
expressed	O
and	O
partially	O
purified	O
using	O
Ni	O
-	O
ion	O
columns	O
)	O
significantly	O
suppressed	O
the	O
tumor	S-Phenotype
necrosis	O
factor	O
-	O
a	O
(	O
TNF	O
-	O
a	O
)	O
-	O
stimulated	O
human	O
umbilical	O
cord	O
vascular	O
endothelial	O
cell	O
(	O
HUVEC	O
)	O
tube	O
formation	O
.	O

Mutations	O
in	O
the	O
COL4A5	O
gene	O
result	O
in	O
X	O
-	O
linked	O
Alport	O
syndrome	O
,	O
homozygous	O
or	O
compound	O
heterozygous	O
mutations	O
in	O
COL4A3	O
or	O
COL4A4	O
are	O
responsible	O
for	O
autosomal	B-Phenotype
recessive	E-Phenotype
Alport	O
syndrome	O
,	O
and	O
heterozygous	O
mutations	O
in	O
COL4A3	O
or	O
COL4A4	O
cause	O
autosomal	O
dominant	O
Alport	O
syndrome	O
or	O
benign	O
familial	B-Phenotype
hematuria	E-Phenotype
.	O

In	O
our	O
patient	O
cohort	O
,	O
causative	O
variants	O
in	O
GJB2	O
,	O
USH2A	O
,	O
MYO15A	O
and	O
STRC	O
,	O
and	O
in	O
MYO6	O
were	O
the	O
leading	O
causes	O
for	O
autosomal	B-Phenotype
recessive	E-Phenotype
and	O
dominant	O
HI	O
,	O
respectively	O
.	O

However	O
,	O
whether	O
β	O
-	O
elemene	O
could	O
enhance	O
anti	O
-	O
cancer	S-Phenotype
effects	O
of	O
TRAIL	O
on	O
gastric	B-Phenotype
cancer	E-Phenotype
cells	O
is	O
unknown	O
.	O

To	O
investigate	O
the	O
mechanism	O
of	O
DFNB30	O
-	O
type	O
deafness	S-Phenotype
,	O
we	O
established	O
a	O
mouse	O
model	O
of	O
Myo3a	O
kinase	O
domain	O
Y137C	O
mutation	O
by	O
using	O
CRISPR	O
/	O
Cas9	O
system	O
.	O

Typical	O
HHT	O
clinical	O
features	O
are	O
mucocutaneous	B-Phenotype
telangiectases	E-Phenotype
,	O
arteriovenous	B-Phenotype
malformations	E-Phenotype
,	O
spontaneous	B-Phenotype
and	I-Phenotype
recurrent	I-Phenotype
epistaxis	E-Phenotype
,	O
as	O
well	O
as	O
gastrointestinal	B-Phenotype
bleedings	E-Phenotype
.	O

Although	O
disruption	O
of	O
the	O
CDKN2A	O
(	O
INK4A	O
/	O
ARF	O
)	O
locus	O
has	O
been	O
reported	O
in	O
end	O
-	O
stage	O
disease	O
,	O
information	O
is	O
lacking	O
on	O
the	O
status	O
of	O
this	O
key	O
tumor	S-Phenotype
suppressor	O
gene	O
in	O
pleural	O
lesions	O
preceding	O
mesothelioma	O
.	O

A	O
set	O
of	O
ten	O
plasma	O
and	O
serum	O
samples	O
from	O
subjects	O
with	O
multiple	B-Phenotype
sclerosis	E-Phenotype
,	O
narcolepsy	S-Phenotype
,	O
and	O
without	O
any	O
disease	O
diagnosis	O
were	O
profiled	O
on	O
a	O
peptide	O
array	O
representing	O
the	O
whole	O
proteome	O
,	O
hosting	O
2.2	O
million	O
12	O
-	O
mer	O
peptides	O
with	O
a	O
six	O
amino	O
acid	O
lateral	O
shift	O
.	O

Furthermore	O
,	O
we	O
identified	O
differential	O
Raf1	O
-	O
tr	O
expression	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
and	O
showed	O
that	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
with	O
increased	O
Raf1	O
-	O
tr	O
expression	O
become	O
sensitized	O
to	O
bleomycin	O
-	O
induced	O
apoptosis	O
.	O

Altogether	O
,	O
our	O
study	O
provides	O
direct	O
evidence	O
that	O
endogenous	O
Rspo2	O
and	O
Rspo3	O
chromosome	O
rearrangements	O
can	O
initiate	O
and	O
maintain	O
tumour	S-Phenotype
development	O
,	O
and	O
indicate	O
a	O
viable	O
therapeutic	O
window	O
for	O
LGK974	O
treatment	O
of	O
RSPO	O
-	O
fusion	O
cancers	S-Phenotype

Taken	O
together	O
,	O
we	O
firstly	O
revealed	O
that	O
quercetin	O
suppressed	O
the	O
progression	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
by	O
inhibiting	O
cell	O
mobility	O
and	O
glycolysis	O
through	O
Akt	O
-	O
mTOR	O
pathway	O
mediated	O
autophagy	O
induction	O
and	O
may	O
provide	O
a	O
potential	O
therapeutic	O
target	O
for	O
breast	B-Phenotype
cancer	E-Phenotype
treatment	O

Moebius	O
syndrome	O
(	O
MBS	O
)	O
is	O
a	O
rare	O
congenital	O
disorder	O
characterized	O
by	O
rhombencephalic	O
mal	O
development	O
,	O
mainly	O
presenting	O
with	O
facial	B-Phenotype
palsy	E-Phenotype
with	O
limited	O
gaze	O
abduction	O
.	O

In	O
conclusion	O
,	O
the	O
inverse	O
relation	O
observed	O
between	O
bone	O
cell	O
activity	O
and	O
tumor	S-Phenotype
cell	O
AR	O
activity	O
in	O
prostate	B-Phenotype
cancer	E-Phenotype
bone	B-Phenotype
metastasis	E-Phenotype
may	O
be	O
of	O
importance	O
for	O
patient	O
response	O
to	O
AR	O
and	O
/	O
or	O
bone	O
targeting	O
therapies	O
,	O
but	O
needs	O
to	O
be	O
evaluated	O
in	O
clinical	O
settings	O
in	O
relation	O
to	O
serum	O
markers	O
for	O
bone	O
remodeling	O
,	O
radiography	O
and	O
patient	O
response	O
to	O
therapy	O
.	O

Thus	O
,	O
chronic	O
colonization	O
with	O
liETEC	O
/	O
i	O
producing	O
ST	O
could	O
contribute	O
to	O
endemic	O
cancer	S-Phenotype
resistance	O
in	O
developing	O
countries	O
,	O
reinforcing	O
a	O
novel	O
paradigm	O
of	O
colorectal	B-Phenotype
cancer	E-Phenotype
chemoprevention	O
with	O
oral	O
GUCY2C	O
-	O
targeted	O
agents	O

Mutations	O
in	O
GJB2	O
or	O
GJB6	O
and	O
the	O
mitochondrial	O
A7445G	O
mutation	O
,	O
known	O
to	O
be	O
the	O
major	O
causes	O
of	O
diverse	O
Inherited	O
Palmoplantar	B-Phenotype
Keratodermas	E-Phenotype
-	O
hearing	B-Phenotype
loss	E-Phenotype
syndromes	O
were	O
not	O
detected	O
by	O
Sanger	O
sequencing	O
.	O

Additional	O
predictors	O
included	O
age	O
,	O
as	O
well	O
as	O
gender	O
and	O
the	O
interaction	O
of	O
liMTHFR	O
/	O
i	O
677	O
with	O
overweight	S-Phenotype
status	O
(	O
measured	O
by	O
body	O
mass	O
index	O
)	O
in	O
predicting	O
CRC	O
,	O
with	O
the	O
cancer	S-Phenotype
group	O
having	O
more	O
men	O
and	O
overweight	S-Phenotype
cases	O
.	O

In	O
Japan	O
,	O
26	O
mutations	O
in	O
the	O
ATP2A2	O
gene	O
in	O
7	O
pedigrees	O
and	O
19	O
sporadic	S-Phenotype
cases	O
with	O
DD	O
have	O
been	O
reported	O
,	O
among	O
which	O
one	O
pedigree	O
and	O
one	O
sporadic	S-Phenotype
case	O
were	O
accompanied	O
by	O
neuropsychiatric	O
symptoms	O
.	O

We	O
characterize	O
MYMK	O
-	O
CFZS	O
as	O
a	O
congenital	B-Phenotype
myopathy	E-Phenotype
with	O
marked	O
facial	B-Phenotype
weakness	E-Phenotype
and	O
additional	O
clinical	O
and	O
pathologic	O
features	O
that	O
distinguish	O
it	O
from	O
other	O
congenital	O
neuromuscular	O
syndromes	O
.	O

This	O
manuscript	O
describes	O
the	O
case	O
of	O
a	O
nine	O
-	O
year	O
-	O
old	O
girl	O
with	O
microcephaly	S-Phenotype
,	O
mild	O
facial	B-Phenotype
dysmorphisms	E-Phenotype
,	O
epileptic	B-Phenotype
seizures	E-Phenotype
,	O
and	O
severe	O
developmental	B-Phenotype
delay	E-Phenotype
,	O
with	O
a	O
de	O
novo	O
heterozygous	O
c.320AAAAAG	O
[	O
p.	O
(	O
His	O
107	O
Arg	O
)	O
]	O
mutation	O
in	O
liTUBA1A	O
/	O
i	O
gene	O
,	O
and	O
the	O
clinical	O
aspects	O
and	O
neuroimaging	O
features	O
of	O
AAAAAAlissencephaly	O
syndromeAAAAAA	O
are	O
summarized	O
.	O

We	O
report	O
a	O
novel	O
ARL2BP	O
splice	O
site	O
mutation	O
after	O
whole	O
-	O
exome	O
sequencing	O
(	O
WES	O
)	O
applied	O
to	O
a	O
Moroccan	O
family	O
including	O
two	O
sisters	O
affected	O
with	O
autosomal	B-Phenotype
recessive	I-Phenotype
rod	I-Phenotype
-	I-Phenotype
cone	I-Phenotype
dystrophy	E-Phenotype
(	O
arRCD	S-Phenotype
)	O
.	O

By	O
using	O
immunohistochemical	O
and	O
western	O
blot	O
analysis	O
,	O
there	O
is	O
an	O
adverse	O
correlation	O
between	O
TRIM2	O
and	O
Bim	O
in	O
TAM	O
-	O
resistant	O
breast	B-Phenotype
tumor	E-Phenotype
tissues	O
and	O
MCF	O
-	O
7R	O
cells	O
.	O

The	O
therapeutic	O
strategy	O
to	O
recover	O
immune	O
function	O
through	O
the	O
restoration	O
of	O
impaired	O
Tregs	O
function	O
with	O
the	O
mounting	O
evidences	O
regarding	O
KRAS	O
in	O
autoimmune	O
mediated	O
disorder	O
(	O
MS	O
,	O
SLE	O
,	O
RA	O
,	O
T1D	O
)	O
suggest	O
as	O
working	O
hypothesis	O
the	O
direct	O
targeting	O
KRAS	O
activation	O
using	O
cancer	S-Phenotype
-	O
derived	O
small	O
molecules	O
may	O
be	O
clinically	O
relevant	O

Overexpression	O
of	O
many	O
factors	O
predicted	O
poor	O
prognosis	O
in	O
breast	O
(	O
EEF1D	O
,	O
EEF1E1	O
,	O
EEF2	O
)	O
and	O
lung	B-Phenotype
cancer	E-Phenotype
(	O
EEF1A2	O
,	O
EEF1B2	O
,	O
EEF1G	O
,	O
EEF1E1	O
)	O
.	O

We	O
found	O
a	O
significant	O
enrichment	O
of	O
potentially	O
pathologic	O
heterozygous	O
alleles	O
in	O
ZNF469	O
associated	O
with	O
the	O
development	O
of	O
keratoconus	S-Phenotype
(	O
P	O
=	O
0.00102	O
)	O
resulting	O
in	O
a	O
relative	O
risk	O
of	O
12.0	O
.	O

Herein	O
,	O
we	O
performed	O
comparative	O
quantitative	O
proteomics	O
on	O
whole	O
plasma	O
sampled	O
from	O
patients	O
with	O
stable	O
angina	O
(	O
NMI	O
)	O
,	O
acute	O
myocardial	B-Phenotype
infarction	E-Phenotype
(	O
MI	O
)	O
,	O
and	O
healthy	O
control	O
subjects	O
(	O
Ctrl	O
)	O
.	O

Small	O
series	O
of	O
cases	O
have	O
documented	O
the	O
co	O
-	O
occurrence	O
of	O
ganglioneuroma	S-Phenotype
with	O
a	O
pheochromocytoma	S-Phenotype
(	O
Pheo	O
)	O
/	O
paraganglioma	S-Phenotype
(	O
PGL	O
)	O
component	O
.	O

We	O
also	O
demonstrate	O
that	O
tumor	S-Phenotype
-	O
associated	O
MSCs	O
induce	O
the	O
expression	O
of	O
genes	O
associated	O
with	O
an	O
aggressive	O
phenotype	O
in	O
primary	O
lung	B-Phenotype
cancer	E-Phenotype
cells	O
and	O
selectively	O
promote	O
their	O
dissemination	O
rather	O
than	O
local	O
growth	O
.	O

We	O
further	O
replicated	O
pleiotropic	O
associations	O
of	O
GYS2	O
in	O
a	O
childhood	O
obesity	S-Phenotype
study	O
(	O
n=482	O
)	O
and	O
in	O
a	O
gestational	B-Phenotype
diabetes	E-Phenotype
study	O
(	O
n=1710	O
)	O
,	O
respectively	O
.	O

We	O
report	O
on	O
an	O
8	O
-	O
year	O
-	O
old	O
girl	O
born	O
to	O
consanguineous	O
Iraqi	O
parents	O
presenting	O
with	O
slowly	O
progressive	O
encephalomyopathy	O
,	O
severe	B-Phenotype
failure	I-Phenotype
to	I-Phenotype
thrive	E-Phenotype
,	O
significant	O
delays	O
in	O
verbal	O
and	O
communicative	O
skills	O
and	O
bilateral	O
retinal	O
cherry	O
red	O
spots	O
on	O
fundoscopy	O
.	O

Recently	O
,	O
TMEM98	O
is	O
supposed	O
to	O
be	O
of	O
great	O
value	O
for	O
the	O
discoveries	O
of	O
anti	O
-	O
tumor	S-Phenotype
drugs	O
.	O

Increased	O
RAD6	O
levels	O
cause	O
histone	O
2B	O
ubiquitination	O
-	O
mediated	O
epigenetic	O
changes	O
that	O
stimulate	O
transcription	O
of	O
stem	O
cell	O
genes	O
,	O
including	O
ALDH1A1	O
and	O
SOX2	O
,	O
leading	O
to	O
a	O
cancer	S-Phenotype
stem	O
cell	O
phenotype	O
,	O
which	O
is	O
implicated	O
in	O
disease	O
recurrence	O
and	O
metastasis	O
.	O

This	O
region	O
contained	O
the	O
GRXCR1	O
gene	O
,	O
and	O
the	O
orthologous	O
mouse	O
gene	O
was	O
described	O
to	O
be	O
mutated	O
in	O
the	O
pirouette	O
(	O
pi	O
)	O
mutant	O
with	O
resulting	O
hearing	B-Phenotype
loss	E-Phenotype
and	O
circling	O
behavior	O
.	O

PI3	O
-	O
kinase	O
inhibition	O
or	O
expression	O
of	O
wild	O
-	O
type	O
,	O
but	O
not	O
catalytically	O
inactive	O
HA	O
-	O
INPP5E	O
partially	O
rescued	O
cilia	O
loss	O
in	O
Inpp5e	O
-	O
null	O
tumor	S-Phenotype
cells	O
in	O
vitro	O
.	O

Mechanistically	O
,	O
BCKDK	O
promotes	O
colorectal	B-Phenotype
cancer	E-Phenotype
by	O
enhancing	O
the	O
MAPK	O
signaling	O
pathway	O
through	O
direct	O
MEK	O
phosphorylation	O
,	O
rather	O
than	O
by	O
branched	O
-	O
chain	O
amino	O
acids	O
catabolism	O
.	O

A	O
frame	O
-	O
shift	O
carboxyl	O
-	O
terminal	O
deletion	O
was	O
reported	O
in	O
DISC1	O
in	O
an	O
American	O
family	O
with	O
schizophrenia	S-Phenotype
,	O
but	O
subsequently	O
found	O
in	O
two	O
controls	O
.	O

To	O
investigate	O
genetic	O
predispositions	O
for	O
MYCN	O
-	O
amplified	O
neuroblastoma	S-Phenotype
,	O
we	O
performed	O
a	O
meta	O
-	O
analysis	O
of	O
three	O
genome	O
-	O
wide	O
association	O
studies	O
totaling	O
615	O
MYCN	O
-	O
amplified	O
high	O
-	O
risk	O
neuroblastoma	S-Phenotype
cases	O
and	O
1869	O
MYCN	O
-	O
nonamplified	O
non	O
-	O
high	O
-	O
risk	O
neuroblastoma	S-Phenotype
cases	O
as	O
controls	O
using	O
a	O
fixed	O
-	O
effects	O
model	O
with	O
inverse	O
variance	O
weighting	O
.	O

DNA	O
samples	O
from	O
3,881	O
breast	B-Phenotype
cancer	E-Phenotype
affected	O
and	O
4,330	O
unaffected	O
BRCA2	O
mutation	O
carriers	O
from	O
47	O
studies	O
belonging	O
to	O
the	O
Consortium	O
of	O
Investigators	O
of	O
Modifiers	O
of	O
BRCA1	O
/	O
2	O
were	O
genotyped	O
and	O
available	O
for	O
analysis	O
.	O

Here	O
,	O
integrated	O
analysis	O
of	O
gene	O
expression	O
in	O
non	B-Phenotype
-	I-Phenotype
small	I-Phenotype
cell	I-Phenotype
lung	I-Phenotype
cancer	E-Phenotype
revealed	O
that	O
SLC39A4	O
expression	O
is	O
significantly	O
correlated	O
with	O
increased	O
tumour	S-Phenotype
size	O
and	O
regional	O
lymph	O
node	O
spread	O
,	O
as	O
well	O
as	O
shorter	O
overall	O
survival	O
(	O
OS	O
)	O
and	O
disease	O
-	O
free	O
survival	O
(	O
DFS	O
)	O
.	O

Here	O
,	O
the	O
effects	O
of	O
stable	O
DIO1	O
re	O
-	O
expression	O
were	O
analyzed	O
on	O
the	O
proteome	O
of	O
renal	B-Phenotype
cancer	E-Phenotype
cells	O
,	O
followed	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
validation	O
in	O
two	O
renal	B-Phenotype
cancer	E-Phenotype
-	O
derived	O
cell	O
lines	O
.	O

Our	O
most	O
significant	O
AM	O
association	O
was	O
upstream	O
of	O
RSF1	O
,	O
a	O
gene	O
implicated	O
in	O
ovarian	O
and	O
breast	B-Phenotype
cancers	E-Phenotype
(	O
rs11604207	O
,	O
p	O
=	O
1.6×10⁻⁰⁶	O
)	O
.	O

A	O
founder	O
mutation	O
in	O
RIC1	O
(	O
KIAA1432	O
)	O
was	O
identified	O
in	O
patients	O
with	O
cataract	S-Phenotype
,	O
brain	B-Phenotype
atrophy	E-Phenotype
,	O
microcephaly	S-Phenotype
with	O
or	O
without	O
cleft	B-Phenotype
lip	I-Phenotype
and	I-Phenotype
palate	E-Phenotype
.	O

The	O
patients	O
'	O
phenotype	O
consisted	O
of	O
amelogenesis	B-Phenotype
imperfecta	E-Phenotype
,	O
skeletal	B-Phenotype
dysplasia	E-Phenotype
,	O
and	O
decreased	B-Phenotype
bone	I-Phenotype
mineral	I-Phenotype
density	E-Phenotype
compatible	O
with	O
osteoporosis	S-Phenotype
.	O

SAMHD1	O
regulates	O
cellular	O
deoxynucleotide	O
levels	O
and	O
acts	O
as	O
a	O
potential	O
tumor	S-Phenotype
suppressor	O
in	O
other	O
leukemias	S-Phenotype
.	O

In	O
the	O
present	O
study	O
,	O
we	O
characterize	O
SIRT2	O
inhibition	O
activity	O
of	O
the	O
brain	O
-	O
permeable	O
compound	O
AK7	O
and	O
examine	O
the	O
efficacy	O
of	O
this	O
small	O
molecule	O
in	O
models	O
of	O
Parkinson	O
's	O
disease	O
,	O
amyotrophic	B-Phenotype
lateral	I-Phenotype
sclerosis	E-Phenotype
and	O
cerebral	B-Phenotype
ischemia	E-Phenotype
.	O

Spinal	B-Phenotype
muscular	I-Phenotype
atrophy	E-Phenotype
(	O
SMA	S-Phenotype
)	O
is	O
a	O
lethal	O
autosomal	B-Phenotype
recessive	E-Phenotype
neurological	O
disease	O
characterized	O
by	O
selective	B-Phenotype
degeneration	I-Phenotype
of	I-Phenotype
motor	I-Phenotype
neurons	I-Phenotype
in	I-Phenotype
the	I-Phenotype
spinal	I-Phenotype
cord	E-Phenotype
.	O

This	O
is	O
the	O
first	O
report	O
linking	O
mutations	O
in	O
CRYBA4	O
to	O
cataractogenesis	S-Phenotype
and	O
microphthalmia	S-Phenotype

Taken	O
together	O
,	O
our	O
study	O
demonstrates	O
that	O
EMX2	O
inhibits	O
proliferation	O
and	O
tumorigenesis	S-Phenotype
through	O
inactivation	O
of	O
the	O
Wnt	O
/	O
β	O
-	O
catenin	O
pathway	O
in	O
CRC	O
cells	O
.	O

Recessive	O
mutations	O
in	O
BRAT1	O
cause	O
lethal	B-Phenotype
neonatal	I-Phenotype
rigidity	E-Phenotype
and	O
multifocal	S-Phenotype
seizure	S-Phenotype
syndrome	O
,	O
a	O
phenotype	O
characterized	O
by	O
neonatal	B-Phenotype
microcephaly	E-Phenotype
,	O
hypertonia	S-Phenotype
,	O
and	O
refractory	B-Phenotype
epilepsy	E-Phenotype
with	O
premature	O
death	O
by	O
age	O
2	O
years	O
.	O

Deficiency	O
of	O
the	O
extracellular	O
matrix	O
molecule	O
FRAS1	O
,	O
normally	O
expressed	O
by	O
the	O
ureteric	O
bud	O
,	O
leads	O
to	O
bilateral	B-Phenotype
renal	I-Phenotype
agenesis	E-Phenotype
in	O
humans	O
with	O
Fraser	O
syndrome	O
and	O
blebbed	O
(	O
Fras1	O
(	O
bl	O
/	O
bl	O
)	O
)	O
mice	O
.	O

Objective	O
:	O
To	O
investigate	O
the	O
expression	O
of	O
succinate	O
dehydrogenase	O
complex	O
subunit	O
protein	O
in	O
succinate	B-Phenotype
dehydrogenase	I-Phenotype
-	I-Phenotype
deficient	I-Phenotype
gastrointestinal	I-Phenotype
stromal	I-Phenotype
tumors	E-Phenotype
(	O
SDH	B-Phenotype
-	I-Phenotype
deficient	I-Phenotype
GISTs	E-Phenotype
)	O
.	O

Odds	O
ratios	O
(	O
ORs	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CIs	O
)	O
were	O
conducted	O
to	O
evaluate	O
the	O
overall	O
strength	O
of	O
the	O
associations	O
in	O
five	O
genetic	O
models	O
,	O
as	O
well	O
as	O
in	O
subgroup	O
analyses	O
,	O
stratified	O
by	O
ethnicity	O
,	O
cancer	S-Phenotype
type	O
or	O
source	O
of	O
control	O
.	O

PEPCK	O
-	O
M	O
(	O
PCK2	O
)	O
,	O
the	O
mitochondrial	O
isoform	O
of	O
phosphoenolpyruvate	O
carboxykinase	O
(	O
PEPCK	O
)	O
,	O
has	O
been	O
shown	O
by	O
us	O
and	O
others	O
to	O
be	O
functionally	O
expressed	O
and	O
to	O
mediate	O
gluconeogenesis	O
,	O
the	O
reverse	O
pathway	O
of	O
glycolysis	O
,	O
in	O
different	O
cancer	S-Phenotype
cells	O
.	O

Upregulation	O
of	O
TMEM98	O
was	O
significantly	O
correlated	O
with	O
advanced	O
tumor	S-Phenotype
stage	O
(	O
P	O
=	O
0.048	O
)	O
,	O
high	O
incidence	O
of	O
early	O
tumor	S-Phenotype
recurrence	O
(	O
P	O
=	O
0.005	O
)	O
,	O
poor	O
overall	O
survival	O
(	O
P	O
=	O
0.029	O
)	O
,	O
and	O
poor	O
disease	O
-	O
free	O
survival	O
(	O
P	O
=	O
0.011	O
)	O
of	O
patients	O
with	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
after	O
hepatectomy	O
.	O

All	O
these	O
findings	O
indicate	O
that	O
circulating	O
soluble	O
corin	O
has	O
the	O
potential	O
to	O
be	O
a	O
sensitive	O
and	O
specific	O
biomarker	O
for	O
risk	O
prediction	O
and	O
prognostic	O
assessment	O
of	O
cardiovascular	B-Phenotype
diseases	E-Phenotype
.	O

Mutations	O
in	O
the	O
human	O
TRNT1	O
gene	O
encoding	O
tRNA	O
nucleotidyltransferase	O
(	O
tRNA	O
-	O
NT	O
)	O
,	O
an	O
essential	O
enzyme	O
responsible	O
for	O
addition	O
of	O
the	O
CCA	O
(	O
cytidine	O
-	O
cytidine	O
-	O
adenosine	O
)	O
sequence	O
to	O
the	O
3	O
*	O
-	O
termini	O
of	O
tRNAs	O
,	O
have	O
been	O
linked	O
to	O
disease	O
phenotypes	O
including	O
congenital	B-Phenotype
sideroblastic	I-Phenotype
anemia	E-Phenotype
with	O
B	B-Phenotype
-	I-Phenotype
cell	I-Phenotype
immunodeficiency	E-Phenotype
,	O
periodic	B-Phenotype
fevers	E-Phenotype
and	O
developmental	B-Phenotype
delay	E-Phenotype
(	O
SIFD	S-Phenotype
)	O
or	O
retinitis	B-Phenotype
pigmentosa	E-Phenotype
with	O
erythrocyte	B-Phenotype
microcytosis	E-Phenotype
.	O

Polo	O
-	O
Like	O
Kinase	O
1	O
(	O
PLK1	O
)	O
,	O
a	O
serine	O
-	O
threonine	O
kinase	O
that	O
is	O
often	O
overexpressed	O
across	O
multiple	O
tumor	S-Phenotype
types	O
,	O
is	O
one	O
of	O
the	O
key	O
regulators	O
of	O
CIN	O
and	O
is	O
considered	O
as	O
a	O
potential	O
therapeutic	O
target	O
.	O

We	O
find	O
evidence	O
of	O
genetic	O
heterogeneity	S-Phenotype
between	O
the	O
sub	O
-	O
phenotypes	O
of	O
NSOFC	O
and	O
among	O
different	O
populations	O
.	O

In	O
the	O
present	O
study	O
,	O
KIF14	O
was	O
observed	O
to	O
be	O
markedly	O
overexpressed	O
in	O
CRC	O
,	O
and	O
this	O
upregulation	O
was	O
associated	O
with	O
tumor	S-Phenotype
size	O
and	O
marker	O
of	O
proliferation	O
Ki	O
-	O
67	O
immunostaining	O
scores	O
.	O

Hemizygosity	O
of	O
the	O
distal	O
region	O
,	O
designated	O
HDR1	O
,	O
can	O
cause	O
hypoparathyroidism	S-Phenotype
and	O
in	O
addition	O
sensorineuronal	B-Phenotype
deafness	E-Phenotype
and	O
renal	B-Phenotype
dysplasia	I-Phenotype
/	I-Phenotype
insufficiency	E-Phenotype
or	O
a	O
subset	O
of	O
this	O
triad	O

Seventy	O
resected	O
tumours	S-Phenotype
were	O
dissociated	O
into	O
single	O
cells	O
and	O
stained	O
with	O
antibodies	O
to	O
CD44	O
as	O
well	O
as	O
CD45	O
and	O
CD31	O
(	O
together	O
referred	O
as	O
Lineage	O
/	O
Lin	O
)	O
.	O

Empty	O
spiracles	O
homeobox	O
2	O
(	O
EMX2	O
)	O
is	O
a	O
homeodomain	O
-	O
containing	O
transcription	O
factor	O
that	O
plays	O
an	O
essential	O
role	O
in	O
tumorigenesis	S-Phenotype
.	O

Our	O
aim	O
was	O
to	O
understand	O
the	O
role	O
of	O
RNASEH2A	O
in	O
cancer	S-Phenotype
prognostication	O
and	O
to	O
establish	O
a	O
scoring	O
system	O
based	O
on	O
the	O
expressions	O
of	O
genes	O
interacting	O
with	O
RNASEH2A	O
.	O

Homozygous	O
and	O
compound	O
heterozygous	O
mutations	O
in	O
C12orf57	O
have	O
recently	O
been	O
described	O
to	O
cause	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
syndromic	O
form	O
of	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
including	O
agenesis	B-Phenotype
/	I-Phenotype
hypoplasia	I-Phenotype
of	I-Phenotype
the	I-Phenotype
corpus	I-Phenotype
callosum	E-Phenotype
,	O
optic	B-Phenotype
coloboma	E-Phenotype
,	O
and	O
intractable	B-Phenotype
seizures	E-Phenotype
.	O

Squamous	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
SCC	S-Phenotype
)	O
can	O
progress	O
to	O
malignant	B-Phenotype
metastatic	I-Phenotype
cancer	E-Phenotype
,	O
including	O
an	O
aggressive	O
subtype	O
known	O
as	O
spindle	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
spSCC	S-Phenotype
)	O
.	O

These	O
include	O
a	O
triple	O
proline	O
deletion	O
in	O
HCN2	O
that	O
increases	O
channel	O
function	O
and	O
occurs	O
more	O
often	O
in	O
patients	O
with	O
febrile	B-Phenotype
seizure	E-Phenotype
syndromes	O
.	O

Some	O
of	O
the	O
RP	O
genes	O
are	O
also	O
associated	O
with	O
other	O
retinal	B-Phenotype
diseases	E-Phenotype
,	O
such	O
as	O
LCA	S-Phenotype
(	O
Leber	B-Phenotype
's	I-Phenotype
congenital	I-Phenotype
amaurosis	E-Phenotype
)	O
and	O
CORD	S-Phenotype
(	O
cone	B-Phenotype
-	I-Phenotype
rod	I-Phenotype
dystrophy	E-Phenotype
)	O
.	O

For	O
combined	O
mothers	O
'	O
and	O
fathers	O
'	O
attained	O
age	O
,	O
10	O
loci	O
were	O
associated	O
(	O
pAAAA5	O
*	O
10sup	O
-	O
8	O
/	O
sup	O
)	O
,	O
including	O
8	O
previously	O
identified	O
for	O
traits	O
including	O
survival	O
,	O
Alzheimer	O
's	O
and	O
cardiovascular	B-Phenotype
disease	E-Phenotype
.	O

Taken	O
together	O
,	O
our	O
findings	O
suggest	O
that	O
NONO	O
might	O
play	O
an	O
important	O
role	O
in	O
promoting	O
tumorigenesis	S-Phenotype
of	O
ESCC	O
.	O

The	O
ID2	O
gene	O
expression	O
was	O
increased	O
in	O
the	O
most	O
advanced	O
stage	O
of	O
endometriosis	S-Phenotype
and	O
in	O
ovarian	B-Phenotype
endometriomas	E-Phenotype
,	O
the	O
PRELP	O
was	O
more	O
expressed	O
in	O
peritoneal	B-Phenotype
lesions	E-Phenotype
,	O
and	O
the	O
SMOC2	O
was	O
highly	O
expressed	O
in	O
both	O
peritoneal	B-Phenotype
and	I-Phenotype
endometrioma	I-Phenotype
lesions	E-Phenotype
.	O

Due	O
to	O
the	O
heterogeneity	S-Phenotype
of	O
the	O
studies	O
assessed	O
,	O
no	O
meta	O
-	O
analysis	O
could	O
be	O
performed	O
.	O

The	O
BARD1	O
mutations	O
also	O
caused	O
loss	O
of	O
transcriptional	O
repression	O
of	O
BRCA1	O
-	O
regulated	O
estrogen	O
metabolism	O
genes	O
CYP1A1	O
and	O
CYP3A4	O
;	O
breast	O
epithelial	O
cells	O
edited	O
to	O
create	O
heterozygous	O
loss	O
of	O
BARD1	O
showed	O
significantly	O
higher	O
expression	O
of	O
CYP1A1	O
and	O
CYP3A4	O
Reintroduction	O
of	O
wild	O
-	O
type	O
BARD1	O
into	O
these	O
cells	O
restored	O
CYP1A1	O
and	O
CYP3A4	O
transcription	O
to	O
normal	O
levels	O
,	O
but	O
introduction	O
of	O
the	O
cancer	S-Phenotype
-	O
predisposing	O
BARD1	O
RING	O
mutants	O
failed	O
to	O
do	O
so	O
.	O

This	O
entails	O
failing	O
in	O
identification	O
of	O
reliable	O
serum	O
tumor	S-Phenotype
markers	O
for	O
screening	O
early	O
GC	O
(	O
EGC	O
)	O
as	O
well	O
as	O
persisting	O
ominous	O
prognosis	O
of	O
this	O
disease	O
.	O

Oncogenic	O
mutations	O
in	O
the	O
PI3K	O
/	O
AKT	O
pathway	O
are	O
present	O
in	O
nearly	O
half	O
of	O
human	O
tumors	S-Phenotype
.	O

Treatment	O
with	O
DNA	O
methyltransferase	O
inhibitors	O
has	O
been	O
proposed	O
as	O
an	O
attractive	O
strategy	O
to	O
increase	O
the	O
expression	O
of	O
cancer	S-Phenotype
/	O
testis	O
antigens	O
in	O
tumors	S-Phenotype
before	O
immunotargeting	O
;	O
however	O
,	O
neither	O
ADAM2	O
,	O
CALR3	O
nor	O
SAGE1	O
could	O
be	O
significantly	O
induced	O
in	O
lung	B-Phenotype
and	I-Phenotype
breast	I-Phenotype
cancer	E-Phenotype
cell	O
lines	O
using	O
this	O
strategy	O
.	O

Oncogene	O
-	O
induced	O
senescence	O
appears	O
to	O
decrease	O
the	O
frequency	O
of	O
the	O
multistep	O
progression	O
in	O
KRAS	O
-	O
or	O
BRAF	O
-	O
mutated	O
adenocarcinoma	O
,	O
whose	O
tumor	S-Phenotype
evolution	O
may	O
be	O
associated	O
with	O
epigenetic	O
alterations	O
and	O
kinase	O
-	O
inactive	O
mutations	O
.	O

Uveal	B-Phenotype
melanomas	E-Phenotype
are	O
molecularly	O
distinct	O
from	O
cutaneous	B-Phenotype
melanomas	E-Phenotype
and	O
lack	O
mutations	O
in	O
BRAF	O
,	O
NRAS	O
,	O
KIT	O
,	O
and	O
NF1	O
.	O

This	O
close	O
biochemical	O
relationship	O
indicates	O
an	O
oncogenic	O
role	O
for	O
WIP	O
in	O
the	O
physiology	O
of	O
cancer	S-Phenotype
pathology	O
by	O
increasing	O
YAP	O
/	O
TAZ	O
stability	O

Spinocerebellar	B-Phenotype
ataxia	I-Phenotype
type	I-Phenotype
5	E-Phenotype
(	O
SCA5	S-Phenotype
)	O
is	O
a	O
neurodegenerative	B-Phenotype
disease	E-Phenotype
caused	O
by	O
mutations	O
in	O
the	O
cytoskeletal	O
protein	O
β	O
-	O
III	O
-	O
spectrin	O
.	O

To	O
investigate	O
the	O
function	O
of	O
PAK4	O
in	O
neuroblastoma	S-Phenotype
,	O
we	O
used	O
a	O
small	O
-	O
molecule	O
inhibitor	O
that	O
targets	O
PAK4	O
,	O
that	O
is	O
,	O
PF	O
-	O
3758309	O
.	O

Genomic	O
and	O
transcriptomic	O
analysis	O
of	O
AAAA5000	O
patients	O
demonstrates	O
that	O
KRT8	O
mutation	O
and	O
copy	O
number	O
amplification	O
are	O
frequently	O
evident	O
in	O
epithelial	B-Phenotype
-	I-Phenotype
derived	I-Phenotype
cancers	E-Phenotype
.	O

CD44	O
was	O
expressed	O
on	O
the	O
surface	O
of	O
poorly	O
differentiated	O
tumour	S-Phenotype
cells	O
,	O
and	O
within	O
the	O
The	O
Cancer	S-Phenotype
Genome	O
Atlas	O
-	O
Head	O
and	O
Neck	O
Squamous	B-Phenotype
Cell	I-Phenotype
Carcinoma	E-Phenotype
samples	O
,	O
its	O
messenger	O
RNA	O
levels	O
were	O
higher	O
in	O
tumours	S-Phenotype
compared	O
to	O
normal	O
.	O

In	O
the	O
case	O
of	O
GC	O
,	O
in	O
fact	O
,	O
several	O
cytological	O
and	O
molecular	O
works	O
have	O
already	O
demonstrated	O
GJ	O
to	O
be	O
an	O
interesting	O
biological	O
material	O
for	O
improving	O
clinicopathologic	O
and	O
prognostic	O
knowledge	O
of	O
this	O
cancer	S-Phenotype
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
successful	O
application	O
of	O
PGD	O
for	O
hearing	B-Phenotype
loss	E-Phenotype
in	O
Iran	O
.	O

In	O
humans	O
,	O
TPRN	O
mutations	O
cause	O
autosomal	B-Phenotype
recessive	I-Phenotype
nonsyndromic	I-Phenotype
deafness	E-Phenotype
(	O
DFNB79	S-Phenotype
)	O
by	O
an	O
unknown	O
mechanism	O
.	O

Primary	O
hyperoxaluria	S-Phenotype
Type	O
II	O
and	O
primary	O
hyperoxaluria	S-Phenotype
Type	O
III	O
are	O
due	O
to	O
the	O
deficit	O
of	O
glyoxylate	O
reductase	O
/	O
hydroxypyruvate	O
reductase	O
(	O
GRHPR	O
)	O
and	O
4	O
-	O
hydroxy	O
-	O
2	O
-	O
oxoglutarate	O
aldolase	O
(	O
HOGA1	O
)	O
,	O
respectively	O
.	O

Mechanically	O
,	O
miR	O
-	O
9	O
plays	O
a	O
tumor	S-Phenotype
suppressive	O
role	O
partially	O
through	O
a	O
functional	O
miR	O
-	O
9	O
/	O
IGF2BP1	O
/	O
AKTAAAAAERK	O
axis	O
.	O

Most	O
of	O
the	O
available	O
anticancer	O
drugs	O
are	O
designed	O
to	O
act	O
on	O
specific	O
targets	O
by	O
altering	O
the	O
activity	O
of	O
involved	O
transporters	O
and	O
genes	O
.	O

Mutations	O
in	O
ST3GAL5	O
,	O
which	O
codes	O
for	O
an	O
enzyme	O
early	O
in	O
brain	O
ganglioside	O
biosynthesis	O
,	O
result	O
in	O
an	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
seizure	E-Phenotype
disorder	O
with	O
profound	O
motor	O
and	O
cognitive	O
decay	O
,	O
whereas	O
mutations	O
in	O
B4GALNT1	O
,	O
a	O
gene	O
encoding	O
a	O
later	O
step	O
,	O
result	O
in	O
hereditary	B-Phenotype
spastic	I-Phenotype
paraplegia	E-Phenotype
accompanied	O
by	O
intellectual	B-Phenotype
deficits	E-Phenotype
.	O

While	O
mutations	O
in	O
TMEM165	O
are	O
known	O
to	O
cause	O
human	O
'congenital	O
disorders	O
of	O
glycosylation	O
'	O
,	O
a	O
recessive	O
autosomal	O
metabolic	O
disease	O
,	O
the	O
potential	O
association	O
of	O
this	O
protein	O
with	O
human	O
cancer	S-Phenotype
development	O
has	O
not	O
been	O
explored	O
to	O
date	O
.	O

Our	O
case	O
report	O
support	O
clinical	O
heterogeneity	S-Phenotype
of	O
SCA31	O
,	O
and	O
highlight	O
the	O
importance	O
of	O
considering	O
this	O
type	O
in	O
patients	O
with	O
dystonia	S-Phenotype
and	O
ataxia	S-Phenotype
.	O

Thus	O
,	O
the	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
elucidate	O
the	O
influence	O
of	O
LMNB1	O
upregulation	O
on	O
colon	B-Phenotype
cancer	E-Phenotype
cell	O
line	O
after	O
treatment	O
with	O
5	O
-	O
FU	O
.	O

The	O
second	O
most	O
frequently	O
mutated	O
gene	O
,	O
histone	O
methyltransferase	O
SETD2	O
,	O
has	O
known	O
roles	O
in	O
multiple	O
cancers	S-Phenotype
,	O
but	O
has	O
not	O
previously	O
been	O
strongly	O
implicated	O
in	O
osteosarcoma	S-Phenotype
.	O

Proteomic	O
analysis	O
of	O
12	O
tumours	S-Phenotype
from	O
an	O
mTOR	O
-	O
driven	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
mouse	O
model	O
revealed	O
that	O
NME1	O
and	O
NME2	O
,	O
the	O
only	O
known	O
mammalian	O
histidine	O
kinases	O
,	O
were	O
upregulated	O
.	O

Thus	O
,	O
LHPP	O
is	O
a	O
protein	O
histidine	O
phosphatase	O
and	O
tumour	S-Phenotype
suppressor	O
,	O
suggesting	O
that	O
deregulated	O
histidine	O
phosphorylation	O
is	O
oncogenic	O

However	O
,	O
the	O
relationship	O
of	O
NDRG1	O
to	O
prognosis	O
or	O
c	O
-	O
Myc	O
expression	O
in	O
lung	B-Phenotype
adenocarcinoma	E-Phenotype
has	O
not	O
been	O
well	O
clarified	O
.	O

Down	O
regulation	O
of	O
Protein	O
Kinase	O
D1	O
(	O
PrKD1	O
)	O
,	O
a	O
novel	O
serine	O
threonine	O
kinase	O
,	O
in	O
prostate	B-Phenotype
,	I-Phenotype
gastric	I-Phenotype
,	I-Phenotype
breast	I-Phenotype
and	I-Phenotype
colon	I-Phenotype
cancers	E-Phenotype
in	O
humans	O
leads	O
to	O
disease	O
progression	O
.	O

This	O
study	O
showed	O
that	O
ADSSL1	O
myopathy	S-Phenotype
was	O
not	O
rare	O
among	O
distal	B-Phenotype
myopathy	E-Phenotype
patients	O
of	O
Korean	O
origin	O
,	O
and	O
expanded	O
the	O
clinical	O
and	O
genetic	O
spectrum	O
.	O

Using	O
exome	O
sequencing	O
,	O
we	O
identified	O
three	O
unrelated	O
patients	O
with	O
bi	O
-	O
allelic	O
mutations	O
in	O
THOC6	O
associated	O
with	O
intellectual	B-Phenotype
disability	E-Phenotype
and	O
additional	O
clinical	O
features	O
.	O

Additionally	O
,	O
adult	O
pkd2l1	O
mutant	O
zebrafish	O
develop	O
an	O
exaggerated	O
spine	O
curvature	O
,	O
reminiscent	O
of	O
kyphosis	S-Phenotype
in	O
humans	O
.	O

In	O
a	O
tumor	S-Phenotype
with	O
inv	O
(	O
12	O
)	O
,	O
exon	O
3	O
of	O
HMGA2	O
was	O
fused	O
to	O
a	O
sequence	O
in	O
intron	O
1	O
of	O
the	O
CRADD	O
gene	O
from	O
12q22	O
.	O

The	O
major	O
question	O
to	O
be	O
solved	O
is	O
the	O
genetic	O
basis	O
of	O
bilateral	B-Phenotype
adrenal	I-Phenotype
hyperplasia	E-Phenotype
(	O
BAH	S-Phenotype
)	O
.	O

The	O
clinical	O
presentation	O
of	O
our	O
patients	O
differs	O
from	O
the	O
original	O
QARS	O
-	O
associated	O
syndrome	O
in	O
the	O
severe	B-Phenotype
postnatal	I-Phenotype
growth	I-Phenotype
failure	E-Phenotype
,	O
absence	O
of	O
epilepsy	S-Phenotype
,	O
and	O
minor	O
MRI	O
findings	O
,	O
thus	O
further	O
expanding	O
the	O
phenotypic	O
spectrum	O
of	O
the	O
glutaminyl	O
-	O
tRNA	O
synthetase	O
deficiency	O
syndromes	O

Epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
mutation	O
is	O
prevalently	O
expressed	O
in	O
lung	B-Phenotype
adenocarcinoma	E-Phenotype
cases	O
and	O
acts	O
as	O
one	O
of	O
the	O
major	O
driving	O
oncogenes	O
.	O

We	O
report	O
the	O
identification	O
of	O
mutations	O
in	O
PMPCA	O
in	O
17	O
patients	O
from	O
four	O
families	O
affected	O
with	O
cerebellar	B-Phenotype
ataxia	E-Phenotype
,	O
including	O
the	O
large	O
Lebanese	O
family	O
previously	O
described	O
with	O
autosomal	B-Phenotype
recessive	I-Phenotype
cerebellar	I-Phenotype
ataxia	E-Phenotype
and	O
short	B-Phenotype
stature	E-Phenotype
of	O
Norman	O
type	O
and	O
localized	O
to	O
chromosome	O
9q34	O
(	O
OMIM	O
#	O
213200	O
)	O
.	O

5	O
*	O
-	O
Aza	O
-	O
2	O
*	O
-	O
deoxycytidine	O
(	O
5	O
-	O
Aza	O
-	O
dC	O
)	O
is	O
a	O
demethylating	O
drug	O
that	O
causes	O
genome	O
-	O
wide	O
hypomethylation	O
resulting	O
in	O
the	O
expression	O
of	O
several	O
tumor	S-Phenotype
suppressor	O
genes	O
causing	O
growth	O
arrest	O
of	O
cancer	S-Phenotype
cells	O
.	O

In	O
patients	O
with	O
thyroid	B-Phenotype
cancer	E-Phenotype
,	O
a	O
positive	O
correlation	O
between	O
SLC6A9	O
-	O
5:2	O
and	O
PARP	O
-	O
1	O
was	O
identified	O
,	O
and	O
low	O
SLC6A9	O
-	O
5:2	O
expression	O
was	O
associated	O
with	O
a	O
worse	O
prognosis	O
of	O
papillary	B-Phenotype
thyroid	I-Phenotype
carcinoma	E-Phenotype
.	O

A	O
hypomorphic	O
variant	O
in	O
CCDC22	O
was	O
previously	O
reported	O
in	O
association	O
with	O
a	O
familial	O
case	O
of	O
syndromic	B-Phenotype
X	I-Phenotype
-	I-Phenotype
linked	I-Phenotype
intellectual	I-Phenotype
disability	E-Phenotype
,	O
which	O
shows	O
phenotypic	O
overlap	O
with	O
RSS	O
/	O
3C	O
syndrome	O
.	O

LncRNA	O
MAP3K20	O
antisense	O
RNA	O
1	O
(	O
MLK7	O
-	O
AS1	O
)	O
has	O
been	O
identified	O
as	O
one	O
of	O
gastric	B-Phenotype
cancer	E-Phenotype
-	O
specific	O
lncRNAs	O
.	O

The	O
Wnt	O
/	O
beta	O
-	O
catenin	O
pathway	O
can	O
be	O
activated	O
in	O
both	O
benign	O
and	O
malignant	O
tumors	S-Phenotype
by	O
liCTNNB1	O
/	O
i	O
mutations	O
and	O
by	O
liZNRF3	O
/	O
i	O
inactivation	O
in	O
adrenal	B-Phenotype
cancer	E-Phenotype
(	O
ACC	S-Phenotype
)	O
.	O

Niemann	O
-	O
Pick	O
disease	O
type	O
C1	O
(	O
NPC1	O
)	O
is	O
a	O
rare	O
autosomal	B-Phenotype
recessive	E-Phenotype
lysosomal	O
storage	O
disease	O
primarily	O
caused	O
by	O
mutations	O
in	O
NPC1	O
NPC1	O
is	O
characterized	O
by	O
abnormal	B-Phenotype
accumulation	I-Phenotype
of	I-Phenotype
unesterified	I-Phenotype
cholesterol	E-Phenotype
and	O
glycolipids	B-Phenotype
in	I-Phenotype
late	I-Phenotype
endosomes	I-Phenotype
and	I-Phenotype
lysosomes	E-Phenotype
.	O

This	O
study	O
represents	O
the	O
first	O
evidence	O
of	O
the	O
abnormal	O
changes	O
in	O
VGSCs	O
subtypes	O
and	O
CaM	O
/	O
CaMKII	O
pathway	O
in	O
human	O
brain	B-Phenotype
low	I-Phenotype
-	I-Phenotype
grade	I-Phenotype
astrocytoma	E-Phenotype
,	O
providing	O
new	O
potential	O
targets	O
for	O
molecular	O
therapies	O
of	O
this	O
disease	O

The	O
deregulation	O
of	O
its	O
expression	O
or	O
activity	O
contributes	O
to	O
leukemia	S-Phenotype
,	O
in	O
which	O
Spi1	O
can	O
be	O
either	O
an	O
oncogene	O
or	O
a	O
tumor	S-Phenotype
suppressor	O
.	O

Since	O
RAPSN	O
-	O
associated	O
limb	O
-	O
girdle	O
type	O
CMS	O
was	O
only	O
manifested	O
in	O
AK9	O
homozygous	O
variant	O
carriers	O
,	O
the	O
disease	O
phenotype	O
was	O
of	O
digenic	B-Phenotype
inheritance	E-Phenotype
,	O
and	O
was	O
determined	O
by	O
the	O
novel	O
disease	O
modifier	O
AK9	O
which	O
provides	O
NTPs	O
for	O
N	O
-	O
glycosylation	O
.	O

In	O
summary	O
,	O
our	O
results	O
reveal	O
the	O
molecular	O
mechanism	O
of	O
Aldolase	O
A	O
in	O
promoting	O
lung	B-Phenotype
cancer	E-Phenotype
metastasis	O
via	O
PHD	O
-	O
mediated	O
stabilization	O
of	O
HIF	O
-	O
1α	O
and	O
the	O
subsequent	O
activation	O
of	O
MMP9	O
.	O

Mutations	O
in	O
LEPREL1	O
,	O
the	O
gene	O
encoding	O
prolyl	O
3	O
-	O
hydroxylase	O
-	O
2	O
(	O
P3H2	O
)	O
,	O
have	O
recently	O
been	O
identified	O
in	O
individuals	O
with	O
recessively	B-Phenotype
inherited	I-Phenotype
nonsyndromic	I-Phenotype
severe	I-Phenotype
myopia	E-Phenotype
.	O

Importantly	O
,	O
cardiac	O
ANKRD1	O
has	O
been	O
shown	O
to	O
be	O
highly	O
induced	O
in	O
various	O
cardiomyopathies	S-Phenotype
and	O
in	O
heart	B-Phenotype
failure	E-Phenotype
,	O
although	O
it	O
is	O
still	O
unclear	O
what	O
impact	O
this	O
may	O
have	O
on	O
the	O
pathophysiology	O
of	O
heart	B-Phenotype
failure	E-Phenotype
.	O

Feingold	O
syndrome	O
is	O
a	O
skeletal	B-Phenotype
dysplasia	E-Phenotype
caused	O
by	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
of	O
either	O
MYCN	O
(	O
type	O
1	O
)	O
or	O
MIR17HG	O
that	O
encodes	O
miR	O
-	O
17	O
-	O
92	O
microRNAs	O
(	O
type	O
2	O
)	O
.	O

We	O
investigated	O
plasma	O
microRNA	O
(	O
miRNA	O
)	O
profiles	O
associated	O
with	O
variation	O
of	O
hyperglycemia	S-Phenotype
,	O
measured	O
as	O
hemoglobin	O
A1c	O
(	O
HbA1c	O
)	O
,	O
in	O
two	O
panels	O
of	O
patients	O
with	O
type	B-Phenotype
1	I-Phenotype
diabetes	E-Phenotype
(	O
T1D	S-Phenotype
)	O
.	O

In	O
the	O
present	O
study	O
,	O
PNPO	O
expression	O
in	O
human	O
ovarian	B-Phenotype
tumour	E-Phenotype
tissue	O
and	O
its	O
association	O
with	O
the	O
clinicopathological	O
features	O
of	O
patients	O
with	O
EOC	O
were	O
examined	O
.	O

The	O
increased	O
levels	O
of	O
SELENBP1	O
and	O
Glycogen	O
synthase	O
kinase	O
3	O
subunit	O
α	O
(	O
GSK3α	O
)	O
genes	O
in	O
contrast	O
with	O
reduced	O
levels	O
of	O
B	O
-	O
cell	O
translocation	O
gene	O
1	O
(	O
BTG1	O
)	O
,	O
human	O
leukocyte	O
antigen	O
DRB1	O
(	O
HLA	O
-	O
DRB1	O
)	O
,	O
heterogeneous	S-Phenotype
nuclear	O
ribonucleoprotein	O
A3	O
(	O
HNRPA3	O
)	O
,	O
and	O
serine	O
/	O
arginine	O
-	O
rich	O
splicing	O
factor	O
1	O
(	O
SFRS1	O
)	O
genes	O
have	O
also	O
been	O
reported	O
.	O

Here	O
,	O
we	O
are	O
elucidating	O
the	O
mechanism	O
of	O
a	O
heritable	O
CCT5	O
subunit	O
mutation	O
that	O
causes	O
profound	B-Phenotype
neuropathy	E-Phenotype
in	O
humans	O
.	O

Higher	O
gene	O
expression	O
of	O
the	O
inositol	O
1,4,5	O
-	O
trisphosphate	O
receptor	O
2	O
gene	O
(	O
ITPR2	O
)	O
,	O
encoding	O
the	O
IP3	O
receptor	O
2	O
(	O
IP3R2	O
)	O
,	O
was	O
detected	O
in	O
sporadic	S-Phenotype
ALS	O
patients	O
.	O

Other	O
EXOSC3	O
mutations	O
and	O
EXOSC8	O
cases	O
are	O
intermediate	O
-	O
SMA	O
type	O
1	O
-	O
like	O
presentation	O
,	O
spasticity	S-Phenotype
(	O
mostly	O
in	O
EXOSC8	O
)	O
and	O
death	O
between	O
3	O
months	O
and	O
5	O
years	O
.	O

In	O
this	O
study	O
,	O
we	O
generated	O
GCN2	O
inhibitors	O
and	O
demonstrated	O
that	O
inhibition	O
of	O
GCN2	O
sensitizes	O
cancer	S-Phenotype
cells	O
with	O
low	O
basal	O
-	O
level	O
expression	O
of	O
asparagine	O
synthetase	O
(	O
ASNS	O
)	O
to	O
the	O
antileukemic	O
agent	O
l	O
-	O
asparaginase	O
(	O
ASNase	O
)	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
inhibition	O
of	O
CTGF	O
/	O
CCN2	O
with	O
the	O
monoclonal	O
neutralizing	O
antibody	O
FG	O
-	O
3019	O
reduces	O
fibrosis	O
in	O
several	O
chronic	O
disorders	O
including	O
the	O
mdx	O
mice	O
,	O
a	O
murine	O
model	O
for	O
Duchenne	B-Phenotype
muscular	I-Phenotype
dystrophy	E-Phenotype
(	O
DMD	S-Phenotype
)	O
.	O

On	O
comparing	O
Nesprin	O
-	O
2	O
and	O
BRCA1	O
localization	O
in	O
the	O
ovarian	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
SKOV	O
-	O
3	O
and	O
Caov	O
-	O
3	O
,	O
Nesprin	O
-	O
2	O
and	O
BRCA1	O
were	O
localized	O
to	O
the	O
NE	O
envelope	O
and	O
the	O
nucleus	O
in	O
SKOV	O
-	O
3	O
,	O
respectively	O
,	O
and	O
to	O
the	O
cytoplasm	O
in	O
Caov	O
-	O
3	O
cells	O
.	O

The	O
genetic	O
and	O
functional	O
evidences	O
here	O
reported	O
suggest	O
a	O
possible	O
role	O
of	O
the	O
DGCR2	O
gene	O
in	O
the	O
pathology	O
of	O
schizophrenia	S-Phenotype
and	O
also	O
in	O
the	O
therapeutic	O
effects	O
of	O
antipsychotic	O
drugs	O

Our	O
data	O
,	O
therefore	O
,	O
highlight	O
ITGA7	O
as	O
a	O
glioblastoma	S-Phenotype
biomarker	O
and	O
candidate	O
therapeutic	O
target	O

However	O
,	O
the	O
prognostic	O
value	O
of	O
ALDH5A1	O
in	O
ovarian	B-Phenotype
cancer	E-Phenotype
remains	O
unclear	O
.	O

HOT	O
should	O
be	O
considered	O
as	O
an	O
emerging	O
renal	O
entity	O
because	O
it	O
does	O
not	O
meet	O
the	O
diagnostic	O
criteria	O
for	O
other	O
recognized	O
eosinophilic	B-Phenotype
renal	I-Phenotype
tumors	E-Phenotype
,	O
such	O
as	O
oncocytoma	S-Phenotype
,	O
chromophobe	B-Phenotype
renal	I-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
RCC	O
)	O
,	O
TFE3	O
and	O
TFEB	O
RCC	O
,	O
SDH	O
-	O
deficient	O
RCC	O
,	O
and	O
eosinophilic	O
solid	O
and	O
cystic	O
RCC	O

Low	O
CMG2	O
mRNA	O
expression	O
was	O
correlated	O
with	O
a	O
worsened	O
patients	O
'	O
disease	O
-	O
specific	O
survival	O
in	O
Kaplan	O
-	O
Meier	O
analyses	O
(	O
mean	O
patient	O
survival	O
was	O
25	O
vs.	O
96	O
months	O
;	O
lip	O
/	O
i	O
=	O
0.013	O
)	O
,	O
especially	O
in	O
high	O
-	O
stage	O
tumors	S-Phenotype
.	O

In	O
addition	O
,	O
we	O
also	O
found	O
that	O
upregulation	O
of	O
the	O
Kankl	O
gene	O
resulted	O
in	O
the	O
inhibition	O
of	O
tumor	S-Phenotype
cell	O
invasion	O
and	O
metastasis	O
.	O

Accordingly	O
,	O
CRIPTO	O
was	O
detectable	O
in	O
serum	O
from	O
6	O
/	O
15	O
patients	O
with	O
embryonal	B-Phenotype
carcinoma	E-Phenotype
,	O
5	O
/	O
15	O
patients	O
with	O
seminoma	O
,	O
4	O
/	O
5	O
patients	O
with	O
germ	B-Phenotype
cell	I-Phenotype
neoplasia	E-Phenotype
in	O
situ	O
cells	O
only	O
and	O
in	O
1	O
/	O
15	O
control	O
patients	O
.	O

Three	O
neurodegenerative	B-Phenotype
diseases	E-Phenotype
[	O
Amyotrophic	B-Phenotype
Lateral	I-Phenotype
Sclerosis	E-Phenotype
(	O
ALS	S-Phenotype
)	O
,	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
and	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
]	O
have	O
many	O
characteristics	O
like	O
pathological	O
mechanisms	O
and	O
genes	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
autophagic	O
tumor	S-Phenotype
suppressor	O
UVRAG	O
plays	O
an	O
integral	O
role	O
in	O
melanogenesis	O
by	O
interaction	O
with	O
the	O
biogenesis	O
of	O
lysosome	O
-	O
related	O
organelles	O
complex	O
1	O
(	O
BLOC	O
-	O
1	O
)	O
.	O

We	O
detected	O
11	O
novel	O
mutations	O
in	O
GJA3	O
,	O
GJA8	O
,	O
CRYAA	O
,	O
CRYBB2	O
,	O
CRYGS	O
,	O
CRYGA	O
,	O
GCNT2	O
,	O
CRYGA	O
,	O
and	O
MIP	O
;	O
and	O
three	O
previously	O
reported	O
cataract	S-Phenotype
-	O
causing	O
mutations	O
in	O
GJA8	O
,	O
CRYAA	O
,	O
and	O
CRYBB2	O
The	O
most	O
commonly	O
mutated	O
genes	O
were	O
those	O
coding	O
for	O
gap	O
junctions	O
and	O
crystallin	O
proteins	O
.	O

This	O
work	O
highlights	O
the	O
importance	O
of	O
classifying	O
mutations	O
based	O
on	O
structural	O
and	O
phenotypic	O
consequences	O
,	O
both	O
in	O
terms	O
of	O
pathway	O
signaling	O
output	O
and	O
response	O
to	O
pharmacologic	O
inhibition	O
.	O

Implications	O
:	O
/	O
b	O
This	O
study	O
suggests	O
that	O
alternate	O
modes	O
of	O
target	O
inhibition	O
,	O
such	O
as	O
ERK	O
inhibition	O
,	O
will	O
be	O
required	O
to	O
effectively	O
treat	O
tumors	S-Phenotype
harboring	O
these	O
MEK1	O
/	O
2	O
-	O
resistant	O
alleles	O
.	O

We	O
also	O
emphasized	O
that	O
the	O
ERK	O
and	O
AKT	O
signaling	O
pathways	O
were	O
the	O
mechanisms	O
underlying	O
the	O
inhibitory	O
effect	O
of	O
HCRP1	O
on	O
glioma	S-Phenotype
cells	O
.	O

Since	O
diffuse	B-Phenotype
hepatic	I-Phenotype
hemangiomatosis	E-Phenotype
(	O
DHH	S-Phenotype
)	O
is	O
an	O
extremely	O
rare	O
disease	O
especially	O
in	O
adults	O
,	O
the	O
etiology	O
and	O
natural	O
course	O
of	O
adult	O
-	O
onset	O
DHH	O
has	O
not	O
been	O
well	O
understood	O
.	O

Extensive	O
search	O
of	O
the	O
literature	O
revealed	O
a	O
potential	O
key	O
role	O
of	O
genes	O
at	O
the	O
identified	O
porcine	O
loci	O
in	O
tumor	S-Phenotype
invasion	O
(	O
DST	O
,	O
PLEKHA5	O
,	O
CBY1	O
,	O
LIMK2	O
and	O
ETV5	O
)	O
and	O
immune	O
response	O
modulation	O
(	O
ETV5	O
,	O
HERC3	O
and	O
DICER1	O
)	O
of	O
the	O
progression	O
phenotypes	O
.	O

Global	O
Ptchd1	O
deletion	O
recapitulates	O
learning	O
impairment	O
,	O
hyper	O
-	O
aggression	S-Phenotype
,	O
and	O
motor	O
defects	O
,	O
all	O
of	O
which	O
are	O
insensitive	O
to	O
SK	O
pharmacological	O
targeting	O
and	O
not	O
found	O
in	O
the	O
TRN	O
-	O
restricted	O
deletion	O
mouse	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
CD133	O
mRNA	O
expression	O
was	O
a	O
prognostic	O
marker	O
in	O
three	O
independent	O
glioma	S-Phenotype
patient	O
cohorts	O
,	O
corroborating	O
a	O
putative	O
role	O
for	O
CD133	O
in	O
glioma	S-Phenotype
progression	O
.	O

Breast	B-Phenotype
cancers	E-Phenotype
may	O
express	O
various	O
profiles	O
of	O
hormone	O
receptors	O
:	O
ER	O
(	O
+	O
)	O
/	O
PgR	O
(	O
+	O
)	O
,	O
ER	O
(	O
-	O
)	O
/	O
PgR	O
(	O
-	O
)	O
,	O
ER	O
(	O
+	O
)	O
/	O
PgR	O
(	O
-	O
)	O
and	O
ER	O
(	O
-	O
)	O
/	O
PgR	O
(	O
+	O
)	O
.	O

These	O
results	O
expand	O
the	O
genetic	O
heterogeneity	S-Phenotype
of	O
EKVP	O
and	O
the	O
human	O
disease	O
phenotypes	O
associated	O
with	O
GJA1	O
mutations	O
.	O

In	O
response	O
to	O
surgical	O
induction	O
of	O
endometriosis	S-Phenotype
,	O
Klf11	O
-	O
/	O
-	O
female	O
mice	O
develop	O
significant	O
fibrosis	O
in	O
contrast	O
to	O
wild	O
-	O
type	O
mice	O
.	O

First	O
,	O
a	O
novel	O
variation	O
c.460	O
-	O
650AAAAAG	O
was	O
found	O
in	O
our	O
study	O
which	O
might	O
cause	O
premature	O
termination	O
of	O
splicing	O
of	O
the	O
conserved	O
domain	O
in	O
WDR36	O
;	O
second	O
,	O
c.1494+1111GAAAAT	O
(	O
rs13178997	O
)	O
had	O
significantly	O
different	O
frequency	O
in	O
our	O
JOAG	O
patients	O
compared	O
to	O
the	O
reference	O
frequency	O
on	O
NCBI	O
;	O
third	O
,	O
a	O
variation	O
c.710+30CAAAAT	O
(	O
rs10038177	O
)	O
was	O
found	O
in	O
our	O
study	O
,	O
which	O
had	O
already	O
been	O
reported	O
to	O
be	O
related	O
to	O
high	O
-	O
pressure	O
glaucoma	S-Phenotype
.	O

Moreover	O
,	O
we	O
demonstrated	O
that	O
ERG	O
and	O
FLI1	O
expression	O
is	O
downregulated	O
in	O
ECs	O
within	O
tumors	S-Phenotype
by	O
soluble	O
factors	O
enriched	O
in	O
the	O
tumor	S-Phenotype
microenvironment	O
.	O

However	O
,	O
the	O
role	O
of	O
TRIM44	O
in	O
thyroid	B-Phenotype
cancer	E-Phenotype
has	O
never	O
been	O
revealed	O
.	O

Objective	O
:	O
To	O
investigate	O
the	O
histomorpholgic	O
spectrum	O
,	O
immunophenotypic	O
,	O
and	O
molecular	O
genetic	O
features	O
of	O
Sertoli	O
cell	O
tumor	S-Phenotype
,	O
not	O
otherwise	O
specified	O
(	O
SCT	O
,	O
NOS	O
)	O
of	O
the	O
testis	O
.	O

An	O
oncogenic	O
role	O
for	O
CHD4	O
,	O
a	O
NuRD	O
component	O
,	O
is	O
defined	O
for	O
initiating	O
and	O
supporting	O
tumor	S-Phenotype
suppressor	O
gene	O
(	O
TSG	O
)	O
silencing	O
in	O
human	O
colorectal	B-Phenotype
cancer	E-Phenotype
.	O

Mechanical	O
compression	O
induced	O
miR	O
-	O
9	O
downregulation	O
by	O
DNMT3A	O
-	O
dependent	O
promoter	O
methylation	O
in	O
the	O
MDA	O
-	O
MB	O
-	O
231	O
and	O
BT	O
-	O
474	O
breast	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
and	O
in	O
cancer	S-Phenotype
-	O
associated	O
fibroblasts	O
.	O

In	O
hepatic	B-Phenotype
tumor	E-Phenotype
cells	O
derived	O
from	O
Tet	O
-	O
O	O
-	O
MYC	O
mice	O
,	O
the	O
expression	O
of	O
mRNA	O
and	O
protein	O
of	O
FAM83H	O
were	O
dependent	O
on	O
MYC	O
expression	O
.	O

Response	O
rates	O
in	O
both	O
treatment	O
arms	O
were	O
less	O
than	O
5	O
%	O
in	O
the	O
overall	O
population	O
and	O
in	O
the	O
liposarcoma	S-Phenotype
subgroup	O
.	O

Human	O
kallikrein	O
-	O
related	O
peptidases	O
KLK1	O
-	O
15	O
provide	O
a	O
rich	O
source	O
of	O
serine	O
protease	O
-	O
type	O
biomarkers	O
associated	O
with	O
tumor	S-Phenotype
growth	O
and	O
cancer	S-Phenotype
progression	O
for	O
a	O
variety	O
of	O
malignant	O
diseases	O
.	O

Common	O
genetic	O
variants	O
contribute	O
to	O
the	O
observed	O
variation	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
risk	O
for	O
BRCA2	O
mutation	O
carriers	O
;	O
those	O
known	O
to	O
date	O
have	O
all	O
been	O
found	O
through	O
population	O
-	O
based	O
genome	O
-	O
wide	O
association	O
studies	O
(	O
GWAS	O
)	O
.	O

This	O
study	O
shows	O
a	O
relationship	O
between	O
genotype	O
and	O
the	O
clinical	O
form	O
of	O
cystinuria	S-Phenotype
,	O
suggesting	O
that	O
only	O
the	O
patients	O
with	O
the	O
most	O
severe	O
mutations	O
presented	O
with	O
an	O
HEC	O
.	O

In	O
clinical	O
practices	O
,	O
the	O
therapeutic	O
outcomes	O
and	O
prognosis	O
of	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
patients	O
with	O
different	O
tumor	S-Phenotype
numbers	O
after	O
surgery	O
are	O
very	O
different	O
;	O
however	O
,	O
the	O
underlying	O
mechanisms	O
of	O
the	O
tumorigenesis	O
and	O
development	O
of	O
HCC	S-Phenotype
with	O
different	O
tumor	S-Phenotype
numbers	O
are	O
still	O
not	O
well	O
understood	O
.	O

While	O
examining	O
pedigrees	O
of	O
JEB	O
patients	O
with	O
LAMA3	O
mutations	O
,	O
we	O
observed	O
that	O
heterozygous	O
carriers	O
of	O
functional	O
null	O
mutations	O
displayed	O
subtle	O
enamel	O
pitting	O
in	O
the	O
absence	O
of	O
skin	B-Phenotype
fragility	E-Phenotype
or	O
other	O
JEB	O
symptoms	O
.	O

A	O
further	O
XX	O
male	O
,	O
ascertained	O
because	O
of	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
carried	O
a	O
de	O
novo	O
cryptic	O
duplication	O
at	O
Xq27.1	O
,	O
involving	O
SOX3	O
.	O

Several	O
studies	O
have	O
suggested	O
a	O
role	O
for	O
the	O
glutamyl	O
prolyl	O
tRNA	O
synthetase	O
(	O
EPRS	O
)	O
in	O
breast	B-Phenotype
cancers	E-Phenotype
,	O
although	O
none	O
has	O
identified	O
any	O
underlying	O
mechanism	O
about	O
how	O
EPRS	O
contributes	O
to	O
carcinogenesis	O
.	O

Mutations	O
in	O
C8ORF37	O
were	O
previously	O
associated	O
with	O
severe	O
autosomal	B-Phenotype
recessive	I-Phenotype
retinal	I-Phenotype
dystrophies	E-Phenotype
(	O
retinitis	B-Phenotype
pigmentosa	I-Phenotype
RP64	E-Phenotype
and	O
cone	B-Phenotype
-	I-Phenotype
rod	I-Phenotype
dystrophy	I-Phenotype
CORD16	E-Phenotype
)	O
but	O
not	O
BBS	O
.	O

Certain	O
phenotypic	O
features	O
have	O
been	O
identified	O
as	O
being	O
more	O
prevalent	O
in	O
individuals	O
with	O
a	O
SUFU	O
mutation	O
such	O
as	O
childhood	B-Phenotype
medulloblastoma	E-Phenotype
,	O
infundibulocystic	B-Phenotype
BCCs	E-Phenotype
and	O
trichoepitheliomas	S-Phenotype
.	O

In	O
this	O
study	O
,	O
we	O
employed	O
a	O
siRNA	O
knockdown	O
approach	O
for	O
heparan	O
sulphate	O
(	O
EXT1	O
)	O
and	O
heparan	O
/	O
chondroitin	O
/	O
dermatan	O
sulphate	O
-	O
biosynthetic	O
enzymes	O
(	O
b4GalT7	O
)	O
in	O
the	O
aggressive	O
human	O
breast	B-Phenotype
cancer	E-Phenotype
cell	O
line	O
MDA	O
-	O
MB	O
-	O
231	O
to	O
study	O
the	O
impact	O
on	O
cell	O
behaviour	O
and	O
hyaluronan	O
biosynthesis	O
.	O

Corresponding	O
tumor	S-Phenotype
tissue	O
slices	O
were	O
stained	O
immunohistochemically	O
for	O
L1CAM	O
.	O

HGK	O
is	O
also	O
involved	O
in	O
cancer	S-Phenotype
cell	O
migration	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
offer	O
additional	O
insight	O
into	O
the	O
early	O
transcriptional	O
changes	O
caused	O
by	O
Cryaa	O
and	O
Cryab	O
mutations	O
associated	O
with	O
autosomal	O
dominant	O
human	O
cataracts	S-Phenotype
,	O
and	O
indicate	O
that	O
the	O
transcript	O
levels	O
of	O
certain	O
genes	O
are	O
affected	O
by	O
the	O
expression	O
of	O
mutant	O
α	O
-	O
crystallin	O
in	O
vivo	O

Additionally	O
,	O
the	O
previously	O
reported	O
LMO1	O
neuroblastoma	S-Phenotype
risk	O
locus	O
was	O
statistically	O
significant	O
only	O
in	O
patients	O
with	O
MYCN	O
-	O
nonamplified	O
high	O
-	O
risk	O
tumors	S-Phenotype
(	O
OR	O
=	O
0.63	O
,	O
95	O
%	O
CI	O
=	O
0.53	O
to	O
0.75	O
,	O
Pmeta	O
=	O
1.51	O
×	O
10	O
-	O
8	O
;	O
Pmeta	O
=	O
.95	O
)	O
.	O

Deficient	O
transient	O
receptor	O
potential	O
vanilloid	O
type	O
4	O
function	O
contributes	O
to	O
compromised	O
[	O
Casup2+	O
/	O
sup	O
]	O
subi	O
/	O
sub	O
homeostasis	O
in	O
human	O
autosomal	O
-	O
dominant	O
polycystic	B-Phenotype
kidney	E-Phenotype
disease	O
cells	O

Importantly	O
,	O
high	O
expression	O
levels	O
of	O
HIF	O
-	O
1α	O
/	O
TGF	O
-	O
β2	O
/	O
GLI2	O
correlated	O
robustly	O
with	O
the	O
patient	O
relapse	O
following	O
chemotherapy	O
,	O
highlighting	O
a	O
potential	O
biomarker	O
and	O
therapeutic	O
target	O
for	O
chemoresistance	O
in	O
colorectal	B-Phenotype
cancer	E-Phenotype
.	O

Gain	O
-	O
of	O
-	O
function	O
mutations	O
in	O
the	O
human	O
PIEZO2	O
gene	O
cause	O
three	O
clinical	O
types	O
of	O
autosomal	O
dominant	O
distal	S-Phenotype
arthrogryposis	S-Phenotype
.	O

Our	O
results	O
suggested	O
that	O
variants	O
in	O
DCTN1	O
are	O
not	O
common	O
risk	O
factors	O
for	O
Chinese	O
sporadic	S-Phenotype
ALS	O
and	O
that	O
the	O
frequency	O
of	O
variants	O
of	O
unknown	O
significance	O
in	O
the	O
cohort	O
study	O
was	O
0.39	O
%	O

Pitx3	O
-	O
/	O
-	O
mice	O
reproduced	O
the	O
alterations	O
described	O
in	O
patients	O
with	O
advanced	O
PD	O
and	O
in	O
well	O
accepted	O
toxin	O
-	O
based	O
models	O
of	O
PD	O
and	O
dyskinesia	S-Phenotype
.	O

Anthocyanin	O
consumption	O
is	O
linked	O
to	O
benefits	O
in	O
obesity	S-Phenotype
-	O
related	O
metabolic	O
alterations	O
and	O
non	B-Phenotype
-	I-Phenotype
alcoholic	I-Phenotype
fatty	I-Phenotype
liver	I-Phenotype
disease	E-Phenotype
(	O
NAFLD	S-Phenotype
)	O
,	O
though	O
the	O
functional	O
role	O
of	O
delphinidin	O
(	O
Dp	O
)	O
is	O
yet	O
to	O
be	O
established	O
.	O

However	O
,	O
case	O
4	O
had	O
special	O
face	O
,	O
low	B-Phenotype
IQ	E-Phenotype
,	O
mild	B-Phenotype
pulmonary	I-Phenotype
artery	I-Phenotype
stenosis	E-Phenotype
,	O
and	O
only	O
mild	B-Phenotype
ventricular	I-Phenotype
hypertrophy	E-Phenotype
.	O

For	O
example	O
,	O
the	O
cerebellar	B-Phenotype
malformations	E-Phenotype
observed	O
in	O
RIKEN	O
4930444A02	O
knockout	O
mice	O
show	O
similarities	O
to	O
a	O
number	O
of	O
developmental	O
disorders	O
,	O
such	O
as	O
Joubert	O
,	O
Meckel	O
-	O
Gruber	O
,	O
and	O
Bardet	O
-	O
Biedl	O
syndromes	O
,	O
which	O
involve	O
mutations	O
in	O
cilia	O
-	O
related	O
genes	O
.	O

Most	O
studies	O
are	O
in	O
agreement	O
as	O
to	O
the	O
belief	O
that	O
,	O
in	O
a	O
large	O
range	O
of	O
human	O
cancers	S-Phenotype
,	O
the	O
SPINT2	O
gene	O
promoter	O
is	O
frequently	O
methylated	O
,	O
resulting	O
in	O
the	O
epigenetic	O
silence	O
of	O
this	O
gene	O
.	O

Chronic	O
l	O
-	O
DOPA	O
treatment	O
that	O
induces	O
dyskinesia	S-Phenotype
selectively	O
restores	O
spine	O
density	O
and	O
excitability	O
in	O
indirect	O
pathway	O
SPNs	O
(	O
iSPNs	O
)	O
,	O
whereas	O
spine	O
loss	O
and	O
hyperexcitability	O
persist	O
in	O
direct	O
pathway	O
SPNs	O
(	O
dSPNs	O
)	O
.	O

Lactate	O
dehydrogenase	O
A	O
(	O
LDHA	O
)	O
,	O
a	O
key	O
enzyme	O
in	O
glycolysis	O
,	O
is	O
highly	O
expressed	O
in	O
a	O
variety	O
of	O
tumors	S-Phenotype
and	O
catalyzes	O
pyruvate	O
to	O
lactate	O
.	O

The	O
HECT	O
-	O
type	O
ubiquitin	O
ligase	O
HECT	O
,	O
UBA	O
and	O
WWE	O
Domain	O
Containing	O
1	O
,	O
(	O
HUWE1	O
)	O
regulates	O
key	O
cancer	S-Phenotype
-	O
related	O
pathways	O
,	O
including	O
the	O
Myc	O
oncogene	O
.	O

We	O
confirmed	O
that	O
this	O
nonsense	O
MYO6	O
mutation	O
segregated	O
with	O
deafness	S-Phenotype
in	O
this	O
family	O
.	O

Leucine	O
-	O
rich	O
glioma	S-Phenotype
-	O
inactivated	O
protein	O
1	O
(	O
LGI1	O
)	O
is	O
a	O
secreted	O
neuronal	O
protein	O
and	O
a	O
Nogo	O
receptor	O
1	O
(	O
NgR1	O
)	O
ligand	O
.	O

Chorein	O
,	O
SGK1	O
,	O
ORAI1	O
and	O
SOCE	O
further	O
confer	O
survival	O
of	O
tumor	S-Phenotype
cells	O
.	O

Special	O
attention	O
is	O
given	O
to	O
p53	O
-	O
independent	O
SALL2	O
regulation	O
of	O
pro	O
-	O
apoptotic	O
genes	O
BAX	O
and	O
PMAIP1	O
,	O
and	O
the	O
implication	O
of	O
these	O
findings	O
on	O
the	O
apoptotic	O
response	O
of	O
cancer	S-Phenotype
cells	O
to	O
therapy	O
.	O

In	O
renal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
RCC	S-Phenotype
)	O
,	O
expression	O
of	O
microRNA	O
-	O
451a	O
(	O
miR	O
-	O
451a	O
)	O
was	O
significantly	O
downregulated	O
in	O
patient	O
specimens	O
and	O
low	O
expression	O
of	O
miR	O
-	O
451a	O
was	O
significantly	O
associated	O
with	O
poor	O
prognosis	O
of	O
RCC	O
patients	O
(	O
P	O
=	O
.00305	O
)	O
based	O
on	O
data	O
in	O
The	O
Cancer	S-Phenotype
Genome	O
Atlas	O
.	O

The	O
combination	O
of	O
sensorineural	B-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
and	O
partial	B-Phenotype
agenesis	I-Phenotype
of	I-Phenotype
the	I-Phenotype
corpus	I-Phenotype
callosum	E-Phenotype
is	O
a	O
highly	O
recognizable	O
clinico	O
-	O
radiological	O
entity	O
that	O
should	O
prompt	O
mutational	O
analysis	O
of	O
the	O
GPSM2	O
gene	O
.	O

Since	O
this	O
is	O
an	O
atypical	O
but	O
previously	O
described	O
rare	O
presentation	O
of	O
PHP1b	O
,	O
we	O
reemphasize	O
STX16	O
deletions	O
and	O
PHP1b	O
as	O
a	O
rare	O
cause	O
for	O
early	B-Phenotype
onset	I-Phenotype
obesity	E-Phenotype
and	O
macrosomia	S-Phenotype
.	O

Spinocerebellar	B-Phenotype
ataxia	I-Phenotype
type	I-Phenotype
1	E-Phenotype
(	O
SCA1	S-Phenotype
)	O
is	O
a	O
dominantly	O
inherited	O
neurodegenerative	B-Phenotype
disease	E-Phenotype
of	O
the	O
cerebellum	O
caused	O
by	O
a	O
polyglutamine	O
-	O
repeat	O
expansion	O
in	O
the	O
protein	O
ATXN1	O
.	O

Having	O
used	O
a	O
similar	O
strategy	O
for	O
the	O
in	O
silico	O
evaluation	O
of	O
150	O
mutations	O
of	O
liCYP21A2	O
/	O
i	O
,	O
the	O
disease	O
-	O
causing	O
gene	O
in	O
congenital	B-Phenotype
adrenal	I-Phenotype
hyperplasia	E-Phenotype
,	O
we	O
now	O
provide	O
a	O
full	O
structural	O
explanation	O
for	O
the	O
clinical	O
severity	O
of	O
AME	O
resulting	O
from	O
each	O
known	O
liHSD11B2	O
/	O
i	O
missense	O
mutation	O
.	O

The	O
lysosome	O
-	O
associated	O
membrane	O
proteins	O
(	O
LAMPs	O
)	O
display	O
differential	O
expression	O
particularly	O
in	O
cancer	S-Phenotype
.	O

This	O
mutation	O
was	O
also	O
found	O
in	O
a	O
second	O
unrelated	O
family	O
with	O
the	O
same	O
clinical	O
phenotype	O
,	O
while	O
no	O
germline	O
or	O
somatic	O
liMAFA	O
/	O
i	O
mutations	O
were	O
identified	O
in	O
nine	O
patients	O
with	O
sporadic	B-Phenotype
insulinomatosis	E-Phenotype
.	O

Our	O
results	O
indicate	O
that	O
BBS	O
in	O
Japan	O
is	O
genetically	O
heterogeneous	S-Phenotype
and	O
at	O
least	O
partly	O
shares	O
genetic	O
features	O
with	O
BBS	O
in	O
other	O
countries	O
.	O

PTEN	O
,	O
KRAS	O
and	O
PIK3R1	O
were	O
the	O
most	O
frequently	O
mutated	O
canonical	O
cancer	S-Phenotype
-	O
related	O
genes	O
.	O

In	O
tumors	S-Phenotype
with	O
high	O
PIK3R2	O
expression	O
,	O
and	O
independently	O
of	O
PIK3CA	O
,	O
KRAS	O
,	O
or	O
PTEN	O
mutations	O
,	O
PIK3R2	O
depletion	O
induced	O
lung	O
SQCC	O
xenograft	O
regression	O
without	O
triggering	O
PI3K	O
/	O
AKT	O
pathway	O
rebound	O
.	O

Here	O
,	O
we	O
presented	O
an	O
X	O
-	O
ALD	O
case	O
of	O
a	O
46	O
-	O
year	O
-	O
old	O
Asian	O
male	O
with	O
severe	O
autonomic	B-Phenotype
dysfunction	E-Phenotype
.	O

GATA4	O
,	O
a	O
transcription	O
factor	O
crucial	O
for	O
early	O
liver	O
development	O
,	O
has	O
been	O
implicated	O
in	O
the	O
pathophysiology	O
of	O
hepatoblastoma	S-Phenotype
,	O
an	O
embryonal	B-Phenotype
tumor	E-Phenotype
of	O
childhood	O
.	O

Methods	O
:	O
The	O
fallopian	O
tubes	O
in	O
58	O
cases	O
of	O
pelvic	O
HGSC	O
(	O
54	O
cases	O
of	O
ovarian	O
primary	O
,	O
3	O
cases	O
of	O
tubal	O
primary	O
,	O
1	O
case	O
of	O
peritoneum	O
)	O
and	O
25	O
cases	O
of	O
pelvic	O
non	O
-	O
HGSC	O
(	O
5	O
cases	O
of	O
ovarian	B-Phenotype
low	I-Phenotype
-	I-Phenotype
grade	I-Phenotype
serous	I-Phenotype
cancer	E-Phenotype
,	O
9	O
cases	O
of	O
endometrioid	B-Phenotype
cancer	E-Phenotype
,	O
and	O
11	O
cases	O
of	O
clear	O
cell	O
ovary	B-Phenotype
carcinoma	E-Phenotype
)	O
were	O
collected	O
from	O
June	O
2015	O
to	O
December	O
2016	O
,	O
and	O
serially	O
examined	O
under	O
light	O
microscope	O
(	O
SEE	O
-	O
FIM	O
protocol	O
)	O
.	O

The	O
encoded	O
protein	O
,	O
complexin	O
1	O
,	O
is	O
crucially	O
involved	O
in	O
neuronal	O
synaptic	O
regulation	O
,	O
and	O
homozygous	O
Cplx1	O
knockout	O
mice	O
have	O
the	O
earliest	O
known	O
onset	O
of	O
ataxia	S-Phenotype
seen	O
in	O
a	O
mouse	O
model	O
.	O

Through	O
gene	O
set	O
enrichment	O
analysis	O
and	O
bi	O
-	O
clustering	O
,	O
we	O
also	O
found	O
that	O
most	O
of	O
the	O
differential	O
expressed	O
lncRNAs	O
were	O
closely	O
associated	O
with	O
mitochondrial	O
functions	O
(	O
e.g	O
.	O

In	O
Mfrprd6	O
eyes	O
,	O
a	O
significant	O
1.5	O
-	O
to	O
2.0	O
-	O
fold	O
decrease	O
was	O
observed	O
among	O
transcripts	O
of	O
genes	O
linked	O
to	O
retinal	B-Phenotype
degeneration	E-Phenotype
,	O
including	O
those	O
involved	O
in	O
visual	O
cycle	O
(	O
Rpe65	O
,	O
Lrat	O
,	O
Rgr	O
)	O
,	O
phototransduction	O
(	O
Pde6a	O
,	O
Guca1b	O
,	O
Rgs9	O
)	O
,	O
and	O
photoreceptor	O
disc	O
morphogenesis	O
(	O
Rpgrip1	O
and	O
Fscn2	O
)	O
.	O

MiR	O
-	O
93	O
-	O
5p	O
upregulation	O
was	O
also	O
shown	O
to	O
inhibit	O
the	O
expression	O
of	O
two	O
well	O
-	O
characterized	O
Hippo	O
pathway	O
regulators	O
,	O
protocadherin	O
Fat	O
4	O
(	O
FAT4	O
)	O
,	O
and	O
large	O
tumor	S-Phenotype
suppressors	O
2	O
(	O
LATS2	O
)	O
,	O
at	O
both	O
the	O
mRNA	O
and	O
protein	O
level	O
.	O

GPT2	O
overexpression	O
increased	O
the	O
subpopulation	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
stem	O
cells	O
in	O
vitro	O
and	O
promoted	O
tumorigenesis	O
in	O
mice	O
.	O

We	O
report	O
here	O
that	O
the	O
tumor	S-Phenotype
suppressor	O
ING1b	O
binds	O
rDNA	O
,	O
regulates	O
rDNA	O
chromatin	O
modifications	O
and	O
affects	O
nucleolar	O
localization	O
of	O
mTOR	O
to	O
modulate	O
rRNA	O
levels	O
.	O

Mutations	O
in	O
SAMHD1	O
are	O
implicated	O
in	O
cancer	S-Phenotype
development	O
and	O
in	O
a	O
severe	O
congenital	O
inflammatory	O
disease	O
known	O
as	O
Aicardi	O
-	O
Goutieres	O
syndrome	O
.	O

In	O
this	O
review	O
,	O
we	O
will	O
focus	O
on	O
the	O
ability	O
of	O
TRIM32	O
to	O
mark	O
specific	O
substrates	O
for	O
proteasomal	O
degradation	O
discussing	O
how	O
the	O
TRIM32	O
-	O
proteasome	O
axis	O
may	O
(	O
i	O
)	O
be	O
important	O
for	O
muscle	O
homeostasis	O
and	O
for	O
the	O
pathogenesis	O
of	O
muscular	B-Phenotype
dystrophy	E-Phenotype
;	O
and	O
(	O
ii	O
)	O
define	O
either	O
an	O
oncogenic	O
or	O
tumour	S-Phenotype
suppressive	O
role	O
for	O
TRIM32	O
in	O
the	O
context	O
of	O
different	O
types	O
of	O
cancer	S-Phenotype

Therefore	O
,	O
we	O
propose	O
that	O
MRE11	O
inhibition	O
might	O
be	O
an	O
effective	O
strategy	O
to	O
treat	O
MYCN	O
-	O
amplified	O
and	O
p53	O
wild	O
-	O
type	O
neuroblastoma	S-Phenotype
,	O
and	O
suggest	O
that	O
targeting	O
replication	O
stress	O
with	O
appropriate	O
tools	O
should	O
be	O
further	O
exploited	O
to	O
tackle	O
MYCN	O
-	O
driven	O
tumors	S-Phenotype

Our	O
findings	O
indicate	O
that	O
BM	O
-	O
derived	O
MSCs	O
from	O
patients	O
with	O
newly	O
diagnosed	O
AML	O
display	O
phenotypic	O
and	O
functional	O
alterations	O
such	O
as	O
proliferative	O
deficiency	O
that	O
could	O
be	O
attributed	O
to	O
tumor	S-Phenotype
progression	O
,	O
but	O
does	O
not	O
seem	O
to	O
play	O
a	O
special	O
role	O
in	O
the	O
leukemic	O
process	O

CONCLUSIONS	O
Our	O
findings	O
indicate	O
that	O
resveratrol	O
induces	O
apoptosis	O
via	O
HIF	O
-	O
1α	O
/	O
ROS	O
/	O
p53	O
signaling	O
in	O
prostate	B-Phenotype
cancer	E-Phenotype
cells	O
and	O
may	O
be	O
a	O
useful	O
therapeutic	O
agent	O
against	O
prostate	B-Phenotype
cancer	E-Phenotype

Here	O
we	O
discuss	O
the	O
heterogeneity	S-Phenotype
of	O
T	O
-	O
bet	O
expressing	O
B	O
cells	O
and	O
related	O
cells	O

In	O
summary	O
,	O
our	O
results	O
reveal	O
that	O
rare	O
loss	O
-	O
of	O
-	O
function	O
variants	O
in	O
GABRA3	O
increase	O
the	O
risk	O
for	O
a	O
varying	O
combination	O
of	O
epilepsy	S-Phenotype
,	O
intellectual	B-Phenotype
disability	E-Phenotype
/	O
developmental	B-Phenotype
delay	E-Phenotype
and	O
dysmorphic	O
features	O
,	O
presenting	O
in	O
some	O
pedigrees	O
with	O
an	O
X	O
-	O
linked	O
inheritance	O
pattern	O

Thus	O
,	O
our	O
data	O
indicate	O
that	O
miR	O
-	O
132	O
induces	O
temozolomide	O
resistance	O
and	O
promotes	O
the	O
formation	O
of	O
cancer	S-Phenotype
stem	O
cell	O
phenotypes	O
by	O
targeting	O
TUSC3	O
in	O
glioblastoma	S-Phenotype

We	O
therefore	O
conducted	O
this	O
study	O
to	O
explore	O
the	O
clinical	O
involvements	O
of	O
WWOX	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
cervical	B-Phenotype
cancer	E-Phenotype
.	O

Raptor	O
-	O
cKO	O
mice	O
developed	O
hearing	B-Phenotype
loss	E-Phenotype
considerably	O
more	O
slowly	O
than	O
WT	O
littermates	O
.	O

Moreover	O
,	O
CARD9	O
-	O
dependent	O
functions	O
have	O
recently	O
been	O
indicated	O
to	O
modulate	O
the	O
development	O
of	O
autoimmunity	S-Phenotype
,	O
inflammatory	B-Phenotype
bowel	I-Phenotype
diseases	E-Phenotype
,	O
and	O
cancer	S-Phenotype
.	O

Results	O
/	O
b	O
:	O
AMACR	O
overexpression	O
was	O
significantly	O
associated	O
with	O
advanced	O
tumor	S-Phenotype
status	O
(	O
liP	O
/	O
i=0.001	O
)	O
,	O
advanced	O
nodal	O
status	O
(	O
liP	O
/	O
i=0.036	O
)	O
,	O
increased	O
vascular	O
invasion	O
(	O
liP	O
/	O
i=0.026	O
)	O
and	O
increased	O
perineural	O
invasion	O
(	O
liP	O
/	O
i=0.004	O
)	O
.	O

These	O
findings	O
suggest	O
that	O
miR	O
-	O
493	O
acts	O
as	O
a	O
negative	O
regulator	O
in	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
progression	O
and	O
may	O
be	O
a	O
potential	O
therapeutic	O
target	O
for	O
HCC	O

We	O
also	O
observed	O
a	O
suggestive	O
association	O
for	O
FANCA	O
(	O
p	O
=	O
.002	O
)	O
,	O
a	O
gene	O
previously	O
implicated	O
in	O
melanoma	S-Phenotype
survival	O
.	O

Children	O
with	O
DS	O
have	O
an	O
elevated	O
risk	O
of	O
pulmonary	B-Phenotype
arterial	I-Phenotype
hypertension	E-Phenotype
(	O
PAH	S-Phenotype
)	O
.	O

The	O
enriched	O
genes	O
included	O
MMP9	O
,	O
SERPINE2	O
,	O
CAV1	O
,	O
KRT14	O
,	O
and	O
RASA3	O
in	O
basal	B-Phenotype
tumors	E-Phenotype
,	O
and	O
PPARG	O
,	O
LY6E	O
,	O
CTSE	O
,	O
CDK3	O
,	O
and	O
TBX2	O
in	O
luminal	B-Phenotype
tumors	E-Phenotype
.	O

We	O
previously	O
demonstrated	O
that	O
transforming	O
growth	O
factor	O
-	O
b1	O
(	O
TGF	O
-	O
b1	O
)	O
promotes	O
the	O
epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
of	O
human	O
oral	B-Phenotype
squamous	I-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
hOSCC	S-Phenotype
)	O
cells	O
;	O
however	O
,	O
it	O
remains	O
to	O
be	O
clarified	O
whether	O
the	O
TGF	O
-	O
b	O
superfamily	O
member	O
bone	O
morphogenetic	O
protein	O
(	O
BMP	O
)	O
affects	O
this	O
process	O
in	O
hOSCC	O
cells	O
.	O

Downregulation	O
of	O
a	O
-	O
actinin	O
-	O
1	O
in	O
E	O
-	O
cadherin	O
expressing	O
basal	O
-	O
like	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
demonstrate	O
that	O
a	O
-	O
actinin	O
-	O
1	O
-	O
assembled	O
actin	O
fibers	O
destabilize	O
E	O
-	O
cadherin	O
-	O
based	O
adhesions	O
.	O

This	O
study	O
aimed	O
to	O
examine	O
the	O
influence	O
of	O
patient	O
characteristics	O
,	O
including	O
polymorphisms	O
in	O
CPS1	O
4217CAAAAA	O
and	O
NAGS	O
-	O
3064CAAAAA	O
,	O
on	O
the	O
development	O
of	O
hyperammonemia	S-Phenotype
in	O
Japanese	O
pediatric	B-Phenotype
epilepsy	E-Phenotype
patients	O
.	O

miR	O
-	O
142	O
-	O
3p	O
overexpression	O
resulted	O
in	O
a	O
strong	O
decline	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
stem	O
cell	O
characteristics	O
with	O
a	O
decrease	O
in	O
CD44	O
,	O
CD133	O
,	O
ALDH1	O
,	O
Bod1	O
,	O
BRCA2	O
,	O
and	O
mammosphere	O
formation	O
as	O
well	O
as	O
reduced	O
survival	O
after	O
irradiation	O
.	O

Lastly	O
,	O
the	O
etiology	O
of	O
unsolved	O
cases	O
of	O
apparently	O
familial	B-Phenotype
hyperaldosteronism	E-Phenotype
remains	O
to	O
be	O
discovered	O
.	O

All	O
of	O
these	O
data	O
indicate	O
that	O
SPARCL1	O
may	O
be	O
a	O
novel	O
cancer	S-Phenotype
predictive	O
marker	O
and	O
a	O
potential	O
therapeutic	O
target	O
for	O
tumor	S-Phenotype
development	O
and	O
progression	O
in	O
cervical	B-Phenotype
cancer	E-Phenotype

Our	O
findings	O
revealed	O
that	O
both	O
PYCR1	O
mRNA	O
and	O
protein	O
expression	O
were	O
significantly	O
associated	O
with	O
tumor	S-Phenotype
size	O
,	O
grade	O
and	O
invasive	O
molecular	O
subtypes	O
of	O
breast	B-Phenotype
cancers	E-Phenotype
.	O

Our	O
findings	O
expand	O
the	O
clinical	O
phenotype	O
and	O
further	O
demonstrate	O
the	O
clinical	O
heterogeneity	S-Phenotype
related	O
to	O
PTRH2	O
variants	O

Moreover	O
,	O
knockdown	O
of	O
LKB1	O
reversed	O
growth	O
inhibitory	O
effect	O
of	O
CAB39L	O
,	O
indicating	O
that	O
tumor	S-Phenotype
suppression	O
by	O
CAB39L	O
depended	O
on	O
LKB1	O
-	O
AMPK	O
.	O

Highlights	O
include	O
the	O
discoveries	O
of	O
(	O
i	O
)	O
a	O
new	O
genetic	O
etiology	O
,	O
autosomal	B-Phenotype
recessive	E-Phenotype
SPPL2a	O
deficiency	O
,	O
(	O
ii	O
)	O
TYK2	O
-	O
deficient	O
patients	O
with	O
a	O
clinical	O
phenotype	O
of	O
MSMD	O
,	O
(	O
iii	O
)	O
an	O
allelic	O
form	O
of	O
partial	O
recessive	O
IFN	O
-	O
yR2	O
deficiency	O
,	O
and	O
(	O
iv	O
)	O
two	O
forms	O
of	O
syndromic	O
MSMD	O
:	O
RORy	O
/	O
RORyT	O
and	O
JAK1	O
deficiencies	O
.	O

Analysis	O
of	O
specific	O
DKD	O
phenotypes	O
identified	O
a	O
novel	O
signal	O
near	O
GABRR1	O
(	O
rs9942471	O
,	O
P	O
=	O
4.5	O
x	O
10	O
-	O
8	O
)	O
associated	O
with	O
microalbuminuria	S-Phenotype
in	O
European	O
T2D	O
case	O
subjects	O
.	O

Here	O
,	O
we	O
discuss	O
the	O
unique	O
function	O
of	O
HDAC6	O
and	O
recapitulate	O
the	O
alluring	O
potential	O
of	O
its	O
inhibitors	O
in	O
kidney	B-Phenotype
diseases	E-Phenotype

We	O
observed	O
a	O
higher	O
rate	O
of	O
individuals	O
with	O
a	O
history	O
of	O
high	B-Phenotype
blood	I-Phenotype
pressure	E-Phenotype
among	O
affected	O
versus	O
healthy	O
individuals	O
carrying	O
ANGPTL6	O
variants	O
,	O
suggesting	O
that	O
ANGPTL6	O
could	O
trigger	O
cerebrovascular	O
lesions	O
when	O
combined	O
with	O
other	O
risk	O
factors	O
such	O
as	O
hypertension	S-Phenotype
.	O

Haploinsufficiency	O
of	O
USP9X	O
in	O
females	O
has	O
been	O
associated	O
with	O
ID	O
and	O
congenital	O
malformations	O
that	O
include	O
heart	B-Phenotype
defects	E-Phenotype
,	O
scoliosis	S-Phenotype
,	O
dental	B-Phenotype
abnormalities	E-Phenotype
,	O
anal	B-Phenotype
atresia	E-Phenotype
,	O
polydactyly	S-Phenotype
,	O
Dandy	B-Phenotype
Walker	I-Phenotype
malformation	E-Phenotype
and	O
hypoplastic	B-Phenotype
corpus	I-Phenotype
callosum	E-Phenotype
.	O

Objective	O
:	O
/	O
bTo	O
investigate	O
the	O
expression	O
and	O
significance	O
of	O
CTHRC1	O
in	O
patients	O
with	O
papillary	O
thyroid	O
cancinoma	O
.	O

Method	O
:	O
/	O
bWe	O
collected	O
63	O
specimens	O
of	O
papillary	B-Phenotype
thyroid	I-Phenotype
carcinoma	E-Phenotype
tissue	O
with	O
36	O
specimens	O
of	O
the	O
adjacent	O
normal	O
thyroid	O
tissue	O
and	O
23	O
specimens	O
of	O
thyroid	B-Phenotype
nodular	I-Phenotype
goiter	E-Phenotype
.	O

Typical	O
ciliopathy	O
phenotypes	O
(	O
curved	B-Phenotype
body	I-Phenotype
shape	E-Phenotype
,	O
retinal	B-Phenotype
dystrophy	E-Phenotype
,	O
coloboma	S-Phenotype
,	O
and	O
decreased	B-Phenotype
cilia	E-Phenotype
)	O
in	O
a	O
CRISPR	O
/	O
Cas9	O
-	O
engineered	O
zebrafish	O
mutant	O
model	O
provide	O
additional	O
support	O
for	O
ARMC9	O
as	O
a	O
ciliopathy	O
-	O
associated	O
gene	O
.	O

The	O
roles	O
of	O
STX3	O
in	O
human	O
breast	B-Phenotype
cancer	E-Phenotype
remains	O
elusive	O
.	O

We	O
noted	O
that	O
Sirtuin	O
1	O
(	O
SIRT1	O
)	O
is	O
overexpressed	O
in	O
HPV	O
-	O
infected	O
cervical	B-Phenotype
cancer	E-Phenotype
cells	O
and	O
hypothesized	O
that	O
SIRT1	O
counteracts	O
antiviral	O
immunity	O
.	O

Moreover	O
,	O
we	O
show	O
that	O
over	O
-	O
expression	O
of	O
PNPLA8	O
dramatically	O
decreases	O
hepatic	B-Phenotype
steatosis	E-Phenotype
through	O
increased	O
autophagy	O
in	O
hepatocytes	O
of	O
HFD	O
-	O
fed	O
mice	O
.	O

Altogether	O
,	O
our	O
data	O
indicate	O
that	O
the	O
levels	O
of	O
these	O
miRNAs	O
may	O
be	O
used	O
as	O
biological	O
markers	O
for	O
evaluating	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
progression	O
.	O

NRF	O
-	O
1	O
mRNA	O
expression	O
was	O
reduced	O
in	O
schizophrenia	S-Phenotype
,	O
and	O
its	O
transcript	O
levels	O
predicted	O
that	O
of	O
PGC	O
-	O
1α	O
-	O
dependent	O
targets	O
in	O
schizophrenia	S-Phenotype
.	O

The	O
WNT10A	O
p.G213S	O
mutation	O
was	O
confirmed	O
to	O
be	O
the	O
etiological	O
cause	O
of	O
tooth	B-Phenotype
agenesis	E-Phenotype
and	O
ectodermal	B-Phenotype
dysplasia	E-Phenotype
as	O
previously	O
described	O
.	O

Immunohistochemical	O
method	O
was	O
used	O
to	O
examine	O
the	O
immunoexpression	O
of	O
ADAM10	O
and	O
microvessel	O
density	O
in	O
80	O
cases	O
of	O
oral	B-Phenotype
squamous	I-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
OSCC	S-Phenotype
)	O
:	O
without	O
metastases	O
-	O
OSCC	O
M	O
(	O
-	O
)	O
(	O
n	O
=	O
38	O
)	O
,	O
and	O
with	O
metastases	O
-	O
OSCC	O
M	O
(	O
+	O
)	O
(	O
n	O
=	O
42	O
)	O
,	O
in	O
24	O
cases	O
of	O
oral	B-Phenotype
leukoplakia	E-Phenotype
(	O
OLK	S-Phenotype
)	O
,	O
(	O
15	O
cases	O
with	O
low	O
-	O
grade	O
dysplasia	O
-	O
OLK	O
-	O
LG	O
,	O
and	O
9	O
cases	O
with	O
high	O
-	O
grade	O
dysplasia	O
-	O
OLK	O
-	O
HG	O
)	O
,	O
and	O
19	O
controls	O
.	O

We	O
herein	O
report	O
the	O
case	O
of	O
a	O
59	O
-	O
year	O
-	O
old	O
man	O
with	O
anti	O
-	O
leucine	O
-	O
rich	O
glioma	S-Phenotype
-	O
inactivated	O
1	O
(	O
LGI1	O
)	O
antibody	O
encephalitis	S-Phenotype
who	O
presented	O
with	O
slowly	O
progressive	B-Phenotype
cognitive	I-Phenotype
impairment	I-Phenotype
mimicking	I-Phenotype
dementia	E-Phenotype
for	O
over	O
3	O
years	O
and	O
then	O
developed	O
seizures	S-Phenotype
.	O

Sustained	O
,	O
hepatic	O
expression	O
of	O
LHPP	O
in	O
the	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
mouse	O
model	O
reduced	O
tumour	S-Phenotype
burden	O
and	O
prevented	O
the	O
loss	O
of	O
liver	O
function	O
.	O

Here	O
we	O
describe	O
the	O
approaches	O
and	O
methods	O
used	O
to	O
identify	O
SMARCA4	O
mutations	O
,	O
which	O
drive	O
development	O
of	O
the	O
rare	O
ovarian	B-Phenotype
cancer	E-Phenotype
,	O
small	B-Phenotype
cell	I-Phenotype
carcinoma	I-Phenotype
of	I-Phenotype
the	I-Phenotype
ovary	I-Phenotype
,	I-Phenotype
hypercalcemic	I-Phenotype
type	E-Phenotype
(	O
SCCOHT	S-Phenotype
)	O
,	O
and	O
point	O
to	O
the	O
broader	O
relevance	O
of	O
this	O
paradigm	O
for	O
future	O
research	O
in	O
rare	O
cancers	S-Phenotype

We	O
hypothesized	O
that	O
dual	O
inhibition	O
of	O
MDH1	O
and	O
MDH2	O
might	O
be	O
a	O
powerful	O
approach	O
to	O
target	O
cancer	S-Phenotype
metabolism	O
and	O
selected	O
methyl	O
-	O
3	O
-	O
(	O
3	O
-	O
(	O
4	O
-	O
(	O
2,4,4	O
-	O
trimethylpentan	O
-	O
2	O
-	O
yl	O
)	O
phenoxy	O
)	O
propanamido	O
)	O
-	O
benzoate	O
(	O
16c	O
)	O
as	O
the	O
most	O
potent	O
dual	O
inhibitor	O
.	O

These	O
findings	O
underscore	O
the	O
specificity	O
of	O
protective	O
effects	O
observed	O
here	O
in	O
models	O
of	O
Parkinson	O
's	O
disease	O
,	O
and	O
previously	O
in	O
Huntington	O
's	O
disease	O
,	O
and	O
support	O
the	O
development	O
of	O
SIRT2	O
inhibitors	O
as	O
potential	O
therapeutics	O
for	O
the	O
two	O
neurodegenerative	B-Phenotype
diseases	E-Phenotype
.	O

Furthermore	O
,	O
we	O
demonstrated	O
that	O
in	O
three	O
different	O
experimental	O
models	O
characterised	O
by	O
an	O
upregulation	O
of	O
rRNA	O
synthesis	O
,	O
cancer	S-Phenotype
cells	O
treated	O
with	O
insulin	O
or	O
exposed	O
to	O
the	O
insulin	O
-	O
like	O
growth	O
factor	O
1	O
,	O
rat	O
liver	O
stimulated	O
by	O
cortisol	O
and	O
regenerating	O
rat	O
liver	O
after	O
partial	O
hepatectomy	O
,	O
the	O
p53	O
protein	O
level	O
was	O
reduced	O
due	O
to	O
a	O
lowered	O
ribosomal	O
protein	O
availability	O
for	O
MDM2	O
binding	O
.	O

Furthermore	O
,	O
since	O
adipocytes	O
provide	O
the	O
largest	O
storage	O
depot	O
for	O
TG	O
and	O
play	O
a	O
crucial	O
role	O
in	O
the	O
development	O
of	O
obesity	S-Phenotype
,	O
we	O
could	O
infer	O
that	O
apoA5	O
also	O
acts	O
as	O
a	O
novel	O
regulator	O
to	O
modulate	O
TG	O
storage	O
in	O
adipocytes	O
.	O

mRNA	O
expression	O
of	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
and	O
protein	O
synthesis	O
of	O
high	O
(	O
NTRK1	O
)	O
and	O
low	O
affinity	O
neurotrophin	O
(	O
p75	O
neurotrophin	O
receptor	O
;	O
NTR	O
)	O
receptors	O
were	O
investigated	O
in	O
normal	O
oral	O
mucosa	O
and	O
in	O
HNSCC	O
.	O

Sheldon	O
-	O
Hall	O
syndrome	O
(	O
SHS	O
)	O
is	O
the	O
most	O
common	O
of	O
the	O
distal	O
arthrogryposes	O
(	O
DAs	O
)	O
,	O
a	O
group	O
of	O
disorders	O
characterized	O
by	O
congenital	B-Phenotype
non	I-Phenotype
-	I-Phenotype
progressive	I-Phenotype
contractures	E-Phenotype
.	O

Our	O
work	O
confirms	O
that	O
the	O
phenotype	O
and	O
the	O
mode	B-Phenotype
of	I-Phenotype
inheritance	E-Phenotype
associated	O
with	O
GNAT1	O
variants	O
can	O
vary	O
from	O
autosomal	O
dominant	O
,	O
autosomal	B-Phenotype
recessive	I-Phenotype
congenital	I-Phenotype
stationary	I-Phenotype
night	I-Phenotype
blindness	E-Phenotype
to	O
autosomal	B-Phenotype
recessive	I-Phenotype
rod	I-Phenotype
-	I-Phenotype
cone	I-Phenotype
dystrophy	E-Phenotype

mitochondrion	O
organization	O
,	O
P=3.21×10sup	O
-	O
17	O
/	O
sup	O
;	O
mitochondrial	O
ATP	O
synthesis	O
coupled	O
electron	O
transport	O
,	O
P=1.73×10sup	O
-	O
19	O
/	O
sup	O
and	O
mitochondrial	O
membrane	O
organization	O
,	O
P=4.04×10sup	O
-	O
8	O
/	O
sup	O
)	O
.	O

We	O
show	O
that	O
signaling	O
through	O
herpes	O
virus	O
entry	O
mediator	O
(	O
HVEM	O
)	O
,	O
a	O
member	O
of	O
the	O
tumor	S-Phenotype
necrosis	O
factor	O
(	O
TNF	O
)	O
receptor	O
superfamily	O
,	O
in	O
ILC3	O
is	O
important	O
for	O
host	O
defense	O
against	O
oral	O
infection	O
with	O
the	O
bacterial	O
pathogen	O
Yersinia	O
enterocolitica	O
.	O

In	O
2003	O
,	O
inactivating	O
mutations	O
of	O
Kiss1R	O
gene	O
were	O
first	O
associated	O
to	O
lack	O
of	O
pubertal	O
maturation	O
and	O
hypogonadotropic	B-Phenotype
hypogonadism	E-Phenotype
in	O
humans	O
and	O
rodents	O
.	O

We	O
found	O
that	O
JIP3	O
was	O
markedly	O
increased	O
in	O
TLE	O
patients	O
and	O
a	O
mouse	O
model	O
of	O
epileptic	B-Phenotype
seizures	E-Phenotype
;	O
mice	O
underexpressing	O
JIP3	O
through	O
lentivirus	O
bearing	O
LV	O
-	O
Letm1	O
-	O
RNAi	O
showed	O
decreased	O
susceptibility	O
,	O
delayed	O
first	O
seizure	S-Phenotype
and	O
decreased	O
seizure	S-Phenotype
duration	O
response	O
to	O
the	O
epileptogenic	O
properties	O
of	O
KA	O
.	O

In	O
conclusion	O
,	O
overexpression	O
of	O
the	O
DTNA	O
-	O
p.N49S	O
mutation	O
in	O
a	O
mouse	O
heart	O
can	O
be	O
responsible	O
for	O
the	O
phenotype	O
of	O
deep	B-Phenotype
trabeculation	E-Phenotype
,	O
dilated	B-Phenotype
cardiomyopathy	E-Phenotype
,	O
and	O
cardiac	B-Phenotype
dysfunction	E-Phenotype
,	O
which	O
resembles	O
the	O
phenotype	O
of	O
LVNC	O

Schnyder	B-Phenotype
corneal	I-Phenotype
dystrophy	E-Phenotype
(	O
SCD	S-Phenotype
)	O
is	O
a	O
rare	O
autosomal	O
dominant	O
disease	O
in	O
humans	O
,	O
characterized	O
by	O
abnormal	B-Phenotype
deposition	I-Phenotype
of	I-Phenotype
cholesterol	I-Phenotype
and	I-Phenotype
phospholipids	I-Phenotype
in	I-Phenotype
cornea	E-Phenotype
caused	O
by	O
mutations	O
in	O
the	O
UbiA	O
prenyltransferase	O
domain	O
containing	O
1	O
(	O
UBIAD1	O
)	O
gene	O
.	O

Additionally	O
,	O
inhibition	O
of	O
Chmp1A	O
expression	O
by	O
shRNA	O
induced	O
tumor	S-Phenotype
formation	O
in	O
normal	O
renal	O
cells	O
.	O

Patients	O
carrying	O
homozygous	O
WNT1	O
mutations	O
have	O
more	O
frequent	B-Phenotype
fractures	E-Phenotype
while	O
heterozygous	O
carriers	O
of	O
the	O
mutation	O
in	O
WNT1	O
gene	O
are	O
also	O
found	O
to	O
have	O
early	B-Phenotype
onset	I-Phenotype
osteoporosis	E-Phenotype
.	O

Among	O
the	O
363	O
outbreaks	O
with	O
a	O
confirmed	O
infectious	O
etiology	O
,	O
212	O
(	O
58	O
%	O
)	O
were	O
caused	O
by	O
Cryptosporidium	O
(	O
which	O
causes	O
predominantly	O
gastrointestinal	O
illness	O
)	O
,	O
57	O
(	O
16	O
%	O
)	O
by	O
Legionella	O
(	O
which	O
causes	O
Legionnaires	O
'	O
disease	O
,	O
a	O
severe	O
pneumonia	S-Phenotype
,	O
and	O
Pontiac	O
fever	S-Phenotype
,	O
a	O
milder	O
illness	O
with	O
flu	O
-	O
like	O
symptoms	O
)	O
,	O
and	O
47	O
(	O
13	O
%	O
)	O
by	O
Pseudomonas	O
(	O
which	O
causes	O
folliculitis	S-Phenotype
[	O
AAAAAAhot	O
tub	O
rashAAAAAA	O
]	O
and	O
otitis	B-Phenotype
externa	E-Phenotype
[	O
AAAAAAswimmers	O
'	O
earAAAAAA	O
]	O
)	O
.	O

Recessive	O
mutations	O
in	O
the	O
secreted	O
metalloprotease	O
ADAMTS17	O
cause	O
ectopia	B-Phenotype
lentis	E-Phenotype
and	O
short	B-Phenotype
stature	E-Phenotype
in	O
humans	O
with	O
Weill	O
-	O
Marchesani	O
-	O
like	O
syndrome	O
and	O
primary	B-Phenotype
open	I-Phenotype
angle	I-Phenotype
glaucoma	E-Phenotype
and	O
ectopia	B-Phenotype
lentis	E-Phenotype
in	O
dogs	O
.	O

We	O
hypothesized	O
that	O
additional	O
rare	O
AP2σ	O
variants	O
may	O
also	O
be	O
associated	O
with	O
altered	O
CaSR	O
function	O
and	O
hypercalcaemia	S-Phenotype
,	O
and	O
sought	O
for	O
these	O
by	O
analysing	O
AAAA111	O
995	O
exomes	O
(	O
AAAA60	O
706	O
from	O
ExAc	O
and	O
dbSNP	O
,	O
and	O
51	O
289	O
from	O
the	O
Geisinger	O
Health	O
System	O
-	O
Regeneron	O
DiscovEHR	O
dataset	O
,	O
which	O
also	O
contains	O
clinical	O
data	O
)	O
.	O

Recently	O
,	O
the	O
roles	O
of	O
FAM83H	O
in	O
tumorigenesis	S-Phenotype
have	O
been	O
interested	O
and	O
increased	O
expression	O
of	O
FAM83H	O
and	O
MYC	O
in	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
have	O
been	O
reported	O
.	O

Here	O
we	O
show	O
that	O
mitochondrial	O
Sirtuin5	O
(	O
SIRT5	O
)	O
,	O
which	O
mediates	O
lysine	O
desuccinylation	O
,	O
deglutarylation	O
,	O
and	O
demalonylation	O
,	O
plays	O
a	O
role	O
in	O
colorectal	B-Phenotype
cancer	E-Phenotype
(	O
CRC	S-Phenotype
)	O
glutamine	O
metabolic	O
rewiring	O
.	O

Whole	O
-	O
genome	O
sequencing	O
documented	O
two	O
rare	O
truncating	O
variants	O
in	O
DOCK6	O
,	O
a	O
gene	O
associated	O
with	O
a	O
type	O
of	O
autosomal	B-Phenotype
recessive	E-Phenotype
AOS	O
that	O
recurrently	O
features	O
periventricular	O
calcification	O
and	O
impaired	O
neurodevelopment	O
.	O

Cystinuria	S-Phenotype
is	O
a	O
heterogeneous	S-Phenotype
,	O
rare	O
but	O
important	O
cause	O
of	O
inherited	B-Phenotype
kidney	I-Phenotype
stone	E-Phenotype
disease	O
due	O
to	O
mutations	O
in	O
2	O
genes	O
:	O
SLC3A1	O
and	O
SLC7A9	O
.	O

Several	O
gene	O
encoding	O
proteins	O
related	O
to	O
collagen	O
metabolism	O
have	O
been	O
described	O
in	O
some	O
cases	O
of	O
autosomal	B-Phenotype
recessive	E-Phenotype
OI	O
(	O
including	O
CRTAP	O
,	O
LEPRE1	O
,	O
PPIB	O
,	O
FKBP65	O
,	O
SERPINF1	O
,	O
BMP1	O
,	O
WNT1	O
,	O
FKBP10	O
)	O
.	O

Pharmacological	O
manipulation	O
of	O
peripheral	O
CB1	O
signaling	O
regulates	O
hyperphagia	S-Phenotype
in	O
an	O
adipocyte	O
OGT	O
-	O
dependent	O
manner	O
.	O

However	O
,	O
mechanistic	O
aspects	O
by	O
which	O
NRF1	O
may	O
contribute	O
to	O
susceptibility	O
to	O
different	O
breast	B-Phenotype
tumor	E-Phenotype
subtypes	O
are	O
still	O
not	O
fully	O
understood	O
.	O

When	O
the	O
Kankl	O
gene	O
was	O
upregulated	O
,	O
we	O
found	O
that	O
the	O
proliferation	O
of	O
lung	B-Phenotype
cancer	E-Phenotype
cells	O
was	O
significantly	O
inhibited	O
,	O
the	O
cells	O
were	O
arrested	O
in	O
the	O
G0	O
/	O
G1	O
phase	O
,	O
the	O
apoptosis	O
of	O
cells	O
was	O
observed	O
,	O
the	O
expression	O
of	O
the	O
caspase	O
family	O
of	O
genes	O
was	O
altered	O
with	O
mainly	O
the	O
activation	O
of	O
caspase	O
-	O
3	O
and	O
-	O
9	O
,	O
and	O
Bcl	O
-	O
2	O
/	O
Bax	O
ratio	O
was	O
significantly	O
imbalanced	O
.	O

The	O
use	O
of	O
recombinant	O
human	O
erythropoietin	O
(	O
Epo	O
)	O
has	O
consistently	O
been	O
shown	O
to	O
reduce	O
the	O
need	O
for	O
blood	O
transfusions	O
and	O
to	O
increase	O
hemoglobin	O
levels	O
in	O
lung	B-Phenotype
cancer	E-Phenotype
patients	O
with	O
chemotherapy	B-Phenotype
-	I-Phenotype
induced	I-Phenotype
anemia	E-Phenotype
.	O

Our	O
study	O
aimed	O
to	O
investigate	O
the	O
roles	O
and	O
possible	O
regulatory	O
mechanism	O
of	O
miR	O
-	O
1277	O
in	O
the	O
development	O
of	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
.	O

The	O
copy	O
number	O
variations	O
and	O
mutations	O
were	O
also	O
used	O
to	O
identify	O
single	O
nucleotide	O
variations	O
(	O
SNVs	O
)	O
in	O
crystallin	O
mu	O
(	O
CRYM	O
)	O
,	O
RAB3	O
GTPase	O
activating	O
protein	O
catalytic	O
subunit	O
1	O
(	O
RAB3GAP1	O
)	O
and	O
Wnt	O
family	O
member	O
10A	O
(	O
WNT10A	O
)	O
,	O
implicated	O
in	O
deafness	S-Phenotype
,	O
hypogonadism	S-Phenotype
and	O
tooth	B-Phenotype
/	I-Phenotype
skin	I-Phenotype
abnormalities	E-Phenotype
,	O
respectively	O
.	O

Mutations	O
in	O
the	O
kinesin	O
family	O
member	O
1A	O
(	O
KIF1A	O
)	O
gene	O
have	O
been	O
associated	O
with	O
a	O
wide	O
range	O
of	O
phenotypes	O
including	O
recessive	O
mutations	O
causing	O
hereditary	B-Phenotype
sensory	I-Phenotype
neuropathy	E-Phenotype
and	O
hereditary	B-Phenotype
spastic	I-Phenotype
paraplegia	E-Phenotype
and	O
de	O
novo	O
dominant	O
mutations	O
causing	O
a	O
more	O
complex	O
neurological	O
disorder	O
affecting	O
both	O
the	O
central	O
and	O
peripheral	O
nervous	O
system	O
.	O

The	O
study	O
indicated	O
genetic	O
heterogeneity	S-Phenotype
as	O
the	O
mutation	O
was	O
present	O
in	O
all	O
PRA	O
-	O
affected	O
individuals	O
in	O
one	O
large	O
family	O
of	O
Shelties	O
,	O
whereas	O
some	O
other	O
cases	O
in	O
the	O
studied	O
Sheltie	O
population	O
were	O
not	O
associated	O
with	O
this	O
CNGA1	O
mutation	O
.	O

Hyper	O
-	O
methylated	O
CpG	O
loci	O
included	O
the	O
known	O
the	O
tumor	S-Phenotype
suppressor	O
gene	O
RET	O
(	O
p	O
=	O
5.72	O
x	O
10	O
-	O
10	O
)	O
,	O
as	O
well	O
as	O
loci	O
in	O
differentially	O
methylated	O
regions	O
for	O
GSG1L	O
,	O
MIR4493	O
,	O
NTNG1	O
,	O
MCIDAS	O
,	O
ZNF568	O
,	O
and	O
RERG	O
.	O

Recessively	O
inherited	O
,	O
pathogenic	O
defects	O
in	O
LonP1	O
have	O
been	O
previously	O
reported	O
to	O
underlie	O
cerebral	B-Phenotype
,	I-Phenotype
ocular	I-Phenotype
,	I-Phenotype
dental	I-Phenotype
,	I-Phenotype
auricular	I-Phenotype
and	I-Phenotype
skeletal	I-Phenotype
anomalies	E-Phenotype
(	O
CODAS	S-Phenotype
)	O
syndrome	O
,	O
a	O
complex	O
multisystemic	O
and	O
developmental	O
disorder	O
.	O

We	O
analyzed	O
,	O
by	O
conventional	O
and	O
molecular	O
cytogenetics	O
,	O
19	O
novel	O
SRY	O
-	O
negative	O
unrelated	O
46	O
,	O
XX	O
subjects	O
both	O
familial	O
and	O
sporadic	S-Phenotype
,	O
with	O
isolated	O
DSD	O
.	O

Thus	O
,	O
it	O
is	O
possible	O
that	O
subtle	O
dysfunction	O
arising	O
from	O
multiple	O
cell	O
types	O
is	O
necessary	O
for	O
the	O
expression	O
of	O
certain	O
ataxia	S-Phenotype
syndromes	O
.	O

The	O
promoter	O
methylation	O
levels	O
of	O
ELMO1	O
and	O
ELMO2	O
were	O
generally	O
low	O
,	O
whereas	O
ELMO3	O
methylation	O
levels	O
were	O
high	O
,	O
in	O
the	O
tumor	S-Phenotype
biopsies	O
.	O

TRIP13	O
promotes	O
lung	B-Phenotype
adenocarcinoma	E-Phenotype
cell	O
proliferation	O
,	O
clonogenicity	O
,	O
and	O
migration	O
while	O
inhibiting	O
apoptosis	O
and	O
G2	O
/	O
M	O
phase	O
shift	O
in	O
vitro	O
.	O

We	O
previously	O
found	O
ADAMTS18	O
as	O
frequently	O
methylated	O
tumor	S-Phenotype
suppressor	O
gene	O
(	O
TSG	O
)	O
for	O
multiple	O
carcinomas	S-Phenotype
,	O
however	O
,	O
its	O
biological	O
functions	O
and	O
underlying	O
molecular	O
mechanisms	O
in	O
breast	O
carcinogenesis	O
remain	O
unknown	O
.	O

The	O
autosomal	B-Phenotype
recessive	I-Phenotype
neurodegenerative	I-Phenotype
disease	I-Phenotype
spinal	I-Phenotype
muscular	I-Phenotype
atrophy	E-Phenotype
(	O
SMA	S-Phenotype
)	O
results	O
from	O
low	O
levels	O
of	O
survival	O
motor	O
neuron	O
(	O
SMN	O
)	O
protein	O
;	O
however	O
,	O
it	O
is	O
unclear	O
how	O
reduced	O
SMN	O
promotes	O
SMA	O
development	O
.	O

Main	O
complications	O
were	O
due	O
to	O
anemia	S-Phenotype
and	O
ineffective	B-Phenotype
erythropoiesis	E-Phenotype
[	O
osteoporosis	S-Phenotype
(	O
8	O
/	O
9	O
,	O
89	O
%	O
)	O
,	O
cholelithiasis	S-Phenotype
(	O
21	O
/	O
30	O
,	O
70	O
%	O
)	O
,	O
pulmonary	B-Phenotype
arterial	I-Phenotype
hypertension	E-Phenotype
(	O
PAH	S-Phenotype
)	O
(	O
6	O
/	O
25	O
,	O
24	O
%	O
)	O
]	O
and	O
iron	O
overload	O
[	O
hypothyroidism	S-Phenotype
(	O
9	O
/	O
24	O
,	O
38	O
%	O
)	O
,	O
and	O
diabetes	B-Phenotype
mellitus	E-Phenotype
(	O
6	O
/	O
32	O
,	O
19	O
%	O
)	O
]	O
.	O

Results	O
from	O
the	O
current	O
study	O
showed	O
that	O
NEK2	O
mediates	O
tumor	S-Phenotype
growth	O
,	O
metastasis	O
and	O
angiogenesis	O
in	O
vivo	O
.	O

These	O
findings	O
may	O
provide	O
a	O
better	O
understanding	O
about	O
the	O
mechanism	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
and	O
suggest	O
that	O
MFAP5	O
may	O
be	O
a	O
potential	O
prognostic	O
biomarker	O
and	O
therapeutic	O
target	O
for	O
breast	B-Phenotype
cancer	E-Phenotype
,	O
especially	O
for	O
bone	O
metastasis	O
of	O
breast	B-Phenotype
cancer	E-Phenotype

The	O
clinical	O
history	O
for	O
migraine	S-Phenotype
and	O
hypertension	S-Phenotype
was	O
collected	O
;	O
genomic	O
DNA	O
was	O
characterized	O
for	O
a	O
panel	O
of	O
33	O
SNPs	O
encoding	O
proteins	O
involved	O
in	O
ionic	O
transport	O
.	O

Myelodysplastic	B-Phenotype
syndromes	E-Phenotype
(	O
MDS	S-Phenotype
)	O
in	O
children	O
and	O
adolescents	O
are	O
a	O
rare	O
heterogeneous	S-Phenotype
group	O
of	O
clonal	O
stem	O
cell	O
disorders	O
.	O

This	O
study	O
points	O
to	O
the	O
likely	O
importance	O
of	O
histone	O
modifications	O
in	O
osteosarcoma	S-Phenotype
and	O
highlights	O
the	O
strong	O
genetic	O
similarities	O
between	O
human	O
and	O
dog	O
osteosarcoma	S-Phenotype
,	O
suggesting	O
that	O
canine	O
osteosarcoma	S-Phenotype
may	O
serve	O
as	O
an	O
excellent	O
model	O
for	O
developing	O
treatment	O
strategies	O
in	O
both	O
species	O
.	O

Significance	O
:	O
/	O
b	O
Canine	O
osteosarcoma	S-Phenotype
genomics	O
identify	O
SETD2	O
as	O
a	O
possible	O
oncogenic	O
driver	O
of	O
osteosarcoma	S-Phenotype
,	O
and	O
findings	O
establish	O
the	O
canine	O
model	O
as	O
a	O
useful	O
comparative	O
model	O
for	O
the	O
corresponding	O
human	O
disease	O
.	O

A	O
mutation	O
of	O
Lrrc6	O
has	O
been	O
identified	O
in	O
human	O
patients	O
with	O
primary	B-Phenotype
ciliary	I-Phenotype
dyskinesia	E-Phenotype
(	O
PCD	S-Phenotype
)	O
.	O

However	O
,	O
in	O
HaCaT	O
and	O
HEK293T	O
cells	O
that	O
display	O
transformed	O
phenotypes	O
,	O
but	O
do	O
not	O
originate	O
from	O
patient	O
-	O
derived	O
tumors	S-Phenotype
,	O
the	O
ER	O
stress	O
-	O
inducing	O
treatments	O
resulted	O
in	O
an	O
upregulation	O
of	O
FAM129A	O
and	O
HKDC1	O
,	O
but	O
not	O
KRT16	O
transcripts	O
,	O
By	O
a	O
luciferase	O
reporter	O
approach	O
we	O
identified	O
a	O
highly	O
active	O
ATF4	O
-	O
responsive	O
element	O
within	O
the	O
upstream	O
region	O
of	O
the	O
KRT16	O
gene	O
.	O

We	O
hypothesized	O
that	O
newly	O
identified	O
genetic	O
risk	O
factors	O
for	O
the	O
general	O
African	O
American	O
population	O
could	O
also	O
impact	O
laboratory	O
biomarkers	O
known	O
to	O
contribute	O
to	O
the	O
clinical	O
disease	O
expression	O
of	O
SCA	O
,	O
including	O
variants	O
influencing	O
the	O
white	O
blood	O
cell	O
count	O
and	O
the	O
development	O
of	O
albuminuria	S-Phenotype
and	O
abnormal	B-Phenotype
glomerular	I-Phenotype
filtration	I-Phenotype
rate	E-Phenotype
.	O

Here	O
we	O
show	O
that	O
mitochondrial	O
Sirtuin5	O
(	O
SIRT5	O
)	O
,	O
which	O
mediates	O
lysine	O
desuccinylation	O
,	O
deglutarylation	O
,	O
and	O
demalonylation	O
,	O
plays	O
a	O
role	O
in	O
colorectal	B-Phenotype
cancer	E-Phenotype
(	O
CRC	S-Phenotype
)	O
glutamine	O
metabolic	O
rewiring	O
.	O

Recent	O
studies	O
in	O
RAS	B-Phenotype
wild	I-Phenotype
-	I-Phenotype
type	I-Phenotype
(	I-Phenotype
WT	I-Phenotype
)	I-Phenotype
metastatic	I-Phenotype
colorectal	I-Phenotype
cancer	E-Phenotype
(	O
mCRC	O
)	O
suggest	O
that	O
the	O
survival	O
benefits	O
of	O
therapy	O
using	O
anti	O
-	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
anti	O
-	O
EGFR	O
)	O
and	O
anti	O
-	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
anti	O
-	O
VEGF	O
)	O
antibodies	O
combined	O
with	O
chemotherapy	O
are	O
maximized	O
when	O
the	O
anti	O
-	O
EGFR	O
antibody	O
is	O
given	O
as	O
first	O
-	O
line	O
,	O
followed	O
by	O
subsequent	O
anti	O
-	O
VEGF	O
antibody	O
therapy	O
.	O

Among	O
the	O
246	O
paired	O
cases	O
,	O
3	O
(	O
1.22	O
%	O
)	O
cases	O
of	O
primary	O
tumor	S-Phenotype
had	O
identified	O
RET	O
rearrangement	O
and	O
2	O
(	O
0.81	O
%	O
)	O
cases	O
of	O
metastases	O
had	O
identified	O
RET	O
rearrangement	O
.	O

These	O
data	O
suggest	O
that	O
Spi	O
-	O
B	O
participates	O
in	O
mesenchymal	O
invasion	O
,	O
linking	O
epithelial	B-Phenotype
cancer	E-Phenotype
metastasis	O
with	O
a	O
lymphatic	O
transcriptional	O
program	O
.	O

Inherited	O
mutations	O
in	O
NAA10	O
,	O
encoding	O
the	O
catalytic	O
subunit	O
of	O
the	O
major	O
N	O
-	O
terminal	O
acetylation	O
complex	O
NatA	O
have	O
been	O
associated	O
with	O
diverse	O
,	O
syndromic	O
X	O
-	O
linked	O
recessive	O
disorders	O
,	O
whereas	O
de	O
novo	O
missense	O
mutations	O
have	O
been	O
reported	O
in	O
one	O
male	O
and	O
one	O
female	O
individual	O
with	O
severe	O
intellectual	B-Phenotype
disability	E-Phenotype
but	O
otherwise	O
unspecific	O
phenotypes	O
.	O

We	O
also	O
confirmed	O
that	O
OGFOD1	O
is	O
highly	O
expressed	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
tissues	O
by	O
bioinformatic	O
analysis	O
and	O
immunohistochemistry	O
.	O

Overexpression	O
of	O
miR	O
-	O
493	O
in	O
HCC	O
cells	O
dramatically	O
inhibited	O
cell	O
proliferation	O
and	O
colony	O
-	O
formation	O
in	O
vitro	O
and	O
inhibited	O
tumor	S-Phenotype
formation	O
of	O
HCC	O
cell	O
xenografts	O
in	O
vivo	O
.	O

Our	O
study	O
suggested	O
that	O
RAD50	O
germline	O
mutations	O
are	O
not	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
,	O
but	O
patients	O
with	O
RAD50	O
germline	O
mutations	O
have	O
unfavourable	O
survival	O
compared	O
to	O
patients	O
without	O
these	O
mutations	O

Our	O
study	O
expands	O
the	O
mutational	O
spectrum	O
of	O
GDAP1	O
-	O
related	O
CMT	O
disease	O
with	O
the	O
identification	O
of	O
new	O
and	O
unreported	O
GDAP1	O
variants	O
and	O
demonstrates	O
the	O
predominance	O
of	O
the	O
axonal	O
form	O
of	O
neuropathy	S-Phenotype
in	O
CMT	O
disease	O
associated	O
with	O
GDAP1	O
.	O

TUNEL	O
assay	O
was	O
used	O
to	O
detect	O
the	O
effect	O
of	O
each	O
group	O
on	O
the	O
apoptosis	O
of	O
the	O
gastric	B-Phenotype
cancer	E-Phenotype
cells	O
,	O
and	O
Western	O
blot	O
was	O
used	O
to	O
detect	O
the	O
expression	O
of	O
caspase	O
-	O
3	O
,	O
caspase	O
-	O
8	O
,	O
bcl	O
-	O
2	O
,	O
and	O
c	O
-	O
myc	O
,	O
which	O
are	O
the	O
proteins	O
related	O
to	O
apoptosis	O
,	O
after	O
the	O
drug	O
effect	O
in	O
each	O
group	O
.	O

Therefore	O
,	O
quantification	O
of	O
glioma	S-Phenotype
extracellular	O
pH	O
(	O
pHe	O
)	O
is	O
of	O
crucial	O
importance	O
.	O

MATERIAL	O
AND	O
METHODS	O
The	O
proliferation	O
of	O
prostate	B-Phenotype
cancer	E-Phenotype
cells	O
was	O
determined	O
by	O
CCK	O
-	O
8	O
assay	O
.	O

The	O
protein	O
product	O
of	O
the	O
breast	B-Phenotype
and	I-Phenotype
ovarian	I-Phenotype
cancer	E-Phenotype
gene	O
,	O
BRCA1	O
,	O
is	O
part	O
of	O
an	O
obligate	O
heterodimer	O
with	O
BARD1	O
.	O

Individuals	O
with	O
PTCHD1	O
deletion	O
show	O
symptoms	O
of	O
ADHD	S-Phenotype
,	O
sleep	B-Phenotype
disruption	E-Phenotype
,	O
hypotonia	S-Phenotype
,	O
aggression	S-Phenotype
,	O
ASD	S-Phenotype
,	O
and	O
ID	S-Phenotype
.	O

In	O
conclusion	O
,	O
our	O
results	O
indicated	O
that	O
liERCC1	O
,	O
XPC	O
and	O
liERCC2	O
might	O
influence	O
ovarian	B-Phenotype
cancer	E-Phenotype
susceptibility	O
.	O

Results	O
Clinical	O
evaluations	O
suggested	O
autosomal	B-Phenotype
recessive	E-Phenotype
nonsyndromic	O
HL	O
.	O

We	O
review	O
the	O
literature	O
of	O
genetic	O
PD	O
autopsies	O
from	O
cases	O
with	O
molecularly	O
confirmed	O
PD	O
or	O
parkinsonism	S-Phenotype
and	O
summarize	O
main	O
findings	O
on	O
SNCA	O
(	O
n	O
=	O
25	O
)	O
,	O
Parkin	O
(	O
n	O
=	O
20	O
,	O
17	O
bi	O
-	O
allelic	O
and	O
3	O
heterozygotes	O
)	O
,	O
PINK1	O
(	O
n	O
=	O
5	O
,	O
1	O
bi	O
-	O
allelic	O
and	O
4	O
heterozygotes	O
)	O
,	O
DJ	O
-	O
1	O
(	O
n	O
=	O
1	O
)	O
,	O
LRRK2	O
(	O
n	O
=	O
55	O
)	O
,	O
GBA	O
(	O
n	O
=	O
10	O
Gaucher	O
disease	O
patients	O
with	O
parkinsonism	S-Phenotype
)	O
,	O
DNAJC13	O
,	O
GCH1	O
,	O
ATP13A2	O
,	O
PLA2G6	O
(	O
n	O
=	O
8	O
patients	O
,	O
2	O
with	O
PD	O
)	O
,	O
MPAN	O
(	O
n	O
=	O
2	O
)	O
,	O
FBXO7	O
,	O
RAB39B	O
,	O
and	O
ATXN2	O
(	O
SCA2	O
)	O
,	O
as	O
well	O
as	O
on	O
22q	O
deletion	O
syndrome	O
(	O
n	O
=	O
3	O
)	O
.	O

The	O
reported	O
hypertrophic	B-Phenotype
cardiomyopathy	E-Phenotype
relevant	O
genes	O
MYPN	O
,	O
MYH6	O
and	O
MYBP3	O
had	O
also	O
been	O
found	O
in	O
case	O
1	O
and	O
2	O
.	O

SBF2	O
-	O
AS1	O
knockdown	O
could	O
inhibit	O
the	O
proliferation	O
of	O
HCC	O
cells	O
and	O
attenuate	O
the	O
development	O
of	O
HCC	B-Phenotype
tumor	E-Phenotype
in	O
vivo	O
.	O

Although	O
serum	O
CK18	O
,	O
MMP	O
-	O
9	O
,	O
and	O
TIMP1	O
preop	O
measurements	O
in	O
patients	O
scheduled	O
for	O
curative	O
surgery	O
due	O
to	O
gastric	B-Phenotype
adenocarcinoma	E-Phenotype
did	O
not	O
help	O
to	O
gain	O
any	O
idea	O
of	O
tumor	S-Phenotype
resectability	O
,	O
we	O
concluded	O
that	O
our	O
study	O
had	O
valuable	O
results	O
in	O
significantly	O
predicting	O
N3	O
stage	O

Our	O
cases	O
confirm	O
that	O
ATP1A3	O
-	O
related	O
neurological	O
disorders	O
make	O
up	O
a	O
phenotypic	O
continuum	O
rather	O
than	O
overlapping	O
syndromes	O
,	O
in	O
which	O
early	B-Phenotype
onset	I-Phenotype
dystonia	E-Phenotype
,	O
ataxia	S-Phenotype
and	O
paroxysmal	B-Phenotype
episodes	E-Phenotype
with	O
triggering	O
or	O
worsening	O
factors	O
are	O
key	O
diagnostic	O
clues	O
.	O

We	O
propose	O
that	O
Cep68	O
protein	O
level	O
needs	O
to	O
be	O
fine	O
-	O
tuned	O
in	O
order	O
to	O
ensure	O
that	O
its	O
direct	O
interactors	O
,	O
such	O
as	O
the	O
microcephaly	S-Phenotype
protein	O
Cep215	O
and	O
PCNT	O
,	O
function	O
properly	O

The	O
RS	O
-	O
MC	O
algorithm	O
demonstrated	O
improved	O
dosimetric	O
accuracy	O
over	O
the	O
RS	O
-	O
PBA	O
in	O
the	O
presence	O
of	O
homogenous	O
,	O
heterogeneous	S-Phenotype
and	O
anthropomorphic	O
phantoms	O
.	O

MED1	O
mediates	O
induction	O
of	O
cell	O
proliferation	O
and	O
migration	O
and	O
the	O
genes	O
associated	O
with	O
it	O
(	O
JUN	O
,	O
FOS	O
,	O
EGFR	O
,	O
VEGF	O
,	O
MMP1	O
,	O
and	O
ERBB4	O
)	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
,	O
which	O
is	O
abrogated	O
when	O
used	O
together	O
with	O
miR	O
-	O
191	O
-	O
inhibition	O
.	O

Intradermal	O
injection	O
of	O
Flii	O
neutralizing	O
antibodies	O
during	O
SCC	O
initiation	O
and	O
progression	O
significantly	O
reduced	O
the	O
size	O
of	O
the	O
tumors	S-Phenotype
and	O
,	O
in	O
vitro	O
,	O
decreased	O
cellular	O
sphere	O
formation	O
and	O
invasion	O
.	O

Using	O
whole	O
-	O
exome	O
sequencing	O
,	O
we	O
identified	O
seven	O
unrelated	O
individuals	O
with	O
global	B-Phenotype
developmental	I-Phenotype
delay	E-Phenotype
,	O
hypotonia	S-Phenotype
,	O
dysmorphic	B-Phenotype
facial	I-Phenotype
features	E-Phenotype
,	O
and	O
an	O
increased	O
frequency	O
of	O
short	B-Phenotype
stature	E-Phenotype
,	O
ataxia	S-Phenotype
,	O
and	O
autism	S-Phenotype
with	O
de	O
novo	O
heterozygous	O
frameshift	O
,	O
nonsense	O
,	O
splice	O
,	O
and	O
missense	O
variants	O
in	O
the	O
Early	O
B	O
-	O
cell	O
Transcription	O
Factor	O
Family	O
Member	O
3	O
(	O
EBF3	O
)	O
gene	O
.	O

Gene	O
set	O
enrichment	O
analysis	O
was	O
conducted	O
to	O
study	O
the	O
relevant	O
mechanisms	O
.	O

Bladder	B-Phenotype
cancer	E-Phenotype
patients	O
in	O
COL5A2	O
low	O
expression	O
group	O
were	O
associated	O
with	O
better	O
invasiveness	O
(	O
P	O
AAAA	O
.0001	O
)	O
,	O
tumor	S-Phenotype
grade	O
(	O
P	O
=	O
.001	O
)	O
,	O
T	O
staging	O
(	O
P	O
AAAA	O
.0001	O
)	O
,	O
N	O
staging	O
(	O
P	O
=	O
.002	O
)	O
,	O
cancer	S-Phenotype
specific	O
survival	O
(	O
P	O
AAAA	O
.0001	O
)	O
,	O
overall	O
survival	O
(	O
P	O
AAAA	O
.0001	O
)	O
,	O
and	O
a	O
trend	O
of	O
better	O
M	O
staging	O
(	O
P	O
=	O
.053	O
)	O
than	O
those	O
in	O
COL5A2	O
high	O
expression	O
group.COL5A2	O
might	O
affect	O
the	O
progression	O
of	O
bladder	B-Phenotype
cancer	E-Phenotype
through	O
AAAAAACoagulation	O
,	O
AAAAAA	O
AAAAAAHypoxia	O
,	O
AAAAAA	O
AAAAAAApical	O
junction	O
,	O
AAAAAA	O
AAAAAAUltraviolet	O
response	O
,	O
AAAAAA	O
AAAAAAEpithelial	O
mesenchymal	O
transition	O
,	O
AAAAAA	O
AAAAAAAngiogenesis	O
,	O
AAAAAA	O
AAAAAAKRAS	O
(	O
KRAS	O
proto	O
-	O
oncogene	O
,	O
GTPase	O
)	O
signaling	O
,	O
AAAAAAComplement	O
,	O
AAAAAAIL2	O
-	O
STAT5	O
-	O
signaling	O
,	O
AAAAAA	O
AAAAAAInflammatory	O
response	O
,	O
AAAAAA	O
AAAAAAIL6	O
-	O
JAK	O
-	O
STAT3	O
-	O
signaling	O
,	O
AAAAAA	O
AAAAAAMyogenesis	O
,	O
AAAAAA	O
AAAAAATNF	O
a	O
signaling	O
,	O
AAAAAA	O
AAAAAAApoptosis	O
,	O
AAAAAA	O
and	O
AAAAAAHedgehog	O
-	O
signaling.AAAAA	O
;	O
Our	O
results	O
demonstrated	O
that	O
COL5A2	O
was	O
correlated	O
with	O
poor	O
clinical	O
outcomes	O
and	O
survivals	O
of	O
patients	O
with	O
bladder	B-Phenotype
cancer	E-Phenotype
,	O
suggesting	O
that	O
it	O
could	O
be	O
regarded	O
as	O
a	O
biomarker	O
of	O
bladder	B-Phenotype
cancer	E-Phenotype

Moreover	O
,	O
double	O
knockdown	O
of	O
APC2	O
and	O
miR	O
-	O
4326	O
promoted	O
lung	B-Phenotype
cancer	E-Phenotype
cell	O
proliferation	O
,	O
confirming	O
that	O
miR	O
-	O
4326	O
promoted	O
lung	B-Phenotype
cancer	E-Phenotype
cell	O
proliferation	O
by	O
inhibiting	O
APC2	O

Specifically	O
,	O
ADHFE1	O
,	O
HAND2	O
,	O
and	O
GNAO1	O
were	O
hypermethylated	O
and	O
downregulated	O
in	O
colon	B-Phenotype
cancer	E-Phenotype
,	O
suggesting	O
that	O
the	O
low	O
expression	O
levels	O
of	O
these	O
genes	O
may	O
be	O
regulated	O
by	O
DNA	O
hypermethylation	O
.	O

Thus	O
,	O
AF1q	O
contributes	O
to	O
CRC	O
tumorigenesis	S-Phenotype
and	O
progression	O
through	O
the	O
activation	O
of	O
the	O
AKT	O
signaling	O
pathway	O
.	O

With	O
alignment	O
to	O
T2DM	O
susceptibility	O
genes	O
and	O
deafness	S-Phenotype
genes	O
published	O
,	O
KCNJ11	O
was	O
found	O
to	O
be	O
the	O
only	O
overlapped	O
gene	O
.	O

The	O
proband	O
carried	O
the	O
two	O
kinds	O
of	O
mutations	O
and	O
expressed	O
various	O
clinical	O
manifestations	O
of	O
heart	B-Phenotype
failure	E-Phenotype
and	O
had	O
history	O
of	O
ventricular	B-Phenotype
tachycardia	E-Phenotype
,	O
paraxial	B-Phenotype
atrial	I-Phenotype
fibrillation	E-Phenotype
,	O
pacemaker	B-Phenotype
implantation	E-Phenotype
,	O
electrocardiogram	S-Phenotype
showed	O
right	B-Phenotype
bundle	I-Phenotype
branch	I-Phenotype
block	E-Phenotype
and	O
echocardiography	O
examination	O
evidenced	O
thickened	B-Phenotype
interventricular	I-Phenotype
septum	E-Phenotype
(	O
23.3	O
mm	O
)	O
and	O
apex	O
and	O
reduced	O
wall	O
motion	O
of	O
these	O
segments	O
.	O

Several	O
studies	O
have	O
investigated	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
a	O
number	O
of	O
genes	O
associated	O
with	O
the	O
susceptibility	O
to	O
or	O
severity	O
and	O
outcome	O
of	O
community	O
-	O
acquired	O
pneumonia	S-Phenotype
(	O
CAP	O
)	O
,	O
but	O
no	O
research	O
has	O
yet	O
been	O
conducted	O
on	O
the	O
role	O
of	O
IRF5	O
gene	O
polymorphisms	O
in	O
CAP	O
.	O

Reciprocally	O
,	O
the	O
cytosine	O
methylation	O
heterogeneity	S-Phenotype
characteristic	O
of	O
normal	O
GC	O
B	O
cells	O
is	O
lost	O
upon	O
AICDA	O
depletion	O
.	O

Although	O
the	O
patient	O
showed	O
cardiac	B-Phenotype
anomalies	E-Phenotype
,	O
which	O
is	O
one	O
of	O
the	O
typical	O
symptoms	O
of	O
22q11.2	O
deletion	O
syndrome	O
,	O
her	O
rather	O
severe	O
phenotype	O
and	O
atypical	O
face	O
prompted	O
us	O
to	O
search	O
for	O
additional	O
pathogenic	O
mutations	O
.	O

Herein	O
,	O
we	O
report	O
that	O
ZNF687	O
was	O
markedly	O
upregulated	O
in	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
cell	O
lines	O
and	O
HCC	S-Phenotype
tissues	O
,	O
and	O
was	O
significantly	O
correlated	O
with	O
relapse	O
-	O
free	O
survival	O
in	O
HCC	S-Phenotype
.	O

HIV	O
-	O
1	O
transgenic	O
mice	O
on	O
the	O
FVB	O
/	O
NJ	O
background	O
(	O
TgFVB	O
)	O
represent	O
a	O
validated	O
model	O
of	O
HIV	B-Phenotype
-	I-Phenotype
associated	I-Phenotype
nephropathy	E-Phenotype
(	O
HIVAN	S-Phenotype
)	O
.	O

We	O
also	O
found	O
that	O
targeting	O
of	O
ITGA7	O
by	O
RNAi	O
or	O
blocking	O
mAbs	O
impaired	O
laminin	O
-	O
induced	O
signaling	O
,	O
and	O
it	O
led	O
to	O
a	O
significant	O
delay	O
in	O
tumor	S-Phenotype
engraftment	O
plus	O
a	O
strong	O
reduction	O
in	O
tumor	S-Phenotype
size	O
and	O
invasion	O
.	O

The	O
polo	O
family	O
serine	O
threonine	O
kinase	O
Plk4	O
has	O
been	O
proposed	O
as	O
a	O
therapeutic	O
target	O
in	O
advanced	O
cancers	S-Phenotype
based	O
on	O
increased	O
expression	O
in	O
primary	O
human	O
cancers	S-Phenotype
,	O
facilitation	O
of	O
tumor	S-Phenotype
growth	O
in	O
murine	O
xenograft	O
models	O
,	O
and	O
centrosomal	O
amplification	O
induced	O
by	O
its	O
overexpression	O
.	O

This	O
case	O
suggested	O
a	O
broad	O
phenotypic	O
spectrum	O
arises	O
from	O
SZT2	O
mutations	O
,	O
forming	O
a	O
continuum	O
from	O
epileptic	B-Phenotype
encephalopathy	E-Phenotype
and	O
severe	O
developmental	B-Phenotype
delay	E-Phenotype
to	O
mild	O
intellectual	B-Phenotype
disability	E-Phenotype
without	O
epilepsy	S-Phenotype
.	O

The	O
positive	O
expression	O
of	O
SRPX2	O
was	O
prominently	O
correlated	O
with	O
venous	O
infiltration	O
and	O
advanced	O
TNM	O
tumor	S-Phenotype
stage	O
.	O

ETV1	O
/	O
4	O
/	O
5	O
factors	O
are	O
often	O
overexpressed	O
in	O
prostate	B-Phenotype
cancer	E-Phenotype
and	O
genome	O
-	O
wide	O
studies	O
in	O
a	O
prostate	B-Phenotype
cancer	E-Phenotype
cell	O
line	O
indicate	O
that	O
ETV4	O
and	O
MED25	O
occupy	O
enhancers	O
that	O
are	O
enriched	O
for	O
ETS	O
-	O
binding	O
sequences	O
and	O
are	O
both	O
functionally	O
important	O
for	O
the	O
transcription	O
of	O
genes	O
regulated	O
by	O
these	O
enhancers	O
.	O

BACKGROUND	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
prognostic	O
relevance	O
of	O
CEP55	O
in	O
lung	B-Phenotype
cancer	E-Phenotype
(	O
LC	S-Phenotype
)	O
.	O

Mitochondrial	O
3	O
-	O
hydroxy	O
-	O
3	O
-	O
methylglutaryl	O
-	O
CoA	O
lyase	O
(	O
HMGCL	O
)	O
deficiency	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
affecting	O
the	O
leucine	O
catabolic	O
pathway	O
and	O
ketone	O
body	O
synthesis	O
,	O
and	O
is	O
clinically	O
characterized	O
by	O
metabolic	O
crises	O
with	O
hypoketotic	B-Phenotype
hypoglycemia	E-Phenotype
,	O
metabolic	B-Phenotype
acidosis	E-Phenotype
and	O
hyperammonemia	S-Phenotype
.	O

Seventy	O
resected	O
tumours	S-Phenotype
were	O
dissociated	O
into	O
single	O
cells	O
and	O
stained	O
with	O
antibodies	O
to	O
CD44	O
as	O
well	O
as	O
CD45	O
and	O
CD31	O
(	O
together	O
referred	O
as	O
Lineage	O
/	O
Lin	O
)	O
.	O

Congenital	O
myasthenic	O
syndromes	O
(	O
CMS	O
)	O
are	O
a	O
heterogeneous	S-Phenotype
group	O
of	O
genetic	O
disorders	O
.	O

In	O
a	O
patient	O
with	O
Leigh	O
-	O
like	O
syndrome	O
presenting	O
with	O
leukodystrophy	S-Phenotype
and	O
severe	O
epilepsy	S-Phenotype
,	O
we	O
identified	O
a	O
homozygous	O
splice	O
site	O
mutation	O
in	O
COX8A	O
,	O
which	O
codes	O
for	O
the	O
ubiquitously	O
expressed	O
isoform	O
of	O
subunit	O
VIII	O
,	O
the	O
smallest	O
nuclear	O
-	O
encoded	O
subunit	O
of	O
complex	O
IV	O
.	O

Here	O
we	O
describe	O
4	O
families	O
with	O
autosomal	B-Phenotype
recessive	I-Phenotype
inherited	I-Phenotype
macrothrombocytopenia	E-Phenotype
with	O
focal	B-Phenotype
myelofibrosis	E-Phenotype
due	O
to	O
germ	O
line	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
the	O
megakaryocyte	O
-	O
specific	O
immunoreceptor	O
tyrosine	O
-	O
based	O
inhibitory	O
motif	O
(	O
ITIM	O
)	O
-	O
containing	O
receptor	O
G6b	O
-	O
B	O
(	O
G6b	O
,	O
C6orf25	O
,	O
or	O
MPIG6B	O
)	O
.	O

Germline	O
mutations	O
in	O
KCNJ5	O
and	O
CACNA1H	O
cause	O
FH	O
-	O
III	O
and	O
FH	O
-	O
IV	O
,	O
respectively	O
,	O
while	O
germline	O
mutations	O
in	O
CACNA1D	O
cause	O
the	O
rare	O
PASNA	O
syndrome	O
,	O
featuring	O
primary	B-Phenotype
aldosteronism	I-Phenotype
seizures	E-Phenotype
and	O
neurological	B-Phenotype
abnormalities	E-Phenotype
.	O

Lamb	O
-	O
Shaffer	O
syndrome	O
(	O
OMIM	O
:	O
616803	O
)	O
is	O
a	O
neurodevelopmental	O
disorder	O
characterized	O
by	O
developmental	B-Phenotype
delay	E-Phenotype
,	O
mild	B-Phenotype
to	I-Phenotype
moderate	I-Phenotype
intellectual	I-Phenotype
disability	E-Phenotype
,	O
speech	B-Phenotype
delay	E-Phenotype
,	O
and	O
mild	O
characteristic	O
facial	O
appearance	O
caused	O
by	O
SOX5	O
haploinsufficiency	O
on	O
chromosome	O
12p12.1	O
.	O

The	O
'best	O
'	O
combination	O
of	O
tumour	S-Phenotype
markers	O
in	O
our	O
study	O
includes	O
all	O
tested	O
markers	O
with	O
AUC	O
of	O
0.967	O
.	O

This	O
study	O
adds	O
knowledge	O
to	O
the	O
increasingly	O
growing	O
list	O
of	O
causative	O
and	O
candidate	O
genes	O
in	O
ID	S-Phenotype
and	O
epilepsy	S-Phenotype
,	O
and	O
highlights	O
CSNK2B	O
as	O
a	O
new	O
gene	O
for	O
neurodevelopmental	O
disorders	O

Until	O
now	O
,	O
more	O
than	O
90	O
GHR	O
mutations	O
relevant	O
to	O
human	O
short	B-Phenotype
stature	E-Phenotype
(	O
Laron	O
syndrome	O
and	O
idiopathic	O
short	B-Phenotype
stature	E-Phenotype
)	O
,	O
including	O
deletions	O
,	O
missense	O
,	O
nonsense	O
,	O
frameshift	O
,	O
and	O
splice	O
site	O
mutations	O
,	O
and	O
four	O
GHR	O
defects	O
associated	O
with	O
chicken	O
dwarfism	S-Phenotype
,	O
have	O
been	O
described	O
.	O

Mutations	O
in	O
three	O
subunits	O
(	O
DRC1	O
,	O
DRC2	O
/	O
CCDC65	O
,	O
DRC4	O
/	O
GAS8	O
)	O
have	O
been	O
linked	O
to	O
defects	O
in	O
ciliary	O
motility	O
in	O
humans	O
and	O
lead	O
to	O
a	O
ciliopathy	O
known	O
as	O
primary	B-Phenotype
ciliary	I-Phenotype
dyskinesia	E-Phenotype
(	O
PCD	S-Phenotype
)	O
.	O

These	O
immunohistochemical	O
results	O
are	O
consistent	O
with	O
our	O
pHe	O
mapping	O
(	O
Pearson	O
correlation	O
coefficient	O
AAAA	O
0.70	O
)	O
and	O
provide	O
evidence	O
for	O
the	O
feasibility	O
of	O
the	O
CEST	O
-	O
MRI	O
method	O
with	O
the	O
YbHPDO3A	O
probe	O
for	O
glioma	S-Phenotype
pHe	O
quantification	O
at	O
4.7	O
T	O
.	O

We	O
demonstrated	O
that	O
linc	O
-	O
ADAL	O
interacts	O
with	O
heterogeneous	S-Phenotype
nuclear	O
ribonucleoprotein	O
U	O
(	O
hnRNPU	O
)	O
and	O
insulin	O
-	O
like	O
growth	O
factor	O
2	O
mRNA	O
binding	O
protein	O
2	O
(	O
IGF2BP2	O
)	O
at	O
distinct	O
subcellular	O
locations	O
to	O
regulate	O
adipocyte	O
differentiation	O
and	O
lipogenesis	O

Finally	O
,	O
we	O
demonstrate	O
that	O
genetic	O
inactivation	O
of	O
Prss56	O
rescues	O
axial	O
elongation	O
in	O
a	O
mouse	O
model	O
of	O
myopia	S-Phenotype
caused	O
by	O
a	O
null	O
mutation	O
in	O
Egr1	O
.	O

MicroRNA	O
-	O
200a	O
(	O
miR	O
-	O
200a	O
)	O
is	O
frequently	O
downregulated	O
in	O
most	O
cancer	S-Phenotype
types	O
and	O
plays	O
an	O
important	O
role	O
in	O
carcinogenesis	O
and	O
cancer	S-Phenotype
progression	O
.	O

Mutations	O
in	O
the	O
EFHC1	O
gene	O
(	O
unknown	O
function	O
)	O
occur	O
in	O
other	O
rare	O
JME	O
families	O
,	O
and	O
yet	O
in	O
other	O
families	O
,	O
associations	O
are	O
present	O
between	O
JME	O
(	O
or	O
other	O
generalized	O
epilepsies	S-Phenotype
)	O
and	O
single	O
nucleotide	O
polymorphisms	O
in	O
the	O
BRD2	O
gene	O
(	O
unknown	O
function	O
)	O
and	O
the	O
malic	O
enzyme	O
2	O
(	O
ME2	O
)	O
gene	O
.	O

UCA1	O
knockdown	O
significantly	O
inhibited	O
PTC	O
cell	O
viability	O
,	O
colony	O
formation	O
and	O
the	O
bromodomain	O
containing	O
4	O
(	O
BRD4	O
)	O
expression	O
level	O
in	O
vitro	O
,	O
and	O
retarded	O
PTC	O
tumor	S-Phenotype
growth	O
in	O
vivo	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
COX15	O
mutations	O
are	O
associated	O
with	O
typical	O
LS	O
as	O
well	O
as	O
fatal	B-Phenotype
infantile	I-Phenotype
hypertrophic	I-Phenotype
cardiomyopathy	E-Phenotype
.	O

Further	O
haplotype	O
and	O
imputation	O
analyses	O
also	O
validated	O
these	O
results	O
,	O
and	O
bioinformatics	O
analyses	O
indicated	O
that	O
CALHM1	O
,	O
which	O
is	O
located	O
approximately	O
630kb	O
away	O
from	O
CNNM2	O
,	O
might	O
be	O
a	O
susceptible	O
gene	O
for	O
schizophrenia	S-Phenotype
.	O

Approximately	O
one	O
-	O
third	O
of	O
pediatric	O
malignant	O
rhabdoid	O
tumors	S-Phenotype
are	O
linked	O
to	O
germline	O
SWI	O
/	O
SNF	O
alterations	O
(	O
SMARCB1	O
/	O
INI1	O
,	O
rarely	O
SMARCA4	O
)	O
resulting	O
in	O
occasional	O
familial	O
clustering	O
of	O
these	O
highly	O
aggressive	O
malignancies	O
(	O
so	O
-	O
called	O
rhabdoid	O
tumor	S-Phenotype
predisposition	O
syndrome	O
,	O
RTPS	O
,	O
types	O
1	O
and	O
2	O
,	O
respectively	O
)	O
.	O

Biallelic	O
mutations	O
in	O
the	O
YARS2	O
gene	O
encoding	O
mitochondrial	O
tyrosyl	O
-	O
tRNA	O
synthetase	O
cause	O
myopathy	S-Phenotype
,	O
lactic	B-Phenotype
acidosis	E-Phenotype
,	O
and	O
sideroblastic	B-Phenotype
anemia	I-Phenotype
2	E-Phenotype
(	O
MLASA2	S-Phenotype
)	O
,	O
a	O
type	O
of	O
mitochondrial	O
disease	O
.	O

Study	O
of	O
RetGC1	O
regulation	O
in	O
vitro	O
and	O
its	O
association	O
with	O
fluorescently	O
tagged	O
GCAP	O
in	O
transfected	O
cells	O
showed	O
that	O
R822P	O
substitution	O
in	O
the	O
cyclase	O
dimerization	O
domain	O
causing	O
congenital	B-Phenotype
early	I-Phenotype
onset	I-Phenotype
blindness	E-Phenotype
disrupted	O
RetGC1	O
ability	O
to	O
bind	O
GCAP	O
but	O
did	O
not	O
eliminate	O
its	O
affinity	O
for	O
another	O
photoreceptor	O
-	O
specific	O
protein	O
,	O
retinal	B-Phenotype
degeneration	I-Phenotype
3	E-Phenotype
(	O
RD3	S-Phenotype
)	O
.	O

Cellular	O
studies	O
showed	O
that	O
Rab3IP	O
could	O
induce	O
an	O
aggressive	O
phenotype	O
in	O
gastric	B-Phenotype
cancer	E-Phenotype
cells	O
and	O
that	O
its	O
expression	O
was	O
correlated	O
with	O
markers	O
of	O
the	O
epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
.	O

Pain	S-Phenotype
was	O
significantly	O
higher	O
in	O
LZTR1	O
-	O
mutant	O
than	O
in	O
SMARCB1	O
-	O
mutant	O
patients	O
,	O
though	O
spinal	B-Phenotype
tumor	E-Phenotype
location	O
did	O
not	O
significantly	O
correlate	O
with	O
pain	S-Phenotype
.	O

Given	O
that	O
patients	O
with	O
KID	O
syndrome	O
are	O
at	O
high	O
risk	O
of	O
developing	O
squamous	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
,	O
biopsies	O
were	O
performed	O
.	O

The	O
PCH1sub	O
-	O
types	O
with	O
early	O
death	O
(	O
between	O
ages	O
1	O
day	O
and	O
17	O
months	O
)	O
,	O
seen	O
in	O
patients	O
with	O
p.G31A	O
/	O
EXOSC3	O
or	O
SLC25A46	O
mutations	O
have	O
a	O
SMA	O
type	O
1	O
-	O
like	O
clinical	O
presentation	O
but	O
with	O
global	B-Phenotype
developmental	I-Phenotype
delay	E-Phenotype
,	O
visual	B-Phenotype
and	I-Phenotype
hearing	I-Phenotype
impairment	E-Phenotype
,	O
with	O
or	O
without	O
microcephaly	S-Phenotype
,	O
nystagmus	S-Phenotype
and	O
optic	B-Phenotype
atrophy	E-Phenotype
.	O

Disruption	O
of	O
PHF21A	O
has	O
previously	O
been	O
implicated	O
in	O
the	O
causation	O
of	O
intellectual	B-Phenotype
disability	E-Phenotype
(	O
but	O
not	O
aniridia	S-Phenotype
)	O
.	O

Mining	O
GWAS	O
databases	O
revealed	O
association	O
of	O
cis	O
-	O
eSNPs	O
for	O
more	O
than	O
50	O
genes	O
with	O
T2D	O
(	O
e.g	O
.	O

A	O
majority	O
of	O
the	O
familial	B-Phenotype
breast	I-Phenotype
cancer	E-Phenotype
cases	O
are	O
not	O
explained	O
by	O
mutations	O
in	O
the	O
best	O
-	O
known	O
high	O
susceptibility	O
genes	O
BRCA1	O
and	O
BRCA2	O
.	O

Ectodermal	B-Phenotype
dysplasia	I-Phenotype
-	I-Phenotype
9	E-Phenotype
(	O
ED	B-Phenotype
-	I-Phenotype
9	E-Phenotype
)	O
is	O
a	O
congenital	O
condition	O
characterized	O
by	O
hypotrichosis	S-Phenotype
and	O
nail	B-Phenotype
dystrophy	E-Phenotype
without	O
other	O
disorders	O
,	O
and	O
Hoxc13	O
is	O
a	O
pathogenic	O
gene	O
for	O
ED	O
-	O
9	O
.	O

We	O
identified	O
the	O
first	O
de	O
novo	O
variant	O
in	O
KCNMA1	O
(	O
c.2984	O
A	O
AAAA	O
G	O
(	O
p.	O
(	O
N995S	O
)	O
)	O
)	O
-	O
encoding	O
the	O
BK	O
channel	O
-	O
that	O
causes	O
epilepsy	S-Phenotype
,	O
but	O
not	O
paroxysmal	B-Phenotype
dyskinesia	E-Phenotype
,	O
in	O
two	O
independent	O
families	O
.	O

Horstick	O
et	O
al	O
.	O

Al	O
-	O
Awadi	O
-	O
Raas	O
-	O
Rothschild	O
syndrome	O
(	O
AARRS	O
;	O
OMIM	O
276820	O
)	O
is	O
a	O
very	O
rare	O
autosomal	B-Phenotype
recessive	E-Phenotype
limb	O
malformation	O
syndrome	O
caused	O
by	O
WNT7A	O
mutations	O
.	O

RESULTS	O
Gli	O
-	O
1	O
was	O
associated	O
with	O
patient	O
age	O
,	O
gender	O
,	O
lymphatic	O
metastasis	O
,	O
tumor	S-Phenotype
recurrence	O
,	O
and	O
stage	O
,	O
with	O
significantly	O
(	O
PAAAA0.05	O
)	O
positive	O
correlations	O
with	O
age	O
,	O
lymphatic	O
metastasis	O
,	O
tumor	S-Phenotype
recurrence	O
,	O
and	O
stage	O
.	O

We	O
investigated	O
the	O
possible	O
association	O
between	O
chemoresistance	O
and	O
cellular	O
redox	O
state	O
regulation	O
in	O
patients	O
undergoing	O
neoadjuvant	O
chemotherapy	O
(	O
NACT	O
)	O
for	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

We	O
describe	O
a	O
child	O
with	O
PCD	O
who	O
presented	O
at	O
term	O
with	O
severe	O
neonatal	B-Phenotype
respiratory	I-Phenotype
distress	E-Phenotype
,	O
persistent	O
right	O
upper	O
lobe	O
collapse	O
and	O
failure	B-Phenotype
to	I-Phenotype
thrive	E-Phenotype
who	O
underwent	O
lobectomy	O
prior	O
to	O
the	O
diagnosis	O
of	O
PCD	O
at	O
the	O
age	O
of	O
3	O
years	O
.	O

Misregulation	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
A	O
(	O
VEGF‑A	O
)	O
has	O
been	O
implicated	O
in	O
numerous	O
types	O
of	O
ovarian	B-Phenotype
disease	E-Phenotype
,	O
such	O
as	O
polycystic	B-Phenotype
ovarian	I-Phenotype
syndrome	E-Phenotype
,	O
ovarian	B-Phenotype
hyperstimulation	I-Phenotype
syndrome	E-Phenotype
,	O
endometriosis	S-Phenotype
and	O
ovarian	B-Phenotype
cancer	E-Phenotype
.	O

Chromosome	O
conformation	O
capture	O
analysis	O
showed	O
that	O
iCHAV2	O
interacts	O
with	O
the	O
ZNF365	O
and	O
NRBF2	O
(	O
more	O
than	O
600	O
kb	O
away	O
)	O
promoters	O
in	O
normal	O
and	O
cancerous	S-Phenotype
breast	O
epithelial	O
cells	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
sought	O
to	O
identify	O
the	O
factors	O
involved	O
in	O
the	O
RARAAAAAalpha	O
;	O
-	O
mediated	O
transcriptional	O
regulation	O
of	O
the	O
tumor	S-Phenotype
suppressor	O
gene	O
and	O
the	O
tissue	O
factor	O
pathway	O
inhibitor	O
2	O
(	O
TFPI2	O
)	O
in	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
.	O

Overexpression	O
of	O
LARP7	O
inhibited	O
the	O
proliferation	O
and	O
increased	O
the	O
radioiodine	O
uptake	O
ability	O
of	O
PTC	O
cells	O
in	O
vitro	O
and	O
inhibited	O
the	O
tumor	S-Phenotype
growth	O
in	O
vivo	O
.	O

Recent	O
research	O
published	O
in	O
the	O
Journal	O
of	O
Pathology	O
showed	O
that	O
genetic	O
depletion	O
of	O
any	O
of	O
the	O
NOX2	O
subunits	O
Cyba	O
,	O
Cybb	O
,	O
Ncf1	O
,	O
Ncf2	O
and	O
Ncf4	O
reduced	O
the	O
formation	O
of	O
lung	O
metastases	O
following	O
intravenous	O
injection	O
of	O
murine	O
tumor	S-Phenotype
cells	O
.	O

However	O
,	O
the	O
global	O
effects	O
of	O
DIO1	O
expression	O
in	O
various	O
tissues	O
affected	O
by	O
cancer	S-Phenotype
remain	O
unknown	O
.	O

Recent	O
clinical	O
,	O
morphological	O
and	O
molecular	O
investigations	O
of	O
CMT	O
families	O
with	O
autosomal	B-Phenotype
recessive	I-Phenotype
inheritance	E-Phenotype
allowed	O
the	O
identification	O
of	O
many	O
genes	O
such	O
as	O
GDAP1	O
,	O
MTMR2	O
,	O
SBF2	O
,	O
NDRG1	O
,	O
EGR2	O
,	O
SH3TC2	O
,	O
PRX	O
,	O
FGD4	O
,	O
and	O
FIG4	O
,	O
implicated	O
in	O
demyelinating	O
forms	O
(	O
ARCMT1	O
or	O
CMT4	O
)	O
,	O
and	O
LMNA	O
,	O
MED25	O
,	O
HINT1	O
,	O
GDAP1	O
,	O
LRSAM1	O
,	O
NEFL	O
,	O
HSPB1	O
and	O
MFN2	O
in	O
axonal	O
forms	O
(	O
ARCMT2	O
)	O
.	O

However	O
,	O
THAP1	O
downstream	O
targets	O
in	O
neurons	O
,	O
and	O
the	O
mechanism	O
via	O
which	O
it	O
causes	O
dystonia	S-Phenotype
are	O
largely	O
unknown	O
.	O

Dominantly	O
inherited	O
digitotalar	O
dysmorphism	O
(	O
DTD	O
)	O
,	O
which	O
is	O
characterised	O
by	O
flexion	B-Phenotype
contractures	E-Phenotype
of	O
digits	O
and	O
'rocker	O
-	O
bottom	O
'	O
feet	O
due	O
to	O
a	O
vertical	B-Phenotype
talus	E-Phenotype
,	O
was	O
first	O
described	O
in	O
a	O
South	O
African	O
family	O
of	O
European	O
stock	O
in	O
1972	O
.	O

However	O
,	O
the	O
precise	O
roles	O
and	O
mechanisms	O
of	O
NEK2	O
in	O
liver	B-Phenotype
cancer	E-Phenotype
progression	O
remain	O
largely	O
unknown	O
.	O

Several	O
advances	O
have	O
been	O
made	O
in	O
the	O
treatment	O
of	O
HER2	O
-	O
positive	O
breast	B-Phenotype
cancer	E-Phenotype
,	O
yet	O
issues	O
of	O
resistance	O
and	O
poor	O
response	O
to	O
therapy	O
remains	O
prevalent	O
.	O

Functional	O
loss	O
of	O
expression	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
susceptibility	O
gene	O
1	O
(	O
BRCA1	O
)	O
has	O
been	O
implicated	O
in	O
genomic	O
instability	O
and	O
cancer	S-Phenotype
progression	O
.	O

However	O
,	O
the	O
inherent	O
susceptibility	O
of	O
these	O
tissues	O
to	O
SCO1	O
mutations	O
and	O
the	O
clinical	O
heterogeneity	S-Phenotype
observed	O
across	O
SCO1	O
pedigrees	O
remain	O
poorly	O
understood	O
phenomena	O
.	O

In	O
addition	O
,	O
there	O
were	O
hyperkeratotic	B-Phenotype
papules	E-Phenotype
,	O
alternating	O
red	O
and	O
white	O
nail	O
-	O
bed	O
discolouration	O
,	O
and	O
V	O
-	O
shaped	O
nail	O
notching	O
consistent	O
with	O
Darier	O
disease	O
(	O
DD	O
)	O
.	O

We	O
examined	O
184	O
lung	B-Phenotype
adenocarcinomas	E-Phenotype
and	O
observed	O
low	O
expression	O
of	O
NDRG1	O
in	O
adenocarcinoma	O
in	O
situ	O
(	O
AIS	O
)	O
and	O
minimally	O
invasive	O
adenocarcinoma	O
(	O
MIA	O
)	O
,	O
whereas	O
high	O
expression	O
of	O
NDRG1	O
was	O
seen	O
in	O
invasive	O
adenocarcinoma	O
.	O

Here	O
we	O
report	O
six	O
affected	O
individuals	O
from	O
four	O
families	O
with	O
intellectual	B-Phenotype
disability	E-Phenotype
(	O
ID	S-Phenotype
)	O
and	O
neurological	O
and	O
other	O
congenital	O
abnormalities	O
associated	O
with	O
compound	O
heterozygous	O
variants	O
in	O
TELO2	O
.	O

As	O
it	O
is	O
currently	O
unclear	O
whether	O
localized	O
production	O
of	O
either	O
Hsub2	O
/	O
subS	O
or	O
GSH	O
contributes	O
to	O
retinal	O
homeostasis	O
,	O
we	O
undertook	O
a	O
comparative	O
analysis	O
of	O
CBS	O
and	O
CSE	O
expression	O
in	O
canine	O
,	O
non	O
-	O
human	O
primate	O
(	O
NHP	O
)	O
and	O
human	O
retinas	O
to	O
determine	O
if	O
these	O
antioxidants	O
could	O
play	O
a	O
regulatory	O
role	O
in	O
age	O
-	O
related	O
or	O
disease	O
-	O
associated	O
retinal	B-Phenotype
degeneration	E-Phenotype
.	O

Here	O
we	O
show	O
that	O
CCN6	O
(	O
WISP3	O
)	O
,	O
a	O
secreted	O
matricellular	O
protein	O
of	O
the	O
CCN	O
(	O
CYR61	O
/	O
CTGF	O
/	O
NOV	O
)	O
family	O
,	O
is	O
significantly	O
downregulated	O
in	O
clinical	O
samples	O
of	O
human	O
spindle	B-Phenotype
cell	I-Phenotype
metaplastic	I-Phenotype
breast	I-Phenotype
carcinoma	E-Phenotype
.	O

By	O
trio	O
exome	O
sequencing	O
we	O
now	O
identified	O
a	O
novel	O
,	O
homozygous	O
2kb	O
deletion	O
,	O
partially	O
affecting	O
exon	O
12	O
in	O
an	O
adult	O
female	O
with	O
the	O
typical	O
facial	O
gestalt	O
of	O
3MC	O
syndrome	O
and	O
hearing	B-Phenotype
loss	E-Phenotype
,	O
but	O
without	O
the	O
main	O
feature	O
cleft	B-Phenotype
lip	I-Phenotype
/	I-Phenotype
palate	E-Phenotype
,	O
and	O
without	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
or	O
short	B-Phenotype
stature	E-Phenotype
.	O

Episodic	B-Phenotype
ataxia	I-Phenotype
type	I-Phenotype
2	E-Phenotype
(	O
EA2	S-Phenotype
)	O
is	O
an	O
autosomal	O
dominant	O
disorder	O
associated	O
with	O
attacks	O
of	O
ataxia	S-Phenotype
that	O
are	O
typically	O
precipitated	O
by	O
stress	O
,	O
ethanol	O
,	O
caffeine	O
or	O
exercise	O
.	O

Top	O
10	O
genes	O
in	O
the	O
brown	O
module	O
,	O
including	O
EGF	O
containing	O
fibulin	O
like	O
extracellular	O
matrix	O
protein	O
2	O
(	O
EFEMP2	O
)	O
,	O
fibrillin	O
1	O
(	O
FBN1	O
)	O
and	O
secreted	O
protein	O
acidic	O
and	O
cysteine	O
rich	O
(	O
SPARC	O
)	O
were	O
also	O
associated	O
with	O
survival	O
time	O
of	O
colon	B-Phenotype
cancer	E-Phenotype
patients	O
.	O

In	O
addition	O
,	O
TNFSF15	O
/	O
DR3	O
signaling	O
pathways	O
in	O
A549	O
cells	O
include	O
activation	O
of	O
NF	O
-	O
kB	O
during	O
tumor	S-Phenotype
lymphangiogenesis	O
.	O

We	O
summarize	O
recent	O
updates	O
on	O
the	O
genes	O
and	O
related	O
clinical	O
syndromes	O
involved	O
in	O
the	O
pathogenesis	O
of	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
epileptic	I-Phenotype
encephalopathies	E-Phenotype
:	O
Aristaless	O
-	O
related	O
homeobox	O
(	O
ARX	O
)	O
,	O
cyclin	O
-	O
dependent	O
kinase	O
-	O
like	O
5	O
(	O
CDKL5	O
)	O
,	O
syntaxin	O
-	O
binding	O
protein	O
1	O
(	O
STXBP1	O
)	O
,	O
solute	O
carrier	O
family	O
25	O
member	O
22	O
(	O
SLC25A22	O
)	O
,	O
nonerythrocytic	O
α	O
-	O
spectrin	O
-	O
1	O
(	O
SPTAN1	O
)	O
,	O
phospholipase	O
Cβ1	O
(	O
PLCβ1	O
)	O
,	O
membrane	O
-	O
associated	O
guanylate	O
kinase	O
inverted	O
-	O
2	O
(	O
MAGI2	O
)	O
,	O
polynucleotide	O
kinase	O
3	O
'	O
-	O
phosphatase	O
(	O
PNKP	O
)	O
,	O
sodium	O
channel	O
neuronal	O
type	O
1α	O
subunit	O
(	O
SCN1A	O
)	O
,	O
protocadherin	O
19	O
(	O
PCDH19	O
)	O
,	O
and	O
pyridoxamine	O
5	O
-	O
prime	O
-	O
phosphate	O
oxidase	O
(	O
PNPO	O
)	O

Single	O
-	O
gene	O
variant	O
analysis	O
showed	O
significant	O
associations	O
of	O
the	O
TT	O
genotype	O
of	O
CYP1A1	O
and	O
the	O
rare	O
GG	O
genotype	O
of	O
ERCC2	O
with	O
bladder	B-Phenotype
cancer	E-Phenotype
susceptibility	O
(	O
OR	O
=	O
1.34	O
,	O
95	O
%	O
CI	O
1.22	O
-	O
1.40	O
,	O
P	O
AAAA	O
0.0001	O
)	O
.	O

INPP5E	O
mRNA	O
and	O
copy	O
number	O
were	O
reduced	O
in	O
human	O
SHH	O
medulloblastoma	S-Phenotype
compared	O
to	O
other	O
molecular	O
subtypes	O
and	O
consistent	O
with	O
the	O
murine	O
model	O
,	O
reduced	O
INPP5E	O
was	O
associated	O
with	O
improved	O
overall	O
survival	O
.	O

Mutations	O
,	O
A147T	O
and	O
A165V	O
,	O
within	O
the	O
ZM	O
of	O
ZASP	O
-	O
LDex10	O
cause	O
myofibrillar	B-Phenotype
myopathy	E-Phenotype
,	O
but	O
the	O
mechanism	O
is	O
unknown	O
.	O

We	O
present	O
a	O
family	O
in	O
which	O
we	O
found	O
both	O
germline	O
and	O
somatic	B-Phenotype
mosaicism	E-Phenotype
for	O
MEN1	O
.	O

Lethality	O
was	O
observed	O
in	O
both	O
models	O
due	O
to	O
a	O
combined	O
COX	O
and	O
copper	B-Phenotype
deficiency	E-Phenotype
that	O
resulted	O
in	O
a	O
dilated	B-Phenotype
cardiomyopathy	E-Phenotype
.	O

These	O
findings	O
reveal	O
that	O
RTTN	O
contributes	O
to	O
building	O
full	O
-	O
length	O
centrioles	O
and	O
illuminate	O
the	O
molecular	O
mechanism	O
through	O
which	O
the	O
RTTN	O
(	O
A578P	O
)	O
mutation	O
causes	O
primary	O
microcephaly	S-Phenotype
.	O

Mutations	O
in	O
many	O
centriolar	O
protein	O
-	O
encoding	O
genes	O
cause	O
primary	B-Phenotype
microcephaly	E-Phenotype
.	O

Unlike	O
patients	O
with	O
ECTD	O
-	O
9	O
,	O
Hoxc13	O
-	O
mutated	O
mice	O
and	O
pigs	O
do	O
not	O
faithfully	O
recapitulate	O
the	O
phenotype	O
of	O
hypotrichosis	S-Phenotype
,	O
so	O
there	O
is	O
a	O
limited	O
understanding	O
of	O
the	O
molecular	O
mechanism	O
of	O
Hoxc13	O
-	O
mediated	O
hypotrichosis	S-Phenotype
in	O
animal	O
models	O
and	O
clinically	O
.	O

Zinc	O
finger	O
protein	O
687	O
(	O
ZNF687	O
)	O
,	O
identified	O
as	O
a	O
C2H2	O
zinc	O
finger	O
protein	O
,	O
has	O
been	O
found	O
to	O
be	O
mutated	O
and	O
upregulated	O
in	O
giant	B-Phenotype
cell	I-Phenotype
tumor	I-Phenotype
of	I-Phenotype
bone	E-Phenotype
and	O
acute	B-Phenotype
myeloid	I-Phenotype
leukemia	E-Phenotype
,	O
suggesting	O
an	O
oncogenic	O
role	O
for	O
ZNF687	O
in	O
cancer	S-Phenotype
.	O

Transcription	O
factors	O
(	O
TFs	O
)	O
are	O
major	O
cell	O
fate	O
regulators	O
frequently	O
involved	O
in	O
cancer	S-Phenotype
,	O
particularly	O
in	O
leukemia	S-Phenotype
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
identified	O
as	O
key	O
regulators	O
in	O
cancer	S-Phenotype
initiation	O
,	O
progression	O
and	O
metastasis	O
including	O
gastric	B-Phenotype
cancer	E-Phenotype
(	O
GC	S-Phenotype
)	O
.	O

However	O
,	O
the	O
role	O
of	O
FUZ	O
in	O
tumor	S-Phenotype
biology	O
remains	O
poorly	O
studied	O
.	O

These	O
observations	O
indicate	O
that	O
LO	O
represent	O
a	O
discrete	O
EV	O
type	O
that	O
may	O
play	O
a	O
distinct	O
role	O
in	O
tumor	S-Phenotype
progression	O
and	O
that	O
may	O
be	O
a	O
source	O
of	O
cancer	S-Phenotype
-	O
specific	O
markers	O

Using	O
whole	O
-	O
exome	O
sequencing	O
,	O
we	O
identified	O
compound	O
heterozygous	O
RMND1	O
variants	O
in	O
a	O
4	O
-	O
year	O
-	O
old	O
patient	O
with	O
congenital	B-Phenotype
lactic	I-Phenotype
acidosis	E-Phenotype
,	O
severe	O
myopathy	S-Phenotype
,	O
hearing	B-Phenotype
loss	E-Phenotype
,	O
renal	B-Phenotype
failure	E-Phenotype
,	O
and	O
dysautonomia	S-Phenotype
.	O

Diabetes	S-Phenotype
is	O
a	O
metabolic	O
disorder	O
characterized	O
by	O
hyperglycemia	S-Phenotype
and	O
associated	O
with	O
microvascular	O
and	O
macrovascular	O
syndromes	O
mediated	O
by	O
mast	O
cells	O
.	O

To	O
elucidate	O
the	O
underlying	O
molecular	O
mechanisms	O
of	O
tamoxifen	O
resistance	O
,	O
we	O
performed	O
a	O
systematic	O
analysis	O
of	O
miRNA	O
-	O
mediated	O
gene	O
regulation	O
in	O
three	O
clinically	O
-	O
relevant	O
tamoxifen	O
-	O
resistant	O
breast	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
(	O
TamRs	O
)	O
compared	O
to	O
their	O
parental	O
tamoxifen	O
-	O
sensitive	O
cell	O
line	O
.	O

We	O
analyzed	O
commonly	O
reported	O
European	O
and	O
Asian	O
obesity	S-Phenotype
-	O
related	O
gene	O
variants	O
in	O
a	O
Mexican	O
-	O
Mestizo	O
population	O
through	O
each	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
and	O
a	O
genetic	O
risk	O
score	O
(	O
GRS	O
)	O
based	O
on	O
23	O
selected	O
SNPs	O
.	O

We	O
identified	O
integrin	O
α7	O
(	O
ITGA7	O
)	O
as	O
a	O
major	O
laminin	O
receptor	O
in	O
GSCs	O
and	O
in	O
primary	O
high	O
-	O
grade	O
glioma	S-Phenotype
specimens	O
.	O

These	O
findings	O
suggested	O
that	O
HtrA3	O
is	O
an	O
important	O
adaptor	O
in	O
hypoxic	O
regions	O
that	O
drives	O
endometrial	B-Phenotype
cancer	E-Phenotype
development	O

Conversely	O
,	O
Tsc1	O
loss	O
led	O
to	O
the	O
early	O
-	O
onset	O
death	O
of	O
cochlear	O
hair	O
cells	O
and	O
consequently	O
accelerated	O
hearing	B-Phenotype
loss	E-Phenotype
.	O

Tumor	S-Phenotype
proliferation	O
promoted	O
by	O
the	O
regulation	O
of	O
miRNA	O
expression	O
can	O
be	O
regulated	O
in	O
thyroid	B-Phenotype
cancer	E-Phenotype
by	O
upregulating	O
transforming	O
growth	O
factor	O
-	O
β1	O
(	O
TGF	O
-	O
β1	O
)	O
,	O
which	O
is	O
thought	O
to	O
interact	O
with	O
Pard3	O
.	O

Dysfunction	O
of	O
SNORD115	O
-	O
PBRM1	O
connecting	O
with	O
SMARCA2	O
as	O
well	O
as	O
other	O
proven	O
schizophrenia	S-Phenotype
-	O
associated	O
genes	O
might	O
explain	O
why	O
traditionally	O
catatonia	O
has	O
been	O
classified	O
with	O
schizophrenia	S-Phenotype
.	O

Functional	O
enrichment	O
analysis	O
indicated	O
high	O
bone	O
morphogenetic	O
protein	O
(	O
BMP	O
)	O
signaling	O
in	O
metastases	O
with	O
high	O
bone	O
cell	O
activity	O
and	O
low	O
tumor	S-Phenotype
cell	O
AR	O
activity	O
.	O

To	O
investigate	O
the	O
role	O
of	O
MEGF10	O
variants	O
with	O
putative	O
transcription	O
regulatory	O
function	O
in	O
the	O
etiology	O
of	O
autism	S-Phenotype
,	O
we	O
performed	O
a	O
family	O
-	O
based	O
association	O
study	O
in	O
410	O
Chinese	O
Han	O
trios	O
.	O

HS	O
expression	O
was	O
demonstrated	O
in	O
50	O
-	O
55	O
%	O
of	O
the	O
GBM	O
tumours	S-Phenotype
by	O
immunohistochemistry	O
(	O
IHC	O
)	O
,	O
while	O
almost	O
no	O
HS	O
content	O
was	O
detected	O
in	O
the	O
surrounding	O
paratumourous	O
brain	O
tissues	O
.	O

Mutations	O
in	O
the	O
gene	O
encoding	O
the	O
single	O
transmembrane	O
receptor	O
multiple	O
epidermal	O
growth	O
factor	O
-	O
like	O
domain	O
10	O
(	O
MEGF10	O
)	O
cause	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
congenital	O
muscle	O
disease	O
in	O
humans	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
whether	O
SASS6	O
expression	O
is	O
abnormally	O
regulated	O
in	O
colorectal	B-Phenotype
cancers	E-Phenotype
(	O
CRCs	S-Phenotype
)	O
.	O

In	O
addition	O
to	O
the	O
POU3F4	O
gene	O
,	O
which	O
was	O
the	O
first	O
gene	O
identified	O
as	O
causing	O
nonsyndromic	B-Phenotype
X	I-Phenotype
-	I-Phenotype
linked	I-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
,	O
a	O
second	O
gene	O
,	O
PRPS1	O
,	O
has	O
recently	O
been	O
identified	O
to	O
be	O
the	O
causative	O
gene	O
of	O
DFNX1	O
(	O
DFN2	O
)	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
use	O
of	O
iterative	O
decomposition	O
of	O
water	O
and	O
fat	O
with	O
echo	O
asymmetry	O
and	O
least	O
-	O
squares	O
estimation	O
Carr	O
-	O
Purcell	O
-	O
Meiboom	O
-	O
Gill	O
(	O
IDEAL	O
-	O
CPMG	O
)	O
to	O
simultaneously	O
measure	O
skeletal	O
muscle	O
apparent	O
fat	O
fraction	O
and	O
water	O
Tsub2	O
/	O
sub	O
(	O
Tsub2	O
,	O
w	O
/	O
sub	O
)	O
in	O
patients	O
with	O
Duchenne	B-Phenotype
muscular	I-Phenotype
dystrophy	E-Phenotype
(	O
DMD	S-Phenotype
)	O
.	O

Although	O
p53R2	O
has	O
been	O
linked	O
to	O
human	O
cancer	S-Phenotype
,	O
its	O
role	O
in	O
cervical	B-Phenotype
cancer	E-Phenotype
remains	O
unknown	O
.	O

Moreover	O
,	O
results	O
from	O
our	O
real	O
-	O
time	O
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
qPCR	O
)	O
using	O
72	O
normal	O
liver	O
tissues	O
adjacent	O
to	O
the	O
tumors	S-Phenotype
showed	O
that	O
SERPINA6	O
expression	O
was	O
significantly	O
different	O
among	O
different	O
genotypes	O
of	O
this	O
variant	O
(	O
GG	O
versus	O
CC	O
:	O
P	O
=	O
0.032	O
;	O
Group	O
test	O
:	O
P	O
=	O
0.060	O
)	O
.	O

Mice	O
with	O
a	O
neuronal	O
deletion	O
of	O
Arv1	O
recapitulated	O
the	O
human	O
phenotype	O
,	O
exhibiting	O
seizures	S-Phenotype
and	O
a	O
severe	O
survival	O
defect	O
in	O
adulthood	O
.	O

MTORC1	O
/	O
2	O
inhibition	O
shows	O
antitumor	O
activity	S-Phenotype
in	O
cell	O
culture	O
models	O
of	O
DIPG	O
due	O
to	O
the	O
effect	O
of	O
MTORC2	O
inhibition	O
on	O
AKT	O
.	O

In	O
neonatal	B-Phenotype
seizures	E-Phenotype
,	O
defects	O
in	O
ALDH7A1	O
and	O
PNPO	O
explain	O
a	O
major	O
fraction	O
of	O
cases	O
.	O

While	O
a	O
distinct	O
set	O
of	O
processes	O
drive	O
metastasis	O
when	O
compared	O
to	O
tumorigenesis	S-Phenotype
,	O
it	O
is	O
yet	O
unclear	O
if	O
genetic	O
alterations	O
in	O
metabolic	O
pathways	O
are	O
associated	O
with	O
metastatic	O
progression	O
of	O
human	O
cancers	S-Phenotype
.	O

The	O
variants	O
GJB2	O
c.235delC	O
,	O
SLC26A4	O
c.919	O
-	O
2AAAAAG	O
,	O
and	O
mitochondrial	S-Phenotype
variants	O
m.1555AAAAAG	O
and	O
m.1494CAAAAT	O
were	O
assayed	O
using	O
real	O
time	O
PCR	O
.	O

Codeletion	O
of	O
Adrb2	O
and	O
Cox10	O
,	O
a	O
gene	O
encoding	O
a	O
cytochrome	O
IV	O
oxidase	O
assembly	O
factor	O
,	O
prevented	O
the	O
metabolic	O
shift	O
induced	O
by	O
Adrb2	O
deletion	O
and	O
rescued	O
prostate	B-Phenotype
cancer	E-Phenotype
progression	O
.	O

Fourteen	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
three	O
genes	O
were	O
genotyped	O
by	O
the	O
TaqMan	O
method	O
using	O
the	O
real	O
-	O
time	O
PCR	O
system.ResultsThree	O
SNPs	O
GRM6	O
-	O
rs11746675	O
,	O
GRM6	O
-	O
rs2067011	O
,	O
and	O
GRM6	O
-	O
rs2645339	O
were	O
associated	O
with	O
high	B-Phenotype
myopia	E-Phenotype
(	O
odds	O
ratio	O
(	O
OR	O
)	O
=0.74	O
,	O
P=0.003	O
;	O
OR=0.78	O
,	O
P=0.018	O
;	O
and	O
OR=0.78	O
,	O
P=0.023	O
;	O
respectively	O
)	O
.	O

siRNA	O
-	O
mediated	O
suppression	O
of	O
UBE2T	O
inhibited	O
gastric	B-Phenotype
cancer	E-Phenotype
cell	O
proliferation	O
and	O
colony	O
formation	O
by	O
promoting	O
cell	O
cycle	O
arrest	O
at	O
G2	O
/	O
M	O
phase	O
and	O
increasing	O
apoptosis	O
.	O

The	O
18	O
new	O
diagnoses	O
made	O
with	O
WGS	O
included	O
structural	O
and	O
non	O
-	O
exonic	O
sequence	O
variants	O
not	O
detectable	O
with	O
whole	O
-	O
exome	O
sequencing	O
,	O
and	O
confirmed	O
recent	O
disease	O
associations	O
with	O
the	O
genes	O
PIGG	O
,	O
RNU4ATAC	O
,	O
TRIO	O
,	O
and	O
UNC13A.ConclusionWGS	O
as	O
a	O
primary	O
clinical	O
test	O
provided	O
a	O
higher	O
diagnostic	O
yield	O
than	O
conventional	O
genetic	O
testing	O
in	O
a	O
clinically	O
heterogeneous	S-Phenotype
cohort	O

Finally	O
,	O
in	O
diffuse	O
-	O
type	O
gastric	B-Phenotype
cancer	E-Phenotype
,	O
CDH1	O
mutation	O
was	O
found	O
to	O
be	O
associated	O
with	O
shortened	O
patient	O
survival	O
,	O
independently	O
of	O
disease	O
staging	O
.	O

As	O
expected	O
,	O
we	O
found	O
that	O
PIK3CA	O
mutant	O
cancer	S-Phenotype
cells	O
require	O
PIK3CA	O
but	O
also	O
require	O
the	O
expression	O
of	O
the	O
TCA	O
cycle	O
enzyme	O
2	O
-	O
oxoglutarate	O
dehydrogenase	O
(	O
OGDH	O
)	O
.	O

In	O
order	O
to	O
determine	O
the	O
role	O
of	O
Flii	O
during	O
carcinogenesis	O
,	O
squamous	B-Phenotype
cell	I-Phenotype
carcinomas	E-Phenotype
(	O
SCCs	O
)	O
were	O
induced	O
in	O
Flii	O
heterozygous	O
(	O
Flii+	O
/	O
-	O
)	O
,	O
wild	O
-	O
type	O
and	O
Flii	O
overexpressing	O
(	O
FliiTg	O
/	O
Tg	O
)	O
mice	O
by	O
intradermal	O
injection	O
of	O
3	O
-	O
methylcholanthrene	O
(	O
MCA	O
)	O
.	O

We	O
suggest	O
that	O
the	O
combination	O
of	O
reduced	O
NM23	O
-	O
H1	O
,	O
induced	O
MACC1	O
,	O
and	O
the	O
presence	O
of	O
tumor	S-Phenotype
budding	O
are	O
promising	O
biomarkers	O
for	O
the	O
prediction	O
of	O
recurrence	O
and	O
may	O
aid	O
the	O
stratification	O
of	O
patients	O
with	O
stage	B-Phenotype
II	I-Phenotype
colon	I-Phenotype
cancer	E-Phenotype
for	O
adjuvant	O
chemotherapy	O

In	O
respect	O
to	O
achalasia	S-Phenotype
,	O
per	O
-	O
oral	O
endoscopic	O
myotomy	O
(	O
POEM	O
)	O
which	O
was	O
developed	O
in	O
Japan	O
,	O
has	O
become	O
an	O
alternative	O
to	O
the	O
traditional	O
Heller	O
's	O
myotomy	O
.	O

Here	O
,	O
we	O
found	O
that	O
the	O
levels	O
of	O
SRPX2	O
in	O
HCC	O
tissues	O
were	O
notably	O
overexpressed	O
compared	O
to	O
non	O
-	O
cancerous	S-Phenotype
specimens	O
.	O

Conversely	O
,	O
mGluR5	O
regulatory	O
proteins	O
were	O
expressed	O
at	O
lower	O
levels	O
in	O
schizophrenia	S-Phenotype
subjects	O
compared	O
to	O
controls	O
(	O
Norbin	O
-	O
37	O
%	O
,	O
p	O
AAAA	O
0.001	O
;	O
Tamalin	O
-	O
30	O
%	O
,	O
p	O
=	O
0.084	O
;	O
Preso1	O
-	O
29	O
%	O
,	O
p	O
=	O
0.001	O
)	O
.	O

Some	O
aspects	O
of	O
the	O
disease	O
are	O
now	O
well	O
known	O
,	O
such	O
as	O
nephrocalcinosis	S-Phenotype
and	O
craniosynostosis	S-Phenotype
,	O
related	O
to	O
the	O
natural	O
course	O
of	O
the	O
disease	O
,	O
which	O
persisted	O
despite	O
the	O
ERT	O
.	O

Heterozygous	O
de	O
novo	O
NALCN	O
missense	O
variants	O
in	O
the	O
S5	O
/	O
S6	O
pore	O
-	O
forming	O
segments	O
lead	O
to	O
congenital	B-Phenotype
contractures	E-Phenotype
of	O
the	O
limbs	B-Phenotype
and	I-Phenotype
face	I-Phenotype
,	I-Phenotype
hypotonia	E-Phenotype
,	O
and	O
developmental	B-Phenotype
delay	E-Phenotype
(	O
CLIFAHDD	O
,	O
OMIM	O
616266	O
)	O
with	O
some	O
clinical	O
overlap	O
.	O

Immunohistochemistry	O
analysis	O
showed	O
reduced	O
FRG1	O
levels	O
in	O
tumors	S-Phenotype
which	O
were	O
supported	O
by	O
in	O
silico	O
analysis	O
data	O
.	O

Motif	O
analysis	O
of	O
tumor	S-Phenotype
-	O
specific	O
methylated	O
regions	O
identified	O
enrichment	O
of	O
binding	O
sites	O
for	O
several	O
neural	O
cell	O
fate	O
-	O
specifying	O
transcription	O
factors	O
including	O
NEUROD1	O
,	O
HAND1	O
,	O
ZNF423	O
and	O
REST	O
.	O

Squamous	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
SCC	S-Phenotype
)	O
is	O
the	O
most	O
common	O
cancer	S-Phenotype
of	O
the	O
equine	O
eye	O
,	O
frequently	O
originating	O
at	O
the	O
limbus	O
,	O
with	O
the	O
potential	O
to	O
invade	O
the	O
cornea	O
,	O
cause	O
visual	B-Phenotype
impairment	E-Phenotype
,	O
and	O
result	O
in	O
loss	O
of	O
the	O
eye	O
.	O

Main	O
subtypes	O
of	O
the	O
disease	O
are	O
pseudohypoparathyroidism	S-Phenotype
1b	O
(	O
PHP1b	O
)	O
and	O
pseudohypoparathyroidism	S-Phenotype
1a	O
(	O
PHP1a	O
)	O
.	O

Zic2	O
has	O
been	O
shown	O
to	O
be	O
crucial	O
to	O
the	O
progression	O
of	O
human	O
cancers	S-Phenotype
.	O

We	O
find	O
NF1	O
mutations	O
in	O
neuroblastoma	S-Phenotype
cell	O
lines	O
and	O
in	O
primary	O
tumors	S-Phenotype
.	O

We	O
further	O
show	O
that	O
p53R2	O
is	O
important	O
for	O
oncogenic	O
growth	O
,	O
migration	O
and	O
invasion	O
in	O
cervical	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Expression	O
of	O
DIO1	O
-	O
affected	O
genes	O
strongly	O
correlated	O
with	O
DIO1	O
transcript	O
levels	O
in	O
tissue	O
samples	O
from	O
renal	B-Phenotype
cancer	E-Phenotype
patients	O
as	O
well	O
as	O
with	O
their	O
poor	O
survival	O
.	O

Basic	O
immunological	O
assessments	O
have	O
confirmed	O
that	O
this	O
strain	O
of	O
human	O
CD3	O
EDG	O
-	O
replaced	O
mice	O
are	O
entirely	O
immune	O
competent	S-Phenotype
,	O
and	O
we	O
have	O
also	O
demonstrated	O
that	O
a	O
bispecific	O
antibody	O
that	O
simultaneously	O
binds	O
to	O
human	O
CD3	O
and	O
a	O
tumor	S-Phenotype
-	O
associated	O
antigen	O
(	O
e.g	O
.	O

It	O
is	O
dominated	O
by	O
cerebellar	B-Phenotype
ataxia	E-Phenotype
and	O
susceptible	O
to	O
stresses	O
that	O
act	O
as	O
factors	O
provoking	O
disease	O
onset	O
or	O
episodes	O
of	O
rapid	O
neurological	O
deterioration	O
possibly	O
leading	O
to	O
death	O
.	O

c.886GAAAAT	O
is	O
a	O
novel	O
idiopathic	B-Phenotype
congenital	I-Phenotype
nystagmus‑inducing	E-Phenotype
mutation	O
in	O
the	O
FRMD7	O
gene	O
.	O

The	O
results	O
show	O
miR	O
-	O
214	O
serve	O
as	O
a	O
tumor	S-Phenotype
promoter	O
regulating	O
cells	O
migration	O
,	O
invasion	O
and	O
apoptosis	O
in	O
ESCC	O
.	O

We	O
evaluated	O
the	O
molecular	O
heterogeneity	S-Phenotype
of	O
sCRC	B-Phenotype
tumors	E-Phenotype
based	O
on	O
simultaneous	O
assessment	O
of	O
the	O
overall	O
GEP	O
of	O
both	O
coding	O
mRNA	O
and	O
non	O
-	O
coding	O
RNA	O
genes	O
in	O
primary	O
sCRC	B-Phenotype
tumor	E-Phenotype
samples	O
from	O
23	O
consecutive	O
patients	O
and	O
their	O
paired	O
liver	O
metastases	O
.	O

These	O
results	O
reveal	O
a	O
mechanism	O
of	O
PGAM2	O
regulation	O
and	O
NADPH	O
homeostasis	O
in	O
response	O
to	O
oxidative	B-Phenotype
stress	E-Phenotype
that	O
impacts	O
cell	O
proliferation	O
and	O
tumor	S-Phenotype
growth	O

Immunoblot	O
analysis	O
revealed	O
that	O
CDK10	O
protein	O
expression	O
was	O
notably	O
decreased	O
in	O
gastric	B-Phenotype
cancer	E-Phenotype
compared	O
with	O
normal	O
tissues	O
.	O

We	O
genotyped	O
7	O
potentially	O
functional	O
polymorphisms	O
in	O
CASP3	O
,	O
CASP7	O
,	O
CASP8	O
,	O
CASP9	O
,	O
CASP10	O
genes	O
in	O
362	O
HCC	O
patients	O
of	O
receiving	O
surgical	O
resection	O
of	O
HCC	B-Phenotype
tumor	E-Phenotype
.	O

Patients	O
with	O
non	O
-	O
AR	O
driven	O
metastases	O
may	O
,	O
however	O
,	O
benefit	O
from	O
therapies	O
targeting	O
the	O
tumor	S-Phenotype
microenvironment	O
.	O

Because	O
of	O
the	O
distinct	O
ear	B-Phenotype
anomalies	E-Phenotype
and	O
the	O
hearing	B-Phenotype
loss	E-Phenotype
a	O
HOXA2	O
mutation	O
was	O
taken	O
into	O
account	O
.	O

Hepatocellular	B-Phenotype
carcinoma	I-Phenotype
related	I-Phenotype
protein	I-Phenotype
1	E-Phenotype
(	O
HCRP1	S-Phenotype
)	O
,	O
which	O
is	O
essential	O
for	O
internalization	O
and	O
degradation	O
of	O
ubiquitinated	O
membrane	O
receptors	O
,	O
is	O
downregulated	O
in	O
several	O
tumors	S-Phenotype
and	O
strongly	O
affects	O
the	O
outcomes	O
of	O
cancer	S-Phenotype
patients	O
.	O

We	O
show	O
that	O
obesity	S-Phenotype
in	O
humans	O
correlates	O
with	O
reduced	O
expression	O
of	O
adipose	O
tissue	O
NLRP12	O
.	O

USP18	O
was	O
also	O
significantly	O
enhanced	O
in	O
patients	O
with	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2	O
-	O
positive	O
breast	B-Phenotype
cancer	E-Phenotype
;	O
furthermore	O
,	O
Kaplan	O
-	O
Meier	O
curve	O
demonstrated	O
that	O
combining	O
USP18	O
and	O
Skp2	O
expression	O
improved	O
prognostic	O
capability	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

The	O
purpose	O
of	O
the	O
article	O
is	O
to	O
investigate	O
the	O
role	O
of	O
IARS2	O
in	O
proliferation	O
,	O
apoptosis	O
,	O
and	O
cell	O
cycle	O
of	O
gastric	B-Phenotype
cancer	E-Phenotype
(	O
GC	S-Phenotype
)	O
cells	O
in	O
vitro	O
.	O

It	O
is	O
well	O
known	O
that	O
miR	O
-	O
145	O
-	O
5p	O
(	O
the	O
guide	O
strand	O
)	O
functions	O
as	O
a	O
tumor	S-Phenotype
suppressor	O
in	O
several	O
types	O
of	O
cancer	S-Phenotype
.	O

Mutations	O
in	O
the	O
cyclin	O
F	O
gene	O
(	O
CCNF	O
)	O
have	O
been	O
recently	O
identified	O
in	O
a	O
small	O
number	O
of	O
patients	O
with	O
amyotrophic	B-Phenotype
lateral	I-Phenotype
sclerosis	E-Phenotype
(	O
ALS	S-Phenotype
)	O
and	O
/	O
or	O
frontotemporal	B-Phenotype
dementia	E-Phenotype
,	O
and	O
their	O
role	O
in	O
patients	O
with	O
ALS	O
in	O
Taiwan	O
remains	O
elusive	O
.	O

Furthermore	O
,	O
we	O
identified	O
some	O
potential	O
lung	B-Phenotype
cancer	E-Phenotype
driver	O
genes	O
,	O
such	O
as	O
TBX2	O
,	O
MCM4	O
,	O
SLC2A1	O
,	O
BIRC5	O
,	O
and	O
CDC20	O
,	O
whose	O
expression	O
is	O
significantly	O
upregulated	O
in	O
lung	B-Phenotype
cancer	E-Phenotype
,	O
and	O
the	O
copy	O
number	O
of	O
these	O
genes	O
is	O
amplified	O
in	O
the	O
genome	O
of	O
patients	O
with	O
lung	B-Phenotype
cancer	E-Phenotype
.	O

Before	O
and	O
after	O
eight	O
weeks	O
daily	O
treatment	O
with	O
six	O
capsules	O
of	O
FAAAAAamp	O
;	O
V	O
juice	O
concentrate	O
or	O
placebo	O
,	O
peripheral	O
blood	O
gene	O
expression	O
(	O
microarray	O
,	O
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
qPCR	O
)	O
)	O
,	O
plasma	O
tumour	S-Phenotype
necrosis	O
factor	O
(	O
TNF	O
)	O
a	O
(	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
)	O
,	O
body	O
composition	O
(	O
Dual	O
-	O
energy	O
X	O
-	O
ray	O
absorptiometry	O
(	O
DEXA	O
)	O
)	O
and	O
lipid	O
profiles	O
were	O
assessed	O
.	O

Mutations	O
in	O
PINK1	O
,	O
a	O
mitochondrially	O
targeted	O
serine	O
/	O
threonine	O
kinase	O
,	O
cause	O
autosomal	B-Phenotype
recessive	I-Phenotype
Parkinson	I-Phenotype
's	I-Phenotype
disease	E-Phenotype
(	O
PD	S-Phenotype
)	O
.	O

Our	O
study	O
suggests	O
that	O
miR	O
-	O
9	O
functions	O
as	O
a	O
tumor	S-Phenotype
suppressor	O
in	O
HCC	O
progression	O
by	O
inhibiting	O
a	O
series	O
of	O
target	O
genes	O
,	O
including	O
the	O
newly	O
validated	O
miR	O
-	O
9	O
/	O
IGF2BP1	O
/	O
AKTAAAAAERK	O
axis	O
,	O
thus	O
providing	O
potential	O
therapeutic	O
targets	O
and	O
novel	O
prognostic	O
biomarkers	O
for	O
HCC	S-Phenotype
patients	O
.	O

Finally	O
,	O
we	O
validated	O
these	O
observations	O
by	O
investigating	O
SPARCL1	O
expression	O
in	O
cervical	B-Phenotype
cancer	E-Phenotype
tissue	O
and	O
serum	O
samples	O
.	O

In	O
this	O
study	O
,	O
a	O
novel	O
insert	O
mutation	O
in	O
GJA8	O
was	O
identified	O
in	O
a	O
Chinese	O
congenital	B-Phenotype
cataract	E-Phenotype
family	O
and	O
cosegregated	O
with	O
the	O
disease	O
in	O
this	O
pedigree	O
.	O

DTNBP1	O
encodes	O
dysbindin	O
protein	O
,	O
which	O
is	O
localized	O
to	O
synaptic	O
sites	O
and	O
is	O
reduced	O
in	O
the	O
prefrontal	O
cortex	O
and	O
hippocampus	O
of	O
patients	O
with	O
schizophrenia	S-Phenotype
,	O
indicating	O
a	O
potential	O
role	O
in	O
schizophrenia	S-Phenotype
etiology	O
.	O

Downregulation	O
of	O
Gli1	O
,	O
Gli2	O
,	O
Gli3	O
and	O
Kif7	O
was	O
demonstrated	O
in	O
clinical	O
samples	O
of	O
choriocarcinoma	S-Phenotype
and	O
hydatidiform	B-Phenotype
moles	E-Phenotype
as	O
well	O
as	O
choriocarcinoma	S-Phenotype
cell	O
lines	O
when	O
compared	O
with	O
normal	O
placentas	O
.	O

To	O
explore	O
the	O
complementary	O
behaviors	O
of	O
KIF15	O
and	O
Eg5	O
,	O
we	O
also	O
scored	O
the	O
effects	O
of	O
small	O
-	O
molecule	O
inhibitors	O
on	O
admixtures	O
of	O
both	O
motors	O
,	O
using	O
both	O
a	O
microtubule	O
(	O
MT	O
)	O
-	O
gliding	O
assay	O
and	O
an	O
assay	O
for	O
cancer	S-Phenotype
cell	O
viability	O
.	O

This	O
finding	O
expands	O
the	O
lists	O
of	O
the	O
ALK	O
-	O
positive	O
tumors	S-Phenotype
,	O
and	O
ALK	O
-	O
positive	O
extramedullary	O
plasmacytoma	S-Phenotype
may	O
benefit	O
from	O
the	O
treatment	O
of	O
ALK	O
inhibitor	O
in	O
the	O
future	O

OMIM	O
194050	O
)	O
is	O
a	O
rare	O
multisystem	O
genetic	O
disorder	O
caused	O
by	O
a	O
microdeletion	O
on	O
chromosome	O
7q11.23	O
and	O
characterized	O
by	O
cardiovascular	B-Phenotype
malformations	E-Phenotype
,	O
mental	B-Phenotype
retardation	E-Phenotype
,	O
and	O
a	O
specific	O
facial	B-Phenotype
dysmorphism	E-Phenotype
.	O

To	O
address	O
these	O
issues	O
,	O
we	O
performed	O
immunohistochemical	O
analysis	O
of	O
multiple	O
markers	O
of	O
DNA	O
damage	O
signalling	O
,	O
oxidative	B-Phenotype
stress	E-Phenotype
,	O
DNA	O
repair	O
and	O
cell	O
cycle	O
control	O
pathways	O
during	O
progression	O
of	O
human	O
prostate	O
disease	O
from	O
benign	O
hyperplasia	O
,	O
through	O
intraepithelial	B-Phenotype
neoplasia	E-Phenotype
to	O
CaP	O
,	O
complemented	O
by	O
genetic	O
analyses	O
of	O
TMPRSS2	O
-	O
ERG	O
rearrangement	O
and	O
NQO1	O
,	O
an	O
anti	O
-	O
oxidant	O
factor	O
and	O
p53	O
protector	O
.	O

The	O
aberrant	O
activation	O
of	O
STAT3	O
contributes	O
to	O
several	O
human	O
diseases	O
,	O
particularly	O
cancer	S-Phenotype
.	O

The	O
level	O
of	O
gene	O
expression	O
of	O
IRAK1	O
,	O
NF	O
-	O
kB	O
,	O
tumor	S-Phenotype
necrosis	O
factor	O
-	O
a	O
(	O
TNF	O
-	O
a	O
)	O
,	O
and	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
)	O
was	O
measured	O
by	O
RT	O
-	O
PCR	O
,	O
and	O
TNF	O
-	O
a	O
,	O
IL	O
-	O
6	O
levels	O
in	O
the	O
cell	O
supernatant	O
were	O
determined	O
by	O
ELISA	O
.	O

We	O
hope	O
that	O
our	O
study	O
will	O
stimulate	O
further	O
studies	O
and	O
a	O
new	O
targeted	O
therapy	O
and	O
early	O
medical	O
intervention	O
for	O
YAP	O
/	O
TAZ	O
could	O
be	O
a	O
useful	O
option	O
for	O
breast	B-Phenotype
cancer	E-Phenotype
cases	O
complicated	O
with	O
LKB1	O
deficiency	O

Gastrointestinal	B-Phenotype
stromal	I-Phenotype
tumors	E-Phenotype
(	O
GISTs	S-Phenotype
)	O
are	O
the	O
most	O
common	O
type	O
of	O
mesenchymal	B-Phenotype
tumor	E-Phenotype
of	O
the	O
digestive	O
tract	O
.	O

The	O
aim	O
this	O
study	O
was	O
to	O
investigate	O
the	O
prevalence	O
of	O
single	O
nucleotide	O
polymorphisms	O
in	O
LEP	O
gene	O
(	O
LEP	O
3'UTR	O
A	O
/	O
C	O
,	O
-	O
2548	O
G	O
/	O
A	O
)	O
and	O
LEPR	O
(	O
K109R	O
and	O
Q223R	O
)	O
and	O
their	O
association	O
with	O
Leptin	O
level	O
and	O
obesity	S-Phenotype
.	O

MDR	O
rectal	O
colonization	O
occurs	O
in	O
6.5	O
%	O
of	O
haematological	O
inpatients	O
and	O
predicts	O
a	O
16	O
%	O
probability	O
of	O
MDRrel	O
BSI	O
,	O
particularly	O
during	O
neutropenia	S-Phenotype
,	O
as	O
well	O
as	O
a	O
higher	O
probability	O
of	O
unfavourable	O
outcomes	O
in	O
CR	O
-	O
rel	O
BSIs	O
.	O

Leber	B-Phenotype
's	I-Phenotype
hereditary	I-Phenotype
optic	I-Phenotype
neuropathy	E-Phenotype
(	O
LHON	S-Phenotype
)	O
is	O
a	O
common	O
inherited	O
mitochondrial	O
disorder	O
that	O
is	O
characterized	O
by	O
the	O
degeneration	B-Phenotype
of	I-Phenotype
the	I-Phenotype
optic	I-Phenotype
nerves	E-Phenotype
,	O
leading	O
to	O
vision	B-Phenotype
loss	E-Phenotype
.	O

SLC4A3	O
is	O
important	O
for	O
retinal	O
function	O
and	O
has	O
not	O
previously	O
been	O
associated	O
with	O
spontaneously	O
occurring	O
retinal	B-Phenotype
degenerations	E-Phenotype
in	O
any	O
other	O
species	O
,	O
including	O
humans	O

However	O
,	O
there	O
is	O
much	O
debate	O
over	O
the	O
roles	O
of	O
the	O
reversionless	O
3	O
-	O
like	O
(	O
REV3L	O
)	O
protein	O
responsible	O
for	O
TLS	O
and	O
p53	O
in	O
regulating	O
cancer	S-Phenotype
cell	O
metabolism	O
.	O

Biological	O
relationships	O
among	O
these	O
mutated	O
genes	O
were	O
mined	O
using	O
Ingenuity	O
Pathway	O
Analysis	O
,	O
and	O
the	O
results	O
demonstrated	O
that	O
top	O
two	O
networks	O
with	O
highest	O
scores	O
were	O
highly	O
associated	O
with	O
cancer	S-Phenotype
and	O
hematological	O
diseases	O
,	O
indicating	O
that	O
the	O
mutated	O
genes	O
identified	O
by	O
our	O
method	O
were	O
highly	O
relevant	O
to	O
MDS	O
.	O

Treatments	O
in	O
GSC	O
and	O
primary	O
gastric	B-Phenotype
cancer	E-Phenotype
are	O
the	O
same	O
and	O
include	O
resection	O
of	O
the	O
lesion	O
and	O
radical	O
lymph	O
node	O
dissection	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
clinical	O
,	O
laboratory	O
and	O
genetic	O
findings	O
and	O
the	O
prognostic	O
effects	O
of	O
molecular	O
inheritance	O
of	O
our	O
24	O
CGD	O
cases	O
(	O
14	O
XR	O
,	O
10	O
autosomal	B-Phenotype
recessive	I-Phenotype
-	I-Phenotype
AR	E-Phenotype
)	O
.	O

Because	O
Dfnb31	O
(	O
wi	O
/	O
wi	O
)	O
and	O
Dfnb31	O
(	O
neo	O
/	O
neo	O
)	O
mice	O
faithfully	O
recapitulate	O
hearing	O
and	O
vision	O
symptoms	O
in	O
patients	O
,	O
our	O
findings	O
of	O
vestibular	B-Phenotype
dysfunction	E-Phenotype
in	O
these	O
Dfnb31	O
mutants	O
raise	O
the	O
question	O
of	O
whether	O
DFNB31	O
-	O
deficient	O
patients	O
may	O
acquire	O
vestibular	O
as	O
well	O
as	O
hearing	B-Phenotype
and	I-Phenotype
vision	I-Phenotype
loss	E-Phenotype
.	O

Immunohistochemistry	O
demonstrated	O
that	O
the	O
loss	O
of	O
CDK10	O
expression	O
,	O
which	O
was	O
observed	O
in	O
50.8	O
%	O
of	O
primary	O
gastric	B-Phenotype
cancer	E-Phenotype
tissues	O
(	O
n=128	O
)	O
,	O
significantly	O
correlated	O
with	O
advanced	O
tumor	S-Phenotype
stage	O
(	O
PAAAA0.001	O
)	O
,	O
frequent	O
lymph	O
node	O
metastasis	O
(	O
PAAAA0.001	O
)	O
,	O
distant	O
metastasis	O
(	O
P=0.013	O
)	O
,	O
tumor	S-Phenotype
differentiation	O
(	O
P=0.004	O
)	O
and	O
unfavorable	O
overall	O
survival	O
(	O
PAAAA0.001	O
)	O
.	O

Mutations	O
in	O
RPE65	O
result	O
in	O
a	O
disrupted	O
chromophore	O
supply	O
,	O
retinal	B-Phenotype
degeneration	E-Phenotype
,	O
and	O
blindness	S-Phenotype
.	O

The	O
purpose	O
of	O
these	O
recommendations	O
is	O
to	O
answer	O
the	O
following	O
question	O
:	O
in	O
case	O
of	O
deeply	B-Phenotype
infiltrating	I-Phenotype
endometriosis	I-Phenotype
associated	I-Phenotype
infertility	E-Phenotype
,	O
what	O
is	O
the	O
best	O
therapeutic	O
strategy	O
?	O

The	O
Nodal	O
co	O
-	O
receptor	O
Cripto	O
is	O
expressed	O
transiently	O
during	O
normal	O
germ	O
cell	O
development	O
and	O
is	O
ectopically	O
expressed	O
in	O
non	O
-	O
seminomas	O
that	O
arise	O
from	O
germ	B-Phenotype
cell	I-Phenotype
neoplasia	E-Phenotype
in	O
situ	O
,	O
suggesting	O
that	O
its	O
aberrant	O
expression	O
may	O
underlie	O
germ	B-Phenotype
cell	I-Phenotype
dysregulation	E-Phenotype
and	O
hence	O
germ	B-Phenotype
cell	I-Phenotype
cancer	E-Phenotype
.	O

Solute	O
carrier	O
family	O
34	O
member	O
2	O
(	O
SLC34A2	O
)	O
is	O
a	O
well	O
-	O
known	O
sodium	O
-	O
dependent	O
phosphate	O
transporter	O
that	O
has	O
recently	O
been	O
linked	O
to	O
cancer	S-Phenotype
development	O
.	O

In	O
contrast	O
,	O
a	O
single	O
nucleotide	O
variant	O
identified	O
in	O
patients	O
with	O
intellectual	B-Phenotype
disability	E-Phenotype
and	O
located	O
at	O
the	O
C	O
-	O
terminus	O
of	O
ZBTB20	O
affected	O
dendritic	O
arborization	O
and	O
dendritic	O
length	O
but	O
had	O
no	O
effect	O
on	O
dendritic	O
spine	O
morphology	O
.	O

Multivariable	O
logistic	O
regression	O
analysis	O
with	O
adjustment	O
for	O
age	O
,	O
sex	O
and	O
the	O
prevalence	O
of	O
hypertension	S-Phenotype
and	O
diabetes	B-Phenotype
mellitus	E-Phenotype
revealed	O
that	O
4	O
of	O
these	O
SNPs	O
[	O
rs3212335	O
of	O
GABRB3	O
(	O
P=0.0036	O
;	O
odds	O
ratio	O
,	O
1.29	O
)	O
,	O
rs147783135	O
of	O
TMPRSS7	O
(	O
P=0.0024	O
;	O
odds	O
ratio	O
,	O
0.37	O
)	O
,	O
rs2292661	O
of	O
PDIA5	O
(	O
P=0.0054	O
;	O
odds	O
ratio	O
,	O
0.35	O
)	O
and	O
rs191885206	O
of	O
CYP4F12	O
(	O
P=0.0082	O
;	O
odds	O
ratio	O
,	O
2.60	O
)	O
]	O
were	O
related	O
(	O
PAAAA0.01	O
)	O
to	O
ischemic	B-Phenotype
stroke	E-Phenotype
.	O

ITGA9	O
could	O
also	O
be	O
regarded	O
as	O
a	O
diagnostic	O
marker	O
differentiating	O
NSCLC	O
subtypes	O
,	O
as	O
its	O
expression	O
level	O
was	O
significantly	O
lower	O
in	O
squamous	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
P	O
=	O
0.001	O
)	O
.	O

In	O
an	O
unrelated	O
sporadic	S-Phenotype
case	O
of	O
CGHT	O
,	O
we	O
identified	O
a	O
1.3	O
Mb	O
cryptic	O
deletion	O
of	O
chr17q24.2	O
-	O
q24.3	O
encompassing	O
ABCA5	O
and	O
found	O
that	O
ABCA5	O
levels	O
are	O
dramatically	O
reduced	O
throughout	O
patient	O
hair	O
follicles	O
.	O

Metabolic	O
syndrome	O
(	O
MeS	O
)	O
is	O
associated	O
with	O
increased	O
PCa	O
aggressiveness	O
and	O
recurrence	O
.	O

Germline	O
de	O
novo	O
truncating	O
variants	O
in	O
ASXL1	O
and	O
ASXL3	O
have	O
been	O
respectively	O
implicated	O
in	O
causing	O
Bohring	O
-	O
Opitz	O
and	O
Bainbridge	O
-	O
Ropers	O
syndromes	O
,	O
which	O
result	O
in	O
overlapping	O
features	O
of	O
severe	O
intellectual	B-Phenotype
disability	E-Phenotype
and	O
dysmorphic	O
features	O
.	O

In	O
summary	O
,	O
we	O
provide	O
novel	O
evidence	O
that	O
the	O
expression	O
of	O
Cx31	O
was	O
decreased	O
in	O
thyroid	B-Phenotype
cancer	E-Phenotype
cells	O
,	O
but	O
Rg1	O
treatment	O
could	O
significantly	O
enhance	O
the	O
expression	O
of	O
Cx31	O
thereby	O
suppressing	O
thyroid	B-Phenotype
cancer	E-Phenotype
cell	O
proliferation	O
and	O
migration	O

A	O
novel	O
missense	O
mutation	O
(	O
c.1462GAAAAA	O
,	O
p.Ala488Thr	O
,	O
A488T	O
)	O
adjacent	O
to	O
this	O
hotspot	O
UBQLN2	O
domain	O
was	O
identified	O
in	O
a	O
sporadic	S-Phenotype
case	O
of	O
ALS	O
.	O

Here	O
,	O
we	O
analyzed	O
the	O
mutation	O
,	O
copy	O
number	O
variation	O
and	O
gene	O
expression	O
patterns	O
of	O
a	O
literature	O
-	O
derived	O
model	O
of	O
metabolic	O
genes	O
associated	O
with	O
glycolysis	O
(	O
Warburg	O
effect	O
)	O
,	O
fatty	O
acid	O
metabolism	O
(	O
lipogenesis	O
,	O
oxidation	O
,	O
lipolysis	O
,	O
esterification	O
)	O
and	O
fatty	O
acid	O
uptake	O
in	O
AAAA9000	O
primary	O
or	O
metastatic	O
tumor	S-Phenotype
samples	O
from	O
the	O
multi	O
-	O
cancer	S-Phenotype
TCGA	O
datasets	O
.	O

Conclusions	O
:	O
The	O
growth	O
of	O
ovarian	B-Phenotype
cancer	E-Phenotype
cells	O
could	O
be	O
decreased	O
by	O
S1PR2	O
inhibition	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
present	O
a	O
novel	O
pathogenic	O
RDH5	O
gene	O
mutation	O
in	O
a	O
16	O
-	O
year	O
-	O
old	O
female	O
patient	O
with	O
symptoms	O
of	O
night	B-Phenotype
blindness	E-Phenotype
.	O

Therefore	O
,	O
in	O
this	O
study	O
,	O
we	O
examined	O
the	O
roles	O
of	O
ZMYND10	O
using	O
Zmynd10	O
-	O
/	O
-	O
mice	O
exhibiting	O
typical	O
PCD	O
phenotypes	O
,	O
including	O
hydrocephalus	S-Phenotype
and	O
laterality	B-Phenotype
defects	E-Phenotype
.	O

Overall	O
,	O
our	O
results	O
define	O
an	O
oncogenic	O
role	O
of	O
lipancEts	O
-	O
1	O
/	O
i	O
in	O
neuroblastoma	S-Phenotype
progression	O
through	O
hnRNPK	O
-	O
mediated	O
β	O
-	O
catenin	O
stabilization	O
,	O
with	O
potential	O
implications	O
for	O
the	O
clinical	O
therapeutics	O
of	O
neuroblastoma	O
.	O

Significance	O
:	O
/	O
b	O
These	O
findings	O
reveal	O
the	O
oncogenic	O
functions	O
of	O
a	O
long	O
noncoding	O
RNA	O
in	O
neuroblastoma	S-Phenotype
progression	O
,	O
offering	O
a	O
potential	O
target	O
for	O
clinical	O
therapeutics	O
.	O

Our	O
findings	O
are	O
both	O
important	O
for	O
the	O
differential	O
diagnosis	O
of	O
patients	O
with	O
urea	O
cycle	O
disorders	O
and	O
also	O
broaden	O
the	O
differential	O
diagnosis	O
of	O
hyperammonemia	S-Phenotype
associated	O
with	O
3	B-Phenotype
-	I-Phenotype
methylglutaconic	I-Phenotype
aciduria	E-Phenotype
,	O
which	O
was	O
earlier	O
only	O
reported	O
in	O
TMEM70	O
and	O
SERAC1	O
defect	O

Truncating	O
mutations	O
in	O
the	O
last	O
and	O
penultimate	O
exons	O
of	O
the	O
PPM1D	O
gene	O
were	O
recently	O
described	O
as	O
a	O
cause	O
for	O
mild	O
to	O
severe	O
intellectual	B-Phenotype
disability	E-Phenotype
in	O
fourteen	O
patients	O
.	O

To	O
examine	O
the	O
pathomechanisms	O
of	O
early	B-Phenotype
craniofacial	E-Phenotype
and	O
dental	B-Phenotype
abnormalities	E-Phenotype
,	O
we	O
analyzed	O
mice	O
with	O
an	O
MLII	O
patient	O
mutation	O
that	O
mimic	O
the	O
clinical	O
and	O
biochemical	O
symptoms	O
of	O
MLII	O
patients	O
.	O

Here	O
,	O
we	O
describe	O
two	O
brothers	O
with	O
congenital	B-Phenotype
prelingual	I-Phenotype
deafness	E-Phenotype
and	O
a	O
homozygous	O
nonsense	O
c.292CAAAAT	O
(	O
p.Arg98	O
*	O
)	O
COCH	O
variant	O
,	O
suggesting	O
a	O
loss	O
-	O
of	O
-	O
function	O
effect	O
.	O

Reproductive	O
aging	O
phenotypes	O
,	O
including	O
age	O
at	O
menarche	O
(	O
AM	O
)	O
and	O
age	O
at	O
natural	O
menopause	O
(	O
ANM	O
)	O
,	O
are	O
well	O
-	O
established	O
risk	O
factors	O
for	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

A	O
putative	O
tumor	S-Phenotype
suppressor	O
BLU	O
mapped	O
on	O
the	O
chromosomal	O
3p21	O
region	O
,	O
is	O
frequently	O
lost	O
in	O
human	O
tumors	S-Phenotype
including	O
nasopharyngeal	B-Phenotype
carcinoma	E-Phenotype
(	O
NPC	S-Phenotype
)	O
.	O

Oral	B-Phenotype
and	I-Phenotype
pharyngeal	I-Phenotype
cancers	E-Phenotype
combined	O
were	O
associated	O
with	O
loci	O
at	O
6p21.32	O
(	O
rs3828805	O
,	O
HLA	O
-	O
DQB1	O
)	O
,	O
10q26.13	O
(	O
rs201982221	O
,	O
LHPP	O
)	O
and	O
11p15.4	O
(	O
rs1453414	O
,	O
OR52N2	O
-	O
TRIM5	O
)	O
.	O

A	O
pathogenic	O
R474Q	O
mutation	O
of	O
LGI1	O
,	O
which	O
does	O
not	O
exceptionally	O
affect	O
either	O
the	O
secretion	O
or	O
the	O
ADAM22	O
binding	O
,	O
is	O
located	O
in	O
the	O
LGI1	O
-	O
LGI1	O
interface	O
and	O
disrupts	O
the	O
higher	O
-	O
order	O
assembly	O
of	O
the	O
LGI1	O
-	O
ADAM22	O
complex	O
in	O
vitro	O
and	O
in	O
a	O
mouse	O
model	O
for	O
familial	B-Phenotype
epilepsy	E-Phenotype
.	O

Importantly	O
,	O
we	O
demonstrate	O
a	O
significant	O
positive	O
correlation	O
between	O
miR	O
-	O
106b	O
-	O
25	O
and	O
NOTCH1	O
protein	O
,	O
yet	O
a	O
significant	O
inverse	O
correlation	O
between	O
miR	O
-	O
106b	O
-	O
25	O
and	O
NEDD4L	O
mRNA	O
in	O
human	O
breast	B-Phenotype
cancer	E-Phenotype
,	O
suggesting	O
a	O
critical	O
role	O
for	O
the	O
miR106b	O
-	O
25	O
/	O
NEDD4L	O
/	O
NOTCH1	O
axis	O
in	O
the	O
disease	O
.	O

These	O
results	O
indicate	O
that	O
Smad4	O
acts	O
as	O
a	O
tumor	S-Phenotype
suppressor	O
by	O
activating	O
FOXH1	O
,	O
and	O
then	O
suppressing	O
the	O
expression	O
of	O
estrogen	O
receptor	O
,	O
in	O
addition	O
to	O
tumor	S-Phenotype
migration	O
and	O
invasion	O
.	O

Here	O
we	O
investigated	O
roles	O
for	O
the	O
vertebrate	O
-	O
specific	O
BTB	O
domain	O
zinc	O
finger	O
gene	O
ZNF131	O
in	O
the	O
context	O
of	O
human	O
brain	B-Phenotype
tumors	E-Phenotype
.	O

The	O
authors	O
report	O
a	O
patient	O
with	O
a	O
novel	O
PAK3	O
mutation	O
,	O
who	O
presented	O
with	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
severe	B-Phenotype
automutilation	E-Phenotype
,	O
and	O
epilepsy	S-Phenotype
.	O

Therefore	O
,	O
we	O
investigated	O
the	O
impact	O
of	O
altering	O
the	O
MPC1	O
gene	O
expression	O
on	O
the	O
malignant	O
potential	O
of	O
cancer	S-Phenotype
cells	O
using	O
biliary	O
tract	O
cancer	S-Phenotype
cell	O
lines	O
in	O
vitro	O
.	O

Genomics	O
of	O
tumors	S-Phenotype
identified	O
several	O
new	O
genes	O
-	O
including	O
ZNRF3	O
in	O
adrenocortical	B-Phenotype
carcinomas	E-Phenotype
,	O
PRKACA	O
in	O
cortisol	O
-	O
producing	O
adrenal	O
adenomas	O
,	O
ARMC5	O
in	O
primary	B-Phenotype
macronodular	I-Phenotype
adrenal	I-Phenotype
hyperplasia	E-Phenotype
and	O
USP8	O
in	O
pituitary	B-Phenotype
corticotroph	I-Phenotype
adenomas	E-Phenotype
.	O

This	O
suggests	O
that	O
children	O
with	O
CCDC88C	O
-	O
related	O
autosomal	B-Phenotype
recessive	I-Phenotype
hydrocephalus	E-Phenotype
can	O
have	O
normal	O
developmental	O
outcomes	O
under	O
certain	O
circumstances	O
.	O

Kaposi	B-Phenotype
*	I-Phenotype
s	I-Phenotype
sarcoma	E-Phenotype
(	O
KS	S-Phenotype
)	O
-	O
associated	O
herpesvirus	O
(	O
KSHV	O
)	O
vFLIP	O
,	O
a	O
latent	O
gene	O
of	O
KSHV	O
,	O
was	O
first	O
identified	O
as	O
a	O
FLICE	O
-	O
inhibitory	O
protein	O
(	O
FLIP	O
)	O
protecting	O
cells	O
from	O
apoptosis	O
.	O

While	O
Epo	O
markedly	O
enhanced	O
the	O
proliferation	O
and	O
reduced	O
apoptosis	O
of	O
Epo	O
-	O
dependent	O
UT	O
-	O
7	O
/	O
Epo	O
leukemia	S-Phenotype
cells	O
,	O
it	O
did	O
not	O
affect	O
tumor	S-Phenotype
cell	O
proliferation	O
or	O
the	O
cisplatin	O
-	O
induced	O
apoptosis	O
of	O
NSCLC	O
cells	O
.	O

Leber	B-Phenotype
congenital	I-Phenotype
amaurosis	E-Phenotype
(	O
LCA	S-Phenotype
)	O
and	O
juvenile	B-Phenotype
retinitis	I-Phenotype
pigmentosa	E-Phenotype
(	O
RP	S-Phenotype
)	O
are	O
severe	O
hereditary	O
diseases	O
that	O
causes	O
visual	B-Phenotype
impairment	E-Phenotype
in	O
infants	O
and	O
children	O
.	O

Third	O
,	O
the	O
retinal	B-Phenotype
degeneration	E-Phenotype
associated	O
with	O
the	O
disruption	O
of	O
the	O
visual	O
cycle	O
in	O
Mitf	O
-	O
deficient	O
mice	O
can	O
be	O
partially	O
corrected	O
both	O
structurally	O
and	O
functionally	O
by	O
an	O
exogenous	O
supply	O
of	O
9	O
-	O
cis	O
-	O
retinal	O
.	O

Loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
MTM1	O
cause	O
the	O
severe	O
congenital	B-Phenotype
myopathy	E-Phenotype
called	O
myotubular	B-Phenotype
myopathy	E-Phenotype
(	O
or	O
X	B-Phenotype
-	I-Phenotype
linked	I-Phenotype
centronuclear	I-Phenotype
myopathy	E-Phenotype
)	O
while	O
mutations	O
in	O
the	O
MTM1	O
-	O
related	O
protein	O
MTMR2	O
cause	O
a	O
recessive	O
Charcot	B-Phenotype
-	I-Phenotype
Marie	I-Phenotype
-	I-Phenotype
Tooth	I-Phenotype
peripheral	I-Phenotype
neuropathy	E-Phenotype
.	O

RESULTS	O
For	O
those	O
384	O
cases	O
,	O
7	O
(	O
1.82	O
%	O
)	O
cases	O
had	O
tumors	S-Phenotype
with	O
identified	O
RET	O
rearrangement	O
.	O

Here	O
,	O
we	O
determine	O
that	O
somatic	O
mutations	O
in	O
PIK3CA	O
(	O
44	O
%	O
)	O
,	O
PIK3R1	O
(	O
17	O
%	O
)	O
,	O
AKT3	O
(	O
15	O
%	O
)	O
,	O
and	O
PTEN	O
(	O
12	O
%	O
)	O
are	O
prevalent	O
and	O
diverse	O
in	O
Chinese	O
breast	B-Phenotype
cancer	E-Phenotype
patients	O
,	O
with	O
60	O
novel	O
mutations	O
identified	O
.	O

Mutations	O
in	O
the	O
DNAJB2	O
gene	O
lead	O
to	O
inherited	B-Phenotype
neuropathies	E-Phenotype
such	O
as	O
Charcot	B-Phenotype
-	I-Phenotype
Marie	I-Phenotype
-	I-Phenotype
Tooth	I-Phenotype
type	I-Phenotype
-	I-Phenotype
2	I-Phenotype
,	I-Phenotype
distal	I-Phenotype
hereditary	I-Phenotype
motor	I-Phenotype
neuropathies	E-Phenotype
,	O
spinal	B-Phenotype
muscular	I-Phenotype
atrophy	E-Phenotype
with	O
parkinsonism	S-Phenotype
and	O
the	O
later	O
stages	O
can	O
resemble	O
amyotrophic	B-Phenotype
lateral	I-Phenotype
sclerosis	E-Phenotype
.	O

Previous	O
studies	O
have	O
identified	O
a	O
critical	O
role	O
for	O
the	O
tumor	S-Phenotype
suppressors	O
BRCA1	O
and	O
BRCA2	O
in	O
preventing	O
the	O
degradation	O
of	O
nascent	O
DNA	O
by	O
the	O
MRE11	O
nuclease	O
after	O
replication	O
stress	O
.	O

To	O
conclude	O
,	O
our	O
results	O
indicated	O
that	O
siRNA	O
-	O
TMEM98	O
inhibited	O
the	O
invasion	O
and	O
migration	O
of	O
lung	B-Phenotype
cancer	E-Phenotype
cells	O
,	O
which	O
can	O
be	O
considered	O
as	O
a	O
novel	O
target	O
for	O
NSCLC	O
treatment	O
.	O

Genetic	O
rearrangements	O
involving	O
androgen	O
-	O
regulated	O
transmembrane	O
protease	O
serine	O
2	O
(	O
TMPRSS2	O
)	O
and	O
genes	O
from	O
the	O
ETS	O
transcription	O
factor	O
family	O
,	O
most	O
commonly	O
ERG	O
and	O
ETV1	O
,	O
result	O
in	O
alteration	O
that	O
responsible	O
for	O
oncogenic	O
activity	O
in	O
prostate	B-Phenotype
cancer	E-Phenotype
(	O
PC	S-Phenotype
)	O
.	O

Multivariable	O
logistic	O
regression	O
analysis	O
with	O
adjustment	O
for	O
age	O
and	O
sex	O
revealed	O
that	O
all	O
25	O
,	O
28	O
and	O
65	O
of	O
these	O
SNPs	O
were	O
significantly	O
associated	O
with	O
hypertriglyceridemia	S-Phenotype
,	O
hypo‑HDL‑cholesterolemia	S-Phenotype
and	O
hyper‑LDL‑cholesterolemia	S-Phenotype
,	O
respectively	O
.	O

Our	O
data	O
demonstrate	O
that	O
G211	O
mutation	O
in	O
the	O
UGT1A1	O
gene	O
,	O
ABO	O
incompatibility	O
,	O
G6PD	O
deficiency	O
,	O
and	O
the	O
SS	O
genotype	O
of	O
the	O
repeats	O
in	O
the	O
promoter	O
region	O
of	O
the	O
HO	O
-	O
1	O
gene	O
are	O
risk	O
factors	O
for	O
neonatal	B-Phenotype
hyperbilirubinemia	E-Phenotype
in	O
Fujian	O
,	O
Southeastern	O
China	O

Recently	O
,	O
a	O
few	O
Rho	O
GTPase	O
activating	O
proteins	O
(	O
RhoGAPs	O
)	O
have	O
been	O
identified	O
as	O
tumor	S-Phenotype
suppressors	O
in	O
some	O
human	O
cancers	S-Phenotype
.	O

Our	O
analyses	O
identified	O
15	O
CpG	O
sites	O
within	O
the	O
APC	O
1A	O
promoter	O
that	O
were	O
significantly	O
hypermethylated	O
and	O
14	O
CpG	O
loci	O
within	O
the	O
NFATC1	O
gene	O
body	O
that	O
were	O
significantly	O
hypomethylated	O
(	O
pLIS	O
AAAA	O
1	O
x	O
10	O
-	O
5	O
)	O
in	O
the	O
tumours	S-Phenotype
of	O
active	O
smokers	O
.	O

Based	O
on	O
these	O
findings	O
,	O
we	O
securely	O
implicate	O
PPP3CA	O
in	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
refractory	I-Phenotype
epilepsy	E-Phenotype
and	O
further	O
support	O
the	O
emerging	O
role	O
for	O
synaptic	O
dysregulation	O
in	O
epilepsy	S-Phenotype

The	O
continuum	O
of	O
epithelial	O
changes	O
in	O
the	O
process	O
of	O
serous	O
neoplasia	S-Phenotype
including	O
p53	O
signature	O
,	O
STIL	O
,	O
STIC	O
and	O
invasive	O
carcinoma	S-Phenotype
was	O
identified	O
in	O
8	O
cases	O
of	O
pelvic	O
HGSC	O
.	O

A	O
MMP9	O
inhibitor	O
significantly	O
inhibited	O
cell	O
invasion	O
and	O
migration	O
in	O
ALDOA	O
-	O
HIF	O
-	O
1α	O
axis	O
-	O
induced	O
lung	B-Phenotype
cancer	E-Phenotype
.	O

We	O
present	O
detailed	O
phenotypic	O
information	O
on	O
seven	O
unrelated	O
individuals	O
with	O
a	O
recurrent	O
de	O
novo	O
nonsense	O
variant	O
(	O
c.2737CAAAAT	O
[	O
p.Arg913Ter	O
]	O
)	O
in	O
the	O
penultimate	O
exon	O
of	O
ZSWIM6	O
who	O
have	O
severe	O
-	O
profound	O
intellectual	B-Phenotype
disability	E-Phenotype
and	O
additional	O
central	O
and	O
peripheral	O
nervous	O
system	O
symptoms	O
but	O
an	O
absence	O
of	O
frontonasal	O
or	O
limb	O
malformations	O
.	O

Based	O
on	O
these	O
findings	O
,	O
we	O
infer	O
that	O
high	O
SLC4A11	O
expression	O
is	O
an	O
independent	O
predictor	O
for	O
poor	O
OS	O
in	O
grade	O
3	O
/	O
4	O
serous	O
ovarian	B-Phenotype
cancer	E-Phenotype
.	O

We	O
screened	O
516	O
patients	O
for	O
germline	O
mutations	O
in	O
telomere	O
-	O
associated	O
genes	O
by	O
next	O
-	O
generation	O
sequencing	O
in	O
2	O
independent	O
cohorts	O
;	O
one	O
constituting	O
unselected	O
patients	O
with	O
idiopathic	O
BMF	O
,	O
unexplained	O
cytopenia	O
,	O
or	O
myeloid	O
neoplasms	S-Phenotype
(	O
n	O
=	O
457	O
)	O
and	O
a	O
second	O
cohort	O
comprising	O
selected	O
patients	O
on	O
the	O
basis	O
of	O
the	O
suspicion	O
of	O
constitutional	O
/	O
familial	O
BMF	O
(	O
n	O
=	O
59	O
)	O
.	O

In	O
one	O
of	O
the	O
families	O
with	O
additional	O
cardiomyopathy	S-Phenotype
and	O
steroid	B-Phenotype
-	I-Phenotype
resistant	I-Phenotype
nephrotic	I-Phenotype
syndrome	E-Phenotype
(	O
SRNS	S-Phenotype
)	O
,	O
we	O
found	O
a	O
homozygous	O
variant	O
in	O
KAT2B	O
,	O
encoding	O
the	O
lysine	O
acetyltransferase	O
2B	O
,	O
with	O
impact	O
on	O
KAT2B	O
protein	O
levels	O
in	O
patient	O
fibroblasts	O
,	O
suggesting	O
that	O
this	O
second	O
mutation	O
might	O
contribute	O
to	O
the	O
increased	O
disease	O
spectrum	O
.	O

We	O
report	O
a	O
case	O
with	O
novel	O
AARS2	O
gene	O
mutations	O
with	O
developed	O
striking	O
cerebellar	B-Phenotype
atrophy	E-Phenotype
and	O
leukoencephalopathy	S-Phenotype
,	O
which	O
helps	O
to	O
further	O
understand	O
the	O
clinical	O
and	O
genetic	O
heterogeneity	S-Phenotype
of	O
AARS2	O
-	O
L	O

In	O
a	O
large	O
Scottish	O
pedigree	O
,	O
a	O
balanced	O
translocation	O
t	O
(	O
1	O
;	O
11	O
)	O
(	O
q42.1	O
;	O
q14.3	O
)	O
disrupting	O
the	O
DISC1	O
and	O
DISC2	O
genes	O
segregates	O
with	O
major	O
mental	O
illness	O
,	O
including	O
schizophrenia	S-Phenotype
and	O
depression	S-Phenotype
.	O

Epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
is	O
a	O
process	O
whereby	O
epithelial	O
cells	O
assume	O
mesenchymal	O
characteristics	O
to	O
facilitate	O
cancer	S-Phenotype
metastasis	O
.	O

Uterine	O
carcinosarcoma	O
(	O
UCS	O
)	O
has	O
been	O
proposed	O
as	O
a	O
model	O
for	O
epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
,	O
a	O
process	O
characterized	O
by	O
a	O
functional	O
change	O
facilitating	O
migration	O
and	O
metastasis	O
in	O
many	O
types	O
of	O
cancer	S-Phenotype
.	O

Ectodysplasin	O
-	O
A2	O
(	O
EDA	O
-	O
A2	O
)	O
is	O
a	O
recently	O
isolated	O
member	O
of	O
the	O
tumor	S-Phenotype
necrosis	O
factor	O
superfamily	O
that	O
binds	O
to	O
X	B-Phenotype
-	I-Phenotype
linked	I-Phenotype
ectodermal	I-Phenotype
dysplasia	E-Phenotype
receptor	O
(	O
XEDAR	O
)	O
.	O

This	O
family	O
demonstrates	O
phenotypic	O
variability	O
of	O
FGF14	O
deletions	O
(	O
SCA	O
27	O
)	O
,	O
fever	S-Phenotype
sensitivity	O
of	O
ataxia	S-Phenotype
and	O
the	O
added	O
value	O
of	O
SNP	O
-	O
array	O
analysis	O
in	O
making	O
a	O
diagnosis	O

Our	O
case	O
presented	O
the	O
specific	O
characteristics	O
:	O
macrocephaly	S-Phenotype
,	O
midline	B-Phenotype
cleft	I-Phenotype
-	I-Phenotype
lip	E-Phenotype
,	O
cleft	B-Phenotype
palate	E-Phenotype
,	O
polydactyly	S-Phenotype
of	O
both	O
hands	O
and	O
feet	O
but	O
without	O
occipitoschisis	O
,	O
considered	O
as	O
the	O
pathognomonic	O
sign	O
of	O
the	O
syndrome	O
.	O

In	O
this	O
study	O
,	O
we	O
focused	O
on	O
127	O
significantly	O
mutated	O
genes	O
from	O
The	O
Cancer	S-Phenotype
Genome	O
Atlas	O
(	O
TCGA	O
)	O
Pan	O
-	O
Cancer	S-Phenotype
Analysis	O
across	O
12	O
major	O
cancer	S-Phenotype
sites	O
to	O
identify	O
potential	O
genetic	O
variants	O
predictive	O
of	O
RCC	O
risk	O
and	O
clinical	O
outcomes	O
.	O

Germ	B-Phenotype
cell	I-Phenotype
tumors	E-Phenotype
(	O
GCT	S-Phenotype
)	O
are	O
a	O
rare	O
form	O
of	O
childhood	O
cancer	S-Phenotype
that	O
originate	O
from	O
the	O
primordial	O
germ	O
cell	O
.	O

However	O
,	O
more	O
recently	O
,	O
inherited	O
SWI	O
/	O
SNF	O
-	O
deficiency	O
has	O
been	O
linked	O
to	O
several	O
benign	O
syndromic	O
tumors	S-Phenotype
including	O
a	O
subset	O
of	O
familial	O
schwannomatosis	O
(	O
linked	O
to	O
SMARCB1	O
)	O
and	O
multiple	O
meningiomas	S-Phenotype
(	O
linked	O
to	O
SMARCE1	O
)	O
as	O
well	O
as	O
others	O
.	O

Tbx3	O
expression	O
was	O
positively	O
associated	O
with	O
multiple	O
tumor	S-Phenotype
nodes	O
,	O
venous	O
infiltration	O
,	O
and	O
advanced	O
TNM	B-Phenotype
tumor	E-Phenotype
stage	O
.	O

Models	O
were	O
constructed	O
using	O
CHAF1B	O
-	O
knockdown	O
cells	O
and	O
investigated	O
for	O
tumor	S-Phenotype
growth	O
and	O
pathological	O
changes	O
.	O

Since	O
the	O
protein	O
expression	O
of	O
both	O
Epo	O
and	O
EpoR	O
is	O
induced	O
by	O
hypoxia	S-Phenotype
,	O
which	O
is	O
frequently	O
present	O
in	O
lung	B-Phenotype
cancer	E-Phenotype
,	O
the	O
cells	O
were	O
treated	O
with	O
Epo	O
under	O
both	O
normoxic	O
and	O
hypoxic	O
conditions	O
(	O
1	O
%	O
O2	O
)	O
.	O

Defects	O
in	O
neurodevelopment	O
likewise	O
seem	O
to	O
be	O
a	O
recurrent	O
scheme	O
underpinning	O
mainly	O
complex	O
dystonias	S-Phenotype
,	O
for	O
example	O
those	O
attributable	O
to	O
biallelic	O
mutations	O
in	O
GCH1	O
,	O
TH	O
,	O
SPR	O
,	O
or	O
to	O
heterozygous	O
TUBB4A	O
mutations	O
.	O

Reporting	O
in	O
this	O
issue	O
of	O
Developmental	O
Cell	O
,	O
Kanie	O
et	O
al	O
.	O

TSPY	O
and	O
TSPX	O
co	O
-	O
localize	O
with	O
the	O
endogenous	O
AR	O
,	O
in	O
the	O
presence	O
of	O
ligand	O
,	O
on	O
the	O
promoters	O
and	O
differentially	O
regulate	O
the	O
expression	O
of	O
the	O
endogenous	O
AR	O
target	O
genes	O
in	O
the	O
androgen	O
-	O
responsive	O
LNCaP	O
prostate	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

The	O
mutational	O
analysis	O
of	O
the	O
whole	O
mitochondrial	O
DNA	O
revealed	O
the	O
presence	O
of	O
m.1555AAAAAG	O
mutation	O
in	O
MT	O
-	O
RNR1	O
gene	O
associated	O
to	O
the	O
m.8527AAAAAG	O
(	O
p.MAAAAV	O
)	O
and	O
the	O
m.8392CAAAAT	O
(	O
p.136PAAAAS	O
)	O
variations	O
in	O
the	O
mitochondrial	O
MT	O
-	O
ATP6	O
gene	O
in	O
patient1	O
and	O
his	O
family	O
members	O
with	O
variable	O
phenotype	O
including	O
hearing	B-Phenotype
impairment	E-Phenotype
.	O

Here	O
,	O
we	O
report	O
a	O
novel	O
donor	O
splice	O
site	O
variant	O
in	O
the	O
G	O
-	O
patch	O
domain	O
and	O
KOW	O
motifs	O
(	O
GPKOW	O
)	O
gene	O
(	O
NG_021310.2	O
:	O
g.6126GAAAAA	O
,	O
NM_015698.4	O
:	O
c.331+5GAAAAA	O
)	O
that	O
segregates	O
with	O
affected	O
and	O
carrier	O
status	O
in	O
a	O
multigenerational	O
family	O
with	O
an	O
X	O
-	O
linked	O
perinatal	O
lethal	O
condition	O
characterized	O
by	O
severe	B-Phenotype
microcephaly	E-Phenotype
and	O
intrauterine	B-Phenotype
growth	I-Phenotype
restriction	E-Phenotype
(	O
IUGR	S-Phenotype
)	O
.	O

Although	O
PLOD2	O
was	O
confirmed	O
to	O
be	O
related	O
to	O
poor	O
prognosis	O
in	O
lung	B-Phenotype
adenocarcinoma	E-Phenotype
,	O
the	O
regulatory	O
mechanism	O
and	O
function	O
of	O
PLOD2	O
in	O
human	O
lung	B-Phenotype
adenocarcinoma	E-Phenotype
is	O
poorly	O
understood	O
.	O

The	O
CTNNB1	O
mutations	O
were	O
also	O
identified	O
in	O
cortisol	B-Phenotype
-	I-Phenotype
producing	I-Phenotype
adenomas	E-Phenotype
and	O
adrenal	B-Phenotype
cancer	E-Phenotype
,	O
but	O
their	O
role	O
in	O
APA	O
development	O
and	O
the	O
mechanisms	O
specifying	O
the	O
hormonal	O
production	O
or	O
the	O
malignant	O
phenotype	O
remain	O
unknown	O
.	O

By	O
creating	O
new	O
Pcnxl2	O
frameshift	O
alleles	O
using	O
TALEN	O
mutagenesis	O
,	O
we	O
show	O
that	O
Pcnxl2	O
deficiency	O
is	O
responsible	O
for	O
mitigating	O
the	O
seizure	S-Phenotype
phenotype	O
-	O
making	O
Pcnxl2	O
the	O
first	O
known	O
modifier	O
gene	O
for	O
absence	B-Phenotype
seizures	E-Phenotype
in	O
any	O
species	O
.	O

We	O
performed	O
a	O
retrospective	O
review	O
of	O
electronic	O
patient	O
records	O
to	O
identify	O
patients	O
with	O
macular	B-Phenotype
dystrophy	E-Phenotype
due	O
to	O
bi	O
-	O
allelic	O
variants	O
in	O
CRB1	O
.	O

NOTCH	O
signaling	O
has	O
been	O
identified	O
as	O
an	O
important	O
driver	O
of	O
the	O
TIC	S-Phenotype
population	O
,	O
yet	O
mechanisms	O
governing	O
regulation	O
of	O
this	O
pathway	O
in	O
cancer	S-Phenotype
remain	O
to	O
be	O
fully	O
elucidated	O
.	O

Mutations	O
in	O
THAP1	O
[	O
THAP	O
(	O
Thanatos	O
-	O
associated	O
protein	O
)	O
domain	O
containing	O
,	O
apoptosis	O
associated	O
protein	O
1	O
]	O
,	O
a	O
ubiquitously	O
expressed	O
transcription	O
factor	O
with	O
DNA	O
binding	O
and	O
protein	O
-	O
interaction	O
domains	O
,	O
cause	O
dystonia	S-Phenotype
,	O
DYT6	O
.	O

These	O
3	O
patients	O
shared	O
congenital	B-Phenotype
neutropenia	E-Phenotype
linked	O
with	O
various	O
other	O
SDS	O
phenotypes	O
.	O

PCD	O
is	O
characterized	O
by	O
clinical	O
variability	O
and	O
extensive	O
genetic	O
heterogeneity	S-Phenotype
,	O
associated	O
with	O
different	O
cilia	O
ultrastructural	O
defects	O
and	O
mutations	O
identified	O
in	O
AAAA20	O
genes	O
.	O

Results	O
We	O
demonstrated	O
an	O
association	O
between	O
six	O
previously	O
published	O
single	O
nucleotide	O
polymorphisms	O
(	O
rs15869	O
[	O
BRCA2	O
]	O
,	O
rs1805389	O
[	O
LIG4	O
]	O
,	O
rs8079544	O
[	O
TP53	O
]	O
,	O
rs25489	O
[	O
XRCC1	O
]	O
,	O
rs1673041	O
[	O
POLD1	O
]	O
,	O
and	O
rs11615	O
[	O
ERCC1	O
]	O
)	O
and	O
subsequent	O
CNS	O
tumors	S-Phenotype
in	O
survivors	O
of	O
childhood	O
cancer	S-Phenotype
.	O

Moreover	O
,	O
adoptively	O
transferred	O
human	O
naive	O
CD4sup+	O
/	O
sup	O
T	O
cells	O
infiltrate	O
human	O
breast	B-Phenotype
cancer	E-Phenotype
orthotopic	O
xenografts	O
in	O
a	O
CCL18	O
-	O
dependent	O
manner	O
.	O

Liver	B-Phenotype
cancer	E-Phenotype
is	O
very	O
common	O
worldwide	O
and	O
the	O
rates	O
of	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
have	O
increased	O
by	O
over	O
70	O
%	O
in	O
the	O
last	O
2	O
decades	O
in	O
the	O
US	O
.	O

These	O
results	O
provide	O
new	O
insights	O
on	O
the	O
biological	O
relevance	O
of	O
the	O
mTOR	O
pathway	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
progression	O
and	O
underscore	O
the	O
need	O
for	O
more	O
genetic	O
epidemiology	O
studies	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
in	O
the	O
African	O
Diaspora	O

Here	O
,	O
we	O
identify	O
a	O
cause	O
of	O
the	O
autosomal	B-Phenotype
recessive	E-Phenotype
cblC	O
class	O
of	O
inborn	O
errors	O
of	O
vitamin	O
Bsub12	O
/	O
sub	O
metabolism	O
that	O
we	O
name	O
AAAAAAepi	O
-	O
cblCAAAAAA	O
.	O

Further	O
analysis	O
revealed	O
a	O
reduced	O
SMARCA4	O
expression	O
and	O
a	O
complete	O
loss	O
of	O
SMARCA2	O
expression	O
in	O
tumor	S-Phenotype
cells	O
.	O

We	O
here	O
demonstrate	O
that	O
the	O
expression	O
of	O
ZEB1	O
and	O
BMP	O
-	O
inhibitors	O
is	O
correlated	O
with	O
bone	O
metastasis	O
,	O
but	O
not	O
with	O
brain	O
or	O
lung	O
metastasis	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
patients	O
.	O

However	O
,	O
when	O
SDHB	B-Phenotype
-	I-Phenotype
tumors	E-Phenotype
give	O
rise	O
to	O
metastases	O
,	O
metastatic	O
cells	O
are	O
able	O
to	O
thrive	O
with	O
decreased	O
probability	O
of	O
regression	O
compared	O
with	O
SDHD	O
counterparts	O
(	O
p	O
=	O
0.17	O
vs	O
0.89	O
)	O
.	O

Mutations	O
in	O
the	O
glutaminyl	O
-	O
tRNA	O
synthetase	O
(	O
QARS	O
)	O
gene	O
have	O
been	O
reported	O
in	O
patients	O
with	O
progressive	B-Phenotype
microcephaly	E-Phenotype
,	O
cerebral	B-Phenotype
-	I-Phenotype
cerebellar	I-Phenotype
atrophy	E-Phenotype
,	O
and	O
intractable	B-Phenotype
seizures	E-Phenotype
.	O

Myotonic	O
dystrophy	O
type	O
2	O
(	O
DM2	O
)	O
is	O
a	O
progressive	O
multisystem	O
disease	O
with	O
muscle	B-Phenotype
weakness	E-Phenotype
and	O
myotonia	S-Phenotype
as	O
main	O
characteristics	O
.	O

In	O
the	O
second	O
example	O
,	O
Mdx	O
mice	O
,	O
a	O
model	O
for	O
Duchenne	B-Phenotype
muscular	I-Phenotype
dystrophy	E-Phenotype
,	O
were	O
intravenously	O
injected	O
with	O
AAV8	O
-	O
BGN	O
.	O

We	O
found	O
that	O
y	O
-	O
OH	O
-	O
PdG	O
and	O
a	O
-	O
methyl	O
-	O
y	O
-	O
OH	O
-	O
PdG	O
are	O
the	O
major	O
adducts	O
formed	O
in	O
tobacco	O
smokers	O
*	O
buccal	O
cells	O
as	O
well	O
as	O
the	O
normal	O
lung	O
tissues	O
of	O
tobacco	B-Phenotype
-	I-Phenotype
smoking	I-Phenotype
lung	I-Phenotype
cancer	E-Phenotype
patients	O
,	O
but	O
not	O
in	O
lung	O
tissues	O
of	O
nonsmokers	O
.	O

Primary	O
renal	O
PGL	O
and	O
neoplasia	S-Phenotype
was	O
associated	O
with	O
about	O
2	O
%	O
of	O
710	O
cases	O
of	O
PC	O
/	O
PGL	O
.	O

Cerebellar	O
involvement	O
is	O
an	O
important	O
feature	O
of	O
PMM2	O
-	O
CDG	O
,	O
the	O
congenital	B-Phenotype
muscular	I-Phenotype
dystrophies	E-Phenotype
due	O
to	O
dystroglycanopathy	O
,	O
and	O
SRD5A3	O
-	O
CDG	O
.	O

Isobutyryl	O
-	O
CoA	O
dehydrogenase	O
deficiency	O
(	O
IBDHD	O
)	O
is	O
a	O
rare	O
autosomal	B-Phenotype
recessive	E-Phenotype
metabolic	O
disorder	O
related	O
to	O
valine	O
catabolism	O
and	O
results	O
from	O
variants	O
in	O
ACAD8	O
.	O

ERCC1	O
overexpression	O
associated	O
with	O
advanced	O
tumor	S-Phenotype
clinical	O
stage	O
and	O
lymph	O
node	O
metastasis	O
(	O
P	O
AAAA	O
.05	O
)	O
,	O
but	O
not	O
with	O
tumor	S-Phenotype
size	O
,	O
depth	O
of	O
invasion	O
,	O
or	O
differentiation	O
(	O
P	O
AAAA	O
.05	O
)	O
.	O

Promoter	O
hypermethylation	O
was	O
positively	O
associated	O
with	O
duration	O
of	O
smoking	O
(	O
Spearman	O
rank	O
correlation	O
,	O
ρ	O
=	O
0.26	O
,	O
p	O
=	O
0.03	O
)	O
and	O
was	O
confined	O
to	O
tumours	S-Phenotype
,	O
with	O
hypermethylation	O
never	O
being	O
observed	O
in	O
adjacent	O
mucosa	O
.	O

The	O
genes	O
with	O
the	O
highest	O
number	O
of	O
hypermethylated	O
CpG	O
sites	O
in	O
INRG	O
M	O
tumors	S-Phenotype
are	O
TERT	O
,	O
PCDHGA4	O
,	O
DLX5	O
,	O
and	O
DLX6	O
-	O
AS1	O
.	O

Our	O
studies	O
identified	O
a	O
novel	O
homozygous	O
mutation	O
in	O
the	O
ciliary	O
protein	O
IFT43	O
as	O
the	O
underlying	O
cause	O
of	O
recessive	B-Phenotype
inherited	I-Phenotype
retinal	I-Phenotype
degeneration	E-Phenotype
.	O

Recent	O
studies	O
have	O
suggested	O
possible	O
therapeutic	O
targets	O
for	O
some	O
patients	O
with	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
glaucoma	E-Phenotype
based	O
on	O
the	O
molecular	O
and	O
cellular	O
events	O
caused	O
by	O
MYOC	O
,	O
OPTN	O
and	O
TBK1	O
mutations	O
.	O

The	O
tumor	S-Phenotype
number	O
and	O
weight	O
in	O
the	O
JTE	O
-	O
013	O
group	O
were	O
significantly	O
less	O
than	O
those	O
in	O
the	O
control	O
group	O
(	O
all	O
PAAAA0.01	O
)	O
.	O

MESP2	O
,	O
HES7	O
and	O
DUSP6	O
genes	O
have	O
been	O
proved	O
to	O
be	O
involved	O
in	O
the	O
etiopathogenesis	O
of	O
congenital	B-Phenotype
scoliosis	E-Phenotype
(	O
CS	S-Phenotype
)	O
in	O
animal	O
embryo	O
studies	O
,	O
however	O
,	O
whether	O
this	O
association	O
was	O
detected	O
in	O
human	O
CS	O
patients	O
also	O
remains	O
unknown	O
.	O

We	O
identified	O
a	O
homozygous	O
missense	O
mutation	O
,	O
c.1308	O
G	O
-	O
A	O
(	O
p.V421M	O
)	O
in	O
FOXRED1	O
in	O
a	O
patient	O
who	O
presented	O
with	O
epilepsy	S-Phenotype
and	O
severe	B-Phenotype
psychomotor	I-Phenotype
retardation	E-Phenotype
.	O

For	O
individual	O
RP	O
patients	O
,	O
our	O
study	O
may	O
help	O
to	O
predict	O
time	O
-	O
courses	O
for	O
Pde6a	O
-	O
related	O
retinal	B-Phenotype
degeneration	E-Phenotype
and	O
thereby	O
facilitate	O
the	O
definition	O
of	O
a	O
window	O
-	O
of	O
-	O
opportunity	O
for	O
clinical	O
interventions	O
.	O

In	O
addition	O
,	O
the	O
results	O
indicated	O
that	O
USP18	O
may	O
promote	O
the	O
epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
-	O
mediated	O
EGF	O
receptor	O
(	O
EGFR	O
)	O
/	O
AKT	O
/	O
S	O
-	O
phase	O
kinase	O
-	O
associated	O
protein	O
2	O
(	O
Skp2	O
)	O
pathway	O
by	O
upregulating	O
EGFR	O
and	O
Skp2	O
in	O
a	O
AKT	O
/	O
forkhead	O
box	O
O3	O
-	O
dependent	O
manner	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

Our	O
results	O
provide	O
evidence	O
that	O
sequence	O
variants	O
in	O
human	O
SIPA1L3	O
cause	O
autosomal	B-Phenotype
recessive	E-Phenotype
isolated	O
CC	O
and	O
give	O
new	O
insight	O
into	O
the	O
molecular	O
pathogenesis	O
underlying	O
human	O
cataracts	S-Phenotype
.	O

By	O
3	O
months	O
,	O
zonular	O
fibers	O
invariably	O
ruptured	O
and	O
mice	O
developed	O
ectopia	B-Phenotype
lentis	E-Phenotype
,	O
a	O
hallmark	O
of	O
Marfan	O
syndrome	O
.	O

In	O
this	O
work	O
we	O
investigated	O
the	O
role	O
of	O
forkhead	O
box	O
O1	O
(	O
FoxO1	O
)	O
in	O
the	O
transcriptional	O
regulation	O
in	O
macrophages	O
,	O
which	O
affects	O
the	O
anti	O
-	O
tumor	S-Phenotype
functions	O
of	O
tumor	S-Phenotype
-	O
associated	O
macrophages	O
(	O
TAMs	O
)	O
.	O

Increased	O
catabolite	O
concentrations	O
in	O
serum	O
are	O
associated	O
with	O
several	O
cardiovascular	B-Phenotype
diseases	E-Phenotype
(	O
CVD	S-Phenotype
)	O
,	O
including	O
heart	O
disease	O
,	O
atherosclerosis	S-Phenotype
,	O
and	O
endothelial	B-Phenotype
dysfunction	E-Phenotype
,	O
as	O
well	O
as	O
their	O
risk	O
factors	O
,	O
including	O
hypertension	S-Phenotype
,	O
diabetes	S-Phenotype
,	O
obesity	S-Phenotype
,	O
and	O
aging	S-Phenotype
.	O

Mice	O
carrying	O
kinase	O
-	O
dead	O
CLP1	O
also	O
displayed	O
microcephaly	S-Phenotype
and	O
reduced	O
cortical	O
brain	O
volume	O
due	O
to	O
the	O
enhanced	O
cell	O
death	O
of	O
neuronal	O
progenitors	O
that	O
is	O
associated	O
with	O
reduced	O
numbers	O
of	O
cortical	O
neurons	O
.	O

SOX11	O
is	O
a	O
key	O
Transcription	O
Factor	O
(	O
TF	O
)	O
in	O
the	O
regulation	O
of	O
embryonic	O
and	O
adult	O
neurogenesis	O
,	O
whose	O
mutation	O
has	O
recently	O
been	O
linked	O
to	O
an	O
intellectual	B-Phenotype
disability	E-Phenotype
syndrome	O
in	O
humans	O
.	O

However	O
,	O
the	O
negative	O
association	O
between	O
25	O
(	O
OH	O
)	O
D	O
and	O
GRS	O
was	O
modified	O
by	O
obesity	S-Phenotype
and	O
sun	O
exposure	O
.	O

Mutations	O
in	O
the	O
immunoglobulin	O
superfamily	O
,	O
member	O
1	O
gene	O
(	O
IGSF1	O
/	O
Igsf1	O
)	O
cause	O
an	O
X	O
-	O
linked	O
form	O
of	O
central	B-Phenotype
hypothyroidism	E-Phenotype
.	O

Mice	O
bearing	O
tumors	S-Phenotype
induced	O
by	O
A549	O
cells	O
stably	O
overexpressing	O
TNFSF15	O
exhibited	O
a	O
significant	O
increase	O
in	O
densities	O
of	O
lymphatic	O
vessels	O
and	O
a	O
marked	O
enhancement	O
of	O
A549	O
tumor	S-Phenotype
cells	O
in	O
newly	O
formed	O
lymphatic	O
vessels	O
in	O
the	O
primary	O
tumors	S-Phenotype
as	O
well	O
as	O
in	O
lymph	O
nodes	O
.	O

However	O
,	O
the	O
precise	O
role	O
of	O
miRNAs	O
in	O
gastric	B-Phenotype
cancer	E-Phenotype
(	O
GC	S-Phenotype
)	O
has	O
not	O
been	O
elucidated	O
.	O

We	O
found	O
evidence	O
for	O
at	O
least	O
five	O
independent	O
causal	O
variants	O
,	O
each	O
associated	O
with	O
different	O
phenotype	O
sets	O
,	O
including	O
estrogen	O
receptor	O
(	O
ER	O
(	O
+	O
)	O
or	O
ER	O
(	O
-	O
)	O
)	O
and	O
human	O
ERBB2	O
(	O
HER2	O
(	O
+	O
)	O
or	O
HER2	O
(	O
-	O
)	O
)	O
tumor	S-Phenotype
subtypes	O
,	O
mammographic	O
density	O
and	O
tumor	S-Phenotype
grade	O
.	O

Our	O
exome	O
analysis	O
indicated	O
the	O
proband	O
as	O
a	O
compound	O
heterozygote	O
for	O
two	O
missense	O
variants	O
in	O
the	O
TECPR2	O
gene	O
according	O
to	O
a	O
recessive	O
mode	B-Phenotype
of	I-Phenotype
inheritance	E-Phenotype
.	O

POMC	O
,	O
CPEB4	O
)	O
.	O

To	O
date	O
,	O
researchers	O
have	O
discovered	O
that	O
Nrf2	O
deletion	O
results	O
in	O
high	O
susceptibility	O
and	O
severity	O
of	O
insults	O
in	O
various	O
models	O
of	O
respiratory	O
diseases	O
,	O
including	O
bronchopulmonary	B-Phenotype
dysplasia	E-Phenotype
(	O
BPD	S-Phenotype
)	O
,	O
respiratory	B-Phenotype
infections	E-Phenotype
,	O
acute	B-Phenotype
respiratory	I-Phenotype
distress	I-Phenotype
syndrome	E-Phenotype
(	O
ARDS	S-Phenotype
)	O
,	O
chronic	B-Phenotype
obstructive	I-Phenotype
pulmonary	I-Phenotype
disease	E-Phenotype
(	O
COPD	S-Phenotype
)	O
,	O
asthma	S-Phenotype
,	O
idiopathic	B-Phenotype
pulmonary	I-Phenotype
fibrosis	E-Phenotype
(	O
IPF	S-Phenotype
)	O
,	O
and	O
lung	B-Phenotype
cancer	E-Phenotype
.	O

Generalized	B-Phenotype
epilepsies	E-Phenotype
,	O
particularly	O
the	O
idiopathic	B-Phenotype
or	I-Phenotype
genetic	I-Phenotype
generalized	I-Phenotype
epilepsies	E-Phenotype
(	O
GGEs	S-Phenotype
)	O
,	O
represent	O
some	O
of	O
the	O
most	O
common	O
epilepsies	S-Phenotype
.	O

We	O
investigated	O
which	O
host	O
factors	O
control	O
NETs	O
in	O
vivo	O
and	O
found	O
that	O
two	O
deoxyribonucleases	O
(	O
DNases	O
)	O
,	O
DNase1	O
and	O
DNase1	O
-	O
like	O
3	O
,	O
degraded	O
NETs	O
in	O
circulation	O
during	O
sterile	B-Phenotype
neutrophilia	E-Phenotype
and	O
septicemia	S-Phenotype
.	O

A	O
novel	O
mutation	O
of	O
an	O
essential	O
splice	O
site	O
in	O
the	O
C19orf70	O
gene	O
encoding	O
QIL1	O
induces	O
severe	O
mitochondrial	B-Phenotype
encephalopathy	E-Phenotype
,	O
hepatopathy	S-Phenotype
and	O
lactate	B-Phenotype
acidosis	E-Phenotype
consistent	O
with	O
psychomotor	B-Phenotype
retardation	E-Phenotype
.	O

We	O
conclude	O
that	O
QIL1	O
/	O
MIC13	O
deficiency	O
in	O
human	O
,	O
is	O
associated	O
with	O
disassembly	O
of	O
the	O
MICOS	O
complex	O
,	O
with	O
the	O
associated	O
aberration	B-Phenotype
of	I-Phenotype
cristae	I-Phenotype
morphology	E-Phenotype
and	O
mitochondrial	B-Phenotype
respiratory	I-Phenotype
dysfunction	E-Phenotype
.	O

The	O
colonic	O
expression	O
of	O
D2HGDH	O
is	O
decreased	O
in	O
ulcerative	B-Phenotype
colitis	E-Phenotype
(	O
UC	S-Phenotype
)	O
patients	O
at	O
baseline	O
who	O
progress	O
to	O
cancer	S-Phenotype
.	O

Overall	O
,	O
our	O
findings	O
identify	O
PRSS56	O
as	O
a	O
potential	O
therapeutic	O
target	O
for	O
modulating	O
ocular	O
growth	O
aimed	O
at	O
preventing	O
or	O
slowing	O
down	O
myopia	S-Phenotype
,	O
which	O
is	O
reaching	O
epidemic	O
proportions	O

We	O
present	O
a	O
case	O
of	O
type	O
2	O
autosomal	B-Phenotype
recessive	E-Phenotype
AOS	O
associated	O
with	O
heterozygous	O
mutations	O
in	O
the	O
dedicator	O
of	O
cytokinesis	O
6	O
(	O
DOCK6	O
)	O
gene	O
,	O
with	O
characteristic	O
findings	O
of	O
ACC	O
,	O
TTLD	O
,	O
intracerebral	B-Phenotype
periventricular	I-Phenotype
calcifications	E-Phenotype
,	O
and	O
polymicrogyria	S-Phenotype

Following	O
examination	O
of	O
the	O
association	O
of	O
the	O
identified	O
SNPs	O
to	O
serum	O
concentrations	O
of	O
triglycerides	O
,	O
HDL‑cholesterol	O
,	O
or	O
LDL‑cholesterol	O
,	O
linkage	O
disequilibrium	O
of	O
the	O
SNPs	O
,	O
and	O
results	O
of	O
previous	O
genome‑wide	O
association	O
studies	O
,	O
we	O
newly	O
identified	O
chromosomal	O
region	O
19p12	O
as	O
a	O
susceptibility	O
locus	O
for	O
hypertriglyceridemia	S-Phenotype
,	O
eight	O
loci	O
(	O
MOB3C‑TMOD4	O
,	O
LPGAT1	O
,	O
EHD3	O
,	O
COL6A3	O
,	O
ZNF860‑CACNA1D	O
,	O
COL6A5	O
,	O
DCLRE1C	O
,	O
ZNF77	O
)	O
for	O
hypo‑HDL‑cholesterolemia	S-Phenotype
,	O
and	O
three	O
loci	O
(	O
KIAA0319‑FAM65B	O
,	O
UBD	O
,	O
LOC105375015	O
)	O
for	O
hyper‑LDL‑cholesterolemia	S-Phenotype
.	O

Genes	O
harboring	O
the	O
most	O
significant	O
mutations	O
include	O
PCDH9	O
,	O
KLHL12	O
,	O
DCAF4L1	O
,	O
and	O
VHL	O
in	O
sporadic	S-Phenotype
HBs	O
,	O
and	O
ZNF814	O
,	O
DLG2	O
,	O
RIMS1	O
,	O
PNN	O
,	O
and	O
MUC7	O
in	O
familial	O
HBs	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
associate	O
a	O
component	O
of	O
the	O
RAR	O
pathway	O
with	O
renal	B-Phenotype
agenesis	E-Phenotype
in	O
humans	O

The	O
present	O
study	O
further	O
revealed	O
that	O
cancer	S-Phenotype
cell	O
death	O
was	O
primarily	O
caused	O
by	O
ATP	O
exhaustion	O
in	O
excessive	O
DNA	O
repair	O
with	O
high	O
PARP	O
-	O
1	O
activity	O
.	O

In	O
this	O
article	O
,	O
we	O
report	O
a	O
clinically	O
recognizable	O
craniofacial	O
disorder	O
characterized	O
by	O
facial	B-Phenotype
dysmorphisms	E-Phenotype
,	O
severe	O
micrognathia	S-Phenotype
,	O
rhizomelic	B-Phenotype
shortening	E-Phenotype
,	O
microcephalic	B-Phenotype
dwarfism	E-Phenotype
,	O
and	O
mild	B-Phenotype
developmental	I-Phenotype
delay	E-Phenotype
due	O
to	O
loss	O
-	O
of	O
-	O
function	O
heterozygous	O
mutations	O
in	O
ARCN1	O
,	O
which	O
encodes	O
the	O
coatomer	O
subunit	O
delta	O
of	O
COPI	O
.	O

BACKGROUND	O
The	O
present	O
study	O
explored	O
the	O
expression	O
of	O
coiled	O
-	O
coil	O
domain	O
-	O
containing	O
34	O
(	O
CCDC34	O
)	O
in	O
cervical	B-Phenotype
cancer	E-Phenotype
(	O
CC	S-Phenotype
)	O
and	O
its	O
prognostic	O
value	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
tumor	S-Phenotype
characteristics	O
,	O
including	O
size	O
at	O
pathologic	O
examination	O
,	O
grade	O
,	O
hormone	O
receptor	O
status	O
,	O
and	O
nodal	O
status	O
,	O
between	O
the	O
screening	O
-	O
detected	O
invasive	O
cancers	S-Phenotype
on	O
DM	O
versus	O
DBT	O
(	O
P	O
=	O
.09	O
-	O
.99	O
)	O
.	O

Several	O
myotubularins	O
have	O
been	O
genetically	O
linked	O
to	O
human	O
diseases	O
:	O
MTM1	O
is	O
mutated	O
in	O
the	O
congenital	B-Phenotype
myopathy	I-Phenotype
X	I-Phenotype
-	I-Phenotype
linked	I-Phenotype
centronuclear	E-Phenotype
or	O
myotubular	B-Phenotype
myopathy	E-Phenotype
(	O
XLCNM	O
)	O
and	O
MTMR14	O
(	O
JUMPY	O
)	O
has	O
been	O
linked	O
to	O
an	O
autosomal	O
form	O
of	O
such	O
disease	O
,	O
while	O
MTMR2	O
and	O
MTMR13	O
are	O
mutated	O
in	O
Charcot	O
-	O
Marie	O
-	O
Tooth	O
(	O
CMT	O
)	O
neuropathies	S-Phenotype
.	O

Necropsy	O
revealed	O
extensive	O
granulomatous	B-Phenotype
pneumonia	E-Phenotype
,	O
from	O
which	O
Mtb	O
was	O
isolated	O
and	O
identified	O
as	O
a	O
member	O
of	O
LAM3	O
/	O
F11	O
lineage	O
;	O
a	O
common	O
lineage	O
found	O
in	O
humans	O
in	O
South	O
Africa	O
.	O

t	O
(	O
12	O
;	O
22	O
)	O
(	O
p13	O
;	O
q12	O
)	O
is	O
a	O
rare	O
but	O
recurrent	O
chromosomal	O
abnormality	O
involving	O
the	O
ETS	O
transcription	O
factor	O
ETV6	O
and	O
meningioma	S-Phenotype
1	O
(	O
MN1	O
)	O
genes	O
.	O

Group	O
1	O
tumors	S-Phenotype
(	O
63	O
%	O
)	O
were	O
defined	O
as	O
11p15	O
-	O
mutant	O
and	O
WT1	O
-	O
normal	O
;	O
a	O
third	O
also	O
had	O
WTX	O
mutations	O
.	O

On	O
the	O
other	O
hand	O
,	O
MYH1	O
,	O
MYH2	O
,	O
MYH3	O
,	O
MYH7	O
,	O
MYH8	O
,	O
FOXO3	O
,	O
NFATC1	O
,	O
PTGS2	O
,	O
KAT6B	O
,	O
HDAC4	O
,	O
and	O
RUNX2	O
expression	O
is	O
suspected	O
to	O
be	O
involved	O
in	O
the	O
epigenetic	O
regulations	O
behind	O
the	O
mandibular	B-Phenotype
prognathism	E-Phenotype
phenotype	O

Logistic	O
regression	O
analysis	O
adjusted	O
for	O
age	O
and	O
gender	O
reported	O
a	O
moderate	O
association	O
between	O
rectal	B-Phenotype
cancer	E-Phenotype
risk	O
and	O
two	O
NLRC5	O
SNPs	O
,	O
rs1684575	O
TAAAAG	O
(	O
OR	O
:	O
1.60	O
,	O
95	O
%	O
CI	O
:	O
1.13	O
-	O
2.27	O
,	O
recessive	O
model	O
)	O
and	O
rs3751710	O
(	O
OR	O
:	O
0.70	O
,	O
95	O
%	O
CI	O
:	O
0.51	O
-	O
0.96	O
,	O
dominant	O
model	O
)	O
.	O

The	O
RAD51	O
recombinase	O
plays	O
a	O
central	O
role	O
in	O
homologous	O
recombination	O
(	O
HR	O
)	O
,	O
which	O
is	O
critical	O
for	O
repair	O
of	O
DNA	O
double	O
-	O
strand	O
breaks	O
,	O
maintenance	O
of	O
genomic	O
stability	O
,	O
and	O
prevention	O
of	O
developmental	O
disorders	O
and	O
cancer	S-Phenotype
.	O

CRIPTO	O
protein	O
was	O
strongly	O
expressed	O
in	O
germ	B-Phenotype
cell	I-Phenotype
neoplasia	E-Phenotype
in	O
situ	O
along	O
with	O
embryonal	B-Phenotype
carcinoma	E-Phenotype
,	O
yolk	B-Phenotype
sac	I-Phenotype
tumor	E-Phenotype
and	O
seminomas	S-Phenotype
.	O

In	O
the	O
present	O
study	O
,	O
we	O
evaluated	O
the	O
association	O
of	O
SENPs	O
polymorphism	O
with	O
susceptibility	O
as	O
well	O
as	O
clinicopathologic	O
features	O
and	O
patients	O
'	O
response	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
(	O
BC	S-Phenotype
)	O
in	O
a	O
Chinese	O
population	O
.	O

We	O
genotyped	O
SENP1	O
(	O
rs61918808	O
)	O
,	O
SENP2	O
(	O
rs6762208	O
)	O
,	O
SENP7	O
(	O
rs61697963	O
)	O
by	O
sequencing	O
in	O
a	O
case	O
-	O
control	O
study	O
including	O
210	O
BC	O
patients	O
and	O
225	O
healthy	O
volunteers	O
.	O

This	O
trend	O
is	O
,	O
in	O
part	O
,	O
secondary	O
,	O
to	O
the	O
growing	O
incidence	O
of	O
obesity	S-Phenotype
,	O
type	B-Phenotype
2	I-Phenotype
diabetes	E-Phenotype
,	O
and	O
metabolic	O
syndrome	O
.	O

Primary	B-Phenotype
macronodular	I-Phenotype
adrenal	I-Phenotype
hyperplasia	E-Phenotype
(	O
PMAH	S-Phenotype
)	O
,	O
also	O
known	O
in	O
the	O
past	O
as	O
bilateral	B-Phenotype
macronodular	I-Phenotype
adrenalhyperplasia	E-Phenotype
or	O
adrenocorticotropin	S-Phenotype
(	O
ACTH	S-Phenotype
)	O
-	O
independent	O
macronodular	B-Phenotype
adrenal	I-Phenotype
hyperplasia	E-Phenotype
,	O
is	O
a	O
rare	O
type	O
of	O
Cushing	O
's	O
syndrome	O
(	O
CS	O
)	O
and	O
is	O
associated	O
with	O
bilateralenlargement	O
of	O
the	O
adrenal	O
glands	O
.	O

We	O
show	O
that	O
loss	O
of	O
the	O
Drosophila	O
long	O
-	O
/	O
very	O
-	O
long	O
-	O
chain	O
acyl	O
-	O
CoA	O
synthetase	O
genes	O
bgm	O
and	O
/	O
or	O
dbb	O
is	O
indistinguishable	O
from	O
loss	O
of	O
the	O
Drosophila	O
ABC	O
transporter	O
gene	O
ABCD	O
Shared	O
loss	O
-	O
of	O
-	O
function	O
phenotypes	O
for	O
synthetase	O
and	O
transporter	O
mutants	O
point	O
to	O
a	O
lipid	O
metabolic	O
pathway	O
association	O
with	O
ALD	O
-	O
like	O
neurodegenerative	B-Phenotype
disease	E-Phenotype
in	O
Drosophila	O
;	O
a	O
pathway	O
association	O
that	O
has	O
yet	O
to	O
be	O
established	O
in	O
humans	O
.	O

Previous	O
studies	O
have	O
reported	O
the	O
association	O
of	O
prodynorphin	O
(	O
PDYN	O
)	O
promoter	O
polymorphism	O
with	O
temporal	B-Phenotype
lobe	I-Phenotype
epilepsy	E-Phenotype
(	O
TLE	S-Phenotype
)	O
susceptibility	O
,	O
but	O
the	O
results	O
remain	O
inconclusive	O
.	O

Furthermore	O
,	O
microRNA	O
-	O
22	O
targeted	O
NRAS	O
proto	O
-	O
oncogene	O
,	O
GTPase	O
(	O
NRAS	O
)	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Differently	O
from	O
other	O
digestive	O
malignancies	O
,	O
gastric	B-Phenotype
cancer	E-Phenotype
(	O
GC	S-Phenotype
)	O
carcinogenesis	O
seems	O
more	O
heterogeneous	S-Phenotype
and	O
unclear	O
.	O

In	O
two	O
different	O
patients	O
with	O
unilateral	B-Phenotype
cryptorchidism	E-Phenotype
,	O
we	O
found	O
the	O
variants	O
rs121912556	O
and	O
p.R105R	O
of	O
INSL3	O
gene	O
in	O
a	O
heterozygous	O
form	O
associated	O
with	O
cryptorchidism	S-Phenotype
,	O
so	O
we	O
could	O
considered	O
them	O
as	O
risk	O
factors	O
for	O
cryptorchidism	S-Phenotype
.	O

Recently	O
hamartomatous	O
skin	O
lesions	O
have	O
also	O
been	O
noted	O
in	O
families	O
with	O
childhood	O
medulloblastoma	S-Phenotype
,	O
a	O
AAAAAAGorlin	O
likeAAAAAA	O
phenotype	O
and	O
a	O
SUFU	O
mutation	O
.	O

The	O
tumor	S-Phenotype
cells	O
resembled	O
pro	O
-	O
B	O
cells	O
,	O
and	O
were	O
CD19+IgM	O
-	O
IgD	O
-	O
CD93+CD43+CD21	O
-	O
CD23	O
-	O
VpreB+CXCR4+	O
Consistent	O
with	O
the	O
pro	O
-	O
B	O
-	O
cell	O
stage	O
of	O
B	O
-	O
cell	O
development	O
,	O
microarray	O
analysis	O
revealed	O
enrichment	O
of	O
transcripts	O
,	O
including	O
Rag1	O
,	O
Rag2	O
,	O
CD93	O
,	O
Vpreb1	O
,	O
Vpreb3	O
,	O
and	O
Igll1	O
We	O
confirmed	O
RAG1	O
expression	O
in	O
Tg26	O
tumors	S-Phenotype
,	O
and	O
hypothesized	O
that	O
HIV	O
-	O
1	O
matrix	O
protein	O
p17	O
may	O
directly	O
induce	O
RAG1	O
in	O
B	O
cells	O
.	O

We	O
tried	O
to	O
elucidate	O
the	O
role	O
of	O
three	O
3p21.3	O
TSGs	O
:	O
DLEC1	O
,	O
ITGA9	O
and	O
MLH1	O
,	O
in	O
non	B-Phenotype
-	I-Phenotype
small	I-Phenotype
cell	I-Phenotype
lung	I-Phenotype
cancer	E-Phenotype
(	O
NSCLC	S-Phenotype
)	O
.	O

We	O
examined	O
the	O
effects	O
of	O
a	O
mutation	O
in	O
the	O
Sh3pxd2b	O
gene	O
(	O
Sh3pxd2b	O
(	O
nee	O
)	O
)	O
on	O
the	O
progression	O
of	O
otitis	B-Phenotype
media	E-Phenotype
and	O
hearing	B-Phenotype
impairment	E-Phenotype
at	O
various	O
developmental	O
stages	O
.	O

The	O
expression	O
of	O
the	O
ID2	O
,	O
PRELP	O
and	O
SMOC2	O
genes	O
was	O
compared	O
between	O
the	O
endometrium	O
of	O
women	O
without	O
endometriosis	S-Phenotype
in	O
the	O
proliferative	O
phase	O
of	O
their	O
menstrual	O
cycle	O
and	O
the	O
eutopic	O
and	O
ectopic	O
endometrium	O
of	O
women	O
with	O
endometriosis	S-Phenotype
in	O
the	O
proliferative	O
phase	O
.	O

In	O
addition	O
,	O
inactivation	O
of	O
the	O
tumor	S-Phenotype
suppressor	O
retinoblastoma	B-Phenotype
1	E-Phenotype
(	O
RB1	S-Phenotype
)	O
,	O
reflected	O
by	O
CCND1	O
/	O
CDK6	O
-	O
inactivating	O
phosphorylation	O
of	O
RB1	O
at	O
T356	O
,	O
inversely	O
correlated	O
with	O
expression	O
of	O
EGFR	O
in	O
patient	O
HNSCC	O
samples	O
.	O

The	O
triggering	O
receptor	O
expressed	O
on	O
myeloid	O
cells	O
2	O
(	O
TREM2	O
)	O
is	O
a	O
microglial	O
innate	O
immune	O
receptor	O
associated	O
with	O
a	O
lethal	O
form	O
of	O
early	O
,	O
progressive	B-Phenotype
dementia	E-Phenotype
,	O
Nasu	O
-	O
Hakola	O
disease	O
,	O
and	O
with	O
an	O
increased	O
risk	O
of	O
Alzheimer	O
*	O
s	O
disease	O
.	O

Collectively	O
,	O
our	O
data	O
highlight	O
that	O
,	O
by	O
inhibiting	O
ANT1	O
and	O
mitochondrial	B-Phenotype
dysfunction	E-Phenotype
,	O
SHP2	O
orchestrates	O
an	O
intrinsic	O
regulatory	O
loop	O
to	O
limit	O
excessive	O
NLRP3	O
inflammasome	O
activation	O

Recent	O
studies	O
have	O
revealed	O
severe	O
cases	O
of	O
microcephaly	S-Phenotype
resulting	O
from	O
human	O
mutations	O
in	O
the	O
NDE1	O
gene	O
,	O
which	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
cytoplasmic	O
dynein	O
.	O

Over	O
60	O
years	O
after	O
the	O
initial	O
description	O
of	O
PDE	O
,	O
we	O
report	O
the	O
first	O
animal	O
model	O
for	O
this	O
disease	O
:	O
an	O
aldh7a1	O
-	O
null	O
zebrafish	O
(	O
liDanio	O
rerio	O
/	O
i	O
)	O
displaying	O
deficient	O
lysine	O
metabolism	O
and	O
spontaneous	O
and	O
recurrent	O
seizures	S-Phenotype
in	O
the	O
larval	O
stage	O
(	O
10	O
days	O
postfertilization	O
)	O
.	O

Seborrhoeic	B-Phenotype
Dermatitis	E-Phenotype
(	O
SD	S-Phenotype
)	O
is	O
a	O
common	O
inflammatory	B-Phenotype
skin	I-Phenotype
disease	E-Phenotype
that	O
presents	O
as	O
itchy	B-Phenotype
,	I-Phenotype
flaking	I-Phenotype
skin	E-Phenotype
in	O
the	O
seborrhoeic	O
areas	O
.	O

We	O
provide	O
herein	O
a	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
review	O
of	O
the	O
genetic	O
bases	O
of	O
atrial	B-Phenotype
fibrillation	E-Phenotype
,	O
our	O
current	O
understanding	O
of	O
the	O
genetic	O
regulatory	O
networks	O
involved	O
in	O
AF	O
and	O
its	O
plausible	O
usage	O
for	O
searching	O
novel	O
therapeutic	O
targets	O

The	O
AP4B1	O
-	O
associated	O
phenotype	O
has	O
previously	O
been	O
assigned	O
to	O
spastic	B-Phenotype
paraplegia	E-Phenotype
-	O
47	O
.	O

Colorectal	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
with	O
CHFR	O
methylation	O
demonstrated	O
increased	O
sensitivity	O
to	O
irinotecan	O
.	O

Minichromosome	O
maintenance	O
protein	O
5	O
(	O
MCM5	O
)	O
has	O
been	O
suggested	O
overexpressed	O
in	O
cervical	B-Phenotype
cancer	E-Phenotype
,	O
but	O
the	O
clinical	O
value	O
and	O
biological	O
function	O
of	O
MCM5	O
in	O
cervical	B-Phenotype
cancer	E-Phenotype
is	O
still	O
unknown	O
.	O

RESULTS	O
Both	O
GEPIA	O
and	O
Oncomine	O
cancer	S-Phenotype
databases	O
mining	O
results	O
revealed	O
that	O
CCDC34	O
was	O
more	O
highly	O
expressed	O
in	O
the	O
CC	O
group	O
than	O
in	O
the	O
normal	O
group	O
(	O
all	O
PAAAA0.05	O
)	O
.	O

However	O
,	O
more	O
recently	O
,	O
inherited	O
SWI	O
/	O
SNF	O
-	O
deficiency	O
has	O
been	O
linked	O
to	O
several	O
benign	O
syndromic	O
tumors	S-Phenotype
including	O
a	O
subset	O
of	O
familial	O
schwannomatosis	O
(	O
linked	O
to	O
SMARCB1	O
)	O
and	O
multiple	O
meningiomas	S-Phenotype
(	O
linked	O
to	O
SMARCE1	O
)	O
as	O
well	O
as	O
others	O
.	O

The	O
expression	O
level	O
of	O
lncRNA	O
FEZF	O
-	O
AS1	O
and	O
FEZF1	O
was	O
determined	O
by	O
the	O
quantitative	O
Real	O
-	O
time	O
PCR	O
in	O
160	O
cases	O
of	O
NSCLC	O
tissues	O
and	O
their	O
adjacent	O
non	O
-	O
tumour	S-Phenotype
tissues	O
.	O

Overexpression	O
of	O
Rab3IP	O
in	O
gastric	B-Phenotype
cancer	E-Phenotype
was	O
verified	O
at	O
both	O
transcriptional	O
and	O
translational	O
levels	O
.	O

In	O
CSTA	O
-	O
positive	O
tumor	S-Phenotype
samples	O
,	O
CSTA	O
-	O
expressing	O
cancer	S-Phenotype
cells	O
often	O
expressed	O
Ki67	O
,	O
a	O
proliferation	O
marker	O
,	O
which	O
was	O
in	O
sharp	O
contrast	O
to	O
normal	O
mucosa	O
,	O
where	O
Ki67	O
-	O
expressing	O
cells	O
were	O
limited	O
to	O
the	O
basal	O
layer	O
and	O
did	O
not	O
express	O
CSTA	O
.	O

Hereditary	O
sensory	O
and	O
autonomic	O
neuropathy	S-Phenotype
type	O
III	O
,	O
or	O
familial	O
dysautonomia	S-Phenotype
[	O
FD	O
;	O
Online	O
Mendelian	O
Inheritance	O
in	O
Man	O
(	O
OMIM	O
)	O
223900	O
]	O
,	O
affects	O
the	O
development	O
and	O
long	O
-	O
term	O
viability	O
of	O
neurons	O
in	O
the	O
peripheral	O
nervous	O
system	O
(	O
PNS	O
)	O
and	O
retina	O
.	O

Collectively	O
,	O
we	O
found	O
attenuation	O
of	O
HDAC3	O
and	O
overexpression	O
of	O
collagen	O
type	O
I	O
in	O
the	O
eutopic	O
endometrium	O
of	O
infertile	O
patients	O
with	O
endometriosis	S-Phenotype
.	O

Estrogen	O
receptor	O
alpha	O
(	O
ERa	O
)	O
and	O
retinoic	O
acid	O
receptors	O
(	O
RARs	O
)	O
play	O
important	O
and	O
opposite	O
roles	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
growth	O
.	O

The	O
expression	O
level	O
of	O
CLDN10	O
was	O
reduced	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
tissues	O
compared	O
with	O
normal	O
breast	O
tissues	O
according	O
to	O
the	O
analysis	O
of	O
The	O
Cancer	S-Phenotype
Genome	O
Atlas	O
(	O
TCGA	O
)	O
data	O
through	O
GEPIA.Our	O
results	O
suggest	O
that	O
the	O
polymorphism	O
of	O
rs1325774	O
associate	O
with	O
increase	O
the	O
breast	B-Phenotype
cancer	E-Phenotype
risk	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
indicate	O
that	O
anti	O
-	O
LGI1	O
encephalitis	S-Phenotype
may	O
present	O
as	O
slowly	O
progressive	O
cognitive	B-Phenotype
impairment	I-Phenotype
mimicking	I-Phenotype
dementia	E-Phenotype
and	O
that	O
fluctuating	O
MRI	O
striatal	O
lesions	O
may	O
be	O
a	O
characteristic	O
radiological	O
finding	O
of	O
this	O
disorder	O

Because	O
RSPRY1	O
was	O
been	O
discovered	O
as	O
the	O
cause	O
of	O
progressive	O
skeletal	B-Phenotype
dysplasia	E-Phenotype
,	O
a	O
loss	O
of	O
this	O
gene	O
might	O
explain	O
the	O
skeletal	O
defects	O
observed	O
in	O
the	O
patient	O

However	O
,	O
the	O
mechanism	O
by	O
which	O
HMGA2	O
promotes	O
the	O
growth	O
of	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
remains	O
unclear	O
.	O

Mutations	O
in	O
the	O
KARS	O
gene	O
,	O
which	O
encodes	O
both	O
the	O
cytosolic	O
and	O
mitochondrial	O
isoform	O
of	O
lysyl	O
-	O
tRNA	O
synthetase	O
,	O
cause	O
predominantly	O
neurological	O
diseases	O
that	O
often	O
involve	O
deafness	S-Phenotype
,	O
but	O
have	O
also	O
been	O
linked	O
to	O
cardiomyopathy	S-Phenotype
,	O
developmental	B-Phenotype
delay	E-Phenotype
,	O
and	O
lactic	B-Phenotype
acidosis	E-Phenotype
.	O

The	O
most	O
important	O
parameters	O
to	O
consider	O
when	O
determining	O
arrhythmic	O
risk	O
include	O
electric	O
instability	O
,	O
including	O
the	O
frequency	O
of	O
premature	B-Phenotype
ventricular	I-Phenotype
contractions	E-Phenotype
and	O
sustained	O
ventricular	B-Phenotype
arrhythmia	E-Phenotype
;	O
proband	O
status	O
;	O
extent	O
of	O
structural	O
disease	O
;	O
cardiac	B-Phenotype
syncope	E-Phenotype
;	O
male	O
sex	O
;	O
the	O
presence	O
of	O
multiple	O
mutations	O
or	O
a	O
mutation	O
in	O
TMEM43	O
;	O
and	O
the	O
patient	O
*	O
s	O
willingness	O
to	O
restrict	O
exercise	O
and	O
to	O
eliminate	O
participation	O
in	O
competitive	O
or	O
endurance	O
exercise	O

Objective	O
clinical	O
response	O
was	O
19	O
%	O
(	O
one	O
confirmed	O
partial	O
response	O
(	O
PR	O
)	O
in	O
small	B-Phenotype
cell	I-Phenotype
lung	I-Phenotype
cancer	E-Phenotype
(	O
SCLC	S-Phenotype
)	O
and	O
two	O
unconfirmed	O
)	O
;	O
stable	O
disease	O
(	O
SD	O
)	O
was	O
6	O
%	O
for	O
a	O
disease	O
control	O
rate	O
(	O
DCR	O
)	O
of	O
25	O
%	O
.	O

Peroxisome	O
biogenesis	O
disorders	O
(	O
PBD	O
)	O
are	O
a	O
heterogeneous	S-Phenotype
group	O
of	O
disorders	O
due	O
to	O
PEX	O
genes	O
mutations	O
,	O
with	O
a	O
broad	O
clinical	O
spectrum	O
comprising	O
severe	O
neonatal	O
disease	O
to	O
mild	O
presentation	O
.	O

Both	O
display	O
heterotaxy	S-Phenotype
,	O
cardiopulmonary	B-Phenotype
malformations	E-Phenotype
and	O
cystic	B-Phenotype
kidneys	E-Phenotype
,	O
a	O
syndrome	O
also	O
characteristic	O
of	O
mutations	O
in	O
Invs	O
and	O
Nphp3	O
,	O
the	O
other	O
known	O
components	O
of	O
the	O
IC	O
.	O

Our	O
objective	O
was	O
to	O
determine	O
molecular	O
phenotypes	O
of	O
asthma	S-Phenotype
by	O
analysing	O
sputum	O
cell	O
transcriptomics	O
from	O
104	O
moderate	O
-	O
to	O
-	O
severe	O
asthmatic	O
subjects	O
and	O
16	O
nonasthmatic	O
subjects.After	O
filtering	O
on	O
the	O
differentially	O
expressed	O
genes	O
between	O
eosinophil	O
-	O
and	O
noneosinophil	O
-	O
associated	O
sputum	O
inflammation	O
,	O
we	O
used	O
unbiased	O
hierarchical	O
clustering	O
on	O
508	O
differentially	O
expressed	O
genes	O
and	O
gene	O
set	O
variation	O
analysis	O
of	O
specific	O
gene	O
sets	O
.	O

We	O
defined	O
three	O
transcriptome	O
-	O
associated	O
clusters	O
(	O
TACs	O
)	O
:	O
TAC1	O
(	O
characterised	O
by	O
immune	O
receptors	O
liIL33R	O
/	O
i	O
,	O
liCCR3	O
/	O
i	O
and	O
liTSLPR	O
/	O
i	O
)	O
,	O
TAC2	O
(	O
characterised	O
by	O
interferon	O
-	O
,	O
tumour	S-Phenotype
necrosis	O
factor	O
-	O
α	O
-	O
and	O
inflammasome	O
-	O
associated	O
genes	O
)	O
and	O
TAC3	O
(	O
characterised	O
by	O
genes	O
of	O
metabolic	O
pathways	O
,	O
ubiquitination	O
and	O
mitochondrial	O
function	O
)	O
.	O

Herein	O
we	O
explored	O
whether	O
cellular	O
senescence	O
,	O
an	O
anti	O
-	O
tumoral	S-Phenotype
pathway	O
that	O
restrains	O
cell	O
proliferation	O
,	O
is	O
a	O
mechanism	O
by	O
which	O
Spi1	O
limits	O
hematopoietic	O
cell	O
expansion	O
,	O
and	O
thus	O
prevents	O
the	O
development	O
of	O
leukemia	S-Phenotype
.	O

Low	B-Phenotype
-	I-Phenotype
grade	I-Phenotype
fibromyxoid	I-Phenotype
sarcoma	E-Phenotype
(	O
LGFMS	S-Phenotype
)	O
and	O
sclerosing	B-Phenotype
epithelioid	I-Phenotype
fibrosarcoma	E-Phenotype
(	O
SEF	S-Phenotype
)	O
are	O
rare	O
tumors	S-Phenotype
with	O
distinct	O
sets	O
of	O
morphological	O
features	O
,	O
both	O
characterized	O
by	O
MUC4	O
immunoreactivity	O
.	O

In	O
vitro	O
test	O
on	O
colon	B-Phenotype
cancer	E-Phenotype
resistant	O
/	O
susceptible	O
to	O
chemoradioterapy	O
cells	O
,	O
finally	O
prove	O
that	O
XRCC3	O
deregulation	O
is	O
extensively	O
involved	O
in	O
the	O
chemoresistance	O
mechanisms	O
.	O

Recent	O
studies	O
have	O
suggested	O
possible	O
therapeutic	O
targets	O
for	O
some	O
patients	O
with	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
glaucoma	E-Phenotype
based	O
on	O
the	O
molecular	O
and	O
cellular	O
events	O
caused	O
by	O
MYOC	O
,	O
OPTN	O
and	O
TBK1	O
mutations	O
.	O

Our	O
data	O
,	O
with	O
previously	O
published	O
reports	O
,	O
suggest	O
that	O
duplications	O
involving	O
SHROOM4	O
and	O
DGKK	O
may	O
represent	O
a	O
new	O
syndromic	O
X	O
-	O
linked	O
ID	O
critical	O
region	O
associated	O
with	O
mild	O
to	O
severe	O
ID	S-Phenotype
,	O
speech	B-Phenotype
delay	E-Phenotype
+	O
/	O
-	O
dysarthria	S-Phenotype
,	O
attention	B-Phenotype
deficit	E-Phenotype
disorder	O
,	O
precocious	B-Phenotype
puberty	E-Phenotype
,	O
constipation	S-Phenotype
,	O
and	O
motor	B-Phenotype
delay	E-Phenotype
.	O

These	O
effects	O
are	O
thought	O
to	O
have	O
a	O
significant	O
impact	O
upon	O
both	O
vascular	O
and	O
cerebrovascular	O
health	O
,	O
ultimately	O
with	O
the	O
potential	O
to	O
prevent	O
cardiovascular	B-Phenotype
and	I-Phenotype
potentially	I-Phenotype
neurodegenerative	I-Phenotype
disease	E-Phenotype
with	O
a	O
vascular	O
component	O
,	O
for	O
example	O
vascular	B-Phenotype
dementia	E-Phenotype
.	O

Based	O
on	O
screening	O
results	O
,	O
five	O
unique	O
genes	O
(	O
GNPAT	O
,	O
SUMO1	O
,	O
SPINT2	O
,	O
FLI1	O
,	O
and	O
SSX1	O
)	O
significantly	O
potentiated	O
the	O
growth	O
inhibitory	O
effects	O
of	O
CDDO	O
-	O
Me	O
and	O
induced	O
apoptosis	O
in	O
A375	O
,	O
a	O
BRAF	O
mutated	O
melanoma	S-Phenotype
line	O
(	O
P	O
AAAA	O
0.001	O
)	O
.	O

Ellis	O
-	O
van	O
Creveld	O
(	O
EVC	O
)	O
syndrome	O
is	O
a	O
rare	O
autosomal	O
recessive	O
disorder	O
characterized	O
by	O
hypoplastic	B-Phenotype
nails	E-Phenotype
,	O
polydactyly	S-Phenotype
,	O
and	O
achondroplasia	S-Phenotype
.	O

Since	O
RAPSN	O
-	O
associated	O
limb	O
-	O
girdle	O
type	O
CMS	O
was	O
only	O
manifested	O
in	O
AK9	O
homozygous	O
variant	O
carriers	O
,	O
the	O
disease	O
phenotype	O
was	O
of	O
digenic	B-Phenotype
inheritance	E-Phenotype
,	O
and	O
was	O
determined	O
by	O
the	O
novel	O
disease	O
modifier	O
AK9	O
which	O
provides	O
NTPs	O
for	O
N	O
-	O
glycosylation	O
.	O

Mutant	O
mice	O
manifest	O
the	O
main	O
clinical	O
features	O
identified	O
in	O
patients	O
,	O
including	O
ataxia	S-Phenotype
,	O
optic	B-Phenotype
atrophy	E-Phenotype
and	O
cerebellar	B-Phenotype
hypoplasia	E-Phenotype
,	O
which	O
were	O
completely	O
rescued	O
by	O
expression	O
of	O
the	O
human	O
ortholog	O
.	O

We	O
identified	O
52	O
variants	O
contributing	O
to	O
obesity	S-Phenotype
in	O
2	O
%	O
of	O
cases	O
including	O
multiple	O
novel	O
variants	O
in	O
GNAS	O
,	O
which	O
were	O
sometimes	O
found	O
with	O
accelerated	O
growth	O
rather	O
than	O
short	B-Phenotype
stature	E-Phenotype
as	O
described	O
previously	O
.	O

Of	O
the	O
2	O
204	O
genes	O
that	O
were	O
mutated	O
,	O
APC	O
,	O
TTN	O
,	O
TP53	O
,	O
KRAS	O
,	O
OBSCN	O
,	O
SOX9	O
,	O
PCDH17	O
,	O
SIGLEC10	O
,	O
MYH6	O
,	O
and	O
BRD9	O
were	O
consistent	O
with	O
genes	O
being	O
an	O
early	O
driver	O
of	O
carcinogenesis	O
,	O
in	O
that	O
they	O
were	O
mutated	O
in	O
multiple	O
adenomas	O
and	O
multiple	O
carcinomas	S-Phenotype
.	O

Bone	O
morphogenetic	O
protein	O
7	O
(	O
BMP7	O
)	O
,	O
a	O
member	O
of	O
the	O
BMP	O
family	O
of	O
signaling	O
molecules	O
,	O
has	O
been	O
implicated	O
in	O
various	O
types	O
of	O
cancer	S-Phenotype
,	O
particularly	O
prostate	B-Phenotype
cancer	E-Phenotype
and	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

We	O
found	O
that	O
Tctn3	O
KO	O
mice	O
exhibited	O
abnormal	O
global	O
development	O
,	O
including	O
prenatal	B-Phenotype
lethality	E-Phenotype
,	O
microphthalmia	S-Phenotype
,	O
polysyndactyly	S-Phenotype
,	O
and	O
abnormal	B-Phenotype
head	E-Phenotype
,	O
sternum	S-Phenotype
,	O
and	O
neural	B-Phenotype
tube	E-Phenotype
,	O
whereas	O
Tctn3	O
heterozygous	O
KO	O
mice	O
did	O
not	O
show	O
abnormal	O
development	O
or	O
behaviors	O
.	O

Additionally	O
,	O
immunohistochemistry	O
staining	O
and	O
Western	O
blot	O
showed	O
that	O
highly	O
expressed	O
miR	O
-	O
135b	O
-	O
5p	O
accelerated	O
EMT	O
process	O
of	O
pancreatic	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

The	O
suppression	O
of	O
FoxO1	O
expression	O
in	O
TAM	O
was	O
induced	O
by	O
the	O
hypoxic	O
condition	O
in	O
the	O
tumor	S-Phenotype
microenviroment	O
.	O

Clinical	O
comparisons	O
showed	O
that	O
ataxias	S-Phenotype
due	O
to	O
channelopathies	O
had	O
a	O
significantly	O
earlier	O
age	O
at	O
onset	O
with	O
an	O
average	O
of	O
24.6	O
years	O
,	O
versus	O
40.9	O
years	O
for	O
polyglutamine	O
expansion	O
spinocerebellar	B-Phenotype
ataxias	E-Phenotype
and	O
37.8	O
years	O
for	O
SPG7	O
-	O
related	O
forms	O
(	O
P	O
=	O
0.001	O
)	O
.	O

Importantly	O
,	O
dysfunction	O
in	O
other	O
family	O
members	O
leads	O
to	O
learning	O
deficits	O
(	O
TRPC1	O
/	O
4	O
/	O
5	O
)	O
and	O
ataxia	S-Phenotype
(	O
TRPC3	O
)	O
.	O

CSD	O
is	O
clinically	O
and	O
genetically	O
heterogeneous	S-Phenotype
.	O

Cases	O
were	O
reviewed	O
for	O
consanguinity	O
,	O
sex	O
,	O
age	O
at	O
onset	O
,	O
death	O
,	O
clinical	O
findings	O
(	O
including	O
spasticity	S-Phenotype
,	O
seizures	S-Phenotype
,	O
psychomotor	B-Phenotype
retardation	E-Phenotype
,	O
feeding	B-Phenotype
difficulties	E-Phenotype
,	O
ectopia	B-Phenotype
lentis	E-Phenotype
,	O
microcephaly	S-Phenotype
)	O
,	O
laboratory	O
findings	O
[	O
urinary	O
sulfite	O
,	O
S	O
-	O
sulfocysteine	O
(	O
in	O
plasma	O
and	O
urine	O
)	O
,	O
plasma	O
cystine	O
,	O
total	O
homocysteine	O
,	O
uric	O
acid	O
,	O
and	O
oxypurines	O
in	O
urine	O
]	O
and	O
radiological	O
findings	O
(	O
including	O
cerebral	B-Phenotype
/	I-Phenotype
cerebellar	I-Phenotype
atrophy	E-Phenotype
,	O
cystic	O
white	O
matter	O
changes	O
,	O
ventriculomegaly	S-Phenotype
)	O
.	O

Somatic	O
mutations	O
in	O
four	O
genes	O
(	O
KCNJ5	O
,	O
ATP1A1	O
,	O
ATP2B3	O
and	O
CACNA1D	O
)	O
,	O
differently	O
implicated	O
in	O
intracellular	O
ion	O
homeostasis	O
,	O
have	O
been	O
identified	O
in	O
nearly	O
60	O
%	O
of	O
the	O
sporadic	S-Phenotype
APAs	O
.	O

Moreover	O
,	O
the	O
novel	O
mutation	O
,	O
p.R414C	O
,	O
adds	O
up	O
to	O
the	O
literature	O
for	O
the	O
infantile	O
-	O
onset	O
form	O
of	O
autosomal	B-Phenotype
recessive	I-Phenotype
ataxia	E-Phenotype
associated	O
with	O
SPTBN2	O
.	O

The	O
tumor	S-Phenotype
suppressor	O
miR	O
-	O
145	O
has	O
been	O
reported	O
to	O
be	O
lowly	O
expressed	O
in	O
numerous	O
types	O
of	O
human	O
cancer	S-Phenotype
;	O
in	O
the	O
present	O
study	O
,	O
the	O
expression	O
levels	O
of	O
miR	O
-	O
145	O
were	O
decreased	O
in	O
patients	O
with	O
NSCLC	O
.	O

TUFM	O
expression	O
level	O
was	O
positively	O
correlated	O
with	O
that	O
of	O
E	O
-	O
cadherin	O
and	O
decreased	O
significantly	O
during	O
the	O
progression	O
of	O
human	O
lung	B-Phenotype
cancer	E-Phenotype
.	O

This	O
Perspective	O
reviews	O
evidence	O
that	O
1	O
)	O
the	O
relationship	O
between	O
hyperglycemia	S-Phenotype
and	O
microvascular	B-Phenotype
dysfunction	E-Phenotype
(	O
MVD	O
)	O
is	O
bidirectional	O
and	O
constitutes	O
a	O
vicious	O
cycle	O
;	O
2	O
)	O
MVD	O
in	O
diabetes	O
affects	O
many	O
,	O
if	O
not	O
all	O
,	O
organs	O
,	O
which	O
may	O
play	O
a	O
role	O
in	O
diabetes	O
-	O
associated	O
comorbidities	O
such	O
as	O
depression	S-Phenotype
and	O
cognitive	B-Phenotype
impairment	E-Phenotype
;	O
and	O
3	O
)	O
MVD	O
precedes	O
,	O
and	O
contributes	O
to	O
,	O
hyperglycemia	S-Phenotype
in	O
type	B-Phenotype
2	I-Phenotype
diabetes	E-Phenotype
(	O
T2D	S-Phenotype
)	O
through	O
impairment	O
of	O
insulin	O
-	O
mediated	O
glucose	O
disposal	O
and	O
,	O
possibly	O
,	O
insulin	O
secretion	O
.	O

Of	O
all	O
the	O
movement	B-Phenotype
disorders	E-Phenotype
,	O
myoclonus	S-Phenotype
is	O
the	O
most	O
difficult	O
to	O
encapsulate	O
into	O
any	O
simple	O
framework	O
.	O

The	O
heterogeneous	S-Phenotype
expression	O
of	O
LASS2	O
had	O
been	O
exhibited	O
in	O
diverse	O
ovarian	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Refractory	B-Phenotype
anemia	I-Phenotype
with	I-Phenotype
ring	I-Phenotype
sideroblasts	E-Phenotype
(	O
RARS	S-Phenotype
)	O
is	O
a	O
myelodysplastic	B-Phenotype
syndrome	E-Phenotype
characterized	O
mainly	O
by	O
anemia	B-Phenotype
attributable	E-Phenotype
to	O
ineffective	B-Phenotype
erythropoiesis	E-Phenotype
.	O

Identifying	O
genetic	O
risk	O
alleles	O
for	O
ovarian	B-Phenotype
cancer	E-Phenotype
has	O
had	O
a	O
significant	O
impact	O
on	O
disease	O
prevention	O
strategies	O
;	O
for	O
example	O
it	O
is	O
now	O
routine	O
clinical	O
practice	O
for	O
individuals	O
with	O
germline	O
BRCA1	O
and	O
BRCA2	O
mutations	O
to	O
undergo	O
risk	O
reducing	O
salpingo	O
-	O
oophorectomy	O
.	O

Though	O
using	O
the	O
term	O
gray	B-Phenotype
platelets	E-Phenotype
for	O
GATA1	O
deficiency	O
has	O
been	O
debated	O
,	O
a	O
reduced	O
number	O
of	O
α	O
-	O
granules	O
has	O
been	O
described	O
for	O
macrothrombocytopenia	S-Phenotype
due	O
to	O
liGATA1	O
/	O
i	O
mutations	O
.	O

Weight	B-Phenotype
gain	E-Phenotype
and	O
growth	B-Phenotype
failure	E-Phenotype
,	O
the	O
hallmarks	O
of	O
hypercortisolism	S-Phenotype
in	O
pediatrics	O
,	O
may	O
be	O
inconsistent	O
,	O
especially	O
in	O
ACTH	O
-	O
independent	O
forms	O
of	O
CS	O
.	O

Because	O
of	O
these	O
wide	O
-	O
ranging	O
roles	O
,	O
dysregulation	O
of	O
the	O
GUCY2C	O
-	O
cGMP	O
signaling	O
axis	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
bowel	B-Phenotype
transit	I-Phenotype
disorders	E-Phenotype
,	O
inflammatory	B-Phenotype
bowel	I-Phenotype
disease	E-Phenotype
,	O
and	O
colorectal	B-Phenotype
cancer	E-Phenotype
.	O

We	O
present	O
a	O
case	O
of	O
myoclonus	B-Phenotype
-	I-Phenotype
dystonia	E-Phenotype
syndrome	O
illustrated	O
by	O
three	O
videos	O
in	O
which	O
we	O
found	O
a	O
novel	O
SGCE	O
mutation	O
.	O

We	O
conclude	O
that	O
both	O
genes	O
contribute	O
to	O
the	O
phenotypic	O
severity	O
of	O
3p25	O
deletion	O
syndrome	O
but	O
that	O
some	O
specific	O
features	O
,	O
such	O
as	O
ptosis	S-Phenotype
and	O
blepharophimosis	S-Phenotype
,	O
are	O
mostly	O
driven	O
by	O
BRPF1	O
haploinsufficiency	O

Despite	O
their	O
clinical	O
heterogeneity	S-Phenotype
,	O
which	O
remains	O
an	O
open	O
question	O
,	O
laminopathies	O
are	O
commonly	O
caused	O
by	O
mutations	O
in	O
the	O
LMNA	O
gene	O
,	O
encoding	O
the	O
nuclear	O
proteins	O
Lamin	O
A	O
and	O
C	O
.	O

Researchers	O
have	O
identified	O
a	O
subset	O
of	O
Holstein	O
having	O
a	O
range	O
of	O
skeletal	O
deformities	O
,	O
including	O
vertebral	B-Phenotype
anomalies	E-Phenotype
,	O
referred	O
to	O
as	O
complex	O
vertebral	O
malformation	O
due	O
to	O
mutations	O
in	O
the	O
SLC35A3	O
gene	O
.	O

The	O
aim	O
of	O
this	O
cross	O
-	O
sectional	O
study	O
was	O
to	O
evaluate	O
the	O
functioning	O
and	O
HR	O
-	O
QoL	O
determinants	O
in	O
67	O
patients	O
with	O
anti	O
-	O
MAG	O
neuropathy	S-Phenotype
in	O
terms	O
of	O
the	O
International	O
Classification	O
of	O
Functioning	O
,	O
Disability	O
,	O
and	O
Health	O
(	O
ICF	O
)	O
.	O

Ectodermal	B-Phenotype
dysplasia	I-Phenotype
-	I-Phenotype
9	E-Phenotype
(	O
ED	B-Phenotype
-	I-Phenotype
9	E-Phenotype
)	O
is	O
a	O
congenital	O
condition	O
characterized	O
by	O
hypotrichosis	S-Phenotype
and	O
nail	B-Phenotype
dystrophy	E-Phenotype
without	O
other	O
disorders	O
,	O
and	O
Hoxc13	O
is	O
a	O
pathogenic	O
gene	O
for	O
ED	O
-	O
9	O
.	O

Upregulated	O
LINC00963	O
led	O
to	O
elevated	O
expression	O
of	O
NACC1	O
through	O
inhibiting	O
miR	O
-	O
608	O
,	O
which	O
consequently	O
promoted	O
melanoma	S-Phenotype
malignant	O
progression	O
.	O

Brain	O
somatic	O
mutations	O
in	O
the	O
gene	O
encoding	O
mTOR	O
(	O
MTOR	O
)	O
have	O
recently	O
been	O
linked	O
to	O
focal	B-Phenotype
cortical	I-Phenotype
dysplasia	E-Phenotype
and	O
other	O
associated	O
brain	O
pathologies	O
including	O
hemimegalencephaly	S-Phenotype
.	O

Here	O
,	O
we	O
investigated	O
associations	O
between	O
genetic	O
variants	O
of	O
Rho	O
GTPases	O
-	O
related	O
genes	O
and	O
cutaneous	B-Phenotype
melanoma	E-Phenotype
-	O
specific	O
survival	O
(	O
CMSS	O
)	O
by	O
re	O
-	O
analyzing	O
a	O
published	O
melanoma	S-Phenotype
genome	O
-	O
wide	O
association	O
study	O
(	O
GWAS	O
)	O
and	O
validating	O
the	O
results	O
in	O
another	O
melanoma	S-Phenotype
GWAS	O
.	O

Our	O
findings	O
offer	O
a	O
foundation	O
for	O
understanding	O
MATR3	O
-	O
related	O
neurodegeneration	S-Phenotype
and	O
how	O
nucleic	O
acid	O
binding	O
functions	O
,	O
localization	O
,	O
and	O
pathogenic	O
mutations	O
drive	O
sporadic	S-Phenotype
and	O
familial	O
disease	O

These	O
results	O
,	O
if	O
confirmed	O
by	O
independent	O
investigations	O
,	O
will	O
aid	O
in	O
devising	O
personalized	O
GARP	O
-	O
based	O
immunotherapeutic	O
strategies	O
against	O
breast	B-Phenotype
cancer	E-Phenotype
and	O
other	O
GARP	O
-	O
overexpressing	O
malignancies	O

In	O
our	O
study	O
,	O
MCM5	O
mRNA	O
and	O
protein	O
were	O
significantly	O
overexpressed	O
in	O
cervical	B-Phenotype
cancer	E-Phenotype
tissues	O
and	O
cell	O
lines	O
compared	O
with	O
normal	O
cervical	O
tissues	O
and	O
cell	O
lines	O
,	O
and	O
were	O
obviously	O
increased	O
in	O
cervical	O
adenocarcinoma	O
tissues	O
and	O
cell	O
lines	O
in	O
comparison	O
to	O
cervical	B-Phenotype
squamous	I-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
tissues	O
and	O
cell	O
lines	O
.	O

We	O
describe	O
two	O
families	O
in	O
which	O
two	O
different	O
homozygous	O
PUS7	O
mutations	O
(	O
missense	O
and	O
frameshift	O
deletion	O
)	O
segregate	O
with	O
a	O
phenotype	O
comprising	O
intellectual	B-Phenotype
disability	E-Phenotype
and	O
progressive	B-Phenotype
microcephaly	E-Phenotype
.	O

CHRNA4	O
led	O
the	O
way	O
to	O
mutation	O
identifications	O
in	O
15	O
ion	O
channel	O
genes	O
,	O
most	O
causing	O
primarily	O
generalized	O
epilepsies	S-Phenotype
.	O

Small	B-Phenotype
intestine	I-Phenotype
neuroendocrine	I-Phenotype
tumors	E-Phenotype
(	O
SI	B-Phenotype
-	I-Phenotype
NETs	E-Phenotype
)	O
represent	O
the	O
most	O
common	O
histotype	O
among	O
small	O
intestine	O
neoplasms	S-Phenotype
,	O
and	O
metastatic	O
disease	O
is	O
usually	O
present	O
at	O
diagnosis	O
.	O

EBF3	O
is	O
a	O
member	O
of	O
the	O
collier	O
/	O
olfactory	O
-	O
1	O
/	O
early	O
B	O
-	O
cell	O
factor	O
(	O
COE	O
)	O
family	O
of	O
proteins	O
,	O
which	O
are	O
required	O
for	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
development	O
.	O

The	O
first	O
decade	O
of	O
the	O
21st	O
century	O
was	O
marked	O
by	O
progress	O
in	O
understanding	O
the	O
basic	O
biology	O
of	O
generalized	B-Phenotype
epilepsies	E-Phenotype
including	O
generalized	B-Phenotype
/	I-Phenotype
genetic	I-Phenotype
epilepsies	I-Phenotype
with	I-Phenotype
febrile	I-Phenotype
seizures	I-Phenotype
plus	E-Phenotype
(	O
GEFS+	S-Phenotype
)	O
and	O
GGE	O
through	O
studies	O
of	O
large	O
families	O
,	O
discovering	O
causative	O
mutations	O
in	O
SCN1A	O
,	O
SCN1B	O
,	O
GABRG2	O
,	O
and	O
GABRA1	O
.	O

These	O
results	O
indirectly	O
demonstrate	O
that	O
CUL4B	O
enhances	O
the	O
proliferation	O
and	O
invasion	O
abilities	O
of	O
gastric	B-Phenotype
cancer	E-Phenotype
cells	O
by	O
upregulating	O
the	O
constituent	O
factors	O
Wnt	O
and	O
b	O
-	O
catenin	O
,	O
as	O
well	O
as	O
by	O
negatively	O
regulating	O
the	O
mRNA	O
and	O
protein	O
expression	O
of	O
GSK	O
-	O
3b	O
,	O
caspase	O
-	O
3	O
and	O
cyclin	O
E	O
.	O

Using	O
several	O
genetic	O
mouse	O
models	O
of	O
PDAC	O
,	O
we	O
detected	O
a	O
marked	O
increase	O
in	O
Twist1	O
expression	O
in	O
muscle	O
undergoing	O
cachexia	S-Phenotype
.	O

Variants	O
of	O
WNK1	O
(	O
lysine	O
deficient	O
protein	O
kinase	O
1	O
)	O
,	O
ADRB2	O
(	O
b2	O
adrenergic	O
receptor	O
)	O
,	O
NEDD4L	O
(	O
ubiquitin	O
-	O
protein	O
ligase	O
NEDD4	O
-	O
like	O
)	O
,	O
KLK1	O
(	O
kallikrein	O
1	O
)	O
contribute	O
to	O
hypertension	S-Phenotype
,	O
and	O
AKR1C3	O
(	O
aldo	O
-	O
keto	O
reductase	O
family1	O
member	O
C3	O
)	O
,	O
is	O
associated	O
with	O
preeclampsia	S-Phenotype
.	O

Genetic	O
variation	O
in	O
the	O
TMC6	O
/	O
TMC8	O
region	O
has	O
been	O
linked	O
to	O
beta	O
-	O
type	O
HPV	O
infection	O
and	O
squamous	B-Phenotype
cell	I-Phenotype
carcinoma	I-Phenotype
of	I-Phenotype
the	I-Phenotype
skin	I-Phenotype
,	I-Phenotype
cervical	I-Phenotype
cancer	E-Phenotype
,	O
HPV	O
persistence	O
and	O
progression	O
to	O
cervical	B-Phenotype
cancer	E-Phenotype
.	O

The	O
deafness	S-Phenotype
genes	O
GJB3	O
,	O
CRYM	O
,	O
GRHL2	O
,	O
DFNA5	O
,	O
and	O
ATP6B1	O
were	O
expressed	O
in	O
marmoset	O
cochleae	O
in	O
patterns	O
different	O
from	O
those	O
in	O
mouse	O
cochleae	O
.	O

The	O
gene	O
that	O
encodes	O
C1q	O
/	O
TNF	O
-	O
related	O
protein	O
5	O
(	O
CTRP5	O
)	O
,	O
a	O
secreted	O
protein	O
of	O
the	O
C1q	O
family	O
,	O
is	O
mutated	O
in	O
individuals	O
with	O
late	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
retinal	I-Phenotype
degeneration	E-Phenotype
.	O

The	O
clinical	O
phenotype	O
of	O
CMT1A	O
is	O
determined	O
by	O
the	O
degree	O
of	O
axonal	B-Phenotype
loss	E-Phenotype
,	O
and	O
patients	O
suffer	O
from	O
progressive	B-Phenotype
muscle	I-Phenotype
weakness	E-Phenotype
and	O
impaired	B-Phenotype
sensation	E-Phenotype
.	O

We	O
surveyed	O
GATA4	O
expression	O
in	O
24	O
hepatoblastomas	S-Phenotype
using	O
RNA	O
in	O
situ	O
hybridization	O
and	O
immunohistochemistry	O
.	O

We	O
will	O
prospectively	O
evaluate	O
the	O
predictive	O
performance	O
of	O
HSD17B4	O
hypermethylation	O
in	O
patients	O
with	O
HER2	O
-	O
positive	O
/	O
HR	O
-	O
negative	O
breast	B-Phenotype
cancer	E-Phenotype
treated	O
with	O
sequential	O
chemo	O
-	O
radiotherapy	O
.	O

As	O
in	O
MOPDII	O
patients	O
,	O
disruption	O
of	O
pericentrin	O
(	O
Pcnt	O
)	O
in	O
mice	O
caused	O
a	O
number	O
of	O
abnormalities	O
including	O
microcephaly	S-Phenotype
,	O
aberrant	B-Phenotype
hemodynamics	I-Phenotype
analyzed	I-Phenotype
by	I-Phenotype
in	I-Phenotype
utero	I-Phenotype
echocardiography	E-Phenotype
,	O
and	O
cardiovascular	B-Phenotype
anomalies	E-Phenotype
;	O
the	O
latter	O
being	O
associated	O
with	O
mortality	O
,	O
as	O
in	O
the	O
human	O
condition	O
.	O

This	O
observation	O
enlarges	O
the	O
clinical	O
spectrum	O
of	O
DDHD1	O
-	O
associated	O
disorders	O
and	O
sheds	O
light	O
on	O
a	O
new	O
aetiology	O
for	O
syndromes	O
associating	O
retinopathy	S-Phenotype
and	O
NBIA	O
.	O

PPV	O
of	O
the	O
recall	O
was	O
13.0	O
%	O
and	O
24.1	O
%	O
,	O
respectively	O
(	O
P	O
=	O
.0002	O
)	O
;	O
72	O
of	O
80	O
cancers	S-Phenotype
found	O
in	O
the	O
DBT+DM	O
arm	O
and	O
with	O
complete	O
DBT	O
imaging	O
were	O
positive	O
at	O
least	O
at	O
one	O
DBT	O
-	O
alone	O
reading	O
.	O

Thus	O
,	O
our	O
results	O
demonstrate	O
that	O
Chmp1A	O
functions	O
as	O
a	O
tumor	S-Phenotype
suppressor	O
gene	O
in	O
renal	O
cells	O
and	O
may	O
be	O
a	O
useful	O
target	O
for	O
treatment	O
of	O
RCC	O

Previous	O
genome	O
-	O
wide	O
association	O
studies	O
have	O
identified	O
several	O
genes	O
associated	O
with	O
obesity	S-Phenotype
,	O
including	O
LEP	O
,	O
LEPR	O
,	O
POMC	O
,	O
PCSK1	O
,	O
FTO	O
,	O
MC3R	O
,	O
MC4R	O
,	O
GNPDA2	O
,	O
TMEM18	O
,	O
QPCTL	O
/	O
GIPR	O
,	O
BDNF	O
,	O
ETV5	O
,	O
MAP2K5	O
/	O
SKOR1	O
,	O
SEC16B	O
,	O
SIM1	O
,	O
and	O
TNKS	O
/	O
MSRA	O
.	O

Here	O
,	O
we	O
show	O
that	O
selective	O
overexpression	O
of	O
the	O
stress	O
protein	O
,	O
heme	O
oxygenase	O
-	O
1	O
(	O
HO	O
-	O
1	O
)	O
in	O
astrocytes	O
of	O
GFAP.HMOX1	O
transgenic	O
mice	O
between	O
8.5	O
and	O
19	O
months	O
of	O
age	O
results	O
in	O
nigrostriatal	O
hypodopaminergia	O
associated	O
with	O
locomotor	B-Phenotype
incoordination	E-Phenotype
and	O
stereotypy	S-Phenotype
;	O
downregulation	B-Phenotype
of	I-Phenotype
tyrosine	I-Phenotype
hydroxylase	E-Phenotype
,	O
DAT	O
,	O
LMX1B	O
,	O
Nurr1	O
,	O
Pitx3	O
and	O
DJ	O
-	O
1	O
mRNA	O
and	O
/	O
or	O
protein	O
;	O
overproduction	O
of	O
α	O
-	O
synuclein	O
and	O
ubiquitin	O
;	O
oxidative	B-Phenotype
stress	E-Phenotype
;	O
basal	O
ganglia	O
siderosis	O
;	O
mitochondrial	O
damage	O
/	O
mitophagy	O
;	O
and	O
augmented	O
GABAergic	O
systems	O
(	O
increased	O
GABA	O
,	O
GAD67	O
and	O
reelin	O
)	O
.	O

The	O
question	O
has	O
been	O
raised	O
whether	O
Epo	O
promotes	O
tumor	S-Phenotype
growth	O
and	O
inhibits	O
the	O
death	O
of	O
cancer	S-Phenotype
cells	O
.	O

Locations	O
of	O
mutations	O
linked	O
to	O
human	O
disease	O
,	O
including	O
those	O
responsible	O
for	O
Southeast	O
Asian	O
ovalocytosis	S-Phenotype
,	O
hereditary	B-Phenotype
stomatocytosis	E-Phenotype
,	O
hereditary	B-Phenotype
spherocytosis	E-Phenotype
,	O
and	O
distal	B-Phenotype
renal	I-Phenotype
tubular	I-Phenotype
acidosis	E-Phenotype
,	O
provide	O
molecular	O
insights	O
into	O
their	O
effect	O
on	O
Band	O
3	O
folding	O
.	O

Nine	O
variants	O
in	O
GATM	O
were	O
shown	O
to	O
have	O
a	O
lower	O
minor	O
allele	O
frequency	O
(	O
MAF	O
)	O
in	O
the	O
autism	S-Phenotype
population	O
than	O
in	O
the	O
1000	O
Genomes	O
database	O
,	O
specifically	O
in	O
the	O
East	O
Asian	O
population	O
(	O
Fisher	O
*	O
s	O
exact	O
test	O
)	O
.	O

The	O
findings	O
indicate	O
that	O
although	O
PIK3CA	O
mutations	O
are	O
found	O
in	O
AAAA10	O
%	O
of	O
vulvar	B-Phenotype
squamous	I-Phenotype
cell	I-Phenotype
carcinomas	E-Phenotype
,	O
they	O
may	O
be	O
specific	O
for	O
a	O
particular	O
pathway	O
involving	O
atypical	O
verruciform	O
lesions	O
,	O
which	O
could	O
function	O
as	O
either	O
a	O
direct	O
precursor	O
or	O
a	O
risk	O
factor	O
for	O
vulvar	B-Phenotype
squamous	I-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
.	O

Consistent	O
with	O
this	O
result	O
,	O
mutations	O
in	O
the	O
CNTNAP2	O
gene	O
coding	O
for	O
CASPR2	O
in	O
human	O
have	O
been	O
identified	O
in	O
neurodevelopmental	O
disorders	O
such	O
as	O
autism	S-Phenotype
,	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
and	O
epilepsy	S-Phenotype
.	O

The	O
deficiency	O
of	O
3	O
-	O
methycrotonyl	O
-	O
CoA	O
carboxylase	O
(	O
3	O
-	O
MCC	O
;	O
EC	O
6.4.1.4	O
)	O
is	O
an	O
autosomal	B-Phenotype
recessive	I-Phenotype
organic	I-Phenotype
aciduria	E-Phenotype
that	O
is	O
included	O
in	O
the	O
newborn	O
screening	O
programs	O
of	O
several	O
countries	O
.	O

This	O
study	O
indicates	O
that	O
the	O
elastic	O
net	O
has	O
a	O
higher	O
capacity	O
than	O
the	O
Lasso	O
and	O
boosting	O
for	O
the	O
prediction	O
of	O
survival	O
time	O
in	O
bladder	B-Phenotype
cancer	E-Phenotype
patients	O
.	O

Lymphatic	O
metastasis	O
is	O
facilitated	O
by	O
lymphangiogenic	O
growth	O
factor	O
vascular	O
endothelial	O
growth	O
factor	O
-	O
C	O
(	O
VEGFC	O
)	O
that	O
is	O
secreted	O
by	O
some	O
primary	O
tumors	S-Phenotype
.	O

More	O
importantly	O
,	O
overexpression	O
of	O
MRPL33	O
-	O
L	O
could	O
increase	O
tumorigenic	S-Phenotype
potential	O
of	O
hnRNPK	O
-	O
depleted	O
cancer	S-Phenotype
cells	O
,	O
likely	O
indicating	O
that	O
hnRNPK	O
mediates	O
tumorigenesis	O
through	O
splicing	O
regulation	O
of	O
MRPL33	O
pre	O
-	O
mRNA	O
.	O

While	O
direct	O
pharmacological	O
inhibition	O
of	O
NRF2	O
has	O
proven	O
challenging	O
,	O
its	O
aberrant	O
activation	O
rewires	O
biochemical	O
networks	O
in	O
cancer	S-Phenotype
cells	O
that	O
may	O
create	O
special	O
vulnerabilities	O
.	O

Including	O
genetic	O
variants	O
in	O
a	O
Final	O
Model	O
containing	O
age	O
at	O
primary	O
cancer	S-Phenotype
,	O
sex	O
,	O
and	O
cranial	O
radiation	O
therapy	O
dose	O
yielded	O
an	O
area	O
under	O
the	O
curve	O
of	O
0.81	O
(	O
95	O
%	O
CI	O
,	O
0.76	O
to	O
0.86	O
)	O
,	O
which	O
was	O
superior	O
(	O
P	O
=	O
.002	O
)	O
to	O
the	O
Clinical	O
Model	O
(	O
area	O
under	O
the	O
curve	O
,	O
0.73	O
;	O
95	O
%	O
CI	O
,	O
0.66	O
to	O
0.80	O
)	O
.	O

Cognitive	B-Phenotype
impairment	E-Phenotype
or	O
autism	S-Phenotype
-	O
like	O
performance	O
were	O
often	O
identified	O
in	O
these	O
patients	O
,	O
hematuria	S-Phenotype
metabolic	O
diseases	O
screening	O
was	O
normal	O
,	O
no	O
abnormal	O
MRI	O
imaging	O
of	O
the	O
head	O
,	O
and	O
de	O
novo	O
PCDH19	O
gene	O
mutations	O
were	O
found	O
in	O
their	O
epilepsy	S-Phenotype
gene	O
chip	O
sequencing	O
.	O

Finally	O
,	O
we	O
show	O
that	O
inhibition	O
of	O
SMYD2	O
cooperates	O
with	O
standard	O
chemotherapy	O
to	O
treat	O
PDAC	O
cells	O
and	O
tumors	S-Phenotype
.	O

The	O
human	O
tongue	B-Phenotype
cancer	E-Phenotype
cell	O
line	O
CAL27	O
was	O
used	O
to	O
study	O
the	O
effects	O
of	O
FRMD4A	O
.	O

In	O
clinical	O
specimens	O
,	O
elevated	O
LAMB3	O
expression	O
correlated	O
with	O
poorer	O
survival	O
in	O
lung	B-Phenotype
cancer	E-Phenotype
patients	O
with	O
an	O
oncogenic	O
KRAS	O
gene	O
signature	O
,	O
suggesting	O
a	O
novel	O
candidate	O
biomarker	O
in	O
this	O
disease	O
setting	O
.	O

Atypical	B-Phenotype
teratoid	E-Phenotype
/	O
rhabdoid	B-Phenotype
tumors	E-Phenotype
(	O
AT	S-Phenotype
/	O
RT	S-Phenotype
)	O
and	O
renal	B-Phenotype
/	I-Phenotype
extrarenal	I-Phenotype
malignant	I-Phenotype
rhabdoid	I-Phenotype
tumors	I-Phenotype
of	I-Phenotype
childhood	E-Phenotype
,	O
epithelioid	B-Phenotype
sarcoma	E-Phenotype
and	O
small	B-Phenotype
cell	I-Phenotype
carcinoma	I-Phenotype
of	I-Phenotype
the	I-Phenotype
ovary	E-Phenotype
,	O
hypercalcemic	O
type	O
(	O
SCCOHT	O
)	O
represent	O
the	O
most	O
commonly	O
recognized	O
SWI	O
/	O
SNF	O
-	O
driven	O
neoplasms	S-Phenotype
.	O

Direct	O
sequencing	O
revealed	O
a	O
G	O
to	O
T	O
transition	O
(	O
c.886GAAAAT	O
)	O
in	O
exon	O
9	O
of	O
the	O
four‑point‑one	O
,	O
ezrin	O
,	O
radixin	O
,	O
moesin	O
domain‑containing	O
7	O
(	O
FRMD7	O
)	O
gene	O
,	O
which	O
resulted	O
in	O
a	O
conservative	O
substitution	O
of	O
glycine	O
to	O
cysteine	O
at	O
codon	O
296	O
(	O
p.G296C	O
)	O
,	O
leading	O
to	O
idiopathic	B-Phenotype
congenital	I-Phenotype
nystagmus	E-Phenotype
in	O
the	O
two	O
affected	O
brothers	O
.	O

Our	O
results	O
suggest	O
that	O
HOXB1	O
functions	O
as	O
a	O
tumor	S-Phenotype
suppressor	O
,	O
regulated	O
by	O
miR	O
-	O
3175	O
in	O
glioma	S-Phenotype
.	O

This	O
review	O
goes	O
over	O
recent	O
scientific	O
progress	O
in	O
understanding	O
the	O
molecular	O
mechanisms	O
governing	O
pruritus	S-Phenotype
,	O
the	O
cross	O
-	O
talk	O
between	O
the	O
immune	O
and	O
nervous	O
systems	O
that	O
regulate	O
itch	S-Phenotype
,	O
and	O
central	O
nervous	O
pathways	O
and	O
projections	O
affected	O
by	O
itch	S-Phenotype
.	O

Both	O
single	O
-	O
gene	O
and	O
gene	O
-	O
set	O
enrichment	O
analyses	O
in	O
genome	O
-	O
wide	O
association	O
data	O
from	O
the	O
largest	O
schizophrenia	S-Phenotype
sample	O
to	O
date	O
of	O
13,689	O
cases	O
and	O
18,226	O
controls	O
show	O
significant	O
association	O
of	O
HIST1H1E	O
and	O
MAPK3	O
,	O
and	O
enrichment	O
of	O
our	O
PSD	O
proteome	O
.	O

We	O
have	O
already	O
reported	O
that	O
RNF31	O
mRNA	O
levels	O
are	O
higher	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
samples	O
compared	O
to	O
adjacent	O
non	O
-	O
tumor	S-Phenotype
tissue	O
.	O

Genome	O
-	O
wide	O
association	O
studies	O
(	O
GWAS	O
)	O
have	O
identified	O
13	O
susceptibility	O
loci	O
for	O
renal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
RCC	S-Phenotype
)	O
.	O

In	O
addition	O
,	O
the	O
coexistence	O
of	O
high	O
MACC1	O
and	O
low	O
NM23	O
-	O
H1	O
expression	O
and	O
tumor	S-Phenotype
budding	O
was	O
associated	O
with	O
short	O
OS	O
(	O
p	O
AAAA	O
0.001	O
)	O
.	O

Our	O
data	O
reinforces	O
the	O
recent	O
observation	O
that	O
the	O
KDM5B	O
haploinsufficiency	O
is	O
not	O
a	O
mechanism	O
involved	O
in	O
intellectual	B-Phenotype
disability	E-Phenotype
and	O
that	O
KDM5B	O
disorder	O
associated	O
with	O
LOF	O
variants	O
is	O
a	O
recessive	O
disorder	O
.	O

EPRS	O
expression	O
is	O
associated	O
with	O
reduced	O
overall	O
survival	O
in	O
patients	O
with	O
ER+	O
tumors	S-Phenotype
in	O
TCGA	O
and	O
METABRIC	O
datasets	O
.	O

Two	O
ZBTB20	O
single	O
nucleotide	O
variants	O
,	O
located	O
at	O
the	O
N	O
-	O
terminal	O
and	O
central	O
regions	O
of	O
the	O
protein	O
and	O
potentially	O
conferring	O
autism	S-Phenotype
risk	O
,	O
altered	O
dendritic	O
spine	O
morphology	O
.	O

RNA	O
was	O
extracted	O
from	O
thirteen	O
canine	O
meningiomas	S-Phenotype
-	O
eleven	O
from	O
formalin	O
fixed	O
and	O
two	O
flash	O
-	O
frozen	O
.	O

Wnt	O
transgenic	O
mice	O
provide	O
convincing	O
evidence	O
that	O
Wnt	O
signaling	O
is	O
involved	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
initiation	O
and	O
progression	O
,	O
which	O
is	O
further	O
strengthened	O
by	O
observations	O
on	O
human	O
clinical	O
breast	B-Phenotype
cancer	E-Phenotype
patients	O
and	O
studies	O
on	O
in	O
vitro	O
cultured	O
human	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Conversely	O
,	O
Th17	O
cells	O
and	O
their	O
effector	O
molecules	O
interleukin	O
17A	O
(	O
IL	O
-	O
17A	O
)	O
,	O
IL	O
-	O
17F	O
,	O
interferon	O
(	O
IFN	O
)	O
γ	O
,	O
tumor	S-Phenotype
necrosis	O
factor	O
(	O
TNF	O
)	O
α	O
,	O
and	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
are	O
implicated	O
in	O
the	O
pathology	O
of	O
rheumatoid	B-Phenotype
arthritis	E-Phenotype
(	O
RA	S-Phenotype
)	O
.	O

In	O
conclusion	O
,	O
ERCC6	O
rs1917799	O
,	O
ERCC8	O
rs158572	O
and	O
rs158916	O
demonstrated	O
pairwise	O
epistatic	O
interactions	O
to	O
associate	O
with	O
chronic	B-Phenotype
atrophic	I-Phenotype
gastritis	E-Phenotype
and	O
gastric	B-Phenotype
cancer	E-Phenotype
risk	O
.	O

Most	O
instances	O
of	O
renal	O
karyomegaly	O
reported	O
in	O
humans	O
represented	O
cases	O
of	O
the	O
genetic	O
syndrome	O
,	O
karyomegalic	B-Phenotype
interstitial	I-Phenotype
nephritis	E-Phenotype
,	O
known	O
to	O
be	O
caused	O
by	O
a	O
mutation	O
in	O
the	O
FAN1	O
gene	O
.	O

Mutations	O
affecting	O
human	O
COG1	O
,	O
COG2	O
and	O
COG4	O
-	O
COG8	O
cause	O
monogenic	O
forms	O
of	O
inherited	B-Phenotype
,	I-Phenotype
autosomal	I-Phenotype
recessive	I-Phenotype
CDGs	E-Phenotype
.	O

These	O
results	O
reveal	O
that	O
ARHGAP17	O
functions	O
as	O
a	O
tumor	S-Phenotype
suppressor	O
in	O
cervical	B-Phenotype
cancer	E-Phenotype
that	O
suppresses	O
tumor	S-Phenotype
growth	O
,	O
at	O
least	O
partly	O
,	O
through	O
inhibition	O
of	O
PI3K	O
/	O
AKT	O
signaling	O
and	O
up	O
-	O
regulation	O
of	O
P21	O
and	O
P27	O
expression	O

Leber	B-Phenotype
congenital	I-Phenotype
amaurosis	E-Phenotype
(	O
LCA	S-Phenotype
)	O
and	O
retinitis	B-Phenotype
pigmentosa	E-Phenotype
(	O
RP	S-Phenotype
)	O
are	O
retinal	O
degenerative	O
diseases	O
which	O
cause	O
severe	O
retinal	B-Phenotype
dystrophy	E-Phenotype
affecting	O
the	O
photoreceptors	O
.	O

Mutations	O
in	O
peripherin	O
2	O
(	O
PRPH2	O
)	O
,	O
also	O
known	O
as	O
retinal	B-Phenotype
degeneration	E-Phenotype
slow	O
/	O
RDS	O
,	O
lead	O
to	O
various	O
retinal	B-Phenotype
degenerations	E-Phenotype
including	O
retinitis	B-Phenotype
pigmentosa	E-Phenotype
(	O
RP	S-Phenotype
)	O
and	O
macular	B-Phenotype
/	I-Phenotype
pattern	I-Phenotype
dystrophy	E-Phenotype
(	O
MD	S-Phenotype
/	O
PD	S-Phenotype
)	O
.	O

Here	O
we	O
established	O
a	O
mutation	O
detection	O
system	O
based	O
on	O
multiple	O
fluorescent	O
probe	O
technique	O
,	O
which	O
can	O
detect	O
and	O
genotype	O
nine	O
hotspot	O
mutations	O
of	O
four	O
prominent	O
hearing	B-Phenotype
loss	E-Phenotype
-	O
related	O
genes	O
in	O
two	O
reactions	O
on	O
a	O
four	O
-	O
channel	O
real	O
-	O
time	O
PCR	O
instrument	O
,	O
including	O
GJB2	O
(	O
rs750188782	O
,	O
rs80338943	O
,	O
rs1110333204	O
,	O
and	O
rs80338939	O
)	O
,	O
GJB3	O
(	O
rs74315319	O
)	O
,	O
SLC26A4	O
(	O
rs111033313	O
and	O
rs121908362	O
)	O
,	O
and	O
mtDNA	O
12S	O
rRNA	O
(	O
rs267606617	O
and	O
rs267606619	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
first	O
analyzed	O
two	O
expression	O
quantitative	O
trait	O
loci	O
(	O
eQTL	O
)	O
datasets	O
in	O
healthy	O
individuals	O
and	O
investigated	O
the	O
associations	O
of	O
eQTL	O
of	O
AHI1	O
with	O
schizophrenia	S-Phenotype
in	O
independent	O
European	O
samples	O
.	O

Eleven	O
(	O
79	O
%	O
)	O
and	O
five	O
(	O
36	O
%	O
)	O
of	O
fourteen	O
keratinizing	B-Phenotype
squamous	I-Phenotype
cell	I-Phenotype
carcinomas	E-Phenotype
tested	O
contained	O
TP53	O
and	O
CDKN2A	O
mutations	O
,	O
respectively	O
.	O

Growth	B-Phenotype
abnormalities	E-Phenotype
,	O
motor	B-Phenotype
dysfunction	E-Phenotype
,	O
hindlimb	B-Phenotype
paralysis	E-Phenotype
,	O
muscle	B-Phenotype
wasting	E-Phenotype
,	O
neurogenic	B-Phenotype
atrophy	E-Phenotype
,	O
motor	B-Phenotype
neuron	I-Phenotype
degeneration	E-Phenotype
,	O
and	O
loss	O
of	O
large	O
-	O
caliber	O
axons	O
in	O
peripheral	O
nerves	O
occurred	O
at	O
an	O
earlier	O
age	O
in	O
Scyl1	O
/	O
Scyl3	O
double	O
-	O
deficient	O
mice	O
than	O
in	O
Scyl1	O
-	O
deficient	O
mice	O
.	O

The	O
genetic	O
diagnosis	O
is	O
difficult	O
owing	O
to	O
the	O
large	O
genetic	O
heterogeneity	S-Phenotype
of	O
the	O
6p21.3	O
region	O
,	O
which	O
contains	O
the	O
CYP21A2	O
gene	O
,	O
especially	O
with	O
respect	O
to	O
the	O
use	O
of	O
new	O
-	O
generation	O
techniques	O
of	O
sequencing	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
biological	O
functions	O
and	O
clinical	O
significance	O
of	O
TRIM44	O
in	O
human	B-Phenotype
esophageal	I-Phenotype
cancer	E-Phenotype
(	O
HEC	S-Phenotype
)	O
.	O

In	O
conclusion	O
,	O
IL	O
-	O
21	O
used	O
alone	O
and	O
in	O
combination	O
with	O
5	O
-	O
Fluorouracil	O
are	O
anti	O
-	O
tumor	S-Phenotype
mechanisms	O
in	O
SGC	O
-	O
7901	O

Therefore	O
,	O
we	O
conducted	O
genotyping	O
for	O
17	O
SNPs	O
of	O
six	O
NER	O
core	O
genes	O
(	O
liXPA	O
,	O
XPC	O
,	O
XPG	O
,	O
ERCC1	O
,	O
ERCC2	O
,	O
and	O
liERCC4	O
)	O
in	O
89	O
ovarian	B-Phenotype
cancer	E-Phenotype
cases	O
and	O
356	O
cancer	S-Phenotype
-	O
free	O
controls	O
.	O

Cerebral	O
,	O
ocular	O
,	O
dental	O
,	O
auricular	O
,	O
skeletal	O
(	O
CODAS	O
)	O
syndrome	O
is	O
a	O
rare	O
autosomal	B-Phenotype
recessive	I-Phenotype
multisystem	I-Phenotype
disorder	E-Phenotype
caused	O
by	O
mutations	O
in	O
LONP1	O
.	O

We	O
also	O
analyzed	O
two	O
mutations	O
in	O
a	O
Drosophila	O
NCKX	O
gene	O
that	O
have	O
been	O
reported	O
to	O
result	O
in	O
an	O
increased	O
susceptibility	O
for	O
seizures	S-Phenotype
,	O
and	O
found	O
that	O
both	O
resulted	O
in	O
mutant	O
proteins	O
with	O
significantly	O
reduced	O
but	O
observable	O
NCKX	O
activity	O
.	O

After	O
targeting	O
to	O
endothelial	O
differentiation	O
gene	O
(	O
Edg	O
)	O
family	O
LPA	O
receptors	O
(	O
LPA1	O
,	O
LPA2	O
,	O
LPA3	O
)	O
and	O
non	O
-	O
Edg	O
family	O
LPA	O
receptors	O
(	O
LPA4	O
,	O
LPA5	O
,	O
LPA6	O
)	O
,	O
LPA	O
mediates	O
physiological	O
and	O
pathological	O
processes	O
such	O
as	O
embryonic	O
development	O
,	O
angiogenesis	O
,	O
tumor	S-Phenotype
progression	O
,	O
fibrogenesis	O
,	O
wound	O
healing	O
,	O
ischemia	O
/	O
reperfusion	O
injury	O
,	O
and	O
inflammatory	O
reactions	O
.	O

The	O
predicted	O
effect	O
of	O
Csf1R	O
blockade	O
in	O
attenuating	O
epilepsy	B-Phenotype
seizures	E-Phenotype
was	O
validated	O
in	O
three	O
pre	O
-	O
clinical	O
models	O
of	O
epilepsy	S-Phenotype
.	O

Acad10	O
mice	O
accumulate	O
excess	O
abdominal	O
adipose	O
tissue	O
,	O
develop	O
an	O
early	O
inflammatory	O
liver	O
process	O
,	O
exhibit	O
fasting	O
rhabdomyolysis	S-Phenotype
,	O
and	O
have	O
abnormal	O
skeletal	O
muscle	O
mitochondria	O
.	O

β	O
-	O
Ureidopropionase	O
deficiency	O
is	O
a	O
rare	O
autosomal	B-Phenotype
recessive	E-Phenotype
disease	O
affecting	O
the	O
last	O
step	O
of	O
pyrimidine	O
degradation	O
,	O
and	O
it	O
is	O
caused	O
by	O
a	O
mutation	O
in	O
the	O
UPB1	O
gene	O
.	O

Analysis	O
of	O
Hydin	O
-	O
disrupted	O
spermatozoa	O
in	O
mice	O
is	O
difficult	O
as	O
Hydin	O
-	O
mutant	O
mice	O
(	O
hy3	O
)	O
die	O
within	O
3	O
weeks	O
,	O
before	O
sexual	O
maturation	O
,	O
due	O
to	O
hydrocephaly	S-Phenotype
.	O

Other	O
EXOSC3	O
mutations	O
and	O
EXOSC8	O
cases	O
are	O
intermediate	O
-	O
SMA	O
type	O
1	O
-	O
like	O
presentation	O
,	O
spasticity	S-Phenotype
(	O
mostly	O
in	O
EXOSC8	O
)	O
and	O
death	O
between	O
3	O
months	O
and	O
5	O
years	O
.	O

We	O
summarize	O
the	O
phenotypic	O
extent	O
of	O
GLI2	O
/	O
3	O
syndromes	O
in	O
the	O
literature	O
and	O
determine	O
that	O
these	O
2	O
syndromes	O
manifest	O
opposite	O
features	O
to	O
a	O
certain	O
extent	O
,	O
such	O
as	O
midface	B-Phenotype
hypoplasia	E-Phenotype
or	O
macrocephaly	S-Phenotype
,	O
and	O
anterior	B-Phenotype
or	I-Phenotype
posterior	I-Phenotype
side	I-Phenotype
of	I-Phenotype
polydactyly	E-Phenotype
.	O

Nevertheless	O
,	O
the	O
ratio	O
of	O
RANK	O
to	O
RANK	O
-	O
c	O
(	O
RANK	O
/	O
RANK	O
-	O
c	O
)	O
is	O
increased	O
in	O
ER	O
-	O
negative	O
breast	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
compared	O
to	O
ER	O
-	O
positive	O
breast	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
.	O

HCRP1	O
expression	O
was	O
significantly	O
related	O
to	O
age	O
(	O
P=0.017	O
)	O
,	O
pathological	O
grade	O
(	O
P=0.003	O
)	O
,	O
tumor	S-Phenotype
encapsulation	O
(	O
P=0.037	O
)	O
,	O
recurrence	O
(	O
P=0.039	O
)	O
and	O
death	O
(	O
P=0.015	O
)	O
,	O
but	O
unrelated	O
to	O
cirrhosis	S-Phenotype
(	O
P=0.216	O
)	O
,	O
tumor	S-Phenotype
size	O
(	O
P=0.273	O
)	O
,	O
and	O
distant	O
metastasis	O
(	O
P=0.554	O
)	O
.	O

Moreover	O
,	O
mice	O
colonized	O
with	O
ST	O
-	O
producing	O
liE	O
.	O

Homozygous	O
RSPO1	O
mutations	O
cause	O
a	O
syndrome	O
of	O
46	O
,	O
XX	O
disorder	O
of	O
sexual	O
development	O
(	O
DSD	O
)	O
,	O
palmoplantar	B-Phenotype
keratoderma	E-Phenotype
(	O
PPK	S-Phenotype
)	O
,	O
and	O
predisposition	B-Phenotype
to	I-Phenotype
squamous	I-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
.	O

Cervical	B-Phenotype
cancer	E-Phenotype
patients	O
with	O
genotypes	O
GA	O
/	O
AA	O
in	O
WWOX	O
SNP	O
rs12918952	O
were	O
associated	O
with	O
parametrium	O
invasion	O
and	O
pelvic	O
lymph	O
node	O
metastasis	O
.	O

EphA2	O
,	O
EphB4	O
and	O
EphB6	O
are	O
the	O
members	O
most	O
extensively	O
studied	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

Biallelic	O
DNAJC12	O
mutations	O
were	O
described	O
in	O
children	O
with	O
hyperphenylalaninemia	S-Phenotype
,	O
neurodevelopmental	B-Phenotype
delay	E-Phenotype
,	O
and	O
dystonia	S-Phenotype
.	O

Consequently	O
,	O
hallmarks	O
of	O
cancer	S-Phenotype
invasion	O
and	O
metastasis	O
related	O
to	O
RhoA	O
,	O
actin	O
cytoskeleton	O
,	O
and	O
/	O
or	O
force	O
transmission	O
,	O
such	O
as	O
migration	O
,	O
extracellular	O
matrix	O
degradation	O
,	O
and	O
Serpin	O
B2	O
secretion	O
,	O
were	O
reduced	O
in	O
cells	O
lacking	O
Piezo2	O

The	O
KEGG	O
enrichment	O
analysis	O
of	O
DEGs	O
showed	O
significantly	O
enriched	O
pathways	O
in	O
cancer	S-Phenotype
,	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
-	O
receptor	O
interaction	O
pathway	O
,	O
and	O
cyclic	O
adenosine	O
monophosphate	O
(	O
cAMP	O
)	O
signaling	O
pathway	O
.	O

Sequencing	O
of	O
these	O
tumors	S-Phenotype
has	O
identified	O
multiple	O
important	O
genes	O
in	O
the	O
pathogenesis	O
of	O
PanNETs	O
,	O
such	O
as	O
DAXX	O
/	O
ATRX	O
,	O
MEN1	O
,	O
TP53	O
,	O
RB	O
,	O
and	O
mTOR	O
pathway	O
genes	O
.	O

We	O
found	O
previously	O
that	O
the	O
candidate	O
tumor	S-Phenotype
suppressor	O
CLCA2	O
is	O
expressed	O
in	O
differentiated	O
,	O
growth	O
-	O
arrested	O
mammary	O
epithelial	O
cells	O
but	O
is	O
downregulated	O
during	O
tumor	S-Phenotype
progression	O
and	O
EMT	O
.	O

Concurrently	O
,	O
global	O
transcriptional	O
profiling	O
analysis	O
reveals	O
that	O
multiple	O
tumor	S-Phenotype
-	O
associated	O
genes	O
such	O
as	O
CCND3	O
,	O
E2F1	O
/	O
2	O
,	O
HOXA1	O
,	O
Bcl2	O
modifying	O
factor	O
(	O
BMF	O
)	O
,	O
Met	O
,	O
and	O
Myc	O
;	O
and	O
signaling	O
pathways	O
of	O
cellular	O
dedifferentiation	O
,	O
proliferation	O
,	O
adhesion	O
,	O
survival	O
including	O
p53	O
,	O
cadherin	O
,	O
Myc	O
,	O
and	O
anti	O
-	O
apoptotic	O
pathways	O
are	O
differentially	O
expressed	O
or	O
significantly	O
altered	O
in	O
these	O
lung	O
epithelial	O
cells	O
upon	O
downregulation	O
of	O
H2Bub1	O
.	O

Corresponding	O
implicated	O
genes	O
,	O
such	O
as	O
TNNI3K	O
,	O
ErbB3	O
,	O
MKL2	O
,	O
MTNR1B	O
and	O
PRKD1	O
,	O
may	O
explain	O
the	O
associations	O
between	O
reproductive	O
factors	O
and	O
heart	B-Phenotype
failure	E-Phenotype
.	O

Taken	O
together	O
,	O
we	O
show	O
here	O
that	O
mutations	O
leading	O
either	O
to	O
BCL11B	O
haploinsufficiency	O
or	O
to	O
a	O
truncated	O
BCL11B	O
protein	O
clinically	O
cause	O
a	O
non	B-Phenotype
-	I-Phenotype
syndromic	I-Phenotype
neurodevelopmental	I-Phenotype
delay	E-Phenotype
.	O

Microscopic	O
sections	O
showed	O
a	O
circumscribed	O
tumor	S-Phenotype
in	O
the	O
dermis	O
and	O
subcutaneous	O
fat	O
,	O
composed	O
of	O
spindle	O
cells	O
,	O
inflammatory	O
cells	O
,	O
including	O
lymphocytes	O
,	O
plasma	O
cells	O
,	O
and	O
eosinophils	O
,	O
along	O
with	O
interspersed	O
markedly	O
pleomorphic	O
giant	O
cells	O
containing	O
moderate	O
-	O
to	O
-	O
abundant	O
AAAAAAglassyAAAAAA	O
cytoplasm	O
,	O
vesicular	O
nuclei	O
,	O
exhibiting	O
prominent	O
nucleoli	O
,	O
and	O
intranuclear	O
pseudoinclusions	O
.	O

The	O
transcription	O
factor	O
NRF2	O
is	O
a	O
master	O
regulator	O
of	O
the	O
cellular	O
antioxidant	O
response	O
,	O
and	O
it	O
is	O
often	O
genetically	O
activated	O
in	O
non	B-Phenotype
-	I-Phenotype
small	I-Phenotype
-	I-Phenotype
cell	I-Phenotype
lung	I-Phenotype
cancers	E-Phenotype
(	O
NSCLCs	S-Phenotype
)	O
by	O
,	O
for	O
instance	O
,	O
mutations	O
in	O
the	O
negative	O
regulator	O
KEAP1	O
.	O

The	O
interaction	O
required	O
the	O
tumor	S-Phenotype
necrosis	O
factor	O
receptor	O
-	O
associated	O
factor	O
domain	O
of	O
USP7	O
and	O
the	O
central	O
region	O
of	O
UVSSA	O
and	O
was	O
disrupted	O
by	O
an	O
amino	O
acid	O
substitution	O
in	O
the	O
tumor	S-Phenotype
necrosis	O
factor	O
receptor	O
-	O
associated	O
factor	O
-	O
binding	O
motif	O
of	O
UVSSA	O
.	O

/	O
i	O
Eleven	O
of	O
the	O
43	O
kindreds	O
affected	O
by	O
sporadic	S-Phenotype
disease	O
(	O
26	O
%	O
)	O
carry	O
liRPSA	O
/	O
i	O
mutations	O
,	O
whereas	O
12	O
of	O
the	O
13	O
multiplex	O
kindreds	O
(	O
92	O
%	O
)	O
carry	O
liRPSA	O
/	O
i	O
mutations	O
.	O

This	O
mouse	O
line	O
is	O
an	O
excellent	O
model	O
for	O
studying	O
DFNB30	O
-	O
type	O
deafness	S-Phenotype
in	O
humans	O

We	O
previously	O
developed	O
specific	O
and	O
sensitive	O
anti	O
-	O
PODXL	O
monoclonal	O
antibodies	O
,	O
PcMab	O
-	O
47	O
(	O
mouse	O
IgG1	O
,	O
kappa	O
)	O
and	O
its	O
mouse	O
IgG2a	O
-	O
type	O
(	O
47	O
-	O
mG2a	O
)	O
,	O
both	O
of	O
which	O
were	O
suitable	O
for	O
immunohistochemical	O
analyses	O
of	O
oral	B-Phenotype
cancers	E-Phenotype
.	O

FREM2	O
is	O
thus	O
proposed	O
as	O
a	O
novel	O
GB	O
biomarker	O
and	O
a	O
putative	O
biomarker	O
of	O
glioblastoma	S-Phenotype
stem	O
cells	O
.	O

Autosomal	B-Phenotype
recessive	I-Phenotype
spastic	I-Phenotype
ataxia	E-Phenotype
of	O
Charlevoix	O
-	O
Saguenay	O
(	O
ARSACS	O
)	O
is	O
a	O
neurodegenerative	B-Phenotype
disease	E-Phenotype
that	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
liSACS	O
/	O
i	O
gene	O
.	O

The	O
tumorigenesis	O
and	O
metastasis	O
of	O
tumors	S-Phenotype
are	O
associated	O
with	O
human	O
collagen	O
triple	O
helix	O
repeats	O
containing	O
1	O
(	O
CTHRC1	O
)	O
.	O

The	O
results	O
showed	O
that	O
the	O
concentration	O
of	O
inflammatory	O
cytokines	O
[	O
interleukin	O
1β	O
(	O
IL1β	O
)	O
and	O
tumor	S-Phenotype
necrosis	O
factor	O
α	O
(	O
TNF	O
-	O
α	O
)	O
]	O
,	O
myeloperoxidase	O
(	O
MPO	O
)	O
activity	O
in	O
the	O
lung	O
tissue	O
and	O
blood	O
,	O
protein	O
abundance	O
of	O
toll	O
-	O
like	O
receptor	O
4	O
(	O
TLR4	O
)	O
,	O
nuclear	O
factor	O
κB	O
(	O
NF	O
-	O
κB	O
,	O
p65	O
)	O
,	O
phosphorylated	O
p65	O
(	O
p	O
-	O
p65	O
)	O
,	O
inhibitor	O
κBα	O
(	O
IκBα	O
)	O
,	O
and	O
phosphorylated	O
IκBα	O
(	O
p	O
-	O
IκBα	O
)	O
,	O
and	O
relative	O
mRNA	O
expression	O
of	O
genes	O
associated	O
with	O
inflammation	O
,	O
such	O
as	O
TLR4	O
,	O
NF	O
-	O
κB	O
,	O
IL1β	O
,	O
interleukin	O
6	O
(	O
IL6	O
)	O
,	O
and	O
TNF	O
-	O
α	O
,	O
were	O
significantly	O
upregulated	O
in	O
the	O
LPS	O
group	O
compared	O
to	O
the	O
PBS	O
group	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
found	O
that	O
TPI1	O
expression	O
was	O
greatly	O
decreased	O
in	O
clinical	O
HCC	O
samples	O
,	O
positively	O
correlated	O
with	O
overall	O
survival	O
,	O
and	O
negatively	O
associated	O
with	O
histological	O
differentiation	O
,	O
tumor	S-Phenotype
size	O
and	O
organ	O
metastasis	O
.	O

Our	O
results	O
recognize	O
the	O
sensitivity	O
of	O
tumor	S-Phenotype
cell	O
types	O
to	O
GANT61	O
in	O
cell	O
culture	O
and	O
support	O
a	O
critical	O
role	O
for	O
GLI	O
factors	O
in	O
tumor	S-Phenotype
progression	O
through	O
restraining	O
apoptosis	O
.	O

This	O
review	O
focuses	O
on	O
the	O
molecular	O
basis	O
of	O
the	O
pathogenesis	O
of	O
cardiac	B-Phenotype
abnormality	E-Phenotype
due	O
to	O
PRKAG2	O
mutation	O
and	O
will	O
provide	O
current	O
overviews	O
of	O
the	O
mechanism	O
of	O
glycogen	O
regulation	O
by	O
AMPK	O
.	O

Gorlin	O
syndrome	O
is	O
a	O
rare	O
multisystem	O
inherited	O
disorder	O
which	O
can	O
predispose	O
to	O
basal	B-Phenotype
cell	I-Phenotype
carcinomas	E-Phenotype
(	O
BCCs	S-Phenotype
)	O
,	O
childhood	B-Phenotype
medulloblastomas	E-Phenotype
in	O
addition	O
to	O
various	O
developmental	O
abnormalities	O
;	O
the	O
majority	O
of	O
cases	O
are	O
due	O
to	O
mutations	O
in	O
the	O
PTCH1	O
gene	O
.	O

Here	O
we	O
took	O
advantage	O
of	O
a	O
transgenic	O
mouse	O
line	O
expressing	O
an	O
RDS	O
mutant	O
(	O
R172W	O
)	O
known	O
to	O
cause	O
macular	B-Phenotype
degeneration	E-Phenotype
(	O
MD	S-Phenotype
)	O
in	O
humans	O
.	O

Candidate	O
markers	O
were	O
identified	O
by	O
bisulfite	O
conversion	O
-	O
based	O
genome	O
-	O
wide	O
methylation	O
screening	O
of	O
lung	O
tissue	O
from	O
lung	B-Phenotype
cancer	E-Phenotype
,	O
fibrotic	B-Phenotype
ILD	E-Phenotype
,	O
and	O
COPD	S-Phenotype
.	O

Using	O
a	O
targeted	O
sequencing	O
skeletal	B-Phenotype
dysplasia	E-Phenotype
panel	O
,	O
the	O
proband	O
was	O
found	O
to	O
be	O
a	O
compound	O
heterozygote	O
for	O
two	O
mutations	O
in	O
SLC26A2	O
,	O
one	O
novel	O
mutation	O
,	O
p.Ser522Phe	O
and	O
the	O
other	O
,	O
the	O
common	O
mutation	O
,	O
p.Arg279Trp	O
.	O

Schizophrenia	S-Phenotype
(	O
SZ	S-Phenotype
)	O
and	O
autism	B-Phenotype
spectrum	I-Phenotype
disorders	E-Phenotype
(	O
ASD	S-Phenotype
)	O
are	O
highly	O
heritable	O
neuropsychiatric	O
disorders	O
,	O
although	O
environmental	O
factors	O
,	O
such	O
as	O
maternal	O
immune	O
activation	O
(	O
MIA	O
)	O
,	O
play	O
a	O
role	O
as	O
well	O
.	O

Although	O
the	O
molecular	O
role	O
of	O
the	O
peroxisomal	O
protein	O
SZT2	O
in	O
neuronal	O
excitability	O
and	O
brain	O
development	O
remains	O
to	O
be	O
defined	O
,	O
Szt2	O
has	O
been	O
shown	O
to	O
influence	O
seizure	S-Phenotype
threshold	O
and	O
epileptogenesis	O
in	O
mice	O
,	O
consistent	O
with	O
our	O
findings	O
in	O
humans	O
.	O

Familial	B-Phenotype
amyloid	I-Phenotype
polyneuropathy	E-Phenotype
(	O
FAP	S-Phenotype
)	O
is	O
a	O
rare	O
autosomal	O
dominant	O
disorder	O
characterized	O
by	O
amyloid	O
accumulation	O
in	O
the	O
peripheral	O
nerves	O
and	O
other	O
organs	O
,	O
including	O
the	O
heart	O
,	O
kidney	O
,	O
and	O
eyes	O
.	O

Meesmann	B-Phenotype
epithelial	I-Phenotype
corneal	I-Phenotype
dystrophy	E-Phenotype
(	O
MECD	S-Phenotype
)	O
is	O
a	O
rare	O
autosomal	O
dominant	O
disorder	O
caused	O
by	O
dominant	O
-	O
negative	O
mutations	O
within	O
the	O
KRT3	O
or	O
KRT12	O
genes	O
,	O
which	O
encode	O
the	O
cytoskeletal	O
protein	O
keratins	O
K3	O
and	O
K12	O
,	O
respectively	O
.	O

According	O
to	O
the	O
Ottawa	O
Heart	O
Genomics	O
Study	O
genome	O
-	O
wide	O
association	O
study	O
,	O
a	O
recent	O
research	O
identified	O
that	O
Q688	O
spastic	B-Phenotype
paraplegia	I-Phenotype
7	E-Phenotype
(	O
SPG7	S-Phenotype
)	O
variant	O
is	O
associated	O
with	O
CAD	O
as	O
it	O
bypasses	O
the	O
regulation	O
of	O
tyrosine	O
phosphorylation	O
of	O
AFG3L2	O
and	O
enhances	O
the	O
processing	O
and	O
maturation	O
of	O
SPG7	O
protein	O
.	O

In	O
the	O
following	O
review	O
,	O
we	O
present	O
background	O
theories	O
on	O
the	O
ER	O
(	O
-	O
)	O
/	O
PgR	O
(	O
+	O
)	O
breast	B-Phenotype
cancer	E-Phenotype
origin	O
and	O
their	O
epidemiological	O
and	O
clinicopathological	O
characteristics	O
,	O
including	O
the	O
predictive	O
and	O
prognostic	O
significance	O
of	O
these	O
rare	O
tumors	S-Phenotype

Mutations	O
of	O
the	O
CYP21A2	O
gene	O
encoding	O
adrenal	O
21	O
-	O
hydroxylase	O
cause	O
congenital	B-Phenotype
adrenal	I-Phenotype
hyperplasia	E-Phenotype
(	O
CAH	S-Phenotype
)	O
.	O

Purpose	O
To	O
determine	O
whether	O
the	O
rates	O
and	O
tumor	S-Phenotype
characteristics	O
of	O
screening	O
-	O
detected	O
and	O
interval	O
cancers	S-Phenotype
differ	O
for	O
two	O
-	O
dimensional	O
digital	O
mammography	O
(	O
DM	O
)	O
versus	O
digital	O
breast	O
tomosynthesis	O
(	O
DBT	O
)	O
mammography	O
.	O

To	O
confirm	O
this	O
signal	O
is	O
exclusive	O
to	O
MYCN	O
-	O
amplified	O
tumors	S-Phenotype
,	O
we	O
performed	O
a	O
second	O
meta	O
-	O
analysis	O
comparing	O
728	O
MYCN	O
-	O
nonamplified	O
high	O
-	O
risk	O
patients	O
to	O
identical	O
controls	O
.	O

In	O
the	O
independent	O
dataset	O
,	O
81.2	O
%	O
of	O
the	O
positive	O
tested	O
tumours	S-Phenotype
had	O
known	O
metastatic	O
disease	O
to	O
the	O
bone	O
(	O
p	O
4.28e	O
-	O
10	O
)	O
.	O

Overexpression	O
of	O
Cx31	O
reduced	O
thyroid	B-Phenotype
cancer	E-Phenotype
cell	O
proliferation	O
,	O
migration	O
and	O
invasion	O
.	O

RESULTS	O
There	O
was	O
an	O
increased	O
expression	O
of	O
ALG3	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
tissues	O
compared	O
to	O
normal	O
breast	O
tissues	O
(	O
pAAAA0.05	O
)	O
.	O

Here	O
we	O
show	O
that	O
adipocyte	O
OGT	O
is	O
essential	O
for	O
high	O
fat	O
diet	O
-	O
induced	O
hyperphagia	S-Phenotype
,	O
but	O
is	O
dispensable	O
for	O
baseline	O
food	O
intake	O
.	O

However	O
,	O
Pdha1supf	O
/	O
Y	O
;	O
/	O
sup	O
CnpsupCre	O
/	O
+	O
/	O
sup	O
mice	O
showed	O
reduced	O
fiber	O
density	O
and	O
signs	O
of	O
axonal	B-Phenotype
degeneration	E-Phenotype
in	O
both	O
sciatic	O
and	O
optic	O
nerves	O
from	O
6	O
months	O
of	O
age	O
.	O

Genetic	O
modification	O
of	O
a	O
human	O
prostate	B-Phenotype
cancer	E-Phenotype
cell	O
line	O
to	O
induce	O
miR	O
-	O
101	O
and	O
suppress	O
CENPF	O
decreased	O
cell	O
migration	O
and	O
invasion	O
.	O

The	O
ID2	O
gene	O
expression	O
was	O
increased	O
in	O
the	O
most	O
advanced	O
stage	O
of	O
endometriosis	S-Phenotype
and	O
in	O
ovarian	O
endometriomas	O
,	O
the	O
PRELP	O
was	O
more	O
expressed	O
in	O
peritoneal	O
lesions	O
,	O
and	O
the	O
SMOC2	O
was	O
highly	O
expressed	O
in	O
both	O
peritoneal	O
and	O
endometrioma	O
lesions	O
.	O

Single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
WRAP53	O
have	O
been	O
associated	O
with	O
risk	O
of	O
cancer	S-Phenotype
,	O
which	O
strengthens	O
the	O
role	O
of	O
WRAP53	O
in	O
the	O
pathogenesis	O
of	O
human	O
malignancies	O
.	O

Defects	O
of	O
CIB2	O
,	O
calcium	O
-	O
and	O
integrin	O
-	O
binding	O
protein	O
2	O
,	O
have	O
been	O
reported	O
to	O
cause	O
isolated	O
deafness	S-Phenotype
,	O
DFNB48	O
and	O
Usher	O
syndrome	O
type	O
-	O
IJ	O
,	O
characterized	O
by	O
congenital	B-Phenotype
profound	I-Phenotype
deafness	E-Phenotype
,	O
balance	B-Phenotype
defects	E-Phenotype
and	O
blindness	S-Phenotype
.	O

A	O
novel	O
mutation	O
of	O
an	O
essential	O
splice	O
site	O
in	O
the	O
C19orf70	O
gene	O
encoding	O
QIL1	O
induces	O
severe	O
mitochondrial	B-Phenotype
encephalopathy	E-Phenotype
,	O
hepatopathy	S-Phenotype
and	O
lactate	B-Phenotype
acidosis	E-Phenotype
consistent	O
with	O
psychomotor	B-Phenotype
retardation	E-Phenotype
.	O

Silencing	O
expression	O
of	O
CCND1	O
,	O
JUN	O
and	O
SPP1	O
in	O
the	O
human	O
oral	B-Phenotype
cancer	E-Phenotype
cell	O
line	O
OECM	O
-	O
1	O
confirmed	O
that	O
those	O
genes	O
play	O
essential	O
roles	O
in	O
oral	B-Phenotype
cancer	E-Phenotype
cell	O
invasion	O
.	O

All	O
three	O
and	O
two	O
patients	O
with	O
NKX2.1	O
variants	O
had	O
hypothyroidism	S-Phenotype
and	O
developmental	B-Phenotype
delay	E-Phenotype
,	O
respectively	O
.	O

Bardet	O
-	O
Biedl	O
syndrome	O
(	O
BBS	O
)	O
is	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
disorder	O
that	O
is	O
both	O
genetically	O
and	O
clinically	O
heterogeneous	S-Phenotype
.	O

These	O
findings	O
facilitate	O
interpretation	O
of	O
the	O
genetic	O
essence	O
of	O
this	O
rare	O
melanoma	S-Phenotype
subtype	O
as	O
well	O
as	O
the	O
pattern	O
of	O
cancer	S-Phenotype
evolution	O
,	O
thus	O
reinforcing	O
the	O
therapeutic	O
challenges	O
associated	O
with	O
PMME	O
.	O

Significance	O
:	O
This	O
study	O
highlights	O
the	O
use	O
of	O
multiregion	O
exome	O
sequencing	O
and	O
whole	O
genome	O
SNP	O
array	O
genotyping	O
to	O
comprehensively	O
characterize	O
the	O
genetic	O
landscape	O
of	O
a	O
rare	O
type	O
of	O
esophogeal	B-Phenotype
melanoma	E-Phenotype
.	O

Hermansky	O
-	O
Pudlak	O
syndrome	O
(	O
HPS	O
)	O
-	O
characterized	O
by	O
the	O
distinct	O
clinical	O
phenotypes	O
of	O
both	O
oculocutaneous	B-Phenotype
albinism	E-Phenotype
and	O
mild	B-Phenotype
bleeding	I-Phenotype
diathesis	E-Phenotype
-	O
is	O
caused	O
by	O
mutations	O
in	O
genes	O
that	O
have	O
crucial	O
roles	O
in	O
the	O
assembly	O
of	O
cellular	O
organelles	O
(	O
skin	O
melanosomes	O
,	O
platelet	O
delta	O
[	O
dense	O
]	O
granules	O
,	O
lung	O
lamellar	O
bodies	O
,	O
and	O
cytotoxic	O
T	O
-	O
cell	O
lymphocyte	O
granules	O
)	O
.	O

CTR1	O
was	O
similarly	O
mislocalized	O
to	O
the	O
cytosol	O
in	O
the	O
heart	O
of	O
knockin	O
mice	O
carrying	O
a	O
homozygous	O
G115S	O
substitution	O
in	O
Sco1	O
,	O
which	O
in	O
humans	O
causes	O
a	O
hypertrophic	B-Phenotype
cardiomyopathy	E-Phenotype
.	O

Mutations	O
and	O
deletions	O
of	O
the	O
interleukin	O
-	O
1	O
receptor	O
accessory	O
protein	O
like	O
1	O
(	O
IL1RAPL1	O
)	O
gene	O
,	O
located	O
on	O
the	O
X	O
chromosome	O
,	O
are	O
associated	O
with	O
intellectual	B-Phenotype
disability	E-Phenotype
(	O
ID	S-Phenotype
)	O
and	O
autism	B-Phenotype
spectrum	I-Phenotype
disorder	E-Phenotype
(	O
ASD	S-Phenotype
)	O
.	O

It	O
is	O
therefore	O
recommended	O
that	O
,	O
depending	O
on	O
local	O
resources	O
and	O
availability	O
,	O
at	O
least	O
some	O
degree	O
of	O
genetic	O
testing	O
should	O
be	O
offered	O
to	O
all	O
PHEO	O
/	O
PGL	O
patients	O
,	O
including	O
those	O
with	O
clinically	O
sporadic	S-Phenotype
disease	O
.	O

Here	O
,	O
we	O
identified	O
,	O
by	O
next	O
generation	O
sequencing	O
,	O
sequence	O
variants	O
affecting	O
function	O
in	O
the	O
PCYT1A	O
gene	O
in	O
three	O
young	O
patients	O
with	O
isolated	O
retinal	B-Phenotype
dystrophy	E-Phenotype
from	O
two	O
different	O
Italian	O
families	O
.	O

ATL3	O
is	O
a	O
paralogue	O
of	O
ATL1	O
,	O
a	O
membrane	O
curvature	O
-	O
generating	O
molecule	O
that	O
is	O
involved	O
in	O
spastic	B-Phenotype
paraplegia	E-Phenotype
and	O
hereditary	B-Phenotype
sensory	I-Phenotype
neuropathy	E-Phenotype
.	O

More	O
recently	O
,	O
cancer	S-Phenotype
-	O
associated	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
in	O
Rac1	O
have	O
been	O
identified	O
which	O
contribute	O
to	O
tumor	S-Phenotype
phenotypes	O
and	O
confer	O
resistance	O
to	O
targeted	O
therapies	O
.	O

Molecular	O
biomarkers	O
in	O
blood	O
are	O
needed	O
to	O
aid	O
the	O
early	O
diagnosis	O
and	O
clinical	O
assessment	O
of	O
glioblastoma	S-Phenotype
(	O
GBM	S-Phenotype
)	O
.	O

Importantly	O
,	O
bone	O
cell	O
activity	O
was	O
inversely	O
correlated	O
to	O
tumor	S-Phenotype
cell	O
AR	O
activity	O
(	O
measured	O
as	O
AR	O
,	O
FOXA1	O
,	O
HOXB13	O
,	O
KLK2	O
,	O
KLK3	O
,	O
NKX3	O
-	O
1	O
,	O
STEAP2	O
,	O
and	O
TMPRSS2	O
expression	O
)	O
and	O
to	O
patient	O
serum	O
prostate	O
-	O
specific	O
antigen	O
(	O
PSA	O
)	O
levels	O
.	O

Absence	B-Phenotype
epilepsy	E-Phenotype
(	O
AE	S-Phenotype
)	O
is	O
a	O
common	O
type	O
of	O
genetic	B-Phenotype
generalized	I-Phenotype
epilepsy	E-Phenotype
(	O
GGE	S-Phenotype
)	O
,	O
particularly	O
in	O
children	O
.	O

Additionally	O
,	O
c	O
-	O
Myc	O
was	O
demonstrated	O
to	O
drive	O
OVAAL	O
transcription	O
,	O
indicating	O
a	O
positive	O
feedback	O
loop	O
between	O
c	O
-	O
Myc	O
and	O
OVAAL	O
in	O
controlling	O
tumor	S-Phenotype
growth	O
.	O

Here	O
,	O
we	O
employed	O
a	O
gel	O
free	O
quantitative	O
proteomics	O
approach	O
to	O
identify	O
the	O
downstream	O
effectors	O
and	O
targets	O
of	O
SIRT1	O
in	O
melanoma	S-Phenotype
.	O

Inactivation	O
of	O
ALX4	O
/	O
Alx4	O
causes	O
lacrimal	B-Phenotype
gland	I-Phenotype
aplasia	E-Phenotype
in	O
both	O
human	O
and	O
mouse	O
.	O

In	O
cancer	S-Phenotype
,	O
elevated	O
XIAP	O
expression	O
has	O
been	O
associated	O
with	O
malignancy	O
,	O
poor	O
prognosis	O
,	O
and	O
treatment	O
resistance	O
.	O

In	O
A549	O
lung	B-Phenotype
cancer	E-Phenotype
cells	O
,	O
which	O
endogenously	O
express	O
CXCR1	O
,	O
the	O
depletion	O
of	O
REEP5	O
and	O
REEP6	O
significantly	O
reduced	O
growth	O
and	O
invasion	O
by	O
downregulating	O
IL	O
-	O
8	O
-	O
stimulated	O
ERK	O
phosphorylation	O
,	O
actin	O
polymerization	O
and	O
the	O
expression	O
of	O
genes	O
related	O
to	O
metastasis	O
.	O

Cystinosis	O
is	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
lysosomal	O
storage	O
disease	O
caused	O
by	O
mutations	O
in	O
CTNS	O
.	O

In	O
proximal	O
renal	O
tubules	O
,	O
FGF23	O
suppresses	O
the	O
membrane	O
expression	O
of	O
the	O
sodium	O
-	O
phosphate	O
cotransporters	O
Npt2a	O
and	O
Npt2c	O
which	O
mediate	O
urinary	O
reabsorption	O
of	O
filtered	O
phosphate	O
.	O

The	O
21	O
genes	O
comprised	O
8	O
tumor	S-Phenotype
suppressor	O
candidates	O
(	O
ATM	O
,	O
MSH2	O
,	O
PIK3R1	O
,	O
PTCH1	O
,	O
PTEN	O
,	O
TET2	O
,	O
TP53	O
,	O
and	O
TSC1	O
)	O
and	O
13	O
oncogene	O
candidates	O
(	O
ALK	O
,	O
BCL9	O
,	O
CTNNB1	O
,	O
ERBB2	O
,	O
FGFR2	O
,	O
FLT3	O
,	O
HNF1A	O
,	O
KIT	O
,	O
MTOR	O
,	O
PDGFRA	O
,	O
PPP2R1A	O
,	O
PTPN11	O
,	O
and	O
SF3B1	O
)	O
.	O

LTBP3	O
was	O
dispensable	O
in	O
the	O
late	O
steps	O
of	O
carcinoma	S-Phenotype
cell	O
metastasis	O
that	O
follow	O
tumor	S-Phenotype
cell	O
intravasation	O
,	O
including	O
vascular	O
arrest	O
,	O
extravasation	O
,	O
and	O
tissue	O
colonization	O
.	O

CONCLUSIONS	O
The	O
results	O
of	O
this	O
research	O
indicate	O
that	O
the	O
metastases	O
of	O
non	B-Phenotype
-	I-Phenotype
small	I-Phenotype
cell	I-Phenotype
lung	I-Phenotype
cancer	E-Phenotype
can	O
predict	O
RET	O
rearrangement	O
of	O
the	O
primary	O
tumor	S-Phenotype
tissue	O
in	O
the	O
majority	O
of	O
cases	O
.	O

We	O
report	O
the	O
association	O
of	O
many	O
previously	O
unreported	O
variants	O
with	O
retinal	B-Phenotype
disease	E-Phenotype
,	O
as	O
well	O
as	O
new	O
disease	O
phenotypes	O
associated	O
with	O
known	O
genes	O
,	O
including	O
the	O
first	O
association	O
of	O
the	O
SLC24A1	O
gene	O
with	O
retinitis	B-Phenotype
pigmentosa	E-Phenotype
.	O

Certain	O
breeds	O
have	O
a	O
higher	O
risk	O
of	O
developing	O
mast	O
cell	O
tumours	S-Phenotype
,	O
suggesting	O
that	O
underlying	O
predisposing	O
germ	O
-	O
line	O
genetic	O
factors	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
this	O
disease	O
.	O

From	O
the	O
integrative	O
analysis	O
of	O
the	O
transcriptome	O
and	O
clinicopathologic	O
data	O
of	O
human	O
multi	O
-	O
stage	O
HCC	O
tissues	O
,	O
we	O
were	O
able	O
to	O
identify	O
barrier	O
-	O
to	O
-	O
autointegration	O
factor	O
1	O
(	O
BANF1	O
)	O
,	O
procollagen	O
-	O
lysine	O
,	O
2	O
-	O
oxoglutarate	O
5	O
-	O
dioxygenase	O
3	O
(	O
PLOD3	O
)	O
and	O
splicing	O
factor	O
3b	O
subunit	O
4	O
(	O
SF3B4	O
)	O
as	O
early	O
HCC	O
biomarkers	O
which	O
could	O
be	O
detected	O
in	O
precancerous	B-Phenotype
lesions	I-Phenotype
of	I-Phenotype
HCC	E-Phenotype
,	O
with	O
superior	O
capabilities	O
to	O
diagnose	O
eHCC	O
compared	O
to	O
the	O
currently	O
popular	O
HCC	O
diagnostic	O
biomarkers	O
:	O
GPC3	O
,	O
GS	O
,	O
and	O
HSP70	O
.	O

In	O
vivo	O
imaging	O
,	O
ex	O
vivo	O
imaging	O
and	O
tumor	S-Phenotype
tissue	O
slides	O
showed	O
that	O
PDT	O
further	O
contribute	O
EGFP	O
-	O
EGF1	O
-	O
NP	O
accumulation	O
in	O
tumor	S-Phenotype
.	O

While	O
the	O
liSCN2A	O
/	O
i	O
variant	O
is	O
likely	O
to	O
be	O
causal	O
for	O
episodic	S-Phenotype
ataxia	S-Phenotype
,	O
each	O
variant	O
may	O
potentially	O
contribute	O
to	O
the	O
phenotypes	O
observed	O
in	O
this	O
family	O
.	O

Furthermore	O
,	O
TR2	O
-	O
3	O
suppressed	O
the	O
tumor	S-Phenotype
growth	O
significantly	O
in	O
the	O
xenograft	O
model	O
.	O

The	O
variety	O
of	O
growth	O
patterns	O
and	O
cell	O
features	O
led	O
us	O
to	O
speculate	O
a	O
possibility	O
of	O
ALK	B-Phenotype
-	I-Phenotype
positive	I-Phenotype
renal	I-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
ALK	B-Phenotype
+	I-Phenotype
RCC	E-Phenotype
)	O
.	O

First	O
,	O
we	O
tested	O
whether	O
the	O
pretreatment	O
of	O
liMomordica	O
charantia	O
/	O
i	O
ethanol	O
extract	O
(	O
MCEE	O
)	O
attenuates	O
H₂O₂	O
-	O
induced	O
cell	O
death	O
in	O
human	O
neuroblastoma	S-Phenotype
SK	O
-	O
N	O
-	O
MC	O
cells	O
.	O

Herein	O
,	O
we	O
report	O
biallelic	O
pathogenic	O
variants	O
in	O
OTUD6B	O
in	O
12	O
individuals	O
from	O
6	O
independent	O
families	O
with	O
an	O
intellectual	B-Phenotype
disability	E-Phenotype
syndrome	O
associated	O
with	O
seizures	S-Phenotype
and	O
dysmorphic	O
features	O
.	O

The	O
mean	O
pulmonary	O
arterial	O
pressure	O
(	O
mPAP	O
)	O
,	O
right	B-Phenotype
ventricular	I-Phenotype
hypertrophy	E-Phenotype
index	O
(	O
RVHI	O
)	O
,	O
pulmonary	O
vascular	O
remodeling	O
,	O
serum	O
tumor	S-Phenotype
necrosis	O
factor	O
α	O
(	O
TNFα	O
)	O
,	O
and	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
)	O
were	O
higher	O
either	O
in	O
SI	O
or	O
in	O
TI	O
28	O
and	O
35	O
days	O
after	O
the	O
first	O
MCT	O
injection	O
.	O

Of	O
note	O
,	O
C	O
/	O
EBPβ	O
,	O
an	O
independent	O
prognostic	O
factor	O
for	O
patients	O
with	O
ovarian	B-Phenotype
cancer	E-Phenotype
,	O
mediates	O
an	O
important	O
mechanism	O
through	O
which	O
epigenetic	O
enzyme	O
modifies	O
groups	O
of	O
functionally	O
related	O
genes	O
in	O
a	O
context	O
-	O
dependent	O
manner	O
.	O

Nevertheless	O
,	O
it	O
is	O
still	O
ambiguous	O
whether	O
NIBP	O
is	O
involved	O
in	O
the	O
chemoresistance	O
of	O
gastric	B-Phenotype
cancer	E-Phenotype
.	O

The	O
molecular	O
signatures	O
unique	O
to	O
primary	O
and	O
metastatic	O
LMSs	O
may	O
aid	O
in	O
understanding	O
tumor	S-Phenotype
progression	O
in	O
this	O
cancer	S-Phenotype
and	O
in	O
providing	O
a	O
molecular	O
basis	O
for	O
prognostic	O
studies	O
and	O
therapeutic	O
target	O
discovery	O
.	O

The	O
tumour	S-Phenotype
suppressor	O
p53	O
negatively	O
controls	O
cell	O
cycle	O
progression	O
in	O
response	O
to	O
perturbed	O
ribosome	O
biogenesis	O
in	O
mammalian	O
cells	O
,	O
thus	O
coordinating	O
growth	O
with	O
proliferation	O
.	O

The	O
relationship	O
between	O
the	O
altered	O
expression	O
of	O
MACC1	O
,	O
c	O
-	O
MET	O
,	O
and	O
NM23	O
-	O
H1	O
and	O
pathological	O
microenvironmental	O
features	O
,	O
including	O
the	O
presence	O
of	O
tumor	S-Phenotype
budding	O
and	O
desmoplasia	O
,	O
were	O
assessed	O
.	O

Kank1	O
,	O
an	O
important	O
member	O
of	O
the	O
Kank	O
gene	O
family	O
,	O
plays	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
many	O
malignant	B-Phenotype
tumors	E-Phenotype
.	O

Bartter	O
syndrome	O
Type	O
IV	O
is	O
a	O
rare	O
subtype	O
of	O
the	O
Bartter	O
syndromes	O
that	O
leads	O
to	O
both	O
severe	O
renal	B-Phenotype
salt	I-Phenotype
wasting	E-Phenotype
and	O
sensorineural	B-Phenotype
deafness	E-Phenotype
.	O

We	O
used	O
a	O
set	O
of	O
previously	O
uncharacterized	O
antibodies	O
against	O
the	O
cancer	S-Phenotype
/	O
testis	O
antigens	O
ADAM2	O
,	O
CALR3	O
and	O
SAGE1	O
to	O
investigate	O
their	O
expression	O
in	O
a	O
large	O
panel	O
of	O
normal	O
tissues	O
as	O
well	O
as	O
breast	B-Phenotype
and	I-Phenotype
lung	I-Phenotype
cancers	E-Phenotype
.	O

Sensenbrenner	O
syndrome	O
(	O
cranioectodermal	O
dysplasia	O
,	O
CED	O
)	O
is	O
a	O
very	O
rare	O
autosomal	B-Phenotype
recessive	E-Phenotype
ciliopathy	O
.	O

Hexavalent	O
chromium	O
[	O
Cr	O
(	O
VI	O
)	O
]	O
damages	O
DNA	O
and	O
causes	O
cancer	S-Phenotype
,	O
but	O
it	O
is	O
unclear	O
which	O
DNA	O
damage	O
responses	O
(	O
DDRs	O
)	O
most	O
critically	O
protect	O
cells	O
from	O
chromate	O
toxicity	O
.	O

Somatic	O
genetic	O
rearrangements	O
that	O
juxtapose	O
the	O
PAX3	O
DNA	O
binding	O
domain	O
to	O
the	O
transcriptional	O
activation	O
domain	O
of	O
other	O
transcription	O
factors	O
deregulate	O
PAX3	O
function	O
and	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
the	O
soft	O
tissue	O
cancers	S-Phenotype
alveolar	B-Phenotype
rhabdomyosarcoma	E-Phenotype
and	O
biphenotypic	B-Phenotype
sinonasal	I-Phenotype
sarcoma	E-Phenotype
.	O

Recent	O
prevalent	O
research	O
topic	O
concentrated	O
in	O
the	O
three	O
neighboring	O
genes	O
of	O
FTO	O
:	O
RPGRIP1L	O
,	O
IRX3	O
and	O
IRX5	O
,	O
as	O
having	O
a	O
functional	O
link	O
between	O
obesity	S-Phenotype
-	O
associated	O
common	O
variants	O
within	O
FTO	O
and	O
the	O
observed	O
human	O
phenotypes	O
.	O

Through	O
genetic	O
mapping	O
of	O
disease	O
loci	O
and	O
whole	O
-	O
exome	O
sequencing	O
in	O
four	O
unrelated	O
multiplex	O
families	O
presenting	O
with	O
severe	O
AMC	O
,	O
we	O
identified	O
biallelic	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
LGI4	O
(	O
leucine	O
-	O
rich	O
glioma	S-Phenotype
-	O
inactivated	O
4	O
)	O
.	O

The	O
discovery	O
of	O
mutations	O
in	O
genes	O
encoding	O
the	O
metabolic	O
enzymes	O
isocitrate	O
dehydrogenase	O
(	O
IDH	O
)	O
,	O
succinate	O
dehydrogenase	O
(	O
SDH	O
)	O
,	O
and	O
fumarate	O
hydratase	O
(	O
FH	O
)	O
has	O
expanded	O
our	O
understanding	O
not	O
only	O
of	O
altered	O
metabolic	O
pathways	O
but	O
also	O
epigenetic	O
dysregulation	O
in	O
cancer	S-Phenotype
.	O

In	O
conclusion	O
,	O
we	O
identified	O
relevant	O
genetic	O
variations	O
in	O
up	O
to	O
15	O
%	O
of	O
cases	O
after	O
exclusion	O
of	O
polyglutamine	O
expansion	O
spinocerebellar	B-Phenotype
ataxias	E-Phenotype
,	O
and	O
confirmed	O
CACNA1A	O
and	O
SPG7	O
as	O
major	O
ataxia	S-Phenotype
genes	O
.	O

However	O
,	O
little	O
is	O
known	O
regarding	O
LIMK	O
/	O
cofilin	O
and	O
SSH	O
in	O
human	O
colorectal	B-Phenotype
cancer	E-Phenotype
(	O
CRC	S-Phenotype
)	O
.	O

In	O
a	O
clinical	O
sense	O
,	O
recognizing	O
those	O
IHH	O
genes	O
and	O
associated	O
phenotypes	O
may	O
improve	O
our	O
diagnostic	O
capabilities	O
by	O
enabling	O
us	O
to	O
prioritize	O
the	O
screening	O
of	O
particular	O
gene	O
(	O
s	O
)	O
such	O
as	O
synkinesia	O
(	O
ANOS1	O
)	O
,	O
dental	B-Phenotype
agenesis	E-Phenotype
(	O
FGF8	O
/	O
FGFR1	O
)	O
and	O
hearing	B-Phenotype
loss	E-Phenotype
(	O
CHD7	O
)	O
.	O

Mutations	O
in	O
the	O
RNA	O
exosome	O
gene	O
EXOSC2	O
cause	O
a	O
distinct	O
syndrome	O
with	O
various	O
tissue	O
-	O
specific	O
phenotypes	O
including	O
retinitis	B-Phenotype
pigmentosa	E-Phenotype
and	O
mild	O
intellectual	B-Phenotype
disability	E-Phenotype
.	O

In	O
the	O
current	O
study	O
,	O
we	O
investigated	O
the	O
miRNA	O
expressional	O
profiles	O
in	O
the	O
highly	O
invasive	O
human	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
cell	O
line	O
MHCC97	O
-	O
H	O
and	O
MHCC97	O
-	O
L	O
with	O
lower	O
metastatic	O
potential	O
using	O
miRNA	O
microarrays	O
.	O

The	O
MKK1	O
/	O
2	O
kinase	O
tumour	S-Phenotype
progression	O
locus	O
2	O
(	O
TPL	O
-	O
2	O
)	O
is	O
critical	O
for	O
the	O
production	O
of	O
tumour	S-Phenotype
necrosis	O
factor	O
alpha	O
(	O
TNFa	O
)	O
in	O
innate	O
immune	O
responses	O
and	O
a	O
potential	O
anti	O
-	O
inflammatory	O
drug	O
target	O
.	O

Targeting	O
CDKN1C	O
may	O
be	O
a	O
promising	O
strategy	O
for	O
anticancer	O
therapeutics	S-Phenotype

In	O
vivo	O
experiments	O
were	O
performed	O
in	O
nude	O
mice	O
bearing	O
transfected	O
tumors	S-Phenotype
;	O
results	O
revealed	O
that	O
NET	O
-	O
VMAT2	O
-	O
coexpressing	O
tumors	S-Phenotype
had	O
longer	O
lsup131	O
/	O
supI	O
-	O
MIBG	O
retention	O
time	O
than	O
NET	O
-	O
expressing	O
tumors	S-Phenotype
.	O

Retrospectively	O
study	O
revealed	O
that	O
miR	O
-	O
34a	O
expression	O
was	O
downregulated	O
in	O
human	O
primary	O
GC	O
tissues	O
compared	O
with	O
non	O
-	O
tumor	S-Phenotype
tissues	O
and	O
low	O
miR	O
-	O
34a	O
expression	O
was	O
associated	O
with	O
a	O
significantly	O
shorter	O
overall	O
survival	O
and	O
disease	O
-	O
free	O
survival	O
.	O

We	O
describe	O
a	O
neurological	O
disorder	O
with	O
epilepsy	S-Phenotype
and	O
prominent	B-Phenotype
choreoathetosis	E-Phenotype
caused	O
by	O
biallelic	O
pathogenic	O
variants	O
in	O
FRRS1L	O
,	O
which	O
encodes	O
an	O
AMPA	O
receptor	O
outer	O
-	O
core	O
protein	O
.	O

Our	O
case	O
-	O
control	O
study	O
investigates	O
the	O
possible	O
association	O
between	O
seven	O
DPYD	O
gene	O
polymophisms	O
(	O
rs1801267	O
,	O
rs72547602	O
,	O
rs1801160	O
,	O
rs3918290	O
,	O
rs1801159	O
,	O
rs1801158	O
,	O
rs1801265	O
)	O
and	O
risk	O
of	O
colorectal	B-Phenotype
cancer	E-Phenotype
(	O
CRC	S-Phenotype
)	O
.	O

Results	O
:	O
We	O
identified	O
one	O
independent	O
SNP	O
,	O
rs2394882	O
,	O
in	O
POU5F1	O
that	O
was	O
associated	O
with	O
prostate	B-Phenotype
cancer	E-Phenotype
recurrence	O
(	O
hazard	O
ratio	O
0.32	O
,	O
95	O
%	O
confidence	O
interval	O
0.14	O
-	O
0.71	O
,	O
P	O
=	O
0.005	O
)	O
after	O
adjustment	O
for	O
known	O
clinical	O
predictors	O
.	O

Exome	O
analysis	O
of	O
APA	O
has	O
allowed	O
the	O
identification	O
of	O
recurrent	O
somatic	O
mutations	O
in	O
KCNJ5	O
,	O
CACNA1D	O
,	O
ATP1A1	O
,	O
and	O
ATP2B3	O
in	O
more	O
than	O
50	O
%	O
of	O
sporadic	S-Phenotype
cases	O
.	O

Increased	O
Spi	O
-	O
B	O
expression	O
was	O
associated	O
with	O
tumor	S-Phenotype
grade	O
,	O
lymphatic	O
metastasis	O
,	O
and	O
short	O
overall	O
survival	O
.	O

We	O
describe	O
a	O
neurological	O
disorder	O
with	O
epilepsy	S-Phenotype
and	O
prominent	B-Phenotype
choreoathetosis	E-Phenotype
caused	O
by	O
biallelic	O
pathogenic	O
variants	O
in	O
FRRS1L	O
,	O
which	O
encodes	O
an	O
AMPA	O
receptor	O
outer	O
-	O
core	O
protein	O
.	O

Clinical	O
confirmation	O
of	O
our	O
machine	O
learned	O
Bayesian	O
networks	O
will	O
have	O
significant	O
impact	O
on	O
our	O
understanding	O
of	O
the	O
role	O
of	O
NRF1	O
as	O
a	O
valuable	O
biomarker	O
for	O
breast	B-Phenotype
cancer	E-Phenotype
diagnosis	O
and	O
prognosis	O
as	O
well	O
as	O
provide	O
strong	O
rationale	O
for	O
future	O
studies	O
to	O
develop	O
NRF1	O
signaling	O
-	O
based	O
therapeutics	O
to	O
target	O
HER2+	O
breast	B-Phenotype
cancer	E-Phenotype

Both	O
lipancEts	O
-	O
1	O
/	O
i	O
and	O
lihnRNPK	O
/	O
i	O
were	O
upregulated	O
in	O
clinical	O
neuroblastoma	S-Phenotype
tissues	O
,	O
and	O
were	O
associated	O
with	O
unfavorable	O
outcome	O
of	O
patients	O
.	O

Western	O
blot	O
analysis	O
,	O
real	O
-	O
time	O
PCR	O
,	O
MTT	O
assay	O
and	O
flow	O
cytometric	O
analysis	O
were	O
performed	O
and	O
the	O
results	O
demonstrated	O
that	O
compared	O
with	O
the	O
gastric	B-Phenotype
cancer	E-Phenotype
SGC	O
-	O
7901	O
cells	O
,	O
the	O
expression	O
of	O
NIBP	O
,	O
NF	O
-	O
kB	O
p65	O
,	O
NF	O
-	O
kB	O
p	O
-	O
p65	O
and	O
mesenchymal	O
marker	O
vimentin	O
were	O
significantly	O
increased	O
in	O
gastric	B-Phenotype
cancer	E-Phenotype
multidrug	O
-	O
resistant	O
SGC	O
-	O
7901	O
/	O
CDDP	O
cells	O
,	O
and	O
the	O
epithelial	O
cell	O
marker	O
ZO	O
-	O
1	O
was	O
significantly	O
decreased	O
.	O

Remarkably	O
,	O
variable	O
expressivity	O
of	O
the	O
human	O
phenotype	O
can	O
be	O
recapitulated	O
in	O
Cwc27	O
mutant	O
mouse	O
models	O
,	O
with	O
significant	O
embryonic	O
lethality	O
and	O
severe	O
phenotypes	O
in	O
the	O
complete	O
knockout	O
mice	O
while	O
mice	O
with	O
a	O
partial	O
loss	O
-	O
of	O
-	O
function	O
allele	O
mimic	O
the	O
isolated	O
retinal	B-Phenotype
degeneration	E-Phenotype
phenotype	O
.	O

Efficacy	O
of	O
siAKT2	O
-	O
PM	O
was	O
validated	O
in	O
CSC	O
isolated	O
from	O
two	O
breast	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
:	O
MCF	O
-	O
7	O
and	O
Triple	O
Negative	O
MDA	O
-	O
MB	O
-	O
231	O
corresponding	O
to	O
an	O
aggressive	O
subtype	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

Although	O
some	O
causative	O
genes	O
have	O
been	O
identified	O
,	O
little	O
progress	O
has	O
been	O
made	O
in	O
identifying	O
genes	O
in	O
which	O
low	O
-	O
penetrance	O
susceptibility	O
variants	O
occur	O
in	O
the	O
majority	O
of	O
sporadic	S-Phenotype
CHM	O
cases	O
.	O

In	O
addition	O
to	O
CRD	O
,	O
these	O
three	O
individuals	O
had	O
hearing	B-Phenotype
loss	E-Phenotype
or	O
hearing	B-Phenotype
deficit	E-Phenotype
.	O

The	O
aim	O
of	O
this	O
work	O
is	O
to	O
provide	O
supplementary	O
information	O
about	O
MVK	O
variability	O
useful	O
in	O
the	O
molecular	O
diagnosis	O
of	O
MKD	O
,	O
as	O
well	O
as	O
to	O
unravel	O
the	O
presence	O
of	O
novel	O
genes	O
potentially	O
involved	O
as	O
involved	O
in	O
the	O
clinical	O
heterogeneity	S-Phenotype
of	O
MKD	O
phenotype	O
.	O

Analysis	O
of	O
the	O
tumors	S-Phenotype
from	O
the	O
Flii	O
overexpressing	O
mice	O
showed	O
reduced	O
caspase	O
I	O
and	O
annexin	O
V	O
expression	O
suggesting	O
Flii	O
may	O
negatively	O
regulate	O
apoptosis	O
within	O
these	O
tumors	S-Phenotype
.	O

In	O
conclusion	O
,	O
truncating	O
variants	O
in	O
TEX15	O
and	O
FANCD2	O
are	O
potential	O
breast	B-Phenotype
cancer	E-Phenotype
risk	O
factors	O
,	O
warranting	O
further	O
investigations	O
in	O
other	O
populations	O
.	O

Silencing	O
FBP1	O
expression	O
attenuated	O
the	O
decrease	O
in	O
glycolytic	O
capacity	O
that	O
caused	O
by	O
CBX3	O
knockdown	O
in	O
pancreatic	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Conclusions	O
:	O
During	O
the	O
natural	O
course	O
of	O
advanced	O
lung	B-Phenotype
cancer	E-Phenotype
,	O
the	O
incidence	O
of	O
anemia	S-Phenotype
is	O
high	O
,	O
especially	O
ACD	O
.	O

In	O
summary	O
,	O
the	O
regulatory	O
role	O
of	O
Mfsd2a	O
deepens	O
our	O
knowledge	O
of	O
the	O
function	O
of	O
the	O
BBB	O
,	O
potentially	O
contributing	O
to	O
the	O
effective	O
drug	O
delivery	O
in	O
the	O
treatments	O
for	O
neurodegenerative	B-Phenotype
diseases	E-Phenotype
,	O
brain	B-Phenotype
tumors	E-Phenotype
,	O
and	O
life	O
-	O
threatening	O
infections	O
in	O
the	O
CNS	O
.	O

The	O
AP4B1	O
-	O
associated	O
phenotype	O
has	O
previously	O
been	O
assigned	O
to	O
spastic	B-Phenotype
paraplegia	I-Phenotype
-	I-Phenotype
47	E-Phenotype
.	O

These	O
results	O
show	O
that	O
a	O
previously	O
-	O
unknown	O
,	O
fully	O
penetrant	O
epistatic	O
interaction	O
between	O
Pnpla2	O
and	O
Lipe	O
can	O
cause	O
liposarcoma	S-Phenotype
in	O
mice	O
.	O

We	O
performed	O
trio	O
-	O
based	O
whole	O
exome	O
sequencing	O
in	O
seven	O
subjects	O
from	O
five	O
non	O
-	O
consanguineous	O
families	O
who	O
presented	O
with	O
either	O
microcephaly	S-Phenotype
or	O
microlissencephaly	S-Phenotype
.	O

Physical	O
deconditioning	O
is	O
associated	O
with	O
the	O
development	O
of	O
chronic	O
diseases	O
,	O
including	O
type	B-Phenotype
2	I-Phenotype
diabetes	E-Phenotype
and	O
cardiovascular	B-Phenotype
disease	E-Phenotype
.	O

PFKFB4	O
and	O
phosphorylated	O
SRC	O
-	O
3	O
levels	O
are	O
increased	O
and	O
correlate	O
in	O
oestrogen	O
receptor	O
-	O
positive	O
tumours	S-Phenotype
,	O
whereas	O
,	O
in	O
patients	O
with	O
the	O
basal	O
subtype	O
,	O
PFKFB4	O
and	O
SRC	O
-	O
3	O
drive	O
a	O
common	O
protein	O
signature	O
that	O
correlates	O
with	O
the	O
poor	O
survival	O
of	O
patients	O
with	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

In	O
this	O
article	O
,	O
we	O
report	O
a	O
case	O
of	O
Limb	B-Phenotype
-	I-Phenotype
girdle	I-Phenotype
muscular	I-Phenotype
dystrophy	I-Phenotype
type	I-Phenotype
2B	E-Phenotype
with	O
a	O
rare	O
homozygous	O
duplication	O
c.164dupA	O
,	O
p.	O
(	O
Ile57Hisfs	O
*	O
8	O
)	O
(	O
rs863225020	O
)	O
in	O
DYSF	O
in	O
a	O
Saudi	O
patient	O
.	O

Using	O
super	O
-	O
resolution	O
and	O
electron	O
microscopy	O
,	O
we	O
find	O
that	O
the	O
human	O
microcephaly	S-Phenotype
protein	O
,	O
RTTN	O
,	O
is	O
recruited	O
to	O
the	O
proximal	O
end	O
of	O
the	O
procentriole	O
at	O
early	O
S	O
phase	O
,	O
and	O
is	O
located	O
at	O
the	O
inner	O
luminal	O
walls	O
of	O
centrioles	O
.	O

Despite	O
this	O
multisystemic	O
involvement	O
and	O
contrasting	O
with	O
a	O
cachectic	O
appearance	O
,	O
the	O
anthropometric	O
parameters	O
showed	O
marked	O
overgrowth	S-Phenotype
(	O
+4	O
DS	O
)	O
,	O
leading	O
to	O
diagnosis	O
of	O
congenital	B-Phenotype
lipodystrophy	E-Phenotype
,	O
which	O
was	O
confirmed	O
by	O
the	O
presence	O
of	O
the	O
new	O
homozygous	O
c.259CAAAAT	O
(	O
p.Gln87	O
*	O
)	O
mutation	O
in	O
the	O
AGPAT2	O
gene	O
.	O

Hirschsprung	B-Phenotype
disease	E-Phenotype
(	O
HSCR	S-Phenotype
)	O
is	O
a	O
congenital	O
and	O
heterogeneous	S-Phenotype
disorder	O
characterized	O
by	O
the	B-Phenotype
absence	I-Phenotype
of	I-Phenotype
intramural	I-Phenotype
nervous	I-Phenotype
plexuses	E-Phenotype
along	O
variable	B-Phenotype
lengths	I-Phenotype
of	I-Phenotype
the	I-Phenotype
hindgut	E-Phenotype
.	O

Unlike	O
patients	O
with	O
ECTD	O
-	O
9	O
,	O
Hoxc13	O
-	O
mutated	O
mice	O
and	O
pigs	O
do	O
not	O
faithfully	O
recapitulate	O
the	O
phenotype	O
of	O
hypotrichosis	S-Phenotype
,	O
so	O
there	O
is	O
a	O
limited	O
understanding	O
of	O
the	O
molecular	O
mechanism	O
of	O
Hoxc13	O
-	O
mediated	O
hypotrichosis	S-Phenotype
in	O
animal	O
models	O
and	O
clinically	O
.	O

We	O
also	O
highlight	O
a	O
recognizable	O
syndrome	O
that	O
resembles	O
galactosemia	S-Phenotype
(	O
a	O
fulminant	O
infantile	O
liver	B-Phenotype
disease	E-Phenotype
with	O
cataract	S-Phenotype
)	O
caused	O
by	O
biallelic	O
mutations	O
in	O
CYP51A1	O
.	O

Genetic	O
alterations	O
in	O
the	O
expression	O
of	O
EN2	O
have	O
been	O
related	O
to	O
different	O
neurologic	O
conditions	O
and	O
more	O
particularly	O
to	O
autism	B-Phenotype
spectrum	I-Phenotype
disorders	E-Phenotype
(	O
ASD	S-Phenotype
)	O
.	O

Subsequent	O
FISH	O
analysis	O
with	O
region	O
-	O
specific	O
YAC	O
clones	O
was	O
used	O
to	O
relate	O
the	O
phenotypic	O
findings	O
such	O
as	O
bilateral	B-Phenotype
split	I-Phenotype
hand	I-Phenotype
formation	E-Phenotype
,	O
specific	B-Phenotype
cardiac	I-Phenotype
and	I-Phenotype
kidney	I-Phenotype
anomalies	E-Phenotype
,	O
microtia	S-Phenotype
,	O
and	O
hypoplastic	O
thorax	O
more	O
exactly	O
to	O
the	O
partial	O
trisomy	O
of	O
the	O
segment	O
4q26	O
-	O
qter	O

FLNB	O
-	O
related	O
disorders	O
are	O
classified	O
as	O
spondylocarpotarsal	O
synostosis	O
(	O
SCT	O
)	O
,	O
Larsen	O
syndrome	O
(	O
LS	O
)	O
,	O
atelosteogenesis	O
(	O
AO	O
)	O
,	O
boomerang	O
dysplasia	O
(	O
BD	O
)	O
,	O
and	O
isolated	O
congenital	B-Phenotype
talipes	I-Phenotype
equinovarus	E-Phenotype
,	O
presenting	O
with	O
scoliosis	S-Phenotype
,	O
short	B-Phenotype
-	I-Phenotype
limbed	I-Phenotype
dwarfism	E-Phenotype
,	O
clubfoot	S-Phenotype
,	O
joint	B-Phenotype
dislocation	E-Phenotype
and	O
other	O
unique	O
skeletal	B-Phenotype
abnormalities	E-Phenotype
.	O

The	O
immunohistochemistry	O
showed	O
that	O
Kif2a	O
expression	O
was	O
stronger	O
in	O
oral	B-Phenotype
tongue	I-Phenotype
cancer	E-Phenotype
tissues	O
than	O
in	O
paired	O
adjacent	O
tissues	O
(	O
PAAAA0.01	O
)	O
,	O
and	O
the	O
higher	O
expression	O
of	O
Kif2a	O
was	O
also	O
significantly	O
associated	O
with	O
lymph	O
node	O
metastasis	O
(	O
PAAAA0.01	O
)	O
,	O
tumor	S-Phenotype
clinical	O
stage	O
(	O
PAAAA0.01	O
)	O
.	O

Furthermore	O
,	O
lower	O
miR	O
-	O
129	O
-	O
5p	O
expression	O
closely	O
associated	O
with	O
tumor	S-Phenotype
size	O
and	O
lymph	O
node	O
invasion	O
and	O
poor	O
prognosis	O
of	O
GC	O
patients	O
.	O

In	O
order	O
to	O
investigate	O
whether	O
somatic	O
THPO	O
gene	O
mutations	O
play	O
a	O
role	O
in	O
sporadic	S-Phenotype
pediatric	O
myeloproliferative	O
diseases	O
,	O
we	O
performed	O
a	O
mutation	O
screening	O
of	O
a	O
large	O
representative	O
cohort	O
of	O
pediatric	B-Phenotype
acute	I-Phenotype
myeloid	I-Phenotype
leukemia	E-Phenotype
,	O
myeloid	B-Phenotype
leukemia	E-Phenotype
of	O
Down	O
syndrome	O
,	O
and	O
juvenile	B-Phenotype
myelomonocytic	I-Phenotype
leukemia	E-Phenotype
samples	O
and	O
show	O
that	O
gain	O
-	O
of	O
-	O
function	O
THPO	O
mutations	O
are	O
extremely	O
rare	O
in	O
sporadic	O
pediatric	O
myeloproliferative	O
diseases	O

In	O
human	O
plasma	O
,	O
osmotic	O
shock	S-Phenotype
increased	O
cBIN1	O
detection	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
,	O
and	O
cBIN1	O
level	O
decreased	O
in	O
humans	O
with	O
heart	B-Phenotype
failure	E-Phenotype
,	O
a	O
condition	O
with	O
reduced	O
cardiac	O
muscle	O
cBIN1	O
,	O
both	O
of	O
which	O
support	O
cBIN1	O
release	O
in	O
MPs	O
from	O
human	O
hearts	O
.	O

Eif4a3	O
haploinsufficient	O
embryos	O
presented	O
altered	O
mandibular	O
process	O
fusion	O
and	O
micrognathia	S-Phenotype
,	O
thus	O
recapitulating	O
the	O
most	O
penetrant	O
phenotypes	O
of	O
the	O
syndrome	O
.	O

PAH	O
in	O
children	O
is	O
much	O
more	O
heterogeneous	S-Phenotype
than	O
in	O
adults	O
,	O
and	O
can	O
be	O
associated	O
with	O
several	O
genetic	O
syndromes	O
,	O
congenital	O
heart	O
disease	O
,	O
pulmonary	O
disease	O
,	O
and	O
vascular	O
disease	O
.	O

Moreover	O
,	O
ALDOA	O
predicted	O
poor	O
prognosis	O
of	O
pancreatic	B-Phenotype
cancer	E-Phenotype
,	O
partially	O
due	O
to	O
its	O
role	O
in	O
E	O
-	O
cadherin	O
expression	O
regulation	O
,	O
and	O
the	O
results	O
were	O
further	O
validated	O
by	O
analysis	O
of	O
the	O
correlation	O
between	O
ALDOA	O
and	O
E	O
-	O
cadherin	O
expression	O
in	O
pancreatic	B-Phenotype
cancer	E-Phenotype
tissue	O
samples	O
.	O

Furthermore	O
,	O
CSTA	O
expression	O
was	O
observed	O
in	O
all	O
22	O
lymph	O
node	O
metastases	O
analyzed	O
.	O

Relatively	O
high	O
levels	O
of	O
CSTA	O
expression	O
in	O
tumors	S-Phenotype
were	O
correlated	O
with	O
tumor	S-Phenotype
progression	O
and	O
advanced	O
cancer	S-Phenotype
stage	O
,	O
including	O
lymph	O
node	O
metastasis	O

Furthermore	O
,	O
these	O
in	O
vitro	O
findings	O
were	O
validated	O
in	O
vivo	O
and	O
the	O
ERK1	O
/	O
2	O
and	O
PI3k	O
/	O
AKT	O
signaling	O
pathways	O
were	O
involved	O
in	O
PSMB8	O
-	O
triggered	O
migration	O
and	O
proliferation	O
of	O
glioma	S-Phenotype
cells	O
.	O

Although	O
univariate	O
analysis	O
showed	O
that	O
tumor	S-Phenotype
size	O
(	O
P	O
=	O
.012	O
)	O
,	O
grade	O
(	O
Z	O
=	O
-	O
2.114	O
,	O
P	O
=	O
.034	O
)	O
,	O
and	O
peritumoral	O
enhancement	O
(	O
x	O
=	O
4.464	O
,	O
P	O
=	O
.035	O
)	O
were	O
associated	O
with	O
MVI	O
,	O
multiple	O
logistic	O
regression	O
analysis	O
showed	O
that	O
capsular	O
invasion	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
=	O
23.469	O
,	O
P	O
AAAA	O
.001	O
)	O
,	O
margins	O
(	O
OR	O
=	O
6.751	O
,	O
P	O
AAAA	O
.001	O
)	O
,	O
and	O
serum	O
AFP	O
level	O
(	O
OR	O
=	O
1.001	O
,	O
P	O
=	O
.038	O
)	O
were	O
associated	O
with	O
MVI	O
in	O
HCC	O
(	O
P	O
AAAA	O
.05	O
)	O
.	O

Enhancing	O
chromatin	O
dynamics	O
may	O
be	O
a	O
treatment	O
approach	O
to	O
amyotrophic	B-Phenotype
lateral	I-Phenotype
scleorosis	E-Phenotype
(	O
ALS	S-Phenotype
)	O
/	O
frontotemporal	B-Phenotype
dementia	E-Phenotype
(	O
FTD	S-Phenotype
)	O

Friedreich	B-Phenotype
's	I-Phenotype
ataxia	E-Phenotype
(	O
FRDA	S-Phenotype
)	O
,	O
the	O
autosomal	O
neurodegenerative	O
disorder	O
is	O
the	O
only	O
human	O
disease	O
known	O
so	O
far	O
,	O
where	O
a	O
large	O
purine	O
(	O
GAA	O
)	O
repeat	O
in	O
the	O
FXN	O
gene	O
is	O
known	O
to	O
inhibit	O
the	O
expression	O
of	O
frataxin	O
protein	O
.	O

Mutations	O
in	O
LIAS	O
have	O
been	O
identified	O
that	O
result	O
in	O
a	O
variant	O
form	O
of	O
nonketotic	B-Phenotype
hyperglycinemia	E-Phenotype
with	O
early	O
-	O
onset	O
convulsions	O
combined	O
with	O
a	O
defect	O
in	O
mitochondrial	O
energy	O
metabolism	O
with	O
encephalopathy	S-Phenotype
and	O
cardiomyopathy	S-Phenotype
.	O

To	O
gain	O
insight	O
into	O
the	O
molecular	O
basis	O
of	O
the	O
heterogeneous	S-Phenotype
phenotype	O
observed	O
in	O
men	O
with	O
the	O
deletion	O
we	O
defined	O
the	O
type	O
of	O
DAZ	O
and	O
CDY1	O
genes	O
deleted	O
.	O

The	O
Ki	O
-	O
67	O
positive	O
index	O
of	O
tumor	S-Phenotype
varied	O
from	O
less	O
than	O
2	O
%	O
(	O
51.4	O
%	O
)	O
,	O
3	O
%	O
to	O
10	O
%	O
(	O
41.3	O
%	O
)	O
to	O
AAAA10	O
%	O
(	O
7.2	O
%	O
)	O
.	O

Trio	O
exome	O
sequencing	O
has	O
been	O
successful	O
in	O
identifying	O
genes	O
with	O
de	O
novo	O
mutations	O
(	O
DNMs	O
)	O
causing	O
epileptic	B-Phenotype
encephalopathy	E-Phenotype
(	O
EE	S-Phenotype
)	O
and	O
other	O
neurodevelopmental	O
disorders	O
.	O

Limb	B-Phenotype
-	I-Phenotype
girdle	I-Phenotype
muscular	I-Phenotype
dystrophies	E-Phenotype
(	O
LGMD	S-Phenotype
)	O
are	O
a	O
highly	O
heterogeneous	S-Phenotype
group	O
of	O
muscle	O
disorders	O
,	O
which	O
first	O
affect	O
the	O
voluntary	O
muscles	O
of	O
the	O
hip	O
and	O
shoulder	O
areas	O
.	O

Studies	O
in	O
humans	O
with	O
autosomal	B-Phenotype
recessive	E-Phenotype
CARD9	O
deficiency	O
have	O
indicated	O
a	O
highly	O
specific	O
role	O
for	O
this	O
molecule	O
in	O
the	O
activation	O
of	O
antifungal	O
immune	O
responses	O
in	O
the	O
central	O
nervous	O
system	O
,	O
the	O
oral	O
mucosa	O
,	O
and	O
the	O
skin	O
.	O

Our	O
findings	O
indicate	O
that	O
GNPAT	O
,	O
SUMO1	O
,	O
SPINT2	O
,	O
FLI1	O
,	O
and	O
SSX1	O
play	O
critical	O
roles	O
in	O
synergy	O
with	O
inflammation	O
pathways	O
in	O
modulating	O
melanoma	S-Phenotype
cell	O
survival	O
and	O
could	O
serve	O
as	O
sensitizing	O
targets	O
to	O
enhance	O
CDDO	O
-	O
Me	O
efficacy	O
in	O
melanoma	S-Phenotype
growth	O
control	O

Furthermore	O
,	O
the	O
inhibition	O
of	O
MPC1	O
expression	O
induced	O
EMT	O
in	O
cancer	S-Phenotype
cells	O
,	O
and	O
the	O
overexpression	O
of	O
MPC1	O
suppressed	O
the	O
migration	O
of	O
tumor	S-Phenotype
cells	O
.	O

Ectopic	O
expression	O
of	O
ADAMTS18	O
in	O
breast	B-Phenotype
tumor	E-Phenotype
cells	O
resulted	O
in	O
inhibition	O
of	O
cell	O
migration	O
and	O
invasion	O
.	O

There	O
has	O
been	O
virtually	O
no	O
tissue	O
study	O
on	O
the	O
expression	O
of	O
PLZF	O
in	O
prostate	B-Phenotype
cancer	E-Phenotype
(	O
PCa	S-Phenotype
)	O
.	O

By	O
whole	O
exome	O
sequencing	O
we	O
identified	O
a	O
de	O
novo	O
splicing	O
mutation	O
in	O
FOXP1	O
in	O
a	O
patient	O
,	O
initially	O
diagnosed	O
as	O
C	O
syndrome	O
,	O
who	O
suffers	O
from	O
syndromic	O
intellectual	B-Phenotype
disability	E-Phenotype
with	O
trigonocephaly	S-Phenotype
.	O

PRMT7	O
plays	O
important	O
roles	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
,	O
splicing	O
,	O
DNA	O
damage	O
,	O
paternal	O
imprinting	O
,	O
cancer	S-Phenotype
and	O
metastasis	O
.	O

Hypohidrotic	B-Phenotype
ectodermal	I-Phenotype
dysplasia	E-Phenotype
(	O
HED	S-Phenotype
)	O
results	O
from	O
mutation	O
of	O
the	O
EDA	O
,	O
EDAR	O
or	O
EDARADD	O
genes	O
and	O
is	O
characterized	O
by	O
reduced	B-Phenotype
or	I-Phenotype
absent	I-Phenotype
eccrine	I-Phenotype
sweat	I-Phenotype
glands	E-Phenotype
,	O
hair	B-Phenotype
follicles	I-Phenotype
and	I-Phenotype
teeth	E-Phenotype
,	O
and	O
defective	B-Phenotype
formation	I-Phenotype
of	I-Phenotype
salivary	E-Phenotype
,	O
mammary	S-Phenotype
and	O
craniofacial	B-Phenotype
glands	E-Phenotype
.	O

Subsequently	O
,	O
the	O
top	O
12	O
highly	O
mutated	O
genes	O
were	O
selected	O
for	O
validation	O
by	O
polymerase	O
chain	O
reaction	O
and	O
DNA	O
sequencing	O
in	O
an	O
expanded	O
sample	O
set	O
including	O
FLC	S-Phenotype
,	O
sporadic	B-Phenotype
lung	I-Phenotype
cancer	E-Phenotype
,	O
and	O
healthy	O
population	O
.	O

Mechanistically	O
,	O
lncSHGL	O
recruited	O
heterogeneous	S-Phenotype
nuclear	O
ribonucleoprotein	O
A1	O
(	O
hnRNPA1	O
)	O
to	O
enhance	O
the	O
translation	O
efficiency	O
of	O
CALM	O
mRNAs	O
to	O
increase	O
calmodulin	O
(	O
CaM	O
)	O
protein	O
level	O
without	O
affecting	O
their	O
transcription	O
,	O
leading	O
to	O
the	O
activation	O
of	O
the	O
phosphatidyl	O
inositol	O
3	O
-	O
kinase	O
(	O
PI3K	O
)	O
/	O
Akt	O
pathway	O
and	O
repression	O
of	O
the	O
mTOR	O
/	O
SREBP	O
-	O
1C	O
pathway	O
independent	O
of	O
insulin	O
and	O
calcium	O
in	O
hepatocytes	O
.	O

In	O
the	O
present	O
study	O
the	O
expression	O
status	O
of	O
CDK10	O
and	O
its	O
prognostic	O
significance	O
in	O
gastric	B-Phenotype
cancer	E-Phenotype
was	O
determined	O
,	O
as	O
well	O
as	O
its	O
role	O
in	O
cell	O
proliferation	O
and	O
invasion	O
.	O

We	O
studied	O
a	O
consanguineous	O
Pakistani	O
family	O
with	O
postnatal	B-Phenotype
microcephaly	E-Phenotype
,	O
orofacial	B-Phenotype
dyskinesia	E-Phenotype
,	O
spastic	B-Phenotype
quadriplegia	E-Phenotype
and	O
,	O
on	O
MRI	O
,	O
cortical	B-Phenotype
atrophy	E-Phenotype
with	O
myelination	B-Phenotype
delay	E-Phenotype
,	O
suggestive	O
of	O
a	O
FOXG1	O
-	O
like	O
presentation	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
Kif2a	O
expression	O
and	O
its	O
role	O
in	O
tumor	S-Phenotype
progression	O
,	O
invasion	O
and	O
metastasis	O
in	O
squamous	B-Phenotype
cell	I-Phenotype
carcinoma	I-Phenotype
of	I-Phenotype
the	I-Phenotype
oral	I-Phenotype
tongue	E-Phenotype
(	O
SCCOT	O
)	O
.	O

However	O
,	O
the	O
major	O
driver	O
mutations	O
in	O
USP8	O
wild	O
-	O
type	O
tumors	S-Phenotype
remain	O
elusive	O
.	O

We	O
confirmed	O
the	O
association	O
between	O
DGCR2	O
and	O
schizophrenia	S-Phenotype
through	O
individual	O
genotyping	O
of	O
1,400	O
subjects	O
.	O

Only	O
overexpression	O
of	O
LAT	O
induced	O
a	O
reduction	O
of	O
brain	O
proliferating	O
cells	O
and	O
concomitant	O
microcephaly	S-Phenotype
.	O

Furthermore	O
,	O
the	O
Gene	O
Set	O
Enrichment	O
Analysis	O
results	O
demonstrated	O
that	O
USP18	O
may	O
be	O
negatively	O
associated	O
with	O
apoptosis	O
in	O
patients	O
with	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

80.5	O
%	O
of	O
luminal	O
-	O
type	O
tumours	S-Phenotype
developed	O
bone	O
metastasis	O
as	O
opposed	O
to	O
41.7	O
%	O
of	O
basal	O
and	O
55.6	O
%	O
of	O
HER2	O
-	O
like	O
tumours	S-Phenotype
.	O

The	O
autosomal	B-Phenotype
recessive	I-Phenotype
disease	I-Phenotype
propionic	I-Phenotype
acidemia	E-Phenotype
(	O
PA	S-Phenotype
)	O
is	O
an	O
inborn	O
error	O
of	O
metabolism	O
with	O
highly	O
variable	O
clinical	O
manifestations	O
,	O
caused	O
by	O
a	O
deficiency	O
of	O
propionyl	O
-	O
CoA	O
carboxylase	O
(	O
PCC	O
)	O
enzyme	O
,	O
due	O
to	O
mutations	O
in	O
either	O
PCCA	O
or	O
PCCB	O
genes	O
,	O
which	O
encode	O
the	O
alpha	O
and	O
beta	O
subunits	O
of	O
the	O
PCC	O
enzyme	O
,	O
respectively	O
.	O

Mechanistically	O
,	O
TUFM	O
knockdown	O
activated	O
AMPK	O
and	O
phosphorylated	O
GSK3β	O
and	O
increased	O
the	O
nuclear	O
accumulation	O
of	O
β	O
-	O
catenin	O
,	O
leading	O
to	O
the	O
induction	O
of	O
EMT	O
and	O
increased	O
migration	O
and	O
metastasis	O
of	O
A549	O
lung	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Here	O
,	O
we	O
present	O
a	O
familial	O
case	O
of	O
a	O
lethal	B-Phenotype
early	I-Phenotype
-	I-Phenotype
onset	I-Phenotype
epileptic	I-Phenotype
encephalopathy	E-Phenotype
,	O
associated	O
with	O
two	O
novel	O
compound	O
heterozygous	O
missense	O
variants	O
on	O
the	O
TBC1D24	O
gene	O
,	O
which	O
were	O
detected	O
by	O
exome	O
sequencing	O
.	O

PMM2	O
-	O
CDG	O
is	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
disease	O
with	O
a	O
large	O
phenotypic	O
spectrum	O
,	O
and	O
is	O
associated	O
with	O
mutations	O
in	O
the	O
liPMM2	O
/	O
i	O
gene	O
.	O

In	O
the	O
present	O
study	O
,	O
an	O
association	O
of	O
rs7521902	O
(	O
WNT4	O
)	O
and	O
rs10859871	O
(	O
VEZT	O
)	O
was	O
confirmed	O
in	O
women	O
with	O
endometriosis	S-Phenotype
at	O
the	O
genotypic	O
but	O
not	O
the	O
allelic	O
level	O

However	O
,	O
β‑catenin	O
inhibitors	O
may	O
be	O
applicable	O
for	O
the	O
prevention	O
of	O
organ	O
fibrosis	O
,	O
second‑line	O
HCC	S-Phenotype
prevention	O
and	O
treating	O
β‑catenin‑driven	O
cancer	S-Phenotype
.	O

The	O
novel	O
aspects	O
of	O
this	O
study	O
are	O
the	O
direct	O
identification	O
of	O
serine	O
biosynthesis	O
as	O
a	O
critical	O
mechanism	O
of	O
BRAF	O
V600E	O
inhibitor	O
resistance	O
and	O
the	O
first	O
successful	O
example	O
of	O
using	O
gemcitabine	O
+	O
BRAFis	O
in	O
combination	O
to	O
kill	O
previously	O
drug	O
-	O
resistant	O
cancer	S-Phenotype
cells	O
,	O
creating	O
the	O
translational	O
potential	O
of	O
pretreatment	O
with	O
gemcitabine	O
prior	O
to	O
BRAFi	O
treatment	O
of	O
tumor	S-Phenotype
cells	O
to	O
reverse	O
resistance	O
within	O
the	O
mutational	O
profile	O
and	O
the	O
WT	O
.	O

Other	O
novel	O
mutations	O
detected	O
in	O
unclassified	O
epilepsy	S-Phenotype
patients	O
involve	O
the	O
SCN8A	O
,	O
CACNA1A	O
,	O
GABRB3	O
,	O
GABRA1	O
,	O
IQSEC2	O
,	O
TSC1	O
,	O
VRK2	O
,	O
ATP1A2	O
,	O
PCDH19	O
,	O
SLC9A6	O
and	O
CHD2	O
genes	O
.	O

Sequencing	O
of	O
SPTLC2	O
should	O
be	O
considered	O
in	O
all	O
patients	O
presenting	O
with	O
mild	B-Phenotype
late	I-Phenotype
-	I-Phenotype
onset	I-Phenotype
sensory	I-Phenotype
-	I-Phenotype
predominant	I-Phenotype
small	I-Phenotype
or	I-Phenotype
large	I-Phenotype
fiber	I-Phenotype
neuropathy	E-Phenotype
.	O

This	O
progressive	O
muscle	O
pathology	O
resembles	O
the	O
muscular	B-Phenotype
dystrophy	E-Phenotype
phenotype	O
in	O
humans	O
and	O
mice	O
lacking	O
the	O
α7	O
integrin	O
.	O

The	O
spontaneous	O
mutant	O
mouse	O
staggerer	O
,	O
with	O
an	O
ataxic	B-Phenotype
gait	E-Phenotype
caused	O
by	O
neurodegeneration	S-Phenotype
of	O
cerebellar	O
Purkinje	O
cells	O
,	O
was	O
discovered	O
two	O
decades	O
ago	O
to	O
result	O
from	O
homozygous	O
intragenic	O
Rora	O
deletions	O
.	O

These	O
results	O
prompt	O
AKT2	O
inhibition	O
as	O
a	O
powerful	O
therapeutic	O
target	O
against	O
CSC	O
and	O
pave	O
the	O
way	O
to	O
the	O
appearance	O
of	O
more	O
effective	O
nanomedicine	O
-	O
based	O
gene	O
therapies	O
aimed	O
to	O
prevent	O
CSC	O
-	O
related	O
tumor	S-Phenotype
recurrence	O

Results	O
Our	O
cohort	O
consisted	O
mostly	O
of	O
children	O
and	O
displayed	O
a	O
wide	O
phenotypic	O
variability	O
in	O
the	O
presenting	O
symptoms	O
ranging	O
from	O
hypoglycemic	B-Phenotype
seizures	E-Phenotype
at	O
the	O
severe	O
end	O
of	O
the	O
spectrum	O
to	O
insidious	B-Phenotype
hyperpigmentation	E-Phenotype
and	O
delayed	B-Phenotype
development	E-Phenotype
.	O

The	O
analyzed	O
microRNAs	O
,	O
their	O
target	O
genes	O
and	O
TGF	O
-	O
b1	O
formed	O
a	O
network	O
of	O
strong	O
correlations	O
in	O
tissue	O
samples	O
from	O
renal	B-Phenotype
cancer	E-Phenotype
patients	O
.	O